<SEC-DOCUMENT>0001193125-24-083584.txt : 20240401
<SEC-HEADER>0001193125-24-083584.hdr.sgml : 20240401
<ACCEPTANCE-DATETIME>20240401171136
ACCESSION NUMBER:		0001193125-24-083584
CONFORMED SUBMISSION TYPE:	40-F
PUBLIC DOCUMENT COUNT:		120
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240401
DATE AS OF CHANGE:		20240401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EUPRAXIA PHARMACEUTICALS INC.
		CENTRAL INDEX KEY:			0001581178
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		40-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41923
		FILM NUMBER:		24810820

	BUSINESS ADDRESS:	
		STREET 1:		201-2067 CADBORO BAY RD.
		CITY:			VICTORIA
		STATE:			A1
		ZIP:			V8R 5G4
		BUSINESS PHONE:		250-590-3968

	MAIL ADDRESS:	
		STREET 1:		201-2067 CADBORO BAY RD.
		CITY:			VICTORIA
		STATE:			A1
		ZIP:			V8R 5G4
</SEC-HEADER>
<DOCUMENT>
<TYPE>40-F
<SEQUENCE>1
<FILENAME>d800041d40f.htm
<DESCRIPTION>40-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:eprx="http://eupraxiapharma.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>40-F</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="line-height:normal;background-color:white;"><div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2023To12_31_2023" id="ixv-508">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P01_01_2023To12_31_2023" id="ixv-509">FY</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2023To12_31_2023" id="ixv-510">0001581178</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden108159564" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">NY</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="eprx-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="P01_01_2023To12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_20_2022To04_20_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-20</xbrli:startDate> <xbrli:endDate>2022-04-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-03</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_ImmediateVestingMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">eprx:ImmediateVestingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-03</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-03</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-03</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-03</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_18_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_21_2021_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_18_2023To08_18_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-18</xbrli:startDate> <xbrli:endDate>2023-08-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_18_2023To08_18_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-18</xbrli:startDate> <xbrli:endDate>2023-08-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_15_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_15_2024To03_15_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-03-15</xbrli:startDate> <xbrli:endDate>2024-03-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_15_2024To03_15_2024_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-03-15</xbrli:startDate> <xbrli:endDate>2024-03-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2021To10_01_2021_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">eprx:NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-01</xbrli:startDate> <xbrli:endDate>2021-10-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2021To10_01_2021_LoansPayableMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-01</xbrli:startDate> <xbrli:endDate>2021-10-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AmdmHoldingsMemberEPRXAmdmHoldingsAxis_EuphraxiaUsaMembersrtOwnershipAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:AmdmHoldingsAxis">eprx:AmdmHoldingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis">eprx:EuphraxiaUsaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AmdmHoldingsMemberEPRXAmdmHoldingsAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:AmdmHoldingsAxis">eprx:AmdmHoldingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EuphraxiaPharmaIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis_OutstandingOfAMDMHoldingsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EuphraxiaPharmaIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">eprx:OutstandingOfAMDMHoldingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EuphraxiaPharmaIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AmdmHoldingsMemberEPRXAmdmHoldingsAxis_ChiefScientificOfficerMembersrtTitleOfIndividualAxis_ClassBNonVotingStockMemberusgaapStatementClassOfStockAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:AmdmHoldingsAxis">eprx:AmdmHoldingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EuphraxiaPharmaIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eprx:ClassBNonVotingStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eprx:ChiefScientificOfficerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_31_2021To01_31_2021_AmdmHoldingsMemberEPRXAmdmHoldingsAxis_ChiefScientificOfficerMembersrtTitleOfIndividualAxis_ClassBNonVotingStockMemberusgaapStatementClassOfStockAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:AmdmHoldingsAxis">eprx:AmdmHoldingsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EuphraxiaPharmaIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eprx:ClassBNonVotingStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eprx:ChiefScientificOfficerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-31</xbrli:startDate> <xbrli:endDate>2021-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_03_2021_AmendedPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-04-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_CompensationWarrantMemberEPRXWarrantAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:WarrantAxis">eprx:CompensationWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-04-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-04-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-20</xbrli:startDate> <xbrli:endDate>2022-04-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_WarrantMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-20</xbrli:startDate> <xbrli:endDate>2022-04-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_20_2022To04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-20</xbrli:startDate> <xbrli:endDate>2022-04-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_21_2021To06_21_2021_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-21</xbrli:startDate> <xbrli:endDate>2021-06-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_21_2021To06_21_2021_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-21</xbrli:startDate> <xbrli:endDate>2021-06-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_01_2021_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">eprx:NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-10-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_01_2021_LoansPayableMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-10-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_13_2021_LoansPayableMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_10_2021_LoansPayableMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:EventAxis">eprx:ExcerciseOfWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ExcerciseOfWarrantsMemberEPRXEventAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:EventAxis">eprx:ExcerciseOfWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:EventAxis">eprx:ExcerciseOfWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SiliconValleyBankMemberEPRXLenderAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_LoanMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:LoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_ArithmeticAverageMembersrtRangeAxis_EupraxiaUsaMembersrtCounterpartyNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:ArithmeticAverageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMemberEPRXTrancheAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:TrancheAxis">eprx:AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMemberEPRXTrancheAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:TrancheAxis">eprx:AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMemberEPRXTrancheAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:TrancheAxis">eprx:AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PriorToSuccessfulCompletionOfPhaseTwoBStudyMemberEPRXTrancheAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:TrancheAxis">eprx:PriorToSuccessfulCompletionOfPhaseTwoBStudyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:LoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyFirstMarchTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:ThirtyFirstMarchTwoThousandAndTwentyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:NineDecemberTwoThousandAndTwentyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThreeMayTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:ThreeMayTwoThousandAndTwentyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOne1MemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:NineMarchTwoThousandAndTwentyOne1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:NineMarchTwoThousandAndTwentyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_FiveMarchTwoThousandAndEighteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:FiveMarchTwoThousandAndEighteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwoNovemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:TwoNovemberTwoThousandAndFifteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:TwentySeventhSeptemberTwoThousandAndFifteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:NineDecemberTwoThousandAndTwentyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EighteenthMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:EighteenthMayTwoThousandAndTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:ThirtyMayTwoThousandAndTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:TwentySeventhSeptemberTwoThousandAndTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">eprx:NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MinimumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MaximumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMemberEPRXCallRightAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:CallRightAxis">eprx:AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis_WithEighteenMonthsFromTheDateOfTheDebtAgreementMemberEPRXCallRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:CallRightAxis">eprx:WithEighteenMonthsFromTheDateOfTheDebtAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EupraxiaPharmaceuticalsAustraliaPtyLtdMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaPharmaceuticalsAustraliaPtyLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EupraxiaPharmaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaPharmaIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmdmHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:AmdmHoldingsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EupraxiaPharmaceuticalsUsaLlcMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaPharmaceuticalsUsaLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EupraxiaHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaHoldingsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EupraxiaPharmaUsaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaPharmaUsaIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PreclinicalMemberEPRXResearchAndDevelopmentExpensesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:PreclinicalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ClinicalMemberEPRXResearchAndDevelopmentExpensesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:ClinicalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ManufacturingAndAnalyticaMemberEPRXResearchAndDevelopmentExpensesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:ManufacturingAndAnalyticaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RegulatoryMemberEPRXResearchAndDevelopmentExpensesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:RegulatoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ConsultingMemberEPRXResearchAndDevelopmentExpensesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:ConsultingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_CanadianFederalInvestmentTaxCreditsMemberusgaapTaxCreditCarryforwardAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">eprx:CanadianFederalInvestmentTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_ProvincialInvestmentTaxCreditsMemberusgaapTaxCreditCarryforwardAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">eprx:ProvincialInvestmentTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ExpiryPeriodTwoMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ExpiryPeriodOneMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ExpiryPeriodTenMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodTenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ExpiryPeriodNineMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ExpiryPeriodEightMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ExpiryPeriodSevenMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodSevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ExpiryPeriodSixMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodSixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ExpiryPeriodFiveMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ExpiryPeriodFourMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ExcerciseOfOptionsMemberEPRXEventAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:EventAxis">eprx:ExcerciseOfOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eprx:LabEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_SuccessfulCompletionOfPhaseTwoBStudyMemberEPRXMilestoneAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:MilestoneAxis">eprx:SuccessfulCompletionOfPhaseTwoBStudyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:EventAxis">eprx:ExcerciseOfWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OvernightMarketedPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eprx:OvernightMarketedPublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OvernightMarketedPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eprx:OvernightMarketedPublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_OvernightMarketedPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eprx:OvernightMarketedPublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ExcerciseOfWarrantsMemberEPRXEventAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:EventAxis">eprx:ExcerciseOfWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:EventAxis">eprx:ExcerciseOfWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:LoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">eprx:NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MinimumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MaximumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PreclinicalMemberEPRXResearchAndDevelopmentExpensesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:PreclinicalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ConsultingMemberEPRXResearchAndDevelopmentExpensesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:ConsultingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ClinicalMemberEPRXResearchAndDevelopmentExpensesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:ClinicalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ManufacturingAndAnalyticaMemberEPRXResearchAndDevelopmentExpensesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:ManufacturingAndAnalyticaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RegulatoryMemberEPRXResearchAndDevelopmentExpensesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:RegulatoryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eprx:LabEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SiliconValleyBankMemberEPRXLenderAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMemberEPRXMilestoneAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:MilestoneAxis">eprx:SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_FirstOaRegulatoryApprovalMemberEPRXMilestoneAxis_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:MilestoneAxis">eprx:FirstOaRegulatoryApprovalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_SuccessfulCompletionOfPhaseTwoBStudyMemberEPRXMilestoneAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:MilestoneAxis">eprx:SuccessfulCompletionOfPhaseTwoBStudyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_SecondOaRegulatoryApprovalMemberEPRXMilestoneAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:MilestoneAxis">eprx:SecondOaRegulatoryApprovalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_NonOaIndicationRegulatoryApprovalMemberEPRXMilestoneAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:MilestoneAxis">eprx:NonOaIndicationRegulatoryApprovalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_FiveMarchTwoThousandAndEighteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:FiveMarchTwoThousandAndEighteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:NineMarchTwoThousandAndTwentyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOne1MemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:NineMarchTwoThousandAndTwentyOne1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThreeMayTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:ThreeMayTwoThousandAndTwentyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:NineDecemberTwoThousandAndTwentyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:TwentySeventhSeptemberTwoThousandAndFifteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwoNovemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:TwoNovemberTwoThousandAndFifteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyFirstMarchTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:ThirtyFirstMarchTwoThousandAndTwentyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:NineDecemberTwoThousandAndTwentyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EighteenthMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:EighteenthMayTwoThousandAndTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:ThirtyMayTwoThousandAndTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:TwentySeventhSeptemberTwoThousandAndTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">eprx:NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_BioTalentCanadaMemberusgaapGovernmentAssistanceTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">eprx:BioTalentCanadaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ExcerciseOfWarrantsMemberEPRXEventAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:EventAxis">eprx:ExcerciseOfWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TaxYear2033MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2033Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2032MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2032Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TaxYear2032MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2032Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2031MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2031Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TaxYear2031MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2031Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2031MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2031Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TaxYear2036MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2036Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2035MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2035Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TaxYear2035MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2035Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2034MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2034Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TaxYear2034MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2034Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2033MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2033Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TaxYear2041MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2041Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2040MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2040Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TaxYear2040MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2040Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2039MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2039Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TaxYear2039MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2039Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2036MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2036Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYearAfter2043MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYearAfter2043Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2043MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2043Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2043MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2043Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2042MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2042Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TaxYear2042MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2042Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2041MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2041Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TaxYear2038MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2038Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2038MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2038Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYearAfter2043MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYearAfter2043Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TaxYearAfter2043MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYearAfter2043Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2034MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2034Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2033MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2033Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2037MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2037Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TaxYear2037MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2037Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2037MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2037Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2038MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2038Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2042MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2042Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2041MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2041Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2040MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2040Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2039MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2039Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2036MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2036Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2035MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2035Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2032MemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2032Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_ProvincialInvestmentTaxCreditsMemberusgaapTaxCreditCarryforwardAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">eprx:ProvincialInvestmentTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_CanadianFederalInvestmentTaxCreditsMemberusgaapTaxCreditCarryforwardAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">eprx:CanadianFederalInvestmentTaxCreditsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_EquipmentLoanMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">eprx:EquipmentLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CADsrtCurrencyAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CurrencyRiskMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">eprx:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CADsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ExpiryPeriodOneMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ExpiryPeriodTenMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodTenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ExpiryPeriodNineMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodNineMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ExpiryPeriodEightMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodEightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ExpiryPeriodSevenMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodSevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ExpiryPeriodSixMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodSixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ExpiryPeriodFiveMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ExpiryPeriodTwoMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ExpiryPeriodFourMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_EupraxiaHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaHoldingsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_EupraxiaPharmaceuticalsUsaLlcMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaPharmaceuticalsUsaLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmdmHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:AmdmHoldingsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_EupraxiaPharmaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaPharmaIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_EupraxiaPharmaceuticalsAustraliaPtyLtdMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaPharmaceuticalsAustraliaPtyLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_EupraxiaPharmaUsaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaPharmaUsaIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MinimumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eprx:LabEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BioTalentCanadaMemberusgaapGovernmentAssistanceTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">eprx:BioTalentCanadaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">eprx:NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ExcerciseOfWarrantsMemberEPRXEventAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="eprx:EventAxis">eprx:ExcerciseOfWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CurrencyRiskMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">eprx:CurrencyRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CADsrtCurrencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eprx:LabEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:LoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eprx:LabEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:LoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:LoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AmendedPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AmendedPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001581178</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_CAD"> <xbrli:measure>iso4217:CAD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month"> <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year"> <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_sqft"> <xbrli:measure>utr:sqft</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day"> <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_CAD_per_Share"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:CAD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit></ix:resources></ix:header></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div><div style="line-height: 3pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div><div style="margin-top: 4pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">UNITED STATES </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Washington, D.C. 20549 </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2023To12_31_2023" id="ixv-2896">40-F</ix:nonNumeric></div> </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:DocumentRegistrationStatement" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:boolballotbox" id="ixv-2897">&#9744;</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;"><div style="font-weight:bold;display:inline;">REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></td></tr></table><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:DocumentAnnualReport" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:boolballotbox" id="ixv-2898">&#9746;</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;"><div style="font-weight:bold;display:inline;">ANNUAL REPORT PURSUANT TO SECTION 13(A) OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></td></tr></table><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P01_01_2023To12_31_2023" format="ixt:date-monthname-day-year-en" id="ixv-2899"><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P01_01_2023To12_31_2023" format="ixt:date-monthname-day-en" id="ixv-2900">December 31</ix:nonNumeric>, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P01_01_2023To12_31_2023" id="ixv-2901">2023</ix:nonNumeric></ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Commission File Number <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P01_01_2023To12_31_2023" id="ixv-2902">001-41923</ix:nonNumeric></div> </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 24pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2023To12_31_2023" id="ixv-2903">EUPRAXIA PHARMACEUTICALS INC.</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Exact name of registrant as specified in its charter) </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:edgarprovcountryen" id="ixv-2904">British Columbia</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityPrimarySicNumber" contextRef="P01_01_2023To12_31_2023" id="ixv-2905">2834</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Not Applicable</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(Province or other jurisdiction of</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">incorporation or organization)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(Primary standard industrial</div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">classification code number,</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">if applicable)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(I.R.S. Employer Identification No.,</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">if applicable)</div></div></td></tr></table><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2023To12_31_2023" id="ixv-115"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">201-2067</div> Cadboro Bay Road</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To12_31_2023" id="ixv-2906">Victoria</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:stateprovnameen" id="ixv-2907">British Columbia</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:countrynameen" id="ixv-2908">Canada</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2023To12_31_2023" id="ixv-2909">V8R 5G4</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Telephone: (<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2023To12_31_2023" id="ixv-2910">250</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2023To12_31_2023" id="ixv-2911">590-3968</ix:nonNumeric></div> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Address and telephone number of registrant&#8217;s principal executive offices) </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-2912">Corporation Service Company</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-2913">19 West 44th Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-2914">Suite 200</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-2915">New York</ix:nonNumeric>, <div style="-sec-ix-hidden:hidden108159564;display:inline;">NY</div> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-2916">10036</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-2917">800</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-2918">927-9800</ix:nonNumeric></div> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Name, address (including zip code) and telephone number (including area code) of agent for service in the United States) </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(b) of the Act: None </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(g) of the Act: None </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities for which there is a reporting obligation pursuant to Section&#160;15(d) of the Act: common shares </div></div></div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">For annual reports, indicate by check mark the information filed with this form: </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:51%"/>
<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="dei:AnnualInformationForm" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:boolballotbox" id="ixv-2919">&#9746;</ix:nonNumeric>&#8194;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Annual Information Form</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:AuditedAnnualFinancialStatements" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:boolballotbox" id="ixv-2920">&#9746;</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;Audited Annual Financial Statements</div></div></td></tr></table><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Indicate the number of outstanding shares of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report: <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-2921">27,282,165</ix:nonFraction>&#160;Common Shares (as at December&#160;31, 2023). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90 days.&#8195;Yes&#8194;&#9744;&#8195;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P01_01_2023To12_31_2023" id="ixv-2922">No</ix:nonNumeric>&#8194;&#9746; </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-T</div> (s.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).&#8195;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P01_01_2023To12_31_2023" id="ixv-2923">Yes</ix:nonNumeric>&#8194;&#9746;&#8195;No&#8194;&#9744; </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. Emerging growth company.&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:boolballotbox" id="ixv-2924">&#9746;</ix:nonNumeric></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section&#160;13(a) of the Exchange Act.<div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px; background: none; text-decoration: none;;display:inline;">&#8194;</div></div><ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:boolballotbox" id="ixv-2925">&#9744;</ix:nonNumeric></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">&#8224;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;">The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April&#160;5, 2012. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#8194;<ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:boolballotbox" id="ixv-2926">&#9744;</ix:nonNumeric></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">If securities are registered pursuant to Section&#160;12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.<div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px; background: none; text-decoration: none;;display:inline;">&#8194;</div></div><ix:nonNumeric name="dei:DocumentFinStmtErrorCorrectionFlag" contextRef="P01_01_2023To12_31_2023" format="ixt:fixed-false" id="ixv-2927">&#9744;</ix:nonNumeric></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#167;240.10D-1(b).&#8194;&#9744;</div> </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 35%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 32%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 31%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Auditor Name: <ix:nonNumeric name="dei:AuditorName" contextRef="P01_01_2023To12_31_2023" id="ixv-2928">KPMG LLP</ix:nonNumeric></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Auditor Location: <ix:nonNumeric name="dei:AuditorLocation" contextRef="P01_01_2023To12_31_2023" id="ixv-2929">Vancouver, Canada</ix:nonNumeric></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Auditor Firm ID: <ix:nonNumeric name="dei:AuditorFirmId" contextRef="P01_01_2023To12_31_2023" id="ixv-2930">85</ix:nonNumeric></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;<br/></div></div></div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PRINCIPAL DOCUMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The following documents are filed as part of this Annual Report on Form <span style="white-space:nowrap">40-F:</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A. Annual Information Form </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">For the Registrant&#8217;s Annual Information Form for the year ended December&#160;31, 2023, see Exhibit 99.1 of this Annual Report on Form <span style="white-space:nowrap">40-F</span> (&#8220;<span style="font-weight:bold"><span style="font-style:italic">AIF</span></span>&#8221;). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">B. Audited Annual Financial Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">For the Registrant&#8217;s Audited Consolidated Financial Statements as of and for the years ended December&#160;31, 2023 and 2022 (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">2023 Financial Statements</span></span>&#8221;), including the Independent Auditor&#8217;s Report with respect thereto, see Exhibit 99.2 of this Annual Report on Form <span style="white-space:nowrap">40-F.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">C. Management&#8217;s Discussion and Analysis </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">For the Registrant&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations for the year ended December&#160;31, 2023 (&#8220;<span style="font-weight:bold"><span style="font-style:italic">MD&amp;A</span></span>&#8221;), see Exhibit 99.3 of this Annual Report on Form <span style="white-space:nowrap">40-F.</span> </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONTROLS AND PROCEDURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A. Certifications </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The required disclosure is included in Exhibits 99.5, 99.6, 99.7 and 99.8 of this Annual Report on Form <span style="white-space:nowrap">40-F.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">B. Disclosure Controls and Procedures </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The information provided under the heading &#8220;Disclosure Controls and Procedures and Internal Controls Over Financial Reporting&#8221; contained in the MD&amp;A, filed as Exhibit 99.3 to this Annual Report on Form <span style="white-space:nowrap">40-F,</span> is incorporated by reference herein. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">C. Management&#8217;s Annual Report on Internal Control over Financial Reporting and Attestation Report of the Registered Public Accounting Firm </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">This annual report does not include a report of management&#8217;s assessment regarding internal control over financial reporting or an attestation report of the company&#8217;s registered public accounting firm due to a transition period established by rules of the Securities and Exchange Commission for newly public companies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">D. Changes in Internal Control over Financial Reporting </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The information provided under the heading &#8220;Disclosure Controls and Procedures and Internal Controls Over Financial Reporting&#8221; contained in the MD&amp;A, filed as Exhibit 99.3 to this Annual Report on Form <span style="white-space:nowrap">40-F,</span> is incorporated by reference herein. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AUDIT COMMITTEE FINANCIAL EXPERT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Registrant&#8217;s Board of Directors has determined that each member of the Audit Committee, John Montalbano, Simon Pimstone and Paul Geyer, are &#8220;independent&#8221; (as defined by Rule 10A-3 of the Exchange Act and Nasdaq Rule 5605(a)(2)) and that each of Mr. Montalbano and Dr. Pimstone are &#8220;audit committee financial experts&#8221; (as that term is defined in paragraph 8(b) of General Instruction B to Form 40-F). For a description of Mr. Montalbano&#8217;s and Dr. Pimstone&#8217;s relevant experience in financial matters, see the biographical descriptions for each under &#8220;Directors and Executive Officers&#8221; in the AIF, which is filed as Exhibit 99.1 to this Annual Report on Form 40-F. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The SEC has indicated that the designation or identification of a person as an audit committee financial expert does not make such person an &#8220;expert&#8221; for any purpose, impose any duties, obligations or liability on such person that are greater than those imposed on members of the audit committee and the board of directors who do not carry this designation or identification, or affect the duties, obligations or liability of any other member of the audit committee or board of directors. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CODE OF ETHICS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Board of Directors of the Registrant (the &#8220;Board&#8221;) has adopted a written code of business conduct and ethics (the &#8220;Code&#8221;) which emphasizes the importance of matters relating to honest and ethical conduct, full, fair, accurate, timely, and understandable disclosure in reports that the Registrant files with, or submits to, the Securities and Exchange Commission (the &#8220;Commission&#8221;) and in other public communications, compliance with applicable laws, rules and regulations, the prompt internal reporting of violations of the Code and accountability for adherence to the Code. All individuals representing the Registrant, including the Registrant&#8217;s principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, are expected to abide by all applicable provisions of the Code and adhere to its principles and values when representing the Registrant to the public or performing services for, or on behalf of, the Registrant. The Board will review the effectiveness of the Code on an ongoing basis to ensure that the Registrant&#8217;s business activities are conducted in accordance with the principles and rules set out therein. A copy of the Code can be obtained from the Registrant&#8217;s website at www.eupraxiapharma.com/investors. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PRINCIPAL ACCOUNTANT FEES AND SERVICES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The information provided under the heading &#8220;Audit Committee Information &#8212; External Auditor Fees&#8221; by Category contained in the AIF, filed as Exhibit 99.1 to this Annual Report on Form <span style="white-space:nowrap">40-F,</span> is incorporated by reference herein. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AUDIT COMMITTEE <span style="white-space:nowrap">PRE-APPROVAL</span> POLICIES AND PROCEDURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The information provided under the heading &#8220;Audit Committee Information &#8212; Pre-Approval Policies and Procedures&#8221; contained in the AIF, filed as Exhibit 99.1 to this Annual Report on Form <span style="white-space:nowrap">40-F,</span> is incorporated by reference herein. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">OFF-BALANCE</span> SHEET ARRANGEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The information provided under the heading &#8220;Off-Balance Sheet Arrangements&#8221; contained in the MD&amp;A, filed as Exhibit 99.3 to this Annual Report on Form <span style="white-space:nowrap">40-F,</span> is incorporated by reference herein. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONTRACTUAL OBLIGATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The information provided under the heading &#8220;Contractual Obligations&#8221; contained in the MD&amp;A, filed as Exhibit 99.3 to this Annual Report on Form <span style="white-space:nowrap">40-F,</span> is incorporated by reference herein. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">IDENTIFICATION OF THE AUDIT COMMITTEE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The information provided under the heading &#8220; Audit Committee Information &#8212; Audit Committee&#8221; contained in the AIF, filed as Exhibit 99.1 to this Annual Report on Form <span style="white-space:nowrap">40-F,</span> is incorporated by reference herein. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DIFFERENCES IN NASDAQ AND CANADIAN CORPORATE GOVERNANCE REQUIREMENTS </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Registrant is a foreign private issuer and has applied to list its common shares on the Nasdaq Capital Market (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Nasdaq</span></span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Nasdaq Rule 5615(a)(3) permits a foreign private issuer to follow its home country practice in lieu of the requirements of the Rule 5600 Series, the requirement to disclose third party director and nominee compensation set forth in Rule 5250(b)(3), and the requirement to distribute annual and interim reports set forth in Rule 5250(d), provided, however, that such a Company shall: comply with the Notification of Noncompliance requirement (Rule 5625), the Voting Rights requirement (Rule 5640), the Diverse Board Representation Rule (Rule 5605(f)), the Board Diversity Disclosure Rule (Rule 5606), have an audit committee that satisfies Rule 5605(c)(3), and ensure that such audit committee&#8217;s members meet the independence requirement in Rule 5605(c)(2)(A)(ii). </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Registrant does not follow Rule 5620(c) regarding minimum quorum for meetings of shareholders and instead follows its home country practice. The Nasdaq minimum quorum requirement under Rule 5620(c) for a shareholder meeting is <span style="white-space:nowrap">33-1/3%</span> of the outstanding shares of a company&#8217;s common voting stock. In addition, a registrant listed on Nasdaq is required to state its quorum requirement in its <span style="white-space:nowrap">by-laws.</span> Under the Registrant&#8217;s articles, quorum for a meeting of the Registrant&#8217;s shareholders is at least one person who is, or who represents by proxy, one or more shareholders who, in the aggregate, hold at least 5% of the issued shares of the Registrant entitled to be voted at the meeting. The Business Corporations Act (British Columbia) (&#8220;<span style="font-weight:bold"><span style="font-style:italic">BCBCA</span></span>&#8221;) defers to the quorum requirements in a corporation&#8217;s articles. The primary market for the Registrant&#8217;s common shares in Canada is the Toronto Stock Exchange (the &#8220;TSX&#8221;). The rules of the TSX do not contain quorum requirements. As a result, the Registrant&#8217;s quorum requirements in respect of shareholder meetings are not prohibited by the BCBCA or the rules of the TSX. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Certain statements in this Annual Report on Form <span style="white-space:nowrap">40-F</span> are forward-looking statements within the meaning of Section&#160;21E of the Exchange Act and Section&#160;27A of the Securities Act of 1933, as amended. Please see &#8220;CAUTION REGARDING FORWARD-LOOKING STATEMENTS AND RISK FACTORS&#8221; in the AIF, filed as Exhibit 99.1 to this Annual Report on Form <span style="white-space:nowrap">40-F</span> for a discussion of risks, assumptions, uncertainties and other factors that could cause actual results to vary from those forward-looking statements. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INCORPORATION BY REFERENCE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">This Annual Report is incorporated by reference into the Registrant&#8217;s Registration Statement on Form F-10 (File No. 333- 276586). </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNDERTAKING </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Registrant undertakes to make available, in person or by telephone, representatives to respond to inquiries made by the <span style="font-weight:bold"><span style="font-style:italic">Commission</span></span> staff, and to furnish promptly, when requested to do so by the Commission staff, information relating to the securities in relation to which the obligation to file an annual report on Form <span style="white-space:nowrap">40-F</span> arises or transactions in said securities. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">BOARD DIVERSITY MATRIX </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman;text-align:justify">The table below reports self-identified diversity statistics for the Board of Directors of the Registrant as of December 31, 2023, as required by Nasdaq Rule 5606. </p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g800041g07j01.jpg" alt="LOGO"/>
 </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONSENT TO SERVICE OF PROCESS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Registrant has previously filed a Form <span style="white-space:nowrap">F-X</span> in connection with the class of securities in relation to which the obligation to file this report arises. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman;text-align:justify">Any change to the name or address of the Registrant&#8217;s agent for service shall be communicated promptly to the Commission by amendment to Form <span style="white-space:nowrap">F-X</span> referencing the file number of the Registrant. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Exhibit Index </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:90%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="font-weight:bold">Exhibit<br/>No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Document</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">97.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Compensation Recovery Policy of the Registrant.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Annual Information Form of the Registrant for the fiscal year ended December&#160;31, 2023.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Consolidated Financial Statements as of and for the years ended December 31, 2023 and 2022.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations for the year ended December 31, 2023</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Consent of KPMG LLP, dated April&#160;1, 2024.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Certification of Chief Executive Officer (Principal Executive Officer) pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Certification of Chief Financial Officer (Principal Financial Officer) pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Certification of Chief Executive Officer (Principal Executive Officer) under Section&#160;906 of the Sarbanes-Oxley Act of 2002.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.8</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Certification of Chief Financial Officer (Principal Financial Officer) under Section&#160;906 of the Sarbanes-Oxley Act of 2002.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Inline XBRL Instance Document.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Inline XBRL Taxonomy Schema Linkbase Document.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Inline XBRL Taxonomy Calculation Linkbase Document.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Inline XBRL Taxonomy Definition Linkbase Document.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Inline XBRL Taxonomy Extension Label Linkbase Document.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Inline XBRL Taxonomy Presentation Linkbase Document.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</p></td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Pursuant to the requirements of the Exchange Act, the Registrant certifies that it meets all of the requirements for filing on Form <span style="white-space:nowrap">40-F</span> and has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: April 1, 2024 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;font-weight:bold;text-align:justify">Eupraxia Pharmaceuticals Inc.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:justify">By:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:justify">/s/ James A. Helliwell</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: James A. Helliwell</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: Chief Executive Officer</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>2
<FILENAME>d800041dex971.htm
<DESCRIPTION>EX-97.1 COMPENSATION RECOVERY POLICY
<TEXT>
<HTML><HEAD>
<TITLE>EX-97.1 Compensation Recovery Policy</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 97.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUPRAXIA PHARMACEUTICALS INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPENSATION RECOVERY POLICY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">As adopted on December&nbsp;21, 2023 and effective </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">as of the effective date of the Company&#146;s Form <FONT STYLE="white-space:nowrap">8-A</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">filed with the Securities and Exchange Commission </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Eupraxia Pharmaceuticals Inc. (the &#147;<B>Company</B>&#148;) is committed to strong corporate governance. As part of this
commitment, the Company&#146;s Board of Directors (the &#147;<B>Board</B>&#148;) has adopted this clawback policy called the Compensation Recovery Policy (the &#147;<B>Policy</B>&#148;). The Policy is intended to further the Company&#146;s <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay-for-performance</FONT></FONT> philosophy and to comply with applicable laws by providing rules relating to the reasonably prompt recovery of certain compensation received by Covered
Executives in the event of an Accounting Restatement. The application of the Policy to Covered Executives is not discretionary, except to the limited extent provided below, and applies without regard to whether a Covered Executive was at fault.
Capitalized terms used in the Policy are defined below, and the definitions have substantive impact on its application so reviewing them carefully is important to your understanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Policy is intended to comply with, and will be interpreted in a manner consistent with, Section&nbsp;10D of the Securities
Exchange Act of 1934 (the &#147;<B>Exchange Act</B>&#148;), with Exchange Act Rule <FONT STYLE="white-space:nowrap">10D-1</FONT> and with the listing standards of the national securities exchange (the &#147;<B>Exchange</B>&#148;) on which the
securities of the Company are listed, including any official interpretive guidance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Persons Covered by the Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Policy is binding and enforceable against all &#147;<B>Covered Executives</B>.&#148; A Covered Executive is each individual
who is or was ever designated as an &#147;officer&#148; by the Board in accordance with Exchange Act Rule <FONT STYLE="white-space:nowrap">16a-1(f)</FONT> (a &#147;<B>Section</B><B></B><B>&nbsp;16 Officer</B>&#148;). The Committee may (but is not
obligated to) request or require a Covered Executive to sign and return to the Company an acknowledgement that such Covered Executive will be bound by the terms and comply with the Policy. The Policy is binding on each Covered Executive whether or
not the Covered Executive signs and/or returns any acknowledgment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Administration of the Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Compensation Committee (the &#147;<B>Committee</B>&#148;) of the Board has full delegated authority to administer the
Policy. The Committee is authorized to interpret and construe the Policy and to make all determinations necessary, appropriate, or advisable for the administration of the Policy. In addition, if determined in the discretion of the Board, the Policy
may be administered by the independent members of the Board or another committee of the Board made up of independent members of the Board, in which case all references to the Committee will be deemed to refer to the independent members of the Board
or the other Board committee. All determinations of the Committee will be final and binding and will be given the maximum deference permitted by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting Restatements Requiring Application of the Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any
financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would
result in a material misstatement if the error were corrected </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
in the current period or left uncorrected in the current period (an &#147;<B>Accounting Restatement</B>&#148;), then the Committee must determine the Excess Compensation, if any, that must be
recovered. The Company&#146;s obligation to recover Excess Compensation is not dependent on if or when restated financial statements are filed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Covered by the Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Policy applies to certain <B>Incentive-Based Compensation</B> (certain terms used in this Section are defined below) that
is <B>Received</B> on or after October&nbsp;2, 2023 (the &#147;<B>Effective Date</B>&#148;), during the <B>Covered Period</B> while the Company has a class of securities listed on a national securities exchange. Such Incentive-Based Compensation is
considered &#147;<B>Clawback Eligible Incentive-Based Compensation</B>&#148; if the Incentive-Based Compensation is Received by a person after such person became a Section&nbsp;16 Officer and the person served as a Section&nbsp;16 Officer at any
time during the performance period for the Incentive-Based Compensation. &#147;<B>Excess Compensation</B>&#148; means the amount of Clawback Eligible Incentive-Based Compensation that exceeds the amount of Clawback Eligible Incentive-Based
Compensation that otherwise would have been Received had such Clawback Eligible Incentive-Based Compensation been determined based on the restated amounts. Excess Compensation must be computed without regard to any taxes paid and is referred to in
the listing standards of the Exchange as &#147;erroneously awarded compensation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To determine the amount of Excess
Compensation for Incentive-Based Compensation based on stock price or total shareholder return, where it is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the amount must be based on a
reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was Received and the Company must maintain documentation of the determination of that
reasonable estimate and provide that documentation to the Exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Incentive-Based Compensation</B>&#148; means
any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. For the avoidance of doubt, no compensation that is potentially subject to recovery under the Policy will be earned
until the Company&#146;s right to recover under the Policy has lapsed.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Financial Reporting Measures</B>&#148; are measures that are determined and presented in accordance with the
accounting principles used in preparing the Company&#146;s financial statements, and any measures that are derived wholly or in part from such measures. Stock price and total shareholder return are also Financial Reporting Measures. A Financial
Reporting Measure need not be presented within the financial statements or included in a filing with the Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Incentive-Based Compensation is &#147;<B>Received</B>&#148; under the Policy in the Company&#146;s fiscal period during which
the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment, vesting, settlement or grant of the Incentive-Based Compensation occurs after the end of that period. For the avoidance of doubt,
the Policy does not apply to Incentive-Based Compensation for which the Financial Reporting Measure is attained prior to the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Covered Period</B>&#148; means the three completed fiscal years immediately preceding the Accounting Restatement
Determination Date. In addition, Covered Period can include certain transition periods resulting from a change in the Company&#146;s fiscal year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>Accounting Restatement Determination Date</B>&#148; means the earliest to occur of: (a)&nbsp;the date the Board, a
committee of the Board, or one or more of the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement;
and (b)&nbsp;the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Repayment of Excess Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company must recover Excess Compensation reasonably promptly and Covered Executives are required to repay Excess
Compensation to the Company. Subject to applicable law, the Company may recover Excess Compensation by requiring the Covered Executive to repay such amount to the Company by direct payment to the Company or such other means or combination of means
as the Committee determines to be appropriate (these determinations do not need to be identical as to each Covered Executive). These means include (but are not limited to): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">requiring reimbursement of cash Incentive-Based Compensation previously paid; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other
disposition of any equity-based awards (including, but not limited to, time-based vesting awards), without regard to whether such awards are Incentive-Based Compensation or vest based on the achievement of performance goals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">offsetting the amount to be recovered from any unpaid or future compensation to be paid by the Company or
any affiliate of the Company to the Covered Executive, including (but not limited to) payments of severance that might otherwise be due in connection with a Covered Executive&#146;s termination of employment and without regard to whether such
amounts are Incentive-Based Compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">cancelling outstanding vested or unvested equity awards (including, but not limited to, time-based vesting
awards), without regard to whether such awards are Incentive-Based Compensation; and/or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">taking any other remedial and recovery action permitted by law, as determined by the Committee.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The repayment of Excess Compensation must be made by a Covered Executive notwithstanding any Covered
Executive&#146;s belief (whether or not legitimate) that the Excess Compensation had been previously earned under applicable law and therefore is not subject to clawback. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to its rights to recovery under the Policy, the Company or any affiliate of the Company may take any legal actions
it determines appropriate to enforce a Covered Executive&#146;s obligations to the Company or to discipline a Covered Executive. Failure of a Covered Executive to comply with their obligations under the Policy may result in (without limitation)
termination of that Covered Executive&#146;s employment, institution of civil proceedings, reporting of misconduct to appropriate governmental authorities, reduction of future compensation opportunities or change in role. The decision to take any
actions described in the preceding sentence will not be subject to the approval of the Committee and can be made by the Board, any committee of the Board, or any duly authorized officer of the Company or of any applicable affiliate of the Company.
For avoidance of doubt, any decisions of the Company or the Covered Executive&#146;s employer to discipline a Covered Executive or terminate the employment of a Covered Executive are independent of determinations under this Policy. For example, if a
Covered Executive was involved in activities that led to an Accounting Restatement, the Company&#146;s decision as to whether to not to terminate such Covered Executive&#146;s employment would be made under its employment arrangements with such
Covered Executive and the requirement to apply this <FONT STYLE="white-space:nowrap">no-fault</FONT> and <FONT STYLE="white-space:nowrap">non-discretionary</FONT> clawback policy will not be determinative of whether any such termination is for
cause, although failure to comply with the Policy might be something that could result in a termination for cause depending on the terms of such arrangements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limited Exceptions to the Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company must recover the Excess Compensation in accordance with the Policy except to the limited extent that any of the
conditions set forth below is met, and the Committee determines that recovery of the Excess Compensation would be impracticable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be
recovered. Before reaching this conclusion, the Company must make a reasonable attempt to recover such Excess Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Recovery would violate a law in the country where the Company was incorporated that was adopted prior to
November&nbsp;28, 2022. Before making this determination, the Company must obtain an opinion of home country counsel, acceptable to the Exchange, that recovery would result in such a violation, and must provide such opinion to the Exchange; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Recovery would likely cause an otherwise <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement
plan, under which benefits are broadly available to employees of the Company, to fail to meet the legal requirements as such. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other
Important Information in the Policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Policy is in addition to the requirements of Section&nbsp;304 of the
Sarbanes-Oxley Act of 2002 that are applicable to the Company&#146;s Chief Executive Officer and Chief Financial Officer, as well as any other applicable laws, regulatory requirements, rules, or pursuant to the terms of any existing Company policy
or agreement providing for the recovery of compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the terms of any of the Company&#146;s
organizational documents (including, but not limited to, the Company&#146;s bylaws), any corporate policy or any contract (including, but not limited to, any indemnification agreement), neither the Company nor any affiliate of the Company will
indemnify or provide advancement for any Covered Executive against any loss of Excess Compensation. Neither the Company nor any affiliate of the Company will pay for or reimburse insurance premiums for an insurance policy that covers potential
recovery obligations. In the event that the Company is required to recover Excess Compensation pursuant to the Policy from a Covered Executive who is no longer an employee, the Company will be entitled to seek recovery in order to comply with
applicable law, regardless of the terms of any release of claims or separation agreement that individual may have signed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Committee or Board may review and modify the Policy from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If any provision of the Policy or the application of any such provision to any Covered Executive is adjudicated to be invalid,
illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provisions of the Policy or the application of such provision to another Covered Executive, and the invalid, illegal or unenforceable
provisions will be deemed amended to the minimum extent necessary to render any such provision or application enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Policy will terminate and no longer be enforceable when the Company ceases to be a listed issuer within the meaning of
Section&nbsp;10D of the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACKNOWLEDGEMENT </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">I acknowledge that I have received and read the Compensation Recovery Policy (the &#147;<B>Policy</B>&#148;)
of Eupraxia Pharmaceuticals Inc. (the &#147;<B>Company</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">I understand and acknowledge that the Policy applies to me, and all of my beneficiaries, heirs, executors,
administrators or other legal representatives and that the Company&#146;s right to recovery in order to comply with applicable law will apply, regardless of the terms of any release of claims or separation agreement I have signed or will sign in the
future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">I agree to be bound by and to comply with the Policy and understand that determinations of the Committee (as
such term is used in the Policy) will be final and binding and will be given the maximum deference permitted by law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">I understand and agree that my current indemnification rights, whether in an individual agreement or the
Company&#146;s organizational documents, exclude the right to be indemnified for amounts required to be recovered under the Policy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">I understand that my failure to comply in all respects with the Policy is a basis for termination of my
employment with the Company and any affiliate of the Company as well as any other appropriate discipline. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">I understand that neither the Policy, nor the application of the Policy to me, gives rise to a resignation for
good reason (or similar concept) by me under any applicable employment agreement or arrangement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">I acknowledge that if I have questions concerning the meaning or application of the Policy, it is my
responsibility to seek guidance from &#8195;&#8195;&#8195;&#8195;&#8195;. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">I acknowledge that neither this Acknowledgement nor the Policy is meant to constitute an employment contract.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Please review, sign and return this form to &#8195;&#8195;&#8195;&#8195;&#8195;. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"><B>Covered Executive</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(<I>print name</I>)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(<I>signature</I>)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(date)</I></P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d800041dex991.htm
<DESCRIPTION>EX-99.1 ANNUAL INFORMATION FORM
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1 Annual Information Form</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g800041g01e01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUPRAXIA PHARMACEUTICALS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNUAL INFORMATION FORM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated April&nbsp;1, 2024 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INTRODUCTION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CAUTION REGARDING FORWARD-LOOKING STATEMENTS AND RISK FACTORS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CORPORATE STRUCTURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intercorporate Relationships</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>GENERAL DEVELOPMENT OF THE BUSINESS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Three-Year History</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DESCRIPTION OF THE BUSINESS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>RISK FACTORS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>35</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risks Relating to Our Limited Operating History, Financial Position and Capital
Requirements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risks Relating to the Company&#146;s Business</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risks Relating to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory
Compliance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risks Relating to our Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DIVIDENDS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>87</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CAPITAL STRUCTURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>87</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>MARKET FOR SECURITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>89</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trading Price and Volume</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prior Sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>DIRECTORS AND OFFICERS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>90</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cease Trade Orders, Bankruptcies, Penalties and Sanctions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conflicts of Interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PROMOTERS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>93</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>AUDIT COMMITTEE INFORMATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>93</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LEGAL PROCEEDINGS AND REGULATORY ACTIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>95</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>95</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TRANSFER AGENT AND REGISTRAR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>96</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>MATERIAL CONTRACTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>96</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INTERESTS OF EXPERTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>96</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ADDITIONAL INFORMATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>96</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SCHEDULE &#147;A&#148; Audit Committee Charter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>97</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTRODUCTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In this annual information form (this &#147;<B>AIF</B>&#148;), unless the context requires otherwise, references to the &#147;Company&#148;,
&#147;Eupraxia&#148;, &#147;we&#148;, &#147;us&#148;, &#147;our&#148; and similar words refer to Eupraxia Pharmaceuticals Inc. or any predecessor thereto, as the context requires. The information in this AIF is presented as of December&nbsp;31,
2023, unless otherwise indicated. All dollar amounts in this AIF are in Canadian dollars, except where otherwise indicated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All
regulatory filings <FONT STYLE="white-space:nowrap">to-date</FONT> and communication from the Company have been made referencing <FONT STYLE="white-space:nowrap">EP-104IAR.</FONT> In the interest of greater clarity for investors, the Company will
use <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> when referring to the product candidate that is intended for intra-articular (&#147;<B>IAR</B>&#148;) injections for indications such as osteoarthritis (&#147;<B>OA</B>&#148;), <FONT
STYLE="white-space:nowrap">EP-104GI</FONT> when referring to the product candidate that is intended for submucosal injections in the GI tract for indications such as eosinophilic esophagitis (&#147;<B>EoE</B>&#148;), and simply refer to the product
candidate as <FONT STYLE="white-space:nowrap">EP-104</FONT> in conjunction with topics that are related to both <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> and <FONT STYLE="white-space:nowrap">EP-104GI.</FONT> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CAUTION REGARDING FORWARD-LOOKING STATEMENTS AND RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain statements and information in this AIF contain forward-looking statements or forward-looking information under applicable securities
legislation that may not be based on historical fact, including, without limitation, statements containing the words &#147;may,&#148; &#147;might,&#148; &#147;will,&#148; &#147;likely&#148;, &#147;could,&#148; &#147;would,&#148; &#147;should,&#148;
&#147;expect,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;objective,&#148; &#147;goal,&#148; &#147;outlook,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;project,&#148;
&#147;forecast,&#148; &#147;estimate,&#148; &#147;potential,&#148; &#147;target,&#148; &#147;seek,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;design,&#148; and &#147;ongoing,&#148; or the negative of these terms or other comparable
terminology, although not all forward-looking statements contain these words and similar expressions. Forward-looking statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are
not statements of fact. Such forward-looking statements are made as of the date of this AIF. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Forward-looking statements are necessarily
based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as factors that we believe are appropriate. Forward-looking statements in this
AIF include, but are not limited to, statements relating to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s business strategies and objectives, including current and future plans, expectations and
intentions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s intent to use capital resources previously identified for EP-104IAR to continue the
development of EP-104GI; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s intention to evaluate funding alternatives for the continued development of EP-104IAR,
including potential partnership opportunities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s ability to obtain sufficient funding for our operations, including funding for research,
development and commercial activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s projected operating expenses and capital expenditures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s ability to achieve profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">projected revenues, future trends, opportunities and growth in the Company&#146;s industry and the drug
development markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s ability to maintain and enhance its competitive advantages and technological advantages;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the entry into commercial partnerships and commercialization of our technology; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s ability to enter into definitive agreements with its contract research organizations
(&#147;<B>CROs</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s ability to enter into <FONT STYLE="white-space:nowrap">co-development</FONT> and/or
collaborative partnerships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s clinical development programs and activities and the estimated timing thereof;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, status and results of clinical trials, including with respect to patient recruitment and data
readout; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of regulatory submissions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the obtaining of potential regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the hiring of additional research and development team members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential for the Company&#146;s technology to impact the drug delivery process; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the development of additional intellectual property, ability to patent or otherwise protect such developed
intellectual property and licenses with third parties for intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of patents and notices of allowance to provide protection over intellectual property in applicable
jurisdictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s ability to protect, expand upon and exploit its existing intellectual property;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the entry into sponsored research agreements and the benefits therefrom; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the competitive advantages of the Company and its technology; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s product candidates and results gathered from studies thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the development of products from the Company&#146;s competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the application of regulations and standards to the Company&#146;s future products and services or research
and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s retention of funds or payment of dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the translation of the Company&#146;s technologies and expansion of its offerings into clinical applications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the benefits to patients from Eupraxia&#146;s platforms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the value of the strategic relationship to Eupraxia&#146;s clients and investors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s engagement with legal and regulatory authorities in various jurisdictions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s anticipated use of proceeds from the Offering (as defined herein) and its existing cash and
cash equivalents and the related estimated cash runway; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sufficiency of the Company&#146;s existing cash and cash equivalents to fund its future operating expenses
and capital expenditure requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s application for approval to list its common shares (the &#147;Common Shares&#148;) on the
Nasdaq Capital Market (the &#147;Nasdaq&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s ability to successfully refinance the Debt Agreement (as defined herein) with Silicon
Valley Bank (&#147;<B>SVB</B>&#148;) and SVB Innovation Credit Fund VIII, L.P.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the demand and commercial viability of the Company&#146;s technology; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the demand and market acceptance for products developed by the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Forward-looking statements and information involve significant risks, assumptions, uncertainties and other factors that may cause actual
future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements or information and, accordingly, should not be read as guarantees of future performance or results. These risks and factors
include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have a limited operating history and have no products approved for commercial sale, which may make it
difficult for you to evaluate our current business and predict our future success and viability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will require substantial additional financing to achieve our goals and a failure to obtain this necessary
capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are substantially dependent on the success of our lead product candidates EP-104GI, which is currently
being studied in an open label Phase 1b/2a clinical study, and EP-104IAR, for which we are evaluating funding alternatives for the continued development, including potential partnership opportunities. If we are unable to complete development of,
obtain approval for and commercialize EP-104GI or EP-104IAR, alone or through a potential partnership, in a timely manner, our business will be harmed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we breach any of the agreements under which we license rights to our product candidates or technology from
third parties, we could lose license rights that are important to our business. Our current license agreement may not provide an adequate remedy for its breach by the licensor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse developments affecting the financial services industry, such as actual events or concerns involving
liquidity, defaults, or <FONT STYLE="white-space:nowrap">non-performance</FONT> by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results
of operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials are expensive, time consuming and difficult to design and implement and may fail to
demonstrate adequate safety and efficacy of our product candidates. Furthermore, the results of previous preclinical studies and clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may
not satisfy the requirements of the U.S. Food and Drug Administration (the &#147;<B>FDA</B>&#148;) or comparable non-U.S. regulatory authorities or provide the basis for regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our lead product candidates may not be successful for their intended use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our current and future product candidates will require regulatory approval, which is costly, and we may not be
able to obtain it and we may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical trials of our product candidates may not demonstrate safety and efficacy to the satisfaction of
the FDA, European Medicine Agency (&#147;<B>EMA</B>&#148;) or other comparable foreign regulatory authorities or otherwise produce positive results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we completely rely on third parties to provide supplies and inputs required for our products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we rely on CROs to provide clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> research
services; if such CROs do not successfully carry out their contractual duties including to comply with applicable laws and regulations or meet expected deadlines, our business could be substantially harmed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in
production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties requires us to share our trade secrets, which increases the possibility that a
competitor or other third party will discover them or that our trade secrets will be misappropriated or disclosed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of preclinical testing and early clinical trials may not be predictive of the success of later
clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities. Terminating the development of any of our product candidates could materially harm our
business and the market price of our Common Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interim, initial, &#147;top-line&#148;, and preliminary data from our clinical trials that we announce or
publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any safety concerns observed in any one of our clinical trials in our targeted indications could limit the
prospects for regulatory approval of our product candidates in those and other indications, which could seriously harm our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our current or future product candidates may cause significant adverse events, toxicities or other undesirable
side effects when used alone or in combination with other products that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative
consequences; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where appropriate and applicable, we may seek approval from the FDA or comparable foreign regulatory
authorities through the use of expedited approval pathways, such as Fast Track designation or orphan drug designation. Even if we receive Fast Track designation or other designation, we can provide no assurance that we will be able to obtain FDA
approval sooner or if at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we are unable to establish sales and marketing capabilities or enter into agreements with third parties to
market and sell our drug candidates, if approved, we may be unable to generate any product revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have a novel technology with uncertain market acceptance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials,
our clinical development activities could be delayed or otherwise adversely affected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in
locations outside of their jurisdiction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that
we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the market opportunity for any product candidate that we or our strategic partners develop is smaller than
we believe, our revenue may be adversely affected and our business may suffer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">even if our product candidates receive regulatory approval, we will be subject to significant post marketing
regulatory requirements and oversight; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA&#146;s and other regulatory authorities&#146; policies may change, and additional government regulations
may be enacted that could prevent, limit or delay regulatory approval of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of
off-label uses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions at the FDA and other government agencies caused by funding shortages or global health concerns
could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from
performing normal business functions on which the operation of our business may rely, which could negatively impact our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we rely on key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to successfully execute our business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are in a highly competitive industry which is continuously evolving with technological changes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our future success will depend on our ability to continually enhance and develop our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may expend our limited resources to pursue a particular product candidate or indication and fail to
capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in methods of product candidate manufacturing or formulation may result in additional costs or delay;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we are unable to differentiate <FONT STYLE="white-space:nowrap">EP-104</FONT> from existing therapies or if
the FDA or other applicable regulatory authorities approve additional, and potentially less costly, therapies that compete with <FONT STYLE="white-space:nowrap">EP-104,</FONT> our ability to successfully commercialize
<FONT STYLE="white-space:nowrap">EP-104GI</FONT> or EP-104IAR would be adversely affected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a variety of risks associated with potential international business relationships could materially adversely
affect our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaboration arrangements we may enter into in the future may not be successful; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions of our existing and any future debt instruments may restrict our ability to pursue our business
strategies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may acquire businesses or products, or form strategic alliances in the future, and we may not realize the
benefits of such acquisitions or alliances; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have traditionally relied on key collaborations and grants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are subject to evolving global laws and regulations relating to privacy, data protection and information
security, which may require us to incur substantial compliance costs, and any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our business and operations could suffer in the event of an actual or perceived information security incident
such as a cybersecurity breach, system failure, or other compromise of our systems or those of a third-party or other contractor or vendor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may fail to manage our growth successfully, which may adversely impact our operating results;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we use hazardous chemicals and biological materials in our business. Any claims relating to improper handling,
storage or disposal of these materials could be time consuming and costly; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if product liability lawsuits are brought against us, then we may incur substantial liabilities and may be
required to limit commercialization of <FONT STYLE="white-space:nowrap">EP-104,</FONT> if approved, for any indication, and any other future products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our employees, independent contractors, principal investigators, consultants, commercial partners and vendors
may engage in misconduct or other improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading, which could significantly harm our business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to securities litigation, which is expensive and could divert management attention;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our directors and executive officers may be affiliated with other biotech companies and may have conflicts of
interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our business may be affected by macroeconomic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our business may be affected by global geopolitical risks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be responsible for corruption and anti-bribery law violations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are subject to foreign exchange risks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are subject to taxation risks and changing rules by different tax authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are subject to a number of risks and hazards and may not be sufficiently insured for all of them;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will devote significant resources to regulatory compliance as a public entity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in accounting standards from IFRS to U.S. GAAP can be difficult to predict and could adversely impact
how we record and report our financial condition and results of operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the past, we have had to restate our previously issued consolidated financial statements and as part of
that process identified a material weakness in our disclosure controls and procedures and internal control over financial reporting as of December 31, 2022. If we are unable to develop and maintain effective disclosure controls and procedures and
internal control over financial reporting, we may not be able to accurately report our financial results in a timely manner, which may adversely affect investor confidence in us and may adversely affect our business, financial condition and results
of operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our success depends on our ability to protect our intellectual property and our proprietary technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent
protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">intellectual property rights do not necessarily address all potential threats to our competitive advantage;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our patent rights may prove to be an inadequate barrier to competition; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercial success depends significantly on our ability to operate without infringing the patents and
other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be successful in obtaining or maintaining necessary rights to our product candidates through
acquisitions and in-licenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be involved in lawsuits to protect or enforce our patents or our future licensors&#146; patents, which
could be expensive, time consuming, and unsuccessful. Further, our issued patents or our current or future licensors&#146; patents could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or
abroad; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the
market price of our Common Shares to decline; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may
require us to cease using the related technology or to attempt to license rights from the prevailing party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or
expiration of a third-party patent, which might adversely affect our ability to develop and market our products and product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in U.S. patent law, or laws in other countries, or their interpretation could diminish the value of
patents in general, thereby impairing our ability to protect our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to claims challenging the inventorship or ownership of our patents, the patents we license,
and other intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent terms may be inadequate to protect our competitive position on our product candidates for an adequate
amount of time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to protect or enforce our intellectual property rights throughout the world;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining our patent protection depends on compliance with various procedural, documentary
submission, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if our trademarks and trade names are not adequately protected, then we may not be able to build name
recognition in our markets of interest and our business may be adversely affected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we are unable to protect the confidentiality of our trade secrets, the value of our technology could be
materially adversely affected, harming our business and competitive position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to claims that we or our employees, independent contractors, or consultants have wrongfully
used or disclosed alleged confidential information or trade secrets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our
employees, independent contractors, or consultants have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to claims challenging the inventorship of our patents and other intellectual property;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our rights to develop and commercialize our technology and product candidates may be subject, in part, to the
terms and conditions of any future licenses granted to us by others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to comply with our obligations in the agreements under which we license intellectual property
rights from third parties or otherwise experience disruptions to our business relationships with our future licensors, we could lose license rights that are important to our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patent protection and patent prosecution for some of our product candidates may be dependent on third
parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coverage and reimbursement may be limited or unavailable in certain market segments for our product
candidates, if approved, which could make it difficult for us to sell any product candidates or therapies profitably; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our relationships with healthcare providers and physicians and third-party payors will be subject to
applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs,
suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our research and development activities could be affected or delayed as a result of possible restrictions on
animal testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our
business and results of operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market price of the Common Shares may be volatile; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors may lose their entire investment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have no history of dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our existing executive officers and directors own a significant percentage of Common Shares and may have a
significant impact over matters submitted to our shareholders for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future sales of Common Shares by our existing shareholders could cause our share price to decline;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will need to raise additional financing in the future which may dilute our share capital;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if securities or industry analysts either do not publish research about us or publish inaccurate or
unfavorable research about us, our business or our market, or if they adversely change their recommendations regarding our Common Shares, the trading price or trading volume of our Common Shares could decline; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any issuance of preferred shares could make it difficult for another company to acquire us or could otherwise
adversely affect holders of our Common Shares, which could depress the price of our Common Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our constating documents permit us to issue an unlimited number of Common Shares without additional
shareholder approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">raising additional capital may cause dilution to our shareholders, restrict our operations or require us to
relinquish rights to our technologies or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have warrants, convertible debt, and shares of a subsidiary exchangeable for Common Shares outstanding,
which in each case, if exercised, converted or exchanged, respectively, could cause dilution to existing shareholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Common Shares may have limited liquidity; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">even if our Common Shares are approved for listing, we cannot assure you that an active market will develop
for Common Shares on the Nasdaq; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">United States investors may not be able to obtain enforcement of civil liabilities against us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as a foreign private issuer, we are subject to different U.S. securities laws and rules than a domestic U.S.
issuer, which may limit the information publicly available to our U.S. shareholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may lose our foreign private issuer status in the future, which could result in significant additional
costs and expenses to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. holders of our Common Shares may suffer adverse tax consequences if we are characterized as a passive
foreign investment company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if a U.S. holder is treated as owning at least 10% of our Common Shares, such U.S. holder may be subject to
adverse U.S. federal income tax consequences. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Such forward-looking statements reflect our current views with respect to
future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Eupraxia as of the date of such statements, are inherently subject to significant
medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance, or achievements to be materially different from any future results, performance, or
achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this AIF, the Company has made various material assumptions, including but not limited to (i)&nbsp;the
Company&#146;s ability to attract and retain skilled staff; (ii)&nbsp;future research and development plans for the Company proceeding substantially as currently envisioned; (iii)&nbsp;industry growth trends, including with respect to projected and
actual industry sales; (iv)&nbsp;the Company&#146;s ability to obtain positive results from the Company&#146;s research and development activities, including clinical trials; (v)&nbsp;sufficient working capital and the Company&#146;s ability to
control costs and raise additional financing going forward; (vi)&nbsp;obtaining regulatory approvals and the potential benefits of our products, if approved; (vii)&nbsp;general business and economic conditions; (viii)&nbsp;the Company&#146;s ability
to achieve profitability; (ix)&nbsp;the Company&#146;s ability to successfully commercialize its current product candidates, enter into commercial partnerships and develop new products; (x)&nbsp;the availability of financing on reasonable terms;
(xi)&nbsp;market competition; (xii)&nbsp;the products and technology offered by the Company&#146;s competitors; (xiii)&nbsp;the Company&#146;s ability to protect patents and proprietary rights; and (xiv)&nbsp;the availability and cost of personnel,
materials and supplies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In evaluating forward-looking statements, current and prospective shareholders should specifically consider
various factors, including the risks outlined herein under the heading &#147;<I>Risk Factors</I>&#148;. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying
those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this AIF and we do not intend, and do not assume any obligation, to update
these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned
not to put undue reliance on forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, statements that &#147;we believe&#148; and similar statements
reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and although we believe such information forms a reasonable basis for such statements, such
information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and
you are cautioned not to unduly rely upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORPORATE STRUCTURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company was incorporated
under the name &#147;Plaza Capital Partners Inc.&#148; pursuant to the <I>Business Corporations Act </I>(Alberta) on May&nbsp;12, 2011. On May&nbsp;11, 2012, the Company was continued to British Columbia under the <I>Business Corporations Act
</I>(British Columbia) (the &#147;<B>BCBCA</B>&#148;), with the name &#147;Eupraxia Pharmaceuticals Inc.&#148;. Our registered and records office is located at Suite 3500, 1133 Melville Street, The Stack, Vancouver, British Columbia, Canada, V6E
4E5. Our head office is located at 201 - 2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intercorporate Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The chart below illustrates the Company&#146;s inter-corporate relationships of its subsidiaries as at the date hereof. All ownership is 100%
unless otherwise stated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g800041g10b01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Amanda Malone, the Chief Scientific Officer of the Company, holds 225
<FONT STYLE="white-space:nowrap">non-voting</FONT> Class&nbsp;B shares (the &#147;<B>Class</B><B></B><B>&nbsp;B Shares</B>&#148;) of Eupraxia Pharma Inc. (&#147;<B>Eupraxia Pharma</B>&#148;), representing 5% of the outstanding securities of Eupraxia
Pharma. The Company holds the remaining 95% of such securities, which consists of 4,275 voting Class&nbsp;A shares. Each Class&nbsp;B Share is exchangeable into Common Shares based on an exchange rate of 2,500 Common Shares for each Class&nbsp;B
Share, subject to adjustments upon the occurrence of certain events, for a total of 562,500 Common Shares. The Class&nbsp;B Shares are exchangeable by Dr.&nbsp;Malone at her election, provided that the Company may force the exchange of the
Class&nbsp;B Shares into Common Shares at any time on or after January&nbsp;31, 2031, or on or after January&nbsp;31, 2026, if the Company is listed on a stock exchange and is a reporting issuer in Canada at such time. The Company may also force the
exchange of the Class&nbsp;B Shares into Common Shares if there is a change of control transaction involving the Company, a change in law which makes the exchange necessary or desirable or if there are a <I>de minimis </I>number of Class&nbsp;B
Shares outstanding. If the Company is listed on a stock exchange at the time of the applicable exchange, the Company may elect to pay Dr.&nbsp;Malone cash in lieu of issuing Common Shares, with such cash amount to be determined based on the then
current market price of the Common Shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL DEVELOPMENT OF THE BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Three-Year History </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2024 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On January 30, 2024 the Company announced positive data from a Magnetic Resonance Imaging (&#147;<B>MRI</B>&#148;) exploratory sub-study in its
Phase 2 SPRINGBOARD trial evaluating the safety and efficacy of EP-104IAR for the treatment of osteoarthritis of the knee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February 1,
2024 the Company announced summary results from the End-of-Phase 2 meeting with the FDA and the initiation of the Phase 3 Development program for EP-104IAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February 5, 2024 the Company announced updated positive clinical trial data in its EP-104GI RESOLVE trial for the treatment of Eosinophilic
Esophagitis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February 5, 2024, the Company filed and obtained a receipt for a final short form base shelf prospectus (the
&#147;<B>Shelf Prospectus</B>&#148;). The Shelf Prospectus replaced the Company&#146;s 2023 Shelf Prospectus filed in June 2023. The Shelf Prospectus will allow the Company and certain of its securityholders to qualify the distribution of up to
US$200 million of Common Shares, preferred shares, debt securities, warrants, subscription receipts, and units, or any combination thereof during the 25-month period that the Shelf Prospectus is effective, in amounts, at prices and on terms based on
market conditions at the time of any offering, and set forth in an accompanying shelf prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March 15, 2024 the
Company announced the closing of an overnight marketed offering (the &#147;<B>Offering</B>&#148;) of Common Shares. The Company issued 8,260,435 Common Shares at a price of CDN$4.10 per Common Share for gross proceeds of CDN$33,867,784, which
included the issuance of 943,435 Common Shares upon partial exercise of the over-allotment option. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2023 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On May&nbsp;18, 2023, the Company announced the appointment of Dr.&nbsp;Mark Kowalski to the role of Chief Medical Officer. This new position
reports directly to the Chief Executive Officer (&#147;CEO&#148;) and is responsible for advancing clinical trials and pipeline development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On June&nbsp;8, 2023, the Company announced the dosing of the first patient in an open label Phase 1b/2a clinical study (RESOLVE) using <FONT
STYLE="white-space:nowrap">EP-104GI</FONT> in EoE. The RESOLVE study will be conducted in up to 24 adult patients with a confirmed diagnosis and active EoE symptoms. Primary outcomes for safety, PK and efficacy will be collected at various points
over a <FONT STYLE="white-space:nowrap">12-week</FONT> total period, with a subsequent follow up at six (6)&nbsp;months. Initial <FONT STYLE="white-space:nowrap">low-dose</FONT> cohorts presented early signals of efficacy, and we anticipate ongoing
safety, efficacy and PK readouts from subsequent dose-escalation cohorts throughout 2024. The RESOLVE protocol is active at sites in Canada, the Netherlands and Australia. Additional sites and jurisdictions will be added as necessary to complete
target recruitment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On June&nbsp;13, 2023, the Company announced that it had received U.S. Fast Track designation for <FONT
STYLE="white-space:nowrap">EP-104IAR</FONT> in the treatment of OA. This process is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On June&nbsp;22, 2023, the Company filed and obtained a receipt for a final short form base shelf prospectus (the &#147;<B>2023 Shelf
Prospectus</B>&#148;). The 2023 Shelf Prospectus replaced the Company&#146;s 2022 Shelf Prospectus filed in January 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On
June&nbsp;26, 2023, the Company announced positive results from its Phase 2b clinical trial of <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> for pain associated with knee OA. <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> met its primary
endpoint with a clinically meaningful and statistically significant (p=0.004) improvement over vehicle-placebo in WOMAC Pain at 12 weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On August&nbsp;18, 2023, the Company announced the closing of a <FONT STYLE="white-space:nowrap">non-brokered</FONT> private placement. The
Company issued 3,183,875 Common Shares at a price of CDN$7.00 per Common Share for gross proceeds of CDN$22,287,125. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On September&nbsp;7,
2023, the Company announced the appointment of KPMG LLP as the auditor of the Company, effective August&nbsp;30, 2023. Concurrently, Baker Tilly WM, LLP resigned as the Company&#146;s auditor. There were no reportable events involving Baker Tilly
WM, LLP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On October&nbsp;11, 2023, the Company announced the initiation of a second cohort in its Phase 1b/2a clinical trial in EoE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On December&nbsp;12, 2023 the Company announced positive clinical data in its <FONT STYLE="white-space:nowrap">EP-104GI</FONT> RESOLVE trial.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On January 10, 2022, the Company filed a final short form base shelf prospectus with the securities regulatory authorities in each of the
provinces and territories of Canada (the &#147;<B>2022 Shelf Prospectus</B>&#148;). The 2022 Shelf Prospectus allowed the Company and certain of its securityholders to qualify the distribution of up to CDN$30 million of common shares, preferred
shares, debt securities, warrants, subscription receipts, and units, or any combination thereof during the 25-month period that the 2022 Shelf Prospectus is effective, in amounts, at prices and on terms based on market conditions at the time of any
offering, and set forth in an accompanying shelf prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;20, 2022, the Company announced that it had closed
an overnight marketed public offering (the &#147;<B>2022 Offering</B>&#148;). Pursuant to the 2022 Offering, Eupraxia issued 7,150,550 units of the Company (the &#147;<B>Units</B>&#148;) at a price of CDN$2.05 per Unit and 181,000 common share
purchase warrants of the Company (the &#147;<B>Warrants</B>&#148;) at a price of CDN$0.30 per Warrant for aggregate gross proceeds of approximately CDN$14.7&nbsp;million. The completion of the 2022 Offering satisfied the requirement to raise
CDN$10&nbsp;million in additional net new capital under the terms of a contingent convertible debt agreement (the &#147;<B>Debt Agreement</B>&#148;) with SVB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On September&nbsp;26, 2022, the Company announced the grant of a patent and a notice of allowance for
<FONT STYLE="white-space:nowrap">EP-104.</FONT> The grant of European Patent EP2976062B1 provides compositional and method of use coverage for <FONT STYLE="white-space:nowrap">EP-104</FONT> and covers major European markets of commercial
significance. The Company believes the new European patent offers strong protection for <FONT STYLE="white-space:nowrap">EP-104</FONT> in key European markets until 2034, pending any adjustments or extensions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On September&nbsp;26, 2022, the Company also announced the grant of a Brazilian notice of allowance, which will provide compositional and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> coverage for <FONT STYLE="white-space:nowrap">EP-104.</FONT> The Company believes this grant will provide extensive protection for
<FONT STYLE="white-space:nowrap">EP-104</FONT> in the Brazilian market until 2034, also pending any adjustments or extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On
October&nbsp;11, 2022, the Company provided the following updates to its Phase 2 OA trial: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The study successfully completed all Data Safety Monitoring Board reviews, with no drug-related serious
adverse events noted and was observed to be well tolerated. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The inclusion criteria were expanded to include diagnosed diabetic patients. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MRIs were added as an elective assessment for remaining patients to be enrolled in the study.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On October&nbsp;12, 2022, the Company announced the initiation of the Phase 1b/2a trial of <FONT
STYLE="white-space:nowrap">EP-104GI</FONT> for EoE. Eupraxia has received regulatory and ethics committee clearance to begin the trial in Canada, Australia and the Netherlands, and data from the open label trial is anticipated to start reading out
in the first half of 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On November&nbsp;2, 2022, the Company announced the appointment of Mr.&nbsp;Paul Brennan to the role of Chief
Business Officer. This new position reports directly to the CEO and is responsible for advancing partnership opportunities for the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On December&nbsp;7, 2022, the Company announced that it had completed enrollment, randomization and dosing of the last patient, in its Phase 2
trial that is evaluating the efficacy and safety of <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> for the treatment of OA of the knee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2021
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On January&nbsp;31, 2021, the Company entered into a contribution agreement with Amanda Malone, the Chief Scientific Officer of the
Company, and certain of the Company&#146;s subsidiaries (the &#147;<B>Contribution Agreement</B>&#148;). Pursuant to the Contribution Agreement, the Company acquired AMDM Holdings Inc., a corporation wholly owned by Ms.&nbsp;Malone, which held 5% of
the equity interest in the Company&#146;s subsidiary, Eupraxia Pharmaceuticals USA, LLC (&#147;<B>Eupraxia USA</B>&#148;). In exchange, the Company issued to Ms.&nbsp;Malone 225 <FONT STYLE="white-space:nowrap">non-voting</FONT> Class&nbsp;B Shares
in Eupraxia Pharma, representing 5% of the outstanding securities of Eupraxia Pharma. The Company holds the remaining 95% of such securities, which consists of 4,275 voting Class&nbsp;A shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;3, 2021, the Company obtained a receipt for its final prospectus filed with the securities regulatory authorities in each of the
provinces of Canada, other than Qu&eacute;bec, in connection with the initial public offering (the &#147;<B>IPO</B>&#148;) of 5,125,000 Units at a price of CDN$8.00 per Unit (the &#147;<B>IPO</B>&#148;) for gross proceeds of CDN$41,000,000. Each
Unit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
consisted of one common share in the Company and <FONT STYLE="white-space:nowrap">one-half</FONT> of one Warrant. Each Warrant is exercisable into one common share of the Company (each, a
&#147;<B>Warrant Share</B>&#148;) at an exercise price of CDN$11.20 per Warrant Share at any time prior to 5:00 p.m. (Toronto time) on the date that is five years following the closing of the IPO, subject to adjustment in certain events. The
Warrants include an acceleration provision, exercisable at the Company&#146;s option, if the Company&#146;s daily volume weighted average share price is greater than CDN$22.40 for five consecutive trading days. The closing of the IPO occurred on
March&nbsp;9, 2021. The Company was listed on the Toronto Stock Exchange (&#147;<B>TSX</B>&#148;) with the listing of both the Common Shares and the Warrants under the symbols &#147;EPRX&#148; and &#147;EPRX.WT&#148;, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;9, 2021, upon the closing of the IPO, (i)&nbsp;the CDN$6,690,000 aggregate principal amount of convertible notes issued from
June&nbsp;19, 2018 to May&nbsp;23, 2019 (collectively, the &#147;<B>Convertible Notes (10%)</B>&#148;), plus accrued and unpaid interest of CDN$1,457,086; (ii) the CDN$831,000 aggregate principal amount of convertible notes issued from June&nbsp;1,
2020 to January, 2021 (collectively, the &#147;<B>Convertible Notes (30%)</B>&#148;, and together with the Convertible Notes (10%), the &#147;<B>Convertible Notes</B>&#148;), plus accrued and unpaid interest CDN$50,918; and (iii) 857,500 special
warrants (collectively, the &#147;<B>Special Warrants</B>&#148;), were automatically converted into 1,103,886 Common Shares and 157,501 Common Shares and exercised into 298,798 Common Shares, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;14, 2021, the Company entered into an agreement with Nordic Bioscience Clinical Development A/S (&#147;<B>NBCD</B>&#148;), a CRO
dedicated to clinical drug development and research in OA, to conduct Eupraxia&#146;s <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> Phase 2 clinical trial (protocol
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">EP-104IAR-201).</FONT></FONT> The randomized, placebo-controlled trial evaluates the safety, efficacy and pharmacokinetics (&#147;<B>PK</B>&#148;) of a single 25 mg injection into the
knees of 300 subjects with knee OA. NBCD agreed to make a&nbsp;$500,000 USD&nbsp;investment in the Company on the same terms as the IPO (the &#147;<B>Equity Investment</B>&#148;). NBCD&#146;s subscription for the Equity Investment was satisfied by
setting off&nbsp;$500,000 USD&nbsp;of service fees otherwise payable by Eupraxia to NBCD and allowed Eupraxia to expand enrollment in its <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> Phase 2 clinical trial from the original 240 to 300 patients.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;29, 2021, the Company issued to NBCD 78,456 Units at a price of&nbsp;CDN$8.00&nbsp;per Unit, with each Unit consisting of
one Common Share and <FONT STYLE="white-space:nowrap">one-half</FONT> of one common share purchase warrant of the Company (each whole common share purchase warrant, a &#147;<B>Nordic Warrant</B>&#148;). Each Nordic Warrant is exercisable into one
Common Share at an exercise price of&nbsp;CDN$11.20&nbsp;per share at any time prior to&nbsp;5:00 p.m.&nbsp;on the date that is five years from the date of issuance, subject to adjustment in certain events. The Nordic Warrants include the same
acceleration provision as the Warrants under the IPO, which is exercisable at the Company&#146;s option if the Company&#146;s daily volume weighted average share price is greater than&nbsp;CDN$22.40&nbsp;for five consecutive trading days. The Nordic
Warrants are transferable but are not listed on the TSX. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On May&nbsp;3, 2021, the Company announced the appointment of Bruce Cousins as
the Company&#146;s new President and Chief Financial Officer, replacing Alex Rothwell. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On May&nbsp;18, 2021, the Company offered existing
lenders the opportunity to convert their outstanding principal and accrued interest into Common Shares at a conversion price equal to CDN$4.6106 per Common Share. Principal and interest totaling CDN$5,987,642 was subsequently converted into
1,298,664 Common Shares on June&nbsp;8, 2021. Accrued interest totaling CDN$180,197 was paid in cash to lenders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On June&nbsp;21, 2021,
the Company entered into the Debt Agreement with SVB and concurrently drew down in full the CDN$10&nbsp;million principal amount under the Debt Agreement. The Debt Agreement has a term of 36 months or 48 months on SVB&#146;s election. The Debt
Agreement accrues interest at the greater of 2.45% and the Canadian prime rate, requiring monthly interest payments. An additional payment in kind will accrue at a rate of 7% per annum, which will be settled on maturity or conversion. Subject to the
terms and conditions of the Debt Agreement, SVB may elect to convert the principal amount of the convertible debt and the accrued and unpaid interest thereon into Common Shares at a conversion price equal to CDN$5.68 per Common Share. The Company
has agreed to grant SVB a security interest in all of its assets, excluding its patents and other intellectual property, as security for its obligations under the Debt Agreement. The Company is required, on or prior to June&nbsp;30, 2022, to raise
additional net new capital, as defined in the Debt Agreement, in the aggregate amount of CDN$10&nbsp;million. This net new capital can originate from, but is not restricted to, a variety of sources as outlined in the Debt Agreement and can include
up to CDN$5&nbsp;million in reduced project expenses. This obligation has been fully satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On July&nbsp;19, 2021, the Company announced that it had received authorization from the
Danish Medicines Agency to initiate the <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> Phase 2 clinical trial. This was followed by central ethics approval on September&nbsp;1, 2021. On September&nbsp;14, 2021, the Company announced that it had
initiated patient screening. Successful candidates were subsequently enrolled and dosed in the last quarter, with patient recruitment completed in 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On September&nbsp;16, 2021, the Company announced the publication of <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> Phase 1 results in
<I>Osteoarthritis and Cartilage Open</I>. The article, entitled, &#147;Safety and Pharmacokinetics of <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> (sustained-release fluticasone propionate) in Knee Osteoarthritis: A Randomized, Double-Blind,
Placebo-Controlled Phase 1 Trial,&#148; was made available to all readers through the medical journal&#146;s website.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> On this date, the Company also announced receipt of a Notice of Allowance
from the Israel Patent Office with respect to its patent application &#147;Injectable Sustained Release Composition and Method of using the Same for Treating Inflammation in Joints and Pain Associated Therewith.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On November&nbsp;4, 2021, the Company announced receipt of advisory services and funding of up to CDN$700,000 from the National Research
Council of Canada Industrial Research Assistance Program <FONT STYLE="white-space:nowrap">(NRC-IRAP)</FONT> to support a research and development project to further develop the Company&#146;s polymer-based proprietary drug delivery technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On December&nbsp;2, 2021, the Company announced its intent to increase the number of clinical research sites and modify patient enrollment
criteria in the <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> Phase 2 trial to facilitate patient recruitment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On December&nbsp;3,
2021, the Company amended its stock option plan (the &#147;<B>Amended Plan</B>&#148;) to: (i)&nbsp;amend the maximum number of Common Shares that may be reserved and available for issuance upon exercise of stock options (&#147;<B>Options</B>&#148;),
from 15% of the aggregate of the Company&#146;s issued and outstanding Common Shares to 18.5% of the total number of issued and outstanding Common Shares (on a <FONT STYLE="white-space:nowrap">non-diluted</FONT> basis) at the relevant time; and
(ii)&nbsp;remove the overall Common Share limitation for all security based compensation arrangements contained in the Company&#146;s existing amended and restated stock option plan. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Amanda Malone, James Price, Nicola Price, Vik Peck, Alan Getgood, Robert Petrella, James Helliwell. Safety
and pharmacokinetics of <FONT STYLE="white-space:nowrap">EP-104</FONT> (sustained-release fluticasone propionate) in knee osteoarthritis: A randomized, double-blind, placebo-controlled Phase 1 trial, <I>Osteoarthritis and Cartilage Open</I>, Volume
3, Issue 4,2021,100213, ISSN 2665-9131, <U>https://doi.org/10.1016/j.ocarto.2021.100213</U>. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DESCRIPTION OF THE BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview of the Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a
clinical-stage biotechnology company seeking to leverage our proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical need. Each of our product candidates are designed to improve patient benefit by
providing more prolonged activity than currently available treatments, combined with an improved pharmacokinetics (&#147;PK&#148;) and related safety profile and precisely targeted local delivery. We believe a product with this profile could offer
the dual potential of providing long-lasting treatment while minimizing tolerability complications in target and <FONT STYLE="white-space:nowrap">non-target</FONT> tissues. Our strategy is to develop a portfolio of product candidates based on this
delivery technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently have two distinct clinical development programs, one targeting EoE and the second targeting chronic OA
pain in the knee. Currently, both programs are broadly based upon the same drug candidate <FONT STYLE="white-space:nowrap">(EP-104).</FONT> The injectable drug is dispensed together with a &#147;vehicle&#148; diluent specifically designed for the
target delivery modality and <FONT STYLE="white-space:nowrap">co-administered</FONT> with the active pharmaceutical ingredient (&#147;API&#148;). For our ongoing clinical studies we are using the same underlying API and extended-release formulation.
In the future, we anticipate that therapeutic targets will be differentiated by dosing levels, vehicle and delivery methods and will be distinct product candidates. The product candidate that is being developed specifically for submucosal injections
in the GI tract with an initial indication of EoE is referred to as <FONT STYLE="white-space:nowrap">EP-104GI,</FONT> and the product candidate that is being developed for intra-articular (&#147;IA&#148;) injections with an initial indication of
knee OA is referred to as <FONT STYLE="white-space:nowrap">EP-104IAR.</FONT> <FONT STYLE="white-space:nowrap">EP-104</FONT> is intended to refer to the extended-release Diffusphere technology, which is used in the formulation of both <FONT
STYLE="white-space:nowrap">EP-104GI</FONT> and <FONT STYLE="white-space:nowrap">EP-104IAR.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have successfully completed a Phase
2b trial with <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> in knee OA, and in January 2024 held a meeting with the FDA to determine the preclinical and clinical requirements for an NDA submission and approval in the United States. We believe
that the future success of the product will be dependent on late phase development and commercialization expertise, and will require significant resources. We are currently evaluating funding alternatives for the continued development of <FONT
STYLE="white-space:nowrap">EP-104IAR,</FONT> including potential partnership opportunities and intend to modulate investment levels pending the outcomes. We intend to undertake certain preclinical and manufacturing activities as well as Phase 3
planning and preparation related to <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> to ensure continuity of the project, but we intend to wait until we have funding needs further sorted before committing to additional significant spend for this
program. We intend to use our capital resources previously identified for EP-104IAR development to continue development of EP- 104GI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
are currently conducting a Phase 1b/2a clinical trial with <FONT STYLE="white-space:nowrap">EP-104GI.</FONT> We intend to continue development of <FONT STYLE="white-space:nowrap">EP-104GI</FONT> through the ongoing clinical trial and any subsequent
trials required by the FDA to obtain commercial approval. We intend to evaluate the possibility of identifying a corporate partner to help with the development of <FONT STYLE="white-space:nowrap">EP-104GI.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Product Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The primary active
ingredient of the <FONT STYLE="white-space:nowrap">EP-104</FONT> product candidates consists of a solid core of fluticasone propionate (&#147;FP&#148;) coated with an outer layer of polyvinyl alcohol (&#147;PVA&#148;). FP is a synthetic
trifluorinated corticosteroid with potent anti-inflammatory activity and a well-established systemic safety record in the form of widely used inhaled, intranasal, and topical agents. It has been shown to be locally active, and FP that is
systemically absorbed is rapidly metabolized. Relative to other corticosteroids (including triamcinolone acetonide or &#147;TCA&#148;), FP has a high affinity for the glucocorticoid receptor, low solubility, a low rate of dissociation, and a
comparatively long half-life. It is currently approved by the FDA, Health Canada, European Medicines Agency and many other regulatory agencies around the world. PVA is a biocompatible polymer with numerous biomedical applications and a <FONT
STYLE="white-space:nowrap">30-year</FONT> safety record in various human tissues. We believe these characteristics make <FONT STYLE="white-space:nowrap">EP-104</FONT> a promising candidate for prolonged anti-inflammatory use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">EP-104</FONT> technology is designed to work through the diffusion of the drug particles through a
microns-thin polymer membrane. When the particles are injected at the disease site, extracellular fluid diffuses across the polymer membrane and into the particles themselves, dissolving some of the solid drug core and creating a saturated drug
solution inside </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the microsphere with relatively low drug concentrations in the outside microenvironment. Steady-state diffusion of FP across the polymer membrane and into the extracellular space then delivers
the drug candidate to the intended area at a prolonged and steady release rate with close to constant drug levels. This rate can be controlled by changing the size of the drug core and the properties of the polymer membrane, creating a target drug
release profile designed to maximize disease treatment and reduce systemic and local side effects often accompanying drugs having conventional release profiles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following figure illustrates the differences between immediate release drugs, standard extended-release drugs and the release profile
intended by <FONT STYLE="white-space:nowrap">EP-104.</FONT> Immediate-release drugs release high initial drug levels into the blood (which can result in side effects), followed by rapid drug clearance. Standard extended-release profiles tend to
blunt the early peak effects but still decline at a rapid rate. <FONT STYLE="white-space:nowrap">EP-104</FONT> is designed to prevent early peak concentrations associated with side effects and extend the duration of FP residence time in the intended
area of administration to achieve prolonged activity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Drug Plasma Levels and Release Profiles </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g800041g18c01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Another key feature differentiating <FONT STYLE="white-space:nowrap">EP-104</FONT> from other
extended-release IA corticosteroid formulations is that more than 90% by weight of <FONT STYLE="white-space:nowrap">EP-104</FONT> is the active FP component in the investigational drug product, compared to less than 20% in other polymer based
extended release products using degradation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">FP, although approved by the FDA, Health Canada, EMA and other regulatory agencies, is not
currently approved for use in any formulation for the treatment of symptoms in either EoE or OA. To our knowledge, <FONT STYLE="white-space:nowrap">EP-104GI</FONT> and <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> are the only extended-release
formulations of FP in development for these conditions. We believe that the <FONT STYLE="white-space:nowrap">EP-104</FONT> drug delivery technology platform has the potential to have a beneficial application for EoE, given the already-established
efficacy of oral immediate release of FP in this indication. The drug delivery technology platform also has the potential to be an effective treatment for OA based on the proven efficacy of other corticosteroids for this condition. The potential for
an improved treatment of EoE and OA with our proprietary formulations of <FONT STYLE="white-space:nowrap">EP-104</FONT> is further supported by a continually expanding library of data supporting the value of extended-release steroids. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">EP-104GI</FONT> for Eosinophilic Esophagitis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Overview </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">EP-104</FONT> is being developed for the treatment of EoE,
a rare immune-mediated disease recognized by the U.S. National Organization for Rare Disorders (&#147;NORD&#148;). Adaptations to the original formulation of <FONT STYLE="white-space:nowrap">EP-104</FONT> will result in the creation of <FONT
STYLE="white-space:nowrap">EP-104GI</FONT> for this specific indication, including modifications to the carrier vehicle and dose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">EoE is
characterized by inflammation and the accumulation of large numbers of eosinophils (a type of white blood cells) within the epithelial lining of the esophagus. In adults, EoE leads to dysphagia and food impaction. In children, it often presents with
irritability, nausea and vomiting. Patients with EoE frequently develop esophageal strictures, a narrowing or tightening of the esophagus, accompanied by proliferations of fibrotic tissue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Market Size </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">According to NORD criteria, EoE is
categorized as a rare disease. US population-based studies have shown that the incidence is increasing by approximately 10 cases per 100,000 persons annually. As a result, the most accurate estimates of the incidence and prevalence of EoE are the
most recently published studies. In 2021 Kamat et al., performed a retrospective analysis via the MarketScan claims database covering <FONT STYLE="white-space:nowrap">19-21&nbsp;million</FONT> US patients to identify patients diagnosed with EoE
according to <FONT STYLE="white-space:nowrap">ICD-9/10</FONT> codes from 2015 to 2018. The authors reported prevalence of 117 patients per 100,000 in 2018. Using a ~2.9% annual prevalence growth rate since the data was collected, we estimate that
EoE has a U.S. prevalence of 451,000 patients in 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patients with EoE often experience debilitating impacts from both symptoms and
interventions, leading to mental health issues and compounding the overall disease burden on the health care system and the individual. Approximately US$1&nbsp;billion is spent annually in hospitalizations, endoscopic procedures and medications to
treat EoE, and a significant unmet medical need exists for cost-effective and less burdensome long-term treatment options. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Current Treatments </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Current EoE treatment guidelines aim to lower eosinophil counts and improve symptoms. Recommended treatment progresses from strict dietary
protocols to pharmacological intervention (proton pump inhibitors, swallowed corticosteroids) to mechanical intervention (endoscopic dilation for established strictures). The American Gastroenterological Association and the Joint Task Force on
Allergy-Immunology Practice recommend the use of topical corticosteroids (budesonide, swallowed fluticasone) over systemic steroids for long-term EoE management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are two approved treatments for EoE in the U.S. &#150; Dupixent<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>(dupilumab), a
monoclonal antibody (mAb) marketed by Sanofi and Regeneron, and Takeda&#146;s recently-approved Eohilia, a twice-daily oral suspension of budesonide approved for up to 12 weeks of use. Dupixent was originally approved in March 2017 for atopic
dermatitis and was approved for EoE in May 2022. The U.S. list price is US$3,803 per carton. Each carton contains two injections; prescribing information for EoE indicates either a once weekly or twice-monthly injection by weight, thus the expected
annual list cost to a patient is up to US$91,000. In 2023, Dupixent was also approved for EoE in Canada and Europe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Jorveza<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>is an effervescent orodispersible budesonide tablet available in the European Union and Canada. The Canadian list price is CDN$3,413 per annum to maintain remission; however, the Canadian Agency for
Drugs and Technologies in Health (CADTH) reports that &#147;the cost-effectiveness of budesonide is highly uncertain due to the sponsor&#146;s pharmacoeconomic model&#148; and that insufficient evidence exists for maintenance of remission vs relapse
past the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">6-12-week</FONT></FONT> remission induction window. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future Competitive
Landscape </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Several pharmaceuticals in development are lifecycle extensions of currently marketed products: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">AstraZeneca&#146;s Tezspire (tezepilumab) has an annual cost of US$52,789 based on their list price and
recommended frequency of administration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">AstraZeneca&#146;s Fasenra (benralizumab) has an annual cost of US$44,091 based on their list price and
recommended frequency of administration. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pfizer&#146;s Velsipity (etrasimod), approved for ulcerative colitis, recently demonstrated proof of concept
in a Phase 2 trial. Currently Velsipity is marketed as a once daily oral formulation with a wholesale cost of US$6,164 for a <FONT STYLE="white-space:nowrap">30-day</FONT> bottle (amounting to approximately US$75,000 per year).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other products in late-stage development include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ellodi&#146;s <FONT STYLE="white-space:nowrap">APT-1011</FONT> (FP), an orodispersable tablet in Phase 3
development for adult subjects. Clinical and histological response noted at week 12 and sustained until <FONT STYLE="white-space:nowrap">follow-up</FONT> at week 52. Studies found increased response with increased dosage but recommends taking once
daily to optimize risk-benefit profile.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EsoCap&#146;s <FONT STYLE="white-space:nowrap">ESO-101,</FONT> a capsule with a rolled up mucoadhesive film
containing the cortiscosteroid mometasone furoate. On December&nbsp;5, 2023, EsoCap announced positive results from a Phase 2 study. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bristol Myer&#146;s Squibb&#146;s cendakimab, a mAb in Phase 3 development </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturing </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">EP-104</FONT> consists of a vial of <FONT STYLE="white-space:nowrap">EP-104</FONT> powder and a separate vial
of liquid (referred to as the &#147;Vehicle&#148;). Before injection, the Vehicle is mixed with the dry powder to suspend the <FONT STYLE="white-space:nowrap">EP-104</FONT> particles; this enables the <FONT STYLE="white-space:nowrap">EP-104</FONT>
powder to be injected into the patient. In an ongoing stability study, the powder has proven stable for 48 months when stored at room temperature. Batches of <FONT STYLE="white-space:nowrap">EP-104</FONT> are currently manufactured at the projected
initial batch scale required for launch. We expect to use the same coated and cured FP particles from our <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> program for <FONT STYLE="white-space:nowrap">EP-104GI.</FONT> However, we anticipate
refinements to both the dose and vehicle to optimize patient outcomes in EoE. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical Studies </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We commenced dosing patients in the second quarter of 2023 for an open label Phase 1b/2a clinical study (RESOLVE) using <FONT
STYLE="white-space:nowrap">EP-104GI</FONT> in EoE. The RESOLVE study will be conducted in up to 24 adult patients with a confirmed diagnosis and active EoE symptoms. Primary outcomes for safety, PK and efficacy will be collected at various points
over a <FONT STYLE="white-space:nowrap">12-week</FONT> total period, with a subsequent follow up at six (6)&nbsp;months. Initial <FONT STYLE="white-space:nowrap">low-dose</FONT> cohorts presented early signals of efficacy, and we anticipate ongoing
safety, efficacy and PK readouts from subsequent dose-escalation cohorts throughout 2024. The RESOLVE protocol is active at sites in Canada, the Netherlands and Australia. Additional sites and jurisdictions will be added as necessary to complete
target recruitment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subsequent steps in the research program will be determined following analysis of results as well as interaction with
key opinion leaders and regulatory authorities. To seek marketing approval for <FONT STYLE="white-space:nowrap">EP-104GI,</FONT> we expect to carry out at least one Phase 3 study assessing both efficacy (reduced eosinophils and improved symptoms)
and safety of <FONT STYLE="white-space:nowrap">EP-104GI</FONT> in this indication. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">EP-104IAR</FONT> for
Osteoarthritis </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B><FONT STYLE="white-space:nowrap">EP-104IAR</FONT> Target Product Profile for Knee OA</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Durable pain relief</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Better tolerability than existing steroids</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Long-term repeat dose potential</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Cartilage sparing versus existing steroids</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Bilateral dosing potential</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Supported by major treatment guidelines</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Safe for use by diabetics</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Room temperature storage</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">OA is a chronic progressive disease characterized by deterioration of joint cartilage and inflammation, which
results in pain and stiffness, usually in the morning or after a period of inactivity; and loss of joint function which limits daily activities. In normal joints, cartilage acts as a cushion between bones and provides a smooth gliding surface for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
movement. In OA, the inflammatory processes integral to disease progression damages the cartilage, and over time cartilage wears away, causing bone to rub directly against bone resulting in joint
damage, severe pain and disability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Globally, OA is a leading cause of disability in older adults. Estimates of prevalence and incidence
vary according to the definition of OA used (i.e., radiographic <FONT STYLE="white-space:nowrap">(X-Ray)</FONT> versus symptomatic) and the joints assessed. The global prevalence of knee OA is estimated at approximately 23% in adults over the age of
40. According to a report by the Centers for Disease Control and Prevention, OA is estimated to affect more than 32.5&nbsp;million adults in the United States alone. A 2018 report estimated there were 14&nbsp;million people with symptomatic knee OA.
OA is also often associated with depression and loss of sleep which can greatly affect quality of life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Current evidence-based OA
treatment guidelines aim to manage signs and symptoms, with the goal of slowing progression if possible. Recommended pharmacological interventions include topical and oral <FONT STYLE="white-space:nowrap">non-steroidal</FONT> anti-inflammatory
drugs, and IA corticosteroids. IA corticosteroid injections have been used for decades to manage pain and stiffness associated with inflammation in knee OA and have been approved by regulatory authorities as safe and effective. However, IA
corticosteroid injections often result in suboptimal patient outcomes because of their short duration of activity and systemic side effects such as flushing, glucose alterations and cortisol suppression due to the high peak exposures required to
maintain efficacious concentrations for prolonged durations. Evidence is also emerging regarding the risk of adverse joint findings and/or OA progression following frequent/repeated immediate release IA corticosteroid injections. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Market Opportunity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Arthritis has
profound societal and economic impacts. According to a 2013 U.S. survey, the financial burden from arthritis totaled US$304&nbsp;billion (US$140&nbsp;billion in medical costs and US$164&nbsp;billion in lost wages). OA is the most common joint
disorder and the leading cause of chronic disability in older adults, affecting approximately 30&nbsp;million adults in the United States. OA is the second most expensive condition treated in US hospitals, accounting for US$16.5&nbsp;billion or 4.3%
of aggregate hospital costs in 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The market for OA therapeutics is large and growing. The estimated 2020 global market size for knee
OA therapeutics was just over US$5.6&nbsp;billion and is expected to grow to US$8.7&nbsp;billion by 2025 (representing a 10% compound annual growth rate for this period). This represents approximately 80% of the US$7.3&nbsp;billion global OA market.
Geographically, about 34.2% of the global spend is attributed to North America, 37.6% to Europe, 21.3% to Asia Pacific and 6.9% to the rest of the world. In the United States, the estimated market for knee OA therapeutics was US$1.8&nbsp;billion in
2020, and this number is expected to grow to US$2.9&nbsp;billion by 2025. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current Treatments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Current OA treatments aim to manage signs and symptoms, in combination with therapy to slow disease progression.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>There are several international evidence-based guidelines&nbsp;for OA management, each promoting similar treatment escalation paradigms. These approaches are typically stepwise and dictated by patient
symptoms, disease severity and comorbidities. They range from general lifestyle measures (e.g., exercise, weight loss, etc.) to physiotherapy, orthopedic aids and orthoses for patients with milder symptoms, followed by pharmacotherapy, and finally
surgery and rehabilitation in the most severe patients. The American Association of Orthopedic Surgeons reported 1,168,826 total knee replacement surgeries from 2012 and 2020 and this number is expected to reach 1,921,000 by 2030. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The most recently published OA treatment guidance is the 2019 American College of Rheumatology (&#147;ACR&#148;)/Arthritis Foundation
guidelines for OA management.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>The only pharmacotherapy treatments strongly recommended for knee OA in these guidelines are topical and oral NSAIDs and IA corticosteroids (see below).
Tramadol-based opioids and duloxetine are conditionally recommended in specific circumstances and usually in late-stage disease just before total joint replacement is considered. A broad range of other
<FONT STYLE="white-space:nowrap">non-pharmaceutical</FONT> therapies are also available, such as hyaluronic acid/hyaluronate, platelet rich plasma or mesenchymal stem cells. Many of the major treatment guidelines do not recommend these <FONT
STYLE="white-space:nowrap">non-pharmaceutical</FONT> therapies primarily due to a lack of proven efficacy from well-controlled clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview of ACR / Arthritis Foundation Recommended Pharmacotherapies for Knee OA </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-LEFT:1px solid #7f7f7f; BORDER-TOP:1px solid #7f7f7f; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACR/Arthritis Foundation</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Recommendation</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #7f7f7f; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #7f7f7f; BORDER-RIGHT:1px solid #7f7f7f; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>Pharmacotherapy</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Strongly Recommended</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Oral / topical NSAIDs</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IA Steroids</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Conditionally</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Recommended</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Acetaminophen, Tramadol, Duloxetine, Topical Capsaicin</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Conditionally Against</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IA Hyaluronic Acid, IA Botulinum Toxin, Prolotherapy, Colchicine,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">Non-Tramadol</FONT> Opioids, Fish Oil, Vitamin&nbsp;D</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Strongly Against</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Bisphosphonates, Glucosamine, Hydroxychloroquine, Methotrexate,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TNF Inhibitors, <FONT STYLE="white-space:nowrap">IL-1</FONT> Receptor Antagonists, Platelet Rich Plasma,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stem Cell Injection, Chondroitin</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Source: 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of
Osteoarthritis of the Hand, Hip, and Knee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">OA pharmacotherapy typically starts with oral NSAIDs <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">(over-the-counter</FONT></FONT> or prescription). Oral NSAIDs provide short-term, moderate pain relief but come with systemic toxicity concerns such as gastrointestinal, cardiovascular, and renal side effects and potential
drug interactions. For example, the oral prescription NSAID celecoxib is approved to treat OA pain but has a boxed warning that highlights the increased risk of cardiovascular events associated with the product. Topical NSAIDs provide a moderate
degree of efficacy relative to oral NSAIDs, with side effects being less pronounced due to their lower systemic exposures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IA
corticosteroids are strongly recommended in the ACR guidelines. IA corticosteroid injections for managing pain and stiffness associated with inflammation in OA patients have been used for decades. They have been approved by regulatory authorities as
safe and effective with a rapid onset of action. However, injections of currently approved instant-release corticosteroids often result in suboptimal patient outcomes due to their short duration of efficacy and systemic side effects as a result of
the steroid reaching the circulation from the knee. These include flushing, glucose alterations and cortisol suppression due to the high peak exposures required to maintain efficacious concentrations for prolonged durations. The local safety of
frequent, repeated doses of currently approved instant release IA steroids has also not been conclusively established. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The label of the
only approved extended-release corticosteroid for knee OA in the U.S. market states that &#147;the efficacy and safety of multiple doses has not been demonstrated.&#148; Comments from the <FONT STYLE="white-space:nowrap">non-clinical</FONT> reviewer
in the FDA&#146;s Summary Basis of Approval state that the drug &#147;caused a dose-dependent loss of cartilage with peak effects at 3 months following administration.&#148; It also stated that animals treated with the drug &#147;showed clear
increases in microscopic changes to the local tissue and more severe cartilage loss relative to control and immediate-release TCA, and these local responses were not fully reversed at the end of the <FONT STYLE="white-space:nowrap">9-month</FONT>
recovery period.&#148;<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe the current range of available pharmacotherapies
suggests a need for a product with rapid onset, prolonged duration, a chronic dosing paradigm, minimal side effects and no impact on cartilage. Further, an improved safety profile would potentially enable dosing of multiple joints, which would
greatly benefit the approximately 70% of knee OA patients who are thought to develop OA in both knees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Market Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IA treatments comprise approximately half of the global market share for OA therapeutics, with the other half shared by NSAIDs (31.2%) and
analgesics (18.9%) as of 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Oral and topical NSAIDs are typically used as the first-line pharmacotherapy in OA
treatment. The majority of NSAIDs <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">are&nbsp;over-the-counter&nbsp;products;</FONT></FONT> however, prescription products are also used. We estimate that oral analgesics accounted for
approximately US$397&nbsp;million in 2019 in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of 2020, market share for IA treatments is dominated by
corticosteroids and HA injections, with HA injections leading in market volume. Within North America, corticosteroids accounted for approximately US$272&nbsp;million in 2020 and are expected to grow to US$452&nbsp;million by 2025 (representing a
compound annual growth rate of 10.7% for this timeframe). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Zilretta (extended-release TCA) is currently the only marketed extended-release
corticosteroid for OA. Zilretta demands a premium list price (US$691 per dose) as compared to generic instant-release TCA, which is generally available in the United States for under US$20 per 40 mg dose. Assuming four injections per year, we
estimate an annual Zilretta <FONT STYLE="white-space:nowrap">per-patient</FONT> cost of US$2,764. The continued growth of Zilretta<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>highlights the considerable need for effective OA pain relief.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While corticosteroids lead the market in volume, branded HA injections lead in value. HA is produced naturally by the body as a lubricant
and has a generally favorable safety profile. Considered medical devices, HA treatments are subject to different regulatory requirements than pharmaceutical drugs. Costing on average US$1,128 per treatment course, they represent the highest annual
treatment cost for OA other than knee replacement surgery. At this cost, we estimate that the annual <FONT STYLE="white-space:nowrap">per-patient</FONT> cost for HA is approximately US$2,256 (based on 2 injections/year). Despite IA HA being
conditionally recommended <I>against</I> in the ACR guidelines, North American sales for HA preparations were estimated at US$991&nbsp;million in 2020, and this segment is projected to grow to US$1.6&nbsp;billion by 2025 (representing a compound
annual growth rate of 10.3%). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Market Feedback </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that there is an unmet need for a product that has the efficacy of a steroid, provides sustained relief, and approaches the safety
of HA treatment. Such a treatment could promote IA corticosteroid treatment in earlier stages of the disease, allow long-term multi-dose therapy and provide an alternative option to systemic treatments for patients with bilateral knee OA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To assess market reception to <FONT STYLE="white-space:nowrap">EP-104IAR&#146;s</FONT> target product profile, we sponsored a market research
study involving 80 U.S. and European rheumatologists, orthopedists, orthopedic surgeons and sports medicine specialists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Results
supported a new therapeutic with <FONT STYLE="white-space:nowrap">EP-104IAR&#146;s</FONT> proposed characteristics: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A large majority (86%) of respondents indicated they would probably or definitely prescribe a drug with <FONT
STYLE="white-space:nowrap">EP-104IAR&#146;s</FONT> target characteristics. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Corticosteroid injections were generally preferred over HA injections (32% versus 25%). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The preferred duration of pain relief for an IA therapy varies but averages six months, aligning with the
target duration of effect for <FONT STYLE="white-space:nowrap">EP-104IAR.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The potential for cartilage damage is a key safety concern for any new or existing OA therapeutics.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Future Competitive Landscape </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of the date of this AIF, there is no known cure for knee OA, short of knee replacement surgery. Current therapy focuses on a combination of
nonpharmacologic (e.g., exercise, weight loss) and pharmacologic approaches to reduce pain and improve function. Marketed pharmacologic therapies include NSAIDs, HA preparations, instant and extended-release corticosteroid injections, opioids and
topical capsaicin. Despite these options, there exists unmet medical need for safe and long-term relief of knee OA pain. See &#147;<I>Current OA Treatments.&#148;</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Several companies are engaged in late-stage development for OA treatments. A summary of
their current status is provided below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On January&nbsp;17, 2023, Ampio Pharmaceuticals, Inc.<B> </B>confirmed in a letter to stakeholders that it had
discontinued its program for Ampion (a low molecular weight fraction of human serum albumin). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Taiwan Liposome Company presented late-breaking results from its Phase 3 EXCELLENCE study comparing TLC599
(liposomal dexamethasone sodium phosphate) at the 2023 ACR congress. The abstract stated that TLC599 met its primary endpoint (change in WOMAC Pain versus placebo at 12 weeks) for single dose and showed numerical superiority to placebo upon second
dose out to 52 weeks. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Centrexion Therapeutics Corp. also presented Phase 3 results at ACR 2023 for
<FONT STYLE="white-space:nowrap">CNTX-4975-05,</FONT> a purified form of capsaicin. The drug failed to meet its primary endpoint of pain upon walking at 12 weeks using a numerical pain rating scale. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Grunenthal is currently recruiting in a global Phase 3 program of resiniferatoxin (RTX), a capsaicin analogue
found in the succulent plant <I>Euphorbia resinifera</I>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November&nbsp;13, 2023 Biosplice Therapeutics, Inc. presented interim results from its long-term extension
trial of Lorecivivint (SMO4690) &#150; a small molecule Wnt inhibitor. The <FONT STYLE="white-space:nowrap">OA-7</FONT> trial was a <FONT STYLE="white-space:nowrap">two-year</FONT> extension trial, which enrolled patients who completed <FONT
STYLE="white-space:nowrap">OA-11</FONT> (a prior <FONT STYLE="white-space:nowrap">12-month</FONT> Phase 3 trial). Although final results are not anticipated until late 2024, patients completing 3 annual injections to date support the potential for
multiple injections of lorecivivint to delay structural progression and provide symptomatic benefit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kolon TissueGene, Inc. is moving forward with its U.S. Phase 3 program for Invossa &#150; an IA injection of
normal and modified chondrocytes that claims to modify disease progression. As of January 2024, clinicaltrials.gov lists two recruiting Phase 3 studies in degenerative knee OA.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>A Phase 2 study in
symptomatic early hip OA is listed as &#147;not yet recruiting.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;13, 2023, Levicept Ltd, announced it had completed recruitment in its Phase 2 clinical trial
of <FONT STYLE="white-space:nowrap">LEVI-04,</FONT> a neurotrophin-modulating biological agent. Top line data are expected to be announced in late first half of 2024. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;11, 2023, Paradigm Pharmaceuticals Ltd. announced that
<FONT STYLE="white-space:nowrap">six-month</FONT> results from its Phase 2 trial of injectable pentosan polysulfate sodium (iPPS) suggests it may slow progression of knee OA. Twelve-month data were expected by the end of the year. As of January
2024, clinicaltrials.gov lists active recruitment in a phase 2/3 trial of iPPS as well as a Phase 3 trial that is not yet recruiting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November&nbsp;1, 2022, Anika Therapeutics Inc. announced that Cingal, a combination of HA and instant
release triamcinolone hexacetonide (TH) met its primary endpoint and demonstrated superiority over TH alone at 25 weeks. This is the product&#146;s third Phase 3 trial. Cingal<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>is already marketed
in multiple countries outside of the U.S. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TrialSpark acquired Sprifermin from Merck KGaA in January 2022. This recombinant form of human fibroblast
growth factor 18 has been evaluated in over 800 patients.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Development Program
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturing </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT
STYLE="white-space:nowrap">EP-104</FONT> consists of a vial of <FONT STYLE="white-space:nowrap">EP-104</FONT> powder and the Vehicle. Just before injection, the Vehicle is mixed with the dry powder to suspend the
<FONT STYLE="white-space:nowrap">EP-104</FONT> particles; this enables the <FONT STYLE="white-space:nowrap">EP-104</FONT> powder to be injected into the patient&#146;s knee. In an ongoing stability study, the powder has proven stable for 48 months
when stored at room temperature. Batches of <FONT STYLE="white-space:nowrap">EP-104</FONT> are currently manufactured at the projected initial batch scale required for launch. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-clinical</FONT> Studies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have completed multiple <FONT STYLE="white-space:nowrap">non-clinical</FONT>
investigations with <FONT STYLE="white-space:nowrap">EP-104,</FONT> including a large <FONT STYLE="white-space:nowrap">IND-enabling</FONT> <FONT STYLE="white-space:nowrap">non-clinical</FONT> study in dogs.
<FONT STYLE="white-space:nowrap">Non-clinical</FONT> data have indicated that after a single high-dose IA injection of <FONT STYLE="white-space:nowrap">EP-104</FONT> to the knees of dogs, FP was released locally for greater than ten months with
moderate exposure in the plasma. There was no evidence of cartilage damage in dogs over the <FONT STYLE="white-space:nowrap">ten-month</FONT> <FONT STYLE="white-space:nowrap">follow-up</FONT> period at any administered doses. In this study, a low
dose of <FONT STYLE="white-space:nowrap">EP-104</FONT> released FP locally for longer than eight months with minimal systemic exposure. This dose was used to justify the dose selection in our Phase 2 clinical trial. Both U.S. and European competent
authorities have reviewed our <FONT STYLE="white-space:nowrap">non-clinical</FONT> safety data and deemed this information suitable to support clinical research studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Several <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies are underway to support the Phase 3 and registration program. These
activities include safety and biocompatibility evaluations of <FONT STYLE="white-space:nowrap">EP-104</FONT> excipients as well as <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies to provide information needed to support the continued
clinical investigation of <FONT STYLE="white-space:nowrap">EP-104</FONT> product candidates in humans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical Studies </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">EP-104IAR</FONT> has been evaluated in two clinical studies in OA patients. The first clinical study was a
Phase 1, double-blind, placebo-controlled clinical study (protocol <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">EP-104-101)</FONT></FONT> to assess safety, PK and preliminary efficacy in 32 knee OA patients at three sites in
Canada. The single 15 mg dose was generally well tolerated and showed predictable PK. The study was not powered to detect efficacy; however, patient-reported outcome measures were collected and analyzed to evaluate pain and symptom relief. Despite
the limitations of this study (small size, low dose, significant underdosing in nine subjects, and high placebo response), we believe it provides promising tolerability and PK data and preliminary clinical activity data that support future
development of <FONT STYLE="white-space:nowrap">EP-104IAR.</FONT> Results of the study have been published in <I>Osteoarthritis and Cartilage Open</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The second clinical study was SPRINGBOARD &#150; a Phase 2, double-blind, placebo-controlled clinical study (protocol <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">EP-104IAR-201)</FONT></FONT> that assessed the efficacy, safety and PK of a single 25 mg dose of <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> in 318 patients with moderate knee OA. The
trial was conducted at 12 sites in Denmark, Poland and Czech Republic, with the last patient visit announced on May&nbsp;25, 2023. <FONT STYLE="white-space:nowrap">Top-line</FONT> data readout was announced on June&nbsp;26, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">EP-104IAR-201</FONT></FONT> met its primary endpoint with a clinically
meaningful and statistically significant (p=0.004) improvement over vehicle-placebo in Western Ontario and McMaster Universities Osteoarthritis (&#147;WOMAC&#148;) Pain at 12 weeks in the Intent to Treat population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">EP-104IAR-201</FONT></FONT> also showed statistically significant
improvement over placebo at 12 weeks in three of four secondary endpoints: WOMAC Function (p=0.014), OMERACT-OARSI strict responders (p=0.011) and Area Under the Curve (&#147;AUC&#148;) for WOMAC Pain (p&lt;0.001).&nbsp;Importantly, statistical
significance with OMERACT-OARSI strict responders to 15 weeks and AUC for WOMAC Pain to 24 weeks was also seen in the Phase 2b study, highlighting a strong and durable response. The secondary endpoint of the difference in change from baseline in the
WOMAC Pain subscale at 24 weeks was not met, delivering statistical significance to 14 weeks.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also performed <FONT
STYLE="white-space:nowrap">pre-specified</FONT> analyses in the moderate <FONT STYLE="white-space:nowrap">sub-population</FONT> which comprised 68% of the study population (n=214). Statistically significant efficacy was seen for WOMAC Pain (17
weeks) and OMERACT-OARSI strict responders (22 weeks). Additionally, 40% of moderate patients achieved near complete pain relief (WOMAC Pain score of &#8804;2) which was statistically significant for 22 weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">EP-104IAR</FONT> was well tolerated, with adverse events similar to placebo, and no withdrawals due to drug
side effects. Changes in cortisol were minimal and transient and there were no differences in blood glucose levels between treatment groups, including diabetics. We believe these safety data and the observed pharmacokinetic profile support our goal
of developing a product that can be used for repeat and bilateral dosing, and in certain <FONT STYLE="white-space:nowrap">at-risk</FONT> populations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In parallel to the main study, MRI, with macrocyclic gadolinium-based contrast agent, was obtained from participating patients who received <FONT
STYLE="white-space:nowrap">EP-104IAR</FONT> (n=6) or placebo (n=6). Scans were performed at baseline and weeks 12, 24 and 52 (or on early exit). The data obtained in the MRI <FONT STYLE="white-space:nowrap">sub-study</FONT> demonstrated the
following results: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Treatment with <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> resulted in a decrease in inflammation at
weeks 12 and 24 when compared to placebo.&nbsp;The two groups were similar at one year as the clinical effect of the single <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> injection had waned by one year. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A correlation between reduction in inflammation and a reduction in WOMAC Pain scores was observed.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A trend of equivalent or improved T2 relaxation times was observed in the
<FONT STYLE="white-space:nowrap">EP-104IAR</FONT> treated group compared to the placebo group at 12 weeks and that trend held steady, or improved, at 24 weeks and 52 weeks. These data suggest a trend of potential improvement in cartilage quality and
morphology in the treated group. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We participated in a <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting with the FDA regarding the OA program before submission and
subsequent clearance of an IND, allowing evaluation of the product candidate under the SPRINGBOARD Phase 2 OA protocol. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2023, <FONT
STYLE="white-space:nowrap">EP-104IAR</FONT> received Fast Track designation from the FDA. The Fast Track process is designed to facilitate and potentially expedite the development review of drugs to treat serious conditions and fill an unmet medical
need. The designation recognizes both the seriousness of knee OA pain and the potential for <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> to fill the need for extended-release pain relief for this indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe our planned development pathway for <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> is supported by several key factors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">following our recent
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">End-of-Phase</FONT></FONT> 2 meeting with the FDA in January 2024, we believe we have alignment on the required endpoints for our Phase 3 clinical trials in order to support an NDA
submission; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an open Investigational New Drug (IND) application with the FDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an abbreviated New Drug Application (NDA) regulatory pathway under the FDCA, Section&nbsp;505(b)(2);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA Fast Track designation, recognizing the potential of <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> to
meet an unmet medical need in a serious condition such as OA pain; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corticosteroid (FP) with a well-established record of clinical use that supports anti-inflammatory effects,
and a well-characterized systemic tolerability profile; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no evidence of cartilage damage at the therapeutic concentrations intended for humans in the <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> preclinical study; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preliminary evidence of rapid and extended pain reduction versus placebo in both Phase 1 and Phase 2 clinical
trials. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">End-of-Phase-2</FONT></FONT></FONT> Meeting with FDA
for <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2024, we engaged with the FDA in an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">End-of-Phase-2</FONT></FONT></FONT> meeting to discuss results from the SPRINGBOARD study and to discuss planned clinical and
<FONT STYLE="white-space:nowrap">non-clinical</FONT> activities to support a New Drug Application (&#147;NDA&#148;) for <FONT STYLE="white-space:nowrap">EP-104IAR.</FONT> Based on these interactions, we believe that the following clinical trials
will be required in support of a future NDA submission for <FONT STYLE="white-space:nowrap">EP-104IAR:</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PROMENADE 1&nbsp;&#150; A Phase 3 trial in approximately 740 knee OA patients to confirm the safety and
efficacy of a single dose of <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> for six months post-dose. We anticipate that a subset of patients will be followed for one year. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PROMENADE 2&nbsp;&#150; A Phase 3 trial in approximately 300 patients to evaluate the safety and durability of
response after a second dose of <FONT STYLE="white-space:nowrap">EP-104IAR.</FONT> We anticipate that the trial will be run in parallel with PROMENADE 1 and patients will be followed for a maximum of nine months after the second injection.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A Phase 1 study carried out in approximately 30 patients comparing the&nbsp;pharmacokinetics of <FONT
STYLE="white-space:nowrap">EP-104IAR</FONT> and Flovent<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP><SUP STYLE="font-size:75%; vertical-align:top"> </SUP>HFA. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the anticipated clinical trials described above, we anticipate that we or a
potential partner would need to conduct additional <FONT STYLE="white-space:nowrap">non-clinical</FONT> work to support repeat dosing of <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> and the characterization of PVA
<FONT STYLE="white-space:nowrap">in-line</FONT> with the FDA&#146;s feedback. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We anticipate that we or a potential partner would submit
the NDA for <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> under Section&nbsp;505(b)(2) of the FDCA to obtain FDA approval, which is required before marketing a new drug in the United States. A 505(b)(2) NDA would rely in part on <FONT
STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials conducted by us or a potential partner, and in part on the FDA&#146;s prior findings of safety and efficacy for the active ingredient for which we do not have a right of
reference or which have been established in the scientific literature in the public domain. We intend to, either alone or with a partner, pursue marketing approval and commercialization of <FONT STYLE="white-space:nowrap">EP-104</FONT> in the U.S.
and additional <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> geographies along with the potential partner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Lifecycle Opportunities for <FONT
STYLE="white-space:nowrap">EP-104</FONT> Products </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Corticosteroids are broadly used for various indications that may benefit from a
targeted delivery and extended-release profile with minimal side effects. Natural lifecycle extensions for <FONT STYLE="white-space:nowrap">EP-104</FONT> products could include other joints affected by OA, other inflammatory arthropathies, or other
inflammatory conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Near-Term Research Activities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our focus over the 24 months following the date of this AIF will be the execution of the <FONT STYLE="white-space:nowrap">EP-104</FONT>
development program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">EP-104GI</FONT> Program: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continued dose escalation and completed enrollment of the Phase 1b/2a RESOLVE clinical study to evaluate the
safety and effectiveness of <FONT STYLE="white-space:nowrap">EP-104GI</FONT> in EoE; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Engage with the FDA in a <FONT STYLE="white-space:nowrap">Pre-IND</FONT> meeting to discuss clinical and <FONT
STYLE="white-space:nowrap">non-clinical</FONT> topics related to the development program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Manufacture material to support <FONT STYLE="white-space:nowrap">EP-104GI</FONT> clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Following feedback from the FDA, initiate Phase 1b/2a clinical study to evaluate the safety and effectiveness
in <FONT STYLE="white-space:nowrap">EP-104GI</FONT> preventing the recurrence of benign strictures; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Initiate a Phase 2 / 3 trial to demonstrate the effectiveness and safety of
<FONT STYLE="white-space:nowrap">EP-104GI</FONT> in EoE. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">EP-104IAR</FONT> Program:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Complete <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies to support NDA filing that would enhance
the <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> label and evaluate the safety and biocompatibility of all excipients; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Further development of the <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> program would be determined in
conjunction with additional funding opportunities including a potential collaboration partner. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continue to strengthen the IP portfolio around the <FONT STYLE="white-space:nowrap">EP-104</FONT> technology;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continue to evaluate portfolio options for <FONT STYLE="white-space:nowrap">EP-104</FONT> and the Diffusphere
technology platform; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continued development of the manufacturing process to support both programs. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Where appropriate, we may use strategic collaborations or partnerships to accelerate
development and maximize the commercial potential of our development programs. In parallel, we intend to seek out licencing, <FONT STYLE="white-space:nowrap">co-development</FONT> or marketing partners for its technology, with the potential to
expand and exploit its application fully. It is our intention to put in place conditions and resources, including the potential use of licensing partnerships, that support the success of the development program, marketing authorization(s) and
commercialization across multiple jurisdictions, as well as exploitation of any opportunities for lifecycle and patent extension. Depending on market conditions, this may take the form of <FONT STYLE="white-space:nowrap">co-development</FONT> or
commercialization partnerships, transactional opportunities and/or public financing options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pipeline programs are another area of
potential growth in the next 24 months. Our technology is potentially compatible with various drugs and therapeutic indications. The pipeline strategy focuses on modulating the release of existing drugs to achieve better clinical outcomes in areas
of high medical need. The technology has the potential to be particularly suitable for diseases requiring precisely targeted and controlled localized therapy where broader tissue or systemic exposure should be avoided (e.g., tumour oncology). We
have previously investigated indications involving post-surgical pain <FONT STYLE="white-space:nowrap">(EP-105)</FONT> and post-surgical site infections <FONT STYLE="white-space:nowrap">(EP-201).</FONT> While both programs demonstrated preclinical
evidence of supporting our technology, these programs are currently paused so we can remain focused on the other programs described previously in this AIF. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently have several pipeline candidates in development with a goal to add a pipeline product candidate over the next 24 months to allow
for sustained corporate growth. We expect this to involve a multidisciplinary review of candidate drugs, formulation development, <I>in vitro</I> screening to identify the most promising lead candidates and
<FONT STYLE="white-space:nowrap">non-clinical</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> studies. Information generated from these inquiries will determine whether we should proceed with
further development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Specialized Skill and Knowledge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have extensive knowledge in scientific research and clinical development of locally delivered, extended-release alternatives to existing
pharmaceuticals. By enlisting the support of experienced preclinical, clinical trial, regulatory and legal consultants, we are able to use expert knowledge to assist in the development of its products and the protection of its intellectual property.
We continually evaluate our internal resources and may add talented senior professionals to our team as needed to support growth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2023, we had 29 full-time employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our employees are not governed by a collective bargaining agreement. We depend on certain key members of its management and scientific staff
and the loss of services of one or more of these persons could adversely affect us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our head office is located in Victoria, British Columbia, Canada. The nature of the space is immaterial to our operations as operating
activities related to our pipeline product candidates are primarily outsourced to contractors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patents and Proprietary Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>IP strategy </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We strive to protect our
product candidates and other proprietary technologies, processes, and <FONT STYLE="white-space:nowrap">know-how</FONT> through a variety of methods. Our policy is to pursue, maintain and defend patent rights in strategic areas, whether developed
internally or licensed from third parties, and to protect the technology, inventions and improvements that are commercially important to the development of our business. We also rely on trade secrets and other proprietary know how that may be
important to the development of our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of February&nbsp;1, 2024, we have licensed from Auritec Pharmaceuticals, Inc.
(&#147;<B>Auritec</B>&#148;) one issued patent in the United States generally covering the <FONT STYLE="white-space:nowrap">EP-104</FONT> technology, which is expected to expire in 2029 with patent term adjustments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the licensed Auritec patent, as of February&nbsp;1, 2024, we have filed our own patent applications covering the <FONT
STYLE="white-space:nowrap">EP-104</FONT> composition, among other things, which has resulted in two issued patents in the United States (US9987233, US11219604), one granted patent in Europe (EP2976062), and granted patents in more than ten foreign
jurisdictions. These patents covering the <FONT STYLE="white-space:nowrap">EP-104</FONT> composition are expected to expire in 2034, absent any patent term adjustments or extensions. We have also filed our own patent applications covering a method
of manufacturing the <FONT STYLE="white-space:nowrap">EP-104</FONT> composition, which is pending in the United States, Europe, and more than ten foreign jurisdictions outside the United States. These patent applications, if issued, could provide
additional patent protection for <FONT STYLE="white-space:nowrap">EP-104</FONT> until 2040, absent any patent term adjustments or extensions. In addition, we have filed an international patent application directed to various methods of use of <FONT
STYLE="white-space:nowrap">EP-104</FONT> in the treatment of inflammation of the gastrointestinal tract, such as EoE. Patents that issue from this international patent application could provide additional patent protection for the use of <FONT
STYLE="white-space:nowrap">EP-104</FONT> in the treatment of EoE until 2043, absent any patent term adjustments or extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also
seek to protect our intellectual property in part by entering into confidentiality agreements with companies with whom we share proprietary and confidential information in the course of business discussions, and by having confidentiality terms in
our agreements with our employees, consultants, scientific advisors, clinical investigators, and other contractors and also by requiring our employees, commercial contractors, and certain consultants and investigators, to enter into invention
assignment agreements that grant us ownership of any discoveries or inventions made by them while in our employ. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to patent
protection, we also rely on trademark registration, trade secrets, know how, other proprietary information to develop and maintain our competitive position. We seek to protect and maintain the confidentiality of proprietary information of our
business that is not amenable to, or that we do not consider appropriate for, patent protection. We take steps to protect our proprietary information, including trade secrets and unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> by
entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors. We believe that the combination of patent protection and trade secrets will inhibit entry
of generics into the market. However, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets and
unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and
time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. For more information regarding the risks related to our intellectual property,
see &#147;Risk Factors&#151;Risks Related to Our Intellectual Property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License Agreement with Auritec </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Auritec is a privately held clinical-stage drug delivery company that holds patents in the field of extended-release delivery of drug products
utilizing its proprietary drug delivery platform (the &#147;<B>Plexis Platform</B>&#148;). We, through our subsidiary, Eupraxia USA, are a party to an amended and restated license agreement dated effective October&nbsp;9, 2018 (as further amended,
the &#147;<B>Amended and Restated License Agreement</B>&#148;) with Auritec. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms of the Amended and Restated License
Agreement, Auritec has granted Eupraxia USA an exclusive license (including the right to sublicense to its affiliates and third parties) under the licensed patents owned or controlled by Auritec and for all the technical information and <FONT
STYLE="white-space:nowrap">know-how</FONT> relating to the technology claimed in such patents or possessed by Auritec with respect to the use of the Plexis Platform for the delivery of fluticasone in all medical fields (except for
(a)&nbsp;otolaryngology and (b)&nbsp;the prevention, treatment and control of all diseases, disorders and conditions of the eye and its adnexa ((a) and (b)&nbsp;collectively, the &#147;<B>Excluded Fields</B>&#148;)), to develop, make, have made,
manufacture, use, commercialize, sell, <FONT STYLE="white-space:nowrap">sub-license,</FONT> offer for sale, import, and have imported products for the delivery of fluticasone drug products using the Plexis Platform in all medical fields except the
Excluded Fields (such field, the &#147;<B>Eupraxia Field</B>&#148; and such products, the &#147;<B>Products</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the terms of the Amended and Restated License Agreement, in consideration for
the rights and exclusive license granted to Eupraxia USA, Eupraxia USA paid an upfront payment of US$5,000,000 (the &#147;<B>Upfront Fee</B>&#148;). All other licensing payments under the Amended and Restated License Agreement will come due as set
forth in the table below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the Upfront Fee, pursuant to the Amended and Restated License Agreement, Eupraxia USA has agreed
to pay Auritec up to US$30&nbsp;million upon achievement of certain regulatory and commercial milestones related to Products as well as a royalty of 4% of net sales of Products by Eupraxia USA or its affiliates, subject to certain reductions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the milestone payment schedule: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Milestone Event</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Milestone&nbsp;Payment&nbsp;(USD)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Successful Completion of a Phase 2b Study</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8201;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First OA Regulatory Approval</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second OA Regulatory Approval</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-OA</FONT> Indication
Regulatory Approval</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First calendar year in which aggregate net sales by
Eupraxia USA, its affiliates and sublicensees exceed US$500,000,000</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Maximum milestones payable</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Eupraxia USA also agreed to pay to Auritec 20% of royalties or other consideration based on
net sales of Products received by Eupraxia USA or its affiliates pursuant to a sublicensing transaction. Eupraxia USA further agreed to pay Auritec a percentage of <FONT STYLE="white-space:nowrap">Non-Royalty</FONT> Monetization Revenue (as defined
in the Amended and Restated License Agreement), which includes payments received for a sale of Eupraxia USA or its assets or sale or sublicense of a Product, which percentage ranges from 30% to 10% depending on the development stage of the
most-advanced Product, up to a maximum of US$100&nbsp;million. The following table summarizes the <FONT STYLE="white-space:nowrap">Non-Royalty</FONT> Monetization Revenue percentage schedule: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Date of Execution</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&#8201;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Percentage&nbsp;of&nbsp;Non-</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Royalty&nbsp;Monetization<BR>Revenue</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prior to Successful Completion of a Phase 2b Study (as defined in the Amended and Restated License
Agreement)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">After Successful Completion of a Phase 2b Study but prior to Successful Completion of a Phase 3
Study (as defined in the Amended and Restated License Agreement)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">After Successful Completion of a Phase 3 Study but prior to Regulatory Approval (as defined in the
Amended and Restated License Agreement) of a Product in the Eupraxia Field from FDA in the United States</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">After Regulatory Approval of a Product in the Eupraxia Field from FDA in the United
States</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Either party may terminate the Amended and Restated License Agreement in the event of the other party&#146;s
bankruptcy, liquidation, or dissolution. Auritec may also terminate upon a material breach of the Amended and Restated License Agreement by Eupraxia USA that is not cured within 60 days (15 days in the case of a payment breach). Further, if Eupraxia
USA directly or indirectly challenges any claim in any Auritec patent licensed under the Amended and Restated License Agreement, or assist a third party in doing so, Auritec may immediately terminate the Amended and Restated License Agreement. If
Auritec directly or indirectly challenges any Eupraxia patent contemplated in the Amended and Restated License Agreement other than as reasonably required to defend Auritec patents as a basis for such challenge, or assists a third party in doing so,
we may immediately terminate the Amended and Restated License Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Manufacturing Agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since we do not have our own manufacturing facilities, all manufacturing activities are contracted out to Good Manufacturing Practices
(&#147;GMP&#148;) compliant facilities. All of the contract manufacturers used to date are under master service agreements and quality agreements and are compensated with cash and not shares of the Company. We share our proprietary knowhow to
complete any manufacturing campaign with external contract manufacturers; however, all intellectual property associated with our proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> is retained by us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Government
authorities in the United States, at the federal, state, and local level, and other countries extensively regulate, among other things, the research, development, <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical testing,
manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing, and export and import of products such as those we are developing.
Generally, before a new drug can be marketed, considerable data must be generated, which demonstrate the drug&#146;s quality, safety, and efficacy. Such data must then be organized into a format specific for each regulatory authority, submitted for
review and approved by the regulatory authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Drug approval laws in the United States, Canada and Europe generally require licensing
of manufacturing facilities, carefully controlled research and testing of products, government review of results and approval prior to marketing and sale of drug products. In addition, they require adherence to best practices as defined by the
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, as well as national guidelines. The process for pharmaceutical development and approval are subject to inherent risks, described in <I>&#147;Risk
Factors.&#148;</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The principal steps generally required for drug approval in the United States, Canada and
Europe are described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-clinical</FONT> Toxicology Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-clinical</FONT> studies are conducted <I>in vitro</I> and in animals to evaluate toxicokinetics and PK to
provide evidence of the safety and bioavailability of the drug candidate prior to its administration to humans in clinical studies and throughout development. Such studies have been completed, are underway or are planned for <FONT
STYLE="white-space:nowrap">EP-104.</FONT> See <I><FONT STYLE="white-space:nowrap">&#147;Non-clinical</FONT> Studies.&#148;</I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Human Testing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The process of conducting clinical trials with an investigational new drug generally cannot begin until a company has submitted to the
appropriate regulatory authorities an application to do so and the required number of days have lapsed without objection from the applicable regulatory authority. (In certain jurisdictions, a no objection letter or approval may be required before
the clinical trial can proceed). In the United States, this application is called an IND, and in Canada and most European countries, a clinical trial application (&#147;CTA&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the United States, the Sponsor must submit the results of the <FONT STYLE="white-space:nowrap">non-clinical</FONT> tests, manufacturing
information, analytical data and available clinical data or literature, within the IND, to the FDA. Some information, as is the case for <FONT STYLE="white-space:nowrap">EP-104,</FONT> may be omitted from the IND in instances where prior FDA
findings of safety or efficacy of a drug product are being relied upon. Even after the IND is submitted, <FONT STYLE="white-space:nowrap">non-clinical</FONT> testing may continue to occur. An IND becomes effective automatically 30 days after receipt
by the FDA, unless within that time the FDA raises concerns or questions, in which case a clinical hold may be put in place until the concerns are adequately addressed by the Sponsor with the FDA. As a result, a submission of an IND may not result
in the FDA allowing clinical trials to commence. Similar regulations apply in Canada and in other foreign jurisdictions in which we may seek authorization to conduct a clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Two key factors influencing the rate of progression of clinical trials are the rate at which patients can be enrolled to participate in the
research program and whether effective treatments are currently available for the disease that the drug is intended to treat. Patient enrollment is largely dependent upon the incidence and severity of the disease, the treatments available and the
potential side effects of the drug to be tested and any restrictions for enrollment that may be imposed by regulatory agencies. For further information see &#147;<I>Risk Factors.&#148;</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators
in accordance with GCPs (as defined below), which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other
things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product
development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical
trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an
unacceptable health risk or that the clinical trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety
monitoring board, which may review data and endpoints at designated check points, make recommendations or halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of
efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 1 Clinical Trials </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Phase 1 clinical trials are typically conducted on a small number of individuals (healthy
volunteers or patients) to determine safety, dose limiting toxicities, tolerability, PK and to determine dose ranging for Phase 2 clinical trials in humans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 2 Clinical Trials </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Phase 2 clinical
trials typically involve a larger patient population than is required for Phase 1 and are conducted to evaluate the safety and efficacy of a drug candidate in patients having the disease for which the drug is indicated. This phase also serves to
identify possible common short-term side effects and risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 3 Clinical Trials </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Phase 3 clinical
trials typically involve tests in a much larger population of patients suffering from the targeted condition or disease. These studies involve controlled and/or uncontrolled testing in an expanded patient population (several hundred to several
thousand patients) at geographically dispersed test sites to establish clinical safety and effectiveness. These trials also generate information from which the overall risk-benefit relationship relating to the drug can be determined. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Post-approval clinical trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These clinical
trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients
are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug
has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on
its charter, this group may determine whether a clinical trial may move forward at designated check points based on access to certain data from the clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to
submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to
provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 clinical trial to discuss Phase 2 clinical results and present plans for the pivotal
Phase 3 clinical trials that they believe will support approval of the new drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Concurrent with clinical trials, companies usually
complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP (as
defined below) requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and
purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and <FONT
STYLE="white-space:nowrap">non-clinical</FONT> studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected
suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important
increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Marketing Application </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product
development <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are
submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. Additionally,
no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. The FDA reviews an NDA to determine, among other things, whether a product
is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#146;s identity, strength, quality, and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are
currently in effect, the FDA has a goal of ten months from the date of &#147;filing&#148; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes 12 months from the date the NDA is submitted to
FDA because the FDA has approximately two months to make a &#147;filing&#148; decision after the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing,
to determine whether they are sufficiently complete to permit substantive review The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The
resubmitted application is also subject to review before the FDA accepts it for filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA may refer an application for a novel drug
to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under
what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Before the applicable regulatory authority approves the marketing application, they will initiate an inspection of the facility or facilities
where the product is manufactured. Products will not be approved unless there is compliance with GMP. Approval may occur if the inspection is satisfactory and if the marketing application contains data providing substantial evidence that the drug is
safe and effective in the studied indication. In addition to manufacturing inspections, the regulatory authority will typically inspect one or more clinical sites to assure compliance with Good Clinical Practices (&#147;GCP&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the FDA determines that the application, manufacturing process, or manufacturing facilities are not acceptable, it will outline the
deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory
criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter
authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present
form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 clinical trial or other significant and time-consuming
requirements related to clinical trials, <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies, or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the
letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The testing and approval process for a new drug candidate requires substantial time, effort and financial resources, and may take several
years to complete. Data obtained from <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical testing are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.
Approval may not be granted on a timely basis, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if a regulatory authority approves a product candidate, the relevant
authority may limit the approved indications for use, require specific contraindications, warnings or precautions be included in the product label, including a boxed warning, require that post-approval studies, including Phase 4 clinical trials, be
conducted to further assess a drug&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk
management mechanisms. For example, the FDA may require a Risk Evaluation and Mitigation Strategy (&#147;REMS&#148;), (also known as a Risk Management Plan (&#147;RMP&#148;) in Europe) as a condition of, or following, approval to mitigate any
identified or suspected serious risks and ensure safe use of the drug. The REMS or RMP could include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods,
patient registries or other risk minimization tools. A REMS or RMP could materially affect the potential market and profitability of the product. A regulatory authority may prevent or limit further marketing of a product based on the results of
post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional label claims, are subject to further testing requirements,
notification, and regulatory authority review and approval. Further, should new safety information arise, additional testing, product labeling or regulatory notification may be required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA also may offer conditional approval subject to, among other things, changes to proposed labeling or the development of adequate
controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing requirements is not maintained or if problems occur after the product reaches
the marketplace. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#146;s policies may change, which could impact the timeline for regulatory approval or otherwise impact ongoing
development programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expedited Development and Review Programs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA has a fast track designation program that is intended to expedite or facilitate the process for reviewing new drug products that meet
certain criteria. Specifically, new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or
condition. With regard to a fast track product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA,
the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA
programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy
exists or a significant improvement in the treatment, diagnosis, or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority
review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA
review goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or
life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be
measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and
the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA
currently requires <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Food and Drug Administration Safety and Innovation Act established a category of drugs referred to as &#147;breakthrough therapies&#148;
that may be eligible to receive breakthrough therapy designation. A sponsor may seek FDA designation of a product candidate as a &#147;breakthrough therapy&#148; if the product is intended, alone or in combination with one or more other products, to
treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as
substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product
is designated as breakthrough therapy, the FDA will work to expedite the development and review of such drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Fast track designation,
priority review, accelerated approval, and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may
later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate. The
Food and Drug Omnibus Reform Act made several changes to the FDA&#146;s authorities and its regulatory framework, including, among other changes, reforms to the accelerated approval pathway, such as requiring the FDA to specify conditions for
post-approval study requirements and setting forth procedures for the FDA to withdraw a product on an expedited basis for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with post-approval requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Orphan Drugs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Orphan Drug Act,
the FDA may grant orphan designation to a drug intended to treat a rare disease or condition affecting fewer than 200,000 individuals in the United States, or in other limited cases. Orphan drug designation does not convey any advantage in or
shorten the duration of the regulatory review and approval process, though companies developing orphan drugs are eligible for certain incentives, including tax credits for qualified clinical testing. In addition, an NDA for a product that has
received orphan drug designation is not subject to a prescription drug user fee unless the application includes an indication other than the rare disease or condition for which the drug was designated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same active moiety for the same indication for seven years, except in limited circumstances, such as
another drug&#146;s showing of clinical superiority over the drug with orphan exclusivity. Competitors, however, may receive approval of different active moieties for the same indication or obtain approval for the same active moiety for a different
indication. In addition, doctors may prescribe products for <FONT STYLE="white-space:nowrap">off-label</FONT> uses and undermine our exclusivity. Orphan drug exclusivity could block the approval of one of our products for seven years if a competitor
obtains approval for the same active moiety for the same indication before we do, unless we are able to demonstrate that our product is clinically superior. In response to the court decision in <I>Catalyst Pharms., Inc. v. Becerra</I>, 14 F.4th 1299
(11th Cir. 2021), in January 2023, the FDA published a notice in the Federal Register to clarify that while the agency complies with the court&#146;s order in <I>Catalyst</I>, FDA intends to continue to apply its longstanding interpretation of the
regulations to matters outside of the scope of the <I>Catalyst </I>order &#150; that is, the agency will continue tying the scope of orphan-drug exclusivity to the uses or indications for which a drug is approved, which permits other sponsors to
obtain approval of a drug for new uses or indications within the same orphan designated disease or condition that have not yet been approved. It is unclear how future litigation, legislation, agency decisions, and administrative actions will impact
the scope of the orphan drug exclusivity. We cannot guarantee that we will obtain orphan drug designation for any products in any jurisdiction. Even if we are able to obtain orphan drug designation for a product, we cannot be sure that such product
will be approved, that we will be able to obtain orphan drug exclusivity upon approval, if ever, or that we will be able to maintain any exclusivity that is granted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-Approval Requirements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any products
manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting,
product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There are
continuing, annual program fees for any marketed products. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the
FDA and certain state agencies for compliance with cGMP (as defined below), which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and,
depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend
time, money, and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the
product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program.
Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the
market or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters, or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical holds on post-approval or Phase IV clinical studies, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of product license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consent decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandated modification of promotional materials and labeling and the issuance of corrective information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases, and other communications
containing warnings or other safety information about the product; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA closely regulates the marketing, labeling, advertising, and promotion of drug products. A company can make only those claims relating
to safety and efficacy that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of
<FONT STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians
may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#146;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that
such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict
manufacturer&#146;s communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of <FONT
STYLE="white-space:nowrap">off-label</FONT> use and has enjoined companies from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. The FDA and other regulatory agencies have also required that companies enter into consent
decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#146;s <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> labelling. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Marketing Exclusivity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Market exclusivity provisions authorized under the FDCA can delay the submission and approval of certain marketing applications for products
containing the same active ingredient. The FDCA permits patent term restoration of up to five years as compensation for a patent term lost during product development and FDA regulatory review process to the first applicant to obtain approval of an
NDA for a new chemical entity in the United States. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. A </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug
substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section&nbsp;505(b)(2), or a 505(b)(2) NDA, submitted by another company for another
drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data
required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement</FONT> to one of the patents listed with the FDA by the
innovator NDA holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA
if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages, or strengths of an
existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing
the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a
right of reference to any <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an
additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor
to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Healthcare Laws </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pharmaceutical
manufacturers are subject to additional healthcare laws, regulation, and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation,
U.S. federal anti-kickback, anti-self-referral, false claims, transparency, including the federal Physician Payments Sunshine Act, consumer fraud, pricing reporting, data privacy, data protection, and security laws and regulations as well as similar
foreign laws in the jurisdictions outside the U.S. Similar state and local laws and regulations may also restrict business practices in the pharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business
practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including
private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal
government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information; state
and local laws which require the tracking of gifts and other remuneration and any transfer of value provided to physicians, other healthcare providers and entities; and state and local laws that require the registration of pharmaceutical sales
representatives; and state and local laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance
efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The risk of our being found in violation of these or other laws and regulations is increased by the fact that many have not been
fully interpreted by the regulatory authorities or the courts and their provisions are open to various interpretations. These laws and regulations are subject to change, which can increase the resources needed for compliance and delay drug approval
or commercialization. Any action brought against us for violations of these laws or regulations, even successfully defended, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our
business. Also, we may be subject to private &#147;qui tam&#148; actions brought by individual whistleblowers on behalf of the federal or state governments. Actual or alleged violation of any such laws or regulations may lead to investigations and
other claims and proceedings by regulatory authorities and in certain cases, private actors, and violation of any of such laws or any other governmental regulations that apply may result in penalties, including, without limitation, significant
administrative, civil and criminal penalties, damages, fines, additional reporting obligations, and oversight if we become subject to a corporate integrity agreement or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, the curtailment or restructuring of operations, exclusion from participation in
government healthcare programs and imprisonment. See <I>&#147;Risk Factors &#150; Risks Relating to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance&#148; </I>for a list of laws that may affect our ability to
operate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Coverage and Reimbursement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, Canada, and markets in other countries, patients who are prescribed treatments for their conditions and providers
performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which
third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for the product. In
the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. The process for determining
whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly
challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved
list, also known as a formulary, which might not include all of the approved products for a particular indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In international
markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to
restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or
it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have
placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, that it will be
considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available, or that the third-party payors&#146; reimbursement policies will not adversely affect the ability for
manufacturers to sell products profitably. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>U. S. Healthcare Reform </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of products have been a
focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls
and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#146;s revenue generated from the sale of any approved products. Coverage policies and
third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive regulatory approval, less favorable coverage
policies and reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There have been a number of proposals during the last few years
regarding the pricing of pharmaceutical products, limiting coverage and the amount of reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States. For example, in March 2010,
the United States Congress enacted the Affordable Care Act (the &#147;ACA&#148;), which, among other things, includes changes to the coverage and payment for products under government health care programs. Since its enactment, there have been
numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, in June 2021 the U.S. Supreme Court held
that Texas and other challengers had no legal standing to challenge the ACA, dismissing the case on procedural grounds without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form. It is
possible that the ACA will be subject to judicial or Congressional challenges in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other legislative changes have been proposed and adopted in the United States since the ACA
was enacted. For example, the American Rescue Plan Act of 2021 eliminated the statutory Medicaid drug rebate cap manufacturers pay to state Medicaid programs, elimination of this cap may require pharmaceutical manufacturers to pay more in rebates
than it receives on the sale of products, which could have a material impact on our business. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, the Centers for
Medicare&nbsp;&amp; Medicaid Services (&#147;CMS&#148;) may develop new payment and delivery models, such as bundled payment models. Recently, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for
their products. Such scrutiny has resulted in several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of
prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. In August 2022, Congress passed the Inflation Reduction Act of 2022,
or IRA, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced
single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if
their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> prescription drug costs for beneficiaries, among other changes.
Various industry stakeholders, including certain pharmaceutical companies and the Pharmaceutical Research and Manufacturers of America, have initiated lawsuits against the federal government asserting that the price negotiation provisions of the IRA
are unconstitutional. The impact of these judicial challenges, legislative, executive, and administrative actions and any future healthcare measures and agency rules implemented by the government on us and the pharmaceutical industry as a whole is
unclear. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, individual states in the United States have also become increasingly active in implementing regulations designed to control
pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation
from other countries and bulk purchasing. A number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under
such state laws once we begin commercialization after obtaining regulatory approval for any of our products. Further, FDA recently authorized the state of Florida to import certain prescription drugs from Canada for a period of two years to help
reduce drug costs, provided that Florida&#146;s Agency for Health Care Administration meets the requirements set forth by the FDA. Other states may follow Florida. Furthermore, there has been increased interest by third party payors and governmental
authorities in reference to pricing systems and publication of discounts and list prices. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or
commercialize our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Government Regulation Outside of the U.S. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to regulations in the U.S., we will be subject to a variety of regulations in other jurisdictions governing, among other things,
research, development, testing, manufacture, quality control, controlled substances, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and
import of drugs, and reimbursement requirements. Generally, before a new drug can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority,
submitted for review and approved by the regulatory authority. Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical studies
or marketing of the product in those countries. Certain countries outside of the U.S. have a similar process that requires the submission of a clinical study application much like the IND prior to the commencement of human clinical studies. In the
EU, for example, a CTA must be submitted to each country&#146;s national health authority and an independent ethics committee, much like the FDA and the IRB, respectively. Once the CTA is approved in accordance with a country&#146;s requirements,
clinical study development may proceed. Similar requirements regarding a CTA and ethics approval exist in Canada. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The requirements and process governing the conduct of clinical studies, product licensing,
coverage, pricing and reimbursement vary from country to country. In all cases, the clinical studies are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration
of Helsinki. The EU clinical trials legislation currently is undergoing a transition process mainly aimed at harmonizing and streamlining clinical-trial authorization, simplifying adverse-event reporting procedures, improving the supervision of
clinical trials and increasing their transparency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For other countries outside of the EU, such as countries in Eastern Europe, Latin
America or Asia, the requirements governing the conduct of clinical studies, product and establishment licensing, coverage, data protection, pricing and reimbursement vary from country to country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or
withdrawal of regulatory approvals, product recalls, inability to import or export, seizure of products, operating restrictions and criminal prosecution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Investing in our securities involves a high degree of risk. Before deciding to invest in our securities, you should carefully consider the
risks described below, together with other information included in or incorporated by reference into this AIF and filed on SEDAR+ at www.sedarplus.ca. If any of the following risks materialize, the business, financial condition, results of operation
and future prospects of the Company will likely be materially and adversely affected. This could cause actual future events to differ materially from those described in forward-looking statements and may cause the trading price of our securities to
decline. Our Risk Factors are not guarantees that no such conditions exist as of the date of this report and should not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part. The
following discussion highlights some of the risks and uncertainties facing the Company. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Our Limited Operating History, Financial
Position and Capital Requirements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We have a history of negative operating cash flow and may continue to experience negative
operating cash flow. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our incorporation in May 2011, we have generated negative operating cash flows. We anticipate that we will
continue to have negative cash flow and we expect to continue to incur losses for the foreseeable future as we continue to research and develop, and seek regulatory clearances for, our current product candidate and other potential product
candidates. To the extent that we have negative operating cash flow in future periods, we may need to allocate a portion of our cash reserves to fund such negative cash flow. We may also be required to raise additional funds through the issuance of
equity or debt securities. There can be no assurance that we will be able to generate a positive cash flow from our operations, that additional capital or other types of financing will be available when needed or that these financings will be on
terms favourable to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>If we are not successful in refinancing the Debt Agreement with Silicon Valley Bank, we will be required to
repay amounts due in full, which could have an adverse effect on our business and financial condition. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2021, we entered into
the Debt Agreement with SVB and SVB Innovation Credit Fund VIII, L.P., and concurrently drew down, in full, the CDN$10,000,000 principal amount. The Debt Agreement has a term of 36 months (or 48 months at SVB&#146;s election). Interest accrues
monthly in arrears at a rate per annum equal to the greater of (i) 2.45% and (ii) the Canadian prime rate. In addition, payment in kind interest accrues at a rate of 7.0% per annum, compounded monthly, and is payable on the maturity date. The Debt
Agreement is secured by a security interest on substantially all of our assets, but excluding our patents and other intellectual property. As of February 28, 2024, an aggregate of approximately CDN$12 million in principal and accrued interest is
currently outstanding under the Debt Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the terms and conditions of the Debt Agreement, SVB may elect to convert the
principal amount of the convertible debt and the accrued and unpaid interest thereon into Common Shares at a conversion price equal to CDN$5.68 per Common Share. The conversion price of the accrued and unpaid interest will be subject to the minimum
pricing requirements of the TSX, to the extent applicable, at the time of conversion. We have the right to call the convertible debt by paying to SVB an amount equal to 150% of the principal amount of the convertible debt (less principal amounts
previously repaid). If any amounts due under the Debt Agreement are converted into Common Shares, our then holders of Common Shares will experience dilution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2023, SVB was closed and placed into receivership, and its holdings were subsequently transferred to Silicon Valley Bridge Bank, N.A
(&#147;<B>Bridge Bank</B>&#148;) being operated by the U.S. Federal Deposit Insurance Corporation (&#147;<B>FDIC</B>&#148;). The Ontario Superior Court of Justice subsequently granted a winding up order and have appointed a third party to begin an
orderly, court-supervised process to restructure the branch to ensure an orderly transition of SVB&#146;s Canadian branch to Bridge Bank. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Due to SVB&#146;s receivership, we expect the Debt Agreement will mature on June 21, 2024. We are exploring various options to refinance the
Debt Agreement. However, any such refinancing may not be successfully completed by June 21, 2024, on terms commercially attractive to us or at all. If any refinancing is insufficient to repay amounts owed under the Debt Agreement in full, we may
need to use a portion of the proceeds from the Offering to repay the Debt Agreement, which could have an adverse effect on our business and financial condition and reduce our anticipated cash runway following the Offering by at least a full quarter.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms of the Debt Agreement, in the event that we become subject to the reporting requirements of the United States Securities
Exchange Act of 1934 (the &#147;<B>Exchange Act</B>&#148;) and list our Common Shares for trading on any U.S. stock exchange or inter-dealer quotation system, we have agreed to promptly thereafter enter into a registration rights agreement with the
applicable holders under the Debt Agreement, pursuant to which such holders will have customary demand and &#147;piggyback&#148; registration rights with respect to Common Shares issued or issuable upon conversion of the debt. If our Common Shares
become listed on the Nasdaq, this obligation will be triggered. Due to SVB&#146;s receivership and the resulting complexities, it may be difficult for us to meet our obligations to enter into the registration rights agreement. If we are able to
enter into the registration rights agreement, it could result in additional sales of our Common Shares by the holders if the outstanding debt is converted to Common Shares before maturity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to the Company&#146;s Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We have a limited operating history and have no products approved for commercial sale, which may make it difficult for you to evaluate our
current business and predict our future success and viability. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a clinical stage biotechnology company with limited operating
history and in particular, no history of earnings; we have not paid any dividends and we are unlikely to pay any dividends in the immediate or foreseeable future. Our success will depend to a large extent on the expertise, ability, judgement,
discretion, integrity and good faith of our management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have no products approved for commercial sale in any jurisdiction and have not
generated any revenue from product sales. To date, we have devoted substantially all of our resources and efforts to organizing and staffing our company, business planning, discovering, identifying and developing potential product candidates,
securing related intellectual property rights and conducting preclinical studies and clinical trials of our product candidates. We have not yet demonstrated our ability to obtain marketing approvals, manufacture a commercial-scale product or arrange
for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. As a result, it may be more difficult for you to accurately predict our future success or viability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks
frequently experienced by clinical stage pharmaceutical companies in rapidly evolving fields. We also may need to transition from a company with a research focus to a company capable of supporting commercial activities, or enter into strategic
partnerships with one or more companies with such capability. If we do not adequately address these risks and difficulties or successfully make such a transition, our business will suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect to spend a significant amount of capital to fund research and development. As a result, we expect that our operating expenses will
increase significantly and, consequently, we will need to generate significant revenues to become profitable. Even if we do become profitable, we may not be able to sustain or increase profitability on a quarterly or annual basis. We cannot predict
when, if ever, we will be profitable. There can be no assurances that we will be capable of producing our products in commercial quantities at reasonable costs or that we will successfully market them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We will require substantial additional financing to achieve our goals and a failure to obtain this necessary capital when needed could
force us to delay, limit, reduce or terminate our product development or commercialization efforts. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of September 30, 2023, we had
CDN$33.2 million of cash and cash equivalents. Based upon our current operating plan, we estimate that our cash and cash equivalents as of September 30, 2023 are insufficient for us to fund operating, investing, and financing cash flow needs for
twelve months following September 30, 2023, the date of our unaudited condensed interim consolidated financial statements for the most recently completed financial period, and accordingly, we have determined that there is substantial doubt about our
ability to continue as a going concern. We believe that we will continue to expend substantial resources for the foreseeable future as we continue the development of EP-104. Additionally, we expect to expend resources as we develop additional
product candidates, if any, launch clinical trials and pursue commercialization of such product candidates, if approved. In addition, other unanticipated costs may arise. Because the outcome of our planned and anticipated clinical trials are highly
uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of product candidates. Our costs will increase if we suffer any delays in our planned clinical trials for our
current product candidates. Our forecast of the period of time through which our financial reserves will adequately support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result
of a number of factors, including the factors discussed elsewhere in this &#147;Risk Factors&#148; section. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we
currently expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, and the costs involved in, obtaining regulatory approvals for product candidates if clinical
trials are successful; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of developing and advancing product candidates through clinical trials
and researching and discovering new product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain strategic partnerships, licensing or other arrangements and the
financial terms of such agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing product candidates for clinical trials in preparation for regulatory approval and in
preparation for commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of revenue from an approved product candidate, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims,
including litigation costs and the outcome of such litigation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ongoing economic slowdown and downturn of global
capital markets has generally made the raising of capital by equity or debt financing more difficult. Access to financing has been negatively impacted by ongoing global economic risks. We will require substantial additional funds for further
research and development, and the marketing and sale of our technology. We may attempt to raise additional funds for these purposes through public or private equity or debt financing, collaborations with other therapeutic companies, government
grants or other sources. There can be no assurance that additional funding or partnerships will be available on terms acceptable to us, and which would foster the successful commercialization of our technologies. If additional funds are raised
through further issuances of equity or convertible debt securities, existing shareholders could suffer significant dilution, and any new equity securities issued could have rights, preferences and privileges superior to those of the Common Shares.
Any debt financing secured in the future could involve restrictive covenants relating to capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital or to pursue
business opportunities, including potential acquisitions. If adequate funds are not obtained, we may be required to reduce, curtail or discontinue operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We are substantially dependent on the success of our lead product candidates EP-104GI, which is currently being studied in an open label
Phase 1b/2a clinical study, and EP-104IAR, for which we are evaluating funding alternatives for the continued development, including potential partnership opportunities. If we are unable to complete development of, obtain approval for and
commercialize EP-104GI or EP-104IAR, alone or through a potential partnership, in a timely manner, our business will be harmed. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
future success is dependent on our ability to timely complete clinical trials, obtain marketing approval for and successfully commercialize our lead product candidates, EP-104GI, and EP-104IAR. We have invested significant efforts and financial
resources in the research and development of EP-104GI and EP-104IAR. We are conducting a Phase 1b/2a clinical trial for the proposed indication of EoE and have conducted a Phase 2 clinical trial for the proposed indication of OA. Both indications
will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, marketing approval from government regulators, substantial investment and significant marketing efforts before we can generate any
revenues from sales of any approved products. In addition, we are evaluating funding alternatives for the continued development of EP-104IAR, including potential partnership opportunities. If we are unable to secure such funding, we may ultimately
discontinue our efforts with respect to this candidate. We are not permitted to market or promote EP-104GI, EP-104IAR or any other product candidate before we receive marketing approval from the FDA and/or comparable foreign regulatory authorities,
and we may never receive such marketing approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our ability to generate revenue and achieve profitability depends significantly on several
factors, including but not limited to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful and timely completion of non-clinical and clinical development of our product candidates and any
future product candidates, as well as the associated costs, including any unforeseen costs we may incur as a result of non-clinical study or clinical trial delays due to public health crises or other causes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation and successful patient enrollment and completion of additional clinical trials on a timely
basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing and maintaining relationships with CROs and clinical sites for the clinical development, both in
the United States and internationally, of our product candidates and any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entering into strategic partnerships for the development and commercialization of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the frequency and severity of adverse events in the clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy, safety and tolerability profiles that are satisfactory to the FDA, EMA, or any comparable
foreign regulatory authority for obtaining marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely receipt of marketing approvals from applicable regulatory authorities for any product candidates for
which we successfully complete clinical development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making any required post-marketing approval commitments to applicable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing an efficient and scalable manufacturing process for our product candidates, including obtaining
finished products that are appropriately packaged for sale; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing and maintaining commercially viable supply and manufacturing relationships with third parties
that can provide adequate, in both amount and quality, products and services to support clinical development and meet the market demand for product candidates that we develop, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful commercial launch following any marketing approval, including the development of a commercial
infrastructure, whether in-house or with one or more collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a continued acceptable safety profile following any marketing approval of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commercial acceptance of our product candidates by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, assessing and developing new product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining, maintaining and expanding patent protection, trade secret protection and/or regulatory exclusivity;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">protecting our rights in our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">defending against third-party interference or infringement claims, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiating favorable terms in any collaboration, licensing or other arrangements that may be necessary or
desirable to develop, manufacture or commercialize our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining coverage and adequate reimbursement by hospitals, government and third-party payors for product
candidates that we develop and receive regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing any competing therapies and technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attracting, hiring and retaining qualified personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission
process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. To the extent we enter into strategic partnerships, we will be subject to the risks described
under &#147;<I>Collaboration arrangements we may enter into in the future may not be successful.</I>&#148; We may never be successful in achieving our objectives and, even if we do, may never generate revenue that is significant or large enough to
achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable may decrease the value of our company and could impair our
ability to maintain or further our research and development efforts, raise additional necessary capital, grow our business and continue our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to
commercial partners, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all. Changes in the manufacturing process or facilities will require further comparability
analysis and approval by the FDA before implementation, which could delay our clinical trials and product candidate development, and could require additional clinical trials, including bridging studies, to demonstrate consistent and continued safety
and potency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have not previously submitted a NDA to the FDA or similar approval filings to a comparable foreign regulatory authority,
for any product candidate. An NDA or other relevant regulatory filing must include extensive non-clinical and clinical data and supporting information to establish that the product candidate is safe and effective for each desired indication. The NDA
or other relevant regulatory filing must also include significant information regarding the chemistry, manufacturing and controls for the product. We cannot be certain that our current or future product candidates will be successful in clinical
trials or receive regulatory approval. Further, even if such product candidates are successful in clinical trials, our product candidates or any future product candidates may not receive regulatory approval. If we do not receive regulatory approvals
for current or future product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approval to market a product candidate, our revenue will depend, in part, upon the size of the markets in the
territories for which we gain regulatory approval and have commercial rights, as well as the availability of competitive products, whether there is sufficient third-party reimbursement and adoption by physicians. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>If we breach any of the agreements under which we license rights to our product candidates or technology from third parties, we could lose
license rights that are important to our business. Our current license agreement may not provide an adequate remedy for its breach by the licensor. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are developing the Products pursuant to the Amended and Restated License Agreement with Auritec. We are subject to a number of risks
associated with our license from Auritec, including the risk that Auritec may terminate the Amended and Restated License Agreement upon the occurrence of certain specified events. The Amended and Restated License Agreement requires, among other
things, that we make certain payments and use commercially reasonable efforts to meet certain clinical and regulatory milestones. If we fail to comply with any of these obligations or otherwise breach the agreements, Auritec may have the right to
terminate the license in whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We could also suffer the consequences of <FONT STYLE="white-space:nowrap">non-compliance</FONT> or
breaches by Auritec in connection with the Amended and Restated License Agreement. Such <FONT STYLE="white-space:nowrap">non-compliance</FONT> or breach could in turn result in our breach or default under our future agreements with collaboration
partners, and we could be found liable for damages or lose certain rights, including rights to develop and/or commercialize a product or product candidate. Loss of our rights under the Amended and Restated License Agreement or any similar license
granted to us in the future, including the exclusivity rights provided therein, could harm our financial condition and operating results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Adverse developments affecting the financial services industry, such as actual events or
concerns involving liquidity, defaults, or <FONT STYLE="white-space:nowrap">non-performance</FONT> by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial
condition and results of operations. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Actual events involving limited liquidity, defaults,
<FONT STYLE="white-space:nowrap">non-performance</FONT> or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry
generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, in March&nbsp;2023 SVB was closed by the California Department of
Financial Protection and Innovation, which appointed the FDIC as receiver. Also in March&nbsp;2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Although a statement by the U.S. Department of the Treasury, the
Federal Reserve and the FDIC indicated that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts, borrowers under credit agreements, letters of
credit and certain other financial instruments with SVB, Signature Bank or any other financial institution that is placed into receivership by the FDIC were hampered in accessing undrawn amounts thereunder. If any of our suppliers or other parties
with whom we conduct business are unable to access funds pursuant to such instruments or lending arrangements with such a financial institution or other distressed financial institutions, such parties&#146; ability to pay their obligations to us or
to enter into new commercial arrangements requiring additional payments to us could be adversely affected. We currently are a borrower under the Debt Agreement with SVB with the facility being fully drawn. We, and any suppliers or other parties that
are counterparties to SVB credit agreements and arrangements, and third parties such as beneficiaries of letters of credit (among others), may experience direct impacts from the closure of SVB and uncertainty remains over liquidity concerns in the
broader financial services industry. Similar impacts have occurred in the past, such as during the 2008-2010 financial crisis. In addition, due to the complexities surrounding SVB&#146;s receivership, we are not certain that SVB will be able to
exercise its conversion rights under the Debt Agreement and receive Common Shares in satisfaction of amounts owed, even if the conversion feature under the Debt Agreement is in the money. If amounts outstanding under the Debt Agreement are not
converted to Common Shares prior to the maturity date, we will either need to refinance amounts owing with a new debt facility or use our cash resources to pay amounts owing, which would divert such funds from our research and development efforts
and potentially have a material and adverse impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Inflation and rapid increases in interest rates have led to a decline
in the trading value of previously issued government securities with interest rates below current market interest rates. Although the U.S. Department of Treasury, FDIC and Federal Reserve Board previously announced a program to provide loans to
financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of
financial institutions for immediately liquidity may exceed the capacity of such program. Additionally, there is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future
in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we assess
our banking and customer relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be
significantly impaired by factors that affect us, the financial institutions with which we have credit agreements or arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events
such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or
concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which we have financial or business
relationships, but could also include factors involving financial markets or the financial services industry generally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The results of
events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may
not be limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial
assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Delayed or lost access to, or reductions in borrowings available under credit facilities or other working
capital sources and/or delays, inability or reductions in our ability to refund, roll over or extend the maturity of, or enter into new credit facilities or other working capital resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Potential or actual breach of contractual obligations that require us to maintain letters of credit or other
credit support arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Potential or actual breach of financial covenants in our credit agreements or credit arrangements;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Potential or actual cross-defaults in other credit agreements, credit arrangements or operating or financing
agreements; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash
management arrangements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, investor concerns regarding the U.S., Canadian, or international financial
systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more
difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial
obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors
described above or other related or similar factors not described above, could have a material adverse effect on our liquidity and our current and/or projected business operations and financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, any further deterioration in the macroeconomic economy or financial services industry could lead to losses or defaults by our
counterparties, which in turn, could have a material adverse effect on our current and/or projected business operations and results of operations and financial condition. For example, counterparties may fail to make payments when due, default under
their agreements with us, become insolvent or declare bankruptcy, or a supplier may determine that it will no longer deal with us as a customer. In addition, a counterparty could be adversely affected by any of the liquidity or other risks that are
described above as factors that could result in a material adverse effect on us, including but not limited to delayed access or loss of access to uninsured deposits or loss of the ability to draw on existing credit facilities involving a troubled or
failed financial institution. Any counterparty bankruptcy or insolvency, or the failure of any counterparty to make payments when due, or any breach or default by a counterparty, or the loss of any significant supplier relationships, could result in
material losses to us and may have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Clinical trials are expensive, time consuming and
difficult to design and implement and may fail to demonstrate adequate safety and efficacy of our product candidates. Furthermore, the results of previous preclinical studies and clinical trials may not be predictive of future results, and the
results of our current and planned clinical trials may not satisfy the requirements of the FDA or comparable foreign regulatory authorities or provide the basis for regulatory approval. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct preclinical development
and then extensive clinical trials to demonstrate their safety and efficacy. Preclinical and clinical testing is expensive and difficult to design and implement. Preclinical and clinical testing can take many years to complete, and its ultimate
outcome is uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A failure of one or more preclinical or clinical trials can occur at any stage of the process. We will be required
to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective for use in a diverse patient population before we can seek regulatory approvals for their commercial sale. Our
preclinical or clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional and expansive preclinical or clinical testing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because these lead product candidates utilize the same proprietary Diffusphere delivery technology, a failure of one of our clinical trials
may also increase the actual or perceived likelihood that our other product candidates will experience similar failures. If our ongoing or future clinical trials are inconclusive with respect to the safety and efficacy of our product candidates, or
if we encounter safety concerns associated with our product candidates, we may incur unplanned costs and be delayed in or prevented from obtaining marketing approval for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Positive or timely results from preclinical or early-stage trials do not ensure positive or timely results in future clinical trials or
registrational clinical trials because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and comparable foreign regulatory authorities, despite having progressed
through preclinical studies or initial clinical trials. Product candidates that have shown promising results in early clinical trials may still suffer significant setbacks in subsequent clinical trials or registration clinical trials. For example, a
number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our lead product candidates may not be successful for their intended use. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">EP-104GI</FONT> is intended for the treatment of pain and inflammation in adult patients diagnosed with EoE, a
chronic and incurable disease that leads to progressive fibrosis of the esophagus. EoE is characterized by inflammation and the accumulation of large numbers of eosinophils (a type of white blood cells) within the epithelial lining of the esophagus.
The active pharmaceutical ingredient is an anti-inflammatory corticosteroid fluticasone propionate (&#147;<B>FP</B>&#148;) that reduces the pain associated with inflammation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">EP-104IAR is intended as a long-acting pain relief for OA knee pain. EP-104IAR has the same active pharmaceutical ingredient as EP-104GI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Inflammation is not the only contributor to pain in EoE and knee pain, and <FONT STYLE="white-space:nowrap">EP-104GI</FONT> and EP-104IAR may
not provide sufficient pain relief for other sources of pain in EoE, such as damage of the esophagus, esophageal strictures and proliferation of fibrotic tissue, or for other sources of knee pain, such as <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">bone-on-bone</FONT></FONT> interactions. <FONT STYLE="white-space:nowrap">EP-104GI</FONT> and EP-104IAR are the first <FONT STYLE="white-space:nowrap">FP-based</FONT> product candidates intended to have an extended release
profile to be tested in the esophagus and knee, respectively, and the effective doses have not been determined. To achieve regulatory approval in North America, <FONT STYLE="white-space:nowrap">EP-104GI</FONT> and EP-104IAR must each show
significant benefit over placebo. This is complicated by the &#147;placebo effect&#148; in pain-related trials, whereby patients perceive pain relief despite having received no active pharmaceutical. We have not received FDA approval for either lead
product candidate and cannot be certain that our approach will lead to the development of an approvable or marketable product. We may not succeed in demonstrating safety and efficacy of EP-104GI or EP-104IAR in our ongoing clinical trials or in
larger-scale clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Advancing EP-104 creates significant challenges for us, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstrating adequate safety and efficacy to support NDA approval and a sustained safety profile following
any marketing approval of our product candidates, including providing sufficient non-clinical and clinical data to support an extended-release claim in our proposed labeling and sufficient data on systemic exposure and local toxicity to support
repeat dosing in humans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining marketing approval, as the FDA, EMA or other regulatory authorities have never approved an FP-based
product for EoE or OA knee pain; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if EP-104 is approved in any indication, educating medical personnel regarding the potential benefits, as well
as the challenges, of incorporating EP-104 into existing treatment regimens; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing the sales and marketing capabilities upon obtaining any marketing approvals to gain market
acceptance. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our current and future product candidates will require regulatory approval, which is costly, and we may
not be able to obtain it and we may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Marketing authorization of <FONT STYLE="white-space:nowrap">EP-104</FONT> for any indication and other product candidates will fall under the
regulatory purview of the FDA and other equivalent regulatory bodies worldwide. We are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Foreign
regulatory authorities impose similar requirements. The time required to obtain approval by the FDA, EMA and other comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials
and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the
course of a product candidate&#146;s clinical development and may vary among jurisdictions or change over time, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion
in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Even if we eventually complete clinical testing and receive
approval of any regulatory filing for our product candidates, the FDA, EMA and other comparable foreign regulatory authorities may approve our product candidates for a more limited indication, a narrower patient population than we originally
requested or with a REMS. Further, regulatory authorities may not approve the price we intend to charge for products we may develop, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product
candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. We have not submitted for, or obtained, regulatory approval for any product candidate, and it is
possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, development of our product candidates and/or regulatory approval may be delayed for reasons beyond our control. For example, a U.S.
federal government shutdown or budget sequestration, may result in significant reductions to the FDA&#146;s budget, employees and operations, which may lead to slower response times and longer review periods, potentially affecting our ability to
progress development of our product candidates or obtain regulatory approval for our product candidates. Applications for our product candidates could fail to receive regulatory approval for many reasons, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, EMA or other comparable foreign regulatory authorities may disagree with the design, implementation
or results of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, EMA or other comparable foreign regulatory authorities may determine that our product candidates are
not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the population studied in the clinical trial may not be sufficiently broad or representative to assure
efficacy and safety in the full population for which we seek approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, EMA or other comparable foreign regulatory authorities may disagree with our interpretation of data
from preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to support the
submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the FDA, EMA or other comparable foreign regulatory authorities that a
product candidate&#146;s risk-benefit ratio for its proposed indication is acceptable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, EMA or other comparable foreign regulatory authorities may fail to approve the manufacturing
processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA, EMA or other comparable foreign regulatory authorities may
significantly change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The clinical trials of our product candidates may not demonstrate safety and efficacy to
the satisfaction of the FDA, EMA or other comparable foreign regulatory authorities or otherwise produce positive results. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Before
obtaining marketing approval from the FDA, EMA or other comparable foreign regulatory authorities for the sale of our product candidates, we must complete preclinical development and extensive clinical trials to demonstrate the safety and efficacy
of our product candidates. Clinical testing is expensive, difficult to design and implement, can take many years to complete and its ultimate outcome is uncertain. A failure of one or more clinical trials can occur at any stage of the process. The
outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies
that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs. The outcome of preclinical studies and early-stage clinical trials
may not be predictive of the success of later clinical trials. For example, we completed an end of Phase 2 meeting with the FDA in January 2024 regarding <FONT STYLE="white-space:nowrap">EP-104IAR.</FONT> Based on our interactions with the FDA at
that meeting, we believe that we have an understanding of the remaining <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical studies that would be needed to support a 505(b)(2) application for
<FONT STYLE="white-space:nowrap">EP-104IAR,</FONT> including the need to conduct additional animal studies to evaluate the potential for dose dumping and immediate release of fluticasone propionate, sufficient safety and efficacy data to support
repeat dosing, and adequate data to bridge the systemic safety of Flovent HFA to EP-104IAR, among other recommendations and comments received from the FDA. However, we cannot be certain that we and any potential partner will be successful in
completing these anticipated studies, or if the FDA or any other regulatory authority will determine the data we and any potential partner obtain from such studies and any data obtained from any previously conducted clinical or <FONT
STYLE="white-space:nowrap">non-clinical</FONT> studies are sufficient to support an approval or that such regulatory authorities will not require additional trials. We can provide no assurance that FDA will approve the indication we and any
potential partner seek in the NDA, if at all. If FDA grants approval, depending on FDA&#146;s interpretation of the data, FDA may impose labeling restrictions, reject the &#147;extended release&#148; claim in the labeling, restrict repeat dosing, or
require additional safety monitoring or warnings. Ultimately, the FDA will need to conduct a full review of all studies submitted in support of approval and such studies may be unsatisfactory to the FDA. In addition, even if any of our product
candidates receives FDA approval, any labeling restrictions that may be imposed by the FDA may materially and adversely impact our or any potential partner&#146;s ability to successfully commercialize our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we may rely in part on preclinical, clinical and quality data generated by CROs and other third parties for regulatory
submissions for our product candidates. While we have or will have agreements governing these third parties&#146; services, we have limited influence over their actual performance. If these third parties do not make data available to us, or, if
applicable, make regulatory submissions in a timely manner, in each case pursuant to our agreements with them, our development programs may be significantly delayed, and we may need to conduct additional studies or collect additional data
independently. In either case, our development costs would increase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not know whether our future clinical trials will begin on time
or enroll patients on time, or whether our ongoing and/or future clinical trials will be completed on schedule or at all. Clinical trials can be delayed for a variety of reasons, including delays related to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our
clinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on
trial design; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be
subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining approval from one or more institutional review boards (&#147;<B>IRBs</B>&#148;);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding
enrollment of additional subjects, or withdrawing their approval of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical sites deviating from trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing sufficient quantities of product candidate or obtaining sufficient quantities of combination
therapies for use in clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjects failing to enroll or remain in our trial at the rate we expect, or failing to return for post-
treatment <FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjects choosing an alternative treatment for the indication for which we are developing our product
candidates, or participating in competing clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of adequate funding to continue the clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjects experiencing severe or unexpected drug-related adverse effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious adverse events in trials of the same class of agents conducted by other companies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selection of clinical end points that require prolonged periods of clinical observation or analysis of the
resulting data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a facility manufacturing our product candidates or any of their components being ordered by the FDA or
comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of current good manufacturing practice (&#147;<B>cGMP</B>&#148;), regulations or other applicable requirements, or infections or cross-contaminations
of product candidates in the manufacturing process; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any changes to our manufacturing process that may be necessary or desired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials,
not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices (&#147;<B>GCPs</B>&#148;) or other regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party contractors not performing data collection or analysis in a timely or accurate manner; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government
or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing
applications. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We could also encounter delays if a clinical trial is suspended or terminated by us, by the
IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a
number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory
authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate
funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial
protocols to IRBs for <FONT STYLE="white-space:nowrap">re-examination,</FONT> which may impact the costs, timing or successful completion of a clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay
completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative
burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover,
principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of
these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or
otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be
jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more
of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates,
the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. Moreover, any delays in completing our clinical trials will increase our costs,
slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of,
clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our
product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition
and prospects significantly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We completely rely on third parties to provide supplies and inputs required for our products. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently outsource all product manufacturing. The field of manufacturers capable of manufacturing the
<FONT STYLE="white-space:nowrap">EP-104</FONT> API powder is narrow and not easily replaced. Although we depend heavily on these parties, we do not control them and, therefore, cannot be assured that these third parties will adequately perform all
of their contractual obligations to us. If our third-party service providers cannot adequately fulfill their obligations to us in a timely and satisfactory basis, development plans may be delayed or terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain
marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party
manufacturers entails additional risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of the third party to manufacture our product candidates according to our schedule, or at all,
including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the reduction or termination of production or deliveries by suppliers, or the raising of prices or
renegotiation of terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is
costly or inconvenient for us due to any number of reasons including staffing issues, change in strategy, or concerns around manufacture of our drug substance due to perceived or actual safety concerns; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the breach by the third-party contractors of our agreements with them; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of third-party contractors to comply with applicable regulatory requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of the third party to manufacture our product candidates according to our specifications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active
drug or placebo not being properly identified; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or
of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the misappropriation of our proprietary information, including our trade secrets and <FONT
STYLE="white-space:nowrap">know-how.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not have complete control over all aspects of the manufacturing process of, and are
dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar
regulatory requirements internationally. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA or others, they will not be able to secure
and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA,
EMA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which
would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in
sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions,
any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations. Our current and anticipated future dependence upon others for the manufacture of our product
candidates or drugs may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We rely on CROs to provide clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> research services; if such CROs do not
successfully carry out their contractual duties including to comply with applicable laws and regulations or meet expected deadlines, our business could be substantially harmed. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We engage with contractors, including CROs, for various aspects of our non-clinical studies and clinical trials, including trial conduct, data
management, study management and managing, statistical analysis and electronic compilation of our regulatory submissions. We may enter into agreements with CROs to obtain resources and expertise in an attempt to accelerate our progress on new or
ongoing clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> programs. Typically entering into relationships with CROs involves substantial cost and requires extensive management time and focus. In addition, typically there is a
transition period between engagement of a CRO and the time the CRO commences work. As a result, delays may occur, which may materially impact our ability to meet desired <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical development
timelines and ultimately have a material adverse effect on our operating results, financial condition or future prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As CROs are
not our employees, we cannot control whether or not they devote sufficient time and resources to our clinical trials for which they are engaged to perform, and whether they comply with the applicable GCPs and Good Laboratory Practices
(&#147;<B>GLPs</B>&#148;) for our product candidates, which include requirements related to the conduct of the study, subject informed consent, and research ethics board&#146;s approval among others. Regulatory authorities, including the FDA,
monitor compliance with Good Manufacturing Practices, GLPs, and GCPs (collectively, &#147;<B>GxPs</B>&#148;) through periodic inspections of trial sponsors, principal investigators and trial sites. Although we may rely on third parties for the
execution of our clinical trials and <FONT STYLE="white-space:nowrap">non-clinical</FONT> research, we are nevertheless responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and
scientific standards and our reliance on CROs does not relieve us of our regulatory responsibilities. If we or any of our CROs deviate from the approval protocols, make errors during the conduct of the studies, or fail to comply with applicable GCPs
and GLPs, the data generated in the Company&#146;s studies may be deemed unreliable and the applicable regulatory authorities may take regulatory action against us and/or require us to perform additional studies before approving our marketing
applications. We cannot assure you that, upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with
product candidate materials produced under GMP regulations. Our failure to comply with these regulations may require us to discontinue or repeat clinical trials, which would delay the regulatory approval process. If the CROs that we engage do not
successfully carry out their contractual duties or obligations, conduct the studies in accordance with all regulatory requirements, or meet expected deadlines, or if they need to be replaced, or the quality or accuracy of the data they provide is
compromised due to the failure to adhere to regulatory requirements or for other reasons, then our development programs may be extended, delayed or terminated, or we may not be able to obtain marketing approval for or successfully commercialize our
product candidates. Failure to comply with clinical trial regulatory requirements may further subject us to significant penalties potentially including imprisonment or an injunction against manufacture or distribution and debarment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The manufacture of drugs is complex, and our third-party manufacturers may encounter
difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or
prevented. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Manufacturing drugs, especially in large quantities, is complex and may require the use of innovative technologies. Each
lot of an approved drug product must undergo thorough testing for identity, strength, quality, purity, potency, and stability. Manufacturing drugs requires facilities specifically designed for and validated for this purpose, and sophisticated
quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures,
product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such
changes. If microbial, viral or other contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical
trials and adversely harm our business, including exposure to liabilities arising from any GxP non-compliance. If our manufacturers and suppliers are unable to produce sufficient quantities for clinical trials or for commercialization as a result of
these challenges, or otherwise, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor or other third
party will discover them or that our trade secrets will be misappropriated or disclosed. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because we currently rely on third parties to
manufacture our product candidates and to perform quality testing, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by
entering into confidentiality agreements, and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to
beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties,
the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors or other third parties, are intentionally or inadvertently incorporated into the technology of others, or
are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets and despite our efforts to protect our trade secrets, a competitor&#146;s or other third party&#146;s
discovery of our proprietary technology and confidential information or other unauthorized use or disclosure of such technology or information would impair our competitive position and may have a material adverse effect on our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The outcome of preclinical testing and early clinical trials may not be predictive of
the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities. Terminating the development of any of our product candidates could
materially harm our business and the market price of our Common Shares. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our clinical product candidates, along with product candidates
we expect to enter clinical development, are in varying stages of development and will require substantial clinical development, testing and regulatory approval prior to commercialization. Before obtaining regulatory approvals for the commercial
sale of our product candidates, we must demonstrate through lengthy, complex and expensive <FONT STYLE="white-space:nowrap">pre-clinical</FONT> testing and clinical trials that each product candidate is both safe and effective for use in each target
indication. Failure can occur at any time during the clinical trial process. Clinical trials often fail to demonstrate safety and efficacy of the product candidate studied for the target indication. Most product candidates that commence clinical
trials are never approved as products. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in
earlier trials. In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size
and type of the patient populations, differences in and adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. Patients treated with our product candidates may also be undergoing other
treatments and may be using other approved products or investigational new drugs, which can cause side effects or adverse events that are unrelated to our product candidate. As a result, assessments of efficacy can vary widely for a particular
patient, and from patient to patient and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes. While recent data obtained from our ongoing studies of EP-104GI and
EP-104IAR is encouraging, we cannot be certain that future trials will not suffer setbacks, including for lack of efficacy and/or adverse safety profiles, or that previously conducted clinical and non-clinical studies will be deemed adequate for
purposes of regulatory approval. For additional information regarding our recent study results, please see the section of this AIF titled &#147;<I>Description of the Business &#150; Product Candidates</I>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the safety and efficacy trials of any product candidate, clinical trial failures may result from a multitude of factors
including flaws in trial design, dose selection, statistical analysis plan, placebo effect, patient enrollment criteria, patient compliance and trial execution. Data obtained from trials and studies are susceptible to varying interpretations, and
regulators may not interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval. Failure of a clinical trial due to any of these reasons could materially harm our business and the market price of our Common Shares.
In the case of some of our product candidates, we may seek to develop treatments for certain diseases or disorders for which there is relatively limited clinical experience, and clinical trials may use novel endpoints and measurement methodologies
or subjective patient feedback, which adds a layer of complexity to these clinical trials and may delay regulatory approval. Negative or inconclusive results from our clinical trials could lead to a decision or requirement to conduct additional <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> testing or clinical trials or result in a decision to terminate the continued development of a product candidate. Any of the foregoing outcomes would materially and adversely impact our business,
product candidate pipeline and future prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If our product candidates are not shown to be both safe and effective in clinical
trials, such product candidates will be unable to obtain regulatory approval or be successfully commercialized. In addition, our failure to demonstrate positive results in clinical trials in any indication for which we are developing clinical
product candidates could adversely affect development efforts in other indications. In such case, we would need to develop other compounds and conduct associated <FONT STYLE="white-space:nowrap">pre-clinical</FONT> testing and clinical trials, as
well as potentially seek additional financing, all of which would have a material adverse effect on our business, growth prospects, operating results, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Interim, initial, &#147;top-line&#148;, and preliminary data from our clinical trials
that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may publicly disclose preliminary or top-line data from our preclinical studies and clinical trials, which is based on a
preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions,
estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from
future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line data also remain subject to audit and verification procedures that may
result in the final data being materially different from the preliminary data we previously published. As a result, top-line data should be viewed with caution until the final data are available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change
as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly
harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our Common Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the
information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to
include in our disclosure. If the interim, top-line, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and
commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory
approval of our product candidates in those and other indications, which could seriously harm our business. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Preclinical and clinical
data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA, EMA or comparable
foreign regulatory authority approval. We cannot guarantee that the FDA or foreign regulatory authorities will interpret trial results as we do, and more trials could be required before we are able to submit applications seeking approval of our
product candidates. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available
to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product
candidate, which may also limit its commercial potential. Furthermore, the approval policies or regulations of the FDA, EMA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient
for approval, which may lead to the FDA, EMA or comparable foreign regulatory authorities delaying, limiting or denying approval of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our current or future product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone
or in combination with other products that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with our product
candidates&#146; use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory
authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect
patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If our product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical
trials when used alone or in combination with other approved products or investigational new drugs we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side
effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial, or
result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patients in our ongoing and planned clinical trials may in the future suffer significant adverse events or other side effects not observed in
our preclinical studies or previous clinical trials. Some of our product candidates, may be used as chronic therapies or be used in pediatric populations, for which safety concerns may be particularly scrutinized by regulatory agencies. In addition,
if our product candidates are used in combination with other therapies, our product candidates may exacerbate adverse events associated with the therapy. Patients treated with our product candidates may also be undergoing other medical procedures or
treatments, which can cause side effects or adverse events that are unrelated to our product candidate, but may still impact the success of our clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty
recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, EMA, other comparable regulatory authorities
or an IRB may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics
developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product
candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, if any of our product candidates obtains marketing approval, toxicities associated with such product candidates and
not seen during clinical testing may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional contraindications, warnings and precautions being added to the drug label, significant
restrictions on the use of the product or the withdrawal of the product from the market. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on
preclinical studies or early-stage clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Where appropriate and applicable, we may seek approval from the FDA or comparable foreign
regulatory authorities through the use of expedited approval pathways, such as Fast Track designation or orphan drug designation. Even if we receive Fast Track designation or other designation, we can provide no assurance that we will be able to
obtain FDA approval sooner or if at all. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Where possible, we may pursue accelerated development strategies in areas of high unmet need
for one or more of our product candidates. In June 2023, we announced that the FDA has granted Fast Track designation for EP-104IAR in treatment of OA. Fast Track designation is designed to facilitate the development and expedite the review of
therapies for serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communications with the FDA, potential priority review and the ability to submit a rolling application for
regulatory review. Fast Track designation applies to both the product candidate and the specific indication for which it is being studied. If any of our product candidates receive Fast Track designation but do not continue to meet the criteria for
Fast Track designation, or if our clinical trials are delayed, suspended or terminated, or put on clinical hold due to unexpected adverse events or issues with clinical supply, we will not receive the benefits associated with the Fast Track program.
Furthermore, Fast Track designation does not change the standards for approval. Fast Track designation alone does not guarantee qualification for the FDA&#146;s priority review procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition,
which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in
the regulatory review or approval process. If a product that has orphan drug designation from the FDA subsequently receives the first FDA approval for an indication within the orphan disease, the product is entitled to orphan product exclusivity,
which means that the FDA may not approve any other applications to market the same drug for the same indication, for seven years, except in limited circumstances such as a showing of clinical superiority to the product with the orphan product
exclusivity or if FDA finds that the holder of the orphan exclusivity has not shown that it can ensure the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the product
was designated. Even if we or our collaborators obtain orphan designation for a product candidate, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing
pharmaceutical products. The scope of exclusivity is limited to the scope of any approved indication, even if the scope of the orphan designation is broader than the approved indication. Additionally, exclusive marketing rights may be limited if we
or our collaborators seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure
sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if a product obtains orphan drug exclusivity, that exclusivity may not effectively protect the product from competition because
different drugs with different active moieties can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve a product with the same active moiety for the same condition if the FDA concludes that the
later product is safer, more effective, or makes a major contribution to patient care. Furthermore, the FDA can waive orphan exclusivity if we or our collaborators are unable to manufacture sufficient supply of the product. If we or our
collaborators do not receive or maintain orphan drug designation to product candidates for which we seek such designation, it could limit our ability to realize revenues from such product candidates. Further, in view of the court decision in
<I>Catalyst Pharms., Inc. v. Becerra</I>, 14 F.4th 1299 (11th Cir. 2021), the FDA published a notice in the Federal Register in January 2023 to clarify that while the agency complies with the court&#146;s order in <I>Catalyst</I>, FDA intends to
continue to apply its longstanding interpretation of the regulations to matters outside of the scope of the <I>Catalyst</I> order &#150; that is, the agency will continue tying the scope of orphan-drug exclusivity to the uses or indications for
which a drug is approved, which permits other sponsors to obtain approval of a drug for new uses or indications within the same orphan designated disease or condition that have not yet been approved. It is unclear how future litigation, legislation,
agency decisions, and administrative actions will impact the scope of the orphan drug exclusivity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>If we are unable to establish sales
and marketing capabilities or enter into agreements with third parties to market and sell our drug candidates, if approved, we may be unable to generate any product revenue. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To successfully commercialize <FONT STYLE="white-space:nowrap">EP-104,</FONT> in any indication, if approved, or any future product candidate
that may result from our development programs, we will need to build out our sales and marketing capabilities, either on our own or with others. The establishment and development of our own commercial team or the establishment of a contract field
force to market any product candidate we may develop will be expensive and time-consuming and could delay any drug launch. Moreover, we cannot be certain that we will be able to successfully develop this capability. We may seek to enter into
collaborations with other entities to use their established marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If any current or future collaborators do not commit sufficient
resources to commercialize our product candidates, or we are unable to develop the necessary capabilities on our own, we may be unable to generate sufficient revenue to sustain our business. We may compete with many companies that currently have
extensive, experienced and well-funded marketing and sales operations to recruit, hire, train and retain marketing and sales personnel. We will likely also face competition if we seek third parties to assist us with the sales and marketing efforts
any future product candidates. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We have a novel technology with uncertain market acceptance. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if any of our product candidates receive regulatory approval, the approved products may not achieve broad market acceptance among
physicians, patients, the medical community and third-party payors, in which case revenue generated from their sales would be limited. Our delivery platform is at an early stage of development and uses novel technology, with uncertain market
acceptance if our product candidates are approved. Product approval, should this be achieved, does not infer that the product will garner a good market price or be reimbursed by public or private insurers. Further, there are no guarantees that the
product will be positively received by the target patient population. If any of our product candidates is approved but does not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate or derive
sufficient revenue from that product candidate and our financial results could be negatively impacted. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of the product candidate as well as competitive products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications for which the product candidate is approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the use of our product candidates, such as boxed warnings or contraindications in labeling, or
a REMS, if any, which may not be required of alternative treatments and competitor products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential and perceived advantages of product candidates over alternative treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of treatment in relation to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of coverage and adequate reimbursement, as well as pricing, by third-party payors, including
government authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of the approved product candidate for use as a combination therapy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">relative convenience and ease of preparation and administration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these
therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable publicity relating to our products or product candidates or similar approved products or product
candidates in development by third parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval of other new therapies for the same indications. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our clinical development
activities could be delayed or otherwise adversely affected. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patient enrollment is a significant factor in the timing of clinical
trials, and the timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required <FONT STYLE="white-space:nowrap">follow-up</FONT> periods. We may not be
able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial&#146;s conclusion as required by the FDA, EMA or
other comparable foreign regulatory authorities. Additionally, certain clinical trials for future product candidates may be focused on indications with relatively small patient populations, which may further limit enrollment of eligible patients or
may result in slower enrollment than we anticipate. The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patient enrollment may also be affected if our competitors have ongoing clinical trials for product candidates that are under development for
the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors&#146; product candidates. Patient enrollment for any of our clinical trials may
be affected by other factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">size and nature of the patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability and potency of approved drugs for the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient eligibility criteria for the trial in question as defined in the protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perceived risks and benefits of the product candidate under study; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages of the product candidate being
studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proximity and availability of clinical trial sites for prospective patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued enrollment of prospective patients by clinical trial sites; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or
may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of
our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their
jurisdiction. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may choose to conduct international clinical trials in the future. The acceptance of study data by the FDA, EMA or
other comparable foreign regulatory authority from clinical trials conducted outside of their respective jurisdictions may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for
marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (1)&nbsp;the data are applicable to the United States population and United States medical practice; (2)&nbsp;the
trials are performed by clinical investigators of recognized competence and pursuant to current GCP requirements; and (3)&nbsp;the FDA is able to validate the data through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection or other
appropriate mean. Additionally, the FDA&#146;s clinical trial requirements, including the adequacy of the patient population studied and statistical powering, must be met. In addition, such foreign trials would be subject to the applicable local
laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA or any applicable foreign regulatory authority will accept data from trials conducted outside of its applicable jurisdiction. If the FDA,
EMA or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product
candidates not receiving approval for commercialization in the applicable jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Obtaining and maintaining regulatory approval
of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain
or maintain regulatory approval in any other jurisdiction. For example, even if the FDA or EMA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing,
marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval
procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one
jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In
some cases, the price that we intend to charge for our products is also subject to approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Obtaining foreign regulatory approvals and
establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future
collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates
will be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>If the market opportunity for any product candidate that we or our strategic partners develop is smaller than we
believe, our revenue may be adversely affected, and our business may suffer. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to initially focus our product candidate
development on treatments for EoE and OA indications. Our projections of addressable patient populations that may benefit from treatment with our product candidates are based on our estimates. These estimates, which have been derived from a variety
of sources, including scientific literature, surveys of clinics, patient foundations and market research, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of EoE or OA. Additionally, the potentially
addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. FDA, EMA, or other regulatory agencies may also limit our proposed indication or target population. Our market
opportunity may also be limited by future competitor treatments that enter the market. If any of our estimates prove to be inaccurate, the market opportunity for any product candidate that we or our strategic partners develop could be significantly
diminished and have an adverse material impact on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Even if our product candidates receive regulatory approval, we will be subject to
significant post marketing regulatory requirements and oversight. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any regulatory approvals that we may receive for our product
candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups,
warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a
medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or foreign regulatory
authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to
extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as <FONT STYLE="white-space:nowrap">on-going</FONT> compliance with cGMPs and GCP
for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance
with cGMP regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured,
a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, failure to comply with FDA, EMA and other comparable foreign regulatory requirements may subject our company to administrative or
judicially imposed sanctions, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in or the rejection of product approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or
planned trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the products, manufacturers or manufacturing process; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warning or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">civil and criminal penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension or withdrawal of regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizures, detentions or import bans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voluntary or mandatory product recalls and publicity requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">total or partial suspension of production; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of restrictions on operations, including costly new manufacturing requirements.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates
and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>FDA&#146;s and other regulatory authorities&#146; policies may change, and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of our product candidates. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are slow or unable to adapt to changes in existing
requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability. We also cannot
predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If government regulation arises that puts constraints on
FDA&#146;s or other regulatory authorities&#146; ability to exercise their respective regulatory authority, including engaging in oversight and implementation activities in the normal course, our business may be negatively impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is difficult to predict how current and future legislation, executive actions, and litigation, including the executive orders, will be
implemented, and the extent to which they will impact our business, our clinical development, and the FDA&#146;s and other agencies&#146; ability to exercise their regulatory authority, including FDA&#146;s
<FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections and timely review of any regulatory filings or applications we submit to the FDA. In addition, if the Supreme Court reverses or curtails the <I>Chevron</I> doctrine, which gives
deference to regulatory agencies in litigation against FDA and other agencies, more companies may bring lawsuits against FDA to challenge longstanding decisions and policies of FDA, which could undermine FDA&#146;s authority, lead to uncertainties
in the industry, and disrupt FDA&#146;s normal operations, which could delay FDA&#146;s review of our marketing applications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The FDA and other regulatory agencies actively enforce the laws and regulations
prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If any of our product candidates are approved
and we are found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims
that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#146;s
approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of <FONT
STYLE="white-space:nowrap">off-label</FONT> use and has enjoined several companies from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. The FDA has also requested that companies enter into consent decrees or permanent
injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely
affect our business and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Disruptions at the FDA and other government agencies caused by funding shortages or
global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise
prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes, and other events that may otherwise affect the FDA&#146;s ability to perform routine functions. Average review times
at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political
process, which is inherently fluid and unpredictable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Disruptions at the FDA and other agencies may also slow the time necessary for new
drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA, had to
furlough critical employees and stop critical activities. Separately, in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the FDA temporarily postponed certain inspections before resuming normal operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their
regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We rely on key personnel. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our success depends in large measure on certain key personnel, including our executive officers. The loss of the services of such key personnel
could have a material adverse effect on us. The contributions of these individuals to our immediate operations are likely to be of central importance. In addition, the competition for qualified personnel in the biotech industry is intense and there
can be no assurance that we will be able to continue to attract and retain all personnel necessary for the development and operation of our business. Investors must rely upon the ability, expertise, judgment, discretion, integrity and good faith of
our management. Other biotechnology companies with which we compete for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse
opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than those that we have to offer. If we are unable to continue to attract and retain high-quality personnel, the
rate of and success with which we can develop and commercialize product candidates would be limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a technology-driven company,
intellectual input from key management and personnel is critical to achieve our business objectives. Consequently, our ability to retain these individuals and attract other qualified individuals is critical to our success. The loss of the services
of key individuals might significantly delay or prevent achievement of our business objectives. In addition, because of a relative scarcity of individuals with the high degree of education and scientific achievement required for our business,
competition among biotech companies for qualified employees is intense, and as a result we may not be able to attract and retain such individuals on acceptable terms, or at all. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also have relationships with scientific collaborators at academic and other institutions,
some of whom conduct research at our request or assist us in formulating our research and development strategies. These scientific collaborators are not our employees and may have commitments to, or consulting or advisory contracts with, other
entities that may limit their availability to us. In addition, even though our collaborators are required to sign confidentiality agreements prior to working with us, they may have arrangements with other companies to assist such other companies in
developing technologies that may prove competitive to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Incentive provisions for our key executives include the granting of stock
options that vest over time, designed to encourage such individuals to stay with us. However, a low share price could render such agreements of little value to our key executives. In such event, our key executives could be susceptible to being hired
away by our competitors who could offer a better compensation package. If we are unable to attract and retain key personnel our business, financial conditions and results of operations may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We may not be able to successfully execute our business strategy. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The execution of our business strategy poses many challenges and is based on several assumptions. If we experience significant regulatory
delays, supply chain disruptions, cost overruns on our programs, or if our business plan is more costly than we anticipate, certain research and development activities may be delayed or eliminated, resulting in changes or delays to our
commercialization plans, or we may be compelled to secure additional funding (which may or may not be available) to execute our business strategy. We cannot predict with certainty our future revenues or results from our operations. If the
assumptions on which our revenue or expenditure forecasts are based change, the benefits of our business strategy may change as well. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We are in a highly competitive industry which is continuously evolving with technological
changes. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are engaged in an industry that is highly competitive, evolving and characterized by technological change. As a result, it
is difficult for it to predict whether, when and by whom new competing technologies or new competitors may enter the market. We face competition from companies with strong positions in certain markets we are currently targeting, and in new markets
and regions we may enter. Some of these companies have significantly greater financial, technical, human, research and development, and marketing resources than us. We cannot assure you that we will be able to compete effectively against current and
future competitors who may discover and develop products in advance of us that are more effective than those developed by us. As a consequence, our current and future technologies may become obsolete or uncompetitive, resulting in adverse effects on
revenue, margins and profitability. In addition, competition or other competitive pressures may result in price reductions, reduced margins or loss of market share, any of which could have a material adverse effect on our business, financial
condition or results of operations. To the extent that new or improved oral or other systemically administered pain medications are introduced that demonstrate better long-term efficacy and safety, patients and physicians may further delay the
introduction of injectable therapies, such as <FONT STYLE="white-space:nowrap">EP-104,</FONT> in the treatment for any indication we pursue. <FONT STYLE="white-space:nowrap">EP-104</FONT> could also face competition from other formulations or
devices that deliver pain medication on an extended basis, such as transdermal delivery systems or implantable devices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of our
competitors have substantially greater financial, technical and other resources, such as larger research and development staffs and experienced commercial and manufacturing organizations. Mergers and acquisitions in the biotechnology and
pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able and may be more effective in selling and marketing their
products as well. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the
commercial applicability of technologies and greater availability of capital for investment in these industries. Competitors may succeed in developing, acquiring or licensing on an exclusive basis drug products or drug delivery technologies that are
more effective or less costly than <FONT STYLE="white-space:nowrap">EP-104</FONT> for any of our intended applications, or any other product candidate that we are currently developing or may develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that our ability to compete effectively depends upon many factors both within and beyond our control, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the usefulness, ease of use, performance and reliability of our technology compared to our competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the activity, tolerability, and potential benefits of <FONT STYLE="white-space:nowrap">EP-104</FONT> and our
other product candidates, including relative to marketed products and product candidates in development by third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to distinguish safety and efficacy from existing, alternative therapies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing for product candidates to complete clinical development and receive market approval;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of <FONT STYLE="white-space:nowrap">EP-104</FONT> and any of our other product candidates that
receive regulatory approval by patients, physicians and other health providers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to monetize our technology; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the selection of licensing partners for our technology with the necessary skills and resources to drive
uptake; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our marketing and selling efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial condition and results of operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to maintain a good relationship with regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price of our future products, including in comparison to branded or generic competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether coverage and adequate levels of reimbursement are available under private and governmental health
insurance plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquisitions or consolidations within our industry, which may result in more formidable competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect our intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract, retain and motivate talented employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to cost-effectively manage and grow our operations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation and brand strength relative to that of our competitors. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our future success will depend on our ability to continually enhance and develop our product candidates. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There is a broad pipeline of potential new therapies for pain. The market for pain management and treatment solutions is characterized by rapid
technological change and the possibility of frequent new product introductions. Accordingly, our future success depends upon our ability to enhance our current product candidates and to develop, introduce and sell the most accurate products at
competitive prices. The development of new technologies and products involves time, substantial costs and risks. Our ability to successfully develop new technologies depends in large measure on our ability to maintain a technically skilled research
and development staff and to adapt to technological changes and advances in the industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The success of new product introductions
depends on a number of factors including the efficacy and safety as demonstrated in clinical trials, the ability to demonstrate the impact of real world evidence, timely and successful product development, the timing and market introduction of
competitive products, market acceptance, the effective management of purchase commitments and inventory levels in line with anticipated product demand, the availability of pharmaceutical components in appropriate quantities and costs to meet
anticipated demand, the risk that new products may have quality or other defects in the early stages of introduction and our ability to manage distribution and production issues related to new product introductions, the clinical indications for
which the product is approved, acceptance by physicians, the medical community and patients of the product as a safe and effective treatment, the ability to distinguish safety and efficacy from existing, less expensive alternative therapies, the
convenience of prescribing, administrating and initiating patients on the product, the potential and perceived advantages and/or value of the product over alternative treatments, the cost of treatment in relation to alternative treatments, including
any similar generic treatments, the availability of coverage and adequate reimbursement by third-party payors and government authorities to support the product&#146;s pricing, the prevalence and severity of adverse side effects and the effectiveness
of sales and marketing efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are unable, for any reason, to enhance, develop, introduce and sell new products in a timely
manner, or at all, in response to changing market conditions or customer requirements or otherwise, our business would be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if
we successfully advance any other product candidates into clinical development, their success will be subject to all of the clinical, regulatory and commercial risks described elsewhere in this &#147;<I>Risk Factors</I>&#148; section. Accordingly,
we cannot assure you that we will ever be able to discover, develop, obtain regulatory approval of, commercialize or generate significant revenue from our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or
indications that may be more profitable or for which there is a greater likelihood of success. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because we have limited financial and
managerial resources, we focus on research programs, therapeutic platforms and product candidates that we identify for specific indications. As a result, we may forgo or delay pursuit of opportunities with other therapeutic platforms or product
candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. We are currently evaluating funding alternatives for the continued development of EP-104IAR, including potential
partnership opportunities. As a result, we intend to use capital resources previously identified for EP-104IAR development to continue development of EP-104GI. We cannot be certain that our decision to prioritize development of EP-104GI over
EP-104IAR will be beneficial to our shareholders. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development
programs, therapeutic platforms and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may
relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various
aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry
the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the
altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and
jeopardize our ability to commercialize our product candidates, if approved, and generate revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>If we are unable to differentiate <FONT
STYLE="white-space:nowrap">EP-104</FONT> from existing therapies, or if the FDA or other applicable regulatory authorities approve additional, and potentially less costly, therapies that compete with <FONT STYLE="white-space:nowrap">EP-104,</FONT>
our ability to successfully commercialize <FONT STYLE="white-space:nowrap">EP-104GI</FONT> or EP-104IAR would be adversely affected. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial opportunities could be reduced or eliminated if existing or future therapies for EoE, OA or any other indication we may pursue
are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than EP-104. The key competitive factors affecting the success of our product candidates, if approved, are likely to be their efficacy,
safety and/or tolerability, convenience and ease of administration, price, the potential advantages of alternative products, the level of generic competition, and the availability of coverage and adequate reimbursement from government and other
third-party payers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are two approved treatments for EoE in the United States: Dupixent (dupilumab), a monoclonal antibody (mAb)
marketed by Sanofi and Regeneron, and Takeda&#146;s recently-approved Eohilia, a twice-daily oral suspension of budesonide approved for up to 12&nbsp;weeks of use. In addition, Jorveza is an effervescent orodispersible budesonide tablet available in
the European Union and Canada. If these or any future treatment for EoE better meet the competitive factors described above, we may be unsuccessful in commercializing EP-104GI and our business, financial results and prospects could be adversely
affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The current intra-articular standard of care for OA pain, immediate-release triamcinolone acetonide (&#147;<B>TCA</B>&#148;)
and other injectable immediate-release steroids, are available in generic form and are therefore relatively inexpensive compared to the potential pricing for <FONT STYLE="white-space:nowrap">EP-104IAR.</FONT> Although we believe our Phase 2 study
provides preliminary evidence of extended pain relief, it is possible that we and any potential partner will receive data from additional clinical trials or in a post marketing setting from physician and patient experiences with the commercial
product that does not continue to support such interpretations. It is also possible that the FDA, physicians and healthcare payors will not agree with our and any potential partner&#146;s interpretation of existing and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
future clinical trial data. If we and any potential partner are unable to demonstrate the value of <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> based on clinical data, patient experience, as
well as real world evidence, the opportunity for <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> to obtain premium pricing and be commercialized successfully would be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to existing treatments, the FDA or other applicable regulatory authorities may approve other generic products that could compete
with <FONT STYLE="white-space:nowrap">EP-104</FONT> if we cannot adequately protect it with our patent portfolio. For example, in the United States, once an NDA, including a Section&nbsp;505(b)(2) application, is approved, the product covered
thereby becomes a &#147;listed drug&#148; which can, in turn, be cited by potential competitors in support of approval of an abbreviated new drug application (&#147;<B>ANDA</B>&#148;). The Federal Food, Drug, and Cosmetic Act, FDA regulations and
other applicable regulations and policies provide incentives to manufacturers to create modified, <FONT STYLE="white-space:nowrap">non-infringing</FONT> versions of a drug to facilitate the approval of an ANDA or other application for generic
substitutes. These manufacturers might only be required to conduct a relatively inexpensive study to show that their product has the same active ingredient(s), dosage form, strength, route of administration, conditions of use, or labeling as our
product candidate and that the generic product is bioequivalent to ours, meaning it is absorbed in the body at the same rate and to the same extent as <FONT STYLE="white-space:nowrap">EP-104.</FONT> These generic equivalents, which must meet the
same quality standards as branded pharmaceuticals, would be significantly less costly than ours to bring to market and companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, after the
introduction of a generic competitor, a significant percentage of the sales of any branded product is typically lost to the generic product. Accordingly, competition from generic equivalents to our products would materially adversely impact our
ability to successfully commercialize <FONT STYLE="white-space:nowrap">EP-104.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>A variety of risks associated with potential
international business relationships could materially adversely affect our business. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to evaluate from time to time entering
into agreements with third parties for the development and commercialization of <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> and may in the future seek to enter into similar agreements for other product candidates in international markets. If
we do so, we would be subject to additional risks related to entering into international business relationships, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing regulatory requirements in other countries including, among others, marketing approval, pricing,
reimbursement and sales and marketing practices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential for <FONT STYLE="white-space:nowrap">so-called</FONT> parallel importing, which is when a local
seller, faced with higher local prices, opts to import goods from a foreign market with lower prices, rather than buying them locally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees traveling and working abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign taxes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and
other risks incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is more common than in Canada or the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad or supply chain disruptions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including
war and terrorism, or natural disasters, including earthquakes, volcanoes, typhoons, floods, tsunamis, hurricanes and fires. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These and other risks may materially adversely affect our ability to develop and commercialize products in international markets and may harm
our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In particular, there is currently significant uncertainty about the future relationship between the United States and
various other countries, most significantly China, with respect to trade policies, treaties, tariffs, taxes, and other limitations on cross-border operations. The U.S. government has made and continues to make significant additional changes in U.S.
trade policy and may continue to take future actions that could negatively impact U.S. trade. For example, legislation has been introduced in Congress to limit certain U.S. biotechnology companies from using equipment or services produced or
provided by select Chinese biotechnology companies, and others in Congress have advocated for the use of existing executive branch authorities to limit those Chinese service providers&#146; ability to engage in business in the U.S. We cannot predict
what actions may ultimately be taken with respect to trade relations between the United States and China or other countries, what products and services may be subject to such actions or what actions may be taken by the other countries in
retaliation. If we are unable to obtain or use services from existing service providers or become unable to export or sell our products to any of our customers or service providers, our business, liquidity, financial condition, and/or results of
operations would be materially and adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Collaboration arrangements we may enter into in the future may not be
successful. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the ordinary course, we evaluate various partnerships, collaborations and other strategic transaction and may seek to
enter into such transactions to help maximize the commercial potential of <FONT STYLE="white-space:nowrap">EP-104</FONT> and our other product candidates. In particular, we are evaluating funding alternatives for the continued development of <FONT
STYLE="white-space:nowrap">EP-104IAR,</FONT> including potential partnerships. We may enter into such arrangements on a selective basis depending on the merits of retaining commercialization rights as compared to entering into selective
collaboration arrangements with leading pharmaceutical or biotechnology companies for <FONT STYLE="white-space:nowrap">EP-104</FONT> for any intended application and other product candidates, both in the United States and internationally. We face
competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time consuming to negotiate, document and implement. We may not be successful in our efforts to establish and implement collaborations or other
alternative arrangements should we choose to enter into such arrangements. The terms of any collaborations or other arrangements that we may establish may not be favorable to the us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if we enter into partnerships, collaborations or other strategic transactions, such
transactions that we enter into may not be successful. The success of any such arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and
resources that they will apply to these collaborations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Disagreements between parties to a collaboration arrangement regarding clinical
development and commercialization matters could lead to delays in the development process or commercialization of our product candidates and in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve
if neither of the parties has final decision-making authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Collaborations with pharmaceutical or biotechnology companies and other
third parties often are terminated or allowed to expire by the other party. If we do enter into partnerships, collaborations or other strategic transactions, any such termination or expiration could adversely affect us financially and could harm our
business reputation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Provisions of our existing and any future debt instruments may restrict our ability to pursue our business
strategies. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we have used debt financing to provide capital for our business. The Debt Agreement does, and debt
instruments we may enter into in the future may, require us to comply with various covenants that limit our and our subsidiaries&#146; ability to, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dispose of assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complete mergers or acquisitions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur indebtedness; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">encumber assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay dividends or make other distributions to holders of our capital stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make investments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change our organizational structure or jurisdiction of organization; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">engage in any new line of business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">engage in certain transactions with our affiliates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any future debt instruments could further inhibit our ability to pursue our business strategies and may also impose certain financial
covenants that require us to achieve certain revenue targets and/or maintain certain minimum cash balances. If we default under any such debt instruments, the lenders could terminate commitments to lend and cause all amounts outstanding with respect
to such debt to be due and payable immediately, which in turn could result in cross defaults under other debt instruments. Our assets and cash flow may not be sufficient to fully repay borrowings under all of our then outstanding debt instruments if
some or all of these instruments are accelerated upon a default. If we are unable to repay, refinance or restructure indebtedness when payment is due, the lenders could also proceed against any collateral granted to them to secure such indebtedness
or force us into bankruptcy or liquidation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We may acquire businesses or products, or form strategic alliances in the future, and we
may not realize the benefits of such acquisitions or alliances. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may acquire additional businesses or products, form strategic
alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such
businesses if we are unable to successfully integrate them our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or
acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction. In addition, we may
require significant additional funds to either acquire such businesses or products or to commercialize them, which may result in significant dilution to shareholders or the incurrence of significant indebtedness by us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We have traditionally relied on key collaborations and grants. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our development programs may require substantial additional cash. Traditionally, we have received funds under grant reward programs to fund
portions of such development. The grants we have received may become subject to repayment in full, under certain conditions. We cannot provide assurance that grants we have received will not become subject to repayment, that we will continue to
receive all or any of the grant funding that we apply for, that such grants if received will provide sufficient funding or that we will be able to establish future collaborations on commercially reasonable terms or at all. Inability to obtain grant
funding and establish collaboration agreements may result in product development delays or cancellation, particularly in regard to pipeline programs. In addition, the success of collaboration agreements will depend heavily on the efforts and
activities of the third-party collaborators, which are outside our control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We are subject to evolving global laws and regulations relating to privacy, data
protection and information security, which may require us to incur substantial compliance costs, and any failure or perceived failure by us to comply with such laws and regulations may harm our </I><I>business and operations</I><I>. </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the ordinary course of business, we process personal data and other sensitive information, including our proprietary and confidential
business data, trade secrets, intellectual property, data about trial participants collected in connection with clinical trials, and other sensitive data. Our data processing activities subject us to numerous data privacy and security obligations,
such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations that govern the processing of personal data by us and on our behalf. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach
notification laws, personal data privacy laws, and consumer protection laws. For example, the U.S. federal Health Insurance Portability and Accountability Act of 1996 (&#147;<B>HIPAA</B>&#148;), as amended by the Health Information Technology for
Economic and Clinical Health Act of 2009 (&#147;<B>HITECH</B>&#148;), imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. At the state level, the California Consumer
Privacy Act of 2018 (&#147;<B>CCPA</B>&#148;), as amended and supplemented by the California Privacy Rights Act, imposes obligations on businesses to which it applies. The CCPA allows for statutory fines for noncompliance. Although the CCPA exempts
some data processed in the context of clinical trials, the CCPA, to the extent applicable to our business and operations, may increase compliance costs and potential liability with respect to other personal information we may maintain about
California residents. Other states have also enacted data privacy laws, including sector-specific laws such as Washington&#146;s My Health, My Data Act, and numerous general privacy laws that share similarities with the CCPA. Additional data privacy
and security laws have been proposed at the federal, state, and local levels in recent years, which could further complicate compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Outside the U.S., the European Union&#146;s general data protection regulation (&#147;<B>EU GDPR</B>&#148;) and the United Kingdom&#146;s
general data protection regulation impose strict requirements for processing the personal data of individuals. For example, under the EU GDPR, government regulators may impose temporary or definitive bans on data processing, as well as fines of up
to 20&nbsp;million euros or 4% of annual global revenue, whichever is greater. Further, individuals may initiate litigation related to our processing of their personal data. Certain other foreign jurisdictions have enacted laws and regulations
relating to privacy, data protection, and information security, as well as certain data localization laws and cross-border personal data transfer laws, that could make it more difficult to transfer information across jurisdictions, such as
transferring or receiving personal data that originates in the EU. For example, in Canada, where we are headquartered, federal and provincial legislation impose strict requirements for the processing of personal data of individuals, with substantial
penalties for noncompliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we endeavor to comply with all applicable data privacy and security obligations, these obligations
are quickly changing in an increasingly stringent fashion, creating some uncertainty as to how to comply, and potentially requiring us to modify our policies and practices, which may be costly and may divert the attention of management and technical
personnel. Further, we may at times fail, or be perceived to have failed, to have complied with laws, regulations or other actual or asserted obligations relating to privacy, data protection or information security, and could face significant
consequences. These consequences may include, but are not limited to, government enforcement actions, investigations and other proceedings; private claims, demands, and litigation; additional reporting requirements and/or oversight; bans on
processing personal data; orders to destroy or not use personal data; imprisonment of company officials and fines, penalties, and other liabilities. Any of these events could have a material adverse effect on our reputation, business, or financial
condition, including but not limited to: interruptions or stoppages in our business operations, including our clinical trials; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our
products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our business and operations could suffer in the event of an actual or perceived information security incident such as a cybersecurity
breach, system failure, or other compromise of our systems or those of a third-party or other contractor or vendor. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We rely on both
internal information technology systems and networks, and those of third parties and their vendors and contractors, to transmit, store and otherwise process information in connection with our business activities. We are increasingly dependent upon
our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our and our third-party or other contractors&#146; or vendors&#146; technology systems and data.
Any cyberattack, including phishing or other forms of social engineering, business email compromise, ransomware or other malware, or any security breach, security incident, or other destruction, loss, or unauthorized use, modification, or other
processing of data maintained or otherwise processed by us or on our behalf could result in a loss of intellectual property or misappropriation of trade secrets, disruptions to our business and operations, subject us to increased costs and require
us to expend time and resources to address the matter, may subject us to claims, demands, and proceedings by private parties, regulatory investigations and other proceedings, and fines, penalties, and other liability and have a material adverse
effect on our business. In addition, the loss, alteration or other damage to or other unavailability of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data or clinical trial data from completed or ongoing clinical trials for our product
candidates could result in delays in our development and regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Any cyber-attack, security breach or incident, or other destruction, loss or unauthorized
processing of data maintained or otherwise processed by us or on our behalf, or the perception any such matter has occurred, could result in actual or alleged violations of applicable U.S. and international privacy, data protection, information
security and other laws and regulations, harm to our reputation, and subject us to claims, demands and litigation by private parties and governmental investigations and other proceedings by federal, state and local regulatory entities in the U.S.
and by international regulatory entities, resulting in exposure to material civil and/or criminal proceedings and liability. In addition, we may incur significant additional expense to implement further measures and policies relating to privacy,
data protection and information security, whether in response to an actual or perceived security breach or incident or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To
date, although we have faced cyberattacks and suffered information security incidents, we have not experienced any material impact to our business, financial position or operations resulting from cyberattacks or other information security incidents
of which we are aware; however, because of frequently changing attack techniques, along with the increased volume and sophistication of such attacks, our business, financial position or operations could be adversely impacted in the future. Moreover,
the prevalent use of mobile devices that access confidential information, widespread use of cloud-based applications with remote data centers, and ability to work remotely all increase the risk of security breaches and incidents. These risks may be
heightened due to the increasing number of our and our vendors&#146; and contractors&#146; personnel working remotely. Further geopolitical events such as wars and conflicts may increase the cybersecurity threats we and the third parties we work
with face. As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate information security vulnerabilities. While we
have implemented security measures, our computer systems and the external systems and services used by our third-party contract manufacturers and CROs and their vendors and contractors remain potentially vulnerable to these events and there can be
no assurance that we will be successful in preventing cyber-attacks or successfully mitigating their effects. Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyberattacks and
other related incidents, and we cannot be sure that such coverage will continue to be available on acceptable terms or at all. In addition, regulators are considering new cybersecurity laws and regulations. These proposed laws and regulations may
impact the manner in which we operate and require us to incur increasing costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any of the foregoing security risks could have a material adverse effect on our business,
results of operations, or financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We may fail to manage our growth successfully which may adversely impact our operating
results. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our failure to manage our growth successfully may adversely impact our operating results. Managing our growth will require us
to continue to build our operational, financial and management controls, contracting relationships, marketing and business development plans and controls and reporting systems and procedures. Our ability to manage our growth will also depend in
large part upon a number of factors, including the ability for us to rapidly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand our internal and operational and financial controls significantly so that we can maintain control over
operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract and retain qualified technical personnel in order to continue to develop our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">build commercial infrastructure following any approval of product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">An inability to achieve any of these objectives could harm our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Guidelines and recommendations published by various organizations can reduce the use of
products that we may commercialize. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Government agencies promulgate regulations and guidelines directly applicable to us and to our
product candidates and any future products. In addition, professional societies, such as the American Gastroenterological Association, the Joint Task Force for Allergy-Immunology Practice Parameters, the American College of Rheumatology, practice
management groups, private health and science foundations and organizations involved in various diseases from time to time may also publish guidelines or recommendations to the healthcare and patient communities with respect to specific products.
Recommendations of government agencies or these other groups or organizations may relate to such matters as usage, dosage, route of administration and use of concomitant therapies. Recommendations or guidelines that do not recognize our future
products, suggest limitations or inadequacies of our future products, or suggest the use of competitive or alternative products as the standard of care to be followed by patients and healthcare providers, could result in decreased use or adoption of
our future products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We use hazardous chemicals and biological materials in our business. Any claims relating
to improper handling, storage or disposal of these materials could be time consuming and costly. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our product manufacturing, research
and development, and testing activities involve the controlled use of hazardous materials, including chemicals and biological materials. We cannot eliminate the risks of accidental contamination or the accidental discharge of these materials, or any
resulting injury from such an event. We may be subjected to litigation for any injury that results from our use or the use by third parties of these materials, and our liability may exceed our insurance coverage and our total assets. Our use,
manufacture, storage, handling and disposal of these hazardous materials and specified waste products, as well as the discharge of pollutants into the environment and human health and safety matters, are governed by federal, state, provincial and
local legislation. We are also subject to various laws and regulations relating to safe working conditions, laboratory and manufacturing practices. Our operations may require that environmental permits and approvals be issued by applicable
government agencies, which can be costly and time-consuming to attain. These regulations and legislation can change, or new ones come into place, due to future legislative or administrative actions. These events could cause us to incur additional
expense or restrict our operations. Compliance with environmental laws and regulations, current or future, may be expensive and prohibitive for our research, development, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
or production efforts. Failure to comply could incur substantial costs and liabilities, including civil or criminal fines and penalties, <FONT STYLE="white-space:nowrap">clean-up</FONT> costs or
capital expenditures to achieve and maintain compliance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>If product liability lawsuits are brought against us, then we may incur
substantial liabilities and may be required to limit commercialization of <FONT STYLE="white-space:nowrap">EP-104,</FONT> if approved for any indication, and any other future products. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We face a potential risk of product liability as a result of distribution of our product candidates for testing and commercialization of <FONT
STYLE="white-space:nowrap">EP-104</FONT> for any indication and other pipeline products, if approved. For example, we may face claims if use of <FONT STYLE="white-space:nowrap">EP-104</FONT> allegedly causes injury or is found to be otherwise
unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in product quality, a failure to warn of dangers inherent in the product candidate or
product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or
be required to limit commercialization of the product subject to such claims. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any current and future approved product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to defend any related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of management&#146;s time and our resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to commercialize <FONT STYLE="white-space:nowrap">EP-104</FONT> for any indication and other
products, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decline in our stock price; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exposure to adverse publicity. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we currently have product liability insurance in place, we do not know whether the limits of the insurance will be sufficient to
satisfy any claims should they arise. We may not have sufficient resources to pay for any liabilities resulting from a claim excluded from or beyond the limits of, our insurance coverage. If we cannot successfully defend ourselves against a product
liability claim, we may incur substantial liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our employees, independent contractors, principal investigators, consultants,
commercial partners and vendors may engage in misconduct or other improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading, which could significantly harm
our business. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are exposed to the risk that employees, independent contractors, principal investigators, consultants, commercial
partners and vendors may engage in fraudulent or other illegal activity, fraud or other misconduct. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violates:
(i)&nbsp;the law and regulations of the FDA and <FONT STYLE="white-space:nowrap">non-US</FONT> regulators, including those laws that require the reporting of true, complete and accurate information to the FDA and
<FONT STYLE="white-space:nowrap">non-US</FONT> regulators, (ii)&nbsp;healthcare fraud and abuse laws and regulations in the United States and elsewhere, and (iii)&nbsp;laws that require the true, complete and accurate reporting of financial
information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These
laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct in violation of these laws may also involve the
improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by our executives, employees,
consultants and other third parties, and any precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or
lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending itself or asserting our rights, those actions could have a significant impact on our
business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in national healthcare programs, contractual damages, reputational
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate the business and our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We may be subject to securities litigation, which is expensive and could divert management attention. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The market price of the Common Shares may be volatile, and in the past companies that have experienced volatility in the market price of their
shares have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Litigation of this type could result in substantial costs and diversion of management&#146;s attention and resources,
which could adversely impact our business. Any adverse determination in litigation could also subject us to significant liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our directors and executive officers may be affiliated with other biotech companies and
may have conflicts of interest. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain of our directors and executive officers may, from time to time, be employed by or affiliated
with organizations which have entered into agreements or will enter into agreements with us. As disputes may arise between these organizations and us, or certain of these organizations may undertake or have undertaken research with our competitors,
there exists the possibility for such persons to be in a position of conflict. We cannot assure you that any decision or recommendation made by these persons involving us will be made in accordance with his or her duties and obligations to deal
fairly and in good faith with us and such other organizations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our business may be affected by macroeconomic conditions. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Various macroeconomic factors could adversely affect our business and our results of operations and financial condition, including changes in
inflation, interest rates and foreign currency exchange rates, and overall economic conditions and uncertainties, including those resulting from political instability and the current and future conditions in the global financial markets. For
instance, if inflation or other factors were to significantly increase our business costs, it may not be feasible to pass through price increases to patients. Interest rates, the liquidity of the credit markets and the volatility of the capital
markets could also affect the value of our investments and our ability to liquidate our investments in order to fund our operations, if necessary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest rates and the ability to access credit markets could also adversely affect the ability of payors and distributors to purchase, pay
for and effectively distribute our products if and when approved. Similarly, these macroeconomic factors could affect the ability of our current or potential future contract manufacturers, sole-source or single-source suppliers, or licensees to
remain in business or otherwise manufacture or supply our product candidates. Failure by any of them to remain in business could affect our ability to manufacture product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our business may be affected by global geopolitical risks. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the risks specific to the countries in which we operate, global events such as war and occupation, terrorism and related
geopolitical risks may lead to increased market volatility and may have adverse short-term and long-term effects on world economies and markets generally. For example, in late February 2022, Russian military forces launched significant military
action against Ukraine, and conflict and disruption in the region is ongoing. This conflict has the potential to affect our clinical trial operations in Poland, Czech Republic and Denmark. The impact to Ukraine, as well as actions taken by other
countries, including new and stricter sanctions by Canada, the United Kingdom, the European Union, the United States and other countries and organizations against officials, individuals, regions, and industries in Russia, Ukraine and Belarus, and
each country&#146;s potential response to such sanctions, tensions, and military actions could have an adverse effect on our operations. These countries may impose further sanctions or other restrictive actions against governmental or other
individuals or organizations in Russia or elsewhere. The effects of disruptive events could affect the global economy and financial and commodities markets in ways that cannot necessarily be foreseen at the present time. These events could also
exacerbate other <FONT STYLE="white-space:nowrap">pre-existing</FONT> political, social and economic risks, including those described elsewhere in this AIF. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We may be responsible for corruption and anti-bribery law violations. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business activities are subject to the to the United States <I>Foreign Corrupt Practices Act </I>(the &#147;<B>FCPA</B>&#148;) and other
anti-bribery and anti-corruption laws of the United States and other countries in which we operate, as well as U.S. and certain foreign export controls and trade sanctions which generally prohibit companies and company employees from engaging in
bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business. Our employees or other agents may, without our knowledge and despite our efforts, engage in prohibited conduct under our policies and
procedures and the FCPA or other anti-bribery laws for which we may be held responsible. If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties and other consequences that may have a material
adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We are subject to foreign exchange risks. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As we grow and do business in foreign markets, including the United States and Europe, it is quite possible that transactions will take place
in foreign currencies. At this point we do not participate in hedging activities. Although we cannot predict the effect of possible foreign exchange losses in the future, if such losses occurred, they could have a material adverse effect on our
business, results of operation, and financial condition. In addition, fluctuations in exchange rates could affect the pricing of our products and negatively influence customer demand. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We are subject to taxation risks and changing rules by different tax authorities. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Tax examinations are often complex as tax authorities may disagree with the treatment of items reported by us, the result of which could have a
material adverse effect on our financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We are subject to a number of risks and hazards and may
not be sufficiently insured for all of them. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business is subject to a number of general risks and hazards, including general
liability. Such occurrences could result in damage to property, inventory or facilities, personal injury or death to <FONT STYLE="white-space:nowrap">end-customers</FONT> or operators, damage to our properties or the properties of others, monetary
losses and possible legal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
liability. Although we maintain insurance to protect against certain risks in such amounts as we consider to be reasonable, our insurance may not cover all the potential risks associated with our
operations. We may also be unable to maintain insurance to cover these risks at economically feasible premiums. Insurance coverage may not continue to be available or may not be adequate to cover any resulting liability. We might also become subject
to liability which may not be insured against or which we may elect not to insure against because of premium costs or other reasons. Losses from these events may cause us to incur significant costs that could have a material adverse effect upon our
financial performance and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We will devote significant resources to regulatory compliance as a public entity.
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a public company, we incur significant legal, accounting and other expenses. Legal, accounting and other expenses associated with
public company reporting requirements have increased significantly in recent years. We anticipate that costs may continue to increase with corporate governance related requirements, including, without limitation, requirements under National
Instrument <FONT STYLE="white-space:nowrap">52-109</FONT> - <I>Certification of Disclosure in Issuers&#146; Annual and Interim Filings</I>, National Instrument <FONT STYLE="white-space:nowrap">52-110</FONT> - <I>Audit Committees</I> and National
Instrument <FONT STYLE="white-space:nowrap">58-101</FONT> - <I>Disclosure of Corporate Governance Practices</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our management and other
personnel will devote a substantial amount of time to regulatory compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and make some activities more time-consuming and costly. For
example, these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our testing, or any subsequent testing by our independent auditor, has in the past and may in the future reveal deficiencies in our internal
control over financial reporting that are deemed to be material weaknesses. We will incur substantial accounting expense and expend significant management efforts to comply with internal control over financial reporting requirements. We currently do
not have an internal audit group, and we anticipate hiring additional accounting and financial staff with appropriate public company experience and technical accounting knowledge. Moreover, if we are not able to comply with these requirements in a
timely manner or if we or our independent auditor identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of the Common Shares could decline, and we could be subject to
sanctions or investigations by applicable securities regulatory authorities, which would require additional financial and management resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Changes in accounting standards from&nbsp;IFRS&nbsp;to U.S.&nbsp;GAAP&nbsp;can be difficult to predict and could adversely impact how we
record and report our financial condition and results of operations. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have historically reported our financial condition and results
of operation under IFRS. Beginning with our financial statements as of and for the years ended December&nbsp;31, 2023, and 2022, we intend to begin reporting our financial condition and results of operations under United States generally accepted
accounting principles (&#147;<B>U.S. GAAP</B>&#148;), which is periodically revised by the Financial Accounting Standards Board (&#147;<B>FASB</B>&#148;). Accordingly, from time to time we will be required to adopt new or revised accounting
standards or interpretations issued by the FASB. The estimated impact of accounting pronouncements that have been issued but not yet implemented will be disclosed in our reports filed with the United States Securities and Exchange Commission (the
&#147;<B>SEC</B>&#148;) and SEDAR+. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our consolidated financial statements have been prepared in accordance with IFRS&nbsp;as issued by
the International Accounting Standards Board. There are, and may continue to be, certain significant differences between&nbsp;IFRS&nbsp;and U.S.&nbsp;GAAP, including but not limited to potentially significant differences related to the accounting
and disclosure requirements relating to insurance contracts, investments, other nonfinancial assets and taxation. As a result, our financial information and reported earnings for historical or future periods could be significantly different if they
are prepared in accordance with U.S.&nbsp;GAAP, and you may not be able to meaningfully compare our historical financial statements under&nbsp;IFRS with those that we prepare under U.S.&nbsp;GAAP&nbsp;in the future. The transition
from&nbsp;IFRS&nbsp;to U.S.&nbsp;GAAP&nbsp;may also increase our company&#146;s legal, audit, accounting and financial compliance costs, make some activities more difficult, time consuming or costly and may also place undue strain on our
company&#146;s personnel, systems and resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>In the past, we have had to restate our previously issued consolidated financial
statements and as part of that process identified a material weakness in our disclosure controls and procedures and internal control over financial reporting as of December&nbsp;31, 2022. If we are unable to develop and maintain effective disclosure
controls and procedures and internal control over financial reporting, we may not be able to accurately report our financial results in a timely manner, which may adversely affect investor confidence in us and may adversely affect our business,
financial condition and results of operations. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the supervision and with the participation of management, including our chief
executive officer and chief financial officer, and in conjunction with the reaudit of our consolidated financial statements by our new auditor, KPMG LLP, we determined that there were a number of areas where our historical consolidated financial
statements for the periods ending September&nbsp;30, 2022, December&nbsp;31, 2022 and December&nbsp;31, 2021 required adjustment largely related to the accounting treatment of select financial instruments (notably convertible debt instruments and
warrant valuations) and their classification as liabilities versus shareholders equity. We expect that similar adjustments to our historical consolidated financial statements will need to be made for the periods ending March&nbsp;31, 2023 and
June&nbsp;30, 2023 and potentially other periods in connection with the upcoming reviews of the periods ending March&nbsp;31, 2024 and June&nbsp;30, 2024. As a result of these restatements, our management
<FONT STYLE="white-space:nowrap">re-evaluated</FONT> the effectiveness of our disclosure controls and procedures and internal control over financial reporting as of December&nbsp;31, 2022. Management concluded that our disclosure controls and
procedures were not effective as of December&nbsp;31, 2022, and that our internal control over financial reporting was not effective as of December&nbsp;31, 2022, due to a material weakness. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A material weakness is a deficiency, or a combination of deficiencies, in disclosure
controls and procedures and internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.
Effective disclosure controls and procedures and internal control over financial reporting is necessary for us to provide reliable financial reporting and prevent fraud. Specifically, there was insufficient review of the classification of
liabilities and equity under IAS 32 and the valuation of instruments in accordance with IFRS 13. We are working to remediate the material weakness, but we cannot be certain that we will be able to do so in a timely or efficient manner. Even if we
are able to successfully remediate the material weakness, we may identify additional material weaknesses in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a reporting
issuer in the United States, we are required to comply with the requirements of the Exchange Act, Sarbanes-Oxley Act of 2002 (the &#147;<B>Sarbanes-Oxley Act</B>&#148;) and, if we are listed on Nasdaq, the listing standards of Nasdaq, including,
among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are continuing to develop and refine our disclosure controls and other procedures that are designed to ensure that
information required to be disclosed by us in the reports that we will file with the SEC is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in
reports under the Exchange Act is accumulated and communicated to our management, including our principal executive and financial officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also continuing to improve our internal control over financial reporting. Pursuant to the SEC rules that implement Section&nbsp;404 of
the Sarbanes-Oxley Act, beginning with our second annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;40-F</FONT> after we become subject to the reporting requirements of the Exchange Act, we will be required to make a formal assessment of
the effectiveness of our internal control over financial reporting. To achieve compliance with this requirement within the prescribed time period, we will be engaging in a process to document and evaluate our internal control over financial
reporting under such rules, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of
our internal control over financial reporting, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts,
there is a risk that we will not be able to conclude, within the prescribed time period or at all, that our internal control over financial reporting is effective as required by Section&nbsp;404 of the Sarbanes-Oxley Act. Moreover, our testing, or
the subsequent testing by our independent registered public accounting firm, has in the past and may in the future reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any failure to implement and maintain effective disclosure controls and procedures and internal control over financial reporting, including
the identification of one or more material weaknesses, could adversely impact our ability to report our financial condition and results of operations on a timely and accurate basis and could cause investors to lose confidence in the accuracy and
completeness of our financial statements and reports, which would likely adversely affect the market price of our Common Shares. In addition, we could be subject to sanctions or investigations by Nasdaq, if our shares are approved for listing on
such exchange, the SEC and other regulatory authorities. We also face potential for litigation or other disputes which may include, among others, claims invoking the securities laws, contractual claims or other claims arising from the restatement
and the material weakness in our disclosure controls and procedures and internal control over financial reporting and the preparation of our financial statements. As of the date of this AIF, we have no knowledge of any such litigation or dispute.
However, we can provide no assurance that such litigation or dispute will not arise in the future. Any such litigation or dispute, whether successful or not, could adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our success depends on our ability to protect our intellectual property and our proprietary technologies. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial success depends in part on our ability to obtain and maintain patent and other intellectual property protection for our product
candidates, proprietary technologies, and their uses as well as our ability to operate without infringing upon the proprietary rights of others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product
candidates, proprietary technologies, and their uses that are important to our business. We also seek to protect our proprietary position by acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> relevant issued patents or pending
applications from third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pending patent applications cannot be enforced against third parties practicing the technology claimed
in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our patent applications or the patent applications of our future
licensors will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around or
invalidated by third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even issued patents may later be found invalid or unenforceable or may be modified or revoked in
proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our and our future licensors&#146; proprietary rights is uncertain. Only limited protection may be available and may not
adequately protect our rights or permit us to gain or keep any competitive advantage. These uncertainties and/or limitations in our ability to properly protect the intellectual property rights relating to our product candidates could have a material
adverse effect on our financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot be certain that the claims in our U.S. pending patent applications, corresponding
international patent applications and patent applications in certain foreign territories, or those of our future licensors, will be considered patentable by the United States Patent and Trademark Office (the &#147;<B>USPTO</B>&#148;), courts in the
United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our future issued patents will not be found invalid or unenforceable if challenged. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential
future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural,
documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications may not result in any patents being issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or
otherwise may not provide any competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors, many of whom may have substantially greater resources than we do and many of whom may have
made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use and sell our potential product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the
scope of patent protection both inside and outside the United States for treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by
U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The patent prosecution process is also expensive and time-consuming, and we and any future licensors may not be able to file and prosecute all
necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we or any future licensors will fail to identify patentable
aspects of our research and development output before it is too late to obtain patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, although we enter into <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, third-party
manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such
candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to
prevent our competitors from commercializing similar or identical product candidates would be adversely affected. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The patent position
of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value
of our patent rights are highly uncertain. Our pending and future patent applications and those of our future licensors may not result in patents being issued which protect our product candidates or which effectively prevent others from
commercializing competitive product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, the coverage claimed in a patent application can be significantly reduced
before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future issue as patents, they may not issue in a form that will provide
us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> may be
challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether our product candidates will be protectable or remain protected by valid and enforceable
patents. Our competitors or other third parties may be able to circumvent our patents or the patents of our future licensors by developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT>
manner which could materially adversely affect our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The issuance of a
patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents or the patents of our current or future licensors may be challenged in the courts or patent offices in the United States and abroad. We may be
subject to a third-party <FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review
(&#147;<B>PGR</B>&#148;) and inter partes review (&#147;<B>IPR</B>&#148;), or other similar proceedings challenging our owned or licensed patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope
of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products
without infringing third-party patent rights. Moreover, our patents or the patents of our current or future licensors may become subject to post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our priority
of invention or other features of patentability with respect to our patents and patent applications and those of our current or future licensors. Such challenges may result in loss of patent rights, loss of exclusivity or in patent claims being
narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technologies or product
candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our
patents and patent applications or the patents and patent applications of our current or future licensors is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current
or future product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Intellectual property rights do not necessarily address all potential threats to our
competitive advantage. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual
property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to develop products that are similar to our product candidates but that are not covered by
the claims of the patents that we own or license; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or future licensors or collaborators might not have been the first to make the inventions covered by the
issued patents or patent application that we own or license; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our current or future licensors or collaborators might not have been the first to file patent
applications covering certain of our inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies
without infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that the pending patent applications we own or license will not lead to issued patents;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by
our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent
rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may have an adverse effect on our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file a patent in order to maintain certain trade secrets or <FONT
STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent covering such intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Should any of these events occur, it could significantly harm our business, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our patent rights may prove to be an inadequate barrier to competition. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The lifespan of any one patent is limited, and each of these patents will ultimately expire and we cannot be sure that pending applications
will be granted, or that we will discover new inventions which we can successfully patent. Moreover, any of our granted patents may be held invalid by a court of competent jurisdiction, and any of these patents may also be construed narrowly by a
court of competent jurisdiction in such a way that it is held to not directly cover our product candidates. Furthermore, even if our patents are held to be valid and broadly interpreted, third parties may find legitimate ways to compete with our
product candidates by inventing around our patent. Finally, the process of obtaining new patents is lengthy and expensive, as is the process for enforcing patent rights against an alleged infringer. Any such litigation could take years, cost large
sums of money, and pose a significant distraction to management. Indeed, certain jurisdictions outside of the U.S. and European Union, where we hope to commercialize our product candidates have a history of inconsistent, relatively lax or
ineffective enforcement of patent rights. In such jurisdictions, even a valid patent may have limited value. Our failure to effectively enforce our patents would have a harmful impact on our ability to commercialize our product candidates in these
jurisdictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our commercial success depends significantly on our ability to operate without infringing the patents and other
proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research,
development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary
rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and
outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, <FONT STYLE="white-space:nowrap">re-examinations,</FONT> IPR proceedings and
PGR proceedings before the USPTO and/or corresponding foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be
third-party patents or patent applications with claims to materials, compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As the biopharmaceutical industry expands and more patents are issued, the risk increases
that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published, we may
be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover,
because patent applications can take many years to issue, there may be currently-pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights
that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases, and the difficulty in assessing the meaning of patent claims. There is also no assurance
that there is not prior art of which we are aware, but which we do not believe is relevant to our business, which may, nonetheless, ultimately be found to limit our ability to make, use, sell, offer for sale or import our products that may be
approved in the future, or impair our competitive position. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any claims of patent infringement asserted by third parties
would be time consuming and could: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">result in costly litigation that may cause negative publicity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">divert the time and attention of our technical personnel and management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cause development delays; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prevent us from commercializing any of our product candidates until the asserted patent expires or is held
finally invalid or not infringed in a court of law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to develop <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology, which may not be
possible on a cost-effective basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject us to significant liability to third parties; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to enter into royalty or licensing agreements, which may not be available on commercially
reasonable terms, or at all, or which might be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which could result in our competitors gaining access to the same technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although no third party has asserted a claim of patent infringement against us as of the date of this AIF, others may hold proprietary rights
that could prevent our product candidates from being marketed. It is possible that a third party may assert a claim of patent infringement directed at any of our product candidates. Any patent-related legal action against us claiming damages and
seeking to enjoin commercial activities relating to our product candidates, treatment indications, or processes could subject us to significant liability for damages, including treble damages if we were determined to willfully infringe, and require
us to obtain a license to manufacture or market our product candidates. We could be forced, including by court order, to cease commercializing the infringing technology or product. A finding of infringement could prevent us from commercializing our
planned products or force us to cease some of our business operations, which could materially harm our business. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of
employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or
our future strategic partners were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign our product
candidates, treatment indications, or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and
commercializing our product candidates, which could harm our business, financial condition and operating results. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from
marketing or otherwise commercializing our product candidates and technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Parties making claims against us may be able to sustain the
costs of complex patent litigation more effectively than we can because they may have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or
administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse
effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and
<FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because our development programs may in the future require the use of proprietary
rights held by third parties, the growth of our business may depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license,</FONT> or use these third-party proprietary rights. We may be unable to acquire or <FONT
STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of
third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These
established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to
assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that are commercially reasonable or would allow us to make an appropriate return on our investment, or at all. Even if we
are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources
to develop or license replacement technology in order to establish or maintain our competitive position in the market. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing
intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>We may be involved in lawsuits to protect or enforce our patents or our future licensors&#146; patents,
which could be expensive, time consuming, and unsuccessful. Further, our issued patents or our current or future licensors&#146; patents could be found invalid or unenforceable if challenged in court or before administrative bodies in the United
States or abroad. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Competitors may infringe our intellectual property rights. To prevent infringement or unauthorized use, we may be
required to file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or <FONT STYLE="white-space:nowrap">in-license</FONT> is not valid, is
unenforceable and/or is not infringed. If we or any of our potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that
our patent or the patent of our future licensors is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a
validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, lack of sufficient written description, <FONT STYLE="white-space:nowrap">non-enablement,</FONT> or obviousness-type
double patenting. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our patent rights may be subject to priority, validity, inventorship, ownership and enforceability disputes. Third parties may also raise
similar invalidity claims before the USPTO or patent offices abroad, even outside the context of litigation. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> PGR, IPR, derivation proceedings, and equivalent proceedings
in foreign jurisdictions (e.g., opposition proceedings). The outcome following legal assertions of invalidity and/or unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no
invalidating prior art, of which we, our future licensors, and the patent examiners are unaware during prosecution. There is also no assurance that there is not prior art of which we are aware, but which we do not believe affects the validity or
enforceability of a claim in our patents and patent applications or the patents and patent applications of our future licensors, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. If a third party were
to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our technology or platform, or any product candidates that we may develop. Such a loss of patent protection
would have a material adverse impact on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, if the
breadth or strength of protection provided by our patents and patent applications or the patents and patent applications of our current or future licensors is threatened, it could dissuade companies from collaborating with us to license, develop or
commercialize current or future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if resolved in our favor, litigation or other legal proceedings relating to our
intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses
and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our
competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other
proceedings could compromise our ability to compete in the marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, because of the substantial amount of discovery
required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of
litigation or other proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the issuance of a patent does not give us the right to practice the patented invention.
Third parties may have blocking patents that could prevent us from marketing our own patented product and practicing our own patented technology. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our Common Shares to decline.
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as
well as results of hearings, rulings on motions, and other interim proceedings or developments in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing product candidates,
approved products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could
have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable
outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Derivation
proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our future licensors. An unfavorable outcome
could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of
derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our
ability to raise the funds necessary to continue our clinical trials, continue our development programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product
candidates to market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or
expiration of a third-party patent, which might adversely affect our ability to develop and market our products and product candidates. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims
or the expiration of relevant patents, are or will be complete or thorough, nor can we be certain that we have identified or will identify each and every third-party patent and pending patent application in the United States and abroad that is
relevant to or necessary for the commercialization of our current and future products and product candidates in any jurisdiction. Patent applications in the United States and elsewhere are not published until approximately 18 months after the
earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates could have been filed by others without our knowledge. The
scope of a patent claim is determined by the interpretation of the law, the words of a patent claim, the written disclosure in a patent and the patent&#146;s prosecution history. Our interpretation of the relevance or the scope of a patent or a
pending patent application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products or product candidates are not covered by a third-party patent or may incorrectly predict
whether a third party&#146;s pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, and we may
incorrectly conclude that a third-party patent is invalid and unenforceable or not infringed. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products and product
candidates. If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. Also, because the claims of published patent applications can change between publication and patent grant, there may be published
patent applications that may ultimately issue with claims that we infringe. As the number of competitors in the market grows and the number of patents issued in this area increases, the possibility of patent infringement claims escalates. Moreover,
in recent years, individuals and groups that are <FONT STYLE="white-space:nowrap">non-practicing</FONT> entities, commonly referred to as &#147;patent trolls,&#148; have purchased patents and other intellectual property assets for the purpose of
making claims of infringement in order to extract settlements. From time to time, we may receive threatening letters, notices or &#147;invitations to license,&#148; or may be the subject of claims that our products and business operations infringe
or violate the intellectual property rights of others. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, we may
be temporarily or permanently prohibited from commercializing any of our product candidates that are held to be infringing. We might, if possible, also be forced to redesign product candidates or services so that we no longer infringe the
third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes in U.S. patent law, or laws in other countries, or their interpretation could diminish the value of patents in general, thereby impairing our
ability to protect our product candidates. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As is the case with other pharmaceutical companies, our success is heavily dependent on
intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing pharmaceutical patents is costly, time
consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs
surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition, Congress or other
foreign legislative bodies may pass patent reform legislation that is unfavorable to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Assuming that other requirements for
patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March
2013, under the Leahy-Smith America Invents Act (the &#147;<B>America Invents Act</B>&#148;) enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability
are met, the first inventor to file a patent application would be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO
after March 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This requires us to be cognizant of the time from invention to filing of a
patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors are the first to either (i)&nbsp;file any
patent application related to our product candidates and other proprietary technologies we may develop or (ii)&nbsp;invent any of the inventions claimed in our patents or patent applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The America Invents Act also included several significant changes that affect the way patent applications are prosecuted and also affect
patent litigation. These include allowing third party protests and submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including
post-grant review, <I>inter partes</I> review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a
third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.
Accordingly, a third party may attempt to use the USPTO procedures to invalidate our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent claims that would not have been invalidated if first challenged by the third party as a
defendant in a district court action. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The U.S. law relating the patentability of certain inventions in the life sciences is
uncertain and rapidly changing, which may adversely impact our existing patents or our ability to obtain patents in the future. The U.S. Supreme Court and federal courts have ruled on several patent cases in recent years that impact the scope of
patentability of certain inventions or discoveries related to the life, including both narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. The trend of these
decisions along with resulting changes in patentability requirements being implemented by the USPTO could make it increasingly difficult for us to obtain and maintain patents on our products, and could jeopardize or otherwise reduce patent term,
reduce the scope of, or invalidate or render unenforceable our patent rights. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the
value of patents, once obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Depending on future actions and/or decisions by the U.S. Congress, the U.S. federal courts, the USPTO,
or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patent and the patents we might obtain or
license in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the
governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the
future. As an example, beginning June&nbsp;1, 2023, European patent applications and patents may be subjected to the jurisdiction of the Unified Patent Court (the &#147;<B>UPC</B>&#148;). Also, European patent applications will have the option, upon
grant of a patent, of becoming a Unitary Patent, which will be subject to the jurisdiction of the UPC. The UPC and Unitary Patent are significant changes in European patent practice. As the UPC is a new court system, there is no precedent for the
court, increasing the uncertainty of any litigation in the UPC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2012, the European Union Patent Package (the &#147;<B>EU Patent
Package</B>&#148;) regulations were passed with the goal of providing a single <FONT STYLE="white-space:nowrap">pan-European</FONT> Unitary Patent and a new European UPC for litigation involving European patents. The EU Patent Package was
implemented on June&nbsp;1, 2023. As a result, all European patents, including those issued prior to ratification of the EU Patent Package, now by default automatically fall under the jurisdiction of the UPC. It is uncertain how the UPC will impact
granted European patents in the biotechnology and pharmaceutical industries. Our European patent applications, if issued, could be challenged in the UPC. During the first seven years of the UPC&#146;s existence, the UPC legislation allows a patent
owner to opt its European patents out of the jurisdiction of the UPC. We may decide to opt out our future European patents from the UPC, but doing so may preclude us from realizing the benefits of the UPC. Moreover, if we do not meet all of the
formalities and requirements for <FONT STYLE="white-space:nowrap">opt-out</FONT> under the UPC, our future European patents could remain under the jurisdiction of the UPC. The UPC will provide our competitors with a new forum to centrally revoke our
European patents, and allow for the possibility of a competitor to obtain <FONT STYLE="white-space:nowrap">pan-European</FONT> injunction. Such a loss of patent protection could have a material adverse impact on our business and our ability to
commercialize our technology and product candidates due to increased competition and, resultantly, on our business, financial condition, prospects and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>We may be subject to claims challenging the inventorship or ownership of our patents, the patents we license, and other intellectual property. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may also be subject to claims that former employees or other third parties have an ownership interest in our patents, the patents we license
or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other
employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20 years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product
candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting
such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.
If we do not have sufficient patent life to protect our products, our business, financial condition, results of operations, and prospects will be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>We may not be able to protect or enforce our intellectual property rights throughout the world. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we have pending patent applications and patents in the United States, Canada and other countries, filing, prosecuting and defending
patents and trademarks on all of our planned products in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the
United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing
our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not
obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete
with our product candidates, and our patents, the patents of our future licensors, or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many companies have encountered significant problems in protecting and defending
intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make
it difficult for us to stop the infringement of our patents or our future licensors&#146; patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could
result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents or the patents of our future licensors at risk of being invalidated or interpreted narrowly and our patent applications or the
patent applications of our future licensors at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be
commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition,
many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to
grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. In addition, <FONT
STYLE="white-space:nowrap">geo-political</FONT> actions in the United States and in foreign countries (such as the Russia and Ukraine conflict) could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent
applications or those of any future licensors and the maintenance, enforcement or defense of our issued patents which could impair our competitive intellectual property position. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary submission, fee payment and other requirements
imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the
USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications and those of our future licensors. We have systems in place to remind us to pay these fees, and we rely on our outside patent annuity
service to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ
reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are
situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material
adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in
our markets of interest and our business may be adversely affected. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to use registered or unregistered trademarks or trade
names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these
trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build
brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered
or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our
efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could
adversely affect our financial condition or results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>If we are unable to protect the confidentiality of our trade secrets, the value of
our technology could be materially adversely affected, harming our business and competitive position. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we rely on the
protection of our trade secrets, including unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information to maintain our competitive position. Any disclosure to or misappropriation by third parties of our
confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in the market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we have taken steps to protect our trade secrets and unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> including entering
into confidentiality agreements with third parties, and confidential information and inventions assignment agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and
any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or
misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, third
parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we
otherwise lose protection for our trade secrets, the value of this information may be greatly reduced, and our competitive position would be harmed. If we are unable to prevent disclosure of the intellectual property related to our technologies to
third parties, we may not be able to establish or maintain a competitive advantage in our market, which would harm our ability to protect our rights and have a material adverse effect on our business. If we do not apply for patent protection prior
to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>We may be subject to claims that we or our employees, independent contractors, or consultants have
wrongfully used or disclosed alleged confidential information or trade secrets. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into and may enter in the future into <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements to protect the proprietary positions of third parties, such as outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors, potential
partners, and other third parties. We may become subject to litigation where a third party asserts that we or our employees inadvertently or otherwise breached the agreements and used or disclosed trade secrets or other information proprietary to
the third parties. Defense of such matters, regardless of their merit, could involve substantial litigation expense and be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such
actions. Moreover, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing our product candidates and technology. Failure to defend against any such
claim could subject us to significant liability for monetary damages or prevent or delay our developmental and commercialization efforts, which could adversely affect our business. Even if we are successful in defending against these claims,
litigation could result in substantial costs and be a distraction to our management team and other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Parties making claims
against us may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they may have substantially greater resources. Furthermore, because of the substantial amount of discovery required in
connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could
have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, operating results, financial condition and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees, independent contractors, or
consultants have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As is
common in the biotechnology and pharmaceutical industry, we employ individuals and engage the service of consultants, who were previously employed at, may have previously provided, or may be currently providing consulting services to, other
biotechnology or pharmaceutical companies, including our competitors or potential competitors. Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential
competitors. Some of these individuals, including members of our senior management, executed proprietary rights, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> agreements, or
similar agreements, in connection with such previous employment. Although we use reasonable efforts to ensure that our employees, independent contractors, and consultants do not use the proprietary information or
<FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or these individuals inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other
proprietary information, of any such former employers, clients, or third parties. These and other claims that we have misappropriated the confidential information or trade secrets of third parties can have a similar negative impact on our business
to the infringement claims discussed above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Litigation may be necessary to defend against these claims. If we fail in defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in
substantial costs and be a distraction to our management team and other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>We may be subject to claims challenging the inventorship of our
patents and other intellectual property. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may be subject to claims that former employees, consultants, collaborators or other third
parties have an interest in our patent rights, trade secrets, or other intellectual property as an inventor, <FONT STYLE="white-space:nowrap">co-inventor</FONT> or owner of trade secrets. For example, we may have inventorship disputes arise from
conflicting obligations of employees, consultants or others who are involved in developing our product candidates and other proprietary technologies we may develop. Litigation may be necessary to defend against these and other claims challenging
inventorship or our patent rights, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable personnel or intellectual property rights, such as exclusive
ownership of, or the right to use intellectual property that is important to our product candidates and other proprietary technologies we may develop. Such intellectual property rights could be awarded to a third party, and we could be required to
obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result
in substantial costs and be a distraction to our management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our rights to develop and commercialize our technology and product candidates may be subject, in part, to the terms and conditions of any future licenses
granted to us by others. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may enter into license agreements in the future with others to advance our existing or future research or
allow commercialization of our existing or future product candidates. These licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to
develop or commercialize our technology and products in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, subject to the terms of any such license agreements, we may not have the right
to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering the technology that we license from third parties. In such an event, we cannot be certain that these patents and
patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our future licensors fail to prosecute, maintain, enforce, and defend such patents or
patent applications, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our future product candidates that are subject of such licensed
rights could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future licensors may rely on third-party consultants or collaborators or on funds from third
parties such that our future licensors are not the sole and exclusive owners of the patents we <FONT STYLE="white-space:nowrap">in-license.</FONT> If other third parties have ownership rights to our future
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our
competitive position, business, financial conditions, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is possible that we may be unable to
obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed
to us. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible
on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We
cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, product candidates, or future methods or products resulting in either an injunction prohibiting our
manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience
disruptions to our business relationships with our future licensors, we could lose license rights that are important to our business. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Disputes may arise between us and our future licensors regarding intellectual property subject to a license agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor
that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patents and other rights to third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to transfer or assign the license; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting
from the joint creation or use of intellectual property by our future licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the agreements under which we license intellectual property or technology from third parties are complex, and certain provisions
in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or
technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover,
if disputes over intellectual property that we license in the future prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected
product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In spite of our best efforts, our future licensors might conclude that we materially breached our license agreements and might therefore
terminate the license agreements, thereby removing our ability to develop and commercialize products and technology covered by these license agreements. If these <FONT STYLE="white-space:nowrap">in-licenses</FONT> are terminated, or if the
underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. This could have a material adverse effect on our competitive position,
business, financial conditions, results of operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The patent protection and patent prosecution for some of our product candidates may be dependent on third
parties. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we normally seek to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our
product candidates, there may be times when the filing and prosecution activities for patents and patent applications relating to our product candidates are controlled by our future licensors or collaboration partners. If any of our future licensors
or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents covering our product
candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent
competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely affected
or prejudiced by actions or inactions of our licensees, our future licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could
make it difficult for us to sell any product candidates or therapies profitably. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The success of our product candidates, if approved,
depends on the availability of adequate coverage and reimbursement from third-party payors, including government agencies. There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. Coverage may
be more limited than the purposes for which a therapeutic is approved by the FDA or comparable regulatory authorities in other jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States and some other jurisdictions, patients who are provided medical treatment for their conditions generally rely on
third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid in the United States, and commercial payors are
critical to new product acceptance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Government authorities and other third-party payors, such as private health insurers and health
maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. In the United States, the principal decisions about reimbursement for new medicines are typically made by the CMS an agency within the U.S.
Department of Health and Human Services (&#147;<B>HHS</B>&#148;). CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare, and private payors often follow CMS&#146; coverage decisions. Other jurisdictions
have agencies, such as the National Institute for Health and Care Excellence in the UK, that evaluate the use and cost-effectiveness of therapies, which impact the utilization and price of the medicine in such jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, no uniform policy of coverage and reimbursement for products exists
among third-party payors. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting
scientific, clinical and cost-effectiveness data for the use of our products on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. Even if we obtain coverage for a given product, the resulting
reimbursement payment rates might not be adequate for us to maintain pricing sufficient to achieve or sustain profitability or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to seek approval to market our product candidates in different jurisdictions, which could include the United States, Canada and
other selected foreign jurisdictions. If we obtain approval in any of these jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. Market acceptance and sales of our product candidates will
depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future health care reform measures. Thus, even if favorable coverage and
reimbursement status is attained for a product for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud and
abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Healthcare providers, physicians and third-party payors in the United States, Canada, and elsewhere play a primary role in the recommendation
and prescription of any product candidates for which we obtain marketing approval. If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our current and future arrangements with
healthcare providers, third-party payors, customers, and others may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. In particular, the research of our product candidates, as well as the promotion, sales and
marketing of healthcare items and services and certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may
restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business or financial arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The applicable U.S. federal, state and other healthcare laws and regulations laws that may affect our ability to operate include, but are not
limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly
and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an
individual, or the purchase, lease, order, arrangement, or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A
person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. The term remuneration has been interpreted broadly to include anything of value. Further, courts have found that
if &#147;one purpose&#148; of renumeration is to induce referrals, the federal Anti-Kickback Statute is violated. Violations are subject to significant civil and criminal fines and penalties for each violation, plus up to three times the
remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, a claim submitted for payment to any federal healthcare program that includes items or services that were made as a result of a violation of the
federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act (&#147;<B>FCA</B>&#148;). The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the
one hand and prescribers, purchasers, and formulary managers, among others, on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil and criminal false claims laws, including the FCA, and civil monetary penalty laws which
prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment to, or approval by Medicare, Medicaid, or other federal healthcare programs; knowingly
making, using, or causing to be made or used, a false record or statement material to a false, fictitious or fraudulent claim or an obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and
improperly avoiding, decreasing or concealing an obligation to pay money to the federal government. A claim that includes items or services </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim under the FCA. Manufacturers can be held liable under the FCA even when they do not submit
claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#147;whistleblower&#148; to bring qui tam actions on behalf of the
federal government alleging violations of the FCA and to share in any monetary recovery or settlement. When an entity is determined to have violated the FCA, the government may impose civil fines and penalties for each false claim, plus treble
damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, which created additional federal criminal statutes that prohibit knowingly and willfully executing, or
attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the
custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false,
fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false fictitious or fraudulent statement or entry in connection with the delivery of, or payment for,
healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA fraud provisions without actual knowledge of the statute or specific
intent to violate it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by HITECH, and their respective implementing regulations, which impose, among other things,
certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain covered healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as their
respective &#147;business associates,&#148; those independent contractors or agents of covered entities that create, receive, maintain, transmit or obtain protected health information in connection with providing a service on behalf of a covered
entity. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and their covered subcontractors, and gave state attorneys general new authority to file
civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. In addition, there are additional federal, state and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus
complicating compliance efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal <I>Physician Payments Sunshine Act</I>, created under the ACA, as amended by the <I>Health Care
and Education Reconciliation Act of 2010</I>, and its implementing regulations, which require manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health
Insurance Program (with certain exceptions) to report annually to CMS information related to direct or indirect payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and
chiropractors), certain non-physician providers such as physician assistants and nurse practitioners, and teaching hospitals, as well as ownership and investment interests held by the physicians and their immediate family members.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to
government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous U.S. state, local and foreign laws and regulations, such as state anti-kickback and false claims
laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers and may be broader in scope than their federal equivalents; state and foreign
laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and other relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made
to healthcare providers and other potential referral sources, including the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#146;s
Code on Interactions with Healthcare Professionals; state and foreign laws that require drug manufacturers to report information related to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
payments and other transfers of value to physicians and other healthcare providers, marketing expenditures or drug pricing; state and local laws that require the registration of pharmaceutical
sales representatives; and state and foreign laws governing the privacy and security of health information, some of which may be more stringent than those in the United States (such as the European Union, which adopted the General Data Protection
Regulation, which became effective in May 2018) in certain circumstances, and may differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping,
licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The scope and
enforcement of each of the aforementioned laws are uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Ensuring business arrangements comply
with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming, costly, and can divert a company&#146;s attention from the business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is possible that governmental and enforcement authorities will conclude that our business practices, including our arrangements with
physicians and other healthcare providers, may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of
any of the laws described above or any other government regulations that apply to us, we may be subject to significant sanctions, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, reputational harm,
exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate
integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business
are found to be not in compliance with applicable laws, they may be subject to similar penalties. Any action for violation of these laws, even if successfully defended, could cause a pharmaceutical manufacturer to incur significant legal expenses
and divert management&#146;s attention from the operation of the business. In addition, the approval and commercialization of any product candidate in other countries will also likely subject us to foreign equivalents of the healthcare laws
mentioned above, among other foreign laws. All of these could harm our ability to operate our business and our financial results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our
employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and
requirements. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal
investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities. Misconduct by these parties could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with federal and
state health care fraud and abuse laws and regulations, accurately report financial information or data or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to
extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales
commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious
harm to our reputation. It is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in
protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or
asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment,
exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment
or restructuring of our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our research and development activities could be affected or delayed as a result of possible
restrictions on animal testing. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain laws and regulations require us to test our product candidates on animals before initiating
clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for
legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed or become
more expensive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and
results of operations. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Changes in U.S., Canadian, and foreign regulations, statutes or the interpretation of existing regulations
could impact our business in the future by requiring, for example: (i)&nbsp;changes to our manufacturing arrangements; (ii)&nbsp;additions or modifications to product labeling; (iii)&nbsp;the recall or discontinuation of our products; or
(iv)&nbsp;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States and in some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative initiatives
and regulatory changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. For example, in March 2010, the ACA was enacted,
which substantially changed the way health care is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by
lower-cost biosimilars, expands the types of entities eligible for the 340B drug discount program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled,
infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations;
established annual fees and taxes on manufacturers of certain branded prescription drugs; created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget
Act of 2018, effective as of 2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as
a condition for the manufacturer&#146;s outpatient drugs to be covered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
under Medicare Part D; and provided incentives to programs that increase the federal government&#146;s comparative effectiveness research. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA,
and we expect there will be additional challenges and amendments to the ACA in the future. On June&nbsp;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on
the constitutionality of the ACA. Other legislative changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and, due to subsequent legislative
amendments will remain in effect through 2032. Moreover, there has recently been heightened governmental scrutiny over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional
inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program
reimbursement methodologies for drug products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, other legislative changes have been proposed and adopted in the United States
since the ACA was enacted, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On January&nbsp;2, 2013, the <I>American Taxpayer Relief Act of 2012 </I>was signed into law, which, among
other things, further reduced Medicare payments to several types of providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to
five years. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;13, 2017, CMS published a final rule that gives states greater flexibility in setting benchmarks
for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On May&nbsp;30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a
federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek
treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result
of the Right to Try Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On May 23, 2019, CMS published a final rule to allow Medicare Advantage Plans the option of using step therapy
for Part B drugs beginning January&nbsp;1, 2020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;20, 2019, former President Trump signed into law the Further Consolidated Appropriations Act
(H.R. 1865), which repealed the Cadillac tax, the health insurance provider tax, and the medical device excise tax.&nbsp;It is impossible to determine whether similar taxes could be instated in the future. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the American Rescue Plan Act of 2021, the statutory cap on Medicaid Drug Rebate
Program rebates that manufacturers pay to state Medicaid programs was eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of products, which could have a material impact on
our business. In August 2022, Congress passed the Inflation Reduction Act of 2022 (the &#147;<B>IRA</B>&#148;), which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare
beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation
requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for
beneficiaries, among other changes. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these
programs are implemented, although the IRA may be subject to legal challenges. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. The IRA also extends enhanced subsidies
for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025, and eliminates the &#147;donut hole&#148; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum
out-of-pocket cost and through a newly established manufacturer discount program. Various industry stakeholders, including pharmaceutical companies and the Pharmaceutical Research and Manufacturers of America, have initiated lawsuits against the
federal government asserting that the price negotiation provisions of the Inflation Reduction Act are unconstitutional. Further, in response to the Biden administration&#146;s October 2022 executive order, on February 14, 2023, HHS released a report
outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any
health reform measures in the future. The impact of these judicial challenges, legislative, executive, and administrative actions and any future healthcare measures and agency rules implemented by the government on us and the pharmaceutical industry
as a whole is unclear. The implementation of cost containment measures, including the prescription drug provisions under the Inflation Reduction Act, as well as other healthcare reforms may prevent us from being able to generate revenue, attain
profitability, or commercialize our product candidates if approved. Complying with any new legislation and regulatory changes could be time-intensive and expensive, resulting in a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may
obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and
biologic product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and in some cases, designed to encourage importation from
other countries and bulk purchasing. For example, FDA recently authorized the state of Florida to import certain prescription drugs from Canada for a period of two years to help reduce drug costs, provided that Florida&#146;s Agency for Health Care
Administration meets the requirements set forth by the FDA. Other states may follow Florida. Legally mandated price controls on payment amounts by third-party payors or other restrictions on coverage or access could harm our business, results of
operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates that we successfully commercialize or put pressure on our
product pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could
limit the extent to which state and federal governments cover particular healthcare products and services and could limit the amounts that the federal and state governments will pay for healthcare products and services. This could result in reduced
demand for any product candidate we develop or could result in additional pricing pressures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot predict the likelihood, nature or
extent of government regulation that may arise from future legislation or administrative action in the United States. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new
requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to our Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The
market price of the Common Shares may be volatile. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The market price of the Common Shares may fluctuate due to a variety of factors
relative to our business, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of new products, product candidates or new uses for existing products,
significant contracts, commercial relationships or capital commitments and the timing of these introductions or announcements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actions by any of our collaborators regarding our product candidates they are developing, including
announcements regarding clinical or regulatory decisions or developments of our collaboration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated serious safety concerns related to the use of any of our products and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative or inconclusive results from clinical trials of our product candidates, leading to a decision or
requirement to conduct additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> testing or clinical trials or resulting in a decision to terminate the continued development of a product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays of clinical trials of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to obtain or delays in obtaining or maintaining product approvals or clearances from regulatory
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse regulatory or reimbursement announcements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of significant acquisitions, strategic collaborations, licenses, joint
ventures or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our efforts to discover or develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our dependence on third parties, including our collaborators, CROs, clinical trial sponsors and clinical
investigators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legal developments in Canada, the U.S. or other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of expenses related to any of our product candidates or clinical development programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations
by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated quarterly variations in our financial results or those of our competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of Common Shares by us, our insiders or our shareholders in the future, as well as the overall trading
volume of the Common Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commencement of, or our involvement in, litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry and market conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors and other factors that may be unrelated to
our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other factors described in this &#147;<I>Risk Factors</I>&#148; section. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The effect of these and other factors on the market price of the Common Shares on the TSX, or any other exchange that we list securities on in
the future, such as the Nasdaq if the Common Shares are listed on such exchange, cannot be predicted. There can be no assurance that the market price of the Common Shares will not experience significant fluctuations in the future, including
fluctuations that are unrelated to our performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Investors may lose their entire investment. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">An investment in the Common Shares is speculative and may result in the loss of an investor&#146;s entire investment in the Company. Only
investors who are experienced in high-risk investments and who can afford to lose their entire investment should consider an investment in the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We have no history of dividends. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To date, we have not paid any dividends on the outstanding Common Shares. We currently intend to retain future earnings to finance the
operation, development and expansion of our business. We do not anticipate paying cash dividends on the Common Shares in the foreseeable future. Any decision to pay dividends on our shares will be made at the discretion of the board of directors of
the Company (the &#147;<B>Board</B>&#148;) and will depend on the Company&#146;s earnings, financial requirements and other conditions existing at such time, including potential restrictions on paying dividends pursuant to any effective credit
agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our existing executive officers and directors own a significant percentage of Common Shares and may have a significant
impact over matters submitted to our shareholders for approval. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our executive officers and directors own approximately 9.68% of the
issued Common Shares as of September&nbsp;30, 2023. As a result, these shareholders, if they acted together, could significantly impact all matters requiring approval by our shareholders, including the election of directors and the approval of
mergers or other business combination transactions. The interests of these shareholders may not always coincide with our interests or the interests of other shareholders. This may also prevent or discourage unsolicited acquisition proposals or
offers for the Common Shares that other shareholders may feel are in their best interest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Future sales of Common Shares by our
existing shareholders could cause our share price to decline. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to compliance with applicable securities laws, our officers,
directors and significant shareholders may sell some or all of their Common Shares in the future. No prediction can be made as to the effect, if any, such future sales of Common Shares will have on the market price of the Common Shares prevailing
from time to time. However, the future sale of a substantial number of Common Shares by our officers, directors and significant shareholders or the perception that such sales could occur, could adversely affect prevailing market prices for the
Common Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We will need to raise additional financing in the future which may dilute our share capital. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our notice of articles and articles (the &#147;<B>Articles</B>&#148;) permit the issuance of an unlimited number of Common Shares. Future
issuance of Common Shares will result in dilution to the existing shareholders. Additionally, future sales of the Common Shares into the public market may lower the market price that may result in losses to our shareholders. We may, from time to
time, issue stock options to purchase additional Common Shares in accordance with the policies of the TSX and, if applicable, the Nasdaq. Most of these Common Shares, including the Common Shares to be issued upon exercise of options, are freely
tradable or will be freely tradeable after a four-month restriction period. Sales of substantial amounts of the Common Shares into the public market, or even the perception by the market that such sales may occur, may lower the market price of
Common Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>If securities or industry analysts either do not publish research about us or publish
inaccurate or unfavorable research about us, our business or our market, or if they adversely change their recommendations regarding our Common Shares, the trading price or trading volume of our Common Shares could decline. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The trading market for Common Shares will be influenced in part by the research and reports that securities or industry analysts may publish
about us, our business, our market or our competitors. If one or more securities analysts initiate research with an unfavorable rating or downgrade our Common Shares, provide a more favorable recommendation about our competitors or publish
inaccurate or unfavorable research about our business, our Common Shares price would likely decline. If few securities analysts commence coverage of us, or if one or more of these analysts cease coverage of us or fail to publish reports on us
regularly, we could lose visibility in the financial markets and demand for our securities could decrease, which in turn could cause the price and trading volume of our Common Shares to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Any issuance of preferred shares could make it difficult for another company to acquire
us or could otherwise adversely affect holders of our Common Shares, which could depress the price of our Common Shares. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board has
the authority to issue preferred shares and to determine the preferences, limitations and relative rights of preferred shares and to fix the number of shares constituting any series and the designation of such series, without any further vote or
action by our shareholders. Our preferred shares may be issued with liquidation, dividend and other rights superior to the rights of our Common Shares. The potential issuance of preferred shares may delay or prevent a change in control, discourage
bids for our Common Shares at a premium over the market price and adversely affect the market price and other rights of the holders of our Common Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our constating documents permit us to issue an unlimited number of Common Shares without additional shareholder approval. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Articles permit us to issue an unlimited number of Common Shares. We anticipate that we will, from time to time, issue additional Common
Shares in the future. Subject to the requirements of the TSX and, if applicable, Nasdaq, we will not be required to obtain the approval of shareholders for the issuance of additional Common Shares. Any further issuances of Common Shares will result
in immediate dilution to existing shareholders and may have an adverse effect on the value of their shareholdings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Raising additional
capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt
financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or
convertible debt securities, your ownership interest may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. We are authorized to issue an unlimited
number of Common Shares. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital
expenditures or declaring dividends. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we raise additional funds through future collaborations, licenses and other similar arrangements, we may be required to relinquish valuable
rights to our future revenue streams, product candidates, research programs, intellectual property or proprietary technology, or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. If we are
unable to raise additional funds through equity or debt financings or other arrangements when needed or on terms acceptable to us, we would be required to delay, limit, reduce or terminate our product development or future commercialization efforts,
or grant rights to develop and market product candidates that we might otherwise prefer to develop and market ourselves, or on less favorable terms than we would otherwise choose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we have outstanding stock options representing a right to receive Common Shares upon vesting and the exercise of the stock
options as well as outstanding warrants that are exercisable for Common Shares. Pursuant to the terms of our Amended Plan, the number of Common Shares we may grant under such plan will automatically increase upon the closing of an offering of Common
Shares such that the aggregate number of Common Shares that may be reserved for issuance under the Amended Plan equals 18.5% of our outstanding Common Shares. Furthermore, we have outstanding convertible debt that is convertible into Common Shares
at the option of the holders, and Eupraxia Pharma, our subsidiary, has non-voting Class B Shares outstanding that are exchangeable into Common Shares at any time at the election of the holder. The exercise of stock options and warrants, conversion
of such convertible debt and exchange of such Class B Shares and the subsequent resale of such Common Shares in the public market, could adversely affect the prevailing market price of the Common Shares and our ability to raise equity capital in the
future at a time and price which we deem appropriate. We may also enter into commitments in the future which would require the issuance of additional Common Shares and we are expected to grant additional stock options. Any Common Shares issuances
from our treasury will result in immediate dilution to existing shareholders&#146; percentage interest in us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We have warrants, convertible debt, and shares of a subsidiary exchangeable for Common
Shares outstanding, which in each case, if exercised, converted or exchanged, respectively, could cause dilution to existing shareholders. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have outstanding warrants that are exercisable for Common Shares. In addition, we have outstanding convertible debt that are convertible
into Common Shares. Furthermore, Eupraxia Pharma our subsidiary, has <FONT STYLE="white-space:nowrap">non-voting</FONT> Class&nbsp;B <B></B><B></B><B></B>Shares outstanding that are exchangeable into Common Shares. The exercise of such warrants,
conversion of such convertible debt and exchange of such Class&nbsp;B Shares and the subsequent resale of such Common Shares, issuable thereunder in each case, in the public market could adversely affect the prevailing market price and our ability
to raise equity capital in the future at a time and price which it deems appropriate. We may also enter into commitments in the future which would require the issuance of additional Common Shares and we may grant additional share purchase warrants
or stock options. Any share issuances from our treasury will result in immediate dilution to existing shareholders&#146; percentage interest in us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our Common Shares may have limited liquidity. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our shareholders may be unable to sell significant quantities of Common Shares into the public trading markets without a significant reduction
in the price of their Common Shares, or at all. There can be no assurance that there will be sufficient liquidity of the Common Shares on the trading market, and that we will continue to meet the listing requirements of the TSX, achieve and maintain
a listing on Nasdaq, if our Common Shares are listed on such exchange, or achieve or maintain a listing on any other securities exchange. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We cannot assure you that an active market will develop for Common Shares on Nasdaq if the Common Shares are listed. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Common Shares are currently listed on the TSX under the symbol &#147;ERPX&#148;. We have applied to list our Common Shares on Nasdaq under
the symbol &#147;EPRX&#148;, which application is being reviewed by Nasdaq. However, there has been no prior public trading market for the Common Shares on Nasdaq. We cannot assure you that we will complete our listing of the Common Shares on
Nasdaq, if we complete our listing of the Common Shares on Nasdaq that such listing is maintained, or that an active trading market for the Common Shares will develop on Nasdaq or elsewhere or, if developed, that any market will be sustained.
Accordingly, we cannot assure you of the liquidity of any trading market, your ability to sell the Common Shares when desired or the prices that you may obtain for your shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>United States investors may not be able to obtain enforcement of civil liabilities against us. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The enforcement by investors of civil liabilities under the United States federal or state securities laws may be affected adversely by the
fact that we are governed by the <I>Business Corporations Act</I> (British Columbia), that the majority of our officers and directors are residents of Canada or otherwise reside outside the United States, and that all, or a substantial portion of
their assets and a substantial portion of our assets, are located outside the United States. It may not be possible for investors to effect service of process within the United States on certain of our directors and officers or enforce judgments
obtained in the United States courts against us or certain of our directors and officers based upon the civil liability provisions of United States federal securities laws or the securities laws of any state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There is some doubt as to whether a judgment of a United States court based solely upon the civil liability provisions of United States
federal or state securities laws would be enforceable in Canada against us or our directors and officers. There is also doubt as to whether an original action could be brought in Canada against us or our directors and officers to enforce liabilities
based solely upon United States federal or state securities laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>As a foreign private issuer, we are subject to different U.S.
securities laws and rules than a domestic U.S. issuer, which may limit the information publicly available to our U.S. shareholders. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
are a foreign private issuer under applicable U.S. federal securities laws and, therefore, we will not be required to comply with all the periodic disclosure and current reporting requirements of the Exchange Act, as amended, and related rules and
regulations, should we become subject to such requirements in the future. As a result, we will not file the same reports that a U.S. domestic issuer would file with the SEC, although we will be required to file with or furnish to the SEC the
continuous disclosure documents that we are required to file in Canada under Canadian securities laws. In addition, our officers, directors and principal shareholders will be exempt from the reporting and &#147;short swing&#148; profit recovery
provisions of Section&nbsp;16 of the Exchange Act. Therefore, our shareholders may not know on as timely a basis when our officers, directors and principal shareholders purchase or sell Common Shares as the reporting periods under the corresponding
Canadian insider reporting requirements are longer. In addition, as a foreign private issuer, we will be exempt from the proxy rules under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We may lose our foreign private issuer status in the future, which could result in
significant additional costs and expenses to us. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to maintain our current status as a foreign private issuer, a majority of
our Common Shares must be either directly or indirectly owned by <FONT STYLE="white-space:nowrap">non-residents</FONT> of the United States unless we also satisfy one of the additional requirements necessary to preserve this status. We may in the
future lose our foreign private issuer status if a majority of the Common Shares are held in the United States and we fail to meet the additional requirements necessary to avoid loss of foreign private issuer status. The regulatory and compliance
costs to us under U.S. federal securities laws as a U.S. domestic issuer may be significantly more than the costs we incur as a Canadian foreign private issuer eligible to use the multijurisdictional disclosure system. If we are not a foreign
private issuer, we would not be eligible to use the multijurisdictional disclosure system or other foreign issuer forms and would be required to file periodic and current reports and registration statements on U.S. domestic issuer forms with the
SEC, which are more detailed and extensive than the forms available to a foreign private issuer. In addition, should we become listed on the Nasdaq, we may lose the ability to rely upon exemptions from Nasdaq corporate governance requirements that
are available to foreign private issuers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>U.S. holders of our Common Shares may suffer adverse tax consequences if we are
characterized as a passive foreign investment company. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may be treated as a passive foreign investment company (&#147;PFIC&#148;)
for U.S. federal income tax purposes, in which case U.S. holders would be subject to a special, generally adverse tax regime. Generally, for any taxable year in which 75% or more of our gross income is passive income, or at least 50% of the value of
our assets (as determined under applicable U.S. Treasury Regulations, which may be determined in part by the market value of our common shares, which is subject to change) are held for the production of, or produce, passive income, we would be
characterized as a passive foreign investment company, or a PFIC, for U.S. federal income tax purposes. We will be treated as owning the proportionate share of the assets and earning the proportionate share of the income of any other corporation,
the equity of which we own, directly or indirectly, 25% or more (by value). We have not yet completed a formal assessment of our status as a PFIC for 2023; however, based on our gross income and gross assets, we believe that we will be deemed a PFIC
for the taxable year ending December&nbsp;31, 2023, and may be a PFIC for subsequent taxable years. and may be a PFIC for subsequent taxable years. Our status as a PFIC is a fact-intensive determination, and we cannot provide any assurance regarding
our PFIC status for the current taxable year or future taxable years. Our status as a PFIC is a fact-intensive determination, and no assurance can be provided regarding its PFIC status for the current taxable year or future taxable years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are a PFIC for any year, U.S. holders of our common shares may suffer adverse tax consequences. If we are a PFIC in any year with
respect to which a U.S. holder owns our common shares, we will continue to be treated as a PFIC with respect to such U.S. holder in all succeeding years during which the U.S. holder owns our common shares, whether or not we remain a PFIC unless such
U.S. holder makes a qualified electing fund or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. Gains realized by <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holders on the sale
of our common shares would be taxed as ordinary income, rather than as capital gain, and the preferential tax rate applicable to dividends received on our common shares would be lost. Interest charges would also be added to taxes on gains and
dividends realized by all U.S. holders. U.S. holders should consult their own tax advisors with respect to their particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The PFIC rules, including the rules governing any elections that may potentially be made by a U.S. Holder, are extremely complex. Each U.S.
holder should consult its own tax advisor regarding our potential PFIC status and how the PFIC rules (including elections that may be available thereunder) would affect the U.S. federal income tax consequences of the acquisition, ownership and
disposition of our common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>If a U.S. holder is treated as owning at least 10% of our common shares, such U.S. holder may be
subject to adverse U.S. federal income tax consequences. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a U.S. holder is treated as owning, directly, indirectly or
constructively, at least 10% of the value or voting power of our common shares, such U.S. holder may be treated as a &#147;United States shareholder&#148; with respect to each &#147;controlled foreign corporation&#148; in our group, if any.
Generally, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation is deemed as a controlled foreign corporation if more than 50% of its stock (by voting power or value) is owned (directly, indirectly or constructively) by United States
shareholders. We will generally be classified as a controlled foreign corporation if more than 50% of our outstanding shares, measured by reference to voting power or value, are owned (directly, indirectly or by attribution) by United States
shareholders. In addition, since our group includes one or more U.S. subsidiaries, certain of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries could be treated as controlled foreign corporations, regardless of whether we are treated
as a controlled foreign corporation.. If we or any of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries are treated as controlled foreign corporations, a United States shareholder would be required to annually report and include in
its U.S. taxable income its pro rata share of &#147;Subpart F income,&#148; &#147;global intangible <FONT STYLE="white-space:nowrap">low-taxed</FONT> income&#148; and investments in U.S. property by the controlled foreign corporation, regardless of
whether we make any distributions, and generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder of a U.S. corporation. In addition, failure to comply with certain reporting
obligations may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
subject a United States shareholder to monetary penalties and may prevent the statute of limitations with respect to such shareholder&#146;s U.S. federal income tax return for the year for which
reporting was due from starting. We cannot provide any assurances that we will assist our investors in determining whether any of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries are treated as a controlled foreign corporation or
whether such investor is treated as a United States shareholder with respect to any of such controlled foreign corporations. Further, we cannot provide any assurances that we will furnish to any United States shareholder information that may be
necessary to comply with the reporting and tax paying obligations described in this risk factor. U.S. holders should consult their tax advisors regarding the potential application of these rules to their investment in our common shares. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIVIDENDS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company
has not, since its inception, declared or paid any dividends on its Common Shares. The declaration of dividends on our Common Shares is within the discretion of the Board and will depend on the assessment of, among other factors, capital
requirements, earnings, and the operating and financial condition of the Company. At the present time, the Company&#146;s anticipated capital requirements are such that the Company follows a policy of retaining all available funds and any future
earnings in order to finance the Company&#146;s technology advancement, business development and corporate growth. The Company does not intend to declare or pay cash dividends on its Common Shares within the foreseeable future. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CAPITAL STRUCTURE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The
following description of our share capital summarizes certain provisions contained in our Articles and <FONT STYLE="white-space:nowrap">by-laws.</FONT> These summaries do not purport to be complete and are subject to, and are qualified in their
entirety by reference to, all of the provisions of our Articles and <FONT STYLE="white-space:nowrap">by-laws.</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The authorized
share capital of the Company consists of (i)&nbsp;an unlimited number of Common Shares without par value and (ii)&nbsp;an unlimited number of preferred shares in the capital of the Company (the &#147;<B>Preferred Shares</B>&#148;) without par value,
issuable in series. As of the date of this AIF, the Company had 35,622,553 Common Shares issued and outstanding. The maximum number of additional Common Shares issuable, should all convertible rights be exercised are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"><B>Common Shares Issuable:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP><B>As&nbsp;of&nbsp;the&nbsp;date&nbsp;of&nbsp;this&nbsp;AIF</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,482,490</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2013 Warrants<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">380,921</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Founders Warrants<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">315,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underlying Founders Warrants<SUP
STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">315,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B Shares<SUP
STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">562,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants &#150; Listed EPRX.WT<SUP
STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,826,024</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants &#150; Listed EPRX.WT.A<SUP
STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,196,550</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Warrants<SUP
STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,054</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nordic Warrants<SUP
STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,228</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:6pt ;BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVB Debt Facility<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1.50pt solid #000000" ALIGN="right">2,143,445</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:6pt ;BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:6pt ;BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Common Shares Issuable</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1.50pt solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1.50pt solid #000000" ALIGN="right"><B>15,312,212</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:6pt ;BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents options outstanding under the Amended Plan, each having an exercise price between CDN$1.90 and
CDN$8.00 and expiry dates ranging from March&nbsp;31, 2025 to September&nbsp;26, 2033. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents common share purchase warrants to acquire up to 380,921 Common Shares at an exercise price of
CDN$0.7572 per share, with each such common share purchase warrant expiring 120 days after the warrant holder or the holder&#146;s spouse ceases to be a director, officer or consultant of the Company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents common share purchase warrants to acquire 315,500 units, with each unit consisting of one Common
Share and one underlying common share purchase warrant (an &#147;<B>Underlying Founder Warrant</B>&#148;) at an exercise price of CDN$0.4984 per unit, expiring 120 days after the warrant holder ceases to be a director, officer or consultant of the
Company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents Underlying Founder Warrants to acquire up to 315,500 Common Shares, at an exercise price of
CDN$0.75 per share, expiring two years from the date of exercise of the Underlying Founder Warrant. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents 562,500 Common Shares that are issuable upon conversion of the 225 Class&nbsp;B Shares of
Eupraxia Pharma, the Company&#146;s subsidiary, held by Amanda Malone, the Chief Scientific Officer of the Company. Each Class&nbsp;B Share is exchangeable into Common Shares based on an exchange rate of 2,500 Common Shares for each Class&nbsp;B
Share, subject to adjustments upon the occurrence of certain events, for a total of 562,500 Common Shares. The Class&nbsp;B Shares are exchangeable by Ms.&nbsp;Malone at her election, provided that the Company may force the exchange of the
Class&nbsp;B Shares into Common Shares at any time on or after January&nbsp;31, 2031, or on or after January&nbsp;31, 2026 if the Company is listed on a stock exchange and is a reporting issuer in Canada at such time. The Company may also force the
exchange of the Class&nbsp;B Shares into Common Shares if there is a change of control transaction involving the Company, a change in law which makes the exchange necessary or desirable or if there are a de minimis number of Class&nbsp;B Shares
outstanding. If the Company is listed on a stock exchange at the time of the applicable exchange, the Company may elect to pay Ms.&nbsp;Malone cash in lieu of issuing Common Shares, with such cash amount to be determined based on the then current
market price of the Common Shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Each common share purchase warrant is exercisable into one common share of the Company (each, a
&#147;<B>Warrant Share</B>&#148;) at an exercise price of CDN$11.20 per Warrant Share at any time prior to 5:00 p.m. (Eastern time) on the date that is five years following the closing of the Company&#146;s initial public offering in Canada, subject
to adjustment in certain events. The common share purchase warrants include an acceleration provision, exercisable at the Company&#146;s option, if the Company&#146;s daily volume weighted average share price is greater than CDN$22.40 for five
consecutive trading days. Of the 2,826,274 warrants issued, 250 warrants have been exercised as of the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Each common share purchase warrant entitles the holder thereof to acquire one Common Share at an exercise
price of CDN$3.00 per Common Share for a period of 48 months following the closing date of the 2022 Offering, being April&nbsp;20, 2022. Of the 7,331,550 warrants issued, 2,135,000 warrants have been exercised as of the date hereof.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">500,538 common share purchase warrants were issued to the agents of the 2022 Offering and represents 7% of
the units issued in the 2022 Offering including the over-allotment option (the &#147;<B>Compensation Warrants</B>&#148;). Each Compensation Warrant shall entitle the agents to acquire a Common Share at the price of CDN$2.05 for a period of 48 months
following completion of the 2022 Offering, being April&nbsp;20, 2022. Of the 500,538 Compensation Warrants issued, 450,484 Compensation Warrants have been exercised as of the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Each Nordic Warrant is exercisable into one Common Share at an exercise price of CDN$11.20 per share at any
time prior to 5:00 p.m. (Eastern time) on April&nbsp;29, 2026, subject to adjustment in certain events. The Nordic Warrants include an acceleration provision, exercisable at the Company&#146;s option, if the Company&#146;s daily volume weighted
average share price is greater than CDN$22.40 for five consecutive trading days. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">SVB may elect to convert the principal amount of the convertible debt into Common Shares at a conversion
price equal to CDN$5.68 per Common Share. SVB may also elect to convert accrued and unpaid interest, the conversion price of the accrued and unpaid interest will be subject to the minimum pricing requirements of the TSX, to the extent applicable at
the time of conversion. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each Common Share entitles the holder thereof to one vote at any meeting of our shareholders. The holders of Common Shares are entitled to
receive if, as and when declared by the Board, dividends in such amounts as shall be determined by the Board. After the holders of Preferred Shares have first received from the property and assets of the Company the amount they are entitled to, the
holders of Common Shares have the right to receive the Company&#146;s remaining property and assets in the event of a liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> whether voluntary or involuntary. The Common Shares
do not carry any <FONT STYLE="white-space:nowrap">pre-emptive,</FONT> subscription, redemption or conversion rights, nor do they contain any sinking or purchase fund provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may issue Preferred
Shares from time to time in one or more series. The terms of each series of Preferred Shares, including the number of shares, the designation, rights, preferences, privileges, priorities, restrictions, conditions and limitations, will be determined
at the time of creation of each such series by our Board, without shareholder approval, provided that all Preferred Shares will rank equally within their class as to dividends and distributions in the event of our dissolution, liquidation or <FONT
STYLE="white-space:nowrap">winding-up.</FONT> The Preferred Shares are entitled to priority over the Common Shares with respect to the distribution of assets of the Company in the event of any liquidation, dissolution or winding up of the
Company&#146;s affairs, whether voluntary or involuntary. The Preferred Shares are only entitled to voting rights and dividends as provided in the special rights and restrictions attached to any particular series. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARKET FOR SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Trading Price and Volume </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Common
Shares are listed and posted for trading on the TSX under the symbol &#147;EPRX&#148; and the Warrants are listed and posted for trading on the TSX under the symbols &#147;EPRX.WT&#148; and &#147;EPRX.WT.A&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth the reported high and low prices and the aggregate monthly volume of trading of the Common Shares for the year
ended December&nbsp;31, 2023. All amounts in the table are expressed in Canadian dollars: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>&#8195;&#8201;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Volume</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>January 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$4.27</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$3.65</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>802,936</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>February 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$5.23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$3.90</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>516,414</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>March 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$4.26</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$3.27</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>375,854</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>April 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$6.36</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$4.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>292,763</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>May 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$7.50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$5.76</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>503,686</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>June 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$8.86</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$6.50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1,005,249</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>July 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$9.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$7.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>626,339</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>August 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$8.46</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$6.98</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>742,235</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>September 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$8.09</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$6.87</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>642,991</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>October 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$7.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$4.88</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>601,922</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>November 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$6.75</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$5.03</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>243,854</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>December 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$6.46</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$5.36</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>249,124</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth the reported high and low prices and the aggregate monthly volume of trading of
the listed &#147;EPRX.WT&#148; Warrants for the year ended December&nbsp;31, 2023: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Volume</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>January 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$0.35</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$0.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>132,500</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>February 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$0.35</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$0.125</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>94,520</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>March 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$0.39</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$0.30</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>108,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>April 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$0.39</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$0.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11,875</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>May 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$1.24</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$0.405</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>241,561</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>June 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$1.88</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$0.75</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>182,600</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>July 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$2.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$1.55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>39,650</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>August 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$2.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$1.55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>12,500</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>September 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$1.70</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$1.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>9,850</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>October 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$1.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$0.65</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8,800</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>November 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$0.65</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$0.65</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>December 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$0.65</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$0.57</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>9,250</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth the reported high and low prices and the aggregate monthly volume of trading of
the listed &#147;EPRX.WT.A&#148; Warrants for the year ended December 31, 2023: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>&#8195;&#8199;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Volume</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>January 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$2.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$1.45</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>33,900</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>February 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$2.50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$1.95</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>24,800</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>March 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$2.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$1.95</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4,600</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>April 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$3.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$2.55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>23,500</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>May 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$5.35</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$3.50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>146,200</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>June 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$6.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$4.30</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>79,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>July 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$6.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$4.95</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>August 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$5.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$4.70</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10,175</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>September 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$5.50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$4.95</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10,500</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>October 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$4.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#8195;&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$4.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#8195;&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>350</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>November 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$4.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$4.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>100</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>December 2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$4.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$3.50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2,300</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prior Sales </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes details of each class of securities of the Company that is outstanding but not listed or quoted on a
marketplace, issued by the Company during the most recently completed financial year: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Date of Issuance/Grant</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Type&nbsp;of&nbsp;Security</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of&nbsp;Securities</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Issued</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;Issue/Exercise&#8195;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Price</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">May&nbsp;18, 2023</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Options</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">180,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">CDN$6.84</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">May&nbsp;30, 2023</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Options</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">17,200</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">CDN$6.75</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">September&nbsp;26, 2023</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Options</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">60,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">CDN$7.16</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS AND OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The names of the directors and executive officers of the Company as of the date hereof, their province or state and country of residence,
their respective positions with the Company the date upon which the directors were first elected to the Board are set out in the table below. The term of each director expires on the date of our next annual meeting. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR BGCOLOR="#b2b2b2" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:4pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Name, Province of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Residence and Position</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>with Eupraxia</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Principal Occupation
or Business or<BR>Employment in</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>the Past Five Years</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date Appointed as a Director of the<BR>Company</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>James A.
Helliwell</B></P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">British Columbia, Canada</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer and Director</I></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Chief Executive Officer, Eupraxia Pharmaceuticals Inc. (July 2012 &#150; Present)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">July&nbsp;23, 2012</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amanda Malone</B></P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">British Columbia, Canada</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Chief Scientific Officer</I></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Chief Scientific Officer, Eupraxia Pharmaceuticals Inc. (Sep 2012 &#150; Present)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bruce Cousins</B></P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">British Columbia, Canada</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer and President</I></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Chief Financial Officer, Eupraxia Pharmaceuticals Inc. (May 2021 &#150; Present)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Paul Brennan</B></P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">British Columbia, Canada</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Chief Business Officer</I></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Chief Business Officer, Eupraxia Pharmaceuticals Inc. (December 2022 &#150; Present)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mark Kowalski</B></P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Massachusetts, USA</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer</I></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Chief Medical Officer, Eupraxia Pharmaceuticals Inc. (May 2023 &#150; Present)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">N/A</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Simon Pimstone</B></P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">British Columbia, Canada</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Chairman of the Board and Director</I></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Founder and Chief Executive Officer,
XYON Health Inc. (Jan 2019 &#150; Present)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chair of the Board, <FONT STYLE="white-space:nowrap">Alpha-9</FONT> Theranostics (May 2020 &#150; Present)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Chair of the Board, Xenon Pharmaceuticals, Inc. (June 2022 &#150; Present)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Chair of the Board, Xenon Pharmaceuticals, Inc. (June 2021 &#150; June 2022)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer, Xenon Pharmaceuticals, Inc. (January 2003 - June 2021)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">January&nbsp;14, 2013 (as Director) and January&nbsp;24, 2013 (as Chairman)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Richard M. Glickman</B></P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">British Columbia, Canada</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director</I></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman of the Board, ESSA Pharma Inc.
(October 2010 &#150; Present)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Co-founder</FONT> and Executive Chairman (September 2013 - February 2014) and Chairman of
the Board (February 2014 - April 2019) and Chief Executive Officer (February 2017 &#150; April 2019), Aurinia Pharmaceuticals Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Venture Partner, Lumira
Ventures (March 2016 - Present)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">March&nbsp;9, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Paul Geyer<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">British Columbia, Canada</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director</I></P>
<P STYLE="font-size:36pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Chief Executive Officer, Discovery Parks and Nimbus Synergies (May 2017 &#150; Present)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">January&nbsp;14, 2013</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>John Montalbano</B></P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">British Columbia, Canada</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director</I></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director, AbCellera Biologics Inc.
(November 2020 &#150; Present)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director, XYON Health Inc. (June 2021 &#150; Present)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director, Canada Pension Plan Investment Board (February 2017 &#150; Present)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director, Aritzia Inc. (July 2019 &#150; Present)</P> <P STYLE="font-size:48pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">January&nbsp;14, 2013</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Michael Wilmink<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arizona, USA</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director</I></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Orthopaedic Surgeon, Partner in OrthoArizona practice (2002 - Present)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">January&nbsp;14, 2013</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The information as to principal occupation, business or employment (for the preceding five years for any new
director) and Common Shares beneficially owned, controlled or directed is not within the knowledge of the management of the Company and has been furnished by the respective nominees themselves. Beneficial ownership is determined in accordance with
applicable Canadian securities laws. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Members of the Compensation Committee, with Richard Glickman as chair. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Members of the Audit Committee, with John Montalbano as chair. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Members of the Nominating and Corporate Governance Committee, with Simon Pimstone as chair.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of the date of this AIF, the directors and executive officers of the Company owned, directly or indirectly, or
exercised control or direction over 2,649,834 (7.44%)<B> </B>of the issued and outstanding Common Shares of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cease Trade Orders,
Bankruptcies, Penalties and Sanctions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cease Trade Orders </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the best of our knowledge, no director or executive officer of the Company, is, or within
the ten years prior to the date hereof, has been, a director, chief executive officer or chief financial officer that: (i)&nbsp;while that person was acting in that capacity was the subject of a cease trade order or similar order or an order that
denied the other issuer access to any exemptions under Canadian securities legislation, that was in effect for a period of more than thirty consecutive days or, (ii)&nbsp;after that person ceased to act in that capacity, was the subject of a cease
trade order or similar order, or an order that denied the other issuer access to any exemptions under Canadian securities legislation, that was in effect for a period of more than thirty consecutive days and which resulted from an event that
occurred while that person was acting in that capacity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Penalties or Sanctions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the best of our knowledge, no director or executive officer of the Company, or a shareholder holding a sufficient number of shares of the
Company to affect materially the control of the Company, has been subject to any penalties or sanctions imposed by a court relating to Canadian securities legislation or by a Canadian securities regulatory authority or has entered into a settlement
agreement with a Canadian securities authority, or any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable investor in making an investment decision. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Personal Bankruptcies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the best
of our knowledge, no director or executive officer of the Company, or a shareholder holding a sufficient number of shares of the Company to affect materially the control of the Company, (i)&nbsp;has, during the ten years prior to the date hereof,
been a director or executive officer of any company that, while that person was acting in that capacity, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or been subject to or instituted any proceedings,
arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold his, her or its assets or (ii)&nbsp;has, during the ten years prior to the date hereof, become bankrupt, made a proposal under any legislation
relating to bankruptcy or insolvency, or been subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold his, her or its assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conflicts of Interest </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the best of the
Company&#146;s knowledge, there are no existing or potential material conflicts of interest between the Company and any of its directors or officers as of the date hereof. However, certain of the Company&#146;s directors and officers are, or may
become, directors or officers of other companies with businesses which may conflict with its business. Accordingly, conflicts of interest may arise which could influence these individuals in evaluating possible acquisitions or in generally acting on
the Company&#146;s behalf. See also &#147;<I>Risk Factors &#150; Our directors may serve as directors of other biotech companies and may have conflicts of interest</I>&#148;. Pursuant to the BCBCA, directors and officers of the Company are required
to act honestly and in good faith with a view to the best interests of the Company. As required under the BCBCA and the Company&#146;s Articles: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a director or senior officer who holds any office or possesses any property, right or interest that could
result, directly or indirectly, in the creation of a duty or interest that materially conflicts with that individual&#146;s duty or interest as a director or senior officer of the Company, must promptly disclose the nature and extent of that
conflict; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a director who holds a disclosable interest (as such term is defined under the BCBCA) in a contract or
transaction into which the Company has entered or proposes to enter may generally not vote on any directors&#146; resolution to approve such contract or transaction. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Generally, as a matter of practice, directors who have disclosed a material interest in any contract or transaction that the Board is
considering will not take part in any board discussion respecting that contract or transaction. If on occasion such directors do participate in the discussions, they will refrain from voting on any matters relating to matters in which they have
disclosed a material interest. In appropriate cases, the Company will establish a special committee of independent directors to review a matter in which directors or officers may have a conflict. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROMOTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No person or company is, or has acted as, a promoter of the Company within the two most recently completed financial years or during the
current financial year. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AUDIT COMMITTEE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Audit Committee is
comprised of John Montalbano (Chair), Simon Pimstone and Paul Geyer, each of whom is &#147;independent&#148; and &#147;financially literate&#148; pursuant to NI <FONT STYLE="white-space:nowrap">52-110.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Audit Committee assists the Board in fulfilling its obligations relating to the integrity of the internal financial controls and financial
reporting of the Company. The external auditors of the Company report directly to the Audit Committee. The Audit Committee&#146;s principal responsibilities include (i)&nbsp;recommending the external auditor to be nominated for the purpose of
providing audit, review or attest services for the Company, (ii)&nbsp;recommending the compensation of the external auditor, (iii)&nbsp;overseeing the work of the external auditor in performing audit, review or attest services for the Company,
(iv)&nbsp;reviewing the Company&#146;s financial statements, management&#146;s discussion and analysis and annual and interim earnings press releases before the Company publicly discloses this information, and (v)&nbsp;establishing procedures for
addressing complaints or concerns regarding accounting, internal control or auditing matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A copy of the Audit Committee&#146;s
charter is attached as Schedule &#147;A&#148; to this AIF. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Relevant Education and Experience </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each member of the Audit Committee has adequate education and experience that is relevant to their performance as an Audit Committee member
and, in particular, the requisite education and experience that have provided the member with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">an understanding of the accounting principles used by the Company to prepare its financial statements and
the ability to assess the general application of those principles in connection with estimates, accruals and reserves; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">experience preparing, auditing, analyzing or evaluating financial statements that present a breadth and
level of complexity of accounting issues that are generally comparable to the breadth and complexity of issues that can reasonably be expected to be raised by the Company&#146;s financial statements or experience actively supervising individuals
engaged in such activities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">an understanding of internal controls and procedures for financial reporting. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>John Montalbano, CFA, Director </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">John
retired as CEO of RBC Global Asset Management in 2015, at which point the company managed $370&nbsp;billion in assets, placing it among the 50 largest asset managers worldwide. John currently serves as Director and Audit Chair for the following
organizations: Canada Pension Plan Investment Board, AbCellera Inc. (Nasdaq), and Eupraxia Pharmaceuticals (TSX).&nbsp;He also serves as Director for Aritzia Inc.&nbsp;and Chairs White Crane Capital, a Vancouver-based hedge fund. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">John&#146;s past volunteer roles have included&nbsp;Chair of the UBC Board of Governors, Chair of St. Paul&#146;s Foundation, Chair of The
Vancouver Police Foundation, Killam Trusts Trustee, <FONT STYLE="white-space:nowrap">co-Founder</FONT> of Take a Hike Youth at Risk Foundation, Chair of the Vancouver Public Library Capital Campaign and Director/Chair Investments for the Asia
Pacific </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Foundation of Canada. He&nbsp;serves&nbsp;as a Director for the Gairdner Foundation, the Rideau Hall Foundation, and Windmill Microlending.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">John holds a Chartered Financial Analyst designation, a Bachelor of Commerce degree with Honours from the University of British Columbia, and
an Honorary Doctor of Letters degree from Emily Carr University of Art and Design </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Simon Pimstone, MD, PhD, FRCPC (Chair), Chairman of the Board
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Simon Pimstone is a founder and <FONT STYLE="white-space:nowrap">non-executive</FONT> Board Chair at Xenon Pharmaceuticals
Inc. (&#147;Xenon&#148;), a publicly traded Canadian biotechnology company (Nasdaq: XENE). Xenon is engaged in discovering and developing novel pharmaceuticals targeting neurological diseases with a key focus on ion channels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr Pimstone is also a founder and CEO of XYON Health Inc., a privately held Canadian company delivering innovative healthcare solutions for
men and women with hair loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Pimstone received his MD from the University of Cape Town (MBChB, 1991) and is an internal
medicine specialist (FRCPC, UBC, 2001). Prior to his specialization, he trained as a clinical research fellow with the Department of Medical Genetics at the University of British Columbia and obtained his PhD in cardiovascular genetics through the
University of Amsterdam (1998). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Pimstone also serves as a consultant physician at the UBC Medical and Cardiology Clinic at UBC
Hospital in Vancouver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Pimstone has served on numerous <FONT STYLE="white-space:nowrap">non-profit</FONT> boards including
BIOTECanada, LifeSciences BC, the Center for Molecular Medicine and Therapeutics, Providence Healthcare and numerous life sciences company boards including Eupraxia Pharmaceuticals and Alpha9 Oncology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Pimstone has received a number of awards and is widely published. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Paul Geyer, P.Eng., Director </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mr.&nbsp;Geyer is a Medtech Entrepreneur, angel investor and venture capitalist, and has sat on the Boards of several companies. Over the past
30 years Mr.&nbsp;Geyer founded or led three companies through their growth phase, in one case to exit and in another to a public company. These companies have grown to employ more than 350 people. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mr.&nbsp;Geyer is currently the CEO of Discovery Parks and Nimbus Synergies, a venture capital investment program focused on growing BC
Digital Health companies that operate in the intersection between health, life sciences, and technology. He is an active mentor and angel investor in medical technology companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 1991 he founded Mitroflow, a tissue heart valve company. Mr.&nbsp;Geyer grew the company from nine employees to more than 125 employees,
selling in 1999 for more than $50&nbsp;million. In 2001, Mr.&nbsp;Geyer founded Medical Ventures (Neovasc) where he is on the board and held the position of CEO until June 2008 and was responsible for raising over $40&nbsp;million in equity
financing and overseeing the acquisition of three other companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From 2009 to 2017, Mr.&nbsp;Geyer was the first CEO of LightIntegra
Technology which developed the ThromboLux, a point of care device to determine platelet quality for blood transfusions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since 2008,
Mr.&nbsp;Geyer has focused on assisting entrepreneurs to build successful businesses, as a mentor or board member, and as a Fellow of Creative Destruction Labs. He has also worked on building the local community through his involvement as a board
member of BCTech, LifeSciences BC, and Science World, Vancouver General Hospital&nbsp;&amp; UBC Hospital Foundation, and Junior Achievement BC along with a number of <FONT STYLE="white-space:nowrap">non-profit</FONT> community-based organizations.
He also participates in a range of philanthropic endeavours. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Pre-Approval</FONT> Policies and Procedures </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Audit Committee has the authority and responsibility for <FONT STYLE="white-space:nowrap">pre-approval</FONT> of all <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be provided to the Company or its subsidiary entities by the external auditors or the external auditors of the Company&#146;s subsidiary entities unless such
<FONT STYLE="white-space:nowrap">pre-approval</FONT> is otherwise appropriately delegated or if appropriate specific policies and procedures for the engagement of <FONT STYLE="white-space:nowrap">non-audit</FONT> services have been adopted by the
Audit Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>External Auditor Service Fees by Category </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The aggregate fees billed by the Company&#146;s external auditors in the last two fiscal years for audit fees are set out in the table below.
In the table, &#147;Audit Fees&#148; are fees billed by the Company&#146;s external auditor for services provided in auditing the Company&#146;s annual financial statements. &#147;Audit-Related Fees&#148; are fees not included in audit fees that are
billed by the external auditor for assurance and related services that are reasonably related to the performance of the audit review of the Company&#146;s financial statements. &#147;Tax Fees&#148; are fees billed by the external auditor for
professional services rendered for tax compliance, tax advice and tax planning. &#147;All Other Fees&#148; are fees billed by the external auditor for products and services not included in the foregoing categories. All fees are &#147;as billed&#148;
on a cash basis by the Company. All amounts in the table are expressed in Canadian dollars. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="padding-bottom:4pt ;BORDER-BOTTOM:1px solid #000000"><B>Financial Year Ending</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-BOTTOM:1px solid #000000"><B>Audit&nbsp;Fees</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-BOTTOM:1px solid #000000"><B>Audit&nbsp;Related&nbsp;Fees<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-BOTTOM:1px solid #000000"><B>Tax&nbsp;Fees<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-BOTTOM:1px solid #000000"><B>All&nbsp;Other&nbsp;Fees</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">$335,000<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$73,200</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$11,700</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$-</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$42,500</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$13,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$-</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Includes fees for services related to quarterly interim reviews and providing auditor consent letters with
respect to financing related matters. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Tax Fees related to the preparation of income tax returns for the Company and its subsidiaries, and fees
related to the preparation of the Company&#146;s Scientific Research and Experimental Development claims. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Includes fees related to the reaudit of the 2021/2022 financial statements as a result of appointment of
KPMG LLP as auditor. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEGAL PROCEEDINGS AND REGULATORY ACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the Company&#146;s knowledge, there are no legal proceedings or regulatory actions to which the Company is a party, or has been a party to,
or of which any of its property is the subject matter of, or was the subject matter of, since the beginning of the financial year ended December&nbsp;31, 2023, and no such proceedings or actions are known by the Company to be contemplated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2023, and the date of this AIF, the Company is not subject to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">any penalties or sanctions imposed against the Company by a court relating to securities legislation or by a
securities regulatory authority during the financial year ended December&nbsp;31, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">any other penalties or sanctions imposed by a court or regulatory body against the Company that would likely
be considered important to a reasonable investor in making an investment decision; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">settlement agreements the Company entered into before a court relating to securities legislation or with a
securities regulatory authority during the financial year ended December&nbsp;31, 2023. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is unaware of any
condition of default under any debt, regulatory, exchange related or other contractual obligation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTEREST OF MANAGEMENT AND OTHERS IN
MATERIAL TRANSACTIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other than as described elsewhere in this AIF, none of (i)&nbsp;the directors or executive officers of the
Company, (ii)&nbsp;the shareholders who beneficially own or control or direct, directly or indirectly, more than 10% of the voting shares of the Company, or (iii)&nbsp;any associate or affiliate of the persons referred to in (i)&nbsp;and (ii), has
or has had any material interest, direct or indirect, in any transaction within the three most recently completed financial years or during the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
current financial year or in any proposed transaction that has materially affected or is reasonably expected to materially affect Eupraxia. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRANSFER AGENT AND REGISTRAR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The registrar and transfer agent for the Common Shares in Canada and TSX Trust Company at its principal offices in Vancouver, British Columbia
(&#147;<B>TSX Trust</B>&#148;) and in the United States is Continental Stock Transfer and Trust Company at its principal offices in New York, New York. The Warrant Agent in respect of the listed Warrants is TSX Trust. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MATERIAL CONTRACTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
following are &#147;material contracts&#148; of the Company, as defined in National Instrument <FONT STYLE="white-space:nowrap">51-102</FONT> - <I>Continuous Disclosure Obligations</I>, that are outstanding as of the date of this AIF: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Amended and Restated License Agreement between Auritec and Eupraxia USA dated October&nbsp;9, 2018, as
amended, and the Security Agreement between Auritec and Eupraxia USA dated March&nbsp;31, 2020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The warrant indenture between the Company and TSX Trust Company dated March&nbsp;9, 2021.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The 2021 contingent convertible debt agreement between the Company, Eupraxia Pharma, Inc., Eupraxia Holdings,
Inc., Eupraxia Pharmaceuticals USA, LLC, SVB and SVB Innovation Credit Fund VIII, L.P dated June&nbsp;21, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The warrant indenture between the Company and TSX Trust Company dated April&nbsp;20, 2022.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Copies of the foregoing documents are available on SEDAR+ at www.sedarplus.ca. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTERESTS OF EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
auditors are KPMG LLP. KPMG LLP has confirmed with respect to the Company that they are independent within the meaning of the relevant rules and related interpretations prescribed by the relevant professional bodies in Canada and any applicable
legislation or regulations, and are independent accountants with respect to us under all relevant U.S. professional and regulatory standards. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additional information relating to the Company, including directors&#146; and officers&#146; remuneration and indebtedness, principal holders
of the Company&#146;s securities and securities authorized for issuance under equity compensation plans is contained in the Company&#146;s Management Information Circular dated May&nbsp;8, 2023 and filed on SEDAR+ at www.sedarplus.ca. Additional
financial information is provided in our audited consolidated financial statements and management&#146;s discussion and analysis for our most recently completed financial year, each of which and is available under the Company&#146;s profile at
<U>www.sedarplus.ca</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE &#147;A&#148; </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Audit Committee Charter </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PURPOSE
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The primary function of the Audit Committee is to assist the board of directors (the &#147;<B>Board</B>&#148;) of Eupraxia
Pharmaceuticals Inc. (the &#147;<B>Company</B>&#148;) in fulfilling its oversight responsibilities by reviewing the financial information to be provided to the shareholders and others, the systems of internal controls and management information
systems established by the senior officers of the Company (&#147;<B>Management</B>&#148;) and the Company&#146;s internal and external audit process and monitoring compliance with the Company&#146;s legal and regulatory requirements with respect to
its financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Audit Committee is accountable to the Board. In the course of fulfilling its specific responsibilities
hereunder, the Audit Committee is expected to maintain an open communication between the Company&#146;s external auditors and the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Audit Committee does not plan or perform audits or warrant the accuracy or completeness of the Company&#146;s financial statements or
financial disclosure or compliance with generally accepted accounting procedures as these are the responsibility of Management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RESPONSIBILITIES
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the powers and duties of the Board, the Board hereby delegates to the Audit Committee the following powers and duties to be
performed by the Audit Committee on behalf of and for the Board. Nothing in this Charter is intended to or does confer on any member a higher standard of care or diligence than that which applies to the directors as a whole. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>External Auditors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Audit
Committee has primary responsibility for the selection, appointment, dismissal, compensation and oversight of the external auditors, subject to the overall approval of the Board. For this purpose, the Audit Committee may consult with Management.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The external auditors shall report directly to the Audit Committee. In addition, the Audit Committee: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">recommends to the Board: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">whether the current external auditors should be nominated for reappointment for the ensuing year and if
applicable, select and recommend a suitable alternative for nomination; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the amount of compensation payable to the external auditors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">resolves disagreements, if any, between Management and the external auditors regarding financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">provides the Board with such recommendations and reports with respect to the financial statements of the
Company as it deems advisable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">takes reasonable steps to confirm the independence of the external auditors, including but not limited to <FONT
STYLE="white-space:nowrap">pre-approving</FONT> any <FONT STYLE="white-space:nowrap">non-audit</FONT> related services provided by the external auditors to the Company or the Company&#146;s subsidiaries, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">confirms that the external auditors are a &#147;participating audit&#148; firm for the purpose of National
Instrument <FONT STYLE="white-space:nowrap">52-108</FONT> &#150; <I>Auditor Oversight </I>and are in compliance with governing regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">reviews the plan and scope of the audit to be conducted by the external auditors of the Company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">reviews and evaluates the performance of the external auditors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">h.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">reviews and approves the Company&#146;s hiring policy regarding partners, employees and former partners and
employees of the Company&#146;s present and former external auditors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit and Review Process and Results </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Audit Committee has a duty to receive, review and make any inquiry regarding the completeness, accuracy and presentation of the
Company&#146;s financial statements to ensure that the financial statements fairly present the financial position and risks of the organization and that they are prepared in accordance with generally accepted accounting principles. To accomplish
this, the Audit Committee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">considers the scope and general extent of the external auditors&#146; review, including their engagement
letter and major changes to the Company&#146;s auditing and accounting principles and practices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">consults with management regarding the sufficiency of the Company&#146;s internal system of audit and
financial controls, internal audit procedures and results of such audits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">ensures the external auditors have full, unrestricted access to required information and have the
cooperation of management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">reviews with the external auditors the audit process and standards, as well as regulatory or
Company-initiated changes in accounting practices and policies and the financial impact thereof, and selection or application of appropriate accounting principles; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">reviews with the external auditors and, if necessary, legal counsel, any litigation, claim or contingency,
including tax assessments, that could have a material effect upon the financial position of the Company and the manner in which these matters are being disclosed in the financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">reviews the appropriateness and disclosure of any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet
matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">reviews disclosure of related party transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">h.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">receives and reviews with the external auditors, the external auditors&#146; audit report and the audited
financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">makes recommendations to the Board respecting approval of the audited financial statements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">j.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">meets with the external auditors separately from management to review the integrity of the Company&#146;s
financial reporting, including the clarity of financial disclosure and the degree of conservatism or aggressiveness of the accounting policies and estimates, any significant disagreements or difficulties in obtaining information, adequacy of
internal controls over financial reporting, adequacy of disclosure controls and procedures, and the degree of compliance by the Company with prior recommendations of the external auditors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">k.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">directs management to implement such changes as the Audit Committee considers appropriate, subject to any
required approvals of the Board arising out of the review; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">l.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">meets at least annually with the external auditors, independent of management, and reports to the Board on
such meetings. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim Financial Statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Audit Committee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">reviews and determines the Company&#146;s practice with respect to review of interim financial statements by
the external auditors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">conducts all such reviews and discussions with the external auditors and Management as it deems appropriate;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">makes recommendations to the Board respecting approval of the interim financial statements.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Involvement with Management </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Audit Committee has primary responsibility for overseeing the actions of management in all aspects of financial management and reporting.
The Audit Committee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">reviews the Company&#146;s annual and interim financial statements, Management&#146;s Discussion and
Analysis and earnings press releases, if any, before the Company publicly discloses this information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">reviews all of the Company&#146;s public disclosure of financial information extracted from the
Company&#146;s financial statements, if such financial statements have not previously been reviewed by the Committee, prior to such information being made public by the Company and for such purpose,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
the CFO assumes responsibility for providing the information to the Audit Committee for its review; reviews material financial risks with Management, the plan that Management has implemented to
monitor and deal with such risks and the success of Management in following the plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">consults annually and otherwise as required with the Company&#146;s CEO and CFO respecting the adequacy of
the internal controls over financial reporting and disclosure controls and procedures and reviews any breaches or deficiencies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">obtains such certifications of annual and interim filings by the CEO and CFO attesting to internal controls
over financial reporting and disclosure controls and procedures as deemed advisable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">reviews Management&#146;s response to significant written reports and recommendations issued by the external
auditors and the extent to which such recommendations have been implemented by Management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">reviews with Management the Company&#146;s compliance with applicable laws and regulations respecting
financial reporting matters, and any proposed regulatory changes and their impact on the Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">reviews as required with Management and approves disclosure of the Audit Committee Charter, and Audit
Committee disclosure required in the Company&#146;s Annual Information Form, Information Circular and on the Company&#146;s website. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROCEDURAL MATTERS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Audit Committee:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">invites the Company&#146;s external auditors, the CFO, and such other persons as deemed appropriate by the
Audit Committee to attend meetings of the Audit Committee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">reports material decisions and actions of the Audit Committee to the Board, together with such
recommendations as the Audit Committee may deem appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">has the power to conduct or authorize investigations into any matter within the scope of its
responsibilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">has the right to engage independent counsel and other advisors as it determines necessary to carry out its
duties and the right to set the compensation for any advisors employed by the Audit Committee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">has the right to communicate directly with the CFO and other members of Management who have responsibility
for the internal and external audit process, as well as to communicate directly with the internal and external auditors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">pre-approves <FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the external
auditors in accordance with the provisions of National Instrument <FONT STYLE="white-space:nowrap">52-110</FONT> &#150; <I>Audit Committees </I>(&#147;<B>NI <FONT STYLE="white-space:nowrap">52-110</FONT></B>&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COMPOSITION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Audit Committee is
composed of a minimum of three directors, all of whom are independent, subject to any exemptions or relief that may be granted from such requirements under NI <FONT STYLE="white-space:nowrap">52-110,</FONT> and have relevant skills and/or experience
in the Audit Committee&#146;s areas of responsibility as may be required by the securities laws applicable to the Company, including those of any stock exchange on which the Company&#146;s securities are traded. No member shall have served as the
CEO of the Company, or an affiliate, within the past five years, or as the CFO of the Company, or an affiliate, within the past three years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The members of the Audit Committee shall not be members of more than three public company audit committees (including the Company), except for
a member with demonstrable financial expertise such as a former CFO, who shall not be a member of more than four audit committees (including the Company). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Appointment of Committee Members and Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Members of the Audit Committee are appointed or confirmed by the Board annually and hold office at the pleasure of the Board. The Board fills
any vacancy on, and may appoint any additional members to, the Audit Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Committee Chair </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board appoints a Chair for the Audit Committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>STRUCTURE AND OPERATIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Meetings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Chair of the Audit Committee or the Chair of the Board or any two of its members may call a meeting of the Audit Committee. The Audit
Committee must meet at least four times each fiscal year, and at such other times during each year as it deems appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quorum </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A majority of the members appointed to the Audit Committee constitutes a quorum. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice of Meetings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Chair of
the Audit Committee arranges to provide notice of the time and place of every meeting in writing (including by electronic means) to each member of the Audit Committee at least two (2)&nbsp;business days prior to the time fixed for such meeting,
provided, however, that a member may in any manner waive a notice of a meeting. Attendance of a member at a meeting constitutes a waiver of notice of the meeting, except where a member attends a meeting for the express purpose of objecting to the
transaction of any business on the grounds that the meeting is not lawfully called. The Chair also ensures that an agenda for the meeting and all required materials for review by the members of the Audit Committee are delivered to the members with
sufficient time for their review, or that such requirement is waived. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Absence of Committee Chair </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the Chair of the Audit Committee is not present at any meeting of the Audit Committee, the other members of the Audit Committee will choose
a Chair to preside at the meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Secretary of Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At each meeting the Audit Committee appoints a secretary who need not be a director of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Attendance of the Company&#146;s Officers at Meetings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Chair of the Audit Committee or any two members of the Audit Committee may invite one or more officers of the Company to attend any meeting
of the Audit Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delegation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Audit Committee may, in its discretion and where permitted by NI <FONT STYLE="white-space:nowrap">52-110,</FONT> delegate all or a portion
of its duties and responsibilities to a subcommittee, management or, to the extent otherwise permitted by applicable plans, laws or regulations, to any other body or individual. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Procedure and Records </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to
any statute or constating documents of the Company, the Audit Committee determines its own procedures at meetings and may conduct meetings by telephone and keeps records of its proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>REPORTING AND ASSESSMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Audit Committee reports to the Board of Directors, and on an annual basis, presents to the Board a Committee Annual Report consisting of
the Audit Committee&#146;s review of its charter, the Committee&#146;s and its Chair&#146;s performance over the past year, and any recommendations the Audit Committee makes in respect thereto. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EFFECTIVE DATE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Charter was approved
by the Board on March&nbsp;2, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>d800041dex992.htm
<DESCRIPTION>EX-99.2 FINANCIAL STATEMENTS
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:eprx="http://eupraxiapharma.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>EX-99.2 Financial Statements</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style=""><div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="us-gaap:PreferredStockSharesAuthorizedUnlimited" id="hidden108159696" contextRef="P01_01_2022To12_31_2022">Unlimited</ix:nonNumeric><ix:nonNumeric name="us-gaap:PreferredStockSharesAuthorizedUnlimited" id="hidden108159697" contextRef="P01_01_2023To12_31_2023">Unlimited</ix:nonNumeric><ix:nonNumeric name="us-gaap:CommonStockSharesAuthorizedUnlimited" id="hidden108159693" contextRef="P01_01_2022To12_31_2022">Unlimited</ix:nonNumeric><ix:nonNumeric name="us-gaap:CommonStockSharesAuthorizedUnlimited" id="hidden108159695" contextRef="P01_01_2023To12_31_2023">Unlimited</ix:nonNumeric><ix:nonFraction name="us-gaap:CommonStockNoParValue" id="hidden108160218" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockNoParValue" id="hidden108160219" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="0">0</ix:nonFraction><ix:nonNumeric name="us-gaap:CommonStockSharesAuthorizedUnlimited" id="hidden108160215" contextRef="P01_01_2022To12_31_2022">Unlimited</ix:nonNumeric><ix:nonNumeric name="us-gaap:CommonStockSharesAuthorizedUnlimited" id="hidden108160178" contextRef="P01_01_2023To12_31_2023">Unlimited</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="eprx-20231231.xsd"/></ix:references></ix:header></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit 99.2 </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EUPRAXIA PHARMACEUTICALS INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2023 and 2022 </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars) </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC</div></div>. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2023 and 2022 </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div id="index" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">CONTENTS </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 92%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin800041_2">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin800041_3">CONSOLIDATED BALANCE SHEET</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin800041_4">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin800041_5">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin800041_6">CONSOLIDATED STATEMENTS OF CASH FLOWS</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin800041_7">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-8-F-35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin800041_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Shareholders and Board of Directors </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eupraxia Pharmaceuticals Inc: </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Consolidated Financial Statements </div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated balance sheets of Eupraxia Pharmaceuticals Inc. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, changes in shareholders&#8217; equity, and cash flows for each of the years in the two-year period ended December 31, 2023, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles. </div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Going Concern </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and forecasted cash outflows from operations that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis for Opinion </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ KPMG LLP </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chartered Professional Accountants </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2023. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vancouver, Canada </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">April 1, 2024 </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EUPRAXIA PHARMACEUTICALS INC. </div></div></div></div><div id="fin800041_3" style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 78%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">ASSETS</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Current assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Cash and cash equivalents (Note 20)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14126">19,341,756</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14127">18,263,389</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and deposits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14128">270,710</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14129">235,903</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Amounts receivable (Note 4)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NontradeReceivablesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14130">190,612</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NontradeReceivablesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14131">89,715</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total current assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14132">19,803,078</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14133">18,589,007</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14134">6,904</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14135">2,492</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Property and equipment, net (Note 5)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14136">409,587</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14137">443,464</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> asset, net (Note 6)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14138">46,660</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14139">87,286</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14140">20,266,229</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14141">19,122,249</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY (DEFICIT)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Current liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Accounts payable and accrued liabilities (Note 7)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14142">3,921,875</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14143">2,928,566</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Loans payable &#8211; current portion (Note 8)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLongTermDebtCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14144">62,709</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLongTermDebtCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14145">79,418</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Lease liability &#8211; current portion (Note 9)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14146">53,316</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14147">50,403</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Payable to Auritec (Note 10)</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:PayableTowardsRoyaltyAndOthersCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14148">5,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Convertible debt (Note 11)</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:ConvertibleDebtCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14149">10,336,003</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14150">19,373,903</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14151">3,058,387</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> liabilities</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Loans payable (Note 8)</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:OtherLongTermDebtNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14152">62,709</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Lease liability (Note 9)</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14153">51,303</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Convertible debt (Note 11)</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14154">8,741,996</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14155">19,373,903</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14156">11,914,395</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Shareholders&#8217; equity (deficit)</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Share capital, <div style="-sec-ix-hidden:hidden108160218;display:inline;"><div style="-sec-ix-hidden:hidden108160219;display:inline;">without par value</div></div>; <div style="-sec-ix-hidden:hidden108160178;display:inline;"><div style="-sec-ix-hidden:hidden108160215;display:inline;">unlimited</div></div> shares authorized; issued and outstanding: <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14157"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14158">27,282,165</ix:nonFraction></ix:nonFraction> (December 31, 2022 - <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14159"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14160">21,593,145</ix:nonFraction></ix:nonFraction> (Note 12(b))</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14161">92,913,585</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14162">71,003,225</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (Notes 12(b), 12(c) and 12(d))</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14163">17,510,469</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14164">16,850,165</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deficit</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14165">105,501,295</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14166">77,280,499</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Accumulated other comprehensive loss</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14167">2,706,552</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14168">2,786,366</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Equity attributable to the owners of the Company</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14169">2,216,207</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14170">7,786,525</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14171">1,323,881</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14172">578,671</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total shareholders&#8217; equity (deficit)</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14173">892,326</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14174">7,207,854</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total liabilities and shareholders&#8217; equity (deficit)</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14175">20,266,229</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14176">19,122,249</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nature of business and going concern (Note 1) </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments (Note 17) </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent event (Note 21) </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-4 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EUPRAXIA PHARMACEUTICALS INC. </div></div></div></div><div id="fin800041_4" style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 80%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/>December&#160;31,<br/>2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/>December&#160;31,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Expenses</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">General and administrative (Note 13)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14177">7,284,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14178">3,987,598</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Research and development (Note 14)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14179">20,563,225</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14180">13,629,854</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total expenses</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14181">27,847,229</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14182">17,617,452</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other income/(expenses)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14183">862,969</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14184">431,799</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Interest expense (Note 19)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14185">1,170,173</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14186">982,856</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Loss on sale of equipment (Note 5)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14187">4,846</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14188">6,637</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Foreign exchange gain</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14189">66,291</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14190">240,547</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Change in fair value of financial instruments (Note 11)</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14191">836,595</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14192">1,056,165</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Total other income</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14193">1,082,354</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14194">1,373,312</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Net loss before tax expense</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14195">28,929,583</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14196">18,990,764</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Tax expense (Note 16)</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14197">36,423</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;;background-color:rgba(255, 255, 255, 0);"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;;background-color:rgba(255, 255, 255, 0);"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;;background-color:rgba(255, 255, 255, 0);"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;;background-color:rgba(255, 255, 255, 0);"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net loss for the year</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14198">28,966,006</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14199">18,990,764</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Loss attributable to:</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Owners of the Company</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14200">28,220,796</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14201">18,489,629</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14202">745,210</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14203">501,135</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14204">28,966,006</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14205">18,990,764</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation adjustment</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14206">79,814</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14207">1,276,388</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Comprehensive loss for the year</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14208">28,886,192</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14209">20,267,152</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">Loss per share &#8211; basic and diluted (Owners of the Company)</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14210"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14211">1.17</ix:nonFraction></ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14212"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14213">0.96</ix:nonFraction></ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Weighted average shares outstanding &#8211; basic and diluted</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14214"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14215">24,146,623</ix:nonFraction></ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14216"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14217">19,285,447</ix:nonFraction></ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-5 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EUPRAXIA PHARMACEUTICALS INC. </div></div></div></div> <div id="fin800041_5" style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 26%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Additional&#160;paid-</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">in capital</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated&#160;other<br/>comprehensive&#160;income</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div><br/>interest</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, December&#160;31, 2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14218">14,242,595</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14219">62,250,123</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14220">13,226,108</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14221">58,790,870</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14222">1,509,978</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14223">77,536</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14224">15,097,847</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Overnight marketed public offering, net of transaction costs (Note 12(b)(i))</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OvernightMarketedPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14225">7,150,550</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OvernightMarketedPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14226">8,401,439</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_OvernightMarketedPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14227">2,235,138</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To12_31_2022_OvernightMarketedPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14228">10,636,577</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Redemption of warrants (Notes 12(b)(ii) and 12(d))</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14229">200,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14230">351,663</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14231">44,893</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To12_31_2022_ExcerciseOfWarrantsMemberEPRXEventAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14232">306,770</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Share-based payments<br/>(Note 12(c))</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14233">1,433,812</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14234">1,433,812</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss for the year</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14235">18,489,629</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14236">501,135</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14237">18,990,764</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign Currency translation adjustment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14238">1,276,388</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14239">1,276,388</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, December&#160;31, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14240">21,593,145</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14241">71,003,225</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14242">16,850,165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14243">77,280,499</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14244">2,786,366</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14245">578,671</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14246">7,207,854</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-brokered</div> private placement, net of transaction costs<br/>(Note&#160;12(b)(v))</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14247">3,282,936</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14248">15,886,537</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14249">15,886,537</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Share-based payments<br/>(Note 12(c))</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14250">1,412,257</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14251">1,412,257</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Redemption of warrants (Notes 12(b)(iii) and 12(d))</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14252">2,385,484</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14253">5,974,988</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14254">733,177</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_ExcerciseOfWarrantsMemberEPRXEventAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14255">5,241,811</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Redemption of options<br/>(Notes&#160;12(b)(iv) and 12(c))</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14256">20,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14257">48,835</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14258">18,776</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14259">30,059</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss for the year</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14260">28,220,796</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To12_31_2023_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14261">745,210</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14262">28,966,006</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation adjustment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2023To12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14263">79,814</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14264">79,814</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, December&#160;31, 2023</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14265">27,282,165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14266">92,913,585</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14267">17,510,469</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14268">105,501,295</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14269">2,706,552</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14270">1,323,881</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14271">892,326</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-6 </div> </div> </div> </div> <div></div> </div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EUPRAXIA PHARMACEUTICALS INC. </div></div></div></div><div id="fin800041_6" style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars<div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 74%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/>December&#160;31,&#160;2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/>December&#160;31,&#160;2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">CASH FLOWS FROM OPERATING ACTIVITIES</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14272">28,966,006</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14273">18,990,764</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Items not affecting cash</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Accrued interest on convertible debt (Note 11)</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="eprx:InterestOnConvertibleDebtOne" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14274">571,603</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="eprx:InterestOnConvertibleDebtOne" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14275">643,233</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest on short term investments</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="eprx:InterestOnShortTermInvestmentsNonOperating" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14276">4,665</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Depreciation (Note 5 and 6)</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14277">155,527</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14278">147,894</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest &#8211; lease liability</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="eprx:InterestExpensesOnLeaseLiabilityFinancingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14279">14,401</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="eprx:InterestExpensesOnLeaseLiabilityFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14280">21,383</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss on sale of equipment</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="eprx:LossOnSaleOfEquipment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14281">4,846</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="eprx:LossOnSaleOfEquipment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14282">6,879</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Share-based payments (Note 12(c))</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14283">1,412,257</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14284">1,433,812</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Change in fair value of financial instruments (Note 11)</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14285">836,595</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14286">1,056,165</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized foreign exchange</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14287">64,609</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14288">223,709</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)<div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Changes in operating assets and liabilities</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable and accrued liabilities</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14289">577,908</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14290">1,324,049</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Auritec payable (Note 10)</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14291">5,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14292">122,435</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14293">39,959</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amounts receivable</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14294">103,710</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14295">230,481</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 74%;;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash used in operating activities</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14296">20,683,623</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14297">14,395,201</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="8" style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">CASH FLOWS FROM INVESTING ACTIVITIES</div></div></td>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquisition of equipment</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMachineryAndEquipment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14298">73,377</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMachineryAndEquipment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14299">235,550</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Proceeds from sale of equipment (Note 5)</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14300">242</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of short term investments</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14301">3,272,379</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from redemption of short-term investments</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14302">13,342,058</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 74%;;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash provided by (used in) investing activities</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14303">73,377</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14304">9,834,371</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="8" style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">CASH FLOWS FROM FINANCING ACTIVITIES</div></div></td>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Overnight marketed public offering (net of transaction costs) (Note 12(b)(i) and (v))</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14305">15,886,537</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14306">10,636,577</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Redemption of warrants (Note 12(d))</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14307">5,241,811</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14308">306,770</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Redemption of options (Note 12 (c))</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14309">30,059</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Repayment of loans (Note 8)</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:RepaymentsOfOtherLongTermDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14310">79,441</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:RepaymentsOfOtherLongTermDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14311">74,845</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Lease payments (Note 9)</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14312">64,996</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14313">67,423</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 74%;;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash provided by financing activities</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14314">21,013,970</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14315">10,801,079</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 74%;;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Increase in cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14316">256,970</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14317">6,240,249</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Foreign exchange effect on cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14318">821,397</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14319">507,395</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents, beginning of year</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14320">18,263,389</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14321">12,530,535</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 74%;;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 74%;;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents, end of year</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14322">19,341,756</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14323">18,263,389</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 74%;"/>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure with respect to cash flows (Note 20) </div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-7 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div id="fin800041_7" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><ix:nonNumeric name="us-gaap:NatureOfOperations" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_108159597" id="ixv-5486">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">NATURE OF BUSINESS AND GOING CONCERN </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Eupraxia Pharmaceuticals Inc. (the &#8220;Company&#8221;) was incorporated under the laws of the province of Alberta on <ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" contextRef="P01_01_2023To12_31_2023" format="ixt:date-monthname-day-year-en" id="ixv-14324">May 12, 2011</ix:nonNumeric>, under the name Plaza Capital Partners Inc. On May&#160;11, 2012, the Company changed its name to Eupraxia Pharmaceuticals Inc. and continued from the province of Alberta to the province of British Columbia. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On October&#160;10, 2012, Eupraxia Holdings, Inc. (&#8220;Holdings&#8221;) was incorporated under the laws of the State of Delaware, USA. On November&#160;16, 2012, Holdings was registered as an extra-provincial corporation under the laws of the province of British Columbia, Canada. On October 10, 2012, Eupraxia Pharmaceuticals USA, LLC (&#8220;Eupraxia USA&#8221;) was incorporated under the laws of the State of Delaware. On November&#160;16, 2012, Eupraxia USA was registered as an extra-provincial corporation under the laws of the province of British Columbia. On January&#160;7, 2021, Eupraxia Pharma, Inc. (&#8220;Eupraxia Pharma&#8221;) was incorporated under the laws of the State of Delaware. On July&#160;4, 2022, Eupraxia Pharmaceuticals Australia Pty Ltd. (&#8220;Eupraxia Australia&#8221;) was incorporated under the laws of the state of Victoria, Australia. On May&#160;17, 2023, Eupraxia Pharma USA Inc. (&#8220;Eupraxia Pharma USA&#8221;) was incorporated under the laws of the State of Delaware. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On March&#160;9, 2021, the Company completed its initial public offering on the Toronto Stock Exchange (&#8220;TSX&#8221;) and began trading under the symbol &#8220;EPRX&#8221;. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company is a clinical stage biotechnology company leveraging its proprietary Diffusphere<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#8482;</div> technology to optimize drug delivery for applications with significant unmet medical need. The address of the Company&#8217;s corporate office and principal place of business is 201- 2067 Cadboro Bay Road, Victoria, British Columbia, Canada. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">These consolidated financial statements have been prepared on a going concern basis with the assumption that the Company will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. At December&#160;31, 2023, the Company had cash and cash equivalents of $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14325">19,341,756</ix:nonFraction><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">. The</div> Company has <ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-14326">no</ix:nonFraction>t yet generated revenue from operations. The Company incurred a net loss of $<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14327">28,966,006</ix:nonFraction> during the year ended December&#160;31, 2023, and as of that date, the Company&#8217;s accumulated deficit was $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14328">105,501,295</ix:nonFraction>. As the Company is in the research and development stage, the recoverability of the costs incurred to date is dependent upon the ability of the Company to obtain the necessary funding to complete the research and development of its projects and upon future commercialization or proceeds from the monetization of research activities. The Company will periodically have to raise funds to continue operations and raised $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14329">15,886,537</ix:nonFraction> (CDN$<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_CAD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14330">20,836,005</ix:nonFraction>) through a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">non-brokered</div> private placement of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14331">3,183,875</ix:nonFraction> common shares in <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">2023 (2022 - $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_01_2022To12_31_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14332">11,768,459</ix:nonFraction> through a marketed public offering) and raised $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14333">25,026,073</ix:nonFraction> (CDN$<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_CAD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14334">33,867,784</ix:nonFraction>) through an overnight marketed public offering of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14335">8,260,435</ix:nonFraction> common shares in 2024</div>. Although it has been successful in doing so in the past, there is no assurance it will be able to do so in the future, especially with the ongoing conflicts in the Ukraine and the Middle East affecting the global capital markets. Recent developments with Silicon Valley Bank (&#8220;SVB&#8221;) have not impacted the Company&#8217;s outlook for cash runway. The Company holds <ix:nonFraction name="us-gaap:DebtInstrumentCollateralAmount" contextRef="PAsOn12_31_2023_SiliconValleyBankMemberEPRXLenderAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-14336">no</ix:nonFraction> amounts on deposit with SVB and the convertible debt (see Note <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">11</div> &#8211; Convertible Debt) which matures in <ix:nonNumeric name="eprx:DebtInstrumentMonthOfMaturity" contextRef="P01_01_2023To12_31_2023_SiliconValleyBankMemberEPRXLenderAxis" format="ixt:date-monthname-year-en" id="ixv-14337">June 2024</ix:nonNumeric> remains in good standing, is fully drawn and is not callable by SVB. The Company is active in its pursuit of additional funding through potential partnering and other strategic activities as well as grants to fund future research and development activities, and additional equity financing. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-8</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_108159597" continuedAt="TextSelectionAppend_108159597_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159597_1" continuedAt="TextSelectionAppend_108159597_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159597_2" continuedAt="TextSelectionAppend_108159597_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_108159597_3" continuedAt="TextSelectionAppend_108159597_4"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">NATURE OF BUSINESS AND GOING CONCERN (continued) </div></div></td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_108159597_4"><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional funding. There is a risk that in the future, additional financing will not be available on a timely basis or on terms acceptable to the Company. These events and conditions may cast substantial doubt about the Company&#8217;s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue in business. </div></div></div></ix:continuation> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><ix:nonNumeric name="us-gaap:BasisOfAccounting" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-5547">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">BASIS OF PRESENTATION </div></div></td></tr></table><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These consolidated financial statements are presented in U.S. dollars and have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). These consolidated financial statements include the accounts of the Company and the accounts of its subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in Reporting Currency to the US&#160;Dollar </div></div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective December&#160;31, 2023, the Company changed its reporting currency to the US dollar (&#8220;USD&#8221;) from the Canadian dollar (&#8220;CDN&#8221;). As such, all prior amounts originally reported in CDN are now reported in USD. The change in reporting currency was made to enhance comparability of the Company&#8217;s results with other publicly traded companies in the life sciences industry. The Canadian dollar continues to be the functional currency of the Company. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with ASC 830, the consolidated financial statements of the Company are translated into U.S. dollars using the current rate method. Assets and liabilities are translated at the rate of exchange prevailing at the consolidated balance sheet date. Shareholders&#8217; equity is translated at the applicable historical rate. Revenue, expense and cash flow items are translated at the exchange rate in effect on the transaction dates. Translation gains and losses are reported as a separate component of shareholders&#8217; equity titled Accumulated Other Comprehensive Income. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial information for all prior periods is presented in U.S. dollars as if the U.S. dollar had been used as the reporting currency during those periods. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transition to US&#160;GAAP </div></div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">This is the first year that the Company&#8217;s consolidated financial statements are prepared in accordance of generally accepted accounting principles in the United States of America <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(&#8220;GAAP&#8221;</div></div>) as issued by the Financial Accounting Standards Board (<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8220;FASB&#8221;</div></div>). Previously, the Company prepared its financial statements in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (&#8220;IASB&#8221;). </div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The policies set out in the Significant Accounting Policies section have been applied in preparing the financial statements for the years ended December&#160;31, 2023 and 2022. In addition, comparative figures, which were previously prepared in accordance with IFRS, have been adjusted as required to be compliant with the Company&#8217;s accounting policies under US&#160;GAAP. </div></div></div></ix:nonNumeric> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_108159613" id="ixv-5586">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-5599"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Measurement </div></div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements have been prepared on a historical cost basis, except for certain financial instruments which are measured at fair value. The consolidated financial statements are presented in U.S. dollars, which is the Company&#8217;s reporting currency. The Company&#8217;s functional currency is the Canadian dollar. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of consolidated financial statements in accordance with U.S. GAAP requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, expenses, and related disclosure. On an ongoing basis, the Company evaluates its estimates, most notably those related to accrual of expenses including clinical and preclinical study expense accruals, stock-based compensation, valuation allowance for deferred taxes, and fair value measurement of convertible debt. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates. </div></div></div></ix:nonNumeric><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="margin-top: 8pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><ix:exclude>F-9</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_108159613" continuedAt="TextSelectionAppend_108159613_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159613_1" continuedAt="TextSelectionAppend_108159613_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159613_2" continuedAt="TextSelectionAppend_108159613_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_108159613_3" continuedAt="TextSelectionAppend_108159613_4"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) </div></div></td></tr></table><div style="font-size: 0pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;<div style="font-weight:bold;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Measurement (continued) </div></div></div></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159613_4" continuedAt="TextSelectionAppend_108159613_5"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="us-gaap:ConsolidationPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-5660"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidation </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These consolidated financial statements include the accounts of the Company and the accounts of its subsidiaries. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. Control exists when an entity is exposed to or has rights to variable returns from its involvement with the entity and has the ability to affect these returns through its power over the entity. All significant intercompany transactions and balances have been eliminated. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest in the net assets of consolidated subsidiaries are identified separately from the Company&#8217;s equity. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest consists of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest as at the date of the original transaction plus the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest&#8217;s share of changes in equity since that date.</div><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <ix:nonNumeric name="eprx:ScheduleOfInformationAboutSubsidiariesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-5686">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 53%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Company Entity</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Incorporation</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Jurisdiction of<br/>Incorporation</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effective<br/>Interest<br/>(Note&#160;13(e))</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width:53%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Holdings, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" contextRef="P01_01_2023To12_31_2023_EupraxiaHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" format="ixt:date-monthname-day-year-en" id="ixv-14340">October 10, 2012</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To12_31_2023_EupraxiaHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" id="ixv-14341">Delaware</ix:nonNumeric>,&#160;<ix:nonNumeric name="dei:EntityAddressCountry" contextRef="P01_01_2023To12_31_2023_EupraxiaHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" format="ixt-sec:countrynameen" id="ixv-14342">USA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:InvestmentOwnershipPercentage" contextRef="PAsOn12_31_2023_EupraxiaHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14343">95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Pharmaceuticals USA, LLC</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaceuticalsUsaLlcMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" format="ixt:date-monthname-day-year-en" id="ixv-14344">October 10, 2012</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaceuticalsUsaLlcMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" id="ixv-14345">Delaware</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaceuticalsUsaLlcMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" format="ixt-sec:countrynameen" id="ixv-14346">USA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:InvestmentOwnershipPercentage" contextRef="PAsOn12_31_2023_EupraxiaPharmaceuticalsUsaLlcMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14347">95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">AMDM Holdings Inc.<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(2)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" contextRef="P01_01_2023To12_31_2023_AmdmHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" format="ixt:date-monthname-day-year-en" id="ixv-14348">April 6, 2016</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To12_31_2023_AmdmHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" id="ixv-14349">Washington</ix:nonNumeric>,&#160;<ix:nonNumeric name="dei:EntityAddressCountry" contextRef="P01_01_2023To12_31_2023_AmdmHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" format="ixt-sec:countrynameen" id="ixv-14350">USA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:InvestmentOwnershipPercentage" contextRef="PAsOn12_31_2023_AmdmHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14351">95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Pharma, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" format="ixt:date-monthname-day-year-en" id="ixv-14352">January 7, 2021</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" id="ixv-14353">Delaware</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" format="ixt-sec:countrynameen" id="ixv-14354">USA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:InvestmentOwnershipPercentage" contextRef="PAsOn12_31_2023_EupraxiaPharmaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14355">95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Pharmaceuticals Australia Pty Ltd.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaceuticalsAustraliaPtyLtdMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" format="ixt:date-monthname-day-year-en" id="ixv-14356">July 4, 2022</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaceuticalsAustraliaPtyLtdMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" id="ixv-14357">Victoria</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaceuticalsAustraliaPtyLtdMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" format="ixt-sec:countrynameen" id="ixv-14358">Australia</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:InvestmentOwnershipPercentage" contextRef="PAsOn12_31_2023_EupraxiaPharmaceuticalsAustraliaPtyLtdMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14359">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Pharma USA Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaUsaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" format="ixt:date-monthname-day-year-en" id="ixv-14360">May 17, 2023</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaUsaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" id="ixv-14361">Delaware</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaUsaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" format="ixt-sec:countrynameen" id="ixv-14362">USA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:InvestmentOwnershipPercentage" contextRef="PAsOn12_31_2023_EupraxiaPharmaUsaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14363">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Wholly-owned subsidiary of Eupraxia Pharmaceuticals Inc. </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Date of Control occurred on January&#160;31, 2021 (see Note 13(e)). </div></div></div></td></tr></table></ix:nonNumeric></ix:nonNumeric> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-5864"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings (Loss) per Share </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies the &#8220;Treasury Stock Method&#8221; to calculate loss per common share. Under this method, the basic earnings (loss) per share is calculated based on the weighted average aggregate number of common shares outstanding during each period. The diluted earnings (loss) per share assumes that the outstanding stock options and share purchase warrants had been exercised at the beginning of the period, or date of issuance if issued during the period, and proceeds from dilutive instruments are used to purchase common shares at the average market price during the period. Since the Company was in a loss position for the years ended December&#160;31, 2023 and 2022, the assumed conversion of outstanding common share warrants, options, and convertible instruments has an anti-dilutive impact, therefore the diluted loss per share is equal to basic loss per share. </div></div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></ix:nonNumeric> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_108159749" id="ixv-5879"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment </div></div></div></div><ix:nonNumeric name="eprx:PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_108159745" id="ixv-5884"><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment is recorded at historical cost less accumulated depreciation and accumulated impairment losses. Depreciation is provided over the estimated useful lives of the assets as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric><div><ix:continuation id="TextSelection_108159745">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:94%;border:0;margin-left:auto">
<tr>
<td style="width:51%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;">Computers</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonFraction name="eprx:PropertyPlantAndEqupmentRateOfDepreciation" contextRef="P01_01_2023To12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14364">45</ix:nonFraction>% declining balance</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;">Office furniture and equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonFraction name="eprx:PropertyPlantAndEqupmentRateOfDepreciation" contextRef="P01_01_2023To12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14365">20</ix:nonFraction>% declining balance</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="eprx:PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation" contextRef="P01_01_2023To12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="ixv-14366">straight-line over the shorter of the initial term of the lease or useful life</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Lab equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonFraction name="eprx:PropertyPlantAndEqupmentRateOfDepreciation" contextRef="P01_01_2023To12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14367">20</ix:nonFraction>% declining balance</td></tr></table></ix:continuation></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-10</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_108159749" continuedAt="TextSelectionAppend_108159749_1"><ix:continuation id="TextSelectionAppend_108159613_5" continuedAt="TextSelectionAppend_108159613_6"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159613_6" continuedAt="TextSelectionAppend_108159613_7"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159613_7" continuedAt="TextSelectionAppend_108159613_8"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_108159749_1" continuedAt="TextSelectionAppend_108159749_2"><ix:continuation id="TextSelectionAppend_108159613_8" continuedAt="TextSelectionAppend_108159613_9"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) </div></div></td></tr></table><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 0pt; margin-top: 0px; margin-bottom: 0px;"><br/></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Equipment (continued) </div></div></ix:exclude></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_108159613_9" continuedAt="TextSelectionAppend_108159613_10"><ix:continuation id="TextSelectionAppend_108159749_2"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The useful lives and depreciation methods applied to each category of equipment are assessed on an annual basis by management and adjusted where necessary to reflect the recoverability of equipment. </div></div></div></ix:continuation> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-5965"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Research and Development Expenditures </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Research and development costs are expensed as they are incurred. These costs consist primarily of salaries and wages related to research and development activities, including share-based payments for employees engaged in research and development, clinical trial expenses and other research costs. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:RegulatoryIncomeTaxesPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-5969"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Investment Tax Credits </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Investment tax credits (&#8220;ITCs&#8221;) arising from research and development activities are deducted from the related costs and are included in profit or loss when there is reasonable assurance that the credits will be realized. ITCs arising from the acquisition or development of equipment and capitalized development costs are deducted from the cost of those assets with amortization calculated on the net amount. </div></ix:nonNumeric><ix:nonNumeric name="eprx:GovernmentGrantsPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-5973"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Government Grants </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Government grants related to research and development activities are recognized in profit or loss as a deduction from the related expenditure when there is reasonable assurance that the grant will be received. Grants that compensate the Company for the cost of an asset are recognized in profit or loss on a systematic basis over the useful life of the asset. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:GovernmentAssistancePolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-5977"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Government Assistance </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Government contributions are recognized and deducted from the related costs when there is reasonable assurance that the contribution will be received and all attached conditions have been complied with by the Company. Government contributions arising from the acquisition or development of equipment and capitalized development costs are deducted from the cost of those assets with amortization calculated on the net amount. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-5981"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current income tax is the expected tax payable or recoverable on the taxable profit or loss for the year using tax rates enacted at the reporting date and any adjustment to tax payable from previous years. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax is recorded using the asset and liability method, providing for temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Temporary differences are not provided for if they relate to goodwill not deductible for tax purposes, or differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates and laws enacted at the reporting date and expected to apply when these differences reverse. A deferred tax asset is recognized only to the extent that it is more likely than not that future taxable profits will be available against which the asset can be utilized. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company uses a two-step process to recognize and measure the income tax benefit of uncertain tax positions taken or expected to be taken in a tax return. The tax benefit from an uncertain tax position is recognized if it more likely than not that the position will be sustained upon examination of the tax authority based solely on the technical merits of the position. A tax benefit that meets the more likely than not recognition threshold is measured as the largest amount that is greater than <ix:nonFraction name="eprx:PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14369">50</ix:nonFraction>% likely to realized upon settlement with the tax authority. To the extent a full benefit is not expected to be realized, an income tax liability is established. Any change in judgement related to the expected resolution of an uncertain tax provision is recognized in the year of such a change. Interest an penalties related to income tax are included as a component of income tax expense. </div></div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_108159911" id="ixv-5993"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Share-based Payments </div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company grants stock options to employees, directors and officers pursuant to stock option plans described in note 13c. Employee stock-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense, net of actual forfeitures, over the requisite service period with a corresponding increase in additional paid-in capital. Stock-based compensation expense is amortized on a straight-line basis over the requisite service period for the entire award, which is generally the vesting period of the award. </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-11</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_108159911" continuedAt="TextSelectionAppend_108159911_1"><ix:continuation id="TextSelectionAppend_108159613_10" continuedAt="TextSelectionAppend_108159613_11"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159613_11" continuedAt="TextSelectionAppend_108159613_12"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159613_12" continuedAt="TextSelectionAppend_108159613_13"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_108159911_1" continuedAt="TextSelectionAppend_108159911_2"><ix:continuation id="TextSelectionAppend_108159613_13" continuedAt="TextSelectionAppend_108159613_14"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) </div></div></td></tr></table><div style="font-size: 0pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Share-based Payments (continued) </div></div></ix:exclude></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_108159613_14" continuedAt="TextSelectionAppend_108159613_15"><ix:continuation id="TextSelectionAppend_108159911_2"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any consideration received on exercise of stock options is credited to share capital. </div></div></div></ix:continuation><ix:nonNumeric name="us-gaap:StockholdersEquityPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-6050"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share Capital and Warrants </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company records proceeds from share issuances net of issue costs and any related tax effects. Common shares issued for consideration other than cash are valued based on their market value at the date the agreement to issue shares was concluded. When units are issued during a private placement, which include both common shares and share purchase warrants, the warrants are classified as equity and as such, the proceeds should be allocated based on the relative fair values of the base instrument and the warrants on the day of the announcement of the private placement. Any value of the warrants is allocated to the warrants and credited to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_108159847" id="ixv-6059"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign Currency Translation </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The functional currency for each of the Company and the Company&#8217;s subsidiaries is the currency of the primary economic environment in which each entity operates. Determination of functional currency may involve certain judgments to determine the primary economic environment. The Company reconsiders the functional currency of its entities if there is a change in events and conditions which determine the primary economic environment. The functional currency of Eupraxia Pharmaceuticals Inc., the parent entity, and each of the Company&#8217;s subsidiaries is the Canadian dollar. </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-12</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_108159847" continuedAt="TextSelectionAppend_108159847_1"><ix:continuation id="TextSelectionAppend_108159613_15" continuedAt="TextSelectionAppend_108159613_16"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159613_16" continuedAt="TextSelectionAppend_108159613_17"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159613_17" continuedAt="TextSelectionAppend_108159613_18"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_108159847_1" continuedAt="TextSelectionAppend_108159847_2"><ix:continuation id="TextSelectionAppend_108159613_18" continuedAt="TextSelectionAppend_108159613_19"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) </div></div></td></tr></table><div style="font-size: 0pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Foreign Currency Translation (continued) </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></ix:exclude></ix:continuation> </ix:continuation><ix:continuation id="TextSelectionAppend_108159613_19" continuedAt="TextSelectionAppend_108159613_20"><ix:continuation id="TextSelectionAppend_108159847_2"><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transactions in foreign currencies are translated to the functional currency of the entity at the exchange rate at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the reporting date are retranslated at the period end date exchange rates. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-monetary</div> items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-monetary</div> assets and liabilities denominated in foreign currencies that are measured at fair value are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-translated</div> to the functional currency at the exchange rate at the date that the fair value was determined. Foreign currency differences arising on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-translation</div> are recognized in profit or loss. </div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The reporting currency of the Company&#8217;s consolidated financial statements is the U.S. dollar. All assets and liabilities are translated from the functional currency to the reporting currency using the spot rate at the period end date, equity components are translated at the historical rate, and income and expenses are translated using the average exchange rate for the period. All foreign currency differences arising on translation from functional to reporting currency are included in accumulated other comprehensive income. </div></div></div></ix:continuation><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-6125"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of Long-Lived Assets </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or group of assets. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset or asset group. As of December&#160;31, 2023 and 2022, the Company determined that there were no indicators of impairment of long-lived assets. </div></div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-6134"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Cash and cash equivalents include cash on hand, bank deposits, and highly liquid investments with original maturities of three months or less from the date of purchase that are readily convertible to known amounts of cash and subject to insignificant risk of changes in value. Cash equivalents are recorded at cost plus accrued interest. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:MarketableSecuritiesPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-6141"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short Term Investments </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Short term investments include highly liquid investments with original maturity dates greater than three months and less than one year and cannot be redeemed prior to maturity without incurring a penalty. </div></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-13</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_108159613_20" continuedAt="TextSelectionAppend_108159613_21"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159613_21" continuedAt="TextSelectionAppend_108159613_22"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159613_22" continuedAt="TextSelectionAppend_108159613_23"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_108159613_23" continuedAt="TextSelectionAppend_108159613_24"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_108159613_24" continuedAt="TextSelectionAppend_108159613_25"><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-6191"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Instruments and Fair Value</div></div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures certain financial instruments and other items at fair value into a three-level hierarchy established by US GAAP that prioritizes those inputs to valuation techniques used to measure fair value on the degree to which they are observable. This hierarchy includes: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">i.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1 &#8211; Unadjusted quoted prices in active markets for identical instruments. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">ii.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2 &#8211; Inputs other than quoted prices included within Level 1 that are observable for the financial instrument, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability and inputs that are derived principally from or corroborated by observable market data by correlation or other means. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">iii.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inputs are unobservable and reflect the Company&#8217;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and liabilities are classified on the lowest level of input that is significant to the fair value measurements. Reclassification of the level may be a result of changes in the observability of the valuation inputs for certain instruments within the fair value hierarchy. The carrying value of accounts receivable, accounts payable, and accrued expense approximate fair value due to the short-term nature of these instruments. On a recurring basis, the Company&#8217;s cash and cash equivalents and marketable securities are measured at fair value. </div></div></div> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-14</ix:exclude> </div></ix:continuation> </div></div><ix:continuation id="TextSelectionAppend_108159613_25" continuedAt="TextSelectionAppend_108159613_26"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159613_26" continuedAt="TextSelectionAppend_108159613_27"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159613_27" continuedAt="TextSelectionAppend_108159613_28"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_108159613_28" continuedAt="TextSelectionAppend_108159613_29"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) </div></div></td></tr></table> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 0pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Instruments and Fair Value (continued) </div></div></div></div> <div style="font-weight:bold;display:inline;"> </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_108159613_29"><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-6292"> <div style="text-align: justify; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Leases classified as operating leases are recorded as lease liabilities based on the present value of minimum lease payments over the lease term, discounted using the lessor&#8217;s rate implicit in the lease or the Company&#8217;s incremental borrowing rate, if the lessor&#8217;s implicit rate is not readily determinable. The lease term includes all periods covered by renewal and termination options where the Company is reasonably certain to exercise the renewal options or not to exercise the termination options. Corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets are recognized consisting of the lease liabilities, initial direct costs and any lease incentive payments. Lease liabilities are drawn down as lease payments are made and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets are depreciated over the term of the lease. Operating lease expenses are recognized on a straight-line basis over the term of the lease, consisting of interest accrued on the lease liability and depreciation of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, adjusted for changes in index-based variable lease payments in the period of change. Lease payments on short-term operating leases with lease terms twelve months or less are expensed on a straight-line basis over the lease term. </div></div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-6305"> <div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upcoming Accounting Standards and Interpretations </div></div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has not yet adopted certain new standards, amendments and interpretations to existing standards, which have been published but are only effective for accounting periods beginning on or after January&#160;1, 2024 or later periods. The new and amended standards are not expected to have a material impact on the Company&#8217;s consolidated financial statements. </div></div></div> </ix:nonNumeric> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-15 </div> </div></div> </div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><ix:nonNumeric name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-6337">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">AMOUNTS RECEIVABLE </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><ix:nonNumeric name="eprx:NontradeReceivablesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_108159994" id="ixv-6347"> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 74%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Government grants (Note 14)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GrantsReceivableCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14374">13,892</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">GST/HST recoverable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GovernmentAssistanceAmountCumulativeCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14375">85,879</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GovernmentAssistanceAmountCumulativeCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14376">38,658</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other refundable tax credits <div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:OtherRefundableTaxCreditsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14377">104,733</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:OtherRefundableTaxCreditsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14378">37,165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NontradeReceivablesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14379">190,612</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NontradeReceivablesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14380">89,715</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Other refundable tax credits are due to tax incentives for R&amp;D costs incurred by Eupraxia Australia (Note 14 &#8211; Research and Development Expenses). </div></td></tr></table></ix:nonNumeric></ix:nonNumeric> <ix:continuation id="TextSelection_108159994"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-16 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-6527">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">PROPERTY AND EQUIPMENT </div></div></td></tr></table><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-6536"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Property and equipment consisted of the following: <br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 60%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Computers</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Office<br/>furniture&#160;and<br/>equipment</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leasehold<br/>Improvements</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Lab<br/>Equipment</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="20" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Cost</div></div></div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at January&#160;1, 2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14381">101,754</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14382">73,267</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14383">134,333</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14384">289,569</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14385">598,923</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAdditions" contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14386">20,279</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAdditions" contextRef="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14387">5,551</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAdditions" contextRef="P01_01_2022To12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14388">209,720</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAdditions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14389">235,550</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposals</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14390">47,603</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14391">8,158</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14392">55,761</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency adjustments</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14393">3,852</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" contextRef="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14394">4,261</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" contextRef="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14395">8,589</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" contextRef="P01_01_2022To12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14396">25,736</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14397">42,438</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at December&#160;31, 2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14398">70,578</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14399">66,399</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14400">125,744</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14401">473,553</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14402">736,274</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAdditions" contextRef="P01_01_2023To12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14403">18,534</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAdditions" contextRef="P01_01_2023To12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14404">54,843</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAdditions" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14405">73,377</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposals</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="P01_01_2023To12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14406">5,488</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="P01_01_2023To12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14407">16,124</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14408">21,612</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency adjustments</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" contextRef="P01_01_2023To12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14409">2,001</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" contextRef="P01_01_2023To12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14410">1,597</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" contextRef="P01_01_2023To12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14411">3,023</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" contextRef="P01_01_2023To12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14412">12,992</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14413">19,613</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at December&#160;31, 2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14414">85,625</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14415">67,996</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14416">128,767</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14417">525,264</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14418">807,652</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td colspan="21" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="20" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated Depreciation</div></div></div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at January&#160;1, 2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14419">71,187</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14420">46,965</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14421">91,345</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14422">38,631</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14423">248,128</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease" contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14424">17,153</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease" contextRef="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14425">5,256</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease" contextRef="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14426">14,366</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease" contextRef="P01_01_2022To12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14427">73,328</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14428">110,103</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposals</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14429">43,540</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" contextRef="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14430">5,342</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14431">48,882</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency adjustments</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14432">2,295</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" contextRef="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14433">2,853</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" contextRef="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14434">6,410</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" contextRef="P01_01_2022To12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14435">4,981</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14436">16,539</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at December&#160;31, 2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14437">42,505</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14438">44,026</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14439">99,301</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14440">106,978</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14441">292,810</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease" contextRef="P01_01_2023To12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14442">17,612</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease" contextRef="P01_01_2023To12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14443">4,492</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease" contextRef="P01_01_2023To12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14444">13,849</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease" contextRef="P01_01_2023To12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14445">76,930</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14446">112,883</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposals</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" contextRef="P01_01_2023To12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14447">5,162</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" contextRef="P01_01_2023To12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14448">11,604</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14449">16,766</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency adjustments</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" contextRef="P01_01_2023To12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14450">1,226</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" contextRef="P01_01_2023To12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14451">1,149</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" contextRef="P01_01_2023To12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14452">2,666</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" contextRef="P01_01_2023To12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14453">4,097</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14454">9,138</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at December&#160;31, 2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14455">56,181</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14456">49,667</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14457">115,816</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14458">176,401</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14459">398,065</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td colspan="21" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="20" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Net Book Value</div></div></div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at December&#160;31, 2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14460">28,073</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14461">22,373</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14462">26,443</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14463">366,575</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14464">443,464</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at December&#160;31, 2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14465">29,444</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14466">18,329</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14467">12,951</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14468">348,863</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14469">409,587</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr></table></ix:nonNumeric> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, depreciation expense of $</div><ix:nonFraction name="us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14470">112,883</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and $</div><ix:nonFraction name="us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14471">110,103</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively, was recognized with $</div><ix:nonFraction name="us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease" contextRef="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14472">13,276</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included in general and administrative and $</div><ix:nonFraction name="us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease" contextRef="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14473">99,606</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included in research and development ($</div><ix:nonFraction name="us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease" contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14474">13,870</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and $</div><ix:nonFraction name="us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease" contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14475">96,233</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> for general and administrative, and research and development in </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively).</div></div></ix:nonNumeric> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><ix:nonNumeric name="eprx:RightOfUseAssetTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-8379">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RIGHT-OF-USE</div></div> ASSET </div></div></td></tr></table><ix:nonNumeric name="eprx:OperatingLeaseRightOfUseAssetTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-8390"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The following table presents details of movement in the carrying value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, beginning</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14476">87,286</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14477">132,020</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14478">42,644</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14479">37,791</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign Exchange</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14480">2,018</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="eprx:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14481">6,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, ending</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14482">46,660</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14483">87,286</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">During the year ended December&#160;31, 2023 and 2022, depreciation expense of $<ix:nonFraction name="us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14484">42,644</ix:nonFraction> and $<ix:nonFraction name="us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14485">37,791</ix:nonFraction>, respectively, was recognized with $<ix:nonFraction name="us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease" contextRef="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14486">15,740</ix:nonFraction> included in general and administrative and $<ix:nonFraction name="us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease" contextRef="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14487">26,904</ix:nonFraction> included in research and development ($<ix:nonFraction name="us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease" contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14488">13,877</ix:nonFraction> and $<ix:nonFraction name="us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease" contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14489">23,914</ix:nonFraction> for general and administrative, and research and development in 2022, respectively). </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></ix:nonNumeric> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-17 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><ix:nonNumeric name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-8540">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES </div></div></td></tr></table><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><ix:nonNumeric name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-8550">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14490">1,968,263</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14491">2,137,336</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14492">1,040,204</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14493">261,933</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Wages and payroll remittances</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedPayrollTaxesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14494">18,357</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedPayrollTaxesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14495">15,996</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Employee bonus payable<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14496">858,628</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14497">513,301</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Taxes payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14498">36,423</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14499">3,921,875</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14500">2,928,566</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Bonus relates to corporate bonuses for the years ended December&#160;31, 2023 and 2022. </div></td></tr></table></ix:nonNumeric></ix:nonNumeric> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><br/></div><ix:nonNumeric name="eprx:DisclosureInEntiretyOfOtherLoansPayable" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-8702">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">LOANS PAYABLE </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On September&#160;10, 2021, the Company entered into a Master Loan and Security Agreement (&#8220;Loan Agreement&#8221;) whereby the Company borrowed $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn09_10_2021_LoansPayableMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14501">235,000</ix:nonFraction> to purchase production and test equipment (see Note <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">5</div> &#8211; Property and Equipment). </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Loan Agreement has a term of <ix:nonNumeric name="us-gaap:LongTermDebtTerm" contextRef="PAsOn09_13_2021_LoansPayableMemberusgaapLongtermDebtTypeAxis" format="ixt-sec:durmonth" id="ixv-14502">36</ix:nonNumeric> months commencing September&#160;13, 2021. The Loan Agreement accrues interest at <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn10_01_2021_LoansPayableMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-14503">5.84</ix:nonFraction>% per annum with <ix:nonNumeric name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" contextRef="P10_01_2021To10_01_2021_LoansPayableMemberusgaapLongtermDebtTypeAxis" id="ixv-14504">monthly</ix:nonNumeric> payments (principal and interest) being made on the 1<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">st</div> of each month, beginning October&#160;1, 2021. As part of the agreement, the Company granted the lender first priority interest on the equipment it purchased. </div><ix:nonNumeric name="us-gaap:ScheduleOfDebtTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-8715"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Below is a breakdown of loan balance as at December&#160;31, 2023 and December&#160;31, 2022: <br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 73%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width: 73%;"/>
<td style="vertical-align: bottom; width: 6%;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 5%;"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 73%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, beginning</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14505">142,127</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14506">216,994</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 73%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loan repayment</div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14507">79,441</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14508">74,845</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 73%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign exchange adjustment</div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ForeignExchangeAdjustmentOnLoansPayable" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14509">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="eprx:ForeignExchangeAdjustmentOnLoansPayable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14510">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 73%;"/>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 73%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, ending</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14511">62,709</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14512">142,127</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 73%;"/>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 73%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Current portion</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LoansPayableCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14513">62,709</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LoansPayableCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14514">79,418</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 73%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> portion</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LongTermLoansPayable" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14515">62,709</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div></ix:nonNumeric></ix:nonNumeric> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-18 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-8943">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">LEASE LIABILITY </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company entered into an operating lease agreement for its Victoria, BC facility (of approximately <ix:nonFraction name="us-gaap:AreaOfRealEstateProperty" contextRef="PAsOn12_31_2023" unitRef="Unit_sqft" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14516">4,900</ix:nonFraction> square feet of office space) which expires on <ix:nonNumeric name="us-gaap:LeaseExpirationDate1" contextRef="P01_01_2023To12_31_2023" format="ixt:date-monthname-day-year-en" id="ixv-14517">November 30, 2024</ix:nonNumeric>. </div><ix:nonNumeric name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-8953"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The cost components of the operating lease were as follows for the years ended December&#160;31, 2023 and 2022: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:73%"/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Lease Cost</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14518">64,996</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14519">67,423</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14520">68,584</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14521">66,455</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Lease term and Discount Rate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term (years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2023" format="ixt-sec:duryear" id="ixv-14522">0.92</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2022" format="ixt-sec:duryear" id="ixv-14523">1.92</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14524">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14525">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Variable lease costs are payments that vary because of changes in facts or circumstances and include common area maintenance and property taxes related to the premises. Variable lease costs are excluded from the calculation of minimum lease payments. </div><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-9060"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company&#8217;s future minimum lease payments as of December&#160;31, 2023 are as follows: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:88%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Year ending December 31:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14526">60,780</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total undiscounted future minimum lease payments</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14527">60,780</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: balance of unused tenant allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncentiveFromLessor" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14528">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14529">7,464</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Present value of lease liabilities at December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14530">53,316</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="eprx:DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-9151"> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The lease liability balance is comprised as follows: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Current portion</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14531">53,316</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14532">50,403</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> portion</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14533">51,303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14534">53,316</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14535">101,706</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">During the year ended December&#160;31, 202<div style="display:inline;">3</div>, the Company subleased approximately <ix:nonFraction name="eprx:AreaOfSubleasedOfficeSpace" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_sqft" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14536">616</ix:nonFraction> square feet office space with amounts totaling $<ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14537">24,387</ix:nonFraction> for the year ended December&#160;31, 2023 ($<ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14538">24,387</ix:nonFraction> &#8211; year ended December&#160;31, 2022) being recorded as a reduction to general and administrative expenses. </div></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-19 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><ix:nonNumeric name="eprx:DisclosureInEntiretyOfLicenseAgreementTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_108159720" id="ixv-9277">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">AURITEC LICENSE AGREEMENT </div></div></td></tr></table><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Eupraxia USA entered into an amended and restated license agreement with Auritec Pharmaceuticals Inc. (&#8220;Auritec&#8221;) on October&#160;9, 2018 (as further amended, the &#8220;Amended and Restated License Agreement&#8221;). Under the terms of the Amended and Restated License Agreement, Auritec has granted Eupraxia USA an exclusive license (including the right to sublicense to its affiliates and third parties) under the licensed patents owned or controlled by Auritec and for all the technical information and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> relating to the technology claimed in such patents or possessed by Auritec with respect to the use of Auritec&#8217;s &#8220;Plexis Platform&#8221; for the delivery of fluticasone in all medical fields (except for otolaryngology and the prevention, treatment and control of all diseases, disorders and conditions of the eye and its adnexa (collectively, the &#8220;Excluded Fields&#8221;)), to develop, make, have made, manufacture, use, commercialize, sell, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-license,</div> offer for sale, import, and have imported products for the delivery of fluticasone drug products using the Plexis Platform in all medical fields except the Excluded Fields (&#8220;Licensed Products&#8221;). </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Pursuant to the terms of the Amended and Restated License Agreement, Eupraxia USA has paid $<ix:nonFraction name="eprx:PaymentOfUpfrontFees" contextRef="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14539">5,000,000</ix:nonFraction> to Auritec (the &#8220;Upfront Fee&#8221;). In addition, Eupraxia USA has agreed to pay Auritec up to $<ix:nonFraction name="eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement" contextRef="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14540">30,000,000</ix:nonFraction> upon achievement of certain regulatory and commercial milestones related to products licensed under the Amended and Restated License Agreement (&#8220;Licensed Products&#8221;) as well as a royalty of <ix:nonFraction name="eprx:RoyaltyAsAPercentageOfNetSales" contextRef="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14541">4</ix:nonFraction>% of net sales of Licensed Products by Eupraxia USA or its affiliates, subject to certain reductions. </div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="eprx:DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_108159182" id="ixv-14542">The following table summarizes the milestone payment schedule.</ix:nonNumeric> As of December&#160;31, 2023, the only milestone that has been accrued and provided for in the financial statements is $<ix:nonFraction name="eprx:MilestonePaymentRecognizedExpense" contextRef="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_SuccessfulCompletionOfPhaseTwoBStudyMemberEPRXMilestoneAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14543">5,000,000</ix:nonFraction> related to the successful completion of the Phase 2b clinical study. It was recorded under research and development (see Note 14 &#8211; Research and Development Expenses). </div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><ix:continuation id="TextSelection_108159182">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 84%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone Event</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Milestone<br/>Payment</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width:85%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Successful Completion of a Phase 2b Study</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement" contextRef="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_SuccessfulCompletionOfPhaseTwoBStudyMemberEPRXMilestoneAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14544">5,000,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">First OA Regulatory Approval</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement" contextRef="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_FirstOaRegulatoryApprovalMemberEPRXMilestoneAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14545">5,000,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Second OA Regulatory Approval</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement" contextRef="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_SecondOaRegulatoryApprovalMemberEPRXMilestoneAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14546">5,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-OA</div> Indication Regulatory Approval</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement" contextRef="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_NonOaIndicationRegulatoryApprovalMemberEPRXMilestoneAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14547">10,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">First calendar year in which aggregate Net Sales by Eupraxia USA, its affiliates and sublicenses exceed $500,000,000</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement" contextRef="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMemberEPRXMilestoneAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14548">5,000,000</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Maximum milestones payable</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement" contextRef="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14549">30,000,000</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> </ix:continuation><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-<div style="display:inline;">20</div></ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_108159720" continuedAt="TextSelectionAppend_108159720_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159720_1" continuedAt="TextSelectionAppend_108159720_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159720_2" continuedAt="TextSelectionAppend_108159720_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_108159720_3" continuedAt="TextSelectionAppend_108159720_4"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">AURITEC LICENSE AGREEMENT (continued) </div></div></td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_108159720_4"><div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;">Eupraxia USA also agreed to pay to Auritec <ix:nonFraction name="eprx:PercentageOfNonRoyaltyMonetizationRevenuePayable" contextRef="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_ArithmeticAverageMembersrtRangeAxis_EupraxiaUsaMembersrtCounterpartyNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14550">20</ix:nonFraction>% <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">of sublicensing royalties or other consideration based on net sales of Licensed Products. Eupraxia USA further agreed to pay Auritec a percentage of Non-Royalty Monetization Revenue (as defined in the Amended and Restated License Agreement), which includes payments received for a sale of Eupraxia USA or its assets or sale or sublicense of a Licensed Product, which percentage ranges from</div> <ix:nonFraction name="eprx:PercentageOfNonRoyaltyMonetizationRevenuePayable" contextRef="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14551">10</ix:nonFraction>% to <ix:nonFraction name="eprx:PercentageOfNonRoyaltyMonetizationRevenuePayable" contextRef="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14552">30</ix:nonFraction>% depending on the development stage of the most-advanced Licensed Product, up to a maximum of <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div><ix:nonFraction name="eprx:MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization" contextRef="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14553">100,000,000</ix:nonFraction>.<ix:nonNumeric name="eprx:DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_108159708" id="ixv-9442"> The following table summarizes the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Non-Royalty</div> Monetization Revenue percentage schedule: </ix:nonNumeric></div><ix:continuation id="TextSelection_108159708"><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:73%"/>
<td style="vertical-align:bottom;width:26%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Date of Execution</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Percentage&#160;of&#160;Non-Royalty</div><br/> Monetization Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prior to Successful Completion of a Phase 2b Study</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty" contextRef="P01_01_2023To12_31_2023_PriorToSuccessfulCompletionOfPhaseTwoBStudyMemberEPRXTrancheAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14554">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">After Successful Completion of a Phase 2b Study but prior to Successful Completion of a Phase 3 Study</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty" contextRef="P01_01_2023To12_31_2023_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMemberEPRXTrancheAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14555">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">After Successful Completion of a Phase 3 Study but prior to Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty" contextRef="P01_01_2023To12_31_2023_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMemberEPRXTrancheAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14556">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">After Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty" contextRef="P01_01_2023To12_31_2023_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMemberEPRXTrancheAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14557">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:continuation> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Either party may terminate the Amended and Restated License Agreement in the event of the other party&#8217;s bankruptcy, liquidation, or dissolution. Auritec may also terminate upon a material breach of the Amended and Restated License Agreement by Eupraxia USA that is not cured within <div style="display:inline;">60 days</div> (<div style="display:inline;">15 days</div> in the case of a payment breach). Further, if Eupraxia USA directly or indirectly challenges any claim in any Auritec patent licensed under the Amended and Restated License Agreement, or assist a third party in doing so, Auritec may immediately terminate the Amended and Restated License Agreement. If Auritec directly or indirectly challenges any Eupraxia patent contemplated in the Amended and Restated License Agreement other than as reasonably required to defend Auritec patents as a basis for such challenge, or assists a third party in doing so, we may immediately terminate the Amended and Restated License Agreement. </div></div><br/></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div></ix:continuation><ix:nonNumeric name="us-gaap:LongTermDebtTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_108159705" id="ixv-9499">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">CONVERTIBLE DEBT </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On June&#160;21, 2021, the Company entered into a contingent convertible debt agreement (the &#8220;Debt Agreement&#8221;) with Silicon Valley Bank (&#8220;SVB&#8221;) and concurrently drew down, in full, the CDN$<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_21_2021_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis" unitRef="Unit_CAD" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14558"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P06_21_2021To06_21_2021_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis" unitRef="Unit_CAD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14559">10,000,000</ix:nonFraction></ix:nonFraction> principal amount under the Debt Agreement. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Debt Agreement has a term of <ix:nonNumeric name="us-gaap:LongTermDebtTerm" contextRef="PAsOn12_31_2021_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis" format="ixt-sec:durwordsen" id="ixv-14560">36 months</ix:nonNumeric> (or <ix:nonNumeric name="eprx:LongTermDebtTermExtendableAtLendersDiscretion" contextRef="P06_21_2021To06_21_2021_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis" format="ixt-sec:durwordsen" id="ixv-14561">48 months</ix:nonNumeric> at SVB&#8217;s election). The Debt Agreement accrues interest at the greater of <ix:nonFraction name="eprx:LongTermDebtBaseRate" contextRef="P01_01_2022To12_31_2022_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-14562">2.45</ix:nonFraction>% and the Canadian prime rate, requiring monthly interest payments. An additional payment in kind will accrue at a rate of <ix:nonFraction name="eprx:LongTermDebtPaidInKindInterestPercentage" contextRef="P01_01_2023To12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14563">7</ix:nonFraction>% per annum, which will be settled at maturity or on conversion. During the year ended December&#160;31, 2022, the Canadian prime rate ranged from <ix:nonFraction name="eprx:LongTermDebtBaseRate" contextRef="P01_01_2022To12_31_2022_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MinimumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-14564">2.45</ix:nonFraction>% - <ix:nonFraction name="eprx:LongTermDebtBaseRate" contextRef="P01_01_2022To12_31_2022_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MaximumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-14565">6.45</ix:nonFraction>%. During the year ended December&#160;31, 2023, the Canadian prime rate ranged from <ix:nonFraction name="eprx:LongTermDebtBaseRate" contextRef="P01_01_2023To12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MinimumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-14566">6.45</ix:nonFraction>% - <ix:nonFraction name="eprx:LongTermDebtBaseRate" contextRef="P01_01_2023To12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MaximumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-14567">7.20</ix:nonFraction>%. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Subject to the terms and conditions of the Debt Agreement, SVB may elect to convert the principal amount of the convertible debt and the accrued and unpaid interest thereon into common shares at a conversion price equal to CDN$<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn12_31_2023_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14568">5.68</ix:nonFraction> per common share. The conversion price of the accrued and unpaid interest will be subject to the minimum pricing requirements of the TSX, to the extent applicable, at the time of conversion. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company will have the right (the &#8220;Call Right&#8221;) to call the convertible debt by paying to SVB an amount equal to: </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">i.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;"><ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="P01_01_2023To12_31_2023_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis_WithEighteenMonthsFromTheDateOfTheDebtAgreementMemberEPRXCallRightAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14569">125</ix:nonFraction>% of the principal amount of the convertible debt (less principal amounts previously repaid), if the Call Right is exercised on or before the 18 month anniversary of the date of the Debt Agreement; and </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">ii.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;"><ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="P01_01_2023To12_31_2023_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMemberEPRXCallRightAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14570">150</ix:nonFraction>% of the principal amount of the convertible debt (less principal amounts previously repaid), if the Call Right is exercised after the 18 month anniversary of the date of the Debt Agreement, </div></td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-21</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_108159705" continuedAt="TextSelectionAppend_108159705_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159705_1" continuedAt="TextSelectionAppend_108159705_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159705_2" continuedAt="TextSelectionAppend_108159705_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_108159705_3" continuedAt="TextSelectionAppend_108159705_4"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">CONVERTIBLE DEBT (continued) </div></div></td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159705_4"><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in either case together with all accrued and unpaid interest on the principal balance of the convertible debt. If the Call Right is exercised by the Company, SVB will retain certain lookback rights in the event the Company subsequently announces its topline data from its Phase 2 clinical study or the Company enters into an agreement to be acquired in the 12 months following the exercise of the Call Right. The Company has agreed to grant SVB a security interest in all of its assets, excluding its patents and other intellectual property, and the testing and product equipment by way of the loan agreement it entered into on September&#160;10, 2021 (Note 8 &#8211; Loans Payable) as security for its obligations under the Debt Agreement. </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company was required, on or prior to June&#160;30, 2022, to raise additional net new capital, as defined in the Debt Agreement, in the aggregate amount of CDN$<ix:nonFraction name="eprx:AmountToBeRaisedByWayOfEquityIssue" contextRef="PAsOn06_30_2022_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis" unitRef="Unit_CAD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14572">10,000,000</ix:nonFraction>. During the year ended December&#160;31, 2022, the Company completed a CDN$<ix:nonFraction name="eprx:AggegateAmountRaisedByWayOfEquityIssue" contextRef="P01_01_2022To12_31_2022_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis" unitRef="Unit_CAD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-14573">14.7</ix:nonFraction>&#160;million financing which satisfied the net new capital requirement of the Debt Agreement (see Note <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">12</div> &#8211; Share C<div style="display:inline;">apital)</div>. </div><ix:nonNumeric name="eprx:DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock" contextRef="P01_01_2023To12_31_2023_LoanMemberdeiLegalEntityAxis" escape="true" id="ixv-9573"><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The loan balance is comprised of the following: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:84%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance &#8211; December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2021_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14574">7,507,755</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod" contextRef="P01_01_2022To12_31_2022_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14575">958,669</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Interest paid</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod" contextRef="P01_01_2022To12_31_2022_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14576">315,436</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: right; line-height: normal;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2022To12_31_2022_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14577">1,056,165</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign exchange</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss" contextRef="P01_01_2022To12_31_2022_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14578">465,157</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance &#8211; December 31, 2022</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2022_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14579">8,741,996</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod" contextRef="P01_01_2023To12_31_2023_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14580">1,162,773</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest paid</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod" contextRef="P01_01_2023To12_31_2023_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14581">591,170</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To12_31_2023_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14582">836,595</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign exchange</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss" contextRef="P01_01_2023To12_31_2023_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14583">185,809</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance &#8211; December 31, 2023</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14584">10,336,003</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-22 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><ix:nonNumeric name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_108160216" id="ixv-9726">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">SHARE CAPITAL AND OTHER COMPONENTS OF EQUITY </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">a)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;">Authorized </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify; line-height: normal;">An <div style="-sec-ix-hidden:hidden108159697;display:inline;"><div style="-sec-ix-hidden:hidden108159696;display:inline;">unlimited</div></div> number of Common shares, with <ix:nonFraction name="us-gaap:PreferredStockNoParValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-14585"><ix:nonFraction name="us-gaap:PreferredStockNoParValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-14586">no</ix:nonFraction></ix:nonFraction> par value, with one vote per share. </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify; line-height: normal;">An <div style="-sec-ix-hidden:hidden108159695;display:inline;"><div style="-sec-ix-hidden:hidden108159693;display:inline;">unlimited</div></div> number of Preferred shares, with <ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-14587"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-14588">no</ix:nonFraction></ix:nonFraction> par value (none have been issued to date). </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">b)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;">Issued </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify">Capital transactions which took place during the year ended December&#160;31, 2022 are as follows: </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">i)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;">On April&#160;20, 2022, the Company announced that it had closed an overnight marketed public offering (the &#8220;Offering&#8221;). Pursuant to the Offering, Eupraxia issued <ix:nonFraction name="eprx:NumberOfUnitsIssued" contextRef="PAsOn04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14589">7,150,550</ix:nonFraction> units at a price of CDN$<ix:nonFraction name="eprx:SecuritiesIssuedPricePerUnit" contextRef="PAsOn04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14590">2.05</ix:nonFraction> per unit and <ix:nonFraction name="eprx:NumberOfWarrantIssued" contextRef="PAsOn04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14591">181,000</ix:nonFraction> warrants at a price of CDN$<ix:nonFraction name="eprx:WarrantIssuedPricePerUnit" contextRef="PAsOn04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14592">0.30</ix:nonFraction> per warrant for aggregate gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14593">11,768,459</ix:nonFraction> ($<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P04_20_2022To04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14594">9,309,707</ix:nonFraction> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">related to the value of the</div> shares<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;and</div> $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14595">2,458,752</ix:nonFraction> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">related to the value of the</div> warrants). </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman;text-align:justify"><ix:nonNumeric name="us-gaap:CommonStockConversionBasis" contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" id="ixv-14596">Each unit consists of one common share and one common share purchase warrant.</ix:nonNumeric> Each warrant entitles the holder thereof to acquire <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="PAsOn04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-14597">one</ix:nonFraction> common share at an exercise price of CDN$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_CAD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14598">3.00</ix:nonFraction> per common share for a period of <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" format="ixt-sec:durwordsen" id="ixv-14599">48 months</ix:nonNumeric>, expiring on <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="PAsOn04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" format="ixt:date-monthname-day-year-en" id="ixv-14600">April 20, 2026</ix:nonNumeric>. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman;text-align:justify">As consideration for the services rendered by the Underwriters in connection with the Offering, the Company paid the Underwriters a cash commission of $<ix:nonFraction name="us-gaap:PaymentsForUnderwritingExpense" contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14601">823,792</ix:nonFraction> ($<ix:nonFraction name="us-gaap:PaymentsForUnderwritingExpense" contextRef="P04_20_2022To04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14602">660,605</ix:nonFraction> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">for the </div> shares<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">and</div> $<ix:nonFraction name="us-gaap:PaymentsForUnderwritingExpense" contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14603">163,187</ix:nonFraction> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">for the</div> warrants) which is equal to <ix:nonFraction name="eprx:PercentageOfGrossProceedsRaisedUnderTheOffering" contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14604">7</ix:nonFraction>% of the gross proceeds raised under the Offering and granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14605">500,538</ix:nonFraction> warrants (&#8220;Compensation Warrant&#8221;), which is equal to <ix:nonFraction name="eprx:PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering" contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14606">7</ix:nonFraction>% of the total units and warrants issued in the Offering. Each Compensation Warrant entitles the holder thereof to acquire one common share at an exercise price of CDN$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_CompensationWarrantMemberEPRXWarrantAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14607">2.05</ix:nonFraction> per common share for a period of 48 months, expiring on April&#160;20, 2026. An additional $<ix:nonFraction name="us-gaap:LegalFees" contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14608">68,470</ix:nonFraction> in legal and agents&#8217; expenses were also paid to the Underwriters ($<ix:nonFraction name="us-gaap:LegalFees" contextRef="P04_20_2022To04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14609">54,839</ix:nonFraction> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">for the</div> shares<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;and</div> $<ix:nonFraction name="us-gaap:LegalFees" contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14610">13,631</ix:nonFraction> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">for the</div> warrants). The Company incurred an additional $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14611">239,620</ix:nonFraction> ($<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P04_20_2022To04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14612">192,824</ix:nonFraction> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">for the</div> shares<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;and</div> $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14613">46,796</ix:nonFraction> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">for the</div> warrants) in share issuance costs associated with the Offering. </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">ii)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;">During the year ended December&#160;31, 2022, <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To12_31_2022_ExcerciseOfWarrantsMemberEPRXEventAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14614">200,000</ix:nonFraction> common shares were issued on the exercise of warrants for gross proceeds of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To12_31_2022_ExcerciseOfWarrantsMemberEPRXEventAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14615">306,770</ix:nonFraction>. The weighted average share price during the period in which these warrants were exercised was CDN$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_ExcerciseOfWarrantsMemberEPRXEventAxis" unitRef="Unit_CAD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14616">4.18</ix:nonFraction>. On exercise, $<ix:nonFraction name="eprx:TransferredFromAdditionalPaidinCapitalToShareCapital" contextRef="P01_01_2022To12_31_2022_ExcerciseOfWarrantsMemberEPRXEventAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14617">44,893</ix:nonFraction> was transferred from additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital to share capital. </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify">Capital transactions which took place during the year ended December&#160;31, 2023, are as follows: </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">iii)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;">During the year ended December&#160;31, 2023, <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_ExcerciseOfWarrantsMemberEPRXEventAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14618">2,385,484</ix:nonFraction> common shares were issued on the exercise of warrants for gross proceeds of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_ExcerciseOfWarrantsMemberEPRXEventAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14619">5,241,811</ix:nonFraction>. The weighted average share price during the period in which these warrants were exercised was CDN$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_ExcerciseOfWarrantsMemberEPRXEventAxis" unitRef="Unit_CAD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14620">7.15</ix:nonFraction>. On exercise, $<ix:nonFraction name="eprx:TransferredFromAdditionalPaidinCapitalToShareCapital" contextRef="P01_01_2023To12_31_2023_ExcerciseOfWarrantsMemberEPRXEventAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14621">733,177</ix:nonFraction> was transferred from additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital to share capital. </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">iv)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;">During the year ended December&#160;31, 2023, <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14622">20,600</ix:nonFraction> common shares were issued on the exercise of options for gross proceeds of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14623">30,059</ix:nonFraction>. The weighted average share price during the period in which these options were exercised was CDN$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14624">2.00</ix:nonFraction>. On exercise, $<ix:nonFraction name="eprx:TransferredFromAdditionalPaidinCapitalToShareCapital" contextRef="P01_01_2023To12_31_2023_ExcerciseOfOptionsMemberEPRXEventAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14625">18,776</ix:nonFraction> was transferred from additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital to share capital. </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">v)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;;text-indent: 0px;">On August&#160;18, 2023, the Company closed a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">non-brokered</div> private placement (the &#8220;Private Placement&#8221;). Pursuant to the Private Placement, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P08_18_2023To08_18_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14626">3,183,875</ix:nonFraction> common shares at a price of CDN$<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn08_18_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14627">7.00</ix:nonFraction> per Common share for aggregate gross proceeds of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P08_18_2023To08_18_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14628">16,445,635</ix:nonFraction>. The Company incurred cash costs of issuing shares of $<ix:nonFraction name="eprx:CashCostsOfIssuingShares" contextRef="P08_18_2023To08_18_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14629">559,098</ix:nonFraction>. In addition, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P08_18_2023To08_18_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14630">99,061</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">common shares as finder&#8217;s fees which were<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">valued at $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P08_18_2023To08_18_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14631">511,681</ix:nonFraction>.&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div></td></tr></table><ix:exclude><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-23 </div></ix:exclude></ix:nonNumeric></div></div></div><ix:continuation id="TextSelection_108160216" continuedAt="TextSelectionAppend_108160216_1"><div></div></ix:continuation></div><ix:continuation id="TextSelectionAppend_108160216_1" continuedAt="TextSelectionAppend_108160216_2"><div><div style="line-height:normal;background-color:white;display: inline;"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></div></div></ix:continuation></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_108160216_2" continuedAt="TextSelectionAppend_108160216_3"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">SHARE CAPITAL AND OTHER COMPONENTS OF EQUITY (continued) </div></div></td></tr></table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_108160216_3" continuedAt="TextSelectionAppend_108160216_4"><div style="clear:both;max-height:0pt;"></div> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-size: 13.3333px; background-color: rgb(255, 255, 255); float: none; top: 0px; display: inline !important; letter-spacing: 0px;;display:inline;">Under<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Amended Stock Option Plan (the &#8220;Amended Plan&#8221;), approved by the Board of Directors on October&#160;27, 2021, and ratified by Shareholders on December&#160;3, 2021, the Board of Directors may grant stock options to directors, officers, employees and consultants of the Company up to an aggregate of </div><ix:nonFraction name="eprx:PercentageOfOutstandingSharesEligibleForStockOptionsIssuance" contextRef="PAsOn12_03_2021_AmendedPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-14632">18.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company&#8217;s then issued and outstanding common shares.</div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options granted under the Amended Plan have lives of up to </div><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen" id="ixv-14633">ten years</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of grant. The vesting schedule of all granted options is determined at the discretion of the Board. Unless otherwise determined by the Board, in its sole discretion, all grants of options will vest over a </div><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen" id="ixv-14634">three-year</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period, with the first twenty-five percent (</div><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_ImmediateVestingMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14635"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14636"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14637"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14638">25</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%) of the Options vesting on the date of grant, and the remaining o<div style="display:inline;">ptions</div> vesting over the following </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">thirty-six-month</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period in three equal instalments on an annual basis.</div></div> <ix:nonNumeric name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-9901"> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 9%;;text-indent: 0px;"><div style="font-size: 13.3333px; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s option transactions:</div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width:67%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;(CDN$)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding, December 31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2021_AmendedPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14639">2,134,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021_AmendedPlanMemberusgaapPlanNameAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14640">7.83</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14641">1,172,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14642">3.16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding, December 31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2022_AmendedPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14643">3,306,450</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022_AmendedPlanMemberusgaapPlanNameAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14644">6.18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14645">20,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14646">2.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cancelled</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14647">24,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14648">3.73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14649">257,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14650">6.91</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding, December 31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14651">3,518,250</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14652">6.27</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div> <ix:nonNumeric name="eprx:DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-10081">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width:55%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Grant</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options<br/> Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options<br/> Exercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price&#160;(CDN$)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiry</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual<br/> Life&#160;(years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14653">Sep 27, 2015</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14654">186,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14655">186,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14656">8.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(3)</div>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14657">Mar 31, 2025</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt-sec:duryear" id="ixv-14658">1.25</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwoNovemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14659">Nov 2, 2015</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwoNovemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14660">95,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwoNovemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14661">95,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwoNovemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14662">8.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(3)</div>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwoNovemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14663">Nov 2, 2025</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwoNovemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt-sec:duryear" id="ixv-14664">1.85</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_FiveMarchTwoThousandAndEighteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14665">Mar 5, 2018</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_FiveMarchTwoThousandAndEighteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14666">452,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_FiveMarchTwoThousandAndEighteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14667">452,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_FiveMarchTwoThousandAndEighteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14668">8.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(3)</div>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_FiveMarchTwoThousandAndEighteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14669">Mar 5, 2028</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_FiveMarchTwoThousandAndEighteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt-sec:duryear" id="ixv-14670">4.18</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14671">Mar 9, 2021</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14672">756,950</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14673">567,713</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14674">8.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14675">Mar 9, 2031</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt-sec:duryear" id="ixv-14676">7.20</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOne1MemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14677">Mar 9, 2021</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOne1MemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14678">326,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOne1MemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14679">326,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOne1MemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14680">8.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOne1MemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14681">Mar 9, 2031</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOne1MemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt-sec:duryear" id="ixv-14682">7.20</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThreeMayTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14683">May 3, 2021</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThreeMayTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14684">257,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThreeMayTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14685">192,750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThreeMayTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14686">8.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThreeMayTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14687">May 3, 2031</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThreeMayTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt-sec:duryear" id="ixv-14688">7.35</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14689">Dec 9, 2021</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14690">60,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14691">57,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14692">2.02</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14693">Dec 9, 2031</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt-sec:duryear" id="ixv-14694">7.95</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyFirstMarchTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14695">Mar 31, 2022</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyFirstMarchTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14696">392,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyFirstMarchTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14697">186,750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyFirstMarchTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14698">1.90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyFirstMarchTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14699">Mar 31, 2032</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyFirstMarchTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt-sec:duryear" id="ixv-14700">8.26</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14701">Dec 9, 2022</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14702">734,300</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14703">407,983</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14704">3.85</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14705">Dec 9, 2032</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt-sec:duryear" id="ixv-14706">8.95</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EighteenthMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14707">May 18, 2023</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EighteenthMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14708">180,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EighteenthMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14709">45,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EighteenthMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14710">6.84</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EighteenthMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14711">May 18, 2033</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EighteenthMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt-sec:duryear" id="ixv-14712">9.39</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14713">May 30, 2023</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14714">17,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14715">4,300</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14716">6.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14717">May 30, 2033</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt-sec:duryear" id="ixv-14718">9.42</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14719">Sep 27, 2023</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14720">60,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14721">15,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14722">7.16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt:date-monthname-day-year-en" id="ixv-14723">Sep 27, 2033</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis" format="ixt-sec:duryear" id="ixv-14724">9.75</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14725">3,518,250</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14726">2,537,296</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14727">6.27</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear" id="ixv-14728">7.02</ix:nonNumeric></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:continuation><ix:continuation id="TextSelectionAppend_108160216_4" continuedAt="TextSelectionAppend_108160216_5"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-24 </div> </ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_108160216_5" continuedAt="TextSelectionAppend_108160216_6"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108160216_6" continuedAt="TextSelectionAppend_108160216_7"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108160216_7" continuedAt="TextSelectionAppend_108160216_8"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_108160216_8" continuedAt="TextSelectionAppend_108160216_9"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">SHARE CAPITAL AND OTHER COMPONENTS OF EQUITY (continued) </div></div></td></tr></table> <div style="font-size: 0pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; margin-left: 32.625px; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">c) Options (continued)</div></div></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_108160216_9" continuedAt="TextSelectionAppend_108160216_10"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_108159751" id="ixv-14730"> </ix:nonNumeric></ix:continuation><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; margin-left: 73.4375px; font-size: 10pt; text-align: justify;"><ix:continuation id="TextSelection_108159751" continuedAt="TextSelectionAppend_108159751_1"><ix:continuation id="TextSelectionAppend_108160216_10" continuedAt="TextSelectionAppend_108160216_11"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The share-based compensation expense was determined based on the <div style="display:inline;">fai</div>r value of options at the date of measurement using the Black-Scholes option pricing model with the following weighted-average assumptions:</div></div></ix:continuation></ix:continuation></div> <ix:continuation id="TextSelectionAppend_108160216_11" continuedAt="TextSelectionAppend_108160216_12"><ix:continuation id="TextSelectionAppend_108159751_1"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width:73%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Options granted during the year ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-14731">0.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-14732">0.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected forfeiture rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-14733">0.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" contextRef="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-14734">0.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average annual volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-14735">79.60</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-14736">78.66</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-14737">3.54</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-14738">2.80</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average expected option life</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-14739">5.75</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-14740">5.70</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average share price (CDN$)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14741">6.91</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14742">3.16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average exercise price (CDN$)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14743">6.91</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14744">3.16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average fair value of options granted (CDN$)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14745">4.78</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14746">2.17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> </ix:continuation> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">Share-based payments for the year ended December&#160;31, 2023, was $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14747">1,412,257</ix:nonFraction> (2022 - $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14748">1,433,812</ix:nonFraction>) (See Note <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">13</div> &#8211; General&#160;&amp; Administrative Expenses and Note <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">14</div> &#8211; Research&#160;&amp; Development Expenses for breakdown by function). </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">As of December&#160;31, 2023, the unrecognized stock-based compensation expense related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock options was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14749">961,535</ix:nonFraction>, which is expected to be recognized over a weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-14750">2.09</ix:nonNumeric> years. </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">d)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Warrants </div></td></tr></table> <ix:nonNumeric name="eprx:ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-10729"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">The following table summarizes the Company&#8217;s warrant transactions: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width:66%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">exercise&#160;price&#160;(CDN$)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2021_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14751">4,161,898</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14752">8.81</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issued</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2022To12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14753">7,832,088</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14754">2.94</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="P01_01_2022To12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14755">289,172</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14756">8.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="P01_01_2022To12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14757">200,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14758">2.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14759">11,504,814</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14760">4.95</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="P01_01_2023To12_31_2023_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14761">2,385,484</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To12_31_2023_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14762">2.90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2023_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14763">9,119,330</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14764">5.49</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:continuation><ix:continuation id="TextSelectionAppend_108160216_12" continuedAt="TextSelectionAppend_108160216_13"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-25 </div> </ix:exclude></ix:continuation></div></div> <ix:continuation id="TextSelectionAppend_108160216_13" continuedAt="TextSelectionAppend_108160216_14"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_108160216_14" continuedAt="TextSelectionAppend_108160216_15"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108160216_15" continuedAt="TextSelectionAppend_108160216_16"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_108160216_16" continuedAt="TextSelectionAppend_108160216_17"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">SHARE CAPITAL AND OTHER COMPONENTS OF EQUITY (continued) </div></div></td></tr></table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">d)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrants (continued) </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_108160216_17"><ix:nonNumeric name="eprx:ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-10978"> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify">As at December&#160;31, 2023, the following warrants were out<div style="letter-spacing: 0px; top: 0px;;display:inline;">standing:</div> </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:63%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Expiry date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise&#160;price<br/> (CDN$)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> contractual&#160;life<br/> (years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrants<br/> outstanding<br/> and<br/> exercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2023To12_31_2023_ExpiryPeriodOneMemberEPRXMaturityPeriodWarrantsAxis" format="ixt-sec:durwordsen" id="ixv-14765">120 days</ix:nonNumeric> after holder to be a Director/ Officer or consultant</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_ExpiryPeriodOneMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_CAD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-14766">0.7572</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2023_ExpiryPeriodOneMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14767">243,421</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2023To12_31_2023_ExpiryPeriodTwoMemberEPRXMaturityPeriodWarrantsAxis" format="ixt-sec:durwordsen" id="ixv-14768">120 days</ix:nonNumeric> after former spouse ceases to be a Director/ Officer or consultant</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_ExpiryPeriodTwoMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_CAD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-14769">0.7572</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2023_ExpiryPeriodTwoMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14770">137,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2023To12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis" format="ixt-sec:durwordsen" id="ixv-14771">120 days</ix:nonNumeric> after <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">holder ceases to be a Director/ Officer or consultant<div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 7.5pt; line-height: 7.5pt;;display:inline;vertical-align: super;;font-size:8.3px">(1)</div></div></div></div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_CAD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-14772">0.4984</ix:nonFraction></td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">N/A</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14773">315,500</ix:nonFraction></td>
<td style="vertical-align:bottom"/></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_ExpiryPeriodFourMemberEPRXMaturityPeriodWarrantsAxis" format="ixt:date-monthname-day-year-en" id="ixv-14774">January 4, 2024</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_ExpiryPeriodFourMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_CAD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-14775">5.5993</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="P01_01_2023To12_31_2023_ExpiryPeriodFourMemberEPRXMaturityPeriodWarrantsAxis" format="ixt-sec:duryear" id="ixv-14776">0.01</ix:nonNumeric></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2023_ExpiryPeriodFourMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14777">239,080</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_ExpiryPeriodFiveMemberEPRXMaturityPeriodWarrantsAxis" format="ixt:date-monthname-day-year-en" id="ixv-14778">January 4, 2024</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_ExpiryPeriodFiveMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_CAD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-14779">7.1991</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="P01_01_2023To12_31_2023_ExpiryPeriodFiveMemberEPRXMaturityPeriodWarrantsAxis" format="ixt-sec:duryear" id="ixv-14780">0.01</ix:nonNumeric></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2023_ExpiryPeriodFiveMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14781">39,846</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_ExpiryPeriodSixMemberEPRXMaturityPeriodWarrantsAxis" format="ixt:date-monthname-day-year-en" id="ixv-14782">January 8, 2024</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_ExpiryPeriodSixMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_CAD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-14783">5.5993</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="P01_01_2023To12_31_2023_ExpiryPeriodSixMemberEPRXMaturityPeriodWarrantsAxis" format="ixt-sec:duryear" id="ixv-14784">0.02</ix:nonNumeric></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2023_ExpiryPeriodSixMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14785">31,877</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_ExpiryPeriodSevenMemberEPRXMaturityPeriodWarrantsAxis" format="ixt:date-monthname-day-year-en" id="ixv-14786">March 9, 2026</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_ExpiryPeriodSevenMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14787">11.20</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="P01_01_2023To12_31_2023_ExpiryPeriodSevenMemberEPRXMaturityPeriodWarrantsAxis" format="ixt-sec:duryear" id="ixv-14788">2.19</ix:nonNumeric></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2023_ExpiryPeriodSevenMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14789">2,826,274</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_ExpiryPeriodEightMemberEPRXMaturityPeriodWarrantsAxis" format="ixt:date-monthname-day-year-en" id="ixv-14790">April 20, 2026</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_ExpiryPeriodEightMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14791">3.00</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="P01_01_2023To12_31_2023_ExpiryPeriodEightMemberEPRXMaturityPeriodWarrantsAxis" format="ixt-sec:duryear" id="ixv-14792">2.30</ix:nonNumeric></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2023_ExpiryPeriodEightMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14793">5,196,550</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_ExpiryPeriodNineMemberEPRXMaturityPeriodWarrantsAxis" format="ixt:date-monthname-day-year-en" id="ixv-14794">April 20, 2026</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_ExpiryPeriodNineMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14795">2.05</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="P01_01_2023To12_31_2023_ExpiryPeriodNineMemberEPRXMaturityPeriodWarrantsAxis" format="ixt-sec:duryear" id="ixv-14796">2.30</ix:nonNumeric></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2023_ExpiryPeriodNineMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14797">50,054</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P01_01_2023To12_31_2023_ExpiryPeriodTenMemberEPRXMaturityPeriodWarrantsAxis" format="ixt:date-monthname-day-year-en" id="ixv-14798">April 29, 2026</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_ExpiryPeriodTenMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14799">11.20</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="P01_01_2023To12_31_2023_ExpiryPeriodTenMemberEPRXMaturityPeriodWarrantsAxis" format="ixt-sec:duryear" id="ixv-14800">2.33</ix:nonNumeric></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2023_ExpiryPeriodTenMemberEPRXMaturityPeriodWarrantsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14801">39,228</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14802">5.49</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14803">9,119,330</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents unit purchase to acquire <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14804">315,500</ix:nonFraction></div> units consisting of one Common Share and one additional warrant at an exercise price of $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-14805">0.75</ix:nonFraction></div>CDN. These underlying warrants expire <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2023To12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen" id="ixv-14806">two years</ix:nonNumeric> from the date of exercise of the primary warrant. </div></div></div></td></tr></table> </ix:nonNumeric> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">e)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Class&#160;B <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Voting</div> shares </div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify">On January&#160;31, 2021, the Company entered into a contribution agreement with the Chief Scientific Officer of the Company, and certain of the Company&#8217;s subsidiaries (the &#8220;Contribution Agreement&#8221;). Pursuant to the Contribution Agreement, the Company acquired AMDM Holdings Inc., a corporation wholly-owned by the Chief Scientific Officer, which held <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="PAsOn12_31_2021_AmdmHoldingsMemberEPRXAmdmHoldingsAxis_EuphraxiaUsaMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14807">5</ix:nonFraction>% of the equity interest in the Company&#8217;s subsidiary, Eupraxia USA. In exchange, the Company issued to the Chief Scientific Officer <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_31_2021To01_31_2021_AmdmHoldingsMemberEPRXAmdmHoldingsAxis_ChiefScientificOfficerMembersrtTitleOfIndividualAxis_ClassBNonVotingStockMemberusgaapStatementClassOfStockAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14808">225</ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> Class&#160;B shares (the &#8220;Class&#160;B Shares&#8221;) in Eupraxia Pharma Inc. representing <ix:nonFraction name="eprx:StockSharesIssuedAsAPercentageOfOutstandingShares" contextRef="PAsOn12_31_2021_AmdmHoldingsMemberEPRXAmdmHoldingsAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14809">5</ix:nonFraction>% of the outstanding securities of Eupraxia Pharma. The Company holds the remaining <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis_OutstandingOfAMDMHoldingsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14810">95</ix:nonFraction>% of such securities, which consists of <ix:nonFraction name="eprx:EquityMethodInvestmentNumberOfSharedOwned" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14811">4,275</ix:nonFraction> voting Class&#160;A shares. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify">Each Class&#160;B Share is exchangeable into common shares of the Company based on an exchange rate of <ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="P01_31_2021To01_31_2021_AmdmHoldingsMemberEPRXAmdmHoldingsAxis_ChiefScientificOfficerMembersrtTitleOfIndividualAxis_ClassBNonVotingStockMemberusgaapStatementClassOfStockAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14812">2,500</ix:nonFraction> common shares for each Class&#160;B Share, subject to adjustments upon the occurrence of certain events, for a total of <ix:nonFraction name="eprx:CommonStockSharesIssuableAsAResultOfStockSplit" contextRef="PAsOn12_31_2021_AmdmHoldingsMemberEPRXAmdmHoldingsAxis_ChiefScientificOfficerMembersrtTitleOfIndividualAxis_ClassBNonVotingStockMemberusgaapStatementClassOfStockAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-14813">562,500</ix:nonFraction> common shares. The Class&#160;B Shares are exchangeable by the Chief Scientific Officer at her election, provided that the Company may force the exchange of the Class&#160;B Shares into common shares of the Company at any time on or after January&#160;31, 2031, or on or after January&#160;31, 2026, if the Company is listed on a stock exchange and is a reporting issuer in Canada at such time. The Company may also force the exchange of the Class&#160;B Shares into common shares if there is a change of control transaction involving the Company, a change in law which makes the exchange necessary or desirable or if there are a <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">de minimis </div></div>number of Class&#160;B Shares outstanding. If the Company is listed on a stock exchange at the time of the applicable exchange, the Company may elect to pay the Chief Scientific Officer cash in lieu of issuing common shares, with such cash amount to be determined based on the then current market price of the common shares of the Company. </div> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-26 </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><ix:nonNumeric name="eprx:DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-11286">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">GENERAL AND ADMINISTRATIVE EXPENSES </div></div></td></tr></table> <ix:nonNumeric name="eprx:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-11295"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">General and administrative expenses are comprised of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Office expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14814">389,210</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14815">332,951</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Insurance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralInsuranceExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14816">367,472</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralInsuranceExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14817">357,763</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Travel</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TravelAndEntertainmentExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14818">345,992</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TravelAndEntertainmentExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14819">120,115</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Professional fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14820">2,821,798</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14821">268,698</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public company costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreOpeningCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14822">404,073</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreOpeningCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14823">214,264</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Salaries and benefits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14824">2,241,079</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14825">1,641,049</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Share based payments (Note 12(c))</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14826">714,380</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14827">1,052,758</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total expenses during the period</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14828">7,284,004</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14829">3,987,598</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-11463">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">RESEARCH AND DEVELOPMENT EXPENSES </div></div></td></tr></table> <ix:nonNumeric name="eprx:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-11472"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Research and development expenses are comprised of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:71%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">December&#160;31,</div><br/><div style="font-weight:bold;display:inline;">2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">December&#160;31,</div><br/><div style="font-weight:bold;display:inline;">2022</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preclinical</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory" contextRef="P01_01_2023To12_31_2023_PreclinicalMemberEPRXResearchAndDevelopmentExpensesAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14830">1,616,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory" contextRef="P01_01_2022To12_31_2022_PreclinicalMemberEPRXResearchAndDevelopmentExpensesAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14831">1,073,668</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Clinical</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory" contextRef="P01_01_2023To12_31_2023_ClinicalMemberEPRXResearchAndDevelopmentExpensesAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14832">4,595,597</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory" contextRef="P01_01_2022To12_31_2022_ClinicalMemberEPRXResearchAndDevelopmentExpensesAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14833">7,179,535</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Manufacturing&#160;&amp; analytical</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory" contextRef="P01_01_2023To12_31_2023_ManufacturingAndAnalyticaMemberEPRXResearchAndDevelopmentExpensesAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14834">4,986,502</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory" contextRef="P01_01_2022To12_31_2022_ManufacturingAndAnalyticaMemberEPRXResearchAndDevelopmentExpensesAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14835">2,177,070</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Regulatory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory" contextRef="P01_01_2023To12_31_2023_RegulatoryMemberEPRXResearchAndDevelopmentExpensesAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14836">341,589</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory" contextRef="P01_01_2022To12_31_2022_RegulatoryMemberEPRXResearchAndDevelopmentExpensesAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14837">588,652</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consulting</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory" contextRef="P01_01_2023To12_31_2023_ConsultingMemberEPRXResearchAndDevelopmentExpensesAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14838">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory" contextRef="P01_01_2022To12_31_2022_ConsultingMemberEPRXResearchAndDevelopmentExpensesAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14839">660</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;">Direct research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14840">11,539,926</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14841">11,019,585</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Pipeline development</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:PipelineDevelopmentOfResearchAndDevelopmentExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14842">83,637</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:PipelineDevelopmentOfResearchAndDevelopmentExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14843">227,615</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other research and development</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14844">672,295</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14845">424,628</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Salaries and benefits</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:SalariesAndBenefitsOfResearchAndDevelopmentExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14846">2,794,891</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:SalariesAndBenefitsOfResearchAndDevelopmentExpenses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14847">1,901,257</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Share based payments (Note 12(c))</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ShareBasedPaymentsOfResearchAndDevelopmentExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14848">697,877</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:ShareBasedPaymentsOfResearchAndDevelopmentExpenses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14849">381,054</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">License costs (Note 10)</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:ResearchAndDevelopmentLicenseExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14850">5,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:ResearchAndDevelopmentLicenseExpenses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14851">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Government grants (Note 15)</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:GovernmentAssistanceAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14852">122,542</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:GovernmentAssistanceAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14853">288,515</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">SR&amp;ED and other R&amp;D tax incentives</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="eprx:SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14854">102,859</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="eprx:SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14855">35,770</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total expenses during the period</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14856">20,563,225</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14857">13,629,854</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table> </ix:nonNumeric></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-27 </div> </div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">DECEMBER 31, 2023 and 2022 </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div><ix:nonNumeric name="us-gaap:GovernmentAssistanceTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-11740">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">GOVERNMENT GRANTS AND ASSISTANCE </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">National Research Council &#8211; Industrial Research Assistance Program <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;NRC-IRAP&#8221;)</div></div> </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">On October&#160;1, 2021, the Company entered into an agreement with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NRC-IRAP</div> for funding support of specified research and development activities during a project phase, commencing on September&#160;1, 2021, and ending on December&#160;15, 2023. Under the agreement, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NRC-IRAP</div> would reimburse up to <ix:nonFraction name="eprx:PercentageOfReimburseAssistanceToSupportSalaryCost" contextRef="P10_01_2021To10_01_2021_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14858">80</ix:nonFraction>% of supported salary costs, and <ix:nonFraction name="eprx:PercentageOfReimburseAssistanceToSupportContractorFee" contextRef="P10_01_2021To10_01_2021_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14859">50</ix:nonFraction>% of supported contractor fees to a maximum of $<ix:nonFraction name="eprx:ReimbursementAssistanceMaximumForSalaryAndContractorCosts" contextRef="PAsOn10_01_2021_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14860">553,185</ix:nonFraction>. During the year ended December&#160;31, 2023, the Company claimed $<ix:nonFraction name="us-gaap:GovernmentAssistanceAmount" contextRef="P01_01_2023To12_31_2023_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14861">122,542</ix:nonFraction> pertaining to this agreement (2022 - $<ix:nonFraction name="us-gaap:GovernmentAssistanceAmount" contextRef="P01_01_2022To12_31_2022_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14862">277,117</ix:nonFraction>). </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">At December&#160;31, 2023 there was $<ix:nonFraction name="us-gaap:GrantsReceivableCurrent" contextRef="PAsOn12_31_2023_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-14863">nil</ix:nonFraction> (2022 - $<ix:nonFraction name="us-gaap:GrantsReceivableCurrent" contextRef="PAsOn12_31_2022_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14864">13,892</ix:nonFraction>) of government grants recorded in amounts receivable (Note <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">4</div> &#8211; Amounts Receivable) and collected subsequent to year end. </div><ix:nonNumeric name="eprx:GovernmentAssistanceTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-11757"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">The following table summarizes the government grants and assistance the Company received or accrued during the years ended December&#160;31, 2023 and 2022: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width:78%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NRC-IRAP</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GovernmentAssistanceAmountCumulative" contextRef="PAsOn12_31_2023_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14865">122,542</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GovernmentAssistanceAmountCumulative" contextRef="PAsOn12_31_2022_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14866">277,117</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">BioTalent Canada</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GovernmentAssistanceAmountCumulative" contextRef="PAsOn12_31_2023_BioTalentCanadaMemberusgaapGovernmentAssistanceTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14867">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GovernmentAssistanceAmountCumulative" contextRef="PAsOn12_31_2022_BioTalentCanadaMemberusgaapGovernmentAssistanceTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14868">11,398</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:GovernmentAssistanceAmountCumulative" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14869">122,542</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:GovernmentAssistanceAmountCumulative" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14870">288,515</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">Government assistance of $<ix:nonFraction name="eprx:GovernmentAssistanceAmountForResearchAndDevelopment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14871">122,542</ix:nonFraction> (2022 - $<ix:nonFraction name="eprx:GovernmentAssistanceAmountForResearchAndDevelopment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14872">288,515</ix:nonFraction>) relating to research and development activities has been offset against research and development expense. </div></ix:nonNumeric> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_108160206" id="ixv-11860">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">INCOME TAXES </div></div></td></tr></table><ix:nonNumeric name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-11869"><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For financial reporting purposes, loss before taxes includes the following components: </div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:69%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"><div style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Year ended December 31,</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">2022</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canadian</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14873">28,810,717</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14874">18,925,281</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14875">118,866</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14876">65,483</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14877">28,929,583</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14878">18,990,764</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-11964"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The income tax expense consists of the following: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 83%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December 31,</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Canadian</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14879">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14880">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14881">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14882">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14883">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14884">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14885">36,423</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14886">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14887">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14888">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14889">36,423</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14890">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14891">36,423</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14892">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14893">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14894">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div>&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14895">36,423</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div>&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14896">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr></table></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-28 </div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_108160206" continuedAt="TextSelectionAppend_108160206_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108160206_1" continuedAt="TextSelectionAppend_108160206_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108160206_2" continuedAt="TextSelectionAppend_108160206_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_108160206_3" continuedAt="TextSelectionAppend_108160206_4"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">INCOME TAXES (continued) </div></div></td></tr></table></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_108160206_4" continuedAt="TextSelectionAppend_108160206_5"><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-12416"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 69%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December&#160;31,</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14897">28,929,583</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14898">18,990,764</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Statutory Canadian corporate tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14899">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14900">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Expected tax recovery at statutory rates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14901">7,810,987</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14902">5,127,506</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Change in unrecognized deferred tax assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14903">9,523,404</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14904">5,127,732</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Non-deductible share-based payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14905">381,285</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14906">414,724</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other items not deductible for tax purposes and other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14907">242,460</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14908">11,570</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Adjustments related to prior years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14909">624,973</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14910">257,636</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Share issue costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="eprx:EffectiveIncomeTaxReconciliationShareIssuanceCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14911">290,289</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="eprx:EffectiveIncomeTaxReconciliationShareIssuanceCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14912">322,131</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Foreign exchange arising on translation to reporting currency</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="eprx:EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-14913">1,384,477</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14914">153,247</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Income tax expense</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14915">36,423</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14916">&#8212;</ix:nonFraction>&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense for the year ended December 31, 2023 arose from the operations of Eupraxia Pharma USA Inc., the Company&#8217;s wholly-owned subsidiary in the United States. </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-12636"><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax assets and liabilities result from the temporary differences between the amount of assets and liabilities recognized for financial statement and income tax purposes. The significant components of the Company&#8217;s net deferred income tax assets are as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 69%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 8%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Convertible debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="eprx:DeferredTaxAssetsConvertibleDebt" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14917">733,756</ix:nonFraction></td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="eprx:DeferredTaxAssetsConvertibleDebt" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14918">360,307</ix:nonFraction></td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Depreciable assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14919">3,092,163</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14920">1,655,346</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Lease obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:DeferredTaxAssetsLeaseObligation" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14921">4,925</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:DeferredTaxAssetsLeaseObligation" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14922">8,122</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-capital</div> losses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14923">18,348,349</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14924">12,776,875</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Share issue costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:DeferredTaxAssetsShareIssuanceCosts" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14925">728,046</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:DeferredTaxAssetsShareIssuanceCosts" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14926">694,773</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Scientific research and experimental development pool</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14927">2,093,085</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14928">852,776</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14929">1,546,834</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14930">797,401</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Other</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14931">121,846</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14932">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Less: valuation allowance</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14933">26,669,004</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14934">17,145,600</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Net deferred income tax assets</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 10%; padding: 0pt 5pt 0pt 0pt;;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14935">&#8212;</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; width: 10%; padding: 0pt 5pt 0pt 0pt; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14936">&#8212;</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table></ix:nonNumeric><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In assessing the realizability of the Company&#8217;s deferred income tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not b realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which temporary differences become deductible and the loss carry-forwards or tax credits can be utilized. A full valuation allowance continues to be applied against deferred income tax assets as the Company has assessed that the realization of such assets does not meet the more likely than not criteria. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are <ix:nonFraction name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-14937"><ix:nonFraction name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-14938">no</ix:nonFraction></ix:nonFraction> unrecognized income tax benefits as of December 31, 2023, or 2022. Due to the net operating loss carryover position coupled with the lack of any unrecognized tax benefits, <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-14939"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-14940">no</ix:nonFraction></ix:nonFraction> provision has been made for any interest or penalties associated with any uncertain tax positions. It is <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-14941"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-14942">no</ix:nonFraction></ix:nonFraction>t anticipated that there will be any significant changes to unrecognized tax benefits within the next 12 months. </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_108160206_5" continuedAt="TextSelectionAppend_108160206_6"><ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-29 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_108160206_6" continuedAt="TextSelectionAppend_108160206_7"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108160206_7" continuedAt="TextSelectionAppend_108160206_8"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108160206_8" continuedAt="TextSelectionAppend_108160206_9"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto;text-indent: 0px;"><ix:continuation id="TextSelectionAppend_108160206_9" continuedAt="TextSelectionAppend_108160206_10"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">INCOME TAXES (continued) </div></div></td></tr></table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_108160206_10"><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In assessing the realizability of the Company&#8217;s deferred income tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not b realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which temporary differences become deductible and the loss carry-forwards or tax credits can be utilized. A full valuation allowance continues to be applied against deferred income tax assets as the Company has assessed that the realization of such assets does not meet the more likely than not criteria. </div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are no unrecognized income tax benefits as of December 31, 2023, or 2022. Due to the net operating loss carryover position coupled <div style="display:inline;">wit</div>h the lack of any unrecognized tax benefits, no provision has been made for any interest or penalties associated with any uncertain tax positions. It is not anticipated that there will be any significant changes to unrecognized tax benefits within the next 12 months. </div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company and its foreign subsidiaries have available </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-capital</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> losses for Canadian, Australian and US income tax purposes which may be carried forward to reduce taxable income in future years. If not utilized, </div><ix:nonNumeric name="eprx:ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_108159788" id="ixv-12896"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-capital</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> losses in each jurisdiction will expire as follows<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;(all amounts expressed in USD):</div></div></ix:nonNumeric></div> <ix:continuation id="TextSelection_108159788"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 24%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 17%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 17%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 17%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Expiry date</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-capital&#160;losses&#8211;</div><br/>Canada</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-capital&#160;losses&#8211;</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-capital&#160;losses&#8211;</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Australia</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width:21%"/>
<td style="vertical-align:bottom;width:18%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:18%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:18%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2031</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2031MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14943">281,235</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_TaxYear2031MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14944">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2031MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14945">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2032</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2032MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14946">575,606</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_TaxYear2032MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14947">322,050</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2032MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14948">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2033</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2033MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14949">2,481,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_TaxYear2033MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14950">1,111,122</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2033MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14951">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2034</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2034MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14952">2,935,535</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_TaxYear2034MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14953">160,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2034MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14954">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2035</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2035MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14955">2,466,288</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_TaxYear2035MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14956">160,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2035MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14957">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2036</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2036MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14958">3,797,516</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_TaxYear2036MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14959">160,048</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2036MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14960">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>037</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2037MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14961">7,294,414</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_TaxYear2037MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14962">160,000</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2037MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14963">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2038</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2038MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14964">3,060,930</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_TaxYear2038MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14965">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2038MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14966">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2039</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2039MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14967">1,666,415</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_TaxYear2039MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14968">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2039MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14969">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2040</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2040MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14970">144,413</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_TaxYear2040MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14971">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2040MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14972">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2041</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2041MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14973">6,404,809</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_TaxYear2041MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14974">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2041MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14975">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2042</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2042MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14976">13,526,387</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_TaxYear2042MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14977">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2042MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14978">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2043</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2043MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14979">17,642,270</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2043MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14980">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unlimited</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYearAfter2043MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-14981">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_TaxYearAfter2043MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14982">1,479,139</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYearAfter2043MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14983">69,093</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"/>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14984">62,277,418</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14985">3,552,359</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="eprx:NonCapitalLossCarryforwardsToFutureExpire" contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14986">69,093</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"/>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table> </ix:continuation> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company also has approximately $</div><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14987">7,752,165</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of SR&amp;ED expenditures that may be carried forward indefinitely to be deducted against future Canadian taxable income. It also has federal investment tax credits of approximately $</div><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_CanadianFederalInvestmentTaxCreditsMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14988">1,449,886</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> available to offset future Canadian federal income taxes payable as well as provincial investment tax credits of approximately $</div><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_ProvincialInvestmentTaxCreditsMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14989">511,826</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The federal tax credits are available to be carried forward </div><ix:nonNumeric name="eprx:TaxCreditCarryForwardsExpirationTerm" contextRef="P01_01_2023To12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_CanadianFederalInvestmentTaxCreditsMemberusgaapTaxCreditCarryforwardAxis" format="ixt-sec:duryear" id="ixv-14990">20</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> years (expiring in 2036 to 2043) to offset future Canadian federal income taxes payable and the provincial tax credits are available to be carried forward </div><ix:nonNumeric name="eprx:TaxCreditCarryForwardsExpirationTerm" contextRef="P01_01_2023To12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_ProvincialInvestmentTaxCreditsMemberusgaapTaxCreditCarryforwardAxis" format="ixt-sec:duryear" id="ixv-14991">10</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> years (expiring in 2026 to 2033) to offset future BC income taxes payable. The benefit of the investment tax credits has not been recognized as their realization is not reasonably assured.</div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company files income tax returns in Canada, United States and Australia, the jurisdictions in which the Company believes that it is subject to tax. In jurisdictions in which the Company does not believe it is subject to tax and therefore does not file income tax returns, the Company can provide no certainty that tax authorities in those jurisdictions will not subject one or more tax years (since the inception of the Company) to examination. Further, while the statute of limitations in each jurisdiction where an income tax return has been filed generally limits the examination period, as a result of loss carry-forwards, the limitation period for examination generally does not expire until several years after the loss carry-forwards are utilized. Other than routine audits by tax authorities for tax credits and tax refunds that the Company claims, the Company is not aware of any other material income tax examination currently in progress by any taxing jurisdiction. Tax years ranging from 2012 to 2023 remain subject to examinations in Canada and the United States 2022 to 2023 for Australia. </div></div></div></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-30 </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto;text-indent: 0px;"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">DECEMBER 31, 2023 and 2022 </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div><ix:nonNumeric name="us-gaap:CommitmentsDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-13299">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">COMMITMENTS </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">The Company may be required to make milestone, royalty, and other research and development funding payments under research and development collaboration and other agreements with third parties (see Note <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">10</div> &#8211; Auritec License Agreement). These payments are contingent upon the achievement of specific development, regulatory and/or commercial milestones. The Company has not accrued these payments as at December&#160;31, 2023 due to the uncertainty over whether these milestones will be achieved. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">Eupraxia has entered into a number of service contracts with its vendors.&#160;Some of those contracts have cancellation clauses which state Eupraxia would pay a cancellation fee of between <ix:nonFraction name="eprx:CancellationFeeOnTerminationOfContract" contextRef="P01_01_2023To12_31_2023_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14992">15</ix:nonFraction>% and <ix:nonFraction name="eprx:CancellationFeeOnTerminationOfContract" contextRef="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-14993">100</ix:nonFraction>% of the next service milestone if it terminates the contract.&#160;As of December&#160;31, 2023, there have been <ix:nonNumeric name="eprx:CancellationFeeForCancellationOfContract" contextRef="P01_01_2023To12_31_2023" id="ixv-14994">no</ix:nonNumeric> cancellation of contracts that would trigger a cancellation fee.</div> </ix:nonNumeric> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div> <ix:nonNumeric name="us-gaap:FinancialInstrumentsDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_108159566" id="ixv-13312">
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; border: 0px; width: 816px;;text-indent: 0px;">
<tr style="break-inside: avoid;">
<td style="width: 32.625px; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">FINANCIAL INSTRUMENTS </div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial instruments consist of cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities, payable to Auritec, loans payable and convertible debt. </div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no changes to the Company&#8217;s risk exposures or management of risks during the year ended December&#160;31, 2023. The Company&#8217;s risk exposures and the impact on the Company&#8217;s financial instruments are summarized below: </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Credit risk </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company believes it has no significant credit risk, as its cash and cash equivalents and short-term investments, being its primary exposure to credit risk, is with a large Canadian bank. The Company&#8217;s maximum exposure to credit risk is the carrying value of these financial assets. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity risk </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. The Company&#8217;s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at December&#160;31, 2023, the Company had cash and cash equivalents of $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14995">19,341,756</ix:nonFraction> (2022 - $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14996">18,263,389</ix:nonFraction>) in addition to current liabilities of $<ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14997">19,373,903</ix:nonFraction> (2022 - $<ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-14998">3,058,387</ix:nonFraction>). <div style="letter-spacing: 0px; top: 0px;;display:inline;">Management is currently working on certain strategic alternatives including, but not limited to raising additional capital and strategic alternatives to its existing contingent convertible debt facility. There is no assurance, however, that any or all of these alternatives will materialize or that additional funding will be available, if and when needed.</div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"><ix:exclude>F-31</ix:exclude> </div> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_108159566" continuedAt="TextSelectionAppend_108159566_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159566_1" continuedAt="TextSelectionAppend_108159566_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159566_2" continuedAt="TextSelectionAppend_108159566_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto;text-indent: 0px;"><ix:continuation id="TextSelectionAppend_108159566_3" continuedAt="TextSelectionAppend_108159566_4"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">FINANCIAL INSTRUMENTS (continued) </div></div></td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><br/></div></div></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_108159566_4" continuedAt="TextSelectionAppend_108159566_5"><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Market risk </div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: currency risk, interest rate risk and other price risk. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest rate risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market i<div style="display:inline;">nteres</div>t rates. The Company is exposed to interest rate cash flow risk; and to the extent that the prevailing market interest rates differ from the interest rate on the Company&#8217;s monetary assets and liabilities, the Company is exposed to interest rate price risk. At December&#160;31, 2023, the Company maintains a convertible debt facility totaling CDN$<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2023_CADsrtCurrencyAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_CAD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15000">10,000,000</ix:nonFraction> as well as having an equipment loan of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2023_EquipmentLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15001">235,000</ix:nonFraction> of which a principal balance of $<ix:nonFraction name="us-gaap:OtherLongTermDebt" contextRef="PAsOn12_31_2023_EquipmentLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15002">62,709</ix:nonFraction> remains as at December&#160;31, 2023. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The convertible debt accrues interest at the greater of <ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" contextRef="PAsOn12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MinimumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-15003">2.45</ix:nonFraction>% and the Canadian prime rate, requiring monthly interest payments. An additional payment in kind accrues at a rate of <ix:nonFraction name="eprx:LongTermDebtPaidInKindInterestPercentage" contextRef="P01_01_2023To12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-15004">7</ix:nonFraction>% per annum, which will be settled at maturity or on conversion. The equipment loan accrues interest at a fixed rate of <ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" contextRef="PAsOn12_31_2023_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-15005">5.84</ix:nonFraction>%. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">As at December&#160;31, 2023, management has determined the effect on the future results of operations due to a change in the current Canadian prime rate. An impact of a <ix:nonFraction name="eprx:SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate" contextRef="PAsOn12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-15006">1</ix:nonFraction>% change in the Canadian prime rate would impact the amount of interest to be paid over the remaining term of the convertible debt facility by approximately $<ix:nonFraction name="eprx:SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax" contextRef="PAsOn12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15007">43,807</ix:nonFraction>. </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Currency risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company is exposed to currency risk due to its frequency of transactions in US dollars. The Company does not use derivatives to hedge against this risk, however, it has purchased US dollars to cover the majority of the costs of the Company&#8217;s Phase 2 clinical trial.&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>F-32</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_108159566_5" continuedAt="TextSelectionAppend_108159566_6"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_108159566_6" continuedAt="TextSelectionAppend_108159566_7"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159566_7" continuedAt="TextSelectionAppend_108159566_8"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159566_8" continuedAt="TextSelectionAppend_108159566_9"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_108159566_9" continuedAt="TextSelectionAppend_108159566_10"><ix:exclude><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER 31, 2023 and 2022 </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">FINANCIAL INSTRUMENTS (continued) </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Currency risk (continued)</div></div></div></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159566_10" continuedAt="TextSelectionAppend_108159566_11"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>&#160;</ix:exclude></div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">At December 31, 2023, the Company held cash of </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2023_CurrencyRiskMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15010">933,816</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (2022 &#8211; $</div><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2022_CurrencyRiskMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15011">1,159,926</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">, had accounts payable of $<ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15012">1,292,128</ix:nonFraction> (2022 &#8211; $<ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15013">1,814,067</ix:nonFraction>), <div style="display:inline;">a</div> payable owing to Auritec of $<ix:nonFraction name="eprx:PayableTowardsRoyaltyAndOthersCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15014">5,000,000</ix:nonFraction> (2022 &#8211; <ix:nonFraction name="eprx:PayableTowardsRoyaltyAndOthersCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-15015">nil</ix:nonFraction>) and a loan payable of </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div><ix:nonFraction name="us-gaap:OtherLongTermDebt" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15016">62,709</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (2022 &#8211; $</div><ix:nonFraction name="us-gaap:OtherLongTermDebt" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15017">142,127</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">) denominated in US dollars which were translated to Canadian dollars at </div><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="PAsOn12_31_2023_CADsrtCurrencyAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-15018">1.3226</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (2022 &#8211; </div><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="PAsOn12_31_2022_CADsrtCurrencyAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-15019">1.3544</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">). The impact of a 10% change in the exchange rates would have an impact of approximately $</div><ix:nonFraction name="eprx:ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15020">542,102</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (2022 &#8211; $</div><ix:nonFraction name="eprx:ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15021">79,627</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">) on profit or loss. The Company also has cash in accounts payable in Australian dollars, Great British pounds and Euros. The impact of a </div><ix:nonFraction name="eprx:PercentageIncreaseInSignificantUnobservableInputAssets" contextRef="PAsOn12_31_2023_CADsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-15022"><ix:nonFraction name="eprx:PercentageIncreaseInSignificantUnobservableInputAssets" contextRef="PAsOn12_31_2022_CADsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-15023"><ix:nonFraction name="eprx:PercentageIncreaseInSignificantUnobservableInputLiabilities" contextRef="PAsOn12_31_2023_CADsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-15024"><ix:nonFraction name="eprx:PercentageIncreaseInSignificantUnobservableInputLiabilities" contextRef="PAsOn12_31_2022_CADsrtCurrencyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-15025">10</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% change in the exchanges of these currencies would have an immaterial effect on future cash flows.</div></div></ix:continuation></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_108159566_11" continuedAt="TextSelectionAppend_108159566_12"><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other price risk </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk and foreign currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer or by factors affecting all similar financial instruments traded in the market. The Company is not exposed to significant price risk with respect to commodity or equity prices. </div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Fair Value Measurement </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company categorizes its financial instruments measured at fair value into one of three different levels depending on the observation of inputs used in the measurement. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Level&#160;1: Fair value is based on unadjusted quoted prices for identical assets or liabilities in active markets </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Level&#160;2: Fair value is based on inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Level&#160;3: Fair value is based on valuation techniques that require one or more significant unobservable inputs </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company&#8217;s financial instruments consist of cash and cash equivalents, short-term investments, accounts payable and accrued liabilities, loans payable and convertible debt. With the exception of convertible debt, the carrying value of the Company&#8217;s financial instruments approximate their fair values due to their short-term maturities. </div><ix:nonNumeric name="eprx:ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-13503"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The following table summarizes information regarding the classification and carrying values of the Company&#8217;s financial instruments measured at amortized cost: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 72%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets/liabilities</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15026">19,341,756</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15027">18,263,389</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Amounts receivable</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NontradeReceivablesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15028">190,612</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NontradeReceivablesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15029">89,715</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable and accrued liabilities</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:AccountsPayableAndAccruedLiability" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15030">3,921,875</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="eprx:AccountsPayableAndAccruedLiability" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15031">2,928,566</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Payable to Auritec</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:PayableTowardsRoyaltyAndOthersCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15032">5,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><ix:nonFraction name="eprx:PayableTowardsRoyaltyAndOthersCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-15033">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loans payable</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:OtherLongTermDebt" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15034">62,709</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:OtherLongTermDebt" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15035">142,127</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr></table> </ix:nonNumeric>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <ix:nonNumeric name="eprx:DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock" contextRef="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" escape="true" continuedAt="TextSelection_108159752" id="ixv-13615"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes information regarding the changes in fair value of liabilities measured at fair value, categorized as Level&#160;3: </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-33</ix:exclude> </div></ix:nonNumeric></ix:continuation> </div></div><ix:continuation id="TextSelection_108159752" continuedAt="TextSelectionAppend_108159752_1"><ix:continuation id="TextSelectionAppend_108159566_12" continuedAt="TextSelectionAppend_108159566_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159566_13" continuedAt="TextSelectionAppend_108159566_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_108159566_14" continuedAt="TextSelectionAppend_108159566_15"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_108159752_1" continuedAt="TextSelectionAppend_108159752_2"><ix:continuation id="TextSelectionAppend_108159566_15" continuedAt="TextSelectionAppend_108159566_16"><ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">FINANCIAL INSTRUMENTS (continued) </div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:exclude></ix:continuation> </ix:continuation><ix:continuation id="TextSelectionAppend_108159566_16"><ix:continuation id="TextSelectionAppend_108159752_2">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 82%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:82%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible&#160;Debt</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance &#8211; December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15037">7,507,755</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod" contextRef="P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15038">958,669</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod" contextRef="P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-15039">315,436</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-15040">1,056,165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign exchange</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss" contextRef="P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-15041">465,157</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance - December 31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15042">8,741,996</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod" contextRef="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15043">1,162,773</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod" contextRef="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-15044">591,170</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-15045">836,595</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign exchange</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss" contextRef="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15046">185,809</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance - December 31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15047">10,336,003</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:continuation> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">For the convertible debt, the key inputs that affect the ongoing valuation are the discount price, the share price and the share price volatility. </div> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-34 </div> </div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EUPRAXIA PHARMACEUTICALS INC.</div></div> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DECEMBER 31, 2023 and 2022 </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Expressed in U.S. Dollars, except share amounts) </div></div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <ix:nonNumeric name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-13842">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">INTEREST EXPENSE </div></div> </td> </tr> </table> <ix:nonNumeric name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-13851"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Interest expense is comprised of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:73%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Interest on SVB debt facility (Note 11)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15048">1,162,773</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15049">958,669</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other interest and accretion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:OtherInterestAndAccretionExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15050">7,400</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="eprx:OtherInterestAndAccretionExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15051">24,187</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15052">1,170,173</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15053">982,856</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-13960">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company paid interest of $<ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15054">598,046</ix:nonFraction> during the year ended December&#160;31, 2023 (2022 - $<ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15055">326,629</ix:nonFraction>). </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company received interest of $<ix:nonFraction name="us-gaap:ProceedsFromInterestReceived" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15056">912,033</ix:nonFraction> during the year ended December&#160;31, 2023 (2022 - $<ix:nonFraction name="us-gaap:ProceedsFromInterestReceived" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15057">394,188</ix:nonFraction>). </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company had the following significant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> transactions for the year ended December&#160;31, 2023: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify; line-height: normal;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P08_18_2023To08_18_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15058">99,061</ix:nonFraction> common shares (valued at $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P08_18_2023To08_18_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15059">511,678</ix:nonFraction>) were issued as part of the financing on August&#160;18, 2023, as a payment of finder&#8217;s fees (see Note <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">12</div>(b)(v)). </div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company had the following significant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> transactions for the year ended December&#160;31, 2022: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify; line-height: normal;"><ix:nonFraction name="eprx:NumberofWarrantsIssued" contextRef="P04_20_2022To04_20_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15060">500,538</ix:nonFraction> warrants (valued at $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P04_20_2022To04_20_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15061">160,147</ix:nonFraction>) were issued as part of the financing on April&#160;20, 2022, to the Underwriters (see<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;</div>Note&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">12</div>(b)(i)). </div> </td> </tr> </table> <ix:nonNumeric name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-13994"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">A detailed breakdown of cash and cash equivalents is as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15062">19,341,756</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15063">10,830,891</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-15064">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15065">7,432,498</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15066">19,341,756</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15067">18,263,389</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-14101">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">SUBSEQUENT EVENT </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On March&#160;15, 2024, the Company announced it had closed its previously announced overnight marketed public offering (the &#8220;Offering&#8221;) of common shares of the Company (the &#8220;Shares&#8221;). Pursuant to the Offering, Eupraxia issued <ix:nonFraction name="eprx:NumberOfUnitsIssued" contextRef="PAsOn03_15_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-15068">8,260,435</ix:nonFraction> Shares at a price of C$<ix:nonFraction name="eprx:SecuritiesIssuedPricePerUnit" contextRef="PAsOn03_15_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_CAD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-15069">4.10</ix:nonFraction> per Share for gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P03_15_2024To03_15_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15070">25,026,073</ix:nonFraction> (CDN$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P03_15_2024To03_15_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_CAD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-15071">33,867,784</ix:nonFraction><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">), which includes the issuance of</div> <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P03_15_2024To03_15_2024_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-15072">943,435</ix:nonFraction> Shares upon exercise of the over-allotment option. </div> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-35 </div> </div> </div> </div> </div> </div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>5
<FILENAME>d800041dex993.htm
<DESCRIPTION>EX-99.3 MANAGEMENT'S DISCUSSION & ANALYSIS
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3 Management's Discussion &amp;amp; Analysis</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.3 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g800041g0319193556635.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUPRAXIA PHARMACEUTICALS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">For the year ended December&nbsp;31, 2023 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND RESULTS OF OPERATIONS FOR THE YEAR ENDED DECEMBER&nbsp;31, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This management&#146;s discussion and analysis (&#147;<B>MD&amp;A</B>&#148;) has been prepared as of April 1, 2024 and should be read in
conjunction with the audited consolidated financial statements of Eupraxia Pharmaceuticals Inc. (&#147;<B>Eupraxia</B>&#148; or the &#147;<B>Company</B>&#148;) as at and for the year ended December&nbsp;31, 2023 and the related notes which are
prepared in accordance with generally accepted accounting principles in the United States of America (&#147;<B>U.S. GAAP</B>&#148;) as issued by the Financial Accounting Standards Board. All dollar amounts are expressed in U.S. dollars unless
otherwise noted. In this MD&amp;A, unless the context requires otherwise, references to &#147;we&#148; or &#147;our&#148; are references to Eupraxia. Additional information relating to the Company is available in our annual information form
(&#147;<B>AIF</B>&#148;), filed on SEDAR+ and EDGAR on April 1, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All regulatory filings
<FONT STYLE="white-space:nowrap">to-date</FONT> and communication from the Company have been made referencing <FONT STYLE="white-space:nowrap">EP-104IAR.</FONT> In the interest of greater clarity for investors, the Company will use <FONT
STYLE="white-space:nowrap">EP-104IAR</FONT> when referring to the product candidate that is intended for intra-articular (&#147;<B>IAR</B>&#148;) injections for indications such as osteoarthritis (&#147;<B>OA</B>&#148;), <FONT
STYLE="white-space:nowrap">EP-104GI</FONT> when referring to the product candidate that is intended for submucosal injections in the GI tract for indications such as eosinophilic esophagitis (&#147;<B>EoE</B>&#148;), and simply refer to the product
candidate as <FONT STYLE="white-space:nowrap">EP-104</FONT> in conjunction with topics that are related to both <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> and <FONT STYLE="white-space:nowrap">EP-104GI.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Change in Reporting Currency to the US Dollar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective December 31, 2023, the Company changed its reporting currency to the US dollar (&#147;USD&#148;) from the Canadian dollar
(&#147;CDN&#148;). As such, all prior amounts originally reported in CDN are now reported in USD. The change in reporting currency was made to enhance comparability of the Company&#146;s results with other publicly traded companies in the life
sciences industry. The Canadian dollar continues to be the functional currency of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with ASC 830, the
consolidated financial statements of the Company are translated into U.S. dollars using the current rate method. Assets and liabilities are translated at the rate of exchange prevailing at the consolidated balance sheet date. Shareholders&#146;
equity is translated at the applicable historical rate. Revenue, expense and cash flow items are translated at the exchange rate in effect on the transaction dates. Translation gains and losses are reported as a separate component of
shareholders&#146; equity titled Accumulated Other Comprehensive Income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The financial information for all prior periods is presented in
U.S. dollars as if the U.S. dollar had been used as the reporting currency during those periods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transition to U.S. GAAP </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This is the first year that the Company&#146;s consolidated financial statements are prepared in accordance with generally accepted accounting
principles in the United States of America as issued by the Financial Accounting Standards Board (&#147;<B>FASB</B>&#148;). Previously, the Company prepared its financial statements in accordance with IFRS Accounting Standards as issued by the
International Accounting Standards Board (&#147;IASB&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The policies set out in the Significant Accounting Policies section have
been applied in preparing the financial statements for the years ended December 31, 2023 and 2022. In addition, comparative figures, which were previously prepared in accordance with IFRS, have been adjusted as required to be compliant with the
Company&#146;s accounting policies under U.S. GAAP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain statements and information in this MD&amp;A contain forward-looking statements or forward-looking information under applicable
securities legislation that may not be based on historical fact, including, without limitation, statements containing the words &#147;may,&#148; &#147;might,&#148; &#147;will,&#148; &#147;likely,&#148; &#147;could,&#148; &#147;would,&#148;
&#147;should,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;objective,&#148; &#147;goal,&#148; &#147;outlook,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;project,&#148;
&#147;forecast,&#148; &#147;estimate,&#148; &#147;potential,&#148; &#147;target,&#148; &#147;seek,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;design,&#148; and &#147;ongoing,&#148; or the negative of these terms or other comparable
terminology, although not all forward-looking statements contain these words and similar expressions. Forward-looking statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are
not statements of fact. Such forward-looking statements are made as of the date of this MD&amp;A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Forward-looking statements are
necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as factors that we believe are appropriate. Forward-looking
statements in this MD&amp;A include, but are not limited to, statements relating to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s business strategies and objectives, including current and future plans, expectations and
intentions; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s intent to use capital resources previously identified for EP-104IAR to continue the
development of EP-104GI; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s intention to evaluate funding alternatives for the continued development of EP-104IAR,
including potential partnership opportunities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s ability to obtain sufficient funding for our operations, including funding for research,
development and commercial activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s projected operating expenses and capital expenditures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s ability to achieve profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">projected revenues, future trends, opportunities and growth in the Company&#146;s industry and the drug
development markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s ability to maintain and enhance its competitive advantages and technological advantages;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the entry into commercial partnerships and commercialization of our technology; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s ability to enter into definitive agreements with its contract research organizations
(&#147;<B>CROs</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s ability to enter into <FONT STYLE="white-space:nowrap">co-development</FONT> and/or
collaborative partnerships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s clinical development programs and activities and the estimated timing thereof;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, status and results of clinical trials, including with respect to patient recruitment and data
readout; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of regulatory submissions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the obtaining of potential regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the hiring of additional research and development team members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential for the Company&#146;s technology to impact the drug delivery process; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the development of additional intellectual property, ability to patent or otherwise protect such developed
intellectual property and licenses with third parties for intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of patents and notices of allowance to provide protection over intellectual property in applicable
jurisdictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s ability to protect, expand upon and exploit its existing intellectual property;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the entry into sponsored research agreements and the benefits therefrom; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the competitive advantages of the Company and its technology; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s product candidates and results gathered from studies thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the development of products from the Company&#146;s competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the application of regulations and standards to the Company&#146;s future products and services or research
and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s retention of funds or payment of dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the translation of the Company&#146;s technologies and expansion of its offerings into clinical applications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the benefits to patients from Eupraxia&#146;s platforms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the value of the strategic relationship to Eupraxia&#146;s clients and investors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s engagement with legal and regulatory authorities in various jurisdictions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s anticipated use of proceeds from the Offering (as defined herein) and its existing cash and
cash equivalents and the related estimated cash runway; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sufficiency of the Company&#146;s existing cash and cash equivalents to fund its future operating expenses
and capital expenditure requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s application for approval to list its common shares (the &#147;Common Shares&#148;) on the
Nasdaq Capital Market (the &#147;Nasdaq&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s ability to successfully refinance the Debt Agreement (as defined herein) with Silicon
Valley Bank (&#147;SVB&#148;) and SVB Innovation Credit Fund VIII, L.P.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the demand and commercial viability of the Company&#146;s technology; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the demand and market acceptance for products developed by the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Forward-looking statements and information involve significant risks, assumptions, uncertainties and other factors that may cause actual
future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements or information and, accordingly, should not be read as guarantees of future performance or results. These risks and factors
include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have a limited operating history and have no products approved for commercial sale, which may make it
difficult for you to evaluate our current business and predict our future success and viability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will require substantial additional financing to achieve our goals and a failure to obtain this necessary
capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are substantially dependent on the success of our lead product candidates
<FONT STYLE="white-space:nowrap">EP-104GI,</FONT> which is currently being studied in an open label Phase 1b/2a clinical study, and <FONT STYLE="white-space:nowrap">EP-104IAR,</FONT> for which we are evaluating funding alternatives for the continued
development, including potential partnership opportunities. If we are unable to complete development of, obtain approval for and commercialize <FONT STYLE="white-space:nowrap">EP-104GI</FONT> or EP-104IAR, alone or through a potential partnership,
in a timely manner, our business will be harmed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we breach any of the agreements under which we license rights to our product candidates or technology from
third parties, we could lose license rights that are important to our business. Our current license agreement may not provide an adequate remedy for its breach by the licensor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse developments affecting the financial services industry, such as actual events or concerns involving
liquidity, defaults, or <FONT STYLE="white-space:nowrap">non-performance</FONT> by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results
of operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials are expensive, time consuming and difficult to design and implement and may fail to
demonstrate adequate safety and efficacy of our product candidates. Furthermore, the results of previous preclinical studies and clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may
not satisfy the requirements of the U.S. Food and Drug Administration (the &#147;<B>FDA</B>&#148;) or comparable non-U.S. regulatory authorities or provide the basis for regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our lead product candidates may not be successful for their intended use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our current and future product candidates will require regulatory approval, which is costly, and we may not be
able to obtain it and we may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical trials of our product candidates may not demonstrate safety and efficacy to the satisfaction of
the FDA, European Medicine Agency (&#147;<B>EMA</B>&#148;) or other comparable foreign regulatory authorities or otherwise produce positive results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we completely rely on third parties to provide supplies and inputs required for our products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we rely on CROs to provide clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> research
services; if such CROs do not successfully carry out their contractual duties including to comply with applicable laws and regulations or meet expected deadlines, our business could be substantially harmed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in
production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties requires us to share our trade secrets, which increases the possibility that a
competitor or other third party will discover them or that our trade secrets will be misappropriated or disclosed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of preclinical testing and early clinical trials may not be predictive of the success of later
clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities. Terminating the development of any of our product candidates could materially harm our
business and the market price of our Common Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interim, initial, <FONT STYLE="white-space:nowrap">&#147;top-line&#148;,</FONT> and preliminary data from our
clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any safety concerns observed in any one of our clinical trials in our targeted indications could limit the
prospects for regulatory approval of our product candidates in those and other indications, which could seriously harm our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our current or future product candidates may cause significant adverse events, toxicities or other undesirable
side effects when used alone or in combination with other products that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative
consequences; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where appropriate and applicable, we may seek approval from the FDA or comparable foreign regulatory
authorities through the use of expedited approval pathways, such as Fast Track designation or orphan drug designation. Even if we receive Fast Track designation or other designation, we can provide no assurance that we will be able to obtain FDA
approval sooner or if at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we are unable to establish sales and marketing capabilities or enter into agreements with third parties to
market and sell our drug candidates, if approved, we may be unable to generate any product revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have a novel technology with uncertain market acceptance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials,
our clinical development activities could be delayed or otherwise adversely affected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in
locations outside of their jurisdiction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that
we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the market opportunity for any product candidate that we or our strategic partners develop is smaller than
we believe, our revenue may be adversely affected and our business may suffer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">even if our product candidates receive regulatory approval, we will be subject to significant post marketing
regulatory requirements and oversight; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA&#146;s and other regulatory authorities&#146; policies may change, and additional government regulations
may be enacted that could prevent, limit or delay regulatory approval of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of
off-label uses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions at the FDA and other government agencies caused by funding shortages or global health concerns
could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from
performing normal business functions on which the operation of our business may rely, which could negatively impact our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we rely on key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to successfully execute our business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are in a highly competitive industry which is continuously evolving with technological changes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our future success will depend on our ability to continually enhance and develop our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may expend our limited resources to pursue a particular product candidate or indication and fail to
capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in methods of product candidate manufacturing or formulation may result in additional costs or delay;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we are unable to differentiate <FONT STYLE="white-space:nowrap">EP-104</FONT> from existing therapies or if
the FDA or other applicable regulatory authorities approve additional, and potentially less costly, therapies that compete with <FONT STYLE="white-space:nowrap">EP-104,</FONT> our ability to successfully commercialize EP-104GI or <FONT
STYLE="white-space:nowrap">EP-104IAR</FONT> would be adversely affected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a variety of risks associated with potential international business relationships could materially adversely
affect our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaboration arrangements we may enter into in the future may not be successful; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions of our existing and any future debt instruments may restrict our ability to pursue our business
strategies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may acquire businesses or products, or form strategic alliances in the future, and we may not realize the
benefits of such acquisitions or alliances; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have traditionally relied on key collaborations and grants; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are subject to evolving global laws and regulations relating to privacy, data protection and information
security, which may require us to incur substantial compliance costs, and any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our business and operations could suffer in the event of an actual or perceived information security incident
such as a cybersecurity breach, system failure, or other compromise of our systems or those of a third-party or other contractor or vendor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may fail to manage our growth successfully, which may adversely impact our operating results;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we use hazardous chemicals and biological materials in our business. Any claims relating to improper handling,
storage or disposal of these materials could be time consuming and costly; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if product liability lawsuits are brought against us, then we may incur substantial liabilities and may be
required to limit commercialization of <FONT STYLE="white-space:nowrap">EP-104,</FONT> if approved, for any indication, and any other future products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our employees, independent contractors, principal investigators, consultants, commercial partners and vendors
may engage in misconduct or other improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading, which could significantly harm our business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to securities litigation, which is expensive and could divert management attention;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our directors and executive officers may be affiliated with other biotech companies and may have conflicts of
interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our business may be affected by macroeconomic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our business may be affected by global geopolitical risks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be responsible for corruption and anti-bribery law violations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are subject to foreign exchange risks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are subject to taxation risks and changing rules by different tax authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are subject to a number of risks and hazards and may not be sufficiently insured for all of them;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will devote significant resources to regulatory compliance as a public entity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in accounting standards from IFRS to U.S. GAAP can be difficult to predict and could adversely impact
how we record and report our financial condition and results of operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the past, we have had to restate our previously issued consolidated financial statements and as part of
that process identified a material weakness in our disclosure controls and procedures and internal control over financial reporting as of December 31, 2022. If we are unable to develop and maintain effective disclosure controls and procedures and
internal control over financial reporting, we may not be able to accurately report our financial results in a timely manner, which may adversely affect investor confidence in us and may adversely affect our business, financial condition and results
of operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our success depends on our ability to protect our intellectual property and our proprietary technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent
protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">intellectual property rights do not necessarily address all potential threats to our competitive advantage;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our patent rights may prove to be an inadequate barrier to competition; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercial success depends significantly on our ability to operate without infringing the patents and
other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be successful in obtaining or maintaining necessary rights to our product candidates through
acquisitions and in-licenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be involved in lawsuits to protect or enforce our patents or our future licensors&#146; patents, which
could be expensive, time consuming, and unsuccessful. Further, our issued patents or our current or future licensors&#146; patents could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or
abroad; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the
market price of our Common Shares to decline; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may
require us to cease using the related technology or to attempt to license rights from the prevailing party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or
expiration of a third-party patent, which might adversely affect our ability to develop and market our products and product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in U.S. patent law, or laws in other countries, or their interpretation could diminish the value of
patents in general, thereby impairing our ability to protect our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to claims challenging the inventorship or ownership of our patents, the patents we license,
and other intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent terms may be inadequate to protect our competitive position on our product candidates for an adequate
amount of time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to protect or enforce our intellectual property rights throughout the world;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining our patent protection depends on compliance with various procedural, documentary
submission, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if our trademarks and trade names are not adequately protected, then we may not be able to build name
recognition in our markets of interest and our business may be adversely affected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we are unable to protect the confidentiality of our trade secrets, the value of our technology could be
materially adversely affected, harming our business and competitive position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to claims that we or our employees, independent contractors, or consultants have wrongfully
used or disclosed alleged confidential information or trade secrets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our
employees, independent contractors, or consultants have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to claims challenging the inventorship of our patents and other intellectual property;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our rights to develop and commercialize our technology and product candidates may be subject, in part, to the
terms and conditions of any future licenses granted to us by others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to comply with our obligations in the agreements under which we license intellectual property
rights from third parties or otherwise experience disruptions to our business relationships with our future licensors, we could lose license rights that are important to our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patent protection and patent prosecution for some of our product candidates may be dependent on third
parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coverage and reimbursement may be limited or unavailable in certain market segments for our product
candidates, if approved, which could make it difficult for us to sell any product candidates or therapies profitably; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our relationships with healthcare providers and physicians and third-party payors will be subject to
applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs,
suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our research and development activities could be affected or delayed as a result of possible restrictions on
animal testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our
business and results of operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market price of the Common Shares may be volatile; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors may lose their entire investment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have no history of dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our existing executive officers and directors own a significant percentage of Common Shares and may have a
significant impact over matters submitted to our shareholders for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future sales of Common Shares by our existing shareholders could cause our share price to decline;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will need to raise additional financing in the future which may dilute our share capital;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if securities or industry analysts either do not publish research about us or publish inaccurate or
unfavorable research about us, our business or our market, or if they adversely change their recommendations regarding our Common Shares, the trading price or trading volume of our Common Shares could decline; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any issuance of preferred shares could make it difficult for another company to acquire us or could otherwise
adversely affect holders of our Common Shares, which could depress the price of our Common Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our constating documents permit us to issue an unlimited number of Common Shares without additional
shareholder approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">raising additional capital may cause dilution to our shareholders, restrict our operations or require us to
relinquish rights to our technologies or product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have warrants, convertible debt, and shares of a subsidiary exchangeable for Common Shares outstanding,
which in each case, if exercised, converted or exchanged, respectively, could cause dilution to existing shareholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Common Shares may have limited liquidity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[even if our Common Shares are approved for listing, we cannot assure you that an active market will develop
for Common Shares on the Nasdaq;] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">United States investors may not be able to obtain enforcement of civil liabilities against us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as a foreign private issuer, we are subject to different U.S. securities laws and rules than a domestic U.S.
issuer, which may limit the information publicly available to our U.S. shareholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may lose our foreign private issuer status in the future, which could result in significant additional
costs and expenses to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. holders of our Common Shares may suffer adverse tax consequences if we are characterized as a passive
foreign investment company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if a U.S. holder is treated as owning at least 10% of our Common Shares, such U.S. holder may be subject to
adverse U.S. federal income tax consequences. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Such statements reflect our current views with respect to future events,
are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Eupraxia as of the date of such statements, are inherently subject to significant medical, scientific,
business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may
be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this MD&amp;A, the Company has made various material assumptions, including but not limited to (i)&nbsp;the Company&#146;s ability to
attract and retain skilled staff;<B> </B>(ii)&nbsp;future research and development plans for the Company proceeding substantially as currently envisioned; (iii)&nbsp;industry growth trends, including with respect to projected and actual industry
sales; (iv)&nbsp;the Company&#146;s ability to obtain positive results from the Company&#146;s research and development activities, including clinical trials;<B> </B>(v)&nbsp;sufficient working capital and the Company&#146;s ability to control costs
and raise additional financing going forward;<B> </B>(vi)&nbsp;obtaining regulatory approvals and the potential benefits of our products, if approved; (vii)&nbsp;general business and economic conditions; (viii)&nbsp;the Company&#146;s ability to
achieve profitability; (ix)&nbsp;the Company&#146;s ability to successfully commercialize its current product candidates, enter into commercial partnerships and develop new products;<B> </B>(x)&nbsp;the availability of financing on reasonable
terms;<B> </B>(xi)&nbsp;market competition; (xii)&nbsp;the products and technology offered by the Company&#146;s competitors; (xiii)&nbsp;the Company&#146;s ability to protect patents and proprietary rights; and (xiv)&nbsp;the availability and cost
of personnel, materials and supplies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In evaluating forward-looking statements, current and prospective shareholders should specifically
consider various factors, including the risks outlined herein under the headings &#147;<I>Credit risk</I>&#148;, &#147;<I>Liquidity risk</I>&#148;, &#147;<I>Market risk</I>&#148;, <I>&#147;Other price risk&#148;,</I> <I>&#147;Interest rate
risk&#148;</I> and &#147;<I>Currency risk</I>&#148; and under the heading &#147;<I>Risk Factors</I>&#148; in the short form base shelf prospectus dated February 5, 2024 (the &#147;<B>Shelf Prospectus</B>&#148;) and the AIF. Should one or more of
these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These
forward-looking statements are made as of the date of this MD&amp;A and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject.
These statements are based upon information available to us as of the date of this report, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements
should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview of the Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a
clinical-stage biotechnology company seeking to leverage our proprietary Diffusphere<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology to optimize drug delivery for applications with significant unmet medical need. Each of our
product candidates are designed to improve patient benefit by providing more prolonged activity than currently available treatments, combined with an improved pharmacokinetics (&#147;<B>PK</B>&#148;) and related safety profile and precisely targeted
local delivery. We believe a product with this profile could offer the dual potential of providing long-lasting treatment while minimizing tolerability complications in target and <FONT STYLE="white-space:nowrap">non-target</FONT> tissues. Our
strategy is to develop a portfolio of product candidates based on this delivery technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently have two distinct clinical
development programs, one targeting eosinophilic esophagitis (&#147;<B>EoE</B>&#148;) and the second targeting chronic osteoarthritis (&#147;<B>OA</B>&#148;) pain in the knee. Currently, both programs are broadly based upon the same drug candidate <FONT
STYLE="white-space:nowrap">(EP-104).</FONT> The injectable drug is dispensed together with a &#147;vehicle&#148; diluent specifically designed for the target delivery modality and <FONT STYLE="white-space:nowrap">co-administered</FONT> with the
active pharmaceutical ingredient (&#147;<B>API</B>&#148;). For our ongoing clinical studies we are using the same underlying API and extended-release formulation. In the future, we anticipate that therapeutic targets will be differentiated by dosing
levels, vehicle and delivery methods and will be distinct product candidates. The product candidate that is being developed specifically for submucosal injections in the GI tract with an initial indication of EoE is referred to as <FONT
STYLE="white-space:nowrap">EP-104GI,</FONT> and the product candidate that is being developed for intra-articular (&#147;<B>IA</B>&#148;) injections with an initial indication of knee OA is referred to as
<FONT STYLE="white-space:nowrap">EP-104IAR.</FONT> <FONT STYLE="white-space:nowrap">EP-104</FONT> is intended to refer to the extended-release Diffusphere technology, which is used in the formulation of both
<FONT STYLE="white-space:nowrap">EP-104GI</FONT> and <FONT STYLE="white-space:nowrap">EP-104IAR.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have successfully completed a
Phase 2b trial with <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> in knee OA, and in January 2024 held a meeting with the FDA to determine the preclinical and clinical requirements for an NDA submission and approval in the United States. We
believe that the future success of the product will be dependent on late phase development and commercialization expertise, and will require significant resources. We are currently evaluating funding alternatives for the continued development of <FONT
STYLE="white-space:nowrap">EP-104IAR,</FONT> including potential partnership opportunities and intend to modulate investment levels pending the outcomes. We intend to undertake certain preclinical and manufacturing activities as well as Phase 3
planning and preparation related to <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> to ensure continuity of the project, but we intend to wait until we have funding needs further sorted before committing to additional significant spend for this
program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are currently conducting a Phase 1b/2a clinical trial with <FONT STYLE="white-space:nowrap">EP-104GI.</FONT> We intend to
continue development of <FONT STYLE="white-space:nowrap">EP-104GI</FONT> through the ongoing clinical trial and any subsequent trials required by the FDA to obtain commercial approval. We intend to evaluate the possibility of identifying a corporate
partner to help with the development of <FONT STYLE="white-space:nowrap">EP-104GI.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">EP-104</FONT> (Long-Acting
Fluticasone Propionate Injectable Suspension) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The primary active ingredient of the <FONT STYLE="white-space:nowrap">EP-104</FONT>
product candidates consists of a solid core of fluticasone propionate (&#147;<B>FP</B>&#148;) coated with an outer layer of polyvinyl alcohol (&#147;<B>PVA</B>&#148;). FP is a synthetic trifluorinated corticosteroid with potent anti-inflammatory
activity and a well-established systemic safety record in the form of widely used inhaled, intranasal, and topical agents. It has been shown to be locally active, and FP that is systemically absorbed is rapidly metabolized. Relative to other
corticosteroids (including triamcinolone acetonide or &#147;<B>TCA</B>&#148;), FP has a high affinity for the glucocorticoid receptor, low solubility, a low rate of dissociation, and a comparatively long half-life. It is currently approved by the
FDA, Health Canada, European Medicines Agency and many other regulatory agencies around the world. PVA is a biocompatible polymer with numerous biomedical applications and a <FONT STYLE="white-space:nowrap">30-year</FONT> safety record in various
human tissues. We believe these characteristics make <FONT STYLE="white-space:nowrap">EP-104</FONT> a promising candidate for prolonged anti-inflammatory use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">EP-104</FONT> technology is designed to work through the diffusion of the drug particles through a
microns-thin polymer membrane. When the particles are injected at the disease site, extracellular fluid diffuses across the polymer membrane </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and into the particles themselves, dissolving some of the solid drug core and creating a saturated drug solution inside the microsphere with relatively low drug concentrations in the outside
microenvironment. Steady-state diffusion of FP across the polymer membrane and into the extracellular space then delivers the drug candidate to the intended area at a prolonged and steady release rate with close to constant drug levels. This rate
can be controlled by changing the size of the drug core and the properties of the polymer membrane, creating a target drug release profile designed to maximize disease treatment and reduce systemic and local side effects often accompanying drugs
having conventional release profiles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Another key feature differentiating <FONT STYLE="white-space:nowrap">EP-104</FONT> from other
extended-release IA corticosteroid formulations is that more than 90% by weight of <FONT STYLE="white-space:nowrap">EP-104</FONT> is the active FP component in the investigational drug product, compared to less than 20% in other polymer based
extended-release products using degradation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">FP, although approved by the FDA, Health Canada, EMA and other regulatory agencies, is not
currently approved for use in any formulation for the treatment of symptoms in either EoE or OA. To our knowledge, <FONT STYLE="white-space:nowrap">EP-104GI</FONT> and <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> are the only extended-release
formulations of FP in development for these conditions. We believe that the <FONT STYLE="white-space:nowrap">EP-104</FONT> drug delivery technology platform has the potential to have a beneficial application for EoE, given the already-established
efficacy of oral immediate release of FP in this indication. The drug delivery technology platform also has the potential to be an effective treatment for OA based on the proven efficacy of other corticosteroids for this condition. The potential for
an improved treatment of EoE and OA with our proprietary formulations of <FONT STYLE="white-space:nowrap">EP-104</FONT> is further supported by a continually expanding library of data supporting the value of extended-release steroids. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">EP-104GI</FONT> for Eosinophilic Esophagitis (EoE) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">EP-104</FONT> is being developed for the treatment of EoE, a rare immune-mediated disease recognized by the
U.S. National Organization for Rare Disorders. Adaptations to the original formulation of <FONT STYLE="white-space:nowrap">EP-104</FONT> will result in the creation of <FONT STYLE="white-space:nowrap">EP-104GI</FONT> for this specific indication,
including modifications to the carrier vehicle and dose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">EoE is characterized by inflammation and the accumulation of large numbers of
eosinophils (a type of white blood cells) within the epithelial lining of the esophagus. In adults, EoE leads to dysphagia and food impaction. In children, it often presents with irritability, nausea and vomiting. Patients with EoE frequently
develop esophageal strictures, a narrowing or tightening of the esophagus, accompanied by proliferations of fibrotic tissue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Development of <FONT
STYLE="white-space:nowrap">EP-104GI</FONT> for EoE </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Manufacturing </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">EP-104</FONT> consists of a vial of <FONT STYLE="white-space:nowrap">EP-104</FONT> powder and a separate vial
of liquid (referred to as the &#147;<B>Vehicle</B>&#148;). Before injection, the Vehicle is mixed with the dry powder to suspend the <FONT STYLE="white-space:nowrap">EP-104</FONT> particles; this enables the
<FONT STYLE="white-space:nowrap">EP-104</FONT> powder to be injected into the patient. In an ongoing stability study, the powder has proven stable for 48 months when stored at room temperature. Batches of
<FONT STYLE="white-space:nowrap">EP-104</FONT> are currently manufactured at the projected initial batch scale required for launch. We expect to use the same coated and cured FP particles from our <FONT STYLE="white-space:nowrap">EP-104IAR</FONT>
program for <FONT STYLE="white-space:nowrap">EP-104GI.</FONT> However, we anticipate refinements to both the dose and vehicle to optimize patient outcomes in EoE. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Clinical Studies </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We commenced dosing
patients in the second quarter of 2023 for an open label Phase 1b/2a clinical study (RESOLVE) using <FONT STYLE="white-space:nowrap">EP-104GI</FONT> in EoE. The RESOLVE study will be conducted in up to 24 adult patients with a confirmed diagnosis
and active EoE symptoms. Primary outcomes for safety, PK and efficacy will be collected at various points over a <FONT STYLE="white-space:nowrap">12-week</FONT> total period, with a subsequent follow up at six (6)&nbsp;months. Initial <FONT
STYLE="white-space:nowrap">low-dose</FONT> cohorts presented early signals of efficacy, and we anticipate ongoing safety, efficacy and PK readouts from subsequent dose-escalation cohorts throughout 2024. The RESOLVE protocol is active at sites in
Canada, the Netherlands and Australia. Additional sites and jurisdictions will be added as necessary to complete target recruitment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subsequent steps in the research program will be determined following analysis of results as well as interaction with key opinion leaders and
regulatory authorities. To seek marketing approval for <FONT STYLE="white-space:nowrap">EP-104GI,</FONT> we expect to carry out at least one Phase 3 study assessing both efficacy (reduced eosinophils and improved symptoms) and safety of <FONT
STYLE="white-space:nowrap">EP-104GI</FONT> in this indication. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">EP-104IAR</FONT> for Osteoarthritis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">OA is a chronic progressive disease characterized by deterioration of joint cartilage and inflammation, which results in pain and stiffness,
usually in the morning or after a period of inactivity; and loss of joint function which limits daily activities. In normal joints, cartilage acts as a cushion between bones and provides a smooth gliding surface for movement. In OA, the inflammatory
processes integral to disease progression damages the cartilage, and over time cartilage wears away, causing bone to rub directly against bone resulting in joint damage, severe pain and disability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Globally, OA is a leading cause of disability in older adults. Estimates of prevalence and incidence vary according to the definition of OA
used (i.e., radiographic <FONT STYLE="white-space:nowrap">(X-Ray)</FONT> versus symptomatic) and the joints assessed. The global prevalence of knee OA is estimated at approximately 23% in adults over the age of 40. According to a report by the
Centers for Disease Control and Prevention, OA is estimated to affect more than 32.5&nbsp;million adults in the United States alone. A 2018 report estimated there were 14&nbsp;million people with symptomatic knee OA. OA is also often associated with
depression and loss of sleep which can greatly affect quality of life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Current evidence-based OA treatment guidelines aim to manage signs
and symptoms, with the goal of slowing progression if possible. Recommended pharmacological interventions include topical and oral <FONT STYLE="white-space:nowrap">non-steroidal</FONT> anti-inflammatory drugs, and IA corticosteroids. IA
corticosteroid injections have been used for decades to manage pain and stiffness associated with inflammation in knee OA and have been approved by regulatory authorities as safe and effective. However, IA corticosteroid injections often result in
suboptimal patient outcomes because of their short duration of activity and systemic side effects such as flushing, glucose alterations and cortisol suppression due to the high peak exposures required to maintain efficacious concentrations for
prolonged durations. Evidence is also emerging regarding the risk of adverse joint findings and/or OA progression following frequent/repeated immediate release IA corticosteroid injections. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Development of <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Manufacturing </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT
STYLE="white-space:nowrap">EP-104</FONT> consists of a vial of <FONT STYLE="white-space:nowrap">EP-104</FONT> powder and the Vehicle. Before injection, the Vehicle is mixed with the dry powder to suspend the
<FONT STYLE="white-space:nowrap">EP-104</FONT> particles; this enables the <FONT STYLE="white-space:nowrap">EP-104</FONT> powder to be injected into the patient&#146;s knee. In an ongoing stability study, the powder has proven stable for 48 months
when stored at room temperature. Batches of <FONT STYLE="white-space:nowrap">EP-104</FONT> are currently manufactured at the projected initial batch scale required for launch. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">Non-clinical</FONT> Studies </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have completed multiple <FONT STYLE="white-space:nowrap">non-clinical</FONT> investigations with
<FONT STYLE="white-space:nowrap">EP-104,</FONT> including a large <FONT STYLE="white-space:nowrap">IND-enabling</FONT> <FONT STYLE="white-space:nowrap">non-clinical</FONT> study in dogs. <FONT STYLE="white-space:nowrap">Non-clinical</FONT> data have
indicated that after a single high-dose IA injection of <FONT STYLE="white-space:nowrap">EP-104</FONT> to the knees of dogs, FP was released locally for greater than ten months with moderate exposure in the plasma. There was no evidence of cartilage
damage in dogs over the <FONT STYLE="white-space:nowrap">ten-month</FONT> <FONT STYLE="white-space:nowrap">follow-up</FONT> period at any administered doses. In this study, a low dose of <FONT STYLE="white-space:nowrap">EP-104</FONT> released FP
locally for longer than eight months with minimal systemic exposure. This dose was used to justify the dose selection in our Phase 2 clinical trial. Both U.S. and European competent authorities have reviewed our
<FONT STYLE="white-space:nowrap">non-clinical</FONT> safety data and deemed this information suitable to support clinical research studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Several <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies are underway to support the Phase 3 and registration program. These
activities include safety and biocompatibility evaluations of <FONT STYLE="white-space:nowrap">EP-104</FONT> excipients as well as <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies to provide information needed to support the continued
clinical investigation of <FONT STYLE="white-space:nowrap">EP-104</FONT> product candidates in humans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Clinical Studies </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">EP-104IAR</FONT> has been evaluated in two clinical studies in OA patients. The first clinical study was a
Phase 1, double-blind, placebo-controlled clinical study (protocol <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">EP-104-101)</FONT></FONT> to assess safety, PK and preliminary efficacy in 32 knee OA patients at three sites in
Canada. The single 15 mg dose was generally well tolerated and showed predictable PK. The study was not powered to detect efficacy; however, patient-reported outcome measures were collected and analyzed to evaluate pain and symptom relief. Despite
the limitations of this study (small size, low dose, significant underdosing in nine subjects, and high placebo response), we believe it provides promising tolerability and PK data and preliminary clinical activity data that support future
development of <FONT STYLE="white-space:nowrap">EP-104IAR.</FONT> Results of the study have been published in <I>Osteoarthritis and Cartilage Open</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The second clinical study was SPRINGBOARD &#150; a Phase 2, double-blind, placebo-controlled clinical study (protocol <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">EP-104IAR-201)</FONT></FONT> that assessed the efficacy, safety and PK of a single 25 mg dose of <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> in 318 patients with moderate knee OA. The
trial was conducted at 12 sites in Denmark, Poland and Czech Republic, with the last patient visit announced on May&nbsp;25, 2023. <FONT STYLE="white-space:nowrap">Top-line</FONT> data readout was announced on June&nbsp;26, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">EP-104IAR-201</FONT></FONT> met its primary endpoint with a clinically
meaningful and statistically significant (p=0.004) improvement over vehicle-placebo in Western Ontario and McMaster Universities Osteoarthritis (&#147;<B>WOMAC</B>&#148;) Pain at 12 weeks in the Intent to Treat population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">EP-104IAR-201</FONT></FONT> also showed statistically significant
improvement over placebo at 12 weeks in three of four secondary endpoints: WOMAC Function (p=0.014), OMERACT-OARSI strict responders (p=0.011) and Area Under the Curve (&#147;AUC&#148;) for WOMAC Pain (p&lt;0.001).&nbsp;Importantly, statistical
significance with OMERACT-OARSI strict responders to 15 weeks and AUC for WOMAC Pain to 24 weeks was also seen in the Phase 2b study, highlighting a strong and durable response. The secondary endpoint of the difference in change from baseline in the
WOMAC Pain subscale at 24 weeks was not met, delivering statistical significance to 14 weeks.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also performed <FONT
STYLE="white-space:nowrap">pre-specified</FONT> analyses in the moderate <FONT STYLE="white-space:nowrap">sub-population</FONT> which comprised 68% of the study population (n=214). Statistically significant efficacy was seen for WOMAC Pain (17
weeks) and OMERACT-OARSI strict responders (22 weeks). Additionally, 40% of moderate patients achieved near complete pain relief (WOMAC Pain score of &#8804;2) which was statistically significant for 22 weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">EP-104IAR</FONT> was well tolerated, with adverse events similar to placebo, and no withdrawals due to drug
side effects. Changes in cortisol were minimal and transient and there were no differences in blood glucose levels between treatment groups, including diabetics. We believe these safety data and the observed pharmacokinetic profile support our goal
of developing a product that can be used for repeat and bilateral dosing, and in certain <FONT STYLE="white-space:nowrap">at-risk</FONT> populations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In parallel to the main study, Magnetic Resonance Imaging (&#147;<B>MRI</B>&#148;), with macrocyclic gadolinium-based contrast agent, was
obtained from participating patients who received <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> (n=6) or placebo (n=6). Scans were performed at baseline and weeks 12, 24 and 52 (or on early exit). The data obtained in the MRI <FONT
STYLE="white-space:nowrap">sub-study</FONT> demonstrated the following results: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Treatment with <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> resulted in a decrease in inflammation at
weeks 12 and 24 when compared to placebo.&nbsp;The two groups were similar at one year as the clinical effect of the single <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> injection had waned by one year. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A correlation between reduction in inflammation and a reduction in WOMAC Pain scores was observed.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A trend of equivalent or improved T2 relaxation times was observed in the
<FONT STYLE="white-space:nowrap">EP-104IAR</FONT> treated group compared to the placebo group at 12 weeks and that trend held steady, or improved, at 24 weeks and 52 weeks. These data suggest a trend of potential improvement in cartilage quality and
morphology in the treated group. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Regulatory </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We participated in a <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting with the FDA regarding the OA program before submission and
subsequent clearance of an IND, allowing evaluation of the product candidate under the SPRINGBOARD Phase 2 OA protocol. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2023, <FONT
STYLE="white-space:nowrap">EP-104IAR</FONT> received Fast Track designation from the FDA. The Fast Track process is designed to facilitate and potentially expedite the development review of drugs to treat serious conditions and fill an unmet medical
need. The designation recognizes both the seriousness of knee OA pain and the potential for <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> to fill the need for extended-release pain relief for this indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe our planned development pathway for <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> is supported by several key factors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">following our recent
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">End-of-Phase</FONT></FONT> 2 meeting with the FDA in January 2024, we believe we have alignment on the required endpoints for our Phase 3 clinical trials in order to support an NDA
submission; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an open Investigational New Drug (IND) application with the FDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an abbreviated New Drug Application (NDA) regulatory pathway under the FDCA, Section&nbsp;505(b)(2);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA Fast Track designation, recognizing the potential of <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> to
meet an unmet medical need in a serious condition such as OA pain; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corticosteroid (FP) with a well-established record of clinical use that supports anti-inflammatory effects,
and a well-characterized systemic tolerability profile; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no evidence of cartilage damage at the therapeutic concentrations intended for humans in the <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> preclinical study; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preliminary evidence of rapid and extended pain reduction versus placebo in both Phase 1 and Phase 2 clinical
trials. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">End-of-Phase-2</FONT></FONT></FONT> Meeting with FDA
for <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2024, we engaged with the FDA in an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">End-of-Phase-2</FONT></FONT></FONT> meeting to discuss results from the SPRINGBOARD study and to discuss planned clinical and
<FONT STYLE="white-space:nowrap">non-clinical</FONT> activities to support a New Drug Application (&#147;<B>NDA</B>&#148;) for <FONT STYLE="white-space:nowrap">EP-104IAR.</FONT> Based on these interactions, we believe that the following clinical
trials will be required in support of a future NDA submission for <FONT STYLE="white-space:nowrap">EP-104IAR:</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PROMENADE 1&nbsp;&#150; A Phase 3 trial in approximately 740 knee OA patients to confirm the safety and
efficacy of a single dose of <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> for six months post-dose. We anticipate that a subset of patients will be followed for one year. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PROMENADE 2&nbsp;&#150; A Phase 3 trial in approximately 300 patients to evaluate the safety and durability of
response after a second dose of <FONT STYLE="white-space:nowrap">EP-104IAR.</FONT> We anticipate that the trial will be run in parallel with PROMENADE 1 and patients will be followed for a maximum of nine months after the second injection.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A Phase 1 study carried out in approximately 30 patients comparing the&nbsp;pharmacokinetics of <FONT
STYLE="white-space:nowrap">EP-104IAR</FONT> and Flovent<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP><SUP STYLE="font-size:75%; vertical-align:top"> </SUP>HFA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the anticipated clinical trials described above, we anticipate that we or a potential partner would need to conduct additional <FONT
STYLE="white-space:nowrap">non-clinical</FONT> work to support repeat dosing of <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> and the characterization of PVA <FONT STYLE="white-space:nowrap">in-line</FONT> with the FDA&#146;s feedback. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We anticipate that we or a potential partner would submit the NDA for <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> under
Section&nbsp;505(b)(2) of the FDCA to obtain FDA approval, which is required before marketing a new drug in the United States. A 505(b)(2) NDA would rely in part on <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials
conducted by us or a potential partner, and in part on the FDA&#146;s prior findings of safety and efficacy for the active ingredient for which we do not have a right of reference or which have been established in the scientific literature in the
public domain. We intend to, either alone or with a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
partner, pursue marketing approval and commercialization of <FONT STYLE="white-space:nowrap">EP-104</FONT> in the United States and additional <FONT STYLE="white-space:nowrap">ex-U.S.</FONT>
geographies along with the potential partner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Lifecycle Opportunities for <FONT STYLE="white-space:nowrap">EP-104</FONT> Products </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Corticosteroids are broadly used for various indications that may benefit from a targeted delivery and extended-release profile with minimal
side effects. Natural lifecycle extensions for <FONT STYLE="white-space:nowrap">EP-104</FONT> products could include other joints affected by OA, other inflammatory arthropathies, or other inflammatory conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eupraxia Business Strategy </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our focus
over the 24 months following the date of this MD&amp;A will be the execution of the <FONT STYLE="white-space:nowrap">EP-104</FONT> development programs, including: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">EP-104GI</FONT> Program: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continued dose escalation and completed enrollment of the Phase 1b/2a RESOLVE clinical study to evaluate the
safety and effectiveness of <FONT STYLE="white-space:nowrap">EP-104GI</FONT> in EoE; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Engage with the FDA in a <FONT STYLE="white-space:nowrap">Pre-IND</FONT> meeting to discuss clinical and <FONT
STYLE="white-space:nowrap">non-clinical</FONT> topics related to the development program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Manufacture material to support <FONT STYLE="white-space:nowrap">EP-104GI</FONT> clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Following feedback from the FDA, initiate Phase 1b/2a clinical study to evaluate the safety and effectiveness
in <FONT STYLE="white-space:nowrap">EP-104GI</FONT> preventing the recurrence of benign strictures; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Initiate a Phase 2 / 3 trial to demonstrate the effectiveness and safety of
<FONT STYLE="white-space:nowrap">EP-104GI</FONT> in EoE. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">EP-104IAR</FONT> Program:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Complete <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies to support NDA filing that would enhance
the <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> label and evaluate the safety and biocompatibility of all excipients; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Further development of the <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> program would be determined in
conjunction with additional funding opportunities including a potential collaboration partner. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continue to strengthen the IP portfolio around the <FONT STYLE="white-space:nowrap">EP-104</FONT> technology;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continue to evaluate portfolio options for <FONT STYLE="white-space:nowrap">EP-104</FONT> and the Diffusphere
technology platform; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continued development of the manufacturing process to support both programs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Where appropriate, we may use strategic collaborations or partnerships to accelerate development and maximize the commercial potential of our
development programs. In parallel, we intend to seek out licencing, <FONT STYLE="white-space:nowrap">co-development</FONT> or marketing partners for its technology, with the potential to expand and exploit its application fully. It is our intention
to put in place conditions and resources, including the potential use of licensing partnerships, that support the success of the development program, marketing authorization(s) and commercialization across multiple jurisdictions, as well as
exploitation of any opportunities for lifecycle and patent extension. Depending on market conditions, this may take </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the form of <FONT STYLE="white-space:nowrap">co-development</FONT> or commercialization partnerships, transactional opportunities and/or public financing options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pipeline programs are another area of potential growth in the next 24 months. Our technology is potentially compatible with various drugs and
therapeutic indications. The pipeline strategy focuses on modulating the release of existing drugs to achieve better clinical outcomes in areas of high medical need. The technology has the potential to be particularly suitable for diseases requiring
precisely targeted and controlled localized therapy where broader tissue or systemic exposure should be avoided (e.g., tumour oncology). We have previously investigated indications involving post-surgical pain
<FONT STYLE="white-space:nowrap">(EP-105)</FONT> and post-surgical site infections <FONT STYLE="white-space:nowrap">(EP-201).</FONT> While both programs demonstrated preclinical evidence of supporting our technology, these programs are currently
paused so we can remain focused on the other programs described previously in this MD&amp;A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently have several pipeline
candidates in development with a goal to add a pipeline product candidate over the next 24 months to allow for sustained corporate growth. We expect this to involve a multidisciplinary review of candidate drugs, formulation development, <I>in
vitro</I> screening to identify the most promising lead candidates and <FONT STYLE="white-space:nowrap">non-clinical</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> studies. Information
generated from these inquiries will determine whether we should proceed with further development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Significant Company Events </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On May&nbsp;18, 2023, the Company announced the appointment of Dr.&nbsp;Mark Kowalski to the role of Chief Medical Officer. This new position
reports directly to the Chief Executive Officer (&#147;<B>CEO</B>&#148;) and is responsible for advancing clinical trials and pipeline development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On June&nbsp;8, 2023, the Company announced the dosing of the first patient in an open label Phase 1b/2a clinical study (RESOLVE) using <FONT
STYLE="white-space:nowrap">EP-104GI</FONT> in EoE. The RESOLVE study will be conducted in up to 24 adult patients with a confirmed diagnosis and active EoE symptoms. Primary outcomes for safety, PK and efficacy will be collected at various points
over a 12-week total period, with a subsequent follow up at six (6) months. Initial low-dose cohorts presented early signals of efficacy, and we anticipate ongoing safety, efficacy and PK readouts from subsequent dose-escalation cohorts throughout
2024. The RESOLVE protocol is active at sites in Canada, the Netherlands and Australia. Additional sites and jurisdictions will be added as necessary to complete target recruitment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On June&nbsp;13, 2023, the Company announced that it had received U.S. Fast Track designation for
<FONT STYLE="white-space:nowrap">EP-104IAR</FONT> in the treatment of OA. This process is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On June&nbsp;22, 2023, the Company filed and obtained a receipt for a final short form base shelf prospectus (the &#147;<B>2023 Shelf
Prospectus</B>&#148;). The 2023 Shelf Prospectus replaced the Company&#146;s existing shelf prospectus filed in January 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On
June&nbsp;26, 2023, the Company announced positive results from its Phase 2b clinical trial of <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> for pain associated with knee OA. <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> met its primary
endpoint with a clinically meaningful and statistically significant (p=0.004) improvement over vehicle-placebo in WOMAC Pain at 12 weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On August&nbsp;18, 2023, the Company announced the closing of a <FONT STYLE="white-space:nowrap">non-brokered</FONT> private placement. The
Company issued 3,183,875 Common Shares at a price of CDN$7.00 per share for gross proceeds of CDN$22,287,125. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On September&nbsp;7, 2023,
the Company announced the appointment of KPMG LLP as the auditor of the Company, effective August&nbsp;30, 2023. Concurrently, Baker Tilly WM, LLP resigned as the Company&#146;s auditor. There were no reportable events involving Baker Tilly WM, LLP.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On October&nbsp;11, 2023, the Company announced the initiation of a second cohort in its Phase 1b/2a clinical trial in EoE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On December&nbsp;12, 2023 the Company announced positive clinical data in its <FONT STYLE="white-space:nowrap">EP-104GI</FONT> RESOLVE trial.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On January&nbsp;30, 2024 the Company announced positive data from a MRI exploratory <FONT STYLE="white-space:nowrap">sub-study</FONT> in
its Phase 2 SPRINGBOARD trial evaluating the safety and efficacy of <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> for the treatment of osteoarthritis of the knee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February&nbsp;1, 2024 the Company announced summary results from the End-of-Phase 2
meeting with the FDA and the initiation of the Phase 3 Development program for <FONT STYLE="white-space:nowrap">EP-104IAR.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On
February&nbsp;5, 2024 the Company announced updated positive clinical trial data in its <FONT STYLE="white-space:nowrap">EP-104GI</FONT> RESOLVE trial for the treatment of Eosinophilic Esophagitis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February 5, 2024, the Company filed and obtained a receipt for a final short form base shelf prospectus (the &#147;<B>Shelf
Prospectus</B>&#148;). The Shelf Prospectus replaced the Company&#146;s 2023 Shelf Prospectus filed in June 2023. The Shelf Prospectus will allow the Company and certain of its securityholders to qualify the distribution of up to US$200 million of
Common Shares, preferred shares, debt securities, warrants, subscription receipts, and units, or any combination thereof during the 25-month period that the Shelf Prospectus is effective, in amounts, at prices and on terms based on market conditions
at the time of any offering, and set forth in an accompanying shelf prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;15, 2024 the Company announced
the closing of an overnight marketed offering of Common Shares. The Company issued 8,260,435 Common Shares at a price of CDN$4.10 per Common Share for gross proceeds of CDN$33,867,784, which included the issuance of 943,435 Common Shares upon
exercise of the over-allotment option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selected Financial Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The financial information reported herein for the years ended December 31, 2023 and 2022 has been derived from the audited consolidated
financial statements for the period ended December&nbsp;31, 2023 prepared in accordance with U.S. GAAP. Effective December&nbsp;31, 2023, the Company changed its reporting currency to the U.S. dollar from the Canadian dollar. As such, all prior
amounts originally reported in CDN are now reported in USD. The change in reporting currency was made to enhance comparability of the Company&#146;s results with other publicly traded companies in the life sciences industry. The Company has retained
the Canadian dollar as its functional currency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The financial information reported herein for the year ended December 31, 2021 has been
derived from the audited amended and restated consolidated financial statements for the period ended December 31, 2022, prepared in accordance with IFRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Selected Consolidated Statement of Financial Position Data </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,&#8194;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2023&#8194;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,&#8194;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022&#8194;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,&#8194;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(As<BR>Converted)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,&#8194;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:10pt ;BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:10pt ;BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:10pt ;BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:10pt ;BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>CDN$</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">19,341,756&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">18,263,389&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">16,478,994&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000">20,892,069&#8194;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">20,266,229&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">19,122,249&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">24,626,966&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000">31,222,067&#8194;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">non-current</FONT>
financial liabilities</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">8,856,008&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">7,758,536&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000">9,836,272&#8194;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Equity attributable to owners of the Company</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2,216,207&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">7,786,525&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">15,737,374&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000">19,951,843&#8194;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT>
interest</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">(1,323,881)&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">(578,671)&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">(657,703)&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000">(833,836)&#8194;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:6pt ;BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1.50pt solid #000000">892,326&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1.50pt solid #000000">7,207,854&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1.50pt solid #000000">15,079,671&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">19,118,007&#8194;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents amounts previously reported in our Audited Amended and Restated Consolidated Financial Statements
for the years ended December&nbsp;31, 2022 and 2021. These financial statements were prepared under IFRS and presented in CDN dollars and have been converted to USD at the Bank of Canada spot rate as of 31 December 2021 (1USD = 1.2678). The
converted figures are unaudited. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Amounts previously reported in our Audited Amended and Restated Consolidated Financial Statements for the
years ended December&nbsp;31, 2022 and 2021. These financial statements were prepared under IFRS and presented in CDN dollars. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash and cash equivalents increased by $1,078,367 to $19,341,756 as at December&nbsp;31, 2023. This increase was attributable primarily to the
net Private Placement financing of $15,886,537 and redemption of warrants of $5,241,811 offset by the net loss of $28,966,006 less items not affecting cash of $3,006,936. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total assets increased by $1,143,978 to $20,266,227 as at December&nbsp;31, 2023. This increase was primarily due to the increase in cash and
cash equivalents referenced above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total <FONT STYLE="white-space:nowrap">non-current</FONT> financial liabilities decreased by
$8,856,008 to $nil as at December&nbsp;31, 2023. This decrease was primarily attributable to the reclassification of the SVB debt facility being reclassified as a current liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company did not pay any dividends or make any distributions to shareholders in any of the above periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>S</I><I>elected Consolidated Statements of Operations and Comprehensive Loss Data</I>
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Year Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;December&nbsp;31,&#8195;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2023</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Year Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;December&nbsp;31,&#8195;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2021<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP><BR>(As&nbsp;Converted)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Year&nbsp;Ended<BR>December&nbsp;31,&#8195;<BR>2021<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1.50pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1.50pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1.50pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt"><B>CDN$</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000">-&#8195;&#8195;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Loss and comprehensive loss &#150; Owners of the
Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">(28,220,796)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">(18,489,629)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">(19,112,839)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000">(23,957,944)&#8195;&#8195;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Loss and comprehensive loss &#150; <FONT
STYLE="white-space:nowrap">Non-controlling</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">(745,210)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">(501,135)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">(303,107)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000">(379,945)&#8195;&#8195;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Net loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">(28,966,006)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">(18,990,764)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">(19,415,947)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000">(24,337,889)&#8195;&#8195;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Comprehensive loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">(28,886,192)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">(20,267,152)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">(19,415,947)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000">(24,337,889)&#8195;&#8195;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Loss per share, basic
and diluted &#150; Owners of the Company</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1.50pt solid #000000">(1.17)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1.50pt solid #000000">(0.96)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1.50pt solid #000000">(1.54)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">(1.93)&#8195;&#8195;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents amounts previously reported in our Audited Amended and Restated Consolidated Financial Statements
for the years ended December 31, 2022 and 2021. These financial statements were prepared under IFRS and presented in CDN dollars and have been converted to USD at the Bank of Canada annual exchanges rate for 2021 (1USD = 1.2535). The converted
figures are unaudited. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Amounts previously reported in our Audited Amended and Restated Consolidated Financial Statements for the
years ended December 31, 2022 and 2021. These financial statements were prepared under IFRS and presented in CDN dollars. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The net loss for the year ended December&nbsp;31, 2023 increased<B> </B>by $9,975,242<B> </B>when compared to the year ended December&nbsp;31,
2022, primarily due to an increase in general and administrative costs of $3,296,406, research and development costs of $6,933,371 and offset by a decrease to other expenses of $290,958 and tax expense of $36,423. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The comprehensive loss for the year ended December 31, 2022 increased when compared to the year ended December 31, 2021, primarily due to
higher research and development expenses resulting from the activities associated with the Phase 2 clinical trial for EP-104IAR offset by lower general administrative costs and share-based payments. Also, other expenses that were associated with the
Company&#146;s initial public offering in 2021 were not incurred in 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While several of the Company&#146;s vendors have inflationary
clauses in their contracts, the impact of inflation is considered immaterial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of the Year Ended December&nbsp;31, 2023, and 2022 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Results of Operations </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000"><B>Year Ended<BR>December&nbsp;31&nbsp;2023</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000"><B>Year Ended<BR>December&nbsp;31&nbsp;2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt"><B>Change&#8195;&#8195;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:2pt ;BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>%&#8195;&#8195;</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">7,284,004</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3,987,598</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3,296,406</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000">82.67&#8195;&#8195;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">20,563,225</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">13,629,854</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">6,933,371</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000">50.87&#8195;&#8195;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Other income
(expenses)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1,082,354)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1,373,312)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(290,958)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000">(21.19)&#8195;&#8195;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman"><B>Net loss before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">28,929,583</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">18,990,764</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">9,938,819</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000">52.34&#8195;&#8195;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Tax expense</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">36,423</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">-</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">36,423</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000">100&#8195;&#8195;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">28,966,006</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">18,990,764</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">9,975,242</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000">52.53&#8195;&#8195;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Foreign currency
translation</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">79,814</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">(1,276,388)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">1,356,202</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000">106.25&#8195;&#8195;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:6pt ;BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman"><B>Comprehensive loss</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1.50pt solid #000000">28,886,192</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1.50pt solid #000000">20,267,152</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1.50pt solid #000000">8,619,040</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">42.53&#8195;&#8195;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses consist of office and administrative costs, travel, professional fees, public company costs and salaries
and benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Comparing the year ended December&nbsp;31, 2023, to the same period in 2022, general and administrative activities
increased by $3,296,406. This increase is due to the following items: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An increase of $2,553,100 related to professional fees. This increase is a result of increased business
development consulting fees, legal fees associated with financing and compliance activities, and audit fees resulting from our change of auditor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An increase of $600,030 related to salaries, bonuses, and benefits as a result of increased headcount and
salary increases. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An increase of $189,809 related to public company costs associated with investor relation and compliance
activities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An increase of $225,877 related to travel expenses associated with increased business development and
financing activities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A reduction of $338,378 related to share based payments as a result of a number of the awards being fully or
mostly vested thereby decreasing the vesting expense in addition to fewer options awarded in the current compared to the prior year. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Increase in office costs of $56,259 due to increased headcount. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Comparing the
year ended December&nbsp;31, 2023, to the same period in 2022, research and development activities increased by $6,933,371. This increase is primarily due to the following items: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an increase of $5,000,000 in licensing costs due to the successful completion of the Phase 2b study of the
clinical trial related to EP-104IAR. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An increase of $520,341 in costs related to direct research programs. Manufacturing and analytical costs
increased as we commenced preparations for Phase 3 activities. Clinical expenses saw a reduction as we approached the conclusion of our Phase 2b clinical trial of <FONT STYLE="white-space:nowrap">EP-104IAR.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An increase of $103,689 related to pipeline development and other research and development costs.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An increase of $893,634 related to salaries and benefits due to increased head count and salary increases.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An increase of $316,823 related to share-based payments as a result of increased number of options issued.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A decrease of $98,884 related to government grants and tax incentives. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Income/(Expenses) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Comparing the
year ended December&nbsp;31, 2023, to the same period in 2022, other expenses decreased by $290,958. This decrease is due to the following items: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A decrease of $431,170 related to interest income as a result of an increase in the Canadian prime rate for
the purposes of interest on cash. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An increase of $187,317 related to interest expense as a result of an increase in the Canadian prime rate for
the purposes of interest on the convertible debt. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An increase of $174,256 related to foreign exchange loss. The foreign exchange loss is a result of
fluctuations in the U.S. and Australian exchange rate versus the Canadian dollar on our U.S. and Australian denominated assets and liabilities during the current period. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A decrease of $219,570 related to negative changes in fair value of financial instruments on the SVB
convertible debt facility. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Decrease in loss on sale of equipment of $1,791 due to fewer items being sold. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Quarterly Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The information in the tables below has been derived from the Company&#146;s consolidated financial statements. Effective December 31, 2023,
the Company transitioned to U.S. GAAP as well as changing its reporting currency to USD from CDN. As such, all prior amounts originally reported in CDN are now reported in USD. The change in reporting currency was made to enhance comparability of
the Company&#146;s results with other publicly traded companies in the life sciences industry. The Company has retained the Canadian dollar as its functional currency. In addition, all quarters have been retrospectively restated for the adoption of
U.S. GAAP in the current period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s quarterly operating results have varied substantially in the past and may vary
substantially in the future. Accordingly, the information below is not necessarily indicative of results for any future quarter. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Dec 31,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2023</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Restated)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Sep 30,<BR>2023</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Restated)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Jun 30,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2023</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Restated)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Mar 31,<BR>2023</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Restated)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Dec 31,<BR>2022</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Restated)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Sep 30,<BR>2022</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Restated)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Jun 30,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2022</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Restated)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Mar 31,<BR>2022</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Restated)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="4" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000; BORDER-RIGHT:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000; BORDER-RIGHT:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000; BORDER-RIGHT:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000; BORDER-RIGHT:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000; BORDER-RIGHT:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000; BORDER-RIGHT:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000; BORDER-RIGHT:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000; BORDER-RIGHT:1.50pt solid #000000">$</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:10pt ;BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:8pt; font-family:Times New Roman">Total
Revenue</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#8194;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#8194;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#8194;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#8194;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#8194;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#8194;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#8194;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-BOTTOM:1px solid #000000" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&#8194;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:10pt ;BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:-0.50em; font-size:8pt; font-family:Times New Roman">Total</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0.50em; font-size:8pt; font-family:Times New Roman">net loss</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right">(10,607,396)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right">(4,896,080)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right">(9,506,442)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right">(3,956,088)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right">(7,771,019)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right">(4,115,343)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right">(4,206,221)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-BOTTOM:1px solid #000000" ALIGN="right">(2,898,181)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:10pt ;BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:-0.50em; font-size:8pt; font-family:Times New Roman">Loss
per share,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:0.50em; font-size:8pt; font-family:Times New Roman">basic and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0.50em; font-size:8pt; font-family:Times New Roman">diluted (Owners of the Company)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000" ALIGN="right">(0.38)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000" ALIGN="right">(0.18)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000" ALIGN="right">(0.43)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000" ALIGN="right">(0.18)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000" ALIGN="right">(0.36)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000" ALIGN="right">(0.19)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000" ALIGN="right">(0.21)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-BOTTOM:1.50pt solid #000000" ALIGN="right">(0.20)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:10pt ;BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has incurred net losses in each of its preceding eight quarters as a result of continued
activities associated with the Phase 2 clinical trial for <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> and the Phase 1b/2a clinical trial of <FONT STYLE="white-space:nowrap">EP-104GI.</FONT> This trend is expected to continue into the future as
we make further investments in our <FONT STYLE="white-space:nowrap">EP-104</FONT> programs. Research and development expenses are expected to remain high as we undertake clinical trials and incur significant costs for CROs and consultants, and
further investment in additional drug candidates in support of broader pipeline development. General and administrative expenses are likely to remain high in the future as a result of ongoing costs associated with public company compliance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables
show the estimated use of net proceeds for each financing, compared with the actual use of net proceeds: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>March 2024 Financing </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000"><B>Estimated&nbsp;Amount<BR>to be Expended</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000"><B>Estimated&nbsp;Amount&nbsp;to<BR>be Expended<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Actual</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amount&nbsp;Expended&#8195;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>CDN$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>US$</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Research and development activities for</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">EP-104GI</FONT> and <FONT STYLE="white-space:nowrap">EP-104IAR</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12,100,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">8,941,107</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000">-</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">7,700,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5,689,795</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000">-</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Amended and restated
license agreement payment</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">6,700,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">4,950,861</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000">-</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1.50pt solid #000000"><B>26,500,000</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1.50pt solid #000000"><B>19,581,763</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000"><B>-</B></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Converted as of March&nbsp;15, 2024 using the daily rate of exchange published by the Bank of Canada of
US$1.00 = CDN$1.3533. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to use a portion of the capital resources previously identified for <FONT
STYLE="white-space:nowrap">EP-104IAR</FONT> development to continue development of <FONT STYLE="white-space:nowrap">EP-104GI.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>April 2022 </B><B>Financing</B> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;Amount</B><br><B>to be Expended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B><br><B>Amount&nbsp;Expended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>CDN$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>CDN$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,837,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,763,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>13,600,000</B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>13,600,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There have been no material variances to the way the Company intended to use proceeds from the 2022 Offering
(as defined herein). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity, Capital Resources and Outlook, Management of Cash Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As at December&nbsp;31, 2023, the Company had cash and cash equivalents of $19,341,756 (December 31, 2022 - $18,263,389). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s business does not currently generate revenue or positive cash flows from operations and is reliant on equity and debt
financing to provide the necessary cash to continue its research and development activities and ongoing operations. There can be no assurance that equity financings will be available in the future with terms that are satisfactory to the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s cash flow forecasts are continually updated to reflect actual cash inflows and outflows so to monitor the requirements
and timing for additional financial resources. Given the volatility of the Canadian dollar, U.S. dollar, and Australian dollar (&#147;<B>AUD</B>&#148;) exchange rate, the Company estimates its USD and AUD expenses for the year and sets aside
appropriate levels of USD and AUD cash. By holding USD and AUD, the Company remains subject to currency fluctuations which effect its loss during any given year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, we continue to monitor additional opportunities to raise equity capital and/or secure additional funding through <FONT
STYLE="white-space:nowrap">non-dilutive</FONT> sources such as government grants and potential license agreements. However, it is possible that our cash and working capital position may not be enough to meet our business objectives in the event of
unforeseen circumstances or a change in our strategic direction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;15, 2024, the Company announced it had closed an overnight
marketed public offering (the &#147;<B>Offering</B>&#148;) of Common Shares of the Company. Pursuant to the Offering, Eupraxia issued 8,260,435 Common Shares at a price of CDN$4.10 per share for gross proceeds of $25,026,073 (CDN$33,867,784). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets out our pro-forma condensed balance sheet which has been prepared as if the proceeds from the Offering were received
on December 31, 2023. These amounts are presented to provide additional information about the liquidity of the organization after taking into consideration these proceeds. These amounts have not been adjusted for any other matters or expenses
incurred after the balance sheet date and are unaudited. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2023</B><br><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2023</B><br><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,341,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,367,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">924,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">924,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,266,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,292,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,373,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,373,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Shares (no par value &#151; 27,282,165 common shares issued and outstanding, actual;
35,542,600 common shares issued and outstanding, as adjusted)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,913,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,939,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Paid-In Capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,510,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,510,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(105,501,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(105,501,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,706,552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,706,552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-controlling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,323,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,323,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">892,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,918,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and shareholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,266,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,292,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These funds are being used to fund our clinical trials in <FONT STYLE="white-space:nowrap">EP-104GI</FONT> and
<FONT STYLE="white-space:nowrap">EP-104IAR.</FONT> The remainder of the proceeds will be used for general and administrative expenses, a milestone payment, working capital needs and other general corporate purposes. Assuming we are able to refinance
our existing debt facility with Silicon Valley Bank, we anticipate our cash resources will be sufficient to fund the Company through to the third quarter of 2025. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Cash Flow for the year ended December&nbsp;31, 2023 and 2022. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-TOP:1.50pt solid #000000"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,&nbsp;2023</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-TOP:1.50pt solid #000000"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,&nbsp;2022</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(20,683,623)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(14,395,201)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(73,377)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">9,834,371</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:6pt ;BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #000000" ALIGN="center">21,013,970</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #000000" ALIGN="center">10,801,079</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:6pt ;BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman"><B>Net decrease in cash and cash
equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>256,970</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>6,240,249</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1.50pt solid #000000; padding-right:2pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-LEFT:1.50pt solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4" STYLE="BORDER-RIGHT:1.50pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:6pt ;BORDER-LEFT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Foreign Exchange effect on cash</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1.50pt solid #000000" ALIGN="center">821,397</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1.50pt solid #000000" ALIGN="center">(507,395)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:6pt ;BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash used in operating activities for the year ended December&nbsp;31, 2023 increased by $6,288,180 compared
to the same period in the prior year. The primary driver was the increase in expenditure on the <FONT STYLE="white-space:nowrap">EP-104IAR</FONT> and <FONT STYLE="white-space:nowrap">EP-104GI</FONT> </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
clinical trials, increased business development and financing related costs, payment of accounts payable and accrued liabilities, and increased salary costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash used in investing activities for the year ended December&nbsp;31, 2023 2023 increased by $9,907,747 compared to the same period in the
prior year. The primary driver of the decrease was due to no redemptions of short-term investments during the year ended December&nbsp;31, 2023 as compared to the comparable period in 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash provided by financing activities for the year ended December&nbsp;31, 2023 increased by $10,212,891 compared to the same period in the
prior year. The primary driver of the increase was the Private Placement offering which occurred during the year ended December&nbsp;31, 2023 and the redemption of warrants and options during the same period, offset by the overnight marketed public
offering which occurred during the year ended December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Going Concern </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These consolidated financial statements have been prepared on a going concern basis with the assumption that the Company will be able to
realize its assets and discharge its liabilities and commitments in the normal course of business. At December&nbsp;31, 2023, the Company had cash and cash equivalents of $19,341,756 and the Company has not yet generated revenue from operations. The
Company incurred a net loss of $28,966,006 during the year ended December&nbsp;31, 2023, and as of that date, the Company&#146;s accumulated deficit was $105,501,295. As the Company is in the research and development stage, the recoverability of the
costs incurred to date is dependent upon the ability of the Company to obtain the necessary funding to complete the research and development of its projects and upon future commercialization or proceeds from the monetization of research activities
to date. The Company will periodically have to raise funds to continue operations and raised $15,886,537 (CDN$20,836,005) through a non-brokered private placement of 3,183,875 common shares in 2023 (2022 - $11,768,459 through a marketed public
offering) and raised and raised $25,026,073 (CDN$33,867,784) through an overnight marketed public offering of 8,260,435 common shares in March 2024. Although it has been successful in doing so in the past, there is no assurance it will be able to do
so in the future, especially with the ongoing conflicts in the Ukraine and the Middle East affecting the global capital markets. Recent developments with SVB have not impacted the Company&#146;s outlook for cash runway. The Company holds no amounts
on deposit with SVB and the convertible debt which matures in June 2024 remains in good standing, is fully drawn and is not callable by SVB. The Company is active in its pursuit of additional funding through potential partnering and other strategic
activities as well as grants to fund future research and development activities, and additional equity financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The continued
operations of the Company are dependent on its ability to generate future cash flows or obtain additional funding. There is a risk that in the future, additional financing will not be available on a timely basis or on terms acceptable to the
Company. These events and conditions indicate a material uncertainty which may cast significant doubt about the Company&#146;s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to the
amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue in business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Long-Term
Obligations and Other Contractual Commitments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company may be required to make milestone, royalty, and other research and
development funding payments under research and development collaboration and other agreements with third parties. These payments are contingent upon the achievement of specific development, regulatory and/or commercial milestones. The Company has
not accrued for these payments as at December&nbsp;31, 2023 due to the uncertainty over whether these milestones will be achieved. The Company&#146;s significant contingent milestone, royalty and other research and development commitments are as
follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Auritec License Agreement </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Auritec Pharmaceuticals, Inc. (&#147;Auritec&#148;) is a privately held clinical-stage drug delivery company that holds patents in the field of
extended-release delivery of drug products utilizing its proprietary drug delivery platform, the &#147;Plexis Platform&#148;. Eupraxia, through its subsidiary, Eupraxia USA, is a party to an amended and restated license agreement
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
dated effective October&nbsp;9, 2018 (as further amended, the &#147;<B>Amended and Restated License Agreement</B>&#148;) with Auritec. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms of the Amended and Restated License Agreement, Auritec has granted Eupraxia USA an exclusive license (including the right to
sublicense to its affiliates and third parties) under the licensed patents owned or controlled by Auritec and for all the technical information and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to the technology claimed in such patents
or possessed by Auritec with respect to the use of the Plexis Platform for the delivery of fluticasone in all medical fields (except for the Excluded Fields (as defined in the Amended and Restated License Agreement)), to develop, make, have made,
manufacture, use, commercialize, sell, <FONT STYLE="white-space:nowrap">sub-license,</FONT> offer for sale, import, and have imported the Licensed Products (as defined in the Amended and Restated License Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the terms of the Amended and Restated License Agreement, in consideration for the rights and exclusive license granted to Eupraxia
USA, Eupraxia USA paid the Upfront Fee (as defined in the Amended and Restated License Agreement) of $5,000,000 by the end of December&nbsp;31, 2021 with the agreement currently in good standing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the Upfront Fee, pursuant to the Amended and Restated License Agreement, Eupraxia USA has agreed to pay Auritec up to
USD30&nbsp;million upon achievement of certain regulatory and commercial milestones related to Licensed Products under the Amended and Restated License Agreement as well as a royalty of 4% of net sales of Licensed Products by Eupraxia USA or its
affiliates, subject to certain reductions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the milestone payment schedule. As of December&nbsp;31, 2023,
the only milestone that has been accrued and provided for in the financial statements is $5,000,000 related to the successful completion of the Phase 2b clinical study. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman"><B>Milestone Event</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Milestone&nbsp;Payment</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Successful Completion of a Phase 2b Study</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000">5,000,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">First OA Regulatory Approval</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000">5,000,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Second OA Regulatory Approval</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-OA</FONT> Indication Regulatory Approval</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000">5,000,000<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10,000,000</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">First calendar year in which
aggregate Net Sales by Eupraxia USA,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">its affiliates and sublicenses exceed $500,000,000</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">5,000,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman"><B>Maximum milestones
payable</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>$30,000,000</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Eupraxia USA has also agreed to pay to Auritec 20% of sublicensing royalties or other consideration based on
net sales of Licensed Products. Eupraxia USA has further agreed to pay Auritec a percentage of <FONT STYLE="white-space:nowrap">Non-Royalty</FONT> Monetization Revenue (as defined in the Amended and Restated License Agreement), which includes
payments received for a sale of Eupraxia USA or its assets or sale or sublicense of a Licensed Product, which percentage ranges from 10% to 30% depending on the development stage of the most-advanced Licensed Product, up to a maximum of
$100&nbsp;million. The following table summarizes the <FONT STYLE="white-space:nowrap">Non-Royalty</FONT> Monetization Revenue percentage schedule: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Date of Execution</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B><FONT STYLE="white-space:nowrap">Percentage&nbsp;of&nbsp;Non-Royalty&#8195;</FONT></B><BR>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Monetization Revenue&#8195;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; margin-right:0.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prior to Successful
Completion of a Phase 2b Study</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000">30%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; margin-right:0.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">After Successful
Completion of a Phase 2b Study but prior to Successful Completion of a Phase 3 Study</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000">20%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; margin-right:0.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">After Successful
Completion of a Phase 3 Study but prior to Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000">15%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; margin-right:0.50em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">After Regulatory Approval of a Product in the Eupraxia Field from FDA in the United
States</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">10%</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Either party may terminate the Amended and Restated License Agreement in the event of the other party&#146;s
bankruptcy, liquidation, or dissolution. Auritec may also terminate upon a material breach of the Amended and Restated License Agreement by Eupraxia USA that is not cured within 60 days (15 days in the case of a payment breach). Further, if Eupraxia
USA directly or indirectly challenges any claim in any Auritec patent licensed under the Amended and Restated License Agreement, or assist a third party in doing so, Auritec may immediately terminate the Amended and Restated License Agreement. If
Auritec directly or indirectly challenges any Eupraxia patent contemplated in the Amended and Restated License Agreement other than as reasonably required to defend Auritec patents as a basis for such challenge, or assists a third party in doing so,
we may immediately terminate the Amended and Restated License Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lease Agreement </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On October&nbsp;21, 2019, the Company entered into a lease agreement for its head office located at Suite 201 &#150; 2067 Cadboro Bay Road,
Victoria BC. The lease is for a period of 5 years, expiring November&nbsp;30, 2024. The annual base rent for the lease is CDN$87,696 with anticipated additional annual rent of CDN$92,568 to cover the Company&#146;s share of property taxes and
operating costs. Additional rent is subject to adjustment at the end of each lease year based on actual costs incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Convertible Debt Facility
</U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On June&nbsp;21, 2021, the Company entered into a debt agreement with SVB (the &#147;<B>Debt Agreement</B>&#148;) and concurrently
drew down, in full, the CDN$10&nbsp;million principal amount under the Debt Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Debt Agreement has a term of 36 months or 48
months at SVB&#146;s election. The Debt Agreement accrues interest at the greater of 2.45% and the Canadian prime rate, requiring monthly interest payments in cash. An additional payment in kind will accrue at a rate of 7% per annum, which will be
settled at maturity or on conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the terms and conditions of the Debt Agreement, SVB may elect to convert the principal
amount of the convertible debt and the accrued and unpaid interest thereon into Common Shares at a conversion price equal to CDN$5.68 per Common Share. The conversion price of the accrued and unpaid interest will be subject to the minimum pricing
requirements of the TSX, to the extent applicable, at the time of conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company will have the right (the &#147;<B>Call
Right</B>&#148;) to call the convertible debt by paying to SVB an amount equal to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">125% of the principal amount of the convertible debt (less principal amounts previously repaid), if the Call
Right is exercised on or before the 18 month anniversary of the date of the Debt Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">150% of the principal amount of the convertible debt (less principal amounts previously repaid), if the Call
Right is exercised after the 18 month anniversary of the date of the Debt Agreement, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">in either case together with all
accrued and unpaid interest on the principal balance of the convertible debt. If the Call Right is exercised by the Company, SVB will retain certain lookback rights in the event the Company subsequently announces its topline data from its Phase 2
clinical study or the Company enters into an agreement to be acquired in the 12 months following the exercise of the Call Right. The Company has agreed to grant SVB a security interest in all of its assets, excluding its patents and other
intellectual property, and the testing and product equipment by way of the loan agreement it entered into on September&nbsp;10, 2021 as security for its obligations under the Debt Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company was required, on or prior to June&nbsp;30, 2022, to raise additional net new capital, as defined in the Debt Agreement, in the
aggregate amount of CDN$10&nbsp;million. This net new capital could originate from, but was not restricted to, a variety of sources as outlined in the Debt Agreement and could include up to CDN$5&nbsp;million in reduced project expenses. On
April&nbsp;20, 2022, the Company closed an offering for gross proceeds of CDN$14.7&nbsp;million that satisfied this requirement (the &#147;<B>2022 Offering</B>&#148;). The Company&#146;s Debt Agreement with SVB remains in good standing as at the
date of approval of these consolidated financial statements and is fully drawn. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transactions with Related Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There were no transactions with related parties during the year ended December&nbsp;31, 2023 and 2022, reportable under U.S. GAAP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has no material undisclosed <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements that have or are reasonably
likely to have, a current or future effect on our results of operations or financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Estimates and Judgments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting year, which, by their nature, are uncertain. Actual outcomes could
differ from these estimates. The impacts of such estimates are pervasive throughout the consolidated financial statements, and may require accounting adjustments based on future events. Revisions to accounting estimates are recognized in the year in
which the estimate is revised and future periods if the revision affects both current and future years. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future
events that are believed to be reasonable under the circumstances that affect the reported amounts of assets, liabilities, income and expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Critical accounting estimates </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Significant assumptions about the future and other sources of estimation uncertainty that management has made at the end of the reporting
period, that could result in a material adjustment to the carrying amounts of assets and liabilities in the event that actual results differ from assumptions made, relate to, but are not limited to, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Share-based payments are measured at fair value, using the Black-Scholes option pricing model, at the grant
date and expensed over the vesting period. In determining the fair value, the Company makes estimates of the expected volatility of the shares, the expected life of the share-based instrument, and an estimated risk-free interest rate; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The determination of the amount allocated to the liability and equity components (for those financial
instruments that are comprised of both). This requires management to estimate various components and characteristics of present value calculations used in determining the fair value of the instrument, including the market interest rates of <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debentures. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Critical accounting judgments </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Critical accounting judgments are accounting policies that have been identified as being complex or involving subjective judgments or
assessments. The Company&#146;s management made the following critical accounting judgments: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The determination of the functional currency of the Company and its subsidiaries; and </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Assessment of the appropriateness of the going concern assertion and events and conditions that indicate a
material uncertainty that may cast substantial doubt thereon. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting Standards and Amendments Issued but Not Yet Adopted
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has not yet adopted certain new standards, amendments and interpretations to existing standards, which have been published
but are only effective for accounting periods beginning on or after January&nbsp;1, 2024 or later periods. The new and amended standards are not expected to have a material impact on the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Instruments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s
financial instruments consist of cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities, loans payable and convertible debt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There were no changes to the Company&#146;s risk exposures or management of risks during the year ended December&nbsp;31, 2023. The
Company&#146;s risk exposures and the impact on the Company&#146;s financial instruments are summarized below: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Credit risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an
obligation. The Company believes it has no significant credit risk, as its cash and cash equivalents and short-term investments, being its primary exposure to credit risk, is with a large Canadian bank. The Company&#146;s maximum exposure to credit
risk is the carrying value of these financial assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidity risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are
settled by delivering cash or another financial asset. The Company&#146;s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at December&nbsp;31, 2023,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the Company had cash and cash equivalents of $19,341,756 (2022 -$18,263,389) in addition to current liabilities of $19,373,903 (2022 -$3,058,387). Management is currently working on certain
strategic alternatives including, but not limited to raising additional capital and strategic alternatives to its existing contingent convertible debt facility. There is no assurance, however, that any or all of these alternatives will materialize
or that additional funding will be available, if and when needed. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="center"><B>Total</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="center"><B>Less&nbsp;than&nbsp;1&nbsp;year</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="center"><B><FONT STYLE="white-space:nowrap">&#8195;1&nbsp;-&nbsp;3&nbsp;years&#8195;</FONT></B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="24" COLSPAN="4"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD>
<TD HEIGHT="24" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Convertible Debt
<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,101,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 9,101,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-&#8195;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Accounts Payable and Accrued Interest <SUP
STYLE="font-size:75%; vertical-align:top">(2<FONT STYLE="font-size:6.5pt"><B>) </B></FONT></SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,903,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,903,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-&#8195;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Loans Payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-&#8195;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Leases</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">60,780</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">60,780</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">-&#8195;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman"><B>Total Contractual
Obligations</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>&#8195;13,128,840</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>13,128,840</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>-&#8195;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Included principal of CDN$10,000,000 ($7,560,865) and paid in kind interest of CDN$1,961,859.05
($1,540,884). The counterparty to this instrument has the option to extend the maturity to June 2025 or convert this instrument at a price of CDN$5.68 / share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Included amounts owing to vendors as well as accrued interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Market risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Market risk is the risk that
the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: currency risk, interest rate risk and other price risk. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest rate risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest rate risk is
the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate cash flow risk; and to the extent that the prevailing market interest
rates differ from the interest rate on the Company&#146;s monetary assets and liabilities, the Company is exposed to interest rate price risk. At December&nbsp;31, 2023, the Company maintains a convertible debt facility totaling CDN$10,000,000 as
well as having an equipment loan of $235,000 of which a principal balance of $62,709 remains as at December&nbsp;31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
convertible debt accrues interest at the greater of 2.45% and the Canadian prime rate, requiring monthly interest payments. An additional payment in kind accrues at a rate of 7% per annum, which will be settled at maturity or on conversion. The
equipment loan accrues interest at a fixed rate of 5.84%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As at December&nbsp;31, 2023, management has determined the effect on the
future results of operations due to a change in the current Canadian prime rate. An impact of a 1% change in the Canadian prime rate would impact the amount of interest to be paid over the remaining term of the convertible debt facility by
approximately $43,807. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Currency risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign
exchange rates. The Company is exposed to currency risk due to its frequency of transactions in U.S. dollars. The Company does not use derivatives to hedge against this risk, however, it has purchased U.S. dollars to cover the majority of the costs
of the Company&#146;s Phase 2 clinical trial. At December&nbsp;31, 2023, the Company held cash of $933,816 (2022 &#150; $1,159,926) had accounts payable of $1,292,128 (2022 &#150; $1,814,067), a payable to Auritec of $5,000,000 (2022 &#150; $nil)
and a loan payable of $62,709 (2022 &#150; $142,127) denominated in USD which were translated to CDN at 1.3226 (2022 &#150; 1.3544). The impact of a 10% change in the exchange rates would have an impact of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
approximately $542,102 (2022 &#150; $79,627) on profit or loss. The Company also has cash in accounts payable in Australian dollars, Great British pounds and Euros. The impact of a 10% change in
the exchanges of these currencies would have an immaterial effect on future cash flows. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other price risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market
prices (other than those arising from interest rate risk and foreign currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer or by factors affecting all similar financial instruments
traded in the market. The Company is not exposed to significant price risk with respect to commodity or equity prices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair Value Measurement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company categorizes its financial instruments measured at fair value into one of three different levels depending on the observation of
inputs used in the measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Level&nbsp;1: Fair value is based on unadjusted quoted prices for identical assets or liabilities in
active markets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Level&nbsp;2: Fair value is based on inputs other than quoted prices included within Level&nbsp;1 that are observable for
the asset or liability, either directly or indirectly. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Level&nbsp;3: Fair value is based on valuation techniques that require one or more
significant unobservable inputs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s financial instruments consist of cash and cash equivalents, accounts payable and
accrued liabilities, loans payable and convertible debt. With the exception of convertible debt, the carrying value of the Company&#146;s financial instruments approximate their fair values due to their short-term maturities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes information regarding the classification and carrying values of the Company&#146;s financial instruments
measured at amortized cost: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman"><B>Financial assets/liabilities</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"><B></B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>December&nbsp;31,</B><BR>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>2023</B></P></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B></B><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"><B></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"><B></B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>December&nbsp;31,&#8194;</B><BR>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>2022&#8194;</B></P></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B></B><BR>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"><B></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;19,341,756</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;18,263,389&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Amounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 190,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 89,715&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;3,921,875</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;2,928,566&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Payable to Auritec</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Loans payable</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&nbsp;62,709</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&nbsp;142,127&#8194;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes information regarding the changes in fair value of liabilities measured at fair
value, categorized as Level&nbsp;3: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000"> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Convertible&nbsp;Debt</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman"><B>Balance as at December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>7,507,755</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">971,873</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(315,436)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,056,165</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Foreign exchange</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(478,361)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman"><B>Balance as at December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,741,996</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,162,773</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(591,170)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">836,595</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Foreign exchange</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(185,806)</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman"><B>Balance as at
December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>10,336,003</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks and Uncertainties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The primary risk factors affecting the Company are set forth under the heading &#147;<I>Risk Factors</I>&#148; in the Shelf Prospectus and the
AIF. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Share Capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As
of the date of this MD&amp;A, the Company had 35,622,553 Common Shares issued and outstanding. The maximum number of additional Common Shares issuable, should all convertible rights be exercised are as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman"><B>Common Shares Issuable:</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>As&nbsp;of&nbsp;the&nbsp;date&nbsp;of&nbsp;MD&amp;A</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Options<SUP STYLE="font-size:75%; vertical-align:top">
(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,482,490</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="10" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">2013 Warrants<SUP STYLE="font-size:75%; vertical-align:top">
(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">380,921</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="10" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Founders
Warrants<SUP STYLE="font-size:75%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">315,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="10" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Underlying Founders Warrants<SUP
STYLE="font-size:75%; vertical-align:top"> (4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">315,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="10" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;Class&nbsp;B Shares<SUP STYLE="font-size:75%; vertical-align:top"> (5)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">562,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="10" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Warrants &#150; Listed EPRX.WT<SUP
STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,826,024</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="10" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Warrants &#150; Listed EPRX.WT.A<SUP
STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,196,550</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="10" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Compensation Warrants<SUP
STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,054</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="10" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">Nordic Warrants<SUP STYLE="font-size:75%; vertical-align:top">
(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,228</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="10" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman">SVB Debt Facility<SUP
STYLE="font-size:75%; vertical-align:top"> (10)</SUP></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2,143,445</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.50em; font-size:10pt; font-family:Times New Roman"><B>Total
Common Shares Issuable</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>15,312,212</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents options outstanding under the Company&#146;s stock option plan, each having an exercise price
between $1.90 and $8.00 and expiry dates ranging from March 31, 2025 to September 26, 2033. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents common share purchase warrants to acquire up to 380,921 Common Shares at an exercise price of
$0.7572 per share, with each such common share purchase warrant expiring 120 days after the warrant holder or the holder&#146;s spouse ceases to be a director, officer or consultant of the Company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents common share purchase warrants to acquire 315,500 units, with each unit consisting of one Common
Share and one underlying common share purchase warrant (an &#147;<B>Underlying Founder Warrant</B>&#148;) at an exercise price of $0.4984 per unit, expiring 120 days after the warrant holder ceases to be a director, officer or consultant of the
Company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents Underlying Founder Warrants to acquire up to 315,500 Common Shares, at an exercise price of $0.75
per share, expiring two years from the date of exercise of the Underlying Founder Warrant. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents 562,500 Common Shares that are issuable upon conversion of the 225 Class B Shares of Eupraxia
Pharma Inc., the Company&#146;s subsidiary, held by Amanda Malone, the Chief Scientific Officer of the Company. Each Class B Share is exchangeable into Common Shares based on an exchange rate of 2,500 Common Shares for each Class B Share, subject to
adjustments upon the occurrence of certain events, for a total of 562,500 Common Shares. The Class B Shares are exchangeable by Ms. Malone at her election, provided that the Company may force the exchange of the Class B Shares into Common Shares at
any time on or after January 31, 2031, or on or after January 31, 2026 if the Company is listed on a stock exchange and is a reporting issuer in Canada at such time. The Company may also force the exchange of the Class B Shares into Common Shares if
there is a change of control transaction involving the Company, a change in law which makes the exchange necessary or desirable or if there are a de minimis number of Class B Shares outstanding. If the Company is listed on a stock exchange at the
time of the applicable exchange, the Company may elect to pay Ms. Malone cash in lieu of issuing Common Shares, with such cash amount to be determined based on the then current market price of the Common Shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Each common share purchase warrant is exercisable into one common share of the Company (each, a
&#147;<B>Warrant Share</B>&#148;) at an exercise price of $11.20 per Warrant Share at any time prior to 5:00 p.m. (Eastern time) on the date that is five years following the closing of the Company&#146;s initial public offering in Canada, subject to
adjustment in certain events. The common share purchase warrants include an acceleration provision, exercisable at the Company&#146;s option, if the Company&#146;s daily volume weighted average share price is greater than $22.40 for five consecutive
trading days. Of the 2,826,274 warrants issued, 250 warrants have been exercised as of the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Each common share purchase warrant entitles the holder thereof to acquire one Common Share at an exercise
price of $3.00 per Common Share for a period of 48 months following the closing date of the 2022 Offering, being April 20, 2022. Of the 7,331,550 warrants issued, 2,135,000 warrants have been exercised as of the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">500,538 common share purchase warrants were issued to the agents of the 2022 Offering and represents 7% of
the units issued in the 2022 Offering including the over-allotment option (the &#147;<B>Compensation Warrants</B>&#148;). Each Compensation Warrant shall entitle the agents to acquire a Common Share at the price of $2.05 for a period of 48 months
following completion of the 2022 Offering, being April 20, 2022. Of the 500,538 Compensation Warrants issued, 450,484 Compensation Warrants have been exercised as of the date hereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Each Nordic Warrant is exercisable into one Common Share at an exercise price of $11.20 per share at any
time prior to 5:00 p.m. (Eastern time) on April 29, 2026, subject to adjustment in certain events. The Nordic Warrants include an acceleration provision, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
exercisable at the Company&#146;s option, if the Company&#146;s daily volume weighted average share price is greater than $22.40 for five consecutive trading days. </P></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">SVB may elect to convert the principal amount of the convertible debt into Common Shares at a conversion
price equal to $5.68 per Common Share. SVB may also elect to convert accrued and unpaid interest, the conversion price of the accrued and unpaid interest will be subject to the minimum pricing requirements of the TSX, to the extent applicable at the
time of conversion. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclosure Controls and Procedures and Internal Controls Over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Chief Executive Officer (&#147;<B>CEO</B>&#148;) and Chief Financial Officer (&#147;<B>CFO</B>&#148;) have designed or caused to be
designed under their supervision, disclosure controls and procedures which provide reasonable assurance that material information regarding the Company is accumulated and communicated to the Company&#146;s management, including its CEO and CFO, in a
timely manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the CEO and CFO have designed or caused to be designed under their supervision internal controls over
financial reporting (&#147;<B>ICFR</B>&#148;) to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements. The control framework used to design the Company&#146;s ICFR uses the
framework and criteria established in the <I>Internal Control-Integrated Framework</I> (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that its objectives are met.
Due to inherent limitations in all such systems, no evaluations of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures and our ICFR are
designed to be effective in providing reasonable, not absolute, assurance that the objectives of our control systems have been met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
Company had previously identified the following material weakness: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Insufficient management review of the classification of liabilities and equity under IAS 32 and the valuation
of instruments in accordance with IFRS 13. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has since remediated the deficiency by engaging an external
party to assist in the valuation of certain instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The CEO and the CFO have evaluated, or caused to be evaluated under their
supervision, whether or not there were changes to its ICFR during the year ended December&nbsp;31, 2023 that have materially affected or are reasonably likely to materially affect the Company&#146;s ICFR. Other than the remediation of the material
weakness identified above, no such changes were identified through their evaluation and concluded that as at December&nbsp;31, 2023, the Company&#146;s disclosure controls and procedures were effective to provide reasonable assurance that material
information regarding required disclosures was made known to them on a timely basis. The Company&#146;s CEO and CFO will certify Eupraxia&#146;s annual filings with the Canadian securities regulatory authorities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additional
information about the Company is available on SEDAR+ at www.sedarplus.ca. and EDGAR at www.sec.gov/edgar. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>6
<FILENAME>d800041dex994.htm
<DESCRIPTION>EX-99.4 CONSENT OF KPMG LLP
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.4 Consent of KPMG LLP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eupraxia Pharmaceuticals Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We consent to the use of our report dated April&nbsp;1, 2024 on the consolidated financial statements of Eupraxia Pharmaceuticals Inc.<B>
</B>(the &#147;Entity&#148;) which comprise the consolidated balance sheets as of December&nbsp;31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, changes in shareholders&#146; equity, and cash flows for
each of the years in the two-year period ended December&nbsp;31, 2023, and the related notes (collectively the &#147;consolidated financial statements&#148;), which is included in the Annual Report on Form
<FONT STYLE="white-space:nowrap">40-F</FONT> of the Entity for the fiscal year ended December&nbsp;31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also consent to the
incorporation by reference of such report in the Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-276586</FONT> on Form <FONT STYLE="white-space:nowrap">F-10</FONT> of the Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chartered Professional Accountants </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;1, 2024 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vancouver, Canada </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>7
<FILENAME>d800041dex995.htm
<DESCRIPTION>EX-99.5 CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.5 Certification of Chief Executive Officer</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I, James
A. Helliwell, certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. I have reviewed this annual report on Form <FONT STYLE="white-space:nowrap">40-F</FONT> of Eupraxia
Pharmaceuticals Inc.; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. The issuer&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> for the issuer and have: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating to the issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) Evaluated the effectiveness of the issuer&#146;s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) Disclosed in this report any change in the issuer&#146;s internal control over financial reporting that occurred during the
period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the issuer&#146;s internal control over financial reporting; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. The issuer&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the issuer&#146;s auditors and the audit committee of the issuer&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the issuer&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
issuer&#146;s internal control over financial reporting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: April&nbsp;1, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ James A. Helliwell</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>8
<FILENAME>d800041dex996.htm
<DESCRIPTION>EX-99.6 CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.6 Certification of Chief Financial Officer</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I, Bruce
Cousins, certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. I have reviewed this annual report on Form <FONT STYLE="white-space:nowrap">40-F</FONT> of Eupraxia
Pharmaceuticals Inc.; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. The issuer&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> for the issuer and have: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating to the issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) Evaluated the effectiveness of the issuer&#146;s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) Disclosed in this report any change in the issuer&#146;s internal control over financial reporting that occurred during the
period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the issuer&#146;s internal control over financial reporting; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. The issuer&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the issuer&#146;s auditors and the audit committee of the issuer&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the issuer&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
issuer&#146;s internal control over financial reporting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date: April&nbsp;1, 2024</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Bruce Cousins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">President and Chief Financial Officer</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.7
<SEQUENCE>9
<FILENAME>d800041dex997.htm
<DESCRIPTION>EX-99.7 CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.7 Certification of Chief Executive Officer</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUPRAXIA PHARMACEUTICALS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with the Annual Report of Eupraxia Pharmaceuticals Inc. (the &#147;Company&#148;) on Form <FONT
STYLE="white-space:nowrap">40-F</FONT> for the year ended December&nbsp;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I, James A. Helliwell, Chief Executive Officer<I>&nbsp;(Principal
Executive Officer)</I>&nbsp;of the Company, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(1) The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: April&nbsp;1, 2024 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James Helliwell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">James Helliwell</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A signed original of this written statement required by Section&nbsp;906 of the Sarbanes-Oxley
Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission
and is not to be incorporated by reference into any filing of Eupraxia Pharmaceuticals Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report),
irrespective of any general incorporation language contained in such filing. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.8
<SEQUENCE>10
<FILENAME>d800041dex998.htm
<DESCRIPTION>EX-99.8 CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.8 Certification of Chief Financial Officer</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUPRAXIA PHARMACEUTICALS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with the Annual Report of Eupraxia Pharmaceuticals Inc. (the &#147;Company&#148;) on Form <FONT
STYLE="white-space:nowrap">40-F</FONT> for the year ended December&nbsp;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I, Bruce Cousins, President and Chief Financial Officer <I>(Principal
Financial Officer and Principal Accounting Officer)</I>&nbsp;of the Company, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(1) The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: April&nbsp;1, 2024 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">/s/ Bruce Cousins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bruce Cousins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Financial Officer</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A signed original of this written statement required by Section&nbsp;906 of the Sarbanes-Oxley
Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission
and is not to be incorporated by reference into any filing of Eupraxia Pharmaceuticals Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report),
irrespective of any general incorporation language contained in such filing. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>eprx-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 01-April-2024 [11:12:04] {PM}-->
<schema targetNamespace="http://eupraxiapharma.com/20231231" elementFormDefault="qualified" xmlns:eprx="http://eupraxiapharma.com/20231231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://eupraxiapharma.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<link:definition>1004 - Statement - Consolidated Statements of Operations and Comprehensive loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit" id="ConsolidatedStatementsOfChangesInShareholdersEquityDeficit">
<link:definition>1005 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Deficit)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1006 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcern" id="NatureOfBusinessAndGoingConcern">
<link:definition>1007 - Disclosure - Nature of Business and Going Concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/BasisOfPresentation" id="BasisOfPresentation">
<link:definition>1008 - Disclosure - Basis of Presentation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/AmountsReceivable" id="AmountsReceivable">
<link:definition>1010 - Disclosure - Amounts Receivable</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
<link:definition>1011 - Disclosure - Property and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/RightOfUseAsset" id="RightOfUseAsset">
<link:definition>1012 - Disclosure - Right-of-Use Asset</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilities" id="AccountsPayableAndAccruedLiabilities">
<link:definition>1013 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/LoansPayable" id="LoansPayable">
<link:definition>1014 - Disclosure - Loans Payable</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/LeaseLiability" id="LeaseLiability">
<link:definition>1015 - Disclosure - Lease Liability</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/AuritecLicenseAgreement" id="AuritecLicenseAgreement">
<link:definition>1016 - Disclosure - Auritec License Agreement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ConvertibleDebt" id="ConvertibleDebt">
<link:definition>1017 - Disclosure - Convertible Debt</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquity" id="ShareCapitalAndOtherComponentsOfEquity">
<link:definition>1018 - Disclosure - Share Capital and Other Components of Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/GeneralAndAdministrativeExpenses" id="GeneralAndAdministrativeExpenses">
<link:definition>1019 - Disclosure - General And Administrative Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ResearchAndDevelopmentExpenses" id="ResearchAndDevelopmentExpenses">
<link:definition>1020 - Disclosure - Research And Development Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/GovernmentGrantsAndAssistance" id="GovernmentGrantsAndAssistance">
<link:definition>1021 - Disclosure - Government Grants And Assistance</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1022 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/Commitments" id="Commitments">
<link:definition>1023 - Disclosure - Commitments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/FinancialInstruments" id="FinancialInstruments">
<link:definition>1024 - Disclosure - Financial Instruments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/InterestExpense" id="InterestExpense">
<link:definition>1025 - Disclosure - Interest Expense</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlows" id="SupplementalDisclosureWithRespectToCashFlows">
<link:definition>1026 - Disclosure - Supplemental Disclosure with Respect to Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/SubsequentEvent" id="SubsequentEvent">
<link:definition>1027 - Disclosure - Subsequent Event</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1028 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1029 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/AmountsReceivableTables" id="AmountsReceivableTables">
<link:definition>1030 - Disclosure - Amounts Receivable (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
<link:definition>1031 - Disclosure - Property and Equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/RightOfUseAssetTables" id="RightOfUseAssetTables">
<link:definition>1032 - Disclosure - Right-of-Use Asset (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesTables" id="AccountsPayableAndAccruedLiabilitiesTables">
<link:definition>1033 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/LoansPayableTables" id="LoansPayableTables">
<link:definition>1034 - Disclosure - Loans Payable (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/LeaseLiabilityTables" id="LeaseLiabilityTables">
<link:definition>1035 - Disclosure - Lease Liability (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/AuritecLicenseAgreementTables" id="AuritecLicenseAgreementTables">
<link:definition>1036 - Disclosure - Auritec License Agreement (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ConvertibleDebtTables" id="ConvertibleDebtTables">
<link:definition>1037 - Disclosure - Convertible Debt (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityTables" id="ShareCapitalAndOtherComponentsOfEquityTables">
<link:definition>1038 - Disclosure - Share Capital and Other Components of Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesTables" id="GeneralAndAdministrativeExpensesTables">
<link:definition>1039 - Disclosure - General And Administrative Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesTables" id="ResearchAndDevelopmentExpensesTables">
<link:definition>1040 - Disclosure - Research And Development Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceTables" id="GovernmentGrantsAndAssistanceTables">
<link:definition>1041 - Disclosure - Government Grants And Assistance (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1042 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/FinancialInstrumentsTables" id="FinancialInstrumentsTables">
<link:definition>1043 - Disclosure - Financial Instruments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/InterestExpenseTables" id="InterestExpenseTables">
<link:definition>1044 - Disclosure - Interest Expense (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsTables" id="SupplementalDisclosureWithRespectToCashFlowsTables">
<link:definition>1045 - Disclosure - Supplemental Disclosure with Respect to Cash Flows (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail" id="NatureOfBusinessAndGoingConcernAdditionalInformationDetail">
<link:definition>1046 - Disclosure - Nature of Business and Going Concern - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail" id="SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail">
<link:definition>1047 - Disclosure - Summary of Significant Accounting Policies - Summary of Information About Subsidiaries (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail" id="SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail">
<link:definition>1048 - Disclosure - Summary of Significant Accounting Policies - Summary of Property Plant And Equipment Estimated Useful Life (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1049 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/AmountsReceivableSummaryOfAmountsReceivableDetail" id="AmountsReceivableSummaryOfAmountsReceivableDetail">
<link:definition>1050 - Disclosure - Amounts Receivable - Summary of Amounts Receivable (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" id="PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail">
<link:definition>1051 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/PropertyAndEquipmentAdditionalInformationDetail" id="PropertyAndEquipmentAdditionalInformationDetail">
<link:definition>1052 - Disclosure - Property and Equipment - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/RightOfUseAssetSummaryOfRightOfUseAssetsDetail" id="RightOfUseAssetSummaryOfRightOfUseAssetsDetail">
<link:definition>1053 - Disclosure - Right-of-Use Asset - Summary of Right of Use Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/RightOfUseAssetAdditionalInformationDetail" id="RightOfUseAssetAdditionalInformationDetail">
<link:definition>1054 - Disclosure - Right-of-Use Asset - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail" id="AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail">
<link:definition>1055 - Disclosure - Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/LoansPayableAdditionalInformationDetail" id="LoansPayableAdditionalInformationDetail">
<link:definition>1056 - Disclosure - Loans Payable - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/LoansPayableSummaryOfBreakdownOfLoanBalanceDetail" id="LoansPayableSummaryOfBreakdownOfLoanBalanceDetail">
<link:definition>1057 - Disclosure - Loans Payable - Summary of Breakdown of Loan Balance (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfCostComponentsOfTheOperatingLeaseDetail" id="LeaseLiabilitySummaryOfCostComponentsOfTheOperatingLeaseDetail">
<link:definition>1058 - Disclosure - Lease Liability - Summary of Cost Components of The Operating Lease (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail" id="LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail">
<link:definition>1059 - Disclosure - Lease Liability - Summary of Future Minimum Lease Payments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail" id="LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail">
<link:definition>1060 - Disclosure - Lease Liability - Summary of Lease Liability Balance (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/LeaseLiabilityAdditionalInformationDetail" id="LeaseLiabilityAdditionalInformationDetail">
<link:definition>1061 - Disclosure - Lease Liability - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail" id="AuritecLicenseAgreementAdditionalInformationDetail">
<link:definition>1062 - Disclosure - Auritec License Agreement - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail" id="AuritecLicenseAgreementScheduleOfMilestonePaymentDetail">
<link:definition>1063 - Disclosure - Auritec License Agreement - Schedule of Milestone Payment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail" id="AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail">
<link:definition>1064 - Disclosure - Auritec License Agreement - Schedule of Non-Royalty Monetization Revenue Percentage (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail" id="ConvertibleDebtAdditionalInformationDetail">
<link:definition>1065 - Disclosure - Convertible Debt - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail" id="ConvertibleDebtScheduleOfLoanBalanceDetail">
<link:definition>1066 - Disclosure - Convertible Debt - Schedule of Loan Balance (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail" id="ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail">
<link:definition>1067 - Disclosure - Share Capital and Other Components of Equity - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail" id="ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail">
<link:definition>1068 - Disclosure - Share Capital and Other Components of Equity - Summary of Company's Option (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail" id="ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail">
<link:definition>1069 - Disclosure - Share Capital and Other Components of Equity - Summary of Options Outstanding Along with the Grant Dates and Expiry Date (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail" id="ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail">
<link:definition>1070 - Disclosure - Share Capital and Other Components of Equity - Summary of Weighted-Average Assumptions (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail" id="ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail">
<link:definition>1071 - Disclosure - Share Capital and Other Components of Equity - Summary of Share Based Compensation Arrangements by Share Based Payment Warrant (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail" id="ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail">
<link:definition>1072 - Disclosure - Share Capital and Other Components of Equity - Summary of Share Based Compensation of Share Warrants Outstanding (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail" id="ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail">
<link:definition>1073 - Disclosure - Share Capital and Other Components of Equity - Summary of Share Based Compensation of Share Warrants Outstanding (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail" id="GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail">
<link:definition>1074 - Disclosure - General And Administrative Expenses - Schedule Of General And Administrative Expenses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail" id="ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail">
<link:definition>1075 - Disclosure - Research And Development Expenses - Schedule Of Research And Development Expenses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceAdditionalInformationDetail" id="GovernmentGrantsAndAssistanceAdditionalInformationDetail">
<link:definition>1076 - Disclosure - Government Grants And Assistance - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail" id="GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail">
<link:definition>1077 - Disclosure - Government Grants And Assistance - Shedule Of Government Grants And Assistance Received (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsIncludedInLossBeforeTaxesDetail" id="IncomeTaxesScheduleOfComponentsIncludedInLossBeforeTaxesDetail">
<link:definition>1078 - Disclosure - Income Taxes - Schedule of Components Included in Loss Before Taxes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail" id="IncomeTaxesScheduleOfIncomeTaxExpenseDetail">
<link:definition>1079 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail" id="IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail">
<link:definition>1080 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense Benefit (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail" id="IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail">
<link:definition>1081 - Disclosure - Income Taxes - Schedule of Components of Company's Net Deferred Income Tax Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail" id="IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail">
<link:definition>1082 - Disclosure - Income Taxes - Schedule of Non Capital Losses Carry Forward Future Years (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
<link:definition>1083 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/CommitmentsAdditionalInformationDetail" id="CommitmentsAdditionalInformationDetail">
<link:definition>1084 - Disclosure - Commitments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail" id="FinancialInstrumentsAdditionalInformationDetail">
<link:definition>1085 - Disclosure - Financial Instruments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfCarryingValueOfFinancialInstrumentsAtAmortizedCostDetail" id="FinancialInstrumentsSummaryOfCarryingValueOfFinancialInstrumentsAtAmortizedCostDetail">
<link:definition>1086 - Disclosure - Financial Instruments - Summary of Carrying Value of Financial Instruments at Amortized Cost (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail" id="FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail">
<link:definition>1087 - Disclosure - Financial Instruments - Summary of Changes in Fair Value of Liabilities Measured at Fair Value (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/InterestExpenseScheduleOfInterestExpenseDetail" id="InterestExpenseScheduleOfInterestExpenseDetail">
<link:definition>1088 - Disclosure - Interest Expense - Schedule of Interest Expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail" id="SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail">
<link:definition>1089 - Disclosure - Supplemental Disclosure with Respect to Cash Flows - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsSummaryOfDetailedBreakdownOfCashAndCashEquivalentsDetail" id="SupplementalDisclosureWithRespectToCashFlowsSummaryOfDetailedBreakdownOfCashAndCashEquivalentsDetail">
<link:definition>1090 - Disclosure - Supplemental Disclosure with Respect to Cash Flows - Summary of Detailed Breakdown of Cash And Cash Equivalents (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail" id="SubsequentEventAdditionalInformationDetail">
<link:definition>1091 - Disclosure - Subsequent Event - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetailAlternate1" id="LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetailAlternate1">
<link:definition>1092 - Statement - Lease Liability - Summary of Future Minimum Lease Payments (Detail) Alternate 1</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="eprx-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="eprx-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="eprx-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="eprx-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
<import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
<import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
<import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
<import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="PayableTowardsRoyaltyAndOthersCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_PayableTowardsRoyaltyAndOthersCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EventAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_EventAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="EventDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_EventDomain" substitutionGroup="xbrli:item" />
<element name="ExcerciseOfWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ExcerciseOfWarrantsMember" substitutionGroup="xbrli:item" />
<element name="OvernightMarketedPublicOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_OvernightMarketedPublicOfferingMember" substitutionGroup="xbrli:item" />
<element name="InterestExpensesOnLeaseLiabilityFinancingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_InterestExpensesOnLeaseLiabilityFinancingActivities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="InterestOnConvertibleDebtOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_InterestOnConvertibleDebtOne" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="InterestOnShortTermInvestmentsNonOperating" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_InterestOnShortTermInvestmentsNonOperating" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LossOnSaleOfEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_LossOnSaleOfEquipment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RightOfUseAssetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_RightOfUseAssetAbstract" substitutionGroup="xbrli:item" />
<element name="RightOfUseAssetTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_RightOfUseAssetTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureInEntiretyOfOtherLoansPayable" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_DisclosureInEntiretyOfOtherLoansPayable" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_LicenseAgreementAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureInEntiretyOfLicenseAgreementTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_DisclosureInEntiretyOfLicenseAgreementTextBlock" substitutionGroup="xbrli:item" />
<element name="GeneralAndAdministrativeExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_GeneralAndAdministrativeExpensesAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock" substitutionGroup="xbrli:item" />
<element name="FinancialInstrumentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_FinancialInstrumentsAbstract" substitutionGroup="xbrli:item" />
<element name="GovernmentGrantsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_GovernmentGrantsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfInformationAboutSubsidiariesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_ScheduleOfInformationAboutSubsidiariesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="NontradeReceivablesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_NontradeReceivablesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseRightOfUseAssetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_OperatingLeaseRightOfUseAssetAbstract" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseRightOfUseAssetTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_OperatingLeaseRightOfUseAssetTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems" substitutionGroup="xbrli:item" />
<element name="DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock" substitutionGroup="xbrli:item" />
<element name="LoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_LoanMember" substitutionGroup="xbrli:item" />
<element name="DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="GovernmentAssistanceTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_GovernmentAssistanceTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock" substitutionGroup="xbrli:item" />
<element name="NatureOfOperationsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_NatureOfOperationsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="LenderAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_LenderAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="LenderDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_LenderDomain" substitutionGroup="xbrli:item" />
<element name="SiliconValleyBankMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_SiliconValleyBankMember" substitutionGroup="xbrli:item" />
<element name="NatureOfOperationsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_NatureOfOperationsLineItems" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentMonthOfMaturity" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_DebtInstrumentMonthOfMaturity" substitutionGroup="xbrli:item" />
<element name="SummaryOfInformationAboutSubsidiariesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_SummaryOfInformationAboutSubsidiariesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AmdmHoldingsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_AmdmHoldingsIncMember" substitutionGroup="xbrli:item" />
<element name="EupraxiaHoldingsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_EupraxiaHoldingsIncMember" substitutionGroup="xbrli:item" />
<element name="EupraxiaPharmaceuticalsAustraliaPtyLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_EupraxiaPharmaceuticalsAustraliaPtyLtdMember" substitutionGroup="xbrli:item" />
<element name="EupraxiaPharmaceuticalsUsaLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_EupraxiaPharmaceuticalsUsaLlcMember" substitutionGroup="xbrli:item" />
<element name="EupraxiaPharmaIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_EupraxiaPharmaIncMember" substitutionGroup="xbrli:item" />
<element name="EupraxiaPharmaUsaIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_EupraxiaPharmaUsaIncMember" substitutionGroup="xbrli:item" />
<element name="SummaryOfInformationAboutSubsidiariesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_SummaryOfInformationAboutSubsidiariesLineItems" substitutionGroup="xbrli:item" />
<element name="InvestmentOwnershipPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_InvestmentOwnershipPercentage" substitutionGroup="xbrli:item" />
<element name="LabEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_LabEquipmentMember" substitutionGroup="xbrli:item" />
<element name="PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation" substitutionGroup="xbrli:item" />
<element name="PropertyPlantAndEqupmentRateOfDepreciation" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_PropertyPlantAndEqupmentRateOfDepreciation" substitutionGroup="xbrli:item" />
<element name="PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement" substitutionGroup="xbrli:item" />
<element name="OtherRefundableTaxCreditsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_OtherRefundableTaxCreditsCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RightOfUseAssetTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_RightOfUseAssetTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="RightOfUseAssetLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_RightOfUseAssetLineItems" substitutionGroup="xbrli:item" />
<element name="AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ForeignExchangeAdjustmentOnLoansPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_ForeignExchangeAdjustmentOnLoansPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract" substitutionGroup="xbrli:item" />
<element name="AreaOfSubleasedOfficeSpace" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_AreaOfSubleasedOfficeSpace" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_LicenseAgreementTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_AgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_AgreementDomain" substitutionGroup="xbrli:item" />
<element name="AmendedAndRestatedLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_AmendedAndRestatedLicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="EupraxiaUsaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_EupraxiaUsaMember" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_LicenseAgreementLineItems" substitutionGroup="xbrli:item" />
<element name="MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization" substitutionGroup="xbrli:item" />
<element name="MilestonePaymentRecognizedExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_MilestonePaymentRecognizedExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PayableTowardsCommercialAndRegulatorMilestoneAchievement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentOfUpfrontFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_PaymentOfUpfrontFees" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfNonRoyaltyMonetizationRevenuePayable" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable" substitutionGroup="xbrli:item" />
<element name="RoyaltyAsAPercentageOfNetSales" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_RoyaltyAsAPercentageOfNetSales" substitutionGroup="xbrli:item" />
<element name="MilestoneAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_MilestoneAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="MilestoneDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_MilestoneDomain" substitutionGroup="xbrli:item" />
<element name="SuccessfulCompletionOfPhaseTwoBStudyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_SuccessfulCompletionOfPhaseTwoBStudyMember" substitutionGroup="xbrli:item" />
<element name="DisclosureInTabularFormOfMilestonePaymentScheduleTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureInTabularFormOfMilestonePaymentScheduleLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems" substitutionGroup="xbrli:item" />
<element name="FirstOaRegulatoryApprovalMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_FirstOaRegulatoryApprovalMember" substitutionGroup="xbrli:item" />
<element name="NonOaIndicationRegulatoryApprovalMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_NonOaIndicationRegulatoryApprovalMember" substitutionGroup="xbrli:item" />
<element name="SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember" substitutionGroup="xbrli:item" />
<element name="SecondOaRegulatoryApprovalMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_SecondOaRegulatoryApprovalMember" substitutionGroup="xbrli:item" />
<element name="DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems" substitutionGroup="xbrli:item" />
<element name="PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty" substitutionGroup="xbrli:item" />
<element name="TrancheAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TrancheAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TrancheDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TrancheDomain" substitutionGroup="xbrli:item" />
<element name="AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember" substitutionGroup="xbrli:item" />
<element name="AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember" substitutionGroup="xbrli:item" />
<element name="AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember" substitutionGroup="xbrli:item" />
<element name="PriorToSuccessfulCompletionOfPhaseTwoBStudyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_PriorToSuccessfulCompletionOfPhaseTwoBStudyMember" substitutionGroup="xbrli:item" />
<element name="CallRightAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_CallRightAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="CallRightDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_CallRightDomain" substitutionGroup="xbrli:item" />
<element name="AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember" substitutionGroup="xbrli:item" />
<element name="WithEighteenMonthsFromTheDateOfTheDebtAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_WithEighteenMonthsFromTheDateOfTheDebtAgreementMember" substitutionGroup="xbrli:item" />
<element name="AggegateAmountRaisedByWayOfEquityIssue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_AggegateAmountRaisedByWayOfEquityIssue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AmountToBeRaisedByWayOfEquityIssue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_AmountToBeRaisedByWayOfEquityIssue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongTermDebtBaseRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_LongTermDebtBaseRate" substitutionGroup="xbrli:item" />
<element name="LongTermDebtPaidInKindInterestPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_LongTermDebtPaidInKindInterestPercentage" substitutionGroup="xbrli:item" />
<element name="LongTermDebtTermExtendableAtLendersDiscretion" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_LongTermDebtTermExtendableAtLendersDiscretion" substitutionGroup="xbrli:item" />
<element name="CanadianPrimeRateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_CanadianPrimeRateMember" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AmdmHoldingsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_AmdmHoldingsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AmdmHoldingsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_AmdmHoldingsDomain" substitutionGroup="xbrli:item" />
<element name="AmdmHoldingsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_AmdmHoldingsMember" substitutionGroup="xbrli:item" />
<element name="CashCostsOfIssuingShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_CashCostsOfIssuingShares" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CommonStockSharesIssuableAsAResultOfStockSplit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_CommonStockSharesIssuableAsAResultOfStockSplit" substitutionGroup="xbrli:item" />
<element name="EquityMethodInvestmentNumberOfSharedOwned" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_EquityMethodInvestmentNumberOfSharedOwned" substitutionGroup="xbrli:item" />
<element name="NumberOfUnitsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_NumberOfUnitsIssued" substitutionGroup="xbrli:item" />
<element name="NumberOfWarrantIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_NumberOfWarrantIssued" substitutionGroup="xbrli:item" />
<element name="PercentageOfGrossProceedsRaisedUnderTheOffering" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_PercentageOfGrossProceedsRaisedUnderTheOffering" substitutionGroup="xbrli:item" />
<element name="PercentageOfOutstandingSharesEligibleForStockOptionsIssuance" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_PercentageOfOutstandingSharesEligibleForStockOptionsIssuance" substitutionGroup="xbrli:item" />
<element name="PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering" substitutionGroup="xbrli:item" />
<element name="SecuritiesIssuedPricePerUnit" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_SecuritiesIssuedPricePerUnit" substitutionGroup="xbrli:item" />
<element name="StockSharesIssuedAsAPercentageOfOutstandingShares" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_StockSharesIssuedAsAPercentageOfOutstandingShares" substitutionGroup="xbrli:item" />
<element name="TransferredFromAdditionalPaidinCapitalToShareCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_TransferredFromAdditionalPaidinCapitalToShareCapital" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="WarrantIssuedPricePerUnit" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_WarrantIssuedPricePerUnit" substitutionGroup="xbrli:item" />
<element name="ExcerciseOfOptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ExcerciseOfOptionsMember" substitutionGroup="xbrli:item" />
<element name="EuphraxiaPharmaIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_EuphraxiaPharmaIncMember" substitutionGroup="xbrli:item" />
<element name="EuphraxiaUsaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_EuphraxiaUsaMember" substitutionGroup="xbrli:item" />
<element name="AmendedPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_AmendedPlanMember" substitutionGroup="xbrli:item" />
<element name="OutstandingOfAMDMHoldingsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_OutstandingOfAMDMHoldingsMember" substitutionGroup="xbrli:item" />
<element name="ClassBNonVotingStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ClassBNonVotingStockMember" substitutionGroup="xbrli:item" />
<element name="ChiefScientificOfficerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ChiefScientificOfficerMember" substitutionGroup="xbrli:item" />
<element name="ImmediateVestingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ImmediateVestingMember" substitutionGroup="xbrli:item" />
<element name="WarrantAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_WarrantAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="WarrantDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_WarrantDomain" substitutionGroup="xbrli:item" />
<element name="CompensationWarrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_CompensationWarrantMember" substitutionGroup="xbrli:item" />
<element name="DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationOptionsExpiryDateAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ShareBasedCompensationOptionsExpiryDateAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ShareBasedCompensationOptionsExpiryDateDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ShareBasedCompensationOptionsExpiryDateDomain" substitutionGroup="xbrli:item" />
<element name="EighteenthMayTwoThousandAndTwentyThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_EighteenthMayTwoThousandAndTwentyThreeMember" substitutionGroup="xbrli:item" />
<element name="FiveMarchTwoThousandAndEighteenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_FiveMarchTwoThousandAndEighteenMember" substitutionGroup="xbrli:item" />
<element name="NineDecemberTwoThousandAndTwentyOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_NineDecemberTwoThousandAndTwentyOneMember" substitutionGroup="xbrli:item" />
<element name="NineDecemberTwoThousandAndTwentyTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_NineDecemberTwoThousandAndTwentyTwoMember" substitutionGroup="xbrli:item" />
<element name="NineMarchTwoThousandAndTwentyOne1Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_NineMarchTwoThousandAndTwentyOne1Member" substitutionGroup="xbrli:item" />
<element name="NineMarchTwoThousandAndTwentyOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_NineMarchTwoThousandAndTwentyOneMember" substitutionGroup="xbrli:item" />
<element name="ThirtyFirstMarchTwoThousandAndTwentyTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ThirtyFirstMarchTwoThousandAndTwentyTwoMember" substitutionGroup="xbrli:item" />
<element name="ThirtyMayTwoThousandAndTwentyThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ThirtyMayTwoThousandAndTwentyThreeMember" substitutionGroup="xbrli:item" />
<element name="ThreeMayTwoThousandAndTwentyOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ThreeMayTwoThousandAndTwentyOneMember" substitutionGroup="xbrli:item" />
<element name="TwentySeventhSeptemberTwoThousandAndFifteenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TwentySeventhSeptemberTwoThousandAndFifteenMember" substitutionGroup="xbrli:item" />
<element name="TwentySeventhSeptemberTwoThousandAndTwentyThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TwentySeventhSeptemberTwoThousandAndTwentyThreeMember" substitutionGroup="xbrli:item" />
<element name="TwoNovemberTwoThousandAndFifteenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TwoNovemberTwoThousandAndFifteenMember" substitutionGroup="xbrli:item" />
<element name="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" substitutionGroup="xbrli:item" />
<element name="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" substitutionGroup="xbrli:item" />
<element name="ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="MaturityPeriodWarrantsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_MaturityPeriodWarrantsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="MaturityPeriodWarrantsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_MaturityPeriodWarrantsDomain" substitutionGroup="xbrli:item" />
<element name="ExpiryPeriodEightMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ExpiryPeriodEightMember" substitutionGroup="xbrli:item" />
<element name="ExpiryPeriodFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ExpiryPeriodFiveMember" substitutionGroup="xbrli:item" />
<element name="ExpiryPeriodFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ExpiryPeriodFourMember" substitutionGroup="xbrli:item" />
<element name="ExpiryPeriodNineMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ExpiryPeriodNineMember" substitutionGroup="xbrli:item" />
<element name="ExpiryPeriodOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ExpiryPeriodOneMember" substitutionGroup="xbrli:item" />
<element name="ExpiryPeriodSevenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ExpiryPeriodSevenMember" substitutionGroup="xbrli:item" />
<element name="ExpiryPeriodSixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ExpiryPeriodSixMember" substitutionGroup="xbrli:item" />
<element name="ExpiryPeriodTenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ExpiryPeriodTenMember" substitutionGroup="xbrli:item" />
<element name="ExpiryPeriodThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ExpiryPeriodThreeMember" substitutionGroup="xbrli:item" />
<element name="ExpiryPeriodTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ExpiryPeriodTwoMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems" substitutionGroup="xbrli:item" />
<element name="ResearchAndDevelopmentExpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ResearchAndDevelopmentExpensesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ResearchAndDevelopmentExpensesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ResearchAndDevelopmentExpensesAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ResearchAndDevelopmentExpensesDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ResearchAndDevelopmentExpensesDomain" substitutionGroup="xbrli:item" />
<element name="ClinicalMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ClinicalMember" substitutionGroup="xbrli:item" />
<element name="ConsultingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ConsultingMember" substitutionGroup="xbrli:item" />
<element name="ManufacturingAndAnalyticaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ManufacturingAndAnalyticaMember" substitutionGroup="xbrli:item" />
<element name="PreclinicalMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_PreclinicalMember" substitutionGroup="xbrli:item" />
<element name="RegulatoryMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_RegulatoryMember" substitutionGroup="xbrli:item" />
<element name="ResearchAndDevelopmentExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ResearchAndDevelopmentExpensesLineItems" substitutionGroup="xbrli:item" />
<element name="PipelineDevelopmentOfResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ResearchAndDevelopmentCostsGrossExcludingOtherCategory" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ResearchAndDevelopmentLicenseExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_ResearchAndDevelopmentLicenseExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SalariesAndBenefitsOfResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ShareBasedPaymentsOfResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GovernmentAssistanceAmountForResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_GovernmentAssistanceAmountForResearchAndDevelopment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfReimburseAssistanceToSupportContractorFee" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_PercentageOfReimburseAssistanceToSupportContractorFee" substitutionGroup="xbrli:item" />
<element name="PercentageOfReimburseAssistanceToSupportSalaryCost" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_PercentageOfReimburseAssistanceToSupportSalaryCost" substitutionGroup="xbrli:item" />
<element name="ReimbursementAssistanceMaximumForSalaryAndContractorCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_ReimbursementAssistanceMaximumForSalaryAndContractorCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember" substitutionGroup="xbrli:item" />
<element name="BioTalentCanadaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_BioTalentCanadaMember" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxReconciliationDifferencesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EffectiveIncomeTaxReconciliationShareIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_EffectiveIncomeTaxReconciliationShareIssuanceCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxAssetsConvertibleDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_DeferredTaxAssetsConvertibleDebt" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsLeaseObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_DeferredTaxAssetsLeaseObligation" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsShareIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_DeferredTaxAssetsShareIssuanceCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCapitalLossesCarryForwardFutureYearsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_NonCapitalLossesCarryForwardFutureYearsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="NonCapitalLossesCarryForwardFutureYearsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_NonCapitalLossesCarryForwardFutureYearsLineItems" substitutionGroup="xbrli:item" />
<element name="NonCapitalLossCarryforwardsToFutureExpire" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_NonCapitalLossCarryforwardsToFutureExpire" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxYear2031Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TaxYear2031Member" substitutionGroup="xbrli:item" />
<element name="TaxYear2032Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TaxYear2032Member" substitutionGroup="xbrli:item" />
<element name="TaxYear2033Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TaxYear2033Member" substitutionGroup="xbrli:item" />
<element name="TaxYear2034Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TaxYear2034Member" substitutionGroup="xbrli:item" />
<element name="TaxYear2035Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TaxYear2035Member" substitutionGroup="xbrli:item" />
<element name="TaxYear2036Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TaxYear2036Member" substitutionGroup="xbrli:item" />
<element name="TaxYear2037Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TaxYear2037Member" substitutionGroup="xbrli:item" />
<element name="TaxYear2038Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TaxYear2038Member" substitutionGroup="xbrli:item" />
<element name="TaxYear2039Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TaxYear2039Member" substitutionGroup="xbrli:item" />
<element name="TaxYear2040Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TaxYear2040Member" substitutionGroup="xbrli:item" />
<element name="TaxYear2041Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TaxYear2041Member" substitutionGroup="xbrli:item" />
<element name="TaxYear2042Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TaxYear2042Member" substitutionGroup="xbrli:item" />
<element name="TaxYear2043Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TaxYear2043Member" substitutionGroup="xbrli:item" />
<element name="TaxYearAfter2043Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_TaxYearAfter2043Member" substitutionGroup="xbrli:item" />
<element name="TaxCreditCarryForwardsExpirationTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_TaxCreditCarryForwardsExpirationTerm" substitutionGroup="xbrli:item" />
<element name="RelevantPeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_RelevantPeriodAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="RelevantPeriodDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_RelevantPeriodDomain" substitutionGroup="xbrli:item" />
<element name="CanadianFederalInvestmentTaxCreditsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_CanadianFederalInvestmentTaxCreditsMember" substitutionGroup="xbrli:item" />
<element name="ProvincialInvestmentTaxCreditsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ProvincialInvestmentTaxCreditsMember" substitutionGroup="xbrli:item" />
<element name="CancellationFeeForCancellationOfContract" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_CancellationFeeForCancellationOfContract" substitutionGroup="xbrli:item" />
<element name="CancellationFeeOnTerminationOfContract" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_CancellationFeeOnTerminationOfContract" substitutionGroup="xbrli:item" />
<element name="FinancialInstrumentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_FinancialInstrumentsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="FinancialInstrumentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_FinancialInstrumentsLineItems" substitutionGroup="xbrli:item" />
<element name="ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageIncreaseInSignificantUnobservableInputAssets" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_PercentageIncreaseInSignificantUnobservableInputAssets" substitutionGroup="xbrli:item" />
<element name="PercentageIncreaseInSignificantUnobservableInputLiabilities" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_PercentageIncreaseInSignificantUnobservableInputLiabilities" substitutionGroup="xbrli:item" />
<element name="SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate" substitutionGroup="xbrli:item" />
<element name="CurrencyRiskMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_CurrencyRiskMember" substitutionGroup="xbrli:item" />
<element name="EquipmentLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_EquipmentLoanMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems" substitutionGroup="xbrli:item" />
<element name="AccountsPayableAndAccruedLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eprx_AccountsPayableAndAccruedLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherInterestAndAccretionExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_OtherInterestAndAccretionExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NumberofWarrantsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eprx_NumberofWarrantsIssued" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>eprx-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 01-April-2024 [11:12:04] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ConsolidatedBalanceSheets" roleURI="http://eupraxiapharma.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#AmountsReceivableSummaryOfAmountsReceivableDetail" roleURI="http://eupraxiapharma.com/role/AmountsReceivableSummaryOfAmountsReceivableDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail" roleURI="http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail" roleURI="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail" roleURI="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail" roleURI="http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail" roleURI="http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#IncomeTaxesScheduleOfIncomeTaxExpenseDetail" roleURI="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail" roleURI="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail" roleURI="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#InterestExpenseScheduleOfInterestExpenseDetail" roleURI="http://eupraxiapharma.com/role/InterestExpenseScheduleOfInterestExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#SupplementalDisclosureWithRespectToCashFlowsSummaryOfDetailedBreakdownOfCashAndCashEquivalentsDetail" roleURI="http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsSummaryOfDetailedBreakdownOfCashAndCashEquivalentsDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetailAlternate1" roleURI="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetailAlternate1" />
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="loc_us-gaap_NontradeReceivablesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_NontradeReceivablesCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="loc_us-gaap_OtherLongTermDebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherLongTermDebtCurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ConvertibleDebtCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PayableTowardsRoyaltyAndOthersCurrent" xlink:label="loc_EPRX_PayableTowardsRoyaltyAndOthersCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_EPRX_PayableTowardsRoyaltyAndOthersCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLongTermDebtNoncurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_MinorityInterest" use="optional" order="24" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" use="optional" order="15" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsSummaryOfDetailedBreakdownOfCashAndCashEquivalentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaap_Cash" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_Depreciation" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LossOnSaleOfEquipment" xlink:label="loc_EPRX_LossOnSaleOfEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_EPRX_LossOnSaleOfEquipment" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_InterestOnConvertibleDebtOne" xlink:label="loc_EPRX_InterestOnConvertibleDebtOne" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_EPRX_InterestOnConvertibleDebtOne" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_InterestOnShortTermInvestmentsNonOperating" xlink:label="loc_EPRX_InterestOnShortTermInvestmentsNonOperating" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_EPRX_InterestOnShortTermInvestmentsNonOperating" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_InterestExpensesOnLeaseLiabilityFinancingActivities" xlink:label="loc_EPRX_InterestExpensesOnLeaseLiabilityFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_EPRX_InterestExpensesOnLeaseLiabilityFinancingActivities" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent" xlink:label="loc_EPRX_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_EPRX_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments" use="optional" order="18" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt" use="optional" order="24" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments" use="optional" order="25" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/InterestExpenseScheduleOfInterestExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense" xlink:to="loc_us-gaap_InterestExpenseDebt" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OtherInterestAndAccretionExpense" xlink:label="loc_EPRX_OtherInterestAndAccretionExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense" xlink:to="loc_EPRX_OtherInterestAndAccretionExpense" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/AmountsReceivableSummaryOfAmountsReceivableDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="loc_us-gaap_NontradeReceivablesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NontradeReceivablesCurrent" xlink:to="loc_us-gaap_GrantsReceivableCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmountCumulativeCurrent" xlink:label="loc_us-gaap_GovernmentAssistanceAmountCumulativeCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NontradeReceivablesCurrent" xlink:to="loc_us-gaap_GovernmentAssistanceAmountCumulativeCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OtherRefundableTaxCreditsCurrent" xlink:label="loc_EPRX_OtherRefundableTaxCreditsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NontradeReceivablesCurrent" xlink:to="loc_EPRX_OtherRefundableTaxCreditsCurrent" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment" xlink:label="loc_EPRX_AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_EPRX_AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration" xlink:label="loc_EPRX_AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_EPRX_AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedPayrollTaxesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedBonusesCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_TaxesPayableCurrent" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetailAlternate1">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_OperatingLeaseLiability" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaap_GeneralInsuranceExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="loc_us-gaap_GeneralInsuranceExpense" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaap_TravelAndEntertainmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="loc_us-gaap_TravelAndEntertainmentExpense" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="loc_us-gaap_ProfessionalFees" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreOpeningCosts" xlink:label="loc_us-gaap_PreOpeningCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="loc_us-gaap_PreOpeningCosts" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaap_LaborAndRelatedExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="loc_us-gaap_LaborAndRelatedExpense" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense" xlink:label="loc_EPRX_PipelineDevelopmentOfResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="loc_EPRX_PipelineDevelopmentOfResearchAndDevelopmentExpense" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses" xlink:label="loc_EPRX_SalariesAndBenefitsOfResearchAndDevelopmentExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="loc_EPRX_SalariesAndBenefitsOfResearchAndDevelopmentExpenses" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses" xlink:label="loc_EPRX_ShareBasedPaymentsOfResearchAndDevelopmentExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="loc_EPRX_ShareBasedPaymentsOfResearchAndDevelopmentExpenses" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="loc_us-gaap_GovernmentAssistanceAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="loc_us-gaap_GovernmentAssistanceAmount" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses" xlink:label="loc_EPRX_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="loc_EPRX_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory" xlink:label="loc_EPRX_ResearchAndDevelopmentCostsGrossExcludingOtherCategory" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="loc_EPRX_ResearchAndDevelopmentCostsGrossExcludingOtherCategory" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentLicenseExpenses" xlink:label="loc_EPRX_ResearchAndDevelopmentLicenseExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="loc_EPRX_ResearchAndDevelopmentLicenseExpenses" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EffectiveIncomeTaxReconciliationShareIssuanceCosts" xlink:label="loc_EPRX_EffectiveIncomeTaxReconciliationShareIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_EPRX_EffectiveIncomeTaxReconciliationShareIssuanceCosts" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency" xlink:label="loc_EPRX_EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_EPRX_EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DeferredTaxAssetsConvertibleDebt" xlink:label="loc_EPRX_DeferredTaxAssetsConvertibleDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_EPRX_DeferredTaxAssetsConvertibleDebt" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DeferredTaxAssetsLeaseObligation" xlink:label="loc_EPRX_DeferredTaxAssetsLeaseObligation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_EPRX_DeferredTaxAssetsLeaseObligation" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DeferredTaxAssetsShareIssuanceCosts" xlink:label="loc_EPRX_DeferredTaxAssetsShareIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_EPRX_DeferredTaxAssetsShareIssuanceCosts" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" use="optional" order="9" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>eprx-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 01-April-2024 [11:12:04] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#CoverPage" roleURI="http://eupraxiapharma.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ConsolidatedStatementsOfChangesInShareholdersEquityDeficit" roleURI="http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ConvertibleDebtTables" roleURI="http://eupraxiapharma.com/role/ConvertibleDebtTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#FinancialInstrumentsTables" roleURI="http://eupraxiapharma.com/role/FinancialInstrumentsTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#NatureOfBusinessAndGoingConcernAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail" roleURI="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail" roleURI="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" roleURI="http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#PropertyAndEquipmentAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/PropertyAndEquipmentAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#RightOfUseAssetAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/RightOfUseAssetAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#LoansPayableAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/LoansPayableAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#LeaseLiabilitySummaryOfCostComponentsOfTheOperatingLeaseDetail" roleURI="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfCostComponentsOfTheOperatingLeaseDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail" roleURI="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail" roleURI="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#LeaseLiabilityAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/LeaseLiabilityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#AuritecLicenseAgreementAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#AuritecLicenseAgreementScheduleOfMilestonePaymentDetail" roleURI="http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail" roleURI="http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ConvertibleDebtAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ConvertibleDebtScheduleOfLoanBalanceDetail" roleURI="http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail" roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail" roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail" roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail" roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail" roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail" roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail" roleURI="http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#GovernmentGrantsAndAssistanceAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail" roleURI="http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail" roleURI="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#CommitmentsAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/CommitmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#FinancialInstrumentsAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#FinancialInstrumentsSummaryOfCarryingValueOfFinancialInstrumentsAtAmortizedCostDetail" roleURI="http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfCarryingValueOfFinancialInstrumentsAtAmortizedCostDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail" roleURI="http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#SubsequentEventAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentInformationTable_3" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1068" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1068" xlink:to="loc_dei_AddressTypeDomain_1069" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1069_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1068" xlink:to="loc_dei_AddressTypeDomain_1069_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1069" xlink:to="loc_dei_BusinessContactMember_1070" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_AmendmentFlag_11" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_dei_AnnualInformationForm_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_AnnualInformationForm_37" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_dei_AuditedAnnualFinancialStatements_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_AuditedAnnualFinancialStatements_38" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_AuditorName_39" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_AuditorFirmId_40" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_AuditorLocation_41" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentType_7" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentRegistrationStatement_8" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentAnnualReport_9" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentPeriodEndDate_12" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentFiscalYearFocus_13" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_14" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityRegistrantName_15" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityCentralIndexKey_16" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_CurrentFiscalYearEndDate_17" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityCurrentReportingStatus_18" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityInteractiveDataCurrent_19" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityEmergingGrowthCompany_20" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_1204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityExTransitionPeriod_1204" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_21" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityPrimarySicNumber_1073" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityFileNumber_26" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_ContactPersonnelName_27" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_28" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityAddressAddressLine1_29" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityAddressAddressLine2_30" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityAddressCityOrTown_31" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityAddressStateOrProvince_32" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityAddressCountry_33" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityAddressPostalZipCode_34" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_CityAreaCode_35" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_LocalPhoneNumber_36" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_77" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_IcfrAuditorAttestationFlag_77" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_42" use="optional" order="39" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_184" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_StatementTable_161" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_161" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_162" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_162" xlink:to="loc_us-gaap_EquityComponentDomain_163" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_163_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_162" xlink:to="loc_us-gaap_EquityComponentDomain_163_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_163" xlink:to="loc_us-gaap_CommonStockMember_164" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_163" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_165" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_163" xlink:to="loc_us-gaap_RetainedEarningsMember_166" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_163" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_168" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_163" xlink:to="loc_us-gaap_NoncontrollingInterestMember_169" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_161" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_204" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_204" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_205" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_205_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_204" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_205_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OvernightMarketedPublicOfferingMember" xlink:label="loc_eprx_OvernightMarketedPublicOfferingMember_1184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_205" xlink:to="loc_eprx_OvernightMarketedPublicOfferingMember_1184" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_205" xlink:to="loc_us-gaap_PrivatePlacementMember_206" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EventAxis" xlink:label="loc_eprx_EventAxis_1181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_161" xlink:to="loc_eprx_EventAxis_1181" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EventDomain" xlink:label="loc_eprx_EventDomain_1182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eprx_EventAxis_1181" xlink:to="loc_eprx_EventDomain_1182" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EventDomain" xlink:label="loc_eprx_EventDomain_1182_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eprx_EventAxis_1181" xlink:to="loc_eprx_EventDomain_1182_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExcerciseOfWarrantsMember" xlink:label="loc_eprx_ExcerciseOfWarrantsMember_1183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_EventDomain_1182" xlink:to="loc_eprx_ExcerciseOfWarrantsMember_1183" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_196" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_SharesOutstanding_190" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_191" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_192" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_193" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_200" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_201" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_ProfitLoss_197" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_198" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_227" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StatementTable_226" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_226" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_228" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_228" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_229" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_229_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_228" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_229_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_ProfitLoss_224" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_InterestOnConvertibleDebtOne" xlink:label="loc_eprx_InterestOnConvertibleDebtOne_1185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_eprx_InterestOnConvertibleDebtOne_1185" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_InterestOnShortTermInvestmentsNonOperating" xlink:label="loc_eprx_InterestOnShortTermInvestmentsNonOperating_1186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_eprx_InterestOnShortTermInvestmentsNonOperating_1186" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_Depreciation_233" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_InterestExpensesOnLeaseLiabilityFinancingActivities" xlink:label="loc_eprx_InterestExpensesOnLeaseLiabilityFinancingActivities_1187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_eprx_InterestExpensesOnLeaseLiabilityFinancingActivities_1187" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LossOnSaleOfEquipment" xlink:label="loc_eprx_LossOnSaleOfEquipment_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_eprx_LossOnSaleOfEquipment_235" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_ShareBasedCompensation_237" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_239" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_240" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_243" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_243" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_244" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_243" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_245" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_243" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_246" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent" xlink:label="loc_eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent_1422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_243" xlink:to="loc_eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent_1422" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_247" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_249" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_250" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_251" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_252" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_253" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_256" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_256" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_258" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_256" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_261" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_256" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_264" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_256" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_266" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_256" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_267" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_256" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_268" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_270" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_271" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_272" use="optional" order="37" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConvertibleDebtTables">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_1369" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock_323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_1369" xlink:to="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock_323" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_1368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_1369" xlink:to="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_1368" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_1368" xlink:to="loc_dei_LegalEntityAxis_1370" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1370" xlink:to="loc_dei_EntityDomain_1371" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1371_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1370" xlink:to="loc_dei_EntityDomain_1371_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LoanMember" xlink:label="loc_eprx_LoanMember_1372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1371" xlink:to="loc_eprx_LoanMember_1372" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/FinancialInstrumentsTables">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_1361" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock_403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_1361" xlink:to="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock_403" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_1360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_1361" xlink:to="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_1360" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_1360" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1362" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1362" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1363" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1363_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1362" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1363_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1363" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1364" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock" xlink:label="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock_402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_1361" xlink:to="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock_402" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NatureOfOperationsLineItems" xlink:label="loc_eprx_NatureOfOperationsLineItems_144" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_125" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_126" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NatureOfOperationsTable" xlink:label="loc_eprx_NatureOfOperationsTable_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_eprx_NatureOfOperationsTable_137" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_NatureOfOperationsTable_137" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_146" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_146" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_147" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_147_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_146" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_147_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_147" xlink:to="loc_us-gaap_PrivatePlacementMember_148" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_147" xlink:to="loc_us-gaap_IPOMember_1428" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_NatureOfOperationsTable_137" xlink:to="loc_us-gaap_DebtInstrumentAxis_324" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_324" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_325" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_325_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_324" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_325_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LenderAxis" xlink:label="loc_eprx_LenderAxis_1191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_NatureOfOperationsTable_137" xlink:to="loc_eprx_LenderAxis_1191" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LenderDomain" xlink:label="loc_eprx_LenderDomain_1192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eprx_LenderAxis_1191" xlink:to="loc_eprx_LenderDomain_1192" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LenderDomain" xlink:label="loc_eprx_LenderDomain_1192_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eprx_LenderAxis_1191" xlink:to="loc_eprx_LenderDomain_1192_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SiliconValleyBankMember" xlink:label="loc_eprx_SiliconValleyBankMember_1193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_LenderDomain_1192" xlink:to="loc_eprx_SiliconValleyBankMember_1193" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_NatureOfOperationsTable_137" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1425" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1425" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1426" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1426_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1425" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1426_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1426" xlink:to="loc_us-gaap_SubsequentEventMember_1427" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="loc_us-gaap_DebtInstrumentCollateralAmount_157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_us-gaap_DebtInstrumentCollateralAmount_157" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DebtInstrumentMonthOfMaturity" xlink:label="loc_eprx_DebtInstrumentMonthOfMaturity_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_eprx_DebtInstrumentMonthOfMaturity_273" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_us-gaap_Revenues_131" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_us-gaap_ProfitLoss_132" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_135" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_153" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_155" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1423" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SummaryOfInformationAboutSubsidiariesLineItems" xlink:label="loc_eprx_SummaryOfInformationAboutSubsidiariesLineItems_777" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SummaryOfInformationAboutSubsidiariesTable" xlink:label="loc_eprx_SummaryOfInformationAboutSubsidiariesTable_754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eprx_SummaryOfInformationAboutSubsidiariesLineItems_777" xlink:to="loc_eprx_SummaryOfInformationAboutSubsidiariesTable_754" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_SummaryOfInformationAboutSubsidiariesTable_754" xlink:to="loc_dei_LegalEntityAxis_755" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_755" xlink:to="loc_dei_EntityDomain_756" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_756_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_755" xlink:to="loc_dei_EntityDomain_756_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaHoldingsIncMember" xlink:label="loc_eprx_EupraxiaHoldingsIncMember_760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_756" xlink:to="loc_eprx_EupraxiaHoldingsIncMember_760" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaPharmaceuticalsUsaLlcMember" xlink:label="loc_eprx_EupraxiaPharmaceuticalsUsaLlcMember_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_756" xlink:to="loc_eprx_EupraxiaPharmaceuticalsUsaLlcMember_764" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmdmHoldingsIncMember" xlink:label="loc_eprx_AmdmHoldingsIncMember_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_756" xlink:to="loc_eprx_AmdmHoldingsIncMember_767" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaPharmaIncMember" xlink:label="loc_eprx_EupraxiaPharmaIncMember_771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_756" xlink:to="loc_eprx_EupraxiaPharmaIncMember_771" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaPharmaceuticalsAustraliaPtyLtdMember" xlink:label="loc_eprx_EupraxiaPharmaceuticalsAustraliaPtyLtdMember_773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_756" xlink:to="loc_eprx_EupraxiaPharmaceuticalsAustraliaPtyLtdMember_773" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaPharmaUsaIncMember" xlink:label="loc_eprx_EupraxiaPharmaUsaIncMember_775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_756" xlink:to="loc_eprx_EupraxiaPharmaUsaIncMember_775" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_SummaryOfInformationAboutSubsidiariesTable_754" xlink:to="loc_srt_ConsolidatedEntitiesAxis_1205" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1205" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1206" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1206_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1205" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1206_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_1207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1206" xlink:to="loc_srt_SubsidiariesMember_1207" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_SummaryOfInformationAboutSubsidiariesLineItems_777" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_778" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_1208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_SummaryOfInformationAboutSubsidiariesLineItems_777" xlink:to="loc_dei_EntityAddressCityOrTown_1208" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_1210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_SummaryOfInformationAboutSubsidiariesLineItems_777" xlink:to="loc_dei_EntityAddressCountry_1210" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_InvestmentOwnershipPercentage" xlink:label="loc_eprx_InvestmentOwnershipPercentage_1211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_SummaryOfInformationAboutSubsidiariesLineItems_777" xlink:to="loc_eprx_InvestmentOwnershipPercentage_1211" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1062" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1062" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1054" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1054" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1056" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1056" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1057" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1057_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1056" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1057_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1058" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1057" xlink:to="loc_us-gaap_ComputerEquipmentMember_1058" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1057" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1429" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1057" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1060" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LabEquipmentMember" xlink:label="loc_eprx_LabEquipmentMember_1061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1057" xlink:to="loc_eprx_LabEquipmentMember_1061" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PropertyPlantAndEqupmentRateOfDepreciation" xlink:label="loc_eprx_PropertyPlantAndEqupmentRateOfDepreciation_1214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1062" xlink:to="loc_eprx_PropertyPlantAndEqupmentRateOfDepreciation_1214" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation" xlink:label="loc_eprx_PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation_1217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1062" xlink:to="loc_eprx_PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation_1217" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_375" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_375" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_367" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_367" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_368" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_368" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_368" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" xlink:to="loc_us-gaap_ComputerEquipmentMember_369" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_371" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_372" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LabEquipmentMember" xlink:label="loc_eprx_LabEquipmentMember_373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" xlink:to="loc_eprx_LabEquipmentMember_373" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_1440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_375" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_1440" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_1440" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1442" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease" xlink:label="loc_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease_1443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_1440" xlink:to="loc_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease_1443" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_1444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_1440" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_1444" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" xlink:label="loc_eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments_1445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_1440" xlink:to="loc_eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments_1445" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_1438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_375" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_1438" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_1438" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_376" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_1434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_1438" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_1434" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_1435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_1438" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_1435" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" xlink:label="loc_eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments_1436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_1438" xlink:to="loc_eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments_1436" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_375" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1448" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/PropertyAndEquipmentAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1136" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease" xlink:label="loc_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease_392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1136" xlink:to="loc_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease_392" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1136" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1135" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1135" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1137" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1137" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1138" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1138_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1137" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1138_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1138" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1139" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1138" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1140" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/RightOfUseAssetAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RightOfUseAssetLineItems" xlink:label="loc_eprx_RightOfUseAssetLineItems_1145" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease_544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_RightOfUseAssetLineItems_1145" xlink:to="loc_us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease_544" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RightOfUseAssetTable" xlink:label="loc_eprx_RightOfUseAssetTable_1144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eprx_RightOfUseAssetLineItems_1145" xlink:to="loc_eprx_RightOfUseAssetTable_1144" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_RightOfUseAssetTable_1144" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1146" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1146" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1147" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1147_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1146" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1147_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1147" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1148" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1147" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1149" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/LoansPayableAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1158" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1158" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_512" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTerm" xlink:label="loc_us-gaap_LongTermDebtTerm_514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1158" xlink:to="loc_us-gaap_LongTermDebtTerm_514" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1158" xlink:to="loc_us-gaap_DebtInstrumentTable_1157" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1157" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1159" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1159" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1160" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1160_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1159" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1160_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_1161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1160" xlink:to="loc_us-gaap_LoansPayableMember_1161" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1158" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1164" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_1165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1158" xlink:to="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_1165" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfCostComponentsOfTheOperatingLeaseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_576" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_576" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_575" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_576" xlink:to="loc_us-gaap_LeaseCostAbstract_577" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_577" xlink:to="loc_us-gaap_OperatingLeaseCost_578" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_577" xlink:to="loc_us-gaap_VariableLeaseCost_579" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract" xlink:label="loc_eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract_1213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_576" xlink:to="loc_eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract_1213" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract_1213" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_584" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract_1213" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_586" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_610" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_612" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_614" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_614" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncentiveFromLessor" xlink:label="loc_us-gaap_IncentiveFromLessor_1215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_IncentiveFromLessor_1215" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_617" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_OperatingLeaseLiability_618" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_643" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_643" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_642" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_643" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_644" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_643" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_645" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_643" xlink:to="loc_us-gaap_OperatingLeaseLiability_647" use="optional" order="4" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/LeaseLiabilityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_651" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_651" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_650" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_1218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_651" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_1218" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_651" xlink:to="loc_us-gaap_LeaseExpirationDate1_653" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AreaOfSubleasedOfficeSpace" xlink:label="loc_eprx_AreaOfSubleasedOfficeSpace_1395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_651" xlink:to="loc_eprx_AreaOfSubleasedOfficeSpace_1395" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_1396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_651" xlink:to="loc_us-gaap_SubleaseIncome_1396" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LicenseAgreementLineItems" xlink:label="loc_eprx_LicenseAgreementLineItems_421" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LicenseAgreementTable" xlink:label="loc_eprx_LicenseAgreementTable_409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eprx_LicenseAgreementLineItems_421" xlink:to="loc_eprx_LicenseAgreementTable_409" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AgreementAxis" xlink:label="loc_eprx_AgreementAxis_410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_LicenseAgreementTable_409" xlink:to="loc_eprx_AgreementAxis_410" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AgreementDomain" xlink:label="loc_eprx_AgreementDomain_411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eprx_AgreementAxis_410" xlink:to="loc_eprx_AgreementDomain_411" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AgreementDomain" xlink:label="loc_eprx_AgreementDomain_411_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eprx_AgreementAxis_410" xlink:to="loc_eprx_AgreementDomain_411_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmendedAndRestatedLicenseAgreementMember" xlink:label="loc_eprx_AmendedAndRestatedLicenseAgreementMember_412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_AgreementDomain_411" xlink:to="loc_eprx_AmendedAndRestatedLicenseAgreementMember_412" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_LicenseAgreementTable_409" xlink:to="loc_srt_CounterpartyNameAxis_413" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_413" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_414" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_414_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_413" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_414_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaUsaMember" xlink:label="loc_eprx_EupraxiaUsaMember_415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_414" xlink:to="loc_eprx_EupraxiaUsaMember_415" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_LicenseAgreementTable_409" xlink:to="loc_srt_RangeAxis_416" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_416" xlink:to="loc_srt_RangeMember_417" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_417_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_416" xlink:to="loc_srt_RangeMember_417_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_417" xlink:to="loc_srt_MaximumMember_418" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_417" xlink:to="loc_srt_MinimumMember_419" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ArithmeticAverageMember" xlink:label="loc_srt_ArithmeticAverageMember_420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_417" xlink:to="loc_srt_ArithmeticAverageMember_420" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_LicenseAgreementTable_409" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1456" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1456" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1457" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1457_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1456" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1457_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1457" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1458" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MilestoneAxis" xlink:label="loc_eprx_MilestoneAxis_1453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_LicenseAgreementTable_409" xlink:to="loc_eprx_MilestoneAxis_1453" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MilestoneDomain" xlink:label="loc_eprx_MilestoneDomain_1454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eprx_MilestoneAxis_1453" xlink:to="loc_eprx_MilestoneDomain_1454" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MilestoneDomain" xlink:label="loc_eprx_MilestoneDomain_1454_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eprx_MilestoneAxis_1453" xlink:to="loc_eprx_MilestoneDomain_1454_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SuccessfulCompletionOfPhaseTwoBStudyMember" xlink:label="loc_eprx_SuccessfulCompletionOfPhaseTwoBStudyMember_1455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_MilestoneDomain_1454" xlink:to="loc_eprx_SuccessfulCompletionOfPhaseTwoBStudyMember_1455" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PaymentOfUpfrontFees" xlink:label="loc_eprx_PaymentOfUpfrontFees_422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_LicenseAgreementLineItems_421" xlink:to="loc_eprx_PaymentOfUpfrontFees_422" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement" xlink:label="loc_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement_423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_LicenseAgreementLineItems_421" xlink:to="loc_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement_423" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable" xlink:label="loc_eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable_425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_LicenseAgreementLineItems_421" xlink:to="loc_eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable_425" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization" xlink:label="loc_eprx_MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization_428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_LicenseAgreementLineItems_421" xlink:to="loc_eprx_MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization_428" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MilestonePaymentRecognizedExpense" xlink:label="loc_eprx_MilestonePaymentRecognizedExpense_1452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_LicenseAgreementLineItems_421" xlink:to="loc_eprx_MilestonePaymentRecognizedExpense_1452" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RoyaltyAsAPercentageOfNetSales" xlink:label="loc_eprx_RoyaltyAsAPercentageOfNetSales_424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_LicenseAgreementLineItems_421" xlink:to="loc_eprx_RoyaltyAsAPercentageOfNetSales_424" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems" xlink:label="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems_464" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable" xlink:label="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable_445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems_464" xlink:to="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable_445" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AgreementAxis" xlink:label="loc_eprx_AgreementAxis_446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable_445" xlink:to="loc_eprx_AgreementAxis_446" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AgreementDomain" xlink:label="loc_eprx_AgreementDomain_447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eprx_AgreementAxis_446" xlink:to="loc_eprx_AgreementDomain_447" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AgreementDomain" xlink:label="loc_eprx_AgreementDomain_447_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eprx_AgreementAxis_446" xlink:to="loc_eprx_AgreementDomain_447_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmendedAndRestatedLicenseAgreementMember" xlink:label="loc_eprx_AmendedAndRestatedLicenseAgreementMember_448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_AgreementDomain_447" xlink:to="loc_eprx_AmendedAndRestatedLicenseAgreementMember_448" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable_445" xlink:to="loc_srt_CounterpartyNameAxis_451" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_451" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_452" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_452_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_451" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_452_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaUsaMember" xlink:label="loc_eprx_EupraxiaUsaMember_453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_452" xlink:to="loc_eprx_EupraxiaUsaMember_453" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable_445" xlink:to="loc_srt_RangeAxis_454" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_454" xlink:to="loc_srt_RangeMember_455" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_455_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_454" xlink:to="loc_srt_RangeMember_455_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_455" xlink:to="loc_srt_MaximumMember_456" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MilestoneAxis" xlink:label="loc_eprx_MilestoneAxis_457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable_445" xlink:to="loc_eprx_MilestoneAxis_457" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MilestoneDomain" xlink:label="loc_eprx_MilestoneDomain_458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eprx_MilestoneAxis_457" xlink:to="loc_eprx_MilestoneDomain_458" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MilestoneDomain" xlink:label="loc_eprx_MilestoneDomain_458_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eprx_MilestoneAxis_457" xlink:to="loc_eprx_MilestoneDomain_458_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SuccessfulCompletionOfPhaseTwoBStudyMember" xlink:label="loc_eprx_SuccessfulCompletionOfPhaseTwoBStudyMember_459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_MilestoneDomain_458" xlink:to="loc_eprx_SuccessfulCompletionOfPhaseTwoBStudyMember_459" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FirstOaRegulatoryApprovalMember" xlink:label="loc_eprx_FirstOaRegulatoryApprovalMember_460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_MilestoneDomain_458" xlink:to="loc_eprx_FirstOaRegulatoryApprovalMember_460" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SecondOaRegulatoryApprovalMember" xlink:label="loc_eprx_SecondOaRegulatoryApprovalMember_461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_MilestoneDomain_458" xlink:to="loc_eprx_SecondOaRegulatoryApprovalMember_461" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NonOaIndicationRegulatoryApprovalMember" xlink:label="loc_eprx_NonOaIndicationRegulatoryApprovalMember_462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_MilestoneDomain_458" xlink:to="loc_eprx_NonOaIndicationRegulatoryApprovalMember_462" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember" xlink:label="loc_eprx_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember_463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_MilestoneDomain_458" xlink:to="loc_eprx_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember_463" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement" xlink:label="loc_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement_465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems_464" xlink:to="loc_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement_465" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems" xlink:label="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems_481" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable" xlink:label="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable_471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems_481" xlink:to="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable_471" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TrancheAxis" xlink:label="loc_eprx_TrancheAxis_473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable_471" xlink:to="loc_eprx_TrancheAxis_473" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TrancheDomain" xlink:label="loc_eprx_TrancheDomain_474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eprx_TrancheAxis_473" xlink:to="loc_eprx_TrancheDomain_474" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TrancheDomain" xlink:label="loc_eprx_TrancheDomain_474_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eprx_TrancheAxis_473" xlink:to="loc_eprx_TrancheDomain_474_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PriorToSuccessfulCompletionOfPhaseTwoBStudyMember" xlink:label="loc_eprx_PriorToSuccessfulCompletionOfPhaseTwoBStudyMember_475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_TrancheDomain_474" xlink:to="loc_eprx_PriorToSuccessfulCompletionOfPhaseTwoBStudyMember_475" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember" xlink:label="loc_eprx_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember_476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_TrancheDomain_474" xlink:to="loc_eprx_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember_476" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember" xlink:label="loc_eprx_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember_477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_TrancheDomain_474" xlink:to="loc_eprx_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember_477" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember" xlink:label="loc_eprx_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember_479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_TrancheDomain_474" xlink:to="loc_eprx_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember_479" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty" xlink:label="loc_eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty_482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems_481" xlink:to="loc_eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty_482" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_695" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_694" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_us-gaap_DebtInstrumentTable_694" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_694" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1005" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1005" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1006" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1006_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1005" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1006_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_1007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1006" xlink:to="loc_us-gaap_ConvertibleDebtMember_1007" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LenderAxis" xlink:label="loc_eprx_LenderAxis_698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_694" xlink:to="loc_eprx_LenderAxis_698" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LenderDomain" xlink:label="loc_eprx_LenderDomain_699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eprx_LenderAxis_698" xlink:to="loc_eprx_LenderDomain_699" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LenderDomain" xlink:label="loc_eprx_LenderDomain_699_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eprx_LenderAxis_698" xlink:to="loc_eprx_LenderDomain_699_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SiliconValleyBankMember" xlink:label="loc_eprx_SiliconValleyBankMember_701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_LenderDomain_699" xlink:to="loc_eprx_SiliconValleyBankMember_701" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_694" xlink:to="loc_us-gaap_VariableRateAxis_706" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_706" xlink:to="loc_us-gaap_VariableRateDomain_707" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_707_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_706" xlink:to="loc_us-gaap_VariableRateDomain_707_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CanadianPrimeRateMember" xlink:label="loc_eprx_CanadianPrimeRateMember_708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_707" xlink:to="loc_eprx_CanadianPrimeRateMember_708" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_694" xlink:to="loc_srt_RangeAxis_711" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_711" xlink:to="loc_srt_RangeMember_712" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_712_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_711" xlink:to="loc_srt_RangeMember_712_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_712" xlink:to="loc_srt_MaximumMember_713" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_712" xlink:to="loc_srt_MinimumMember_714" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CallRightAxis" xlink:label="loc_eprx_CallRightAxis_727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_694" xlink:to="loc_eprx_CallRightAxis_727" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CallRightDomain" xlink:label="loc_eprx_CallRightDomain_728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eprx_CallRightAxis_727" xlink:to="loc_eprx_CallRightDomain_728" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CallRightDomain" xlink:label="loc_eprx_CallRightDomain_728_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eprx_CallRightAxis_727" xlink:to="loc_eprx_CallRightDomain_728_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_WithEighteenMonthsFromTheDateOfTheDebtAgreementMember" xlink:label="loc_eprx_WithEighteenMonthsFromTheDateOfTheDebtAgreementMember_730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_CallRightDomain_728" xlink:to="loc_eprx_WithEighteenMonthsFromTheDateOfTheDebtAgreementMember_730" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember" xlink:label="loc_eprx_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember_740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_CallRightDomain_728" xlink:to="loc_eprx_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember_740" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_696" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_697" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTerm" xlink:label="loc_us-gaap_LongTermDebtTerm_721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_us-gaap_LongTermDebtTerm_721" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LongTermDebtTermExtendableAtLendersDiscretion" xlink:label="loc_eprx_LongTermDebtTermExtendableAtLendersDiscretion_722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_eprx_LongTermDebtTermExtendableAtLendersDiscretion_722" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LongTermDebtBaseRate" xlink:label="loc_eprx_LongTermDebtBaseRate_723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_eprx_LongTermDebtBaseRate_723" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LongTermDebtPaidInKindInterestPercentage" xlink:label="loc_eprx_LongTermDebtPaidInKindInterestPercentage_724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_eprx_LongTermDebtPaidInKindInterestPercentage_724" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_725" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_726" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmountToBeRaisedByWayOfEquityIssue" xlink:label="loc_eprx_AmountToBeRaisedByWayOfEquityIssue_744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_eprx_AmountToBeRaisedByWayOfEquityIssue_744" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AggegateAmountRaisedByWayOfEquityIssue" xlink:label="loc_eprx_AggegateAmountRaisedByWayOfEquityIssue_745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_eprx_AggegateAmountRaisedByWayOfEquityIssue_745" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_497" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_497" xlink:to="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_491" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_491" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_493" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_493" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_494" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_494_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_493" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_494_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_494" xlink:to="loc_us-gaap_ConvertibleDebtMember_496" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_491" xlink:to="loc_dei_LegalEntityAxis_1373" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1373" xlink:to="loc_dei_EntityDomain_1374" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1374_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1373" xlink:to="loc_dei_EntityDomain_1374_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LoanMember" xlink:label="loc_eprx_LoanMember_1375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1374" xlink:to="loc_eprx_LoanMember_1375" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_497" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_504" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod" xlink:label="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod_505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_497" xlink:to="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod_505" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod" xlink:label="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod_506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_497" xlink:to="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod_506" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_497" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_507" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss" xlink:label="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss_508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_497" xlink:to="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss_508" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_776" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_774" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EventAxis" xlink:label="loc_eprx_EventAxis_787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_eprx_EventAxis_787" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EventDomain" xlink:label="loc_eprx_EventDomain_788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eprx_EventAxis_787" xlink:to="loc_eprx_EventDomain_788" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EventDomain" xlink:label="loc_eprx_EventDomain_788_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eprx_EventAxis_787" xlink:to="loc_eprx_EventDomain_788_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExcerciseOfWarrantsMember" xlink:label="loc_eprx_ExcerciseOfWarrantsMember_789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_EventDomain_788" xlink:to="loc_eprx_ExcerciseOfWarrantsMember_789" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExcerciseOfOptionsMember" xlink:label="loc_eprx_ExcerciseOfOptionsMember_797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_EventDomain_788" xlink:to="loc_eprx_ExcerciseOfOptionsMember_797" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_WarrantAxis" xlink:label="loc_eprx_WarrantAxis_1233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_eprx_WarrantAxis_1233" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_WarrantDomain" xlink:label="loc_eprx_WarrantDomain_1234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eprx_WarrantAxis_1233" xlink:to="loc_eprx_WarrantDomain_1234" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_WarrantDomain" xlink:label="loc_eprx_WarrantDomain_1234_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eprx_WarrantAxis_1233" xlink:to="loc_eprx_WarrantDomain_1234_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CompensationWarrantMember" xlink:label="loc_eprx_CompensationWarrantMember_1235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_WarrantDomain_1234" xlink:to="loc_eprx_CompensationWarrantMember_1235" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_798" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_798" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_799" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_799_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_798" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_799_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_799" xlink:to="loc_us-gaap_PrivatePlacementMember_800" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_1110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_799" xlink:to="loc_us-gaap_OverAllotmentOptionMember_1110" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_us-gaap_PlanNameAxis_812" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_812" xlink:to="loc_us-gaap_PlanNameDomain_813" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_813_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_812" xlink:to="loc_us-gaap_PlanNameDomain_813_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmendedPlanMember" xlink:label="loc_eprx_AmendedPlanMember_814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_813" xlink:to="loc_eprx_AmendedPlanMember_814" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_us-gaap_VestingAxis_816" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_816" xlink:to="loc_us-gaap_VestingDomain_817" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_817_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_816" xlink:to="loc_us-gaap_VestingDomain_817_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ImmediateVestingMember" xlink:label="loc_eprx_ImmediateVestingMember_818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_817" xlink:to="loc_eprx_ImmediateVestingMember_818" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_817" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_819" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_817" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_821" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_817" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_822" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_us-gaap_AwardTypeAxis_834" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_835" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_835_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_835_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_835" xlink:to="loc_us-gaap_EmployeeStockOptionMember_836" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmdmHoldingsAxis" xlink:label="loc_eprx_AmdmHoldingsAxis_1080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_eprx_AmdmHoldingsAxis_1080" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmdmHoldingsDomain" xlink:label="loc_eprx_AmdmHoldingsDomain_1081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eprx_AmdmHoldingsAxis_1080" xlink:to="loc_eprx_AmdmHoldingsDomain_1081" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmdmHoldingsDomain" xlink:label="loc_eprx_AmdmHoldingsDomain_1081_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eprx_AmdmHoldingsAxis_1080" xlink:to="loc_eprx_AmdmHoldingsDomain_1081_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmdmHoldingsMember" xlink:label="loc_eprx_AmdmHoldingsMember_1084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_AmdmHoldingsDomain_1081" xlink:to="loc_eprx_AmdmHoldingsMember_1084" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_dei_LegalEntityAxis_1082" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1082" xlink:to="loc_dei_EntityDomain_1083" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1083_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1082" xlink:to="loc_dei_EntityDomain_1083_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EuphraxiaPharmaIncMember" xlink:label="loc_eprx_EuphraxiaPharmaIncMember_1086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1083" xlink:to="loc_eprx_EuphraxiaPharmaIncMember_1086" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_srt_TitleOfIndividualAxis_1088" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1088" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1089" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1089_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1088" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1089_default" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ChiefScientificOfficerMember" xlink:label="loc_eprx_ChiefScientificOfficerMember_1090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1089" xlink:to="loc_eprx_ChiefScientificOfficerMember_1090" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1091" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1091" xlink:to="loc_us-gaap_ClassOfStockDomain_1092" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1092_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1091" xlink:to="loc_us-gaap_ClassOfStockDomain_1092_default" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ClassBNonVotingStockMember" xlink:label="loc_eprx_ClassBNonVotingStockMember_1093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1092" xlink:to="loc_eprx_ClassBNonVotingStockMember_1093" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1092" xlink:to="loc_us-gaap_CommonClassAMember_1100" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1115" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1115" xlink:to="loc_us-gaap_EquityComponentDomain_1116" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1116_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1115" xlink:to="loc_us-gaap_EquityComponentDomain_1116_default" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1116" xlink:to="loc_us-gaap_CommonStockMember_1117" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1116" xlink:to="loc_us-gaap_WarrantMember_1397" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_1244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_srt_OwnershipAxis_1244" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_1244" xlink:to="loc_srt_OwnershipDomain_1245" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1245_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_1244" xlink:to="loc_srt_OwnershipDomain_1245_default" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EuphraxiaUsaMember" xlink:label="loc_eprx_EuphraxiaUsaMember_1085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1245" xlink:to="loc_eprx_EuphraxiaUsaMember_1085" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1247" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1247" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1248" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1248_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1247" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1248_default" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OutstandingOfAMDMHoldingsMember" xlink:label="loc_eprx_OutstandingOfAMDMHoldingsMember_1250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1248" xlink:to="loc_eprx_OutstandingOfAMDMHoldingsMember_1250" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorizedUnlimited" xlink:label="loc_us-gaap_PreferredStockSharesAuthorizedUnlimited_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_PreferredStockSharesAuthorizedUnlimited_781" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaap_PreferredStockNoParValue_782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_PreferredStockNoParValue_782" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="loc_us-gaap_CommonStockSharesAuthorizedUnlimited_785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_CommonStockSharesAuthorizedUnlimited_785" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_CommonStockNoParValue_784" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_792" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_803" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CashCostsOfIssuingShares" xlink:label="loc_eprx_CashCostsOfIssuingShares_806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_CashCostsOfIssuingShares_806" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfOutstandingSharesEligibleForStockOptionsIssuance" xlink:label="loc_eprx_PercentageOfOutstandingSharesEligibleForStockOptionsIssuance_815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_PercentageOfOutstandingSharesEligibleForStockOptionsIssuance_815" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1079" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1099" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EquityMethodInvestmentNumberOfSharedOwned" xlink:label="loc_eprx_EquityMethodInvestmentNumberOfSharedOwned_1101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_EquityMethodInvestmentNumberOfSharedOwned_1101" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CommonStockSharesIssuableAsAResultOfStockSplit" xlink:label="loc_eprx_CommonStockSharesIssuableAsAResultOfStockSplit_1103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_CommonStockSharesIssuableAsAResultOfStockSplit_1103" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NumberOfUnitsIssued" xlink:label="loc_eprx_NumberOfUnitsIssued_1105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_NumberOfUnitsIssued_1105" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NumberOfWarrantIssued" xlink:label="loc_eprx_NumberOfWarrantIssued_1107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_NumberOfWarrantIssued_1107" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1109" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1406" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaap_CommonStockConversionBasis_1111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_CommonStockConversionBasis_1111" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1112" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_1118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_PaymentsForUnderwritingExpense_1118" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfGrossProceedsRaisedUnderTheOffering" xlink:label="loc_eprx_PercentageOfGrossProceedsRaisedUnderTheOffering_1119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_PercentageOfGrossProceedsRaisedUnderTheOffering_1119" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering" xlink:label="loc_eprx_PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering_1121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering_1121" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_1124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_LegalFees_1124" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_1125" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1168" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1169" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1170" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_790" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_791" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_794" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_795" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_796" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_807" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_809" use="optional" order="93" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_824" use="optional" order="94" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_826" use="optional" order="95" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_827" use="optional" order="96" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_StockSharesIssuedAsAPercentageOfOutstandingShares" xlink:label="loc_eprx_StockSharesIssuedAsAPercentageOfOutstandingShares_1094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_StockSharesIssuedAsAPercentageOfOutstandingShares_1094" use="optional" order="97" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1102" use="optional" order="98" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TransferredFromAdditionalPaidinCapitalToShareCapital" xlink:label="loc_eprx_TransferredFromAdditionalPaidinCapitalToShareCapital_1104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_TransferredFromAdditionalPaidinCapitalToShareCapital_1104" use="optional" order="99" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SecuritiesIssuedPricePerUnit" xlink:label="loc_eprx_SecuritiesIssuedPricePerUnit_1106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_SecuritiesIssuedPricePerUnit_1106" use="optional" order="100" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_WarrantIssuedPricePerUnit" xlink:label="loc_eprx_WarrantIssuedPricePerUnit_1108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_WarrantIssuedPricePerUnit_1108" use="optional" order="101" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_1113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_1113" use="optional" order="102" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1114" use="optional" order="103" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1120" use="optional" order="104" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_549" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_549" xlink:to="loc_us-gaap_PlanNameAxis_550" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_550" xlink:to="loc_us-gaap_PlanNameDomain_551" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_551_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_550" xlink:to="loc_us-gaap_PlanNameDomain_551_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmendedPlanMember" xlink:label="loc_eprx_AmendedPlanMember_553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_551" xlink:to="loc_eprx_AmendedPlanMember_553" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_555" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_561" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_562" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_563" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_567" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_568" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_570" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_571" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems" xlink:label="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems_594" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable" xlink:label="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable_589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems_594" xlink:to="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable_589" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable_589" xlink:to="loc_us-gaap_PlanNameAxis_591" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_591" xlink:to="loc_us-gaap_PlanNameDomain_592" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_592_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_591" xlink:to="loc_us-gaap_PlanNameDomain_592_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmendedPlanMember" xlink:label="loc_eprx_AmendedPlanMember_593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_592" xlink:to="loc_eprx_AmendedPlanMember_593" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationOptionsExpiryDateAxis" xlink:label="loc_eprx_ShareBasedCompensationOptionsExpiryDateAxis_613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable_589" xlink:to="loc_eprx_ShareBasedCompensationOptionsExpiryDateAxis_613" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationOptionsExpiryDateDomain" xlink:label="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateAxis_613" xlink:to="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationOptionsExpiryDateDomain" xlink:label="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateAxis_613" xlink:to="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TwentySeventhSeptemberTwoThousandAndFifteenMember" xlink:label="loc_eprx_TwentySeventhSeptemberTwoThousandAndFifteenMember_619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_TwentySeventhSeptemberTwoThousandAndFifteenMember_619" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TwoNovemberTwoThousandAndFifteenMember" xlink:label="loc_eprx_TwoNovemberTwoThousandAndFifteenMember_620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_TwoNovemberTwoThousandAndFifteenMember_620" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FiveMarchTwoThousandAndEighteenMember" xlink:label="loc_eprx_FiveMarchTwoThousandAndEighteenMember_621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_FiveMarchTwoThousandAndEighteenMember_621" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NineMarchTwoThousandAndTwentyOneMember" xlink:label="loc_eprx_NineMarchTwoThousandAndTwentyOneMember_622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_NineMarchTwoThousandAndTwentyOneMember_622" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NineMarchTwoThousandAndTwentyOne1Member" xlink:label="loc_eprx_NineMarchTwoThousandAndTwentyOne1Member_1167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_NineMarchTwoThousandAndTwentyOne1Member_1167" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ThreeMayTwoThousandAndTwentyOneMember" xlink:label="loc_eprx_ThreeMayTwoThousandAndTwentyOneMember_624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_ThreeMayTwoThousandAndTwentyOneMember_624" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NineDecemberTwoThousandAndTwentyOneMember" xlink:label="loc_eprx_NineDecemberTwoThousandAndTwentyOneMember_625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_NineDecemberTwoThousandAndTwentyOneMember_625" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ThirtyFirstMarchTwoThousandAndTwentyTwoMember" xlink:label="loc_eprx_ThirtyFirstMarchTwoThousandAndTwentyTwoMember_626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_ThirtyFirstMarchTwoThousandAndTwentyTwoMember_626" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NineDecemberTwoThousandAndTwentyTwoMember" xlink:label="loc_eprx_NineDecemberTwoThousandAndTwentyTwoMember_627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_NineDecemberTwoThousandAndTwentyTwoMember_627" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EighteenthMayTwoThousandAndTwentyThreeMember" xlink:label="loc_eprx_EighteenthMayTwoThousandAndTwentyThreeMember_628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_EighteenthMayTwoThousandAndTwentyThreeMember_628" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ThirtyMayTwoThousandAndTwentyThreeMember" xlink:label="loc_eprx_ThirtyMayTwoThousandAndTwentyThreeMember_629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_ThirtyMayTwoThousandAndTwentyThreeMember_629" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TwentySeventhSeptemberTwoThousandAndTwentyThreeMember" xlink:label="loc_eprx_TwentySeventhSeptemberTwoThousandAndTwentyThreeMember_630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_TwentySeventhSeptemberTwoThousandAndTwentyThreeMember_630" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems_594" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_597" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems_594" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_598" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems_594" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_608" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" xlink:label="loc_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant_631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems_594" xlink:to="loc_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant_631" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems_594" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1242" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems_594" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_609" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_659" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_659" xlink:to="loc_us-gaap_PlanNameAxis_663" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_663" xlink:to="loc_us-gaap_PlanNameDomain_664" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_664_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_663" xlink:to="loc_us-gaap_PlanNameDomain_664_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmendedPlanMember" xlink:label="loc_eprx_AmendedPlanMember_665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_664" xlink:to="loc_eprx_AmendedPlanMember_665" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_659" xlink:to="loc_us-gaap_AwardTypeAxis_678" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_678" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_679" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_679_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_678" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_679_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_679" xlink:to="loc_us-gaap_EmployeeStockOptionMember_680" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1133" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:label="loc_eprx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_1134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" xlink:to="loc_eprx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_1134" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_669" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_670" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_671" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_674" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_675" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" xlink:to="loc_us-gaap_SharePrice_673" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable_1017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable_1017" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable_1017" xlink:to="loc_us-gaap_AwardTypeAxis_1024" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1025" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1025_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1025_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember" xlink:label="loc_eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember_1026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1025" xlink:to="loc_eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember_1026" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1019" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1020" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_1021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_1021" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_1022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_1022" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" xlink:label="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice_1027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice_1027" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice" xlink:label="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice_1028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice_1028" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice" xlink:label="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice_1029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice_1029" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice" xlink:label="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice_1030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice_1030" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1035" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable_1034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1035" xlink:to="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable_1034" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MaturityPeriodWarrantsAxis" xlink:label="loc_eprx_MaturityPeriodWarrantsAxis_1038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable_1034" xlink:to="loc_eprx_MaturityPeriodWarrantsAxis_1038" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MaturityPeriodWarrantsDomain" xlink:label="loc_eprx_MaturityPeriodWarrantsDomain_1039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eprx_MaturityPeriodWarrantsAxis_1038" xlink:to="loc_eprx_MaturityPeriodWarrantsDomain_1039" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MaturityPeriodWarrantsDomain" xlink:label="loc_eprx_MaturityPeriodWarrantsDomain_1039_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eprx_MaturityPeriodWarrantsAxis_1038" xlink:to="loc_eprx_MaturityPeriodWarrantsDomain_1039_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodOneMember" xlink:label="loc_eprx_ExpiryPeriodOneMember_1347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodOneMember_1347" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodTwoMember" xlink:label="loc_eprx_ExpiryPeriodTwoMember_1348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodTwoMember_1348" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodThreeMember" xlink:label="loc_eprx_ExpiryPeriodThreeMember_1349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodThreeMember_1349" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodFourMember" xlink:label="loc_eprx_ExpiryPeriodFourMember_1350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodFourMember_1350" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodFiveMember" xlink:label="loc_eprx_ExpiryPeriodFiveMember_1351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodFiveMember_1351" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodSixMember" xlink:label="loc_eprx_ExpiryPeriodSixMember_1352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodSixMember_1352" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodSevenMember" xlink:label="loc_eprx_ExpiryPeriodSevenMember_1353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodSevenMember_1353" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodEightMember" xlink:label="loc_eprx_ExpiryPeriodEightMember_1354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodEightMember_1354" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodNineMember" xlink:label="loc_eprx_ExpiryPeriodNineMember_1355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodNineMember_1355" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodTenMember" xlink:label="loc_eprx_ExpiryPeriodTenMember_1356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodTenMember_1356" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1035" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1358" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_1359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1035" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_1359" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" xlink:label="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice_1036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1035" xlink:to="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice_1036" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_1037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1035" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_1037" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1035" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1050" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1470" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable_1463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1470" xlink:to="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable_1463" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MaturityPeriodWarrantsAxis" xlink:label="loc_eprx_MaturityPeriodWarrantsAxis_1464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable_1463" xlink:to="loc_eprx_MaturityPeriodWarrantsAxis_1464" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MaturityPeriodWarrantsDomain" xlink:label="loc_eprx_MaturityPeriodWarrantsDomain_1465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eprx_MaturityPeriodWarrantsAxis_1464" xlink:to="loc_eprx_MaturityPeriodWarrantsDomain_1465" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MaturityPeriodWarrantsDomain" xlink:label="loc_eprx_MaturityPeriodWarrantsDomain_1465_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eprx_MaturityPeriodWarrantsAxis_1464" xlink:to="loc_eprx_MaturityPeriodWarrantsDomain_1465_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodThreeMember" xlink:label="loc_eprx_ExpiryPeriodThreeMember_1466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1465" xlink:to="loc_eprx_ExpiryPeriodThreeMember_1466" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable_1463" xlink:to="loc_us-gaap_AwardTypeAxis_1467" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1467" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1468" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1468_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1467" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1468_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember" xlink:label="loc_eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember_1469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1468" xlink:to="loc_eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember_1469" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1470" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1471" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1470" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1472" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1470" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1473" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentExpensesLineItems" xlink:label="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentExpensesTable" xlink:label="loc_eprx_ResearchAndDevelopmentExpensesTable_831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_eprx_ResearchAndDevelopmentExpensesTable_831" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentExpensesAxis" xlink:label="loc_eprx_ResearchAndDevelopmentExpensesAxis_837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesTable_831" xlink:to="loc_eprx_ResearchAndDevelopmentExpensesAxis_837" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentExpensesDomain" xlink:label="loc_eprx_ResearchAndDevelopmentExpensesDomain_838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesAxis_837" xlink:to="loc_eprx_ResearchAndDevelopmentExpensesDomain_838" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentExpensesDomain" xlink:label="loc_eprx_ResearchAndDevelopmentExpensesDomain_838_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesAxis_837" xlink:to="loc_eprx_ResearchAndDevelopmentExpensesDomain_838_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PreclinicalMember" xlink:label="loc_eprx_PreclinicalMember_839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesDomain_838" xlink:to="loc_eprx_PreclinicalMember_839" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ClinicalMember" xlink:label="loc_eprx_ClinicalMember_840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesDomain_838" xlink:to="loc_eprx_ClinicalMember_840" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ManufacturingAndAnalyticaMember" xlink:label="loc_eprx_ManufacturingAndAnalyticaMember_841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesDomain_838" xlink:to="loc_eprx_ManufacturingAndAnalyticaMember_841" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RegulatoryMember" xlink:label="loc_eprx_RegulatoryMember_842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesDomain_838" xlink:to="loc_eprx_RegulatoryMember_842" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ConsultingMember" xlink:label="loc_eprx_ConsultingMember_843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesDomain_838" xlink:to="loc_eprx_ConsultingMember_843" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory" xlink:label="loc_eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory_1341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory_1341" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense" xlink:label="loc_eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense_844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense_844" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_845" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses" xlink:label="loc_eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses_846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses_846" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses" xlink:label="loc_eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses_847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses_847" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentLicenseExpenses" xlink:label="loc_eprx_ResearchAndDevelopmentLicenseExpenses_1474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_eprx_ResearchAndDevelopmentLicenseExpenses_1474" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="loc_us-gaap_GovernmentAssistanceAmount_849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_us-gaap_GovernmentAssistanceAmount_849" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses" xlink:label="loc_eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses_851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses_851" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_853" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceLineItems" xlink:label="loc_us-gaap_GovernmentAssistanceLineItems_1317" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfReimburseAssistanceToSupportSalaryCost" xlink:label="loc_eprx_PercentageOfReimburseAssistanceToSupportSalaryCost_715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GovernmentAssistanceLineItems_1317" xlink:to="loc_eprx_PercentageOfReimburseAssistanceToSupportSalaryCost_715" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfReimburseAssistanceToSupportContractorFee" xlink:label="loc_eprx_PercentageOfReimburseAssistanceToSupportContractorFee_716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GovernmentAssistanceLineItems_1317" xlink:to="loc_eprx_PercentageOfReimburseAssistanceToSupportContractorFee_716" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ReimbursementAssistanceMaximumForSalaryAndContractorCosts" xlink:label="loc_eprx_ReimbursementAssistanceMaximumForSalaryAndContractorCosts_1321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GovernmentAssistanceLineItems_1317" xlink:to="loc_eprx_ReimbursementAssistanceMaximumForSalaryAndContractorCosts_1321" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="loc_us-gaap_GovernmentAssistanceAmount_718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GovernmentAssistanceLineItems_1317" xlink:to="loc_us-gaap_GovernmentAssistanceAmount_718" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent_1241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GovernmentAssistanceLineItems_1317" xlink:to="loc_us-gaap_GrantsReceivableCurrent_1241" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTable" xlink:label="loc_us-gaap_GovernmentAssistanceTable_1316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GovernmentAssistanceLineItems_1317" xlink:to="loc_us-gaap_GovernmentAssistanceTable_1316" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="loc_us-gaap_GovernmentAssistanceTypeAxis_1318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GovernmentAssistanceTable_1316" xlink:to="loc_us-gaap_GovernmentAssistanceTypeAxis_1318" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain_1319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis_1318" xlink:to="loc_us-gaap_GovernmentAssistanceTypeDomain_1319" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain_1319_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis_1318" xlink:to="loc_us-gaap_GovernmentAssistanceTypeDomain_1319_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember" xlink:label="loc_eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember_1320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GovernmentAssistanceTypeDomain_1319" xlink:to="loc_eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember_1320" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_GovernmentAssistanceAmountForResearchAndDevelopment" xlink:label="loc_eprx_GovernmentAssistanceAmountForResearchAndDevelopment_720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GovernmentAssistanceLineItems_1317" xlink:to="loc_eprx_GovernmentAssistanceAmountForResearchAndDevelopment_720" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceLineItems" xlink:label="loc_us-gaap_GovernmentAssistanceLineItems_690" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTable" xlink:label="loc_us-gaap_GovernmentAssistanceTable_684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GovernmentAssistanceLineItems_690" xlink:to="loc_us-gaap_GovernmentAssistanceTable_684" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GovernmentAssistanceTable_684" xlink:to="loc_srt_StatementGeographicalAxis_685" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_685" xlink:to="loc_srt_SegmentGeographicalDomain_686" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_686_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_685" xlink:to="loc_srt_SegmentGeographicalDomain_686_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="loc_us-gaap_GovernmentAssistanceTypeAxis_1323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GovernmentAssistanceTable_684" xlink:to="loc_us-gaap_GovernmentAssistanceTypeAxis_1323" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain_1324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis_1323" xlink:to="loc_us-gaap_GovernmentAssistanceTypeDomain_1324" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain_1324_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis_1323" xlink:to="loc_us-gaap_GovernmentAssistanceTypeDomain_1324_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember" xlink:label="loc_eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember_1325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GovernmentAssistanceTypeDomain_1324" xlink:to="loc_eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember_1325" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_BioTalentCanadaMember" xlink:label="loc_eprx_BioTalentCanadaMember_1326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GovernmentAssistanceTypeDomain_1324" xlink:to="loc_eprx_BioTalentCanadaMember_1326" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmountCumulative" xlink:label="loc_us-gaap_GovernmentAssistanceAmountCumulative_693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GovernmentAssistanceLineItems_690" xlink:to="loc_us-gaap_GovernmentAssistanceAmountCumulative_693" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NonCapitalLossesCarryForwardFutureYearsLineItems" xlink:label="loc_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems_928" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NonCapitalLossesCarryForwardFutureYearsTable" xlink:label="loc_eprx_NonCapitalLossesCarryForwardFutureYearsTable_906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems_928" xlink:to="loc_eprx_NonCapitalLossesCarryForwardFutureYearsTable_906" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_NonCapitalLossesCarryForwardFutureYearsTable_906" xlink:to="loc_us-gaap_TaxPeriodAxis_907" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_907" xlink:to="loc_us-gaap_TaxPeriodDomain_908" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_908_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_907" xlink:to="loc_us-gaap_TaxPeriodDomain_908_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2031Member" xlink:label="loc_eprx_TaxYear2031Member_1384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2031Member_1384" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2032Member" xlink:label="loc_eprx_TaxYear2032Member_909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2032Member_909" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2033Member" xlink:label="loc_eprx_TaxYear2033Member_911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2033Member_911" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2034Member" xlink:label="loc_eprx_TaxYear2034Member_912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2034Member_912" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2035Member" xlink:label="loc_eprx_TaxYear2035Member_913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2035Member_913" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2036Member" xlink:label="loc_eprx_TaxYear2036Member_914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2036Member_914" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2037Member" xlink:label="loc_eprx_TaxYear2037Member_916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2037Member_916" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2038Member" xlink:label="loc_eprx_TaxYear2038Member_917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2038Member_917" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2039Member" xlink:label="loc_eprx_TaxYear2039Member_918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2039Member_918" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2040Member" xlink:label="loc_eprx_TaxYear2040Member_919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2040Member_919" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2041Member" xlink:label="loc_eprx_TaxYear2041Member_921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2041Member_921" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2042Member" xlink:label="loc_eprx_TaxYear2042Member_924" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2042Member_924" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2043Member" xlink:label="loc_eprx_TaxYear2043Member_1385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2043Member_1385" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYearAfter2043Member" xlink:label="loc_eprx_TaxYearAfter2043Member_1386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYearAfter2043Member_1386" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_NonCapitalLossesCarryForwardFutureYearsTable_906" xlink:to="loc_srt_StatementGeographicalAxis_1387" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1387" xlink:to="loc_srt_SegmentGeographicalDomain_1388" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1388_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1387" xlink:to="loc_srt_SegmentGeographicalDomain_1388_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="loc_country_CA_1389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1388" xlink:to="loc_country_CA_1389" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_1390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1388" xlink:to="loc_country_US_1390" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU" xlink:label="loc_country_AU_1391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1388" xlink:to="loc_country_AU_1391" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NonCapitalLossCarryforwardsToFutureExpire" xlink:label="loc_eprx_NonCapitalLossCarryforwardsToFutureExpire_930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems_928" xlink:to="loc_eprx_NonCapitalLossCarryforwardsToFutureExpire_930" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_948" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_948" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_967" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_967" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_968" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_968_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_967" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_968_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CanadianFederalInvestmentTaxCreditsMember" xlink:label="loc_eprx_CanadianFederalInvestmentTaxCreditsMember_1306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_968" xlink:to="loc_eprx_CanadianFederalInvestmentTaxCreditsMember_1306" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ProvincialInvestmentTaxCreditsMember" xlink:label="loc_eprx_ProvincialInvestmentTaxCreditsMember_1307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_968" xlink:to="loc_eprx_ProvincialInvestmentTaxCreditsMember_1307" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_948" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_976" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_976" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_977" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_977_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_976" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_977_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember_1304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_977" xlink:to="loc_us-gaap_CanadaRevenueAgencyMember_1304" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RelevantPeriodAxis" xlink:label="loc_eprx_RelevantPeriodAxis_1328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_948" xlink:to="loc_eprx_RelevantPeriodAxis_1328" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RelevantPeriodDomain" xlink:label="loc_eprx_RelevantPeriodDomain_1329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eprx_RelevantPeriodAxis_1328" xlink:to="loc_eprx_RelevantPeriodDomain_1329" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RelevantPeriodDomain" xlink:label="loc_eprx_RelevantPeriodDomain_1329_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eprx_RelevantPeriodAxis_1328" xlink:to="loc_eprx_RelevantPeriodDomain_1329_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_948" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1402" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1402" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1403" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1403_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1402" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1403_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1403" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1404" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_us-gaap_OperatingLossCarryforwards_952" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_956" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxCreditCarryForwardsExpirationTerm" xlink:label="loc_eprx_TaxCreditCarryForwardsExpirationTerm_958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_eprx_TaxCreditCarryForwardsExpirationTerm_958" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1517" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_1518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_1518" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_1519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_1519" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/CommitmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_284" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_284" xlink:to="loc_us-gaap_OtherCommitmentsTable_283" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_283" xlink:to="loc_srt_RangeAxis_297" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_297" xlink:to="loc_srt_RangeMember_306" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_306_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_297" xlink:to="loc_srt_RangeMember_306_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_306" xlink:to="loc_srt_MinimumMember_298" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_306" xlink:to="loc_srt_MaximumMember_299" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CancellationFeeOnTerminationOfContract" xlink:label="loc_eprx_CancellationFeeOnTerminationOfContract_296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_284" xlink:to="loc_eprx_CancellationFeeOnTerminationOfContract_296" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CancellationFeeForCancellationOfContract" xlink:label="loc_eprx_CancellationFeeForCancellationOfContract_300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_284" xlink:to="loc_eprx_CancellationFeeForCancellationOfContract_300" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FinancialInstrumentsLineItems" xlink:label="loc_eprx_FinancialInstrumentsLineItems_982" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FinancialInstrumentsTable" xlink:label="loc_eprx_FinancialInstrumentsTable_941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_eprx_FinancialInstrumentsTable_941" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_FinancialInstrumentsTable_941" xlink:to="loc_srt_CurrencyAxis_944" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_944" xlink:to="loc_currency_AllCurrenciesDomain_945" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_945_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_944" xlink:to="loc_currency_AllCurrenciesDomain_945_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD_946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_945" xlink:to="loc_currency_CAD_946" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_FinancialInstrumentsTable_941" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1000" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1000" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1001" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1001_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1000" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1001_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_1002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1001" xlink:to="loc_us-gaap_ConvertibleDebtMember_1002" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EquipmentLoanMember" xlink:label="loc_eprx_EquipmentLoanMember_1280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1001" xlink:to="loc_eprx_EquipmentLoanMember_1280" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CurrencyRiskMember" xlink:label="loc_eprx_CurrencyRiskMember_1376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1001" xlink:to="loc_eprx_CurrencyRiskMember_1376" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_FinancialInstrumentsTable_941" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_951" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_951" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_953" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_953_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_951" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_953_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_953" xlink:to="loc_us-gaap_EquipmentMember_955" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LenderAxis" xlink:label="loc_eprx_LenderAxis_957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_FinancialInstrumentsTable_941" xlink:to="loc_eprx_LenderAxis_957" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LenderDomain" xlink:label="loc_eprx_LenderDomain_960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eprx_LenderAxis_957" xlink:to="loc_eprx_LenderDomain_960" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LenderDomain" xlink:label="loc_eprx_LenderDomain_960_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eprx_LenderAxis_957" xlink:to="loc_eprx_LenderDomain_960_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SiliconValleyBankMember" xlink:label="loc_eprx_SiliconValleyBankMember_963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_LenderDomain_960" xlink:to="loc_eprx_SiliconValleyBankMember_963" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_FinancialInstrumentsTable_941" xlink:to="loc_us-gaap_VariableRateAxis_964" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_964" xlink:to="loc_us-gaap_VariableRateDomain_965" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_965_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_964" xlink:to="loc_us-gaap_VariableRateDomain_965_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CanadianPrimeRateMember" xlink:label="loc_eprx_CanadianPrimeRateMember_970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_965" xlink:to="loc_eprx_CanadianPrimeRateMember_970" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_FinancialInstrumentsTable_941" xlink:to="loc_srt_RangeAxis_973" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_973" xlink:to="loc_srt_RangeMember_974" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_974_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_973" xlink:to="loc_srt_RangeMember_974_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_974" xlink:to="loc_srt_MinimumMember_975" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_983" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_us-gaap_LiabilitiesCurrent_984" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_985" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaap_OtherLongTermDebt_986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_us-gaap_OtherLongTermDebt_986" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LongTermDebtPaidInKindInterestPercentage" xlink:label="loc_eprx_LongTermDebtPaidInKindInterestPercentage_989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_eprx_LongTermDebtPaidInKindInterestPercentage_989" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_us-gaap_Cash_993" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_us-gaap_AccountsPayableCurrent_994" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_997" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_1285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_1285" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_1286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_1286" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate" xlink:label="loc_eprx_SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate_1287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_eprx_SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate_1287" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax" xlink:label="loc_eprx_SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax_1288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_eprx_SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax_1288" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageIncreaseInSignificantUnobservableInputAssets" xlink:label="loc_eprx_PercentageIncreaseInSignificantUnobservableInputAssets_1289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_eprx_PercentageIncreaseInSignificantUnobservableInputAssets_1289" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageIncreaseInSignificantUnobservableInputLiabilities" xlink:label="loc_eprx_PercentageIncreaseInSignificantUnobservableInputLiabilities_1290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_eprx_PercentageIncreaseInSignificantUnobservableInputLiabilities_1290" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates" xlink:label="loc_eprx_ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates_1291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_eprx_ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates_1291" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PayableTowardsRoyaltyAndOthersCurrent" xlink:label="loc_eprx_PayableTowardsRoyaltyAndOthersCurrent_1520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_eprx_PayableTowardsRoyaltyAndOthersCurrent_1520" use="optional" order="43" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfCarryingValueOfFinancialInstrumentsAtAmortizedCostDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems" xlink:label="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems_441" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTable" xlink:label="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTable_429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems_441" xlink:to="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTable_429" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems_441" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1269" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="loc_us-gaap_NontradeReceivablesCurrent_1418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems_441" xlink:to="loc_us-gaap_NontradeReceivablesCurrent_1418" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AccountsPayableAndAccruedLiability" xlink:label="loc_eprx_AccountsPayableAndAccruedLiability_1377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems_441" xlink:to="loc_eprx_AccountsPayableAndAccruedLiability_1377" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PayableTowardsRoyaltyAndOthersCurrent" xlink:label="loc_eprx_PayableTowardsRoyaltyAndOthersCurrent_1521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems_441" xlink:to="loc_eprx_PayableTowardsRoyaltyAndOthersCurrent_1521" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaap_OtherLongTermDebt_1271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems_441" xlink:to="loc_us-gaap_OtherLongTermDebt_1271" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_828" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_828" xlink:to="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_825" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_825" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_863" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_863" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_866" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_866_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_863" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_866_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_825" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1365" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1365" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1366" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1366_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1365" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1366_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1366" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1367" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_828" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_829" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod" xlink:label="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod_830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_828" xlink:to="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod_830" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod" xlink:label="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod_848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_828" xlink:to="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod_848" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_828" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_850" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss" xlink:label="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss_861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_828" xlink:to="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss_861" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_182" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_182" xlink:to="loc_us-gaap_StatementTable_174" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_174" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_175" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_175" xlink:to="loc_us-gaap_EquityComponentDomain_176" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_176_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_175" xlink:to="loc_us-gaap_EquityComponentDomain_176_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_176" xlink:to="loc_us-gaap_CommonStockMember_177" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_1222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_182" xlink:to="loc_us-gaap_InterestPaidNet_1222" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_182" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_185" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_182" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1225" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_182" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1226" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NumberofWarrantsIssued" xlink:label="loc_eprx_NumberofWarrantsIssued_1228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_182" xlink:to="loc_eprx_NumberofWarrantsIssued_1228" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_182" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_189" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_133" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_133" xlink:to="loc_us-gaap_SubsequentEventTable_115" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_115" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1229" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1229" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1230" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1230_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1229" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1230_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1230" xlink:to="loc_us-gaap_SubsequentEventMember_1231" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_115" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_116" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_116" xlink:to="loc_us-gaap_EquityComponentDomain_117" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_117_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_116" xlink:to="loc_us-gaap_EquityComponentDomain_117_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_115" xlink:to="loc_srt_CurrencyAxis_119" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_119" xlink:to="loc_currency_AllCurrenciesDomain_120" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_120_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_119" xlink:to="loc_currency_AllCurrenciesDomain_120_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_115" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1379" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1379" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1380" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1380_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1379" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1380_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1380" xlink:to="loc_us-gaap_IPOMember_1411" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_1381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1380" xlink:to="loc_us-gaap_OverAllotmentOptionMember_1381" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_133" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1408" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_133" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1410" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NumberOfUnitsIssued" xlink:label="loc_eprx_NumberOfUnitsIssued_1382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_133" xlink:to="loc_eprx_NumberOfUnitsIssued_1382" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SecuritiesIssuedPricePerUnit" xlink:label="loc_eprx_SecuritiesIssuedPricePerUnit_1383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_133" xlink:to="loc_eprx_SecuritiesIssuedPricePerUnit_1383" use="optional" order="20" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>eprx-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 01-April-2024 [11:12:04] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_dei_AnnualInformationForm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AnnualInformationForm" xml:lang="en-US">Annual Information Form</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AnnualInformationForm" xlink:to="lab_dei_AnnualInformationForm" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_dei_AuditedAnnualFinancialStatements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditedAnnualFinancialStatements" xml:lang="en-US">Audited Annual Financial Statements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditedAnnualFinancialStatements" xlink:to="lab_dei_AuditedAnnualFinancialStatements" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId" xml:lang="en-US">Auditor Firm ID</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation" xml:lang="en-US">Auditor Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName" xml:lang="en-US">Auditor Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentRegistrationStatement" xml:lang="en-US">Document Registration Statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Jurisdiction of Incorporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry" xml:lang="en-US">Entity Address, Country</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCountry" xml:lang="en-US">Country of Incorporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPrimarySicNumber" xml:lang="en-US">Entity Primary SIC Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPrimarySicNumber" xlink:to="lab_dei_EntityPrimarySicNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">The amount of cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="loc_us-gaap_NontradeReceivablesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NontradeReceivablesCurrent" xml:lang="en-US">Nontrade Receivables, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NontradeReceivablesCurrent" xml:lang="en-US">Amounts receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NontradeReceivablesCurrent" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NontradeReceivablesCurrent" xlink:to="lab_us-gaap_NontradeReceivablesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses and deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xml:lang="en-US">Non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Right-of-use asset, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Balance, ending</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Balance, beginning</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xml:lang="en-US">Prepaid Expense, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Net Book Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and shareholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xml:lang="en-US">Convertible Debt, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xml:lang="en-US">Convertible debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent" xlink:to="lab_us-gaap_ConvertibleDebtCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Lease liability &#8211; current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="loc_us-gaap_OtherLongTermDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLongTermDebtCurrent" xml:lang="en-US">Other Long-Term Debt, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLongTermDebtCurrent" xml:lang="en-US">Loans payable &#8211; current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebtCurrent" xlink:to="lab_us-gaap_OtherLongTermDebtCurrent" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PayableTowardsRoyaltyAndOthersCurrent" xlink:label="loc_eprx_PayableTowardsRoyaltyAndOthersCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PayableTowardsRoyaltyAndOthersCurrent" xml:lang="en-US">Payable Towards Royalty And Others Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PayableTowardsRoyaltyAndOthersCurrent" xml:lang="en-US">Payable to Auritec</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eprx_PayableTowardsRoyaltyAndOthersCurrent" xml:lang="en-US">Payable towards royalty and others current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PayableTowardsRoyaltyAndOthersCurrent" xlink:to="lab_eprx_PayableTowardsRoyaltyAndOthersCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PayableTowardsRoyaltyAndOthersCurrent" xml:lang="en-US">Payable towards royalty and others current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Non-current&#160;liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xml:lang="en-US">Convertible Debt, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xml:lang="en-US">Convertible debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Lease liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Non-current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLongTermDebtNoncurrent" xml:lang="en-US">Other Long-Term Debt, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLongTermDebtNoncurrent" xml:lang="en-US">Loans payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebtNoncurrent" xlink:to="lab_us-gaap_OtherLongTermDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Non-controlling&#160;interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Equity, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Equity attributable to the owners of the Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total shareholders' equity (deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance at the ending</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance at the beginning</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xml:lang="en-US">Shareholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional&#160;paid-in&#160;capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Share capital, without par value; unlimited shares authorized; issued and outstanding: 27,282,165 (December 31, 2022 - 21,593,145</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockNoParValue" xml:lang="en-US">Common Stock, No Par Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockNoParValue" xml:lang="en-US">Common stock no par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockNoParValue" xml:lang="en-US">Common stock par no par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="loc_us-gaap_CommonStockSharesAuthorizedUnlimited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorizedUnlimited" xml:lang="en-US">Common Stock, Shares Authorized, Unlimited [Fixed List]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorizedUnlimited" xml:lang="en-US">Common stock unlimited shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorizedUnlimited" xml:lang="en-US">Common stock shares authorized unlimited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:to="lab_us-gaap_CommonStockSharesAuthorizedUnlimited" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive loss for the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Loss per share &#8211; basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Loss per share &#8211; diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Loss attributable to:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Owners of the Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Non-controlling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Foreign currency translation adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Foreign Currency translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income/(expenses)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Change in fair value of financial instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Change in fair value of financial instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Change in fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Change in fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign exchange gain</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Loss on sale of equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Net loss before tax expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Tax expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">Total expenses during the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Total expenses during the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average shares outstanding &#8211; diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average shares outstanding &#8211; basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EventAxis" xlink:label="loc_eprx_EventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_EventAxis" xml:lang="en-US">Event [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_EventAxis" xlink:to="lab_eprx_EventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_EventAxis" xml:lang="en-US">Event</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EventDomain" xlink:label="loc_eprx_EventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_EventDomain" xml:lang="en-US">Event [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_EventDomain" xlink:to="lab_eprx_EventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_EventDomain" xml:lang="en-US">Event</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExcerciseOfWarrantsMember" xlink:label="loc_eprx_ExcerciseOfWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ExcerciseOfWarrantsMember" xml:lang="en-US">Excercise Of Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ExcerciseOfWarrantsMember" xml:lang="en-US">Excercise of warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ExcerciseOfWarrantsMember" xlink:to="lab_eprx_ExcerciseOfWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ExcerciseOfWarrantsMember" xml:lang="en-US">Excercise Of Warrants</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated other comprehensive income [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional paid-in capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Noncontrolling Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Non-controlling interest [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Deficit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Share-based payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance at the ending (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance at the beginning (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Overnight marketed public offering and redemption of warrants ( in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Shares issued through non-brokered private placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock issued during the period shares new issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock issued during the period shares exercise of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Redemption of options (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Stock issued during the period shares exercise of stock options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Number of options, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Overnight marketed public offering and redemption of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock issued during period value new issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock issued during the period value new issues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Redemption of options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock issued during period value stock options excercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OvernightMarketedPublicOfferingMember" xlink:label="loc_eprx_OvernightMarketedPublicOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_OvernightMarketedPublicOfferingMember" xml:lang="en-US">Overnight Marketed Public Offering [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_OvernightMarketedPublicOfferingMember" xml:lang="en-US">Overnight marketed public offering [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_OvernightMarketedPublicOfferingMember" xlink:to="lab_eprx_OvernightMarketedPublicOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_OvernightMarketedPublicOfferingMember" xml:lang="en-US">Overnight marketed public offering.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Items not affecting cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xml:lang="en-US">Unrealized foreign exchange</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_InterestExpensesOnLeaseLiabilityFinancingActivities" xlink:label="loc_eprx_InterestExpensesOnLeaseLiabilityFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_InterestExpensesOnLeaseLiabilityFinancingActivities" xml:lang="en-US">Interest Expenses on Lease Liability Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_InterestExpensesOnLeaseLiabilityFinancingActivities" xml:lang="en-US">Interest &#8211; lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_InterestExpensesOnLeaseLiabilityFinancingActivities" xlink:to="lab_eprx_InterestExpensesOnLeaseLiabilityFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_InterestExpensesOnLeaseLiabilityFinancingActivities" xml:lang="en-US">Interest expenses on lease liability financing activities.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_InterestOnConvertibleDebtOne" xlink:label="loc_eprx_InterestOnConvertibleDebtOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_InterestOnConvertibleDebtOne" xml:lang="en-US">Interest on Convertible Debt One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_InterestOnConvertibleDebtOne" xml:lang="en-US">Accrued interest on convertible debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_InterestOnConvertibleDebtOne" xlink:to="lab_eprx_InterestOnConvertibleDebtOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_InterestOnConvertibleDebtOne" xml:lang="en-US">Interest on convertible debt one.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_InterestOnShortTermInvestmentsNonOperating" xlink:label="loc_eprx_InterestOnShortTermInvestmentsNonOperating" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_InterestOnShortTermInvestmentsNonOperating" xml:lang="en-US">Interest on Short Term Investments Non Operating</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_eprx_InterestOnShortTermInvestmentsNonOperating" xml:lang="en-US">Accrued interest on short term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_InterestOnShortTermInvestmentsNonOperating" xlink:to="lab_eprx_InterestOnShortTermInvestmentsNonOperating" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_InterestOnShortTermInvestmentsNonOperating" xml:lang="en-US">Interest on short term investments non operating.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LossOnSaleOfEquipment" xlink:label="loc_eprx_LossOnSaleOfEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_LossOnSaleOfEquipment" xml:lang="en-US">Loss On Sale Of Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_eprx_LossOnSaleOfEquipment" xml:lang="en-US">Loss on sale of equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_LossOnSaleOfEquipment" xlink:to="lab_eprx_LossOnSaleOfEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_LossOnSaleOfEquipment" xml:lang="en-US">Loss on sale of equipment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents, end of year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents, beginning of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Increase in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Foreign exchange effect on cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Amounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent" xlink:label="loc_eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent" xml:lang="en-US">Increase Decrease In Payable Towards Licensing Fees And Others Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent" xml:lang="en-US">Auritec payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent" xlink:to="lab_eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent" xml:lang="en-US">Increase decrease in payable towards licensing fees and others current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xml:lang="en-US">Finance Lease, Principal Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xml:lang="en-US">Lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Overnight marketed public offering (net of transaction costs)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Redemption of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from Warrant Exercises</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Redemption of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xml:lang="en-US">Repayments of Other Long-Term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xml:lang="en-US">Repayment of loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfOtherLongTermDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Cash provided by (used in) investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xml:lang="en-US">Payments to Acquire Machinery and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xml:lang="en-US">Acquisition of equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xml:lang="en-US">Payments to Acquire Short-Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xml:lang="en-US">Purchase of short term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Short-Term Investments, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xml:lang="en-US">Proceeds from redemption of short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xml:lang="en-US">Proceeds from Sale of Machinery and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xml:lang="en-US">Proceeds from sale of equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Operations [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Business and Going Concern</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaap_BasisOfAccounting" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccounting" xml:lang="en-US">Basis of Accounting [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccounting" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccounting" xlink:to="lab_us-gaap_BasisOfAccounting" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivablesAbstract" xml:lang="en-US">Receivables [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xml:lang="en-US">Amounts Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RightOfUseAssetAbstract" xlink:label="loc_eprx_RightOfUseAssetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_RightOfUseAssetAbstract" xml:lang="en-US">Right of Use Asset [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_RightOfUseAssetAbstract" xlink:to="lab_eprx_RightOfUseAssetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_RightOfUseAssetAbstract" xml:lang="en-US">Right of use asset.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RightOfUseAssetTextBlock" xlink:label="loc_eprx_RightOfUseAssetTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_RightOfUseAssetTextBlock" xml:lang="en-US">Right of Use Asset [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_RightOfUseAssetTextBlock" xml:lang="en-US">Right-of-Use Asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_RightOfUseAssetTextBlock" xlink:to="lab_eprx_RightOfUseAssetTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_RightOfUseAssetTextBlock" xml:lang="en-US">Right of use asset.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInEntiretyOfOtherLoansPayable" xlink:label="loc_eprx_DisclosureInEntiretyOfOtherLoansPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DisclosureInEntiretyOfOtherLoansPayable" xml:lang="en-US">Disclosure in Entirety of Other Loans Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_DisclosureInEntiretyOfOtherLoansPayable" xml:lang="en-US">Loans Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DisclosureInEntiretyOfOtherLoansPayable" xlink:to="lab_eprx_DisclosureInEntiretyOfOtherLoansPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DisclosureInEntiretyOfOtherLoansPayable" xml:lang="en-US">Disclosure in entirety of other loans payable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Lease Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LicenseAgreementAbstract" xlink:label="loc_eprx_LicenseAgreementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_LicenseAgreementAbstract" xml:lang="en-US">License Agreement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_LicenseAgreementAbstract" xlink:to="lab_eprx_LicenseAgreementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_LicenseAgreementAbstract" xml:lang="en-US">License Agreement.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInEntiretyOfLicenseAgreementTextBlock" xlink:label="loc_eprx_DisclosureInEntiretyOfLicenseAgreementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DisclosureInEntiretyOfLicenseAgreementTextBlock" xml:lang="en-US">Disclosure In Entirety Of License Agreement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_DisclosureInEntiretyOfLicenseAgreementTextBlock" xml:lang="en-US">Auritec License Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DisclosureInEntiretyOfLicenseAgreementTextBlock" xlink:to="lab_eprx_DisclosureInEntiretyOfLicenseAgreementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DisclosureInEntiretyOfLicenseAgreementTextBlock" xml:lang="en-US">Disclosure In Entirety Of License Agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xml:lang="en-US">Long-Term Debt [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xml:lang="en-US">Convertible Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xml:lang="en-US">Share Capital and Other Components of Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_GeneralAndAdministrativeExpensesAbstract" xlink:label="loc_eprx_GeneralAndAdministrativeExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_GeneralAndAdministrativeExpensesAbstract" xml:lang="en-US">General And Administrative Expenses [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_GeneralAndAdministrativeExpensesAbstract" xlink:to="lab_eprx_GeneralAndAdministrativeExpensesAbstract" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock" xlink:label="loc_eprx_DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock" xml:lang="en-US">Disclosure In Entirety Of General And Administration Expenses [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock" xml:lang="en-US">General And Administrative Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock" xlink:to="lab_eprx_DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock" xml:lang="en-US">Disclosure in entirety of general and administration expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract" xml:lang="en-US">Research and Development Expense [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xml:lang="en-US">Research And Development Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAbstract" xlink:label="loc_us-gaap_GovernmentAssistanceAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GovernmentAssistanceAbstract" xml:lang="en-US">Government Assistance [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceAbstract" xlink:to="lab_us-gaap_GovernmentAssistanceAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTextBlock" xlink:label="loc_us-gaap_GovernmentAssistanceTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GovernmentAssistanceTextBlock" xml:lang="en-US">Government Assistance [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GovernmentAssistanceTextBlock" xml:lang="en-US">Government Grants And Assistance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceTextBlock" xlink:to="lab_us-gaap_GovernmentAssistanceTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xml:lang="en-US">Commitments Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xml:lang="en-US">Commitments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FinancialInstrumentsAbstract" xlink:label="loc_eprx_FinancialInstrumentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_FinancialInstrumentsAbstract" xml:lang="en-US">Financial Instruments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_FinancialInstrumentsAbstract" xlink:to="lab_eprx_FinancialInstrumentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_FinancialInstrumentsAbstract" xml:lang="en-US">Financial Instruments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xml:lang="en-US">Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseAbstract" xlink:label="loc_us-gaap_InterestExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseAbstract" xml:lang="en-US">Interest Expense [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseAbstract" xlink:to="lab_us-gaap_InterestExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xml:lang="en-US">Interest Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xml:lang="en-US">Supplemental Disclosure with Respect to Cash Flows</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Event</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings (Loss) per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Financial Instruments and Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Translation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="loc_us-gaap_GovernmentAssistancePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xml:lang="en-US">Government Assistance [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xml:lang="en-US">Government Assistance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="lab_us-gaap_GovernmentAssistancePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_GovernmentGrantsPolicyTextBlock" xlink:label="loc_eprx_GovernmentGrantsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_GovernmentGrantsPolicyTextBlock" xml:lang="en-US">Government Grants [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eprx_GovernmentGrantsPolicyTextBlock" xml:lang="en-US">Government Grants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_GovernmentGrantsPolicyTextBlock" xlink:to="lab_eprx_GovernmentGrantsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_GovernmentGrantsPolicyTextBlock" xml:lang="en-US">Government grants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xml:lang="en-US">Short Term Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Upcoming Accounting Standards and Interpretations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegulatoryIncomeTaxesPolicy" xlink:label="loc_us-gaap_RegulatoryIncomeTaxesPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RegulatoryIncomeTaxesPolicy" xml:lang="en-US">Regulatory Income Taxes, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RegulatoryIncomeTaxesPolicy" xml:lang="en-US">Investment Tax Credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RegulatoryIncomeTaxesPolicy" xlink:to="lab_us-gaap_RegulatoryIncomeTaxesPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expenditures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xml:lang="en-US">Share Capital and Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock" xlink:label="loc_eprx_PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock" xml:lang="en-US">Property Plant And Equipment Rate Of Depreciation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock" xml:lang="en-US">Summary of Property Plant And Equipment Estimated Useful Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock" xlink:to="lab_eprx_PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock" xml:lang="en-US">Property plant and equipment rate of depreciation.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfInformationAboutSubsidiariesTableTextBlock" xlink:label="loc_eprx_ScheduleOfInformationAboutSubsidiariesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ScheduleOfInformationAboutSubsidiariesTableTextBlock" xml:lang="en-US">Schedule of Information About Subsidiaries [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ScheduleOfInformationAboutSubsidiariesTableTextBlock" xml:lang="en-US">Summary of Information About Subsidiaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ScheduleOfInformationAboutSubsidiariesTableTextBlock" xlink:to="lab_eprx_ScheduleOfInformationAboutSubsidiariesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ScheduleOfInformationAboutSubsidiariesTableTextBlock" xml:lang="en-US">Schedule of information about subsidiaries.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NontradeReceivablesTableTextBlock" xlink:label="loc_eprx_NontradeReceivablesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_NontradeReceivablesTableTextBlock" xml:lang="en-US">Nontrade Receivables [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_NontradeReceivablesTableTextBlock" xml:lang="en-US">Summary of Amounts Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_NontradeReceivablesTableTextBlock" xlink:to="lab_eprx_NontradeReceivablesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_NontradeReceivablesTableTextBlock" xml:lang="en-US">Nontrade receivables.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Summary of Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OperatingLeaseRightOfUseAssetAbstract" xlink:label="loc_eprx_OperatingLeaseRightOfUseAssetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_OperatingLeaseRightOfUseAssetAbstract" xml:lang="en-US">Operating Lease Right of Use Asset [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_OperatingLeaseRightOfUseAssetAbstract" xlink:to="lab_eprx_OperatingLeaseRightOfUseAssetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_OperatingLeaseRightOfUseAssetAbstract" xml:lang="en-US">Operating Lease Right of Use Asset Abstract.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OperatingLeaseRightOfUseAssetTableTextBlock" xlink:label="loc_eprx_OperatingLeaseRightOfUseAssetTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_OperatingLeaseRightOfUseAssetTableTextBlock" xml:lang="en-US">Operating Lease Right of Use Asset [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_OperatingLeaseRightOfUseAssetTableTextBlock" xml:lang="en-US">Summary of Right of Use Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_OperatingLeaseRightOfUseAssetTableTextBlock" xlink:to="lab_eprx_OperatingLeaseRightOfUseAssetTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_OperatingLeaseRightOfUseAssetTableTextBlock" xml:lang="en-US">Operating lease right of use asset.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Summary of Accounts Payable and Accrued Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Schedule of Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Summary of Breakdown of Loan Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock" xlink:label="loc_eprx_DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock" xml:lang="en-US">Disclosure In Tabular Form Of Operating Lease Liability Current And Non Current [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock" xml:lang="en-US">Summary of Lease Liability Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock" xlink:to="lab_eprx_DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock" xml:lang="en-US">Disclosure in tabular form of operating lease liability current and non current [Table Text Block].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Summary of Future Minimum Lease Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Lessee, Operating Lease, Disclosure [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Summary of Cost Components of The Operating Lease</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock" xlink:label="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock" xml:lang="en-US">Disclosure In Tabular Form Of Certain Percentage Of Non Monetization Revenue Payable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock" xml:lang="en-US">Schedule of non-royalty monetization revenue percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock" xlink:to="lab_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock" xml:lang="en-US">Disclosure in tabular form of certain percentage of non monetization revenue payable [Table text block].</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock" xlink:label="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock" xml:lang="en-US">Disclosure In Tabular Form Of Milestone Payment Schedule [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock" xml:lang="en-US">Schedule of milestone payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock" xlink:to="lab_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock" xml:lang="en-US">Disclosure in tabular form of milestone payment schedule.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable" xml:lang="en-US">Disclosure In Tabular Form Of Movement In Convertible Debt At Fair Value [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable" xlink:to="lab_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable" xml:lang="en-US">Disclosure in tabular form of movement in convertible debt at fair value [Table].</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems" xml:lang="en-US">Disclosure In Tabular Form Of Movement In Convertible Debt At Fair Value [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems" xlink:to="lab_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems" xml:lang="en-US">Disclosure in tabular form of movement in convertible debt at fair value [Line items].</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock" xml:lang="en-US">Disclosure In Tabular Form Of Movement In Convertible Debt At Fair Value [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock" xml:lang="en-US">Schedule of loan balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock" xml:lang="en-US">Summary of Changes in Fair Value of Liabilities Measured at Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock" xlink:to="lab_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock" xml:lang="en-US">Disclosure in tabular form of movement in convertible debt at fair value [Table Text Block].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LoanMember" xlink:label="loc_eprx_LoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_LoanMember" xml:lang="en-US">Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_LoanMember" xlink:to="lab_eprx_LoanMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock" xlink:label="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock" xml:lang="en-US">Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock" xml:lang="en-US">Summary of options outstanding along with the grant dates and expiry date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock" xlink:to="lab_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock" xml:lang="en-US">Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock" xml:lang="en-US">Schedule of Share Based Compensation Arrangements By Share Based Payment Award Warrant [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock" xml:lang="en-US">Summary of share based compensation arrangements by share based payment warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock" xlink:to="lab_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock" xml:lang="en-US">Schedule of share based compensation arrangements by share based payment award warrant.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock" xml:lang="en-US">Schedule Of Share Based Compensation of Share Warrants Outstanding [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock" xml:lang="en-US">Summary of share based compensation of share warrants outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock" xlink:to="lab_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock" xml:lang="en-US">schedule of share based compensation of share warrants outstanding.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Summary of weighted-average assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xml:lang="en-US">Schedule of Stock Options Roll Forward [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xml:lang="en-US">Summary of company's option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:label="loc_eprx_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xml:lang="en-US">Schedule Of General And Administrative Expenses [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xml:lang="en-US">Schedule of general and administrative expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="lab_eprx_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xml:lang="en-US">Schedule of general and administrative expenses.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" xlink:label="loc_eprx_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" xml:lang="en-US">Schedule Of Research And Development Expenses [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" xml:lang="en-US">Schedule of research and development expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" xlink:to="lab_eprx_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" xml:lang="en-US">Schedule of research and development expenses.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_GovernmentAssistanceTableTextBlock" xlink:label="loc_eprx_GovernmentAssistanceTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_GovernmentAssistanceTableTextBlock" xml:lang="en-US">Government Assistance [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_GovernmentAssistanceTableTextBlock" xml:lang="en-US">Shedule Of Government Grants And Assistance Received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_GovernmentAssistanceTableTextBlock" xlink:to="lab_eprx_GovernmentAssistanceTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_GovernmentAssistanceTableTextBlock" xml:lang="en-US">Government Assistance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Income Tax Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Components of Company's Net Deferred Income Tax Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense Benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Components Included in Loss Before Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock" xlink:label="loc_eprx_ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock" xml:lang="en-US">Schedule Of Non Capital Losses Carry Forward Future Years [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock" xml:lang="en-US">Schedule of Non Capital Losses Carry Forward Future Years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock" xlink:to="lab_eprx_ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock" xml:lang="en-US">Schedule of non capital losses carry forward future years.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock" xlink:label="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock" xml:lang="en-US">Schedule Of Carrying Value Of Financial Instruments At Amortized Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock" xml:lang="en-US">Summary of Carrying Value of Financial Instruments at Amortized Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock" xlink:to="lab_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock" xml:lang="en-US">Schedule of carrying value of financial instruments at amortized cost.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xml:lang="en-US">Schedule of Interest Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xml:lang="en-US">Summary of Detailed Breakdown of Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NatureOfOperationsTable" xlink:label="loc_eprx_NatureOfOperationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_NatureOfOperationsTable" xml:lang="en-US">Nature of Operations [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_NatureOfOperationsTable" xlink:to="lab_eprx_NatureOfOperationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_NatureOfOperationsTable" xml:lang="en-US">Nature of operations.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LenderAxis" xlink:label="loc_eprx_LenderAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_LenderAxis" xml:lang="en-US">Lender [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_LenderAxis" xlink:to="lab_eprx_LenderAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_LenderAxis" xml:lang="en-US">Lender.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LenderDomain" xlink:label="loc_eprx_LenderDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_LenderDomain" xml:lang="en-US">Lender [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_LenderDomain" xlink:to="lab_eprx_LenderDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_LenderDomain" xml:lang="en-US">Lender.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SiliconValleyBankMember" xlink:label="loc_eprx_SiliconValleyBankMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_SiliconValleyBankMember" xml:lang="en-US">Silicon Valley Bank [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_SiliconValleyBankMember" xml:lang="en-US">Silicon Valley Bank [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_SiliconValleyBankMember" xlink:to="lab_eprx_SiliconValleyBankMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_SiliconValleyBankMember" xml:lang="en-US">Silicon valley bank.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NatureOfOperationsLineItems" xlink:label="loc_eprx_NatureOfOperationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_NatureOfOperationsLineItems" xml:lang="en-US">Nature of Operations [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_NatureOfOperationsLineItems" xlink:to="lab_eprx_NatureOfOperationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_NatureOfOperationsLineItems" xml:lang="en-US">Nature of operations.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="loc_us-gaap_DebtInstrumentCollateralAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCollateralAmount" xml:lang="en-US">Debt Instrument, Collateral Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentCollateralAmount" xml:lang="en-US">Debt instrument collateral amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCollateralAmount" xlink:to="lab_us-gaap_DebtInstrumentCollateralAmount" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DebtInstrumentMonthOfMaturity" xlink:label="loc_eprx_DebtInstrumentMonthOfMaturity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DebtInstrumentMonthOfMaturity" xml:lang="en-US">Debt Instrument Month of Maturity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_DebtInstrumentMonthOfMaturity" xml:lang="en-US">Debt instrument month of maturity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DebtInstrumentMonthOfMaturity" xlink:to="lab_eprx_DebtInstrumentMonthOfMaturity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DebtInstrumentMonthOfMaturity" xml:lang="en-US">Debt instrument month of maturity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xml:lang="en-US">Date of incorporation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xml:lang="en-US">Date of Incorporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationDateOfIncorporation" xlink:to="lab_dei_EntityIncorporationDateOfIncorporation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of stock net consideration received on the transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SummaryOfInformationAboutSubsidiariesTable" xlink:label="loc_eprx_SummaryOfInformationAboutSubsidiariesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_SummaryOfInformationAboutSubsidiariesTable" xml:lang="en-US">Summary Of Information About Subsidiaries [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_SummaryOfInformationAboutSubsidiariesTable" xlink:to="lab_eprx_SummaryOfInformationAboutSubsidiariesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_SummaryOfInformationAboutSubsidiariesTable" xml:lang="en-US">Summary of information about subsidiaries.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xml:lang="en-US">Consolidated Entities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xml:lang="en-US">Consolidated Entities [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SubsidiariesMember" xml:lang="en-US">Subsidiaries [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_SubsidiariesMember" xml:lang="en-US">Subsidiaries [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SubsidiariesMember" xlink:to="lab_srt_SubsidiariesMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmdmHoldingsIncMember" xlink:label="loc_eprx_AmdmHoldingsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AmdmHoldingsIncMember" xml:lang="en-US">AMDM Holdings Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_AmdmHoldingsIncMember" xml:lang="en-US">AMDM Holdings Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AmdmHoldingsIncMember" xlink:to="lab_eprx_AmdmHoldingsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AmdmHoldingsIncMember" xml:lang="en-US">Amdm holdings inc member.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaHoldingsIncMember" xlink:label="loc_eprx_EupraxiaHoldingsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_EupraxiaHoldingsIncMember" xml:lang="en-US">Eupraxia Holdings Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_EupraxiaHoldingsIncMember" xml:lang="en-US">Eupraxia Holdings, Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_EupraxiaHoldingsIncMember" xlink:to="lab_eprx_EupraxiaHoldingsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_EupraxiaHoldingsIncMember" xml:lang="en-US">Eupraxia holdings inc member.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaPharmaceuticalsAustraliaPtyLtdMember" xlink:label="loc_eprx_EupraxiaPharmaceuticalsAustraliaPtyLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_EupraxiaPharmaceuticalsAustraliaPtyLtdMember" xml:lang="en-US">Eupraxia Pharmaceuticals Australia Pty Ltd [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_EupraxiaPharmaceuticalsAustraliaPtyLtdMember" xml:lang="en-US">Eupraxia Pharmaceuticals Australia Pty Ltd. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_EupraxiaPharmaceuticalsAustraliaPtyLtdMember" xlink:to="lab_eprx_EupraxiaPharmaceuticalsAustraliaPtyLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_EupraxiaPharmaceuticalsAustraliaPtyLtdMember" xml:lang="en-US">Eupraxia pharmaceuticals australia pty ltd member.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaPharmaceuticalsUsaLlcMember" xlink:label="loc_eprx_EupraxiaPharmaceuticalsUsaLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_EupraxiaPharmaceuticalsUsaLlcMember" xml:lang="en-US">Eupraxia Pharmaceuticals USA LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_EupraxiaPharmaceuticalsUsaLlcMember" xml:lang="en-US">Eupraxia Pharmaceuticals USA, LLC [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_EupraxiaPharmaceuticalsUsaLlcMember" xlink:to="lab_eprx_EupraxiaPharmaceuticalsUsaLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_EupraxiaPharmaceuticalsUsaLlcMember" xml:lang="en-US">Eupraxia pharmaceuticals usa llc member.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaPharmaIncMember" xlink:label="loc_eprx_EupraxiaPharmaIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_EupraxiaPharmaIncMember" xml:lang="en-US">Eupraxia Pharma Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_EupraxiaPharmaIncMember" xml:lang="en-US">Eupraxia Pharma, Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_EupraxiaPharmaIncMember" xlink:to="lab_eprx_EupraxiaPharmaIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_EupraxiaPharmaIncMember" xml:lang="en-US">Eupraxia pharma inc member.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaPharmaUsaIncMember" xlink:label="loc_eprx_EupraxiaPharmaUsaIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_EupraxiaPharmaUsaIncMember" xml:lang="en-US">Eupraxia Pharma USA Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_EupraxiaPharmaUsaIncMember" xml:lang="en-US">Eupraxia Pharma USA Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_EupraxiaPharmaUsaIncMember" xlink:to="lab_eprx_EupraxiaPharmaUsaIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_EupraxiaPharmaUsaIncMember" xml:lang="en-US">Eupraxia pharma usa inc member.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SummaryOfInformationAboutSubsidiariesLineItems" xlink:label="loc_eprx_SummaryOfInformationAboutSubsidiariesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_SummaryOfInformationAboutSubsidiariesLineItems" xml:lang="en-US">Summary Of Information About Subsidiaries [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_SummaryOfInformationAboutSubsidiariesLineItems" xlink:to="lab_eprx_SummaryOfInformationAboutSubsidiariesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_SummaryOfInformationAboutSubsidiariesLineItems" xml:lang="en-US">Summary of information about subsidiaries line items.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_InvestmentOwnershipPercentage" xlink:label="loc_eprx_InvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_InvestmentOwnershipPercentage" xml:lang="en-US">Investment Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eprx_InvestmentOwnershipPercentage" xml:lang="en-US">Effective Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_InvestmentOwnershipPercentage" xlink:to="lab_eprx_InvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_InvestmentOwnershipPercentage" xml:lang="en-US">Investment ownership percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computers [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Office furniture and equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Office furniture and equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LabEquipmentMember" xlink:label="loc_eprx_LabEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_LabEquipmentMember" xml:lang="en-US">Lab Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eprx_LabEquipmentMember" xml:lang="en-US">Lab equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_LabEquipmentMember" xml:lang="en-US">Lab Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_LabEquipmentMember" xlink:to="lab_eprx_LabEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_LabEquipmentMember" xml:lang="en-US">Lab equipment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation" xlink:label="loc_eprx_PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation" xml:lang="en-US">Property Plant And Equipment Description Of Rate Of Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation" xml:lang="en-US">Property plant and Equipment Description of Rate of Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation" xlink:to="lab_eprx_PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation" xml:lang="en-US">Property plant and equipment description of rate of depreciation.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PropertyPlantAndEqupmentRateOfDepreciation" xlink:label="loc_eprx_PropertyPlantAndEqupmentRateOfDepreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PropertyPlantAndEqupmentRateOfDepreciation" xml:lang="en-US">Property Plant And Equipment Rate Of Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PropertyPlantAndEqupmentRateOfDepreciation" xml:lang="en-US">Property Plant and Equipment Rate of Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PropertyPlantAndEqupmentRateOfDepreciation" xlink:to="lab_eprx_PropertyPlantAndEqupmentRateOfDepreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PropertyPlantAndEqupmentRateOfDepreciation" xml:lang="en-US">Property plant and equpment rate of depreciation.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement" xlink:label="loc_eprx_PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement" xml:lang="en-US">Percentage Of Tax Benefits To Be Realized For Recognition In The Income Statement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement" xml:lang="en-US">Percentage of tax benefits to be realized for recognition in the income statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement" xlink:to="lab_eprx_PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement" xml:lang="en-US">Percentage of tax benefits to be realized for recognition in the income statement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivableCurrentsAbstract" xlink:label="loc_us-gaap_NontradeReceivableCurrentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NontradeReceivableCurrentsAbstract" xml:lang="en-US">Nontrade Receivables, Current [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NontradeReceivableCurrentsAbstract" xlink:to="lab_us-gaap_NontradeReceivableCurrentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmountCumulativeCurrent" xlink:label="loc_us-gaap_GovernmentAssistanceAmountCumulativeCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GovernmentAssistanceAmountCumulativeCurrent" xml:lang="en-US">Government Assistance, Amount, Cumulative, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GovernmentAssistanceAmountCumulativeCurrent" xml:lang="en-US">GST/HST recoverable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceAmountCumulativeCurrent" xlink:to="lab_us-gaap_GovernmentAssistanceAmountCumulativeCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrantsReceivableCurrent" xml:lang="en-US">Grants Receivable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GrantsReceivableCurrent" xml:lang="en-US">Government grants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivableCurrent" xlink:to="lab_us-gaap_GrantsReceivableCurrent" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OtherRefundableTaxCreditsCurrent" xlink:label="loc_eprx_OtherRefundableTaxCreditsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_OtherRefundableTaxCreditsCurrent" xml:lang="en-US">Other Refundable Tax Credits Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_OtherRefundableTaxCreditsCurrent" xml:lang="en-US">Other refundable tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_OtherRefundableTaxCreditsCurrent" xlink:to="lab_eprx_OtherRefundableTaxCreditsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_OtherRefundableTaxCreditsCurrent" xml:lang="en-US">Other refundable tax credits current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract" xml:lang="en-US">Accumulated Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" xlink:label="loc_eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" xml:lang="en-US">Accumulated Depreciation Depletion And Amortization Foreign Currency Translation Adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" xml:lang="en-US">Foreign currency adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" xlink:to="lab_eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" xml:lang="en-US">Accumulated depreciation depletion and amortization foreign currency translation adjustments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Balance, ending</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Balance, beginning</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Sale or Disposal of Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xml:lang="en-US">Disposals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease" xlink:label="loc_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease" xml:lang="en-US">Depreciation, Excluding Lessor Asset under Operating Lease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease" xlink:to="lab_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xml:lang="en-US">Property, Plant and Equipment, Gross [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xml:lang="en-US">Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xml:lang="en-US">Property, Plant and Equipment, Additions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xml:lang="en-US">Additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xml:lang="en-US">Property, Plant and Equipment, Disposals</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xml:lang="en-US">Disposals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" xlink:label="loc_eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" xml:lang="en-US">Property Plant And Equipment Foreign Currency Translation Adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" xml:lang="en-US">Foreign currency adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" xlink:to="lab_eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" xml:lang="en-US">Property plant and equipment foreign currency translation adjustments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Balance, ending</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Balance, beginning</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset" xlink:label="loc_eprx_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset" xml:lang="en-US">Increase Decrease Through Net Exchange Differences, Right Of Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_eprx_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset" xml:lang="en-US">Foreign Exchange</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset" xlink:to="lab_eprx_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset" xml:lang="en-US">Increase decrease through net exchange differences, right of use&#160;asset.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease" xml:lang="en-US">Depreciation, Lessor Asset under Operating Lease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease" xlink:to="lab_us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RightOfUseAssetTable" xlink:label="loc_eprx_RightOfUseAssetTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_RightOfUseAssetTable" xml:lang="en-US">Right of Use Asset [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_RightOfUseAssetTable" xlink:to="lab_eprx_RightOfUseAssetTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_RightOfUseAssetTable" xml:lang="en-US">Right of use asset.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RightOfUseAssetLineItems" xlink:label="loc_eprx_RightOfUseAssetLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_RightOfUseAssetLineItems" xml:lang="en-US">Right of Use Asset [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_RightOfUseAssetLineItems" xlink:to="lab_eprx_RightOfUseAssetLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_RightOfUseAssetLineItems" xml:lang="en-US">Right of use asset.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration" xlink:label="loc_eprx_AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration" xml:lang="en-US">Accounts Payable and Accrued Liabilities Current General and Administration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration" xlink:to="lab_eprx_AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration" xml:lang="en-US">Accounts payable and accrued liabilities current general and administration.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment" xlink:label="loc_eprx_AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment" xml:lang="en-US">Accounts Payable and Accrued Liabilities Current Research and Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment" xlink:to="lab_eprx_AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment" xml:lang="en-US">Accounts payable and accrued liabilities current research and development.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xml:lang="en-US">Accrued Bonuses, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xml:lang="en-US">Employee bonus payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedPayrollTaxesCurrent" xml:lang="en-US">Accrued Payroll Taxes, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedPayrollTaxesCurrent" xml:lang="en-US">Wages and payroll remittances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedPayrollTaxesCurrent" xlink:to="lab_us-gaap_AccruedPayrollTaxesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxesPayableCurrent" xml:lang="en-US">Taxes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxesPayableCurrent" xml:lang="en-US">Taxes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Borrowings of the company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt instrument face value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Convertible debt facility face value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xml:lang="en-US">Debt Instrument, Frequency of Periodic Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xml:lang="en-US">Debt instrument, frequency of periodic payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTerm" xlink:label="loc_us-gaap_LongTermDebtTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtTerm" xml:lang="en-US">Long-Term Debt, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtTerm" xml:lang="en-US">Term of loan agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebtTerm" xml:lang="en-US">Long term debt term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTerm" xlink:to="lab_us-gaap_LongTermDebtTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-Term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-Term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LoansPayableMember" xml:lang="en-US">Loans Payable [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LoansPayableMember" xml:lang="en-US">Loans Payable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ForeignExchangeAdjustmentOnLoansPayable" xlink:label="loc_eprx_ForeignExchangeAdjustmentOnLoansPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ForeignExchangeAdjustmentOnLoansPayable" xml:lang="en-US">Foreign Exchange Adjustment on Loans Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ForeignExchangeAdjustmentOnLoansPayable" xml:lang="en-US">Foreign exchange adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ForeignExchangeAdjustmentOnLoansPayable" xlink:to="lab_eprx_ForeignExchangeAdjustmentOnLoansPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ForeignExchangeAdjustmentOnLoansPayable" xml:lang="en-US">Foreign exchange adjustment on loans payable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaap_LoansPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LoansPayable" xml:lang="en-US">Loans Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_LoansPayable" xml:lang="en-US">Balance, ending</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_LoansPayable" xml:lang="en-US">Balance, beginning</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayable" xlink:to="lab_us-gaap_LoansPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaap_LoansPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LoansPayableCurrent" xml:lang="en-US">Loans Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_LoansPayableCurrent" xml:lang="en-US">Current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableCurrent" xlink:to="lab_us-gaap_LoansPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaap_LongTermLoansPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermLoansPayable" xml:lang="en-US">Loans Payable, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_LongTermLoansPayable" xml:lang="en-US">Non-current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLoansPayable" xlink:to="lab_us-gaap_LongTermLoansPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xml:lang="en-US">Repayments of Long-Term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xml:lang="en-US">Loan repayment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostAbstract" xml:lang="en-US">Lease, Cost [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostAbstract" xml:lang="en-US">Lease Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract" xlink:label="loc_eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract" xml:lang="en-US">Operating Lease Weighted Average Remaining Lease Term And Discount Rate [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract" xml:lang="en-US">Lease term and Discount Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract" xlink:to="lab_eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract" xml:lang="en-US">Operating lease weighted average remaining lease term and discount rate [Abstract].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted average discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted average remaining lease term (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncentiveFromLessor" xlink:label="loc_us-gaap_IncentiveFromLessor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncentiveFromLessor" xml:lang="en-US">Incentive from Lessor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncentiveFromLessor" xml:lang="en-US">Less: balance of unused tenant allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncentiveFromLessor" xlink:to="lab_us-gaap_IncentiveFromLessor" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total undiscounted future minimum lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Present value of lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Present value of lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xml:lang="en-US">Area of Real Estate Property</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xml:lang="en-US">Area of real estate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AreaOfSubleasedOfficeSpace" xlink:label="loc_eprx_AreaOfSubleasedOfficeSpace" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AreaOfSubleasedOfficeSpace" xml:lang="en-US">Area Of Subleased Office Space</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_AreaOfSubleasedOfficeSpace" xml:lang="en-US">Area of subleased office space</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AreaOfSubleasedOfficeSpace" xlink:to="lab_eprx_AreaOfSubleasedOfficeSpace" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AreaOfSubleasedOfficeSpace" xml:lang="en-US">Area of subleased office space.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Expiry date of lease agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseExpirationDate1" xlink:to="lab_us-gaap_LeaseExpirationDate1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubleaseIncome" xml:lang="en-US">Sublease Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubleaseIncome" xml:lang="en-US">Sublease income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LicenseAgreementTable" xlink:label="loc_eprx_LicenseAgreementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_LicenseAgreementTable" xml:lang="en-US">License Agreement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_LicenseAgreementTable" xlink:to="lab_eprx_LicenseAgreementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_LicenseAgreementTable" xml:lang="en-US">License agreement [Table].</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AgreementAxis" xlink:label="loc_eprx_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AgreementAxis" xlink:to="lab_eprx_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AgreementAxis" xml:lang="en-US">Agreement.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AgreementDomain" xlink:label="loc_eprx_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AgreementDomain" xlink:to="lab_eprx_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AgreementDomain" xml:lang="en-US">Agreement</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmendedAndRestatedLicenseAgreementMember" xlink:label="loc_eprx_AmendedAndRestatedLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AmendedAndRestatedLicenseAgreementMember" xml:lang="en-US">Amended And Restated License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_AmendedAndRestatedLicenseAgreementMember" xml:lang="en-US">Amended and Restated License Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AmendedAndRestatedLicenseAgreementMember" xlink:to="lab_eprx_AmendedAndRestatedLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AmendedAndRestatedLicenseAgreementMember" xml:lang="en-US">Amended And Restated License Agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaUsaMember" xlink:label="loc_eprx_EupraxiaUsaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_EupraxiaUsaMember" xml:lang="en-US">Eupraxia USA [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_EupraxiaUsaMember" xml:lang="en-US">Eupraxia USA [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_EupraxiaUsaMember" xlink:to="lab_eprx_EupraxiaUsaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_EupraxiaUsaMember" xml:lang="en-US">Eupraxia USA.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LicenseAgreementLineItems" xlink:label="loc_eprx_LicenseAgreementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_LicenseAgreementLineItems" xml:lang="en-US">License Agreement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_LicenseAgreementLineItems" xlink:to="lab_eprx_LicenseAgreementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_LicenseAgreementLineItems" xml:lang="en-US">License agreement [Line Items].</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization" xlink:label="loc_eprx_MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization" xml:lang="en-US">Maximum Amount Incurrable Out Of Non Royalty Revenue Monetization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization" xml:lang="en-US">Maximum amount incurrable out of non royalty revenue monetization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization" xlink:to="lab_eprx_MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization" xml:lang="en-US">Maximum Amount Incurrable Out Of Non Royalty Revenue Monetization.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MilestonePaymentRecognizedExpense" xlink:label="loc_eprx_MilestonePaymentRecognizedExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_MilestonePaymentRecognizedExpense" xml:lang="en-US">Milestone Payment Recognized Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_MilestonePaymentRecognizedExpense" xml:lang="en-US">Milestone payment recognized expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_MilestonePaymentRecognizedExpense" xlink:to="lab_eprx_MilestonePaymentRecognizedExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_MilestonePaymentRecognizedExpense" xml:lang="en-US">Milestone payment recognized expense.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement" xlink:label="loc_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement" xml:lang="en-US">Payable Towards Commercial And Regulator Milestone Achievement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement" xml:lang="en-US">Payable towards commercial and regulatory milestone achievement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement" xlink:to="lab_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement" xml:lang="en-US">Payable towards commercial and regulator milestone achievement.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PaymentOfUpfrontFees" xlink:label="loc_eprx_PaymentOfUpfrontFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PaymentOfUpfrontFees" xml:lang="en-US">Payment Of Upfront Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PaymentOfUpfrontFees" xml:lang="en-US">Payment of upfront fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PaymentOfUpfrontFees" xlink:to="lab_eprx_PaymentOfUpfrontFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PaymentOfUpfrontFees" xml:lang="en-US">Payment of upfront fees.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable" xlink:label="loc_eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable" xml:lang="en-US">Percentage Of Non Royalty Monetization Revenue Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable" xml:lang="en-US">Percentage of non royalty monetization revenue payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable" xlink:to="lab_eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable" xml:lang="en-US">Percentage of non royalty monetization revenue payable.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RoyaltyAsAPercentageOfNetSales" xlink:label="loc_eprx_RoyaltyAsAPercentageOfNetSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_RoyaltyAsAPercentageOfNetSales" xml:lang="en-US">Royalty As A Percentage Of Net Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_RoyaltyAsAPercentageOfNetSales" xml:lang="en-US">Royalty as a percentage of net sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_RoyaltyAsAPercentageOfNetSales" xlink:to="lab_eprx_RoyaltyAsAPercentageOfNetSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_RoyaltyAsAPercentageOfNetSales" xml:lang="en-US">Royalty as a percentage of net sales.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MilestoneAxis" xlink:label="loc_eprx_MilestoneAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_MilestoneAxis" xml:lang="en-US">Milestone [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_MilestoneAxis" xlink:to="lab_eprx_MilestoneAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_MilestoneAxis" xml:lang="en-US">Milestone.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MilestoneDomain" xlink:label="loc_eprx_MilestoneDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_MilestoneDomain" xml:lang="en-US">Milestone [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_MilestoneDomain" xlink:to="lab_eprx_MilestoneDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_MilestoneDomain" xml:lang="en-US">Milestone.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SuccessfulCompletionOfPhaseTwoBStudyMember" xlink:label="loc_eprx_SuccessfulCompletionOfPhaseTwoBStudyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_SuccessfulCompletionOfPhaseTwoBStudyMember" xml:lang="en-US">Successful Completion Of Phase Two B Study [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_SuccessfulCompletionOfPhaseTwoBStudyMember" xml:lang="en-US">Successful Completion of a Phase 2b Study [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_SuccessfulCompletionOfPhaseTwoBStudyMember" xlink:to="lab_eprx_SuccessfulCompletionOfPhaseTwoBStudyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_SuccessfulCompletionOfPhaseTwoBStudyMember" xml:lang="en-US">Successful Completion Of Phase Two B Study.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ArithmeticAverageMember" xlink:label="loc_srt_ArithmeticAverageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ArithmeticAverageMember" xml:lang="en-US">Arithmetic Average [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ArithmeticAverageMember" xlink:to="lab_srt_ArithmeticAverageMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable" xlink:label="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable" xml:lang="en-US">Disclosure In Tabular Form Of Milestone Payment Schedule [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable" xlink:to="lab_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable" xml:lang="en-US">Disclosure in tabular form of milestone payment schedule [Table].</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems" xlink:label="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems" xml:lang="en-US">Disclosure In Tabular Form Of Milestone Payment Schedule [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems" xlink:to="lab_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems" xml:lang="en-US">Disclosure In Tabular Form Of Milestone Payment Schedule.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FirstOaRegulatoryApprovalMember" xlink:label="loc_eprx_FirstOaRegulatoryApprovalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_FirstOaRegulatoryApprovalMember" xml:lang="en-US">First OA Regulatory Approval [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_FirstOaRegulatoryApprovalMember" xml:lang="en-US">First OA Regulatory Approval [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_FirstOaRegulatoryApprovalMember" xlink:to="lab_eprx_FirstOaRegulatoryApprovalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_FirstOaRegulatoryApprovalMember" xml:lang="en-US">First OA Regulatory Approval.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NonOaIndicationRegulatoryApprovalMember" xlink:label="loc_eprx_NonOaIndicationRegulatoryApprovalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_NonOaIndicationRegulatoryApprovalMember" xml:lang="en-US">Non OA Indication Regulatory Approval [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eprx_NonOaIndicationRegulatoryApprovalMember" xml:lang="en-US">Non-OA Indication Regulatory Approval [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_NonOaIndicationRegulatoryApprovalMember" xlink:to="lab_eprx_NonOaIndicationRegulatoryApprovalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_NonOaIndicationRegulatoryApprovalMember" xml:lang="en-US">Non OA Indication Regulatory Approval.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember" xlink:label="loc_eprx_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember" xml:lang="en-US">Sales Threshold Including Licenses And Sublicenses Exceeding Fifty Crores [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember" xml:lang="en-US">First calendar year in which aggregate Net Sales by Eupraxia USA, its affiliates and sublicenses exceed $500,000,000 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember" xlink:to="lab_eprx_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember" xml:lang="en-US">Sales Threshold Including Licenses And Sublicenses Exceeding Fifty Crores./</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SecondOaRegulatoryApprovalMember" xlink:label="loc_eprx_SecondOaRegulatoryApprovalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_SecondOaRegulatoryApprovalMember" xml:lang="en-US">Second OA Regulatory Approval [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_SecondOaRegulatoryApprovalMember" xml:lang="en-US">Second OA Regulatory Approval [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_SecondOaRegulatoryApprovalMember" xlink:to="lab_eprx_SecondOaRegulatoryApprovalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_SecondOaRegulatoryApprovalMember" xml:lang="en-US">Second OA Regulatory Approval</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable" xlink:label="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable" xml:lang="en-US">Disclosure In Tabular Form Of Certain Percentage Of Non Monetization Revenue Payable [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable" xlink:to="lab_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable" xml:lang="en-US">Disclosure in tabular form of certain percentage of non monetization revenue payable [Table].</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems" xlink:label="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems" xml:lang="en-US">Disclosure In Tabular Form Of Certain Percentage Of Non Monetization Revenue Payable [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems" xlink:to="lab_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems" xml:lang="en-US">Disclosure In Tabular Form Of Certain Percentage Of Non Monetization Revenue Payable.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty" xlink:label="loc_eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty" xml:lang="en-US">Percentage of Non Monetization Revenue To Be Paid To The Counterparty</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty" xml:lang="en-US">Percentage of Non-Royalty Monetization Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty" xlink:to="lab_eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty" xml:lang="en-US">Percentage of non monetization revenue to be paid to the counterparty.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TrancheAxis" xlink:label="loc_eprx_TrancheAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TrancheAxis" xml:lang="en-US">Tranche [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TrancheAxis" xlink:to="lab_eprx_TrancheAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TrancheAxis" xml:lang="en-US">Tranche.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TrancheDomain" xlink:label="loc_eprx_TrancheDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TrancheDomain" xml:lang="en-US">Tranche [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TrancheDomain" xlink:to="lab_eprx_TrancheDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TrancheDomain" xml:lang="en-US">Tranche.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember" xlink:label="loc_eprx_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember" xml:lang="en-US">After Regulatory Approval Of The Product From FDA In The United States [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember" xml:lang="en-US">After Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember" xlink:to="lab_eprx_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember" xml:lang="en-US">After Regulatory Approval Of The Product From FDA In The United States.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember" xlink:label="loc_eprx_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember" xml:lang="en-US">After Successful Completion Of Phase Three Study But Prior To Regulatory Approval Of The Product From FDA In The United Status [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember" xml:lang="en-US">After Successful Completion of a Phase 3 Study but prior to Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember" xlink:to="lab_eprx_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember" xml:lang="en-US">After Successful Completion Of Phase Three Study But Prior To Regulatory Approval Of The Product From FDA In The United Status.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember" xlink:label="loc_eprx_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember" xml:lang="en-US">After Successful Completion Of Phase Two B Study But Prior To Successful Completion Of Phase Three Study [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember" xml:lang="en-US">After Successful Completion of a Phase 2b Study but prior to Successful Completion of a Phase 3 Study [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember" xlink:to="lab_eprx_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember" xml:lang="en-US">After Successful Completion Of Phase Two B Study But Prior To Successful Completion Of Phase Three Study.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PriorToSuccessfulCompletionOfPhaseTwoBStudyMember" xlink:label="loc_eprx_PriorToSuccessfulCompletionOfPhaseTwoBStudyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PriorToSuccessfulCompletionOfPhaseTwoBStudyMember" xml:lang="en-US">Prior To Successful Completion Of Phase Two B Study [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PriorToSuccessfulCompletionOfPhaseTwoBStudyMember" xml:lang="en-US">Prior to Successful Completion of a Phase 2b Study [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PriorToSuccessfulCompletionOfPhaseTwoBStudyMember" xlink:to="lab_eprx_PriorToSuccessfulCompletionOfPhaseTwoBStudyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PriorToSuccessfulCompletionOfPhaseTwoBStudyMember" xml:lang="en-US">Prior To Successful Completion Of Phase Two B Study.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CallRightAxis" xlink:label="loc_eprx_CallRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_CallRightAxis" xml:lang="en-US">Call Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_CallRightAxis" xlink:to="lab_eprx_CallRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_CallRightAxis" xml:lang="en-US">Call right.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CallRightDomain" xlink:label="loc_eprx_CallRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_CallRightDomain" xml:lang="en-US">Call Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_CallRightDomain" xlink:to="lab_eprx_CallRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_CallRightDomain" xml:lang="en-US">Call right.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember" xlink:label="loc_eprx_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember" xml:lang="en-US">After Eighteen Months From The Date Of The Debt Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember" xlink:to="lab_eprx_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember" xml:lang="en-US">After eighteen months from the date of the debt agreement.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_WithEighteenMonthsFromTheDateOfTheDebtAgreementMember" xlink:label="loc_eprx_WithEighteenMonthsFromTheDateOfTheDebtAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_WithEighteenMonthsFromTheDateOfTheDebtAgreementMember" xml:lang="en-US">With Eighteen Months From The Date Of The Debt Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_WithEighteenMonthsFromTheDateOfTheDebtAgreementMember" xlink:to="lab_eprx_WithEighteenMonthsFromTheDateOfTheDebtAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_WithEighteenMonthsFromTheDateOfTheDebtAgreementMember" xml:lang="en-US">With eighteen months from the date of the debt Agreement.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AggegateAmountRaisedByWayOfEquityIssue" xlink:label="loc_eprx_AggegateAmountRaisedByWayOfEquityIssue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AggegateAmountRaisedByWayOfEquityIssue" xml:lang="en-US">Aggegate Amount Raised By Way Of Equity Issue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_AggegateAmountRaisedByWayOfEquityIssue" xml:lang="en-US">Aggregate amount raised by way of equity issue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AggegateAmountRaisedByWayOfEquityIssue" xlink:to="lab_eprx_AggegateAmountRaisedByWayOfEquityIssue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AggegateAmountRaisedByWayOfEquityIssue" xml:lang="en-US">Aggegate amount raised by way of equity issue.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmountToBeRaisedByWayOfEquityIssue" xlink:label="loc_eprx_AmountToBeRaisedByWayOfEquityIssue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AmountToBeRaisedByWayOfEquityIssue" xml:lang="en-US">Amount To Be Raised By Way Of Equity Issue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_AmountToBeRaisedByWayOfEquityIssue" xml:lang="en-US">Amount to be raised by way of equity issue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AmountToBeRaisedByWayOfEquityIssue" xlink:to="lab_eprx_AmountToBeRaisedByWayOfEquityIssue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AmountToBeRaisedByWayOfEquityIssue" xml:lang="en-US">Amount to be raised by way of equity issue.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt instrument conversion price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xml:lang="en-US">Debt instrument redemption price percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LongTermDebtBaseRate" xlink:label="loc_eprx_LongTermDebtBaseRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_LongTermDebtBaseRate" xml:lang="en-US">Long Term Debt Base Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_LongTermDebtBaseRate" xml:lang="en-US">Long term debt base rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_LongTermDebtBaseRate" xlink:to="lab_eprx_LongTermDebtBaseRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_LongTermDebtBaseRate" xml:lang="en-US">Long term debt base rate.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LongTermDebtPaidInKindInterestPercentage" xlink:label="loc_eprx_LongTermDebtPaidInKindInterestPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_LongTermDebtPaidInKindInterestPercentage" xml:lang="en-US">Long Term Debt Paid In Kind Interest Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_LongTermDebtPaidInKindInterestPercentage" xml:lang="en-US">Long term debt paid in kind interest rate percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_LongTermDebtPaidInKindInterestPercentage" xlink:to="lab_eprx_LongTermDebtPaidInKindInterestPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_LongTermDebtPaidInKindInterestPercentage" xml:lang="en-US">Long term debt paid in kind interest percentage.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LongTermDebtTermExtendableAtLendersDiscretion" xlink:label="loc_eprx_LongTermDebtTermExtendableAtLendersDiscretion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_LongTermDebtTermExtendableAtLendersDiscretion" xml:lang="en-US">Long Term Debt Term Extendable At Lenders Discretion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_LongTermDebtTermExtendableAtLendersDiscretion" xml:lang="en-US">Long term debt term extendable at lenders discretion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_LongTermDebtTermExtendableAtLendersDiscretion" xlink:to="lab_eprx_LongTermDebtTermExtendableAtLendersDiscretion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_LongTermDebtTermExtendableAtLendersDiscretion" xml:lang="en-US">Long term debt term extendable at lenders discretion.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from convertible debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CanadianPrimeRateMember" xlink:label="loc_eprx_CanadianPrimeRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_CanadianPrimeRateMember" xml:lang="en-US">Canadian Prime Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_CanadianPrimeRateMember" xml:lang="en-US">Canadian Prime Rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_CanadianPrimeRateMember" xlink:to="lab_eprx_CanadianPrimeRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_CanadianPrimeRateMember" xml:lang="en-US">Canadian prime rate.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod" xlink:label="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod" xml:lang="en-US">Fair Value Measurement With Unobservable Input Reconciliation Recurring Basis Accrued Interest During The Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod" xml:lang="en-US">Accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod" xlink:to="lab_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod" xml:lang="en-US">Fair value measurement with unobservable input reconciliation recurring basis accrued interest during the period.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod" xlink:label="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod" xml:lang="en-US">Fair Value Measurement With Unobservable Input Reconciliation Recurring Basis Interest Paid During The Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod" xml:lang="en-US">Interest paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod" xlink:to="lab_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod" xml:lang="en-US">Fair value measurement with unobservable input reconciliation recurring basis interest paid during the period.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss" xlink:label="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss" xml:lang="en-US">Fair Value Measurement With Unobservable Input Reconciliation Recurring Basis Liability Foreign Exchange Gain Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss" xml:lang="en-US">Foreign exchange</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss" xlink:to="lab_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss" xml:lang="en-US">Fair value measurement with unobservable input reconciliation recurring basis liability foreign exchange gain loss.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Beginning Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmdmHoldingsAxis" xlink:label="loc_eprx_AmdmHoldingsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AmdmHoldingsAxis" xml:lang="en-US">AMDM Holdings [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AmdmHoldingsAxis" xlink:to="lab_eprx_AmdmHoldingsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AmdmHoldingsAxis" xml:lang="en-US">AMDM Holdings.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmdmHoldingsDomain" xlink:label="loc_eprx_AmdmHoldingsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AmdmHoldingsDomain" xml:lang="en-US">AMDM Holdings [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AmdmHoldingsDomain" xlink:to="lab_eprx_AmdmHoldingsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AmdmHoldingsDomain" xml:lang="en-US">AMDM Holdings.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmdmHoldingsMember" xlink:label="loc_eprx_AmdmHoldingsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AmdmHoldingsMember" xml:lang="en-US">AMDM Holdings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AmdmHoldingsMember" xlink:to="lab_eprx_AmdmHoldingsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AmdmHoldingsMember" xml:lang="en-US">AMDM Holdings</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated share based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share based payments (Note 12(c))</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CashCostsOfIssuingShares" xlink:label="loc_eprx_CashCostsOfIssuingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_CashCostsOfIssuingShares" xml:lang="en-US">Cash Costs Of Issuing Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_CashCostsOfIssuingShares" xml:lang="en-US">Cash costs of issuing shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_CashCostsOfIssuingShares" xlink:to="lab_eprx_CashCostsOfIssuingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_CashCostsOfIssuingShares" xml:lang="en-US">Cash Costs Of Issuing Shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of warrants exercise price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of warrants or rights exercise price of warrants or rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Class of warrant or right number of securities called by each warrant or right</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaap_CommonStockConversionBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockConversionBasis" xml:lang="en-US">Common Stock, Conversion Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockConversionBasis" xml:lang="en-US">Common stock conversion basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockConversionBasis" xlink:to="lab_us-gaap_CommonStockConversionBasis" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CommonStockSharesIssuableAsAResultOfStockSplit" xlink:label="loc_eprx_CommonStockSharesIssuableAsAResultOfStockSplit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_CommonStockSharesIssuableAsAResultOfStockSplit" xml:lang="en-US">Common Stock Shares Issuable As A Result Of Stock Split</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_CommonStockSharesIssuableAsAResultOfStockSplit" xml:lang="en-US">Common stock shares issuable as a result of stock split</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_CommonStockSharesIssuableAsAResultOfStockSplit" xlink:to="lab_eprx_CommonStockSharesIssuableAsAResultOfStockSplit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_CommonStockSharesIssuableAsAResultOfStockSplit" xml:lang="en-US">Common Stock Shares Issuable As A Result Of Stock Split.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share based compensation by share based award options unrecognized compensation period for recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Share based compensation by share based award options unrecognized compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EquityMethodInvestmentNumberOfSharedOwned" xlink:label="loc_eprx_EquityMethodInvestmentNumberOfSharedOwned" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_EquityMethodInvestmentNumberOfSharedOwned" xml:lang="en-US">Equity Method Investment Number Of Shared Owned</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_EquityMethodInvestmentNumberOfSharedOwned" xml:lang="en-US">Equity method investment number of shares owned</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_EquityMethodInvestmentNumberOfSharedOwned" xlink:to="lab_eprx_EquityMethodInvestmentNumberOfSharedOwned" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_EquityMethodInvestmentNumberOfSharedOwned" xml:lang="en-US">Equity Method Investment Number Of Shared Owned.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity method investment ownership percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalFees" xml:lang="en-US">Legal Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LegalFees" xml:lang="en-US">Legal fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Minority interest held</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NumberOfUnitsIssued" xlink:label="loc_eprx_NumberOfUnitsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_NumberOfUnitsIssued" xml:lang="en-US">Number of units issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_NumberOfUnitsIssued" xml:lang="en-US">Number of units issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_NumberOfUnitsIssued" xlink:to="lab_eprx_NumberOfUnitsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_NumberOfUnitsIssued" xml:lang="en-US">Number of units issued.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NumberOfWarrantIssued" xlink:label="loc_eprx_NumberOfWarrantIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_NumberOfWarrantIssued" xml:lang="en-US">Number of warrant issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_NumberOfWarrantIssued" xml:lang="en-US">Number of warrant issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_NumberOfWarrantIssued" xlink:to="lab_eprx_NumberOfWarrantIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_NumberOfWarrantIssued" xml:lang="en-US">Number of warrant issued.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForUnderwritingExpense" xml:lang="en-US">Payments for Underwriting Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForUnderwritingExpense" xml:lang="en-US">Payments for underwriting expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForUnderwritingExpense" xlink:to="lab_us-gaap_PaymentsForUnderwritingExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of stock issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfGrossProceedsRaisedUnderTheOffering" xlink:label="loc_eprx_PercentageOfGrossProceedsRaisedUnderTheOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PercentageOfGrossProceedsRaisedUnderTheOffering" xml:lang="en-US">Percentage of gross proceeds raised under the Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PercentageOfGrossProceedsRaisedUnderTheOffering" xml:lang="en-US">Percentage of gross proceeds raised under the Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PercentageOfGrossProceedsRaisedUnderTheOffering" xlink:to="lab_eprx_PercentageOfGrossProceedsRaisedUnderTheOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PercentageOfGrossProceedsRaisedUnderTheOffering" xml:lang="en-US">Percentage of gross proceeds raised under the Offering.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfOutstandingSharesEligibleForStockOptionsIssuance" xlink:label="loc_eprx_PercentageOfOutstandingSharesEligibleForStockOptionsIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PercentageOfOutstandingSharesEligibleForStockOptionsIssuance" xml:lang="en-US">Percentage Of Outstanding Shares Eligible For Stock Options Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PercentageOfOutstandingSharesEligibleForStockOptionsIssuance" xml:lang="en-US">Percentage of outstanding shares eligible for stock option issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PercentageOfOutstandingSharesEligibleForStockOptionsIssuance" xlink:to="lab_eprx_PercentageOfOutstandingSharesEligibleForStockOptionsIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PercentageOfOutstandingSharesEligibleForStockOptionsIssuance" xml:lang="en-US">Percentage Of Outstanding Shares Eligible For Stock Options Issuance.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering" xlink:label="loc_eprx_PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering" xml:lang="en-US">Percentage of total units and warrants issued in the Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering" xml:lang="en-US">Percentage of total units and warrants issued in the Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering" xlink:to="lab_eprx_PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering" xml:lang="en-US">Percentage of total units and warrants issued in the Offering.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaap_PreferredStockNoParValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockNoParValue" xml:lang="en-US">Preferred Stock, No Par Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockNoParValue" xml:lang="en-US">Preferred stock par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNoParValue" xlink:to="lab_us-gaap_PreferredStockNoParValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorizedUnlimited" xlink:label="loc_us-gaap_PreferredStockSharesAuthorizedUnlimited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorizedUnlimited" xml:lang="en-US">Preferred Stock, Shares Authorized, Unlimited [Fixed List]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorizedUnlimited" xml:lang="en-US">Preferred stock shares authorized unlimited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorizedUnlimited" xlink:to="lab_us-gaap_PreferredStockSharesAuthorizedUnlimited" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from issuance of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of stock issue price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SecuritiesIssuedPricePerUnit" xlink:label="loc_eprx_SecuritiesIssuedPricePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_SecuritiesIssuedPricePerUnit" xml:lang="en-US">Securities Issued, Price Per unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_SecuritiesIssuedPricePerUnit" xml:lang="en-US">Securities issued, price per unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_SecuritiesIssuedPricePerUnit" xlink:to="lab_eprx_SecuritiesIssuedPricePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_SecuritiesIssuedPricePerUnit" xml:lang="en-US">Securities Issued, Price Per unit.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share based compensation by share based award vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Share based compensation by share based award vesting percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share based compensation by share based award aggregate term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Class of warrants or rights term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share based compensation arrangement by share based payment award number of shares available for grant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share based compensation by share based award optinoss exercise din period weighted average exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average price, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Stock split ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock issued during the period shares for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Shares, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock issued during the period value for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Share capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_StockSharesIssuedAsAPercentageOfOutstandingShares" xlink:label="loc_eprx_StockSharesIssuedAsAPercentageOfOutstandingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_StockSharesIssuedAsAPercentageOfOutstandingShares" xml:lang="en-US">Stock Shares Issued As A Percentage Of Outstanding Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_StockSharesIssuedAsAPercentageOfOutstandingShares" xml:lang="en-US">Stock shares issued as a percentage of outstanding shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_StockSharesIssuedAsAPercentageOfOutstandingShares" xlink:to="lab_eprx_StockSharesIssuedAsAPercentageOfOutstandingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_StockSharesIssuedAsAPercentageOfOutstandingShares" xml:lang="en-US">Stock Shares Issued As A Percentage Of Outstanding Shares.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TransferredFromAdditionalPaidinCapitalToShareCapital" xlink:label="loc_eprx_TransferredFromAdditionalPaidinCapitalToShareCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TransferredFromAdditionalPaidinCapitalToShareCapital" xml:lang="en-US">Transferred From Additional PaidIn Capital To Share Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_TransferredFromAdditionalPaidinCapitalToShareCapital" xml:lang="en-US">Transferred from additional paid-in capital to share capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TransferredFromAdditionalPaidinCapitalToShareCapital" xlink:to="lab_eprx_TransferredFromAdditionalPaidinCapitalToShareCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TransferredFromAdditionalPaidinCapitalToShareCapital" xml:lang="en-US">Transferred From Additional Paid-In Capital To Share Capital.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_WarrantIssuedPricePerUnit" xlink:label="loc_eprx_WarrantIssuedPricePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_WarrantIssuedPricePerUnit" xml:lang="en-US">Warrant Issued, Price Per unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_WarrantIssuedPricePerUnit" xml:lang="en-US">Warrant Issued, Price Per unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_WarrantIssuedPricePerUnit" xlink:to="lab_eprx_WarrantIssuedPricePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_WarrantIssuedPricePerUnit" xml:lang="en-US">Warrant Issued, Price Per uni.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xml:lang="en-US">Warrants and rights outstanding maturity date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Warrants and rights outstanding term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExcerciseOfOptionsMember" xlink:label="loc_eprx_ExcerciseOfOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ExcerciseOfOptionsMember" xml:lang="en-US">Excercise Of Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ExcerciseOfOptionsMember" xlink:to="lab_eprx_ExcerciseOfOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ExcerciseOfOptionsMember" xml:lang="en-US">Excercise Of Options</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EuphraxiaPharmaIncMember" xlink:label="loc_eprx_EuphraxiaPharmaIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_EuphraxiaPharmaIncMember" xml:lang="en-US">Euphraxia Pharma Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_EuphraxiaPharmaIncMember" xlink:to="lab_eprx_EuphraxiaPharmaIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_EuphraxiaPharmaIncMember" xml:lang="en-US">Euphraxia Pharma Inc.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipAxis" xml:lang="en-US">Ownership [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipDomain" xml:lang="en-US">Ownership [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EuphraxiaUsaMember" xlink:label="loc_eprx_EuphraxiaUsaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_EuphraxiaUsaMember" xml:lang="en-US">Euphraxia USA [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_EuphraxiaUsaMember" xlink:to="lab_eprx_EuphraxiaUsaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_EuphraxiaUsaMember" xml:lang="en-US">Euphraxia USA.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmendedPlanMember" xlink:label="loc_eprx_AmendedPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AmendedPlanMember" xml:lang="en-US">Amended Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AmendedPlanMember" xlink:to="lab_eprx_AmendedPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AmendedPlanMember" xml:lang="en-US">Amended Plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OutstandingOfAMDMHoldingsMember" xlink:label="loc_eprx_OutstandingOfAMDMHoldingsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_OutstandingOfAMDMHoldingsMember" xml:lang="en-US">Outstanding Of AMDM Holdings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_OutstandingOfAMDMHoldingsMember" xml:lang="en-US">Outstanding of AMDM Holdings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_OutstandingOfAMDMHoldingsMember" xlink:to="lab_eprx_OutstandingOfAMDMHoldingsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_OutstandingOfAMDMHoldingsMember" xml:lang="en-US">Outstanding of AMDM holdings.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ClassBNonVotingStockMember" xlink:label="loc_eprx_ClassBNonVotingStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ClassBNonVotingStockMember" xml:lang="en-US">Class B Non Voting Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ClassBNonVotingStockMember" xlink:to="lab_eprx_ClassBNonVotingStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ClassBNonVotingStockMember" xml:lang="en-US">Class B Non Voting Stock.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Common Class A [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ChiefScientificOfficerMember" xlink:label="loc_eprx_ChiefScientificOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ChiefScientificOfficerMember" xml:lang="en-US">Chief Scientific Officer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ChiefScientificOfficerMember" xlink:to="lab_eprx_ChiefScientificOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ChiefScientificOfficerMember" xml:lang="en-US">Chief Scientific Officer.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ImmediateVestingMember" xlink:label="loc_eprx_ImmediateVestingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ImmediateVestingMember" xml:lang="en-US">Immediate Vesting [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ImmediateVestingMember" xlink:to="lab_eprx_ImmediateVestingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ImmediateVestingMember" xml:lang="en-US">Immediate Vesting.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_WarrantAxis" xlink:label="loc_eprx_WarrantAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_WarrantAxis" xml:lang="en-US">Warrant [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_WarrantAxis" xlink:to="lab_eprx_WarrantAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_WarrantAxis" xml:lang="en-US">Warrant.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_WarrantDomain" xlink:label="loc_eprx_WarrantDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_WarrantDomain" xml:lang="en-US">Warrant [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_WarrantDomain" xlink:to="lab_eprx_WarrantDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_WarrantDomain" xml:lang="en-US">Warrant.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CompensationWarrantMember" xlink:label="loc_eprx_CompensationWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_CompensationWarrantMember" xml:lang="en-US">Compensation Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_CompensationWarrantMember" xlink:to="lab_eprx_CompensationWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_CompensationWarrantMember" xml:lang="en-US">Compensation warrant.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Number of options, Cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of options, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of options, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of options, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average price, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average price, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average price, Cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average price, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable" xlink:label="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable" xml:lang="en-US">Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable" xlink:to="lab_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable" xml:lang="en-US">Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems" xlink:label="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems" xml:lang="en-US">Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems" xlink:to="lab_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems" xml:lang="en-US">Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xml:lang="en-US">Expiry Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Options Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Remaining Contractual Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" xlink:label="loc_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" xml:lang="en-US">Share Based Compesnation By Share Based Options Granted Date Of Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" xml:lang="en-US">Grant Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" xlink:to="lab_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" xml:lang="en-US">Share Based Compesnation By Share Based Options Granted Date Of Grant.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationOptionsExpiryDateAxis" xlink:label="loc_eprx_ShareBasedCompensationOptionsExpiryDateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ShareBasedCompensationOptionsExpiryDateAxis" xml:lang="en-US">Share Based Compensation Options Expiry Date [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateAxis" xlink:to="lab_eprx_ShareBasedCompensationOptionsExpiryDateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ShareBasedCompensationOptionsExpiryDateAxis" xml:lang="en-US">Share Based Compensation Options Expiry Date</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationOptionsExpiryDateDomain" xlink:label="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ShareBasedCompensationOptionsExpiryDateDomain" xml:lang="en-US">Share Based Compensation Options Expiry Date [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain" xlink:to="lab_eprx_ShareBasedCompensationOptionsExpiryDateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ShareBasedCompensationOptionsExpiryDateDomain" xml:lang="en-US">Share Based Compensation Options Expiry Date</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EighteenthMayTwoThousandAndTwentyThreeMember" xlink:label="loc_eprx_EighteenthMayTwoThousandAndTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_EighteenthMayTwoThousandAndTwentyThreeMember" xml:lang="en-US">Eighteenth May Two Thousand And Twenty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_EighteenthMayTwoThousandAndTwentyThreeMember" xml:lang="en-US">May 18, 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_EighteenthMayTwoThousandAndTwentyThreeMember" xlink:to="lab_eprx_EighteenthMayTwoThousandAndTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_EighteenthMayTwoThousandAndTwentyThreeMember" xml:lang="en-US">Eighteenth May Two Thousand And Twenty Three.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FiveMarchTwoThousandAndEighteenMember" xlink:label="loc_eprx_FiveMarchTwoThousandAndEighteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_FiveMarchTwoThousandAndEighteenMember" xml:lang="en-US">Five March Two Thousand And Eighteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_FiveMarchTwoThousandAndEighteenMember" xml:lang="en-US">Mar 5, 2018 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_FiveMarchTwoThousandAndEighteenMember" xlink:to="lab_eprx_FiveMarchTwoThousandAndEighteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_FiveMarchTwoThousandAndEighteenMember" xml:lang="en-US">Five March Two Thousand And Eighteen.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NineDecemberTwoThousandAndTwentyOneMember" xlink:label="loc_eprx_NineDecemberTwoThousandAndTwentyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_NineDecemberTwoThousandAndTwentyOneMember" xml:lang="en-US">Nine December Two Thousand And Twenty One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_NineDecemberTwoThousandAndTwentyOneMember" xml:lang="en-US">Dec 9, 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_NineDecemberTwoThousandAndTwentyOneMember" xlink:to="lab_eprx_NineDecemberTwoThousandAndTwentyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_NineDecemberTwoThousandAndTwentyOneMember" xml:lang="en-US">Nine December Two Thousand And Twenty One.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NineDecemberTwoThousandAndTwentyTwoMember" xlink:label="loc_eprx_NineDecemberTwoThousandAndTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_NineDecemberTwoThousandAndTwentyTwoMember" xml:lang="en-US">Nine December Two Thousand And Twenty Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_NineDecemberTwoThousandAndTwentyTwoMember" xml:lang="en-US">Dec 9, 2022 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_NineDecemberTwoThousandAndTwentyTwoMember" xlink:to="lab_eprx_NineDecemberTwoThousandAndTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_NineDecemberTwoThousandAndTwentyTwoMember" xml:lang="en-US">Nine December Two Thousand And Twenty Two.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NineMarchTwoThousandAndTwentyOne1Member" xlink:label="loc_eprx_NineMarchTwoThousandAndTwentyOne1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_NineMarchTwoThousandAndTwentyOne1Member" xml:lang="en-US">Nine March Two Thousand And Twenty One 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_NineMarchTwoThousandAndTwentyOne1Member" xml:lang="en-US">Mar 9, 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_NineMarchTwoThousandAndTwentyOne1Member" xlink:to="lab_eprx_NineMarchTwoThousandAndTwentyOne1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_NineMarchTwoThousandAndTwentyOne1Member" xml:lang="en-US">Nine march two thousand and twenty one 1.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NineMarchTwoThousandAndTwentyOneMember" xlink:label="loc_eprx_NineMarchTwoThousandAndTwentyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_NineMarchTwoThousandAndTwentyOneMember" xml:lang="en-US">Nine March Two Thousand And Twenty One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_NineMarchTwoThousandAndTwentyOneMember" xml:lang="en-US">Mar 9, 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_NineMarchTwoThousandAndTwentyOneMember" xlink:to="lab_eprx_NineMarchTwoThousandAndTwentyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_NineMarchTwoThousandAndTwentyOneMember" xml:lang="en-US">Nine March Two Thousand And Twenty One.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ThirtyFirstMarchTwoThousandAndTwentyTwoMember" xlink:label="loc_eprx_ThirtyFirstMarchTwoThousandAndTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ThirtyFirstMarchTwoThousandAndTwentyTwoMember" xml:lang="en-US">Thirty First March Two Thousand And Twenty Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ThirtyFirstMarchTwoThousandAndTwentyTwoMember" xml:lang="en-US">Mar 31, 2022 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ThirtyFirstMarchTwoThousandAndTwentyTwoMember" xlink:to="lab_eprx_ThirtyFirstMarchTwoThousandAndTwentyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ThirtyFirstMarchTwoThousandAndTwentyTwoMember" xml:lang="en-US">Thirty First March Two Thousand And Twenty Two.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ThirtyMayTwoThousandAndTwentyThreeMember" xlink:label="loc_eprx_ThirtyMayTwoThousandAndTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ThirtyMayTwoThousandAndTwentyThreeMember" xml:lang="en-US">Thirty May Two Thousand And Twenty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ThirtyMayTwoThousandAndTwentyThreeMember" xml:lang="en-US">May 30, 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ThirtyMayTwoThousandAndTwentyThreeMember" xlink:to="lab_eprx_ThirtyMayTwoThousandAndTwentyThreeMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ThreeMayTwoThousandAndTwentyOneMember" xlink:label="loc_eprx_ThreeMayTwoThousandAndTwentyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ThreeMayTwoThousandAndTwentyOneMember" xml:lang="en-US">Three May Two Thousand And Twenty One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ThreeMayTwoThousandAndTwentyOneMember" xml:lang="en-US">May 3, 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ThreeMayTwoThousandAndTwentyOneMember" xlink:to="lab_eprx_ThreeMayTwoThousandAndTwentyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ThreeMayTwoThousandAndTwentyOneMember" xml:lang="en-US">Three May Two Thousand And Twenty One.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TwentySeventhSeptemberTwoThousandAndFifteenMember" xlink:label="loc_eprx_TwentySeventhSeptemberTwoThousandAndFifteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TwentySeventhSeptemberTwoThousandAndFifteenMember" xml:lang="en-US">Twenty Seventh September Two Thousand And Fifteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eprx_TwentySeventhSeptemberTwoThousandAndFifteenMember" xml:lang="en-US">Sep 27, 2015 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TwentySeventhSeptemberTwoThousandAndFifteenMember" xlink:to="lab_eprx_TwentySeventhSeptemberTwoThousandAndFifteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TwentySeventhSeptemberTwoThousandAndFifteenMember" xml:lang="en-US">Twenty Seventh September Two Thousand And Fifteen.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TwentySeventhSeptemberTwoThousandAndTwentyThreeMember" xlink:label="loc_eprx_TwentySeventhSeptemberTwoThousandAndTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TwentySeventhSeptemberTwoThousandAndTwentyThreeMember" xml:lang="en-US">Twenty Seventh September Two Thousand And Twenty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_TwentySeventhSeptemberTwoThousandAndTwentyThreeMember" xml:lang="en-US">Sep 27, 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TwentySeventhSeptemberTwoThousandAndTwentyThreeMember" xlink:to="lab_eprx_TwentySeventhSeptemberTwoThousandAndTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TwentySeventhSeptemberTwoThousandAndTwentyThreeMember" xml:lang="en-US">Twenty Seventh September Two Thousand And Twenty Three.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TwoNovemberTwoThousandAndFifteenMember" xlink:label="loc_eprx_TwoNovemberTwoThousandAndFifteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TwoNovemberTwoThousandAndFifteenMember" xml:lang="en-US">Two November Two Thousand And Fifteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_TwoNovemberTwoThousandAndFifteenMember" xml:lang="en-US">Nov 2, 2015 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TwoNovemberTwoThousandAndFifteenMember" xlink:to="lab_eprx_TwoNovemberTwoThousandAndFifteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TwoNovemberTwoThousandAndFifteenMember" xml:lang="en-US">Two November Two Thousand And Fifteen.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:label="loc_eprx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xml:lang="en-US">ShareBased Compensation Arrangement by ShareBased Payment Award, Fair Value Assumptions, Expected forfeiture rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xml:lang="en-US">Expected forfeiture rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:to="lab_eprx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected forfeiture rate.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Weighted average expected option life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Weighted average risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Weighted average annual volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average fair value of options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Weighted average share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable" xml:lang="en-US">Schedule of Share Based Compensation Arrangements By Share Based Payment Award Warrant [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable" xlink:to="lab_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable" xml:lang="en-US">Schedule of share based compensation arrangements by share based payment award warrant.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember" xlink:label="loc_eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember" xml:lang="en-US">Warrants Granted as Part of Share Based Payment Arrangement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember" xml:lang="en-US">Warrants Granted as Part of Share Based Payment Arrangement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember" xlink:to="lab_eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember" xml:lang="en-US">Warrants granted as part of share based payment arrangement.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems" xml:lang="en-US">Schedule of Share Based Compensation Arrangement By Share Based Payment Award Warrant [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems" xlink:to="lab_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems" xml:lang="en-US">Schedule of share based compensation arrangement by share based payment award warrant.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Number of warrants, Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of warrants, Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of warrants, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Warrants outstanding and exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xml:lang="en-US">Number of warrants, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xml:lang="en-US">Number of warrants, Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice" xlink:label="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation By Share Based Award Equity Instruments Other Than Options Excercised During The Period Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice" xlink:to="lab_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice" xml:lang="en-US">Share based compensation by share based award equity instruments other than options excercised during the period weighted average exercise price.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice" xlink:label="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation By Share Based Award Equity Instruments Other Than Options Expired During The Period Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice" xlink:to="lab_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice" xml:lang="en-US">Share based compensation by share based award equity instruments other than options expired during the period weighted average exercise price.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice" xlink:label="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation By Share Based Award Equity Instruments Other Than Options Granted During The PeriodWeighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice" xlink:to="lab_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice" xml:lang="en-US">Share based compensation by share based award equity instruments other than options granted during the periodweighted average exercise price.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" xlink:label="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation By Share Based Award Equity Instruments Other Than Options Non Vested Outstanding Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" xlink:to="lab_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share based compensation by share based award equity instruments other than options non vested outstanding weighted average exercise price.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable" xml:lang="en-US">Schedule Of Share Based Compensation of Share Warrants Outstanding [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable" xlink:to="lab_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable" xml:lang="en-US">Schedule of share based compensation of share warrants outstanding.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MaturityPeriodWarrantsAxis" xlink:label="loc_eprx_MaturityPeriodWarrantsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_MaturityPeriodWarrantsAxis" xml:lang="en-US">Maturity Period Warrants [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_MaturityPeriodWarrantsAxis" xlink:to="lab_eprx_MaturityPeriodWarrantsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_MaturityPeriodWarrantsAxis" xml:lang="en-US">Maturity period warrants.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MaturityPeriodWarrantsDomain" xlink:label="loc_eprx_MaturityPeriodWarrantsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_MaturityPeriodWarrantsDomain" xml:lang="en-US">Maturity Period Warrants [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain" xlink:to="lab_eprx_MaturityPeriodWarrantsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_MaturityPeriodWarrantsDomain" xml:lang="en-US">Maturity period warrants.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodEightMember" xlink:label="loc_eprx_ExpiryPeriodEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ExpiryPeriodEightMember" xml:lang="en-US">Expiry Period Eight [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ExpiryPeriodEightMember" xlink:to="lab_eprx_ExpiryPeriodEightMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodFiveMember" xlink:label="loc_eprx_ExpiryPeriodFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ExpiryPeriodFiveMember" xml:lang="en-US">Expiry Period Five [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ExpiryPeriodFiveMember" xlink:to="lab_eprx_ExpiryPeriodFiveMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodFourMember" xlink:label="loc_eprx_ExpiryPeriodFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ExpiryPeriodFourMember" xml:lang="en-US">Expiry Period Four [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ExpiryPeriodFourMember" xlink:to="lab_eprx_ExpiryPeriodFourMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodNineMember" xlink:label="loc_eprx_ExpiryPeriodNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ExpiryPeriodNineMember" xml:lang="en-US">Expiry Period Nine [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ExpiryPeriodNineMember" xlink:to="lab_eprx_ExpiryPeriodNineMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodOneMember" xlink:label="loc_eprx_ExpiryPeriodOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ExpiryPeriodOneMember" xml:lang="en-US">Expiry Period One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ExpiryPeriodOneMember" xlink:to="lab_eprx_ExpiryPeriodOneMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodSevenMember" xlink:label="loc_eprx_ExpiryPeriodSevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ExpiryPeriodSevenMember" xml:lang="en-US">Expiry Period Seven [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ExpiryPeriodSevenMember" xlink:to="lab_eprx_ExpiryPeriodSevenMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodSixMember" xlink:label="loc_eprx_ExpiryPeriodSixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ExpiryPeriodSixMember" xml:lang="en-US">Expiry Period Six [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ExpiryPeriodSixMember" xlink:to="lab_eprx_ExpiryPeriodSixMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodTenMember" xlink:label="loc_eprx_ExpiryPeriodTenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ExpiryPeriodTenMember" xml:lang="en-US">Expiry Period Ten [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ExpiryPeriodTenMember" xlink:to="lab_eprx_ExpiryPeriodTenMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodThreeMember" xlink:label="loc_eprx_ExpiryPeriodThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ExpiryPeriodThreeMember" xml:lang="en-US">Expiry Period Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eprx_ExpiryPeriodThreeMember" xml:lang="en-US">Expiry Period Three [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ExpiryPeriodThreeMember" xlink:to="lab_eprx_ExpiryPeriodThreeMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodTwoMember" xlink:label="loc_eprx_ExpiryPeriodTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ExpiryPeriodTwoMember" xml:lang="en-US">Expiry Period Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ExpiryPeriodTwoMember" xlink:to="lab_eprx_ExpiryPeriodTwoMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems" xml:lang="en-US">Schedule Of Share Based Compensation of Share Warrants Outstanding [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems" xlink:to="lab_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems" xml:lang="en-US">Schedule of share based compensation of share warrants outstanding.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Remaining contractual life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of warrants or rights number of shares covered by warrants or rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xml:lang="en-US">General and Administrative Expense [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaap_GeneralInsuranceExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralInsuranceExpense" xml:lang="en-US">General Insurance Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralInsuranceExpense" xml:lang="en-US">Insurance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralInsuranceExpense" xlink:to="lab_us-gaap_GeneralInsuranceExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaap_LaborAndRelatedExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xml:lang="en-US">Labor and Related Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xml:lang="en-US">Salaries and benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xml:lang="en-US">Other General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xml:lang="en-US">Office expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreOpeningCosts" xlink:label="loc_us-gaap_PreOpeningCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreOpeningCosts" xml:lang="en-US">Pre-Opening Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreOpeningCosts" xml:lang="en-US">Public company costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreOpeningCosts" xlink:to="lab_us-gaap_PreOpeningCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfessionalFees" xml:lang="en-US">Professional Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfessionalFees" xml:lang="en-US">Professional fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaap_TravelAndEntertainmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TravelAndEntertainmentExpense" xml:lang="en-US">Travel and Entertainment Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TravelAndEntertainmentExpense" xml:lang="en-US">Travel</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TravelAndEntertainmentExpense" xlink:to="lab_us-gaap_TravelAndEntertainmentExpense" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentExpensesTable" xlink:label="loc_eprx_ResearchAndDevelopmentExpensesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ResearchAndDevelopmentExpensesTable" xml:lang="en-US">Research And Development Expenses [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesTable" xlink:to="lab_eprx_ResearchAndDevelopmentExpensesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ResearchAndDevelopmentExpensesTable" xml:lang="en-US">Research and development expenses.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentExpensesAxis" xlink:label="loc_eprx_ResearchAndDevelopmentExpensesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ResearchAndDevelopmentExpensesAxis" xml:lang="en-US">Research And Development Expenses [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesAxis" xlink:to="lab_eprx_ResearchAndDevelopmentExpensesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ResearchAndDevelopmentExpensesAxis" xml:lang="en-US">Research and development expenses.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentExpensesDomain" xlink:label="loc_eprx_ResearchAndDevelopmentExpensesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ResearchAndDevelopmentExpensesDomain" xml:lang="en-US">Research And Development Expenses [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesDomain" xlink:to="lab_eprx_ResearchAndDevelopmentExpensesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ResearchAndDevelopmentExpensesDomain" xml:lang="en-US">Research and evelopment expenses.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ClinicalMember" xlink:label="loc_eprx_ClinicalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ClinicalMember" xml:lang="en-US">Clinical [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ClinicalMember" xml:lang="en-US">Clinicall [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ClinicalMember" xlink:to="lab_eprx_ClinicalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ClinicalMember" xml:lang="en-US">Clinical.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ConsultingMember" xlink:label="loc_eprx_ConsultingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ConsultingMember" xml:lang="en-US">Consulting [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ConsultingMember" xml:lang="en-US">Consulting [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ConsultingMember" xlink:to="lab_eprx_ConsultingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ConsultingMember" xml:lang="en-US">Consulting.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ManufacturingAndAnalyticaMember" xlink:label="loc_eprx_ManufacturingAndAnalyticaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ManufacturingAndAnalyticaMember" xml:lang="en-US">Manufacturing And Analytica [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ManufacturingAndAnalyticaMember" xml:lang="en-US">Manufacturing &amp; analytical [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ManufacturingAndAnalyticaMember" xlink:to="lab_eprx_ManufacturingAndAnalyticaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ManufacturingAndAnalyticaMember" xml:lang="en-US">Manufacturing&#160;and analytica.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PreclinicalMember" xlink:label="loc_eprx_PreclinicalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PreclinicalMember" xml:lang="en-US">Preclinical [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PreclinicalMember" xml:lang="en-US">Preclinical [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PreclinicalMember" xlink:to="lab_eprx_PreclinicalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PreclinicalMember" xml:lang="en-US">Preclinical.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RegulatoryMember" xlink:label="loc_eprx_RegulatoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_RegulatoryMember" xml:lang="en-US">Regulatory [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_RegulatoryMember" xml:lang="en-US">Regulatory [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_RegulatoryMember" xlink:to="lab_eprx_RegulatoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_RegulatoryMember" xml:lang="en-US">Regulatory.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentExpensesLineItems" xlink:label="loc_eprx_ResearchAndDevelopmentExpensesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ResearchAndDevelopmentExpensesLineItems" xml:lang="en-US">Research And Development Expenses [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems" xlink:to="lab_eprx_ResearchAndDevelopmentExpensesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ResearchAndDevelopmentExpensesLineItems" xml:lang="en-US">Research and development expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="loc_us-gaap_GovernmentAssistanceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GovernmentAssistanceAmount" xml:lang="en-US">Government Assistance, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GovernmentAssistanceAmount" xml:lang="en-US">Government grants (Note 15)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GovernmentAssistanceAmount" xml:lang="en-US">Government assistance, amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceAmount" xlink:to="lab_us-gaap_GovernmentAssistanceAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xml:lang="en-US">Other Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xml:lang="en-US">Other research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_OtherResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense" xlink:label="loc_eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense" xml:lang="en-US">Pipeline Development Of Research And Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense" xml:lang="en-US">Pipeline development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense" xlink:to="lab_eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense" xml:lang="en-US">Pipeline development of research and development expense.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory" xlink:label="loc_eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory" xml:lang="en-US">Research And Development Costs Gross Excluding Other Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory" xml:lang="en-US">Direct research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory" xlink:to="lab_eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory" xml:lang="en-US">Research and development costs gross excluding other category.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentLicenseExpenses" xlink:label="loc_eprx_ResearchAndDevelopmentLicenseExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ResearchAndDevelopmentLicenseExpenses" xml:lang="en-US">Research And Development License Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ResearchAndDevelopmentLicenseExpenses" xml:lang="en-US">License costs (Note 10)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ResearchAndDevelopmentLicenseExpenses" xlink:to="lab_eprx_ResearchAndDevelopmentLicenseExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ResearchAndDevelopmentLicenseExpenses" xml:lang="en-US">License costs.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses" xlink:label="loc_eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses" xml:lang="en-US">Salaries And Benefits Of Research And Development Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses" xml:lang="en-US">Salaries and benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses" xlink:to="lab_eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses" xml:lang="en-US">Salaries and benefits of research and development expenses.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses" xlink:label="loc_eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses" xml:lang="en-US">Share Based Payments Of Research And Development Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses" xml:lang="en-US">Share based payments (Note 12(c))</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses" xlink:to="lab_eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses" xml:lang="en-US">Share based payments of research and development expenses.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses" xlink:label="loc_eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses" xml:lang="en-US">SR And ED And Tax incentives Of Research And Development Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses" xml:lang="en-US">SR&amp;ED and other R&amp;D tax incentives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses" xlink:to="lab_eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses" xml:lang="en-US">Sr and ed and tax incentives of research and development expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTable" xlink:label="loc_us-gaap_GovernmentAssistanceTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GovernmentAssistanceTable" xml:lang="en-US">Government Assistance [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceTable" xlink:to="lab_us-gaap_GovernmentAssistanceTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceLineItems" xlink:label="loc_us-gaap_GovernmentAssistanceLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GovernmentAssistanceLineItems" xml:lang="en-US">Government Assistance [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceLineItems" xlink:to="lab_us-gaap_GovernmentAssistanceLineItems" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_GovernmentAssistanceAmountForResearchAndDevelopment" xlink:label="loc_eprx_GovernmentAssistanceAmountForResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_GovernmentAssistanceAmountForResearchAndDevelopment" xml:lang="en-US">Government Assistance Amount For Research And Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_GovernmentAssistanceAmountForResearchAndDevelopment" xml:lang="en-US">Government assistance amount for research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_GovernmentAssistanceAmountForResearchAndDevelopment" xlink:to="lab_eprx_GovernmentAssistanceAmountForResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_GovernmentAssistanceAmountForResearchAndDevelopment" xml:lang="en-US">Government assistance amount for research and development.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfReimburseAssistanceToSupportContractorFee" xlink:label="loc_eprx_PercentageOfReimburseAssistanceToSupportContractorFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PercentageOfReimburseAssistanceToSupportContractorFee" xml:lang="en-US">Percentage Of Reimburse Assistance To Support Contractor Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PercentageOfReimburseAssistanceToSupportContractorFee" xml:lang="en-US">Percentage of reimburse assistance to support contractor fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PercentageOfReimburseAssistanceToSupportContractorFee" xlink:to="lab_eprx_PercentageOfReimburseAssistanceToSupportContractorFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PercentageOfReimburseAssistanceToSupportContractorFee" xml:lang="en-US">Percentage of reimburse assistance to support contractor fee.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfReimburseAssistanceToSupportSalaryCost" xlink:label="loc_eprx_PercentageOfReimburseAssistanceToSupportSalaryCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PercentageOfReimburseAssistanceToSupportSalaryCost" xml:lang="en-US">Percentage Of Reimburse Assistance To Support Salary Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PercentageOfReimburseAssistanceToSupportSalaryCost" xml:lang="en-US">Percentage of reimburse assistance to support salary costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PercentageOfReimburseAssistanceToSupportSalaryCost" xlink:to="lab_eprx_PercentageOfReimburseAssistanceToSupportSalaryCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PercentageOfReimburseAssistanceToSupportSalaryCost" xml:lang="en-US">Percentage of reimburse assistance to support salary cost.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ReimbursementAssistanceMaximumForSalaryAndContractorCosts" xlink:label="loc_eprx_ReimbursementAssistanceMaximumForSalaryAndContractorCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ReimbursementAssistanceMaximumForSalaryAndContractorCosts" xml:lang="en-US">Reimbursement Assistance Maximum for Salary And Contractor Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ReimbursementAssistanceMaximumForSalaryAndContractorCosts" xml:lang="en-US">Reimbursement assistance eligible maximum for salary and contractor costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ReimbursementAssistanceMaximumForSalaryAndContractorCosts" xlink:to="lab_eprx_ReimbursementAssistanceMaximumForSalaryAndContractorCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ReimbursementAssistanceMaximumForSalaryAndContractorCosts" xml:lang="en-US">Reimbursement assistance maximum for salary and contractor costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="loc_us-gaap_GovernmentAssistanceTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GovernmentAssistanceTypeAxis" xml:lang="en-US">Government Assistance, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis" xlink:to="lab_us-gaap_GovernmentAssistanceTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GovernmentAssistanceTypeDomain" xml:lang="en-US">Government Assistance, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceTypeDomain" xlink:to="lab_us-gaap_GovernmentAssistanceTypeDomain" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember" xlink:label="loc_eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember" xml:lang="en-US">NRC IRAP Specified Research And Development Funding Activities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember" xml:lang="en-US">NRC-IRAP Specified Research And Development Funding Activities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember" xlink:to="lab_eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmountCumulative" xlink:label="loc_us-gaap_GovernmentAssistanceAmountCumulative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GovernmentAssistanceAmountCumulative" xml:lang="en-US">Government Assistance, Amount, Cumulative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GovernmentAssistanceAmountCumulative" xml:lang="en-US">Government Assistance Amount, Cumulative Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceAmountCumulative" xlink:to="lab_us-gaap_GovernmentAssistanceAmountCumulative" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_BioTalentCanadaMember" xlink:label="loc_eprx_BioTalentCanadaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_BioTalentCanadaMember" xml:lang="en-US">Bio Talent Canada [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_BioTalentCanadaMember" xlink:to="lab_eprx_BioTalentCanadaMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Canadian</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Foreign</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Canadian</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Foreign</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xml:lang="en-US">Canadian</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit), Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Canadian</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Statutory Canadian corporate tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract" xlink:label="loc_eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract" xml:lang="en-US">Effective Income Tax Reconciliation Differences [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract" xml:lang="en-US">Difference resulting from:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract" xlink:to="lab_eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract" xml:lang="en-US">Effective income tax reconciliation differences.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency" xlink:label="loc_eprx_EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency" xml:lang="en-US">Effective Income Tax Reconciliation Foreign Exchange Arising On Translation To Reporting Currency</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency" xml:lang="en-US">Foreign exchange arising on translation to reporting currency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency" xlink:to="lab_eprx_EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency" xml:lang="en-US">Effective income tax reconciliation foreign exchange arising on translation to reporting currency.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EffectiveIncomeTaxReconciliationShareIssuanceCosts" xlink:label="loc_eprx_EffectiveIncomeTaxReconciliationShareIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_EffectiveIncomeTaxReconciliationShareIssuanceCosts" xml:lang="en-US">Effective Income Tax Reconciliation Share Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_eprx_EffectiveIncomeTaxReconciliationShareIssuanceCosts" xml:lang="en-US">Share issue costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_EffectiveIncomeTaxReconciliationShareIssuanceCosts" xlink:to="lab_eprx_EffectiveIncomeTaxReconciliationShareIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_EffectiveIncomeTaxReconciliationShareIssuanceCosts" xml:lang="en-US">Effective income tax reconciliation share issuance costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in unrecognized deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xml:lang="en-US">Other items not deductible for tax purposes and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Non-deductible share-based payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xml:lang="en-US">Adjustments related to prior years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Expected tax recovery at statutory rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DeferredTaxAssetsConvertibleDebt" xlink:label="loc_eprx_DeferredTaxAssetsConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DeferredTaxAssetsConvertibleDebt" xml:lang="en-US">Deferred Tax Assets Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eprx_DeferredTaxAssetsConvertibleDebt" xml:lang="en-US">Convertible debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DeferredTaxAssetsConvertibleDebt" xlink:to="lab_eprx_DeferredTaxAssetsConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DeferredTaxAssetsConvertibleDebt" xml:lang="en-US">Deferred tax assets convertible debt.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Scientific research and experimental development pool</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DeferredTaxAssetsLeaseObligation" xlink:label="loc_eprx_DeferredTaxAssetsLeaseObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DeferredTaxAssetsLeaseObligation" xml:lang="en-US">Deferred Tax Assets Lease Obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eprx_DeferredTaxAssetsLeaseObligation" xml:lang="en-US">Lease obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DeferredTaxAssetsLeaseObligation" xlink:to="lab_eprx_DeferredTaxAssetsLeaseObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DeferredTaxAssetsLeaseObligation" xml:lang="en-US">Deferred tax assets lease obligation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Net deferred income tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Non-capital losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US">Depreciable assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DeferredTaxAssetsShareIssuanceCosts" xlink:label="loc_eprx_DeferredTaxAssetsShareIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_DeferredTaxAssetsShareIssuanceCosts" xml:lang="en-US">Deferred Tax Assets Share Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eprx_DeferredTaxAssetsShareIssuanceCosts" xml:lang="en-US">Share issue costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_DeferredTaxAssetsShareIssuanceCosts" xlink:to="lab_eprx_DeferredTaxAssetsShareIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_DeferredTaxAssetsShareIssuanceCosts" xml:lang="en-US">Deferred tax assets share issuance costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Less: valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NonCapitalLossesCarryForwardFutureYearsTable" xlink:label="loc_eprx_NonCapitalLossesCarryForwardFutureYearsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_NonCapitalLossesCarryForwardFutureYearsTable" xml:lang="en-US">Non Capital Losses Carry Forward Future Years [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_NonCapitalLossesCarryForwardFutureYearsTable" xlink:to="lab_eprx_NonCapitalLossesCarryForwardFutureYearsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_NonCapitalLossesCarryForwardFutureYearsTable" xml:lang="en-US">Non capital losses carry forward future ears table.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NonCapitalLossesCarryForwardFutureYearsLineItems" xlink:label="loc_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems" xml:lang="en-US">Non Capital Losses Carry Forward Future Years [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems" xlink:to="lab_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems" xml:lang="en-US">Non capital losses carry forward future years.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NonCapitalLossCarryforwardsToFutureExpire" xlink:label="loc_eprx_NonCapitalLossCarryforwardsToFutureExpire" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_NonCapitalLossCarryforwardsToFutureExpire" xml:lang="en-US">Non Capital Loss Carryforwards To Future Expire</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eprx_NonCapitalLossCarryforwardsToFutureExpire" xml:lang="en-US">Non-capital loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_NonCapitalLossCarryforwardsToFutureExpire" xlink:to="lab_eprx_NonCapitalLossCarryforwardsToFutureExpire" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_NonCapitalLossCarryforwardsToFutureExpire" xml:lang="en-US">Non capital loss carryforwards to future expire.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU" xlink:label="loc_country_AU" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_AU" xml:lang="en-US">AUSTRALIA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_AU" xml:lang="en-US">Australia</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AU" xlink:to="lab_country_AU" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="loc_country_CA" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_CA" xml:lang="en-US">CANADA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_CA" xml:lang="en-US">Canada</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US" xml:lang="en-US">UNITED STATES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_US" xml:lang="en-US">US</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2031Member" xlink:label="loc_eprx_TaxYear2031Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TaxYear2031Member" xml:lang="en-US">Tax Year 2031 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_TaxYear2031Member" xml:lang="en-US">Tax Year 2031 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TaxYear2031Member" xlink:to="lab_eprx_TaxYear2031Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TaxYear2031Member" xml:lang="en-US">Tax year 2031.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2032Member" xlink:label="loc_eprx_TaxYear2032Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TaxYear2032Member" xml:lang="en-US">Tax Year 2032 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_TaxYear2032Member" xml:lang="en-US">Tax Year 2032 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TaxYear2032Member" xlink:to="lab_eprx_TaxYear2032Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TaxYear2032Member" xml:lang="en-US">Tax year 2032.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2033Member" xlink:label="loc_eprx_TaxYear2033Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TaxYear2033Member" xml:lang="en-US">Tax year 2033 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_TaxYear2033Member" xml:lang="en-US">Tax year 2033 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TaxYear2033Member" xlink:to="lab_eprx_TaxYear2033Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TaxYear2033Member" xml:lang="en-US">Tax year 2033.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2034Member" xlink:label="loc_eprx_TaxYear2034Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TaxYear2034Member" xml:lang="en-US">Tax year 2034 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_TaxYear2034Member" xml:lang="en-US">Tax year 2034 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TaxYear2034Member" xlink:to="lab_eprx_TaxYear2034Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TaxYear2034Member" xml:lang="en-US">Tax year 2034.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2035Member" xlink:label="loc_eprx_TaxYear2035Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TaxYear2035Member" xml:lang="en-US">Tax year 2035 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_TaxYear2035Member" xml:lang="en-US">Tax year 2035 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TaxYear2035Member" xlink:to="lab_eprx_TaxYear2035Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TaxYear2035Member" xml:lang="en-US">Tax year 2035.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2036Member" xlink:label="loc_eprx_TaxYear2036Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TaxYear2036Member" xml:lang="en-US">Tax year 2036 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_TaxYear2036Member" xml:lang="en-US">Tax year 2036 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TaxYear2036Member" xlink:to="lab_eprx_TaxYear2036Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TaxYear2036Member" xml:lang="en-US">Tax year 2036.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2037Member" xlink:label="loc_eprx_TaxYear2037Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TaxYear2037Member" xml:lang="en-US">Tax year 2037 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_TaxYear2037Member" xml:lang="en-US">Tax year 2037 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TaxYear2037Member" xlink:to="lab_eprx_TaxYear2037Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TaxYear2037Member" xml:lang="en-US">Tax year 2037.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2038Member" xlink:label="loc_eprx_TaxYear2038Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TaxYear2038Member" xml:lang="en-US">Tax year 2038 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_TaxYear2038Member" xml:lang="en-US">Tax year 2038 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TaxYear2038Member" xlink:to="lab_eprx_TaxYear2038Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TaxYear2038Member" xml:lang="en-US">Tax year 2038.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2039Member" xlink:label="loc_eprx_TaxYear2039Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TaxYear2039Member" xml:lang="en-US">Tax year 2039 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_TaxYear2039Member" xml:lang="en-US">Tax year 2039 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TaxYear2039Member" xlink:to="lab_eprx_TaxYear2039Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TaxYear2039Member" xml:lang="en-US">Tax year 2039.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2040Member" xlink:label="loc_eprx_TaxYear2040Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TaxYear2040Member" xml:lang="en-US">Tax year 2040 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_TaxYear2040Member" xml:lang="en-US">Tax year 2040 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TaxYear2040Member" xlink:to="lab_eprx_TaxYear2040Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TaxYear2040Member" xml:lang="en-US">Tax year 2040.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2041Member" xlink:label="loc_eprx_TaxYear2041Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TaxYear2041Member" xml:lang="en-US">Tax year 2041 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_TaxYear2041Member" xml:lang="en-US">Tax year 2041 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TaxYear2041Member" xlink:to="lab_eprx_TaxYear2041Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TaxYear2041Member" xml:lang="en-US">Tax year 2041.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2042Member" xlink:label="loc_eprx_TaxYear2042Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TaxYear2042Member" xml:lang="en-US">Tax year 2042 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_TaxYear2042Member" xml:lang="en-US">Tax year 2042 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TaxYear2042Member" xlink:to="lab_eprx_TaxYear2042Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TaxYear2042Member" xml:lang="en-US">Tax year 2042.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2043Member" xlink:label="loc_eprx_TaxYear2043Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TaxYear2043Member" xml:lang="en-US">Tax Year 2043 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_TaxYear2043Member" xml:lang="en-US">Tax Year 2043 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TaxYear2043Member" xlink:to="lab_eprx_TaxYear2043Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TaxYear2043Member" xml:lang="en-US">Tax year 2043.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYearAfter2043Member" xlink:label="loc_eprx_TaxYearAfter2043Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TaxYearAfter2043Member" xml:lang="en-US">Tax Year After 2043 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_TaxYearAfter2043Member" xml:lang="en-US">Tax Year After 2043 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TaxYearAfter2043Member" xlink:to="lab_eprx_TaxYearAfter2043Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TaxYearAfter2043Member" xml:lang="en-US">Tax year after 2043.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CanadaRevenueAgencyMember" xml:lang="en-US">Canada Revenue Agency [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CanadaRevenueAgencyMember" xml:lang="en-US">Canada Revenue Agency [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CanadaRevenueAgencyMember" xlink:to="lab_us-gaap_CanadaRevenueAgencyMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xml:lang="en-US">Unrecognized tax benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Non capital loss carryforwards to future expire</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax credit carryforward, amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxCreditCarryForwardsExpirationTerm" xlink:label="loc_eprx_TaxCreditCarryForwardsExpirationTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_TaxCreditCarryForwardsExpirationTerm" xml:lang="en-US">Tax Credit Carry forwards Expiration Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eprx_TaxCreditCarryForwardsExpirationTerm" xml:lang="en-US">Tax credit carry forward expiration term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_TaxCreditCarryForwardsExpirationTerm" xlink:to="lab_eprx_TaxCreditCarryForwardsExpirationTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_TaxCreditCarryForwardsExpirationTerm" xml:lang="en-US">Tax credit carry forwards expiration term.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties Accrued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xml:lang="en-US">Unrecognized tax benefits income tax penalties accrued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xml:lang="en-US">Unrecognized tax benefits interest on income taxes accrued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RelevantPeriodAxis" xlink:label="loc_eprx_RelevantPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_RelevantPeriodAxis" xml:lang="en-US">Relevant Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_RelevantPeriodAxis" xlink:to="lab_eprx_RelevantPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_RelevantPeriodAxis" xml:lang="en-US">Relevant period.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RelevantPeriodDomain" xlink:label="loc_eprx_RelevantPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_RelevantPeriodDomain" xml:lang="en-US">Relevant Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_RelevantPeriodDomain" xlink:to="lab_eprx_RelevantPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_RelevantPeriodDomain" xml:lang="en-US">Relevant period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CanadianFederalInvestmentTaxCreditsMember" xlink:label="loc_eprx_CanadianFederalInvestmentTaxCreditsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_CanadianFederalInvestmentTaxCreditsMember" xml:lang="en-US">Canadian Federal Investment Tax Credits [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_CanadianFederalInvestmentTaxCreditsMember" xml:lang="en-US">Canadian Federal Investment Tax Credits [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_CanadianFederalInvestmentTaxCreditsMember" xlink:to="lab_eprx_CanadianFederalInvestmentTaxCreditsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_CanadianFederalInvestmentTaxCreditsMember" xml:lang="en-US">Canadian federal investment tax credits.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ProvincialInvestmentTaxCreditsMember" xlink:label="loc_eprx_ProvincialInvestmentTaxCreditsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ProvincialInvestmentTaxCreditsMember" xml:lang="en-US">Provincial Investment Tax Credits [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ProvincialInvestmentTaxCreditsMember" xml:lang="en-US">Provincial Investment Tax Credits [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ProvincialInvestmentTaxCreditsMember" xlink:to="lab_eprx_ProvincialInvestmentTaxCreditsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ProvincialInvestmentTaxCreditsMember" xml:lang="en-US">Provincial investment tax credits.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsTable" xml:lang="en-US">Other Commitments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xml:lang="en-US">Other Commitments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CancellationFeeForCancellationOfContract" xlink:label="loc_eprx_CancellationFeeForCancellationOfContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_CancellationFeeForCancellationOfContract" xml:lang="en-US">Cancellation fee for Cancellation of Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_CancellationFeeForCancellationOfContract" xml:lang="en-US">Cancellation of contracts that would lead to cancellation fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_CancellationFeeForCancellationOfContract" xlink:to="lab_eprx_CancellationFeeForCancellationOfContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_CancellationFeeForCancellationOfContract" xml:lang="en-US">Cancellation of contracts that would lead to cancellation fee.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CancellationFeeOnTerminationOfContract" xlink:label="loc_eprx_CancellationFeeOnTerminationOfContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_CancellationFeeOnTerminationOfContract" xml:lang="en-US">Cancellation Fee on Termination of Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_CancellationFeeOnTerminationOfContract" xml:lang="en-US">Cancellation fee for termination of contract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_CancellationFeeOnTerminationOfContract" xlink:to="lab_eprx_CancellationFeeOnTerminationOfContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_CancellationFeeOnTerminationOfContract" xml:lang="en-US">Cancellation fee on termination of contract.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FinancialInstrumentsTable" xlink:label="loc_eprx_FinancialInstrumentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_FinancialInstrumentsTable" xml:lang="en-US">Financial Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_FinancialInstrumentsTable" xlink:to="lab_eprx_FinancialInstrumentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_FinancialInstrumentsTable" xml:lang="en-US">Financial instruments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CurrencyAxis" xml:lang="en-US">Currency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_AllCurrenciesDomain" xml:lang="en-US">All Currencies [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_CAD" xml:lang="en-US">Canada, Dollars</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_CAD" xml:lang="en-US">Canada, Dollars [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD" xlink:to="lab_currency_CAD" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FinancialInstrumentsLineItems" xlink:label="loc_eprx_FinancialInstrumentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_FinancialInstrumentsLineItems" xml:lang="en-US">Financial Instruments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_FinancialInstrumentsLineItems" xlink:to="lab_eprx_FinancialInstrumentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_FinancialInstrumentsLineItems" xml:lang="en-US">Financial instruments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash on hand</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xml:lang="en-US">Foreign exchange rate translation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates" xlink:label="loc_eprx_ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates" xml:lang="en-US">Impact On Profit Or Loss Due To A Reasonable Possible Increase Decrease In Exchange Rates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates" xml:lang="en-US">Impact on profit loss due to change in exchange rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates" xlink:to="lab_eprx_ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates" xml:lang="en-US">Impact on profit loss due to change in exchange rates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xml:lang="en-US">Long term debt bearing fixed interest rate percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xml:lang="en-US">Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xml:lang="en-US">Long term debt variable interest rate percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaap_OtherLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLongTermDebt" xml:lang="en-US">Other Long-Term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherLongTermDebt" xml:lang="en-US">Other loans payables current and non current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLongTermDebt" xml:lang="en-US">Loans payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebt" xlink:to="lab_us-gaap_OtherLongTermDebt" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageIncreaseInSignificantUnobservableInputAssets" xlink:label="loc_eprx_PercentageIncreaseInSignificantUnobservableInputAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PercentageIncreaseInSignificantUnobservableInputAssets" xml:lang="en-US">Percentage Increase In Significant Unobservable Input Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PercentageIncreaseInSignificantUnobservableInputAssets" xml:lang="en-US">Percentage increase in significant unobservable inputs assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PercentageIncreaseInSignificantUnobservableInputAssets" xlink:to="lab_eprx_PercentageIncreaseInSignificantUnobservableInputAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PercentageIncreaseInSignificantUnobservableInputAssets" xml:lang="en-US">Percentage increase in significant unobservable input assets.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageIncreaseInSignificantUnobservableInputLiabilities" xlink:label="loc_eprx_PercentageIncreaseInSignificantUnobservableInputLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_PercentageIncreaseInSignificantUnobservableInputLiabilities" xml:lang="en-US">Percentage Increase In Significant Unobservable Input Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_PercentageIncreaseInSignificantUnobservableInputLiabilities" xml:lang="en-US">Percentage increase in significant unobservable inputs liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_PercentageIncreaseInSignificantUnobservableInputLiabilities" xlink:to="lab_eprx_PercentageIncreaseInSignificantUnobservableInputLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_PercentageIncreaseInSignificantUnobservableInputLiabilities" xml:lang="en-US">Percentage increase in significant unobservable input liabilities.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax" xlink:label="loc_eprx_SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax" xml:lang="en-US">Significant Unobservable Input Impact Of Interest Rate Changes On Profit Or Loss Before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax" xml:lang="en-US">Significant unobservable input impact of interest rate changes on profit or loss before tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax" xlink:to="lab_eprx_SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax" xml:lang="en-US">Significant unobservable input impact of interest rate changes on profit or loss before tax.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate" xlink:label="loc_eprx_SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate" xml:lang="en-US">Significant Unobservable Inputs Percentage Increase Decrease In Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate" xml:lang="en-US">Significant unobservable inputs percentage increase decrease in interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate" xlink:to="lab_eprx_SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate" xml:lang="en-US">Significant unobservable inputs percentage increase decrease in interest rate.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CurrencyRiskMember" xlink:label="loc_eprx_CurrencyRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_CurrencyRiskMember" xml:lang="en-US">Currency Risk [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_CurrencyRiskMember" xlink:to="lab_eprx_CurrencyRiskMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EquipmentLoanMember" xlink:label="loc_eprx_EquipmentLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_EquipmentLoanMember" xml:lang="en-US">Equipment Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eprx_EquipmentLoanMember" xml:lang="en-US">Equipment Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_EquipmentLoanMember" xlink:to="lab_eprx_EquipmentLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_EquipmentLoanMember" xml:lang="en-US">Equipment loan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTable" xlink:label="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTable" xml:lang="en-US">Schedule Of Carrying Value Of Financial Instruments At Amortized Cost [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTable" xlink:to="lab_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTable" xml:lang="en-US">Schedule of carrying value of financial instruments at amortized cost.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems" xlink:label="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems" xml:lang="en-US">Schedule Of Carrying Value Of Financial Instruments At Amortized Cost [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems" xlink:to="lab_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems" xml:lang="en-US">Schedule of carrying value of financial instruments at amortized cost.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AccountsPayableAndAccruedLiability" xlink:label="loc_eprx_AccountsPayableAndAccruedLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_AccountsPayableAndAccruedLiability" xml:lang="en-US">Accounts Payable and Accrued Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_AccountsPayableAndAccruedLiability" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_AccountsPayableAndAccruedLiability" xlink:to="lab_eprx_AccountsPayableAndAccruedLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_AccountsPayableAndAccruedLiability" xml:lang="en-US">Accounts payable and accrued liability.</label>
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss" xlink:label="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss" xml:lang="en-US">Fair Value Measurement With Unobservable Input Reconciliation Recurring Basis Liability Foregin Exchange Gain Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss" xml:lang="en-US">Foreign exchange</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss" xlink:to="lab_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss" xml:lang="en-US">Fair value measurement with unobservable input reconciliation recurring basis liability foreign exchange gain loss.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest Expense, Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest on SVB debt facility (Note 11)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OtherInterestAndAccretionExpense" xlink:label="loc_eprx_OtherInterestAndAccretionExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_OtherInterestAndAccretionExpense" xml:lang="en-US">Other Interest and Accretion Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_OtherInterestAndAccretionExpense" xml:lang="en-US">Other interest and accretion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_OtherInterestAndAccretionExpense" xlink:to="lab_eprx_OtherInterestAndAccretionExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_OtherInterestAndAccretionExpense" xml:lang="en-US">Other interest and accretion expense.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NumberofWarrantsIssued" xlink:label="loc_eprx_NumberofWarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eprx_NumberofWarrantsIssued" xml:lang="en-US">Number of Warrants Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eprx_NumberofWarrantsIssued" xml:lang="en-US">Warrants issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eprx_NumberofWarrantsIssued" xlink:to="lab_eprx_NumberofWarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eprx_NumberofWarrantsIssued" xml:lang="en-US">Number of warrants issued.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xml:lang="en-US">Proceeds from Interest Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xml:lang="en-US">Proceeds from Interest received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestReceived" xlink:to="lab_us-gaap_ProceedsFromInterestReceived" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>eprx-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 01-April-2024 [11:12:04] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#CoverPage" roleURI="http://eupraxiapharma.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ConsolidatedBalanceSheets" roleURI="http://eupraxiapharma.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://eupraxiapharma.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ConsolidatedStatementsOfChangesInShareholdersEquityDeficit" roleURI="http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#NatureOfBusinessAndGoingConcern" roleURI="http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcern" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#BasisOfPresentation" roleURI="http://eupraxiapharma.com/role/BasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#AmountsReceivable" roleURI="http://eupraxiapharma.com/role/AmountsReceivable" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#PropertyAndEquipment" roleURI="http://eupraxiapharma.com/role/PropertyAndEquipment" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#RightOfUseAsset" roleURI="http://eupraxiapharma.com/role/RightOfUseAsset" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#AccountsPayableAndAccruedLiabilities" roleURI="http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilities" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#LoansPayable" roleURI="http://eupraxiapharma.com/role/LoansPayable" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#LeaseLiability" roleURI="http://eupraxiapharma.com/role/LeaseLiability" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#AuritecLicenseAgreement" roleURI="http://eupraxiapharma.com/role/AuritecLicenseAgreement" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ConvertibleDebt" roleURI="http://eupraxiapharma.com/role/ConvertibleDebt" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ShareCapitalAndOtherComponentsOfEquity" roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquity" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#GeneralAndAdministrativeExpenses" roleURI="http://eupraxiapharma.com/role/GeneralAndAdministrativeExpenses" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ResearchAndDevelopmentExpenses" roleURI="http://eupraxiapharma.com/role/ResearchAndDevelopmentExpenses" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#GovernmentGrantsAndAssistance" roleURI="http://eupraxiapharma.com/role/GovernmentGrantsAndAssistance" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#IncomeTaxes" roleURI="http://eupraxiapharma.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#Commitments" roleURI="http://eupraxiapharma.com/role/Commitments" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#FinancialInstruments" roleURI="http://eupraxiapharma.com/role/FinancialInstruments" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#InterestExpense" roleURI="http://eupraxiapharma.com/role/InterestExpense" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#SupplementalDisclosureWithRespectToCashFlows" roleURI="http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlows" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#SubsequentEvent" roleURI="http://eupraxiapharma.com/role/SubsequentEvent" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#AmountsReceivableTables" roleURI="http://eupraxiapharma.com/role/AmountsReceivableTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#PropertyAndEquipmentTables" roleURI="http://eupraxiapharma.com/role/PropertyAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#RightOfUseAssetTables" roleURI="http://eupraxiapharma.com/role/RightOfUseAssetTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#AccountsPayableAndAccruedLiabilitiesTables" roleURI="http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#LoansPayableTables" roleURI="http://eupraxiapharma.com/role/LoansPayableTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#LeaseLiabilityTables" roleURI="http://eupraxiapharma.com/role/LeaseLiabilityTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#AuritecLicenseAgreementTables" roleURI="http://eupraxiapharma.com/role/AuritecLicenseAgreementTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ConvertibleDebtTables" roleURI="http://eupraxiapharma.com/role/ConvertibleDebtTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ShareCapitalAndOtherComponentsOfEquityTables" roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#GeneralAndAdministrativeExpensesTables" roleURI="http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ResearchAndDevelopmentExpensesTables" roleURI="http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#GovernmentGrantsAndAssistanceTables" roleURI="http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#IncomeTaxesTables" roleURI="http://eupraxiapharma.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#FinancialInstrumentsTables" roleURI="http://eupraxiapharma.com/role/FinancialInstrumentsTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#InterestExpenseTables" roleURI="http://eupraxiapharma.com/role/InterestExpenseTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#SupplementalDisclosureWithRespectToCashFlowsTables" roleURI="http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsTables" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#NatureOfBusinessAndGoingConcernAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail" roleURI="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail" roleURI="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#AmountsReceivableSummaryOfAmountsReceivableDetail" roleURI="http://eupraxiapharma.com/role/AmountsReceivableSummaryOfAmountsReceivableDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" roleURI="http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#PropertyAndEquipmentAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/PropertyAndEquipmentAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#RightOfUseAssetSummaryOfRightOfUseAssetsDetail" roleURI="http://eupraxiapharma.com/role/RightOfUseAssetSummaryOfRightOfUseAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#RightOfUseAssetAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/RightOfUseAssetAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail" roleURI="http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#LoansPayableAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/LoansPayableAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#LoansPayableSummaryOfBreakdownOfLoanBalanceDetail" roleURI="http://eupraxiapharma.com/role/LoansPayableSummaryOfBreakdownOfLoanBalanceDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#LeaseLiabilitySummaryOfCostComponentsOfTheOperatingLeaseDetail" roleURI="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfCostComponentsOfTheOperatingLeaseDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail" roleURI="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail" roleURI="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#LeaseLiabilityAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/LeaseLiabilityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#AuritecLicenseAgreementAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#AuritecLicenseAgreementScheduleOfMilestonePaymentDetail" roleURI="http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail" roleURI="http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ConvertibleDebtAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ConvertibleDebtScheduleOfLoanBalanceDetail" roleURI="http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail" roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail" roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail" roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail" roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail" roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail" roleURI="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail" roleURI="http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail" roleURI="http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#GovernmentGrantsAndAssistanceAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail" roleURI="http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#IncomeTaxesScheduleOfComponentsIncludedInLossBeforeTaxesDetail" roleURI="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsIncludedInLossBeforeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#IncomeTaxesScheduleOfIncomeTaxExpenseDetail" roleURI="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail" roleURI="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail" roleURI="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail" roleURI="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#CommitmentsAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/CommitmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#FinancialInstrumentsAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#FinancialInstrumentsSummaryOfCarryingValueOfFinancialInstrumentsAtAmortizedCostDetail" roleURI="http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfCarryingValueOfFinancialInstrumentsAtAmortizedCostDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail" roleURI="http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#InterestExpenseScheduleOfInterestExpenseDetail" roleURI="http://eupraxiapharma.com/role/InterestExpenseScheduleOfInterestExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#SupplementalDisclosureWithRespectToCashFlowsSummaryOfDetailedBreakdownOfCashAndCashEquivalentsDetail" roleURI="http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsSummaryOfDetailedBreakdownOfCashAndCashEquivalentsDetail" />
<roleRef xlink:type="simple" xlink:href="eprx-20231231.xsd#SubsequentEventAdditionalInformationDetail" roleURI="http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail" />
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1068" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1068" xlink:to="loc_dei_AddressTypeDomain_1069" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1069" xlink:to="loc_dei_BusinessContactMember_1070" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_dei_DocumentInformationLineItems_6" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentType_7" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentRegistrationStatement_8" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentAnnualReport_9" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_AmendmentFlag_11" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentPeriodEndDate_12" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentFiscalYearFocus_13" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_14" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityRegistrantName_15" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityCentralIndexKey_16" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_CurrentFiscalYearEndDate_17" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityCurrentReportingStatus_18" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityInteractiveDataCurrent_19" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityEmergingGrowthCompany_20" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_1204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityExTransitionPeriod_1204" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_21" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityPrimarySicNumber_1073" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityFileNumber_26" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_ContactPersonnelName_27" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_28" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityAddressAddressLine1_29" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityAddressAddressLine2_30" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityAddressCityOrTown_31" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityAddressStateOrProvince_32" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityAddressCountry_33" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityAddressPostalZipCode_34" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_CityAreaCode_35" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_LocalPhoneNumber_36" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_dei_AnnualInformationForm_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_AnnualInformationForm_37" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_dei_AuditedAnnualFinancialStatements_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_AuditedAnnualFinancialStatements_38" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_IcfrAuditorAttestationFlag_77" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_42" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_AuditorName_39" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_AuditorFirmId_40" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_AuditorLocation_41" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_44" xlink:to="loc_us-gaap_AssetsAbstract_45" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_45" xlink:to="loc_us-gaap_AssetsCurrentAbstract_46" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_46" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_47" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_46" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_48" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="loc_us-gaap_NontradeReceivablesCurrent_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_46" xlink:to="loc_us-gaap_NontradeReceivablesCurrent_49" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_46" xlink:to="loc_us-gaap_AssetsCurrent_50" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_45" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_51" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_51" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_52" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_51" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_53" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_51" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_54" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_45" xlink:to="loc_us-gaap_Assets_55" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_44" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_56" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_56" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_57" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_57" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_58" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="loc_us-gaap_OtherLongTermDebtCurrent_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_57" xlink:to="loc_us-gaap_OtherLongTermDebtCurrent_59" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_57" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_60" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PayableTowardsRoyaltyAndOthersCurrent" xlink:label="loc_eprx_PayableTowardsRoyaltyAndOthersCurrent_1419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_57" xlink:to="loc_eprx_PayableTowardsRoyaltyAndOthersCurrent_1419" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_57" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_61" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_57" xlink:to="loc_us-gaap_LiabilitiesCurrent_62" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_56" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_63" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_63" xlink:to="loc_us-gaap_OtherLongTermDebtNoncurrent_64" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_63" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_65" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_63" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_66" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_56" xlink:to="loc_us-gaap_Liabilities_67" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_56" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_68" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_68" xlink:to="loc_us-gaap_CommonStockValue_69" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_70" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_68" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_70" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_71" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_68" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_71" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_68" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_72" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_56" xlink:to="loc_us-gaap_StockholdersEquity_73" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_56" xlink:to="loc_us-gaap_MinorityInterest_74" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_56" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_75" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_56" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_76" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1413" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_1420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1413" xlink:to="loc_us-gaap_CommonStockNoParValue_1420" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="loc_us-gaap_CommonStockSharesAuthorizedUnlimited_1414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1413" xlink:to="loc_us-gaap_CommonStockSharesAuthorizedUnlimited_1414" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1413" xlink:to="loc_us-gaap_CommonStockSharesIssued_1416" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1413" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1417" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_79" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_79" xlink:to="loc_us-gaap_OperatingExpensesAbstract_80" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_80" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_81" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_80" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_82" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_80" xlink:to="loc_us-gaap_OperatingExpenses_83" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_84" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_79" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_84" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_85" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_84" xlink:to="loc_us-gaap_InvestmentIncomeInterest_85" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_86" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_84" xlink:to="loc_us-gaap_InterestExpense_86" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_88" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_84" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_88" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_84" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_90" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_94" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_84" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_94" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_84" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_97" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_84" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1421" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_84" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_92" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_79" xlink:to="loc_us-gaap_ProfitLoss_98" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_79" xlink:to="loc_us-gaap_NetIncomeLossAbstract_99" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_99" xlink:to="loc_us-gaap_NetIncomeLoss_101" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_99" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_102" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_99" xlink:to="loc_us-gaap_ProfitLoss_103" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_104" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_79" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_105" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_79" xlink:to="loc_us-gaap_EarningsPerShareBasic_110" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_79" xlink:to="loc_us-gaap_EarningsPerShareDiluted_111" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_79" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_112" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_79" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_113" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_160" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_StatementTable_161" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_161" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_162" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_162" xlink:to="loc_us-gaap_EquityComponentDomain_163" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_163" xlink:to="loc_us-gaap_CommonStockMember_164" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_163" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_165" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_163" xlink:to="loc_us-gaap_RetainedEarningsMember_166" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_163" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_168" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_163" xlink:to="loc_us-gaap_NoncontrollingInterestMember_169" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_161" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_204" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_204" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_205" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OvernightMarketedPublicOfferingMember" xlink:label="loc_eprx_OvernightMarketedPublicOfferingMember_1184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_205" xlink:to="loc_eprx_OvernightMarketedPublicOfferingMember_1184" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_205" xlink:to="loc_us-gaap_PrivatePlacementMember_206" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EventAxis" xlink:label="loc_eprx_EventAxis_1181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_161" xlink:to="loc_eprx_EventAxis_1181" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EventDomain" xlink:label="loc_eprx_EventDomain_1182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_EventAxis_1181" xlink:to="loc_eprx_EventDomain_1182" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExcerciseOfWarrantsMember" xlink:label="loc_eprx_ExcerciseOfWarrantsMember_1183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_EventDomain_1182" xlink:to="loc_eprx_ExcerciseOfWarrantsMember_1183" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_161" xlink:to="loc_us-gaap_StatementLineItems_184" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_SharesOutstanding_190" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_191" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_192" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_193" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_196" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_200" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_201" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_ProfitLoss_197" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_198" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_SharesOutstanding_202" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_184" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_203" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_208" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_208" xlink:to="loc_us-gaap_StatementTable_226" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_226" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_228" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_228" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_229" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_226" xlink:to="loc_us-gaap_StatementLineItems_227" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_ProfitLoss_224" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_InterestOnConvertibleDebtOne" xlink:label="loc_eprx_InterestOnConvertibleDebtOne_1185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_eprx_InterestOnConvertibleDebtOne_1185" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_InterestOnShortTermInvestmentsNonOperating" xlink:label="loc_eprx_InterestOnShortTermInvestmentsNonOperating_1186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_eprx_InterestOnShortTermInvestmentsNonOperating_1186" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_Depreciation_233" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_InterestExpensesOnLeaseLiabilityFinancingActivities" xlink:label="loc_eprx_InterestExpensesOnLeaseLiabilityFinancingActivities_1187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_eprx_InterestExpensesOnLeaseLiabilityFinancingActivities_1187" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LossOnSaleOfEquipment" xlink:label="loc_eprx_LossOnSaleOfEquipment_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_eprx_LossOnSaleOfEquipment_235" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_ShareBasedCompensation_237" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_239" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_240" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_243" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_243" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_244" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_243" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_245" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_243" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_246" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent" xlink:label="loc_eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent_1422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_243" xlink:to="loc_eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent_1422" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_247" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_249" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_250" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_251" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_252" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_253" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_256" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_256" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_258" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_256" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_261" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_256" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_264" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_256" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_266" use="optional" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_256" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_267" use="optional" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_256" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_268" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_270" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_271" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_272" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_223" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_274" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcern">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_95" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_96" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_95" xlink:to="loc_us-gaap_NatureOfOperations_96" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/BasisOfPresentation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_279" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaap_BasisOfAccounting_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_279" xlink:to="loc_us-gaap_BasisOfAccounting_280" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_286" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_286" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_287" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/AmountsReceivable">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_335" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_335" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_336" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/PropertyAndEquipment">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_355" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_355" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_356" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/RightOfUseAsset">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RightOfUseAssetAbstract" xlink:label="loc_eprx_RightOfUseAssetAbstract_1141" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RightOfUseAssetTextBlock" xlink:label="loc_eprx_RightOfUseAssetTextBlock_1142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_RightOfUseAssetAbstract_1141" xlink:to="loc_eprx_RightOfUseAssetTextBlock_1142" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_359" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_359" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_360" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/LoansPayable">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_495" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInEntiretyOfOtherLoansPayable" xlink:label="loc_eprx_DisclosureInEntiretyOfOtherLoansPayable_1173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_495" xlink:to="loc_eprx_DisclosureInEntiretyOfOtherLoansPayable_1173" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/LeaseLiability">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_556" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_556" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_557" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/AuritecLicenseAgreement">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LicenseAgreementAbstract" xlink:label="loc_eprx_LicenseAgreementAbstract_405" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInEntiretyOfLicenseAgreementTextBlock" xlink:label="loc_eprx_DisclosureInEntiretyOfLicenseAgreementTextBlock_406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LicenseAgreementAbstract_405" xlink:to="loc_eprx_DisclosureInEntiretyOfLicenseAgreementTextBlock_406" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConvertibleDebt">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_317" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_317" xlink:to="loc_us-gaap_LongTermDebtTextBlock_319" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_529" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_529" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_530" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/GeneralAndAdministrativeExpenses">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_GeneralAndAdministrativeExpensesAbstract" xlink:label="loc_eprx_GeneralAndAdministrativeExpensesAbstract_747" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock" xlink:label="loc_eprx_DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock_748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_GeneralAndAdministrativeExpensesAbstract_747" xlink:to="loc_eprx_DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock_748" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ResearchAndDevelopmentExpenses">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_801" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_801" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_802" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/GovernmentGrantsAndAssistance">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAbstract" xlink:label="loc_us-gaap_GovernmentAssistanceAbstract_667" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTextBlock" xlink:label="loc_us-gaap_GovernmentAssistanceTextBlock_668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceAbstract_667" xlink:to="loc_us-gaap_GovernmentAssistanceTextBlock_668" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_855" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_855" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_856" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/Commitments">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_276" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_276" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_277" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/FinancialInstruments">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FinancialInstrumentsAbstract" xlink:label="loc_eprx_FinancialInstrumentsAbstract_396" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsAbstract_396" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_397" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/InterestExpense">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseAbstract" xlink:label="loc_us-gaap_InterestExpenseAbstract_210" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseAbstract_210" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock_211" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_139" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_1221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_139" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_1221" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/SubsequentEvent">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_89" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_89" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_91" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_289" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_289" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_290" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_289" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_291" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_289" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_292" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_289" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_293" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_289" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_294" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RegulatoryIncomeTaxesPolicy" xlink:label="loc_us-gaap_RegulatoryIncomeTaxesPolicy_1194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_289" xlink:to="loc_us-gaap_RegulatoryIncomeTaxesPolicy_1194" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_GovernmentGrantsPolicyTextBlock" xlink:label="loc_eprx_GovernmentGrantsPolicyTextBlock_1196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_289" xlink:to="loc_eprx_GovernmentGrantsPolicyTextBlock_1196" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="loc_us-gaap_GovernmentAssistancePolicyTextBlock_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_289" xlink:to="loc_us-gaap_GovernmentAssistancePolicyTextBlock_302" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_289" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_303" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_289" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_304" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_1197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_289" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_1197" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_289" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_309" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_289" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_310" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_289" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_311" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_1201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_289" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_1201" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_289" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_313" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_289" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_314" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_289" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_315" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_328" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfInformationAboutSubsidiariesTableTextBlock" xlink:label="loc_eprx_ScheduleOfInformationAboutSubsidiariesTableTextBlock_1126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_328" xlink:to="loc_eprx_ScheduleOfInformationAboutSubsidiariesTableTextBlock_1126" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock" xlink:label="loc_eprx_PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock_1212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_328" xlink:to="loc_eprx_PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock_1212" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/AmountsReceivableTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_363" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NontradeReceivablesTableTextBlock" xlink:label="loc_eprx_NontradeReceivablesTableTextBlock_1152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_363" xlink:to="loc_eprx_NontradeReceivablesTableTextBlock_1152" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/PropertyAndEquipmentTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_365" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_365" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_366" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/RightOfUseAssetTables">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OperatingLeaseRightOfUseAssetAbstract" xlink:label="loc_eprx_OperatingLeaseRightOfUseAssetAbstract_526" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OperatingLeaseRightOfUseAssetTableTextBlock" xlink:label="loc_eprx_OperatingLeaseRightOfUseAssetTableTextBlock_527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_OperatingLeaseRightOfUseAssetAbstract_526" xlink:to="loc_eprx_OperatingLeaseRightOfUseAssetTableTextBlock_527" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_379" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_379" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_380" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/LoansPayableTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_500" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_500" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_501" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/LeaseLiabilityTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_566" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_566" xlink:to="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_569" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_566" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1003" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock" xlink:label="loc_eprx_DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock_1216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_566" xlink:to="loc_eprx_DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock_1216" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/AuritecLicenseAgreementTables">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LicenseAgreementAbstract" xlink:label="loc_eprx_LicenseAgreementAbstract_438" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock" xlink:label="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock_439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LicenseAgreementAbstract_438" xlink:to="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock_439" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock" xlink:label="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock_440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LicenseAgreementAbstract_438" xlink:to="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock_440" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConvertibleDebtTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_321" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_1368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_321" xlink:to="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_1368" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_1368" xlink:to="loc_dei_LegalEntityAxis_1370" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1370" xlink:to="loc_dei_EntityDomain_1371" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LoanMember" xlink:label="loc_eprx_LoanMember_1372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1371" xlink:to="loc_eprx_LoanMember_1372" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_1369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_1368" xlink:to="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_1369" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_1369" xlink:to="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock_323" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_533" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_533" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_536" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock" xlink:label="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock_540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_533" xlink:to="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock_540" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_533" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_541" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock_1014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_533" xlink:to="loc_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock_1014" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock_1013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_533" xlink:to="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock_1013" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesTables">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_GeneralAndAdministrativeExpensesAbstract" xlink:label="loc_eprx_GeneralAndAdministrativeExpensesAbstract_751" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:label="loc_eprx_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_GeneralAndAdministrativeExpensesAbstract_751" xlink:to="loc_eprx_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_753" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_805" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock" xlink:label="loc_eprx_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock_808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_805" xlink:to="loc_eprx_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock_808" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAbstract" xlink:label="loc_us-gaap_GovernmentAssistanceAbstract_676" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_GovernmentAssistanceTableTextBlock" xlink:label="loc_eprx_GovernmentAssistanceTableTextBlock_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceAbstract_676" xlink:to="loc_eprx_GovernmentAssistanceTableTextBlock_677" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_858" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_858" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1475" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_858" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1476" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_858" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_859" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_858" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1500" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock" xlink:label="loc_eprx_ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock_874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_858" xlink:to="loc_eprx_ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock_874" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/FinancialInstrumentsTables">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FinancialInstrumentsAbstract" xlink:label="loc_eprx_FinancialInstrumentsAbstract_399" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_1360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsAbstract_399" xlink:to="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_1360" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_1360" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1362" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1362" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1363" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1363" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1364" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_1361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_1360" xlink:to="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_1361" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock" xlink:label="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_1361" xlink:to="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock_402" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_1361" xlink:to="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock_403" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/InterestExpenseTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseAbstract" xlink:label="loc_us-gaap_InterestExpenseAbstract_213" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseAbstract_213" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_215" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_142" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_1224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_142" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_1224" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_124" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NatureOfOperationsTable" xlink:label="loc_eprx_NatureOfOperationsTable_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_124" xlink:to="loc_eprx_NatureOfOperationsTable_137" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NatureOfOperationsTable_137" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_146" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_146" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_147" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_147" xlink:to="loc_us-gaap_PrivatePlacementMember_148" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_147" xlink:to="loc_us-gaap_IPOMember_1428" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NatureOfOperationsTable_137" xlink:to="loc_us-gaap_DebtInstrumentAxis_324" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_324" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_325" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LenderAxis" xlink:label="loc_eprx_LenderAxis_1191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NatureOfOperationsTable_137" xlink:to="loc_eprx_LenderAxis_1191" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LenderDomain" xlink:label="loc_eprx_LenderDomain_1192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LenderAxis_1191" xlink:to="loc_eprx_LenderDomain_1192" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SiliconValleyBankMember" xlink:label="loc_eprx_SiliconValleyBankMember_1193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LenderDomain_1192" xlink:to="loc_eprx_SiliconValleyBankMember_1193" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NatureOfOperationsTable_137" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1425" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1425" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1426" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1426" xlink:to="loc_us-gaap_SubsequentEventMember_1427" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NatureOfOperationsLineItems" xlink:label="loc_eprx_NatureOfOperationsLineItems_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NatureOfOperationsTable_137" xlink:to="loc_eprx_NatureOfOperationsLineItems_144" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_125" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_126" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_us-gaap_Revenues_131" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_us-gaap_ProfitLoss_132" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_135" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_153" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_155" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="loc_us-gaap_DebtInstrumentCollateralAmount_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_us-gaap_DebtInstrumentCollateralAmount_157" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DebtInstrumentMonthOfMaturity" xlink:label="loc_eprx_DebtInstrumentMonthOfMaturity_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_eprx_DebtInstrumentMonthOfMaturity_273" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NatureOfOperationsLineItems_144" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1423" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_752" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SummaryOfInformationAboutSubsidiariesTable" xlink:label="loc_eprx_SummaryOfInformationAboutSubsidiariesTable_754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_752" xlink:to="loc_eprx_SummaryOfInformationAboutSubsidiariesTable_754" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_SummaryOfInformationAboutSubsidiariesTable_754" xlink:to="loc_dei_LegalEntityAxis_755" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_755" xlink:to="loc_dei_EntityDomain_756" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaHoldingsIncMember" xlink:label="loc_eprx_EupraxiaHoldingsIncMember_760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_756" xlink:to="loc_eprx_EupraxiaHoldingsIncMember_760" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaPharmaceuticalsUsaLlcMember" xlink:label="loc_eprx_EupraxiaPharmaceuticalsUsaLlcMember_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_756" xlink:to="loc_eprx_EupraxiaPharmaceuticalsUsaLlcMember_764" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmdmHoldingsIncMember" xlink:label="loc_eprx_AmdmHoldingsIncMember_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_756" xlink:to="loc_eprx_AmdmHoldingsIncMember_767" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaPharmaIncMember" xlink:label="loc_eprx_EupraxiaPharmaIncMember_771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_756" xlink:to="loc_eprx_EupraxiaPharmaIncMember_771" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaPharmaceuticalsAustraliaPtyLtdMember" xlink:label="loc_eprx_EupraxiaPharmaceuticalsAustraliaPtyLtdMember_773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_756" xlink:to="loc_eprx_EupraxiaPharmaceuticalsAustraliaPtyLtdMember_773" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaPharmaUsaIncMember" xlink:label="loc_eprx_EupraxiaPharmaUsaIncMember_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_756" xlink:to="loc_eprx_EupraxiaPharmaUsaIncMember_775" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_SummaryOfInformationAboutSubsidiariesTable_754" xlink:to="loc_srt_ConsolidatedEntitiesAxis_1205" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1205" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1206" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_1207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1206" xlink:to="loc_srt_SubsidiariesMember_1207" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SummaryOfInformationAboutSubsidiariesLineItems" xlink:label="loc_eprx_SummaryOfInformationAboutSubsidiariesLineItems_777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_SummaryOfInformationAboutSubsidiariesTable_754" xlink:to="loc_eprx_SummaryOfInformationAboutSubsidiariesLineItems_777" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_SummaryOfInformationAboutSubsidiariesLineItems_777" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_778" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_1208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_SummaryOfInformationAboutSubsidiariesLineItems_777" xlink:to="loc_dei_EntityAddressCityOrTown_1208" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_1210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_SummaryOfInformationAboutSubsidiariesLineItems_777" xlink:to="loc_dei_EntityAddressCountry_1210" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_InvestmentOwnershipPercentage" xlink:label="loc_eprx_InvestmentOwnershipPercentage_1211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_SummaryOfInformationAboutSubsidiariesLineItems_777" xlink:to="loc_eprx_InvestmentOwnershipPercentage_1211" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1053" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1053" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1054" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1054" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1056" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1056" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1057" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1057" xlink:to="loc_us-gaap_ComputerEquipmentMember_1058" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1057" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1429" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1057" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1060" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LabEquipmentMember" xlink:label="loc_eprx_LabEquipmentMember_1061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1057" xlink:to="loc_eprx_LabEquipmentMember_1061" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1054" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1062" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PropertyPlantAndEqupmentRateOfDepreciation" xlink:label="loc_eprx_PropertyPlantAndEqupmentRateOfDepreciation_1214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1062" xlink:to="loc_eprx_PropertyPlantAndEqupmentRateOfDepreciation_1214" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation" xlink:label="loc_eprx_PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation_1217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1062" xlink:to="loc_eprx_PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation_1217" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1431" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement" xlink:label="loc_eprx_PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement_1432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1431" xlink:to="loc_eprx_PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement_1432" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/AmountsReceivableSummaryOfAmountsReceivableDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivableCurrentsAbstract" xlink:label="loc_us-gaap_NontradeReceivableCurrentsAbstract_338" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent_1128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NontradeReceivableCurrentsAbstract_338" xlink:to="loc_us-gaap_GrantsReceivableCurrent_1128" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmountCumulativeCurrent" xlink:label="loc_us-gaap_GovernmentAssistanceAmountCumulativeCurrent_1129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NontradeReceivableCurrentsAbstract_338" xlink:to="loc_us-gaap_GovernmentAssistanceAmountCumulativeCurrent_1129" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OtherRefundableTaxCreditsCurrent" xlink:label="loc_eprx_OtherRefundableTaxCreditsCurrent_1131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NontradeReceivableCurrentsAbstract_338" xlink:to="loc_eprx_OtherRefundableTaxCreditsCurrent_1131" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="loc_us-gaap_NontradeReceivablesCurrent_1130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NontradeReceivableCurrentsAbstract_338" xlink:to="loc_us-gaap_NontradeReceivablesCurrent_1130" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_358" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_358" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_367" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_367" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_368" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_368" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" xlink:to="loc_us-gaap_ComputerEquipmentMember_369" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_371" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_372" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LabEquipmentMember" xlink:label="loc_eprx_LabEquipmentMember_373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_370" xlink:to="loc_eprx_LabEquipmentMember_373" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_367" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_375" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_1438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_375" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_1438" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_1438" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_376" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_1434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_1438" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_1434" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_1435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_1438" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_1435" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments" xlink:label="loc_eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments_1436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_1438" xlink:to="loc_eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments_1436" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_1438" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1449" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_1440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_375" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_1440" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_1440" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1442" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease" xlink:label="loc_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease_1443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_1440" xlink:to="loc_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease_1443" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_1444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_1440" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_1444" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments" xlink:label="loc_eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments_1445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_1440" xlink:to="loc_eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments_1445" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_1440" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1450" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_375" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1448" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/PropertyAndEquipmentAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_390" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_390" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1135" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1135" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1137" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1137" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1138" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1138" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1139" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1138" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1140" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1135" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1136" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease" xlink:label="loc_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1136" xlink:to="loc_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease_392" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/RightOfUseAssetSummaryOfRightOfUseAssetsDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OperatingLeaseRightOfUseAssetAbstract" xlink:label="loc_eprx_OperatingLeaseRightOfUseAssetAbstract_534" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_OperatingLeaseRightOfUseAssetAbstract_534" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_535" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease_537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_OperatingLeaseRightOfUseAssetAbstract_534" xlink:to="loc_us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease_537" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset" xlink:label="loc_eprx_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset_538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_OperatingLeaseRightOfUseAssetAbstract_534" xlink:to="loc_eprx_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset_538" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_OperatingLeaseRightOfUseAssetAbstract_534" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_539" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/RightOfUseAssetAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OperatingLeaseRightOfUseAssetAbstract" xlink:label="loc_eprx_OperatingLeaseRightOfUseAssetAbstract_543" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RightOfUseAssetTable" xlink:label="loc_eprx_RightOfUseAssetTable_1144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_OperatingLeaseRightOfUseAssetAbstract_543" xlink:to="loc_eprx_RightOfUseAssetTable_1144" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_RightOfUseAssetTable_1144" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1146" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1146" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1147" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1147" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1148" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1147" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1149" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RightOfUseAssetLineItems" xlink:label="loc_eprx_RightOfUseAssetLineItems_1145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_RightOfUseAssetTable_1144" xlink:to="loc_eprx_RightOfUseAssetLineItems_1145" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease_544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_RightOfUseAssetLineItems_1145" xlink:to="loc_us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease_544" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_382" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment" xlink:label="loc_eprx_AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_382" xlink:to="loc_eprx_AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment_383" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration" xlink:label="loc_eprx_AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_382" xlink:to="loc_eprx_AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration_384" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent_385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_382" xlink:to="loc_us-gaap_AccruedPayrollTaxesCurrent_385" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_382" xlink:to="loc_us-gaap_AccruedBonusesCurrent_386" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_382" xlink:to="loc_us-gaap_TaxesPayableCurrent_387" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_382" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_388" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/LoansPayableAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_503" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_503" xlink:to="loc_us-gaap_DebtInstrumentTable_1157" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1157" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1159" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1159" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1160" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_1161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1160" xlink:to="loc_us-gaap_LoansPayableMember_1161" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1157" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1158" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1158" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_512" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTerm" xlink:label="loc_us-gaap_LongTermDebtTerm_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1158" xlink:to="loc_us-gaap_LongTermDebtTerm_514" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1158" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1164" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_1165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1158" xlink:to="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_1165" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/LoansPayableSummaryOfBreakdownOfLoanBalanceDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_517" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaap_LoansPayable_518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_517" xlink:to="loc_us-gaap_LoansPayable_518" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_517" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_519" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ForeignExchangeAdjustmentOnLoansPayable" xlink:label="loc_eprx_ForeignExchangeAdjustmentOnLoansPayable_1175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_517" xlink:to="loc_eprx_ForeignExchangeAdjustmentOnLoansPayable_1175" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaap_LoansPayable_521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_517" xlink:to="loc_us-gaap_LoansPayable_521" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaap_LoansPayableCurrent_522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_517" xlink:to="loc_us-gaap_LoansPayableCurrent_522" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaap_LongTermLoansPayable_523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_517" xlink:to="loc_us-gaap_LongTermLoansPayable_523" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfCostComponentsOfTheOperatingLeaseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_574" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_574" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_575" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_575" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_576" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_576" xlink:to="loc_us-gaap_LeaseCostAbstract_577" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_577" xlink:to="loc_us-gaap_OperatingLeaseCost_578" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_577" xlink:to="loc_us-gaap_VariableLeaseCost_579" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract" xlink:label="loc_eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract_1213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_576" xlink:to="loc_eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract_1213" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract_1213" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_584" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract_1213" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_586" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_599" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_599" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_610" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_610" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_612" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_614" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncentiveFromLessor" xlink:label="loc_us-gaap_IncentiveFromLessor_1215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_IncentiveFromLessor_1215" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_617" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_OperatingLeaseLiability_618" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_640" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_640" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_642" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_642" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_643" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_643" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_644" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_643" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_645" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_643" xlink:to="loc_us-gaap_OperatingLeaseLiability_647" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/LeaseLiabilityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_649" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_649" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_650" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_650" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_651" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_1218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_651" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_1218" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_651" xlink:to="loc_us-gaap_LeaseExpirationDate1_653" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AreaOfSubleasedOfficeSpace" xlink:label="loc_eprx_AreaOfSubleasedOfficeSpace_1395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_651" xlink:to="loc_eprx_AreaOfSubleasedOfficeSpace_1395" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_1396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_651" xlink:to="loc_us-gaap_SubleaseIncome_1396" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LicenseAgreementAbstract" xlink:label="loc_eprx_LicenseAgreementAbstract_408" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LicenseAgreementTable" xlink:label="loc_eprx_LicenseAgreementTable_409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LicenseAgreementAbstract_408" xlink:to="loc_eprx_LicenseAgreementTable_409" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AgreementAxis" xlink:label="loc_eprx_AgreementAxis_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LicenseAgreementTable_409" xlink:to="loc_eprx_AgreementAxis_410" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AgreementDomain" xlink:label="loc_eprx_AgreementDomain_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_AgreementAxis_410" xlink:to="loc_eprx_AgreementDomain_411" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmendedAndRestatedLicenseAgreementMember" xlink:label="loc_eprx_AmendedAndRestatedLicenseAgreementMember_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_AgreementDomain_411" xlink:to="loc_eprx_AmendedAndRestatedLicenseAgreementMember_412" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LicenseAgreementTable_409" xlink:to="loc_srt_CounterpartyNameAxis_413" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_413" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_414" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaUsaMember" xlink:label="loc_eprx_EupraxiaUsaMember_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_414" xlink:to="loc_eprx_EupraxiaUsaMember_415" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LicenseAgreementTable_409" xlink:to="loc_srt_RangeAxis_416" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_416" xlink:to="loc_srt_RangeMember_417" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_417" xlink:to="loc_srt_MaximumMember_418" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_417" xlink:to="loc_srt_MinimumMember_419" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ArithmeticAverageMember" xlink:label="loc_srt_ArithmeticAverageMember_420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_417" xlink:to="loc_srt_ArithmeticAverageMember_420" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LicenseAgreementTable_409" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1456" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1456" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1457" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1457" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1458" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MilestoneAxis" xlink:label="loc_eprx_MilestoneAxis_1453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LicenseAgreementTable_409" xlink:to="loc_eprx_MilestoneAxis_1453" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MilestoneDomain" xlink:label="loc_eprx_MilestoneDomain_1454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MilestoneAxis_1453" xlink:to="loc_eprx_MilestoneDomain_1454" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SuccessfulCompletionOfPhaseTwoBStudyMember" xlink:label="loc_eprx_SuccessfulCompletionOfPhaseTwoBStudyMember_1455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MilestoneDomain_1454" xlink:to="loc_eprx_SuccessfulCompletionOfPhaseTwoBStudyMember_1455" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LicenseAgreementLineItems" xlink:label="loc_eprx_LicenseAgreementLineItems_421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LicenseAgreementTable_409" xlink:to="loc_eprx_LicenseAgreementLineItems_421" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PaymentOfUpfrontFees" xlink:label="loc_eprx_PaymentOfUpfrontFees_422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LicenseAgreementLineItems_421" xlink:to="loc_eprx_PaymentOfUpfrontFees_422" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement" xlink:label="loc_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement_423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LicenseAgreementLineItems_421" xlink:to="loc_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement_423" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RoyaltyAsAPercentageOfNetSales" xlink:label="loc_eprx_RoyaltyAsAPercentageOfNetSales_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LicenseAgreementLineItems_421" xlink:to="loc_eprx_RoyaltyAsAPercentageOfNetSales_424" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable" xlink:label="loc_eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LicenseAgreementLineItems_421" xlink:to="loc_eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable_425" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization" xlink:label="loc_eprx_MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LicenseAgreementLineItems_421" xlink:to="loc_eprx_MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization_428" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MilestonePaymentRecognizedExpense" xlink:label="loc_eprx_MilestonePaymentRecognizedExpense_1452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LicenseAgreementLineItems_421" xlink:to="loc_eprx_MilestonePaymentRecognizedExpense_1452" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LicenseAgreementAbstract" xlink:label="loc_eprx_LicenseAgreementAbstract_444" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable" xlink:label="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable_445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LicenseAgreementAbstract_444" xlink:to="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable_445" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AgreementAxis" xlink:label="loc_eprx_AgreementAxis_446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable_445" xlink:to="loc_eprx_AgreementAxis_446" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AgreementDomain" xlink:label="loc_eprx_AgreementDomain_447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_AgreementAxis_446" xlink:to="loc_eprx_AgreementDomain_447" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmendedAndRestatedLicenseAgreementMember" xlink:label="loc_eprx_AmendedAndRestatedLicenseAgreementMember_448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_AgreementDomain_447" xlink:to="loc_eprx_AmendedAndRestatedLicenseAgreementMember_448" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable_445" xlink:to="loc_srt_CounterpartyNameAxis_451" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_451" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_452" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EupraxiaUsaMember" xlink:label="loc_eprx_EupraxiaUsaMember_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_452" xlink:to="loc_eprx_EupraxiaUsaMember_453" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable_445" xlink:to="loc_srt_RangeAxis_454" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_454" xlink:to="loc_srt_RangeMember_455" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_455" xlink:to="loc_srt_MaximumMember_456" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MilestoneAxis" xlink:label="loc_eprx_MilestoneAxis_457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable_445" xlink:to="loc_eprx_MilestoneAxis_457" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MilestoneDomain" xlink:label="loc_eprx_MilestoneDomain_458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MilestoneAxis_457" xlink:to="loc_eprx_MilestoneDomain_458" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SuccessfulCompletionOfPhaseTwoBStudyMember" xlink:label="loc_eprx_SuccessfulCompletionOfPhaseTwoBStudyMember_459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MilestoneDomain_458" xlink:to="loc_eprx_SuccessfulCompletionOfPhaseTwoBStudyMember_459" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FirstOaRegulatoryApprovalMember" xlink:label="loc_eprx_FirstOaRegulatoryApprovalMember_460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MilestoneDomain_458" xlink:to="loc_eprx_FirstOaRegulatoryApprovalMember_460" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SecondOaRegulatoryApprovalMember" xlink:label="loc_eprx_SecondOaRegulatoryApprovalMember_461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MilestoneDomain_458" xlink:to="loc_eprx_SecondOaRegulatoryApprovalMember_461" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NonOaIndicationRegulatoryApprovalMember" xlink:label="loc_eprx_NonOaIndicationRegulatoryApprovalMember_462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MilestoneDomain_458" xlink:to="loc_eprx_NonOaIndicationRegulatoryApprovalMember_462" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember" xlink:label="loc_eprx_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember_463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MilestoneDomain_458" xlink:to="loc_eprx_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember_463" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems" xlink:label="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems_464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable_445" xlink:to="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems_464" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement" xlink:label="loc_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement_465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems_464" xlink:to="loc_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement_465" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail">
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LicenseAgreementAbstract" xlink:label="loc_eprx_LicenseAgreementAbstract_470" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable" xlink:label="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable_471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LicenseAgreementAbstract_470" xlink:to="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable_471" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TrancheAxis" xlink:label="loc_eprx_TrancheAxis_473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable_471" xlink:to="loc_eprx_TrancheAxis_473" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TrancheDomain" xlink:label="loc_eprx_TrancheDomain_474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_TrancheAxis_473" xlink:to="loc_eprx_TrancheDomain_474" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PriorToSuccessfulCompletionOfPhaseTwoBStudyMember" xlink:label="loc_eprx_PriorToSuccessfulCompletionOfPhaseTwoBStudyMember_475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_TrancheDomain_474" xlink:to="loc_eprx_PriorToSuccessfulCompletionOfPhaseTwoBStudyMember_475" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember" xlink:label="loc_eprx_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember_476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_TrancheDomain_474" xlink:to="loc_eprx_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember_476" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember" xlink:label="loc_eprx_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember_477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_TrancheDomain_474" xlink:to="loc_eprx_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember_477" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember" xlink:label="loc_eprx_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember_479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_TrancheDomain_474" xlink:to="loc_eprx_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember_479" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems" xlink:label="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems_481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable_471" xlink:to="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems_481" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty" xlink:label="loc_eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty_482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems_481" xlink:to="loc_eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty_482" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_692" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_692" xlink:to="loc_us-gaap_DebtInstrumentTable_694" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_694" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1005" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1005" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1006" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_1007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1006" xlink:to="loc_us-gaap_ConvertibleDebtMember_1007" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LenderAxis" xlink:label="loc_eprx_LenderAxis_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_694" xlink:to="loc_eprx_LenderAxis_698" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LenderDomain" xlink:label="loc_eprx_LenderDomain_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LenderAxis_698" xlink:to="loc_eprx_LenderDomain_699" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SiliconValleyBankMember" xlink:label="loc_eprx_SiliconValleyBankMember_701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LenderDomain_699" xlink:to="loc_eprx_SiliconValleyBankMember_701" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_694" xlink:to="loc_us-gaap_VariableRateAxis_706" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_706" xlink:to="loc_us-gaap_VariableRateDomain_707" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CanadianPrimeRateMember" xlink:label="loc_eprx_CanadianPrimeRateMember_708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_707" xlink:to="loc_eprx_CanadianPrimeRateMember_708" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_694" xlink:to="loc_srt_RangeAxis_711" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_711" xlink:to="loc_srt_RangeMember_712" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_712" xlink:to="loc_srt_MaximumMember_713" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_712" xlink:to="loc_srt_MinimumMember_714" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CallRightAxis" xlink:label="loc_eprx_CallRightAxis_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_694" xlink:to="loc_eprx_CallRightAxis_727" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CallRightDomain" xlink:label="loc_eprx_CallRightDomain_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_CallRightAxis_727" xlink:to="loc_eprx_CallRightDomain_728" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_WithEighteenMonthsFromTheDateOfTheDebtAgreementMember" xlink:label="loc_eprx_WithEighteenMonthsFromTheDateOfTheDebtAgreementMember_730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_CallRightDomain_728" xlink:to="loc_eprx_WithEighteenMonthsFromTheDateOfTheDebtAgreementMember_730" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember" xlink:label="loc_eprx_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_CallRightDomain_728" xlink:to="loc_eprx_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember_740" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_694" xlink:to="loc_us-gaap_DebtInstrumentLineItems_695" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_696" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_697" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTerm" xlink:label="loc_us-gaap_LongTermDebtTerm_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_us-gaap_LongTermDebtTerm_721" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LongTermDebtTermExtendableAtLendersDiscretion" xlink:label="loc_eprx_LongTermDebtTermExtendableAtLendersDiscretion_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_eprx_LongTermDebtTermExtendableAtLendersDiscretion_722" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LongTermDebtBaseRate" xlink:label="loc_eprx_LongTermDebtBaseRate_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_eprx_LongTermDebtBaseRate_723" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LongTermDebtPaidInKindInterestPercentage" xlink:label="loc_eprx_LongTermDebtPaidInKindInterestPercentage_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_eprx_LongTermDebtPaidInKindInterestPercentage_724" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_725" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_726" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmountToBeRaisedByWayOfEquityIssue" xlink:label="loc_eprx_AmountToBeRaisedByWayOfEquityIssue_744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_eprx_AmountToBeRaisedByWayOfEquityIssue_744" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AggegateAmountRaisedByWayOfEquityIssue" xlink:label="loc_eprx_AggegateAmountRaisedByWayOfEquityIssue_745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_695" xlink:to="loc_eprx_AggegateAmountRaisedByWayOfEquityIssue_745" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_490" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_490" xlink:to="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_491" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_491" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_493" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_493" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_494" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_494" xlink:to="loc_us-gaap_ConvertibleDebtMember_496" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_491" xlink:to="loc_dei_LegalEntityAxis_1373" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1373" xlink:to="loc_dei_EntityDomain_1374" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LoanMember" xlink:label="loc_eprx_LoanMember_1375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1374" xlink:to="loc_eprx_LoanMember_1375" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_491" xlink:to="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_497" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_497" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_504" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod" xlink:label="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod_505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_497" xlink:to="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod_505" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod" xlink:label="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_497" xlink:to="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod_506" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_497" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_507" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss" xlink:label="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_497" xlink:to="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss_508" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_497" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_509" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_772" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_772" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_774" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EventAxis" xlink:label="loc_eprx_EventAxis_787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_eprx_EventAxis_787" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EventDomain" xlink:label="loc_eprx_EventDomain_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_EventAxis_787" xlink:to="loc_eprx_EventDomain_788" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExcerciseOfWarrantsMember" xlink:label="loc_eprx_ExcerciseOfWarrantsMember_789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_EventDomain_788" xlink:to="loc_eprx_ExcerciseOfWarrantsMember_789" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExcerciseOfOptionsMember" xlink:label="loc_eprx_ExcerciseOfOptionsMember_797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_EventDomain_788" xlink:to="loc_eprx_ExcerciseOfOptionsMember_797" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_WarrantAxis" xlink:label="loc_eprx_WarrantAxis_1233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_eprx_WarrantAxis_1233" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_WarrantDomain" xlink:label="loc_eprx_WarrantDomain_1234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_WarrantAxis_1233" xlink:to="loc_eprx_WarrantDomain_1234" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CompensationWarrantMember" xlink:label="loc_eprx_CompensationWarrantMember_1235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_WarrantDomain_1234" xlink:to="loc_eprx_CompensationWarrantMember_1235" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_798" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_798" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_799" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_799" xlink:to="loc_us-gaap_PrivatePlacementMember_800" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_1110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_799" xlink:to="loc_us-gaap_OverAllotmentOptionMember_1110" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_us-gaap_PlanNameAxis_812" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_812" xlink:to="loc_us-gaap_PlanNameDomain_813" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmendedPlanMember" xlink:label="loc_eprx_AmendedPlanMember_814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_813" xlink:to="loc_eprx_AmendedPlanMember_814" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_us-gaap_VestingAxis_816" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_816" xlink:to="loc_us-gaap_VestingDomain_817" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ImmediateVestingMember" xlink:label="loc_eprx_ImmediateVestingMember_818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_817" xlink:to="loc_eprx_ImmediateVestingMember_818" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_817" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_819" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_817" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_821" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_817" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_822" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_us-gaap_AwardTypeAxis_834" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_835" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_835" xlink:to="loc_us-gaap_EmployeeStockOptionMember_836" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmdmHoldingsAxis" xlink:label="loc_eprx_AmdmHoldingsAxis_1080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_eprx_AmdmHoldingsAxis_1080" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmdmHoldingsDomain" xlink:label="loc_eprx_AmdmHoldingsDomain_1081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_AmdmHoldingsAxis_1080" xlink:to="loc_eprx_AmdmHoldingsDomain_1081" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmdmHoldingsMember" xlink:label="loc_eprx_AmdmHoldingsMember_1084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_AmdmHoldingsDomain_1081" xlink:to="loc_eprx_AmdmHoldingsMember_1084" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_dei_LegalEntityAxis_1082" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1082" xlink:to="loc_dei_EntityDomain_1083" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EuphraxiaPharmaIncMember" xlink:label="loc_eprx_EuphraxiaPharmaIncMember_1086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1083" xlink:to="loc_eprx_EuphraxiaPharmaIncMember_1086" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_srt_TitleOfIndividualAxis_1088" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1088" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1089" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ChiefScientificOfficerMember" xlink:label="loc_eprx_ChiefScientificOfficerMember_1090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1089" xlink:to="loc_eprx_ChiefScientificOfficerMember_1090" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1091" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1091" xlink:to="loc_us-gaap_ClassOfStockDomain_1092" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ClassBNonVotingStockMember" xlink:label="loc_eprx_ClassBNonVotingStockMember_1093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1092" xlink:to="loc_eprx_ClassBNonVotingStockMember_1093" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1092" xlink:to="loc_us-gaap_CommonClassAMember_1100" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1115" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1115" xlink:to="loc_us-gaap_EquityComponentDomain_1116" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1116" xlink:to="loc_us-gaap_CommonStockMember_1117" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1116" xlink:to="loc_us-gaap_WarrantMember_1397" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_1244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_srt_OwnershipAxis_1244" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_1245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_1244" xlink:to="loc_srt_OwnershipDomain_1245" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EuphraxiaUsaMember" xlink:label="loc_eprx_EuphraxiaUsaMember_1085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1245" xlink:to="loc_eprx_EuphraxiaUsaMember_1085" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1247" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1247" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1248" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OutstandingOfAMDMHoldingsMember" xlink:label="loc_eprx_OutstandingOfAMDMHoldingsMember_1250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1248" xlink:to="loc_eprx_OutstandingOfAMDMHoldingsMember_1250" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_774" xlink:to="loc_us-gaap_ClassOfStockLineItems_776" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorizedUnlimited" xlink:label="loc_us-gaap_PreferredStockSharesAuthorizedUnlimited_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_PreferredStockSharesAuthorizedUnlimited_781" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaap_PreferredStockNoParValue_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_PreferredStockNoParValue_782" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="loc_us-gaap_CommonStockSharesAuthorizedUnlimited_785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_CommonStockSharesAuthorizedUnlimited_785" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_CommonStockNoParValue_784" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_790" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_791" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_792" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_794" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_795" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_796" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_803" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CashCostsOfIssuingShares" xlink:label="loc_eprx_CashCostsOfIssuingShares_806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_CashCostsOfIssuingShares_806" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_807" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_809" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfOutstandingSharesEligibleForStockOptionsIssuance" xlink:label="loc_eprx_PercentageOfOutstandingSharesEligibleForStockOptionsIssuance_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_PercentageOfOutstandingSharesEligibleForStockOptionsIssuance_815" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_824" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_826" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_827" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1079" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_StockSharesIssuedAsAPercentageOfOutstandingShares" xlink:label="loc_eprx_StockSharesIssuedAsAPercentageOfOutstandingShares_1094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_StockSharesIssuedAsAPercentageOfOutstandingShares_1094" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1099" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EquityMethodInvestmentNumberOfSharedOwned" xlink:label="loc_eprx_EquityMethodInvestmentNumberOfSharedOwned_1101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_EquityMethodInvestmentNumberOfSharedOwned_1101" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1102" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CommonStockSharesIssuableAsAResultOfStockSplit" xlink:label="loc_eprx_CommonStockSharesIssuableAsAResultOfStockSplit_1103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_CommonStockSharesIssuableAsAResultOfStockSplit_1103" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TransferredFromAdditionalPaidinCapitalToShareCapital" xlink:label="loc_eprx_TransferredFromAdditionalPaidinCapitalToShareCapital_1104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_TransferredFromAdditionalPaidinCapitalToShareCapital_1104" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NumberOfUnitsIssued" xlink:label="loc_eprx_NumberOfUnitsIssued_1105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_NumberOfUnitsIssued_1105" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SecuritiesIssuedPricePerUnit" xlink:label="loc_eprx_SecuritiesIssuedPricePerUnit_1106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_SecuritiesIssuedPricePerUnit_1106" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NumberOfWarrantIssued" xlink:label="loc_eprx_NumberOfWarrantIssued_1107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_NumberOfWarrantIssued_1107" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_WarrantIssuedPricePerUnit" xlink:label="loc_eprx_WarrantIssuedPricePerUnit_1108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_WarrantIssuedPricePerUnit_1108" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1109" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1406" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaap_CommonStockConversionBasis_1111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_CommonStockConversionBasis_1111" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1112" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_1113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_1113" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1114" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_1118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_PaymentsForUnderwritingExpense_1118" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfGrossProceedsRaisedUnderTheOffering" xlink:label="loc_eprx_PercentageOfGrossProceedsRaisedUnderTheOffering_1119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_PercentageOfGrossProceedsRaisedUnderTheOffering_1119" use="optional" order="85" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1120" use="optional" order="86" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering" xlink:label="loc_eprx_PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering_1121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_eprx_PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering_1121" use="optional" order="87" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_1124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_LegalFees_1124" use="optional" order="88" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_1125" use="optional" order="89" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1168" use="optional" order="90" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1169" use="optional" order="91" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_776" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1170" use="optional" order="92" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_548" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_548" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_549" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_549" xlink:to="loc_us-gaap_PlanNameAxis_550" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_550" xlink:to="loc_us-gaap_PlanNameDomain_551" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmendedPlanMember" xlink:label="loc_eprx_AmendedPlanMember_553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_551" xlink:to="loc_eprx_AmendedPlanMember_553" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_549" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_555" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_561" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_562" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_563" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_565" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_567" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_568" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_570" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_571" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_572" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_585" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable" xlink:label="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_585" xlink:to="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable_589" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable_589" xlink:to="loc_us-gaap_PlanNameAxis_591" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_591" xlink:to="loc_us-gaap_PlanNameDomain_592" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmendedPlanMember" xlink:label="loc_eprx_AmendedPlanMember_593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_592" xlink:to="loc_eprx_AmendedPlanMember_593" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationOptionsExpiryDateAxis" xlink:label="loc_eprx_ShareBasedCompensationOptionsExpiryDateAxis_613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable_589" xlink:to="loc_eprx_ShareBasedCompensationOptionsExpiryDateAxis_613" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationOptionsExpiryDateDomain" xlink:label="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateAxis_613" xlink:to="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TwentySeventhSeptemberTwoThousandAndFifteenMember" xlink:label="loc_eprx_TwentySeventhSeptemberTwoThousandAndFifteenMember_619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_TwentySeventhSeptemberTwoThousandAndFifteenMember_619" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TwoNovemberTwoThousandAndFifteenMember" xlink:label="loc_eprx_TwoNovemberTwoThousandAndFifteenMember_620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_TwoNovemberTwoThousandAndFifteenMember_620" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FiveMarchTwoThousandAndEighteenMember" xlink:label="loc_eprx_FiveMarchTwoThousandAndEighteenMember_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_FiveMarchTwoThousandAndEighteenMember_621" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NineMarchTwoThousandAndTwentyOneMember" xlink:label="loc_eprx_NineMarchTwoThousandAndTwentyOneMember_622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_NineMarchTwoThousandAndTwentyOneMember_622" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NineMarchTwoThousandAndTwentyOne1Member" xlink:label="loc_eprx_NineMarchTwoThousandAndTwentyOne1Member_1167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_NineMarchTwoThousandAndTwentyOne1Member_1167" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ThreeMayTwoThousandAndTwentyOneMember" xlink:label="loc_eprx_ThreeMayTwoThousandAndTwentyOneMember_624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_ThreeMayTwoThousandAndTwentyOneMember_624" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NineDecemberTwoThousandAndTwentyOneMember" xlink:label="loc_eprx_NineDecemberTwoThousandAndTwentyOneMember_625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_NineDecemberTwoThousandAndTwentyOneMember_625" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ThirtyFirstMarchTwoThousandAndTwentyTwoMember" xlink:label="loc_eprx_ThirtyFirstMarchTwoThousandAndTwentyTwoMember_626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_ThirtyFirstMarchTwoThousandAndTwentyTwoMember_626" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NineDecemberTwoThousandAndTwentyTwoMember" xlink:label="loc_eprx_NineDecemberTwoThousandAndTwentyTwoMember_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_NineDecemberTwoThousandAndTwentyTwoMember_627" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EighteenthMayTwoThousandAndTwentyThreeMember" xlink:label="loc_eprx_EighteenthMayTwoThousandAndTwentyThreeMember_628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_EighteenthMayTwoThousandAndTwentyThreeMember_628" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ThirtyMayTwoThousandAndTwentyThreeMember" xlink:label="loc_eprx_ThirtyMayTwoThousandAndTwentyThreeMember_629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_ThirtyMayTwoThousandAndTwentyThreeMember_629" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TwentySeventhSeptemberTwoThousandAndTwentyThreeMember" xlink:label="loc_eprx_TwentySeventhSeptemberTwoThousandAndTwentyThreeMember_630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ShareBasedCompensationOptionsExpiryDateDomain_615" xlink:to="loc_eprx_TwentySeventhSeptemberTwoThousandAndTwentyThreeMember_630" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems" xlink:label="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable_589" xlink:to="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems_594" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant" xlink:label="loc_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant_631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems_594" xlink:to="loc_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant_631" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems_594" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_597" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems_594" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_598" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems_594" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1242" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems_594" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_608" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems_594" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_609" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_656" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_656" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_659" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_659" xlink:to="loc_us-gaap_PlanNameAxis_663" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_663" xlink:to="loc_us-gaap_PlanNameDomain_664" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AmendedPlanMember" xlink:label="loc_eprx_AmendedPlanMember_665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_664" xlink:to="loc_eprx_AmendedPlanMember_665" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_659" xlink:to="loc_us-gaap_AwardTypeAxis_678" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_678" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_679" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_679" xlink:to="loc_us-gaap_EmployeeStockOptionMember_680" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_659" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1133" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:label="loc_eprx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_1134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" xlink:to="loc_eprx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_1134" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_669" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_670" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_671" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" xlink:to="loc_us-gaap_SharePrice_673" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_674" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_662" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_675" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1016" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable_1017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1016" xlink:to="loc_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable_1017" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable_1017" xlink:to="loc_us-gaap_AwardTypeAxis_1024" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1024" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1025" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember" xlink:label="loc_eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember_1026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1025" xlink:to="loc_eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember_1026" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable_1017" xlink:to="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1019" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1020" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_1021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_1021" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_1022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_1022" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1023" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" xlink:label="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice_1027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice_1027" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice" xlink:label="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice_1028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice_1028" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice" xlink:label="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice_1029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice_1029" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice" xlink:label="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice_1030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice_1030" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" xlink:label="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice_1031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems_1018" xlink:to="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice_1031" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1033" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable_1034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1033" xlink:to="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable_1034" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MaturityPeriodWarrantsAxis" xlink:label="loc_eprx_MaturityPeriodWarrantsAxis_1038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable_1034" xlink:to="loc_eprx_MaturityPeriodWarrantsAxis_1038" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MaturityPeriodWarrantsDomain" xlink:label="loc_eprx_MaturityPeriodWarrantsDomain_1039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MaturityPeriodWarrantsAxis_1038" xlink:to="loc_eprx_MaturityPeriodWarrantsDomain_1039" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodOneMember" xlink:label="loc_eprx_ExpiryPeriodOneMember_1347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodOneMember_1347" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodTwoMember" xlink:label="loc_eprx_ExpiryPeriodTwoMember_1348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodTwoMember_1348" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodThreeMember" xlink:label="loc_eprx_ExpiryPeriodThreeMember_1349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodThreeMember_1349" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodFourMember" xlink:label="loc_eprx_ExpiryPeriodFourMember_1350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodFourMember_1350" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodFiveMember" xlink:label="loc_eprx_ExpiryPeriodFiveMember_1351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodFiveMember_1351" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodSixMember" xlink:label="loc_eprx_ExpiryPeriodSixMember_1352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodSixMember_1352" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodSevenMember" xlink:label="loc_eprx_ExpiryPeriodSevenMember_1353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodSevenMember_1353" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodEightMember" xlink:label="loc_eprx_ExpiryPeriodEightMember_1354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodEightMember_1354" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodNineMember" xlink:label="loc_eprx_ExpiryPeriodNineMember_1355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodNineMember_1355" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodTenMember" xlink:label="loc_eprx_ExpiryPeriodTenMember_1356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1039" xlink:to="loc_eprx_ExpiryPeriodTenMember_1356" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable_1034" xlink:to="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1035" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1035" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1358" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_1359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1035" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_1359" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice" xlink:label="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice_1036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1035" xlink:to="loc_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice_1036" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_1037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1035" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_1037" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1035" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1050" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1462" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable_1463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1462" xlink:to="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable_1463" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MaturityPeriodWarrantsAxis" xlink:label="loc_eprx_MaturityPeriodWarrantsAxis_1464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable_1463" xlink:to="loc_eprx_MaturityPeriodWarrantsAxis_1464" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_MaturityPeriodWarrantsDomain" xlink:label="loc_eprx_MaturityPeriodWarrantsDomain_1465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MaturityPeriodWarrantsAxis_1464" xlink:to="loc_eprx_MaturityPeriodWarrantsDomain_1465" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ExpiryPeriodThreeMember" xlink:label="loc_eprx_ExpiryPeriodThreeMember_1466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_MaturityPeriodWarrantsDomain_1465" xlink:to="loc_eprx_ExpiryPeriodThreeMember_1466" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable_1463" xlink:to="loc_us-gaap_AwardTypeAxis_1467" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1467" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1468" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember" xlink:label="loc_eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember_1469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1468" xlink:to="loc_eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember_1469" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems" xlink:label="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable_1463" xlink:to="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1470" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1470" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1471" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1470" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1472" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems_1470" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1473" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_758" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_758" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_759" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaap_GeneralInsuranceExpense_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_758" xlink:to="loc_us-gaap_GeneralInsuranceExpense_761" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaap_TravelAndEntertainmentExpense_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_758" xlink:to="loc_us-gaap_TravelAndEntertainmentExpense_762" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_758" xlink:to="loc_us-gaap_ProfessionalFees_763" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreOpeningCosts" xlink:label="loc_us-gaap_PreOpeningCosts_765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_758" xlink:to="loc_us-gaap_PreOpeningCosts_765" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaap_LaborAndRelatedExpense_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_758" xlink:to="loc_us-gaap_LaborAndRelatedExpense_766" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_758" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_768" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_758" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_769" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_811" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentExpensesTable" xlink:label="loc_eprx_ResearchAndDevelopmentExpensesTable_831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_811" xlink:to="loc_eprx_ResearchAndDevelopmentExpensesTable_831" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentExpensesAxis" xlink:label="loc_eprx_ResearchAndDevelopmentExpensesAxis_837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesTable_831" xlink:to="loc_eprx_ResearchAndDevelopmentExpensesAxis_837" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentExpensesDomain" xlink:label="loc_eprx_ResearchAndDevelopmentExpensesDomain_838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesAxis_837" xlink:to="loc_eprx_ResearchAndDevelopmentExpensesDomain_838" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PreclinicalMember" xlink:label="loc_eprx_PreclinicalMember_839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesDomain_838" xlink:to="loc_eprx_PreclinicalMember_839" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ClinicalMember" xlink:label="loc_eprx_ClinicalMember_840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesDomain_838" xlink:to="loc_eprx_ClinicalMember_840" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ManufacturingAndAnalyticaMember" xlink:label="loc_eprx_ManufacturingAndAnalyticaMember_841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesDomain_838" xlink:to="loc_eprx_ManufacturingAndAnalyticaMember_841" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RegulatoryMember" xlink:label="loc_eprx_RegulatoryMember_842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesDomain_838" xlink:to="loc_eprx_RegulatoryMember_842" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ConsultingMember" xlink:label="loc_eprx_ConsultingMember_843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesDomain_838" xlink:to="loc_eprx_ConsultingMember_843" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentExpensesLineItems" xlink:label="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesTable_831" xlink:to="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory" xlink:label="loc_eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory_1341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory_1341" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense" xlink:label="loc_eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense_844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense_844" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_845" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses" xlink:label="loc_eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses_846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses_846" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses" xlink:label="loc_eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses_847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses_847" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ResearchAndDevelopmentLicenseExpenses" xlink:label="loc_eprx_ResearchAndDevelopmentLicenseExpenses_1474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_eprx_ResearchAndDevelopmentLicenseExpenses_1474" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="loc_us-gaap_GovernmentAssistanceAmount_849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_us-gaap_GovernmentAssistanceAmount_849" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses" xlink:label="loc_eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses_851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses_851" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ResearchAndDevelopmentExpensesLineItems_832" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_853" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAbstract" xlink:label="loc_us-gaap_GovernmentAssistanceAbstract_703" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTable" xlink:label="loc_us-gaap_GovernmentAssistanceTable_1316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceAbstract_703" xlink:to="loc_us-gaap_GovernmentAssistanceTable_1316" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="loc_us-gaap_GovernmentAssistanceTypeAxis_1318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceTable_1316" xlink:to="loc_us-gaap_GovernmentAssistanceTypeAxis_1318" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain_1319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis_1318" xlink:to="loc_us-gaap_GovernmentAssistanceTypeDomain_1319" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember" xlink:label="loc_eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember_1320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceTypeDomain_1319" xlink:to="loc_eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember_1320" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceLineItems" xlink:label="loc_us-gaap_GovernmentAssistanceLineItems_1317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceTable_1316" xlink:to="loc_us-gaap_GovernmentAssistanceLineItems_1317" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfReimburseAssistanceToSupportSalaryCost" xlink:label="loc_eprx_PercentageOfReimburseAssistanceToSupportSalaryCost_715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceLineItems_1317" xlink:to="loc_eprx_PercentageOfReimburseAssistanceToSupportSalaryCost_715" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageOfReimburseAssistanceToSupportContractorFee" xlink:label="loc_eprx_PercentageOfReimburseAssistanceToSupportContractorFee_716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceLineItems_1317" xlink:to="loc_eprx_PercentageOfReimburseAssistanceToSupportContractorFee_716" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ReimbursementAssistanceMaximumForSalaryAndContractorCosts" xlink:label="loc_eprx_ReimbursementAssistanceMaximumForSalaryAndContractorCosts_1321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceLineItems_1317" xlink:to="loc_eprx_ReimbursementAssistanceMaximumForSalaryAndContractorCosts_1321" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="loc_us-gaap_GovernmentAssistanceAmount_718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceLineItems_1317" xlink:to="loc_us-gaap_GovernmentAssistanceAmount_718" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaap_GrantsReceivableCurrent_1241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceLineItems_1317" xlink:to="loc_us-gaap_GrantsReceivableCurrent_1241" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_GovernmentAssistanceAmountForResearchAndDevelopment" xlink:label="loc_eprx_GovernmentAssistanceAmountForResearchAndDevelopment_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceLineItems_1317" xlink:to="loc_eprx_GovernmentAssistanceAmountForResearchAndDevelopment_720" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAbstract" xlink:label="loc_us-gaap_GovernmentAssistanceAbstract_683" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTable" xlink:label="loc_us-gaap_GovernmentAssistanceTable_684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceAbstract_683" xlink:to="loc_us-gaap_GovernmentAssistanceTable_684" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceTable_684" xlink:to="loc_srt_StatementGeographicalAxis_685" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_685" xlink:to="loc_srt_SegmentGeographicalDomain_686" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="loc_us-gaap_GovernmentAssistanceTypeAxis_1323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceTable_684" xlink:to="loc_us-gaap_GovernmentAssistanceTypeAxis_1323" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain_1324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis_1323" xlink:to="loc_us-gaap_GovernmentAssistanceTypeDomain_1324" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember" xlink:label="loc_eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember_1325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceTypeDomain_1324" xlink:to="loc_eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember_1325" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_BioTalentCanadaMember" xlink:label="loc_eprx_BioTalentCanadaMember_1326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceTypeDomain_1324" xlink:to="loc_eprx_BioTalentCanadaMember_1326" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceLineItems" xlink:label="loc_us-gaap_GovernmentAssistanceLineItems_690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceTable_684" xlink:to="loc_us-gaap_GovernmentAssistanceLineItems_690" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmountCumulative" xlink:label="loc_us-gaap_GovernmentAssistanceAmountCumulative_693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceLineItems_690" xlink:to="loc_us-gaap_GovernmentAssistanceAmountCumulative_693" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsIncludedInLossBeforeTaxesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1479" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1479" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1480" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1479" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1481" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1479" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1482" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_1484" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_1484" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1485" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1485" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1486" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1485" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1487" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_1488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1485" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_1488" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_1489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_1484" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_1489" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_1489" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1490" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_1489" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1491" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_1492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_1489" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_1492" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_1493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_1484" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_1493" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_1493" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1494" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_1493" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1495" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_1493" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1496" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_879" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_879" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_882" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_879" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_883" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_879" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_884" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract" xlink:label="loc_eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract_1292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_879" xlink:to="loc_eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract_1292" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract_1292" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_887" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract_1292" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1497" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_1498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract_1292" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_1498" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_1499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract_1292" xlink:to="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_1499" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EffectiveIncomeTaxReconciliationShareIssuanceCosts" xlink:label="loc_eprx_EffectiveIncomeTaxReconciliationShareIssuanceCosts_886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract_1292" xlink:to="loc_eprx_EffectiveIncomeTaxReconciliationShareIssuanceCosts_886" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency" xlink:label="loc_eprx_EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency_1393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract_1292" xlink:to="loc_eprx_EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency_1393" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract_1292" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_889" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1502" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DeferredTaxAssetsConvertibleDebt" xlink:label="loc_eprx_DeferredTaxAssetsConvertibleDebt_1506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1502" xlink:to="loc_eprx_DeferredTaxAssetsConvertibleDebt_1506" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1502" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1507" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DeferredTaxAssetsLeaseObligation" xlink:label="loc_eprx_DeferredTaxAssetsLeaseObligation_1508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1502" xlink:to="loc_eprx_DeferredTaxAssetsLeaseObligation_1508" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1502" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1509" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DeferredTaxAssetsShareIssuanceCosts" xlink:label="loc_eprx_DeferredTaxAssetsShareIssuanceCosts_1510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1502" xlink:to="loc_eprx_DeferredTaxAssetsShareIssuanceCosts_1510" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1502" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1516" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1502" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1512" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1502" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1513" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1502" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1514" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1502" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1515" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_903" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NonCapitalLossesCarryForwardFutureYearsTable" xlink:label="loc_eprx_NonCapitalLossesCarryForwardFutureYearsTable_906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_903" xlink:to="loc_eprx_NonCapitalLossesCarryForwardFutureYearsTable_906" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NonCapitalLossesCarryForwardFutureYearsTable_906" xlink:to="loc_us-gaap_TaxPeriodAxis_907" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_907" xlink:to="loc_us-gaap_TaxPeriodDomain_908" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2031Member" xlink:label="loc_eprx_TaxYear2031Member_1384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2031Member_1384" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2032Member" xlink:label="loc_eprx_TaxYear2032Member_909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2032Member_909" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2033Member" xlink:label="loc_eprx_TaxYear2033Member_911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2033Member_911" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2034Member" xlink:label="loc_eprx_TaxYear2034Member_912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2034Member_912" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2035Member" xlink:label="loc_eprx_TaxYear2035Member_913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2035Member_913" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2036Member" xlink:label="loc_eprx_TaxYear2036Member_914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2036Member_914" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2037Member" xlink:label="loc_eprx_TaxYear2037Member_916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2037Member_916" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2038Member" xlink:label="loc_eprx_TaxYear2038Member_917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2038Member_917" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2039Member" xlink:label="loc_eprx_TaxYear2039Member_918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2039Member_918" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2040Member" xlink:label="loc_eprx_TaxYear2040Member_919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2040Member_919" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2041Member" xlink:label="loc_eprx_TaxYear2041Member_921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2041Member_921" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2042Member" xlink:label="loc_eprx_TaxYear2042Member_924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2042Member_924" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYear2043Member" xlink:label="loc_eprx_TaxYear2043Member_1385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYear2043Member_1385" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxYearAfter2043Member" xlink:label="loc_eprx_TaxYearAfter2043Member_1386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_908" xlink:to="loc_eprx_TaxYearAfter2043Member_1386" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NonCapitalLossesCarryForwardFutureYearsTable_906" xlink:to="loc_srt_StatementGeographicalAxis_1387" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1387" xlink:to="loc_srt_SegmentGeographicalDomain_1388" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="loc_country_CA_1389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1388" xlink:to="loc_country_CA_1389" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_country_US_1390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1388" xlink:to="loc_country_US_1390" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU" xlink:label="loc_country_AU_1391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1388" xlink:to="loc_country_AU_1391" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NonCapitalLossesCarryForwardFutureYearsLineItems" xlink:label="loc_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems_928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NonCapitalLossesCarryForwardFutureYearsTable_906" xlink:to="loc_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems_928" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NonCapitalLossCarryforwardsToFutureExpire" xlink:label="loc_eprx_NonCapitalLossCarryforwardsToFutureExpire_930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems_928" xlink:to="loc_eprx_NonCapitalLossCarryforwardsToFutureExpire_930" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_939" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_939" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_948" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_948" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_967" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_967" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_968" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CanadianFederalInvestmentTaxCreditsMember" xlink:label="loc_eprx_CanadianFederalInvestmentTaxCreditsMember_1306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_968" xlink:to="loc_eprx_CanadianFederalInvestmentTaxCreditsMember_1306" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ProvincialInvestmentTaxCreditsMember" xlink:label="loc_eprx_ProvincialInvestmentTaxCreditsMember_1307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_968" xlink:to="loc_eprx_ProvincialInvestmentTaxCreditsMember_1307" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_948" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_976" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_976" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_977" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember_1304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_977" xlink:to="loc_us-gaap_CanadaRevenueAgencyMember_1304" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RelevantPeriodAxis" xlink:label="loc_eprx_RelevantPeriodAxis_1328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_948" xlink:to="loc_eprx_RelevantPeriodAxis_1328" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_RelevantPeriodDomain" xlink:label="loc_eprx_RelevantPeriodDomain_1329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_RelevantPeriodAxis_1328" xlink:to="loc_eprx_RelevantPeriodDomain_1329" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_948" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1402" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1402" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1403" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1403" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1404" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_948" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_us-gaap_OperatingLossCarryforwards_952" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_956" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_TaxCreditCarryForwardsExpirationTerm" xlink:label="loc_eprx_TaxCreditCarryForwardsExpirationTerm_958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_eprx_TaxCreditCarryForwardsExpirationTerm_958" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1517" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_1518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_1518" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_1519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_949" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_1519" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/CommitmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_282" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_282" xlink:to="loc_us-gaap_OtherCommitmentsTable_283" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_283" xlink:to="loc_srt_RangeAxis_297" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_297" xlink:to="loc_srt_RangeMember_306" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_306" xlink:to="loc_srt_MinimumMember_298" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_306" xlink:to="loc_srt_MaximumMember_299" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_283" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_284" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CancellationFeeOnTerminationOfContract" xlink:label="loc_eprx_CancellationFeeOnTerminationOfContract_296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_284" xlink:to="loc_eprx_CancellationFeeOnTerminationOfContract_296" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CancellationFeeForCancellationOfContract" xlink:label="loc_eprx_CancellationFeeForCancellationOfContract_300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_284" xlink:to="loc_eprx_CancellationFeeForCancellationOfContract_300" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_869" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FinancialInstrumentsTable" xlink:label="loc_eprx_FinancialInstrumentsTable_941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_869" xlink:to="loc_eprx_FinancialInstrumentsTable_941" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsTable_941" xlink:to="loc_srt_CurrencyAxis_944" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_944" xlink:to="loc_currency_AllCurrenciesDomain_945" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD" xlink:label="loc_currency_CAD_946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_945" xlink:to="loc_currency_CAD_946" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsTable_941" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1000" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1000" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1001" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_1002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1001" xlink:to="loc_us-gaap_ConvertibleDebtMember_1002" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_EquipmentLoanMember" xlink:label="loc_eprx_EquipmentLoanMember_1280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1001" xlink:to="loc_eprx_EquipmentLoanMember_1280" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CurrencyRiskMember" xlink:label="loc_eprx_CurrencyRiskMember_1376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1001" xlink:to="loc_eprx_CurrencyRiskMember_1376" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsTable_941" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_951" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_951" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_953" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_953" xlink:to="loc_us-gaap_EquipmentMember_955" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LenderAxis" xlink:label="loc_eprx_LenderAxis_957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsTable_941" xlink:to="loc_eprx_LenderAxis_957" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LenderDomain" xlink:label="loc_eprx_LenderDomain_960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LenderAxis_957" xlink:to="loc_eprx_LenderDomain_960" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SiliconValleyBankMember" xlink:label="loc_eprx_SiliconValleyBankMember_963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_LenderDomain_960" xlink:to="loc_eprx_SiliconValleyBankMember_963" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsTable_941" xlink:to="loc_us-gaap_VariableRateAxis_964" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_964" xlink:to="loc_us-gaap_VariableRateDomain_965" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_CanadianPrimeRateMember" xlink:label="loc_eprx_CanadianPrimeRateMember_970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_965" xlink:to="loc_eprx_CanadianPrimeRateMember_970" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsTable_941" xlink:to="loc_srt_RangeAxis_973" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_973" xlink:to="loc_srt_RangeMember_974" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_974" xlink:to="loc_srt_MinimumMember_975" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FinancialInstrumentsLineItems" xlink:label="loc_eprx_FinancialInstrumentsLineItems_982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsTable_941" xlink:to="loc_eprx_FinancialInstrumentsLineItems_982" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_983" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_us-gaap_LiabilitiesCurrent_984" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_985" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaap_OtherLongTermDebt_986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_us-gaap_OtherLongTermDebt_986" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_LongTermDebtPaidInKindInterestPercentage" xlink:label="loc_eprx_LongTermDebtPaidInKindInterestPercentage_989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_eprx_LongTermDebtPaidInKindInterestPercentage_989" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_us-gaap_Cash_993" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_us-gaap_AccountsPayableCurrent_994" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_997" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_1285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_1285" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_1286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_1286" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate" xlink:label="loc_eprx_SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate_1287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_eprx_SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate_1287" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax" xlink:label="loc_eprx_SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax_1288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_eprx_SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax_1288" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageIncreaseInSignificantUnobservableInputAssets" xlink:label="loc_eprx_PercentageIncreaseInSignificantUnobservableInputAssets_1289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_eprx_PercentageIncreaseInSignificantUnobservableInputAssets_1289" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PercentageIncreaseInSignificantUnobservableInputLiabilities" xlink:label="loc_eprx_PercentageIncreaseInSignificantUnobservableInputLiabilities_1290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_eprx_PercentageIncreaseInSignificantUnobservableInputLiabilities_1290" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates" xlink:label="loc_eprx_ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates_1291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_eprx_ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates_1291" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PayableTowardsRoyaltyAndOthersCurrent" xlink:label="loc_eprx_PayableTowardsRoyaltyAndOthersCurrent_1520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_FinancialInstrumentsLineItems_982" xlink:to="loc_eprx_PayableTowardsRoyaltyAndOthersCurrent_1520" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfCarryingValueOfFinancialInstrumentsAtAmortizedCostDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_427" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTable" xlink:label="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTable_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_427" xlink:to="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTable_429" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems" xlink:label="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems_441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTable_429" xlink:to="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems_441" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems_441" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1269" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="loc_us-gaap_NontradeReceivablesCurrent_1418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems_441" xlink:to="loc_us-gaap_NontradeReceivablesCurrent_1418" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_AccountsPayableAndAccruedLiability" xlink:label="loc_eprx_AccountsPayableAndAccruedLiability_1377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems_441" xlink:to="loc_eprx_AccountsPayableAndAccruedLiability_1377" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_PayableTowardsRoyaltyAndOthersCurrent" xlink:label="loc_eprx_PayableTowardsRoyaltyAndOthersCurrent_1521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems_441" xlink:to="loc_eprx_PayableTowardsRoyaltyAndOthersCurrent_1521" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaap_OtherLongTermDebt_1271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems_441" xlink:to="loc_us-gaap_OtherLongTermDebt_1271" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_823" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_823" xlink:to="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_825" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_825" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_863" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_863" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_866" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_825" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1365" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1365" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1366" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1366" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1367" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems" xlink:label="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable_825" xlink:to="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_828" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_828" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_829" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod" xlink:label="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod_830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_828" xlink:to="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod_830" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod" xlink:label="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod_848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_828" xlink:to="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod_848" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_828" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_850" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss" xlink:label="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss_861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_828" xlink:to="loc_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss_861" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems_828" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_862" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/InterestExpenseScheduleOfInterestExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseAbstract" xlink:label="loc_us-gaap_InterestExpenseAbstract_217" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseAbstract_217" xlink:to="loc_us-gaap_InterestExpenseDebt_220" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_OtherInterestAndAccretionExpense" xlink:label="loc_eprx_OtherInterestAndAccretionExpense_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseAbstract_217" xlink:to="loc_eprx_OtherInterestAndAccretionExpense_221" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseAbstract_217" xlink:to="loc_us-gaap_InterestExpense_222" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_170" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_170" xlink:to="loc_us-gaap_StatementTable_174" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_174" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_175" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_175" xlink:to="loc_us-gaap_EquityComponentDomain_176" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_176" xlink:to="loc_us-gaap_CommonStockMember_177" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_174" xlink:to="loc_us-gaap_StatementLineItems_182" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_1222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_182" xlink:to="loc_us-gaap_InterestPaidNet_1222" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_182" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_185" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_182" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1225" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_182" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1226" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NumberofWarrantsIssued" xlink:label="loc_eprx_NumberofWarrantsIssued_1228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_182" xlink:to="loc_eprx_NumberofWarrantsIssued_1228" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_182" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_189" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsSummaryOfDetailedBreakdownOfCashAndCashEquivalentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_150" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_150" xlink:to="loc_us-gaap_Cash_154" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_150" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_156" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_150" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_681" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_114" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_114" xlink:to="loc_us-gaap_SubsequentEventTable_115" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_115" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1229" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1229" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1230" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1230" xlink:to="loc_us-gaap_SubsequentEventMember_1231" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_115" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_116" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_116" xlink:to="loc_us-gaap_EquityComponentDomain_117" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_115" xlink:to="loc_srt_CurrencyAxis_119" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_119" xlink:to="loc_currency_AllCurrenciesDomain_120" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_115" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1379" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1379" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1380" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1380" xlink:to="loc_us-gaap_IPOMember_1411" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_1381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1380" xlink:to="loc_us-gaap_OverAllotmentOptionMember_1381" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_115" xlink:to="loc_us-gaap_SubsequentEventLineItems_133" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_133" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1408" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_133" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1410" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_NumberOfUnitsIssued" xlink:label="loc_eprx_NumberOfUnitsIssued_1382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_133" xlink:to="loc_eprx_NumberOfUnitsIssued_1382" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="eprx-20231231.xsd#eprx_SecuritiesIssuedPricePerUnit" xlink:label="loc_eprx_SecuritiesIssuedPricePerUnit_1383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_133" xlink:to="loc_eprx_SecuritiesIssuedPricePerUnit_1383" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g800041g01e01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g800041g01e01.jpg
M_]C_X0=X17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    )    L8=I  0    !    O    .@ +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P(#(U+C0@*%=I;F1O=W,I #(P,C0Z,#,Z,S @
M,#DZ,#0Z,3< <G(T,34P,S0      Z !  ,    !__\  * "  0    !   !
MBJ #  0    !    9P         & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M140N9&]C>#A"24T$)0      $/(@M%#31+E+W7<&MM,*8"(X0DE-!#H
M .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
M  !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG
M3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F14
M56YT1B-2;'0               !";&0@56YT1B-2;'0               !2
M<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0
M<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M     %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M        $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O
M;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T
M4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M    $ $L     0 ! 2P    !  $X0DE-!"8       X             /X
M #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S       )
M           ! #A"24TG$       "@ !          $X0DE- _4      $@
M+V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@
M  8       $ -0    $ +0    8       $X0DE- _@      '   /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z   .$))300(       0     0   D    )      #A"
M24T$1       $     (   )    "0      X0DE-!!X       0     .$))
M300:      -W    !@              9P   8H    A $4 =0!P '( 80!X
M &D 80 @ "T (  R #  ,@ S "  00!) $8 ( !4 $\ ( !" $4 ( !& $D
M3 !% $0 +0 Q     0                         !              &*
M    9P                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M    9P    !29VAT;&]N9P   8H    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   &<     4F=H=&QO
M;F<   &*     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    ".$))300,      9&     0   %\    9   !(   '"    8J !@
M ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  9 %\# 2(
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M &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
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M :(    & @,!              <(!@4$"0,* @$ "P$   8# 0$!
M    !@4$ P<"" $)  H+$  " 0,$ 0,# @,# P(&"74! @,$$042!B$'$R(
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MAJT[?D:?X.I0MN6=@M$T1;5"?FRAR?S:IZ9,_P!4[-SL4FG&IBJQM;)6XO\
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MC4TH 3CJIG_H*6_E9_\ *U\D?_1$Y7_Z]>UO[IN_X?Y-_P! ]!3_ %S>6/\
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M<TX&M/*H-''_ $"/?$G_ +RL^3G_ )S]6?\ V%^S/]^W/^^U_GT O]9[8O\
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MR=P[!QK&)W89*@6GW-1PZTC3Q920*6<W+-ZM0"MU'\#<:?/S_:>)]:#AT/\
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M;K?[YKNX[8E%(T!J$7R ]2>+-Q8_*@'2#V=]H^7O9WE*#ES9OUMPD(DO+ME
MEN[BE#(V3I11VPQ Z(H\"K%W>H#_ (5 ?]NI-X_^)TZ"_P#>Y@]IMJ_W-B_+
M_".CCW+_ .55NOM/_5N3HB'_  D+_P"9-_.;_P 35U7_ .^XJ_:O??[>/_5^
M%>@_[0?\DF[_ -I_Q^?K<*]D74O]4<?\* ?GN_PB^"&Z<+LO-'&][_)MLITE
MU(::0)D<'0Y7&,W9O8E.#&^A-D;+J76"561XLMD: @\\+]NMC<W*+3L!J?\
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M0D]@S4KGKA/[E;QOD?N7[CQQ\P;DD2[_ 'X55N[E54"YDH%590  ,    4
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M8O\ ]C'LOT;/_$/VIT-OJ?=#_?<W^\7/^;KW]]O^%4'_ "K?S#O_ $7>Q?\
M[&/?M&S_ ,0_:G7OJ?=#_?<W^\7/^;K99_D%9K^9[F>O/DPW\R^#O>+/4_8V
MR$Z>;OG ;>P.9?;LFT*AMUC;\6$Q^.FJ<.F9%/K:9&43EA&WZP"B_%L'7Z8C
M3_M?0?P_.O'/Y4ZD[DJ3?Y+2<[^KB<!::A*,ZI*T\7/P^'\/9_MM75:/_"OH
MC^Z_P 'Y_OG\AS;\V_NSUB+_ .M?VOV'^TE^T?X&Z!?O)_N)M'V3?\?M^K8O
M^$WW_;H7XU_3_B]=U?0@_P#-:=]_6WT/M'N_^YTG^E7_ (Z.A;[:?\JA8_\
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M]F[3P.^^O]\82OVWN_9^Z,;39? ;BP63@:GKL9E,=5QR05%/-&WY&I6 92&
M(2JQ4AE-".A!/!#<Q207$8>%A0@\#_L^8/$'(SUK@]I_\)3OY>&\<])E^MM^
M?([I#&U%775,VTML[[PF\=MTL%0T;4>/PI['VQNC<&-H<:%98U>OJ&96LS'2
M#[-H]YNXQ0T;]O\ GH/L '4;7WM3RY=R"2.2:(>@*G_C176Q]2[.3YFN>@Q_
MZ!(OAQ_WE%\J?^I_4O\ ]KGVY^_;K_?:_P ^D7^L_L'_ "FW'_&?\W2AVO\
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MD2-QZ6=3T/NE)F6#(8:JA !2:1ZB!R3^I3$8)-.FW^J-_:4;I;$5*N#]@/\
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M9E/B,WN_+Y# U-!B\.D6.IJZLP\\,E4576TY8N2?I(>[\[,UW3;K6UDM1%&
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M6_9=/N[INCZDWKLW?^ZZS9=3AFV_N:IW)AL[@\O2X^OBJ8:MJYHYXG1F!CX
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M:FJG]G4?\X^U7MQ[@"O.7)EA?S4H))(@)@ * "=-,R@#A1Q3K5D_F ].=?\
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'O>_=>Z__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g800041g0319193556635.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g800041g0319193556635.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "2 FX# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ/DK:/OT.YHH!!&1R#17.>R%%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0OB/XC\.:5'ING7$*6T99E#0JQR3D\GZUJU='GT:BIS;9]2T5\V?\+D\8_\
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M,2/T(KLZBMK:*SM8K:! D,2!$4=  , 5+63W/1C'EBD?'WB#_D8]2_Z^I/\
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MWTJ^EB<95X[=V4CV(%2_\(WKW_0%U+_P%?\ PKZWM;:&RM(;6W0)#"@1%'0
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MN^!M8%S:/ILK[I+?F,G^)/\ ZW]:Z?[':@8%M#_W[%9TOAZV.LPZG!(UO-&
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M?]!*[_,5JZ+X<L]$,CPM))+)PTDAYQ5+EBG9W,)*O6G#FARI.^]S8HHHK(]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!Y1XK4?\ "2WG ^\.W^R*H::J
M_P!I6W _U@[>]%%>A'X#XZM_O$O\3_,]FHHHKSS[$**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
>HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g800041g07j01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g800041g07j01.jpg
M_]C_X1<V17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    ?    <@$R  (    4
M    D8=I  0    !    J    -0 #J8    G$  .I@   "<0061O8F4@4&AO
M=&]S:&]P(#(U+C4@*%=I;F1O=W,I #(P,C0Z,#,Z,C<@,3$Z-#8Z-#@
M  .@ 0 #     ?__  "@ @ $     0   S2@ P $     0   @$
M!@$#  ,    !  8   $:  4    !   !(@$;  4    !   !*@$H  ,    !
M  (   (!  0    !   !,@("  0    !   5_         !(     0   $@
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M\6KO[!Z7_P!PA_X)_P"E%5<R]OJ!O2+[A6!ML%UE?J$C\RE]KW5?]<L_1_\
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M(:'#;[?6;K.[?!_X/:W_ #TE-G_F]T?_ +C_ /3?_P"32_YO='_[C_\ 3?\
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M8$O^;70/^X%'^8$E-']G=2_[G97_ &QB_P#O&E^SNI?]SLK_ +8Q?_>-7O\
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MZI)J7Z*_[(?^[W_L@E_V0_\ =[_V07SJDDI^BO\ LA_[O?\ L@E_V0_]WO\
MV07SJDDI^BO^R'_N]_[((.7^U?0_7OMOV7?7ZO\ 0>-[/W/?_7V?I/\ 1?I5
M\]I)*?_9_^T?&%!H;W1O<VAO<" S+C  .$))300E       0
M         #A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 &     !  $ 8     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))301$       0     @   D    )      #A"
M24T$'@      !      X0DE-!!H      T<    &              (!   #
M-     D 0P!A '  = !U '( 90 @ #$    !
M  $              S0   (!                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   (!     %)G:'1L;VYG   #-     9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   " 0    !29VAT;&]N9P   S0    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     ,X0DE-! P     %A@    !    H    &0
M  '@  "[@   %?P &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( &0 H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
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M,N#I@G3^?:[=M_DI_LE4_P#)=Y$P(N;/+F[G3D-9M]N_VO\ \(DIA^P>E_\
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MSLK_ +8Q?_>-7O\ FUT#_N!1_F!+_FUT#_N!1_F!)31_9W4O^YV5_P!L8O\
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MJ2F__P U?J__ -PF?>[_ ,DE_P U?J__ -PF?>[_ ,DJM>!@VW,I9F=4W/,
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    % !! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <  @ #( ,  R #0    ! #A"24T$!@      !P (
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\
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M^]5O47_HC=^__=/>_=>Z]_PZ!_PKT_[U6]1?^B-W[_\ =/>_=>Z]_P .@?\
M"O3_ +U6]1?^B-W[_P#=/>_=>Z]_PZ!_PKT_[U6]1?\ HC=^_P#W3WOW7NO?
M\.@?\*]/^]5O47_HC=^__=/>_=>Z]_PZ!_PKT_[U6]1?^B-W[_\ =/>_=>Z]
M_P .@?\ "O3_ +U6]1?^B-W[_P#=/>_=>Z]_PZ!_PKT_[U6]1?\ HC=^_P#W
M3WOW7NO?\.@?\*]/^]5O47_HC=^__=/>_=>Z]_PZ!_PKT_[U6]1?^B-W[_\
M=/>_=>Z]_P .@?\ "O3_ +U6]1?^B-W[_P#=/>_=>Z]_PZ!_PKT_[U6]1?\
MHC=^_P#W3WOW7NO?\.@?\*]/^]5O47_HC=^__=/>_=>Z]_PZ!_PKT_[U6]1?
M^B-W[_\ =/>_=>Z]_P .@?\ "O3_ +U6]1?^B-W[_P#=/>_=>Z]_PZ!_PKT_
M[U6]1?\ HC=^_P#W3WOW7NO?\.@?\*]/^]5O47_HC=^__=/>_=>Z]_PZ!_PK
MT_[U6]1?^B-W[_\ =/>_=>Z]_P .@?\ "O3_ +U6]1?^B-W[_P#=/>_=>Z]_
MPZ!_PKT_[U6]1?\ HC=^_P#W3WOW7NO?\.@?\*]/^]5O47_HC=^__=/>_=>Z
M]_PZ!_PKT_[U6]1?^B-W[_\ =/>_=>Z]_P .@?\ "O3_ +U6]1?^B-W[_P#=
M/>_=>Z]_PZ!_PKT_[U6]1?\ HC=^_P#W3WOW7NO?\.@?\*]/^]5O47_HC=^_
M_=/>_=>Z]_PZ!_PKT_[U6]1?^B-W[_\ =/>_=>Z]_P .@?\ "O3_ +U6]1?^
MB-W[_P#=/>_=>Z]_PZ!_PKT_[U6]1?\ HC=^_P#W3WOW7NO?\.@?\*]/^]5O
M47_HC=^__=/>_=>Z]_PZ!_PKT_[U6]1?^B-W[_\ =/>_=>Z]_P .@?\ "O3_
M +U6]1?^B-W[_P#=/>_=>Z]_PZ!_PKT_[U6]1?\ HC=^_P#W3WOW7NO?\.@?
M\*]/^]5O47_HC=^__=/>_=>Z]_PZ!_PKT_[U6]1?^B-W[_\ =/>_=>Z]_P .
M@?\ "O3_ +U6]1?^B-W[_P#=/>_=>Z]_PZ!_PKT_[U6]1?\ HC=^_P#W3WOW
M7NO?\.@?\*]/^]5O47_HC=^__=/>_=>Z]_PZ!_PKT_[U6]1?^B-W[_\ =/>_
M=>Z]_P .@?\ "O3_ +U6]1?^B-W[_P#=/>_=>Z]_PZ!_PKT_[U6]1?\ HC=^
M_P#W3WOW7NO?\.@?\*]/^]5O47_HC=^__=/>_=>Z]_PZ!_PKT_[U6]1?^B-W
M[_\ =/>_=>Z]_P .@?\ "O3_ +U6]1?^B-W[_P#=/>_=>Z]_PZ!_PKT_[U6]
M1?\ HC=^_P#W3WOW7NO?\.@?\*]/^]5O47_HC=^__=/>_=>Z]_PZ!_PKT_[U
M6]1?^B-W[_\ =/>_=>Z]_P .@?\ "O3_ +U6]1?^B-W[_P#=/>_=>Z]_PZ!_
MPKT_[U6]1?\ HC=^_P#W3WOW7NO?\.@?\*]/^]5O47_HC=^__=/>_=>Z]_PZ
M!_PKT_[U6]1?^B-W[_\ =/>_=>Z]_P .@?\ "O3_ +U6]1?^B-W[_P#=/>_=
M>Z]_PZ!_PKT_[U6]1?\ HC=^_P#W3WOW7NO?\.@?\*]/^]5O47_HC=^__=/>
M_=>Z]_PZ!_PKT_[U6]1?^B-W[_\ =/>_=>Z]_P .@?\ "O3_ +U6]1?^B-W[
M_P#=/>_=>Z]_PZ!_PKT_[U6]1?\ HC=^_P#W3WOW7NO?\.@?\*]/^]5O47_H
MC=^__=/>_=>Z]_PZ!_PKT_[U6]1?^B-W[_\ =/>_=>Z]_P .@?\ "O3_ +U6
M]1?^B-W[_P#=/>_=>Z]_PZ!_PKT_[U6]1?\ HC=^_P#W3WOW7NO?\.@?\*]/
M^]5O47_HC=^__=/>_=>Z]_PZ!_PKT_[U6]1?^B-W[_\ =/>_=>Z]_P .@?\
M"O3_ +U6]1?^B-W[_P#=/>_=>Z]_PZ!_PKT_[U6]1?\ HC=^_P#W3WOW7NO?
M\.@?\*]/^]5O47_HC=^__=/>_=>Z]_PZ!_PKT_[U6]1?^B-W[_\ =/>_=>Z]
M_P .@?\ "O3_ +U6]1?^B-W[_P#=/>_=>Z]_PZ!_PKT_[U6]1?\ HC=^_P#W
M3WOW7NO?\.@?\*]/^]5O47_HC=^__=/>_=>Z]_PZ!_PKT_[U6]1?^B-W[_\
M=/>_=>Z]_P .@?\ "O3_ +U6]1?^B-W[_P#=/>_=>Z]_PZ!_PKT_[U6]1?\
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M;'_RAG_>W_S]>^ONO]^?R'^;KW^D7>/_ #M8O_/=0?\ 7CW[^K&Q_P#*&?\
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M71BC,E&)18WL&XVR7EMJ-LY;0Q%-:!BJ2+_0E4"2,FA*,I(!) !=_P#.2_\
M+:;_ *VO[F5?A3_2C_ .@[YG[3UQ][ZUU[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW6O)\@OE#ONK_ )C/S&Z&WW_.0V?_ "RNJ>D=E?%;*=/;.W/M
M+X9SR]D5G:_6>2W)V1E:3-?):AAS^6&!SE!3ZTH:B>&F%>JN(P8U(%AN[FYB
MW:Y;F"!;N/=I[<0.8$,<$=M:21R9C9V\22:9:L*?IT4G(!_?6\-LG+*1;8Y2
MXVHSR2C60TWU<\.GB%4^&BF@XT)IQ)/GT=\E=F=6[$^.&$S_ ,TLG_,F?Y7?
M);+]%];?)38^"^/&-VSA-SQ;'SF[IMLYW_0-6T&PY=N[:I=EU:S3TJUF8%;6
MI'+'XP"@EL;QWNMFV:6)1>3;?>W8E4ZHYHK37([U 0!J P)H0QEHCK8-J(#L
MR_3Q;KN37)>V2\LX/"HH:%[HB) *5)4M^J^LZ@KC0"M!TJ.^_P"8_P!'?'*F
M^9%=O_:W9=5C_@Y@/C?N?MZMV_CMOUB9K#_)VI-/LZ;8T%1G::JR,VUT5I<Q
M'5)3/H6U(*ER%*2XYBL[9;>682+#+O:;6"$+E9G2U?Q"J$L\=+J, (#(6# 1
MMVZC8;5=NT*1!7EDVFXW!5!I6*VEDB:.K442N\1T5(CH07=<TP;-_F/=7;CS
M?86U=Y]*?)GH3=NUNDNR/DGUOMWOSKK%;$J_D?T1U;C7RNZ=^=,U<.Y\OCA7
MTE(]+)/M[/RX?<..@KZ>:MHX(W8I2?F&*RVSF?<+^(QS[.FN[M\&>!"64.RA
MBCQB13"[H_9-IC<*70LU9V+[A?<O6EFX>WW6816L]&\*20@,4R!(K>&?%4,@
M\2,,R5TD!)[6_FC]<[MZ9VEWCC_C%\R$VUW'E.O]O_%;;*=6;>R?8'R[W#V!
ML[-;WCI>F-LXK>E6V'V]M'$;>JGS&>W=+MW"T].J5<=1)32)(5-YNS6LJ6:6
M[R[F\D](0 KI;6\<<QO)=3A(X)8I%>)9'2:H,3QK+I1DUJB74-S=F=(]MA5
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MJJS:M*@L+-_=.M=>]^Z]UK"_\*[_ /MS7OK_ ,3YT1_[T.0]^Z]U=M_W3_\
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MFWMBZ:IRR5-"U-CZ6JK999F0E@L+Z78=RY7N[V)'O^9 7D"HUO:V4UG''+-
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M'_@/[.O5'KU[RQ?\=8_^2U_XK[]H?^ _LZ]4>O7O+%_QUC_Y+7_BOOVA_P"
M_LZ]4>O7O+%_QUC_ .2U_P"*^_:'_@/[.O5'KU[RQ?\ '6/_ )+7_BOOVA_X
M#^SKU1Z]>\L7_'6/_DM?^*^_:'_@/[.O5'KU[RQ?\=8_^2U_XK[]H?\ @/[.
MO5'KU[RQ?\=8_P#DM?\ BOOVA_X#^SKU1Z]>\L7_ !UC_P"2U_XK[]H?^ _L
MZ]4>O7O+%_QUC_Y+7_BOOVA_X#^SKU1Z]>\L7_'6/_DM?^*^_:'_ (#^SKU1
MZ]>\L7_'6/\ Y+7_ (K[]H?^ _LZ]4>O7O+%_P =8_\ DM?^*^_:'_@/[.O5
M'KU[RQ?\=8_^2U_XK[]H?^ _LZ]4>O7O+%_QUC_Y+7_BOOVA_P" _LZ]4>O7
MO+%_QUC_ .2U_P"*^_:'_@/[.O5'KU[RQ?\ '6/_ )+7_BOOVA_X#^SKU1Z]
M>\L7_'6/_DM?^*^_:'_@/[.O5'KU[RQ?\=8_^2U_XK[]H?\ @/[.O5'KU[RQ
M?\=8_P#DM?\ BOOVA_X#^SKU1Z]>\L7_ !UC_P"2U_XK[]H?^ _LZ]4>O7O+
M%_QUC_Y+7_BOOVA_X#^SKU1Z]>\L7_'6/_DM?^*^_:'_ (#^SKU1Z]>\L7_'
M6/\ Y+7_ (K[]H?^ _LZ]4>O7O+%_P =8_\ DM?^*^_:'_@/[.O5'KUCEEB\
M4O[L?^;?^VO^I/\ C[LB/K3L/$>76B10YZ./B/\ BTXO_M747_N-%[@Z]_W,
MN_\ FJW_ !X]"N'^RB_TH_P=./M-TYU[W[KW0;];=.]4].0[RINJ.N]G=<TW
M8G8&YNUM]4^S-OXW;U/NWLO><E--NW?>?AQE/3QY+=6Y)J.)ZVME#3U+Q@NQ
M(O[LK,MK8V2M2SMHO#A0?!%'K9]$:\$36[L%4!06) SUYSXEQ<7;YN92I=OQ
M.554!8\68(JKJ-20!4]"1[KU[KWOW7NO>_=>Z][]U[KWOW7NBS]B,R;RR#HQ
M5E@QI5A]012)8^Y5Y:19-AMT=04+2 @\""QQT'K^HNW(.<?X!T4#8?Q!^(_5
M?:&;[PZO^+7Q\ZX[HW)_%/X]VOLCJC:&V]^Y$YQ]>;<[@QF-@J:*3,M_P+:E
M\#5%R'+!FNOV_:K3:HYK?;T\*UDIJC4*JD E@&TJ&9=1U:79E+48BH!">ZFE
MOI8I[US+.GPLYU$$#2"*^84 !OB'KQZ'+.X+";IP6;VON;$8[<&V=RX?)[>W
M'M_+TT=;B,]@,W0SXS,X3*T4H,59C,KC:J6GJ(F],D4C*>#[47ME:[C:7%C?
M0)+:2H5=& 964BA!4@@CY$$>HZM;W%Q9W$-U:3-'<QL&1U-&5E-0RD9!!R#Z
M](W"].]1[;R'7>7V]UCL?!Y7J#8M?U=U+D<7@*2EK.L>M,I#B*;*; V+,BZM
MN[4R5-MZ@BGI(-*21T4*GA /;OA?XW>7[,3>7,:I,Y U3*CB1!(U*L%D =14
M*&HU*@43+'&D%M:I&!;02-)&@^&-W4H[H. 9D9D)XE6(X$])ONWXT_&_Y,X?
M#[>^2'0'3O?F#V[7RY3;N-[;V!M_>L>W\C/$T%15X.HRU)+78EZJ%RLRP2QQ
MS"VM6(%D-YM%A?31W,T"_4J*!]*DZ?0ZE8$?:.E45U<0QR0Q3LL+$$J"0"1P
M-/7RKQICH4-M;9VSLK;N#V=LK;6W]F;/VOBZ7";8VEM/#8_;NV=N86A3QT>)
MP>#Q-/2X[&4%,OZ8XHU%R6-V)),R7=FDDD9Y6-2S&I)I3)/H   ,*H"J H "
M.*&&"-8H(E2(< HH,Y/YDY).2<DD])-.G.HHY^W*N/K'9$57\@(UA[WJXL%2
MQU/<L*;:;9B1=CS(%?<R)L]SBP)CQ0$Q?I/LM?:=ODV^XVE[9#M<LDDAB*KX
M>N;3XKZ=-"TFA"Y;5JTK6H%.E:7-Q%>V^Y1S,NXQ1I&DH)$BQQ%C$BMQ"QEW
M* ?"6)''I/\ 8OQP^/'<'6&%Z0[9Z-ZM[*Z5VW_=P;=ZDWGM+'YGKS!C9V-E
MPVT%Q>V9E%!1IM;$3O34"JMJ:%BJBWMS<]OM]XE6XW%1-=B5I!(ZH[^(X8.]
M75@&<,VH@ FI' GJEC(^V0/:[<W@6K1B,HG:IC#*X0@?A#HK4_B4'B.@,V9_
M+/\ Y</7&[=M;_Z]^!GQ1V/OO9><QFY]G;RVQU!M[%[CVMN7"5D60PVX,#DX
M4\V/R^)KX(YZ>=/7%*BLO('MNQVR/;KA;JSF:.8*ZU58E)61&CD4E8P=+QLR
M, 156(X'K5PWU43P7(\2%J55JD&AJ*@GR(!'S'0J=G_$+XD]W[]V[VKW5\7/
MC]VYVAM'^'_W8[$[&ZJVENO>.'&)JHZW$K%F\ICIJJLCQ=7$LE,E49T@*@(%
M46]ZCVFR@W!MTM8Q#?,02Z*H8D#2#J*EE('PLA4J<@AL].RW-Q/:BRGF9[,:
M@$8DJ WQ "N WF.!],GK#WG\._B/\H,M@,]\EOC'T?W_ )O:>+FP6U<KVSL+
M%;OK=M82IJFKJC#X.6O7_<;C9ZUC*T,8"%^;<#VU<['MUS<O>- HN64*S:(V
M9@I8KJ9T8FA9B,\6)XD];2[N(X([9)F%LA)5 2%4D*"544 J%4&GDJC@!TW]
M)_"7X9?&C<V0WM\<?BCT%T/O/+82HVSE=U]4]=X?:.?R6VZRJHZZKP-9DL>H
MGFQ-56X^GFDA)TM) C'E1[66-FNWQW$-O*P@E*EUHBJQ0DH2$1:E=3::UI4]
M)I@MQ)!-,@::+5H8U)74-+::G&H8/RQT-FX.O-@;LW)L+>>ZME;9W'O#JK*Y
MC/=7[HS.*IZ[.]=YS<6&EVYN#,;.R$H,V$R.;V].]#52Q$--2N8SP?;AMH?K
M$OU0"[6&2'6 -1BETF2(L06T.40LH(#%5K6G5S([0-:LQ-LTD<A7\)DB+&)Z
M<-499BA_#J-./2P]O]4Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NA<ZB_X'YW_J#Q__ %NJ_8+YT_W'V_\ T[_X%Z-=K^.;[!_EZ5FY.G>J
M=X]B=;]N;KZ[V=N/M#IV'>%/U3O_ #6W\;DMV]<P]A8NDPF^5V9G*JGEK]N_
MWMPU##29 TKQFJIHQ'(63CV 8)'MGO)+=BCW$*Q2D8+Q+()5C;U02*'"G&H
M\1T<2#QHXH9>Z%)1(JG@) K*'IPU!68 \0&-*5/0D>Z=;Z][]U[K6%_X5W_]
MN:]]?^)\Z(_]Z'(>_=>ZNV_[I_\ _EG?_P Q7W[KW7__U# _S-/E+UY\+_\
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M^^_?47'^_P!_]Z/^?KVA?X1U[_H)I_EQ?\^F^</_ *1UOK_K[[]]1<?[_?\
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M^</_ *1UOK_K[[]]1<?[_?\ WH_Y^O:%_A'7O^@FG^7%_P ^F^</_I'6^O\
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M>"."/^!'X]NUOO6;_C75?TOZ/\NO?]!._P#+6_Y]E\U__20=Z_\ U1[]6_\
M6;_C77OTOZ/\NO?]!._\M;_GV7S7_P#20=Z__5'OU;_UF_XUU[]+^C_+KW_0
M3O\ RUO^?9?-?_TD'>O_ -4>_5O_ %F_XUU[]+^C_+KW_03O_+6_Y]E\U_\
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M^^<7_I).^_\ ZK]^\"?_ 'R_[#U[6O\ $.O?]!0O\N/_ )]]\XO_ $DG??\
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M_P!=/?OW[S%_RDR_[P/^@>O?1V7^^U_:?\_7O^@D7^5G_P ^C^;?_I*/8_\
M]=/?OW[S%_RDR_[P/^@>O?1V7^^U_:?\_4D?\*.?Y7S ,O3/SC96 ((^)79A
M!!%P01D;$$>VCS'O@)!OVK_I5_Z!ZM]#:?[Y'[3_ )^N_P#H(X_E@?\ /E_G
M)_Z23V9_]<??OZR;W_RGM^Q?^@>O?0VG^^1^T_Y^G7$_\*5/Y:N"DGEQ/4?S
MGHY*E(XYV3XC=CN9$B9VC4B:MD TM(?I;Z^T=YNE_N"QI>7)=4)(J *$TKP
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M?\[W,_\ GTK?^O\ []^[-M_Z-\'_ #C3_-U[Q9?]^-^T]>_O%N#_ )WN9_\
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M?YNO>++_ +\;]IZ]_>+<'_.]S/\ Y]*W_K_[]^[-M_Z-\'_.-/\ -U[Q9?\
M?C?M/7O[Q;@_YWN9_P#/I6_]?_?OW9MO_1O@_P"<:?YNO>++_OQOVGKW]XMP
M?\[W,_\ GTK?^O\ []^[-M_Z-\'_ #C3_-U[Q9?]^-^T]>_O%N#_ )WN9_\
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MUUOMGK]MP4&:V_D,U%G\SU]68C)9MZIS53YRG@FGM)"RN).:Q+;Q>YUQ<O\
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MU N+Q_9\^Q]M2]@4..CIGHHZ*DWA)C6S]/3QT4KPJJ5 "PNR"R$@[B)@:X>
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M8XP$0D$J@"K0"G3<:K#+!/"-,\6K0PPR:V#OI(RNMU5FH1J9034@=8Z_X[]
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MJU-!YX' <3TUH3Q'ETCQ6XGS/VGB>FO>OQZZ$[(W=A=_]A]*=3[ZWSMN.*'
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M6[I_])Q^1W_VK??NO=>_Z"KOY'W_ 'E;NG_TG'Y'?_:M]^Z]U[_H*N_D??\
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MO?ND_P#*2/\ >3_GZ]_T$E_R0?\ O-;</_I*OR5_^P'W[^O"_P#1H;_G*/\
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MOW]>%_Z-#?\ .4?]:^O?ND_\I(_WD_Y^O?\ 027_ "0?^\UMP_\ I*OR5_\
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M_P#L!]^_KPO_ $:&_P"<H_ZU]>_=)_Y21_O)_P _7O\ H)+_ )(/_>:VX?\
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MPOW[KW7O^&]_@/\ ]X0?$'_TFKIC_P"POW[KW7O^&]_@/_WA!\0?_2:NF/\
M["_?NO=>_P"&]_@/_P!X0?$'_P!)JZ8_^POW[KW7O^&]_@/_ -X0?$'_ -)J
MZ8_^POW[KW7O^&]_@/\ ]X0?$'_TFKIC_P"POW[KW7O^&]_@/_WA!\0?_2:N
MF/\ ["_?NO=>_P"&]_@/_P!X0?$'_P!)JZ8_^POW[KW7O^&]_@/_ -X0?$'_
M -)JZ8_^POW[KW7O^&]_@/\ ]X0?$'_TFKIC_P"POW[KW7O^&]_@/_WA!\0?
M_2:NF/\ ["_?NO=>_P"&]_@/_P!X0?$'_P!)JZ8_^POW[KW7O^&]_@/_ -X0
M?$'_ -)JZ8_^POW[KW7O^&]_@/\ ]X0?$'_TFKIC_P"POW[KW7O^&]_@/_WA
M!\0?_2:NF/\ ["_?NO=>_P"&]_@/_P!X0?$'_P!)JZ8_^POW[KW7O^&]_@/_
M -X0?$'_ -)JZ8_^POW[KW7O^&]_@/\ ]X0?$'_TFKIC_P"POW[KW7O^&]_@
M/_WA!\0?_2:NF/\ ["_?NO=>_P"&]_@/_P!X0?$'_P!)JZ8_^POW[KW7O^&]
M_@/_ -X0?$'_ -)JZ8_^POW[KW7O^&]_@/\ ]X0?$'_TFKIC_P"POW[KW7O^
M&]_@/_WA!\0?_2:NF/\ ["_?NO=>_P"&]_@/_P!X0?$'_P!)JZ8_^POW[KW7
MO^&]_@/_ -X0?$'_ -)JZ8_^POW[KW7O^&]_@/\ ]X0?$'_TFKIC_P"POW[K
MW7O^&]_@/_WA!\0?_2:NF/\ ["_?NO=>_P"&]_@/_P!X0?$'_P!)JZ8_^POW
M[KW7O^&]_@/_ -X0?$'_ -)JZ8_^POW[KW7O^&]_@/\ ]X0?$'_TFKIC_P"P
MOW[KW7O^&]_@/_WA!\0?_2:NF/\ ["_?NO=>_P"&]_@/_P!X0?$'_P!)JZ8_
M^POW[KW7O^&]_@/_ -X0?$'_ -)JZ8_^POW[KW7O^&]_@/\ ]X0?$'_TFKIC
M_P"POW[KW7O^&]_@/_WA!\0?_2:NF/\ ["_?NO=>_P"&]_@/_P!X0?$'_P!)
MJZ8_^POW[KW7O^&]_@/_ -X0?$'_ -)JZ8_^POW[KW7O^&]_@/\ ]X0?$'_T
MFKIC_P"POW[KW7O^&]_@/_WA!\0?_2:NF/\ ["_?NO=>_P"&]_@/_P!X0?$'
M_P!)JZ8_^POW[KW7O^&]_@/_ -X0?$'_ -)JZ8_^POW[KW7O^&]_@/\ ]X0?
M$'_TFKIC_P"POW[KW7O^&]_@/_WA!\0?_2:NF/\ ["_?NO=>_P"&]_@/_P!X
M0?$'_P!)JZ8_^POW[KW7O^&]_@/_ -X0?$'_ -)JZ8_^POW[KW5+G_"A[X:?
M#_K'^37\W-]=;?%+XU]?;VP&U.L)<%O'9'1?5^U-TX26L[XZKQM7+B-P8+:U
M!EL;+4XZMF@D:&9&>&5T)*L0?=>ZLY^-OPR_EU=H?'CHGLC;'Q&^&V]=N[\Z
M>ZVW=A-X4'QPZ?J*+=&,W#L[#Y2CW!2SU.Q8*F:#+PU0G5I$1V#W90;CW[KW
M0U?\-[_ ?_O"#X@_^DU=,?\ V%^_=>Z]_P -[_ ?_O"#X@_^DU=,?_87[]U[
MKW_#>_P'_P"\(/B#_P"DU=,?_87[]U[KW_#>_P !_P#O"#X@_P#I-73'_P!A
M?OW7NO?\-[_ ?_O"#X@_^DU=,?\ V%^_=>Z]_P -[_ ?_O"#X@_^DU=,?_87
M[]U[KW_#>_P'_P"\(/B#_P"DU=,?_87[]U[KW_#>_P !_P#O"#X@_P#I-73'
M_P!A?OW7NO?\-[_ ?_O"#X@_^DU=,?\ V%^_=>Z]_P -[_ ?_O"#X@_^DU=,
M?_87[]U[KW_#>_P'_P"\(/B#_P"DU=,?_87[]U[KW_#>_P !_P#O"#X@_P#I
M-73'_P!A?OW7NO?\-[_ ?_O"#X@_^DU=,?\ V%^_=>Z]_P -[_ ?_O"#X@_^
MDU=,?_87[]U[KW_#>_P'_P"\(/B#_P"DU=,?_87[]U[KW_#>_P !_P#O"#X@
M_P#I-73'_P!A?OW7NO?\-[_ ?_O"#X@_^DU=,?\ V%^_=>Z]_P -[_ ?_O"#
MX@_^DU=,?_87[]U[KW_#>_P'_P"\(/B#_P"DU=,?_87[]U[I+;U^#'P-VKM?
M+[@I_@M\/:V;&013)2S?&_IN".8R5,$!5Y4V/*R "6_"GZ>S?8=M3>-WLMMD
MF,:2L06 J112>!(KP]>DUY.;6VEG5:E1PX>8'1>O] /P?_[UZ_"[_P!$#U%_
M]KOW)?\ K8V/_1XE_P"<:_\ 0?1!^_YO^45?]Z/^;KW^@'X/_P#>O7X7?^B!
MZB_^UW[]_K8V/_1XE_YQK_T'U[]_S?\ **O^]'_-U[_0#\'_ /O7K\+O_1 ]
M1?\ VN_?O];&Q_Z/$O\ SC7_ *#Z]^_YO^45?]Z/^;KW^@'X/_\ >O7X7?\
MH@>HO_M=^_?ZV-C_ -'B7_G&O_0?7OW_ #?\HJ_[T?\ -U[_ $ _!_\ [UZ_
M"[_T0/47_P!KOW[_ %L;'_H\2_\ .-?^@^O?O^;_ )15_P!Z/^;KW^@'X/\
M_>O7X7?^B!ZB_P#M=^_?ZV-C_P!'B7_G&O\ T'U[]_S?\HJ_[T?\W7O] /P?
M_P"]>OPN_P#1 ]1?_:[]^_UL;'_H\2_\XU_Z#Z]^_P";_E%7_>C_ )NO?Z ?
M@_\ ]Z]?A=_Z('J+_P"UW[]_K8V/_1XE_P"<:_\ 0?7OW_-_RBK_ +T?\W7O
M] /P?_[UZ_"[_P!$#U%_]KOW[_6QL?\ H\2_\XU_Z#Z]^_YO^45?]Z/^;IUP
MGQK^%&>RM%AZ/^7S\)XJFN>9(I*KH/J5*=/!33U;F5H^MY9 /%3M:RDDV]H=
MSY!VK:K"ZW&YW:<P0J"P6)2U"0N 9!YD>?3UOO-S<S1P1VR!V-!5C3A7^'I>
M#X5?#IB /@;\#N2 /^,"];CZ_3_FDWL&^%RG_P!'"_\ ^<$?_6[HUU;E_OF'
M_>V_Z!Z9^E/C#_+][AJ>SJ:D^!_P^H_]&'8.6ZTRDZ?&WJ$PUNX]O)&,\U$*
MK85--)C::IG6**9D0S,CL%T:&9+N5IML-M8W>VW,TD<QD!\1%0C0P7&EVK7/
MIY=6MYIWEGAGC560*>TD@Z@3Y@>G0Z_\-[_ ?_O"#X@_^DU=,?\ V%^R?I7U
M[_AO?X#_ />$'Q!_])JZ8_\ L+]^Z]U[_AO?X#_]X0?$'_TFKIC_ .POW[KW
M7O\ AO?X#_\ >$'Q!_\ 2:NF/_L+]^Z]U[_AO?X#_P#>$'Q!_P#2:NF/_L+]
M^Z]U[_AO?X#_ />$'Q!_])JZ8_\ L+]^Z]U[_AO?X#_]X0?$'_TFKIC_ .PO
MW[KW7O\ AO?X#_\ >$'Q!_\ 2:NF/_L+]^Z]U[_AO?X#_P#>$'Q!_P#2:NF/
M_L+]^Z]U[_AO?X#_ />$'Q!_])JZ8_\ L+]^Z]U[_AO?X#_]X0?$'_TFKIC_
M .POW[KW7O\ AO?X#_\ >$'Q!_\ 2:NF/_L+]^Z]U[_AO?X#_P#>$'Q!_P#2
M:NF/_L+]^Z]U[_AO?X#_ />$'Q!_])JZ8_\ L+]^Z]U[_AO?X#_]X0?$'_TF
MKIC_ .POW[KW7O\ AO?X#_\ >$'Q!_\ 2:NF/_L+]^Z]U[_AO?X#_P#>$'Q!
M_P#2:NF/_L+]^Z]U[_AO?X#_ />$'Q!_])JZ8_\ L+]^Z]U[_AO?X#_]X0?$
M'_TFKIC_ .POW[KW6N%_PJH^)?Q5Z<_E(;WWGU'\9?CUU;O&+N_I/&P[LZZZ
M6ZVV5N:#'U^X*Q:ZBI\_MO;6-RL%+6I&JS(DRK*@TL"+CW[KW6QO_P!T_P#_
M ,L[_P#F*^_=>Z__T[$^_?\ N,7^$7_C.C=G_NE^7?OW7NMN7W[KW2<J-X;1
MH\U!MNKW3MREW%5&-:7 5&;QD&:J6F4M$L&*EJEKIC*HNH6,ZA]/?E[R0F2*
MUIFE,G]@%3UYNP!FP#PK\\?X>E'[]U[KWOW7NDUE]Y[/V_G-J[8SVZ]M83<N
M^ZS*8[9&WLOG<7C<YO+(83$U.?S5#M7$UM5#7[AK,1@J*:MJHJ2.9Z>DB>:0
M+&K,-H#([1H-4BQF0@9(161&<CB$5I(U+< SH":LH.V!2$W#BEOXBQZCA=;A
MBB:N&MPCE5K5@K4!TFBE]ZZUU[W[KW3-4[BV_196AP-9G<-29S)K(^-PU3DZ
M*#*Y%(D:25J''2SI65:Q1HS,8T8* 2?I[\O>S*F6 J0,D#C4^@IGK3$(H9S1
M20 3@5)H!]I.!ZG'7'<NYMM[+V[G-W[QW!A-I[3VQB<AG]R[HW+E:#!;=V]@
ML32RUV5S6<S64J*7&XG$XRB@>:HJ:B6.&&)&=V"@GW5G1-.MP-3*HJ:59V"H
MH]69B%4<68@"I(Z<2.25@D2%GS@ DX%3@>@!)^6>G*BK:/)4=)D<=5TU?CZ^
MF@K:"OHIXJJCK:.JB2>EJZ2J@>2"IIJF"17CD1F1T8$$@^WI8I8)98)XF2=&
M*LK AE8&A5@<@@X(.0<'IF*6.:..:&17A=0RLI!# BH((P01D$8(ZD^V^K]8
MH9X:B,2T\T4\19T$D,B2QEHW:.10Z%EU1R(58?4,"#S[]Y ^1'7O,CS!H?D>
MLOOW7NL4,T-1&LU/-%/$Q8++#(DL;%&*.%="RDJZD'G@BWOWIUX@@D'B.LOO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[JC#_ (4K?]N0?GE_X:'4_P#\$-U%[]U[HWW\HG_MU9_+?_\ %'/BU_[Y
M;9GOW7NK$??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!MV_
M_P RWW5_U!T__NPH_8IY*_Y6G9_^:C?\<;HNW;_DGW/V#_".JA,5\G]AUORM
MW1\.,M@MY;2[8Q74^-[OV3D=QX_&0[([HZVER'\%W/E>J\Y0Y6MJ<KE.N<XR
MTN>QU93T592ZQ-''+3@RB;]NWBVW"YWNR%8[ZPEC62)P YBF'Z5T@!;5;/)^
MAXO;IG*QL*NM0A>0M9IL\LAU07RR>&ZUT"6',ENY(%)Q'^LJ"H:+O!\NLF_?
MDWL'8OR&Z0^+46)W9O;N7O#"[NWO2[?V70XVNI>LNI]D((<YW#VU7Y#*XU=J
M[!GSKIB,=)&M369/*OX:>!]$C+N'=X+G>[W9+=6:6TM!<7#X\.)7;PX(V.H,
M9;F2JPHJM\+LY1$+=;N+>6VVR#=)5_1FNQ;Q*/CE?3KE9<:=$"=\S%A0$!0S
M8Z,JM#6O2O7)1U3T4;:9*Q*>9J6-N/2]0$,2MR."?S[,#<6ZRK;M.@G/!=0U
M'[!6O3(!-:"M./75)15M?(8J&DJJV55UM%24\M1(J @%RD*.P4$_6UO?IKB"
MW4/<3)&A-*L0HKZ5)'6AD@#CU'961F5E*LI*LK AE8&Q5@;$$'\>W000"#4'
MKQ%,'CUQ][Z]U[W[KW7O?NO=>]^Z]TM>N?\ C]]O_P#+7(_^Z7)^PQSG_P J
MKO?_ #2'_5Q.C#:O^2C:?Z;_ "'HQ4?UC_UU_P!['O'?H;=%W^"/_ WY<_\
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M\>'L&-X2NYHVV+008DBIUC[")8?T #VRT4;64.VL@-A'</.L?X%F>197E"\
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MX.?^E4=(_P#V;>_=>Z]_P[-_*W_[V-?!S_TJCI'_ .S;W[KW7O\ AV;^5O\
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M_2J.D?\ [-O?NO=>_P"'9OY6_P#WL:^#G_I5'2/_ -FWOW7NO?\ #LW\K?\
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MX.?^E4=(_P#V;>_=>Z]_P[-_*W_[V-?!S_TJCI'_ .S;W[KW7O\ AV;^5O\
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M8 ()'7W7NK>_^&:_Y3?_ 'K?^%?_ *3EU;_]C?OW7NO?\,U_RF_^];_PK_\
M2<NK?_L;]^Z]U[_AFO\ E-_]ZW_A7_Z3EU;_ /8W[]U[KW_#-?\ *;_[UO\
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M  S7_*;_ .];_P *_P#TG+JW_P"QOW[KW7O^&:_Y3?\ WK?^%?\ Z3EU;_\
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MO=>]^Z]U[W[KW7O?NO=>]^Z]U1A_PI6_[<@_/+_PT.I__@ANHO?NO=&]_E$
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MKW7O?NO=>]^Z]U[W[KW2UZY_X_?;_P#RUR/_ +I<G[#'.?\ RJN]_P#-(?\
M5Q.C#:O^2C:?Z;_(>C%1_6/_ %U_WL>\=^AMT7?X(_\  WY<_P#BWG<'_NPI
M?9K<?\D;9_\ 33_]7.DD?^YUY_I8_P# >C_^RKI7U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]UK"_\ "N__ +<U[Z_\3YT1_P"]#D/?NO=7;?\
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MV.O9E5V!L+;U=EZG*8_:NR-X46THU04\$N4HJA85I)U5YBQKS&+;E]?=W<C
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M*I9'IL1@-FU-!NVFZP;9>:CJHJV7(UF/>JH113TIAF>HIYTQWZ&W7/X(_P#
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M>._0VZ+O\$?^!ORY_P#%O.X/_=A2^S6X_P"2-L_^FG_ZN=)(_P#<Z\_TL?\
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M]E?OW7NO?[.U\,O^\N?C%_Z/OJK_ .ROW[KW7O\ 9VOAE_WES\8O_1]]5?\
MV5^_=>Z]_L[7PR_[RY^,7_H^^JO_ +*_?NO=>_V=KX9?]Y<_&+_T??57_P!E
M?OW7NO?[.U\,O^\N?C%_Z/OJK_[*_?NO=>_V=KX9?]Y<_&+_ -'WU5_]E?OW
M7NDKO?Y=?#K=6U<QM^E^87Q<HZC)0111U-1WQU;+#$8ZJ"<L\<>[4=@5B(X(
MY/LXV#<H]HWBQW*:)GCB8DJ" 352,$X\^DM[ UU;2P*P#,.)^T'HNO\ I1^*
M?_>;_P 2?_1U]<?_ &:>Y._US=L_Z-,_^]I_T#T0?N"?_E(3]AZ]_I1^*?\
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MO^\N?C%_Z/OJK_[*_?NO=>_V=KX9?]Y<_&+_ -'WU5_]E?OW7NO?[.U\,O\
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M;SVY>I/D7WS\I,!DMU;UI<H^6[7^1NR<_L/L:IW''3X"@CK=O_PC<M5)C<?
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M*L9C3W3[GG5[U:RM:0\M01@%-J@N88*Y)6Z6^60R<-3 ;A/H. I$=0=!U7D
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M .W->^O_ !/G1'_O0Y#W[KW5VW_=/_\ \L[_ /F*^_=>Z__0L4[\4G_A8O\
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M-_\ VO/?NO=>_P"&'/B1_P!Y)_S-?_2X<W_]KSW[KW7O^&'/B1_WDG_,U_\
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MPYO_ .UY[]U[KW_##GQ(_P"\D_YFO_I<.;_^UY[]U[KW_##GQ(_[R3_F:_\
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M]^Z]U[_AASXD?]Y)_P S7_TN'-__ &O/?NO=>_X8<^)'_>2?\S7_ -+AS?\
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M,LT8>,##2(<AHU;2T@IGL!-*XP>O;A_NJ>=-P(C,3$2?B$9&3XC+J6.GF7(
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M:2D@?HW2L3I2H&R_K<\W\X<"?;+O:+Z%M6)(AM5M%N%M4&A,D*B55XB>V5:
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M04\,5/34U/"@C@IJ:F@2."FIH(U"I'&JHBBP 'NQ))+,26)J234D^I)R3UH
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MI8L)+,&$\^!BIZ&./!3U*R,)9*00O*'8.2&:^ZFM:G52E?/3_#7CIP!I^&@
MI@=>H*$4%":D>1/'41P+5SJ/=6IK4]=UN.Q.4A%-F<)@<_2*XE2BW%@L1N&@
M29056HCH<W15])'4JK$"14#A20#8GW6@)!*@D<#3(^P^7SIQZ]4BH!-#_/[?
M7\^N;46-:&@IOX1@UI,04?"428/$1T. EB+F&HV]11T2TF JH/(VB6C2"1-3
M:6%S>U26UEB9*4K4UI2E*\:$8(K0C!%,=:HNG1I&BM:4%*UK4C@37(-*@Y&<
M]8AB\.J0Q)@=O1PTU6<C1T\>W\+'34&49F=\SCZ=*%8,?G)))&9JZ%8ZMF=F
M,A+,3H$KITFFD4%,:5\U6GPJ1@J**1@BG6SW:M0KJ-37.H^K5^(CR)J1Z]93
M18LS3U/\$V^*RJJ4KJK(+M_"+DJO(1PR4T>2K,DM *^KR<=+-)$M3)(TXBD=
M ^AV!]@ *!V=V/+N^/'#OH->.^@#5H.O')U'+4 J<FB_#GCV?@_A_#3H%_D3
MT-M[Y&?'KMKXV9#<FX.J]F]R;(R?76XL[U7C]L8K<&&VEGI(DW)C=LT.2P];
MMG'KN+&":AJ2:,VIZN8IIE(<)KRU2^2WBN'<P)/#(RU_M!#(LBQ,34B-BB@Z
M:,  %(Z565V]C.US#&IF\.1037M,B,AD%*5=0Q()KDU->A-V;M/;^P-F[.V!
MM+'08C:>PMI;9V/M;$TR+'!C=M[0P=#M[!T,2* JK38S'1+P "03[--POKC<
M]POMSNVK=7$SRN?Z4C%C3Y F@]!0=%5A90[;866W6U?IX(EC6N20HI4GS9N+
M'S8D^?2C]I.E?6N9_,5_[B#/Y#7_ &H-^?\ O;]D>_=>ZV,_?NO=>]^Z]U[W
M[KW51W\QK(5&_P#Y-_RZ?B!V%OO=76?Q5^3N[N]&[NKMH[UR_6%;W-NSK;9&
M.S'57QIR?9&$K<5E,%@^R<K7S-44%+64E3F1&*='O:S%A;Q;COVZVMW;FY%I
ML4]W;6E:"ZN5E6-JBJE_IXB9535I!8.X*KT]?2O8\OVE[;3B&:?>[:TGGP3;
M6LD4LAD&"5\25%C,@&!V_BH:Y:KYC=<?R_NI_EGU[\1/@?WE\-_D#LKY!_#S
MH#=G2?:':-9\N-N;4W+\H:/?&:V;VCUQUE0=L;IQF?WC'M';\\O]WX<_10[@
MR-9CJ>IE41.H6"6_W/;N4X;2]K9WN]W=F0L0FG@>UMHKBXCA4Z!,7UHD4>HH
M'\605/&IM8+*ZYBN;JT426>Q+>JS2F&*XC>ZCMHS*PU&-49_$>33K5 4(&KH
M4XOG]_,KQ?5/5^W=T[4FZW[?WM_,M^.WQ%VAVO\ *GX@-\>LKVMTQWML/>6<
MR6Z-[?%;%]@[EJ.LMP;'W1A(X8Y\-G N5HHX'1HVGJ"%=A9?OF]Y9L+>:&VN
M+I-W%PH8S:$L+:.X@N$KITS2([$VSGPA*NEF\+'2&666SMN<;N:*26VL;;;Y
MX&*B(2-<3O#<6S9>L:L@ N%&O1)5!XBX5$WSQ^<^(K*GXAU/:71]7\H*G^:U
MC_Y=N(^8F0Z+Q^)V)1[+R'4U+W$G9%3\<*?=!VE5]E34=2N'QF%.4_A]9.?W
M)3+:8H]E_P"1!_4Y[9&M7NK?>IIP/U]7[F*]L>K04^I$BZSGPM)*4U#2[ODB
M\NMS-]52ZCA&S^ *^"$_?&L?J,-99+81.=6"VL:JA2&)CL?YA_(CX<;+^>J;
M6J-K=G?)'Y#?SR<A\:ZWL_IKIFL[6Q6.SF9ZBPV4W-O_ *K^-U3OC'KV/V!7
MQ;;-/BMH5>XXJ)\S420R5+Q1!63[5X=YRS[;[?M=O+;V]RN^7+Z$^H:EM.LC
M"*NC5%(SK2=P62W5I-+.!T9[RB6.^<YWVYRB>:UL-GB36?IU+2K-'&9V&LQ^
M&BMK1,--H0:5)Z-CA_G-_,\W1L?XK]95F(PWQ^[[[L^?V_?B..T/DM\45Z[S
M&]NF8NEJGLC:'>NX/BP-[9O_ $4]AX6H$COMVES<N,R-51Q0R2K2SS>URP)>
M;CR]:QS)!]1L^ZW5PB,)_#?;GAT&-B5-9XF:L4F(Y&:M42,]%5W.-LLMVO&C
M>YCBOMJBA+J8 YW!IXY(7TU)CAE10+B.C/%0J Y;K85V[1YO'[=V]C]SYZ'=
M6Y\?@</0[FW538.EVO3;IW%28^GI\WN2FVO0U5?0[8I\[DXY:I,=#//#0K*(
M4D=4#%NY>"6YN)+6W,-JSDI&7,A12>U"Y +E1C60"W$@=7A26.)$GF$DP'<X
M4)J-3G2"0N*8!Z>/;/3G7O?NO=4!?\*=_P#MS_V3_P"+$_'7_P!R]\^_=>ZV
M:?\ NG__ .6=_P#S%??NO=?_UCI?,[_N+A^'W_C-W>?_ +SGS"]^Z]U?M[]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NJ@?Y^G_;GSYO?^&;UA_P#! =2>_=>Z-%_++_[=
ML_R^_P#Q3/X[_P#OML%[]U[H[GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z"CO\ _P"R=ODG_P"*U?(C_P!\OOGW[KW6
MN)_PD@_[=W?(+_Q<[/?^^1ZB]^Z]UM)>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM1?^7W_P!Q5O\ -2_\,'Y+
M?^_!Z+]^Z]UMT>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NM<S^8K_W$&?R&O\ M0;\_P#>W[(]^Z]UL9^_=>Z]
M[]U[KWOW7N@M[FZ/Z;^1?7^4ZI[ZZPV7V]UQF9Z:KK]G[YP\>6Q?W]$7-#EL
M=*'@R6"SE 9":>OH)Z6MIR;QRJ?;,UO!<>$9HZM&Q*D$JRDBA*LI#+4&AH14
M8-1T[%/+#X@C>BN*," 585J RL"IH<BH-#D4/0#;#_EU_!#K'J+L3H/8GQ0Z
MBP?3G;IHW[3V)4X[.;GI>P)L9)--AZG=&?WAGMP[QR-;@)JAWQD_\26;%NY:
MD:!N?;UW_C]I;6%YWV<,OBQI\(27'ZJZ-)$I  ,@.LJ I8J*=-6W^)W<M]:]
MEW)'X;-Q+1GC&0U1X?GHIIKFE<]..QO@'\*>LME[&Z[V#\:NN]K[+ZT[CVU\
MAMB86BFW=528'O/9E/64>TNTY,[E-SY#<VX=U[;H\A-#1MEJVOIHH'\?A**B
MJMCW&^BGL;J*Z9;BVBFBB(H-$=R@CN%  TGQD 61F!8@ ZJ@'IKP(? O[8Q@
MP7003 U/B"-BT:DDU"HQ+*JE5!9L=S5?-_\ PI^)':NV>X=F]D_'SK_>NV/D
M#V/1=P]SXK-KN&3^_G;&.Q]-B<?V-/D:7/4N8VSNVBQ=)'3Q56#J,65B# #]
MR364I:6L=O86D< 6VM9Y)H5%1X<LQ!F=2"&)E(&L,2K !2ND =+'N;B2XN[N
M24M<SV\4$C&AUPP"D,; C25B'P&FH<:USTR+\ _A%'U+V#T+'\6.GHNE^U<]
MAMU]A]:0X*MAVQN3=FWL+0;>P6[5ABRB5NWMU8K#8N"&')8F;'UJNAF,IJ))
M9757)-Y';17)+1P322QCX?#DE.J5HRNDH'(%54A O8%"=O3%L3:/,]MVM)"D
M+_BUQ1DE$D#5$FDL6#.&8L=18L 0\; ^$OQ&ZJP74FV>N/C[L+9V#Z&["K^V
MNGJ+$-N4R['[0RN$?;>2W_#DZ[<%9E]R[HKMOO\ 9R5.;J,H3 J+8&.,HZUQ
M.UQ:W;2'ZF"UFMHVH!HM[D 7$2@#2%FH/$--3&K:M1)*<VELT%S;-"#!-<0S
MN#4ZIK9BUO(236L+$F,5TBM--,=&A]L]*.O>_=>Z][]U[J@+_A3O_P!N?^R?
M_%B?CK_[E[Y]^Z]ULT_]T_\ _P L[_\ F*^_=>Z__]<1_P"<4GS@QO\ PI$Z
M=W]_+ZZCZ][K[_ZQ_EHT6Y_[E]H9K$839_\ <7/[_P"_.L=UYBLFR^_.N$JJ
MO&IV! ::&')K-YW5_%)&D@]^Z]THO]F6_P"%2_\ WKO^$7_H<;5_^ZY]^Z]U
M[_9EO^%2_P#WKO\ A%_Z'&U?_NN??NO=>_V9;_A4O_WKO^$7_H<;5_\ NN??
MNO=>_P!F6_X5+_\ >N_X1?\ H<;5_P#NN??NO=>_V9;_ (5+_P#>N_X1?^AQ
MM7_[KGW[KW7O]F6_X5+_ />N_P"$7_H<;5_^ZY]^Z]U[_9EO^%2__>N_X1?^
MAQM7_P"ZY]^Z]U[_ &9;_A4O_P!Z[_A%_P"AQM7_ .ZY]^Z]U[_9EO\ A4O_
M -Z[_A%_Z'&U?_NN??NO=>_V9;_A4O\ ]Z[_ (1?^AQM7_[KGW[KW7O]F6_X
M5+_]Z[_A%_Z'&U?_ +KGW[KW7O\ 9EO^%2__ 'KO^$7_ *'&U?\ [KGW[KW7
MO]F6_P"%2_\ WKO^$7_H<;5_^ZY]^Z]U[_9EO^%2_P#WKO\ A%_Z'&U?_NN?
M?NO=>_V9;_A4O_WKO^$7_H<;5_\ NN??NO=>_P!F6_X5+_\ >N_X1?\ H<;5
M_P#NN??NO=>_V9;_ (5+_P#>N_X1?^AQM7_[KGW[KW7O]F6_X5+_ />N_P"$
M7_H<;5_^ZY]^Z]U[_9EO^%2__>N_X1?^AQM7_P"ZY]^Z]U[_ &9;_A4O_P!Z
M[_A%_P"AQM7_ .ZY]^Z]U[_9EO\ A4O_ -Z[_A%_Z'&U?_NN??NO=>_V9;_A
M4O\ ]Z[_ (1?^AQM7_[KGW[KW7O]F6_X5+_]Z[_A%_Z'&U?_ +KGW[KW7O\
M9EO^%2__ 'KO^$7_ *'&U?\ [KGW[KW7O]F6_P"%2_\ WKO^$7_H<;5_^ZY]
M^Z]U[_9EO^%2_P#WKO\ A%_Z'&U?_NN??NO=>_V9;_A4O_WKO^$7_H<;5_\
MNN??NO=>_P!F6_X5+_\ >N_X1?\ H<;5_P#NN??NO=>_V9;_ (5+_P#>N_X1
M?^AQM7_[KGW[KW7O]F6_X5+_ />N_P"$7_H<;5_^ZY]^Z]U[_9EO^%2__>N_
MX1?^AQM7_P"ZY]^Z]U[_ &9;_A4O_P!Z[_A%_P"AQM7_ .ZY]^Z]U[_9EO\
MA4O_ -Z[_A%_Z'&U?_NN??NO=>_V9;_A4O\ ]Z[_ (1?^AQM7_[KGW[KW7O]
MF6_X5+_]Z[_A%_Z'&U?_ +KGW[KW7O\ 9EO^%2__ 'KO^$7_ *'&U?\ [KGW
M[KW7O]F6_P"%2_\ WKO^$7_H<;5_^ZY]^Z]U[_9EO^%2_P#WKO\ A%_Z'&U?
M_NN??NO=>_V9;_A4O_WKO^$7_H<;5_\ NN??NO=>_P!F6_X5+_\ >N_X1?\
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M_=>Z]_LRW_"I?_O7?\(O_0XVK_\ =<^_=>Z]_LRW_"I?_O7?\(O_ $.-J_\
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M -US[]U[KW^S+?\ "I?_ +UW_"+_ -#C:O\ ]US[]U[KW^S+?\*E_P#O7?\
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MI'IF5 BNYRO$=VN]LCNHR+'=+#<+JW=AX;%+:*62.2UC75JMP\?A,;DAV%2
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M=4FT<*,UV]NW<$%9)NK(;+W]2H:/'05<*T:U$+&%@Z.91KOP']8N?/%'B/\
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M\9_Y=?\ YV; _P#MO^_=>Z]X?^%=O_>,_P#+K_\ .S8'_P!M_P!^Z]U[P_\
M"NW_ +QG_EU_^=FP/_MO^_=>Z]X?^%=O_>,_\NO_ ,[-@?\ VW_?NO=>\/\
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M_?NO=>\/_"NW_O&?^77_ .=FP/\ [;_OW7NO>'_A7;_WC/\ RZ__ #LV!_\
M;?\ ?NO=%X^5WR<_X5&_"WX^]C_)WOSH#^7]M[J+JF@PV2WGF,/CMI;ER5%2
MY[<V$VCC6I<'B.V:C)9!Y<WN"EC*Q(Q57+'A3[]U[H<<#E/^%;NY,'AMQ8GX
MV?R[)\5G\5CLUC)S5; 4S8_*T<-=1RE?],!TF2FG4VN;7]^Z]T[>'_A7;_WC
M/_+K_P#.S8'_ -M_W[KW7O#_ ,*[?^\9_P"77_YV; _^V_[]U[KWA_X5V_\
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M.C$&3H9%0RQKY8[.MT92?=>Z-9X?^%=O_>,_\NO_ ,[-@?\ VW_?NO=>\/\
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M-@?_ &W_ '[KW7O#_P *[?\ O&?^77_YV; _^V_[]U[KWA_X5V_]XS_RZ_\
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M\9_Y=?\ YV; _P#MO^_=>Z]X?^%=O_>,_P#+K_\ .S8'_P!M_P!^Z]U[P_\
M"NW_ +QG_EU_^=FP/_MO^_=>Z]X?^%=O_>,_\NO_ ,[-@?\ VW_?NO=>\/\
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M3<_[_;]O7O[U;G_YZ'+?^=1_Z-]^_<^T_P#1LA_WGKWU-S_O]OV]>_O5N?\
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MY27J2*DT8@=$5[/,ES(J2L%H, _+I(_WJW/_ ,]#EO\ SJ/_ $;[.OW/M/\
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M7O?NO=>]^Z]U[W[KW7O?NO=&"ZH_X]VK_P"UQ4_^XM%[C;G'_DIP_P#-!?\
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M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z,%U1_Q[M7_VN*G_ -Q:+W&W./\
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M?NVY_H_M_P!CKW^B_=7^IQ?_ )W2?_4GOW];=G]9O]X'_077OW;<_P!']O\
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MO]3B_P#SND_^I/?OZV[/ZS?[P/\ H+KW[MN?Z/[?]CKW^B_=7^IQ?_G=)_\
M4GOW];=G]9O]X'_077OW;<_T?V_['7O]%^ZO]3B__.Z3_P"I/?OZV[/ZS?[P
M/^@NO?NVY_H_M_V.O?Z+]U?ZG%_^=TG_ -2>_?UMV?UF_P!X'_077OW;<_T?
MV_['7O\ 1?NK_4XO_P [I/\ ZD]^_K;L_K-_O _Z"Z]^[;G^C^W_ &.A9V)@
M<AM[$5%%DA3B>3(35*_;3-,GB>"FC6[-'$0VJ(\6]@WF+<;;<[V.>UU>&(@O
M<*&H+'U/KT9V4$D$3))2I:N/L'6DO_*PBE_Z"Z_YL!\4EH^H.^99#H:T<4G:
M'Q<5)7X],;M,@#'@EA_4>R'I9UN:;OV)N#-;AKLG0B@^UGCHUC,]6\4MX::.
M*35&M-(%&M3;DW'L=[+S#MMAMEO:W!D\92U:*",L2,ZAY?+HHNK*>:=Y$TZ3
M3B?0?9TFO]%^ZO\ 4XO_ ,[I/_J3V:_UMV?UF_W@?]!=)_W;<_T?V_['7O\
M1?NK_4XO_P [I/\ ZD]^_K;L_K-_O _Z"Z]^[;G^C^W_ &.O?Z+]U?ZG%_\
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MO^@6_P"(O_>:O\P;_P!#[K+_ .P#W[KW7O\ H%O^(O\ WFK_ #!O_0^ZR_\
ML ]^Z]U[_H%O^(O_ 'FK_,&_]#[K+_[ /?NO=>_Z!;_B+_WFK_,&_P#0^ZR_
M^P#W[KW7O^@6_P"(O_>:O\P;_P!#[K+_ .P#W[KW7O\ H%O^(O\ WFK_ #!O
M_0^ZR_\ L ]^Z]U[_H%O^(O_ 'FK_,&_]#[K+_[ /?NO=>_Z!;_B+_WFK_,&
M_P#0^ZR_^P#W[KW7O^@6_P"(O_>:O\P;_P!#[K+_ .P#W[KW7O\ H%O^(O\
MWFK_ #!O_0^ZR_\ L ]^Z]U[_H%O^(O_ 'FK_,&_]#[K+_[ /?NO=>_Z!;_B
M+_WFK_,&_P#0^ZR_^P#W[KW7O^@6_P"(O_>:O\P;_P!#[K+_ .P#W[KW7O\
MH%O^(O\ WFK_ #!O_0^ZR_\ L ]^Z]U[_H%O^(O_ 'FK_,&_]#[K+_[ /?NO
M=>_Z!;_B+_WFK_,&_P#0^ZR_^P#W[KW7O^@6_P"(O_>:O\P;_P!#[K+_ .P#
MW[KW7O\ H%O^(O\ WFK_ #!O_0^ZR_\ L ]^Z]U[_H%O^(O_ 'FK_,&_]#[K
M+_[ /?NO=>_Z!;_B+_WFK_,&_P#0^ZR_^P#W[KW7O^@6_P"(O_>:O\P;_P!#
M[K+_ .P#W[KW7O\ H%O^(O\ WFK_ #!O_0^ZR_\ L ]^Z]U[_H%O^(O_ 'FK
M_,&_]#[K+_[ /?NO=>_Z!;_B+_WFK_,&_P#0^ZR_^P#W[KW7O^@6_P"(O_>:
MO\P;_P!#[K+_ .P#W[KW7O\ H%O^(O\ WFK_ #!O_0^ZR_\ L ]^Z]U[_H%O
M^(O_ 'FK_,&_]#[K+_[ /?NO=>_Z!;_B+_WFK_,&_P#0^ZR_^P#W[KW7O^@6
M_P"(O_>:O\P;_P!#[K+_ .P#W[KW7O\ H%O^(O\ WFK_ #!O_0^ZR_\ L ]^
MZ]U[_H%O^(O_ 'FK_,&_]#[K+_[ /?NO=>_Z!;_B+_WFK_,&_P#0^ZR_^P#W
M[KW7O^@6_P"(O_>:O\P;_P!#[K+_ .P#W[KW7O\ H%O^(O\ WFK_ #!O_0^Z
MR_\ L ]^Z]U[_H%O^(O_ 'FK_,&_]#[K+_[ /?NO=>_Z!;_B+_WFK_,&_P#0
M^ZR_^P#W[KW7O^@6_P"(O_>:O\P;_P!#[K+_ .P#W[KW7O\ H%O^(O\ WFK_
M #!O_0^ZR_\ L ]^Z]U[_H%O^(O_ 'FK_,&_]#[K+_[ /?NO=)#?O_"5/XO[
MDVAF\)MWYO?->CS=?#2ICZK?U?U[O[:$,D5?25$S9O9]!B-EUF;A:EA=8D3*
M49BJ#'*6<1F-_=>Z4F/_ .$L?Q QV.Q^/@^9WS[IHZ''T5&(,?O3K"@QT;TU
M+%#*,?0)L.1<?C_*A,%/KD,$6E"[E=9]U[J7_P! M_Q%_P"\U?Y@W_H?=9?_
M & >_=>Z]_T"W_$7_O-7^8-_Z'W67_V >_=>Z]_T"W_$7_O-7^8-_P"A]UE_
M]@'OW7NO?] M_P 1?^\U?Y@W_H?=9?\ V >_=>Z]_P! M_Q%_P"\U?Y@W_H?
M=9?_ & >_=>Z]_T"W_$7_O-7^8-_Z'W67_V >_=>Z]_T"W_$7_O-7^8-_P"A
M]UE_]@'OW7NO?] M_P 1?^\U?Y@W_H?=9?\ V >_=>Z]_P! M_Q%_P"\U?Y@
MW_H?=9?_ & >_=>Z]_T"W_$7_O-7^8-_Z'W67_V >_=>Z]_T"W_$7_O-7^8-
M_P"A]UE_]@'OW7NHF1_X2S_$JKQV2I(/FM\^EJ*K'5]-2OD=Y]:9''1UE123
M0TDN2QJ;)HI,ECHJET:HIEGIVJ(0T:RQ%A(ONO=(GK'_ (2B?%[9VTX<5N3Y
ML_,6JW$^0KJS)U_6"]>]8[3K$F,4= 8=I5]!OZNI\A!20K'/4296<5!52J1*
MNGW[KW0@_P#0+?\ $7_O-7^8-_Z'W67_ -@'OW7NO?\ 0+?\1?\ O-7^8-_Z
M'W67_P!@'OW7NO?] M_Q%_[S5_F#?^A]UE_]@'OW7NO?] M_Q%_[S5_F#?\
MH?=9?_8![]U[KW_0+?\ $7_O-7^8-_Z'W67_ -@'OW7NO?\ 0+?\1?\ O-7^
M8-_Z'W67_P!@'OW7NO?] M_Q%_[S5_F#?^A]UE_]@'OW7NO?] M_Q%_[S5_F
M#?\ H?=9?_8![]U[KW_0+?\ $7_O-7^8-_Z'W67_ -@'OW7NO?\ 0+?\1?\
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M[))4,WVWE\0=2UM0O0N@D:(N!*!4K4:@ :5*\0*XJ12N./5PCM&)E1C#4#4
M2M2*@:N%2,@5J1D8ZR479/6>2R>.P>,[/ZQR>=S#M'A\!C.Q=EY#/9B1,%3[
MI>/$X2CSD^4R<B;4JX<L1!#(1BIHZP_Y,Z2EQD>-I4D1E>,.7!!!01,$E+@_
M"(G(24M01N0CZ6('38=" 0X()0#(R9 QC ]3(%8Q@9D"L4U!32/ANU>I]QX3
M/;GVWVWU-N3:^TZR3'[NW1MWM#8>>VQL_(0LJS4&[]Q8G<-9A=K5T+. \.0G
MIY%) (!(]Z )C@E /A2D!&_"Y)  1N#DEE "DDEE %2*V.))H3_;1BKK^)
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M\=?_ '+WS[]U[K9I_P"Z?_\ Y9W_ /,5]^Z]U__3.E\SO^XN'X??^,W=Y_\
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MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J@+_A3O\
M]N?^R?\ Q8GXZ_\ N7OGW[KW6S3_ -T__P#RSO\ ^8K[]U[K_]0Z'S0>*/\
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MZ]]U0?\ .VPO_GZQ/_U9[]U[KWW5!_SML+_Y^L3_ /5GOW7NO?=4'_.VPO\
MY^L3_P#5GOW7NO?=4'_.VPO_ )^L3_\ 5GOW7NO?=4'_ #ML+_Y^L3_]6>_=
M>Z]]U0?\[;"_^?K$_P#U9[]U[KWW5!_SML+_ .?K$_\ U9[]U[KWW5!_SML+
M_P"?K$__ %9[]U[KWW5!_P [;"_^?K$__5GOW7NO?=4'_.VPO_GZQ/\ ]6>_
M=>Z]]U0?\[;"_P#GZQ/_ -6>_=>Z]]U0?\[;"_\ GZQ/_P!6>_=>Z]]U0?\
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ML+_Y^L3_ /5GOW7NO?=4'_.VPO\ Y^L3_P#5GOW7NO?=4'_.VPO_ )^L3_\
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M &5>_=>Z]_T!&=!_]Y^]X_\ HI]F?_95[]U[KW_0$9T'_P!Y^]X_^BGV9_\
M95[]U[KW_0$9T'_WG[WC_P"BGV9_]E7OW7NO?] 1G0?_ 'G[WC_Z*?9G_P!E
M7OW7NO?] 1G0?_>?O>/_ **?9G_V5>_=>Z]_T!&=!_\ >?O>/_HI]F?_ &5>
M_=>Z]_T!&=!_]Y^]X_\ HI]F?_95[]U[KW_0$9T'_P!Y^]X_^BGV9_\ 95[]
MU[KW_0$9T'_WG[WC_P"BGV9_]E7OW7NO?] 1G0?_ 'G[WC_Z*?9G_P!E7OW7
MNO?] 1G0?_>?O>/_ **?9G_V5>_=>Z]_T!&=!_\ >?O>/_HI]F?_ &5>_=>Z
M]_T!&=!_]Y^]X_\ HI]F?_95[]U[KW_0$9T'_P!Y^]X_^BGV9_\ 95[]U[KW
M_0$9T'_WG[WC_P"BGV9_]E7OW7NO?] 1G0?_ 'G[WC_Z*?9G_P!E7OW7NO?]
M 1G0?_>?O>/_ **?9G_V5>_=>Z]_T!&=!_\ >?O>/_HI]F?_ &5>_=>Z]_T!
M&=!_]Y^]X_\ HI]F?_95[]U[KW_0$9T'_P!Y^]X_^BGV9_\ 95[]U[KW_0$9
MT'_WG[WC_P"BGV9_]E7OW7NO?] 1G0?_ 'G[WC_Z*?9G_P!E7OW7NO?] 1G0
M?_>?O>/_ **?9G_V5>_=>Z]_T!&=!_\ >?O>/_HI]F?_ &5>_=>Z]_T!&=!_
M]Y^]X_\ HI]F?_95[]U[KW_0$9T'_P!Y^]X_^BGV9_\ 95[]U[KW_0$9T'_W
MG[WC_P"BGV9_]E7OW7NO?] 1G0?_ 'G[WC_Z*?9G_P!E7OW7NO?] 1G0?_>?
MO>/_ **?9G_V5>_=>Z]_T!&=!_\ >?O>/_HI]F?_ &5>_=>Z]_T!&=!_]Y^]
MX_\ HI]F?_95[]U[KW_0$9T'_P!Y^]X_^BGV9_\ 95[]U[KW_0$9T'_WG[WC
M_P"BGV9_]E7OW7NO?] 1G0?_ 'G[WC_Z*?9G_P!E7OW7NB _S2?^$J_4/\OG
MX%?(;YB;8^8_;78V=Z4PFT,KC]E9WKS;&$Q.=DW-V3LS8LD-;E,?N.JK*-*6
M#=+SJR1N2\04BQ/OW7NA@^(7_"1'H;Y(_#SXR_*+<?SG[BV94][_ !^Z>[FS
M6WZ3K+:59C-L9+LS8FW]UUV#HJ^HW0M374&*K\TU-!/(J231HKLB,Q4/6]O-
M=3);V\9>9N '$T%?\ ZJ[K&I=VHH\^AR_P"@,;XJ?]['>X?_ $5>SO\ [)_9
MG_5[>O\ HVR?L_V>F/K+7_?Z]>_Z QOBI_WL=[A_]%7L[_[)_?OZO;U_T;9/
MV?[/7OK+7_?Z]>_Z QOBI_WL=[A_]%7L[_[)_?OZO;U_T;9/V?[/7OK+7_?Z
M]>_Z QOBI_WL=[A_]%7L[_[)_?OZO;U_T;9/V?[/7OK+7_?Z]>_Z QOBI_WL
M=[A_]%7L[_[)_?OZO;U_T;9/V?[/7OK+7_?Z]>_Z QOBI_WL=[A_]%7L[_[)
M_?OZO;U_T;9/V?[/7OK+7_?Z]>_Z QOBI_WL=[A_]%7L[_[)_?OZO;U_T;9/
MV?[/7OK+7_?Z]>_Z QOBI_WL=[A_]%7L[_[)_?OZO;U_T;9/V?[/7OK+7_?Z
M]>_Z QOBI_WL=[A_]%7L[_[)_?OZO;U_T;9/V?[/7OK+7_?Z]>_Z QOBI_WL
M=[A_]%7L[_[)_?OZO;U_T;9/V?[/7OK+7_?Z]3L=_P (M/C'EJD4>-_F)]S5
ME48WF$$/56S2YBC*"1['= ]*EQ?_ %_:>YVC<K.+Q[JS=(:@5(Q4\!_(]72X
M@E;1'*"W3]_T!&=!_P#>?O>/_HI]F?\ V5>R[I[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[KW_ $!&=!_]Y^]X_P#HI]F?_95[]U[KW_0$9T'_ -Y^]X_^BGV9
M_P#95[]U[JJ'^<__ ,)GNI_Y77P=W'\K]J?+#M#MS-87L/KS94&S-T; VU@<
M/51[TRLU!45TV3QNX*VKAEH(82\86)P[>DV!U#W7NOH2_P#=/_\ \L[_ /F*
M^_=>Z__6L3[]_P"XQ?X1?^,Z-V?^Z7Y=^_=>ZVY??NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U1A_PI6_[<@_/+_PT.I__@ANHO?NO=&+_EE_]N>_Y?7_ (HO\4/_ 'TN
MPO9[RU_R7+#[6_XXW22^_P!Q9OR_PCH=/<L=!SKWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[H0>L/\ C[$_[5>0_P"ME'[#?-G_ "1F
M_P":R?X&Z7[=_N3_ +4_Y.C'^XNZ/^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NM87_A7?\ ]N:]]?\ B?.B/_>AR'OW7NKMO^Z?_P#Y9W_\Q7W[
MKW7_U[$^_?\ N,7^$7_C.C=G_NE^7?OW7NMN7W[KW1<>UODSLSJ+O'XO]"Y_
M";HR&Z?E;N+M#;6Q<MAZ;%2[?P%9U1UIE>T<[/NV>MRU%D:6ER&$Q,D%(:.F
MK&:K95D6..\@M;+]3>3V28DCL9;HD\-$4UK RCSUEKN,@4II5ZD$ &MVWTFW
M+N4F83?6]K0?%KN%G=&]- $#:C6M2M <T3&*^:'3%1W9\E^D]S9-NN:OXLP]
M OOW?O8F6VKM7KK*5/R.QV6K>OL=MW<%?N!9'R$E9BQ02Q5L%&TM?500TWG:
M3C5L/JK3ZN,C.Y362H?C>:&VMKIM"CX@8KE: =U8Y"5"J":3RBWO5LG4ZCMR
MWI8? D37%S;=Q_"0]L[,2-(5D.JI( J8[Y#=#9?K_=/:^,[GZMK^L=CU66H=
MZ=@TN_-LS;-VE78%XX\S1;EW&F3.*P=7C7FC\T53+$Z"1"19U)HSJMO;7;&E
MM, 8V_"]6T#0?Q$N"E!4ZP4^+'2F**2>\GV^%==[$VET&60A=1# 97M[LT[>
M[AGHOO3GSRZB[>WS\N<1!D]J;?ZN^*&5ZGHZ_O.K[$VS6]>;VQ?:'4N [3.?
MI<I$T&,VYC]N+GUQTWW%9*TM1&6_;N$]O^%X>Q1;U=MX);<KRS,;8(:T^G&N
MOGXIG 5:5!6F2U VM9KZ"RM/UO$L(KH,F1IDENXRM!_ +4R,W#2X. M2.S?)
M;X[)L+!=IR][=00]:[HK:O&;:W[4=C[1I]I;@RM!0Y3)UV(PV?GR\>,R>7H\
M=@ZV>6DAD>HCBHYF9 (GTTF5K=E2=2CM"90"*$Q+35(!Q*#4M6&!45.>M0D7
M"N\)U(KA"1P#%M(4G@"6P*TJ>''K/A?D7T#N3=&#V/M[NOJO.[TW+34M;@MH
M8??NV,ENC)TE=M.DWY15--@*/)S94P5FR:^#+1,8@),=-'4+>)U8N/;SQO<H
M\+!H?$\2H/9X3K'+J/!3'(RHX.58@&AZ:%Q 8K:?QE\&;1X9J*/XFK04_B#:
M&TD5!TFG#K!MOY+?';>.(WUN#:G>W4&XL#UA-/#V/G,/V-M'(8?8C4IE6H?=
MV3ILO)1;?IXFIY 9:IXHKQ.-5T:S)(6WAO&Q:2.J*Y^%G<JJ(K<"SEE"*#5M
M2Z0=0JH966YELF'^.)&TC)^-44%F<KQ"J 2Q(HH!U4H>N='\DOCSD*+L#)47
M>G4-1C>IZFBI.T,@G8^T!0]=SY-E3&+O:K;+K3[83)2-IIWK6A2=@0A8@@;4
M%XUE45C,W@@^1EU!?"K_ +\U,HT?$2RX[A70!:3P5S+X!FH,GP0I<RT'^AA%
M9B_P@*Q)P:-^7^4_QIV_LZD[#SO?_3F'V'D-S9'9F/WCD^Q]I4.V<CNS#U<]
M#EMNX[-5.5CQ]?E\954TBU$$,CO#XV+ *I(U0Z[&.GZERNJ(<#(M2-2CS6HH
M3P!QQZUDQ7DP!,5N0)2!41DC4 Q\B0:@')&1TK,_W7T[M3/[#VKN;M/KW ;E
M[1$C=;8',;PP&/RV_$BA@G>3:-!55\=3N"+Q541#TJRJQE0 DNH-Q'(UW)8+
M&QOD!+1T.M0M=19>*THU:@?"W\)IIB%M1?,P%GJ5==>TL_P@'@2WE3Y>HZQT
MW>/3-9V?5])TG:_755W#08TY>NZOI]Y;?FW[1XU88JEJNIVI'7MFX(DI)TF.
MJ$$0NLA&A@QI!_C,=Q-;_J11-I<KD*U:48C@0<&O X.<=>E(@:))NQI/A!QJ
MJ"12O&H!(IQ )& >F#;OR;^..[\\-K;2[ZZ=W3N1MO9S=B8+;?9.S\[E9-L[
M8R-1B-RYR*BQ>7JIYL9MW*4DM/7RJI6CF0I,486]["L;6YO0#])#$DCO^%(Y
M!JCD8\ CC*.>U@10FHZ<>-X[E+.1"MTTS1!"*,94^..ASXB_B3XA0U&#T!OQ
MT_F*?$_Y+=.[\[SV=VOL[ [!ZQW?O7:6_LEN[>.S<=%M/^Z&^MR[%HMP9ZMH
M]PY#%XK ;XJ-LR5V#EGJ$DKJ"HA;0LCF-=LI3;=DW.4A(+ZWBD0-AE>5%?P'
M\O'0, \:EJ$X)P>F3(G[UW;:$8/<V<C*Q&0Z*!^LGF8220'( JK5I3H?LK\B
M^@L'U?C>[<SW3U;B^G\R^.AP_9]?OO;5+L3*U&7K/X=C*3';HFR28>MK:_(@
MT\4,<K2O.#&%U@@6>*6.X@M)(V%U*0$0CN<D%AI'%NT%L5[06^$$]7B_62>2
M(ZHX@2Y&0@4@'4>"T)"FM.XA>) Z";XM_+S;GR?V#W=V-B-LS[?VYTW\@.^.
MCXZJ#<.+W73[TH^CMPSX*;?N#KL3%#0KBMW1TYJ:2G$DQCC*AI6)N$=_<IMO
M*NU\U72MX-QMDMXT8%7C6*:YB,=20&8BV+ X'>%\JEVUA>\W^^V" J9H;FWA
M#U[6:XM;6Y!X54)]4(V!J:H6H*Z0W=7?/OXP=B="]2?(+/\ 9^T.F=M=Q]38
M7NK;FV^Y=Y[(V9O3'[ S=508^'-9G#R;DJX8Z*BRF4IJ6IJ:>:HHX:F=(VEU
M, 3C==NDVB^DL+B5&F5;<DJ<#ZF,21 D@4+#4!6FHH^FH4GI-:,]XDKPPOI6
M:YCX?$;1V28K2M0NG6:9",I8"M.AO[%[^Z6ZHQ&VLSV!VIUUM&EWR[4^P'W-
MO;;> BWU7''C)P46U*G*9&F@S4D]&Z2!J<R(L<BNQ"L"2?<)I;"/<@+9Y+^V
MMIIC ,2%8%+2=IRH4C2Q(HK$ Y('2FQ2*]:S=;A!9S2QH):U2LIHE",-4590
M*E@I(J >BD_%W^81MKY#;0Z;[#W/M_K_ *4V;W)\=^LNZ\6-Y=^;#GWQB=R]
MI]D9+K?;G7U7L"2CPV9J,7E,M!1P8S<BLM!E\O6C&4T+5*>L^NMK-M<7-IXV
MNZ#6*QJJD^(;RR>\*&GP21JC*D9!:=%DF0!(V'13#?B>+ZH1:;)9-Q5W8A0B
MV%S';^)Z,CAS)(P-+?\ 360GQD/1D^U^_<-U]N?8.S<)6=9[AW3N/M+K/8N\
M-N;C[FV9UUN'9>W.STW:FW]TT&#SJU>2WEG\Q6[0J8<-MZFCIZ[/&"J-)(?L
MY@"VT0W-W%  ? *W +J"Y$D%LUR(] R25"F0@_H0MX[@QC)E.DL-I)<>$2P6
M-E![59&N8;9WUG"JAE.DG$DH6W4B21: MWA\_NF>I>TND^F=M9G:/:_9':7R
M<V-\:]W[.VEV-M;^]/3M=O;9>^=Z1;MWGMR.3)9@4N.I-EB*2A,5/,6KHF9X
MUMJWMD+;GNEKM\0(@EM;^82TJE;"!IGC%.+,5,9(-(VKJR"O5=PU;?MUW?3+
M1XGLQX9[69;R[@M485\E$_BC^-%[<'4#2T?<74>0Q>U<Y0=I==5N%WUNNLV)
MLC+TF]MM5&,WCOC'5.;H\ALW:U=#DWI=P;JH:O;62BFQ](TU7%)CZE6C!@E"
MMHK2O!'$"TDL!G0#)>$1B4S*!EHA$1(9!5!&0]=)KUN;_%S="X[#!,(I-6/#
ME+B(1O7X)#(RQA&HQ<A*:B!T&FY_E9TM0;;[VKMC]A; [/WK\?\ K[=>_M[=
M:;2WYMRLW7CX-M8#)9N*@R]'1U.0K, N5DQQIDJ9Z<Q1RMR"05]HKZ[^CV3<
M=]CA,ME;QNQ*\"41WT:L@%@C::\:$BH!Z6V%F+W>MMV228175S*B#5Q =U4M
MIP2%U@L!PJ :5'2'@^6<F6^%'6'S"PNS-L8\=F]9=$]F4VQ^RNX-J=6X# 47
M=$FQI)L3F^V-RT#;7IJ[;5%O%O 6IT_C%;3QTD CEJH](BW+:_W=S,.7FGUJ
M-Q%J9%4ZB#(8]:15+2.>*PJ=3DZ5->B+;=P3<MF?=UC* 6<TX4D4K%$\FEWX
M(A*4>4]L2$R,-*D=#))\C?C]'O>BZT?N_J4=B9#<^2V11[&'8>TVW9-O3$8V
MDS&3VB-OIEFRB;HHL3D(*F3'M$*L4\R2>/2RDE<*M<,JP#6Q21P%R2L3%96%
M.(C965R/@*L&II:AC,K6T;RW T1*T:DM@ S"L()/ RC,=?CJ--:BJ3[R^3VR
MNA.Q/C!UMNG![IRV8^5G<F0Z3V-6[?IL3/C,#N3'=9;[[3FR>[9,CE\;54V#
M?!]?U<"O1Q5D_P!W-$#$(R\B;L$.X;PNRQ8N3M]W>:C\/AV8B,BU%3K;QET"
MFDT.IEQ7=RIM=GNMZ?-M#=VEN5'Q%KR4Q1D>6E6%7J00/A#''3'M#YA]6;L^
M07RK^/,L69VKFOA]M;I?=_:F]]W28#"]>R8?N[;&ZMW8*HPV;ESCU20[?Q&T
MIVRLU?34,$#2)XWE4.R5CT2;5<;P9%2TBW"6S.HT/B16]I<,WIH*WD:J:ZBZ
MN---):DQ,>Y;=M2(TEU<V/U2Z16B?436VD^9?5"S8!701W:J@"%MSY*?'C=^
MS(NQ=L=Z=1YS8,VY*/9R;RQW8FTZC;/][LC4P4>.VL^:7+?P^/<>1JJJ*.GH
M6D%3.TT8C1M:7L\<D8MV="%E#%"1APBLSE?XM"H[/2ND(Y:FDTT'0FX <$PT
MUY^#40JZOX=190*TJ6 '$=-^%^5/QFW'%LF? _('IK,0]D[AR&T=@28[LC:-
M4F\MU8F>2ER6VMN&'+-_%L_1U<1BDHX=50);)HU$ Z5&=[>)%+22Q&1 ,EXP
M"2ZT^)0 Q)' *U::6I>8?3"[-Q2,6\JQ2:L>'(WPH]?A9JC2#0FJTKJ%53E>
M\>F,'V1ANG,UVQUSB>V=PTJUN"ZTR.\]O4>^LO2.DLD4^/VK49"/-54<\<$C
M1Z(3Y5C<I<(UM0*UT]Q%; R20KJ<+DHM*U:G"@(8UX*0QQGKTP-NEM+."D<Q
M(0G <@D=I/'((QY@CCCI&?(#Y);,^/T77F*RN*W%O;LGN;>3]=]+=3;)I:2M
MWIV5O2+!9;=%=0X[^)5N-PN#P&W=M8.KR69S63JJ3%8C'T[S5$RDQI)1/%FN
M5L[:$R71ADF(J%"Q0Z?$D=F(545I(XQDL\DL<<:O(ZJ71$JVEQ?W$RQ6431H
M6:O=)*VF*)  2\LA#:5&-*.[%41V7U!\A\'MSK:M[&^1.#;XK4F&KZ3%YR#N
M3>?7=/B*6MR$<4V.7';TVYNO-[1S<=8LZQJ(*KRBH62(QZD/N\S6\(@/U*DR
M'2!D-J !(H0*TR05J"%+8 -&8EGE,P$#:4742*%=)8J"2/AS0$-0U90*ZA41
M,+VYU5N,[$7;_9>P<V_:6(RVX.LX\3O#;^0D["P6 @HJG.YC9$=+D)7W3C,)
M3Y*G>LGH1/%2K/&9"H=;N-!,LUQ T3>-"@=UIE$9@JNP\D9F558]I+  DD=4
M$D;1I,''A-)X8/D7H[:/]/ICD)7X@$<T[6HDLW\F?CEMO#4FX<_WWTUB,'D/
M[\#&Y:O[,V93T&3?K'(?PGLB+%U,F9$>2FV!E?\ )<TD!D?%U/[52(W]/M-X
ML?AQS!P8GACE5AD&*9@L4H(P8Y&("2#L8D4)KT[I82W$)%)H9C%(IP4E5&D,
M3C\,@16<QFCZ5+4H#T"7:O\ ,*^+?3_;_P 8.GMU]E[7.2^6F/W5F>KMU4.[
M-G2[-?";>P$6<Q.;K\O-N&GDJL3OR>9:#!5&/BK8JZN/C!46;VNM[.>XW*_V
MC04W.W@$C1,"'):>"!8E6FKQ6,VM5(%4BE-:J 6)9X8=KCWAIE_=[3>'KK@#
MP9IFD)X".-8=+FM5:2,4HQ(&JG^3OQOK-T#9-)W[TU5[O.:AVU_=NF[,V;49
MG^\M1N2OV;3[:-!%F7J!N.?=V*J<6E 5^[;(4\E.(_*C(&(4>YCCEMT,D3J&
M4KD,&B>8%2,,##&\M14>$C2? I/3DQ%O))%.=$J E@V"H#QQDL#E1KEB3-.^
M1%XL 10QV[MJ9C<&Y-IXC<VW\INC9HPS;NVYCLQCJW.[6&XJ.7(;?_O'B::H
MEK\)_'*"!YZ3[F.+[F%2\>I>?>M#F(3:#X)<IJIVZU",RUX:E61&9>(#J2*,
M*V960H'%"R:Q7%4+,@8>JED=0PQJ1EK52 7KJ'Y@=1=N9;M;"Q5TFPZ_JWY1
M;N^(R0=A9+;. D[![9V?M3"[SJJ+KF),]5S;CBR6 R[STE/IBR4D=#5.:58X
MBYO!"]S:[9<PC4UW#=2J@S(([2ZGM)G91^%7MV<L*JL;(6*DD!NX=;:\O[.4
MT-O]-J;@E;J"">( GS(N(XZ&E9*JNJH)$+<GR+^/VSZ/,9#=?>/46W*+;VYL
MSLG.5&;['VAC8\3O7;NW5W?GMFY U>8B-+NW#;4=<G58Q[5L% PG>(1$-[3^
M)'^EWCO21US\212"&5E]5CF(BD(PDI$;4;'2@P3*65HF!5HE-12AF0R0@UX&
M6,%XP?C0:EJN>D%B/E-L*&N[WR78&Z.H-@]9=.YG8%+0=C3=Y;'S4&;P>_\
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M#UE+45]$\PIG>HCCAE]92I9[M+=W"N;2;:[FT)1=3))-/97$3%*BL9:T,4C
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MSA-1KNUM;WNV7&V[?)'%//R_:0'M"QR/:[[/>O9S/3M2>SI$&TM&%E5'[#(
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MT>/S5?/BX*NHW%414,.E)S[/-X _K3S3=7+,+:[YPV.4PNM"(MLW6ZDO+F9
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M+[6^<.X*CY5[@V/4U6-J,WMK;VY]KX#!=.=7T^=F>CI:ZEVGU-MG#00R2O%
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M>7$]W=3-)=2NSN[$LS,Q+,S$Y+,222<DFIZ2V]O!:006MM$L=M&@1%44554
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M]U[W[KW7O?NO="#UA_Q]B?\ :KR'_6RC]AOFS_DC-_S63_ W2_;O]R?]J?\
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MVI_Z*'Y%_P#VG_?NO=>_Z"6_Y'__ 'GCM3_T4/R+_P#M/^_=>Z]_T$M_R/\
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M_P#:?]^Z]U[_ *"6_P"1_P#]YX[4_P#10_(O_P"T_P"_=>Z]_P!!+?\ (_\
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MR%?^\[\-_P"BR^2/_P!I[W[^M^\>L7^\#KW[MMOZ7[>O?]!!'\A7_O._#?\
MHLODC_\ :>]^_K?O'K%_O Z]^[;;^E^WIVPG_"B+^1%@*\9+'_/# BI$$M.#
M/U;\CYH_',8V?]MNGK:KQ"Q_'M%?\P;AN5N;6Y,?A:@V% -16F?SZ<ALX8'\
M2.NJE,GI8?\ 02W_ "/_ /O/':G_ **'Y%__ &G_ &2=*^O?]!+?\C__ +SQ
MVI_Z*'Y%_P#VG_?NO=>_Z"6_Y'__ 'GCM3_T4/R+_P#M/^_=>Z]_T$M_R/\
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M_P#:?]^Z]U[_ *"6_P"1_P#]YX[4_P#10_(O_P"T_P"_=>Z]_P!!+?\ (_\
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M=?=P[=J:C";<S=74YJN7)[RZ\VY@T6AIY0Y1ZI9''"*QX]^Z]UM[_P#=/_\
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M]^Z]U[_H&\_DE?\ >!&P/_1A=X__ &T??NO=>_Z!O/Y)7_>!&P/_ $87>/\
M]M'W[KW7O^@;S^25_P!X$; _]&%WC_\ ;1]^Z]U[_H&\_DE?]X$; _\ 1A=X
M_P#VT??NO=>_Z!O/Y)7_ '@1L#_T87>/_P!M'W[KW7O^@;S^25_W@1L#_P!&
M%WC_ /;1]^Z]U[_H&\_DE?\ >!&P/_1A=X__ &T??NO=>_Z!O/Y)7_>!&P/_
M $87>/\ ]M'W[KW7O^@;S^25_P!X$; _]&%WC_\ ;1]^Z]U[_H&\_DE?]X$;
M _\ 1A=X_P#VT??NO=>_Z!O/Y)7_ '@1L#_T87>/_P!M'W[KW7O^@;S^25_W
M@1L#_P!&%WC_ /;1]^Z]U[_H&\_DE?\ >!&P/_1A=X__ &T??NO=>_Z!O/Y)
M7_>!&P/_ $87>/\ ]M'W[KW7O^@;S^25_P!X$; _]&%WC_\ ;1]^Z]U[_H&\
M_DE?]X$; _\ 1A=X_P#VT??NO=>_Z!O/Y)7_ '@1L#_T87>/_P!M'W[KW7O^
M@;S^25_W@1L#_P!&%WC_ /;1]^Z]U[_H&\_DE?\ >!&P/_1A=X__ &T??NO=
M>_Z!O/Y)7_>!&P/_ $87>/\ ]M'W[KW7O^@;S^25_P!X$; _]&%WC_\ ;1]^
MZ]U[_H&\_DE?]X$; _\ 1A=X_P#VT??NO=>_Z!O/Y)7_ '@1L#_T87>/_P!M
M'W[KW7O^@;S^25_W@1L#_P!&%WC_ /;1]^Z]U[_H&\_DE?\ >!&P/_1A=X__
M &T??NO=>_Z!O/Y)7_>!&P/_ $87>/\ ]M'W[KW7O^@;S^25_P!X$; _]&%W
MC_\ ;1]^Z]U[_H&\_DE?]X$; _\ 1A=X_P#VT??NO=>_Z!O/Y)7_ '@1L#_T
M87>/_P!M'W[KW7O^@;S^25_W@1L#_P!&%WC_ /;1]^Z]U[_H&\_DE?\ >!&P
M/_1A=X__ &T??NO=>_Z!O/Y)7_>!&P/_ $87>/\ ]M'W[KW7O^@;S^25_P!X
M$; _]&%WC_\ ;1]^Z]U[_H&\_DE?]X$; _\ 1A=X_P#VT??NO=>_Z!O/Y)7_
M '@1L#_T87>/_P!M'W[KW7O^@;S^25_W@1L#_P!&%WC_ /;1]^Z]U[_H&\_D
ME?\ >!&P/_1A=X__ &T??NO=>_Z!O/Y)7_>!&P/_ $87>/\ ]M'W[KW7O^@;
MS^25_P!X$; _]&%WC_\ ;1]^Z]U4M_/3_D?_ ,JWXJ_RH_E[W_\ '_X?[.ZW
M[?ZZVUUW6[+WMC=Y]L9.MP-5FNZ.M]L9.:GH=P;_ ,OAZAJK!YNJIR)Z:50L
MI( 8*P]U[H?/@!_(B_E"=G_RWOA7WOV;\'MB[S[)[%^)/QV[!W]N"IW_ -S8
MZIW1O+>'6.T,IN;/54..[&AQU'59C,9&:JDCIX(J=))"L4<<>E57[99#<;ZW
MLS)H#DYI6E 3PJ/3UZ9GE\&)Y=-:>7YTZ,#_ ,,-?R3O^]='7W_HU>\?_MA^
MQ=_4I?\ HY'_ )Q_]#]%O[U/^^/Y_P"QU[_AAK^2=_WKHZ^_]&KWC_\ ;#]^
M_J4O_1R/_./_ *'Z]^]3_OC^?^QU[_AAK^2=_P!ZZ.OO_1J]X_\ VP_?OZE+
M_P!'(_\ ./\ Z'Z]^]3_ +X_G_L=>_X8:_DG?]ZZ.OO_ $:O>/\ ]L/W[^I2
M_P#1R/\ SC_Z'Z]^]3_OC^?^QU[_ (8:_DG?]ZZ.OO\ T:O>/_VP_?OZE+_T
M<C_SC_Z'Z]^]3_OC^?\ L=>_X8:_DG?]ZZ.OO_1J]X__ &P_?OZE+_T<C_SC
M_P"A^O?O4_[X_G_L=>_X8:_DG?\ >NCK[_T:O>/_ -L/W[^I2_\ 1R/_ #C_
M .A^O?O4_P"^/Y_['7O^&&OY)W_>NCK[_P!&KWC_ /;#]^_J4O\ T<C_ ,X_
M^A^O?O4_[X_G_L=>_P"&&OY)W_>NCK[_ -&KWC_]L/W[^I2_]'(_\X_^A^O?
MO4_[X_G_ +'7O^&&OY)W_>NCK[_T:O>/_P!L/W[^I2_]'(_\X_\ H?KW[U/^
M^/Y_['2BVM_PG\_DF[DRZXMOY>77]&&I*BI\X[/[QG_S#0KH\?\ I'B_5Y?K
MJXM[+-WY:7:[(W8O-?>JTTTXUS74?3TZ46U\;B7P_"I@GC7_ "="5_T#>?R2
MO^\"-@?^C"[Q_P#MH^PKT8=>_P"@;S^25_W@1L#_ -&%WC_]M'W[KW7O^@;S
M^25_W@1L#_T87>/_ -M'W[KW7O\ H&\_DE?]X$; _P#1A=X__;1]^Z]U[_H&
M\_DE?]X$; _]&%WC_P#;1]^Z]U[_ *!O/Y)7_>!&P/\ T87>/_VT??NO=>_Z
M!O/Y)7_>!&P/_1A=X_\ VT??NO=>_P"@;S^25_W@1L#_ -&%WC_]M'W[KW7O
M^@;S^25_W@1L#_T87>/_ -M'W[KW7O\ H&\_DE?]X$; _P#1A=X__;1]^Z]U
M[_H&\_DE?]X$; _]&%WC_P#;1]^Z]U[_ *!O/Y)7_>!&P/\ T87>/_VT??NO
M=>_Z!O/Y)7_>!&P/_1A=X_\ VT??NO=>_P"@;S^25_W@1L#_ -&%WC_]M'W[
MKW7O^@;S^25_W@1L#_T87>/_ -M'W[KW7O\ H&\_DE?]X$; _P#1A=X__;1]
M^Z]U[_H&\_DE?]X$; _]&%WC_P#;1]^Z]U[_ *!O/Y)7_>!&P/\ T87>/_VT
M??NO=>_Z!O/Y)7_>!&P/_1A=X_\ VT??NO=>_P"@;S^25_W@1L#_ -&%WC_]
MM'W[KW7O^@;S^25_W@1L#_T87>/_ -M'W[KW7O\ H&\_DE?]X$; _P#1A=X_
M_;1]^Z]U[_H&\_DE?]X$; _]&%WC_P#;1]^Z]U[_ *!O/Y)7_>!&P/\ T87>
M/_VT??NO=>_Z!O/Y)7_>!&P/_1A=X_\ VT??NO=>_P"@;S^25_W@1L#_ -&%
MWC_]M'W[KW7O^@;S^25_W@1L#_T87>/_ -M'W[KW7O\ H&\_DE?]X$; _P#1
MA=X__;1]^Z]U[_H&\_DE?]X$; _]&%WC_P#;1]^Z]U[_ *!O/Y)7_>!&P/\
MT87>/_VT??NO=>_Z!O/Y)7_>!&P/_1A=X_\ VT??NO=>_P"@;S^25_W@1L#_
M -&%WC_]M'W[KW7O^@;S^25_W@1L#_T87>/_ -M'W[KW7O\ H&\_DE?]X$;
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M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0@]8?\?8G_:KR'_6RC]AOFS_DC-_S63_
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M7O!B_P!]+^P=>_Z#2.G?^]9';?\ Z-3:W_VKO?OKK[_E,E_WMO\ /U[P8O\
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M[KWAB_XY1_\ )"_\4]^Z]U[PQ?\ '*/_ )(7_BGOW7NO>&+_ (Y1_P#)"_\
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MG_>W_P _7OK[K_?G\A_FZ]_I W;_ ,[&G_\ /9CO_J?W[^K&Q_\ *&?][?\
MS]>^ONO]^?R'^;KW^D#=O_.QI_\ SV8[_P"I_?OZL;'_ ,H9_P![?_/U[Z^Z
M_P!^?R'^;KW^D#=O_.QI_P#SV8[_ .I_?OZL;'_RAG_>W_S]>^ONO]^?R'^;
MKW^D#=O_ #L:?_SV8[_ZG]^_JQL?_*&?][?_ #]>^ONO]^?R'^;KW^D#=O\
MSL:?_P ]F._^I_?OZL;'_P H9_WM_P#/U[Z^Z_WY_(?YNO?Z0-V_\[&G_P#/
M9CO_ *G]^_JQL?\ RAG_ 'M_\_7OK[K_ 'Y_(?YNO?Z0-V_\[&G_ //9CO\
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MC_Y(7_BGOW7NO>&+_CE'_P D+_Q3W[KW7O#%_P <H_\ DA?^*>_=>Z]X8O\
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M>Z]X8O\ CE'_ ,D+_P 4]^Z]U[PQ?\<H_P#DA?\ BGOW7NO>&+_CE'_R0O\
MQ3W[KW7O#%_QRC_Y(7_BGOW7NO>&+_CE'_R0O_%/?NO=:P__  KM1%_DV;Z*
MHBG_ $]]$"X10;?WBK_H;7'T]^Z]U=Q_W3__ /+._P#YBOOW7NO_TK$^_?\
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M?NO=>]^Z]U&AK*2HFJJ>GJJ:>>AD2&MAAGBEFHYI(DGCBJHT9GIY)()%=5<
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M[1VSLS=>W\#ORHV5)D9SAZO)4]15XT2LL$J+90DMW:U='B.4NH[E >X)<Q-
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MWE_^@>B/Z*Z_WR?VC_/U[^XF[O\ G23_ /G3C_\ ZK]^_K%LO_*>O^\O_P!
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M )TX_P#^J_?OZQ;+_P IZ_[R_P#T#U[Z*Z_WR?VC_/U[^XF[O^=)/_YTX_\
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M_P"7#_YSX[_['O?NO=>_A/\ PL4_YZ?^7#_YSX[_ .Q[W[KW7OX3_P +%/\
MGI_Y</\ YSX[_P"Q[W[KW7OX3_PL4_YZ?^7#_P"<^._^Q[W[KW7OX3_PL4_Y
MZ?\ EP_^<^._^Q[W[KW7OX3_ ,+%/^>G_EP_^<^._P#L>]^Z]U[^$_\ "Q3_
M )Z?^7#_ .<^._\ L>]^Z]U[^$_\+%/^>G_EP_\ G/CO_L>]^Z]U[^$_\+%/
M^>G_ )</_G/CO_L>]^Z]U[^$_P#"Q3_GI_Y</_G/CO\ ['O?NO=>_A/_  L4
M_P">G_EP_P#G/CO_ +'O?NO=>_A/_"Q3_GI_Y</_ )SX[_['O?NO=>_A/_"Q
M3_GI_P"7#_YSX[_['O?NO=>_A/\ PL4_YZ?^7#_YSX[_ .Q[W[KW7OX3_P +
M%/\ GI_Y</\ YSX[_P"Q[W[KW7OX3_PL4_YZ?^7#_P"<^._^Q[W[KW7OX3_P
ML4_YZ?\ EP_^<^._^Q[W[KW7OX3_ ,+%/^>G_EP_^<^._P#L>]^Z]U[^$_\
M"Q3_ )Z?^7#_ .<^._\ L>]^Z]U[^$_\+%/^>G_EP_\ G/CO_L>]^Z]U[^$_
M\+%/^>G_ )</_G/CO_L>]^Z]U[^$_P#"Q3_GI_Y</_G/CO\ ['O?NO=>_A/_
M  L4_P">G_EP_P#G/CO_ +'O?NO=>_A/_"Q3_GI_Y</_ )SX[_['O?NO=>_A
M/_"Q3_GI_P"7#_YSX[_['O?NO=>_A/\ PL4_YZ?^7#_YSX[_ .Q[W[KW7OX3
M_P +%/\ GI_Y</\ YSX[_P"Q[W[KW7OX3_PL4_YZ?^7#_P"<^._^Q[W[KW7O
MX3_PL4_YZ?\ EP_^<^._^Q[W[KW7OX3_ ,+%/^>G_EP_^<^._P#L>]^Z]U[^
M$_\ "Q3_ )Z?^7#_ .<^._\ L>]^Z]U[^$_\+%/^>G_EP_\ G/CO_L>]^Z]U
M[^$_\+%/^>G_ )</_G/CO_L>]^Z]U[^$_P#"Q3_GI_Y</_G/CO\ ['O?NO=>
M_A/_  L4_P">G_EP_P#G/CO_ +'O?NO=>_A/_"Q3_GI_Y</_ )SX[_['O?NO
M=>_A/_"Q3_GI_P"7#_YSX[_['O?NO=>_A/\ PL4_YZ?^7#_YSX[_ .Q[W[KW
M7OX3_P +%/\ GI_Y</\ YSX[_P"Q[W[KW7OX3_PL4_YZ?^7#_P"<^._^Q[W[
MKW7OX3_PL4_YZ?\ EP_^<^._^Q[W[KW7OX3_ ,+%/^>G_EP_^<^._P#L>]^Z
M]T6_Y=?#_P#X5<_-SXZ=F?%OO7-_R_:_JCMK'X7&[PI-M9*CV]G)J7 ;IP>\
M,<,?F8=LSRT,B9K;M,S,J$M&&7B]_?NO=+[HWHC_ (5O_'GI?J3H3K?/_P N
M^EZ]Z4ZUV1U1L:FRDF.R.4@VCU]MK&[4VY%D\C_=F!LED4Q&*A$]0RAYY=4C
M>IB??NO="E_"?^%BG_/3_P N'_SGQW_V/>_=>Z]_"?\ A8I_ST_\N'_SGQW_
M -CWOW7NO?PG_A8I_P ]/_+A_P#.?'?_ &/>_=>Z]_"?^%BG_/3_ ,N'_P Y
M\=_]CWOW7NO?PG_A8I_ST_\ +A_\Y\=_]CWOW7NO?PG_ (6*?\]/_+A_\Y\=
M_P#8][]U[KW\)_X6*?\ /3_RX?\ SGQW_P!CWOW7NO?PG_A8I_ST_P#+A_\
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M?_.?'?\ V/>_=>Z]_"?^%BG_ #T_\N'_ ,Y\=_\ 8][]U[KW\)_X6*?\]/\
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M6*?\]/\ RX?_ #GQW_V/>_=>Z]_"?^%BG_/3_P N'_SGQW_V/>_=>Z]_"?\
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9O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g800041g10b01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g800041g10b01.jpg
M_]C_X0T[17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    )    L8=I  0    !    O    .@ +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P(#(U+C0@*%=I;F1O=W,I #(P,C0Z,#,Z,S @
M,#DZ,#@Z,3  <G(T,34P,S0      Z !  ,    !__\  * "  0    !   "
MGZ #  0    !   !&P         & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M]E=K;O2WI*=3U^I?]Q6?]O?^HDO7ZE_W%K_[>_\ 42H8O3<RQUK,BW,I8]L
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M<[J0#760]K\02U\-&]FVO^;V.?7[=]7J_P"$_P "E-C[/?\ ]QLG_P!C'_\
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M_P""+YJ224_2OZ'_ +O?^")?H?\ N]_X(OFI))3]*_H?^[W_ ((E^A_[O?\
M@B^:DDE/TE;Z'Z.?M7\]3'K>KLGU:]N[;_*_ZW_I?T2V%\JI)*?JI)?*J22G
MZJ27RJDDI^JDE\JI)*?_V?_M%9Y0:&]T;W-H;W @,RXP #A"24T$!
M5AP!6@ #&R5'' (   (  !P"4  (<G(T,34P,S0< @4 -4UI8W)O<V]F="!7
M;W)D("T@175P<F%X:6$@+2 R,#(S($%)1B!43R!"12!&24Q%1"YD;V-X.$))
M300E       0\B"T4--$N4O==P:VTPI@(CA"24T$.@      Y0   !     !
M       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU
M;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +
M<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 2P    !
M  $!+     $  3A"24T$)@      #@             _@   .$))300-
M   $    6CA"24T$&0      !    !XX0DE- _,       D           $
M.$))32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8
M!@       0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M     0 M    !@       3A"24T#^       <   ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H   X0DE-! @      !     !   "0    D      .$))301$       0
M     @   D    )      #A"24T$'@      !      X0DE-!!H      WD
M   &              $;   "GP   "( 10!U '  <@!A '@ :0!A "  +0 @
M #( ,  R #, ( !! $D 1@ @ %0 3P @ $( 10 @ $8 20!, $4 1  M #$
M,     $                          0             "GP   1L
M                 0                         0     0       &YU
M;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   1L
M4F=H=&QO;F<   *?    !G-L:6-E<U9L3',    !3V)J8P    $       5S
M;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M      9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A
M=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   $;     %)G:'1L;VYG   "GP
M  -U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB
M;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M  ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E
M96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E
M=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S
M971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
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M!SF['.KZ):YS"S=674!Q:X/>_9^L.;ZE>S^;?Z?\[5[_ .<].0=CD@#H]VI
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MP+6BOT[+*MV[=O0G&H2!T:UIVN(+S0UNX#=77O;D/_G7_H6_\)_(5[U^I_\
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M>\U7#, =#BT2YGI['-VL]E=K;O2WI*=3U^I?]Q6?]O?^HDO7ZE_W%K_[>_\
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M?T2V%\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?_V0 X0DE-!"$      %<
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     4 $$
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M(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TB=R(_/O_N  Y!9&]B90!D0
M  '_VP"$  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$" @(" @(" @(" @,# P,# P,# P,! 0$! 0$! 0$! 0(" 0(" P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M __  !$( 1L"GP,!$0 "$0$#$0'_W0 $ %3_Q &B    !@(# 0
M   '" 8%! D#"@(!  L!   & P$! 0            8%! ,' @@!"0 *"Q
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M]^Z]U[_1O_/2_P"\L?Y9/_I&7R/_ /NP??NO=>_T;_STO^\L?Y9/_I&7R/\
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M_P LG_TC+Y'_ /W8/OW7NO?Z-_YZ7_>6/\LG_P!(R^1__P!V#[]U[KW^C?\
MGI?]Y8_RR?\ TC+Y'_\ W8/OW7NO?Z-_YZ7_ 'EC_+)_](R^1_\ ]V#[]U[K
MW^C?^>E_WEC_ "R?_2,OD?\ _=@^_=>Z]_HW_GI?]Y8_RR?_ $C+Y'__ '8/
MOW7NO?Z-_P">E_WEC_+)_P#2,OD?_P#=@^_=>Z]_HW_GI?\ >6/\LG_TC+Y'
M_P#W8/OW7NO?Z-_YZ7_>6/\ +)_](R^1_P#]V#[]U[KW^C?^>E_WEC_+)_\
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M='N^,/\ .C^/_;7QDP':?:.,WSM'N':NV_BUC>_.MMN=7[UJ\=M+LSY-_'+
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MKA@?GIB-@X7JW<7<F7KMX[4^4'?FX.D/B[E-D])[[Z^WGD<]M'9F^<OG]O\
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ML];?$#=V-W?7=8=,X[IV'JO-TF^MQ8[M/K_<707\#FZA[ V[V105D&Y*3?\
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MW^<__P"FW>W?_JOW[KW7O^'I=L_]ZS?YS_\ Z;=[=_\ JOW[KW7O^'I=L_\
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MY_\ ]-N]N_\ U7[]U[KL?SI=L$@'^6?_ #GE!(!8_P MWM\A03]2%JF8@?X
MGW[KW2Y_D;=;]H]2_P K7XO;&[GV!O;J[LJB'=6;W%L/LC$5. WW@$WG\A^V
M]Z82/=6%K7DK,9F*_;VX:2JEAE9I$,]F)-S[]U[JV7W[KW7O?NO=5(_SS^M^
MPNV/Y8/?VS.KNL-[]S[P;>WQ7W7#UCUOMF3>F^-V[?Z[^7W0O8>]Z/;FTXGC
MDW%74NR-K9&I-&&'GC@9?S[]U[I'G^=)M@$@?RS_ .<\P!(##^6[V^ P_! :
MJ5@#_B ?\/?NO==?\/2[9_[UF_SG_P#TV[V[_P#5?OW7NO?\/2[9_P"]9O\
M.?\ _3;O;O\ ]5^_=>Z]_P /2[9_[UF_SG__ $V[V[_]5^_=>Z]_P]+MG_O6
M;_.?_P#3;O;O_P!5^_=>Z]_P]+MG_O6;_.?_ /3;O;O_ -5^_=>Z]_P]+MG_
M +UF_P Y_P#]-N]N_P#U7[]U[KW_  ]+MG_O6;_.?_\ 3;O;O_U7[]U[KW_#
MTNV?^]9O\Y__ --N]N__ %7[]U[KW_#TNV?^]9O\Y_\ ]-N]N_\ U7[]U[KW
M_#TNV?\ O6;_ #G_ /TV[V[_ /5?OW7NO?\ #TNV?^]9O\Y__P!-N]N__5?O
MW7NO?\/2[9_[UF_SG_\ TV[V[_\ 5?OW7NO?\/2[9_[UF_SG_P#TV[V[_P#5
M?OW7NO?\/2[9_P"]9O\ .?\ _3;O;O\ ]5^_=>Z]_P /2[9_[UF_SG__ $V[
MV[_]5^_=>Z]_P]+MG_O6;_.?_P#3;O;O_P!5^_=>Z]_P]+MG_O6;_.?_ /3;
MO;O_ -5^_=>Z]_P]+MG_ +UF_P Y_P#]-N]N_P#U7[]U[KW_  ]+MG_O6;_.
M?_\ 3;O;O_U7[]U[KW_#TNV?^]9O\Y__ --N]N__ %7[]U[KW_#TNV?^]9O\
MY_\ ]-N]N_\ U7[]U[KW_#TNV?\ O6;_ #G_ /TV[V[_ /5?OW7NO?\ #TNV
M?^]9O\Y__P!-N]N__5?OW7NO?\/2[9_[UF_SG_\ TV[V[_\ 5?OW7NBQ97Y)
M;]^=O\SO^5%NCK[X2_S$.F>O/C1OKYB[R[CWY\G_ (H;[Z(ZZPV.[$^'W8W7
M&QV&X=S53T&2R^2W?E8Z*GA1&D5JH\J'&OW7NMCSW[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_];?X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UKT?\)S23T7_,7)))/\XOYX$D
MFY).5Z])))_J??NO=;"_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO_7W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4H3?SM]D9?.[RH^I/Y=_\U?Y#;-V?
MV#O_ *T3M_H_XG8'=75.[-R]8;RS77V]O[G;DR_;FVZ[+8[";SVY7XZ2:2BI
MR*BDD73Z??NO=<S_ #FLP"0/Y07\ZP@'@CX;[$L?\1?Y  V_UP/?NO=<E_G,
MYIC8?R@OYU0-B?5\.M@H./\ :G^02K?W[KW7(_SE<[^/Y0/\ZAOZ@?$#KE;?
MX_N?(= ?]A?W[KW7)?YR>X'O;^3_ /SIA;_5?$;K%/\ ;:_D:M_]A[]U[KE_
MP\AN+_O3_P#SI/\ TDGJ[_[H_P!^Z]UVO\X[<S ,/Y/?\Z0 WX;XH]1*>/ZJ
MWR7!'OW7NN_^'C-S_P#>GO\ G1?^DI]0_P#W3'OW7NN9_G#[L_'\GG^<^PL#
M<?%SI5?K^+/\H$8$?ZWOW7NNQ_.&W:2!_P ,\?SGKDVY^+W20'^Q)^48 '^O
M[]U[KF?YP6\ ./Y/'\YMC_0?&7HH'_;M\J%7C_7]^Z]UY?YP.\W-A_)T_G-@
MVOZOC3T&@_V[_*U1?W[KW7/_ (=]WK_WIV_G,?\ I-WQ_P#_ +J_W[KW7)?Y
MO.^GN5_DY_SE;#_5_';X[QG^OTD^6BGW[KW7+_AW???_ 'IT_G)?^D\_'3_[
MK;W[KW7,?S<M_L 4_DZ?SC"#]?)T#\;XB/\ D%OEOJ_VX'OW7NO?\.X=A?\
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M#^_=>Z]_T$/?R6_^]@'4'_GI['_^P?W[KW7O^@A[^2W_ -[ .H/_ #T]C_\
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M!U!_YZ>Q_P#[!_?NO=>_Z"'OY+?_ 'L Z@_\]/8__P!@_OW7NO?]!#W\EO\
M[V =0?\ GI['_P#L']^Z]UDB_P"%#/\ )=FECA3^8#TX'E<(IEQ_84$0+< R
M3S[*CAB3^K.RJ/R??NO=7&XO)T&:QF.S.*JX:_%Y:AI,GC:ZG;73UE!7T\=5
M1U<#V&J&HIY5=3^5(]^Z]U.]^Z]T@]^]I]8]5T%'E.S^QMA];XS(5#TE!D=^
M[OV_L^@KJJ-!))34=9N'(8ZGJ:A$8,41F8 WM[]U[H*_]G(^(?\ WE3\;_\
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M>_=>Z]_LY'Q#_P"\J?C?_P"CQZQ_^RCW[KW7O]G(^(?_ 'E3\;__ $>/6/\
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M?P _](W^.O\ ]KGW[KW7O^&G?Y67_>M/X ?^D;_'7_[7/OW7NO?\-._RLO\
MO6G\ /\ TC?XZ_\ VN??NO=>_P"&G?Y67_>M/X ?^D;_ !U_^US[]U[KW_#3
MO\K+_O6G\ /_ $C?XZ__ &N??NO=>_X:=_E9?]ZT_@!_Z1O\=?\ [7/OW7NL
MH_E2?RN!"U,/Y;/P%%.TJSM /AU\>/"TR(\:3-%_HZT&5$D90UK@,1^3[]U[
MK%_PT[_*R_[UI_ #_P!(W^.O_P!KGW[KW7O^&G?Y67_>M/X ?^D;_'7_ .US
M[]U[KW_#3O\ *R_[UI_ #_TC?XZ__:Y]^Z]U[_AIW^5E_P!ZT_@!_P"D;_'7
M_P"US[]U[KW_  T[_*R_[UI_ #_TC?XZ_P#VN??NO=>_X:=_E9?]ZT_@!_Z1
MO\=?_M<^_=>Z]_PT[_*R_P"]:?P _P#2-_CK_P#:Y]^Z]U[_ (:=_E9?]ZT_
M@!_Z1O\ '7_[7/OW7NO?\-._RLO^]:?P _\ 2-_CK_\ :Y]^Z]U[_AIW^5E_
MWK3^ '_I&_QU_P#M<^_=>Z]_PT[_ "LO^]:?P _](W^.O_VN??NO=>_X:=_E
M9?\ >M/X ?\ I&_QU_\ M<^_=>Z)S\1?CMTI\9OYQOS1V1T)TEU%T)U_N'X!
M?"G>%+LSI;KW9W6>U*[+2=V_+W!9G<5;MG8^(PF'3/5C8B&GEG:#SSP4T6IB
MJ+;W7NKQ??NO=>]^Z]U1)_-,ZMZH[E_F&_R1NNN\^M=@=O\ 5.Z.[OFOC=R=
M=]H;,V]V'L;<-=%\+-_YC; SFS=U8W+X'+KB]QXBGK:=ZBGD%)5T\4ZZ9$1U
M]U[H[G_#3O\ *R_[UI_ #_TC?XZ__:Y]^Z]U[_AIW^5E_P!ZT_@!_P"D;_'7
M_P"US[]U[KW_  T[_*R_[UI_ #_TC?XZ_P#VN??NO=>_X:=_E9?]ZT_@!_Z1
MO\=?_M<^_=>Z]_PT[_*R_P"]:?P _P#2-_CK_P#:Y]^Z]U[_ (:=_E9?]ZT_
M@!_Z1O\ '7_[7/OW7NO?\-._RLO^]:?P _\ 2-_CK_\ :Y]^Z]U[_AIW^5E_
MWK3^ '_I&_QU_P#M<^_=>Z]_PT[_ "LO^]:?P _](W^.O_VN??NO=>_X:=_E
M9?\ >M/X ?\ I&_QU_\ M<^_=>Z]_P -._RLO^]:?P _](W^.O\ ]KGW[KW7
MO^&G?Y67_>M/X ?^D;_'7_[7/OW7NO?\-._RLO\ O6G\ /\ TC?XZ_\ VN??
MNO=>_P"&G?Y67_>M/X ?^D;_ !U_^US[]U[KW_#3O\K+_O6G\ /_ $C?XZ__
M &N??NO=>_X:=_E9?]ZT_@!_Z1O\=?\ [7/OW7NO?\-._P K+_O6G\ /_2-_
MCK_]KGW[KW7O^&G?Y67_ 'K3^ '_ *1O\=?_ +7/OW7NO?\ #3O\K+_O6G\
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M5..Q>RJK^*)/-1.)<BNB6%Z=WC;W7NBH[!_D 8C9.<I=V5'R[WGN;=<G?/\
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MO='#Z*_YDCTY_P"(KZ]_]Y+$>_=>Z%3W[KW5)7\Q#_MZ7_(;_P#$\_-__P"
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M8*;MRMRTDV!=\E5]M4M)##NJ28N^Y(88X\D:E$11[KW2:Q_QU^#^^,_V!M_
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MZ,=G]R]0?'C8U9FJVFVYUQUUALS20Y^KV_@(,;MG:U7N*LI8VSFY8-OT*TN
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M#V=BZ_!Q1L5CF?(".1E1F8>Z]T4?YJ_ FG_F#[UZL[$V#G,-C^A>_/C+V?\
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M_?NO='#Z*_YDCTY_XBOKW_WDL1[]U[H5/?NO=4E?S$/^WI?\AO\ \3S\W_\
MX"??WOW7NKM??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7B 001<'@@\@@_4$>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO6M]./J?\
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M[Y9?^F^_G5_]SS[]U[KW_#[7\OG_ )7OEE_Z;[^=7_W//OW7NO?\/M?R^?\
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MW7NO?\/M?R^?^5[Y9?\ IOOYU?\ W//OW7NO?\/M?R^?^5[Y9?\ IOOYU?\
MW//OW7NO?\/M?R^?^5[Y9?\ IOOYU?\ W//OW7NO?\/M?R^?^5[Y9?\ IOOY
MU?\ W//OW7NO?\/M?R^?^5[Y9?\ IOOYU?\ W//OW7NO?\/M?R^?^5[Y9?\
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M[KW7O^'VOY?/_*]\LO\ TWW\ZO\ [GGW[KW7O^'VOY?/_*]\LO\ TWW\ZO\
M[GGW[KW7O^'VOY?/_*]\LO\ TWW\ZO\ [GGW[KW7O^'VOY?/_*]\LO\ TWW\
MZO\ [GGW[KW7O^'VOY?/_*]\LO\ TWW\ZO\ [GGW[KW7O^'VOY?/_*]\LO\
MTWW\ZO\ [GGW[KW7O^'VOY?/_*]\LO\ TWW\ZO\ [GGW[KW7O^'VOY?/_*]\
MLO\ TWW\ZO\ [GGW[KW7O^'VOY?/_*]\LO\ TWW\ZO\ [GGW[KW7O^'VOY?/
M_*]\LO\ TWW\ZO\ [GGW[KW7O^'VOY?/_*]\LO\ TWW\ZO\ [GGW[KW7O^'V
MOY?/_*]\LO\ TWW\ZO\ [GGW[KW7O^'VOY?/_*]\LO\ TWW\ZO\ [GGW[KW7
MO^'VOY?/_*]\LO\ TWW\ZO\ [GGW[KW7O^'VOY?/_*]\LO\ TWW\ZO\ [GGW
M[KW7O^'VOY?/_*]\LO\ TWW\ZO\ [GGW[KW7O^'VOY?/_*]\LO\ TWW\ZO\
M[GGW[KW7O^'VOY?/_*]\LO\ TWW\ZO\ [GGW[KW7O^'VOY?/_*]\LO\ TWW\
MZO\ [GGW[KW7O^'VOY?/_*]\LO\ TWW\ZO\ [GGW[KW7O^'VOY?/_*]\LO\
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MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4#VU_,_[<PGRT[_\
MB3\;?Y>?>_RYW/\ &7!]+YKMO=NP^V?CQUOM[!-WOM/*;PV'14U/W#V'LW)9
M66KQN"K5E:F240R4K>30'B,GNO=0/^'"OYAW_>CWY5_^E1_!7_[?'OW7NO?\
M.%?S#O\ O1[\J_\ TJ/X*_\ V^/?NO=>_P"'"OYAW_>CWY5_^E1_!7_[?'OW
M7NO?\.%?S#O^]'ORK_\ 2H_@K_\ ;X]^Z]U[_APK^8=_WH]^5?\ Z5'\%?\
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MJ=MK(L;@0R^Z]U:5\ _DO\D\#3].?&7YM]2=T1?(?L/_ &8/*4G<]/CJ7/\
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MZ<[^/O\ ]JOW[KW7O]G4_G%_]Z1L!_Z<[^/O_P!JOW[KW7O]G4_G%_\ >D;
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M(_\ [E#W[KW7O^&W?E=_WN>_F$_^@E\(_P#[E#W[KW7O^&W?E=_WN>_F$_\
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M_P#02^$?_P!RA[]U[KW_  V[\KO^]SW\PG_T$OA'_P#<H>_=>Z]_PV[\KO\
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M_P"R+W[KW7O^'F/Y3/\ WL?^%W_I1/6/_P!D7OW7NO?\/,?RF?\ O8_\+O\
MTHGK'_[(O?NO=>_X>8_E,_\ >Q_X7?\ I1/6/_V1>_=>Z]_P\Q_*9_[V/_"[
M_P!*)ZQ_^R+W[KW7O^'F/Y3/_>Q_X7?^E$]8_P#V1>_=>Z]_P\Q_*9_[V/\
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MW[KW7O\ TTG[]U[KW_II/W[KW7O_ $TG[]U[KW_II/W[KW7O_32?OW7NO?\
MII/W[KW7O_32?OW7NO?^FD_?NO=>_P#32?OW7NO?^FD_?NO=>_\ 32?OW7NO
M?^FD_?NO=>_]-)^_=>Z]_P"FD_?NO=>/T/\ VZ2_V/T_V/OW7NK /C]_S+7'
M?\R3_P"+CE?^R?O^9:_\"V_XMW_5Q_Y6_P#F[?W[KW0V>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
7>_=>Z][]U[KWOW7NO>_=>Z][]U[K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g800041g18c01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g800041g18c01.jpg
M_]C_X0ZS17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    )    L8=I  0    !    O    .@ +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P(#(U+C0@*%=I;F1O=W,I #(P,C0Z,#,Z,S @
M,#DZ,3$Z,CD <G(T,34P,S0      Z !  ,    !__\  * "  0    !   !
MIJ #  0    !   !4@         & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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MCZP9WJTU@.#&>]Q.E60]GH;6/;958^SU-G_=A%Q.J]-KRZK1U[+RPVW^CNK
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MZA^GH;M_2-9=_A7WV4?HUJY#/M/464F#73277#Q]1P;4S;^Z_P"SW;_^V_\
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M-,APXFH^/_",R/\ P)8--_6=HW?6#"LW_0WUM82R'0]@:^K^<:WU_7_F[/\
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ $L     0 ! 2P    !  $X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -Y    !@             !4@   :8    B $4 =0!P
M '( 80!X &D 80 @ "T (  R #  ,@ S "  00!) $8 ( !4 $\ ( !" $4
M( !& $D 3 !% $0 +0 Q #8    !                          $
M         :8   %2                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   %2     %)G:'1L;VYG   !I@    9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !4@
M  !29VAT;&]N9P   :8    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M       ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M       X0DE-!"@       P    "/_         X0DE-!!$       $! #A"
M24T$%       !     (X0DE-! P     #8$    !    90   %$   $P  !@
M,   #64 &  !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@     '_VP"$
M  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,
M# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$(
M %$ 90,!(@ "$0$#$0'_W0 $  ?_Q $_   !!0$! 0$! 0         #  $"
M! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($
M @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#
M!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&
M!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S
M-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /2^ILM?
MT[)93<[&L-3MM]8!<PQ]-@?[-RM(&<8PKSX5O_ZDJ1R&>#_\UW]R!(&Y 4E2
M0O79X._S7?W)?:*P)(< -22T@#XR$.(=PIXROJ73*MC']<ZG78-KF5/V.<X%
MGJ4V?S5K/2M_X1_OM_GD]>7TU[#=7]8>H7#]&ZQP;M)J97_/-W55N^SM_G\A
M^/\ ]/\ PG5-S*A6UF%0ZQC1#2UNRIH [/V^YG_A=ER!D#(L?6'7/9<\D-%+
M-H8S_#/WV-LL?L;]#_!>KZ'Z%/%=2 BW LZCTNRMM8^L&=ZM-8#@QGO<3I5D
M/9Z&UCVV56/L]39_W81<3JO3:\NJT=>R\L-M_H[JP&/W"VOTW/\ 09N;5ZGK
M>RW_  5?\Y^@6UU#'S;!4[I>1]B<QSG6L=3N99O@O]1NW=OU<_=O5;T/K**7
MC[?2;B6EC_LS@T>RT6CT]S_I7.IL9[_YO]#_ ,+:VQW"7=26$:?K/( ZE1$F
M7?9'3!#_ &M;ZI^B\L]V_P"A_P"#0^S?6>6 ]4J+6B3^JD%S@3&[:6_HMNWV
M-_[<_G/57%'N%/0)+/Z:>H4U/'4LAN582"QU5+JPT;0"SE^_WMW;U:&7CFTT
MATVM#7%D&0UQ<QCN/HN=6]+BCW'VJ3)))(J?_]#M<?)OMZAU^M]C[*6,9Z+7
M$PW]&YEC*F$-;M]1GO\ ^_\ Z-;6DGXK P&,'4_K*YC2S=L#Q+=NX5.=OV5E
M_P"DL:_>[W?Z/U*F6+H33J3N3)@FJ%J07WO:]M-#6OO>"[W&&M:W3U+(_ENV
M,;^?_8>H8U5%];+KMUKY,BV#L>T['L]-D4[J[&N9O8Q/B5^JZ[(G2Q_IL_J5
M36/\ZWU[?^N)Z:]F7D4SH[;<W^V/2>/\^C?_ -=2'$-@K1L/MK8QSWD-8T%S
MG'@ :N*J47.=E-LOJ-1O9% )DM#3ZCJ[&D-].^QKO4=LW_S7_=?]+++K#W4X
MLR+GS8/^#K_26?V7O]*E_P#QR?.9LH%\F<=[;2?!H,7_ /@#K4@9=E.-F]7;
MC=4M;9UAN/30]IMQ+,5SH8&LLLK;E#9NW,]_JMW^EZJKNZG=2Y]5OUAK]7:"
MX'#T8Z/\'M=[*G?Z*WUK/^&75>F?WBEZ9_>*8('M^27EK>O1ZCF=9I&\AM+3
MA6PV36_=]/==MHJR_P#MS_!^A^D=W5;C55>WKU(I?8YC7?87'>X%GZ+^=_<M
M;^;^D?\ ]MKJ/3/[Q3>F?WBEP']W\E.)T;J!S[VFGJM6?556?5971Z>]SG.=
M7<V[<YOIUUFNKTZ_^,?9^D6DT#[?:>_I4Z_V\A6&T!K0UIVM'    ^04&X8&
M2[(]1Q+V,86'Z(V.>_<&_ON]7W)"$K.FX\/WD'HV$DDE,I__T>SQ1/5OK&X%
MVC:0X$B)]#\RO:U[6;/SGOM98_\ F?2_2+<R[C1C6W 2YC"6CQ('M;_:<L"F
MW';USKM#&VFY]+7V$U;:VAM;-OZSZCZ['W>M^B8RJC^9N];U?YQ;F;[C13_I
M;FS\*YR?_1.Q)23&I%&/72#(K:&SXP(E"N]F=CV=K ^D^9(%[/\ -;1:G=DN
M>TOJ+:Z!S>_@C_@F:;_^,_[;]55LIECJA=%CQ4]CPZQVSVAP;9^BK#?;Z+K/
MYQJ7FFBV&D.S[;''VT,;4"= '/\ TMO_ $/LRG==B65NILM9ML:6D%PX(VJK
MB,I96ZZV@$66/?ZH >-NXLJ_X3^:97^8K[-FT%D;2)!'!'R2T51:N'FU/Q*7
MV6 V%@WQK[A[;/\ IA&^U4]MQ^#''\C5#"EKLBD_X.YQ$^%D9'_56O8K*6B$
M7VFOPL_[;?\ ^02^TU^#_P#MM_\ Y!9^?UN[#S?LS>GY66S:PBW'87#<_P!8
M[7&P54[&?9_>]M_T[Z?T:C_S@?MK/[+SR;'O8&BILC8YM>Y^ZQK6,?N]CWI:
M*= 9=3A+0]PU$AC^Q@_FIQDM) #+-?Y!'Y5D=-Z[?96^MW2\YCF>I8"^H,#@
MY\U5MWO9^F<VQF__ *[^D_1IF?6FTZOZ-U)H<6^G%$F'%E?Z5N_]$]KWO>[Z
M?Z"OU?4_P2.BG>26/_SB/V3[5^S.H?S_ *'H^A^D_F_7^T^EOW?9O\!ZGT_7
M_P &D@I__]+LL/U?VI]8O6=0]^VN/2L:^UK/3L]*N^H?IZ&[?TC67?X5]]E'
MZ-:N0S[3U%E)@UTTEUP\?4<&U,V_NO\ L]V__MO_  BRL5^[J_UD9O#[&LIC
M5LL::7;*MC7E[?=ON]WI^IZO]=7J/5MNRRTAKLF\UAP!D5TM;4]WTOW]_P#U
MVQ+;5(%FF[6!D6>L[6MA_0M[$C_#?^DO^W/\(GSH^Q7[M0:WB/&0=%,-L: &
MEH:-  T\?YZKYHL<VFESFGU;F"((^@?M#OSOW*+$%$VSZ=(P*&GZ5;!6\<PY
MGZ*QO]E[%)S302^L$U$S96-2"?\ "5-_\^5?VZ_TO\\&GU*<JW&W- MFZF6F
M-=,A@]_YMWZ;_KZM1;^\W_-/_DTE TUVN:,\.:0YF33(<.)J/C_PC,C_ ,"6
M#3?UG:-WU@PK-_T-];6$LAT/8&OJ_G&M]?U_YNS_  'Z!;67C75M&300;*7>
MKZ0:8=H66[6R[](^M]OT/IV*JSI?1B!:<+&:UP!9=Z+7MV_2K<RYI]C&_H_3
M_FOS-G^#2M5=M6B<WJX(J_;W3-T%VXL&XP?H[/M&WT_<WWI,R.K/R'68W7\.
MQMMKVT8]C&/86NL+J6U.I./<^UE?ZO\ SMS/Z]JTV=!Z,:=E>%A^BYI;M90S
M:6N!8]GM]NUS';41G0^FLL;:W#Q18V"UXH;(((<W:9]NUR*'&QNKY8NI'[<P
M;F.L#K:RPFUS ;&V4U^F^KT[/T/IU_J_\]O72T7U9%3;J7;ZWB6N"SF]&Z,V
MS[.VC$]:M@>6^F#9M@T,ML._UG_S>SU;/]$K6,***F48]E;:P2UC1),AWZ1N
MYUA<ZS?]/_A$E-M)0%U1L=4'M-C6A[F2-P:XN:Q[F_2V/=79M_J))*?_T^[Q
M.F96$_J^5EVMN&67/J>"_>VH>JZO'>+'/9^A]3V>G_Z25KHS2[#KR#S:W</[
M9-]CO[=EG^9Z:MY-#,G'MQ["0RYCJW%I@PX;';3^]JH5XKJZVUUW/:Q@#6M
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M)3]5)+Y5204_522^54D5/__9 #A"24T$(0      5P    $!    #P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H
M &\ = !O ', : !O '  (  R #  ,@ T     0 X0DE-! 8       < "
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M  (1 0,1 ?_=  0 -?_$ :(    & @,!              <(!@4$"0,* @$
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MY'_$7IGM_M.?:0V/5[VW;MQJC,9#;<0"4=-DS2U5+39/(8J$"*AKZB.7(4$
M\5//%'Z?>JCUZ]TV]Q_RF_Y;_P A-SS;U[K^'G3/96[ZB;K:2;<^Z,%4UN>D
M@ZBP:[9Z^Q)RPKXZW^[N#P*"EDQ@?^'5\0M5P3_7WOKW1@X/B3\;:;NVM^1M
M/T[LN+NG(]+T_P =:S>XH)3--T=2Y5<U!UB<(U2=MIM1,B@?P+1J650A8Q@)
M[]U[H&OCI_+#_E__ !([3WAW9\;OBCU%U#VIOJ+)TNX-Y[5P4J9)*#-54=9E
M\3MV*OK*V@V9A<G40H9Z+#0T%)($56C*J /=>Z#C<?\ )I_E<[KV#V!U=G?A
M;TU5;$[/[87O+>> @H<SC(ZWM1:6JH!NW%5V+S5%E-JS&@KIX#38F>AH6@GE
MC,)21PWNO<>'31M_^6-U7L_YT='_ "^QFY\'MKJGXI_%_-?'#XL_%;;>P=O[
M7ZTZ3S.]\Z:C?G:>"SM'7AY]R;KVSHPS4RT,&F"\CSRR&PVBM(=,:EF] *]:
M) %2:#HT79/Q0^)G8>_=X=Z=I]8;#SV_=U]"[F^+&].P<_65$$^1Z#WS7RS;
MGZLR54,K2XVGP6>R&182Z52J+RZ5E&H#W=(9I)!%'$S2G@ "2?/@,\ 3U5I8
MT4N\BA!YD@#/SZ OO3X&;-H>H]G2_#7KCHCK/Y/?&KHW=72/PJW]V?A]V9K8
MG1FUMZ8C&;4W%@7QN#R,V3JL17;0I&IU:6*MD24([+(AECD;KU?H$/CG_)E^
M*NT/Y;7QO_EU_*W8FQ_EGM3HO#9"LFW!N_ U6-";]W1N?.[VW7F=BU]#D*;=
M.S: YO<M32TYI:^&HGQZ(E06NZ>_=>Z,[NK^6#_+\WI\8]M_#;<OQ.Z@R/QF
MV=7C,;3ZICV]+08G;6=-3454^Y,'F,754>Z,9N?(3ULYJ\G#7)7U@GE6>:19
M'#>Z]U,RG\M+X$YJA^,6*K_BSU.]#\,,O2YWXPTM-A)L>G3^1ILE29M'V_\
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M]U[W[KW7O>CP/7NB(_S$..A=N'D6^07QU/'UY[>VH!_K\GW1.!'SZ]Y]'I!
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MF0QF:VAELO75E6A'\0EI<A2YFCBIX:A0?&K1L8_R3[VW/O,%3HM;:@'HV?\
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MW%FJ2LHM^[.@^ZQU735TT5R8YC%(DBH6OR3N$=ZMJ742>$7.:T (7C0 ZF-
M  0?(XK75":-5J?S_/IMVC_.NZB[3[W^$/5/3'QU^2?96S/FGMWM>M7L?&[&
MJL?DNB=V]/[KDV5OO9W;.R*_QUF'EZ_W#3/#NBI6I:+$++ Z?<B0Z-R<FR6U
MGN<\LJ^-" 0*U+"A;L/!AIHQ.D5%:!:9L#&2% .>C._./^91T'_+W_NUD?D!
MM/O:KV5EJ?'Y+<W:77/6L^[.N.L<!DL]#MJFS>_-P')X^=5.4J4O18NGR>16
M ^4P:.26;+RU<[T)S#*IE05TJ5/;CN%?B-333V_-A7K3!(Z!S4GA3IE^*O\
M,0IOE%\K?E]\7:3XZ=W]>0?%3<^VL+2=T;EP=^KNQL=N;:V(W5AZB/+M]M-M
M[/Y_#YFGR6+QLD<KU>&J(JIGC9C"MMSY=-AM=IN/CHRR5'F*?$0&%2 [:3I
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M>JU_YGA/^RS[1/Y7Y,]! $?T&\Z3Z>\MONOA4]R]Z"FH_JYN7\[=NH@][O\
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MK^MV#A]\[Y[LV1LS$]F4\=!T3"FY,:&[*Q.>V?$NXH*G[6EQ;P5*1U51&GE
MQ@Y-M%5D,K/))""&%-.6B[!4,1)W,"1459,"I'51-0X0 <#]GSZ.#O/^??\
M G8_4/3';TZ=U9FB[GV=VQV+'L"BV/@L7V9U9L/HO=E;L;N'<';6 W=O+;M%
M@&V)NS&U-#+CZ.LR.4K9J=_LZ>I4:O9/#R/N%Q<7D,3*5C;CJ& >'=I(8Y%
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MQJV@/_ F>@0?_0SI/>6?W6O^GD[V"/\ G7-R_P"T=NHA][Q_R#=NI_T=[/\
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M.D^^CJY#"C5BR!B&/ ]IH>:%E'A7# 1&V\,D(*Z@0:4U :32FL\/-:=;94.
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MV;?'G$'_ +_Q\>?_ '[VT_9=N.-KW,_\);_!U=!JD45\^C#5LX7(UU[>FOJ
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M=.#V;M_/[RW-6)C]L[,P&9W;N*OF*B.CPFV\?49;(SRM(RIH6GI2.3S>WM3
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ME4]=Y'8_PGZQW%N..8;T[UR6\ODCO>>H9FGJ\]WCN?([YHYI=8\BF':^2QT
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M^M]U[#P7;>V\>F4S_7U;N?$U.)&YL/0/6XTS9#'Q5+-$5J:>1'LR2(ZJP?'
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MF)O'(G7?;OWO4.\89);%4HI9]VT$DM_3: '^S[=0XSZ]:ZL]12H(M;U.0/\
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M@$GCWZJ+$\LSA$4$DUQ0>?5HHKBXFM[>VA:2YED5$102S,QHJ@#)))H !4G
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M;(PGP*^&/\NOXR?$K$2]F?R@>L_F9BL/VGO+L+"=?]'4F)%13;AP6-GH/O\
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M=(?!S 28CX9?'_Y._.G8O;7R@P^__DQG>Q]N_&CIGXJX/>.>Q735'N+^YO\
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M^&G"L(XYFJ*=SKW16OEADOF5\B^X?@#_ #0]Z?RKN^>PNGOC7GN_>O\ =O\
M+QWI5[+W1WQAWWUA**BV/\K\)UI63-M?+Y^CJ:44:8BI2?)4(ITJ(Y(D=:J+
MW7NB.Y+^67\L=]=#[2W%N7X*9;KOKCY5?S_/CQ\M<W\$<;%M[=F"^/\ \0L9
MMO-;;WUN7LG X2I&"V\V](:H?WCQ<$<4%+ D4;P0QD01^Z]T)'R@_EF_*?<6
M,_FXXWJ+XCU&0ZUA_F8_"/Y9=<_'ZEQN)V9L#Y:=&=.;#:/M3KWKO%01IMK(
M'-9-DGJZ9X4CJ:J$1A7J D9]U[IY^<O1GS(^4&V?@]\Z/CI_+O[A^)FQ?BU\
MB.TMP;^^$V ZEZ(W'WSN&IW/L[ X7;_RCQ/QZW#3XOJG>NY,55T[XJ"@RB5&
M9AA3[R,>%5D3W7N@_P"O_P"6EW;G^A/Y?>$S/Q*^1&:VCO;^?9#\Q^^^L_D1
ML+JW&Y?9G3VX]GTV,W5O+>W5'5\]3U]UAUCD,K2SO)M\(*=% 1Z?QS)&WNO=
M2.X/Y;'R=E^-?\X3!;'^&.1RXHOYRNR?EWT'U%%L[!XR#MWHC96X]KY/<,G1
M&+DH*G%2R[FVS1RTS1TD"BKIWEHRDA+0'W7NK(.K_B[OGO#^;I2?,?>OP0GV
M3UO-_)ZZ^QG1NV>^=C;;?:?1'R)G[0S+U/3.2H<;+7;>V]O;&[4R#0UJ4$:S
M4N+J)%0Q>21#[KW52OPJ^*'\Q'=_\S7^6WVW\E/AE\D-A_Z!>QOF/@/D[F*_
MK[H'8_PRV11]J["WGAMF8+XR;3ZJQ5'N6OZDR%-+30Y3)[AKLW#D*ZI @D"E
MP?=>Z<\!\*OF'@/Y9O<WP7_X;Q[.VOV]T1_,JZ=[9G[.VGM':;[,^3'5^;^6
M6?WY#D>M,A@VI<UN/;W5FRJN%ZCSI)18V@9%62)DDIXO=>Z';YC_ !9^576W
MR0_F_P"PZS^5IG?GM4?S0Z'!T?Q=^5.WY-FYS =.4.0ZV&PJ#8G;6<W3-1;@
MZ=V]U)N)(LO2U-'4TL=3)10.DG$,U-[KW2WVK_*S[OP/R;K\#W3\?YOD+1=.
M_P#";S:WQ,VEW!NW;>.WCLK._+? 9'.4%=M'8>4W DR3;H?%9.6CH:AT6N3&
MVO(@E;5[KW2Y[M^.?>&V/^$C69Z(WOL'>FR^Y>MOAQ@:[>?76>QM5%N["1=<
M]GX[>VX<;E,4&DJJ846TL++4F,@F*G074 6'NO=/_<7P^RG\Q#Y'?R_,MC^N
M\EO'XA=U?R4N[^EMX=WX6AH\OLC8.=[AV3M*KZ^GH<__ )314>\L?E(*:LQH
M"M(LD.H B.0+[KW568_ER?S,>SOY:GR7[?\ DWT#OW?_ ,Z]Y=Q?!?XE=;["
MQVU8O[W;6^'OPMWGLPG=FUX#65%8N*[-S@KLIG*YIO'DVI!7:$AE]^Z]T;#Y
M8?'F;9?\YCYP?)#OW^3!\H_YB&SMX5GQ!SWQ<[6Z?QTTN Z_RW6/6>WZ?=E1
M2.NXMNT596/NZCIC(TDDPB?'-%/&D+EF]U[HT^W\K\Z/Y6/SM^?'<&U?Y=W?
M7S9^/G\QC>&P/D-L'-]!5>W7['ZD[*H]JRXW.]4=P[:K\C5# X^BK<NZ#*1O
M)1PQP*T35+2314WNO="WLG,[K[H_X4==*[TR&R9]C;HZL_DJ8?+?(+9B9C'[
ME?J#LCN7NY\QC>G=S;DPXCQ^2S^(IIGGCE0>&KIXON(1XV4^_=>ZV4O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_]7?'["_AIV+O09K/5FU<,=H;G&7W1CY
MVILAMK%_P6L^_P!P4-2D<KP5F'IM51$X1BCH" ;6]^Z]U\V3^7KN3X0;6^,]
M?M_>?_"?OY(_S)Q@.T>YJ+;/SGV!TQO7<^+^2&QZ?L+<8V_O>LJ<O1UM1MW<
M=+C#%05.,QM370P24VLNE0\L2^Z]U]$7XES[;J/C+T1/L_IC.?'3:L_5FS9M
MN]#[EQ46#W!U'AWPM*:'869Q$3NF.R.W8"*>6*Y*.A!YO[T>!Z]T"G\Q:>GI
MOC]@ZJKGAI:2D[\^/%35553(L-+2T\/;NTWEJ*F=R$A@B2Y9R0!^?;08(CNS
M *,DG@!\SY=>/V=&^Q^_=CYD97^$;TVKE$Q"B7+OCL_BZU<3"QT^7(R4U5(E
M%&64@-(57CZ^TJ7UG+XKQW<+(F20X( ]6\@/G6G5CJ-*CJB7LC,[0[_^8?3-
M:NYMNYBEW=\T*C*VILU1U&/Q?2?PEZTK]SP9FLD6=EHL7N+M/)>022:()G1"
MK$@V%6^7]E#M?+VT6UW$T44)N)R'7M>4G2'H?P*!2OKTD@1VFN9F0T9@JX]!
MG]O5ZU!V-L/*XO)9S&;VVED<'ARIR^8H=PXNJQF+$EC%_$:^&I:EHS("+>1A
M<>PE]=:.C2B[A,2\2'!"_:>E>EJTH:]%P^2G>V+Q?5\&-ZPWCM/(;T[6W%3]
M7;+S=)N#'38G 5V9C_W\6Z,CDZ>HDIZ*GVEMXS53.6!27Q7_ %>RK==W@BL5
M6SO(C<W#^&C!AI75Q8GRTCS/G3J1O;#EZPW3?+O?-_-.5ME@:[NOZ6C^Q@']
M*>72@%#4:NA/ZQ_T0=9=4[=P.U-X[/78>Q*&CVV<]'G\2^+.4B"M6U65RB51
MHUS&8R$KU,^N35)-,3SJ]K;23;K2RACM[N+Z2+M+:A35YU/J3GY]!+F3?-QY
MFW[=-_W5RU[=2ES7\(X*BC%%10$44PH \NA"'8>Q3@SN==Z[2;;*U!HVW&,_
MBS@Q6@V:D.5%4:$5(/\ 8UZO\/:CZVT\,S_6Q> #0MJ&FOIJX5^71-0X%.N!
M[&V(,+'N8[WVB-LS5/V46X3N'%#"25P;0:),I]S]DU5K%O'KU_X>_&^LA")S
M>1>"3346&FOH#PZ]I:M*=<Y^Q=ATV&I=QS[UVE#M^ME:GHL[-N'%Q8:KJ$+!
MX*;)/5?9SS(4-U5R18^_&]M%C6=KV(0-P;4*'[#P)ZUFM*9Z]5]B[$H<309^
MMWKM&CP659H\7FJK<.+@Q61E35KCH*^6I6EJW32;B-V(M[VU[:)$LS7D0A8T
M#%@%)^1X'KU&%:CKU;V+L/&8S&YO);UVEC\-FA(</EJ[<.+I,;EA$NN5L;6S
MU*4]:L:\L8V:P]^>]LXXTD>[B"-P8L-)^P\">O9K2G761[$V+AJ'&Y/,;VVE
MBL;FHVFP^0R.X,714.5A1!(\N-JZFJBAKHE1@2T98 'W5[ZTC1'FNXD1OA)8
M#5]E?+KV:TIT2+^9SVMBMI_ GY!SXC=&"ILSV-US+UUL^09>C1LQ)VKD<;UZ
M]1AV\P:NCAH=SR3&2+4J1H7)"B_MXWEI"$:2[B&L=M6 J/,CU'V5ZWI)%:8Z
M,YUW_HZZ%ZHZEZOR&[]H[>H=F=:[+V?A!D\]BL9'D,?M?;^-P4570?=5$(K(
M)?M ?(EPS->]S[K->V<1C,EY"JL,$N!J'J/7/6@"> /16?YF6T<-V;\4][4&
M"W7MK%=P=9G;_P D.C$K=P8W&9"J[ Z4R<.^]OMCEJ)DJ9Z7/08FHQK-"#KB
MK&%R"0;?76D1$<UW$C, 15@"0?, \0?+K6<XX=&/Z>^3G4W;G3_4';]!OS9V
M,Q7<77^V-]8"FR&?Q^/DFASM' :FFI(*^HAJ)_L,N\E&Y /[T3+<D>]7%Y:6
M\H2>ZB0D5 9@#0\"!YUZL%8\!T+66[#V+@,C#A\[O3:6&R\Z4[Q8O*[@Q=!D
MI5JFTTS14-351U$BU#<1V7UGZ>Z/>V<3K'-=Q)(172S $^F#_J/6J'TZ[R/8
M6QL1ETV_E=Y[4QN>D:F5,)D,_C*++NU9;[15QU14K5LU3?\ ; 3U_CWY[VTC
MD$4MU$DM/A+ -^SK=&(J%QUZJ["V-0YL;9K-Y[3I-R-)! -OU.X,93YDSU*>
M2GA7&2U*UC2SIRBZ+L.1[\]Y:1RB![R)9S^ L W[#GKP!/ ==/V%L>'-C;$N
M\MJ1[F:H2D7;TF?QD><:KD4-'2C%M4"M-1(IN$":B/I[V;RT$IMVNHQ<C\&H
M:O\ >>/7J-2H&.O+V'L9L[_=8;SVFVY_/]K_ '<7<&,.<^[T&3[4XH5'WWG"
M"Y31JM^/>EO;0S_3_5Q&:M-&H:J^E./6B& K3'7H>P]BU.=;:]-O3:4^Y5GE
MI6V]#N#%RYM:N :IZ8XM*DUHFA7EET7 ^H]^%[:&8VXO(C<?P!@6KZ4K6ORX
M];(85[3UZDW_ +$R^7EVSCMY[4R&X(Y*FGGP5#N#&5.9CFI 35POC8:F2L26
MF%S(I0%/S;WN*^LY)O"CNXFE'X0P+8_H\?MZTRDKD8/01=C;5Z0[[I%V)E=T
MX');HPU5-D]N9+:6Z\?3]C;$S>--CG-L9#'U#Y7$UF/D4>8$>)U&B9&7T^TU
MTNV;J6M9;N,W*U*E&'B1GS92.Y?GT).5N:M[Y.OGO=G=3%*H2>&1==O/'7,<
MT1[74\/)A6JL#GHM]3VQD-KX;<W4W?.8V[WUTKG]LYW9V>[CZ_JZ#*;KQ&V,
MK056#S4'=77V"^[JL?30XZI=*G-X^.2FM=IH8R6/LNM]UDL)?!O+B.XLP,3(
M0SJ!_OY%J?\ ;#\^AQ)R]RE[@J]YR5*FV<UL27VJ9Z12>OT-Q(16I^&"6C>2
MN0!TC/Y378]"/C9FOCUD=];?WIG_ (>=A;PZ(3<F-S4>3CW)U9MNL3*=1;W$
M^MBV,K^N\K14HEOH$M!("001[/XK_;[DA[6]BD73J[6![?4YJ /,GAU%^X;7
MN>S7LVV;QMTUIN$9S'*C(P],$"OVBHZL@PW8NQ=QM7KM[>NT<ZV+IFK,D,1N
M#&9)L?1IJUU=<*2IE-+3)I-W>RBQY]^BO[.8N(KN-](JU&!('J:>72,J1Q!Z
M]A^Q=A[A7(28'>VT<W'BJ8UN3?$[@Q>17'48U:JJO:DJI124X*GUOI7CZ^ZI
MN-C+XGA7<3:!5J,#0>IIPZ\%)ICKK%]C;#S=)DJ_#;VVAEJ'#P+4Y:LQFX<7
M74N+IV5G6?(STU5)%10,JDAI"H('O<6XV4RR/%=QLJ\2&! ^WTZV484JISUR
MQW8FQ,OC<AF,5O7:63Q.'17RV4Q^X,768[%HRZE?(5E/524]$C+R#(R@CW5=
MRLI(WECNXFC7XB&!"_:?+KQ5@:%3UQHNQ=BY'$Y#/4.]=HUV#Q#*N7S5%N'%
MU.*Q1<*8QD*^*J:EI&DU"PD=;W]V3<;"2)YX[R-H5XL&%!]IX#K6DXQUW3]B
M[%K,16[AH]Z;2JMOXV84^2SD&X,7-B<?4'0%@K<C'5&DII&,@LKN#R/ZCWL7
M]FT+SB[B\$<6U#2/M/ =>TFH%#UZ/L38DV$GW+%O7:,NW:2H^SJL_'N#%OAJ
M:K8JJTTV46J-%%4,S@:"X;D<>ZKN5BT!N1>1&"M-08%:^E>'7B#6E#7KW^D7
M81P3;G_OKM([:6J^Q;<']X,6<(*Z^G[,Y3[K[(56KCQZ]7^'OW[QLO",_P!7
M%X(.6U#2/E7A7Y=;"L30#/7I.Q=B0X6#<DV]=HQ[<JJ@T=-GI-PXM,-45:Z@
M:6')M4_92U *D: Y;CZ>_?7VAB$_UD7A'SU#3_O7#K7Y==3]C;"I<-1[BJ=[
M;1I]OY"8TU!G)]PXJ+#5M0K,KT])DWJEHZF92C75&)N/>SN%FD0GDNXA"30-
MJ%"?2O7@"> ZZJ>QMA4.'H=PUN]MHT>W\HS)BLY4[@Q=/B,DZ:M:T&1EJEHZ
MMETFXC=K6/OS7]HD2S27<2QMP8L*'\^'7M)\E/7==V-L+&8W&YG);VVCC\/F
M0YP^5KMPXNDQN5$7^=..KIZI*:M$?]KQLUO?GW"Q1(Y'O(EC;@2P /V$GKVD
MC%.F;>NY>J<IM*JP^_=Q[$EV7O\ P64PU52;ASN)APF[-NY>@EH,Q0(]741T
M^3Q];CJIXI@A8&-S?@^_2[E80JCRWD2HW E@ ?L)X_EUZGRZ0O56V_CE\5NI
MNN>F>LZC8?5/4>T=OKBNL=IMNI(\31;;2IFK4@P=9N#*U==7X^.:M9D8SS!5
M8 '3;WZ6_LX55IKN-%;@2P%?LKQSUZAS@]"GF.Q=B;>^Q_C^]=H8,Y.E6NQO
M\7W%B\=_$*%[>.LHONZJ'[JEDN+.EU/X/O4FXV<142W425R-3 5'J*\>O:32
MM,=>R_8VPMOS4M-G][;2PE17T\5904^6W!B\=/6T<S!(*NEAJZJ&2HIIW(".
M@*L3P?>YMPLK=E$UW$FH5&I@"1Z@>G7@"> Z[RW8NP\!6P8W.[UVEA<A5105
M%-0Y7<&+Q]94P53!:>>"FJJJ*6:*H8V1E!#'@<^_2;A90LJ37<22$8!8 FO#
MS\^O4-*TQT"&U>KOBGTIW?W%V[MS%=:[&[[^2$^QJCN/=U7GX*?>_8PV3B'V
MWL"')1Y;)23"BPF)G:GHJ>EBA@(<G2SG5[\^X6<3:)KJ)),8+ '/RZUGTZ'#
M(=A;'Q68CV]E-Z;3QN?E>!(\)7Y_%T>7D>J_X"QIC:BI2K9JC^P-%W_%_=FO
MK))? >ZC$U::2P!_8<];H:5ICKT_8>QZ3.+MFKWGM.EW')/#2Q[?J,_C(<V]
M54*&IZ9<9)5+6-/.INBA-3#Z ^Z_O&Q$WTYNXQ/6FDL-5?\ 2\>O:32H&.LT
M>^MGS9Z3:L6Z]M2;HBN)-MIF\>V>B81^4K)B1.:Y2(_4;IP.?I[M];:F8VPN
M(S<U^#4-7[./7J&E:8Z5:L&4'_;_ .O_ +Q[4:P./'K77*_OVL?/KU.N_=JX
MKU[K_];??W#%+/A,Q!"^-CFGQ.3AADS5/]WA8Y9:*9$?,TIDA%1BD8WJ(]:Z
MX@5N+W]^Z]UHU]===?,;^6[\6]C5>Q?^%%/PJZ)^(G<7:?9<G035?QFPN]-A
MQ[DR>\,U6;UVQU)7[AAW-7X?K_;NZ*FI>>*G=L+B9I'9B@<L_NO=;IOQ_I=_
MT?2'5%/VIV3MKN3L9-@[7.\NV-F82CVYM/L?.R8FFEK-Y[<PF/J:R@QN'W"S
MBI@C@E>$1R#0=)'O1X'KW1:OYC--35GQZP]%74T-;0UW?7QYI*VBJ466FK*6
M?MW:<<U-4PL"LT$JFS(>"/;)C$L;QL*HV"/4>8/7B>AG[3HNMND>I^X]_P"-
MV/M'$4V-V)N3+Y:GQ^!Q]##GIZ3&5+X['9&*EAB2JAJ\@Z1JI%AKX][V38+"
M?=;7;H+")4N)0'"K0%:Y!' ^M.'5993'%(]> ZJ7^&?3^WA\Y-L['DVKA%IO
MC5_+KVA0=B1+BJ2.*M[8^5^_JO?^9H,M$$/W@I=K8*>!/*7;PR$7"D*##F"V
MVR7>=\:SL(H[-Y"@4* &1!I%1\Z5'IPZI;F400B1ZMIJ?M/'JZ['=6]=X?#Y
M+;F*V+M'&8'/,AS&#H,'04V,RQC0+&V2HHH4@K!$B\:P;6]A^+;+&.,V\-G"
ML#?$H448?/\ S]/LYR03J/KT3SI+8'7/;G:?9':./V3M.+J;:8R'2W5>!IL%
MCX]N[@J,97,_978/\-6$4E149#,K_"Z6I5"9*.F8:C?V1;9MNWW][=[B+.,;
M<@\*)-(TL0>^2GK^$8X#UZF#G*,\D\C;![>E=.^W[)N>X<0RAU M+9O](GZS
M(3VNXQ3HXD'4_7%-@:K:T.P]H1;9KJP9"MV]%@:"/"UE<F@QUE3C1":6:JC,
M8L[*3P/Z>SX;?8K$UNEC$+9LE=(H3ZGY]0^68FI:I]>N2]4]=1[=;:$>Q-I+
MM1ZTY%]M#!T P+Y!FUM7-BQ#]H:LL/UE;^]#;-O\ VOT<7TQ-=&GM)]2.%>O
M5/$\>O'JKKIMOIM-MA[0_NO'7G)Q[=; T!PL>09BS5T>-\7VJU9;G7I!O[\V
MVV)@-K]'$;;^$KVC\NM9XUZ[GZIZXJL#2;5J=B;2GVS05#U=%M^7!4$F&HZM
MRQ>II<<T1IH)WUF[*H)O[J=LL3$L!LHO !J%T]H/V=6U-Z]<*SJGKK(8+&[8
MK]B;0K=N8>5IL1@JK!4,^*QDCW#R4%#)"U/32.&-RBCZ^[/MMA(D<,EE&T"?
M"M, GC0=>U$FI)KUSR/577&7Q&)V_E=B[3R6"P2NF$P]=@Z"JQF'252LJXVB
MEA:"C6138Z +^]2;9M\T202V$1A7@I&!]@X _/KVH]=97JCK?.XW$X;-[$VE
ME\1@(GI\%B\C@J"LH</3RH(Y8<;33PO%21R(+$( "./I[])MME,L<<UE$\2"
MB@BNGY#K53Y=5P_S$]G;5WMO/^7G\>5VIA*VDWQ\M=N9NLH?X;3,E%UCTQM3
M/;TW9BJ5!':'%U<\>.AFCMX]# %>![>.V[?,D(FLHF"84%0=(_H^G7@[+6C<
M>K(=P=8=?;N-$^Y]C[3W V*A-'B?XS@J"O7&T:.#'34"S0LM)3J4!"H +CW2
M;;MNN- FL(F5.%5&//'IGKVIJ4!QUSS76VP,]5X_(9_9&U,[6XNB&.QT^6P6
M/R,M%CE! H*5JN"414MB1XP-)!Y!]UFVVPN)(II[")WC "DBM . S_Q76JTK
MD]57?$#K3KGI7Y%?(CX'[TV1MK*XG9^5J/E'\4ZG<.&I<B8NANX=Q33[KV7@
M:FL5S2474O;E/5T<--#814E53O8 BSMSMNWWC"6ZL8G9?A)45 '"AXXZ\&*_
M":=6F9KJWKS<F5@W!N#8NT,YG:=*2.#,93!T%=D8HZ%M=&L5940O.BTK<QV/
MI/T]M2[=97,BS7%G$\J\"5R*<,_+K8+#@3UWE.K.N\YG8]T9K8VU,KN6%Z5X
ML_D<+0U>71Z*WV;QU\L+5,;TMOVR&]%N/?I-MV^687,MC&UT.#$5/7@S#@33
MKE6=6]>9'/+NO(;'VK7;ICGIZF/<55A:&;-+4TJA*:H_B+P&J$U.@LAU74?2
MWO3[782SK<3V4;SC\97NK]O7M1X XZX2]6]?S;A7=TNR-IR[K2KBKUW++A*%
M\Z*^)0B5BY,P_=+4(H 5@UP![\=ML6N#=M9Q_5?QT[OR)_XKKQ9B*5-/MZ\O
M5O7R[D&\5V+M)=V_=FO.YAA*$9S[YD,;5?\ $Q"*LU#(2-6J]C[VNW60F^J%
MG$+JM=>D:J^M?7K1)/$XZ]!U7UW2[B;=]+L7:5-NQZF6L;<L&$H8\T:NH71/
M5'(K"*LSRIP6UW/Y]^&VV*3&XCLHQ<5KKTC57UKQ!ZWJ;AJ-.O8_JOKS#Y]]
MU8G8^U,=N>26KGDW%186BILT\]<I6LGDR,4*U,DU4"?(Q8EOS[\NW64<WU,=
MG&MS7XP.[YYZ\68CB>N\1U;U]@,S-N+![&VIA\_4?=?<9O'8:BI,K/\ ?'56
M"6NAA6ID^[-_+=CK_-_>EVRPBD>>&TC6Y;BX%&/Y_/SZ]J8"@)_;UPP_577F
MWLA6Y; ;&VA@\KD:>II:_(XO!4%'5UM-6/KJZ:LEA@5JFGJFYD1[JY^H][@V
MVPMI6G@L8DF(() XUX@^H/GUHECFIJ,@UR#\CQ'50WR6ZIQ'QJ^=W07;VR-P
M5_1?7/RNP<_QAW5E=B8?#0;*Q7?,,\FY.FJS?6U)J./!Y+#=B4E/78-M6B1J
MQ(+R(7#^T+<L[<)6O=N06MZ5H60#2P]&7@0?RKU(VV^YFXK91[)SAMT6^[!P
M5+EF\>#RK!=#]5?0*Q=1Z4QT<+#Y3='0]7ECV1\:]J5VW*ZB?&Y?M/XX;>@G
MHJO%*K-41;QZY=8]R4-,FLM.T,E;"26T+;CVGAA;:VF^JV6,(X[I(%PR_P!)
M./VC/RZ6#E3DOF1!+R=S7])?EJ?1;B?#:M<"*[%8I*\%5@C>IZ&CIO*?&O>V
M/R]9TO!UM6T^3HC0[BQ^V\918G,M0L2KT.Y-OR4]'EZ>'6Y5DJ85!8D<^UUA
M#L<R2KMBP&-OB"BA/J&!S3UKT#^8N5.:.5+A(.8MEN+75\+,-4;^FB124;&>
MUC3SZ$W"]6=;[?I,OC<#L/:.%H,]3K29JAQN!Q]#3YBF561:?(P00HE9 BL0
M%<$"_M1'MMA;B2.&QB57%& %-0^?K]O0>$C$5K_L=<\9U3UOA,3EL%B-B[2Q
M6&W J19W$4&#H*7&YB.-2L<>1HX85AK%1> '!%O?H]ML(8Y(H;*)86%&4**,
M/0^O7M35K7/7L?U5UUB\'E]LX[8FT,?MW/&,YK!4>!H(,3EC$%6(Y&ACA6GJ
MC&J"VI3:P_I[\FVV$<,EO'8Q+ _Q*!AO2HZ]J8FI)Z[I>JNNJ# Y#:U#L;:5
M)MK+SK4Y;;]/@J"+#Y*H71IGK<>D(IZB5?&MBRGZ#^GOPVZR6![86,(@8U*Z
M<&G#'^7KVIN(8UZ[@ZKZ[I]OU.THMB[1BVM65(K:O;D6!H$PE36*RLM7/CO#
M]M+4!D'J*WX'O:[=81PFUCLHA:G)2G;7UIP_EU[4U:USUT.JNN1M[^Z(V)M(
M;5-:,D=N#!T(PAR .H5IQ@A^T-4#_;TZO=6VVR:#Z7Z"+Z6M2M,5]>O5:I->
M/74O5/74V I]J3;%VG-M>EJC74VW9,'0-A*:N+,S5L&-:$TT=2Q8W8*#?GWO
M]VV/TXL_HHOHOX-(TU]1UO4?7/7&JZIZZK,'C]KU.Q-HU6V<54&KQ>WZC!T,
MN(Q]4S.SU-)CWA--#,YD)+*H)O[K^Z]O,"VC641M%X)3 /K0]:U-UZLZIZ[R
M&#Q>V:_8FSZW;N$=I</@:K!4,^'Q4CZO(^.Q[PM34C2%S<HHO<^]-M5@\2P2
M641@7@A4:1]@ZWK;B*U^WKO(]4=;YC$8G 9;8>TLE@\"LBX3#UV#H:K&8@3W
M\XQM'-"T-();\Z +^]R;7M\L<,4MC$T4?PJ5J%^SKQ=CY]>RW5'6^?Q^*Q&<
MV'M+,8K!0O383'Y+"4-918BGD0(\&-IIX7CHXY% #!  0+>]R[;83QQPSV,3
MPI\(*CM^STZUJ;UZY9GJKKG<=/BZ3<.Q=I9REPE)]AAJ;*X*@KX,31:53[3'
M1U,+K24^E0-* "P][DVVQF$:SV<<B)\(85TCT%?+KP9AP8]<<[U1USN<X_\
MO)L/:.?&)HDQN+.7P5#7MCL=$%\5#1-4PRFGI(PHTQK91;W6?:["ZI]38Q2
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M[)SJ2&ACA /%IY-,8'F&;TZ&7K3K[!]7[&VIU_MN!(,#L_"4.$QH1-#3?;1
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MZ-^E@W%^.> ;?[W[]U[KPDC-O6O/(Y%^/\/?NO=!!E/D)T;A>ZML?'#+]L[
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MKL97TDK4F8VUN+&36K<!NG;N1BDI,ACZE4J*6IB='4$>ZL*''#KPQT,;QK(
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M\LV*VWE%C  N2; >W![9\Q.=-O/82-Z+>6W_ #](O1=_7#:13Q([E:^L$O\
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MO=:ZZ>5 1$)$6617,2%D#N$ +-&A.IU4,+D V]^Z]T1C87SNV3O[Y_\ ?/\
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MSZ]J'KU[_9\_B#_S_;:'_4G.?_6CW[1\^O:AZ]=_[/C\07(4=[;0NQ"B\6;
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MKW7OX-C/^==CO_.&D_Z\>_=>Z]_!L9_SKL=_YPTG_7CW[KW7OX-C/^==CO\
MSAI/^O'OW7NO?P;&?\Z['?\ G#2?]>/?NO==C#8P'G&XXC^GV-+_ ,1"/>C6
MF./7NNCA\9?C'T"C^@H:3_B8#[:+./,=>IUU_!\;_P J%#_YPT?_ -3^_:W]
M1UZGR'7OX/C?^5"A_P#.&C_^I_?M;^HZ]3Y#KW\'QO\ RH4/_G#1_P#U/[]K
M?U'7J?(=>_@^-_Y4*'_SAH__ *G]^UOZCKU/D.O?P?&_\J%#_P"<-'_]3^_:
MW]1UZGR'7OX/C?\ E0H?_.&C_P#J?W[6_J.O4^0Z]_!\;_RH4/\ YPT?_P!3
M^_:W]1UZGR'7OX/C?^5"A_\ .&C_ /J?W[6_J.O4^0Z]_!\;_P J%#_YPT?_
M -3^_:W]1UZGR'0?=M],[$[LZJ[)Z:WSC#-LCM?9&Y>O-Y4^+,&,R%5M?=N*
MJ<-FZ6CR$%.9:*HGH:MPDR@O$]G6S*"/!VKW<.O4Z*#\1OY3O\O3X,XJBHOC
M;\6NL-H9JEI*:DGW[F\,N]NR,F:86%5D-];O;,[B:IE;U/XIXHR?H@%A[V7/
MD.MTZL/CC6)0B!550%55144 ?0!4 4 #^@]TZ]UF_'M[\'Y=:Z__U]_;VG/$
M];Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z['NZ<>O'KOV[UKKWOW7NO>_=>Z][]U[KBX)4@?4BP_WUQ[]U[K5C_GA_+W
M^<=_+JI<S\FNF.[?AY/\7]V]O]9=1=:]5[IZAW3F.V-O56]\2]+/E]S;CDKZ
M7#96&#<6-J97\,@*TLL06/4K:O=>Z%WN_NW^8S\3]C_#/;?S-_F,?%_J_M[O
M?Y^[%Z[PF<ZC^*F[]Y;4[AZHW)B,-3ITC5463HZN78NXJ_<35/\ OX&%/!'!
M5P!ZE'C]7NO=&+^1G_"@G^6+\6]]=S=7]J]M[U@[+Z%[)I>M.QNO]K]8;QW3
MN?%U,N"H\_7;UIJ+$T$\,_76$IZZ.GK,PTB0QUK+3H'E>-7]U[I3=7?SYOY8
M/=?RAV%\2^KOD5#O/L/M!:6BZ^W=B=L9X=/[PW35XNES$.P<'V744D. KM\K
M35T,4E"C$QUT@HV85?['OW7NI'R;_GH?RZ?B/WON'X^=L=G;WJ]X]?-M:/N7
M<77G5N]^Q.M^B)]YU,<&WJ3N7?>UL5D,)LRNJTE262G=I9J>-U\R1L=/OW7N
MK;]NYW#;IP6&W/MS*T.=V]N/%8[/X#-XNJBKL9F<)F*.'(XK*XVM@9X:N@R%
M#4)-#(A*O&X8$@@^_=>Z>??NO=>]^Z]U[W[KW7O?NO=>]Z/ ]>ZX^V3QZWU[
MWKKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]UR_'M[\'Y=:Z__T-_;VG/$];Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z['NZ<>O'KOV[UKKWOW7NO>_=>Z][]U
M[KWOW7NM<7_A3YTMW)WK_+_ZUVCT?U1V'W#NRC^7G1&;K-M=:[5RV\,Y182C
MJ\Y%5YNLQ6%IJNM@PU%/41+4513P4PE#RLD89U]U[IO_ )_71O=7<>[?Y-]3
MU+U+V#V9#UC_ #,.C-\=C3;'VQD]RQ;$VAB*W$SY/<N[)<73U,>!P%%%3R-+
M6U)CI8_&=<BDK?W7NBJ=?_%'N27O[_A4ANK,?&G>U3)WOLFHVUT=N3-=;5$D
MO<./K.F=W>3;O6.7R%"HWEC:O,BB=X*!Y8#6B!7_ ,HC"I[KW0"TOQ+[QP?\
MO7_A,!MS$?%?LV@WQTC\^>@.Q.\=N8;J;+8_=G5VWH]T;@SN^-U]FT,6+@R.
MRZ/*I#!6Y2IR@IEFF2/[EA,(T]^Z]T7+NGXV]B?'CY"_S7NBOEKUQ_.CSO3?
MS5^5/:7?FQZ/^6=U3U]VWT9\@>H>V\C65E-M?L3,[FVIN#-[;[-HA/!155-]
M]24\$<#JT?C$3S^Z]UNQ?##JK:O1WQ,^.74>Q\)V9MK9^P.G-A;=VSMKN>NH
M,CVSMS"T>WJ$T&W^Q:O%?[C&WCA()!2UZ4P\$-1$T<?I4>_=>Z,U[]U[KWOW
M7NO>_=>Z][]U[KWO1X'KW7'VR>/6^O>]=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN7X]O?@_+K77__1W^/?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UQ7]3?I^H^G^Q_5_M7OW7NN
M7]/]?_B#]/\ 'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
3O?NO=>]^Z]U[W[KW7O?NO=?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461007968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">40-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EUPRAXIA PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001581178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">27,282,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPrimarySicNumber', window );">Entity Primary SIC Number</a></td>
<td class="text">2834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">201-2067 Cadboro Bay Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Victoria<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">BC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">V8R 5G4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">590-3968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AnnualInformationForm', window );">Annual Information Form</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditedAnnualFinancialStatements', window );">Audited Annual Financial Statements</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Vancouver, Canada<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Corporation Service Company<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">19 West 44th Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">927-9800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AnnualInformationForm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag with value true on a form if it is an annual report containing an annual information form.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AnnualInformationForm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditedAnnualFinancialStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag with value true on a form if it is an annual report containing audited financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditedAnnualFinancialStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPrimarySicNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primary Standard Industrial Classification (SIC) Number for the Entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPrimarySicNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:sicNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486459409072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,341,756<span></span>
</td>
<td class="nump">$ 18,263,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and deposits</a></td>
<td class="nump">270,710<span></span>
</td>
<td class="nump">235,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NontradeReceivablesCurrent', window );">Amounts receivable</a></td>
<td class="nump">190,612<span></span>
</td>
<td class="nump">89,715<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">19,803,078<span></span>
</td>
<td class="nump">18,589,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expenses</a></td>
<td class="nump">6,904<span></span>
</td>
<td class="nump">2,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">409,587<span></span>
</td>
<td class="nump">443,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset, net</a></td>
<td class="nump">46,660<span></span>
</td>
<td class="nump">87,286<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">20,266,229<span></span>
</td>
<td class="nump">19,122,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">3,921,875<span></span>
</td>
<td class="nump">2,928,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtCurrent', window );">Loans payable &#8211; current portion</a></td>
<td class="nump">62,709<span></span>
</td>
<td class="nump">79,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability &#8211; current portion</a></td>
<td class="nump">53,316<span></span>
</td>
<td class="nump">50,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PayableTowardsRoyaltyAndOthersCurrent', window );">Payable to Auritec</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible debt</a></td>
<td class="nump">10,336,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">19,373,903<span></span>
</td>
<td class="nump">3,058,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current&#160;liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Loans payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,741,996<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">19,373,903<span></span>
</td>
<td class="nump">11,914,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Share capital, without par value; unlimited shares authorized; issued and outstanding: 27,282,165 (December 31, 2022 - 21,593,145</a></td>
<td class="nump">92,913,585<span></span>
</td>
<td class="nump">71,003,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional&#160;paid-in&#160;capital</a></td>
<td class="nump">17,510,469<span></span>
</td>
<td class="nump">16,850,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Deficit</a></td>
<td class="num">(105,501,295)<span></span>
</td>
<td class="num">(77,280,499)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,706,552)<span></span>
</td>
<td class="num">(2,786,366)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity attributable to the owners of the Company</a></td>
<td class="nump">2,216,207<span></span>
</td>
<td class="nump">7,786,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling&#160;interest</a></td>
<td class="num">(1,323,881)<span></span>
</td>
<td class="num">(578,671)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders' equity (deficit)</a></td>
<td class="nump">892,326<span></span>
</td>
<td class="nump">7,207,854<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity (deficit)</a></td>
<td class="nump">$ 20,266,229<span></span>
</td>
<td class="nump">$ 19,122,249<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PayableTowardsRoyaltyAndOthersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payable towards royalty and others current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PayableTowardsRoyaltyAndOthersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NontradeReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NontradeReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486459244672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock no par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorizedUnlimited', window );">Common stock unlimited shares authorized</a></td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">27,282,165<span></span>
</td>
<td class="nump">21,593,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="nump">27,282,165<span></span>
</td>
<td class="nump">21,593,145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorizedUnlimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is "Unlimited".</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorizedUnlimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:authorizedUnlimitedItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486463434240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 7,284,004<span></span>
</td>
<td class="nump">$ 3,987,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">20,563,225<span></span>
</td>
<td class="nump">13,629,854<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total expenses</a></td>
<td class="nump">27,847,229<span></span>
</td>
<td class="nump">17,617,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income/(expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">862,969<span></span>
</td>
<td class="nump">431,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,170,173)<span></span>
</td>
<td class="num">(982,856)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on sale of equipment</a></td>
<td class="num">(4,846)<span></span>
</td>
<td class="num">(6,637)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain</a></td>
<td class="nump">66,291<span></span>
</td>
<td class="nump">240,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of financial instruments</a></td>
<td class="num">(836,595)<span></span>
</td>
<td class="num">(1,056,165)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="num">(1,082,354)<span></span>
</td>
<td class="num">(1,373,312)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before tax expense</a></td>
<td class="num">(28,929,583)<span></span>
</td>
<td class="num">(18,990,764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax expense</a></td>
<td class="num">(36,423)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">(28,966,006)<span></span>
</td>
<td class="num">(18,990,764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Loss attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Owners of the Company</a></td>
<td class="num">(28,220,796)<span></span>
</td>
<td class="num">(18,489,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Non-controlling interest</a></td>
<td class="num">(745,210)<span></span>
</td>
<td class="num">(501,135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">(28,966,006)<span></span>
</td>
<td class="num">(18,990,764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">79,814<span></span>
</td>
<td class="num">(1,276,388)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss for the year</a></td>
<td class="num">$ (28,886,192)<span></span>
</td>
<td class="num">$ (20,267,152)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share &#8211; basic</a></td>
<td class="num">$ (1.17)<span></span>
</td>
<td class="num">$ (0.96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share &#8211; diluted</a></td>
<td class="num">$ (1.17)<span></span>
</td>
<td class="num">$ (0.96)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding &#8211; basic</a></td>
<td class="nump">24,146,623<span></span>
</td>
<td class="nump">19,285,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding &#8211; diluted</a></td>
<td class="nump">24,146,623<span></span>
</td>
<td class="nump">19,285,447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486546304400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders' Equity (Deficit)<br></strong></div></th>
<th class="th">
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Excercise of warrants [Member] </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Overnight marketed public offering [Member] </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Private placement [Member] </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Private placement [Member] </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Common stock [Member] </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Common stock [Member] </div>
<div>Excercise of warrants [Member] </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Common stock [Member] </div>
<div>Overnight marketed public offering [Member] </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Common stock [Member] </div>
<div>Private placement [Member] </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Additional paid-in capital [Member] </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Additional paid-in capital [Member] </div>
<div>Excercise of warrants [Member] </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Additional paid-in capital [Member] </div>
<div>Overnight marketed public offering [Member] </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Deficit [Member] </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Accumulated other comprehensive income [Member] </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Non-controlling interest [Member] </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (in shares) at Dec. 31, 2021 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,242,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at the beginning at Dec. 31, 2021</a></td>
<td class="nump">$ 15,097,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,250,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,226,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (58,790,870)<span></span>
</td>
<td class="num">$ (1,509,978)<span></span>
</td>
<td class="num">$ (77,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Overnight marketed public offering and redemption of warrants ( in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">7,150,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Overnight marketed public offering and redemption of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306,770<span></span>
</td>
<td class="nump">$ 10,636,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351,663<span></span>
</td>
<td class="nump">$ 8,401,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (44,893)<span></span>
</td>
<td class="nump">$ 2,235,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based payments</a></td>
<td class="nump">1,433,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,433,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">(18,990,764)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,489,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(501,135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency translation adjustment</a></td>
<td class="num">(1,276,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,276,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the ending (in shares) at Dec. 31, 2022 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,593,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at the ending at Dec. 31, 2022</a></td>
<td class="nump">7,207,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,003,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,850,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,280,499)<span></span>
</td>
<td class="num">(2,786,366)<span></span>
</td>
<td class="num">(578,671)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Overnight marketed public offering and redemption of warrants ( in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,385,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,183,875<span></span>
</td>
<td class="nump">3,183,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,385,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,282,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Overnight marketed public offering and redemption of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,241,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,886,537<span></span>
</td>
<td class="nump">$ 20,836,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,974,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,886,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (733,177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based payments</a></td>
<td class="nump">$ 1,412,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,412,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Redemption of options (in shares) | shares</a></td>
<td class="nump">20,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Redemption of options</a></td>
<td class="nump">$ 30,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,776)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">(28,966,006)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,220,796)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(745,210)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign Currency translation adjustment</a></td>
<td class="nump">79,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the ending (in shares) at Dec. 31, 2023 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,282,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at the ending at Dec. 31, 2023</a></td>
<td class="nump">$ 892,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,913,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,510,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (105,501,295)<span></span>
</td>
<td class="num">$ (2,706,552)<span></span>
</td>
<td class="num">$ (1,323,881)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486545864400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (28,966,006)<span></span>
</td>
<td class="num">$ (18,990,764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Items not affecting cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_InterestOnConvertibleDebtOne', window );">Accrued interest on convertible debt</a></td>
<td class="nump">571,603<span></span>
</td>
<td class="nump">643,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_InterestOnShortTermInvestmentsNonOperating', window );">Accrued interest on short term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,665)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">155,527<span></span>
</td>
<td class="nump">147,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_InterestExpensesOnLeaseLiabilityFinancingActivities', window );">Interest &#8211; lease liability</a></td>
<td class="nump">14,401<span></span>
</td>
<td class="nump">21,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_LossOnSaleOfEquipment', window );">Loss on sale of equipment</a></td>
<td class="nump">4,846<span></span>
</td>
<td class="nump">6,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based payments</a></td>
<td class="nump">1,412,257<span></span>
</td>
<td class="nump">1,433,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of financial instruments</a></td>
<td class="nump">836,595<span></span>
</td>
<td class="nump">1,056,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange</a></td>
<td class="num">(64,609)<span></span>
</td>
<td class="num">(223,709)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">577,908<span></span>
</td>
<td class="nump">1,324,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(122,435)<span></span>
</td>
<td class="num">(39,959)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Amounts receivable</a></td>
<td class="num">(103,710)<span></span>
</td>
<td class="nump">230,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent', window );">Auritec payable</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(20,683,623)<span></span>
</td>
<td class="num">(14,395,201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Acquisition of equipment</a></td>
<td class="num">(73,377)<span></span>
</td>
<td class="num">(235,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,272,379)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from redemption of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,342,058<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash provided by (used in) investing activities</a></td>
<td class="num">(73,377)<span></span>
</td>
<td class="nump">9,834,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Overnight marketed public offering (net of transaction costs)</a></td>
<td class="nump">15,886,537<span></span>
</td>
<td class="nump">10,636,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Redemption of warrants</a></td>
<td class="nump">5,241,811<span></span>
</td>
<td class="nump">306,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Redemption of options</a></td>
<td class="nump">30,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherLongTermDebt', window );">Repayment of loans</a></td>
<td class="num">(79,441)<span></span>
</td>
<td class="num">(74,845)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Lease payments</a></td>
<td class="num">(64,996)<span></span>
</td>
<td class="num">(67,423)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">21,013,970<span></span>
</td>
<td class="nump">10,801,079<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase in cash and cash equivalents</a></td>
<td class="nump">256,970<span></span>
</td>
<td class="nump">6,240,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Foreign exchange effect on cash and cash equivalents</a></td>
<td class="nump">821,397<span></span>
</td>
<td class="num">(507,395)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">18,263,389<span></span>
</td>
<td class="nump">12,530,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">$ 19,341,756<span></span>
</td>
<td class="nump">$ 18,263,389<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in payable towards licensing fees and others current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_InterestExpensesOnLeaseLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expenses on lease liability financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_InterestExpensesOnLeaseLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_InterestOnConvertibleDebtOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest on convertible debt one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_InterestOnConvertibleDebtOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_InterestOnShortTermInvestmentsNonOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest on short term investments non operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_InterestOnShortTermInvestmentsNonOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_LossOnSaleOfEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on sale of equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_LossOnSaleOfEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486456830096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business and Going Concern</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">NATURE OF BUSINESS AND GOING CONCERN </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Eupraxia Pharmaceuticals Inc. (the &#8220;Company&#8221;) was incorporated under the laws of the province of Alberta on May 12, 2011, under the name Plaza Capital Partners Inc. On May&#160;11, 2012, the Company changed its name to Eupraxia Pharmaceuticals Inc. and continued from the province of Alberta to the province of British Columbia. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On October&#160;10, 2012, Eupraxia Holdings, Inc. (&#8220;Holdings&#8221;) was incorporated under the laws of the State of Delaware, USA. On November&#160;16, 2012, Holdings was registered as an extra-provincial corporation under the laws of the province of British Columbia, Canada. On October 10, 2012, Eupraxia Pharmaceuticals USA, LLC (&#8220;Eupraxia USA&#8221;) was incorporated under the laws of the State of Delaware. On November&#160;16, 2012, Eupraxia USA was registered as an extra-provincial corporation under the laws of the province of British Columbia. On January&#160;7, 2021, Eupraxia Pharma, Inc. (&#8220;Eupraxia Pharma&#8221;) was incorporated under the laws of the State of Delaware. On July&#160;4, 2022, Eupraxia Pharmaceuticals Australia Pty Ltd. (&#8220;Eupraxia Australia&#8221;) was incorporated under the laws of the state of Victoria, Australia. On May&#160;17, 2023, Eupraxia Pharma USA Inc. (&#8220;Eupraxia Pharma USA&#8221;) was incorporated under the laws of the State of Delaware. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On March&#160;9, 2021, the Company completed its initial public offering on the Toronto Stock Exchange (&#8220;TSX&#8221;) and began trading under the symbol &#8220;EPRX&#8221;. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company is a clinical stage biotechnology company leveraging its proprietary Diffusphere<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#8482;</div> technology to optimize drug delivery for applications with significant unmet medical need. The address of the Company&#8217;s corporate office and principal place of business is 201- 2067 Cadboro Bay Road, Victoria, British Columbia, Canada. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">These consolidated financial statements have been prepared on a going concern basis with the assumption that the Company will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. At December&#160;31, 2023, the Company had cash and cash equivalents of $19,341,756<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">. The</div> Company has not yet generated revenue from operations. The Company incurred a net loss of $28,966,006 during the year ended December&#160;31, 2023, and as of that date, the Company&#8217;s accumulated deficit was $105,501,295. As the Company is in the research and development stage, the recoverability of the costs incurred to date is dependent upon the ability of the Company to obtain the necessary funding to complete the research and development of its projects and upon future commercialization or proceeds from the monetization of research activities. The Company will periodically have to raise funds to continue operations and raised $15,886,537 (CDN$20,836,005) through a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">non-brokered</div> private placement of 3,183,875 common shares in <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">2023 (2022 - $11,768,459 through a marketed public offering) and raised $25,026,073 (CDN$33,867,784) through an overnight marketed public offering of 8,260,435 common shares in 2024</div>. Although it has been successful in doing so in the past, there is no assurance it will be able to do so in the future, especially with the ongoing conflicts in the Ukraine and the Middle East affecting the global capital markets. Recent developments with Silicon Valley Bank (&#8220;SVB&#8221;) have not impacted the Company&#8217;s outlook for cash runway. The Company holds no amounts on deposit with SVB and the convertible debt (see Note <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">11</div> &#8211; Convertible Debt) which matures in June 2024 remains in good standing, is fully drawn and is not callable by SVB. The Company is active in its pursuit of additional funding through potential partnering and other strategic activities as well as grants to fund future research and development activities, and additional equity financing. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional funding. There is a risk that in the future, additional financing will not be available on a timely basis or on terms acceptable to the Company. These events and conditions may cast substantial doubt about the Company&#8217;s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue in business. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461280272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">BASIS OF PRESENTATION </div></div></td></tr></table><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These consolidated financial statements are presented in U.S. dollars and have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). These consolidated financial statements include the accounts of the Company and the accounts of its subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in Reporting Currency to the US&#160;Dollar </div></div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective December&#160;31, 2023, the Company changed its reporting currency to the US dollar (&#8220;USD&#8221;) from the Canadian dollar (&#8220;CDN&#8221;). As such, all prior amounts originally reported in CDN are now reported in USD. The change in reporting currency was made to enhance comparability of the Company&#8217;s results with other publicly traded companies in the life sciences industry. The Canadian dollar continues to be the functional currency of the Company. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with ASC 830, the consolidated financial statements of the Company are translated into U.S. dollars using the current rate method. Assets and liabilities are translated at the rate of exchange prevailing at the consolidated balance sheet date. Shareholders&#8217; equity is translated at the applicable historical rate. Revenue, expense and cash flow items are translated at the exchange rate in effect on the transaction dates. Translation gains and losses are reported as a separate component of shareholders&#8217; equity titled Accumulated Other Comprehensive Income. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial information for all prior periods is presented in U.S. dollars as if the U.S. dollar had been used as the reporting currency during those periods. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transition to US&#160;GAAP </div></div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">This is the first year that the Company&#8217;s consolidated financial statements are prepared in accordance of generally accepted accounting principles in the United States of America <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(&#8220;GAAP&#8221;</div></div>) as issued by the Financial Accounting Standards Board (<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8220;FASB&#8221;</div></div>). Previously, the Company prepared its financial statements in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (&#8220;IASB&#8221;). </div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The policies set out in the Significant Accounting Policies section have been applied in preparing the financial statements for the years ended December&#160;31, 2023 and 2022. In addition, comparative figures, which were previously prepared in accordance with IFRS, have been adjusted as required to be compliant with the Company&#8217;s accounting policies under US&#160;GAAP. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486456919344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Measurement </div></div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements have been prepared on a historical cost basis, except for certain financial instruments which are measured at fair value. The consolidated financial statements are presented in U.S. dollars, which is the Company&#8217;s reporting currency. The Company&#8217;s functional currency is the Canadian dollar. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of consolidated financial statements in accordance with U.S. GAAP requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, expenses, and related disclosure. On an ongoing basis, the Company evaluates its estimates, most notably those related to accrual of expenses including clinical and preclinical study expense accruals, stock-based compensation, valuation allowance for deferred taxes, and fair value measurement of convertible debt. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates. </div></div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="margin-top: 8pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidation </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These consolidated financial statements include the accounts of the Company and the accounts of its subsidiaries. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. Control exists when an entity is exposed to or has rights to variable returns from its involvement with the entity and has the ability to affect these returns through its power over the entity. All significant intercompany transactions and balances have been eliminated. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest in the net assets of consolidated subsidiaries are identified separately from the Company&#8217;s equity. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest consists of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest as at the date of the original transaction plus the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest&#8217;s share of changes in equity since that date.</div><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 53%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Company Entity</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Incorporation</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Jurisdiction of<br/>Incorporation</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effective<br/>Interest<br/>(Note&#160;13(e))</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width:53%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Holdings, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">October 10, 2012</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Delaware,&#160;USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Pharmaceuticals USA, LLC</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">October 10, 2012</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Delaware, USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">AMDM Holdings Inc.<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(2)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">April 6, 2016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Washington,&#160;USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Pharma, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">January 7, 2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Delaware, USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Pharmaceuticals Australia Pty Ltd.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">July 4, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Victoria, Australia</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Pharma USA Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">May 17, 2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Delaware, USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Wholly-owned subsidiary of Eupraxia Pharmaceuticals Inc. </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Date of Control occurred on January&#160;31, 2021 (see Note 13(e)). </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings (Loss) per Share </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies the &#8220;Treasury Stock Method&#8221; to calculate loss per common share. Under this method, the basic earnings (loss) per share is calculated based on the weighted average aggregate number of common shares outstanding during each period. The diluted earnings (loss) per share assumes that the outstanding stock options and share purchase warrants had been exercised at the beginning of the period, or date of issuance if issued during the period, and proceeds from dilutive instruments are used to purchase common shares at the average market price during the period. Since the Company was in a loss position for the years ended December&#160;31, 2023 and 2022, the assumed conversion of outstanding common share warrants, options, and convertible instruments has an anti-dilutive impact, therefore the diluted loss per share is equal to basic loss per share. </div></div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment </div></div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment is recorded at historical cost less accumulated depreciation and accumulated impairment losses. Depreciation is provided over the estimated useful lives of the assets as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:94%;border:0;margin-left:auto">
<tr>
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;">Computers</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">45% declining balance</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;">Office furniture and equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">20% declining balance</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">straight-line over the shorter of the initial term of the lease or useful life</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Lab equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">20% declining balance</td></tr></table></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The useful lives and depreciation methods applied to each category of equipment are assessed on an annual basis by management and adjusted where necessary to reflect the recoverability of equipment. </div></div></div>  <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Research and Development Expenditures </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Research and development costs are expensed as they are incurred. These costs consist primarily of salaries and wages related to research and development activities, including share-based payments for employees engaged in research and development, clinical trial expenses and other research costs. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Investment Tax Credits </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Investment tax credits (&#8220;ITCs&#8221;) arising from research and development activities are deducted from the related costs and are included in profit or loss when there is reasonable assurance that the credits will be realized. ITCs arising from the acquisition or development of equipment and capitalized development costs are deducted from the cost of those assets with amortization calculated on the net amount. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Government Grants </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Government grants related to research and development activities are recognized in profit or loss as a deduction from the related expenditure when there is reasonable assurance that the grant will be received. Grants that compensate the Company for the cost of an asset are recognized in profit or loss on a systematic basis over the useful life of the asset. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Government Assistance </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Government contributions are recognized and deducted from the related costs when there is reasonable assurance that the contribution will be received and all attached conditions have been complied with by the Company. Government contributions arising from the acquisition or development of equipment and capitalized development costs are deducted from the cost of those assets with amortization calculated on the net amount. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current income tax is the expected tax payable or recoverable on the taxable profit or loss for the year using tax rates enacted at the reporting date and any adjustment to tax payable from previous years. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax is recorded using the asset and liability method, providing for temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Temporary differences are not provided for if they relate to goodwill not deductible for tax purposes, or differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates and laws enacted at the reporting date and expected to apply when these differences reverse. A deferred tax asset is recognized only to the extent that it is more likely than not that future taxable profits will be available against which the asset can be utilized. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company uses a two-step process to recognize and measure the income tax benefit of uncertain tax positions taken or expected to be taken in a tax return. The tax benefit from an uncertain tax position is recognized if it more likely than not that the position will be sustained upon examination of the tax authority based solely on the technical merits of the position. A tax benefit that meets the more likely than not recognition threshold is measured as the largest amount that is greater than 50% likely to realized upon settlement with the tax authority. To the extent a full benefit is not expected to be realized, an income tax liability is established. Any change in judgement related to the expected resolution of an uncertain tax provision is recognized in the year of such a change. Interest an penalties related to income tax are included as a component of income tax expense. </div></div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Share-based Payments </div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company grants stock options to employees, directors and officers pursuant to stock option plans described in note 13c. Employee stock-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense, net of actual forfeitures, over the requisite service period with a corresponding increase in additional paid-in capital. Stock-based compensation expense is amortized on a straight-line basis over the requisite service period for the entire award, which is generally the vesting period of the award. </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any consideration received on exercise of stock options is credited to share capital. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share Capital and Warrants </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company records proceeds from share issuances net of issue costs and any related tax effects. Common shares issued for consideration other than cash are valued based on their market value at the date the agreement to issue shares was concluded. When units are issued during a private placement, which include both common shares and share purchase warrants, the warrants are classified as equity and as such, the proceeds should be allocated based on the relative fair values of the base instrument and the warrants on the day of the announcement of the private placement. Any value of the warrants is allocated to the warrants and credited to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign Currency Translation </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The functional currency for each of the Company and the Company&#8217;s subsidiaries is the currency of the primary economic environment in which each entity operates. Determination of functional currency may involve certain judgments to determine the primary economic environment. The Company reconsiders the functional currency of its entities if there is a change in events and conditions which determine the primary economic environment. The functional currency of Eupraxia Pharmaceuticals Inc., the parent entity, and each of the Company&#8217;s subsidiaries is the Canadian dollar. </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transactions in foreign currencies are translated to the functional currency of the entity at the exchange rate at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the reporting date are retranslated at the period end date exchange rates. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-monetary</div> items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-monetary</div> assets and liabilities denominated in foreign currencies that are measured at fair value are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-translated</div> to the functional currency at the exchange rate at the date that the fair value was determined. Foreign currency differences arising on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-translation</div> are recognized in profit or loss. </div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The reporting currency of the Company&#8217;s consolidated financial statements is the U.S. dollar. All assets and liabilities are translated from the functional currency to the reporting currency using the spot rate at the period end date, equity components are translated at the historical rate, and income and expenses are translated using the average exchange rate for the period. All foreign currency differences arising on translation from functional to reporting currency are included in accumulated other comprehensive income. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of Long-Lived Assets </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or group of assets. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset or asset group. As of December&#160;31, 2023 and 2022, the Company determined that there were no indicators of impairment of long-lived assets. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Cash and cash equivalents include cash on hand, bank deposits, and highly liquid investments with original maturities of three months or less from the date of purchase that are readily convertible to known amounts of cash and subject to insignificant risk of changes in value. Cash equivalents are recorded at cost plus accrued interest. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short Term Investments </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Short term investments include highly liquid investments with original maturity dates greater than three months and less than one year and cannot be redeemed prior to maturity without incurring a penalty. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Instruments and Fair Value</div></div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures certain financial instruments and other items at fair value into a three-level hierarchy established by US GAAP that prioritizes those inputs to valuation techniques used to measure fair value on the degree to which they are observable. This hierarchy includes: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">i.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1 &#8211; Unadjusted quoted prices in active markets for identical instruments. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">ii.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2 &#8211; Inputs other than quoted prices included within Level 1 that are observable for the financial instrument, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability and inputs that are derived principally from or corroborated by observable market data by correlation or other means. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">iii.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inputs are unobservable and reflect the Company&#8217;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and liabilities are classified on the lowest level of input that is significant to the fair value measurements. Reclassification of the level may be a result of changes in the observability of the valuation inputs for certain instruments within the fair value hierarchy. The carrying value of accounts receivable, accounts payable, and accrued expense approximate fair value due to the short-term nature of these instruments. On a recurring basis, the Company&#8217;s cash and cash equivalents and marketable securities are measured at fair value. </div></div></div>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="text-align: justify; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Leases classified as operating leases are recorded as lease liabilities based on the present value of minimum lease payments over the lease term, discounted using the lessor&#8217;s rate implicit in the lease or the Company&#8217;s incremental borrowing rate, if the lessor&#8217;s implicit rate is not readily determinable. The lease term includes all periods covered by renewal and termination options where the Company is reasonably certain to exercise the renewal options or not to exercise the termination options. Corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets are recognized consisting of the lease liabilities, initial direct costs and any lease incentive payments. Lease liabilities are drawn down as lease payments are made and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets are depreciated over the term of the lease. Operating lease expenses are recognized on a straight-line basis over the term of the lease, consisting of interest accrued on the lease liability and depreciation of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, adjusted for changes in index-based variable lease payments in the period of change. Lease payments on short-term operating leases with lease terms twelve months or less are expensed on a straight-line basis over the lease term. </div></div>  <div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upcoming Accounting Standards and Interpretations </div></div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has not yet adopted certain new standards, amendments and interpretations to existing standards, which have been published but are only effective for accounting periods beginning on or after January&#160;1, 2024 or later periods. The new and amended standards are not expected to have a material impact on the Company&#8217;s consolidated financial statements. </div></div></div>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461332736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Amounts Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Amounts Receivable</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">AMOUNTS RECEIVABLE </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 74%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Government grants (Note 14)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,892</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">GST/HST recoverable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">85,879</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,658</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other refundable tax credits <div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104,733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37,165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">190,612</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">89,715</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Other refundable tax credits are due to tax incentives for R&amp;D costs incurred by Eupraxia Australia (Note 14 &#8211; Research and Development Expenses). </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//310-10/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486545342816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">PROPERTY AND EQUIPMENT </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Property and equipment consisted of the following: <br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 60%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Computers</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Office<br/>furniture&#160;and<br/>equipment</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leasehold<br/>Improvements</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Lab<br/>Equipment</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="20" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Cost</div></div></div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at January&#160;1, 2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">101,754</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">73,267</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">134,333</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">289,569</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">598,923</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20,279</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,551</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">209,720</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">235,550</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposals</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(47,603</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(8,158</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(55,761</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency adjustments</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3,852</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(4,261</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(8,589</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(25,736</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(42,438</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at December&#160;31, 2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">70,578</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">66,399</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">125,744</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">473,553</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">736,274</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">18,534</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">54,843</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">73,377</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposals</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5,488</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(16,124</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(21,612</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency adjustments</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,001</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,597</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,023</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12,992</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,613</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at December&#160;31, 2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">85,625</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67,996</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">128,767</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">525,264</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">807,652</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td colspan="21" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="20" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated Depreciation</div></div></div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at January&#160;1, 2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">71,187</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">46,965</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">91,345</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">38,631</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">248,128</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17,153</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,256</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14,366</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">73,328</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">110,103</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposals</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(43,540</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5,342</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(48,882</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency adjustments</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2,295</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2,853</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(6,410</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(4,981</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(16,539</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at December&#160;31, 2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">42,505</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44,026</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">99,301</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">106,978</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">292,810</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17,612</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,492</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13,849</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">76,930</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">112,883</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposals</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5,162</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(11,604</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(16,766</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency adjustments</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,226</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,149</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,666</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,097</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9,138</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at December&#160;31, 2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">56,181</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">49,667</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">115,816</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">176,401</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">398,065</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td colspan="21" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="20" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Net Book Value</div></div></div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at December&#160;31, 2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">28,073</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,373</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26,443</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">366,575</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">443,464</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at December&#160;31, 2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,444</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18,329</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,951</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">348,863</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">409,587</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr></table> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, depreciation expense of $</div>112,883<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and $</div>110,103<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively, was recognized with $</div>13,276<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included in general and administrative and $</div>99,606<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included in research and development ($</div>13,870<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and $</div>96,233<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> for general and administrative, and research and development in </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively).</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486456842544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Asset<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_RightOfUseAssetAbstract', window );"><strong>Right of Use Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_RightOfUseAssetTextBlock', window );">Right-of-Use Asset</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RIGHT-OF-USE</div></div> ASSET </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The following table presents details of movement in the carrying value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, beginning</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">87,286</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">132,020</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(42,644</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37,791</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign Exchange</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,943</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, ending</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">46,660</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">87,286</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">During the year ended December&#160;31, 2023 and 2022, depreciation expense of $42,644 and $37,791, respectively, was recognized with $15,740 included in general and administrative and $26,904 included in research and development ($13,877 and $23,914 for general and administrative, and research and development in 2022, respectively). </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_RightOfUseAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_RightOfUseAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_RightOfUseAssetTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_RightOfUseAssetTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486463449568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES </div></div></td></tr></table><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,968,263</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,137,336</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,040,204</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">261,933</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Wages and payroll remittances</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,996</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Employee bonus payable<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">858,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">513,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Taxes payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,921,875</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,928,566</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Bonus relates to corporate bonuses for the years ended December&#160;31, 2023 and 2022. </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461267760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInEntiretyOfOtherLoansPayable', window );">Loans Payable</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">LOANS PAYABLE </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On September&#160;10, 2021, the Company entered into a Master Loan and Security Agreement (&#8220;Loan Agreement&#8221;) whereby the Company borrowed $235,000 to purchase production and test equipment (see Note <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">5</div> &#8211; Property and Equipment). </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Loan Agreement has a term of 36 months commencing September&#160;13, 2021. The Loan Agreement accrues interest at 5.84% per annum with monthly payments (principal and interest) being made on the 1<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">st</div> of each month, beginning October&#160;1, 2021. As part of the agreement, the Company granted the lender first priority interest on the equipment it purchased. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Below is a breakdown of loan balance as at December&#160;31, 2023 and December&#160;31, 2022: <br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 73%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width: 73%;"></td>
<td style="vertical-align: bottom; width: 6%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 5%;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 73%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, beginning</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">142,127</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">216,994</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 73%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loan repayment</div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(79,441</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(74,845</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 73%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign exchange adjustment</div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 73%;"></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 73%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, ending</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">62,709</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">142,127</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 73%;"></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 73%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Current portion</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">62,709</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">79,418</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 73%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> portion</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">62,709</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DisclosureInEntiretyOfOtherLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in entirety of other loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DisclosureInEntiretyOfOtherLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486464073648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lease Liability</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">LEASE LIABILITY </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company entered into an operating lease agreement for its Victoria, BC facility (of approximately 4,900 square feet of office space) which expires on November 30, 2024. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The cost components of the operating lease were as follows for the years ended December&#160;31, 2023 and 2022: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Lease Cost</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64,996</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68,584</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">66,455</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Lease term and Discount Rate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term (years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Variable lease costs are payments that vary because of changes in facts or circumstances and include common area maintenance and property taxes related to the premises. Variable lease costs are excluded from the calculation of minimum lease payments. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company&#8217;s future minimum lease payments as of December&#160;31, 2023 are as follows: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Year ending December 31:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60,780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total undiscounted future minimum lease payments</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">60,780</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: balance of unused tenant allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,464</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Present value of lease liabilities at December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">53,316</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The lease liability balance is comprised as follows: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Current portion</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50,403</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> portion</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">53,316</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">101,706</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">During the year ended December&#160;31, 202<div style="display:inline;">3</div>, the Company subleased approximately 616 square feet office space with amounts totaling $24,387 for the year ended December&#160;31, 2023 ($24,387 &#8211; year ended December&#160;31, 2022) being recorded as a reduction to general and administrative expenses. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486545342816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Auritec License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInEntiretyOfLicenseAgreementTextBlock', window );">Auritec License Agreement</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">AURITEC LICENSE AGREEMENT </div></div></td></tr></table><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Eupraxia USA entered into an amended and restated license agreement with Auritec Pharmaceuticals Inc. (&#8220;Auritec&#8221;) on October&#160;9, 2018 (as further amended, the &#8220;Amended and Restated License Agreement&#8221;). Under the terms of the Amended and Restated License Agreement, Auritec has granted Eupraxia USA an exclusive license (including the right to sublicense to its affiliates and third parties) under the licensed patents owned or controlled by Auritec and for all the technical information and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> relating to the technology claimed in such patents or possessed by Auritec with respect to the use of Auritec&#8217;s &#8220;Plexis Platform&#8221; for the delivery of fluticasone in all medical fields (except for otolaryngology and the prevention, treatment and control of all diseases, disorders and conditions of the eye and its adnexa (collectively, the &#8220;Excluded Fields&#8221;)), to develop, make, have made, manufacture, use, commercialize, sell, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-license,</div> offer for sale, import, and have imported products for the delivery of fluticasone drug products using the Plexis Platform in all medical fields except the Excluded Fields (&#8220;Licensed Products&#8221;). </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Pursuant to the terms of the Amended and Restated License Agreement, Eupraxia USA has paid $5,000,000 to Auritec (the &#8220;Upfront Fee&#8221;). In addition, Eupraxia USA has agreed to pay Auritec up to $30,000,000 upon achievement of certain regulatory and commercial milestones related to products licensed under the Amended and Restated License Agreement (&#8220;Licensed Products&#8221;) as well as a royalty of 4% of net sales of Licensed Products by Eupraxia USA or its affiliates, subject to certain reductions. </div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the milestone payment schedule. As of December&#160;31, 2023, the only milestone that has been accrued and provided for in the financial statements is $5,000,000 related to the successful completion of the Phase 2b clinical study. It was recorded under research and development (see Note 14 &#8211; Research and Development Expenses). </div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 84%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone Event</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Milestone<br/>Payment</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Successful Completion of a Phase 2b Study</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">First OA Regulatory Approval</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Second OA Regulatory Approval</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">5,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-OA</div> Indication Regulatory Approval</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">10,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">First calendar year in which aggregate Net Sales by Eupraxia USA, its affiliates and sublicenses exceed $500,000,000</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">5,000,000</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Maximum milestones payable</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">30,000,000</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;">Eupraxia USA also agreed to pay to Auritec 20% <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">of sublicensing royalties or other consideration based on net sales of Licensed Products. Eupraxia USA further agreed to pay Auritec a percentage of Non-Royalty Monetization Revenue (as defined in the Amended and Restated License Agreement), which includes payments received for a sale of Eupraxia USA or its assets or sale or sublicense of a Licensed Product, which percentage ranges from</div> 10% to 30% depending on the development stage of the most-advanced Licensed Product, up to a maximum of <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div>100,000,000. The following table summarizes the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Non-Royalty</div> Monetization Revenue percentage schedule: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:26%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Date of Execution</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Percentage&#160;of&#160;Non-Royalty</div><br/> Monetization Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prior to Successful Completion of a Phase 2b Study</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">After Successful Completion of a Phase 2b Study but prior to Successful Completion of a Phase 3 Study</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">After Successful Completion of a Phase 3 Study but prior to Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">After Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Either party may terminate the Amended and Restated License Agreement in the event of the other party&#8217;s bankruptcy, liquidation, or dissolution. Auritec may also terminate upon a material breach of the Amended and Restated License Agreement by Eupraxia USA that is not cured within <div style="display:inline;">60 days</div> (<div style="display:inline;">15 days</div> in the case of a payment breach). Further, if Eupraxia USA directly or indirectly challenges any claim in any Auritec patent licensed under the Amended and Restated License Agreement, or assist a third party in doing so, Auritec may immediately terminate the Amended and Restated License Agreement. If Auritec directly or indirectly challenges any Eupraxia patent contemplated in the Amended and Restated License Agreement other than as reasonably required to defend Auritec patents as a basis for such challenge, or assists a third party in doing so, we may immediately terminate the Amended and Restated License Agreement. </div></div><br/></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DisclosureInEntiretyOfLicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure In Entirety Of License Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DisclosureInEntiretyOfLicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461328448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Convertible Debt</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">CONVERTIBLE DEBT </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On June&#160;21, 2021, the Company entered into a contingent convertible debt agreement (the &#8220;Debt Agreement&#8221;) with Silicon Valley Bank (&#8220;SVB&#8221;) and concurrently drew down, in full, the CDN$10,000,000 principal amount under the Debt Agreement. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Debt Agreement has a term of 36 months (or 48 months at SVB&#8217;s election). The Debt Agreement accrues interest at the greater of 2.45% and the Canadian prime rate, requiring monthly interest payments. An additional payment in kind will accrue at a rate of 7% per annum, which will be settled at maturity or on conversion. During the year ended December&#160;31, 2022, the Canadian prime rate ranged from 2.45% - 6.45%. During the year ended December&#160;31, 2023, the Canadian prime rate ranged from 6.45% - 7.20%. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Subject to the terms and conditions of the Debt Agreement, SVB may elect to convert the principal amount of the convertible debt and the accrued and unpaid interest thereon into common shares at a conversion price equal to CDN$5.68 per common share. The conversion price of the accrued and unpaid interest will be subject to the minimum pricing requirements of the TSX, to the extent applicable, at the time of conversion. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company will have the right (the &#8220;Call Right&#8221;) to call the convertible debt by paying to SVB an amount equal to: </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">i.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;">125% of the principal amount of the convertible debt (less principal amounts previously repaid), if the Call Right is exercised on or before the 18 month anniversary of the date of the Debt Agreement; and </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">ii.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;">150% of the principal amount of the convertible debt (less principal amounts previously repaid), if the Call Right is exercised after the 18 month anniversary of the date of the Debt Agreement, </div></td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in either case together with all accrued and unpaid interest on the principal balance of the convertible debt. If the Call Right is exercised by the Company, SVB will retain certain lookback rights in the event the Company subsequently announces its topline data from its Phase 2 clinical study or the Company enters into an agreement to be acquired in the 12 months following the exercise of the Call Right. The Company has agreed to grant SVB a security interest in all of its assets, excluding its patents and other intellectual property, and the testing and product equipment by way of the loan agreement it entered into on September&#160;10, 2021 (Note 8 &#8211; Loans Payable) as security for its obligations under the Debt Agreement. </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company was required, on or prior to June&#160;30, 2022, to raise additional net new capital, as defined in the Debt Agreement, in the aggregate amount of CDN$10,000,000. During the year ended December&#160;31, 2022, the Company completed a CDN$14.7&#160;million financing which satisfied the net new capital requirement of the Debt Agreement (see Note <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">12</div> &#8211; Share C<div style="display:inline;">apital)</div>. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The loan balance is comprised of the following: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance &#8211; December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,507,755</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">958,669</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Interest paid</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(315,436</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: right; line-height: normal;">1,056,165</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign exchange</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(465,157</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance &#8211; December 31, 2022</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,741,996</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">1,162,773</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest paid</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(591,170</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">836,595</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign exchange</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">185,809</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance &#8211; December 31, 2023</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,336,003</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486460974048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Components of Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Share Capital and Other Components of Equity</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">SHARE CAPITAL AND OTHER COMPONENTS OF EQUITY </div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">a)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;">Authorized </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify; line-height: normal;">An <div style="-sec-ix-hidden:hidden108159697;display:inline;"><div style="-sec-ix-hidden:hidden108159696;display:inline;">unlimited</div></div> number of Common shares, with no par value, with one vote per share. </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify; line-height: normal;">An <div style="-sec-ix-hidden:hidden108159695;display:inline;"><div style="-sec-ix-hidden:hidden108159693;display:inline;">unlimited</div></div> number of Preferred shares, with no par value (none have been issued to date). </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">b)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;">Issued </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify">Capital transactions which took place during the year ended December&#160;31, 2022 are as follows: </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">i)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;">On April&#160;20, 2022, the Company announced that it had closed an overnight marketed public offering (the &#8220;Offering&#8221;). Pursuant to the Offering, Eupraxia issued 7,150,550 units at a price of CDN$2.05 per unit and 181,000 warrants at a price of CDN$0.30 per warrant for aggregate gross proceeds of $11,768,459 ($9,309,707 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">related to the value of the</div> shares<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;and</div> $2,458,752 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">related to the value of the</div> warrants). </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman;text-align:justify">Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at an exercise price of CDN$3.00 per common share for a period of 48 months, expiring on April 20, 2026. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman;text-align:justify">As consideration for the services rendered by the Underwriters in connection with the Offering, the Company paid the Underwriters a cash commission of $823,792 ($660,605 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">for the </div> shares<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">and</div> $163,187 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">for the</div> warrants) which is equal to 7% of the gross proceeds raised under the Offering and granted 500,538 warrants (&#8220;Compensation Warrant&#8221;), which is equal to 7% of the total units and warrants issued in the Offering. Each Compensation Warrant entitles the holder thereof to acquire one common share at an exercise price of CDN$2.05 per common share for a period of 48 months, expiring on April&#160;20, 2026. An additional $68,470 in legal and agents&#8217; expenses were also paid to the Underwriters ($54,839 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">for the</div> shares<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;and</div> $13,631 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">for the</div> warrants). The Company incurred an additional $239,620 ($192,824 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">for the</div> shares<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;and</div> $46,796 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">for the</div> warrants) in share issuance costs associated with the Offering. </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">ii)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;">During the year ended December&#160;31, 2022, 200,000 common shares were issued on the exercise of warrants for gross proceeds of $306,770. The weighted average share price during the period in which these warrants were exercised was CDN$4.18. On exercise, $44,893 was transferred from additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital to share capital. </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify">Capital transactions which took place during the year ended December&#160;31, 2023, are as follows: </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">iii)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;">During the year ended December&#160;31, 2023, 2,385,484 common shares were issued on the exercise of warrants for gross proceeds of $5,241,811. The weighted average share price during the period in which these warrants were exercised was CDN$7.15. On exercise, $733,177 was transferred from additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital to share capital. </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">iv)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;">During the year ended December&#160;31, 2023, 20,600 common shares were issued on the exercise of options for gross proceeds of $30,059. The weighted average share price during the period in which these options were exercised was CDN$2.00. On exercise, $18,776 was transferred from additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital to share capital. </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">v)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify; line-height: normal;;text-indent: 0px;">On August&#160;18, 2023, the Company closed a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">non-brokered</div> private placement (the &#8220;Private Placement&#8221;). Pursuant to the Private Placement, the Company issued 3,183,875 common shares at a price of CDN$7.00 per Common share for aggregate gross proceeds of $16,445,635. The Company incurred cash costs of issuing shares of $559,098. In addition, the Company issued 99,061 <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">common shares as finder&#8217;s fees which were<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">valued at $511,681.&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div></td></tr></table><div></div><div><div style="line-height:normal;background-color:white;display: inline;"></div></div><div style="clear:both;max-height:0pt;"></div> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-size: 13.3333px; background-color: rgb(255, 255, 255); float: none; top: 0px; display: inline !important; letter-spacing: 0px;;display:inline;">Under<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Amended Stock Option Plan (the &#8220;Amended Plan&#8221;), approved by the Board of Directors on October&#160;27, 2021, and ratified by Shareholders on December&#160;3, 2021, the Board of Directors may grant stock options to directors, officers, employees and consultants of the Company up to an aggregate of </div>18.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company&#8217;s then issued and outstanding common shares.</div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options granted under the Amended Plan have lives of up to </div>ten years<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of grant. The vesting schedule of all granted options is determined at the discretion of the Board. Unless otherwise determined by the Board, in its sole discretion, all grants of options will vest over a </div>three-year<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period, with the first twenty-five percent (</div>25<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%) of the Options vesting on the date of grant, and the remaining o<div style="display:inline;">ptions</div> vesting over the following </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">thirty-six-month</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period in three equal instalments on an annual basis.</div></div>  <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 9%;;text-indent: 0px;"><div style="font-size: 13.3333px; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s option transactions:</div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;(CDN$)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding, December 31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,134,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,172,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding, December 31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,306,450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20,600</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cancelled</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(24,800</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">257,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding, December 31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,518,250</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.27</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width:55%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Grant</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options<br/> Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options<br/> Exercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price&#160;(CDN$)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiry</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual<br/> Life&#160;(years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sep 27, 2015</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">186,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">186,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.00</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(3)</div>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Mar 31, 2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Nov 2, 2015</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.00</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(3)</div>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Nov 2, 2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.85</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Mar 5, 2018</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">452,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">452,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.00</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(3)</div>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Mar 5, 2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Mar 9, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">756,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">567,713</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Mar 9, 2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Mar 9, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">326,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">326,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Mar 9, 2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">May 3, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">257,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">192,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">May 3, 2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dec 9, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Dec 9, 2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Mar 31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">392,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">186,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Mar 31, 2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dec 9, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">734,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">407,983</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.85</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Dec 9, 2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">May 18, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">180,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.84</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">May 18, 2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">May 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">May 30, 2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sep 27, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Sep 27, 2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,518,250</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,537,296</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.27</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.02</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The share-based compensation expense was determined based on the <div style="display:inline;">fai</div>r value of options at the date of measurement using the Black-Scholes option pricing model with the following weighted-average assumptions:</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Options granted during the year ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected forfeiture rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average annual volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">79.60</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.54</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.80</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average expected option life</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.75&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.70&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average share price (CDN$)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average exercise price (CDN$)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average fair value of options granted (CDN$)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>  <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">Share-based payments for the year ended December&#160;31, 2023, was $1,412,257 (2022 - $1,433,812) (See Note <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">13</div> &#8211; General&#160;&amp; Administrative Expenses and Note <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">14</div> &#8211; Research&#160;&amp; Development Expenses for breakdown by function). </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">As of December&#160;31, 2023, the unrecognized stock-based compensation expense related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock options was $961,535, which is expected to be recognized over a weighted-average period of 2.09 years. </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">d)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Warrants </div></td></tr></table>  <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">The following table summarizes the Company&#8217;s warrant transactions: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">exercise&#160;price&#160;(CDN$)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,161,898</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.81</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issued</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,832,088</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.94</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(289,172</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(200,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,504,814</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.95</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,385,484</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,119,330</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.49</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify">As at December&#160;31, 2023, the following warrants were out<div style="letter-spacing: 0px; top: 0px;;display:inline;">standing:</div> </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:63%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Expiry date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise&#160;price<br/> (CDN$)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> contractual&#160;life<br/> (years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrants<br/> outstanding<br/> and<br/> exercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">120 days after holder to be a Director/ Officer or consultant</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.7572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">243,421</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">120 days after former spouse ceases to be a Director/ Officer or consultant</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.7572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">120 days after <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">holder ceases to be a Director/ Officer or consultant<div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 7.5pt; line-height: 7.5pt;;display:inline;vertical-align: super;;font-size:8.3px">(1)</div></div></div></div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.4984</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">N/A</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">315,500</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">January 4, 2024</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">5.5993</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">0.01</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">239,080</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">January 4, 2024</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">7.1991</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">0.01</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">39,846</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">January 8, 2024</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">5.5993</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">0.02</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">31,877</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">March 9, 2026</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">11.20</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">2.19</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">2,826,274</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April 20, 2026</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">3.00</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">2.30</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">5,196,550</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April 20, 2026</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">2.05</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">2.30</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">50,054</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April 29, 2026</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">11.20</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">2.33</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">39,228</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.49</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,119,330</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents unit purchase to acquire <div style="letter-spacing: 0px; top: 0px;;display:inline;">315,500</div> units consisting of one Common Share and one additional warrant at an exercise price of $<div style="letter-spacing: 0px; top: 0px;;display:inline;">0.75</div>CDN. These underlying warrants expire two years from the date of exercise of the primary warrant. </div></div></div></td></tr></table>  <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">e)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Class&#160;B <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Voting</div> shares </div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify">On January&#160;31, 2021, the Company entered into a contribution agreement with the Chief Scientific Officer of the Company, and certain of the Company&#8217;s subsidiaries (the &#8220;Contribution Agreement&#8221;). Pursuant to the Contribution Agreement, the Company acquired AMDM Holdings Inc., a corporation wholly-owned by the Chief Scientific Officer, which held 5% of the equity interest in the Company&#8217;s subsidiary, Eupraxia USA. In exchange, the Company issued to the Chief Scientific Officer 225 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> Class&#160;B shares (the &#8220;Class&#160;B Shares&#8221;) in Eupraxia Pharma Inc. representing 5% of the outstanding securities of Eupraxia Pharma. The Company holds the remaining 95% of such securities, which consists of 4,275 voting Class&#160;A shares. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify">Each Class&#160;B Share is exchangeable into common shares of the Company based on an exchange rate of 2,500 common shares for each Class&#160;B Share, subject to adjustments upon the occurrence of certain events, for a total of 562,500 common shares. The Class&#160;B Shares are exchangeable by the Chief Scientific Officer at her election, provided that the Company may force the exchange of the Class&#160;B Shares into common shares of the Company at any time on or after January&#160;31, 2031, or on or after January&#160;31, 2026, if the Company is listed on a stock exchange and is a reporting issuer in Canada at such time. The Company may also force the exchange of the Class&#160;B Shares into common shares if there is a change of control transaction involving the Company, a change in law which makes the exchange necessary or desirable or if there are a <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">de minimis </div></div>number of Class&#160;B Shares outstanding. If the Company is listed on a stock exchange at the time of the applicable exchange, the Company may elect to pay the Chief Scientific Officer cash in lieu of issuing common shares, with such cash amount to be determined based on the then current market price of the common shares of the Company. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486459959856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General And Administrative Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_GeneralAndAdministrativeExpensesAbstract', window );"><strong>General And Administrative Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock', window );">General And Administrative Expenses</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">GENERAL AND ADMINISTRATIVE EXPENSES </div></div></td></tr></table>  <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">General and administrative expenses are comprised of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Office expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">389,210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">332,951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Insurance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">367,472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">357,763</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Travel</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">345,992</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Professional fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,821,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">268,698</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public company costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">404,073</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">214,264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Salaries and benefits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,241,079</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,641,049</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Share based payments (Note 12(c))</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">714,380</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,052,758</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total expenses during the period</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,284,004</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,987,598</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in entirety of general and administration expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_GeneralAndAdministrativeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_GeneralAndAdministrativeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461320400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research And Development Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research And Development Expenses</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">RESEARCH AND DEVELOPMENT EXPENSES </div></div></td></tr></table>  <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Research and development expenses are comprised of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">December&#160;31,</div><br/><div style="font-weight:bold;display:inline;">2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">December&#160;31,</div><br/><div style="font-weight:bold;display:inline;">2022</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preclinical</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,616,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,073,668</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Clinical</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,595,597</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,179,535</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Manufacturing&#160;&amp; analytical</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,986,502</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,177,070</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Regulatory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">341,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">588,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consulting</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">660</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;">Direct research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,539,926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,019,585</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Pipeline development</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83,637</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">227,615</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other research and development</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">672,295</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">424,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Salaries and benefits</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,794,891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,901,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Share based payments (Note 12(c))</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">697,877</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">381,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">License costs (Note 10)</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">5,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Government grants (Note 15)</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(122,542</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(288,515</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">SR&amp;ED and other R&amp;D tax incentives</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(102,859</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(35,770</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total expenses during the period</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,563,225</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,629,854</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 985<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//985-730/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486545792736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Government Grants And Assistance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAbstract', window );"><strong>Government Assistance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTextBlock', window );">Government Grants And Assistance</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">GOVERNMENT GRANTS AND ASSISTANCE </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">National Research Council &#8211; Industrial Research Assistance Program <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;NRC-IRAP&#8221;)</div></div> </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">On October&#160;1, 2021, the Company entered into an agreement with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NRC-IRAP</div> for funding support of specified research and development activities during a project phase, commencing on September&#160;1, 2021, and ending on December&#160;15, 2023. Under the agreement, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NRC-IRAP</div> would reimburse up to 80% of supported salary costs, and 50% of supported contractor fees to a maximum of $553,185. During the year ended December&#160;31, 2023, the Company claimed $122,542 pertaining to this agreement (2022 - $277,117). </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">At December&#160;31, 2023 there was $nil (2022 - $13,892) of government grants recorded in amounts receivable (Note <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">4</div> &#8211; Amounts Receivable) and collected subsequent to year end. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">The following table summarizes the government grants and assistance the Company received or accrued during the years ended December&#160;31, 2023 and 2022: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NRC-IRAP</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122,542</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">277,117</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">BioTalent Canada</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,398</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">122,542</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">288,515</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">Government assistance of $122,542 (2022 - $288,515) relating to research and development activities has been offset against research and development expense. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461487952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">INCOME TAXES </div></div></td></tr></table><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For financial reporting purposes, loss before taxes includes the following components: </div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:69%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"><div style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Year ended December 31,</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">2022</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canadian</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28,810,717</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18,925,281</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(118,866</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(65,483</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(28,929,583</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(18,990,764</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The income tax expense consists of the following: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 83%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December 31,</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Canadian</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">36,423</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">36,423</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">36,423</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div>&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36,423</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div>&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr></table><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 69%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December&#160;31,</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28,929,583</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18,990,764</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Statutory Canadian corporate tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Expected tax recovery at statutory rates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(7,810,987</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5,127,506</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Change in unrecognized deferred tax assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,523,404</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,127,732</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Non-deductible share-based payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">381,285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">414,724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other items not deductible for tax purposes and other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">242,460</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,570</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Adjustments related to prior years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(624,973</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(257,636</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Share issue costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(290,289</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(322,131</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Foreign exchange arising on translation to reporting currency</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,384,477</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">153,247</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Income tax expense</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36,423</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense for the year ended December 31, 2023 arose from the operations of Eupraxia Pharma USA Inc., the Company&#8217;s wholly-owned subsidiary in the United States. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax assets and liabilities result from the temporary differences between the amount of assets and liabilities recognized for financial statement and income tax purposes. The significant components of the Company&#8217;s net deferred income tax assets are as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 69%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 8%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Convertible debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">733,756</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">360,307</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Depreciable assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,092,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,655,346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Lease obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-capital</div> losses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,348,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,776,875</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Share issue costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">728,046</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">694,773</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Scientific research and experimental development pool</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,093,085</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">852,776</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,546,834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">797,401</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Other</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">121,846</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Less: valuation allowance</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(26,669,004</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(17,145,600</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Net deferred income tax assets</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 10%; padding: 0pt 5pt 0pt 0pt;;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; width: 10%; padding: 0pt 5pt 0pt 0pt; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In assessing the realizability of the Company&#8217;s deferred income tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not b realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which temporary differences become deductible and the loss carry-forwards or tax credits can be utilized. A full valuation allowance continues to be applied against deferred income tax assets as the Company has assessed that the realization of such assets does not meet the more likely than not criteria. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are no unrecognized income tax benefits as of December 31, 2023, or 2022. Due to the net operating loss carryover position coupled with the lack of any unrecognized tax benefits, no provision has been made for any interest or penalties associated with any uncertain tax positions. It is not anticipated that there will be any significant changes to unrecognized tax benefits within the next 12 months. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In assessing the realizability of the Company&#8217;s deferred income tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not b realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which temporary differences become deductible and the loss carry-forwards or tax credits can be utilized. A full valuation allowance continues to be applied against deferred income tax assets as the Company has assessed that the realization of such assets does not meet the more likely than not criteria. </div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are no unrecognized income tax benefits as of December 31, 2023, or 2022. Due to the net operating loss carryover position coupled <div style="display:inline;">wit</div>h the lack of any unrecognized tax benefits, no provision has been made for any interest or penalties associated with any uncertain tax positions. It is not anticipated that there will be any significant changes to unrecognized tax benefits within the next 12 months. </div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company and its foreign subsidiaries have available </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-capital</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> losses for Canadian, Australian and US income tax purposes which may be carried forward to reduce taxable income in future years. If not utilized, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-capital</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> losses in each jurisdiction will expire as follows<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;(all amounts expressed in USD):</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 24%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 17%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 17%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 17%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Expiry date</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-capital&#160;losses&#8211;</div><br/>Canada</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-capital&#160;losses&#8211;</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-capital&#160;losses&#8211;</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Australia</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width:21%"></td>
<td style="vertical-align:bottom;width:18%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:18%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:18%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2031</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">281,235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2032</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">575,606</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">322,050</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2033</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,481,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,111,122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2034</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,935,535</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">160,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2035</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,466,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">160,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2036</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,797,516</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">160,048</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>037</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">7,294,414</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">160,000</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2038</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">3,060,930</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2039</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">1,666,415</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2040</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">144,413</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2041</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">6,404,809</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2042</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">13,526,387</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2043</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">17,642,270</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unlimited</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">1,479,139</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">69,093</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">62,277,418</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,552,359</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">69,093</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table>  <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company also has approximately $</div>7,752,165<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of SR&amp;ED expenditures that may be carried forward indefinitely to be deducted against future Canadian taxable income. It also has federal investment tax credits of approximately $</div>1,449,886<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> available to offset future Canadian federal income taxes payable as well as provincial investment tax credits of approximately $</div>511,826<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The federal tax credits are available to be carried forward </div>20<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> years (expiring in 2036 to 2043) to offset future Canadian federal income taxes payable and the provincial tax credits are available to be carried forward </div>10<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> years (expiring in 2026 to 2033) to offset future BC income taxes payable. The benefit of the investment tax credits has not been recognized as their realization is not reasonably assured.</div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company files income tax returns in Canada, United States and Australia, the jurisdictions in which the Company believes that it is subject to tax. In jurisdictions in which the Company does not believe it is subject to tax and therefore does not file income tax returns, the Company can provide no certainty that tax authorities in those jurisdictions will not subject one or more tax years (since the inception of the Company) to examination. Further, while the statute of limitations in each jurisdiction where an income tax return has been filed generally limits the examination period, as a result of loss carry-forwards, the limitation period for examination generally does not expire until several years after the loss carry-forwards are utilized. Other than routine audits by tax authorities for tax credits and tax refunds that the Company claims, the Company is not aware of any other material income tax examination currently in progress by any taxing jurisdiction. Tax years ranging from 2012 to 2023 remain subject to examinations in Canada and the United States 2022 to 2023 for Australia. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486545586960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">COMMITMENTS </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">The Company may be required to make milestone, royalty, and other research and development funding payments under research and development collaboration and other agreements with third parties (see Note <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">10</div> &#8211; Auritec License Agreement). These payments are contingent upon the achievement of specific development, regulatory and/or commercial milestones. The Company has not accrued these payments as at December&#160;31, 2023 due to the uncertainty over whether these milestones will be achieved. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">Eupraxia has entered into a number of service contracts with its vendors.&#160;Some of those contracts have cancellation clauses which state Eupraxia would pay a cancellation fee of between 15% and 100% of the next service milestone if it terminates the contract.&#160;As of December&#160;31, 2023, there have been no cancellation of contracts that would trigger a cancellation fee.</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461408528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; border: 0px; width: 816px;;text-indent: 0px;">
<tr style="break-inside: avoid;">
<td style="width: 32.625px; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">FINANCIAL INSTRUMENTS </div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial instruments consist of cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities, payable to Auritec, loans payable and convertible debt. </div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no changes to the Company&#8217;s risk exposures or management of risks during the year ended December&#160;31, 2023. The Company&#8217;s risk exposures and the impact on the Company&#8217;s financial instruments are summarized below: </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Credit risk </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company believes it has no significant credit risk, as its cash and cash equivalents and short-term investments, being its primary exposure to credit risk, is with a large Canadian bank. The Company&#8217;s maximum exposure to credit risk is the carrying value of these financial assets. </div> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity risk </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. The Company&#8217;s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at December&#160;31, 2023, the Company had cash and cash equivalents of $19,341,756 (2022 - $18,263,389) in addition to current liabilities of $19,373,903 (2022 - $3,058,387). <div style="letter-spacing: 0px; top: 0px;;display:inline;">Management is currently working on certain strategic alternatives including, but not limited to raising additional capital and strategic alternatives to its existing contingent convertible debt facility. There is no assurance, however, that any or all of these alternatives will materialize or that additional funding will be available, if and when needed.</div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"> </div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Market risk </div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: currency risk, interest rate risk and other price risk. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest rate risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market i<div style="display:inline;">nteres</div>t rates. The Company is exposed to interest rate cash flow risk; and to the extent that the prevailing market interest rates differ from the interest rate on the Company&#8217;s monetary assets and liabilities, the Company is exposed to interest rate price risk. At December&#160;31, 2023, the Company maintains a convertible debt facility totaling CDN$10,000,000 as well as having an equipment loan of $235,000 of which a principal balance of $62,709 remains as at December&#160;31, 2023. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The convertible debt accrues interest at the greater of 2.45% and the Canadian prime rate, requiring monthly interest payments. An additional payment in kind accrues at a rate of 7% per annum, which will be settled at maturity or on conversion. The equipment loan accrues interest at a fixed rate of 5.84%. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">As at December&#160;31, 2023, management has determined the effect on the future results of operations due to a change in the current Canadian prime rate. An impact of a 1% change in the Canadian prime rate would impact the amount of interest to be paid over the remaining term of the convertible debt facility by approximately $43,807. </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Currency risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company is exposed to currency risk due to its frequency of transactions in US dollars. The Company does not use derivatives to hedge against this risk, however, it has purchased US dollars to cover the majority of the costs of the Company&#8217;s Phase 2 clinical trial.&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">At December 31, 2023, the Company held cash of </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div>933,816<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (2022 &#8211; $</div>1,159,926<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">, had accounts payable of $1,292,128 (2022 &#8211; $1,814,067), <div style="display:inline;">a</div> payable owing to Auritec of $5,000,000 (2022 &#8211; nil) and a loan payable of </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div>62,709<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (2022 &#8211; $</div>142,127<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">) denominated in US dollars which were translated to Canadian dollars at </div>1.3226<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (2022 &#8211; </div>1.3544<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">). The impact of a 10% change in the exchange rates would have an impact of approximately $</div>542,102<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (2022 &#8211; $</div>79,627<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">) on profit or loss. The Company also has cash in accounts payable in Australian dollars, Great British pounds and Euros. The impact of a </div>10<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% change in the exchanges of these currencies would have an immaterial effect on future cash flows.</div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other price risk </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk and foreign currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer or by factors affecting all similar financial instruments traded in the market. The Company is not exposed to significant price risk with respect to commodity or equity prices. </div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Fair Value Measurement </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company categorizes its financial instruments measured at fair value into one of three different levels depending on the observation of inputs used in the measurement. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Level&#160;1: Fair value is based on unadjusted quoted prices for identical assets or liabilities in active markets </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Level&#160;2: Fair value is based on inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Level&#160;3: Fair value is based on valuation techniques that require one or more significant unobservable inputs </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company&#8217;s financial instruments consist of cash and cash equivalents, short-term investments, accounts payable and accrued liabilities, loans payable and convertible debt. With the exception of convertible debt, the carrying value of the Company&#8217;s financial instruments approximate their fair values due to their short-term maturities. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The following table summarizes information regarding the classification and carrying values of the Company&#8217;s financial instruments measured at amortized cost: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 72%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets/liabilities</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,341,756</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,263,389</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Amounts receivable</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">190,612</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89,715</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable and accrued liabilities</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">3,921,875</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">2,928,566</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Payable to Auritec</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">5,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loans payable</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">62,709</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">142,127</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes information regarding the changes in fair value of liabilities measured at fair value, categorized as Level&#160;3: </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 82%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible&#160;Debt</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance &#8211; December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,507,755</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">958,669</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(315,436</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,056,165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign exchange</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(465,157</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance - December 31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,741,996</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,162,773</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(591,170</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">836,595</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign exchange</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">185,809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance - December 31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,336,003</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">For the convertible debt, the key inputs that affect the ongoing valuation are the discount price, the share price and the share price volatility. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486545586960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest Expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseAbstract', window );"><strong>Interest Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock', window );">Interest Expense</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">INTEREST EXPENSE </div></div> </td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Interest expense is comprised of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Interest on SVB debt facility (Note 11)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,162,773</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">958,669</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other interest and accretion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,170,173</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">982,856</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for interest income and interest expense for enterprises that derive a significant portion of their revenue from interest collected on investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.1-12)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461408528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Disclosure with Respect to Cash Flows<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Disclosure with Respect to Cash Flows</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company paid interest of $598,046 during the year ended December&#160;31, 2023 (2022 - $326,629). </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company received interest of $912,033 during the year ended December&#160;31, 2023 (2022 - $394,188). </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company had the following significant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> transactions for the year ended December&#160;31, 2023: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify; line-height: normal;">99,061 common shares (valued at $511,678) were issued as part of the financing on August&#160;18, 2023, as a payment of finder&#8217;s fees (see Note <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">12</div>(b)(v)). </div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company had the following significant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> transactions for the year ended December&#160;31, 2022: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify; line-height: normal;">500,538 warrants (valued at $160,147) were issued as part of the financing on April&#160;20, 2022, to the Underwriters (see<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;</div>Note&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">12</div>(b)(i)). </div> </td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">A detailed breakdown of cash and cash equivalents is as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,341,756</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,830,891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,432,498</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,341,756</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18,263,389</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//230/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461383072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">SUBSEQUENT EVENT </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">On March&#160;15, 2024, the Company announced it had closed its previously announced overnight marketed public offering (the &#8220;Offering&#8221;) of common shares of the Company (the &#8220;Shares&#8221;). Pursuant to the Offering, Eupraxia issued 8,260,435 Shares at a price of C$4.10 per Share for gross proceeds of $25,026,073 (CDN$33,867,784<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">), which includes the issuance of</div> 943,435 Shares upon exercise of the over-allotment option. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486463609168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Measurement</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Measurement </div></div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements have been prepared on a historical cost basis, except for certain financial instruments which are measured at fair value. The consolidated financial statements are presented in U.S. dollars, which is the Company&#8217;s reporting currency. The Company&#8217;s functional currency is the Canadian dollar. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of consolidated financial statements in accordance with U.S. GAAP requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, expenses, and related disclosure. On an ongoing basis, the Company evaluates its estimates, most notably those related to accrual of expenses including clinical and preclinical study expense accruals, stock-based compensation, valuation allowance for deferred taxes, and fair value measurement of convertible debt. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidation </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These consolidated financial statements include the accounts of the Company and the accounts of its subsidiaries. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. Control exists when an entity is exposed to or has rights to variable returns from its involvement with the entity and has the ability to affect these returns through its power over the entity. All significant intercompany transactions and balances have been eliminated. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest in the net assets of consolidated subsidiaries are identified separately from the Company&#8217;s equity. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interest consists of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest as at the date of the original transaction plus the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest&#8217;s share of changes in equity since that date.</div><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 53%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Company Entity</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Incorporation</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Jurisdiction of<br/>Incorporation</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effective<br/>Interest<br/>(Note&#160;13(e))</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width:53%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Holdings, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">October 10, 2012</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Delaware,&#160;USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Pharmaceuticals USA, LLC</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">October 10, 2012</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Delaware, USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">AMDM Holdings Inc.<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(2)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">April 6, 2016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Washington,&#160;USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Pharma, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">January 7, 2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Delaware, USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Pharmaceuticals Australia Pty Ltd.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">July 4, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Victoria, Australia</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Pharma USA Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">May 17, 2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Delaware, USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Wholly-owned subsidiary of Eupraxia Pharmaceuticals Inc. </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Date of Control occurred on January&#160;31, 2021 (see Note 13(e)). </div></div></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) per Share</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings (Loss) per Share </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies the &#8220;Treasury Stock Method&#8221; to calculate loss per common share. Under this method, the basic earnings (loss) per share is calculated based on the weighted average aggregate number of common shares outstanding during each period. The diluted earnings (loss) per share assumes that the outstanding stock options and share purchase warrants had been exercised at the beginning of the period, or date of issuance if issued during the period, and proceeds from dilutive instruments are used to purchase common shares at the average market price during the period. Since the Company was in a loss position for the years ended December&#160;31, 2023 and 2022, the assumed conversion of outstanding common share warrants, options, and convertible instruments has an anti-dilutive impact, therefore the diluted loss per share is equal to basic loss per share. </div></div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Equipment</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment </div></div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment is recorded at historical cost less accumulated depreciation and accumulated impairment losses. Depreciation is provided over the estimated useful lives of the assets as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:94%;border:0;margin-left:auto">
<tr>
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;">Computers</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">45% declining balance</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;">Office furniture and equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">20% declining balance</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">straight-line over the shorter of the initial term of the lease or useful life</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Lab equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">20% declining balance</td></tr></table></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The useful lives and depreciation methods applied to each category of equipment are assessed on an annual basis by management and adjusted where necessary to reflect the recoverability of equipment. </div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenditures</a></td>
<td class="text"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Research and Development Expenditures </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Research and development costs are expensed as they are incurred. These costs consist primarily of salaries and wages related to research and development activities, including share-based payments for employees engaged in research and development, clinical trial expenses and other research costs. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RegulatoryIncomeTaxesPolicy', window );">Investment Tax Credits</a></td>
<td class="text"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Investment Tax Credits </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Investment tax credits (&#8220;ITCs&#8221;) arising from research and development activities are deducted from the related costs and are included in profit or loss when there is reasonable assurance that the credits will be realized. ITCs arising from the acquisition or development of equipment and capitalized development costs are deducted from the cost of those assets with amortization calculated on the net amount. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_GovernmentGrantsPolicyTextBlock', window );">Government Grants</a></td>
<td class="text"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Government Grants </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Government grants related to research and development activities are recognized in profit or loss as a deduction from the related expenditure when there is reasonable assurance that the grant will be received. Grants that compensate the Company for the cost of an asset are recognized in profit or loss on a systematic basis over the useful life of the asset. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Government Assistance</a></td>
<td class="text"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Government Assistance </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Government contributions are recognized and deducted from the related costs when there is reasonable assurance that the contribution will be received and all attached conditions have been complied with by the Company. Government contributions arising from the acquisition or development of equipment and capitalized development costs are deducted from the cost of those assets with amortization calculated on the net amount. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current income tax is the expected tax payable or recoverable on the taxable profit or loss for the year using tax rates enacted at the reporting date and any adjustment to tax payable from previous years. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax is recorded using the asset and liability method, providing for temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Temporary differences are not provided for if they relate to goodwill not deductible for tax purposes, or differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates and laws enacted at the reporting date and expected to apply when these differences reverse. A deferred tax asset is recognized only to the extent that it is more likely than not that future taxable profits will be available against which the asset can be utilized. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company uses a two-step process to recognize and measure the income tax benefit of uncertain tax positions taken or expected to be taken in a tax return. The tax benefit from an uncertain tax position is recognized if it more likely than not that the position will be sustained upon examination of the tax authority based solely on the technical merits of the position. A tax benefit that meets the more likely than not recognition threshold is measured as the largest amount that is greater than 50% likely to realized upon settlement with the tax authority. To the extent a full benefit is not expected to be realized, an income tax liability is established. Any change in judgement related to the expected resolution of an uncertain tax provision is recognized in the year of such a change. Interest an penalties related to income tax are included as a component of income tax expense. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payments</a></td>
<td class="text"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><div style="font-weight:bold;display:inline;">Share-based Payments </div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company grants stock options to employees, directors and officers pursuant to stock option plans described in note 13c. Employee stock-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense, net of actual forfeitures, over the requisite service period with a corresponding increase in additional paid-in capital. Stock-based compensation expense is amortized on a straight-line basis over the requisite service period for the entire award, which is generally the vesting period of the award. </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any consideration received on exercise of stock options is credited to share capital. </div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Share Capital and Warrants</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share Capital and Warrants </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company records proceeds from share issuances net of issue costs and any related tax effects. Common shares issued for consideration other than cash are valued based on their market value at the date the agreement to issue shares was concluded. When units are issued during a private placement, which include both common shares and share purchase warrants, the warrants are classified as equity and as such, the proceeds should be allocated based on the relative fair values of the base instrument and the warrants on the day of the announcement of the private placement. Any value of the warrants is allocated to the warrants and credited to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign Currency Translation </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The functional currency for each of the Company and the Company&#8217;s subsidiaries is the currency of the primary economic environment in which each entity operates. Determination of functional currency may involve certain judgments to determine the primary economic environment. The Company reconsiders the functional currency of its entities if there is a change in events and conditions which determine the primary economic environment. The functional currency of Eupraxia Pharmaceuticals Inc., the parent entity, and each of the Company&#8217;s subsidiaries is the Canadian dollar. </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transactions in foreign currencies are translated to the functional currency of the entity at the exchange rate at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the reporting date are retranslated at the period end date exchange rates. </div></div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-monetary</div> items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-monetary</div> assets and liabilities denominated in foreign currencies that are measured at fair value are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-translated</div> to the functional currency at the exchange rate at the date that the fair value was determined. Foreign currency differences arising on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-translation</div> are recognized in profit or loss. </div></div><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The reporting currency of the Company&#8217;s consolidated financial statements is the U.S. dollar. All assets and liabilities are translated from the functional currency to the reporting currency using the spot rate at the period end date, equity components are translated at the historical rate, and income and expenses are translated using the average exchange rate for the period. All foreign currency differences arising on translation from functional to reporting currency are included in accumulated other comprehensive income. </div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of Long-Lived Assets </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or group of assets. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset or asset group. As of December&#160;31, 2023 and 2022, the Company determined that there were no indicators of impairment of long-lived assets. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Cash and cash equivalents include cash on hand, bank deposits, and highly liquid investments with original maturities of three months or less from the date of purchase that are readily convertible to known amounts of cash and subject to insignificant risk of changes in value. Cash equivalents are recorded at cost plus accrued interest. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Short Term Investments</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short Term Investments </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Short term investments include highly liquid investments with original maturity dates greater than three months and less than one year and cannot be redeemed prior to maturity without incurring a penalty. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments and Fair Value</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Instruments and Fair Value</div></div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures certain financial instruments and other items at fair value into a three-level hierarchy established by US GAAP that prioritizes those inputs to valuation techniques used to measure fair value on the degree to which they are observable. This hierarchy includes: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">i.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1 &#8211; Unadjusted quoted prices in active markets for identical instruments. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">ii.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2 &#8211; Inputs other than quoted prices included within Level 1 that are observable for the financial instrument, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability and inputs that are derived principally from or corroborated by observable market data by correlation or other means. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">iii.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inputs are unobservable and reflect the Company&#8217;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and liabilities are classified on the lowest level of input that is significant to the fair value measurements. Reclassification of the level may be a result of changes in the observability of the valuation inputs for certain instruments within the fair value hierarchy. The carrying value of accounts receivable, accounts payable, and accrued expense approximate fair value due to the short-term nature of these instruments. On a recurring basis, the Company&#8217;s cash and cash equivalents and marketable securities are measured at fair value. </div></div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"> <div style="text-align: justify; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Leases classified as operating leases are recorded as lease liabilities based on the present value of minimum lease payments over the lease term, discounted using the lessor&#8217;s rate implicit in the lease or the Company&#8217;s incremental borrowing rate, if the lessor&#8217;s implicit rate is not readily determinable. The lease term includes all periods covered by renewal and termination options where the Company is reasonably certain to exercise the renewal options or not to exercise the termination options. Corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets are recognized consisting of the lease liabilities, initial direct costs and any lease incentive payments. Lease liabilities are drawn down as lease payments are made and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets are depreciated over the term of the lease. Operating lease expenses are recognized on a straight-line basis over the term of the lease, consisting of interest accrued on the lease liability and depreciation of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, adjusted for changes in index-based variable lease payments in the period of change. Lease payments on short-term operating leases with lease terms twelve months or less are expensed on a straight-line basis over the lease term. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Upcoming Accounting Standards and Interpretations</a></td>
<td class="text"> <div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upcoming Accounting Standards and Interpretations </div></div></div></div> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has not yet adopted certain new standards, amendments and interpretations to existing standards, which have been published but are only effective for accounting periods beginning on or after January&#160;1, 2024 or later periods. The new and amended standards are not expected to have a material impact on the Company&#8217;s consolidated financial statements. </div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_GovernmentGrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_GovernmentGrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegulatoryIncomeTaxesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, including investment tax credits, and the related regulatory treatment (for example, whether deferred income tax accounting - normalization - is allowed in rate making).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 980<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481974/980-740-25-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 980<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481974/980-740-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegulatoryIncomeTaxesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486464158528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfInformationAboutSubsidiariesTableTextBlock', window );">Summary of Information About Subsidiaries</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 53%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Company Entity</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Incorporation</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Jurisdiction of<br/>Incorporation</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effective<br/>Interest<br/>(Note&#160;13(e))</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width:53%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Holdings, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">October 10, 2012</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Delaware,&#160;USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Pharmaceuticals USA, LLC</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">October 10, 2012</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Delaware, USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">AMDM Holdings Inc.<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(2)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">April 6, 2016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Washington,&#160;USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Pharma, Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">January 7, 2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Delaware, USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Pharmaceuticals Australia Pty Ltd.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">July 4, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Victoria, Australia</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Eupraxia Pharma USA Inc.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">May 17, 2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Delaware, USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Wholly-owned subsidiary of Eupraxia Pharmaceuticals Inc. </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Date of Control occurred on January&#160;31, 2021 (see Note 13(e)). </div></div></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock', window );">Summary of Property Plant And Equipment Estimated Useful Life</a></td>
<td class="text"><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment is recorded at historical cost less accumulated depreciation and accumulated impairment losses. Depreciation is provided over the estimated useful lives of the assets as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:94%;border:0;margin-left:auto">
<tr>
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;">Computers</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">45% declining balance</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;">Office furniture and equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">20% declining balance</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">straight-line over the shorter of the initial term of the lease or useful life</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Lab equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">20% declining balance</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment rate of depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ScheduleOfInformationAboutSubsidiariesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of information about subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ScheduleOfInformationAboutSubsidiariesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486463976368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Amounts Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NontradeReceivablesTableTextBlock', window );">Summary of Amounts Receivable</a></td>
<td class="text"> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 74%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Government grants (Note 14)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,892</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">GST/HST recoverable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">85,879</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,658</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other refundable tax credits <div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104,733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37,165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">190,612</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">89,715</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Other refundable tax credits are due to tax incentives for R&amp;D costs incurred by Eupraxia Australia (Note 14 &#8211; Research and Development Expenses). </div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_NontradeReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nontrade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_NontradeReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486463585008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Property and equipment consisted of the following: <br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 60%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Computers</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Office<br/>furniture&#160;and<br/>equipment</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leasehold<br/>Improvements</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Lab<br/>Equipment</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="20" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Cost</div></div></div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at January&#160;1, 2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">101,754</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">73,267</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">134,333</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">289,569</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">598,923</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20,279</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,551</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">209,720</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">235,550</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposals</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(47,603</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(8,158</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(55,761</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency adjustments</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3,852</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(4,261</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(8,589</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(25,736</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(42,438</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at December&#160;31, 2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">70,578</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">66,399</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">125,744</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">473,553</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">736,274</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">18,534</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">54,843</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">73,377</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposals</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5,488</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(16,124</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(21,612</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency adjustments</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,001</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,597</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,023</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12,992</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19,613</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at December&#160;31, 2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">85,625</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">67,996</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">128,767</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">525,264</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">807,652</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td colspan="21" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="20" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated Depreciation</div></div></div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at January&#160;1, 2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">71,187</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">46,965</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">91,345</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">38,631</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">248,128</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17,153</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,256</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14,366</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">73,328</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">110,103</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposals</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(43,540</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5,342</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(48,882</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency adjustments</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2,295</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2,853</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(6,410</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(4,981</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(16,539</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at December&#160;31, 2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">42,505</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44,026</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">99,301</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">106,978</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">292,810</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17,612</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,492</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13,849</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">76,930</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">112,883</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disposals</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5,162</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(11,604</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(16,766</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency adjustments</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,226</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,149</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,666</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,097</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9,138</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at December&#160;31, 2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">56,181</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">49,667</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">115,816</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">176,401</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">398,065</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td colspan="21" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="20" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Net Book Value</div></div></div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="4" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at December&#160;31, 2022</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">28,073</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,373</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26,443</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">366,575</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">443,464</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As at December&#160;31, 2023</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">29,444</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18,329</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12,951</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">348,863</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">409,587</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461383632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Asset (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_OperatingLeaseRightOfUseAssetAbstract', window );"><strong>Operating Lease Right of Use Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_OperatingLeaseRightOfUseAssetTableTextBlock', window );">Summary of Right of Use Assets</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The following table presents details of movement in the carrying value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, beginning</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">87,286</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">132,020</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(42,644</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37,791</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign Exchange</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,943</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, ending</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">46,660</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">87,286</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_OperatingLeaseRightOfUseAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Right of Use Asset Abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_OperatingLeaseRightOfUseAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_OperatingLeaseRightOfUseAssetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_OperatingLeaseRightOfUseAssetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486456855008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Summary of Accounts Payable and Accrued Liabilities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,968,263</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,137,336</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,040,204</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">261,933</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Wages and payroll remittances</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,996</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Employee bonus payable<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">858,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">513,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Taxes payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,921,875</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,928,566</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Bonus relates to corporate bonuses for the years ended December&#160;31, 2023 and 2022. </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461324720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Breakdown of Loan Balance</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Below is a breakdown of loan balance as at December&#160;31, 2023 and December&#160;31, 2022: <br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 73%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width: 73%;"></td>
<td style="vertical-align: bottom; width: 6%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 5%;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 73%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, beginning</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">142,127</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">216,994</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 73%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loan repayment</div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(79,441</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(74,845</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 73%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign exchange adjustment</div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 73%;"></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 73%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, ending</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">62,709</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">142,127</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 73%;"></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; width: 73%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Current portion</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">62,709</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">79,418</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; width: 73%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> portion</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">62,709</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461198944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Summary of Cost Components of The Operating Lease</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The cost components of the operating lease were as follows for the years ended December&#160;31, 2023 and 2022: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Lease Cost</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64,996</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68,584</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">66,455</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Lease term and Discount Rate</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term (years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Payments</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The Company&#8217;s future minimum lease payments as of December&#160;31, 2023 are as follows: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Year ending December 31:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60,780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total undiscounted future minimum lease payments</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">60,780</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: balance of unused tenant allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,464</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Present value of lease liabilities at December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">53,316</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock', window );">Summary of Lease Liability Balance</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The lease liability balance is comprised as follows: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Current portion</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50,403</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> portion</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">53,316</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">101,706</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of operating lease liability current and non current [Table Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481440/840-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461304304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Auritec License Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock', window );">Schedule of milestone payment</a></td>
<td class="text">The following table summarizes the milestone payment schedule.
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 84%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone Event</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Milestone<br/>Payment</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Successful Completion of a Phase 2b Study</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">First OA Regulatory Approval</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Second OA Regulatory Approval</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">5,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-OA</div> Indication Regulatory Approval</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">10,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">First calendar year in which aggregate Net Sales by Eupraxia USA, its affiliates and sublicenses exceed $500,000,000</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">5,000,000</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Maximum milestones payable</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">30,000,000</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock', window );">Schedule of non-royalty monetization revenue percentage</a></td>
<td class="text"> The following table summarizes the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Non-Royalty</div> Monetization Revenue percentage schedule: <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:26%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Date of Execution</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Percentage&#160;of&#160;Non-Royalty</div><br/> Monetization Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prior to Successful Completion of a Phase 2b Study</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">After Successful Completion of a Phase 2b Study but prior to Successful Completion of a Phase 3 Study</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">After Successful Completion of a Phase 3 Study but prior to Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">After Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of certain percentage of non monetization revenue payable [Table text block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of milestone payment schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486545460352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=eprx_LoanMember', window );">Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems', window );"><strong>Disclosure In Tabular Form Of Movement In Convertible Debt At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock', window );">Schedule of loan balance</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The loan balance is comprised of the following: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance &#8211; December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,507,755</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">958,669</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Interest paid</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(315,436</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160; <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: right; line-height: normal;">1,056,165</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign exchange</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(465,157</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance &#8211; December 31, 2022</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,741,996</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">1,162,773</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest paid</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(591,170</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">836,595</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign exchange</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">185,809</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance &#8211; December 31, 2023</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,336,003</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of movement in convertible debt at fair value [Line items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of movement in convertible debt at fair value [Table Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eprx_LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eprx_LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461170608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Components of Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Summary of company's option</a></td>
<td class="text"> <div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 9%;;text-indent: 0px;"><div style="font-size: 13.3333px; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s option transactions:</div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise&#160;price&#160;(CDN$)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding, December 31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,134,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,172,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding, December 31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,306,450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20,600</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cancelled</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(24,800</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">257,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding, December 31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,518,250</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.27</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock', window );">Summary of options outstanding along with the grant dates and expiry date</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width:55%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Grant</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options<br/> Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options<br/> Exercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price&#160;(CDN$)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiry</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual<br/> Life&#160;(years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sep 27, 2015</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">186,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">186,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.00</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(3)</div>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Mar 31, 2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Nov 2, 2015</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.00</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(3)</div>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Nov 2, 2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.85</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Mar 5, 2018</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">452,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">452,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.00</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(3)</div>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Mar 5, 2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Mar 9, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">756,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">567,713</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Mar 9, 2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Mar 9, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">326,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">326,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Mar 9, 2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">May 3, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">257,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">192,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">May 3, 2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dec 9, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Dec 9, 2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Mar 31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">392,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">186,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Mar 31, 2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dec 9, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">734,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">407,983</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.85</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Dec 9, 2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">May 18, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">180,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.84</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">May 18, 2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">May 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">May 30, 2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sep 27, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Sep 27, 2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,518,250</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,537,296</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.27</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.02</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of weighted-average assumptions</a></td>
<td class="text"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The share-based compensation expense was determined based on the <div style="display:inline;">fai</div>r value of options at the date of measurement using the Black-Scholes option pricing model with the following weighted-average assumptions:</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Options granted during the year ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected forfeiture rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average annual volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">79.60</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">78.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.54</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.80</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average expected option life</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.75&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.70&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average share price (CDN$)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average exercise price (CDN$)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average fair value of options granted (CDN$)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock', window );">Summary of share based compensation arrangements by share based payment warrant</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">The following table summarizes the Company&#8217;s warrant transactions: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">exercise&#160;price&#160;(CDN$)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,161,898</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.81</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issued</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,832,088</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.94</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(289,172</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(200,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,504,814</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.95</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,385,484</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,119,330</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.49</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock', window );">Summary of share based compensation of share warrants outstanding</a></td>
<td class="text"> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify">As at December&#160;31, 2023, the following warrants were out<div style="letter-spacing: 0px; top: 0px;;display:inline;">standing:</div> </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:63%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Expiry date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise&#160;price<br/> (CDN$)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> contractual&#160;life<br/> (years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrants<br/> outstanding<br/> and<br/> exercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">120 days after holder to be a Director/ Officer or consultant</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.7572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">243,421</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">120 days after former spouse ceases to be a Director/ Officer or consultant</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.7572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">120 days after <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">holder ceases to be a Director/ Officer or consultant<div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 7.5pt; line-height: 7.5pt;;display:inline;vertical-align: super;;font-size:8.3px">(1)</div></div></div></div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.4984</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">N/A</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">315,500</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">January 4, 2024</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">5.5993</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">0.01</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">239,080</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">January 4, 2024</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">7.1991</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">0.01</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">39,846</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">January 8, 2024</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">5.5993</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">0.02</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">31,877</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">March 9, 2026</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">11.20</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">2.19</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">2,826,274</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April 20, 2026</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">3.00</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">2.30</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">5,196,550</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April 20, 2026</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">2.05</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">2.30</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">50,054</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">April 29, 2026</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">11.20</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">2.33</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">39,228</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.49</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,119,330</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents unit purchase to acquire <div style="letter-spacing: 0px; top: 0px;;display:inline;">315,500</div> units consisting of one Common Share and one additional warrant at an exercise price of $<div style="letter-spacing: 0px; top: 0px;;display:inline;">0.75</div>CDN. These underlying warrants expire two years from the date of exercise of the primary warrant. </div></div></div></td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of share based compensation arrangements by share based payment award warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>schedule of share based compensation of share warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486546170880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General And Administrative Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_GeneralAndAdministrativeExpensesAbstract', window );"><strong>General And Administrative Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock', window );">Schedule of general and administrative expenses</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">General and administrative expenses are comprised of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Office expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">389,210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">332,951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Insurance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">367,472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">357,763</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Travel</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">345,992</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Professional fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,821,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">268,698</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public company costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">404,073</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">214,264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Salaries and benefits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,241,079</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,641,049</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Share based payments (Note 12(c))</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">714,380</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,052,758</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total expenses during the period</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,284,004</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,987,598</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_GeneralAndAdministrativeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_GeneralAndAdministrativeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486456907840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research And Development Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock', window );">Schedule of research and development expenses</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">Research and development expenses are comprised of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">December&#160;31,</div><br/><div style="font-weight:bold;display:inline;">2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">December&#160;31,</div><br/><div style="font-weight:bold;display:inline;">2022</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preclinical</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,616,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,073,668</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Clinical</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,595,597</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,179,535</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Manufacturing&#160;&amp; analytical</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,986,502</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,177,070</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Regulatory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">341,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">588,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consulting</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">660</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;">Direct research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,539,926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,019,585</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Pipeline development</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83,637</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">227,615</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other research and development</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">672,295</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">424,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Salaries and benefits</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,794,891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,901,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Share based payments (Note 12(c))</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">697,877</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">381,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">License costs (Note 10)</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">5,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Government grants (Note 15)</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(122,542</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">(288,515</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">SR&amp;ED and other R&amp;D tax incentives</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(102,859</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(35,770</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total expenses during the period</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20,563,225</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,629,854</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461335360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Government Grants And Assistance (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAbstract', window );"><strong>Government Assistance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_GovernmentAssistanceTableTextBlock', window );">Shedule Of Government Grants And Assistance Received</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;">The following table summarizes the government grants and assistance the Company received or accrued during the years ended December&#160;31, 2023 and 2022: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NRC-IRAP</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122,542</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">277,117</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">BioTalent Canada</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,398</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">122,542</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">288,515</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_GovernmentAssistanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_GovernmentAssistanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461076784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components Included in Loss Before Taxes</a></td>
<td class="text"><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For financial reporting purposes, loss before taxes includes the following components: </div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:69%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"><div style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Year ended December 31,</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">2022</div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canadian</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28,810,717</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18,925,281</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(118,866</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(65,483</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(28,929,583</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-weight:bold;display:inline;">(18,990,764</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-weight:bold;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"><div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Expense</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The income tax expense consists of the following: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 83%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December 31,</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Canadian</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">36,423</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">36,423</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">36,423</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div>&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36,423</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div>&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Components of Income Tax Expense Benefit</a></td>
<td class="text"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 69%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 5%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December&#160;31,</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28,929,583</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18,990,764</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Statutory Canadian corporate tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Expected tax recovery at statutory rates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(7,810,987</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5,127,506</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Change in unrecognized deferred tax assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,523,404</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,127,732</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Non-deductible share-based payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">381,285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">414,724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other items not deductible for tax purposes and other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">242,460</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,570</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Adjustments related to prior years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(624,973</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(257,636</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Share issue costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(290,289</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(322,131</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Foreign exchange arising on translation to reporting currency</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,384,477</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">153,247</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Income tax expense</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36,423</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Company's Net Deferred Income Tax Assets</a></td>
<td class="text"><div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax assets and liabilities result from the temporary differences between the amount of assets and liabilities recognized for financial statement and income tax purposes. The significant components of the Company&#8217;s net deferred income tax assets are as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 69%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 8%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Convertible debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">733,756</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">360,307</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Depreciable assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,092,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,655,346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Lease obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-capital</div> losses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,348,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,776,875</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Share issue costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">728,046</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">694,773</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Scientific research and experimental development pool</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,093,085</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">852,776</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,546,834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">797,401</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Other</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">121,846</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Less: valuation allowance</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(26,669,004</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">(17,145,600</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Net deferred income tax assets</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 10%; padding: 0pt 5pt 0pt 0pt;;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; width: 10%; padding: 0pt 5pt 0pt 0pt; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock', window );">Schedule of Non Capital Losses Carry Forward Future Years</a></td>
<td class="text"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-capital</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> losses in each jurisdiction will expire as follows<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;(all amounts expressed in USD):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 24%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 17%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 17%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 17%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Expiry date</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-capital&#160;losses&#8211;</div><br/>Canada</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-capital&#160;losses&#8211;</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">US</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-capital&#160;losses&#8211;</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Australia</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="width:21%"></td>
<td style="vertical-align:bottom;width:18%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:18%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:18%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2031</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">281,235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2032</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">575,606</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">322,050</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2033</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,481,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,111,122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2034</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,935,535</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">160,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2035</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,466,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">160,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2036</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,797,516</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">160,048</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>037</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">7,294,414</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">160,000</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2038</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">3,060,930</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2039</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">1,666,415</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2040</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">144,413</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2041</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">6,404,809</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2042</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">13,526,387</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2043</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">17,642,270</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unlimited</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">1,479,139</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">69,093</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">62,277,418</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3,552,359</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">69,093</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of non capital losses carry forward future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461396848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems', window );"><strong>Disclosure In Tabular Form Of Movement In Convertible Debt At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock', window );">Summary of Carrying Value of Financial Instruments at Amortized Cost</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">The following table summarizes information regarding the classification and carrying values of the Company&#8217;s financial instruments measured at amortized cost: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;<br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 72%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 3%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets/liabilities</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,341,756</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,263,389</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Amounts receivable</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">190,612</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89,715</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable and accrued liabilities</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">3,921,875</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">2,928,566</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Payable to Auritec</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">5,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loans payable</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">62,709</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);">142,127</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems', window );"><strong>Disclosure In Tabular Form Of Movement In Convertible Debt At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock', window );">Summary of Changes in Fair Value of Liabilities Measured at Fair Value</a></td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes information regarding the changes in fair value of liabilities measured at fair value, categorized as Level&#160;3: </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 82%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 6%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible&#160;Debt</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance &#8211; December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,507,755</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">958,669</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(315,436</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,056,165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign exchange</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(465,157</td>
<td style="white-space:nowrap;vertical-align:bottom">)</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance - December 31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,741,996</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,162,773</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(591,170</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">836,595</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign exchange</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">185,809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance - December 31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,336,003</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of movement in convertible debt at fair value [Line items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of movement in convertible debt at fair value [Table Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of carrying value of financial instruments at amortized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461267952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseAbstract', window );"><strong>Interest Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Interest Expense</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Interest expense is comprised of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Interest on SVB debt facility (Note 11)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,162,773</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">958,669</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other interest and accretion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,170,173</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">982,856</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486545792736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Disclosure with Respect to Cash Flows (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Summary of Detailed Breakdown of Cash and Cash Equivalents</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify">A detailed breakdown of cash and cash equivalents is as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,341,756</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,830,891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,432,498</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,341,756</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18,263,389</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486453211616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Going Concern - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 18, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NatureOfOperationsLineItems', window );"><strong>Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 12,  2011<span></span>
</td>
<td class="text">May 12,  2011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">The amount of cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,341,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,263,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,966,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,990,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105,501,295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,280,499)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_LenderAxis=eprx_SiliconValleyBankMember', window );">Silicon Valley Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NatureOfOperationsLineItems', window );"><strong>Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateralAmount', window );">Debt instrument collateral amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DebtInstrumentMonthOfMaturity', window );">Debt instrument month of maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-06<span></span>
</td>
<td class="text">2024-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NatureOfOperationsLineItems', window );"><strong>Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value new issues</a></td>
<td class="nump">$ 16,445,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,886,537<span></span>
</td>
<td class="nump">$ 20,836,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued through non-brokered private placement | shares</a></td>
<td class="nump">3,183,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,183,875<span></span>
</td>
<td class="nump">3,183,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NatureOfOperationsLineItems', window );"><strong>Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock net consideration received on the transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,768,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NatureOfOperationsLineItems', window );"><strong>Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued through non-brokered private placement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,260,435<span></span>
</td>
<td class="nump">8,260,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock net consideration received on the transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,026,073<span></span>
</td>
<td class="nump">$ 33,867,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DebtInstrumentMonthOfMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument month of maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DebtInstrumentMonthOfMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_NatureOfOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature of operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_NatureOfOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCollateralAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets pledged to secure a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCollateralAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_LenderAxis=eprx_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_LenderAxis=eprx_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486459448256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Information About Subsidiaries (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_SummaryOfInformationAboutSubsidiariesLineItems', window );"><strong>Summary Of Information About Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">May 12,  2011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Jurisdiction of Incorporation</a></td>
<td class="text">Victoria<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Country of Incorporation</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=eprx_EupraxiaHoldingsIncMember', window );">Eupraxia Holdings, Inc. [Member] | Subsidiaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_SummaryOfInformationAboutSubsidiariesLineItems', window );"><strong>Summary Of Information About Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">Oct. 10,  2012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Jurisdiction of Incorporation</a></td>
<td class="text">Delaware<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Country of Incorporation</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_InvestmentOwnershipPercentage', window );">Effective Interest</a></td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=eprx_EupraxiaPharmaceuticalsUsaLlcMember', window );">Eupraxia Pharmaceuticals USA, LLC [Member] | Subsidiaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_SummaryOfInformationAboutSubsidiariesLineItems', window );"><strong>Summary Of Information About Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">Oct. 10,  2012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Jurisdiction of Incorporation</a></td>
<td class="text">Delaware<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Country of Incorporation</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_InvestmentOwnershipPercentage', window );">Effective Interest</a></td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=eprx_AmdmHoldingsIncMember', window );">AMDM Holdings Inc. [Member] | Subsidiaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_SummaryOfInformationAboutSubsidiariesLineItems', window );"><strong>Summary Of Information About Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">Apr.  06,  2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Jurisdiction of Incorporation</a></td>
<td class="text">Washington<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Country of Incorporation</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_InvestmentOwnershipPercentage', window );">Effective Interest</a></td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=eprx_EupraxiaPharmaIncMember', window );">Eupraxia Pharma, Inc. [Member] | Subsidiaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_SummaryOfInformationAboutSubsidiariesLineItems', window );"><strong>Summary Of Information About Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">Jan.  07,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Jurisdiction of Incorporation</a></td>
<td class="text">Delaware<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Country of Incorporation</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_InvestmentOwnershipPercentage', window );">Effective Interest</a></td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=eprx_EupraxiaPharmaceuticalsAustraliaPtyLtdMember', window );">Eupraxia Pharmaceuticals Australia Pty Ltd. [Member] | Subsidiaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_SummaryOfInformationAboutSubsidiariesLineItems', window );"><strong>Summary Of Information About Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">Jul.  04,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Jurisdiction of Incorporation</a></td>
<td class="text">Victoria<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Country of Incorporation</a></td>
<td class="text">AU<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_InvestmentOwnershipPercentage', window );">Effective Interest</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=eprx_EupraxiaPharmaUsaIncMember', window );">Eupraxia Pharma USA Inc. [Member] | Subsidiaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_SummaryOfInformationAboutSubsidiariesLineItems', window );"><strong>Summary Of Information About Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">May 17,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Jurisdiction of Incorporation</a></td>
<td class="text">Delaware<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Country of Incorporation</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_InvestmentOwnershipPercentage', window );">Effective Interest</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_InvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_InvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_SummaryOfInformationAboutSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of information about subsidiaries line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_SummaryOfInformationAboutSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eprx_EupraxiaHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eprx_EupraxiaHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eprx_EupraxiaPharmaceuticalsUsaLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eprx_EupraxiaPharmaceuticalsUsaLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eprx_AmdmHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eprx_AmdmHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eprx_EupraxiaPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eprx_EupraxiaPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eprx_EupraxiaPharmaceuticalsAustraliaPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eprx_EupraxiaPharmaceuticalsAustraliaPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eprx_EupraxiaPharmaUsaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eprx_EupraxiaPharmaUsaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486458740608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Property Plant And Equipment Estimated Useful Life (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PropertyPlantAndEqupmentRateOfDepreciation', window );">Property Plant and Equipment Rate of Depreciation</a></td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PropertyPlantAndEqupmentRateOfDepreciation', window );">Property Plant and Equipment Rate of Depreciation</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation', window );">Property plant and Equipment Description of Rate of Depreciation</a></td>
<td class="text">straight-line over the shorter of the initial term of the lease or useful life<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eprx_LabEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PropertyPlantAndEqupmentRateOfDepreciation', window );">Property Plant and Equipment Rate of Depreciation</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment description of rate of depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PropertyPlantAndEqupmentRateOfDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property plant and equpment rate of depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PropertyPlantAndEqupmentRateOfDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eprx_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eprx_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461390784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement', window );">Percentage of tax benefits to be realized for recognition in the income statement</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of tax benefits to be realized for recognition in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486458883664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Amounts Receivable - Summary of Amounts Receivable (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NontradeReceivableCurrentsAbstract', window );"><strong>Nontrade Receivables, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Government grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmountCumulativeCurrent', window );">GST/HST recoverable</a></td>
<td class="nump">$ 85,879<span></span>
</td>
<td class="nump">38,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_OtherRefundableTaxCreditsCurrent', window );">Other refundable tax credits</a></td>
<td class="nump">104,733<span></span>
</td>
<td class="nump">37,165<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NontradeReceivablesCurrent', window );">Total</a></td>
<td class="nump">$ 190,612<span></span>
</td>
<td class="nump">$ 89,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_OtherRefundableTaxCreditsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other refundable tax credits current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_OtherRefundableTaxCreditsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmountCumulativeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative government assistance recognized classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmountCumulativeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NontradeReceivableCurrentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NontradeReceivableCurrentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NontradeReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NontradeReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486463369104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Balance, beginning</a></td>
<td class="nump">$ 736,274<span></span>
</td>
<td class="nump">$ 598,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="nump">73,377<span></span>
</td>
<td class="nump">235,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Disposals</a></td>
<td class="num">(21,612)<span></span>
</td>
<td class="num">(55,761)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments', window );">Foreign currency adjustments</a></td>
<td class="nump">19,613<span></span>
</td>
<td class="num">(42,438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Balance, ending</a></td>
<td class="nump">807,652<span></span>
</td>
<td class="nump">736,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract', window );"><strong>Accumulated Depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Balance, beginning</a></td>
<td class="nump">292,810<span></span>
</td>
<td class="nump">248,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease', window );">Depreciation</a></td>
<td class="nump">112,883<span></span>
</td>
<td class="nump">110,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1', window );">Disposals</a></td>
<td class="num">(16,766)<span></span>
</td>
<td class="num">(48,882)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments', window );">Foreign currency adjustments</a></td>
<td class="nump">9,138<span></span>
</td>
<td class="num">(16,539)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Balance, ending</a></td>
<td class="nump">398,065<span></span>
</td>
<td class="nump">292,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">409,587<span></span>
</td>
<td class="nump">443,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Balance, beginning</a></td>
<td class="nump">70,578<span></span>
</td>
<td class="nump">101,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="nump">18,534<span></span>
</td>
<td class="nump">20,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Disposals</a></td>
<td class="num">(5,488)<span></span>
</td>
<td class="num">(47,603)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments', window );">Foreign currency adjustments</a></td>
<td class="nump">2,001<span></span>
</td>
<td class="num">(3,852)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Balance, ending</a></td>
<td class="nump">85,625<span></span>
</td>
<td class="nump">70,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract', window );"><strong>Accumulated Depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Balance, beginning</a></td>
<td class="nump">42,505<span></span>
</td>
<td class="nump">71,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease', window );">Depreciation</a></td>
<td class="nump">17,612<span></span>
</td>
<td class="nump">17,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1', window );">Disposals</a></td>
<td class="num">(5,162)<span></span>
</td>
<td class="num">(43,540)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments', window );">Foreign currency adjustments</a></td>
<td class="nump">1,226<span></span>
</td>
<td class="num">(2,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Balance, ending</a></td>
<td class="nump">56,181<span></span>
</td>
<td class="nump">42,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">29,444<span></span>
</td>
<td class="nump">28,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Balance, beginning</a></td>
<td class="nump">66,399<span></span>
</td>
<td class="nump">73,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments', window );">Foreign currency adjustments</a></td>
<td class="nump">1,597<span></span>
</td>
<td class="num">(4,261)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Balance, ending</a></td>
<td class="nump">67,996<span></span>
</td>
<td class="nump">66,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract', window );"><strong>Accumulated Depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Balance, beginning</a></td>
<td class="nump">44,026<span></span>
</td>
<td class="nump">46,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease', window );">Depreciation</a></td>
<td class="nump">4,492<span></span>
</td>
<td class="nump">5,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,342)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments', window );">Foreign currency adjustments</a></td>
<td class="nump">1,149<span></span>
</td>
<td class="num">(2,853)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Balance, ending</a></td>
<td class="nump">49,667<span></span>
</td>
<td class="nump">44,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">18,329<span></span>
</td>
<td class="nump">22,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Balance, beginning</a></td>
<td class="nump">125,744<span></span>
</td>
<td class="nump">134,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments', window );">Foreign currency adjustments</a></td>
<td class="nump">3,023<span></span>
</td>
<td class="num">(8,589)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Balance, ending</a></td>
<td class="nump">128,767<span></span>
</td>
<td class="nump">125,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract', window );"><strong>Accumulated Depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Balance, beginning</a></td>
<td class="nump">99,301<span></span>
</td>
<td class="nump">91,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease', window );">Depreciation</a></td>
<td class="nump">13,849<span></span>
</td>
<td class="nump">14,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments', window );">Foreign currency adjustments</a></td>
<td class="nump">2,666<span></span>
</td>
<td class="num">(6,410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Balance, ending</a></td>
<td class="nump">115,816<span></span>
</td>
<td class="nump">99,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">12,951<span></span>
</td>
<td class="nump">26,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eprx_LabEquipmentMember', window );">Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Balance, beginning</a></td>
<td class="nump">473,553<span></span>
</td>
<td class="nump">289,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="nump">54,843<span></span>
</td>
<td class="nump">209,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Disposals</a></td>
<td class="num">(16,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments', window );">Foreign currency adjustments</a></td>
<td class="nump">12,992<span></span>
</td>
<td class="num">(25,736)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Balance, ending</a></td>
<td class="nump">525,264<span></span>
</td>
<td class="nump">473,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract', window );"><strong>Accumulated Depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Balance, beginning</a></td>
<td class="nump">106,978<span></span>
</td>
<td class="nump">38,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease', window );">Depreciation</a></td>
<td class="nump">76,930<span></span>
</td>
<td class="nump">73,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1', window );">Disposals</a></td>
<td class="num">(11,604)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments', window );">Foreign currency adjustments</a></td>
<td class="nump">4,097<span></span>
</td>
<td class="num">(4,981)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Balance, ending</a></td>
<td class="nump">176,401<span></span>
</td>
<td class="nump">106,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">$ 348,863<span></span>
</td>
<td class="nump">$ 366,575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated depreciation depletion and amortization foreign currency translation adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment foreign currency translation adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in accumulated depreciation, depletion and amortization as a result of sale or disposal of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of depreciation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eprx_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eprx_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486458734736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease', window );">Depreciation expense</a></td>
<td class="nump">$ 112,883<span></span>
</td>
<td class="nump">$ 110,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease', window );">Depreciation expense</a></td>
<td class="nump">13,276<span></span>
</td>
<td class="nump">13,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease', window );">Depreciation expense</a></td>
<td class="nump">$ 99,606<span></span>
</td>
<td class="nump">$ 96,233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of depreciation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486458403264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Asset - Summary of Right of Use Assets (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_OperatingLeaseRightOfUseAssetAbstract', window );"><strong>Operating Lease Right of Use Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Balance, beginning</a></td>
<td class="nump">$ 87,286<span></span>
</td>
<td class="nump">$ 132,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease', window );">Depreciation</a></td>
<td class="num">(42,644)<span></span>
</td>
<td class="num">(37,791)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset', window );">Foreign Exchange</a></td>
<td class="nump">2,018<span></span>
</td>
<td class="num">(6,943)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Balance, ending</a></td>
<td class="nump">$ 46,660<span></span>
</td>
<td class="nump">$ 87,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through net exchange differences, right of use&#160;asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_OperatingLeaseRightOfUseAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Right of Use Asset Abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_OperatingLeaseRightOfUseAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of depreciation expense for lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486459568272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Asset - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_RightOfUseAssetLineItems', window );"><strong>Right of Use Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease', window );">Depreciation expense</a></td>
<td class="nump">$ 42,644<span></span>
</td>
<td class="nump">$ 37,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_RightOfUseAssetLineItems', window );"><strong>Right of Use Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease', window );">Depreciation expense</a></td>
<td class="nump">15,740<span></span>
</td>
<td class="nump">13,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_RightOfUseAssetLineItems', window );"><strong>Right of Use Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease', window );">Depreciation expense</a></td>
<td class="nump">$ 26,904<span></span>
</td>
<td class="nump">$ 23,914<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_RightOfUseAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_RightOfUseAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of depreciation expense for lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486458929040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment', window );">Research and development</a></td>
<td class="nump">$ 1,968,263<span></span>
</td>
<td class="nump">$ 2,137,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration', window );">General and administrative</a></td>
<td class="nump">1,040,204<span></span>
</td>
<td class="nump">261,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Wages and payroll remittances</a></td>
<td class="nump">18,357<span></span>
</td>
<td class="nump">15,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Employee bonus payable</a></td>
<td class="nump">858,628<span></span>
</td>
<td class="nump">513,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">36,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 3,921,875<span></span>
</td>
<td class="nump">$ 2,928,566<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts payable and accrued liabilities current general and administration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts payable and accrued liabilities current research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486458206736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loans Payable - Additional Information (Detail) - Loans Payable [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 13, 2021</div></th>
<th class="th"><div>Sep. 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Borrowings of the company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Term of loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">5.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Debt instrument, frequency of periodic payment</a></td>
<td class="text">monthly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486460761744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Payable - Summary of Breakdown of Loan Balance (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Balance, beginning</a></td>
<td class="nump">$ 142,127<span></span>
</td>
<td class="nump">$ 216,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Loan repayment</a></td>
<td class="num">(79,441)<span></span>
</td>
<td class="num">(74,845)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ForeignExchangeAdjustmentOnLoansPayable', window );">Foreign exchange adjustment</a></td>
<td class="nump">23<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Balance, ending</a></td>
<td class="nump">62,709<span></span>
</td>
<td class="nump">142,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Current portion</a></td>
<td class="nump">$ 62,709<span></span>
</td>
<td class="nump">79,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Non-current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,709<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ForeignExchangeAdjustmentOnLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange adjustment on loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ForeignExchangeAdjustmentOnLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486458217920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Liability - Summary of Cost Components of The Operating Lease (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 64,996<span></span>
</td>
<td class="nump">$ 67,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">$ 68,584<span></span>
</td>
<td class="nump">$ 66,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract', window );"><strong>Lease term and Discount Rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">11 months 1 day<span></span>
</td>
<td class="text">1 year 11 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease weighted average remaining lease term and discount rate [Abstract].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486545198816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Liability - Summary of Future Minimum Lease Payments (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 60,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted future minimum lease payments</a></td>
<td class="nump">60,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncentiveFromLessor', window );">Less: balance of unused tenant allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(7,464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 53,316<span></span>
</td>
<td class="nump">$ 101,706<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveFromLessor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of incentive received by lessee from lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481178/840-20-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481475/840-20-55-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481178/840-20-25-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 5<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479924/842-10-30-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveFromLessor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461345984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Liability - Summary of Lease Liability Balance (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">$ 53,316<span></span>
</td>
<td class="nump">$ 50,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,303<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 53,316<span></span>
</td>
<td class="nump">$ 101,706<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486458398992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Liability - Additional information (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate</a></td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Expiry date of lease agreement</a></td>
<td class="text">Nov. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AreaOfSubleasedOfficeSpace', window );">Area of subleased office space</a></td>
<td class="nump">616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income | $</a></td>
<td class="nump">$ 24,387<span></span>
</td>
<td class="nump">$ 24,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_AreaOfSubleasedOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of subleased office space.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_AreaOfSubleasedOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486545887200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Auritec License Agreement - Additional Information (Detail) - Amended and Restated License Agreement [Member] - Eupraxia USA [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PaymentOfUpfrontFees', window );">Payment of upfront fees</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_RoyaltyAsAPercentageOfNetSales', window );">Royalty as a percentage of net sales</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization', window );">Maximum amount incurrable out of non royalty revenue monetization</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AgreementAxis=eprx_AmendedAndRestatedLicenseAgreementMember', window );">Research and Development Expense [Member] | Successful Completion of a Phase 2b Study [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_MilestonePaymentRecognizedExpense', window );">Milestone payment recognized expense</a></td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AgreementAxis=eprx_AmendedAndRestatedLicenseAgreementMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement', window );">Payable towards commercial and regulatory milestone achievement</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable', window );">Percentage of non royalty monetization revenue payable</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AgreementAxis=eprx_AmendedAndRestatedLicenseAgreementMember', window );">Maximum [Member] | Successful Completion of a Phase 2b Study [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement', window );">Payable towards commercial and regulatory milestone achievement</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AgreementAxis=eprx_AmendedAndRestatedLicenseAgreementMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable', window );">Percentage of non royalty monetization revenue payable</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AgreementAxis=eprx_AmendedAndRestatedLicenseAgreementMember', window );">Arithmetic Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable', window );">Percentage of non royalty monetization revenue payable</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_LicenseAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement [Line Items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_LicenseAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Amount Incurrable Out Of Non Royalty Revenue Monetization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MilestonePaymentRecognizedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment recognized expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MilestonePaymentRecognizedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payable towards commercial and regulator milestone achievement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PaymentOfUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of upfront fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PaymentOfUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of non royalty monetization revenue payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_RoyaltyAsAPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty as a percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_RoyaltyAsAPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_AgreementAxis=eprx_AmendedAndRestatedLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_AgreementAxis=eprx_AmendedAndRestatedLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=eprx_EupraxiaUsaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=eprx_EupraxiaUsaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MilestoneAxis=eprx_SuccessfulCompletionOfPhaseTwoBStudyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MilestoneAxis=eprx_SuccessfulCompletionOfPhaseTwoBStudyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_ArithmeticAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_ArithmeticAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486464245536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Auritec License Agreement - Schedule of Milestone Payment (Detail) - Amended And Restated License Agreement [Member] - Eupraxia USA [Member] - Maximum [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems', window );"><strong>Disclosure In Tabular Form Of Milestone Payment Schedule [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement', window );">Payable towards commercial and regulatory milestone achievement</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AgreementAxis=eprx_AmendedAndRestatedLicenseAgreementMember', window );">Successful Completion of a Phase 2b Study [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems', window );"><strong>Disclosure In Tabular Form Of Milestone Payment Schedule [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement', window );">Payable towards commercial and regulatory milestone achievement</a></td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AgreementAxis=eprx_AmendedAndRestatedLicenseAgreementMember', window );">First OA Regulatory Approval [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems', window );"><strong>Disclosure In Tabular Form Of Milestone Payment Schedule [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement', window );">Payable towards commercial and regulatory milestone achievement</a></td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AgreementAxis=eprx_AmendedAndRestatedLicenseAgreementMember', window );">Second OA Regulatory Approval [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems', window );"><strong>Disclosure In Tabular Form Of Milestone Payment Schedule [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement', window );">Payable towards commercial and regulatory milestone achievement</a></td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AgreementAxis=eprx_AmendedAndRestatedLicenseAgreementMember', window );">Non-OA Indication Regulatory Approval [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems', window );"><strong>Disclosure In Tabular Form Of Milestone Payment Schedule [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement', window );">Payable towards commercial and regulatory milestone achievement</a></td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AgreementAxis=eprx_AmendedAndRestatedLicenseAgreementMember', window );">First calendar year in which aggregate Net Sales by Eupraxia USA, its affiliates and sublicenses exceed $500,000,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems', window );"><strong>Disclosure In Tabular Form Of Milestone Payment Schedule [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement', window );">Payable towards commercial and regulatory milestone achievement</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure In Tabular Form Of Milestone Payment Schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payable towards commercial and regulator milestone achievement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_AgreementAxis=eprx_AmendedAndRestatedLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_AgreementAxis=eprx_AmendedAndRestatedLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=eprx_EupraxiaUsaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=eprx_EupraxiaUsaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MilestoneAxis=eprx_SuccessfulCompletionOfPhaseTwoBStudyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MilestoneAxis=eprx_SuccessfulCompletionOfPhaseTwoBStudyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MilestoneAxis=eprx_FirstOaRegulatoryApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MilestoneAxis=eprx_FirstOaRegulatoryApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MilestoneAxis=eprx_SecondOaRegulatoryApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MilestoneAxis=eprx_SecondOaRegulatoryApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MilestoneAxis=eprx_NonOaIndicationRegulatoryApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MilestoneAxis=eprx_NonOaIndicationRegulatoryApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MilestoneAxis=eprx_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MilestoneAxis=eprx_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486545926048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Auritec License Agreement - Schedule of Non-Royalty Monetization Revenue Percentage (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_TrancheAxis=eprx_PriorToSuccessfulCompletionOfPhaseTwoBStudyMember', window );">Prior to Successful Completion of a Phase 2b Study [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems', window );"><strong>Disclosure In Tabular Form Of Certain Percentage Of Non Monetization Revenue Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty', window );">Percentage of Non-Royalty Monetization Revenue</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_TrancheAxis=eprx_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember', window );">After Successful Completion of a Phase 2b Study but prior to Successful Completion of a Phase 3 Study [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems', window );"><strong>Disclosure In Tabular Form Of Certain Percentage Of Non Monetization Revenue Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty', window );">Percentage of Non-Royalty Monetization Revenue</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_TrancheAxis=eprx_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember', window );">After Successful Completion of a Phase 3 Study but prior to Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems', window );"><strong>Disclosure In Tabular Form Of Certain Percentage Of Non Monetization Revenue Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty', window );">Percentage of Non-Royalty Monetization Revenue</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_TrancheAxis=eprx_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember', window );">After Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems', window );"><strong>Disclosure In Tabular Form Of Certain Percentage Of Non Monetization Revenue Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty', window );">Percentage of Non-Royalty Monetization Revenue</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure In Tabular Form Of Certain Percentage Of Non Monetization Revenue Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of non monetization revenue to be paid to the counterparty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_TrancheAxis=eprx_PriorToSuccessfulCompletionOfPhaseTwoBStudyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_TrancheAxis=eprx_PriorToSuccessfulCompletionOfPhaseTwoBStudyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_TrancheAxis=eprx_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_TrancheAxis=eprx_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_TrancheAxis=eprx_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_TrancheAxis=eprx_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_TrancheAxis=eprx_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_TrancheAxis=eprx_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486463271696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Additional information (Detail) - Convertible Debt [Member] - Silicon Valley Bank [Member] - CAD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 21, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face value</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AmountToBeRaisedByWayOfEquityIssue', window );">Amount to be raised by way of equity issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AggegateAmountRaisedByWayOfEquityIssue', window );">Aggregate amount raised by way of equity issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">With Eighteen Months From The Date Of The Debt Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument redemption price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">After Eighteen Months From The Date Of The Debt Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument redemption price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Canadian Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Long term debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_LongTermDebtTermExtendableAtLendersDiscretion', window );">Long term debt term extendable at lenders discretion</a></td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_LongTermDebtBaseRate', window );">Long term debt base rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_LongTermDebtPaidInKindInterestPercentage', window );">Long term debt paid in kind interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Canadian Prime Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_LongTermDebtBaseRate', window );">Long term debt base rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.20%<span></span>
</td>
<td class="nump">6.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Canadian Prime Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_LongTermDebtBaseRate', window );">Long term debt base rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_AggegateAmountRaisedByWayOfEquityIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggegate amount raised by way of equity issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_AggegateAmountRaisedByWayOfEquityIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_AmountToBeRaisedByWayOfEquityIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be raised by way of equity issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_AmountToBeRaisedByWayOfEquityIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_LongTermDebtBaseRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt base rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_LongTermDebtBaseRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_LongTermDebtPaidInKindInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt paid in kind interest percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_LongTermDebtPaidInKindInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_LongTermDebtTermExtendableAtLendersDiscretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt term extendable at lenders discretion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_LongTermDebtTermExtendableAtLendersDiscretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -SubTopic 470<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_LenderAxis=eprx_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_LenderAxis=eprx_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_CallRightAxis=eprx_WithEighteenMonthsFromTheDateOfTheDebtAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_CallRightAxis=eprx_WithEighteenMonthsFromTheDateOfTheDebtAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_CallRightAxis=eprx_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_CallRightAxis=eprx_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=eprx_CanadianPrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=eprx_CanadianPrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486460819968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Schedule of Loan Balance (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems', window );"><strong>Disclosure In Tabular Form Of Movement In Convertible Debt At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">$ (836,595)<span></span>
</td>
<td class="num">$ (1,056,165)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member] | Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems', window );"><strong>Disclosure In Tabular Form Of Movement In Convertible Debt At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">8,741,996<span></span>
</td>
<td class="nump">7,507,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod', window );">Accrued interest</a></td>
<td class="nump">1,162,773<span></span>
</td>
<td class="nump">958,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod', window );">Interest paid</a></td>
<td class="num">(591,170)<span></span>
</td>
<td class="num">(315,436)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">836,595<span></span>
</td>
<td class="nump">1,056,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss', window );">Foreign exchange</a></td>
<td class="nump">185,809<span></span>
</td>
<td class="num">(465,157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 10,336,003<span></span>
</td>
<td class="nump">$ 8,741,996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of movement in convertible debt at fair value [Line items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable input reconciliation recurring basis accrued interest during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable input reconciliation recurring basis interest paid during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable input reconciliation recurring basis liability foreign exchange gain loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eprx_LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eprx_LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486446107824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Components of Equity - Additional information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 18, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 20, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 18, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 20, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorizedUnlimited', window );">Preferred stock shares authorized unlimited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred stock par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorizedUnlimited', window );">Common stock shares authorized unlimited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock par no par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issued during the period shares exercise of stock options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,600<span></span>
</td>
<td class="nump">20,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock issued during period value stock options excercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share based compensation by share based award optinoss exercise din period weighted average exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,886,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,636,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 714,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,052,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issued during the period shares exercise of stock options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,600<span></span>
</td>
<td class="nump">20,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock issued during period value stock options excercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued during the period shares for services | shares</a></td>
<td class="nump">99,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued during the period value for services</a></td>
<td class="nump">$ 511,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=eprx_EuphraxiaPharmaIncMember', window );">Euphraxia Pharma Inc [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_EquityMethodInvestmentNumberOfSharedOwned', window );">Equity method investment number of shares owned | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=eprx_EuphraxiaPharmaIncMember', window );">Euphraxia Pharma Inc [Member] | Common Class A [Member] | Outstanding of AMDM Holdings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AmdmHoldingsAxis=eprx_AmdmHoldingsMember', window );">AMDM Holdings [Member] | Euphraxia USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority interest held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AmdmHoldingsAxis=eprx_AmdmHoldingsMember', window );">AMDM Holdings [Member] | Euphraxia Pharma Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_StockSharesIssuedAsAPercentageOfOutstandingShares', window );">Stock shares issued as a percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AmdmHoldingsAxis=eprx_AmdmHoldingsMember', window );">AMDM Holdings [Member] | Euphraxia Pharma Inc [Member] | Chief Scientific Officer [Member] | Class B Non Voting Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_CommonStockSharesIssuableAsAResultOfStockSplit', window );">Common stock shares issuable as a result of stock split | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">562,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">Amended Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issued during the period shares exercise of stock options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,600<span></span>
</td>
<td class="nump">20,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share based compensation by share based award optinoss exercise din period weighted average exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PercentageOfOutstandingSharesEligibleForStockOptionsIssuance', window );">Percentage of outstanding shares eligible for stock option issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">Amended Plan [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based compensation by share based award aggregate term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation by share based award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,412,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,433,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share based compensation by share based award options unrecognized compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 961,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share based compensation by share based award options unrecognized compensation period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 2 days<span></span>
</td>
<td class="text">2 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">Amended Plan [Member] | Immediate Vesting [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based compensation by share based award vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">Amended Plan [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based compensation by share based award vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">Amended Plan [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based compensation by share based award vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">Amended Plan [Member] | Share-Based Payment Arrangement, Tranche Three [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based compensation by share based award vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues | shares</a></td>
<td class="nump">3,183,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,183,875<span></span>
</td>
<td class="nump">3,183,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during the period value new issues</a></td>
<td class="nump">$ 16,445,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,886,537<span></span>
</td>
<td class="nump">$ 20,836,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_CashCostsOfIssuingShares', window );">Cash costs of issuing shares</a></td>
<td class="nump">$ 559,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued during the period shares for services | shares</a></td>
<td class="nump">99,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued during the period value for services</a></td>
<td class="nump">$ 511,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,282,936<span></span>
</td>
<td class="nump">3,282,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during the period value new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,886,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NumberOfUnitsIssued', window );">Number of units issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,150,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_SecuritiesIssuedPricePerUnit', window );">Securities issued, price per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NumberOfWarrantIssued', window );">Number of warrant issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_WarrantIssuedPricePerUnit', window );">Warrant Issued, Price Per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,768,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionBasis', window );">Common stock conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each unit consists of one common share and one common share purchase warrant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Payments for underwriting expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 823,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PercentageOfGrossProceedsRaisedUnderTheOffering', window );">Percentage of gross proceeds raised under the Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share based compensation arrangement by share based payment award number of shares available for grant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering', window );">Percentage of total units and warrants issued in the Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrants exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,309,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right number of securities called by each warrant or right | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and rights outstanding maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 20,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Payments for underwriting expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,458,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Payments for underwriting expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_WarrantAxis=eprx_CompensationWarrantMember', window );">Compensation Warrant [Member] | Over-Allotment Option [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrants exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_EventAxis=eprx_ExcerciseOfWarrantsMember', window );">Excercise Of Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,385,484<span></span>
</td>
<td class="nump">2,385,484<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during the period value new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,241,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrants exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_TransferredFromAdditionalPaidinCapitalToShareCapital', window );">Transferred from additional paid-in capital to share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 733,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_EventAxis=eprx_ExcerciseOfWarrantsMember', window );">Excercise Of Warrants [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,385,484<span></span>
</td>
<td class="nump">2,385,484<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during the period value new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,974,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_EventAxis=eprx_ExcerciseOfOptionsMember', window );">Excercise Of Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_TransferredFromAdditionalPaidinCapitalToShareCapital', window );">Transferred from additional paid-in capital to share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_CashCostsOfIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Costs Of Issuing Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_CashCostsOfIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_CommonStockSharesIssuableAsAResultOfStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Shares Issuable As A Result Of Stock Split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_CommonStockSharesIssuableAsAResultOfStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_EquityMethodInvestmentNumberOfSharedOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment Number Of Shared Owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_EquityMethodInvestmentNumberOfSharedOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_NumberOfUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_NumberOfUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_NumberOfWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrant issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_NumberOfWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PercentageOfGrossProceedsRaisedUnderTheOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of gross proceeds raised under the Offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PercentageOfGrossProceedsRaisedUnderTheOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PercentageOfOutstandingSharesEligibleForStockOptionsIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Outstanding Shares Eligible For Stock Options Issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PercentageOfOutstandingSharesEligibleForStockOptionsIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of total units and warrants issued in the Offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_SecuritiesIssuedPricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities Issued, Price Per unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_SecuritiesIssuedPricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_StockSharesIssuedAsAPercentageOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Shares Issued As A Percentage Of Outstanding Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_StockSharesIssuedAsAPercentageOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_TransferredFromAdditionalPaidinCapitalToShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transferred From Additional Paid-In Capital To Share Capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_TransferredFromAdditionalPaidinCapitalToShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_WarrantIssuedPricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Issued, Price Per uni.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_WarrantIssuedPricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of basis for conversion of convertible common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorizedUnlimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is "Unlimited".</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorizedUnlimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:authorizedUnlimitedItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorizedUnlimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the number of nonredeemable preferred shares, or preferred stock redeemable solely at the option of the issuer, permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is "Unlimited".</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorizedUnlimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:authorizedUnlimitedItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eprx_EuphraxiaPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eprx_EuphraxiaPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=eprx_OutstandingOfAMDMHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=eprx_OutstandingOfAMDMHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_AmdmHoldingsAxis=eprx_AmdmHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_AmdmHoldingsAxis=eprx_AmdmHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=eprx_EuphraxiaUsaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=eprx_EuphraxiaUsaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=eprx_ChiefScientificOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=eprx_ChiefScientificOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eprx_ClassBNonVotingStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eprx_ClassBNonVotingStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eprx_AmendedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=eprx_ImmediateVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=eprx_ImmediateVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_WarrantAxis=eprx_CompensationWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_WarrantAxis=eprx_CompensationWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_EventAxis=eprx_ExcerciseOfWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_EventAxis=eprx_ExcerciseOfWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_EventAxis=eprx_ExcerciseOfOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_EventAxis=eprx_ExcerciseOfOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486463878800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Components of Equity - Summary of Company's Option (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, Exercised</a></td>
<td class="num">(20,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average price, Exercised</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">Amended Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding</a></td>
<td class="nump">3,306,450<span></span>
</td>
<td class="nump">2,134,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted</a></td>
<td class="nump">257,200<span></span>
</td>
<td class="nump">1,172,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, Exercised</a></td>
<td class="num">(20,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Cancelled</a></td>
<td class="num">(24,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding</a></td>
<td class="nump">3,518,250<span></span>
</td>
<td class="nump">3,306,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average price, Outstanding</a></td>
<td class="nump">$ 6.18<span></span>
</td>
<td class="nump">$ 7.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average price, Granted</a></td>
<td class="nump">6.91<span></span>
</td>
<td class="nump">3.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average price, Exercised</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average price, Cancelled</a></td>
<td class="nump">3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average price, Outstanding</a></td>
<td class="nump">$ 6.27<span></span>
</td>
<td class="nump">$ 6.18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eprx_AmendedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486459750480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Components of Equity - Summary of Options Outstanding Along with the Grant Dates and Expiry Date (Detail) - Amended Plan [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems', window );"><strong>Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding</a></td>
<td class="nump">3,518,250<span></span>
</td>
<td class="nump">3,306,450<span></span>
</td>
<td class="nump">2,134,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">2,537,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 6.27<span></span>
</td>
<td class="nump">$ 6.18<span></span>
</td>
<td class="nump">$ 7.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life</a></td>
<td class="text">7 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">Sep 27, 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems', window );"><strong>Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant', window );">Grant Date</a></td>
<td class="text">Sep. 27,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding</a></td>
<td class="nump">186,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">186,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life</a></td>
<td class="text">1 year 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">Nov 2, 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems', window );"><strong>Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant', window );">Grant Date</a></td>
<td class="text">Nov.  02,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding</a></td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Nov.  02,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life</a></td>
<td class="text">1 year 10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">Mar 5, 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems', window );"><strong>Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant', window );">Grant Date</a></td>
<td class="text">Mar.  05,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding</a></td>
<td class="nump">452,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">452,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Mar.  05,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life</a></td>
<td class="text">4 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">Mar 9, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems', window );"><strong>Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant', window );">Grant Date</a></td>
<td class="text">Mar.  09,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding</a></td>
<td class="nump">756,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">567,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Mar.  09,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">Mar 9, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems', window );"><strong>Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant', window );">Grant Date</a></td>
<td class="text">Mar.  09,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding</a></td>
<td class="nump">326,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">326,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Mar.  09,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">May 3, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems', window );"><strong>Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant', window );">Grant Date</a></td>
<td class="text">May  03,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding</a></td>
<td class="nump">257,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">192,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">May  03,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life</a></td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">Dec 9, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems', window );"><strong>Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant', window );">Grant Date</a></td>
<td class="text">Dec.  09,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">57,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Dec.  09,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life</a></td>
<td class="text">7 years 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">Mar 31, 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems', window );"><strong>Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant', window );">Grant Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding</a></td>
<td class="nump">392,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">186,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Mar. 31,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life</a></td>
<td class="text">8 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">Dec 9, 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems', window );"><strong>Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant', window );">Grant Date</a></td>
<td class="text">Dec.  09,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding</a></td>
<td class="nump">734,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">407,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Dec.  09,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life</a></td>
<td class="text">8 years 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">May 18, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems', window );"><strong>Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant', window );">Grant Date</a></td>
<td class="text">May 18,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 6.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">May 18,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life</a></td>
<td class="text">9 years 4 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">May 30, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems', window );"><strong>Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant', window );">Grant Date</a></td>
<td class="text">May 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding</a></td>
<td class="nump">17,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">May 30,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life</a></td>
<td class="text">9 years 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember', window );">Sep 27, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems', window );"><strong>Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant', window );">Grant Date</a></td>
<td class="text">Sep. 27,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 7.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry Date</a></td>
<td class="text">Sep. 27,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life</a></td>
<td class="text">9 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compesnation By Share Based Options Granted Date Of Grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eprx_AmendedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_TwentySeventhSeptemberTwoThousandAndFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_TwentySeventhSeptemberTwoThousandAndFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_TwoNovemberTwoThousandAndFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_TwoNovemberTwoThousandAndFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_FiveMarchTwoThousandAndEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_FiveMarchTwoThousandAndEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_NineMarchTwoThousandAndTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_NineMarchTwoThousandAndTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_NineMarchTwoThousandAndTwentyOne1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_NineMarchTwoThousandAndTwentyOne1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_ThreeMayTwoThousandAndTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_ThreeMayTwoThousandAndTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_NineDecemberTwoThousandAndTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_NineDecemberTwoThousandAndTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_ThirtyFirstMarchTwoThousandAndTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_ThirtyFirstMarchTwoThousandAndTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_NineDecemberTwoThousandAndTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_NineDecemberTwoThousandAndTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_EighteenthMayTwoThousandAndTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_EighteenthMayTwoThousandAndTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_ThirtyMayTwoThousandAndTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_ThirtyMayTwoThousandAndTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_TwentySeventhSeptemberTwoThousandAndTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedCompensationOptionsExpiryDateAxis=eprx_TwentySeventhSeptemberTwoThousandAndTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486462636656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Components of Equity - Summary of Weighted-Average Assumptions (Detail) - Amended Plan [Member] - Share-Based Payment Arrangement, Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate', window );">Expected forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted average annual volatility</a></td>
<td class="nump">79.60%<span></span>
</td>
<td class="nump">78.66%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free interest rate</a></td>
<td class="nump">3.54%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted average expected option life</a></td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Weighted average share price</a></td>
<td class="nump">$ 6.91<span></span>
</td>
<td class="nump">$ 3.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">6.91<span></span>
</td>
<td class="nump">3.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted</a></td>
<td class="nump">$ 4.78<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eprx_AmendedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eprx_AmendedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486463434912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Components of Equity - Summary of Share Based Compensation Arrangements by Share Based Payment Warrant (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems', window );"><strong>Schedule of Share Based Compensation Arrangement By Share Based Payment Award Warrant [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of warrants, Ending Balance</a></td>
<td class="nump">9,119,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending Balance</a></td>
<td class="nump">$ 5.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember', window );">Warrants Granted as Part of Share Based Payment Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems', window );"><strong>Schedule of Share Based Compensation Arrangement By Share Based Payment Award Warrant [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of warrants, Beginning Balance</a></td>
<td class="nump">11,504,814<span></span>
</td>
<td class="nump">4,161,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of warrants, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,832,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of warrants, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(289,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of warrants, Exercised</a></td>
<td class="num">(2,385,484)<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of warrants, Ending Balance</a></td>
<td class="nump">9,119,330<span></span>
</td>
<td class="nump">11,504,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning Balance</a></td>
<td class="nump">$ 4.95<span></span>
</td>
<td class="nump">$ 8.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice', window );">Weighted average exercise price, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">2.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending Balance</a></td>
<td class="nump">$ 5.49<span></span>
</td>
<td class="nump">$ 4.95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of share based compensation arrangement by share based payment award warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation by share based award equity instruments other than options excercised during the period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation by share based award equity instruments other than options expired during the period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation by share based award equity instruments other than options granted during the periodweighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation by share based award equity instruments other than options non vested outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486458116480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Components of Equity - Summary of Share Based Compensation of Share Warrants Outstanding (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems', window );"><strong>Schedule Of Share Based Compensation of Share Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 5.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants outstanding and exercisable | shares</a></td>
<td class="nump">9,119,330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodOneMember', window );">Expiry Period One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems', window );"><strong>Schedule Of Share Based Compensation of Share Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</a></td>
<td class="text">120 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 0.7572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants outstanding and exercisable | shares</a></td>
<td class="nump">243,421<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodTwoMember', window );">Expiry Period Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems', window );"><strong>Schedule Of Share Based Compensation of Share Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</a></td>
<td class="text">120 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 0.7572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants outstanding and exercisable | shares</a></td>
<td class="nump">137,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodThreeMember', window );">Expiry Period Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems', window );"><strong>Schedule Of Share Based Compensation of Share Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</a></td>
<td class="text">120 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 0.4984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants outstanding and exercisable | shares</a></td>
<td class="nump">315,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodFourMember', window );">Expiry Period Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems', window );"><strong>Schedule Of Share Based Compensation of Share Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Jan.  04,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 5.5993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Remaining contractual life</a></td>
<td class="text">3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants outstanding and exercisable | shares</a></td>
<td class="nump">239,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodFiveMember', window );">Expiry Period Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems', window );"><strong>Schedule Of Share Based Compensation of Share Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Jan.  04,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 7.1991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Remaining contractual life</a></td>
<td class="text">3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants outstanding and exercisable | shares</a></td>
<td class="nump">39,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodSixMember', window );">Expiry Period Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems', window );"><strong>Schedule Of Share Based Compensation of Share Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Jan.  08,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 5.5993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Remaining contractual life</a></td>
<td class="text">7 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants outstanding and exercisable | shares</a></td>
<td class="nump">31,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodSevenMember', window );">Expiry Period Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems', window );"><strong>Schedule Of Share Based Compensation of Share Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Mar.  09,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 11.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Remaining contractual life</a></td>
<td class="text">2 years 2 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants outstanding and exercisable | shares</a></td>
<td class="nump">2,826,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodEightMember', window );">Expiry Period Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems', window );"><strong>Schedule Of Share Based Compensation of Share Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Apr. 20,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Remaining contractual life</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants outstanding and exercisable | shares</a></td>
<td class="nump">5,196,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodNineMember', window );">Expiry Period Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems', window );"><strong>Schedule Of Share Based Compensation of Share Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Apr. 20,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 2.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Remaining contractual life</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants outstanding and exercisable | shares</a></td>
<td class="nump">50,054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodTenMember', window );">Expiry Period Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems', window );"><strong>Schedule Of Share Based Compensation of Share Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Apr. 29,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 11.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Remaining contractual life</a></td>
<td class="text">2 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants outstanding and exercisable | shares</a></td>
<td class="nump">39,228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of share based compensation of share warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation by share based award equity instruments other than options non vested outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486458397568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Other Components of Equity - Summary of Share Based Compensation of Share Warrants Outstanding (Parenthetical) (Detail) - Expiry Period Three [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems', window );"><strong>Schedule Of Share Based Compensation of Share Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Class of warrants or rights term</a></td>
<td class="text">120 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodThreeMember', window );">Warrants Granted as Part of Share Based Payment Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems', window );"><strong>Schedule Of Share Based Compensation of Share Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrants or rights number of shares covered by warrants or rights | shares</a></td>
<td class="nump">315,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrants or rights exercise price of warrants or rights | $ / shares</a></td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Class of warrants or rights term</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of share based compensation of share warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_MaturityPeriodWarrantsAxis=eprx_ExpiryPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486545744224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General And Administrative Expenses - Schedule Of General And Administrative Expenses (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Office expenses</a></td>
<td class="nump">$ 389,210<span></span>
</td>
<td class="nump">$ 332,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralInsuranceExpense', window );">Insurance</a></td>
<td class="nump">367,472<span></span>
</td>
<td class="nump">357,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Travel</a></td>
<td class="nump">345,992<span></span>
</td>
<td class="nump">120,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">2,821,798<span></span>
</td>
<td class="nump">268,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreOpeningCosts', window );">Public company costs</a></td>
<td class="nump">404,073<span></span>
</td>
<td class="nump">214,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">2,241,079<span></span>
</td>
<td class="nump">1,641,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based payments (Note 12(c))</a></td>
<td class="nump">714,380<span></span>
</td>
<td class="nump">1,052,758<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total expenses during the period</a></td>
<td class="nump">$ 7,284,004<span></span>
</td>
<td class="nump">$ 3,987,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralInsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralInsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreOpeningCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenditures associated with opening new locations which are noncapital in nature and expensed as incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreOpeningCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TravelAndEntertainmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses incurred for travel and entertainment during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TravelAndEntertainmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486545689248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research And Development Expenses - Schedule Of Research And Development Expenses (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ResearchAndDevelopmentExpensesLineItems', window );"><strong>Research And Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory', window );">Direct research and development</a></td>
<td class="nump">$ 11,539,926<span></span>
</td>
<td class="nump">$ 11,019,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense', window );">Pipeline development</a></td>
<td class="nump">83,637<span></span>
</td>
<td class="nump">227,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development</a></td>
<td class="nump">672,295<span></span>
</td>
<td class="nump">424,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses', window );">Salaries and benefits</a></td>
<td class="nump">2,794,891<span></span>
</td>
<td class="nump">1,901,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses', window );">Share based payments (Note 12(c))</a></td>
<td class="nump">697,877<span></span>
</td>
<td class="nump">381,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ResearchAndDevelopmentLicenseExpenses', window );">License costs (Note 10)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Government grants (Note 15)</a></td>
<td class="num">(122,542)<span></span>
</td>
<td class="num">(288,515)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses', window );">SR&amp;ED and other R&amp;D tax incentives</a></td>
<td class="num">(102,859)<span></span>
</td>
<td class="num">(35,770)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total expenses during the period</a></td>
<td class="nump">20,563,225<span></span>
</td>
<td class="nump">13,629,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ResearchAndDevelopmentExpensesAxis=eprx_PreclinicalMember', window );">Preclinical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ResearchAndDevelopmentExpensesLineItems', window );"><strong>Research And Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory', window );">Direct research and development</a></td>
<td class="nump">1,616,238<span></span>
</td>
<td class="nump">1,073,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ResearchAndDevelopmentExpensesAxis=eprx_ClinicalMember', window );">Clinicall [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ResearchAndDevelopmentExpensesLineItems', window );"><strong>Research And Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory', window );">Direct research and development</a></td>
<td class="nump">4,595,597<span></span>
</td>
<td class="nump">7,179,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ResearchAndDevelopmentExpensesAxis=eprx_ManufacturingAndAnalyticaMember', window );">Manufacturing &amp; analytical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ResearchAndDevelopmentExpensesLineItems', window );"><strong>Research And Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory', window );">Direct research and development</a></td>
<td class="nump">4,986,502<span></span>
</td>
<td class="nump">2,177,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ResearchAndDevelopmentExpensesAxis=eprx_RegulatoryMember', window );">Regulatory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ResearchAndDevelopmentExpensesLineItems', window );"><strong>Research And Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory', window );">Direct research and development</a></td>
<td class="nump">341,589<span></span>
</td>
<td class="nump">588,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ResearchAndDevelopmentExpensesAxis=eprx_ConsultingMember', window );">Consulting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ResearchAndDevelopmentExpensesLineItems', window );"><strong>Research And Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory', window );">Direct research and development</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pipeline development of research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development costs gross excluding other category.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ResearchAndDevelopmentExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ResearchAndDevelopmentExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ResearchAndDevelopmentLicenseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ResearchAndDevelopmentLicenseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Salaries and benefits of research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based payments of research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sr and ed and tax incentives of research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ResearchAndDevelopmentExpensesAxis=eprx_PreclinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ResearchAndDevelopmentExpensesAxis=eprx_PreclinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ResearchAndDevelopmentExpensesAxis=eprx_ClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ResearchAndDevelopmentExpensesAxis=eprx_ClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ResearchAndDevelopmentExpensesAxis=eprx_ManufacturingAndAnalyticaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ResearchAndDevelopmentExpensesAxis=eprx_ManufacturingAndAnalyticaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ResearchAndDevelopmentExpensesAxis=eprx_RegulatoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ResearchAndDevelopmentExpensesAxis=eprx_RegulatoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ResearchAndDevelopmentExpensesAxis=eprx_ConsultingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ResearchAndDevelopmentExpensesAxis=eprx_ConsultingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486458774384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Government Grants And Assistance - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLineItems', window );"><strong>Government Assistance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Government assistance, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,542<span></span>
</td>
<td class="nump">$ 288,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Government grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_GovernmentAssistanceAmountForResearchAndDevelopment', window );">Government assistance amount for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,542<span></span>
</td>
<td class="nump">288,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember', window );">NRC-IRAP Specified Research And Development Funding Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLineItems', window );"><strong>Government Assistance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PercentageOfReimburseAssistanceToSupportSalaryCost', window );">Percentage of reimburse assistance to support salary costs</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PercentageOfReimburseAssistanceToSupportContractorFee', window );">Percentage of reimburse assistance to support contractor fees</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ReimbursementAssistanceMaximumForSalaryAndContractorCosts', window );">Reimbursement assistance eligible maximum for salary and contractor costs</a></td>
<td class="nump">$ 553,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Government assistance, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,542<span></span>
</td>
<td class="nump">277,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Government grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13,892<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_GovernmentAssistanceAmountForResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government assistance amount for research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_GovernmentAssistanceAmountForResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PercentageOfReimburseAssistanceToSupportContractorFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reimburse assistance to support contractor fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PercentageOfReimburseAssistanceToSupportContractorFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PercentageOfReimburseAssistanceToSupportSalaryCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reimburse assistance to support salary cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PercentageOfReimburseAssistanceToSupportSalaryCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ReimbursementAssistanceMaximumForSalaryAndContractorCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement assistance maximum for salary and contractor costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ReimbursementAssistanceMaximumForSalaryAndContractorCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486460669808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Government Grants And Assistance - Shedule Of Government Grants And Assistance Received (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLineItems', window );"><strong>Government Assistance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmountCumulative', window );">Government Assistance Amount, Cumulative Current</a></td>
<td class="nump">$ 122,542<span></span>
</td>
<td class="nump">$ 288,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember', window );">NRC-IRAP Specified Research And Development Funding Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLineItems', window );"><strong>Government Assistance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmountCumulative', window );">Government Assistance Amount, Cumulative Current</a></td>
<td class="nump">122,542<span></span>
</td>
<td class="nump">277,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=eprx_BioTalentCanadaMember', window );">Bio Talent Canada [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLineItems', window );"><strong>Government Assistance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmountCumulative', window );">Government Assistance Amount, Cumulative Current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11,398<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmountCumulative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative government assistance recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmountCumulative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=eprx_BioTalentCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=eprx_BioTalentCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461246400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components Included in Loss Before Taxes (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Canadian</a></td>
<td class="num">$ (28,810,717)<span></span>
</td>
<td class="num">$ (18,925,281)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(118,866)<span></span>
</td>
<td class="num">(65,483)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before tax expense</a></td>
<td class="num">$ (28,929,583)<span></span>
</td>
<td class="num">$ (18,990,764)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461161616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax Expense (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Canadian</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Foreign</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Canadian</a></td>
<td class="nump">36,423<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations', window );">Total</a></td>
<td class="nump">36,423<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Canadian</a></td>
<td class="nump">36,423<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 36,423<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486460781856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Income Tax Expense Benefit (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="num">$ (28,929,583)<span></span>
</td>
<td class="num">$ (18,990,764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory Canadian corporate tax rate</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected tax recovery at statutory rates</a></td>
<td class="num">$ (7,810,987)<span></span>
</td>
<td class="num">$ (5,127,506)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract', window );"><strong>Difference resulting from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in unrecognized deferred tax assets</a></td>
<td class="nump">9,523,404<span></span>
</td>
<td class="nump">5,127,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Non-deductible share-based payments</a></td>
<td class="nump">381,285<span></span>
</td>
<td class="nump">414,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other items not deductible for tax purposes and other</a></td>
<td class="nump">242,460<span></span>
</td>
<td class="nump">11,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Adjustments related to prior years</a></td>
<td class="num">(624,973)<span></span>
</td>
<td class="num">(257,636)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_EffectiveIncomeTaxReconciliationShareIssuanceCosts', window );">Share issue costs</a></td>
<td class="num">(290,289)<span></span>
</td>
<td class="num">(322,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency', window );">Foreign exchange arising on translation to reporting currency</a></td>
<td class="num">(1,384,477)<span></span>
</td>
<td class="nump">153,247<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 36,423<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax reconciliation differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax reconciliation foreign exchange arising on translation to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_EffectiveIncomeTaxReconciliationShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax reconciliation share issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_EffectiveIncomeTaxReconciliationShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486545262512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Company's Net Deferred Income Tax Assets (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Components of Deferred Tax Assets and Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DeferredTaxAssetsConvertibleDebt', window );">Convertible debt</a></td>
<td class="nump">$ 733,756<span></span>
</td>
<td class="nump">$ 360,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciable assets</a></td>
<td class="nump">3,092,163<span></span>
</td>
<td class="nump">1,655,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DeferredTaxAssetsLeaseObligation', window );">Lease obligation</a></td>
<td class="nump">4,925<span></span>
</td>
<td class="nump">8,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Non-capital losses</a></td>
<td class="nump">18,348,349<span></span>
</td>
<td class="nump">12,776,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DeferredTaxAssetsShareIssuanceCosts', window );">Share issue costs</a></td>
<td class="nump">728,046<span></span>
</td>
<td class="nump">694,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Scientific research and experimental development pool</a></td>
<td class="nump">2,093,085<span></span>
</td>
<td class="nump">852,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">1,546,834<span></span>
</td>
<td class="nump">797,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">121,846<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(26,669,004)<span></span>
</td>
<td class="num">(17,145,600)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DeferredTaxAssetsConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DeferredTaxAssetsConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DeferredTaxAssetsLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DeferredTaxAssetsLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DeferredTaxAssetsShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets share issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DeferredTaxAssetsShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486460398016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Non Capital Losses Carry Forward Future Years (Detail)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">$ 62,277,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">3,552,359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">69,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2031Member', window );">Tax Year 2031 [Member] | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">281,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2031Member', window );">Tax Year 2031 [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2031Member', window );">Tax Year 2031 [Member] | Australia</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2032Member', window );">Tax Year 2032 [Member] | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">575,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2032Member', window );">Tax Year 2032 [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">322,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2032Member', window );">Tax Year 2032 [Member] | Australia</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2033Member', window );">Tax year 2033 [Member] | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">2,481,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2033Member', window );">Tax year 2033 [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">1,111,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2033Member', window );">Tax year 2033 [Member] | Australia</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2034Member', window );">Tax year 2034 [Member] | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">2,935,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2034Member', window );">Tax year 2034 [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2034Member', window );">Tax year 2034 [Member] | Australia</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2035Member', window );">Tax year 2035 [Member] | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">2,466,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2035Member', window );">Tax year 2035 [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2035Member', window );">Tax year 2035 [Member] | Australia</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2036Member', window );">Tax year 2036 [Member] | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">3,797,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2036Member', window );">Tax year 2036 [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">160,048<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2036Member', window );">Tax year 2036 [Member] | Australia</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2037Member', window );">Tax year 2037 [Member] | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">7,294,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2037Member', window );">Tax year 2037 [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2037Member', window );">Tax year 2037 [Member] | Australia</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2038Member', window );">Tax year 2038 [Member] | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">3,060,930<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2038Member', window );">Tax year 2038 [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2038Member', window );">Tax year 2038 [Member] | Australia</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2039Member', window );">Tax year 2039 [Member] | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">1,666,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2039Member', window );">Tax year 2039 [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2039Member', window );">Tax year 2039 [Member] | Australia</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2040Member', window );">Tax year 2040 [Member] | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">144,413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2040Member', window );">Tax year 2040 [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2040Member', window );">Tax year 2040 [Member] | Australia</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2041Member', window );">Tax year 2041 [Member] | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">6,404,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2041Member', window );">Tax year 2041 [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2041Member', window );">Tax year 2041 [Member] | Australia</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2042Member', window );">Tax year 2042 [Member] | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">13,526,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2042Member', window );">Tax year 2042 [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2042Member', window );">Tax year 2042 [Member] | Australia</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2043Member', window );">Tax Year 2043 [Member] | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">17,642,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2043Member', window );">Tax Year 2043 [Member] | Australia</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYearAfter2043Member', window );">Tax Year After 2043 [Member] | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYearAfter2043Member', window );">Tax Year After 2043 [Member] | US</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">1,479,139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=eprx_TaxYearAfter2043Member', window );">Tax Year After 2043 [Member] | Australia</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems', window );"><strong>Non Capital Losses Carry Forward Future Years [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NonCapitalLossCarryforwardsToFutureExpire', window );">Non-capital loss</a></td>
<td class="nump">$ 69,093<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_NonCapitalLossCarryforwardsToFutureExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non capital loss carryforwards to future expire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_NonCapitalLossCarryforwardsToFutureExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_NonCapitalLossesCarryForwardFutureYearsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non capital losses carry forward future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_NonCapitalLossesCarryForwardFutureYearsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=eprx_TaxYear2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=eprx_TaxYear2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=eprx_TaxYear2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=eprx_TaxYear2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=eprx_TaxYear2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=eprx_TaxYear2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=eprx_TaxYear2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=eprx_TaxYear2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=eprx_TaxYear2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=eprx_TaxYear2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=eprx_TaxYear2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=eprx_TaxYear2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=eprx_TaxYear2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=eprx_TaxYear2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=eprx_TaxYearAfter2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=eprx_TaxYearAfter2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486463412512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued', window );">Unrecognized tax benefits income tax penalties accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Unrecognized tax benefits interest on income taxes accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember', window );">Canada Revenue Agency [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Non capital loss carryforwards to future expire</a></td>
<td class="nump">7,752,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=eprx_CanadianFederalInvestmentTaxCreditsMember', window );">Canadian Federal Investment Tax Credits [Member] | Canada Revenue Agency [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">$ 1,449,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_TaxCreditCarryForwardsExpirationTerm', window );">Tax credit carry forward expiration term</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=eprx_ProvincialInvestmentTaxCreditsMember', window );">Provincial Investment Tax Credits [Member] | Canada Revenue Agency [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">$ 511,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_TaxCreditCarryForwardsExpirationTerm', window );">Tax credit carry forward expiration term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_TaxCreditCarryForwardsExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carry forwards expiration term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_TaxCreditCarryForwardsExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=eprx_CanadianFederalInvestmentTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=eprx_CanadianFederalInvestmentTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=eprx_ProvincialInvestmentTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=eprx_ProvincialInvestmentTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486458390448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_CancellationFeeForCancellationOfContract', window );">Cancellation of contracts that would lead to cancellation fee</a></td>
<td class="text">no<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_CancellationFeeOnTerminationOfContract', window );">Cancellation fee for termination of contract</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_CancellationFeeOnTerminationOfContract', window );">Cancellation fee for termination of contract</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_CancellationFeeForCancellationOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cancellation of contracts that would lead to cancellation fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_CancellationFeeForCancellationOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_CancellationFeeOnTerminationOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cancellation fee on termination of contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_CancellationFeeOnTerminationOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486464210928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 21, 2021 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,341,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,263,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">19,373,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,058,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other loans payables current and non current</a></td>
<td class="nump">62,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash on hand</a></td>
<td class="nump">19,341,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,830,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable current</a></td>
<td class="nump">1,292,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,814,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates', window );">Impact on profit loss due to change in exchange rates</a></td>
<td class="nump">542,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PayableTowardsRoyaltyAndOthersCurrent', window );">Payable towards royalty and others current</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Long term debt bearing fixed interest rate percentage</a></td>
<td class="nump">5.84%<span></span>
</td>
<td class="nump">5.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member] | Canadian Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate', window );">Significant unobservable inputs percentage increase decrease in interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax', window );">Significant unobservable input impact of interest rate changes on profit or loss before tax</a></td>
<td class="nump">$ 43,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member] | Silicon Valley Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible debt facility face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member] | Silicon Valley Bank [Member] | Canadian Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_LongTermDebtPaidInKindInterestPercentage', window );">Long term debt paid in kind interest rate percentage</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member] | Silicon Valley Bank [Member] | Canadian Prime Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Long term debt variable interest rate percentage</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=eprx_EquipmentLoanMember', window );">Equipment Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible debt facility face value</a></td>
<td class="nump">$ 235,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other loans payables current and non current</a></td>
<td class="nump">62,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=eprx_CurrencyRiskMember', window );">Currency Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash on hand</a></td>
<td class="nump">$ 933,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,159,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canada, Dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign exchange rate translation</a></td>
<td class="nump">1.3226<span></span>
</td>
<td class="nump">1.3226<span></span>
</td>
<td class="nump">1.3544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PercentageIncreaseInSignificantUnobservableInputAssets', window );">Percentage increase in significant unobservable inputs assets</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PercentageIncreaseInSignificantUnobservableInputLiabilities', window );">Percentage increase in significant unobservable inputs liabilities</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canada, Dollars [Member] | Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_FinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible debt facility face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_FinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_FinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impact on profit loss due to change in exchange rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_LongTermDebtPaidInKindInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt paid in kind interest percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_LongTermDebtPaidInKindInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PayableTowardsRoyaltyAndOthersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payable towards royalty and others current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PayableTowardsRoyaltyAndOthersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PercentageIncreaseInSignificantUnobservableInputAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in significant unobservable input assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PercentageIncreaseInSignificantUnobservableInputAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PercentageIncreaseInSignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in significant unobservable input liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PercentageIncreaseInSignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant unobservable input impact of interest rate changes on profit or loss before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant unobservable inputs percentage increase decrease in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479424/830-30-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=eprx_CanadianPrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=eprx_CanadianPrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_LenderAxis=eprx_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_LenderAxis=eprx_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=eprx_EquipmentLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=eprx_EquipmentLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=eprx_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=eprx_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486458776272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Carrying Value of Financial Instruments at Amortized Cost (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems', window );"><strong>Schedule Of Carrying Value Of Financial Instruments At Amortized Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,341,756<span></span>
</td>
<td class="nump">$ 18,263,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NontradeReceivablesCurrent', window );">Amounts receivable</a></td>
<td class="nump">190,612<span></span>
</td>
<td class="nump">89,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_AccountsPayableAndAccruedLiability', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">3,921,875<span></span>
</td>
<td class="nump">2,928,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_PayableTowardsRoyaltyAndOthersCurrent', window );">Payable to Auritec</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Loans payable</a></td>
<td class="nump">$ 62,709<span></span>
</td>
<td class="nump">$ 142,127<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_AccountsPayableAndAccruedLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts payable and accrued liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_AccountsPayableAndAccruedLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_PayableTowardsRoyaltyAndOthersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payable towards royalty and others current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_PayableTowardsRoyaltyAndOthersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of carrying value of financial instruments at amortized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NontradeReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NontradeReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486545387904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Summary of Changes in Fair Value of Liabilities Measured at Fair Value (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems', window );"><strong>Disclosure In Tabular Form Of Movement In Convertible Debt At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">$ 836,595<span></span>
</td>
<td class="nump">$ 1,056,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems', window );"><strong>Disclosure In Tabular Form Of Movement In Convertible Debt At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">8,741,996<span></span>
</td>
<td class="nump">7,507,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod', window );">Accrued interest</a></td>
<td class="nump">1,162,773<span></span>
</td>
<td class="nump">958,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod', window );">Interest paid</a></td>
<td class="num">(591,170)<span></span>
</td>
<td class="num">(315,436)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">836,595<span></span>
</td>
<td class="nump">1,056,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss', window );">Foreign exchange</a></td>
<td class="nump">185,809<span></span>
</td>
<td class="num">(465,157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 10,336,003<span></span>
</td>
<td class="nump">$ 8,741,996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of movement in convertible debt at fair value [Line items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable input reconciliation recurring basis accrued interest during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable input reconciliation recurring basis interest paid during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable input reconciliation recurring basis liability foreign exchange gain loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461078448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest Expense - Schedule of Interest Expense (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseAbstract', window );"><strong>Interest Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest on SVB debt facility (Note 11)</a></td>
<td class="nump">$ 1,162,773<span></span>
</td>
<td class="nump">$ 958,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_OtherInterestAndAccretionExpense', window );">Other interest and accretion</a></td>
<td class="nump">7,400<span></span>
</td>
<td class="nump">24,187<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total</a></td>
<td class="nump">$ 1,170,173<span></span>
</td>
<td class="nump">$ 982,856<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_OtherInterestAndAccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other interest and accretion expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_OtherInterestAndAccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486463926528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Disclosure with Respect to Cash Flows - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 18, 2023</div></th>
<th class="th"><div>Apr. 20, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598,046<span></span>
</td>
<td class="nump">$ 326,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Proceeds from Interest received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 912,033<span></span>
</td>
<td class="nump">$ 394,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NumberofWarrantsIssued', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares, issued</a></td>
<td class="nump">99,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Share capital</a></td>
<td class="nump">$ 511,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_NumberofWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_NumberofWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486461403632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Disclosure with Respect to Cash Flows - Summary of Detailed Breakdown of Cash And Cash Equivalents (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 19,341,756<span></span>
</td>
<td class="nump">$ 10,830,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,432,498<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total</a></td>
<td class="nump">$ 19,341,756<span></span>
</td>
<td class="nump">$ 18,263,389<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140486464243888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 15, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 15, 2024 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 20, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,886,537<span></span>
</td>
<td class="nump">$ 10,636,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NumberOfUnitsIssued', window );">Number of units issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,150,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_SecuritiesIssuedPricePerUnit', window );">Securities issued, price per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares</a></td>
<td class="nump">$ 25,026,073<span></span>
</td>
<td class="nump">$ 33,867,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,260,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_NumberOfUnitsIssued', window );">Number of units issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,260,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eprx_SecuritiesIssuedPricePerUnit', window );">Securities issued, price per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares exercise of stock options</a></td>
<td class="nump">943,435<span></span>
</td>
<td class="nump">943,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_NumberOfUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_NumberOfUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eprx_SecuritiesIssuedPricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities Issued, Price Per unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eprx_SecuritiesIssuedPricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eprx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>113
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MPB)[-&'-\Q!",VD!=TH+)FQ5[[,"P4IA  &9;( [98,&:,&5G:7HKV1]>$3
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MQ=VVL':WWH_3(&AZW2D'W7]'I\GJHH#YBX)/]H3$U]$S!\5'09HV#QZ<<G%
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MIA&K?<'8/<+TJ+U@(G*8+=R/ )JC.8):. 4Q$.<<)NDF]4B44ELM.3ND^BC
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M>IWI2(%[NMO2D%H;'6XM[6)W=T_$LZ%,C(BDI1 9FA71<R-NO1S#UY&GT0=
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MR^,#\9#XH7,K?M5VYKK.U?SG$B%D6GH O\\=,$3X0!ND=Z]?_ =02P,$%
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M:#>A/#4<9;S,E80IAIBLV2+%OJT(5^_:X0YC7&%XGV"X'CSR7,42)GF$T;\
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M?&#S7<(?)1[UJS58)1LIO]C-JIAZH6T(!>;&,G!Z/.$"A;!$U,;7,Z?7E;3
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MFE12;XV%3MAHD\2!3AB$C<N@6[LM# =FUR$^:!!P])II'=RJ&9JE?SNP913
M\H+=K^Z?)S?EK?Q3O'S;?!%F*94EARU(-6A>=NI@RO=".7$Z]W?T3#NZ\?UP
M14\L-"Q ^PNMW6["!^P?;:-_ 5!+ P04    " !KB8%8$:\A"UH&  !G$
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MY2%UL? F#U?)L?&XF(;'5'"T/1+ ]XG!B*L69*#^OX63?P!02P,$%     @
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M=6-#N]W&#PU2S&?)NW7R+]Y]#IO,T5ZRTQ@;R)#'XBQ/,::\1\8J3GXJ>13
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MJ*P#_5]+JMQA8!,<[^KQ?U!+ P04    " !KB8%88^ :@H<#  "J!P  &0
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M-D<M<@;7+;MJB?0XWCSR1<KM-;^%T;=<EA8.]82,D!YAMXU#C\<N.WK=4=(
M1'*_7!\B;CUX*KZE0R-3I6-_! C'RX&<!R $ZGITVC$!*;VR,1Z@XKCP 1.Q
M47 H_!4H-H5T;^EL1H$ R3W*QTXI$1UI-?18.TA Q)?K=\]?TN0F">Z4<I\>
MJ+)U(WCUR!-$Y/C#,7JST,<L\XR%-(%%R3?,N]@0LB0CXI0R&H;\Q#^P!A.N
M%T,HT:O "S"3@6,>6!=CW2)*O 3* [!9WS\D+2%I:8H9;/[(*MCC$4=,@M2M
MBN</5K',"T%6,6D^(FA.[!E/%]']IP<6+XA@P[8X2)Y<'",8,6F/GEX:L)1&
M:6_N+YY>'+(@PO"=8J;,GEZ-F0##+L;E,'O@_I>ZE)4=V^Z)"3"K+C#Z+AAQ
MZ$4T>\92D@!.'LQI%O$2L/<H6>"Z7[&7_:51KOHUZ/YWMI>@@#VC\G/]\_>\
M:EZ]?^<&691G))]QY?%(\DHT%XQPT@IQ1=FU@4E5[I-X?%.RG^:6(HQ6K02Z
M*O)$8MIR;PWVF@6QFGMV[XH5U*O5"M7Z@<:=U*$VP:V&;_M!C6T$%0'C^)";
M1K_= ->7!Q73Q7:ZG)IW((#]&Q!;F*B:H_#8%,)J0LCS_]BKO@-/7/J?F!;V
MID6'3'M[== 8%Z&^UPVLYTB "026]Q 9G31-U[^EWNO1/;/$+:-J:-I2MX8A
M/5<:,+^2I7O1/#0F+6!N;1N%C2;W]M^1V.B-Q=GUF6DSF3*BB9ZE !NY'3+&
M,4)TUU]%WMK6S>\L+?T&22/;Z$4>%#:<L79O+L<]Y.X!;_=>'5G:9;%16(+2
ML_=VVY,ADMZU:Z7=2QO+L>EUU;[M(TL=#%.U(,92]6]2!PB!@U-[=R_.13/P
MJXD]%DSBCE>RMD=[QG[H-/GF471*M]F]+!6TU19'/D;P0+MW]*M^&(C=K$.!
M*GH^7 (\5JCCB1-3>A;L$03Y\$:,3'C(;5V(=[;U6RUGFDK<J1P/K6<FH"&R
M9 9'3IGMPL=7H)1'Z31E\HX\NW<REHYJA=LX#][9Q%IN'YSJZAX5MWBR<5IU
M=6%VO'@$3<EE=0](PW2W(4/ZJ=.]"*8*J>5>@=J+@GL'VY;V/26P>$/<B^PD
M$5A,-6=ZIF?V8YN+B<9P2,_MF\G0Q]QGJU(8P7CZ8CQ-E8G.2<J/%7(_\XEL
MC[(H0&,9.&.'OL*=3[Z05D+?V._ ALAWW;J/I>/=\5/SI?O"NEONOE-_Y!H^
M&5:*%;;Z9UERPK3[]NM^M*JQWUN7JFU592_7 O.ZI@5XOE*J'7Z0@O$#_,6_
M %!+ P04    " !KB8%8(5R&V"<#  #E!@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6R%54UOXS80_2L#%5OT$%@?3G87J6T@<5)T#]X&F[0]%#U0
MTD@B0I%:<F3%_[Y#2M8Z:-9[D4AJWIOW2,YH-1C[[!I$@I=6:;>.&J+N.HY=
MT6 KW,)TJ/E+96PKB*>VCEUG490!U*HX2Y+W<2NDCC:KL/9@-RO3DY(:'RRX
MOFV%/=RB,L,Z2J/CPA=9-^07XLVJ$S4^(OW9/5B>Q3-+*5O43AH-%JMU=)->
MWU[Z^!#PE\3!G8S!.\F->?:33^4Z2KP@5%B09Q#\VN,6E?)$+./KQ!G-*3WP
M='QD_RUX9R^Y<+@UZF]94K../D908B5Z15_,\#M.?JX\7V&4"T\8QMBK+(*B
M=V3:"<P*6JG'MWB9]N$$\#'Y#B"; %G0/28**N\$B<W*F@&LCV8V/PA6 YK%
M2>T/Y9$L?Y6,H\W6M*TDWF5RJYB8T"_'Q02^'<'9=\!I!CNCJ7%PKTLL7Q/$
MK&26DQWEW&9G&>^P6, RO8 LR99G^):SO67@6_[8'@A=PI;E2EVC+B0ZN).N
M4,;U%N&?F]R1Y3OR[UO;,":Y?#N)KYMKUXD"UQ$7AD.[QVCS\T_I^^37,Q8N
M9PN7Y]A_=$+GP>F'!6S_V.T^/>WN/S\]PE.#O =M)_2!;]$!<N3*^MI+BR60
MX:5GY%NFD.^=Q@NPYB 4'2["WAEJT((W*&S1A*42]US6G1<'5:]+WEKHQ&'<
M;YZ?B^>;JT1NK!BK<TX@:HLX,@R2&J!&VI)9+?DC^\4APF=#"&D"]WUGQ8L4
MT @'C$!O0VHV(D#W;<YLI@)_(+) 3JC#"4^\D@=[U*6Q;@&/ID4?2XUQIY&-
MV/-4Z(+;QBBT4*)W+&1H))MR)%C*K&,PO?):#RS@%:K"0)\C#8@:TJMWP7&:
M)._&M @:7VC6.I\!R(J5 EOCXN=<+L0>!2[@QGD\EPT&N\?2N?!A?*V#_MRG
MU.:U(D9]LTF-H$D\65G7_AC^9V#QUF6.3UI/B[8.#=8Q=:]I[$+SZMS#;\;6
M]2U\_ 'LA*VE=J"P8FBR^' 5@1V;ZC@ATX5&EAOBMAB&#?^'T/H _EX9OA?3
MQ">8_VR;_P!02P,$%     @ :XF!6-=FCY*J"@  [!T  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&ULQ5E;;]LX%G[WKR \[: !5-N2?$V3 $G:[ 9H
MNT4O,P^+?: EVN94$E522N+]]?L=4I)E6\YT%PO,0V)=R'._?(>Z>%3ZN]D(
M4;"G-,G,97]3%/GY<&BBC4BY&:A<9'BS4CKE!6[U>FAR+7AL-Z7),!B-IL.4
MRZQ_=6&??=)7%ZHL$IF)3YJ9,DVYWMZ(1#U>]OU^_>"S7&\*>C"\NLCY6GP1
MQ;?\D\;=L*$2RU1D1JJ,:;&Z[%_[YS=C6F\7_";%HVE=,])DJ=1WNKF/+_LC
M$D@D(BJ( L?/@[@524*$(,:/BF:_84D;V]<U]3NK.W19<B-N5?*[C(O-97_>
M9[%8\3(I/JO'OXM*GPG1BU1B['_VZ-:&89]%I2E46FV&!*G,W"]_JNS0VC ?
MG=@05!L"*[=C9*5\RPM^=:'5(].T&M3HPJIJ=T,XF9%3OA0:;R7V%5=W,N-9
M)'G"[C-3Z!+V+LS%L !I6C",*C(WCDQP@HP?L \J*S:&O<MB$>\3&$*F1K"@
M%NPF>);B6Q$-6.A[+!@%X3/TPD;1T-(+_QM%V3^OE[A!:/RK2V='<=Q-D=+E
MW.0\$I=]Y(,1^D'TKW[]Q9^.WCPC[[B1=_P<]9]WS+-DNH7TYP-V=__Q^N/M
M_?5[=O_QR]?/WSZ\^_CU"_NZ$>Q6I3G/MK_^,@_\V1O#5HTDLF6Y2"$Q3<'4
MBD7<;!C/8G<A?I3R@2>TR&,\526MUB(2>+I,!)Y%D7N8\RT]L5OQ4)<B9HGD
M2YG(0@KLKA<4BEV76A8B\EBB>+:_%9(\"%U(NH_%LAB0%EJP1_J7*19M>+86
MAJ@4'>II:;XS\90K4\) 3&FD5X9Z1&J2=O3>L!C\L[4EL!5<,T%ASA"D(ET*
MW03JH-."!RQ(:"(DL2H"CZQ3KFZS<^CD"JC\-P184E4]9[=:Q+)P?-K7TEC2
M]KK8<.(E8#M=;,D:O),'"E"2P)6E$7LK$F4@%,Q#%!7^Z8K2<LM6'#XC\R@6
M2S0.KM?D&Z:6B5QS*K][AB&QI7B *2#HAAORDI'K3*YDQ"%!M%,!X4*KS.D@
MLP_-1NGB=2%T"DU N$A=_"T%B47[<RVIZS1N(%GW^,!6C[( #Y98\6\1!;&$
M$DN>?>_V*^JP3,OT%,W:_!'7>DMR0.)24$SA*:R[LRTW1J"WLO<2>F'[UNT_
MN#WR)H2#FO3>^DQD-K'@F%BN8$HTIBW,P5(T!V*_\X8AC@JL"\20U;KEYUT&
M5EPHY$11)!1O6Z18@CYJL\&Z A'!,Q</!PIU&XWGN58\VI"Q;*81I>184P5]
MG%%)"%G%Y88_4 *0>I*"=;>1R!&*:<O_N!$94E<,V#48%\?YZK53#\3C9^(,
M?GOA+[QP['NSR92]POZ O<:SN1=,0R^<+\[(VCR&. 0X*!A*K9V4.YEJ,K/0
M6XS"'9G0&TWFH#([&[ /NPH$4U14DJU%.-:3&8M0\H"Y&+6O0JQEQ'@"UV><
M4 Y2)HN2,L9:Y$!9(,%(B%22OR&7YM(0G5I63@F?RX(\1]G431,;*9/$$^J^
M=3\Z/GY)RL,:C(H0D<+;NAA+F^0(BU(C1- %-NH1%4![=21O;2#!PTUZ[/&V
MS@<(0^#Q!*6/V4)$.W<JK,J,-'9KER#P@++D>HY<6<5L/&1"H':3D?5W465J
M^_HHS>@.%4[7^8M +PN*3!LB*U1@Z]7GRNDJ*:.BA/B0RY56ZIM58Z(4=?Q1
MI")A]D6+$)RXL-FH!=)AF[LHHK?G57!$V[J*4?ZC_C'RH"- BE?UFLC;AP.@
MBJ.%'8_^0EM(YL2Q1>0HOAQ>,#M]*]G6F$RH H)D,!A/7C;-MBGGU B$5=$#
M+$%^VU*6$GI-MCMZ0!BVAZ!T9.T@JYZ3H$C%N!&$0M$9#JQG+UDNJ"YF9>HA
MZB3*71V5=2G%!L0SP1H;^I325DG3=$L2+K?,"/1TJDQV?@*QFO%D,!^_?*;:
MM: -]=U84,L$9'0V$JN5V &2RK%@A49BO8I14%?] T7500CG.#*';755P>NP
MMC5D#7DH0OR7!YL[-J'BE4E<;Z-%#E$2A<8.D&-)L$8BSF% %[&")E*+20@4
MN*)RNDQ18[.-"0T=;!$(+\:A-Q_-!NRVG6 '=W]%>@""8=1$YW^JK$=V,OOX
M2AJ'25RUWRL1M>>HDJ\H_NT;L@\*L^&1<R_X?/O"8I4 "QW0CI4PMI^0:#'J
M\<.N/6Q$3,!OS4DI&$.:JBPUU;X"?'FI(3W)MV-C16T<F/(_E,N-VG7&!6$7
M5OY$M%C (J!00,@$RL"TB+@_;_DBJ5H]]>6J&UNZ_AO<GS'/HH*CF<5V<2]8
M!)X?S ^W^=[<'WNCZ>P,\+63:BPRA;RS^&O/UG6QH)YI/9+PJF<WV5&O1+CM
M$SYSCMK+L=%ADNV'395?%E7QO?3<3X8.%13EJ5K!H8AR&@[VPX0G1EE76^/*
M[-B$>'9=$M1(6EIY[&]4P=D-?"^Q,<>>V&'\=Z56YEC%4PJ:'9*H$D!VZ%M#
MBE;M.\K8 ?O'0?L\?O"7@P;VRO5X,"<[* )0VJ&\E5;I*6!05Y.]&G%&/4M4
MY(A2S91;^4OC)@$4ST(A$$TN(AK=Z@D;;5$^R+@D2-:E'&Q!U4<"#%*GUFU:
MW+K!8E-8P "R(BI.S,((G=CECRL89(VC.DB5JE4+VV-FRWUV!H)Y<HH!6X?2
M5,55:Z8^C*L:G-V15W^S7OT@.(TH5JLVWXC@LZ(1W0VOW?*G;K>% JU0@:>4
M'=1M_!+DHW%.N$$"532AOIT+AW6K7JV6=+1C>[-KC7D)!M91M7EVHF+.)#+,
M/W>Z5&R-/=Z,B62)4O,'<A-W/TI%/U60T?PO8QHZHV9LM?G?&G!D?=9:N<14
M[(*3["IQ6P&\S]4-,]6H"O*5^+OQM%*?JDI]0F%E:XNV]9B0ED,L-=R<6-]2
MK%9WCFIX4DIZXBQ<B&B38?"L)V0'(X5SF@:6I(FY%6AEUA*P4O;_?=)VZ@3D
MYT_;?N9D[7?*DZK*BKP.M\-UWNECCY\]YMJU']H%?^P2I &?[D5+\0I/RQH.
MK=!3U*,%@5:GYN",0LI]T'#?%M9<Q_7Q7I0@=*SGW&<#:^VV)B=1R)]G.< K
MS$0'=P1GSGMW!R= PW8>'2&7HR=![_;D:<4+UCJKP$US2-&[/CJ3M8M'WM0/
M<#5?>#-_TKO^R;C!CM!;!( \LPFN US/O<ETVOMT='B+UQ-O-!K1'ZZMW8(W
M^/$7XS>]]WOA]X)- V\V6I!H8P)9L][_[M$6>&YUY-6>&MW%V&N5\IB.(NLB
MT;MMQ?Q;Q'SOAB=TLM%@I$-G^5!EYDU&,WC$FM=:LFG+B\G<FTX7O?O= (IY
MYE7H3[QQ.&5GO=L&Y;24\+W19.KYTTGO[G L>#6>3CQ_,L/66K37QQ%$#O=F
M")/%8GHLE _2<,,L/!1KLL"KV>B46/-PZDT6'4+Y\PFFJL4S$H7D\9$7@L)H
M%!*%SLG-E9CO8EO74]<+'(BS'3%;JSIEJTRV9XG"GE#;&=)V%T?(;.BM P3U
MB4'[V8,"#J\.M+H^[@Q;7^!2H=?V.R.5;O!Q'^.:I\VGS&OW!6^WW'T'_<#U
M&O4#K7Z%K:/!;-('1K'?%MU-H7+[/6^IBD*E]G(C@(0T+<#[E4+OK&Z(0?.!
M]^H_4$L#!!0    ( &N)@5@Z(##IB0(  'H%   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;(V4;6_3,!#'W_=3G )"($7-0Q]7VDKK*&(O-JIU#!#B
MA9M<&FN)'6QWW;X]9R<-1=JJO4ARMN]^OO/E[^E>JGN=(QIX+ NA9UYN3#4)
M IWD6#+=E14*6LFD*IFAH=H&NE+(4A=4%D$<AL.@9%QX\ZF;6ZGY5.Y,P06N
M%.A=63+UM,!"[F=>Y!TF;O@V-W8BF$\KML4UFF_52M$H:"DI+U%H+@4HS&;>
M>319]*V_<[CCN-='-MA*-E+>V\%E.O-"FQ 6F!A+8/1YP LL"@NB-/XT3*_=
MT@8>VP?Z9U<[U;)A&B]D\9VG)I]Y8P]2S-BN,#=R_P6;>@:6E\A"NS?L:]^8
MG).=-K)L@BF#DHOZRQZ;<S@*&(<O!,1-0.SRKC=R67YBALVG2NY!66^B6<.5
MZJ(I.2YL4]9&T2JG.#._% 85:@/+1^JSQFE@B&K7@J0A+&I"_ (ABN%*"I-K
M6(H4T_\! :73YA0?<EK$)XF?,.E"+_(A#N/>"5ZOK;'G>+U7U@B_SC?:*/HA
M?C]7;@WK/P^S(IGHBB4X\T@%&M4#>O-W;Z)A^/%$JOTVU?XI^JO:<9H0G77A
M\OIV>;-<W\+RQVIYO5Y"B\7F!+B&1):5XAI3D!F8'"&3!4F4B^VD\Q.9 K3M
MA".3^H+E!M6A-W&GY9*^UG<+DL/&0,827G#S!.^OI4&(H@_P%B(_&L;^:-0C
M^VPP]H?#L\Y7VE4!/S"82$FDB4(GUY'?#T.(^WXT'G5NI6%%31F%]#C*./;'
M@^%SAQX<Z:%$M76JMQ7OA*FET<ZV%\MYK:=_[O6M=,74E@L-!684&G9' P]4
MK?1Z8&3EU+61AK3JS)PN1U36@=8S28?0#.P&[74[_PM02P,$%     @ :XF!
M6$I?#QNO P  *P@  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULK5;;
M;MLX$'W/5PS4H&@!U9(HV9;B"^ X#A(@:0S;V3PL]H&6:(N(1*HD%3=_WZ'D
M>-UL&NSM(18O,^><&7(X&>ZD>M0Y8P:^EX70(R<WICKS/)WFK*2Z(RLF<&<C
M54D-3M76TY5B-&N<RL(COM_S2LJ%,QXV:W,U'LK:%%RPN0)=ER55S^>LD+N1
M$S@O"PN^S8U=\,;#BF[9DIG[:JYPYAU0,EXRH;D4H-AFY$R"L_/(VC<&OW&V
MTT=CL)&LI7RTD^MLY/A6$"M8:BP"Q<\3F[*BL$ HX]L>TSE06L?C\0OZ91,[
MQK*FFDUE\< SDX^<V(&,;6A=F(7<7;%]/%V+E\I"-[^P:VV[R)C6VLAR[XSS
MDHOV2[_O\W#D$/N_<"![!]+H;HD:E1?4T/%0R1TH:XUH=M"$VGBC."[LH2R-
MPEV.?F:\K*NJ8)AE0PNXX#HMI*X50Q4FAP73%68/C(0IU3E<XA'JH6>0UWI[
MZ9[CO.4@O^ ("-Q*87(-,Y&Q[&< #P4?5),7U>?D7<0+EG8@#%P@/@G?P0L/
M60@;O/#O9.$0*LS:-0V_3];:*+Q!?[P5?8L=O8UMJ^I,5S1E(P?+1C/UQ)SQ
MQP]!SQ^\HSPZ*(_>0_^?SN]]#N)W8'D_G]_,;F=?5Y,;N+A>3F_NEO>+&3Q<
MKZY@,5O.9],5K.Y@.EE>P>7-W<,25CF#J2PK*IZAHCP#+@S##!B0&SCM)K'K
M1SW(:L7%%@P:/S.J@-DK GC K%PS=3AD^(2_!+[ :4AZ;H\DGSL_$2ATP/)^
M19($Q/7#\%^0))$;Q/$KDIQF#<9&%IA)BZCY5O -3ZDP(*3XDF*:3SY^B GI
M#2!)7+\70"K+$M\?G5/4!9^>:%$C.368@R!P>_WX,^Q0,G"MFPV-V5*-_H:+
M"RI2RX48DWJ+3P($<:O7M<84S9_M!; >:)TQ904$_8&&#;.,FC'X*@T#+,3_
M$$[7]]UN&,..*D5M51R'@M?9#:+^/PBE4KS *)I(B&OOJ+6YM_IWBN,A[I6C
MZ F^LX;R B'7V'D>,[D3%M3* RJR=L"^U1P5-07+M25O ]-G)W\]Z=<KY*2I
MD%,($C>, K??[=F)[\8A_B5!NWU,T229#/ 3)-$ ^FX4$C=*XI.5M+7X&BEV
M22]TPSAYJ^B]HP>\9&K;M"F--Z<6IGW+#ZN'3CAI&\"?YFT;O:5JRX6&@FW0
MU>_TNPZHMC6U$R.KIAVLI<'FT@QS[.9,60/<WTB\*ON))3C\?S#^ 5!+ P04
M    " !KB8%8XNH#C=\"   9!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6R-5=MNVS ,_17"+8H6,.);;FN3 $V:87MHFS5K]S#L0;&96*@MN9*<
MM'\_2DZR#&B#OL@B11X>4B(]V$CUK'-$ Z]E(?30RXVI+H- ISF63+=DA8).
MEE*5S)"H5H&N%++,.95%$(=A-R@9%]YHX'0S-1K(VA1<X$R!KLN2J;<Q%G(S
M]")OIWC@J]Q813 :5&R%<S2/U4R1%.Q1,EZBT%P*4+@<>M?1Y;AM[9W!$\>-
M/MB#S60AY;,5OF=#+[2$L,#46 1&GS5.L"@L$-%XV6)Z^Y#6\7"_0__J<J=<
M%DSC1!:_>&;RH=?W(,,EJPOS(#??<)M/Q^*ELM!NA4UC&W_Q(*VUD>76F1B4
M7#1?]KJMPX%#/_S (=XZQ(YW$\BQO&&&C09*;D!9:T*S&Y>J\R9R7-A+F1M%
MIYS\S&A>+S2^U"@,3->T#@)#J/8L2+<(XP8A_@ ABN%6"I-KF(H,L_\! J*S
MYQ3O.(WCHX@WF+8@B7R(PS@Y@I?L<TP<7O+)'#7\OEYHH^A%_'DOWP:M_3Z:
M[9)+7;$4AQZU@4:U1F]T=A)UPZLC7-M[KNUCZ)^ZC^,(<=2"^>-X/OWQ.+W[
M"=,GN]X+N&4JS2'JN+*V?3 YPD26%1-OP(20M4@Q VX@9QFDA=1.TD!)KKFL
M=7%H)M>HA'WP]!;5,QI25?6BX"G(Y1(5%RLXMP'.3OIQ'%[=;Y5.C*XNR I2
M69;4ECIG5$6K."1TZ#QW%CO7%LQJI6M&!3+2^>S ?9C6E6*OG '7NB9*?3_N
MAGX[Z4"# <P HX1XBC;@Y+3=BD*H4#7G0#,.5DIJF[1,$3/'ZS3N^&'<]<->
M N>3F[O3)/'[W9[?Z[?APH=-SJFN7*1%G5$(R\B&9\(%>>])! ?M6J):N:&D
MJ2"U,$WG[K7[N7?=M/L_\V9HTJ6NN-!0X))<PU:OXX%J!E$C&%FYYE](0Z/$
M;7.:W:BL 9TOI30[P0;8_PU&?P%02P,$%     @ :XF!6"6!_)9N%@  .$@
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M(P=&-NB,"-SC[->4AS4128!J*13$HTU\5A% 4N=TJB5VT8O/8<(6:D )0G]
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MMN49391(H#R3MLYG2!'BX#@W-*Q^'B1A1[&,X2&U@IM$F33<LX():)!42)I
MT0:'2[(VIV;0;JJ1E28T:5-FXOJF"FOD0+*HI<1E#U$_*=DG0DSI4S__-9\>
M ).6V@N!R6S_(_0@1K7J*^; U/$M!KHEL; _: +%-H6TD'R4.^XCY86F>M\;
M*C(ZW/3F"82\-13:3SPI-N"'U/[8713:RXP8Z\6PDP=M">TD49J@:66L&&@X
M'A.S <$Q[$P])6PI!G.F_J"HJJMMR/&&;3%-A=0;@@GC4!BI7 :Y"R,D"R!\
MV/8ZWL"37E1JY[$450B1[-**9I,*A-D)[=DMR)+$"SA@FM6AJ*NJ7'&[Q2FQ
M-S+IWJ2D2& A6AW[5BF32 @%&*7>)\6I:T<N+8^ ;Q%%%&M@OA)(,@()T^ ]
M>P)0XITIUFUS,Z5;_>#1?'KRZ&>$-G95AQRVV*OW-"]2'1U$F@9W1+NF-I$Y
MH9%!0JZ<4ZOER/31X3#B('T*^7<"UK.')X"AQK7;4*N\OK&-DXH)#+@(,.\:
M1G7<UC0RYO724,LI"SW'D-Y /,+D3YHS[(</P<8R0#&?Q6=VR_*(,9"3C6T>
MQK 8<R;"LJ],Z2QT0UJ4)*RO,<G9OQ2_(WA,3H<$O=5<-!$ZBS<?8?<D>V\/
MF>;#3I;;X2QX ;58W&V#^/5J=^08^<Q6&Z+;0,>&T]',ML9DI$=A1G/@IB4"
M'BEHE(;(6NLPHCN&[G@:S(7*[!@Q>1+/;JAP2>\-L/4RW+6). V^(*;,P&7?
MHHK>G@D^QJD[#!D*^[*)9!EB.T*E Y:E&N,8TP(_1[#MRU<(Y]H!_P[(=AI]
M34H7;N$0%F8M_(87<DPJ>44L54CO;K@\*Z6%"9"A7,6P+LY_$'$.A..P;"7U
M7?)2&>.85!F9.+>\19G##E@^9B!!!Q&B,6NZH'(3"PS3P5T_HC6?GM%ZW<\Q
M0)[>N'IU]H:CSBL6AE$?]!6C6NHS^PPGMJ2%[X]TWLG(5@2@DL)]*&Z#/%1P
MBN:5XC=FJ0R=#X;-+:QND292CY7.8@N'G IE\(L,F0KT_^T69EQN.,!LD'8M
M]B$+)H'I*R@CN_<5*@A-J')U-8VUTQL 57/Q"G'HDD9%#LL+DGFTLF4/"T19
M-:[;]J5!I/3+?G\)E.BR!$5TK*S=1LI7V=;]ML,Y^I8BUN3!@J.\E3[RZ'<E
MQY5.%H5HV3Q-+)#T)8DA!?L*,WWK"WJ35)1CYR>;3'$CM;+%P)/#U<_-<T5J
M)$*42<RH'\EC)BZ*(!4!2*0'VG%+N*=UO9^QFD\/6;W@M 7(\@<:C,*ACU9'
MOF+J2AW=H?^%A<=DO\1\A7^@.P=XBZH1]4<:!:(*81AQ6R,_1RI=62PN!]5[
M+A; $:PL65DP%4D2NRYF)_(MM9$;8=36H0+N<'H=;Z5\2.ZAL']';%/M!X-U
MD,R/M=O5>:^DB =#A/0GCPL1<_-Y<*CZ1WZS-T?A*M&+0UK$#FB<4>,VWK;J
MO-P38?\@!;AID>C'CN;3<T?7--VEWM,P5S\-,BX/7S-I- X^/.81LF$31B3A
M"QF]9RX>5'0';.>(A@OW:[X)%,J;(HYULNTE)>8T8FK)_[L>/FWKNC:,-H7\
MFZN?^VD^].,_\^GYGY]3G/8ZGV0%@C^3<?J=Y&64*U\S#G27S08..5A?_YF[
M<_V$%++FC1]>G"/)==3-(,:<5=3'!J/AI*!X^[S234;]P[7<,6-M9'Y8JM7Y
MT,^V];:+%T#BU2CI,?Q%-84X_!N[,KE]#V4$0U48>B>Y#XG#W(*()/[]/8UW
M]R@&Z?0_W+,S]8;QG_- ^7S^H_I0ITG"OSK7BA1)J!%N X>JD'11D4C6G)'E
M])O=LPGR98+\6LZ:59\.-PB1(PDI=HN8)4/6'RG%M6/L0]1M>0^I3E/SIF$O
M)=]ZQ +QH[(.L:$=O-W82C<Q,".;FV43MPAR.@*BI\]=X$7*IB.31LLFIQ'=
MH_2;HE,* _JNC&08(GYQ)>(9=M: "*INN>#+'H9KB$WC%B[%8MDNH4P(XZ7I
M%RYU5ZF]*PA#A&L6##N+DL#C[74&1^X]]K.JAPEA?C-/>Q%ZZJ^%H7<-YT98
MLWWE$EXG%78BT'#D(*?$L#X2YE)\: ,'"@W*?PMJ&]E:;O?S2'5LSLYB$C"6
M>695R  (@:?A>6V21VXD8;/4U\L];ZPNC-Z)]!S!!^C%H*,IH"GNIVIFN(QX
MX,+IO<B$00+0FZ1 A?S2\>"JL2CL 8;)X(2;QL/0G/LIX=J?- B(@*?]PS!;
M<AH'UCEH2)=-M]O&?>*H-]^R[$PD%4][G[%GKC4G'7*J0776RYU:0B"XP]N7
M:OMRQ-' CQOG+(0LQIZ@]7P_=OUZZCY_/P]Y.3T/R2/PHV'.],(C#E7 Q7^&
M=7.I8!*1*OEY&./Y,#V?B_U ;<(E\I[_2"GL!EF9K$N3SJE9)<^)A:<J2]KZ
MF@=%0J[I;YN3-%@::RML&R4[C?2/L93;<+0K#=:3?=L1:*G V.78'@F\;.9#
M!U\B[)@H1:^;'R%Y79[-DWH,E;AP6+&G#1+=7>@9#0K$VUA6-<UP5#.?$]PG
MQ:0.;6RR2=E!X$8X( 7/21R\-K(E-93RIB7?5CUSRS,RJT>_3(EU/\UY.3W-
M^6%;4#USE?]-C6NZ1:2I:T8DXOX]1*IEE,<UX&LF/;]XYX'WH$M*1-T]C;65
MH",5&0)CP ;E(R28-<A=V8>;]@ J\\=*GS5;)5%>]C<CNA1L=L'[TP"2B?=@
MV6;K_BA1\+*[;.RD]9(2CGB;4NH!C]A-<B82EHE0TT'8*&_D7ICOR1-"EKR&
MP[AJ2D$,7T.0*UO1*'QQS7?<;IYG?\QE8YH5_\D:OG1?M_)W7=+3]&=QKN2/
MP?2OR]_4>:L;D(:LV1)++V;?/CX1^8Y?6K?E/PVS<&WK-OQQ#0-@&GH!OR\=
MHK+PA39(?RSH^7\!4$L#!!0    ( &N)@5B]K4K)$00  '0)   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;)56VV[;1A!]]U<,6+BP 4>\R'925Q(@
M7X(DL!LAJN.'H@\K<B@NLMQE]F)9?]_9)46I@:RF#[;(W9DS9V;/['"T4OJ;
MJ1 MO-1"FG%46=M<Q;')*ZR9&:@&)>V42M?,TJM>QJ;1R(K@5(LX2Y++N&9<
M1I-16)OIR4@Y*[C$F0;CZIKI]34*M1I':;19^,*7E?4+\634L"7.T3XV,TUO
M<8]2\!JEX4J"QG(<3=.KZPMO'PR^<ER9G6?PF2R4^N9?/A;C*/&$4&!N/0*C
MGV>\02$\$-'XWF%&?4CON/N\07\?<J=<%LS@C1)/O+#5.'H708$E<\)^4:L/
MV.43".9*F/ ?5JWM919![HQ5=>=,#&HNVU_VTM5AQ^%=\HI#UCED@7<;*+"\
M999-1EJM0'MK0O,/(=7@3>2X](<RMYIV.?G9R;P]#% ES/E2\I+G3%J8YKER
MTG*YA)D2/.=HX.1/MA!H3D>QI<#>/<Z[(-=MD.R5(&D&#TK:RL"=++#X-T!,
MC'O:V8;V=780\1;S 0S3,\B2;'@ ;]B781CPAJ_@[<OWK^G"6$VR^7M?QBW>
M^7X\WTI7IF$YCB/J%8/Z&:/)K[^DE\GO!]B>]VS/#Z'O'MI'V3:F5_AT05T'
M<[<PO.!,4P[[B!^$WD_\1M4-DVLZ/<OM&DAHV,;.E6Z4;J-_<IJ;@K?-1KMW
M98FAY8[N7*/9"V?P08F"2FS.O.L /N=6+5!#FOAS))'<HF KIO$,'N=3^.T"
MCK>^LXI1GCDZ2PH5QEN<P?W]S4^A3!]N'_KH;?"3[!2FC>8"+H/?)3PQ4]&^
M5?+U^!WS3TPZ?P!O@P#3_T5\ZKRJA-^A6M[;@N"<6,-YP,K@*Y50:4ZAMI9I
MDL QG*2G/\*&>('2 UM#VO(9_L!GZTU_\%0I(=9OU$IB07=Q)Y8@IE<Y^PA'
MOF*;H[^A=M9T6:D\=UH3D!= 5Y2N+5,X,8CPAR*/='B"IZ<#.*#]BU[[%S^K
M_9FFV:2IB#,1[BQ9P-UWQQN:&1;NC.74%T3MT6#I!-SS$O?UP^%P6T!N: B1
MX.D" V:AXL8?$Y4'<F4LT,UH:,;DKG8BA"V0&BCG;7,PXK:[R:FAN ZX0AF#
M9D!GMF-/P1JMGKD/IIY)W;9"P#XEUZ8DJ+N,KX3?901CB8*!D@Y8K<S5D>];
M9U$;.+\X)D(Y9>>ON 6C@N5X]+FDZQZA=%IRZS0&FMAGG"7[G.Z1AB!I*"1!
M'-';&O!2]1/PC:_@EK.IE"8&&Y($93F5C);JS9KP@*#T-JN2HK#%?S'9)Z9X
M9Q+6J)=AWAL(EWL[%/O5_I-BVD[2K7G[/?+ ]))+0_1*<DT&;TDHNIWQ[8M5
M39BK"V5I2H?'BCZ+4'L#VB\52;][\0'Z#ZW)/U!+ P04    " !KB8%8IW-"
M1^$"   8!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q]54MOVS ,
MON=7$&Y1M( 1O_)PFL1 ^MBZ0[<BR;;#L(-B,[%1V_(D.4G__2@Y23,LS<42
M*?+C1TJD1QLN7F6*J&!;Y*4<6ZE2U:WCR#C%@LDVK["DDR47!5,DBI4C*X$L
M,4Y%[OBNVW,*EI56-#*Z%Q&->*WRK,07 ;(N"B;>[C#GF['E67O%-%NE2BN<
M:%2Q%<Y0?:]>!$G. 27)"BQEQDL0N!Q;$^_VKJ/MC<&/##?R: \ZDP7GKUKX
MDHPM5Q/"'&.E$1@M:[S'/-= 1.//#M,ZA-2.Q_L]^B>3.^6R8!+O>?XS2U0Z
MMD(+$ERR.E=3OGG"73Y=C1?S7)HO;!K;P+4@KJ7BQ<Z9&!19V:QLNZO#D4/X
MD8._<_ -[R:08?G %(M&@F] :&M"TQN3JO$F<EFI+V6F!)UFY*>B2<'K4DF8
M8HS9FBURA.NY7N3-R%$40)LY\0[LK@'S/P#S?'CFI4HE/)8))O\".,3L0,_?
MT[OSSR(^8-R&P+/!=_W@#%YP2#<P>,$'>.]I2O@U64@EZ%G\/I5I@],YC:-;
MY596+,:Q1;T@4:S1BJXNO)X[/,.R<V#9.8<>S9H. ;Z$_^_G%-FS<*?)4F6Q
M6* PU3T66KK4NMY^ZS-?HRBI!16L!-,TKK]RA>!U;N 2KBY"W_.'M'B#SI 4
M7F"' _*:S9VGV9Q:-M;^YDV%73OL#R ([5XW;'U3*<6B]JO+Q!PKMH588)+I
M$-X->&['[@<!!'W;ZW5;<ZY8K@,,7+M'C^P2PH'=][HM;7L6C F$I"8=-^JL
MC"D9&@,2:)[!](H5U? !8B[)E@YK07ZP>(/'NA)LFS&8U/J-Y+3;I][D[0WI
M2B0R$:? RH0JN*8!5YE:/6YI9$KJH#:<>@S.4;<6*%9F)DDB01?=-.Y!>QA[
MDZ;;W\V;F?G,Q"HK)>2X)%>WW>]:()HYU B*5Z;W%US1)#';E$8W"FU YTM.
M2>T$'>#P,XC^ E!+ P04    " !KB8%8D8L.8H@$  !#"@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S,2YX;6R-5EUOVS84??>ON'"+(@6(FM^2\F$@:3IL
M0[L%3=<]#'N0)3K6*HFN1#?MO]^AY'A.%R=]L4B)]_"><\^E>7KKNT_]RKE
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M2K11]*_XO6_:!BO:CV65<J%KGN+,(REH5(_HQ>^.PF%P>8!IU#&-#J'']XU
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M&_P] DT&^'VEE-U/*$#SPS7]#U!+ P04    " !KB8%8X/"%+7@#  #T"
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MEJ#U!KR?&T/[B0\P?.@L_@902P,$%     @ :XF!6"#]LHD  P   P<  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULM97?;]LV$,??_5<<U*%( 2'Z
M94EV:AN(DQ4+T&!!TW4/Q1YHZ601I4B-I.SLO]]1LM6T==R][$7BC[LO/\<C
MCXN]TE],C6CAJ1'2++W:VO8J"$Q18\/,I6I1TDRE=,,L=?4V,*U&5O9.C0CB
M,,R"AG'IK1;]V(->+51G!9?XH,%T3</T/VL4:K_T(N\X\(%O:^L&@M6B95M\
M1/M'^Z"I%XPJ)6]0&JXD:*R6WG5TM4Z=?6_PB>/>/&N#BV2CU!?7N2N77NB
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M=;FRCTLE@0I#@/UY6>KNQ2CH[Z"N_@%02P,$%     @ :XF!6,Z\0/,7 P
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M4K)2E@2POC#&/]Z0@O'CTL5_ 5!+ P04    " !KB8%8:PUSZCP$   X"P
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MXI4)RB;@^T+B)K0#NT!W"2=_ %!+ P04    " !KB8%8/C UJ)\"  #1!0
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M,L:%D"QK@M5^EN3U?_*]N1$[ >;DE0"S"3"/#;": .O8 +L)L(\-<)H Y]@
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M2;47Y+ 4#+F+' QF05/(>_M [I("P\_XT?AZ7(5V^\R&>VD) W&Q0H(C44W
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M965T<R]S:&5E=#0Y+GAM;'U4VX[3,!#]%2M(""1HTK2[K$H:J=V"V(>5JJV
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M-Q_*QY_E/B#>^EN4>=W]&SSN;"-EO-C63;G>#U8*UEFQ^S_]LC\11P.(< R
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M@^"(7(N9'T5W;CNYL"$77B2'W0I[$2,/FR2C; %M!,.3R)[C]H[HG1IUPKO
M;V<7->RBMQ476'JFLM%)S8(P#)TC=J=6A_6OV=E[G:X$L3 #0)*$+YFJ6T5S
MVLR8H6FM1^<CG#WUJ/@'4P^N1RKPF4I2P!PAG=L(,R;J85!O%*],/YUQA=W9
M+#.<GR"T =[/.5>[C0[03.3X+U!+ P04    " !KB8%8ZQ@.LP(#    "P
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MLKHKJXD617G=+(4VEU<YW)C/"Y#6P#Q?":$?)_8&:SY8XC]02P,$%     @
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M:W-H965T<R]S:&5E=#8R+GAM;+5876_C-A#\*X1:%'= &XET[#BI;<#Y.#3
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MY F::@ ]GVOM'AO52;7]HV'T'U!+ P04    " !KB8%84'M]!%\#  "T#0
M&0   'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6S-5UUOXS80_"L+%2A:H!=]
MV'%\J6W 22YH@$O/L'OMPZ$/M+2RB*-$E5S9<7]]24J6?84MI$%<Y,42*>YP
M9G=D+4<;J;[J#)'@*1>%'GL947GM^SK.,&?Z0I98F">I5#DC,U0K7Y<*6>*"
M<N%'03#P<\8+;S)R<S,U&<F*!"]PID!7><[4]@:%W(R]T-M-S/DJ(SOA3T8E
M6^$"Z7,Y4V;DMR@)S['07!:@,!U[T_#Z)NS; +?B=XX;?7 /5LI2RJ]V\)",
MO< R0H$Q60AF+FN\12$LDN'Q5P/JM7O:P,/['?J]$V_$+)G&6RG^X EE8V_H
M08(IJP3-Y>87; 1=6KQ8"NU^8=.L#3R(*TTR;X(-@YP7]94]-8DX" @')P*B
M)B!RO.N-',L[1FPR4G(#RJXV:/;&2771AAPO;%46I,Q3;N)H,JT4)XSA(X]-
MJA&F*X5HLD[P#A;& DDE$&0*O\KBW5QNF: M/,H"B?_-7%KGN,:B0IBA,@AD
M*@D_W"$Q+GX<^608VGW\N&%S4[.)3K )(PM.F88/18+)MP"^D=;JBW;Z;J).
MQ#N,+Z 7_@11$/4Z\'IMOGH.KW\";Z:X5$ 2%E4<H]9I)>!6YJ5 EPV3*0:S
MS-@$HB4LJ$JV\.41\R6J/X^EHW,S^T9>ZY+%./;,*Z=1K=&;?/]=. A^[I#2
M;Z7T'7KO5&JXCH74E4)X*. WMJP$4V"]#I]2N$5EBE@<UO63L\&)\K,M6QJK
M?/EH=H$'PEP?%=P_@^#+5O!E=^WV4I[AZ&/L:_RAP[?_=^M)<&%<M3Y":M"2
M&G22FJ:$ZC^X:5D1E,\V8>\9'NSD]\*27+7JK]Z>!Z_.('C8"AZ>V8/#(QZ,
MCGOP?4OJ_6MXL'?,@G-<F9J15%N8EJ62:R::&"63*B8P]:,,X4-5*O;$&=QS
M% FD2N9P?S?=/?Y<F,]08C9@A+K3KIU27EB],-A_+H.W9]B&TRMK/F@1PC-[
MMMG@6].&E\==&T9[8M$S?/N_.[";U4O+L>] PMX;M. Y.I5PWZJ$G8W!:UBP
M?\R"_W*@?]!(YZA6[KB@(995075/W<ZV1Y)IW8COE]?GF4>F5KS0(# UH<'%
ME>D=5'U$J <D2]>6+R69)M_=9N98A<HN,,]3*6DWL!NT![7)/U!+ P04
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MZBSQH.VJ.?$NC,]IJ6X-&K^ZU*)VE6+13(T:[\FW>T_O%6&>OE^$4?TG5%J
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M*,KY0[9[6#V6]Q\6Q5?B^^1B9T!3AZCFHII7:<[)+&+P>GXVBT#3A*@6HII
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MHUJ :B&J"52+4$VBFD(U36G-/E!')"?&L-7WF7F0:;%;5'-1S:NTKID'.6:
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M"U%-H%J$:A+5%*II2FOV@3I"Z)@CA,]]X/GJ7O(ER1:K7?]U_<TC]>X1Z#J
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MEG-9SF,YG^4"E@M93K!<Q'*2Y13+:8QK=07GI"N8GRG\\?D^1+*TED_9_MW
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M%/V,>B@Q@2?Y/^ 7:-&]-/T%6M>]>A9-5X% 'UIWV)<_M29ZIT28_%O5:5D
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MN=J.:Q+/XM$[9%VS06S+,,BPR3 \BT;OR)5.KZK22<C@NR[LE7;'AD+.TSW
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M)5K7.5KG.@"32E!36O3V2:\5"1*]01N]>O)#">A3@;['X^H!%&7EM7;]LGE
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M+*N66STT!X(\@SB3>2]%BK*,=^#= "SDXZ ?@,+0QIYW+..HY8^T_/]D@B2
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M*"\-Y/<+QL3^IGQ \UO(]#]02P,$%     @ :XF!6/DL7(?W P  ?!$  !D
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M1^QU !*3^(VR^/P4H->OWDQ,J7JD=<VP:'V1M^X\T[KMH$=&Y4Z@OVD$45W
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MBP02P@3Y*K4F$\ +M(.=S<!0QL\1_S2?D;/WYR/7H#:[@QO7.B:5CN -'7Y
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M4P%R/:54[ 9J@[K!C_X!4$L#!!0    ( &N)@5@8FY*4400  $0-   9
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;+58VV[;.!#]E8&Z6+1
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MDQV)$R>)-YF&5F8$;@1?,AT?N91HL:5(<93H4;FBB.6(/E;7@JCVP#DYZ.Q
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M!=($X'HF\$ U [-!^_3%_P!02P,$%     @ ;(F!6%TA GEW P  K0X  !D
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MSLZ12;9=KPVTJ&SC6 N-;<@.<_Q1@#0)N+X10C\&IA?UOY[D-U!+ P04
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M8%;P0GI*U[D.&,)(]<?"H>W!+5#KY$P4TL2V$>SO:3U]#]CTP"#CO#'8]>W
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " !KB8%8F5R<(Q &  "<)P  $P
M            @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M &N)@5B?FB$Q/@8  $\=   8              " @0P(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " !KB8%8P!C:>D$&  #N&@  &
M            @(& #@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ :XF!6*:%2$_& @  ]0<  !@              ("!]Q0  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( &N)@5CCS?&C? 4  &L5
M   8              " @?,7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    " !KB8%8@ZSXA3@)  "(7   &               @(&E'0
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ :XF!6!H^!VHA
M!P  9!X  !@              ("!$R<  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( &N)@5A!&S]-/@8  +D/   8              "
M@6HN  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !KB8%8
M.W]M1)T%  #F#0  &               @('>-   >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ :XF!6,,P=4LZ%0  AST  !@
M     ("!L3H  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M &N)@5A7QX) Z (  !H&   9              " @2%0  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ :XF!6+&$=%4)!0  3 L  !D
M             ("!0%,  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    " !KB8%8OQ&:1#0#  #^!@  &0              @(& 6   >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( &N)@5CN^B_H%@,
M (X&   9              " @>M;  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ :XF!6)<47S*+ P  B <  !D              ("!
M.%\  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !KB8%8
MR<]XTFL$  # "0  &0              @('Z8@  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( &N)@5@1KR$+6@8  &<0   9
M      " @9QG  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ :XF!6!G2SG+D!@  -A$  !D              ("!+6X  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !KB8%811QNDXH,  #)(0
M&0              @(%(=0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( &N)@5@?!DK6)P,  (<&   9              " @0F"  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ :XF!6$\/$1N[
M P  MP<  !D              ("!9X4  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    " !KB8%88^ :@H<#  "J!P  &0
M@(%9B0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( &N)
M@5C 5QF@[0H  (P?   9              " @1>-  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ :XF!6"%<AM@G P  Y08  !D
M         ("!.Y@  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    " !KB8%8UV:/DJH*  #L'0  &0              @(&9FP  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( &N)@5@Z(##IB0(  'H%
M   9              " @7JF  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ :XF!6$I?#QNO P  *P@  !D              ("!.JD
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !KB8%8XNH#
MC=\"   9!@  &0              @($@K0  >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( &N)@5@E@?R6;A8  #A(   9
M  " @3:P  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M:XF!6+VM2LD1!   = D  !D              ("!V\8  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    " !KB8%8IW-"1^$"   8!@  &0
M            @($CRP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( &N)@5B1BPYBB 0  $,*   9              " @3O.  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ :XF!6")J%E*L @
MR 4  !D              ("!^M(  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    " !KB8%89ZN?Q/X"  !V!@  &0              @('=
MU0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( &N)@5B6
M/DJ,O0(   $&   9              " @1+9  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ :XF!6#VH)%O( P  ? D  !D
M     ("!!MP  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &N)@5A _Y-OJP,  +P'   9              "
M@6?Q  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ :XF!
M6-HJ]DZO @  X 4  !D              ("!2?4  'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    " !KB8%8G3@&I.D&  !H$@  &0
M        @($O^   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( &N)@5AK#7/J/ 0  #@+   9              " @4__  !X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ :XF!6$+RQ*:+ @  D 4
M !D              ("!P@,! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    " !KB8%8/C UJ)\"  #1!0  &0              @(&$!@$
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( &N)@5@8?1Q+
M< 8  "0R   9              " @5H) 0!X;"]W;W)K<VAE971S+W-H965T
M-#8N>&UL4$L! A0#%     @ :XF!6.;>* C;!   7QT  !D
M ("! 1 ! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " !K
MB8%8K2K[$$@#   O#   &0              @($3%0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( &N)@5C: .W95@(  /P$   9
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M970U,RYX;6Q02P$"% ,4    " !KB8%8ZQ@.LP(#    "P  &0
M    @(&I+ $ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (
M &N)@5B'Z)67] (  +P(   9              " @>(O 0!X;"]W;W)K<VAE
M971S+W-H965T-34N>&UL4$L! A0#%     @ :XF!6&9;[&?3 @  U0D  !D
M             ("!#3,! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"
M% ,4    " !KB8%85ES*R0D#  #]"   &0              @($7-@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( &N)@5A=L!7/[ (
M /<(   9              " @5<Y 0!X;"]W;W)K<VAE971S+W-H965T-3@N
M>&UL4$L! A0#%     @ :XF!6$YIM)W3 @  =@@  !D              ("!
M>CP! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " !KB8%8
M.Y&K1&T"  "1!@  &0              @(&$/P$ >&PO=V]R:W-H965T<R]S
M:&5E=#8P+GAM;%!+ 0(4 Q0    ( &N)@5B+I!' W (  $H(   9
M      " @2A" 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%
M  @ :XF!6,"2@BPF!   .!$  !D              ("!.T4! 'AL+W=O<FMS
M:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " !KB8%8B._2P;D#  !T$
M&0              @(&820$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+
M 0(4 Q0    ( &N)@5A0>WT$7P,  +0-   9              " @8A- 0!X
M;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ :XF!6'#;,CT&
M!@  \C$  !D              ("!'E$! 'AL+W=O<FMS:&5E=',O<VAE970V
M-2YX;6Q02P$"% ,4    " !KB8%8-EMW*(@#  #_"P  &0
M@(%;5P$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( &N)
M@5@BZ7%VA!P  #[: 0 9              " @1I; 0!X;"]W;W)K<VAE971S
M+W-H965T-C<N>&UL4$L! A0#%     @ :XF!6/:!R]/N P  K1   !D
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M=#<R+GAM;%!+ 0(4 Q0    ( &N)@5B?**,4$0,  $$)   9
M  " @=Z6 0!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @
M:XF!6,@):#=Y P  = H  !D              ("!)IH! 'AL+W=O<FMS:&5E
M=',O<VAE970W-"YX;6Q02P$"% ,4    " !KB8%8V>24(Q0%   7&0  &0
M            @('6G0$ >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4
M Q0    ( &N)@5CY+%R']P,  'P1   9              " @2&C 0!X;"]W
M;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ :XF!6(W=KE3J @
M[ H  !D              ("!3Z<! 'AL+W=O<FMS:&5E=',O<VAE970W-RYX
M;6Q02P$"% ,4    " !KB8%8)<)TF/,"  !J!P  &0              @(%P
MJ@$ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( &N)@5CT
M"SD4! ,  .P+   9              " @9JM 0!X;"]W;W)K<VAE971S+W-H
M965T-SDN>&UL4$L! A0#%     @ :XF!6!B;DI11!   1 T  !D
M     ("!U; ! 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &R)@5@@WJ%I] <  ,D_   9              "
M@9#) 0!X;"]W;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @ ;(F!
M6)*L QSH @  $@@  !D              ("!N]$! 'AL+W=O<FMS:&5E=',O
M<VAE970X-BYX;6Q02P$"% ,4    " !LB8%85'S@Q)L#   7#   &0
M        @(':U $ >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4 Q0
M   ( &R)@5BVP;M:JP(   8'   9              " @:S8 0!X;"]W;W)K
M<VAE971S+W-H965T.#@N>&UL4$L! A0#%     @ ;(F!6%TA GEW P  K0X
M !D              ("!CML! 'AL+W=O<FMS:&5E=',O<VAE970X.2YX;6Q0
M2P$"% ,4    " !LB8%8/]GP4H,"  "&!@  &0              @($\WP$
M>&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+ 0(4 Q0    ( &R)@5A#:Y,_
M%P4  %\F   9              " @?;A 0!X;"]W;W)K<VAE971S+W-H965T
M.3$N>&UL4$L! A0#%     @ ;(F!6+GXY\U7 P  L!4   T
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;72YX;6Q02P4&     &, 8P L&P  6_<!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>292</ContextCount>
  <ElementCount>392</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>118</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Operations and Comprehensive loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - Nature of Business and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcern</Role>
      <ShortName>Nature of Business and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Amounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/AmountsReceivable</Role>
      <ShortName>Amounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Right-of-Use Asset</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/RightOfUseAsset</Role>
      <ShortName>Right-of-Use Asset</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Loans Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/LoansPayable</Role>
      <ShortName>Loans Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Lease Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/LeaseLiability</Role>
      <ShortName>Lease Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Auritec License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/AuritecLicenseAgreement</Role>
      <ShortName>Auritec License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Share Capital and Other Components of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquity</Role>
      <ShortName>Share Capital and Other Components of Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - General And Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/GeneralAndAdministrativeExpenses</Role>
      <ShortName>General And Administrative Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Research And Development Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ResearchAndDevelopmentExpenses</Role>
      <ShortName>Research And Development Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Government Grants And Assistance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/GovernmentGrantsAndAssistance</Role>
      <ShortName>Government Grants And Assistance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Interest Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/InterestExpense</Role>
      <ShortName>Interest Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Supplemental Disclosure with Respect to Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlows</Role>
      <ShortName>Supplemental Disclosure with Respect to Cash Flows</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Amounts Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/AmountsReceivableTables</Role>
      <ShortName>Amounts Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eupraxiapharma.com/role/AmountsReceivable</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eupraxiapharma.com/role/PropertyAndEquipment</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Right-of-Use Asset (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/RightOfUseAssetTables</Role>
      <ShortName>Right-of-Use Asset (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eupraxiapharma.com/role/RightOfUseAsset</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Loans Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/LoansPayableTables</Role>
      <ShortName>Loans Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eupraxiapharma.com/role/LoansPayable</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Lease Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/LeaseLiabilityTables</Role>
      <ShortName>Lease Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eupraxiapharma.com/role/LeaseLiability</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Auritec License Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/AuritecLicenseAgreementTables</Role>
      <ShortName>Auritec License Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eupraxiapharma.com/role/AuritecLicenseAgreement</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Convertible Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ConvertibleDebtTables</Role>
      <ShortName>Convertible Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eupraxiapharma.com/role/ConvertibleDebt</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Share Capital and Other Components of Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityTables</Role>
      <ShortName>Share Capital and Other Components of Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquity</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - General And Administrative Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesTables</Role>
      <ShortName>General And Administrative Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eupraxiapharma.com/role/GeneralAndAdministrativeExpenses</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Research And Development Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesTables</Role>
      <ShortName>Research And Development Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eupraxiapharma.com/role/ResearchAndDevelopmentExpenses</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Government Grants And Assistance (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceTables</Role>
      <ShortName>Government Grants And Assistance (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eupraxiapharma.com/role/GovernmentGrantsAndAssistance</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eupraxiapharma.com/role/IncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eupraxiapharma.com/role/FinancialInstruments</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Interest Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/InterestExpenseTables</Role>
      <ShortName>Interest Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eupraxiapharma.com/role/InterestExpense</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Supplemental Disclosure with Respect to Cash Flows (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsTables</Role>
      <ShortName>Supplemental Disclosure with Respect to Cash Flows (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlows</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Nature of Business and Going Concern - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail</Role>
      <ShortName>Nature of Business and Going Concern - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Summary of Significant Accounting Policies - Summary of Information About Subsidiaries (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Information About Subsidiaries (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Summary of Significant Accounting Policies - Summary of Property Plant And Equipment Estimated Useful Life (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Property Plant And Equipment Estimated Useful Life (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Amounts Receivable - Summary of Amounts Receivable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/AmountsReceivableSummaryOfAmountsReceivableDetail</Role>
      <ShortName>Amounts Receivable - Summary of Amounts Receivable (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Property and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/PropertyAndEquipmentAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Right-of-Use Asset - Summary of Right of Use Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/RightOfUseAssetSummaryOfRightOfUseAssetsDetail</Role>
      <ShortName>Right-of-Use Asset - Summary of Right of Use Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Right-of-Use Asset - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/RightOfUseAssetAdditionalInformationDetail</Role>
      <ShortName>Right-of-Use Asset - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail</Role>
      <ShortName>Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Loans Payable - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/LoansPayableAdditionalInformationDetail</Role>
      <ShortName>Loans Payable - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Loans Payable - Summary of Breakdown of Loan Balance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/LoansPayableSummaryOfBreakdownOfLoanBalanceDetail</Role>
      <ShortName>Loans Payable - Summary of Breakdown of Loan Balance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Lease Liability - Summary of Cost Components of The Operating Lease (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfCostComponentsOfTheOperatingLeaseDetail</Role>
      <ShortName>Lease Liability - Summary of Cost Components of The Operating Lease (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Lease Liability - Summary of Future Minimum Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail</Role>
      <ShortName>Lease Liability - Summary of Future Minimum Lease Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Lease Liability - Summary of Lease Liability Balance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail</Role>
      <ShortName>Lease Liability - Summary of Lease Liability Balance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Lease Liability - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/LeaseLiabilityAdditionalInformationDetail</Role>
      <ShortName>Lease Liability - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Auritec License Agreement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail</Role>
      <ShortName>Auritec License Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Auritec License Agreement - Schedule of Milestone Payment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail</Role>
      <ShortName>Auritec License Agreement - Schedule of Milestone Payment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Auritec License Agreement - Schedule of Non-Royalty Monetization Revenue Percentage (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail</Role>
      <ShortName>Auritec License Agreement - Schedule of Non-Royalty Monetization Revenue Percentage (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Convertible Debt - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail</Role>
      <ShortName>Convertible Debt - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Convertible Debt - Schedule of Loan Balance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail</Role>
      <ShortName>Convertible Debt - Schedule of Loan Balance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Share Capital and Other Components of Equity - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail</Role>
      <ShortName>Share Capital and Other Components of Equity - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Share Capital and Other Components of Equity - Summary of Company's Option (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail</Role>
      <ShortName>Share Capital and Other Components of Equity - Summary of Company's Option (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Share Capital and Other Components of Equity - Summary of Options Outstanding Along with the Grant Dates and Expiry Date (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail</Role>
      <ShortName>Share Capital and Other Components of Equity - Summary of Options Outstanding Along with the Grant Dates and Expiry Date (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Share Capital and Other Components of Equity - Summary of Weighted-Average Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail</Role>
      <ShortName>Share Capital and Other Components of Equity - Summary of Weighted-Average Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Share Capital and Other Components of Equity - Summary of Share Based Compensation Arrangements by Share Based Payment Warrant (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail</Role>
      <ShortName>Share Capital and Other Components of Equity - Summary of Share Based Compensation Arrangements by Share Based Payment Warrant (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Share Capital and Other Components of Equity - Summary of Share Based Compensation of Share Warrants Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail</Role>
      <ShortName>Share Capital and Other Components of Equity - Summary of Share Based Compensation of Share Warrants Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Share Capital and Other Components of Equity - Summary of Share Based Compensation of Share Warrants Outstanding (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail</Role>
      <ShortName>Share Capital and Other Components of Equity - Summary of Share Based Compensation of Share Warrants Outstanding (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - General And Administrative Expenses - Schedule Of General And Administrative Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail</Role>
      <ShortName>General And Administrative Expenses - Schedule Of General And Administrative Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure - Research And Development Expenses - Schedule Of Research And Development Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail</Role>
      <ShortName>Research And Development Expenses - Schedule Of Research And Development Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure - Government Grants And Assistance - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceAdditionalInformationDetail</Role>
      <ShortName>Government Grants And Assistance - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure - Government Grants And Assistance - Shedule Of Government Grants And Assistance Received (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail</Role>
      <ShortName>Government Grants And Assistance - Shedule Of Government Grants And Assistance Received (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure - Income Taxes - Schedule of Components Included in Loss Before Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsIncludedInLossBeforeTaxesDetail</Role>
      <ShortName>Income Taxes - Schedule of Components Included in Loss Before Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1079 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail</Role>
      <ShortName>Income Taxes - Schedule of Income Tax Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1080 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense Benefit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail</Role>
      <ShortName>Income Taxes - Schedule of Components of Income Tax Expense Benefit (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>1081 - Disclosure - Income Taxes - Schedule of Components of Company's Net Deferred Income Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Schedule of Components of Company's Net Deferred Income Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>1082 - Disclosure - Income Taxes - Schedule of Non Capital Losses Carry Forward Future Years (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail</Role>
      <ShortName>Income Taxes - Schedule of Non Capital Losses Carry Forward Future Years (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>1083 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>1084 - Disclosure - Commitments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/CommitmentsAdditionalInformationDetail</Role>
      <ShortName>Commitments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>1085 - Disclosure - Financial Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Financial Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>1086 - Disclosure - Financial Instruments - Summary of Carrying Value of Financial Instruments at Amortized Cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfCarryingValueOfFinancialInstrumentsAtAmortizedCostDetail</Role>
      <ShortName>Financial Instruments - Summary of Carrying Value of Financial Instruments at Amortized Cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>1087 - Disclosure - Financial Instruments - Summary of Changes in Fair Value of Liabilities Measured at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail</Role>
      <ShortName>Financial Instruments - Summary of Changes in Fair Value of Liabilities Measured at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>1088 - Disclosure - Interest Expense - Schedule of Interest Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/InterestExpenseScheduleOfInterestExpenseDetail</Role>
      <ShortName>Interest Expense - Schedule of Interest Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>1089 - Disclosure - Supplemental Disclosure with Respect to Cash Flows - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail</Role>
      <ShortName>Supplemental Disclosure with Respect to Cash Flows - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>1090 - Disclosure - Supplemental Disclosure with Respect to Cash Flows - Summary of Detailed Breakdown of Cash And Cash Equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsSummaryOfDetailedBreakdownOfCashAndCashEquivalentsDetail</Role>
      <ShortName>Supplemental Disclosure with Respect to Cash Flows - Summary of Detailed Breakdown of Cash And Cash Equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="d800041d40f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>1091 - Disclosure - Subsequent Event - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail</Role>
      <ShortName>Subsequent Event - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince, us-gaap:CommonStockNoParValue -  d800041d40f.htm 7, d800041dex992.htm 7</Log>
  </Logs>
  <InputFiles>
    <File doctype="40-F" isDefinitelyFs="true" isUsgaap="true" original="d800041d40f.htm">d800041d40f.htm</File>
    <File doctype="40-F" isDefinitelyFs="true" isUsgaap="true" original="d800041dex992.htm">d800041dex992.htm</File>
    <File>eprx-20231231.xsd</File>
    <File>eprx-20231231_cal.xml</File>
    <File>eprx-20231231_def.xml</File>
    <File>eprx-20231231_lab.xml</File>
    <File>eprx-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g800041g07j01.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="725">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="59">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>121
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d800041d40f.htm d800041dex992.htm": {
   "nsprefix": "eprx",
   "nsuri": "http://eupraxiapharma.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "d800041d40f.htm",
      "d800041dex992.htm"
     ]
    },
    "schema": {
     "local": [
      "eprx-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "eprx-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "eprx-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "eprx-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eprx-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 291,
   "keyCustom": 101,
   "axisStandard": 27,
   "axisCustom": 11,
   "memberStandard": 34,
   "memberCustom": 83,
   "hidden": {
    "total": 12,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://fasb.org/us-gaap/2023": 8
   },
   "contextCount": 292,
   "entityCount": 1,
   "segmentCount": 118,
   "elementCount": 699,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 725,
    "http://xbrl.sec.gov/dei/2023": 59
   },
   "report": {
    "R1": {
     "role": "http://eupraxiapharma.com/role/CoverPage",
     "longName": "1001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041d40f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041d40f.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets",
     "longName": "1002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://eupraxiapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "1004 - Statement - Consolidated Statements of Operations and Comprehensive loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
     "longName": "1005 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Deficit)",
     "shortName": "Consolidated Statements of Changes in Shareholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "1006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:InterestOnConvertibleDebtOne",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcern",
     "longName": "1007 - Disclosure - Nature of Business and Going Concern",
     "shortName": "Nature of Business and Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://eupraxiapharma.com/role/BasisOfPresentation",
     "longName": "1008 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "1009 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://eupraxiapharma.com/role/AmountsReceivable",
     "longName": "1010 - Disclosure - Amounts Receivable",
     "shortName": "Amounts Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://eupraxiapharma.com/role/PropertyAndEquipment",
     "longName": "1011 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://eupraxiapharma.com/role/RightOfUseAsset",
     "longName": "1012 - Disclosure - Right-of-Use Asset",
     "shortName": "Right-of-Use Asset",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:RightOfUseAssetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:RightOfUseAssetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilities",
     "longName": "1013 - Disclosure - Accounts Payable and Accrued Liabilities",
     "shortName": "Accounts Payable and Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://eupraxiapharma.com/role/LoansPayable",
     "longName": "1014 - Disclosure - Loans Payable",
     "shortName": "Loans Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:DisclosureInEntiretyOfOtherLoansPayable",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:DisclosureInEntiretyOfOtherLoansPayable",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://eupraxiapharma.com/role/LeaseLiability",
     "longName": "1015 - Disclosure - Lease Liability",
     "shortName": "Lease Liability",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://eupraxiapharma.com/role/AuritecLicenseAgreement",
     "longName": "1016 - Disclosure - Auritec License Agreement",
     "shortName": "Auritec License Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:DisclosureInEntiretyOfLicenseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:DisclosureInEntiretyOfLicenseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://eupraxiapharma.com/role/ConvertibleDebt",
     "longName": "1017 - Disclosure - Convertible Debt",
     "shortName": "Convertible Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquity",
     "longName": "1018 - Disclosure - Share Capital and Other Components of Equity",
     "shortName": "Share Capital and Other Components of Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpenses",
     "longName": "1019 - Disclosure - General And Administrative Expenses",
     "shortName": "General And Administrative Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpenses",
     "longName": "1020 - Disclosure - Research And Development Expenses",
     "shortName": "Research And Development Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistance",
     "longName": "1021 - Disclosure - Government Grants And Assistance",
     "shortName": "Government Grants And Assistance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:GovernmentAssistanceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:GovernmentAssistanceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://eupraxiapharma.com/role/IncomeTaxes",
     "longName": "1022 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://eupraxiapharma.com/role/Commitments",
     "longName": "1023 - Disclosure - Commitments",
     "shortName": "Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://eupraxiapharma.com/role/FinancialInstruments",
     "longName": "1024 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://eupraxiapharma.com/role/InterestExpense",
     "longName": "1025 - Disclosure - Interest Expense",
     "shortName": "Interest Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlows",
     "longName": "1026 - Disclosure - Supplemental Disclosure with Respect to Cash Flows",
     "shortName": "Supplemental Disclosure with Respect to Cash Flows",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://eupraxiapharma.com/role/SubsequentEvent",
     "longName": "1027 - Disclosure - Subsequent Event",
     "shortName": "Subsequent Event",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "1028 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "1029 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:ScheduleOfInformationAboutSubsidiariesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ConsolidationPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:ScheduleOfInformationAboutSubsidiariesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ConsolidationPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://eupraxiapharma.com/role/AmountsReceivableTables",
     "longName": "1030 - Disclosure - Amounts Receivable (Tables)",
     "shortName": "Amounts Receivable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:NontradeReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:NontradeReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://eupraxiapharma.com/role/PropertyAndEquipmentTables",
     "longName": "1031 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://eupraxiapharma.com/role/RightOfUseAssetTables",
     "longName": "1032 - Disclosure - Right-of-Use Asset (Tables)",
     "shortName": "Right-of-Use Asset (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:OperatingLeaseRightOfUseAssetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "eprx:RightOfUseAssetTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:OperatingLeaseRightOfUseAssetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "eprx:RightOfUseAssetTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesTables",
     "longName": "1033 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)",
     "shortName": "Accounts Payable and Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://eupraxiapharma.com/role/LoansPayableTables",
     "longName": "1034 - Disclosure - Loans Payable (Tables)",
     "shortName": "Loans Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "eprx:DisclosureInEntiretyOfOtherLoansPayable",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "eprx:DisclosureInEntiretyOfOtherLoansPayable",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://eupraxiapharma.com/role/LeaseLiabilityTables",
     "longName": "1035 - Disclosure - Lease Liability (Tables)",
     "shortName": "Lease Liability (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://eupraxiapharma.com/role/AuritecLicenseAgreementTables",
     "longName": "1036 - Disclosure - Auritec License Agreement (Tables)",
     "shortName": "Auritec License Agreement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "eprx:DisclosureInEntiretyOfLicenseAgreementTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "eprx:DisclosureInEntiretyOfLicenseAgreementTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://eupraxiapharma.com/role/ConvertibleDebtTables",
     "longName": "1037 - Disclosure - Convertible Debt (Tables)",
     "shortName": "Convertible Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_LoanMemberdeiLegalEntityAxis",
      "name": "eprx:DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_LoanMemberdeiLegalEntityAxis",
      "name": "eprx:DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityTables",
     "longName": "1038 - Disclosure - Share Capital and Other Components of Equity (Tables)",
     "shortName": "Share Capital and Other Components of Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesTables",
     "longName": "1039 - Disclosure - General And Administrative Expenses (Tables)",
     "shortName": "General And Administrative Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "eprx:DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "eprx:DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesTables",
     "longName": "1040 - Disclosure - Research And Development Expenses (Tables)",
     "shortName": "Research And Development Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceTables",
     "longName": "1041 - Disclosure - Government Grants And Assistance (Tables)",
     "shortName": "Government Grants And Assistance (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:GovernmentAssistanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GovernmentAssistanceTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:GovernmentAssistanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GovernmentAssistanceTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://eupraxiapharma.com/role/IncomeTaxesTables",
     "longName": "1042 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://eupraxiapharma.com/role/FinancialInstrumentsTables",
     "longName": "1043 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://eupraxiapharma.com/role/InterestExpenseTables",
     "longName": "1044 - Disclosure - Interest Expense (Tables)",
     "shortName": "Interest Expense (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsTables",
     "longName": "1045 - Disclosure - Supplemental Disclosure with Respect to Cash Flows (Tables)",
     "shortName": "Supplemental Disclosure with Respect to Cash Flows (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail",
     "longName": "1046 - Disclosure - Nature of Business and Going Concern - Additional Information (Detail)",
     "shortName": "Nature of Business and Going Concern - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail",
     "longName": "1047 - Disclosure - Summary of Significant Accounting Policies - Summary of Information About Subsidiaries (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Information About Subsidiaries (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_EupraxiaHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "eprx:ScheduleOfInformationAboutSubsidiariesTableTextBlock",
       "us-gaap:ConsolidationPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail",
     "longName": "1048 - Disclosure - Summary of Significant Accounting Policies - Summary of Property Plant And Equipment Estimated Useful Life (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Property Plant And Equipment Estimated Useful Life (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "name": "eprx:PropertyPlantAndEqupmentRateOfDepreciation",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "name": "eprx:PropertyPlantAndEqupmentRateOfDepreciation",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "1049 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://eupraxiapharma.com/role/AmountsReceivableSummaryOfAmountsReceivableDetail",
     "longName": "1050 - Disclosure - Amounts Receivable - Summary of Amounts Receivable (Detail)",
     "shortName": "Amounts Receivable - Summary of Amounts Receivable (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:GrantsReceivableCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "eprx:NontradeReceivablesTableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:GovernmentAssistanceAmountCumulativeCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "eprx:NontradeReceivablesTableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail",
     "longName": "1051 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)",
     "shortName": "Property and Equipment - Summary of Property and Equipment (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2021",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://eupraxiapharma.com/role/PropertyAndEquipmentAdditionalInformationDetail",
     "longName": "1052 - Disclosure - Property and Equipment - Additional Information (Detail)",
     "shortName": "Property and Equipment - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis",
      "name": "us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://eupraxiapharma.com/role/RightOfUseAssetSummaryOfRightOfUseAssetsDetail",
     "longName": "1053 - Disclosure - Right-of-Use Asset - Summary of Right of Use Assets (Detail)",
     "shortName": "Right-of-Use Asset - Summary of Right of Use Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2021",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "eprx:OperatingLeaseRightOfUseAssetTableTextBlock",
       "eprx:RightOfUseAssetTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://eupraxiapharma.com/role/RightOfUseAssetAdditionalInformationDetail",
     "longName": "1054 - Disclosure - Right-of-Use Asset - Additional Information (Detail)",
     "shortName": "Right-of-Use Asset - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "eprx:OperatingLeaseRightOfUseAssetTableTextBlock",
       "eprx:RightOfUseAssetTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis",
      "name": "us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "eprx:RightOfUseAssetTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail",
     "longName": "1055 - Disclosure - Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Detail)",
     "shortName": "Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "eprx:AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "eprx:AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://eupraxiapharma.com/role/LoansPayableAdditionalInformationDetail",
     "longName": "1056 - Disclosure - Loans Payable - Additional Information (Detail)",
     "shortName": "Loans Payable - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "PAsOn09_10_2021_LoansPayableMemberusgaapLongtermDebtTypeAxis",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "eprx:DisclosureInEntiretyOfOtherLoansPayable",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_10_2021_LoansPayableMemberusgaapLongtermDebtTypeAxis",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "eprx:DisclosureInEntiretyOfOtherLoansPayable",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://eupraxiapharma.com/role/LoansPayableSummaryOfBreakdownOfLoanBalanceDetail",
     "longName": "1057 - Disclosure - Loans Payable - Summary of Breakdown of Loan Balance (Detail)",
     "shortName": "Loans Payable - Summary of Breakdown of Loan Balance (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:LoansPayable",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "eprx:DisclosureInEntiretyOfOtherLoansPayable",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2021",
      "name": "us-gaap:LoansPayable",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "eprx:DisclosureInEntiretyOfOtherLoansPayable",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfCostComponentsOfTheOperatingLeaseDetail",
     "longName": "1058 - Disclosure - Lease Liability - Summary of Cost Components of The Operating Lease (Detail)",
     "shortName": "Lease Liability - Summary of Cost Components of The Operating Lease (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail",
     "longName": "1059 - Disclosure - Lease Liability - Summary of Future Minimum Lease Payments (Detail)",
     "shortName": "Lease Liability - Summary of Future Minimum Lease Payments (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail",
     "longName": "1060 - Disclosure - Lease Liability - Summary of Lease Liability Balance (Detail)",
     "shortName": "Lease Liability - Summary of Lease Liability Balance (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R61": {
     "role": "http://eupraxiapharma.com/role/LeaseLiabilityAdditionalInformationDetail",
     "longName": "1061 - Disclosure - Lease Liability - Additional information (Detail)",
     "shortName": "Lease Liability - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "Unit_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "Unit_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail",
     "longName": "1062 - Disclosure - Auritec License Agreement - Additional Information (Detail)",
     "shortName": "Auritec License Agreement - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis",
      "name": "eprx:PaymentOfUpfrontFees",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "eprx:DisclosureInEntiretyOfLicenseAgreementTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis",
      "name": "eprx:PaymentOfUpfrontFees",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "eprx:DisclosureInEntiretyOfLicenseAgreementTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail",
     "longName": "1063 - Disclosure - Auritec License Agreement - Schedule of Milestone Payment (Detail)",
     "shortName": "Auritec License Agreement - Schedule of Milestone Payment (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis",
      "name": "eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "eprx:DisclosureInEntiretyOfLicenseAgreementTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_FirstOaRegulatoryApprovalMemberEPRXMilestoneAxis_MaximumMembersrtRangeAxis",
      "name": "eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "eprx:DisclosureInEntiretyOfLicenseAgreementTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail",
     "longName": "1064 - Disclosure - Auritec License Agreement - Schedule of Non-Royalty Monetization Revenue Percentage (Detail)",
     "shortName": "Auritec License Agreement - Schedule of Non-Royalty Monetization Revenue Percentage (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_PriorToSuccessfulCompletionOfPhaseTwoBStudyMemberEPRXTrancheAxis",
      "name": "eprx:PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_PriorToSuccessfulCompletionOfPhaseTwoBStudyMemberEPRXTrancheAxis",
      "name": "eprx:PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail",
     "longName": "1065 - Disclosure - Convertible Debt - Additional information (Detail)",
     "shortName": "Convertible Debt - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "PAsOn06_21_2021_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_CAD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P06_21_2021To06_21_2021_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "unitRef": "Unit_CAD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:DebtInstrumentFaceAmount",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail",
     "longName": "1066 - Disclosure - Convertible Debt - Schedule of Loan Balance (Detail)",
     "shortName": "Convertible Debt - Schedule of Loan Balance (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2021_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "eprx:DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
     "longName": "1067 - Disclosure - Share Capital and Other Components of Equity - Additional information (Detail)",
     "shortName": "Share Capital and Other Components of Equity - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:PreferredStockNoParValue",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:PreferredStockNoParValue",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail",
     "longName": "1068 - Disclosure - Share Capital and Other Components of Equity - Summary of Company's Option (Detail)",
     "shortName": "Share Capital and Other Components of Equity - Summary of Company's Option (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail",
     "longName": "1069 - Disclosure - Share Capital and Other Components of Equity - Summary of Options Outstanding Along with the Grant Dates and Expiry Date (Detail)",
     "shortName": "Share Capital and Other Components of Equity - Summary of Options Outstanding Along with the Grant Dates and Expiry Date (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "eprx:DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail",
     "longName": "1070 - Disclosure - Share Capital and Other Components of Equity - Summary of Weighted-Average Assumptions (Detail)",
     "shortName": "Share Capital and Other Components of Equity - Summary of Weighted-Average Assumptions (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail",
     "longName": "1071 - Disclosure - Share Capital and Other Components of Equity - Summary of Share Based Compensation Arrangements by Share Based Payment Warrant (Detail)",
     "shortName": "Share Capital and Other Components of Equity - Summary of Share Based Compensation Arrangements by Share Based Payment Warrant (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "eprx:ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2021_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "eprx:ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail",
     "longName": "1072 - Disclosure - Share Capital and Other Components of Equity - Summary of Share Based Compensation of Share Warrants Outstanding (Detail)",
     "shortName": "Share Capital and Other Components of Equity - Summary of Share Based Compensation of Share Warrants Outstanding (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice",
      "unitRef": "Unit_CAD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "eprx:ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_ExpiryPeriodOneMemberEPRXMaturityPeriodWarrantsAxis",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "eprx:ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail",
     "longName": "1073 - Disclosure - Share Capital and Other Components of Equity - Summary of Share Based Compensation of Share Warrants Outstanding (Parenthetical) (Detail)",
     "shortName": "Share Capital and Other Components of Equity - Summary of Share Based Compensation of Share Warrants Outstanding (Parenthetical) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "eprx:ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "eprx:ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail",
     "longName": "1074 - Disclosure - General And Administrative Expenses - Schedule Of General And Administrative Expenses (Detail)",
     "shortName": "General And Administrative Expenses - Schedule Of General And Administrative Expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OtherGeneralAndAdministrativeExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "eprx:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
       "eprx:DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OtherGeneralAndAdministrativeExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "eprx:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
       "eprx:DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail",
     "longName": "1075 - Disclosure - Research And Development Expenses - Schedule Of Research And Development Expenses (Detail)",
     "shortName": "Research And Development Expenses - Schedule Of Research And Development Expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "eprx:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "eprx:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceAdditionalInformationDetail",
     "longName": "1076 - Disclosure - Government Grants And Assistance - Additional Information (Detail)",
     "shortName": "Government Grants And Assistance - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:GovernmentAssistanceAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "eprx:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:GovernmentAssistanceAmountForResearchAndDevelopment",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:GovernmentAssistanceTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail",
     "longName": "1077 - Disclosure - Government Grants And Assistance - Shedule Of Government Grants And Assistance Received (Detail)",
     "shortName": "Government Grants And Assistance - Shedule Of Government Grants And Assistance Received (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:GovernmentAssistanceAmountCumulative",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "eprx:GovernmentAssistanceTableTextBlock",
       "us-gaap:GovernmentAssistanceTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:GovernmentAssistanceAmountCumulative",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "eprx:GovernmentAssistanceTableTextBlock",
       "us-gaap:GovernmentAssistanceTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsIncludedInLossBeforeTaxesDetail",
     "longName": "1078 - Disclosure - Income Taxes - Schedule of Components Included in Loss Before Taxes (Detail)",
     "shortName": "Income Taxes - Schedule of Components Included in Loss Before Taxes (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail",
     "longName": "1079 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Detail)",
     "shortName": "Income Taxes - Schedule of Income Tax Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail",
     "longName": "1080 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense Benefit (Detail)",
     "shortName": "Income Taxes - Schedule of Components of Income Tax Expense Benefit (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail",
     "longName": "1081 - Disclosure - Income Taxes - Schedule of Components of Company's Net Deferred Income Tax Assets (Detail)",
     "shortName": "Income Taxes - Schedule of Components of Company's Net Deferred Income Tax Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "eprx:DeferredTaxAssetsConvertibleDebt",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "eprx:DeferredTaxAssetsConvertibleDebt",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail",
     "longName": "1082 - Disclosure - Income Taxes - Schedule of Non Capital Losses Carry Forward Future Years (Detail)",
     "shortName": "Income Taxes - Schedule of Non Capital Losses Carry Forward Future Years (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023_CAsrtStatementGeographicalAxis",
      "name": "eprx:NonCapitalLossCarryforwardsToFutureExpire",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_CAsrtStatementGeographicalAxis",
      "name": "eprx:NonCapitalLossCarryforwardsToFutureExpire",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail",
     "longName": "1083 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://eupraxiapharma.com/role/CommitmentsAdditionalInformationDetail",
     "longName": "1084 - Disclosure - Commitments - Additional Information (Detail)",
     "shortName": "Commitments - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:CancellationFeeForCancellationOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "eprx:CancellationFeeForCancellationOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail",
     "longName": "1085 - Disclosure - Financial Instruments - Additional Information (Detail)",
     "shortName": "Financial Instruments - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfCarryingValueOfFinancialInstrumentsAtAmortizedCostDetail",
     "longName": "1086 - Disclosure - Financial Instruments - Summary of Carrying Value of Financial Instruments at Amortized Cost (Detail)",
     "shortName": "Financial Instruments - Summary of Carrying Value of Financial Instruments at Amortized Cost (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "eprx:AccountsPayableAndAccruedLiability",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "eprx:ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail",
     "longName": "1087 - Disclosure - Financial Instruments - Summary of Changes in Fair Value of Liabilities Measured at Fair Value (Detail)",
     "shortName": "Financial Instruments - Summary of Changes in Fair Value of Liabilities Measured at Fair Value (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://eupraxiapharma.com/role/InterestExpenseScheduleOfInterestExpenseDetail",
     "longName": "1088 - Disclosure - Interest Expense - Schedule of Interest Expense (Detail)",
     "shortName": "Interest Expense - Schedule of Interest Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail",
     "longName": "1089 - Disclosure - Supplemental Disclosure with Respect to Cash Flows - Additional Information (Detail)",
     "shortName": "Supplemental Disclosure with Respect to Cash Flows - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsSummaryOfDetailedBreakdownOfCashAndCashEquivalentsDetail",
     "longName": "1090 - Disclosure - Supplemental Disclosure with Respect to Cash Flows - Summary of Detailed Breakdown of Cash And Cash Equivalents (Detail)",
     "shortName": "Supplemental Disclosure with Respect to Cash Flows - Summary of Detailed Breakdown of Cash And Cash Equivalents (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:Cash",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail",
     "longName": "1091 - Disclosure - Subsequent Event - Additional Information (Detail)",
     "shortName": "Subsequent Event - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P03_15_2024To03_15_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d800041dex992.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "country_AU": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "AU",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA",
        "terseLabel": "Australia"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      },
      "http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail",
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Total",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Current General and Administration",
        "terseLabel": "General and administrative",
        "documentation": "Accounts payable and accrued liabilities current general and administration."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Current Research and Development",
        "terseLabel": "Research and development",
        "documentation": "Accounts payable and accrued liabilities current research and development."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_AccountsPayableAndAccruedLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AccountsPayableAndAccruedLiability",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfCarryingValueOfFinancialInstrumentsAtAmortizedCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liability",
        "terseLabel": "Accounts payable and accrued liabilities",
        "documentation": "Accounts payable and accrued liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r605"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Employee bonus payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedPayrollTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Payroll Taxes, Current",
        "terseLabel": "Wages and payroll remittances",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "eprx_AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation Depletion And Amortization Foreign Currency Translation Adjustments",
        "terseLabel": "Foreign currency adjustments",
        "documentation": "Accumulated depreciation depletion and amortization foreign currency translation adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r164",
      "r451"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment [Abstract]",
        "terseLabel": "Accumulated Depreciation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Sale or Disposal of Property, Plant and Equipment",
        "negatedLabel": "Disposals",
        "documentation": "Amount of decrease in accumulated depreciation, depletion and amortization as a result of sale or disposal of property, plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r88",
      "r169",
      "r446",
      "r465",
      "r466"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13",
      "r36",
      "r378",
      "r381",
      "r427",
      "r461",
      "r462",
      "r632",
      "r633",
      "r634",
      "r642",
      "r643",
      "r644"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional\u00a0paid-in\u00a0capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r477",
      "r642",
      "r643",
      "r644",
      "r693",
      "r722"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Items not affecting cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based payments",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r302"
     ]
    },
    "eprx_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "After Eighteen Months From The Date Of The Debt Agreement [Member]",
        "documentation": "After eighteen months from the date of the debt agreement."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "After Regulatory Approval Of The Product From FDA In The United States [Member]",
        "terseLabel": "After Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States [Member]",
        "documentation": "After Regulatory Approval Of The Product From FDA In The United States."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "After Successful Completion Of Phase Three Study But Prior To Regulatory Approval Of The Product From FDA In The United Status [Member]",
        "terseLabel": "After Successful Completion of a Phase 3 Study but prior to Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States [Member]",
        "documentation": "After Successful Completion Of Phase Three Study But Prior To Regulatory Approval Of The Product From FDA In The United Status."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "After Successful Completion Of Phase Two B Study But Prior To Successful Completion Of Phase Three Study [Member]",
        "terseLabel": "After Successful Completion of a Phase 2b Study but prior to Successful Completion of a Phase 3 Study [Member]",
        "documentation": "After Successful Completion Of Phase Two B Study But Prior To Successful Completion Of Phase Three Study."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_AggegateAmountRaisedByWayOfEquityIssue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AggegateAmountRaisedByWayOfEquityIssue",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggegate Amount Raised By Way Of Equity Issue",
        "terseLabel": "Aggregate amount raised by way of equity issue",
        "documentation": "Aggegate amount raised by way of equity issue."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_AgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AgreementAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement [Axis]",
        "documentation": "Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_AgreementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AgreementDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement [Domain]",
        "documentation": "Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Allocated share based compensation",
        "verboseLabel": "Share based payments (Note 12(c))",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r342"
     ]
    },
    "eprx_AmdmHoldingsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AmdmHoldingsAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AMDM Holdings [Axis]",
        "documentation": "AMDM Holdings."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_AmdmHoldingsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AmdmHoldingsDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AMDM Holdings [Domain]",
        "documentation": "AMDM Holdings."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_AmdmHoldingsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AmdmHoldingsIncMember",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AMDM Holdings Inc [Member]",
        "terseLabel": "AMDM Holdings Inc. [Member]",
        "documentation": "Amdm holdings inc member."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_AmdmHoldingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AmdmHoldingsMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AMDM Holdings [Member]",
        "documentation": "AMDM Holdings"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_AmendedAndRestatedLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AmendedAndRestatedLicenseAgreementMember",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended And Restated License Agreement [Member]",
        "terseLabel": "Amended and Restated License Agreement [Member]",
        "documentation": "Amended And Restated License Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_AmendedPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AmendedPlanMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended Plan [Member]",
        "documentation": "Amended Plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_AmountToBeRaisedByWayOfEquityIssue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AmountToBeRaisedByWayOfEquityIssue",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount To Be Raised By Way Of Equity Issue",
        "terseLabel": "Amount to be raised by way of equity issue",
        "documentation": "Amount to be raised by way of equity issue."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of real estate",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_AreaOfSubleasedOfficeSpace": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "AreaOfSubleasedOfficeSpace",
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area Of Subleased Office Space",
        "terseLabel": "Area of subleased office space",
        "documentation": "Area of subleased office space."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ArithmeticAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ArithmeticAverageMember",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arithmetic Average [Member]"
       }
      }
     },
     "auth_ref": [
      "r387",
      "r437"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r165",
      "r191",
      "r223",
      "r231",
      "r235",
      "r244",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r371",
      "r375",
      "r389",
      "r443",
      "r516",
      "r605",
      "r617",
      "r651",
      "r652",
      "r705"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r171",
      "r191",
      "r244",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r371",
      "r375",
      "r389",
      "r605",
      "r651",
      "r652",
      "r705"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r620",
      "r621",
      "r622"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r620",
      "r621",
      "r622"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r620",
      "r621",
      "r622"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ]
    },
    "us-gaap_BasisOfAccounting": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccounting",
     "presentation": [
      "http://eupraxiapharma.com/role/BasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Measurement",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_BioTalentCanadaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "BioTalentCanadaMember",
     "presentation": [
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bio Talent Canada [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r622"
     ]
    },
    "country_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CA",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada"
       }
      }
     },
     "auth_ref": []
    },
    "currency_CAD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "CAD",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada, Dollars",
        "terseLabel": "Canada, Dollars [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_CallRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "CallRightAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Call Right [Axis]",
        "documentation": "Call right."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_CallRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "CallRightDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Call Right [Domain]",
        "documentation": "Call right."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CanadaRevenueAgencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CanadaRevenueAgencyMember",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada Revenue Agency [Member]",
        "terseLabel": "Canada Revenue Agency [Member]",
        "documentation": "Designated tax department of the government of Canada."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_CanadianFederalInvestmentTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "CanadianFederalInvestmentTaxCreditsMember",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canadian Federal Investment Tax Credits [Member]",
        "terseLabel": "Canadian Federal Investment Tax Credits [Member]",
        "documentation": "Canadian federal investment tax credits."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_CanadianPrimeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "CanadianPrimeRateMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canadian Prime Rate [Member]",
        "terseLabel": "Canadian Prime Rate [Member]",
        "documentation": "Canadian prime rate."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_CancellationFeeForCancellationOfContract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "CancellationFeeForCancellationOfContract",
     "presentation": [
      "http://eupraxiapharma.com/role/CommitmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancellation fee for Cancellation of Contract",
        "terseLabel": "Cancellation of contracts that would lead to cancellation fee",
        "documentation": "Cancellation of contracts that would lead to cancellation fee."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_CancellationFeeOnTerminationOfContract": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "CancellationFeeOnTerminationOfContract",
     "presentation": [
      "http://eupraxiapharma.com/role/CommitmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancellation Fee on Termination of Contract",
        "terseLabel": "Cancellation fee for termination of contract",
        "documentation": "Cancellation fee on termination of contract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsSummaryOfDetailedBreakdownOfCashAndCashEquivalentsDetail": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsSummaryOfDetailedBreakdownOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Cash on hand",
        "verboseLabel": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r444",
      "r488",
      "r511",
      "r605",
      "r617",
      "r629"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsSummaryOfDetailedBreakdownOfCashAndCashEquivalentsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets",
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfCarryingValueOfFinancialInstrumentsAtAmortizedCostDetail",
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsSummaryOfDetailedBreakdownOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents",
        "terseLabel": "The amount of cash and cash equivalents",
        "totalLabel": "Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r162",
      "r579"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r101",
      "r189"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Increase in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r101"
     ]
    },
    "eprx_CashCostsOfIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "CashCostsOfIssuingShares",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Costs Of Issuing Shares",
        "terseLabel": "Cash costs of issuing shares",
        "documentation": "Cash Costs Of Issuing Shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsSummaryOfDetailedBreakdownOfCashAndCashEquivalentsDetail": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsSummaryOfDetailedBreakdownOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r629",
      "r715"
     ]
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "Supplemental Disclosure with Respect to Cash Flows",
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "eprx_ChiefScientificOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ChiefScientificOfficerMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Scientific Officer [Member]",
        "documentation": "Chief Scientific Officer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ClassBNonVotingStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ClassBNonVotingStockMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class B Non Voting Stock [Member]",
        "documentation": "Class B Non Voting Stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r166",
      "r167",
      "r168",
      "r191",
      "r213",
      "r214",
      "r216",
      "r218",
      "r221",
      "r222",
      "r244",
      "r256",
      "r258",
      "r259",
      "r260",
      "r263",
      "r264",
      "r283",
      "r284",
      "r286",
      "r287",
      "r289",
      "r389",
      "r469",
      "r470",
      "r471",
      "r472",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r503",
      "r526",
      "r546",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r626",
      "r638",
      "r645"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r221",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r469",
      "r470",
      "r471",
      "r472",
      "r594",
      "r626",
      "r638"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Class of warrants exercise price per share",
        "verboseLabel": "Class of warrants or rights exercise price of warrants or rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Class of warrant or right number of securities called by each warrant or right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Class of warrants or rights number of shares covered by warrants or rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "eprx_ClinicalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ClinicalMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical [Member]",
        "terseLabel": "Clinicall [Member]",
        "documentation": "Clinical."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/Commitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "Commitments",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_CommonStockConversionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockConversionBasis",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Conversion Basis",
        "terseLabel": "Common stock conversion basis",
        "documentation": "Description of basis for conversion of convertible common stock."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "verboseLabel": "Common stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r608",
      "r609",
      "r611",
      "r612",
      "r613",
      "r614",
      "r642",
      "r643",
      "r693",
      "r717",
      "r722"
     ]
    },
    "us-gaap_CommonStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockNoParValue",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, No Par Value",
        "verboseLabel": "Common stock no par value",
        "terseLabel": "Common stock par no par value",
        "documentation": "Face amount per share of no-par value common stock."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_CommonStockSharesAuthorizedUnlimited": {
     "xbrltype": "authorizedUnlimitedItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorizedUnlimited",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized, Unlimited [Fixed List]",
        "verboseLabel": "Common stock unlimited shares authorized",
        "terseLabel": "Common stock shares authorized unlimited",
        "documentation": "Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is \"Unlimited\"."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "eprx_CommonStockSharesIssuableAsAResultOfStockSplit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "CommonStockSharesIssuableAsAResultOfStockSplit",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Shares Issuable As A Result Of Stock Split",
        "terseLabel": "Common stock shares issuable as a result of stock split",
        "documentation": "Common Stock Shares Issuable As A Result Of Stock Split."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r82",
      "r503",
      "r522",
      "r722",
      "r723"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Share capital, without par value; unlimited shares authorized; issued and outstanding: 27,282,165 (December 31, 2022 - 21,593,145",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r445",
      "r605"
     ]
    },
    "eprx_CompensationWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "CompensationWarrantMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Warrant [Member]",
        "documentation": "Compensation warrant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss for the year",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r124",
      "r173",
      "r175",
      "r182",
      "r439",
      "r457"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail",
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computers [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r371",
      "r372",
      "r375",
      "r376",
      "r429",
      "r575",
      "r650",
      "r653",
      "r654"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r371",
      "r372",
      "r375",
      "r376",
      "r429",
      "r575",
      "r650",
      "r653",
      "r654"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r584"
     ]
    },
    "eprx_ConsultingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ConsultingMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting [Member]",
        "terseLabel": "Consulting [Member]",
        "documentation": "Consulting."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Current",
        "terseLabel": "Convertible debt",
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r265",
      "r266",
      "r271",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593"
     ]
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible debt",
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r268",
      "r285",
      "r428",
      "r581",
      "r583"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "eprx_CurrencyRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "CurrencyRiskMember",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail": {
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Current",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r641",
      "r692"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail": {
       "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Canadian",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r641"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Total",
        "terseLabel": "Canadian",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r358",
      "r364",
      "r641"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r79",
      "r80",
      "r128",
      "r129",
      "r197",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r412",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r639"
     ]
    },
    "us-gaap_DebtInstrumentCollateralAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCollateralAmount",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Collateral Amount",
        "verboseLabel": "Debt instrument collateral amount",
        "documentation": "Amount of assets pledged to secure a debt instrument."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt instrument conversion price per share",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r267"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/LoansPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Borrowings of the company",
        "terseLabel": "Debt instrument face value",
        "disclosureGuidance": "Convertible debt facility face value",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r73",
      "r265",
      "r412",
      "r590",
      "r591"
     ]
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "presentation": [
      "http://eupraxiapharma.com/role/LoansPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Frequency of Periodic Payment",
        "verboseLabel": "Debt instrument, frequency of periodic payment",
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r76"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://eupraxiapharma.com/role/LoansPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r266"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/LoansPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r412",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r639"
     ]
    },
    "eprx_DebtInstrumentMonthOfMaturity": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DebtInstrumentMonthOfMaturity",
     "presentation": [
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Month of Maturity",
        "terseLabel": "Debt instrument month of maturity",
        "documentation": "Debt instrument month of maturity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r197",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r412",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r639"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt instrument redemption price percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/LoansPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r51",
      "r54",
      "r70",
      "r71",
      "r73",
      "r75",
      "r114",
      "r115",
      "r197",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r412",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r639"
     ]
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "verboseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail": {
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Deferred",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r691",
      "r692"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail": {
       "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Deferred",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r641",
      "r691"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r123",
      "r153",
      "r363",
      "r364",
      "r641"
     ]
    },
    "eprx_DeferredTaxAssetsConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DeferredTaxAssetsConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Convertible Debt",
        "verboseLabel": "Convertible debt",
        "documentation": "Deferred tax assets convertible debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "verboseLabel": "Scientific research and experimental development pool",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r690"
     ]
    },
    "eprx_DeferredTaxAssetsLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DeferredTaxAssetsLeaseObligation",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Lease Obligation",
        "verboseLabel": "Lease obligation",
        "documentation": "Deferred tax assets lease obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance, Total",
        "totalLabel": "Net deferred income tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Non-capital losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r690"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "verboseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r690"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "verboseLabel": "Depreciable assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_DeferredTaxAssetsShareIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DeferredTaxAssetsShareIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Share Issuance Costs",
        "verboseLabel": "Share issue costs",
        "documentation": "Deferred tax assets share issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "verboseLabel": "Tax credits",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r690"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfCompanysNetDeferredIncomeTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r45"
     ]
    },
    "us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationExcludingLessorAssetUnderOperatingLease",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipmentAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Excluding Lessor Asset under Operating Lease",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense",
        "documentation": "Amount, excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of depreciation expense."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r426"
     ]
    },
    "eprx_DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure In Entirety Of General And Administration Expenses [Text Block]",
        "terseLabel": "General And Administrative Expenses",
        "documentation": "Disclosure in entirety of general and administration expenses."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_DisclosureInEntiretyOfLicenseAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DisclosureInEntiretyOfLicenseAgreementTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure In Entirety Of License Agreement [Text Block]",
        "terseLabel": "Auritec License Agreement",
        "documentation": "Disclosure In Entirety Of License Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_DisclosureInEntiretyOfOtherLoansPayable": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DisclosureInEntiretyOfOtherLoansPayable",
     "presentation": [
      "http://eupraxiapharma.com/role/LoansPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure in Entirety of Other Loans Payable",
        "terseLabel": "Loans Payable",
        "documentation": "Disclosure in entirety of other loans payable."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure In Tabular Form Of Certain Percentage Of Non Monetization Revenue Payable [Line Items]",
        "documentation": "Disclosure In Tabular Form Of Certain Percentage Of Non Monetization Revenue Payable."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTable",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure In Tabular Form Of Certain Percentage Of Non Monetization Revenue Payable [Table]",
        "documentation": "Disclosure in tabular form of certain percentage of non monetization revenue payable [Table]."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure In Tabular Form Of Certain Percentage Of Non Monetization Revenue Payable [Table Text Block]",
        "terseLabel": "Schedule of non-royalty monetization revenue percentage",
        "documentation": "Disclosure in tabular form of certain percentage of non monetization revenue payable [Table text block]."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_DisclosureInTabularFormOfMilestonePaymentScheduleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DisclosureInTabularFormOfMilestonePaymentScheduleLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure In Tabular Form Of Milestone Payment Schedule [Line Items]",
        "documentation": "Disclosure In Tabular Form Of Milestone Payment Schedule."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DisclosureInTabularFormOfMilestonePaymentScheduleTable",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure In Tabular Form Of Milestone Payment Schedule [Table]",
        "documentation": "Disclosure in tabular form of milestone payment schedule [Table]."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure In Tabular Form Of Milestone Payment Schedule [Table Text Block]",
        "terseLabel": "Schedule of milestone payment",
        "documentation": "Disclosure in tabular form of milestone payment schedule."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail",
      "http://eupraxiapharma.com/role/ConvertibleDebtTables",
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure In Tabular Form Of Movement In Convertible Debt At Fair Value [Line Items]",
        "documentation": "Disclosure in tabular form of movement in convertible debt at fair value [Line items]."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTable",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail",
      "http://eupraxiapharma.com/role/ConvertibleDebtTables",
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure In Tabular Form Of Movement In Convertible Debt At Fair Value [Table]",
        "documentation": "Disclosure in tabular form of movement in convertible debt at fair value [Table]."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtTables",
      "http://eupraxiapharma.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure In Tabular Form Of Movement In Convertible Debt At Fair Value [Table Text Block]",
        "terseLabel": "Schedule of loan balance",
        "verboseLabel": "Summary of Changes in Fair Value of Liabilities Measured at Fair Value",
        "documentation": "Disclosure in tabular form of movement in convertible debt at fair value [Table Text Block]."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure In Tabular Form Of Operating Lease Liability Current And Non Current [Table Text Block]",
        "terseLabel": "Summary of Lease Liability Balance",
        "documentation": "Disclosure in tabular form of operating lease liability current and non current [Table Text Block]."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Line Items]",
        "documentation": "Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTable",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Table]",
        "documentation": "Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date [Table Text Block]",
        "terseLabel": "Summary of options outstanding along with the grant dates and expiry date",
        "documentation": "Disclosure In Tabular Form Of Share Based Compensation Options Outstanding Along With The Grant Dates And Expiry Date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r621",
      "r622"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r621",
      "r622",
      "r623"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Loss per share \u2013 basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r211",
      "r213",
      "r216",
      "r217",
      "r218",
      "r219",
      "r384",
      "r385",
      "r440",
      "r458",
      "r585"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Loss per share \u2013 diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r213",
      "r216",
      "r217",
      "r218",
      "r219",
      "r384",
      "r385",
      "r440",
      "r458",
      "r585"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings (Loss) per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Foreign exchange effect on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory Canadian corporate tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r350",
      "r366"
     ]
    },
    "eprx_EffectiveIncomeTaxReconciliationDifferencesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "EffectiveIncomeTaxReconciliationDifferencesAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Reconciliation Differences [Abstract]",
        "terseLabel": "Difference resulting from:",
        "documentation": "Effective income tax reconciliation differences."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Reconciliation Foreign Exchange Arising On Translation To Reporting Currency",
        "terseLabel": "Foreign exchange arising on translation to reporting currency",
        "documentation": "Effective income tax reconciliation foreign exchange arising on translation to reporting currency."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_EffectiveIncomeTaxReconciliationShareIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "EffectiveIncomeTaxReconciliationShareIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Reconciliation Share Issuance Costs",
        "negatedLabel": "Share issue costs",
        "documentation": "Effective income tax reconciliation share issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_EighteenthMayTwoThousandAndTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "EighteenthMayTwoThousandAndTwentyThreeMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eighteenth May Two Thousand And Twenty Three [Member]",
        "terseLabel": "May 18, 2023 [Member]",
        "documentation": "Eighteenth May Two Thousand And Twenty Three."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share based compensation by share based award options unrecognized compensation period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Share based compensation by share based award options unrecognized compensation",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage",
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Jurisdiction of Incorporation",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage",
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "terseLabel": "Country of Incorporation",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail",
      "http://eupraxiapharma.com/role/ConvertibleDebtTables",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "terseLabel": "Date of incorporation",
        "verboseLabel": "Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "eprx_EquipmentLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "EquipmentLoanMember",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment Loan [Member]",
        "verboseLabel": "Equipment Loan [Member]",
        "documentation": "Equipment loan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "terseLabel": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r157",
      "r177",
      "r178",
      "r179",
      "r198",
      "r199",
      "r200",
      "r202",
      "r208",
      "r210",
      "r220",
      "r245",
      "r246",
      "r291",
      "r335",
      "r336",
      "r337",
      "r359",
      "r360",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r427",
      "r461",
      "r462",
      "r463",
      "r477",
      "r546"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243"
     ]
    },
    "eprx_EquityMethodInvestmentNumberOfSharedOwned": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "EquityMethodInvestmentNumberOfSharedOwned",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment Number Of Shared Owned",
        "terseLabel": "Equity method investment number of shares owned",
        "documentation": "Equity Method Investment Number Of Shared Owned."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "eprx_EuphraxiaPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "EuphraxiaPharmaIncMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euphraxia Pharma Inc [Member]",
        "documentation": "Euphraxia Pharma Inc."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_EuphraxiaUsaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "EuphraxiaUsaMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euphraxia USA [Member]",
        "documentation": "Euphraxia USA."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_EupraxiaHoldingsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "EupraxiaHoldingsIncMember",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eupraxia Holdings Inc [Member]",
        "terseLabel": "Eupraxia Holdings, Inc. [Member]",
        "documentation": "Eupraxia holdings inc member."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_EupraxiaPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "EupraxiaPharmaIncMember",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eupraxia Pharma Inc [Member]",
        "terseLabel": "Eupraxia Pharma, Inc. [Member]",
        "documentation": "Eupraxia pharma inc member."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_EupraxiaPharmaUsaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "EupraxiaPharmaUsaIncMember",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eupraxia Pharma USA Inc [Member]",
        "terseLabel": "Eupraxia Pharma USA Inc. [Member]",
        "documentation": "Eupraxia pharma usa inc member."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_EupraxiaPharmaceuticalsAustraliaPtyLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "EupraxiaPharmaceuticalsAustraliaPtyLtdMember",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eupraxia Pharmaceuticals Australia Pty Ltd [Member]",
        "terseLabel": "Eupraxia Pharmaceuticals Australia Pty Ltd. [Member]",
        "documentation": "Eupraxia pharmaceuticals australia pty ltd member."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_EupraxiaPharmaceuticalsUsaLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "EupraxiaPharmaceuticalsUsaLlcMember",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eupraxia Pharmaceuticals USA LLC [Member]",
        "terseLabel": "Eupraxia Pharmaceuticals USA, LLC [Member]",
        "documentation": "Eupraxia pharmaceuticals usa llc member."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_EupraxiaUsaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "EupraxiaUsaMember",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eupraxia USA [Member]",
        "terseLabel": "Eupraxia USA [Member]",
        "documentation": "Eupraxia USA."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_EventAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "EventAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Event [Axis]",
        "documentation": "Event"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_EventDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "EventDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Event [Domain]",
        "documentation": "Event"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ExcerciseOfOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ExcerciseOfOptionsMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excercise Of Options [Member]",
        "documentation": "Excercise Of Options"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ExcerciseOfWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ExcerciseOfWarrantsMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excercise Of Warrants [Member]",
        "terseLabel": "Excercise of warrants [Member]",
        "documentation": "Excercise Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ExpiryPeriodEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ExpiryPeriodEightMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiry Period Eight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ExpiryPeriodFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ExpiryPeriodFiveMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiry Period Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ExpiryPeriodFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ExpiryPeriodFourMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiry Period Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ExpiryPeriodNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ExpiryPeriodNineMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiry Period Nine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ExpiryPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ExpiryPeriodOneMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiry Period One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ExpiryPeriodSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ExpiryPeriodSevenMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiry Period Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ExpiryPeriodSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ExpiryPeriodSixMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiry Period Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ExpiryPeriodTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ExpiryPeriodTenMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiry Period Ten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ExpiryPeriodThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ExpiryPeriodThreeMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiry Period Three [Member]",
        "verboseLabel": "Expiry Period Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ExpiryPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ExpiryPeriodTwoMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiry Period Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r386",
      "r433",
      "r434",
      "r435",
      "r590",
      "r591",
      "r596",
      "r597",
      "r598"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r126"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r386",
      "r435",
      "r590",
      "r591",
      "r596",
      "r597",
      "r598"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement With Unobservable Input Reconciliation Recurring Basis Accrued Interest During The Period",
        "terseLabel": "Accrued interest",
        "documentation": "Fair value measurement with unobservable input reconciliation recurring basis accrued interest during the period."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement With Unobservable Input Reconciliation Recurring Basis Interest Paid During The Period",
        "terseLabel": "Interest paid",
        "documentation": "Fair value measurement with unobservable input reconciliation recurring basis interest paid during the period."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement With Unobservable Input Reconciliation Recurring Basis Liability Foregin Exchange Gain Loss",
        "terseLabel": "Foreign exchange",
        "documentation": "Fair value measurement with unobservable input reconciliation recurring basis liability foreign exchange gain loss."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement With Unobservable Input Reconciliation Recurring Basis Liability Foreign Exchange Gain Loss",
        "terseLabel": "Foreign exchange",
        "documentation": "Fair value measurement with unobservable input reconciliation recurring basis liability foreign exchange gain loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      },
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows",
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value of financial instruments",
        "negatedLabel": "Change in fair value of financial instruments",
        "verboseLabel": "Change in fair value",
        "negatedTerseLabel": "Change in fair value",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r433",
      "r434",
      "r435",
      "r590",
      "r591",
      "r596",
      "r597",
      "r598"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Financial Instruments and Fair Value",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r20"
     ]
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations, Total",
        "totalLabel": "Total",
        "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r349"
     ]
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Canadian"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Lease payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r422"
     ]
    },
    "eprx_FinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "FinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Abstract]",
        "documentation": "Financial Instruments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_FinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "FinancialInstrumentsLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Line Items]",
        "documentation": "Financial instruments."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_FinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "FinancialInstrumentsTable",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Table]",
        "documentation": "Financial instruments."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_FirstOaRegulatoryApprovalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "FirstOaRegulatoryApprovalMember",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First OA Regulatory Approval [Member]",
        "terseLabel": "First OA Regulatory Approval [Member]",
        "documentation": "First OA Regulatory Approval."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_FiveMarchTwoThousandAndEighteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "FiveMarchTwoThousandAndEighteenMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Five March Two Thousand And Eighteen [Member]",
        "terseLabel": "Mar 5, 2018 [Member]",
        "documentation": "Five March Two Thousand And Eighteen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Exchange Rate, Translation",
        "terseLabel": "Foreign exchange rate translation",
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r402"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "terseLabel": "Foreign exchange gain",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r394",
      "r543"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "negatedLabel": "Unrealized foreign exchange",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r524",
      "r615",
      "r696",
      "r697",
      "r721"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "eprx_ForeignExchangeAdjustmentOnLoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ForeignExchangeAdjustmentOnLoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/LoansPayableSummaryOfBreakdownOfLoanBalanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Exchange Adjustment on Loans Payable",
        "terseLabel": "Foreign exchange adjustment",
        "documentation": "Foreign exchange adjustment on loans payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations, Total",
        "totalLabel": "Total",
        "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Foreign"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail",
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "verboseLabel": "Office furniture and equipment [Member]",
        "terseLabel": "Office furniture and equipment [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "terseLabel": "Loss on sale of equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 7.0
      },
      "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "definitionGuidance": "General and administrative",
        "totalLabel": "Total expenses during the period",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r528"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipmentAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/RightOfUseAssetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "eprx_GeneralAndAdministrativeExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "GeneralAndAdministrativeExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General And Administrative Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralInsuranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralInsuranceExpense",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Insurance Expense",
        "terseLabel": "Insurance",
        "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales)."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_GovernmentAssistanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GovernmentAssistanceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistanceAmount",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Amount",
        "negatedLabel": "Government grants (Note 15)",
        "terseLabel": "Government assistance, amount",
        "documentation": "Amount of government assistance recognized."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_GovernmentAssistanceAmountCumulative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistanceAmountCumulative",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Amount, Cumulative",
        "terseLabel": "Government Assistance Amount, Cumulative Current",
        "documentation": "Amount of cumulative government assistance recognized."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_GovernmentAssistanceAmountCumulativeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistanceAmountCumulativeCurrent",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/AmountsReceivableSummaryOfAmountsReceivableDetail": {
       "parentTag": "us-gaap_NontradeReceivablesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/AmountsReceivableSummaryOfAmountsReceivableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Amount, Cumulative, Current",
        "terseLabel": "GST/HST recoverable",
        "documentation": "Amount of cumulative government assistance recognized classified as current."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "eprx_GovernmentAssistanceAmountForResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "GovernmentAssistanceAmountForResearchAndDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance Amount For Research And Development",
        "terseLabel": "Government assistance amount for research and development",
        "documentation": "Government assistance amount for research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GovernmentAssistanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistanceLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistancePolicyTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance [Policy Text Block]",
        "terseLabel": "Government Assistance",
        "documentation": "Disclosure of accounting policy for government assistance."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r410"
     ]
    },
    "us-gaap_GovernmentAssistanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistanceTable",
     "presentation": [
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance [Table]",
        "documentation": "Disclosure of information about government assistance."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "eprx_GovernmentAssistanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "GovernmentAssistanceTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance [Table Text Block]",
        "terseLabel": "Shedule Of Government Grants And Assistance Received",
        "documentation": "Government Assistance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GovernmentAssistanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistanceTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance [Text Block]",
        "terseLabel": "Government Grants And Assistance",
        "documentation": "The entire disclosure for government assistance."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r406",
      "r407",
      "r408",
      "r409"
     ]
    },
    "us-gaap_GovernmentAssistanceTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistanceTypeAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Type [Axis]",
        "documentation": "Information by type of government assistance."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_GovernmentAssistanceTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistanceTypeDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Type [Domain]",
        "documentation": "Type of government assistance."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "eprx_GovernmentGrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "GovernmentGrantsPolicyTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Grants [Policy Text Block]",
        "verboseLabel": "Government Grants",
        "documentation": "Government grants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrantsReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/AmountsReceivableSummaryOfAmountsReceivableDetail": {
       "parentTag": "us-gaap_NontradeReceivablesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/AmountsReceivableSummaryOfAmountsReceivableDetail",
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grants Receivable, Current",
        "terseLabel": "Government grants",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r620",
      "r621",
      "r622"
     ]
    },
    "eprx_ImmediateVestingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ImmediateVestingMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Immediate Vesting [Member]",
        "documentation": "Immediate Vesting."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact On Profit Or Loss Due To A Reasonable Possible Increase Decrease In Exchange Rates",
        "terseLabel": "Impact on profit loss due to change in exchange rates",
        "documentation": "Impact on profit loss due to change in exchange rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r108"
     ]
    },
    "us-gaap_IncentiveFromLessor": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncentiveFromLessor",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive from Lessor",
        "terseLabel": "Less: balance of unused tenant allowance",
        "documentation": "Amount of incentive received by lessee from lessor."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r146",
      "r627"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsIncludedInLossBeforeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "verboseLabel": "Canadian",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r365"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsIncludedInLossBeforeTaxesDetail",
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before tax expense",
        "terseLabel": "Loss before taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r89",
      "r132",
      "r223",
      "r230",
      "r234",
      "r236",
      "r441",
      "r453",
      "r587"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsIncludedInLossBeforeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "verboseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r365"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/PropertyAndEquipmentAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/RightOfUseAssetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r529"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/PropertyAndEquipmentAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/RightOfUseAssetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r529"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r346",
      "r351",
      "r352",
      "r356",
      "r361",
      "r367",
      "r368",
      "r369",
      "r474"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 4.0
      },
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Tax expense",
        "totalLabel": "Income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r154",
      "r209",
      "r210",
      "r228",
      "r349",
      "r362",
      "r459"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfIncomeTaxExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r347",
      "r348",
      "r352",
      "r353",
      "r355",
      "r357",
      "r468"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in unrecognized deferred tax assets",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Expected tax recovery at statutory rates",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "verboseLabel": "Other items not deductible for tax purposes and other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Non-deductible share-based payments",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount",
        "verboseLabel": "Adjustments related to prior years",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Amounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Payable Towards Licensing Fees And Others Current",
        "verboseLabel": "Auritec payable",
        "documentation": "Increase decrease in payable towards licensing fees and others current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "eprx_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/RightOfUseAssetSummaryOfRightOfUseAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease Through Net Exchange Differences, Right Of Use Asset",
        "definitionGuidance": "Foreign Exchange",
        "documentation": "Increase decrease through net exchange differences, right of use\u00a0asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 11.0
      },
      "http://eupraxiapharma.com/role/InterestExpenseScheduleOfInterestExpenseDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://eupraxiapharma.com/role/InterestExpenseScheduleOfInterestExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Total",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r135",
      "r180",
      "r227",
      "r411",
      "r530",
      "r615",
      "r718"
     ]
    },
    "us-gaap_InterestExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/InterestExpenseScheduleOfInterestExpenseDetail": {
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/InterestExpenseScheduleOfInterestExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest on SVB debt facility (Note 11)",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r278",
      "r282",
      "r592",
      "r593"
     ]
    },
    "eprx_InterestExpensesOnLeaseLiabilityFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "InterestExpensesOnLeaseLiabilityFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expenses on Lease Liability Financing Activities",
        "terseLabel": "Interest \u2013 lease liability",
        "documentation": "Interest expenses on lease liability financing activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/InterestExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Interest Expense",
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeAndInterestExpenseDisclosureTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/InterestExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income and Interest Expense Disclosure [Text Block]",
        "terseLabel": "Interest Expense",
        "documentation": "The entire disclosure for interest income and interest expense for enterprises that derive a significant portion of their revenue from interest collected on investments, loans, and securities."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "eprx_InterestOnConvertibleDebtOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "InterestOnConvertibleDebtOne",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest on Convertible Debt One",
        "terseLabel": "Accrued interest on convertible debt",
        "documentation": "Interest on convertible debt one."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_InterestOnShortTermInvestmentsNonOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "InterestOnShortTermInvestmentsNonOperating",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest on Short Term Investments Non Operating",
        "negatedLabel": "Accrued interest on short term investments",
        "documentation": "Interest on short term investments non operating."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest Paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r187",
      "r188"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r226"
     ]
    },
    "eprx_InvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "InvestmentOwnershipPercentage",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Ownership Percentage",
        "verboseLabel": "Effective Interest",
        "documentation": "Investment ownership percentage."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail",
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lab Equipment [Member]",
        "verboseLabel": "Lab equipment [Member]",
        "terseLabel": "Lab Equipment [Member]",
        "documentation": "Lab equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Labor and Related Expense",
        "terseLabel": "Salaries and benefits",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfCostComponentsOfTheOperatingLeaseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Expiration Date",
        "terseLabel": "Expiry date of lease agreement",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail",
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "verboseLabel": "Leasehold improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail",
      "http://eupraxiapharma.com/role/ConvertibleDebtTables",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Fees",
        "terseLabel": "Legal fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "eprx_LenderAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "LenderAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lender [Axis]",
        "documentation": "Lender."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_LenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "LenderDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lender [Domain]",
        "documentation": "Lender."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfCostComponentsOfTheOperatingLeaseDetail",
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail",
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfCostComponentsOfTheOperatingLeaseDetail",
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail",
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetailAlternate1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Total",
        "totalLabel": "Total undiscounted future minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetailAlternate1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Lease Liability",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r191",
      "r244",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r372",
      "r375",
      "r376",
      "r389",
      "r502",
      "r586",
      "r617",
      "r651",
      "r705",
      "r706"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity (deficit)",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r131",
      "r449",
      "r605",
      "r640",
      "r648",
      "r695"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets",
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "terseLabel": "Current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r161",
      "r191",
      "r244",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r372",
      "r375",
      "r376",
      "r389",
      "r605",
      "r651",
      "r705",
      "r706"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current\u00a0liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_LicenseAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "LicenseAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Abstract]",
        "documentation": "License Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_LicenseAgreementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "LicenseAgreementLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Line Items]",
        "documentation": "License agreement [Line Items]."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_LicenseAgreementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "LicenseAgreementTable",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Table]",
        "documentation": "License agreement [Table]."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "LoanMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtScheduleOfLoanBalanceDetail",
      "http://eupraxiapharma.com/role/ConvertibleDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/AmountsReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "Amounts Receivable",
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/LoansPayableSummaryOfBreakdownOfLoanBalanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r129",
      "r714"
     ]
    },
    "us-gaap_LoansPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/LoansPayableSummaryOfBreakdownOfLoanBalanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable, Current",
        "definitionGuidance": "Current portion",
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_LoansPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayableMember",
     "presentation": [
      "http://eupraxiapharma.com/role/LoansPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable [Member]",
        "verboseLabel": "Loans Payable [Member]",
        "documentation": "Borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://eupraxiapharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_LongTermDebtBaseRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "LongTermDebtBaseRate",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt Base Rate",
        "terseLabel": "Long term debt base rate",
        "documentation": "Long term debt base rate."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_LongTermDebtPaidInKindInterestPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "LongTermDebtPaidInKindInterestPercentage",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt Paid In Kind Interest Percentage",
        "terseLabel": "Long term debt paid in kind interest rate percentage",
        "documentation": "Long term debt paid in kind interest percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "terseLabel": "Long term debt bearing fixed interest rate percentage",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate",
        "terseLabel": "Long term debt variable interest rate percentage",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_LongTermDebtTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtTerm",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/LoansPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Term",
        "terseLabel": "Term of loan agreement",
        "verboseLabel": "Long term debt term",
        "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "eprx_LongTermDebtTermExtendableAtLendersDiscretion": {
     "xbrltype": "durationItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "LongTermDebtTermExtendableAtLendersDiscretion",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt Term Extendable At Lenders Discretion",
        "terseLabel": "Long term debt term extendable at lenders discretion",
        "documentation": "Long term debt term extendable at lenders discretion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt [Text Block]",
        "terseLabel": "Convertible Debt",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_LongTermLoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermLoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/LoansPayableSummaryOfBreakdownOfLoanBalanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable, Noncurrent",
        "definitionGuidance": "Non-current portion",
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/LoansPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/LoansPayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r47"
     ]
    },
    "eprx_LossOnSaleOfEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "LossOnSaleOfEquipment",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss On Sale Of Equipment",
        "negatedLabel": "Loss on sale of equipment",
        "documentation": "Loss on sale of equipment."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ManufacturingAndAnalyticaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ManufacturingAndAnalyticaMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing And Analytica [Member]",
        "terseLabel": "Manufacturing &amp; analytical [Member]",
        "documentation": "Manufacturing\u00a0and analytica."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Short Term Investments",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "eprx_MaturityPeriodWarrantsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "MaturityPeriodWarrantsAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity Period Warrants [Axis]",
        "documentation": "Maturity period warrants."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_MaturityPeriodWarrantsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "MaturityPeriodWarrantsDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity Period Warrants [Domain]",
        "documentation": "Maturity period warrants."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Amount Incurrable Out Of Non Royalty Revenue Monetization",
        "terseLabel": "Maximum amount incurrable out of non royalty revenue monetization",
        "documentation": "Maximum Amount Incurrable Out Of Non Royalty Revenue Monetization."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail",
      "http://eupraxiapharma.com/role/CommitmentsAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r299",
      "r437",
      "r460",
      "r493",
      "r494",
      "r550",
      "r552",
      "r554",
      "r555",
      "r557",
      "r576",
      "r577",
      "r588",
      "r594",
      "r599",
      "r606",
      "r655",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712"
     ]
    },
    "eprx_MilestoneAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "MilestoneAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone [Axis]",
        "documentation": "Milestone."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_MilestoneDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "MilestoneDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone [Domain]",
        "documentation": "Milestone."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_MilestonePaymentRecognizedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "MilestonePaymentRecognizedExpense",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payment Recognized Expense",
        "terseLabel": "Milestone payment recognized expense",
        "documentation": "Milestone payment recognized expense."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/CommitmentsAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r299",
      "r437",
      "r460",
      "r493",
      "r494",
      "r550",
      "r552",
      "r554",
      "r555",
      "r557",
      "r576",
      "r577",
      "r588",
      "r594",
      "r599",
      "r606",
      "r655",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling\u00a0interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r130",
      "r191",
      "r244",
      "r256",
      "r258",
      "r259",
      "r260",
      "r263",
      "r264",
      "r389",
      "r448",
      "r505"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "terseLabel": "Minority interest held",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember",
     "presentation": [
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NRC IRAP Specified Research And Development Funding Activities [Member]",
        "terseLabel": "NRC-IRAP Specified Research And Development Funding Activities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business and Going Concern",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r155"
     ]
    },
    "eprx_NatureOfOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "NatureOfOperationsLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Line Items]",
        "documentation": "Nature of operations."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_NatureOfOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "NatureOfOperationsTable",
     "presentation": [
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Table]",
        "documentation": "Nature of operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Owners of the Company",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r103",
      "r133",
      "r159",
      "r172",
      "r174",
      "r179",
      "r191",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r209",
      "r210",
      "r215",
      "r223",
      "r230",
      "r234",
      "r236",
      "r244",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r385",
      "r389",
      "r456",
      "r525",
      "r544",
      "r545",
      "r587",
      "r615",
      "r651"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Loss attributable to:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r125",
      "r172",
      "r174",
      "r209",
      "r210",
      "r455",
      "r634"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Upcoming Accounting Standards and Interpretations",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_NineDecemberTwoThousandAndTwentyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "NineDecemberTwoThousandAndTwentyOneMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nine December Two Thousand And Twenty One [Member]",
        "terseLabel": "Dec 9, 2021 [Member]",
        "documentation": "Nine December Two Thousand And Twenty One."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_NineDecemberTwoThousandAndTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "NineDecemberTwoThousandAndTwentyTwoMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nine December Two Thousand And Twenty Two [Member]",
        "terseLabel": "Dec 9, 2022 [Member]",
        "documentation": "Nine December Two Thousand And Twenty Two."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_NineMarchTwoThousandAndTwentyOne1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "NineMarchTwoThousandAndTwentyOne1Member",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nine March Two Thousand And Twenty One 1 [Member]",
        "terseLabel": "Mar 9, 2021 [Member]",
        "documentation": "Nine march two thousand and twenty one 1."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_NineMarchTwoThousandAndTwentyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "NineMarchTwoThousandAndTwentyOneMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nine March Two Thousand And Twenty One [Member]",
        "terseLabel": "Mar 9, 2021 [Member]",
        "documentation": "Nine March Two Thousand And Twenty One."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_NonCapitalLossCarryforwardsToFutureExpire": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "NonCapitalLossCarryforwardsToFutureExpire",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Capital Loss Carryforwards To Future Expire",
        "verboseLabel": "Non-capital loss",
        "documentation": "Non capital loss carryforwards to future expire."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_NonCapitalLossesCarryForwardFutureYearsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "NonCapitalLossesCarryForwardFutureYearsLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Capital Losses Carry Forward Future Years [Line Items]",
        "documentation": "Non capital losses carry forward future years."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_NonCapitalLossesCarryForwardFutureYearsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "NonCapitalLossesCarryForwardFutureYearsTable",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Capital Losses Carry Forward Future Years [Table]",
        "documentation": "Non capital losses carry forward future ears table."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_NonOaIndicationRegulatoryApprovalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "NonOaIndicationRegulatoryApprovalMember",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non OA Indication Regulatory Approval [Member]",
        "verboseLabel": "Non-OA Indication Regulatory Approval [Member]",
        "documentation": "Non OA Indication Regulatory Approval."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r291",
      "r642",
      "r643",
      "r644",
      "r722"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income/(expenses)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NontradeReceivableCurrentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NontradeReceivableCurrentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nontrade Receivables, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NontradeReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NontradeReceivablesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://eupraxiapharma.com/role/AmountsReceivableSummaryOfAmountsReceivableDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/AmountsReceivableSummaryOfAmountsReceivableDetail",
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets",
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfCarryingValueOfFinancialInstrumentsAtAmortizedCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nontrade Receivables, Current",
        "terseLabel": "Amounts receivable",
        "totalLabel": "Total",
        "documentation": "The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "eprx_NontradeReceivablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "NontradeReceivablesTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/AmountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nontrade Receivables [Table Text Block]",
        "terseLabel": "Summary of Amounts Receivable",
        "documentation": "Nontrade receivables."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_NumberOfUnitsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "NumberOfUnitsIssued",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of units issued",
        "terseLabel": "Number of units issued",
        "documentation": "Number of units issued."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_NumberOfWarrantIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "NumberOfWarrantIssued",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrant issued",
        "terseLabel": "Number of warrant issued",
        "documentation": "Number of warrant issued."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_NumberofWarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "NumberofWarrantsIssued",
     "presentation": [
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants Issued",
        "terseLabel": "Warrants issued",
        "documentation": "Number of warrants issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfCostComponentsOfTheOperatingLeaseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease expense",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r604"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetailAlternate1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfFutureMinimumLeasePaymentsDetail",
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities",
        "totalLabel": "Present value of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets",
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liability \u2013 current portion",
        "verboseLabel": "Current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets",
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfLeaseLiabilityBalanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability",
        "verboseLabel": "Non-current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets",
      "http://eupraxiapharma.com/role/RightOfUseAssetSummaryOfRightOfUseAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset, net",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "eprx_OperatingLeaseRightOfUseAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "OperatingLeaseRightOfUseAssetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Right of Use Asset [Abstract]",
        "documentation": "Operating Lease Right of Use Asset Abstract."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_OperatingLeaseRightOfUseAssetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "OperatingLeaseRightOfUseAssetTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/RightOfUseAssetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Right of Use Asset [Table Text Block]",
        "terseLabel": "Summary of Right of Use Assets",
        "documentation": "Operating lease right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfCostComponentsOfTheOperatingLeaseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r604"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfCostComponentsOfTheOperatingLeaseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r604"
     ]
    },
    "eprx_OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfCostComponentsOfTheOperatingLeaseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Weighted Average Remaining Lease Term And Discount Rate [Abstract]",
        "terseLabel": "Lease term and Discount Rate",
        "documentation": "Operating lease weighted average remaining lease term and discount rate [Abstract]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/RightOfUseAssetAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/RightOfUseAssetSummaryOfRightOfUseAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Lessor Asset under Operating Lease",
        "negatedLabel": "Depreciation",
        "verboseLabel": "Depreciation expense",
        "documentation": "Amount of depreciation expense for lessor's underlying asset for which right to use has been conveyed to lessee under operating lease."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r426"
     ]
    },
    "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesOfLesseeDisclosureTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Disclosure [Table Text Block]",
        "terseLabel": "Summary of Cost Components of The Operating Lease",
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r144",
      "r145"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Non capital loss carryforwards to future expire",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/CommitmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://eupraxiapharma.com/role/CommitmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign Currency translation adjustment",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other General and Administrative Expense",
        "terseLabel": "Office expenses",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r720"
     ]
    },
    "eprx_OtherInterestAndAccretionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "OtherInterestAndAccretionExpense",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/InterestExpenseScheduleOfInterestExpenseDetail": {
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/InterestExpenseScheduleOfInterestExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Interest and Accretion Expense",
        "terseLabel": "Other interest and accretion",
        "documentation": "Other interest and accretion expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfCarryingValueOfFinancialInstrumentsAtAmortizedCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Long-Term Debt",
        "verboseLabel": "Other loans payables current and non current",
        "terseLabel": "Loans payable",
        "documentation": "Amount of long-term debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r129",
      "r714"
     ]
    },
    "us-gaap_OtherLongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Long-Term Debt, Current",
        "terseLabel": "Loans payable \u2013 current portion",
        "documentation": "Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r501"
     ]
    },
    "us-gaap_OtherLongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Long-Term Debt, Noncurrent",
        "terseLabel": "Loans payable",
        "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r501"
     ]
    },
    "eprx_OtherRefundableTaxCreditsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "OtherRefundableTaxCreditsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/AmountsReceivableSummaryOfAmountsReceivableDetail": {
       "parentTag": "us-gaap_NontradeReceivablesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/AmountsReceivableSummaryOfAmountsReceivableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Refundable Tax Credits Current",
        "terseLabel": "Other refundable tax credits",
        "documentation": "Other refundable tax credits current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expense",
        "terseLabel": "Other research and development",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "eprx_OutstandingOfAMDMHoldingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "OutstandingOfAMDMHoldingsMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Of AMDM Holdings [Member]",
        "terseLabel": "Outstanding of AMDM Holdings [Member]",
        "documentation": "Outstanding of AMDM holdings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_OvernightMarketedPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "OvernightMarketedPublicOfferingMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Overnight Marketed Public Offering [Member]",
        "terseLabel": "Overnight marketed public offering [Member]",
        "documentation": "Overnight marketed public offering."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_PayableTowardsCommercialAndRegulatorMilestoneAchievement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PayableTowardsCommercialAndRegulatorMilestoneAchievement",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payable Towards Commercial And Regulator Milestone Achievement",
        "terseLabel": "Payable towards commercial and regulatory milestone achievement",
        "documentation": "Payable towards commercial and regulator milestone achievement."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_PayableTowardsRoyaltyAndOthersCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PayableTowardsRoyaltyAndOthersCurrent",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets",
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfCarryingValueOfFinancialInstrumentsAtAmortizedCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payable Towards Royalty And Others Current",
        "terseLabel": "Payable to Auritec",
        "verboseLabel": "Payable towards royalty and others current",
        "documentation": "Payable towards royalty and others current."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_PaymentOfUpfrontFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PaymentOfUpfrontFees",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Of Upfront Fees",
        "terseLabel": "Payment of upfront fees",
        "documentation": "Payment of upfront fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForUnderwritingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForUnderwritingExpense",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Underwriting Expense",
        "terseLabel": "Payments for underwriting expenses",
        "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Payments of stock issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_PaymentsToAcquireMachineryAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMachineryAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Machinery and Equipment",
        "negatedLabel": "Acquisition of equipment",
        "documentation": "The cash outflow for acquisition of machinery and equipment."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Purchase of short term investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "eprx_PercentageIncreaseInSignificantUnobservableInputAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PercentageIncreaseInSignificantUnobservableInputAssets",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Increase In Significant Unobservable Input Assets",
        "terseLabel": "Percentage increase in significant unobservable inputs assets",
        "documentation": "Percentage increase in significant unobservable input assets."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_PercentageIncreaseInSignificantUnobservableInputLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PercentageIncreaseInSignificantUnobservableInputLiabilities",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Increase In Significant Unobservable Input Liabilities",
        "terseLabel": "Percentage increase in significant unobservable inputs liabilities",
        "documentation": "Percentage increase in significant unobservable input liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_PercentageOfGrossProceedsRaisedUnderTheOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PercentageOfGrossProceedsRaisedUnderTheOffering",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of gross proceeds raised under the Offering",
        "terseLabel": "Percentage of gross proceeds raised under the Offering",
        "documentation": "Percentage of gross proceeds raised under the Offering."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Non Monetization Revenue To Be Paid To The Counterparty",
        "terseLabel": "Percentage of Non-Royalty Monetization Revenue",
        "documentation": "Percentage of non monetization revenue to be paid to the counterparty."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_PercentageOfNonRoyaltyMonetizationRevenuePayable": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PercentageOfNonRoyaltyMonetizationRevenuePayable",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Non Royalty Monetization Revenue Payable",
        "terseLabel": "Percentage of non royalty monetization revenue payable",
        "documentation": "Percentage of non royalty monetization revenue payable."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_PercentageOfOutstandingSharesEligibleForStockOptionsIssuance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PercentageOfOutstandingSharesEligibleForStockOptionsIssuance",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Outstanding Shares Eligible For Stock Options Issuance",
        "terseLabel": "Percentage of outstanding shares eligible for stock option issuance",
        "documentation": "Percentage Of Outstanding Shares Eligible For Stock Options Issuance."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_PercentageOfReimburseAssistanceToSupportContractorFee": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PercentageOfReimburseAssistanceToSupportContractorFee",
     "presentation": [
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Reimburse Assistance To Support Contractor Fee",
        "terseLabel": "Percentage of reimburse assistance to support contractor fees",
        "documentation": "Percentage of reimburse assistance to support contractor fee."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_PercentageOfReimburseAssistanceToSupportSalaryCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PercentageOfReimburseAssistanceToSupportSalaryCost",
     "presentation": [
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Reimburse Assistance To Support Salary Cost",
        "terseLabel": "Percentage of reimburse assistance to support salary costs",
        "documentation": "Percentage of reimburse assistance to support salary cost."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Tax Benefits To Be Realized For Recognition In The Income Statement",
        "terseLabel": "Percentage of tax benefits to be realized for recognition in the income statement",
        "documentation": "Percentage of tax benefits to be realized for recognition in the income statement."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of total units and warrants issued in the Offering",
        "terseLabel": "Percentage of total units and warrants issued in the Offering",
        "documentation": "Percentage of total units and warrants issued in the Offering."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_PipelineDevelopmentOfResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PipelineDevelopmentOfResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pipeline Development Of Research And Development Expense",
        "terseLabel": "Pipeline development",
        "documentation": "Pipeline development of research and development expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684"
     ]
    },
    "us-gaap_PreOpeningCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreOpeningCosts",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Opening Costs",
        "terseLabel": "Public company costs",
        "documentation": "Expenditures associated with opening new locations which are noncapital in nature and expensed as incurred."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "eprx_PreclinicalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PreclinicalMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preclinical [Member]",
        "terseLabel": "Preclinical [Member]",
        "documentation": "Preclinical."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockNoParValue",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, No Par Value",
        "terseLabel": "Preferred stock par value",
        "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r656"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorizedUnlimited": {
     "xbrltype": "authorizedUnlimitedItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorizedUnlimited",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized, Unlimited [Fixed List]",
        "terseLabel": "Preferred stock shares authorized unlimited",
        "documentation": "Indicates that the number of nonredeemable preferred shares, or preferred stock redeemable solely at the option of the issuer, permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is \"Unlimited\"."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and deposits",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r247",
      "r248",
      "r580"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Noncurrent",
        "terseLabel": "Prepaid expenses",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "eprx_PriorToSuccessfulCompletionOfPhaseTwoBStudyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PriorToSuccessfulCompletionOfPhaseTwoBStudyMember",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior To Successful Completion Of Phase Two B Study [Member]",
        "terseLabel": "Prior to Successful Completion of a Phase 2b Study [Member]",
        "documentation": "Prior To Successful Completion Of Phase Two B Study."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "verboseLabel": "Private placement [Member]",
        "terseLabel": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Convertible Debt",
        "verboseLabel": "Proceeds from convertible debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ProceedsFromInterestReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromInterestReceived",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Interest Received",
        "terseLabel": "Proceeds from Interest received",
        "documentation": "Interest received on loans and other debt instruments during the current period."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Overnight marketed public offering (net of transaction costs)",
        "verboseLabel": "Proceeds from issuance of shares",
        "definitionGuidance": "Proceeds from issuance of common shares",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from issuance of warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale, Maturity and Collection of Short-Term Investments, Total",
        "terseLabel": "Proceeds from redemption of short-term investments",
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Machinery and Equipment",
        "terseLabel": "Proceeds from sale of equipment",
        "documentation": "The cash inflow from sale of machinery and equipment."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Redemption of options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r18"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Redemption of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional Fees",
        "terseLabel": "Professional fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r719",
      "r720"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      },
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows",
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "presentationGuidance": "Net loss for the year",
        "totalLabel": "Net loss for the year",
        "definitionGuidance": "Net loss for the year",
        "verboseLabel": "Net loss",
        "negatedLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r172",
      "r174",
      "r185",
      "r191",
      "r201",
      "r209",
      "r210",
      "r223",
      "r230",
      "r234",
      "r236",
      "r244",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r370",
      "r373",
      "r374",
      "r385",
      "r389",
      "r441",
      "r454",
      "r476",
      "r525",
      "r544",
      "r545",
      "r587",
      "r602",
      "r603",
      "r616",
      "r634",
      "r651"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAdditions",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Additions",
        "terseLabel": "Additions",
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail",
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "eprx_PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment Description Of Rate Of Depreciation",
        "terseLabel": "Property plant and Equipment Description of Rate of Depreciation",
        "documentation": "Property plant and equipment description of rate of depreciation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r150",
      "r151",
      "r152"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisposals",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Disposals",
        "negatedLabel": "Disposals",
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment Foreign Currency Translation Adjustments",
        "terseLabel": "Foreign currency adjustments",
        "documentation": "Property plant and equipment foreign currency translation adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r163",
      "r452"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGrossAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross [Abstract]",
        "terseLabel": "Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipmentAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail",
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets",
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "verboseLabel": "Net Book Value",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r442",
      "r452",
      "r605"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r150",
      "r151",
      "r450"
     ]
    },
    "eprx_PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment Rate Of Depreciation [Table Text Block]",
        "terseLabel": "Summary of Property Plant And Equipment Estimated Useful Life",
        "documentation": "Property plant and equipment rate of depreciation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail",
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "eprx_PropertyPlantAndEqupmentRateOfDepreciation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "PropertyPlantAndEqupmentRateOfDepreciation",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment Rate Of Depreciation",
        "terseLabel": "Property Plant and Equipment Rate of Depreciation",
        "documentation": "Property plant and equpment rate of depreciation."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ProvincialInvestmentTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ProvincialInvestmentTaxCreditsMember",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provincial Investment Tax Credits [Member]",
        "terseLabel": "Provincial Investment Tax Credits [Member]",
        "documentation": "Provincial investment tax credits."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail",
      "http://eupraxiapharma.com/role/CommitmentsAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r292",
      "r299",
      "r329",
      "r330",
      "r331",
      "r436",
      "r437",
      "r460",
      "r493",
      "r494",
      "r550",
      "r552",
      "r554",
      "r555",
      "r557",
      "r576",
      "r577",
      "r588",
      "r594",
      "r599",
      "r606",
      "r609",
      "r649",
      "r655",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail",
      "http://eupraxiapharma.com/role/CommitmentsAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r292",
      "r299",
      "r329",
      "r330",
      "r331",
      "r436",
      "r437",
      "r460",
      "r493",
      "r494",
      "r550",
      "r552",
      "r554",
      "r555",
      "r557",
      "r576",
      "r577",
      "r588",
      "r594",
      "r599",
      "r606",
      "r609",
      "r649",
      "r655",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RegulatoryIncomeTaxesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RegulatoryIncomeTaxesPolicy",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory Income Taxes, Policy [Policy Text Block]",
        "terseLabel": "Investment Tax Credits",
        "documentation": "Disclosure of accounting policy for income taxes, including investment tax credits, and the related regulatory treatment (for example, whether deferred income tax accounting - normalization - is allowed in rate making)."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137"
     ]
    },
    "eprx_RegulatoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "RegulatoryMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory [Member]",
        "terseLabel": "Regulatory [Member]",
        "documentation": "Regulatory."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ReimbursementAssistanceMaximumForSalaryAndContractorCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ReimbursementAssistanceMaximumForSalaryAndContractorCosts",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursement Assistance Maximum for Salary And Contractor Costs",
        "terseLabel": "Reimbursement assistance eligible maximum for salary and contractor costs",
        "documentation": "Reimbursement assistance maximum for salary and contractor costs."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_RelevantPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "RelevantPeriodAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relevant Period [Axis]",
        "documentation": "Relevant period."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_RelevantPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "RelevantPeriodDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relevant Period [Domain]",
        "documentation": "Relevant period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/LoansPayableSummaryOfBreakdownOfLoanBalanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Loan repayment",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r472"
     ]
    },
    "us-gaap_RepaymentsOfOtherLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfOtherLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Other Long-Term Debt",
        "negatedLabel": "Repayment of loans",
        "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r268",
      "r285",
      "r428",
      "r582",
      "r583"
     ]
    },
    "eprx_ResearchAndDevelopmentCostsGrossExcludingOtherCategory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ResearchAndDevelopmentCostsGrossExcludingOtherCategory",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Costs Gross Excluding Other Category",
        "terseLabel": "Direct research and development",
        "documentation": "Research and development costs gross excluding other category."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 8.0
      },
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "definitionGuidance": "Research and development",
        "totalLabel": "Total expenses during the period",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r344",
      "r713"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/PropertyAndEquipmentAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/RightOfUseAssetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenditures",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "eprx_ResearchAndDevelopmentExpensesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ResearchAndDevelopmentExpensesAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Expenses [Axis]",
        "documentation": "Research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ResearchAndDevelopmentExpensesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ResearchAndDevelopmentExpensesDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Expenses [Domain]",
        "documentation": "Research and evelopment expenses."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ResearchAndDevelopmentExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ResearchAndDevelopmentExpensesLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Expenses [Line Items]",
        "documentation": "Research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ResearchAndDevelopmentExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ResearchAndDevelopmentExpensesTable",
     "presentation": [
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Expenses [Table]",
        "documentation": "Research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ResearchAndDevelopmentLicenseExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ResearchAndDevelopmentLicenseExpenses",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development License Expenses",
        "terseLabel": "License costs (Note 10)",
        "documentation": "License costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "Research And Development Expenses",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r345"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets",
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Deficit",
        "verboseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r116",
      "r447",
      "r464",
      "r466",
      "r473",
      "r504",
      "r605"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r198",
      "r199",
      "r200",
      "r202",
      "r208",
      "r210",
      "r245",
      "r246",
      "r335",
      "r336",
      "r337",
      "r359",
      "r360",
      "r377",
      "r379",
      "r380",
      "r382",
      "r383",
      "r461",
      "r463",
      "r477",
      "r722"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "terseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r191",
      "r224",
      "r225",
      "r229",
      "r232",
      "r233",
      "r237",
      "r238",
      "r240",
      "r244",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r389",
      "r441",
      "r651"
     ]
    },
    "eprx_RightOfUseAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "RightOfUseAssetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of Use Asset [Abstract]",
        "documentation": "Right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_RightOfUseAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "RightOfUseAssetLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/RightOfUseAssetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of Use Asset [Line Items]",
        "documentation": "Right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_RightOfUseAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "RightOfUseAssetTable",
     "presentation": [
      "http://eupraxiapharma.com/role/RightOfUseAssetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of Use Asset [Table]",
        "documentation": "Right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_RightOfUseAssetTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "RightOfUseAssetTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/RightOfUseAsset"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of Use Asset [Text Block]",
        "terseLabel": "Right-of-Use Asset",
        "documentation": "Right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_RoyaltyAsAPercentageOfNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "RoyaltyAsAPercentageOfNetSales",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty As A Percentage Of Net Sales",
        "terseLabel": "Royalty as a percentage of net sales",
        "documentation": "Royalty as a percentage of net sales."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_SalariesAndBenefitsOfResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "SalariesAndBenefitsOfResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salaries And Benefits Of Research And Development Expenses",
        "terseLabel": "Salaries and benefits",
        "documentation": "Salaries and benefits of research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "verboseLabel": "Sale of stock net consideration received on the transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock issue price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Threshold Including Licenses And Sublicenses Exceeding Fifty Crores [Member]",
        "terseLabel": "First calendar year in which aggregate Net Sales by Eupraxia USA, its affiliates and sublicenses exceed $500,000,000 [Member]",
        "documentation": "Sales Threshold Including Licenses And Sublicenses Exceeding Fifty Crores./"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accounts Payable and Accrued Liabilities",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfCarryingValueOfFinancialInstrumentsAtAmortizedCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Carrying Value Of Financial Instruments At Amortized Cost [Line Items]",
        "documentation": "Schedule of carrying value of financial instruments at amortized cost."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTable",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfCarryingValueOfFinancialInstrumentsAtAmortizedCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Carrying Value Of Financial Instruments At Amortized Cost [Table]",
        "documentation": "Schedule of carrying value of financial instruments at amortized cost."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Carrying Value Of Financial Instruments At Amortized Cost [Table Text Block]",
        "terseLabel": "Summary of Carrying Value of Financial Instruments at Amortized Cost",
        "documentation": "Schedule of carrying value of financial instruments at amortized cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Summary of Detailed Breakdown of Cash and Cash Equivalents",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Income Tax Expense",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/LoansPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Summary of Breakdown of Loan Balance",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Company's Net Deferred Income Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense Benefit",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243"
     ]
    },
    "eprx_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of General And Administrative Expenses [Table Text Block]",
        "terseLabel": "Schedule of general and administrative expenses",
        "documentation": "Schedule of general and administrative expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Components Included in Loss Before Taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "eprx_ScheduleOfInformationAboutSubsidiariesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ScheduleOfInformationAboutSubsidiariesTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Information About Subsidiaries [Table Text Block]",
        "terseLabel": "Summary of Information About Subsidiaries",
        "documentation": "Schedule of information about subsidiaries."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Non Capital Losses Carry Forward Future Years [Table Text Block]",
        "terseLabel": "Schedule of Non Capital Losses Carry Forward Future Years",
        "documentation": "Schedule of non capital losses carry forward future years."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://eupraxiapharma.com/role/PropertyAndEquipmentAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail",
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentEstimatedUsefulLifeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "eprx_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ScheduleOfResearchAndDevelopmentExpensesTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Research And Development Expenses [Table Text Block]",
        "terseLabel": "Schedule of research and development expenses",
        "documentation": "Schedule of research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share Based Compensation Arrangement By Share Based Payment Award Warrant [Line Items]",
        "documentation": "Schedule of share based compensation arrangement by share based payment award warrant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ]
    },
    "eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTable",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share Based Compensation Arrangements By Share Based Payment Award Warrant [Table]",
        "documentation": "Schedule of share based compensation arrangements by share based payment award warrant."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share Based Compensation Arrangements By Share Based Payment Award Warrant [Table Text Block]",
        "terseLabel": "Summary of share based compensation arrangements by share based payment warrant",
        "documentation": "Schedule of share based compensation arrangements by share based payment award warrant."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Compensation of Share Warrants Outstanding [Line Items]",
        "documentation": "Schedule of share based compensation of share warrants outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTable",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Compensation of Share Warrants Outstanding [Table]",
        "documentation": "Schedule of share based compensation of share warrants outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Compensation of Share Warrants Outstanding [Table Text Block]",
        "terseLabel": "Summary of share based compensation of share warrants outstanding",
        "documentation": "schedule of share based compensation of share warrants outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of weighted-average assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r114",
      "r115",
      "r116",
      "r166",
      "r167",
      "r168",
      "r221",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r469",
      "r470",
      "r471",
      "r472",
      "r594",
      "r626",
      "r638"
     ]
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "terseLabel": "Summary of company's option",
        "documentation": "Tabular disclosure of the change in stock options."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_SecondOaRegulatoryApprovalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "SecondOaRegulatoryApprovalMember",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second OA Regulatory Approval [Member]",
        "terseLabel": "Second OA Regulatory Approval [Member]",
        "documentation": "Second OA Regulatory Approval"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_SecuritiesIssuedPricePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "SecuritiesIssuedPricePerUnit",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Issued, Price Per unit",
        "terseLabel": "Securities issued, price per unit",
        "documentation": "Securities Issued, Price Per unit."
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail",
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r490",
      "r491",
      "r492",
      "r551",
      "r553",
      "r556",
      "r558",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r578",
      "r595",
      "r609",
      "r657",
      "r716"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based payments",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Share based compensation by share based award vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of warrants, Issued",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of warrants, Ending Balance",
        "periodStartLabel": "Number of warrants, Beginning Balance",
        "terseLabel": "Warrants outstanding and exercisable",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "verboseLabel": "Remaining contractual life",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date",
        "terseLabel": "Expiry Date",
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Weighted average exercise price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Weighted average risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Weighted average annual volatility",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Number of warrants, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations",
        "negatedLabel": "Number of warrants, Expired",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share based compensation arrangement by share based payment award number of shares available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of options, Cancelled",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of options, Outstanding",
        "periodStartLabel": "Number of options, Outstanding",
        "terseLabel": "Options Outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average price, Outstanding",
        "periodStartLabel": "Weighted average price, Outstanding",
        "terseLabel": "Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Share based compensation by share based award optinoss exercise din period weighted average exercise price",
        "terseLabel": "Weighted average price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average price, Cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation By Share Based Award Equity Instruments Other Than Options Excercised During The Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised",
        "documentation": "Share based compensation by share based award equity instruments other than options excercised during the period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation By Share Based Award Equity Instruments Other Than Options Expired During The Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Expired",
        "documentation": "Share based compensation by share based award equity instruments other than options expired during the period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation By Share Based Award Equity Instruments Other Than Options Granted During The PeriodWeighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Issued",
        "documentation": "Share based compensation by share based award equity instruments other than options granted during the periodweighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation By Share Based Award Equity Instruments Other Than Options Non Vested Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Ending Balance",
        "periodStartLabel": "Weighted average exercise price, Beginning Balance",
        "verboseLabel": "Exercise price",
        "documentation": "Share based compensation by share based award equity instruments other than options non vested outstanding weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Payments",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r307",
      "r326",
      "r327",
      "r328",
      "r329",
      "r332",
      "r338",
      "r339",
      "r340",
      "r341"
     ]
    },
    "eprx_ShareBasedCompensationOptionsExpiryDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ShareBasedCompensationOptionsExpiryDateAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Options Expiry Date [Axis]",
        "documentation": "Share Based Compensation Options Expiry Date"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ShareBasedCompensationOptionsExpiryDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ShareBasedCompensationOptionsExpiryDateDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Options Expiry Date [Domain]",
        "documentation": "Share Based Compensation Options Expiry Date"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant": {
     "xbrltype": "dateItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compesnation By Share Based Options Granted Date Of Grant",
        "terseLabel": "Grant Date",
        "documentation": "Share Based Compesnation By Share Based Options Granted Date Of Grant."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ShareBasedPaymentsOfResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ShareBasedPaymentsOfResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payments Of Research And Development Expenses",
        "terseLabel": "Share based payments (Note 12(c))",
        "documentation": "Share based payments of research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Weighted average share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Share based compensation by share based award vesting percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Share based compensation by share based award aggregate term",
        "verboseLabel": "Class of warrants or rights term",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "eprx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBased Compensation Arrangement by ShareBased Payment Award, Fair Value Assumptions, Expected forfeiture rate",
        "terseLabel": "Expected forfeiture rate",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected forfeiture rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfWeightedAverageAssumptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Weighted average expected option life",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Remaining Contractual Life",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "terseLabel": "Share Capital and Other Components of Equity",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r117"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at the ending (in shares)",
        "periodStartLabel": "Balance at the beginning (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows",
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows",
      "http://eupraxiapharma.com/role/FinancialInstrumentsSummaryOfChangesInFairValueOfLiabilitiesMeasuredAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r190"
     ]
    },
    "eprx_SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Unobservable Input Impact Of Interest Rate Changes On Profit Or Loss Before Tax",
        "terseLabel": "Significant unobservable input impact of interest rate changes on profit or loss before tax",
        "documentation": "Significant unobservable input impact of interest rate changes on profit or loss before tax."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate",
     "presentation": [
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Unobservable Inputs Percentage Increase Decrease In Interest Rate",
        "terseLabel": "Significant unobservable inputs percentage increase decrease in interest rate",
        "documentation": "Significant unobservable inputs percentage increase decrease in interest rate."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_SiliconValleyBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "SiliconValleyBankMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Silicon Valley Bank [Member]",
        "terseLabel": "Silicon Valley Bank [Member]",
        "documentation": "Silicon valley bank."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ResearchAndDevelopmentExpensesScheduleOfResearchAndDevelopmentExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SR And ED And Tax incentives Of Research And Development Expenses",
        "terseLabel": "SR&amp;ED and other R&amp;D tax incentives",
        "documentation": "Sr and ed and tax incentives of research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r166",
      "r167",
      "r168",
      "r191",
      "r213",
      "r214",
      "r216",
      "r218",
      "r221",
      "r222",
      "r244",
      "r256",
      "r258",
      "r259",
      "r260",
      "r263",
      "r264",
      "r283",
      "r284",
      "r286",
      "r287",
      "r289",
      "r389",
      "r469",
      "r470",
      "r471",
      "r472",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r503",
      "r526",
      "r546",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r626",
      "r638",
      "r645"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r33",
      "r157",
      "r177",
      "r178",
      "r179",
      "r198",
      "r199",
      "r200",
      "r202",
      "r208",
      "r210",
      "r220",
      "r245",
      "r246",
      "r291",
      "r335",
      "r336",
      "r337",
      "r359",
      "r360",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r427",
      "r461",
      "r462",
      "r463",
      "r477",
      "r546"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/GovernmentGrantsAndAssistanceSheduleOfGovernmentGrantsAndAssistanceReceivedDetail",
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r490",
      "r491",
      "r492",
      "r551",
      "r553",
      "r556",
      "r558",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r578",
      "r595",
      "r609",
      "r657",
      "r716"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows",
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r220",
      "r438",
      "r467",
      "r489",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r503",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r512",
      "r513",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r523",
      "r527",
      "r528",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r546",
      "r610"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfCashFlows",
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r220",
      "r438",
      "r467",
      "r489",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r503",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r512",
      "r513",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r523",
      "r527",
      "r528",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r546",
      "r610"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Stock issued during the period shares for services",
        "verboseLabel": "Shares, issued",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Overnight marketed public offering and redemption of warrants ( in shares)",
        "terseLabel": "Shares issued through non-brokered private placement",
        "definitionGuidance": "Stock issued during the period shares new issues",
        "presentationGuidance": "Stock issued during the period shares exercise of stock options",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r81",
      "r82",
      "r116",
      "r469",
      "r546",
      "r560"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfCompanySOptionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Redemption of options (in shares)",
        "definitionGuidance": "Stock issued during the period shares exercise of stock options",
        "negatedLabel": "Number of options, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r81",
      "r82",
      "r116",
      "r313"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Stock issued during the period value for services",
        "verboseLabel": "Share capital",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Overnight marketed public offering and redemption of warrants",
        "terseLabel": "Stock issued during period value new issues",
        "definitionGuidance": "Stock issued during the period value new issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r81",
      "r82",
      "r116",
      "r477",
      "r546",
      "r560",
      "r616"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Redemption of options",
        "verboseLabel": "Stock issued during period value stock options excercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r33",
      "r116"
     ]
    },
    "eprx_StockSharesIssuedAsAPercentageOfOutstandingShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "StockSharesIssuedAsAPercentageOfOutstandingShares",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Shares Issued As A Percentage Of Outstanding Shares",
        "terseLabel": "Stock shares issued as a percentage of outstanding shares",
        "documentation": "Stock Shares Issued As A Percentage Of Outstanding Shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Equity attributable to the owners of the Company",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r85",
      "r86",
      "r105",
      "r505",
      "r522",
      "r547",
      "r548",
      "r605",
      "r617",
      "r640",
      "r648",
      "r695",
      "r722"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets",
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total shareholders' equity (deficit)",
        "periodEndLabel": "Balance at the ending",
        "periodStartLabel": "Balance at the beginning",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r66",
      "r157",
      "r158",
      "r178",
      "r198",
      "r199",
      "r200",
      "r202",
      "r208",
      "r245",
      "r246",
      "r291",
      "r335",
      "r336",
      "r337",
      "r359",
      "r360",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r395",
      "r396",
      "r400",
      "r427",
      "r462",
      "r463",
      "r475",
      "r505",
      "r522",
      "r547",
      "r548",
      "r564",
      "r616",
      "r640",
      "r648",
      "r695",
      "r722"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Shareholders' equity (deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Share Capital and Warrants",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r549"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublease Income",
        "terseLabel": "Sublease income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r604"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r431"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r431"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r431"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r431"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r431"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://eupraxiapharma.com/role/SubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r432"
     ]
    },
    "srt_SubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SubsidiariesMember",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [Member]",
        "terseLabel": "Subsidiaries [Member]"
       }
      }
     },
     "auth_ref": [
      "r658",
      "r701",
      "r702",
      "r704"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://eupraxiapharma.com/role/NatureOfBusinessAndGoingConcernAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_SuccessfulCompletionOfPhaseTwoBStudyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "SuccessfulCompletionOfPhaseTwoBStudyMember",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfMilestonePaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Successful Completion Of Phase Two B Study [Member]",
        "terseLabel": "Successful Completion of a Phase 2b Study [Member]",
        "documentation": "Successful Completion Of Phase Two B Study."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_SummaryOfInformationAboutSubsidiariesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "SummaryOfInformationAboutSubsidiariesLineItems",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Information About Subsidiaries [Line Items]",
        "documentation": "Summary of information about subsidiaries line items."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_SummaryOfInformationAboutSubsidiariesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "SummaryOfInformationAboutSubsidiariesTable",
     "presentation": [
      "http://eupraxiapharma.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfInformationAboutSubsidiariesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Information About Subsidiaries [Table]",
        "documentation": "Summary of information about subsidiaries."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowElementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TaxCreditCarryForwardsExpirationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TaxCreditCarryForwardsExpirationTerm",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carry forwards Expiration Term",
        "verboseLabel": "Tax credit carry forward expiration term",
        "documentation": "Tax credit carry forwards expiration term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward, amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TaxYear2031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TaxYear2031Member",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2031 [Member]",
        "terseLabel": "Tax Year 2031 [Member]",
        "documentation": "Tax year 2031."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TaxYear2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TaxYear2032Member",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2032 [Member]",
        "terseLabel": "Tax Year 2032 [Member]",
        "documentation": "Tax year 2032."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TaxYear2033Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TaxYear2033Member",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax year 2033 [Member]",
        "terseLabel": "Tax year 2033 [Member]",
        "documentation": "Tax year 2033."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TaxYear2034Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TaxYear2034Member",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax year 2034 [Member]",
        "terseLabel": "Tax year 2034 [Member]",
        "documentation": "Tax year 2034."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TaxYear2035Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TaxYear2035Member",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax year 2035 [Member]",
        "terseLabel": "Tax year 2035 [Member]",
        "documentation": "Tax year 2035."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TaxYear2036Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TaxYear2036Member",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax year 2036 [Member]",
        "terseLabel": "Tax year 2036 [Member]",
        "documentation": "Tax year 2036."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TaxYear2037Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TaxYear2037Member",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax year 2037 [Member]",
        "terseLabel": "Tax year 2037 [Member]",
        "documentation": "Tax year 2037."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TaxYear2038Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TaxYear2038Member",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax year 2038 [Member]",
        "terseLabel": "Tax year 2038 [Member]",
        "documentation": "Tax year 2038."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TaxYear2039Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TaxYear2039Member",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax year 2039 [Member]",
        "terseLabel": "Tax year 2039 [Member]",
        "documentation": "Tax year 2039."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TaxYear2040Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TaxYear2040Member",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax year 2040 [Member]",
        "terseLabel": "Tax year 2040 [Member]",
        "documentation": "Tax year 2040."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TaxYear2041Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TaxYear2041Member",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax year 2041 [Member]",
        "terseLabel": "Tax year 2041 [Member]",
        "documentation": "Tax year 2041."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TaxYear2042Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TaxYear2042Member",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax year 2042 [Member]",
        "terseLabel": "Tax year 2042 [Member]",
        "documentation": "Tax year 2042."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TaxYear2043Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TaxYear2043Member",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2043 [Member]",
        "terseLabel": "Tax Year 2043 [Member]",
        "documentation": "Tax year 2043."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TaxYearAfter2043Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TaxYearAfter2043Member",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year After 2043 [Member]",
        "terseLabel": "Tax Year After 2043 [Member]",
        "documentation": "Tax year after 2043."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/AccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable, Current",
        "terseLabel": "Taxes payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "eprx_ThirtyFirstMarchTwoThousandAndTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ThirtyFirstMarchTwoThousandAndTwentyTwoMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thirty First March Two Thousand And Twenty Two [Member]",
        "terseLabel": "Mar 31, 2022 [Member]",
        "documentation": "Thirty First March Two Thousand And Twenty Two."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ThirtyMayTwoThousandAndTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ThirtyMayTwoThousandAndTwentyThreeMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thirty May Two Thousand And Twenty Three [Member]",
        "terseLabel": "May 30, 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_ThreeMayTwoThousandAndTwentyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "ThreeMayTwoThousandAndTwentyOneMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three May Two Thousand And Twenty One [Member]",
        "terseLabel": "May 3, 2021 [Member]",
        "documentation": "Three May Two Thousand And Twenty One."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r647",
      "r703"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TrancheAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TrancheAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche [Axis]",
        "documentation": "Tranche."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TrancheDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TrancheDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/AuritecLicenseAgreementScheduleOfNonRoyaltyMonetizationRevenuePercentageDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche [Domain]",
        "documentation": "Tranche."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TransferredFromAdditionalPaidinCapitalToShareCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TransferredFromAdditionalPaidinCapitalToShareCapital",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transferred From Additional PaidIn Capital To Share Capital",
        "terseLabel": "Transferred from additional paid-in capital to share capital",
        "documentation": "Transferred From Additional Paid-In Capital To Share Capital."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TravelAndEntertainmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TravelAndEntertainmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://eupraxiapharma.com/role/GeneralAndAdministrativeExpensesScheduleOfGeneralAndAdministrativeExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Travel and Entertainment Expense",
        "terseLabel": "Travel",
        "documentation": "Expenses incurred for travel and entertainment during the period."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "eprx_TwentySeventhSeptemberTwoThousandAndFifteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TwentySeventhSeptemberTwoThousandAndFifteenMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twenty Seventh September Two Thousand And Fifteen [Member]",
        "verboseLabel": "Sep 27, 2015 [Member]",
        "documentation": "Twenty Seventh September Two Thousand And Fifteen."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TwentySeventhSeptemberTwoThousandAndTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TwentySeventhSeptemberTwoThousandAndTwentyThreeMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twenty Seventh September Two Thousand And Twenty Three [Member]",
        "terseLabel": "Sep 27, 2023 [Member]",
        "documentation": "Twenty Seventh September Two Thousand And Twenty Three."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_TwoNovemberTwoThousandAndFifteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "TwoNovemberTwoThousandAndFifteenMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two November Two Thousand And Fifteen [Member]",
        "terseLabel": "Nov 2, 2015 [Member]",
        "documentation": "Two November Two Thousand And Fifteen."
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesScheduleOfNonCapitalLossesCarryForwardFutureYearsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "US"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties Accrued",
        "verboseLabel": "Unrecognized tax benefits income tax penalties accrued",
        "documentation": "Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "crdr": "credit",
     "presentation": [
      "http://eupraxiapharma.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "verboseLabel": "Unrecognized tax benefits interest on income taxes accrued",
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://eupraxiapharma.com/role/LeaseLiabilitySummaryOfCostComponentsOfTheOperatingLeaseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "verboseLabel": "Variable lease expense",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r604"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail",
      "http://eupraxiapharma.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684"
     ]
    },
    "eprx_WarrantAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "WarrantAxis",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Axis]",
        "documentation": "Warrant."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_WarrantDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "WarrantDomain",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Domain]",
        "documentation": "Warrant."
       }
      }
     },
     "auth_ref": []
    },
    "eprx_WarrantIssuedPricePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "WarrantIssuedPricePerUnit",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Issued, Price Per unit",
        "terseLabel": "Warrant Issued, Price Per unit",
        "documentation": "Warrant Issued, Price Per uni."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r608",
      "r611",
      "r612",
      "r613",
      "r614"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "terseLabel": "Warrants and rights outstanding maturity date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants and rights outstanding term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "eprx_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationArrangementsByShareBasedPaymentWarrantDetail",
      "http://eupraxiapharma.com/role/ShareCapitalAndOtherComponentsOfEquitySummaryOfShareBasedCompensationOfShareWarrantsOutstandingParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Granted as Part of Share Based Payment Arrangement [Member]",
        "terseLabel": "Warrants Granted as Part of Share Based Payment Arrangement [Member]",
        "documentation": "Warrants granted as part of share based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding \u2013 diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r218"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://eupraxiapharma.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding \u2013 basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r218"
     ]
    },
    "eprx_WithEighteenMonthsFromTheDateOfTheDebtAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://eupraxiapharma.com/20231231",
     "localname": "WithEighteenMonthsFromTheDateOfTheDebtAgreementMember",
     "presentation": [
      "http://eupraxiapharma.com/role/ConvertibleDebtAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "With Eighteen Months From The Date Of The Debt Agreement [Member]",
        "documentation": "With eighteen months from the date of the debt Agreement."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(4)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "e",
   "SubTopic": "470",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.28)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//230/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.1-12)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "980",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481974/980-740-25-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "980",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481974/980-740-25-2"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "985",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//985-730/tableOfContent"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481440/840-10-50-2"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Subparagraph": "(Note 3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481418/840-10-55-40"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-6"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481475/840-20-55-3"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-4"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-4"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-5"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-13"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479924/842-10-30-5"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-16"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//310-10/tableOfContent"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>122
<FILENAME>0001193125-24-083584-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-083584-xbrl.zip
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M*U<G-X".7*].ID;'5N[XV0 Z<KVG([7=L95[.C9@=^0Z:S\U.K8R:W\#Z"A
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MM8<J9^)1WZ@>N@P]>FAUVF$^^EE-DQYXQ>T!#Z'X*5WT;P?ZSNWRZ8="M_+
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M8"[PN[6ZU+Z1^C^:4LB \(T'N=''V[6SPZ.HLD/:P@\TSKG4KEK]E<I@=<I
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MUCB9U>L@B)BOQ=2YX<+#71([M^^'.1?4K4.X WH77P':1*1-F@DF2K,]YVW
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M>U*C,I@]C?-YW\CE5[2YXP""=5'DA.:O,06AC*8MG"#A0H2@=$VM,_K/T_#
M9RY<#O[%LVJ=N%^6OZ@)[_D@IB?;X,%&?E[K[<WTM>?P+ ':7)Z5'!W8ANS0
M)""K:0-^%OQV<06?IRS8T&6-&1I[;\^7WT*2EP/,"9YC_5I22N\M+28$HI&A
MA9<P?DM (1&NZ'_"WO25"Y&K53,K0ZF?KP;]/U1U" 5U16>R*I@]QT%=D25V
M%6/@25KMP3&BL L12+D/I%2*CI3YY(:M>AU^TC1*Q^.-D@+6?:)Y7F"K4,NE
M;AH\X)M,%\'VO[,QW)[Q/5O&(#-?V:&2&H^F>_AOU*+H3,;@DZI/#<MP/4?U
ML'&X'S"I;#GA:RM,C&:_^,DO:QZS.4=ITW=7,X_>2RKR@="Q]$X,!#Y!+N44
ME>6_RSR?;F3GG%O78(4IS:I4+J<L3-D,W%34N$WZVM&?I1(YRWSRQ)JE=D5J
M-1M2K=7,Z2R+)*:/BPT^4!=T-6W"^*!.GZEISZ:+$*=</0P3_. #TE-/  <@
MG^L%% [.!ULLQ[A6WV$T:J$8X7&<9^Z\L%DNM>6*5%=:Z2LN=V>&VR>YIE=L
MT^%142J*"KJ\;*BRH)LK^/(.7!&6@7&_M]F*NQ1QT;Q,_ ++H,&,H@IN/07^
MC8/I$4T9](B&U*PVTM<JG;<>L?49YJ\[*&P4=!W^KZ8=*'64AM3I^CO98"5B
ML&%*7SX%K#%5T:IP?Q;-_7E,$CSH../CX'F(X[[U#%M&,Y"/,5O3=F>/4AG;
M6-45J547(CG'<\Q?,E=+[6I%EAIIQ]4>I5@^+O]FR.E\*1OX-5LGX]=\IUUV
M (!#NS*;. -=DAME^+^2)9F\V]:]R)PNF\/+G\/52^U64Y&:M90-%[<Y.A&J
M?H>'X;Q5 KCAJKSL!9O=1(,TM7/A9;^IAH7 &%A# ,5@?._88)Y[;_>F:GF]
M "J9L[C4@P&:#5 (I&8U!V(Y33[WL8/=F?VE/]AFJ5V7ZI64(](.QP7/0<6[
ML1VX9&%9RT2UGBAY FPZ%8ZXF6[\K7=9-8GV-G)4R^4W!A3UC15WK@[JWJ/B
MUP*:J4M**^60E/,V<C,XV=RUPE:YU%:J9:E6S90?GM>0@0(SUBYGIX9%QJKA
MD&?5G#/]<U%D#P?A.?-8FPEY2V543 \X@J[G[ZAM-X 6?R!6?*>J.W=8NX4_
M#6_RP[(?7>H\8[UDWYK-/?>!8FL7PS14? S\!GS-L)Z^J:[A!IWMW@+.QGNG
M4[UO]53'@MNR#YRFUOQ:<JG=K-2E6NL8!H%^<-3=4>%W4==URG2W/XNKA5%O
MJ5RK2W+]*"A/=)L\]6Z3HIM[D7OR%4SHG>,)G^.>Q8R"=#,*"FSV\H15.Y*C
M)>8(G-H0Z3O;LH/,3IY%DE=\/+W&6V$:;U.1*OL9RB7&J1_%>HI""7NT_:I(
M"95&1:K(*1.>#T )PMH3UI[0BX6U=VXG?(Y[WI>U)\*3\GH[[8YZQ,34.-[
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M!6'L3#LM:^K K$8 Y6B LID+=_1_S5V/T<O(7J.^,N)BM(7:*K5<%6]ZH*#
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MPCD:*)T%R>2O$C1+;= +I$;C&!J5GE_0[F@T YO]:Z$8D$^:L/_/Q<QA9LV
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M]C]HS?OB=L8AQ576@/AV.J<AAEC<0QP4"^ZX'S\KN=2N2'*S(C4;JT?%F [
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M\OQC?S^!2XKMP%1=E^6\!;'P2,Y4-$N*P7S*7-6/T1"^.['G9LP?B)_/K0"
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ML,&Z+LA"=A_Z'*/G4SFHX7\8P5T5@GMG8[_HHKMV?*+[] W\M1[_#H[F@OW
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M3W-C24\L"TQ3/?ID\_S^T/%&_(POKL&PD"C\9V%B#V;UN.3Q#2!I@0CD=V/
M5,=S@[M?,$^(6%2#+V/= +P(K$C3'Y3-PK*83N5/T8Z^-3F%>-6:W)0O\D!=
MJCK:I&/IU_29FC9[,FACU'+]?-^/I?FVT+].UI'"]JD<'RFJ3J*6M*PK !0[
MO BH"(.5SD(;+EG'Y2-[3D@R6-EP?+^[F:"Q!>N1!6-$GV?S47[,.N&CVM^"
M2?4LE9TE.K(,/[S='X*-N7RP4%@#FW*OFOXT;WC%BXKSGAW*<P 8%J]9 'I0
MGUF=HX1O U;/<B)1O[_@R9LS]8UGV&'B'YW.3/N-4DS\>X*7,!-AW<,EPIRR
M&AN,C=Y\?X]\C38FY2V^R[9VN<YGN9ELGC#9 ?@ %J)/Z4A]I6XVY-(Z"7)9
ME-02@ WI D(97J'H([)"#U:H^2O\Y.<R]T==UT]=_@QT8;B(HRPY=@N\9H2D
M4WVN(2V$$^T#XO I$*4 )SC4=AA:SQQ[;'@8<&)YH" ;+)Y(RC-T5->VF&V'
M>:V.&@Y4QX<'&W@Q3) Z^#+8\/\B'>-6XEM@*34:R!$_OQ93AB,;B8LV3(!5
M9X;''[>&E:QNEB4.L3":[88)/"^&-T$;'NRE_^5R-I*X[:=L6]3SS?Q4I,FB
M4;^AK+1P;;^Q1-Y,*U9:C<I)T.8"2(1#J4AD&5G<$U]<.I'"L!&5IB>+H>LJ
M46'2MH^O++=\F3KI0J"G(D"VW CY:10T2R _'\;L/I 5*(XP/3^:]A[DMP<T
M@^HC$LS[FT%=D[AOH$E.@9XT7]T,0]R1L'4LE6XGH;<XFHZ+R@!N/V,":YP:
M@2T@55 BP_-RC,>Y7XH2QS=.9IO%6"H9%7G9"J5P@0C75,\#2XM7;>@&7]A$
M?::\$ 9)B%ED3): 814A)""V]3L[<?D74&FHD&9+FDWY)$B30X<P?7TM18J\
M\H]Y5[J\=0!JM@AL5*\-7BB(LI61"5X#*X_'R)V%EP-_Y60 =[!?EP1>M!0,
MQ!LK*8-G.4!!:""J[.EJX#N9(:5A'1]*7,9?L'*1N5ZXYF_'5L*(=^;09\.>
MN[S:[+T*+($K'ZRDIV/**N=]+ G+$/RS#306=GJF$?C!@O)07DC &#LB!IUB
M3SCGC>C&&)Y+0?JX$L@-[X5R*07\UG'>\'X_DLC4+;^Z(/(&U"3QB6/# A&&
MCH0%,LWFSLP.7 IL@?ZC6'4D6P?@+N/NP:V79)2T-"8Z+-M;U$/@MXTQ]\9P
M.8LX^F3;.A.7>*^ONC)\Y>\*7\.+/R//9X]@<+2!&@.#E]58NI%F5(P.&'EZ
MC"I\>?W&930L[A'(XXV]'8B#.BY:K>P;F+/D4LJI9XXZ,R^0Y2!!X.K1 P[W
MB3[1:)UNR!@ MRR>D\D-6#40T'!$GDD#^9QPE.M/4EIA%.P&]64;CK%@639S
M!K^%&H]+EV#-('-).O$]<_3U4=M7K&S+?$L"NL%NG&+5J&G\0_&F"1@#"'CV
M.0?Q$F]<V/SJLVJ87/EZ4K%2%=9J@+FTH"(-G@8W@E+D.P<$=]M7P?R<L0SB
MO=@78*[->,FUZW*[UL<,AG%35D5/_:3D4(0^4HLR23@F<T XQU.1!I&H_#)I
M>)3Z#V7$$D7:1^I?9X75C 8H8)'%"37Z9";^ $&2'[^$PEA2[FU 55;H'7PU
M0% 7< B>B^Q]9F-1.YR"Y9/X.!#[F(8VL1UD\YQ'N+:)SP\4 ZI-N(<7U5\O
MK!$+7H8$&-T56\V44H^K((DK]O?%%N)-@*7Q3'LW.(O 10Y,PWD"+AJP'$ZT
M+MC^5/68S0T/W)0M';85'(Q!!_W&E^B.[&_TP??7W=C.PV(U?0L.B2NM0P]>
M@?QO2TT^EV3H5JE=2TJ&#@!JAWY'?L(1KLULGY4C!BR,L4$5>!S#%7YX %L\
MGR5\#MZ!Y?E1$EGH!UA8[V*&@>%.D,UU@  U.)PG)KG^-=?]4%S$N1030X "
MMCD/$'.5)E".N0E$82V44PR0S-%7Y;_XDO0Q6Y-A#V@&('E,IF9$EA#92LPS
MS%Q6:/C:EB__(G?Z$8ZUT<!M#4?6!>8;$EPW\%)A*0<KZ.A8.B AO!L,=<S
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M=H,%>]29LAC8\M1#5B^[=,AORQBY:%.0#M?VL>F=T7@53EA[OJ@[8N/BL]Z
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M-Y[*3<W-@MFU<=QV+5L(5+$UD#5![*4/2BJ('YJR^[R,I%'DYKHGD^ZI:5N
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M;D:$J_GR'M[Q8@9^"+4G-I\8Q4-3]SJM04_HBCVAUTW"#"J ->HXE)6#%L5
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M7ITNG$1>!6^QH_D3LE?U!U9NS4WJ> /%=J;--]VC@Z,OX4WK2J-/&#0^IV3
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M*;0?DN;KON7//_SUA,LIO2]NLT)4X= 6)$T1M%Y"!5S<SLF*/1"2;?D2 ?B
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MJ9.O7!^KKQ^Q^N0$JZ]9JI.[RG5BPE1/N2?":=U.<C+JZRESA[@:A_@&%IW
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MMEHH?#5W)G8_*1S3_?/\R3$,8F+@T7"]$W N2I'A>Z#D%1#RVJ?CT1T3O=9
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M1E5S8<ND8,-D_7Z_+M RU0(;'"^\ 1MS"\9+#., L9=(=8OP58!;7V2+XV6
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MJ/H'808JTVJV :8!47^:E+):GS?-?DD?H"X@'="!AT%F0#EX-FLM%PO#M-&
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MD+XQ(D;:%M9"J+,M_VY'/E':F\V\14E'BE94%\2DJ#]YKF&<E/@7U2+/E.I
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MS]3?:AXAZ5>1UBKM)7YW/F^'D&,+SAZ/H72J[ZIP5V6]5$=A5=;+N9BM;C:
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MU@D84PO;^((I.'F);,3*O[0>]8UE!O@N+"\E$\PVO'33#8DS!=S)L(5/=7@
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M569I$B\@/'X ^=?2LK79QT8J[9:XN9-YZP5F.U92;_-3F'WH?6928W/\0LG
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MK) 59D55"DN-;'8%16EG3%7J+U6;,VP#<1BSF46#]+#&.8(3\0U$MU _V->
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MN"_Q$S>V7!@Z<U# M\48 -LMV*76@DZT&4A'#Q0 Q/3G<J[:AHGNT_0/<%S
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M,7^RPW_C&5;K)!2,PS(U8*$\"$(LV!:&552,*:VWP([]T9^/%,CLHO5BF&B
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M4WU#,IHY#M)][3D\JP)M)L]B.=K>G/W8C,@20&-F^$=@BK X&ULW$PIOIKK
M9S+)LY96]5:@M\'^W;=C98#ZBU6(B.50K%H%"]P; L'_+J[(*D#(Q.8EBLDX
MR?;95BP4TZ3\9F."Y1\>JRHZW7I',85+)G$H8K^<>W_FO;L<4";P')T'ZK<O
MS4<IWJ'V:RKQW^)6X@3(S U1,D+SU9"$EKV7MU([T%?-AW-F;N2V%K0Z2TEX
MI5E(Q0$GSP%2V3D@8(1$#'PA">?*;![K_3:94#J;;;5-8-VUJ+!(S)(1U@?(
MYX9<LDL'1)G#C8I!5"0D'I+Y#C8%P::][3'1' LMXC&_[_U=+ZNS(]"KJ)/\
M,H_G;36D]M;QO ? -@(Y%4(S3N[J;!U)G Y"5])O9V%QR&E]B(3)L) X*.;"
M!1/OM&\1$Q2AQL+.R=3.#A).XDZ&D7&2[R<GY7L +1Z-/JTV7U@9AH29S=V&
MT!9#4CX/@VHRU)PA0K,12-U:3^D*'3'8M#X]?&9CCFV/"*%X(P&#C?D14J,I
M$$E6X$>K=7$5-.M";CH:$ZX?\V0JH=F>)B1C6Q.K"%X>J]ING*2TE("HB$M\
MT6FH&T6+8//T.;;=?-./W+6$W*CU9*$KB8+2B2%7"D-Y0N51\<!I\D FBE7&
ML4O  XK0:B?TW(KB@?A^0_@*U,_P3/9@YT<C8A5A-QZ-*^+0F*>B.@U5>B#L
M4C.&,UG=8?9U@B7%$RT1Y'=L)?&RM*TDOGQ4D(:VK=CDE-ED;T7,QF1=_H>:
MAI]#9$2Y(HG258 _X+K8;9:0"K;YS6&)$0<HQLJ##E/P=]Z,S<I-/GX7H3R-
M2^1F=..2TF"X\HK/E.2S\8-;6[K1E ;%FTK7;3)+W#4[N>ZGG=*\9^%H9,YF
M/!3MG]F96F+N!LX]#]VGLS")KH^XUJS)W,!<_%M]K#XOYZIY XST,/MF_&+5
M9K?ZQAS$OHW5.^RT>H\"B1^K+_,QGJPN2/:V9US=\/5C]>N?&C55<_+RP6[G
M#0C\A1;1->%.-7BG)7G+,=K8XBQ88U 5)\=Y[?YE))ZYA)[2Y9FO["^\KE+P
M5&5.<2:ZOZ(LHCE"N'4?7B^RF2'L3^.*>ER(K[ V^I.7ZJP:+?AGQLGA,^/\
MJB#8.,(/EIW=%KRL$K/) MS[0]RODT/\E[#;Y5@CZD(FU$4,J./SZ>*.I]MC
M?W*R_34CA](YJ7U=]N?*D?@XE([K8AQYD,D,.EA2HAVT8DVAJRLR(&2-,K*:
MH.9#V_KR[A%TA\R8BSN:K10=4#BW)>%-:3_>3#8]4HPW/C)E41DZ@KAD(]HR
M \2^(\TR7-#NX5\9OKP:C57<:*SM\Z%V%.<&C:NL1R^E;1A68XVJL48G/-8H
MA>A#N*PXB7DOD8.-MIN=)!T#O;V7!2G5DHYB2REHV%:*ZH.@9-P'H5T5ZQ]_
ML7YIH[=;;*W]5IG49OGZ\'0]?+H</-S=]1]'PR_N+\FJ%3FOH!!PI$?#,>6^
M-!QW.()]@7MK?^PN"W-?X-[L_YE^SK^R*^5_5XEIPH/-[8_9?%A(@?.&F5QO
M-%9M'QQ+>7>Q6^J%RKLM&,\!!-\D'D.D6NN;>6G(Z5?J)D/I5W6NZA.ZZJ ?
MJ"?'N(&8!,<I5X;F1]V_;]WE0?6HN>UAQX@/]QC/T_H3.\P%&I);3Q1,V8DV
MUY@IB_\$TQ+6^U6U-&N5.K^S4E9,[Y0Q@_R#3JW7$5J-CM!IA=6BI$ ,>:(^
MS $JIL+NF*2E4PVR:II<B(P[\ 'QRTQ9ID%L*> 7 GX9X,#MU@';]1(_&;_0
M1VIJQC0J T'R9"!(I98-2JW7;2E"NYUY*7YEWB1B6)?BP(34IJ?"K9^S9E<7
M:H\ M&/A56PK_-^URP1,VZWU9+$E-.54&Z)<%%NO?DS,.5B-9UGG"YT*CV9C
M6D=8UG]7-1U'D]TZW<EO]:%JZG#;YH"@(V;79@.'V39:;4%L)ZP%K[1LQHSL
M#(-<35@Z%2;.7-&N.!@A"(AS)P:Z#'U"["O6>LUV2Q!;"=/W=VC;+<</G $7
M[UO9S'E0C#!ULJK/,(\^5M*"$^SE8ZI6&1'^MI7A7)BD?V=9EE=P=Y]C$K+[
M16HO5S%:-[]+JL*S57AVG_!LJ4,P3:G64X1.4Q2ZW3!_K@K/GK.!6L5M\XS;
M9E0YEH'0D-&G%+&2NB,?E4]Y,IQ9!6AS"M 6SI3)7<9FK=?J G]V8G0E*E.
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MMS^>C>D'V%\O]NN\]_\#4$L#!!0    ( &Z)@5AB@&U+HR   .J4 0 1
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MJCURDCUDZ5M4YT/F2F&GB[<A=FBB( &AR,.\3KU>'O5Q)?0UU$V]P\'I" 0
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M97KPH_!VG<Z/*Q1F/X!G16%7%I  &MTQS"K">L3ILA(47OM9$B6O.5=*Y X
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M(?AI>R&$'SQLWTCC*,1VY H)SJQ,UGE8S;W1P9=A:S\"Z'0XR6H3$O4.S^Z
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M994%*JY=IL/_*FO_9VH>(Q-S80Y9B7SM=7F99I^YV#0=UL*O69KG A=UL0$
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M?-MD;%4:1\<9N:VFDE'8W?3#=\&R(0F(E0A&=BCO^,R>DYI608KLOZ+\<,&
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MJ'!=OR^BK-[/@$K6HRVI.7# Z<=YYA=(@Z/AAD KB5$MBJ<2OG*8/)Q,IU&
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MRZH#3(H\I31ZFCPW.5@GT_LT>4R7?EPLOP$51?2/ZGKV"*0D)5HAH,I1<AP
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M^\W/(KQ%/?H%[[:^VQ1 6$RZH'A1)X,P%PNE* KN'7"_,2"QG?N:S%R^()H
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M6K>=]4VPCJA]#!1A]!L0P4L)0FSGC0[MY%=2%P*)?HH --@$.*:XR8\$9=C
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MHA;-5/&3S?<FX4..9@( MMW#NXO \6BFDQ.KF2A)2Y9@Q*#0[4(BTCHW,TS
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M:=X!K;][!^<N^"(RV-Z2$X%V6^4$*C*H!I*=%IXQ1R:A<+(=EE%XVB355E$
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MBJH(Y=07?U9S &(HVX^0,K3/TS;?^:3K5HXLR< %U:FK,,RI4M)"N1Q?L80
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M7>(X^\W/(KQ-/?H%3VO8;0HH!O4.Q\;A1+Q+DS3N;7&_,2"Q]2#'9BY?$$T
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MLBC P9Z8"!JW67TPQ59J5"JS70 -Y=%U_643O$0^XWE>_!S]Z_\'4$L#!!0
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MG5#3RQE,#$>C@QC#H5@*/&EV%67[ZU"%E*8-)"Q:G DQD&:(-D#7%T['NZ_
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M# !5]$M2*![%B)N"#OZ 3\G0-^V</HI1*7<XZF+-+C#FU]M=5CZ;6Q<%SHM
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MMRD_XE3DEK3K#H 72WGZ$&I>2J:[U@/*JJ?C7)5C!JN"V9B1 D'>FDQM16Z
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MS27<N_R;8;[5QQ/@&TG107\JE\&I"0CPI+4# 9A C('?.=15Z@TN[Z4] $U
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M89VF7TCKD\)74635@96)7Q5K#4[=#?;%B(I_P:,140X"QP"W%T)8-\(+W)L
M2O"81(LFH,C&@NRV<%BE]-+:@:P#:"RCA.=AV!]O6.>:=(QZ8\8O\"[:1G[
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M4=75Y>/BZ5))=X/.7QU;H:_S AD>>D:OD9<;K&_!WRG?\NNQV^IV3!M)*^L
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M#(>1VS6A :B&28^UB'*?-M_ +@QZ^Y(R7V$GZH3Y/AK,_'(2(Z+O)7U(+6X
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MBM:!61*W=;]]QN$Q)OQ>)[LTVS/BZ\?T6- \!U$8!5F$<S./-8X6E+,:*>G
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MYI+6]',/(VG^: 60/,@?;30>AF!RD#/Z1YS@+(CI%5ZXCY*(GOO1=UZ7_-I
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M^LK6H)DE1-SV<7"_?<;A,69%1&[2Y.G# \[VB/9%3>?<Y7&_@?:'.0>DJG<
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M<U*%Q!(25D<SCM-7^B?']=)D0!%429.A!/#6IFMV5<J\4_GN,[\XZN\!34B
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MJ*32VD6Y@&IZKU#='_UR%;V1_]Q$>3%(.>C":,9)VGES&M2=B8<N>_MC55J
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MJ8(A0]BT..BU@P].DXY^%8/KP[ +M2D)RG(PV)L7G*WC.&7[?QY6HQUX11]
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M#\26FDUG9\6G:75^/8^97]4WO+K3<_BI=A[7N;SN9=/*^SA^7\@'6/O7A1S
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M([V#/&*:_JLU\K+YLA ^3UZ":"" 7O=5'UP8UYS#@5QT\0W*71, P+R _F?
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M.E\QTT@\ FU:1JJF";8N3^K9TUULA_3TPQ,4%ZT!CH![XQUN&P,WP+D!/\]
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M1@W'4Y=142-M-<*1,$GW2<JUQ%\6X/_ ='6+?M(/!Q:=9,9U<PD7'0[.(]:
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MQ.MD WE!18#]BY,0T_*:B#?>82;F/J5A%/#%, \3KE$TCKK4*!1MKA[ K\:
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M9"ZS"%[R,\A+E@" H9< =6O?2WZ!>LDO>%[R"T@YO_CA)7.91?"27T!>L@0
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MA]V&[&BPX:?SPIX>,&<71NCL3R[<0Q,ZMT"QHZT)1X__&W&6)(JGA0QE;Z2
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M4SS-P_M@2CH63I.N]"(L(^/#P*=,GRTW7=K[BRZX!DUW<![=TZ3J'W4A-?Y
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M;<2M1U4%AI,)D)->P3]'R4O\7<SY7FDZZWT6EGG@+/*)UF65WL,DK,M[7E&
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M)6-"/*BQ-:QW]#C"BM_0RZ:[AA/+RZ,[+?B2Q*G*U8Q: _1^S59'W!J5FHK
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M=Y(,PS#.**1RKRSEEUO'&PP&3G,L0V99U%F=01SZ$16(9#6N%O/.L4("MUR
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MN=/<_'+U\JGW;>5VJ[O?F=7;?!:7"EO$EBU3TH][G:5NR:1,M6)2"LT;I0)
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M//N42B!#W%5P)RL,$^4]SUUTZP?)2IX5"^Y7XE.GW<DPV_S]AV&B&HKV\,C
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M>""\.B ,K&=F:C0I4[N#Q]E+T1HPZ<4HLSP5 OKV14R0$JT[:)P-X-&18\H
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M.-3WYZY7G=HM8_BE >C:]Q%&OPONQ&Q.[L*L?\)4*[OP_A_U*'9KG?XV6@\
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M/Q_//UXDN\;_$Z/KZ_+GRX;:WA-N;._R!X[!$4RN!PZ$:_EJ&NOJ_)C.]OU
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M!JEP*@4J!$*\(&"X/6<@Q!/JJQ"HS+W+7(&<WT&+<G/NDL ]E+F__;/,7->
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MTEX+5ZOES+H,E85BY^>VRT)J(F]4/W,?E./QY]?:#!,4+DK$T6X\\)V;SEO
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M@AH84 KSA+7X!R7 .DP?N_ML*/E+5.2PF] +G\_D;'&#E:<G18Z46ANR]4/
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M>Q<NG(]DV;<G[+D49[#C9K$93G0E=RBE.>EUL&/J>H+5:EB[.I;-%^Z'<EN
M?EY\]DE.=R0.FW0Z'QER2A_B"2W(FG8_P<)G ]8[%RMXTOKBDI'4DS4CC[B<
MZL&5R$E>G5Y30R&O5Y>T3STLQ$A*!SN\!1>[7J3V_)B;&=%]M9DW6.AIEB-;
MU\P6CU#AB70]YTOT+\Y2+(D(^UFGOT\\\BJ2BE\#I1\T0SBHGX@9* F5]DM
M7+V+98[;I'_1F:Q=KJCOY; DNN>*=2M#&YJ%U>G=E_%L[B="SSZ_#A,X'A"[
MWN5^6_B=2@-_5>CGL?=EKU7XWCU,=[.DB;<X[\TO)44W1R$EQ2*EI"!RHP:7
MN;GW>D*-%KW%E-5YUS M#LUFE@C6&P\*F%=F4I9MA1"/%QN&RS8VEQ?';XO6
M"B740Z>PRJRE^."TK2*G=97!!=&[5BYCD8XT-V;G^XB/)?&5@M<7[B7'Q@]M
MS$ Z=4^QL1^[DN%^@?^8%^(0E TD.[^=4771N:*J*J91Q)&/RVK,@E)C1+'1
MRBU+']!18MWK^.A4/-Q@"U-3ODR>4B0A8H]SYU]7(]\]BK\BU*<:HVM_]/PL
M;<C9.]DV"@_?",8F;->$6O==E9ZJJDON9[N<4%RM"9T#V1M<A<\<272\>65!
MKWI@0'BE.J!T(G'&-:U^35]W[H$3_J:/J;:R@K*204>#0(^9$?[,1)YC.;JT
M.:VDEG[&HC% $/0>XG;DNG1M,6<R7Z]<FN%)MV&YF-OO*87#/6YZ5R&W"NO?
MYW%?/W=<2[GNO2 ,PO0BK4G5V>? ^P-:DA'\:C=BQW.AO42+,M&GF+@CIXJ\
MU;[F[UV6]+UD)Q[KZ,5J@T^</:#;K';[O=U@86;F?99GP^4'W!4L064QZA=O
M/]!LG5GGFG3+\Y?#Y2A'^T$IQR&0/=>JLS/A811\^YQ?QXBD[I/*S@WB&<,R
MAK()H7-<2Q\I)>P5SSRF$R5N?>*UN#AU./?S*W K[Q1NQ&,.7__JX8VD;GG4
M QM=3(CPDO;H8L V9A$Z-&,SVY\DR3;$OGFGT4D&I[6*O3B?NU9J&?;LP%5I
M$W]MOIB63\HG*(^]N)N<>#=T%-\TZSOQ<5W+$7+?;>@"EK6WE0_3=*Y(F].;
MVQ5IWJ3ULK)<END"RXWBY/_%WGM'-?5_[8*QHA11I(A(49!>I"L(B(ATD=Y!
MZ2V)M 0,$ 01Z1T$!*1WD);0H])[;PDDTFM .H&0#'[?]\Y]9]Z9>]?,'S/W
MKOO[]ZQUGNR]UV?O_>R3<_;S?@#FA:ZWA!U_W<*4Y28W&(8E(3*$/QNT7MPU
M%Y6YQE\Y(AUOF'_MBG843IZKB^A)8)]F%WL'@Q7!%.:D(:"M (+"Y[5-R/ZF
M7Z5%PSMMA/VT+*H0,<NFP(?RJ"M?: 4_M7C)SC"7A. OSKF4:""8$?T%;Y9T
M:/E&PRFTV>>-,9-^E="F--A)Z(M=I._SJFLI=D-,K2E4HD,#!JR(->E^G,W.
M?&S9VZ@Y^S:UAU\1.'WDC=+^N:KLGJJ7S(4[-^O?9%408$3TEM47OZR]> KT
M[/WDXXV/QZ=H"XV:AHIBZ(18:GB]FYD(_," YXUBVI9)H3BSIJ<LRNNGE7:L
MN:;:)?PQ_Q5JDLE\;$^464/3C-3]>M#S^W6(-3_0QNW0!XK.2:F<AH:V#GKB
MH;:1$:"Q:ZH6KAUKOS'@6."A9C]2:ASH&2>6Z*0Y:MYA1^DXW(8%_,EY=X]W
M8OH]+22Z5SOQ]1&\#]MRW#ULK! S[.LX!6<^9!N;,N7"))I$)_B1 4;Q6)9P
MZ993UKU;^;)Y)S;YSJ)/[AW0T+#8$@]X.KD+[E*AO$'(I'CS*6^^ [,3_,1>
M5YO9S\LWN9*/C.@%!_-=/C_XK,SRQ'LQ(F+=0"POL:P_0EJ>;[1:"R[H%C"J
MOOWN;24RR/#+>)XJZ*%[_T?^J9'B-<&"+NUTW&W9T7G0 "&ED<1[=*1-[-CZ
M"N[XRKU^C!L["QDYQ>4T#GH"^Y87IFK&O8&89N@2NZN7_V]7&BT&2]6O(*5[
M-NHA$:7!?H736P46ZUJ!)WPM^1I4C77<@A)U5>&=J4^RQ'JLA2[*/A^NOZ@W
MUR6Q!HH%V6* *K  CD"!1D>'P+PPH9D,:ETEX8\[E)K/&V2*'#MR[X9>^!2^
MF+E'3Y UV876^-]&M?GE#)_/#+":]TH5"!4_5_E6[%GH[I&?I])#)B<-QE-T
M8R_P;0.[\R+2E>&Q$$J'E<TT:S%ZR_G7PY"J)]*1,^YG%3+=KO:8\ONIRP+&
M4YT<U6%.WTPB\O:?CGYYF'HG0C L6S*V<)-^:1.H\LA\MR!\SO+9FS"S))D%
MLY1Y$]_[-ZTVO]&]C%<K;*GF3KS+:V3,GIS)WV*VS_,KH^^8<USV$E"'6+GA
MFVP#R?0_JN6V\MTG ]IJ,34QK^TA#/:=F"?G7*?1JMI#]H22*,_]14,EVIB7
MK3COQQMZM6;_G>3W::YH4*S4Q^HP/(^;"6B^WC@7&79G>$BPA;I;J)?YUGW*
M$^K2BW3A)G0"%/'NE8G(O):D$=5;-4*-/T:X]EX-4!V;QESCU!?A% NE=K[.
MCXO <?FKCA*K\?! JT<JFN ;T].SK#4MF@=0'Z(OQBS-VM5_>%VHOW%7EDHH
M'&MATN!AEHTJ@Y*&9Q/8>">H\X W3$.;NFR\[(Z @<<X4_"M?NI8D*S7S,V^
M4O3PR/*3W$#'KTEOM#\\T+I=S6!=&M(J!W8/19Q&1D9\V)3F!9DRYB>I"?8]
MF.>CN/A-^[8*QR4#]=3OP/MD@ /\43.&8H_C&/D'DP]IN:0P)AM? Q,OE->#
M"EO&;MBT'K%-KQ('P?,R5"5+FI%LZ1O5C\:.B1G;79\%BBHWXO,[V!ETOO!;
MY'C%0W'E\QS<?8W ?4297O&Z"]_],"A 2NB;CZ^09JZV].?81!<?&9T&LW),
MK6G_<TP.=HJK1"<?BSW(_>,5>*.H/(Z/*](@X2<=5U0ISS,AZ%1\KL5__[,0
MJG1E,N#2'NJ (IH,*!OW_^F[1EK DP%K."+5</GD3O\A[>Z^MOQ[8AV^XG/S
M!K%A0W1H$ST8B7I >HUL?W46+?2I2ZOI>V,!4@ID^BI@%J;AKIB2U_%FQ_L<
M!/DPMZ_50,GDZ+O1BUB)&PU=% Y\/GU_=L]ZYH^ 33#(U6!0Z9#YYYZAX^SE
M*RD,BMK7X]L>MNOEE+7[IR5!M0[I-!%,4I%B.U8Y&6_!$@4[ER['/9O-*BY%
MUQ0*"N)F92;_NC+Q'?6GG PX]; \.3^BA&'VTZ'%OY_B0'!'VF0 L1I%LFXY
MFVP@C_PW7NAS04Z@NA6:*_?3?4::47M*=MOLG\ZT]O0D]\+M#^0[CP>UJV6#
M.*>JH$DKVW[(6JB"C_VID4^NF7J0QU;]0GG\[8!..P&GFWJ=!MJWNVX<1C*^
MWO69N;TN#-&J0V.&OHSD8UW@C,^NVX]4=[TP_0A2/\[Z-9R!Y78YW8(T5,I?
MAATL:+VC71<K>2IH\_FP./[WRZ?/2Y7O%%[YCMR(7FQN@8!<"F2@"KN'%M-$
ME/\3WY(20N0(BH56P]K-HD)Q^CN$;05?EE5]U-GU IL8Y.4%Z=Z,7+*(+\@+
M MKL&H35[(\S *FU%F%.=4EMKGI6JB!IUA*@E&$<[>@H^[ :LOWI-_WF_MK<
M3[PFU&Z?J 0Z^KYY9D*44<"C53*@?7X6E 3+^Q;#/AYE\NWCHXN/A=DD10K5
M>*_\ZC42&C+:@1,NV9Y/TZA55 )!.RZ-I;+*@A;-_@"9:Y;4N&#'S;F(\IZ3
M?P:T_-&:JAV7^3 /KXEUJ)5FLC3:ONOX;K2<A5WI*G_ #SY#-<ZXBQNRD-II
M$416'E?:FV07^9NBOY3N2%@T2=H\'#W6G*1[^K&;*T*O]4KK:0H]>-)#,ZR(
M99NQ,4#XJ1KG(SI3- _^UH]WMPQ@3H8WG@=(O47%Y^]-XZ[Z4Q A&]L)](W:
MBPZ[^_CBEM4UJQC= RX??&S*S+0@RBX?# 9G9)3A;DXL(NQ_3Z>G&444?4IV
MTS7D&NK487@>,%19AC]HW39C/$5^C%H?=(@&VL4P,_R6]6L.;@50,L0&-_12
MV;Z8S7V\M287F5@*DW[D:A98@X VUC2&)<BS*+N==OC]FIFLD^EP<,PSI$_4
MD*0?NN1';"'1@*V"#^""'G[!N%'B9RP[/^GE.#%R!M9042'J!Y07?V=_LF$-
MI#ZDN\=X6SJEK?SN/<1(DKFU\H+S4]<8/?5Q<:6'^H=J^#=+^,QDO)"ZDI.'
MGW 5.E6[M-XESJI6);3H2U<7G;2UNC+=\*7J\/#F^07O^MBG:JYE'/S%SXMJ
M5=3+3-(4#5\7MZ<_/^KFI)LUW.H@J2K<-RN09O^UA2-@ @9] ;/IVRC9DO>>
M2&-?<$A%8TA5)6RR4<P"IS>6AFO>/:MH:F.YBG*S9;R7-O^=GMD4+>.5'U6<
MP11K<J,K%C]A'@RLZQ!&E4Q,=(,*$'P/:Q[^3O*4B0A\HAU6^>FU.>?MH@O\
M1RRAR[-/5CS0N+5R:<(6FT-O-^5,1XRZ4&IQI>H01X1ZSXG7D^N&^$?-@\3,
M=5D/![AHGZ#%;J,2U+>/<&68#'AXHN#_]O"2O-7\D9.OSW2S1=#&TZ5[VHV<
M%BMZX8->'R4%=Q \!@SZ"1-/N[KF$'4(M!2+ADN'%@:\+# [(1MFU'!H(*;R
M;5+^>NJ#I4C-AOU(F5?39>P>L]PPB;->K]XDF ;FG=6- 3X=EM<%X,\[ZH4
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M>2?W"P,]$P 722/PW?PCW5]]@W4-[/AS8L*^O'7,#L.4I)T5?)$Z5E WZ]\
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M\W?WV<QF1+(=7BL\.O[Z[&TR@*%LV@P&T6F<6RB(*\YW>N I:*$$V0-BH@Y
M2*G!*Y.V=+1Y@7/8J:EN2<M+LM=&?FM>CE.FKOZE$OE;->N%T17@$0NPV !1
M1V>J:S)VW2Y4$V=%3[_#"%C$' OWS@_>54?EE=&^<& @-OFKO>%M\='UFOQ)
M1'7B0[ H+E1" =@S60,(^H4^"^66MMMG=WZ]>#K0Z 6^.CN^[\6*1.S4K0R
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M]]%.54'O@",3HC1[-S6R"ZV?C=S(SDOX\*>*@=_]FNO^)E+Z-CJ<;]FA^F[
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MG2I(@=XD2_:]39(7&;!V'T)!!NC_H\*T?[MS]P\9D.FP5T$&J%%]5SC)^3N
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MD6=$E)$O:+.K_.R,>B/L]VNVU:?XW&-#!NW4[<Y3"6&Q'JG=0<O/'9]1G#A
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M",B$$A5-B :\5$3:[Z^V:B *8^&)J("_4J&L:  +P]VHXU_!P(HS?32@EB$
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M@9IF56^;3-?[UYC)':=A[VXKSY*8O1SAK<)W/+9/]QE16^0\)-B*K-S)GF@
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M.W#J3%"[:ZF]P@3VJU&^!FC "GOM7\6V9N+_9'+Z'=:(!FP:'E1>!Q2B 8A
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MFK\#O^;&+ME:P\/QNL^,F5E _"9O%^XO15A=W"C[GFFNDO/9=)^EG>EW_=1
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M8VD1DQRW+E67^S;3[C)M76:J)NKP>6M'5<N3I%E;DMOEO@5Y+)Z5/5WUT.<
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M1=^,&FSJLVHR[& C0RMLQOH9%D^6[UCD)^[$R*Z]4LCGTIN;.*E*Y5'4K?-
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MK[FLISOD/[K/&=*VYM8&R4N:=5_@2S9\$N'5Y@(-ZZ+VX$V\^Y)%1\6:=^;
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M6STUN".$*''<D/5O'9@J^UZ_"#@;.X^((  \=W#9GLL7J6@"X+@/+[W(UDD
M>-C_F80XO;Q,$<3J%1R!@ EW<OFESIUBCOP8IR:/.<Y*]Y=J<MJD):&!K]P4
M%Q%@=[3AUUX4*+.E%*-L@9+BJ/BR>6C"Y6QC D_*8RN6?CRQY@)K:%GBA'-<
MGGTEU-&MP(RLZBHT$JH?N*/ZSE/U[JZ]<F3CQRGJCT6;36W-B+R.USC%3+67
M*6(1^AGACDSE\!^^.EPZ3Y-BK0M7O Y%5XLL^T07@9A:J)P;^NSAD4NMQV+Z
MT?769<<U]#568 H"ZQGOZ)J5. NE8#9-,4^;SO)JYGK/Q!0>"-_M$U&7?7[
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MC68"8%", *B3WQ;HP-:#U[2V\&X=^$C,]8M]H>4C<W<"0#<(<S($(@ ^.A$
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MTE#>9=(&X@J;)PK[N&\?\GFJ%-%F)F[)HZBG'/U+L.Z,P9W/"V 9V#DF]P)
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M>*_Q>C!Q$JVMCW4+P??"7!DS5PWJ52D[W&$68FP99I.-L^V$P\0\IOQLI]=
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M>=U6LLQN349JFQ>D@D=]?X%(M:PEI*[5PO8Z1'271_VW9SG>Y@B+L#$G3HD
MP7=4&*SG=9VFK0D%KZ9'EGTUO)T^]=R\B@SQP,G'_1@%HH'7Y(XENOO<*MW"
M(XSVO'/S6'1AC;JV.AE;H1,'XMP5>8J(T[*#?4FT7*A;[XZ0BQF35*B]>V!K
M&5"Y\LYTJ0&6FXO5$"=[X=)G@W:=2X=*KZ*R%B9K5YZCQ::QF_11XYO3P4<2
M/"(V#66\V<IH[*T!^V;&+)!Q25CR"75*S:OTB8#6+[\IK5!:I;BT%KF"ZAMF
M>)DJ4$H3--,(X!LH88D:O7'%L*G(W(V=%3[K&MH,:)(#ZV\X8("7N?1P:(.V
M(BY)6?DUWSQ6CD2EPI[BZL?(B4DOUJIM'@'?&W.=.[S'+IBWP2C<E)"6S(J.
M^U9)(PB,60^:E827_>'*PL-I:W;X]7).2HF#^XJ31\7MF=S52WD\E*7JZ<R2
M 5D3UNH0^HLM>-YEQ?ZS_^*[6W;9XAP55BC( (OT,&"0D7=&ZX%?,S7NP;M9
M<TYQ%F^I<:%-"*[!?8*XLUA?N_[PLTHDP/4DX,YBC>SM,\X+@,$A083J67'[
M86)3T=Z.,++D(I"NA7_/7*R%OU!_X)#LU&"P#M@)ZC%SJ]S4*VMK3!)'U4GY
M.?ONL6X'LY;15)K9=309[\'\J146UT-COK#K)2/VEF:9)5>N>(M> 'T&BFWO
MQXY*[<MPZF888E;?TKFT>K%T$DUZ\S[Q+0I5==+.\9Z/K;AO9+=.(9^IU!F5
MZGL]7L3'=MX)G^NJ7K0PV&D\\'>BS^!RNA<--%7>!VVY'R9KEU?GA<P7LRRD
M4Q-,A2DE_L4:-*$+-*$J+DGCU%)6IDI=S'_U4+@#Z?C%DCDMV$&[96<%KR<C
MVD&S%DRZ$Q  A)<>(&%T>8XU.G>!5?PF2C\12(SCL./4E[=3JC;7 3H3\__P
M-A<-UM,J'<H;R4L^[BS0^W^N>,[_?QJ4\!\9UIZ77P"+(K<U(B3@&[9_!)>:
M9_T?S2!3_UWO#7A)*=+V*3)+UV1=UQ.3:@A:[P+4V<+BP=D-]06PU/P#E;J^
M&:UO39P,C]H>-LV5B/UN>;V_*V'S,R9Y)%AAF+8Z%ZHC86&?PX*E9:JFRS@L
M@)C:]<R@!?QQ%_-1M4KF?A[=@]<5*H$C,=%G["_;2R#2C57'B$ZN2.I?&OTM
M"\7ZP0D<PRV"TT*J?U.R\N!5771"=D+RRNL)\CQ=+A^UM'INOA''*=/"KO5V
M#MSJ3Q57"40%[I%[M<<*.#S&AP4V3YAS4@HZJ4[RRU#6AM-YD5#4S54ENGU<
M8AG^?,YE_4W8.A08JY@ZI<P5KP(?5/G#I2WG]G3R_7C)\A-Z](%O:^$!ZBG/
M<<FJC^373T5&)VD9#PG) NV'G)K62^%9+>DNNWN>/PO1BDZ^-#V::<B:-S1X
M,;$T9ZM"H)*QO62OPRB-S\M=<I2)X@[%9M['ZR<@I_M[>34C06\B1ZNHIQRM
M3&-?.0DF]A)0P9'F?L_]IEI>XPW>3^%7>K0.*09Q@4FBIN.-,N/D7:6/=A>Q
MU;AUH<HU65XWD2%)%4OJJLK;'%C]IQ.04]'E>M\S4IYX3,)+\3?1;WZ(U$ZF
M"7&Q$;IDSJKW?:Q5QC"AX'=493=A$+E4:DV^FO'Q=(4^\<UX*7J;"@C8N!9.
M0-MCDQ=T5$MK6T^QOUO;C<0>H892ZL57,QY]/ZFUBRRNEJ3?F"1X94FP3&GE
M44GGMISOD3+LY<1JC[0EU),3:1Y_FX]9([HJ*UWHZ= =\C3_'/<""!>=%'L!
M( 4M2Y]+[=:T^0FPI0,\4;WF-XKZR!*T4$@-MHL&2!-.=<<7B[B\O 066GFR
M:)K8N5XO&6S$V+]#JDEM/CMB2M9F.*3-TS >P3"6D:W^E(P*BBEN-H2S-BOI
M55K_O<Z-(.8?'I7(==G>5.^1LA0@K9T&[YYX^<G[)R[=J^UWCL<O@& #="^(
MY3&)_[(!7@M3;2.;VJ?Z%9UZ-YZN_D;T2LM$7)&@XR5;PX'AP![I4L&FVZQC
M.C-49M8NC..0_@ZB'^W0&(![$8N8 J-WJGJ@;#5C?:X?OS7;9)U=!]H(?/]_
M8>\MP^**MC3ADT ,0HA @* !0G"")V@(P=TM0'#70!$HH @DN+L$=_?"(00G
MN$-1%.X27,J&W.]YIJ>[O[[=,],S<[O[_MW%6:S]KG76?M]]MC1S?INPT<0)
M_*16V'Z_,UKF96[DQ>$(BV']4>5)W0>U5;< !364,UR#2-"#U<7](,(E1#,V
M]8666'AT MD=O;&>R%23GO%V0"+.QT:;8/Z)VX,M.U"W'G@KVB;.6#I->[PC
M7,8FWB6B4D&"A-)^,BRL>]K-U).E^*%$4]DS J5E?G_/6E'W4NO.RCYAFCJM
MGQS?D-OLY7Z>GLJ;=FN$TKO#)P[C4?9> >+)!M"=]E!;'CUJ._1)S%.8>F+>
MJW&UJ6=MU?1]BL:)2<+;D,.4XIV=<"2L /4FA\8ZBB<.KU/--SHS/I0H[OZ-
M?(-WQKX+4]QREN9<W=\U7K#3LV=,,[RE_%)4#6A3U8->MF.!;_"6K]OH6A@U
MD0=+%1\6D#;B;#+).Q3L,1U?6]Q1*/</3KNO. 7C[E..Z[ Q6<H)4B/78M/
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M711X3HP_BK^HYCRT%,LO$^VR9(?(;VGN]]@0R'8W$R<P*Y*:/AE)\=U3"&H
M/X&<*I*\/DTY+SY,X>!L=;1XDI(KSRY847BLH?<NT_DT<<Z32GTM S89JAJ<
MER?K0)RO'=)-WILG35\OIJT*^IHN\_1U+HOBZW!+F/(SQ2*<0FV"@;P%.>U<
MHNC/]WM?3W'2_=0CQCFE<QVSG)E4H'],@YS6_<N\K;R=PEYU'9Q*CJZJ3A,.
MGR"UZTJ?>^,!KTWJ6=]R A=;K^9WV-O511;TJ*M+2*7"9CUTF&RLZ%F$V=[;
M4027W3U?._"=VN*V$_)8<8J+XN7:D5S\5:CC>E-"/9SF-.O=X"?;[H2'%3HD
MAW1$.C<KEG.RLWTL9:OJ;A+*0KQWO/X6B.R_K4$E ,6DAYGW._Z%!0@>Y&.!
M1?^_'!1&AEB[SC'[;QA#+'"1T?8,<MZ]1V@.YD?%01&7)>F'2^,DAOM"B"VE
MMUK]A@F"";G\&VHG=R1.1$S62/K+?K<[A.U4>O@&5( VE/>$[FB?II@\1P@7
MSL%K&P\O0Q5[9V=VX\UCJ*4KE:>G3;F>!"[[]@_0D\/75^U)P/:3)BO#5K8)
M)/3U$L%,9@_?W29;T%E[8?1><C+S5^*DG(LL6V;P$/[.[("3DJ/=DH:^ ^M/
M;A8?YDQ5QNY"_42K^XSD/'&'Y&N3;KVH %?7!+,3Z,K%])'%BN3ZG*!A2R._
MTSZZ;B:V_NLN904_Q-!AJ'57OY"2X27D-/SJIY3@BC/$2EQ01H%60>E)F,C@
MV4Z]&ULCY=#DS(_Q09SB_ !Z[A^T5K11S A?RYRP]G%F3N;;,6."7]/&+DO8
MC;-K[@DIYJM_$J-K9(VJO24K9!N=3[H0K"BVN8[4F/HW?&\ 75[+/5/>(W(L
M0)S?+'J^8(]PXN#$ GT.CEA 470E._-%!#*(<!9C4)M[33]5(;":5DG(\J&#
M(?I:VE%[1;L4%R]<.ASQEV,872,^GD-,5?>%NJEO-7 V?;I1#=(4$!I"[Z9U
M(,!5Z5:N"!U;5J'JL?9(.&S#=8UIL_#]6)<"X);F_I@TQXB%;^E%;CJ']NQ<
M;?>A]V\8[!U>8;R%REN=X**B BMZ<QIZZP&%&YO^@J9I^OW@D%@_^]I@G8VD
M;4U&XT*WY]8#GYEI?<>D^T/B*8GM4RY3%^+2:?CRNX<31?'JI#K#CF'(3U[V
M^S[S]0;KLPBZ*QA$Y;3T!8,:>-=KK0E$A?C!H7DV1'CO0US;SQVCPI[)=V4U
MD\>R-XD%V9?=5!K>[61AQHCBQL*RI W4_;KKDN*$-'1,0P6(M.[NL&O6B'EX
M1]I-WR"#(@OEI3M55A+$92N'22>7;,*LPTI\%[LMWY8&(/EV_@U+I$C9K^ET
M!*@<,TTLB@R1V.?;H+YDZL "/"08(3B57?J,Z!7DZ$%-"493])S$XE@?"W3*
M(-*1QYA7X'LG9E.SB!=@%E.7;I+:IH!J[B"HQT81E,JPDG]A*3K-H]U_3D_0
M5B%M6"N7DEE&0T_E@<@WU*OWI?1'<6%BYE2K@FQS,).U1PUP%AZGG:PRG=F<
ML4"?L9+==P5E,I1$7D2P\ /*L 85UAQ ^YO&,^N!7<>"8'QN*KQ[1]LY(+?C
M5_NZUIA@!(*V]2;H3@]U4!OC>?Z'7?:82YR8 X.:7<IQG\%S'I6^<0UJ.@$I
M>^/-8R^.X-T@:Z;%W'BA/)O=;>NEX(JW>_FSDRU[)V"44''S+)K_E>PXO5/$
M1+C,8KB,:>VA9&3"<Q-3=15FGNV1"Y\M<Y:D4IAEXSIEF6'AS-XH?;0LD1-.
M;Q1^;.A$;6O^_0]Q#G>#;D9:LHU)+Y#1!XOE2:=F1T$F&CDUJ7=)P?R:6AJN
MO*K,(AV3TIETXV54Y__*Z[(IOYU^<;$CNJ<DBEE70>)]BD!%+V*!Y!6, )S,
M+AW6=J5T%%Z;A[$Q/'_L<$2#!3H^044W]3?V>3>/2],$775B[(M\!\97-=3Q
MXTTH:0#"OI<S&]&!! W1EC?S+_2RPF9\*J*=U# /"LK=L0!7^%J?A2#"&:5[
M0=R*44/97!2WNAWHGK=]-@:/EWGT.)N=MZF,=NC/DRJ%Z_,W5IQ>[N]=\XXO
M:WFE:;(H>MZXFB/Q=Y/T-]45!MMDH.(#*=]"(X]J^H^DN"*>BCM05+V;5K@9
MA6$?ZU[FXRIN[*%CIF2F^E4CW+T*(L=/S$5,=)>3"9C(F+V/8@MMH%;)G&@V
MD@ZM8JE@"V'>MA^9%5Z:U+>"ZUO%8X2GO1HJ^=I,=CT; L<']:#\((84SF"/
M1DUS:Z&OK]0OBHSH$RW"1M*$P\L^1H^M+X\9YVDG?RTL>I5AYO)ZDB)04WK.
M3Y4K&>^$LKHI_&J*O#XNSJ!6D\C4S#@\7"B)4D?;PV\,"\"$F?[ZY]+\L*;K
M:O0 'S--BD#_"IEC&\;(-$6@1B 76UL[D+W%/[6L8Y+JS]P:%M@;!.]@@2<;
M[R$'XI'G^">,VWMM^^E8X-("@NKZLV4'._57N(V-:"V2?"6>HQ@+I)_KG?LO
MSI)9UDD-*%[ZIN=O'[TNJ?OHP!IOL;SQ=N4LE6]HIX"A #[K-9P$;S.C>FS-
MS%=@FR7^0C"(]L$W;@E7R-[ZM$7EX_FNTY1&&.FV@2 4OH^)\V-\0<; PI"M
M=->[F%BV3BK>CK*\D=#=4X.O"P8U3VRX0="HS=1 4'S?G])Z*XJ&08!30,8#
MCAX\OE/JX;9Z1\L!$4W97@&.*&I]#?GI"0+M]JZX-7V?UC_+=W0C@CU99=>[
MF219TC-FS_Y+^UD(/T^E=))Y\%B)CW88'FR_=5$"2'T!VV_I39NK''\?7UJM
M,V 4[F/U9<V=(4B=@.!EH \OX5LY:/.<NYY)K*11H^+;YH9LIH)DX:'MUZ:Q
M_%U"#^]FN;T1X*F5%.!!O#@GZ2WA&+ ?N<BL0:8_&4MUGVI[(K#BB=)82+T\
M9FD1B/8:GT4B0:!24:.S0?.=;!AEB.&1GN!D2O8CWZR".?)TQIE@"C-U)I2(
MMC.M]%VV9^M'#TR;OV1'@*"MOG?5@7:V6[$.Y&B6FW7WG/@G)7C[IE_8U3P-
M5UN6?9&&K\<2KOJE6>8,^0M<R,X\)_>A="PS\,/-9_!H^$H\Z<C='>[6>.EX
M'DH/AVJWV^C+, 3:Z_C)ZKZ)L?U"])PH8>;%91V4Q&K-0_SC6;>H]TDWAR.H
MSGE/.$8NJDO5C9@!L]_ 7<\I%QORA@HO@$Q!X3Z1*U?->&H)V&L5W(*9-F*&
MMW$:ZGFQAIJ";7CDU,SNX01$4%3)3N.<AFRK)WE__\K62,('32'(W3M""]HZ
M*M%O%OGJ#1<TAZ]+1 9'/>ZRQZ63?RM-MFPD,!%LZWEFN,+?;;_2[7)N#*+J
M*X<;#LDYGB!^>?U2FR<_=W-P"&\C0A*NI?WN,0=K"HE<P/7B/'R;7.P&OA&I
M'DAEY179VAM>S,>I\CR<>J]34<+M?%X-$@S9G#.O2C4;BIQ69M@\.U-BW@*[
M)F^3?\X),J#M.O$I%ZDJ=MQ;\%J8?TZ__Q1S/[[;9SNL%.HD_/.]1OQ6AJ]<
M4':1-,O#"$9_D5CX]()P0]VY:*]]SF9;3,L/!&E%.B\D=MCP6C> EL&B+]NJ
M9[YO0,YL/T?$M'!4(X==-.R%ZDP619NR\574Y*+ZUJ_IA<;&>LYCVL M)OB<
M48ICT^H,_]U"HOFN>CW?V_Z-52%F_,_U% 2-F[G?QQ0%65'B^LLY+C?!8'9(
M+>[Y/37-,W9=N20Q@:[263B=[TOET['Q.>_B3IFWQ*8CA<[B5"+]\--TDE;S
M$\P3ICGP-+0QX)/]@^#-UJ8=@H:C3^#I\W3) [NEJ%\C9FY*EBY3:T-K-MX*
MIP[&$Q9.D^YAOQ*+>LW/P@@HHL??U;Q2$%*?,P>CN\^F-)2>0<A_1BGSR%#6
M!GYRX+J1=X? @2<*CM=<+1^EN%P9;X^Y50LS;@[_M*A'6U/9%!<O8][$S/!E
MIV@Q2LB)G _-(_WK1VY($=RB!L[XM[+RY*]L<NS $)5>$W6QRS4LX!^@A@5^
MB[N27/\0>G $Q0)U[[  !Q9 *1N&B2)70 '5PBD869@#:DKIXO=62/DYE<-)
M?A:.FD)4#Q801N?J)"3/E"ZA<OG+7I8;)VX]V>!SZ_>0[S%66_$#Z(M#[B5U
M#RH7Z#0_DP.R9X[-+*<]S]E)# \SFN@G3Z"3D+NXEXP-439HIB<#X2%N"5]W
MT^:9(R;)PW_G8 &%/=;46UZZKQ?\AL5=>[+OE6%<L<" ?3$9+530UI/A@KS&
M+<>)W*L5U;\NR.]FUZ][<A/1:3*C%D3$^2#VJ* V$7S.F(WFKQ_W\4ZVMX;^
M'HXA!477/?-RJ9E:"CQF,62/.H@:XFAI,T;D\!'\B#)DXE?G7/FE(D-F(QL<
MI>P!Y3"VC_G7)9'+WA$AIM=FE1_#HO09<M ,;UTV,,$"T0M+F.^0'JEW<M3G
MCZFK42TV<EC@[G6OZJP\0[% U_)"&W()(X*DW]*2'+_<4C[C@?$O42F5N=EQ
M&&HNM:40=IGWGC$H$4K4.\(_PWS;*OG\YQ%D'Y[JT+>O9<-@^8ZJ,G*WG&OI
M5I-3>N\N]E;2#0Z*S,Z1\72Y4<(K:' 8"L]F8TN>?=%HB'[$P[>O42-'F\KV
M(ZY/2',^>]]VF,B92[OSBN)Q224"QDGP[JZ$$U'5B-^2%$U!N9IU!67M;^J-
M@ Z15)@HDXBJ9^2V0UI3S.K0X#Z!WQ&L:F5O]VP4CN:<(D*7UR'3"ZH=[>!M
M:M/UGW>6/,TM['_DV_<0V$HFD[Y0[MK7R]J?!M-_>0%52);;I"<#FP<O+]#A
M]W?E)+,$[C?3'S[(C:,UHRT+[=YYY%5\OC%Y]V 9SF;W0OEF#RA!CE?V?:,F
MD]W<DS>,Y.KR&H>2)'=V-48M_G6U*HE?)+H"OQ[<:[N4,,NCX+"&'HSLM18:
MO'5-S/FE4BS."#'I*+]2%M&X"'37+&H:<OC8;0.#P@*A5#^]R%P]L,!P %G*
MM;QE'5[GEJCSS&=H>U;E_@;W1K)F^T<6:.LBO(B8>*8;%,]>W]=SF3%=T5;)
MOCC2T^_9)#QAMKNR8&L@AK[5%E@I2L/EK6_XD?%-LH21ZA1_4:O70=U\D<E
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MG<1S.\\O+U^<GHL6)2&]>:WKLM"3F'P2+) Z!CE]V4!X!:N^&L3\%MUD#X*
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MZ7G% 7<XVBA#XM2V?G U4(UFOR;1ILA:C[H"?H/+78*U6D>8DM>^]_Q,+/C
M)JR<3])6==F:/KB5U5.=5TU!PU![FZGCR<I3J+@K5,=>QL^I?F&6_H.IE:T!
MCW.&IS='4.$C,5>\N48EMI]=C09[9M8TL%(.7=V(^Q*?Z9GOH42H Z1 S^^9
MC7F0V8 #\BJ;?AHT])U+R:\(TJ9EX<F&0_M T_HC("'B.'4LX*8@)?*C>+YB
M_\*&F;$GB=;Z.5W'#I O,B<E\U0K;#(*YRF-+Y$DOK1V*&.8F 7#%Z*GUH"2
M;!*E$)M3U0Z>9D:86'@<BV$@-ZB4I;""V6FBT7MTNVA <W%X%#2LKKF'S@[N
MWJCS7LK:W0O2J8/ZX_#*3E[(8_:&QNWO.0F:W/J>H:8BH6?(*\QK"O3A-]Y<
MV'NYF2W#;VJL=#]^[Z8LSE*T)6ZLF8"( %>RRC?K]*+>*+>FYXXD]!DOY'R8
M96]KJG;4<%7%:-#(YR#0X,CVO<'Q\%V#IMX]_35]N9!9<#%U&R@,-+708'T>
MS7Q?9& ^-BFI(J6:,S*>1-=#WN64E[OJU7OC'/S$51WC.LN9#]+WU&D"'(D:
M3 V#?-Y^B,/%O14T=F_;5WI =8C>\ 8!61%/)CWC_7FB^.=OC>\9$[D]%.AC
MOYQQ.9X:5S] ^REHA UWU%2YU JN6(]/+)][2>"8%4)!JFF>S9],ZL(T&?B*
M0YX(]$1%1\GOW LD.1MQ8:RZ<YOO\4-KQO>TU<J_1>[B#BKM^IN."3@6WS8U
M>]X=[-?Y.4!>@T(J&%[Y!)UMQ$OA^B"EZNIGM=FO69?4_,E)+Q,EXO>GPIER
ML^2T^26%'[,+>32JU<_HR;;XS(1<-#(Z.#W6'LD+.5BLP'.Q ,GOL)ZM()XM
M#EBQX0\M#=X[J&<VY;^GRVFLGKT/DA/04E91;9304R9F$8O1539=R;!8R>_7
M3S_2<T:EP9I$'58/.5'Z!TD"3WC3BH:,/LT8=/1B@4^.X+D$\.[V=QK+CW.7
M% 8>+[Z\B':GN$$36>Q34VW1-+O+[_]E66;?X?FC^NQB':63HZ>7@K[J#TMJ
MF#N U ^Q=?/KL*<:D;FE-1C:2)7X-?RBB.0;DKS/BU5&D\^]_R:6^?W':IB\
M ?F9B@7VAM$Q6"#DR>$T%G ^_W,)(-0*"S1"L,#:]:_'Q'\>Q8[_2Q=>G9O1
M<,7\; $7D>PHK05Q0#PS,28IZ6OA%JM3L(N5&5$!OCHKV_)P'O+T)S4B;U 9
M,)B:L9UU*(GY 84Z.2C?_4#>_,EGHTSU\'1N\?!"C]<KR7<LAY*=OT?4V**:
M7)FCFF8/]'('I%>CK(==2AW<GC$!S:/5<8>\A1JX-"B-A8$$\-0A93511?T,
MM,F*(73+_:2==EZWYKN&T<>,"R-*^; %&U^K%F].%'P!,HA? @[#4&F>IA$6
M7\NOVWV[_6D_MX:#X=3!LX(Q*Z[F2R6^U<UU=X:D$*=M#((DCOOW-3S'[-%1
M*&:V0G^?[,1%R^QOZLYRI:D+PZ[U#0$H*>?@-8K/*CT\4^>TC,O2I_CUIB9D
M)&ZXHN%7M[4?)&[DIAT;(:#H\M,7XW5HIHA3TVA!=[OBTD0Z7;G'S\5P\<2"
M!&<3/GQ#L*!*W-B7,8H(#CY-T:566-YETPP6H&NRJ:F,A167@SJ]8"V@-)RU
M,*JSV0MX:?TQ3^T;73QY+*"D,LF 3RFC(2>A<U[U[=UI57,NV"8/5@467-G;
M/[2+VALS@&6QR*F[CZU1OI:C"1M7Y708?0;D:F7>&H4V;Q"Z[B>O>;(@P[I8
M-XSE/4SKOI4N\(G.=D_?G7"2E9,A7\35H_[5VOK+C>,HY/+6%#6U"->!=_[P
M&4>770?4HV,9[ J%[0S]G+WTC*WYI30=-IG"#&VRW2O9+)0I(KB%>R1EY>I7
M.NNUD[)4W_A;HCE=30Y)=MNO6)[)%3?YDRS^9\D$%1BU?V].47"<<Y.$S5V=
MS"O0TVG&.1]]YT0SR4BUY:L@F:@/HSF'./7W.V_"H5?4E: -;\BKZ[R<@SP2
MQ&\5^'2=IJR(+RUZ8=NDEO'?1*0/'I3NY/6<N;VW^Y ^3^0U&]37SU1,)[Z6
MET:7K_;Y-,7A"*8@6K]W M$BF'XCY0JH!3T?S[4?'^C!339C$_L]@C-5$J]A
M:#O)_O6QKG,IO'E7ZDQ->#923_H!;DR7ALK/"-6WFS88JQ;Q&70/JJ3.4-M%
M2M)!ONP\G?K0@:FV5=@692=BZ+G73-6].U0Y?VG0TF.<42RKNYMO8!?*.A'=
M0S%W+]..54KDH.%#G]T0^8,]X7%$;AD6(.X<[^0EB^9F<I]X9OQ.C#CCV3=I
M8MKY1NA&0EUIBUU\Q[:[Q]$<HRG/(QG>AO#7VM=R3E[+_P8/)8GWP0PUNVAB
MSR=(WE#KQ=8"%KCKB+[WVW"=1/H$8[$FGV)1"$ZH$42N#HT$6"]57J0F59W;
M7_2?8H$/NQ=.6, 1&5Q5^SXNCOGW>SQN)GUT"4)\>+IRD%RI45?,YOY=&SH)
MRBOXT%',^]!FZY&N1]:5'M&/@LAA:]_LW]SL7N9_"C-8=;"(+1BAT!;^[B01
M/=1*%Y3SL>8V;W>N\F38(1:X=/-,ZO TNTR7P'SQEM_%C/5!V AV#HVILOI0
M'!=UAVX?SQ),)LWX]+WIJ&NYX?ASY'4@S_X%=;)0?<^+/71ZU]CTY!A)O,<7
M7J5O<9_(>\#5QX]@HSEZ\&&;J$<)[:YZ-DLLTE 9;3M/1NT@,FUKQ2[")0*V
M76,;MIT$DWE3W3G8O@AK_P)797U%\G-R_=[WU??6&#5I<Z1H]'5YHQ7+5C$:
MPM;@M@9RXM_\EC)3;ZA7XT)F4E3QO*L[^FJ=TU]O5J8D?V,<2];D24J/B:T8
MEJ^P8([W7!/*D8X;[6T?NH3*V(.&W?UGELKRX#1>%9( @S"[&?@5</=;-/63
MCC'=V(_BK?F70EWVF!Z&W<;'CU[#Y;\^O,'WCK>9^(4/@7O.*^8;']MF,]XN
MMRT?..[-L7^'B[*TQ6\X0EY94\ZBLEM%/#5WV%(E:@2P0#4_1Q=U3).AW6HE
M.DYA%@:NX9<D]G!6^!53DIE<#%$.3D8YS!(_(),F7__F-;<!9Y&[1V0/J]U]
MHJL?7?BL$\I"WFVOU7@[_'=MNT9G:?'+ESDPDHM0(3_>8?MIJ)?QO!Z@$R+C
M<4 18OLVW!4L$4Y_'TPB^S!;FA=^%)#+SX?CI'"XL69PLZX&.MQCN+;T^TFI
MMPTJ>$Z4^E4;CUMYYW=%'$?[LJ[Y-U10!%EKUTREI\-\U5Y7;J?65#+E +\B
M+4FQ=NF2OX:3P5[8 #D&[9:S6SP XJW_/,B>7U-1\_7G,5>3E_#:.'^$U9(-
M6M]V8(RK+'K:N6:NP7EHX;^Q]Y9!<75AMV G(1 L!/?@[IY @ #!(;@V[MH$
M=T@@!(?@%B#!W;L;)[@[--!-0_ @W5APF[S?G:JIN7?JF[FWINK>F7K/SUVK
MUH^SSWZ>M9^S]K,)CB^6+M@2D(N_$ZAS1K\<!V'8XO,TJ59(?.(W1*HI%UOA
MSR.\#_L$M.!T$[A;F+V7OC!D4IN$I\V?A5NQ3B!8-((5U_8\7]_FGLY*] ]"
MHT8P5G2E<JE-PGW$HG<;D]>$9K;/>F#\C2:F4M(ADW?]EOI>CR')J<VWP;9@
M$_7K9&'6<S+9GRD;BO>;ZB0N6[S,\H*8PGLW-.?D)KTC;?'@86H2"99/82Z,
M5;NX6M$X<%8L%64&V:/*UPEAX#).Z?A0]M:NC8M3$]0*XO*NZUJBZD;N2KL$
M41$N<4SPXY[4Y?(FW_$<_;*1H;%<//*[F-W^SYV]NE?7V>F]H/;C<$^[#^=Y
M/\@$")T.U9T)N-U\N/QLB$Y%^T4@C<K,L7N/E;9%JO23B=>JIF3[";-HMEI+
M5DDWVQ=&Q;B<R%[Y2.Y)).+!V#?]2-=E.*Q91C[2#+XI!#[UHL#PLKZ([,W;
M1ZFGG%P$W#K<FP7_.*:S1IMOWC6&\&RVYE7BUM<C(K<)1FA*;I9R9B)#7%SX
MS$&2W8H(86HW>YTYNL-^K_+4D:QV;?R KQS;NA[?=B@,^$T]S6!'1L]Z)-OU
M#7ZNJ(UJUO%%5-"7P5G>+CR*YE9HL0JT;]@4<B]1'0W._^!XJ)INU+^RH@][
M,=BJX#\RJ?"HP(K>@NS5&9XYUP,@(_T.?B6=<R.W;M[W)F]I_^76O<H=Y;RP
M1& IA%4:O^F&:RMO]C"W_NLP*GL/SUIGL+4-2E!?OEU>65EA="*HU<\TK,4D
M5HG8'_0D$.OY9 =^<]& 1"@ 9O]\&!KW%L;Q*OB9*L<C'/-QC-/)<50&E<BP
M;.J4<")EA+1L\V'3;,Y;29(7*&<U2,'6#,7AF/FA.S$\E84LO1UL S8$;EP%
M'"9F9$KM(T)QRD.X@B*[436M*S? =74"=>\!MJ>+$HH!:!Y4B\#KPW@PM7FH
M'*NW,W_JZ6A^TAO5+>M2^/[K']21 HHD/:M>(;;+?"%-V<R0%$<R.+/Q,$,\
MZ5?CW1GX&:$*D1GL-,%L2R]+#>'U!NILSQ*!V7Q(F%5#F_JU*5_78MRX]]<4
M51L =3LG[BS1<6\5Q(IR61WDRPMEO!:J#0C<(IL^R.K*@"A^0-UO_ 1U/ "2
M_ZJ+Y4SG1H1;G?@LFPQ4R-VZ8J4F]T06)S-Y1IY=.Z]75(!^N275!#'$V JG
M#V-\1I@E/]I6U)?+'<;']OS'$K4,X"M'6[KB$B2J&LT@V-LA?()9&KT6S/>E
MEDP$4S!)7[M4I2%=6Q]\TRG%&H3J#1*ZU)O*"5_G!FZ 7)=+A^^@\=5TI%)"
M0;^N<(]+*\5 ^\65EQLPZIN:0/. @YHOB 9[R#ED)3><;G7KF%B.4@17FT8-
M?9#1]OE\_6XC)>B^6AYCMKN8/N^,ME>6%Z#8&/,JB#'9> !WHHJH IO#I?@+
MQC*:9S[#)?AJ)X%257@:(6R1U4<[ZBN<XA<U;3(DJ]#=-%=-$BQV+-U^/5H;
MFJ[_ZRKVMKW-=_O0U%NZFW?I<J&E\]6,"[H+A=SYF\,V7X9V>&:-MW2)F1N=
M@W[WH@Y"5B;/O'3]%GW51(B&H>SI3)2):IR#@9]A"S0+8P:6& WF*&H:GP61
MF3I5Y\=W0=I*#N>'S,5&VUK5>8PE8%"LJRN:?DFTS:_T17'":8OJ&T#X1K_4
M)V=N&65@1/3G8BN,2FSO.,Z\SR:1?7S)".>K!+>_2X&2+AYXV'@OX'*8*TWE
M6WO#.6O!#F5E\W*-28RY":W\'6)PYN*^H*BQ!&Q; ^T7).=T&UQD-C/Y.^W.
MLT5O8_M4%B.$)UO,,OQKK^+)?IW3=M240K-IA_:8Y#M_);W1'I-3Q3"=9K=2
M5*ZUS-X$84.,A 5*INN) <S5UT#N7:DYV0432,F[Y%<D59Y*PBH3CY]'=?UT
MP3(%K:9W",!I1V&G:P.'J/QMR;A+^^7FR1A#FCOI,=X3U$&^K::U>V[T:4AC
MD)VG).(^H:Y)<,ZEX@\\DV\-/#9%E:FE5<H5!M][KM .MVC 'C>@25KK=2WL
ML?M$?YU3F:IV">6N8?#/FMWCV191&;+^K=ABUO<:LGV][7:A2"[VUCXKIX]_
M*!G7CR=>N+J=>W]=%53.%L%L3LA.^]YG_MY,(K]".CWCI+>__\@*&FIP)NWA
M\GSOWL;\A0]Z!O'BPG>8!K1:N'JY1R6Y"[Z0DB-612[EM8W9.9P(2ZB*?'42
M4M)_QIC /_V)=<??F5ST0,RI4XP7B-)6**=QYI0+=K=TI4)2Q)-NQK@+JO)0
MPEI82#0EK)U]6;O'(,/LT%5>-]U]'P>XJE(-7!]*5,8JG/0.E!3/ON7G#/H-
MSB?HE-T0#_6_*#4.$CKH;-Y_XWL:>+EU6ED<F@%Y\JCNP]U:W35U%230E7=J
MV-7L1S=(K@XB9G'8?F=P' 6Q)5,@UB!YRANN? YL'.?C0P9ZNX<<>K+$PR[M
M^8<N,*E=)\@31@#CZLY/IC?UQ!F(]+]'%HSW,+0A;L(=K7J6^,Z1#11C,0Q&
MI0UY'*4>Y9H8,=540PHM\<KZ#$_LD:%$G3)!$6,74FL'DQ$=I>%+DF>WIYTL
M0?E#9[X6ZY![:]9\\GI:(=//*X$[P25+XYMU<Y=O\-*4%5LL2BO+*?;@T67,
M_G$>]?;IHHNB+<&MX.459/*@QW;6SH\%(NJA1TW,LZI%C1&&69&1KQ-:5=+P
MT9:M+6UFOJUPO%$1V'A]/S:36@+L@MYDH )74)E&9ND30X&^0<6WZ([B([=&
M46_[H!E48H1$2D,(O??%:=:B.;M&KU3S$M LX]$J'273Y:DJ^&3)+'EW+ +T
MQ.+PK@729AS:E>.RDD)KSNV22!:UK##)-^&":J$*WL,N(?,X)6&AE>_[&FP2
M);K[1X+J;65MK]L?4NZ][U09%V54VR#W<+ML]I?H21N+M7:*G6LCRMKOL-CH
M7*]TYB=<]-K]4>4W]]JTA.WBO'3;@*O5.,H'0!2""7KOI'N^H^S]W(,&@W_C
MNDMZ'F$LSMK'.C^TY3//[44IG)T'"0OS=W0G73=^MA0AADFVJH7%X3$Q']R,
M?<$%S!V2I.A,3=XR ]!L*]U*+6X)"W'ZI18^-N[T0_OGN"_S\!AQL]35XZAP
M>R=IR["SER0-4>PE2_\T>5Z]  =]^Y]]J./_>P/_/5>VS(G3";]D?P"L 1\
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MJL3:RN7,F\GOE=F8OZ6DS)/JD6J18   @.\ "P FX D []&GF;^Q5-K8!S:
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M]/UG[<3_5[-U_8\XP2A">]*Z4$/2;[J.IO9"[Y^!"OXI\\7>&X6>[W1MG3T
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M>G@0G?G\SUI%4IL'@*_PVSXF/D90]_.U=MY1,M[WJ[[^9;=2M)E10V!2<<2
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M/0# 9G+W$*T;_%/[VZ2<>V>V2^KB&]^;E/NY!T!*(1V:]_??2/F_R(^'_WP
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MYUK'GDE*I.S:HNHIV=1OF-F+T$::@@=EGB4%/9XN6\BX5,V>7 C2.L#/G7\
M,%_,H-VV<^>E>=JV-=)$D&J^$,Q(ZR#[U3L#.GN82VZ>* P&U_V[:Q![^GYN
MSDO;MM+CD2 !3>M8M_ZXH&O;(*]"$ D")8JZ2ALH\6I>ML"+F2$::!B9L'YW
M$($<)FP4DP_LTP9!<OI[JT[,U6[4J(S*$MUL@Q(<,DD2J.9S!-]%A6OJT>)F
MF4=*(MJA@Z?3]_N_%LJA;F/5:0M W(U5GWE=J]W-R5&9HUE*6-,5>X.A^!YR
M/*;'966HHB),XPW);#]'MI/75U(/RE9(GCDH8=Q-IH7VYD.+GW)I++%DBD+-
M'$?)]JOBSP;Z:7:\J<S\*0XM88/Y/N,GVSP^FBB(EO/PU*Y[T(DCZ7P%'Q&E
M SO-9U)FGX4'@-NM8RU<>C1GF\WNG'?L*J(IT*U4.LW -\BHHC?HXZ27N-?Y
M4H]&H^B @5!C:U: ZA/H;"C*)61M<>A#X)<2#J:"[P8VAK;5V8+V$V+I-Q'(
M^S4K*F>>R4R?2.S77,*Q9 >U.*ITYUJ"L:7*-+SI,#W<=YD+S(;+"+1)*<1,
MI9,5Z1S07WU,$"VZ,CW2G8E=K/R&Q9VXGF'>S)9HI]0\G8ZD4SZH;C%XLNVZ
M<KUD>W&1QOSD>]&EI3QLR;BS><#@HM8>E(#8O1_L61?E?H6:X'\-JMYU+04+
M3F^<ZIVN_ZHL6]8CU.PM9I.:%/LH7?UFUMMCC*?FJM<ZM6=?EA$A!BSGX[5[
MJY)X[#_#(E>^F? :,SF6K(%7/Y=IJU,=^JG)U-@#?0:,$,&[^3))0@89ZM.]
MA K<R367?EFGM1%._ORF2RA$](*9CO]>XC8<_N(V+.<[Q+P_H??RV!S<R2HS
M"PY.G&]#>!S6=$ZNG_[)(8#Z3/Q"+/&VK00JNHU^'AG]G$"3+GUI2Z34H*G*
M'_<QHFW9?T*R?RM)S,^5R:",BSX&"&O^LA7]/)J].<8F0TN.F;OAXP"F 8]^
MH)GYYA;D$:_H8+HR$T9E>6"@PUKZXZ+*T2=RW*RB/[ ]UV5_<8_LTI3V)_1=
M+@"/=0B/%JHZWX4629;#<L5F*'51!Z6Z/O9R;M*)U&P09[&2]<4NI@M7.P73
M[@:Q52/4W7A.#3PKN!+/Q8-X=JH?/UC\KATKW:  9-T,O/GQ<E+"*-@L0MS0
MV)BG2,SG4(O)3"'- +\<1,5_4A&MWN<(JBHP;3 =@"-S_,UKDY=AR<(+L\'O
MZMY'_H'-.'ZV'2J4HW3')8M[M[;37QM.FP*6T$^L[E20.97VW&I=V+%WO^U;
M1!RZH"=2BB];.@S<?<[OD'?.BSFQ'M,6 G<38A\6 U?>O/P%3UO"R7)ZF>R@
M,QKCY"U[%Z;? +\R[?L.RK$;@PGZ%1Z/NDF"1W_J=PK[FG&9? EXXZEA%*[Z
M*"E>K#AFWW>[/)E>='SBGCH3QO\\+;Z:5:EH_BX)G(SHT?ZA]RM&@!:C'Z,K
MGNYY(**F\Z_@XJ81<5/00^'?S7:-J6Z:N_MR"_,U.)Q22]?<,'9MDV#Y[PB^
M^G:0M,7NFT 7A%JLL"[*@S3X<7',^'V,Z!-?-.6!2BD[EW Y.@\=VO)XE'OY
MC J_>,&E+^8NX00HC<OCK9@>?YTY'GS?PKH4"SY\)>^++[".*/G-?!SAX) >
M\9% \06,ONG@MQ1RE>A>?W*F0[F!750ZP)*KDSY42&K_2FAQL:9^R-N;U;XU
M(! BECA,.UM_,3C(W7D;/-L [3S<I[C1P,H+8@VE32BGY%2)40FF?%:VPR%:
M+I4DV=;:8F_HX@\RK;"5J5"JZ4QF)]N0P1!I$QS&BJ6U([L@8 3H*\7$S_&@
M!IMA4PH1%_CPV0]A"I?,G]C"E%T-Y[W4E4:G'P"J V$L5L.LWYEK^_&/9^\^
M'9UNN9EY&XQ,(!>!?%MLPR%W5T_F):%)>[<[0]GCJ!.)[Q^0BI"V4;<S-"Y3
MDR@^31NYQ!<'SKI4=?7DXN+)S8;Z7F:4X)"UM9 1"'*>[&>N@F!!I@K^$(8F
M[WN&NX<2=O*0<S;V'!2JB<\P8JASZ!^JF+F27PJ:T<[T;"7-\<72YN;VIQ%]
MY&T.4O5?Z+N?0V#I'[\3$5L=S?@>J%HB)154N]1V45X>$,ZWN,I_;WN>T+-_
MC9<'J^V?.>!%KBSAC]9M#<R[JF1]()D[6[Q-WO\B\*STFU($0'.,=IO:B/5\
MT&)K7T6U%7BR?%Y-=1Z1.1FDS\)3[+6;+(D?P3[R_EL9$+P\\.VFP\US#X@-
M=5;^''^LE+3D>CPJ!# "M]>-F CP58FH$I>E2F_='6VTBV\T2F<D^#:WB@;Q
MT*F$L@>O'3\  FTN< ^^P0^D=L?/!S47=,^.G+A7C LO:ZP=+059C6-(L\.<
ME(JB]R2MQ(A/O\%NON5M!E-C:]\XP1EBZ>"9/+6P==Y?_,G*SS[,Z;,\FR^I
M4 :T1GF4RX[\%0-[:[\=M-C262$Y-+@?^W$N2C\P.#F1!FE=UIZ$;IR[K</^
MH!+C)4;!/C#[*Y/Y(,IA[Z+7^)^:]P(4(9'>:)X=O?C5YC'8[PRWC>L<".2Y
M(G7BR+8#-8?ZVQRGY.P:S(A?.#E9IF+!C7GG?K+#S>@<N[GIB3\XQJ-.>;BQ
MRC3Q,OUS!>N"O6HS[7T"?ALP1[NI1;,#\KT)[H/7D7X9W?&ZVERCOYG!K5%Z
M#F3/F&.5;/UF=%$X,ZDJMZ[WQG3TIT FFS-R%^\T>Z-!@A/=O:[X.C>JJH2E
MD;7KTRTQX&TLLB.G@;\.C]6GE@FHLV"4[2+J@?TK]H YC(1P@KG=R:WUD(\D
M:+SU8 '/5^GP"G0RI\DUSKH$56,UKF/@$N$IYI8I&B^JJ_0"-AKUNI&-0T&0
M8W"XB2>W 2? &^@ZL3VME4J%R0=(5U+'I^(W52!)6.*+-V=MRZ$\GMS<OOY-
M.P@.1#0] +(> 'TKE^@:\)"=J"G(K?":;V/!'"U5T2=EU9KBJ6_A=)P9$.4L
M1EC:KV\PQKR,UF9-'2.53(6TA6PT(! F?[7V ^!)4$NR+.?T9 MJ01,A.Y"6
M].OSDN'>%,DP+O'2LDFT&WZDH%PH;UL_!,%=6,AA!!OT;&K.6Q.NV%6-#H$<
M$_X>QF4,4B'^WE;>R1R4C6@3NO+Z\W+S<KA%$'BSQG?*@@R>1)HS>^@A_7RV
MK_?1 Z.WR:/CRQV^S:OND^UB$096L^=29*4^6I*2+^7(31(U=/#NGU&4++)&
MB/&J(5FQG9WM1WR!SKW+ UP1<&OP$>QCXN/U;=$L%AU%QQ=#&%_4"3RY>.:"
M;O"+6,U7:'I=@[$I]*/0QZ:7B>6?C*IYO($.]$E4=1'MM#A[J/CCG,U[7+HC
MOHV#55HQ3\6CPZO,<VC@N;DKQ-IJQCO=O%("IW;+9V-18K+&)GC@)L.K^VMD
M\['P5:M;74G-SWF<J.(O%DS^+PX:E-W8N-$UA""7%M$+D,!K1FAY4[\CB6U8
MMHP[-]N[GZ0SOZLJX#VOQV:#W<YN@7T3.;6"BRO]*D0\";M/EVNN8S[QM#)Q
M]2=O^B6UF(JGE)9W98H%7#R?/0 M[-)V@[?AJR^D0KW^:A)@J.49:_=^"/3@
M^?1BKBO9X/Y$Q:KA_?BX6\+I/FJM6?3/:N^I$16WG03:D:A$R:$XIQO'<5UQ
MJS,$$I&M6MV;P?B%QX*IHT>=6J1%1C,6X$B&1(YD@G][F,F.N(!H7X>GYOEM
MQ(R,9LGWDEHS\D C RE:8"-5-KDA>:J9&^JJ7!'>10X!PM+T4H*^D+U[14FC
MX_"G,$J3G6"+ ()?$W-C9]Y2<BX/ ++"Y6#+]@!BIJYZ;1MG3R^$E1$$S#H_
MI"I4["E/7^3V1&6 ?[UZY006ZG%>O8W=Z^I^*M\QJL)5]#8C3"'],^;,"Z?O
MIKJ__DKLX.R)]87D"].&=4FQ&1>)SSAI&%EV#<T)K_8$#'QUR\5E7M/K_B%U
M>P!$YJ* TZOCF"E/9TAKEVB7;B>OG3O$\TIB7#-46Z"#Q@>N2T?HSOPZ=__>
MW# 5<?5*Q7HH26JYJ9:JZ?LF[\<4;L)65NIA\HWY\(&L)IZ$&V_)P5O.UU#J
MBV.JM-IH9V'+ICV[Z#X7=IQPUUTS]$6^D;3VRGX&(S1R>EN]LI<0X$?2IL=5
M$<7Z^*U[;6'@[6"(B _!T KR'LCD] N*LAO96\U\/7ZS3%U;(X:6J_85,S]P
M[!2]^#)3M)QZ W4#F=:WNT_K@I"#"=]#UX@E=:/UM19Z9E[DV.G&YOSJ;.5-
M9[)$_H!5Z?J=\M1^HG84CTH=V%#'H0HI?DJ@6KLC/8\/[\$PXK-#BD*?Z0'_
M_&BQSY:I?-*K-D=K\563")]+!R*=?C&,B>[:EI<V.<CK6S6U;I?0N%([AXT6
MHM"K90=4#X T";8-S.TQ-[JON:PWLXV^Z=O+U>__**4V-0%C5-34SO*H+-:3
MC6SD<WA.4,.COAE1[WQHD+[^C(SA7$#E)B/C7H\8X:H&())+@T@"B\?IAP<C
M"^^&"^^J-P3,"7*[4E&EV$I:TL9-7^9E$6C4S$P.]#E"%N+]L+-SE_U5T_GV
M5O_JZ4EH<Z#S)@AQN=H*232]('!_ '"JB9_16<G5'2$.?::##*Y$<E=SAU>0
M.8U="3"K>@ID?5UCTZ4QN].^L^"2FAUS0_<O$BVIJY!7D.I>RV3T%A736 ,:
M,SNJZ:.+CA$=)R5O39S+**U*YG=[AJ4^%[=QUATP^FCI,I8[J%XD2O;QY0(1
M&G;AP$2_Q0!5EEBNV,O6?8]GJG5BOTXP%#\:=>\M@O2?:>&\FS]A DN1HLT3
MP9<C'2F)0S[<M$;UK2_QAS.[%^9W'*F)?'RV$91D]D-@O%5/5>8Z;%RFMO;*
M-X'>M=!]+F8=8\]V:*/N\U']]OI0RBC,BJGJ[H+YWS94,E^_E.QCP<P\)?RL
ME$JVR)OB('(FU,'C^O0$3VI4-;$+"&;01<&9.;\&[6RE%&^K%Y''&J?DWBY2
M]U>%D$X=[_3=W]73,X8U&<.NDC\(--%F77WGH*-EOZ?HA)852;&6Z[7Z^IE9
MFYGL-D)%-8$X*73)4_51C^K4H(:!)+2$^AUJBN@"F)YWO>>P];9),(NGA@PW
MBEG?J6\$7@WGX11;O] YM%650K2@(# ;!961LG1EMS=$'"Q$ H*28T(,@)R/
M_?KKKRD3:\<GOJ$H[^6"**[BYV]PNJ"(=2G4(>?SWKWXKN1>:[%.MRJ)!T"E
MPM"R1%=-QH?YC0^(\( #FA(".KV79$ZM8J.:&@9XQ,%#8:^)#=^WA>PT+X_5
MN!R*EKLL?Y^;[IHW-I.]%J@039[KY<!HP-;7K&&RY44B%(,AO3BJ)?<(]S T
M_WC)Z\<ROL["+@X.ZUP#Z41S.LPRE%^EOA,&A96@\\8.#\.D103,J6\*>>;R
MJ4ZZ&.E7@PDS"Y;J+NR/7Z[L<TO-+$J.@P.&+[YE5J4[6]K5+]$(S\U34@@V
M75;W:@&5J0=8%#T&9,"@OZIK<XA/] LXZON<ZZ:8CP'>F(+L<B]-W9!^,9Y2
M R"Y19^W,'AD! :CC%-U;I'S^/WS<\L[:$>L!A49)-V0EPGVPV2//<AP Z/.
M*[%?.MF<+C"_6$K;KM7 T_[<U'<T?UL(+NAEUUT)?\W;__L]^*KV/JYK6@_O
MDD,H,[>4^8/]]7DE5YNCP&OL65Q@B^E\16%I1<Y2?-H<T&<5[,+*(O;$(I!H
M^JM%0N@JFWL,'U'L/0]^98Y-SMNWL-]E86*R;9VSH;RGK?(OHU;]&]L+'[.D
MO_(Q0)1FEFC,J7KT^$3EVM(N1:<9&=/UYD>L,OKP.8=R+S\ G+V8?M'_OD/=
MKD)];35TTA;;<FCG_362[A;4VUL]"FC2GIO9#RV #O"]96<6K+ZG5E3UN$&-
M %YMY!%0XWZ,% (B*7GX^=$<?4XF&YC\10)SR#</(N<?&P,%[_.2#]6EMCH]
M)0\^O&ILV_'G2U/&$(&B;Q;7<R,<[RK[Y9GZ%"T1<$/. +X-WR&S9/.MT8[&
M7-KVTNZ@X"N^VS[WFWUK5P[1&AW/@_CP$V#P>8)$\05(PFT6_<K=\VR+58A-
M1M+$2X]/+WI0KV_5T:%$R;5^F5OT39NM/Q-N>8OLH)NO4UT,6@Q>Y-T<D$Q*
M-&$CR N>B_HXG?JGR]<^_2+?S:JRQ[\">*GKGKV(6!DP?BK\% XL=J=VX,:K
M/<81+*SM)$+#S;<&3_FJ?2'3 W]JG6P[38,ZKLP7<@JY=* <QAD!J/P4B9R.
M$&G?YSK2L4,+.MK3^B6+/;J2\N^FY[HC62EGZ%_2Z]Z4;W7JG/?Z?@%<W+:!
M@>K,K\N2L7)K4,=A"V0SZD]>&"EE;G\C1:!V.TY]I0U5JA A=Z$LK77"?*3]
M32_DZ7OIIC.QK;7!1.^>:3H$B*Z.*H%,9X\+^4ZQ?%V6\_C G1_0.(EI@>'6
M<_/63D*!SFZ@X-J/W5X[!K,[=@'BQGNFI7,(>WP,097CMTX5G,RFN!SG@9W&
MM7Q ^,DMYP3$2ME6[S)[&ZW0VEQ!-L,:VP=4 &P:?V<MQ C4&SW,$*.>'W/O
MY2Z0\"[M86S4*-6F-&A]76*$GFY*+X:I:A>%_>H4NTTL1$@?#,YYB5XZ_'X
M?$.CKXX)5(9N3'R_==%Y!K-E[%+L,R">?%"&6A\\$UQBRC"A.W9KR7B>_IR+
M1ON+SV@41")/(]O#EM#E9KRH\\7\FA3*U]_3Q;C8F]N9&]NSH)-8(JG:TDK/
MO,_7__6/[W<"W&TZBNOGE_EM*2#5C^R&@ &8)TCYL69]WBJIXQ.K(*DK@LPK
M0MA=8J>4^*:[A,T#0(+WXNJ3@?*W$1>\-3A2HB6$P*;UIOI&CK?YKM\(QV;S
M@.+W;C\/?_F0M:#+CZ]5F(6(-ZW:@QY;NWQ-A7"/'0%$XY-R[>T;7S%^A3C!
M%9[V!+*WPFD+937?<:K1[Y9%\UR47M2W+[> #*=BA.2MG4G(N7]-<407L'Q-
M]FJ(6%@&)"YUD8LMY\[>=M_H>)_Y#HUPNJR.:L3D[A^G-$B]DH-1QS;\AOH:
MWFK!D3:!=(\:+B!.09AHQ*)DKUY*MVW]ZPI64I)&=<;N==W*^/B&[;W>]',N
MH*,:L"D0=D'_5.^K?$#Z,5L"Q4?+EL0^C,K*<K5V^7!O2#RO6 =,V3K^? EB
M"B&?ZU=V=FZK3"?D1Q/]7$<./'/5U6*A%)>Q%F?;CB"W<EOIOR(_3J1&4H]N
M)9Z,_+P%5@Z<-7K?G!WJ^/+.(DU7,Y<1;(&68L_7*4SC%X)WHE:;\3KUVV@\
M7Y4)+<(K7AO[?1]4EJ!&M@MY7#2;M$'#SW)BEY9_PJ.CJ?#+$..@%$GFQQ,7
M?8$X%5F%S7@X:K6S;7ICD-ONH=M>3X]0']=9LV[F *6TC9;E@NP5U)JIDEF@
ML&%MF<;G*58\CS39P^8'0(;]&"URAJ*FK>_/YAQU+.UMMG2&M-RFP%7'9&.]
M(<\J7)JF4S%A$NT6NX37/&[0K^9;TMVO'I%74<+Z4_6Y+G<:/F$F>XTI; 21
MV0(-S-";_[23F^%!^/1I#8J'OIEXJ.)R 2\AN>*UOG_2"XMT# B9Y_T>'++!
M#FV^6Q@G@U? +5+<@;J-S,6&3+^M*_A5&)-U:?].Y&:@CYB'I11;4,2B.8E$
MHZO6'X(Q_$3X723,*+AE8?']Z3*"FGB>MGK><Q-R/SKHEET5 E(O3UL5!NC,
MV3)FJZEY$TU75=*XCZC:Y*N. T6W/$-J'5EJ=IX(IKL2F1M7":BS6Q3K;6HV
M4E$RO:W9+]*4]'S6NNAK6@(?MVHE=JTI;N),;>J,V39,2M$49]07^*2THE(@
MHJZLB7P $(>H6(>\\U$<>G6M\>'P9<NB]#CTZ<DAPWRJ/VW)U?W![M ]-NI]
M3I_/\_X>7?O"033^UFQN\P9'0J^MW>"\KMZZ;7+RF<#_QMY[QS7];.VB4;$@
M(H(HTI4J71!!J=)!1'H7Z1V"]!(@"@+2>Q$$I)?06X!01#J(])J$2)66A!Y*
M2 [N_?[QWO?L_3OWG/O><_<]K_GDK\DSF9GUG5GK6?.=M694./R05G&8A@]A
MTM=]_Y7-^W@:8P7^%<_2L35^ZOQXGF^8_$%JFE<G"HQ^[J#WT!+O([1R= 7?
ML9>"-SM)"33,<9"3]?YD@AK?B9:Z,X-5LMEFV*7M7^W>Z@-95<=W$M>BLJY"
MQ 6.JW3QS6\J$*K5QEQCDLX1!%/QU#PE>R\F5"0?OS1EVZETT]IZ33WUT\-^
M*SON#2X';@/=@$%9(H _'R0YW^WL-9K2 /=-^I240MFVXN[X)+,T75^K].7R
ME^TIE=587>YSUX\/9N"R:Q@VZBK-)V_.JI+F7(.@'TS5\K#3]3$W2MCM=KD=
M4AAB+'I$.<D8/#'JWY^/ BE";35=VK.( %:0>D4)=ZGK8ZW59FS 4-UN6N;T
MQZ(N*Y[%WB4<OYT5=SI7B*2VKL38X/66D$_U5B:1R5L=^0V'N(>#A-.K[NTI
M;$PR"BUQ261SQ;J7A9.O\XOCRG?7W:F';'3;/Q;.FM\(F\JURU=DLT[Z''0O
MN]+^!*5C3@1<UR,"H/?QNT1 IUP)$7#TH#D2U8Q3%#BV)@+@Y[U*G28\;.^F
M.-N'D<UB^<#];IUHEZ,ECX33L^Z,\TK7-BI!CHTB5W>W";8!Q[LNR\5(&.O2
MU2&!R':FA@;Q=E?)@!G)\.H&:1#>^3MPJ%Y[6C*TU:5!--#=7L=%,JS)WK'J
M0&CTK-QJ5/66V<;4;?1IBT0[YS,T?>I'IB5/:'O]EK-0SU2LLRN5=.=2-YNF
MZD)#^C>3Y$C^F 138R0F;C=YI2(,6ET-J_TD<Z8\9]S5'*2GK3YBAJ7TG!B\
M?R%)P/O\^>U.=Z^"Z&O!:=(_GAUZ'<S +ZVF]D6')*[Q>EN@OQ<.S(MGY_EQ
M%F^?F32 !-AK'D_L@\(<1USPB\L..Z-69D60K/<6GW)U/9IZ>6=0Z->UUE!,
MU9%Q&2QF(8#7@.-.BZ,5-.(%%4D/O6Z*/,F1A0XY4H,4>J6V=54UNA>8-&AY
M<]+<HF8D)!F-]^7TZ>B/4GG+JO]SCI31J+TV"_K7@6RR% ;@WIGL0T@?>&I
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MCV/JGILK F*B1,^NQ(^WX\IBX$3 :$E]^ZD^"+Q9V;XB9(H[UYG2.ML61$"
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MY=R]$$EXID0$L G@M7_[.]O=1 !#WKES0$/@^LV2?<[U2XPF$=!/1@10_R;
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MJ?'7=B"[)J3TA$%<_==P?TQJ'Q$@/#^#:)*,;Q9S.7;X*?+AU+NL@="1%1F
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M,),V4TF;5%M+^_QE:?'$(@CDJ8# YF :",S28@15 ;05 FU)&P1,OBP5-(!
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M?>X=/W_G5^+(Y/1?3+SN!OY( !S]%U!+ 0(4 Q0    ( &Z)@5A=$#R-@SP
M ,)R P /              "  0    !D.# P,#0Q9#0P9BYH=&U02P$"% ,4
M    " !NB8%84ZN@ $XZ 0#8N1( $0              @ &P/   9#@P,# T
M,61E>#DY,BYH=&U02P$"% ,4    " !NB8%88H!M2Z,@  #JE $ $0
M        @ $M=P$ 97!R>"TR,#(S,3(S,2YX<V102P$"% ,4    " !NB8%8
M8\>MI <1  !\_P  %0              @ '_EP$ 97!R>"TR,#(S,3(S,5]C
M86PN>&UL4$L! A0#%     @ ;HF!6""S&#&W6   .F$% !4
M ( !.:D! &5P<G@M,C R,S$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( &Z)@5B'
M?X4L%I\  #Q."0 5              "  2," @!E<')X+3(P,C,Q,C,Q7VQA
M8BYX;6Q02P$"% ,4    " !NB8%8+<G2=5UX  "NT < %0
M@ %LH0( 97!R>"TR,#(S,3(S,5]P<F4N>&UL4$L! A0#%     @ ;HF!6$P?
M4[0F6@( 6V\# !$              ( !_!D# &<X,# P-#%G,#=J,#$N:G!G
64$L%!@     (  @ !@(  %%T!0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>d800041d40f_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:currency="http://xbrl.sec.gov/currency/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:eprx="http://eupraxiapharma.com/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="eprx-20231231.xsd" xlink:type="simple"/>
    <context id="P01_01_2023To12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P04_20_2022To04_20_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
        </entity>
        <period>
            <startDate>2022-04-20</startDate>
            <endDate>2022-04-20</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_ImmediateVestingMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">eprx:ImmediateVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn08_18_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-18</instant>
        </period>
    </context>
    <context id="PAsOn06_21_2021_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-21</instant>
        </period>
    </context>
    <context id="P08_18_2023To08_18_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-18</startDate>
            <endDate>2023-08-18</endDate>
        </period>
    </context>
    <context id="P08_18_2023To08_18_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-18</startDate>
            <endDate>2023-08-18</endDate>
        </period>
    </context>
    <context id="PAsOn03_15_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-15</instant>
        </period>
    </context>
    <context id="P03_15_2024To03_15_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-15</startDate>
            <endDate>2024-03-15</endDate>
        </period>
    </context>
    <context id="P03_15_2024To03_15_2024_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-15</startDate>
            <endDate>2024-03-15</endDate>
        </period>
    </context>
    <context id="P10_01_2021To10_01_2021_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">eprx:NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="P10_01_2021To10_01_2021_LoansPayableMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AmdmHoldingsMemberEPRXAmdmHoldingsAxis_EuphraxiaUsaMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:AmdmHoldingsAxis">eprx:AmdmHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">eprx:EuphraxiaUsaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AmdmHoldingsMemberEPRXAmdmHoldingsAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:AmdmHoldingsAxis">eprx:AmdmHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EuphraxiaPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis_OutstandingOfAMDMHoldingsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">eprx:OutstandingOfAMDMHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EuphraxiaPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EuphraxiaPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AmdmHoldingsMemberEPRXAmdmHoldingsAxis_ChiefScientificOfficerMembersrtTitleOfIndividualAxis_ClassBNonVotingStockMemberusgaapStatementClassOfStockAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:AmdmHoldingsAxis">eprx:AmdmHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eprx:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eprx:ClassBNonVotingStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EuphraxiaPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="P01_31_2021To01_31_2021_AmdmHoldingsMemberEPRXAmdmHoldingsAxis_ChiefScientificOfficerMembersrtTitleOfIndividualAxis_ClassBNonVotingStockMemberusgaapStatementClassOfStockAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:AmdmHoldingsAxis">eprx:AmdmHoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eprx:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eprx:ClassBNonVotingStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EuphraxiaPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-31</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_03_2021_AmendedPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-03</instant>
        </period>
    </context>
    <context id="PAsOn04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-20</instant>
        </period>
    </context>
    <context id="PAsOn04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_CompensationWarrantMemberEPRXWarrantAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:WarrantAxis">eprx:CompensationWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-20</instant>
        </period>
    </context>
    <context id="PAsOn04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-20</instant>
        </period>
    </context>
    <context id="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-20</startDate>
            <endDate>2022-04-20</endDate>
        </period>
    </context>
    <context id="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-20</startDate>
            <endDate>2022-04-20</endDate>
        </period>
    </context>
    <context id="P04_20_2022To04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-20</startDate>
            <endDate>2022-04-20</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2022_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="P06_21_2021To06_21_2021_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="P06_21_2021To06_21_2021_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="PAsOn10_01_2021_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">eprx:NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="PAsOn10_01_2021_LoansPayableMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="PAsOn09_13_2021_LoansPayableMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-13</instant>
        </period>
    </context>
    <context id="PAsOn09_10_2021_LoansPayableMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-10</instant>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:EventAxis">eprx:ExcerciseOfWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ExcerciseOfWarrantsMemberEPRXEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:EventAxis">eprx:ExcerciseOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:EventAxis">eprx:ExcerciseOfWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SiliconValleyBankMemberEPRXLenderAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_LoanMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_ArithmeticAverageMembersrtRangeAxis_EupraxiaUsaMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:ArithmeticAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMemberEPRXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:TrancheAxis">eprx:AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMemberEPRXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:TrancheAxis">eprx:AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMemberEPRXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:TrancheAxis">eprx:AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PriorToSuccessfulCompletionOfPhaseTwoBStudyMemberEPRXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:TrancheAxis">eprx:PriorToSuccessfulCompletionOfPhaseTwoBStudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyFirstMarchTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:ThirtyFirstMarchTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:NineDecemberTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThreeMayTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:ThreeMayTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOne1MemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:NineMarchTwoThousandAndTwentyOne1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:NineMarchTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_FiveMarchTwoThousandAndEighteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:FiveMarchTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwoNovemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:TwoNovemberTwoThousandAndFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:TwentySeventhSeptemberTwoThousandAndFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:NineDecemberTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EighteenthMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:EighteenthMayTwoThousandAndTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:ThirtyMayTwoThousandAndTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:TwentySeventhSeptemberTwoThousandAndTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">eprx:NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MinimumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MaximumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMemberEPRXCallRightAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:CallRightAxis">eprx:AfterEighteenMonthsFromTheDateOfTheDebtAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis_WithEighteenMonthsFromTheDateOfTheDebtAgreementMemberEPRXCallRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:CallRightAxis">eprx:WithEighteenMonthsFromTheDateOfTheDebtAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EupraxiaPharmaceuticalsAustraliaPtyLtdMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaPharmaceuticalsAustraliaPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EupraxiaPharmaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmdmHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:AmdmHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EupraxiaPharmaceuticalsUsaLlcMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaPharmaceuticalsUsaLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EupraxiaHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EupraxiaPharmaUsaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaPharmaUsaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PreclinicalMemberEPRXResearchAndDevelopmentExpensesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:PreclinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ClinicalMemberEPRXResearchAndDevelopmentExpensesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:ClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ManufacturingAndAnalyticaMemberEPRXResearchAndDevelopmentExpensesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:ManufacturingAndAnalyticaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RegulatoryMemberEPRXResearchAndDevelopmentExpensesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:RegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ConsultingMemberEPRXResearchAndDevelopmentExpensesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:ConsultingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_CanadianFederalInvestmentTaxCreditsMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">eprx:CanadianFederalInvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_ProvincialInvestmentTaxCreditsMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">eprx:ProvincialInvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ExpiryPeriodTwoMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ExpiryPeriodOneMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ExpiryPeriodTenMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ExpiryPeriodNineMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ExpiryPeriodEightMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ExpiryPeriodSevenMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ExpiryPeriodSixMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ExpiryPeriodFiveMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ExpiryPeriodFourMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ExcerciseOfOptionsMemberEPRXEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:EventAxis">eprx:ExcerciseOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eprx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_SuccessfulCompletionOfPhaseTwoBStudyMemberEPRXMilestoneAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eprx:MilestoneAxis">eprx:SuccessfulCompletionOfPhaseTwoBStudyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:EventAxis">eprx:ExcerciseOfWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OvernightMarketedPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eprx:OvernightMarketedPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OvernightMarketedPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eprx:OvernightMarketedPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_OvernightMarketedPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eprx:OvernightMarketedPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ExcerciseOfWarrantsMemberEPRXEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:EventAxis">eprx:ExcerciseOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:EventAxis">eprx:ExcerciseOfWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">eprx:NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MinimumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MaximumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PreclinicalMemberEPRXResearchAndDevelopmentExpensesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:PreclinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ConsultingMemberEPRXResearchAndDevelopmentExpensesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:ConsultingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ClinicalMemberEPRXResearchAndDevelopmentExpensesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:ClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ManufacturingAndAnalyticaMemberEPRXResearchAndDevelopmentExpensesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:ManufacturingAndAnalyticaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RegulatoryMemberEPRXResearchAndDevelopmentExpensesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ResearchAndDevelopmentExpensesAxis">eprx:RegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eprx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SiliconValleyBankMemberEPRXLenderAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMemberEPRXMilestoneAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eprx:MilestoneAxis">eprx:SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_FirstOaRegulatoryApprovalMemberEPRXMilestoneAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eprx:MilestoneAxis">eprx:FirstOaRegulatoryApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_SuccessfulCompletionOfPhaseTwoBStudyMemberEPRXMilestoneAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eprx:MilestoneAxis">eprx:SuccessfulCompletionOfPhaseTwoBStudyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_SecondOaRegulatoryApprovalMemberEPRXMilestoneAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eprx:MilestoneAxis">eprx:SecondOaRegulatoryApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_NonOaIndicationRegulatoryApprovalMemberEPRXMilestoneAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:AgreementAxis">eprx:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eprx:MilestoneAxis">eprx:NonOaIndicationRegulatoryApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eprx:EupraxiaUsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_FiveMarchTwoThousandAndEighteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:FiveMarchTwoThousandAndEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:NineMarchTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOne1MemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:NineMarchTwoThousandAndTwentyOne1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThreeMayTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:ThreeMayTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:NineDecemberTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:TwentySeventhSeptemberTwoThousandAndFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwoNovemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:TwoNovemberTwoThousandAndFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyFirstMarchTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:ThirtyFirstMarchTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:NineDecemberTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EighteenthMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:EighteenthMayTwoThousandAndTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:ThirtyMayTwoThousandAndTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:ShareBasedCompensationOptionsExpiryDateAxis">eprx:TwentySeventhSeptemberTwoThousandAndTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">eprx:NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_BioTalentCanadaMemberusgaapGovernmentAssistanceTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">eprx:BioTalentCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ExcerciseOfWarrantsMemberEPRXEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:EventAxis">eprx:ExcerciseOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TaxYear2033MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2032MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TaxYear2032MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2031MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TaxYear2031MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2031MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TaxYear2036MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2035MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TaxYear2035MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2034MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TaxYear2034MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2033MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TaxYear2041MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2040MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TaxYear2040MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2039MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TaxYear2039MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2036MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYearAfter2043MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYearAfter2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2043MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2043MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2042MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2042Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TaxYear2042MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2042Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2041MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TaxYear2038MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2038MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYearAfter2043MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYearAfter2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TaxYearAfter2043MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYearAfter2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2034MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2033MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2037MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TaxYear2037MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2037MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2038MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2042MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2042Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2041MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2040MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2039MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2036MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2035MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2032MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">eprx:TaxYear2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CAsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_ProvincialInvestmentTaxCreditsMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">eprx:ProvincialInvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_CanadianFederalInvestmentTaxCreditsMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">eprx:CanadianFederalInvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_EquipmentLoanMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">eprx:EquipmentLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CADsrtCurrencyAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CurrencyRiskMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">eprx:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CADsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ExpiryPeriodOneMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ExpiryPeriodTenMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ExpiryPeriodNineMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ExpiryPeriodEightMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ExpiryPeriodSevenMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ExpiryPeriodSixMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ExpiryPeriodFiveMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ExpiryPeriodTwoMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ExpiryPeriodFourMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_EupraxiaHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_EupraxiaPharmaceuticalsUsaLlcMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaPharmaceuticalsUsaLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmdmHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:AmdmHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_EupraxiaPharmaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_EupraxiaPharmaceuticalsAustraliaPtyLtdMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaPharmaceuticalsAustraliaPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_EupraxiaPharmaUsaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:EupraxiaPharmaUsaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MinimumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:LenderAxis">eprx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eprx:CanadianPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eprx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:MaturityPeriodWarrantsAxis">eprx:ExpiryPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BioTalentCanadaMemberusgaapGovernmentAssistanceTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">eprx:BioTalentCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">eprx:NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ExcerciseOfWarrantsMemberEPRXEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eprx:EventAxis">eprx:ExcerciseOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CurrencyRiskMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">eprx:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CADsrtCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eprx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eprx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eprx:LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AmendedPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AmendedPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eprx:AmendedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001581178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_CAD">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_CAD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2023To12_31_2023" id="ixv-508">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2023To12_31_2023" id="ixv-509">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="P01_01_2023To12_31_2023" id="ixv-510">0001581178</dei:EntityCentralIndexKey>
    <dei:EntityAddressStateOrProvince
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="hidden108159564">NY</dei:EntityAddressStateOrProvince>
    <dei:DocumentType contextRef="P01_01_2023To12_31_2023" id="ixv-2896">40-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="P01_01_2023To12_31_2023" id="ixv-2897">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="P01_01_2023To12_31_2023" id="ixv-2898">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="P01_01_2023To12_31_2023" id="ixv-2899">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="P01_01_2023To12_31_2023" id="ixv-2900">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2023To12_31_2023" id="ixv-2901">2023</dei:DocumentFiscalYearFocus>
    <dei:EntityFileNumber contextRef="P01_01_2023To12_31_2023" id="ixv-2902">001-41923</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P01_01_2023To12_31_2023" id="ixv-2903">EUPRAXIA PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2023To12_31_2023" id="ixv-2904">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityPrimarySicNumber contextRef="P01_01_2023To12_31_2023" id="ixv-2905">2834</dei:EntityPrimarySicNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2023To12_31_2023" id="ixv-115">201-2067 Cadboro Bay Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2023To12_31_2023" id="ixv-2906">Victoria</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2023To12_31_2023" id="ixv-2907">BC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="P01_01_2023To12_31_2023" id="ixv-2908">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2023To12_31_2023" id="ixv-2909">V8R 5G4</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2023To12_31_2023" id="ixv-2910">250</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2023To12_31_2023" id="ixv-2911">590-3968</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-2912">Corporation Service Company</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-2913">19 West 44th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-2914">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-2915">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-2916">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-2917">800</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-2918">927-9800</dei:LocalPhoneNumber>
    <dei:AnnualInformationForm contextRef="P01_01_2023To12_31_2023" id="ixv-2919">true</dei:AnnualInformationForm>
    <dei:AuditedAnnualFinancialStatements contextRef="P01_01_2023To12_31_2023" id="ixv-2920">true</dei:AuditedAnnualFinancialStatements>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-2921"
      unitRef="Unit_shares">27282165</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCurrentReportingStatus contextRef="P01_01_2023To12_31_2023" id="ixv-2922">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P01_01_2023To12_31_2023" id="ixv-2923">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2023To12_31_2023" id="ixv-2924">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2023To12_31_2023" id="ixv-2925">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="P01_01_2023To12_31_2023" id="ixv-2926">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="P01_01_2023To12_31_2023" id="ixv-2927">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:AuditorName contextRef="P01_01_2023To12_31_2023" id="ixv-2928">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="P01_01_2023To12_31_2023" id="ixv-2929">Vancouver, Canada</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="P01_01_2023To12_31_2023" id="ixv-2930">85</dei:AuditorFirmId>
    <us-gaap:PreferredStockSharesAuthorizedUnlimited contextRef="P01_01_2022To12_31_2022" id="hidden108159696">Unlimited</us-gaap:PreferredStockSharesAuthorizedUnlimited>
    <us-gaap:PreferredStockSharesAuthorizedUnlimited contextRef="P01_01_2023To12_31_2023" id="hidden108159697">Unlimited</us-gaap:PreferredStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="P01_01_2022To12_31_2022" id="hidden108159693">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="P01_01_2023To12_31_2023" id="hidden108159695">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockNoParValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="hidden108160218"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="hidden108160219"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="P01_01_2022To12_31_2022" id="hidden108160215">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="P01_01_2023To12_31_2023" id="hidden108160178">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14126"
      unitRef="Unit_USD">19341756</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14127"
      unitRef="Unit_USD">18263389</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14128"
      unitRef="Unit_USD">270710</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14129"
      unitRef="Unit_USD">235903</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14130"
      unitRef="Unit_USD">190612</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14131"
      unitRef="Unit_USD">89715</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14132"
      unitRef="Unit_USD">19803078</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14133"
      unitRef="Unit_USD">18589007</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14134"
      unitRef="Unit_USD">6904</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14135"
      unitRef="Unit_USD">2492</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14136"
      unitRef="Unit_USD">409587</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14137"
      unitRef="Unit_USD">443464</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14138"
      unitRef="Unit_USD">46660</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14139"
      unitRef="Unit_USD">87286</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14140"
      unitRef="Unit_USD">20266229</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14141"
      unitRef="Unit_USD">19122249</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14142"
      unitRef="Unit_USD">3921875</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14143"
      unitRef="Unit_USD">2928566</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLongTermDebtCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14144"
      unitRef="Unit_USD">62709</us-gaap:OtherLongTermDebtCurrent>
    <us-gaap:OtherLongTermDebtCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14145"
      unitRef="Unit_USD">79418</us-gaap:OtherLongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14146"
      unitRef="Unit_USD">53316</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14147"
      unitRef="Unit_USD">50403</us-gaap:OperatingLeaseLiabilityCurrent>
    <eprx:PayableTowardsRoyaltyAndOthersCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14148"
      unitRef="Unit_USD">5000000</eprx:PayableTowardsRoyaltyAndOthersCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14149"
      unitRef="Unit_USD">10336003</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14150"
      unitRef="Unit_USD">19373903</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14151"
      unitRef="Unit_USD">3058387</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14152"
      unitRef="Unit_USD">62709</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14153"
      unitRef="Unit_USD">51303</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14154"
      unitRef="Unit_USD">8741996</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14155"
      unitRef="Unit_USD">19373903</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14156"
      unitRef="Unit_USD">11914395</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-14157"
      unitRef="Unit_shares">27282165</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-14158"
      unitRef="Unit_shares">27282165</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-14159"
      unitRef="Unit_shares">21593145</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-14160"
      unitRef="Unit_shares">21593145</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14161"
      unitRef="Unit_USD">92913585</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14162"
      unitRef="Unit_USD">71003225</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14163"
      unitRef="Unit_USD">17510469</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14164"
      unitRef="Unit_USD">16850165</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14165"
      unitRef="Unit_USD">-105501295</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14166"
      unitRef="Unit_USD">-77280499</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14167"
      unitRef="Unit_USD">-2706552</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14168"
      unitRef="Unit_USD">-2786366</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14169"
      unitRef="Unit_USD">2216207</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14170"
      unitRef="Unit_USD">7786525</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14171"
      unitRef="Unit_USD">-1323881</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14172"
      unitRef="Unit_USD">-578671</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14173"
      unitRef="Unit_USD">892326</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14174"
      unitRef="Unit_USD">7207854</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14175"
      unitRef="Unit_USD">20266229</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14176"
      unitRef="Unit_USD">19122249</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14177"
      unitRef="Unit_USD">7284004</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14178"
      unitRef="Unit_USD">3987598</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14179"
      unitRef="Unit_USD">20563225</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14180"
      unitRef="Unit_USD">13629854</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14181"
      unitRef="Unit_USD">27847229</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14182"
      unitRef="Unit_USD">17617452</us-gaap:OperatingExpenses>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14183"
      unitRef="Unit_USD">862969</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14184"
      unitRef="Unit_USD">431799</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14185"
      unitRef="Unit_USD">1170173</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14186"
      unitRef="Unit_USD">982856</us-gaap:InterestExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14187"
      unitRef="Unit_USD">-4846</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14188"
      unitRef="Unit_USD">-6637</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14189"
      unitRef="Unit_USD">66291</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14190"
      unitRef="Unit_USD">240547</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14191"
      unitRef="Unit_USD">-836595</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14192"
      unitRef="Unit_USD">-1056165</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14193"
      unitRef="Unit_USD">-1082354</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14194"
      unitRef="Unit_USD">-1373312</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14195"
      unitRef="Unit_USD">-28929583</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14196"
      unitRef="Unit_USD">-18990764</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14197"
      unitRef="Unit_USD">36423</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14198"
      unitRef="Unit_USD">-28966006</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14199"
      unitRef="Unit_USD">-18990764</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14200"
      unitRef="Unit_USD">-28220796</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14201"
      unitRef="Unit_USD">-18489629</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14202"
      unitRef="Unit_USD">-745210</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14203"
      unitRef="Unit_USD">-501135</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14204"
      unitRef="Unit_USD">-28966006</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14205"
      unitRef="Unit_USD">-18990764</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14206"
      unitRef="Unit_USD">79814</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14207"
      unitRef="Unit_USD">-1276388</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14208"
      unitRef="Unit_USD">-28886192</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14209"
      unitRef="Unit_USD">-20267152</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-14210"
      unitRef="Unit_USD_per_Share">-1.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-14211"
      unitRef="Unit_USD_per_Share">-1.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      id="ixv-14212"
      unitRef="Unit_USD_per_Share">-0.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      id="ixv-14213"
      unitRef="Unit_USD_per_Share">-0.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-14214"
      unitRef="Unit_shares">24146623</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14215"
      unitRef="Unit_shares">24146623</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14216"
      unitRef="Unit_shares">19285447</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      id="ixv-14217"
      unitRef="Unit_shares">19285447</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14218"
      unitRef="Unit_shares">14242595</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14219"
      unitRef="Unit_USD">62250123</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14220"
      unitRef="Unit_USD">13226108</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14221"
      unitRef="Unit_USD">-58790870</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14222"
      unitRef="Unit_USD">-1509978</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14223"
      unitRef="Unit_USD">-77536</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021"
      decimals="0"
      id="ixv-14224"
      unitRef="Unit_USD">15097847</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OvernightMarketedPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14225"
      unitRef="Unit_shares">7150550</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OvernightMarketedPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14226"
      unitRef="Unit_USD">8401439</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_OvernightMarketedPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14227"
      unitRef="Unit_USD">2235138</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To12_31_2022_OvernightMarketedPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14228"
      unitRef="Unit_USD">10636577</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis"
      decimals="0"
      id="ixv-14229"
      unitRef="Unit_shares">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis"
      decimals="0"
      id="ixv-14230"
      unitRef="Unit_USD">351663</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis"
      decimals="0"
      id="ixv-14231"
      unitRef="Unit_USD">-44893</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To12_31_2022_ExcerciseOfWarrantsMemberEPRXEventAxis"
      decimals="0"
      id="ixv-14232"
      unitRef="Unit_USD">306770</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14233"
      unitRef="Unit_USD">1433812</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14234"
      unitRef="Unit_USD">1433812</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14235"
      unitRef="Unit_USD">-18489629</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14236"
      unitRef="Unit_USD">-501135</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14237"
      unitRef="Unit_USD">-18990764</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14238"
      unitRef="Unit_USD">-1276388</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14239"
      unitRef="Unit_USD">-1276388</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14240"
      unitRef="Unit_shares">21593145</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14241"
      unitRef="Unit_USD">71003225</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14242"
      unitRef="Unit_USD">16850165</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14243"
      unitRef="Unit_USD">-77280499</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14244"
      unitRef="Unit_USD">-2786366</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14245"
      unitRef="Unit_USD">-578671</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14246"
      unitRef="Unit_USD">7207854</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14247"
      unitRef="Unit_shares">3282936</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14248"
      unitRef="Unit_USD">15886537</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14249"
      unitRef="Unit_USD">15886537</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14250"
      unitRef="Unit_USD">1412257</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14251"
      unitRef="Unit_USD">1412257</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis"
      decimals="0"
      id="ixv-14252"
      unitRef="Unit_shares">2385484</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis"
      decimals="0"
      id="ixv-14253"
      unitRef="Unit_USD">5974988</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_ExcerciseOfWarrantsMemberEPRXEventAxis"
      decimals="0"
      id="ixv-14254"
      unitRef="Unit_USD">-733177</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_ExcerciseOfWarrantsMemberEPRXEventAxis"
      decimals="0"
      id="ixv-14255"
      unitRef="Unit_USD">5241811</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14256"
      unitRef="Unit_shares">20600</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14257"
      unitRef="Unit_USD">48835</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14258"
      unitRef="Unit_USD">-18776</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14259"
      unitRef="Unit_USD">30059</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14260"
      unitRef="Unit_USD">-28220796</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To12_31_2023_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14261"
      unitRef="Unit_USD">-745210</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14262"
      unitRef="Unit_USD">-28966006</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2023To12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14263"
      unitRef="Unit_USD">79814</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14264"
      unitRef="Unit_USD">79814</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14265"
      unitRef="Unit_shares">27282165</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14266"
      unitRef="Unit_USD">92913585</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14267"
      unitRef="Unit_USD">17510469</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14268"
      unitRef="Unit_USD">-105501295</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14269"
      unitRef="Unit_USD">-2706552</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14270"
      unitRef="Unit_USD">-1323881</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14271"
      unitRef="Unit_USD">892326</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14272"
      unitRef="Unit_USD">-28966006</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14273"
      unitRef="Unit_USD">-18990764</us-gaap:ProfitLoss>
    <eprx:InterestOnConvertibleDebtOne
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14274"
      unitRef="Unit_USD">571603</eprx:InterestOnConvertibleDebtOne>
    <eprx:InterestOnConvertibleDebtOne
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14275"
      unitRef="Unit_USD">643233</eprx:InterestOnConvertibleDebtOne>
    <eprx:InterestOnShortTermInvestmentsNonOperating
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14276"
      unitRef="Unit_USD">4665</eprx:InterestOnShortTermInvestmentsNonOperating>
    <us-gaap:Depreciation
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14277"
      unitRef="Unit_USD">155527</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14278"
      unitRef="Unit_USD">147894</us-gaap:Depreciation>
    <eprx:InterestExpensesOnLeaseLiabilityFinancingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14279"
      unitRef="Unit_USD">14401</eprx:InterestExpensesOnLeaseLiabilityFinancingActivities>
    <eprx:InterestExpensesOnLeaseLiabilityFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14280"
      unitRef="Unit_USD">21383</eprx:InterestExpensesOnLeaseLiabilityFinancingActivities>
    <eprx:LossOnSaleOfEquipment
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14281"
      unitRef="Unit_USD">-4846</eprx:LossOnSaleOfEquipment>
    <eprx:LossOnSaleOfEquipment
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14282"
      unitRef="Unit_USD">-6879</eprx:LossOnSaleOfEquipment>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14283"
      unitRef="Unit_USD">1412257</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14284"
      unitRef="Unit_USD">1433812</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14285"
      unitRef="Unit_USD">-836595</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14286"
      unitRef="Unit_USD">-1056165</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14287"
      unitRef="Unit_USD">64609</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14288"
      unitRef="Unit_USD">223709</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14289"
      unitRef="Unit_USD">577908</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14290"
      unitRef="Unit_USD">1324049</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <eprx:IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14291"
      unitRef="Unit_USD">5000000</eprx:IncreaseDecreaseInPayableTowardsLicensingFeesAndOthersCurrent>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14292"
      unitRef="Unit_USD">122435</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14293"
      unitRef="Unit_USD">39959</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14294"
      unitRef="Unit_USD">103710</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14295"
      unitRef="Unit_USD">-230481</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14296"
      unitRef="Unit_USD">-20683623</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14297"
      unitRef="Unit_USD">-14395201</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14298"
      unitRef="Unit_USD">73377</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14299"
      unitRef="Unit_USD">235550</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14300"
      unitRef="Unit_USD">242</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14301"
      unitRef="Unit_USD">3272379</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14302"
      unitRef="Unit_USD">13342058</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14303"
      unitRef="Unit_USD">-73377</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14304"
      unitRef="Unit_USD">9834371</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14305"
      unitRef="Unit_USD">15886537</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14306"
      unitRef="Unit_USD">10636577</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14307"
      unitRef="Unit_USD">5241811</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14308"
      unitRef="Unit_USD">306770</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14309"
      unitRef="Unit_USD">30059</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14310"
      unitRef="Unit_USD">79441</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14311"
      unitRef="Unit_USD">74845</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14312"
      unitRef="Unit_USD">64996</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14313"
      unitRef="Unit_USD">67423</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14314"
      unitRef="Unit_USD">21013970</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14315"
      unitRef="Unit_USD">10801079</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14316"
      unitRef="Unit_USD">256970</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14317"
      unitRef="Unit_USD">6240249</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14318"
      unitRef="Unit_USD">821397</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14319"
      unitRef="Unit_USD">-507395</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14320"
      unitRef="Unit_USD">18263389</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="0"
      id="ixv-14321"
      unitRef="Unit_USD">12530535</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14322"
      unitRef="Unit_USD">19341756</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14323"
      unitRef="Unit_USD">18263389</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations contextRef="P01_01_2023To12_31_2023" id="ixv-5486">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NATURE OF BUSINESS AND GOING CONCERN &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Eupraxia Pharmaceuticals Inc. (the &#x201c;Company&#x201d;) was incorporated under the laws of the province of Alberta on May 12, 2011, under the name Plaza Capital Partners Inc. On May&#160;11, 2012, the Company changed its name to Eupraxia Pharmaceuticals Inc. and continued from the province of Alberta to the province of British Columbia. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;On October&#160;10, 2012, Eupraxia Holdings, Inc. (&#x201c;Holdings&#x201d;) was incorporated under the laws of the State of Delaware, USA. On November&#160;16, 2012, Holdings was registered as an extra-provincial corporation under the laws of the province of British Columbia, Canada. On October 10, 2012, Eupraxia Pharmaceuticals USA, LLC (&#x201c;Eupraxia USA&#x201d;) was incorporated under the laws of the State of Delaware. On November&#160;16, 2012, Eupraxia USA was registered as an extra-provincial corporation under the laws of the province of British Columbia. On January&#160;7, 2021, Eupraxia Pharma, Inc. (&#x201c;Eupraxia Pharma&#x201d;) was incorporated under the laws of the State of Delaware. On July&#160;4, 2022, Eupraxia Pharmaceuticals Australia Pty Ltd. (&#x201c;Eupraxia Australia&#x201d;) was incorporated under the laws of the state of Victoria, Australia. On May&#160;17, 2023, Eupraxia Pharma USA Inc. (&#x201c;Eupraxia Pharma USA&#x201d;) was incorporated under the laws of the State of Delaware. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;On March&#160;9, 2021, the Company completed its initial public offering on the Toronto Stock Exchange (&#x201c;TSX&#x201d;) and began trading under the symbol &#x201c;EPRX&#x201d;. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The Company is a clinical stage biotechnology company leveraging its proprietary Diffusphere&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#x2122;&lt;/div&gt; technology to optimize drug delivery for applications with significant unmet medical need. The address of the Company&#x2019;s corporate office and principal place of business is 201- 2067 Cadboro Bay Road, Victoria, British Columbia, Canada. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;These consolidated financial statements have been prepared on a going concern basis with the assumption that the Company will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. At December&#160;31, 2023, the Company had cash and cash equivalents of $19,341,756&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The&lt;/div&gt; Company has not yet generated revenue from operations. The Company incurred a net loss of $28,966,006 during the year ended December&#160;31, 2023, and as of that date, the Company&#x2019;s accumulated deficit was $105,501,295. As the Company is in the research and development stage, the recoverability of the costs incurred to date is dependent upon the ability of the Company to obtain the necessary funding to complete the research and development of its projects and upon future commercialization or proceeds from the monetization of research activities. The Company will periodically have to raise funds to continue operations and raised $15,886,537 (CDN$20,836,005) through a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;non-brokered&lt;/div&gt; private placement of 3,183,875 common shares in &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023 (2022 - $11,768,459 through a marketed public offering) and raised $25,026,073 (CDN$33,867,784) through an overnight marketed public offering of 8,260,435 common shares in 2024&lt;/div&gt;. Although it has been successful in doing so in the past, there is no assurance it will be able to do so in the future, especially with the ongoing conflicts in the Ukraine and the Middle East affecting the global capital markets. Recent developments with Silicon Valley Bank (&#x201c;SVB&#x201d;) have not impacted the Company&#x2019;s outlook for cash runway. The Company holds no amounts on deposit with SVB and the convertible debt (see Note &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt; &#x2013; Convertible Debt) which matures in June 2024 remains in good standing, is fully drawn and is not callable by SVB. The Company is active in its pursuit of additional funding through potential partnering and other strategic activities as well as grants to fund future research and development activities, and additional equity financing. &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional funding. There is a risk that in the future, additional financing will not be available on a timely basis or on terms acceptable to the Company. These events and conditions may cast substantial doubt about the Company&#x2019;s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue in business. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <dei:EntityIncorporationDateOfIncorporation contextRef="P01_01_2023To12_31_2023" id="ixv-14324">2011-05-12</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14325"
      unitRef="Unit_USD">19341756</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Revenues
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14326"
      unitRef="Unit_USD">0</us-gaap:Revenues>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14327"
      unitRef="Unit_USD">-28966006</us-gaap:ProfitLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14328"
      unitRef="Unit_USD">-105501295</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14329"
      unitRef="Unit_USD">15886537</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14330"
      unitRef="Unit_CAD">20836005</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14331"
      unitRef="Unit_shares">3183875</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_01_2022To12_31_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14332"
      unitRef="Unit_USD">11768459</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-14333"
      unitRef="Unit_USD">25026073</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-14334"
      unitRef="Unit_CAD">33867784</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2024To03_31_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-14335"
      unitRef="Unit_shares">8260435</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentCollateralAmount
      contextRef="PAsOn12_31_2023_SiliconValleyBankMemberEPRXLenderAxis"
      decimals="0"
      id="ixv-14336"
      unitRef="Unit_USD">0</us-gaap:DebtInstrumentCollateralAmount>
    <eprx:DebtInstrumentMonthOfMaturity
      contextRef="P01_01_2023To12_31_2023_SiliconValleyBankMemberEPRXLenderAxis"
      id="ixv-14337">2024-06</eprx:DebtInstrumentMonthOfMaturity>
    <us-gaap:BasisOfAccounting contextRef="P01_01_2023To12_31_2023" id="ixv-5547">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;BASIS OF PRESENTATION &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These consolidated financial statements are presented in U.S. dollars and have been prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). These consolidated financial statements include the accounts of the Company and the accounts of its subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in Reporting Currency to the US&#160;Dollar &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effective December&#160;31, 2023, the Company changed its reporting currency to the US dollar (&#x201c;USD&#x201d;) from the Canadian dollar (&#x201c;CDN&#x201d;). As such, all prior amounts originally reported in CDN are now reported in USD. The change in reporting currency was made to enhance comparability of the Company&#x2019;s results with other publicly traded companies in the life sciences industry. The Canadian dollar continues to be the functional currency of the Company. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance with ASC 830, the consolidated financial statements of the Company are translated into U.S. dollars using the current rate method. Assets and liabilities are translated at the rate of exchange prevailing at the consolidated balance sheet date. Shareholders&#x2019; equity is translated at the applicable historical rate. Revenue, expense and cash flow items are translated at the exchange rate in effect on the transaction dates. Translation gains and losses are reported as a separate component of shareholders&#x2019; equity titled Accumulated Other Comprehensive Income. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The financial information for all prior periods is presented in U.S. dollars as if the U.S. dollar had been used as the reporting currency during those periods. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transition to US&#160;GAAP &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;This is the first year that the Company&#x2019;s consolidated financial statements are prepared in accordance of generally accepted accounting principles in the United States of America &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(&#x201c;GAAP&#x201d;&lt;/div&gt;&lt;/div&gt;) as issued by the Financial Accounting Standards Board (&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x201c;FASB&#x201d;&lt;/div&gt;&lt;/div&gt;). Previously, the Company prepared its financial statements in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The policies set out in the Significant Accounting Policies section have been applied in preparing the financial statements for the years ended December&#160;31, 2023 and 2022. In addition, comparative figures, which were previously prepared in accordance with IFRS, have been adjusted as required to be compliant with the Company&#x2019;s accounting policies under US&#160;GAAP. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-5586">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements have been prepared on a historical cost basis, except for certain financial instruments which are measured at fair value. The consolidated financial statements are presented in U.S. dollars, which is the Company&#x2019;s reporting currency. The Company&#x2019;s functional currency is the Canadian dollar. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of consolidated financial statements in accordance with U.S. GAAP requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, expenses, and related disclosure. On an ongoing basis, the Company evaluates its estimates, most notably those related to accrual of expenses including clinical and preclinical study expense accruals, stock-based compensation, valuation allowance for deferred taxes, and fair value measurement of convertible debt. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 8pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center;"&gt; &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These consolidated financial statements include the accounts of the Company and the accounts of its subsidiaries. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. Control exists when an entity is exposed to or has rights to variable returns from its involvement with the entity and has the ability to affect these returns through its power over the entity. All significant intercompany transactions and balances have been eliminated. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling&lt;/div&gt; interest in the net assets of consolidated subsidiaries are identified separately from the Company&#x2019;s equity. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling&lt;/div&gt; interest consists of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest as at the date of the original transaction plus the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest&#x2019;s share of changes in equity since that date.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 53%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company Entity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Date of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Incorporation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Jurisdiction of&lt;br/&gt;Incorporation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effective&lt;br/&gt;Interest&lt;br/&gt;(Note&#160;13(e))&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width:53%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Eupraxia Holdings, Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;October 10, 2012&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Delaware,&#160;USA&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Eupraxia Pharmaceuticals USA, LLC&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;October 10, 2012&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Delaware, USA&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;AMDM Holdings Inc.&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;April 6, 2016&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Washington,&#160;USA&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Eupraxia Pharma, Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;January 7, 2021&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Delaware, USA&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Eupraxia Pharmaceuticals Australia Pty Ltd.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;July 4, 2022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Victoria, Australia&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Eupraxia Pharma USA Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;May 17, 2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Delaware, USA&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Wholly-owned subsidiary of Eupraxia Pharmaceuticals Inc. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Date of Control occurred on January&#160;31, 2021 (see Note 13(e)). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earnings (Loss) per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company applies the &#x201c;Treasury Stock Method&#x201d; to calculate loss per common share. Under this method, the basic earnings (loss) per share is calculated based on the weighted average aggregate number of common shares outstanding during each period. The diluted earnings (loss) per share assumes that the outstanding stock options and share purchase warrants had been exercised at the beginning of the period, or date of issuance if issued during the period, and proceeds from dilutive instruments are used to purchase common shares at the average market price during the period. Since the Company was in a loss position for the years ended December&#160;31, 2023 and 2022, the assumed conversion of outstanding common share warrants, options, and convertible instruments has an anti-dilutive impact, therefore the diluted loss per share is equal to basic loss per share. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equipment is recorded at historical cost less accumulated depreciation and accumulated impairment losses. Depreciation is provided over the estimated useful lives of the assets as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:94%;border:0;margin-left:auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&lt;/td&gt;
&lt;td style="width:48%"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;Computers&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;45% declining balance&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;Office furniture and equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;20% declining balance&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;straight-line over the shorter of the initial term of the lease or useful life&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Lab equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;20% declining balance&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The useful lives and depreciation methods applied to each category of equipment are assessed on an annual basis by management and adjusted where necessary to reflect the recoverability of equipment. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Research and Development Expenditures &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Research and development costs are expensed as they are incurred. These costs consist primarily of salaries and wages related to research and development activities, including share-based payments for employees engaged in research and development, clinical trial expenses and other research costs. &lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Investment Tax Credits &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Investment tax credits (&#x201c;ITCs&#x201d;) arising from research and development activities are deducted from the related costs and are included in profit or loss when there is reasonable assurance that the credits will be realized. ITCs arising from the acquisition or development of equipment and capitalized development costs are deducted from the cost of those assets with amortization calculated on the net amount. &lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Government Grants &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Government grants related to research and development activities are recognized in profit or loss as a deduction from the related expenditure when there is reasonable assurance that the grant will be received. Grants that compensate the Company for the cost of an asset are recognized in profit or loss on a systematic basis over the useful life of the asset. &lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Government Assistance &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Government contributions are recognized and deducted from the related costs when there is reasonable assurance that the contribution will be received and all attached conditions have been complied with by the Company. Government contributions arising from the acquisition or development of equipment and capitalized development costs are deducted from the cost of those assets with amortization calculated on the net amount. &lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current income tax is the expected tax payable or recoverable on the taxable profit or loss for the year using tax rates enacted at the reporting date and any adjustment to tax payable from previous years. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax is recorded using the asset and liability method, providing for temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Temporary differences are not provided for if they relate to goodwill not deductible for tax purposes, or differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates and laws enacted at the reporting date and expected to apply when these differences reverse. A deferred tax asset is recognized only to the extent that it is more likely than not that future taxable profits will be available against which the asset can be utilized. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company uses a two-step process to recognize and measure the income tax benefit of uncertain tax positions taken or expected to be taken in a tax return. The tax benefit from an uncertain tax position is recognized if it more likely than not that the position will be sustained upon examination of the tax authority based solely on the technical merits of the position. A tax benefit that meets the more likely than not recognition threshold is measured as the largest amount that is greater than 50% likely to realized upon settlement with the tax authority. To the extent a full benefit is not expected to be realized, an income tax liability is established. Any change in judgement related to the expected resolution of an uncertain tax provision is recognized in the year of such a change. Interest an penalties related to income tax are included as a component of income tax expense. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share-based Payments &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company grants stock options to employees, directors and officers pursuant to stock option plans described in note 13c. Employee stock-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense, net of actual forfeitures, over the requisite service period with a corresponding increase in additional paid-in capital. Stock-based compensation expense is amortized on a straight-line basis over the requisite service period for the entire award, which is generally the vesting period of the award. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Any consideration received on exercise of stock options is credited to share capital. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share Capital and Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records proceeds from share issuances net of issue costs and any related tax effects. Common shares issued for consideration other than cash are valued based on their market value at the date the agreement to issue shares was concluded. When units are issued during a private placement, which include both common shares and share purchase warrants, the warrants are classified as equity and as such, the proceeds should be allocated based on the relative fair values of the base instrument and the warrants on the day of the announcement of the private placement. Any value of the warrants is allocated to the warrants and credited to additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign Currency Translation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The functional currency for each of the Company and the Company&#x2019;s subsidiaries is the currency of the primary economic environment in which each entity operates. Determination of functional currency may involve certain judgments to determine the primary economic environment. The Company reconsiders the functional currency of its entities if there is a change in events and conditions which determine the primary economic environment. The functional currency of Eupraxia Pharmaceuticals Inc., the parent entity, and each of the Company&#x2019;s subsidiaries is the Canadian dollar. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transactions in foreign currencies are translated to the functional currency of the entity at the exchange rate at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the reporting date are retranslated at the period end date exchange rates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-monetary&lt;/div&gt; items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-monetary&lt;/div&gt; assets and liabilities denominated in foreign currencies that are measured at fair value are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-translated&lt;/div&gt; to the functional currency at the exchange rate at the date that the fair value was determined. Foreign currency differences arising on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-translation&lt;/div&gt; are recognized in profit or loss. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The reporting currency of the Company&#x2019;s consolidated financial statements is the U.S. dollar. All assets and liabilities are translated from the functional currency to the reporting currency using the spot rate at the period end date, equity components are translated at the historical rate, and income and expenses are translated using the average exchange rate for the period. All foreign currency differences arising on translation from functional to reporting currency are included in accumulated other comprehensive income. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or group of assets. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset or asset group. As of December&#160;31, 2023 and 2022, the Company determined that there were no indicators of impairment of long-lived assets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Cash and cash equivalents include cash on hand, bank deposits, and highly liquid investments with original maturities of three months or less from the date of purchase that are readily convertible to known amounts of cash and subject to insignificant risk of changes in value. Cash equivalents are recorded at cost plus accrued interest. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short Term Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Short term investments include highly liquid investments with original maturity dates greater than three months and less than one year and cannot be redeemed prior to maturity without incurring a penalty. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial Instruments and Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures certain financial instruments and other items at fair value into a three-level hierarchy established by US GAAP that prioritizes those inputs to valuation techniques used to measure fair value on the degree to which they are observable. This hierarchy includes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;i.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 1 &#x2013; Unadjusted quoted prices in active markets for identical instruments. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ii.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 2 &#x2013; Inputs other than quoted prices included within Level 1 that are observable for the financial instrument, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability and inputs that are derived principally from or corroborated by observable market data by correlation or other means. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;iii.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inputs are unobservable and reflect the Company&#x2019;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets and liabilities are classified on the lowest level of input that is significant to the fair value measurements. Reclassification of the level may be a result of changes in the observability of the valuation inputs for certain instruments within the fair value hierarchy. The carrying value of accounts receivable, accounts payable, and accrued expense approximate fair value due to the short-term nature of these instruments. On a recurring basis, the Company&#x2019;s cash and cash equivalents and marketable securities are measured at fair value. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="text-align: justify; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases classified as operating leases are recorded as lease liabilities based on the present value of minimum lease payments over the lease term, discounted using the lessor&#x2019;s rate implicit in the lease or the Company&#x2019;s incremental borrowing rate, if the lessor&#x2019;s implicit rate is not readily determinable. The lease term includes all periods covered by renewal and termination options where the Company is reasonably certain to exercise the renewal options or not to exercise the termination options. Corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets are recognized consisting of the lease liabilities, initial direct costs and any lease incentive payments. Lease liabilities are drawn down as lease payments are made and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets are depreciated over the term of the lease. Operating lease expenses are recognized on a straight-line basis over the term of the lease, consisting of interest accrued on the lease liability and depreciation of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset, adjusted for changes in index-based variable lease payments in the period of change. Lease payments on short-term operating leases with lease terms twelve months or less are expensed on a straight-line basis over the lease term. &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upcoming Accounting Standards and Interpretations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has not yet adopted certain new standards, amendments and interpretations to existing standards, which have been published but are only effective for accounting periods beginning on or after January&#160;1, 2024 or later periods. The new and amended standards are not expected to have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-5599">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements have been prepared on a historical cost basis, except for certain financial instruments which are measured at fair value. The consolidated financial statements are presented in U.S. dollars, which is the Company&#x2019;s reporting currency. The Company&#x2019;s functional currency is the Canadian dollar. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of consolidated financial statements in accordance with U.S. GAAP requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, expenses, and related disclosure. On an ongoing basis, the Company evaluates its estimates, most notably those related to accrual of expenses including clinical and preclinical study expense accruals, stock-based compensation, valuation allowance for deferred taxes, and fair value measurement of convertible debt. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-5660">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These consolidated financial statements include the accounts of the Company and the accounts of its subsidiaries. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. Control exists when an entity is exposed to or has rights to variable returns from its involvement with the entity and has the ability to affect these returns through its power over the entity. All significant intercompany transactions and balances have been eliminated. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling&lt;/div&gt; interest in the net assets of consolidated subsidiaries are identified separately from the Company&#x2019;s equity. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling&lt;/div&gt; interest consists of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest as at the date of the original transaction plus the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest&#x2019;s share of changes in equity since that date.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 53%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company Entity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Date of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Incorporation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Jurisdiction of&lt;br/&gt;Incorporation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effective&lt;br/&gt;Interest&lt;br/&gt;(Note&#160;13(e))&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width:53%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Eupraxia Holdings, Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;October 10, 2012&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Delaware,&#160;USA&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Eupraxia Pharmaceuticals USA, LLC&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;October 10, 2012&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Delaware, USA&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;AMDM Holdings Inc.&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;April 6, 2016&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Washington,&#160;USA&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Eupraxia Pharma, Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;January 7, 2021&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Delaware, USA&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Eupraxia Pharmaceuticals Australia Pty Ltd.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;July 4, 2022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Victoria, Australia&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Eupraxia Pharma USA Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;May 17, 2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Delaware, USA&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Wholly-owned subsidiary of Eupraxia Pharmaceuticals Inc. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Date of Control occurred on January&#160;31, 2021 (see Note 13(e)). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <eprx:ScheduleOfInformationAboutSubsidiariesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-5686">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 53%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company Entity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Date of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Incorporation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Jurisdiction of&lt;br/&gt;Incorporation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effective&lt;br/&gt;Interest&lt;br/&gt;(Note&#160;13(e))&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width:53%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Eupraxia Holdings, Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;October 10, 2012&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Delaware,&#160;USA&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Eupraxia Pharmaceuticals USA, LLC&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;October 10, 2012&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Delaware, USA&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;AMDM Holdings Inc.&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;April 6, 2016&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Washington,&#160;USA&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Eupraxia Pharma, Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;January 7, 2021&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Delaware, USA&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Eupraxia Pharmaceuticals Australia Pty Ltd.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;July 4, 2022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Victoria, Australia&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Eupraxia Pharma USA Inc.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;May 17, 2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Delaware, USA&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Wholly-owned subsidiary of Eupraxia Pharmaceuticals Inc. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Date of Control occurred on January&#160;31, 2021 (see Note 13(e)). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</eprx:ScheduleOfInformationAboutSubsidiariesTableTextBlock>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="P01_01_2023To12_31_2023_EupraxiaHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      id="ixv-14340">2012-10-10</dei:EntityIncorporationDateOfIncorporation>
    <dei:EntityAddressCityOrTown
      contextRef="P01_01_2023To12_31_2023_EupraxiaHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      id="ixv-14341">Delaware</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="P01_01_2023To12_31_2023_EupraxiaHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      id="ixv-14342">US</dei:EntityAddressCountry>
    <eprx:InvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2023_EupraxiaHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      decimals="2"
      id="ixv-14343"
      unitRef="Unit_pure">0.95</eprx:InvestmentOwnershipPercentage>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaceuticalsUsaLlcMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      id="ixv-14344">2012-10-10</dei:EntityIncorporationDateOfIncorporation>
    <dei:EntityAddressCityOrTown
      contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaceuticalsUsaLlcMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      id="ixv-14345">Delaware</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaceuticalsUsaLlcMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      id="ixv-14346">US</dei:EntityAddressCountry>
    <eprx:InvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2023_EupraxiaPharmaceuticalsUsaLlcMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      decimals="2"
      id="ixv-14347"
      unitRef="Unit_pure">0.95</eprx:InvestmentOwnershipPercentage>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="P01_01_2023To12_31_2023_AmdmHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      id="ixv-14348">2016-04-06</dei:EntityIncorporationDateOfIncorporation>
    <dei:EntityAddressCityOrTown
      contextRef="P01_01_2023To12_31_2023_AmdmHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      id="ixv-14349">Washington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="P01_01_2023To12_31_2023_AmdmHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      id="ixv-14350">US</dei:EntityAddressCountry>
    <eprx:InvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2023_AmdmHoldingsIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      decimals="2"
      id="ixv-14351"
      unitRef="Unit_pure">0.95</eprx:InvestmentOwnershipPercentage>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      id="ixv-14352">2021-01-07</dei:EntityIncorporationDateOfIncorporation>
    <dei:EntityAddressCityOrTown
      contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      id="ixv-14353">Delaware</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      id="ixv-14354">US</dei:EntityAddressCountry>
    <eprx:InvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2023_EupraxiaPharmaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      decimals="2"
      id="ixv-14355"
      unitRef="Unit_pure">0.95</eprx:InvestmentOwnershipPercentage>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaceuticalsAustraliaPtyLtdMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      id="ixv-14356">2022-07-04</dei:EntityIncorporationDateOfIncorporation>
    <dei:EntityAddressCityOrTown
      contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaceuticalsAustraliaPtyLtdMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      id="ixv-14357">Victoria</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaceuticalsAustraliaPtyLtdMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      id="ixv-14358">AU</dei:EntityAddressCountry>
    <eprx:InvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2023_EupraxiaPharmaceuticalsAustraliaPtyLtdMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      decimals="2"
      id="ixv-14359"
      unitRef="Unit_pure">1</eprx:InvestmentOwnershipPercentage>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaUsaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      id="ixv-14360">2023-05-17</dei:EntityIncorporationDateOfIncorporation>
    <dei:EntityAddressCityOrTown
      contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaUsaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      id="ixv-14361">Delaware</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="P01_01_2023To12_31_2023_EupraxiaPharmaUsaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      id="ixv-14362">US</dei:EntityAddressCountry>
    <eprx:InvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2023_EupraxiaPharmaUsaIncMemberdeiLegalEntityAxis_SubsidiariesMembersrtConsolidatedEntitiesAxis"
      decimals="2"
      id="ixv-14363"
      unitRef="Unit_pure">1</eprx:InvestmentOwnershipPercentage>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-5864">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earnings (Loss) per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company applies the &#x201c;Treasury Stock Method&#x201d; to calculate loss per common share. Under this method, the basic earnings (loss) per share is calculated based on the weighted average aggregate number of common shares outstanding during each period. The diluted earnings (loss) per share assumes that the outstanding stock options and share purchase warrants had been exercised at the beginning of the period, or date of issuance if issued during the period, and proceeds from dilutive instruments are used to purchase common shares at the average market price during the period. Since the Company was in a loss position for the years ended December&#160;31, 2023 and 2022, the assumed conversion of outstanding common share warrants, options, and convertible instruments has an anti-dilutive impact, therefore the diluted loss per share is equal to basic loss per share. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-5879">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equipment is recorded at historical cost less accumulated depreciation and accumulated impairment losses. Depreciation is provided over the estimated useful lives of the assets as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:94%;border:0;margin-left:auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&lt;/td&gt;
&lt;td style="width:48%"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;Computers&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;45% declining balance&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;Office furniture and equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;20% declining balance&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;straight-line over the shorter of the initial term of the lease or useful life&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Lab equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;20% declining balance&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The useful lives and depreciation methods applied to each category of equipment are assessed on an annual basis by management and adjusted where necessary to reflect the recoverability of equipment. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <eprx:PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-5884">&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equipment is recorded at historical cost less accumulated depreciation and accumulated impairment losses. Depreciation is provided over the estimated useful lives of the assets as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:94%;border:0;margin-left:auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&lt;/td&gt;
&lt;td style="width:48%"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;Computers&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;45% declining balance&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;Office furniture and equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;20% declining balance&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;straight-line over the shorter of the initial term of the lease or useful life&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Lab equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;20% declining balance&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</eprx:PropertyPlantAndEquipmentRateOfDepreciationTableTextBlock>
    <eprx:PropertyPlantAndEqupmentRateOfDepreciation
      contextRef="P01_01_2023To12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="2"
      id="ixv-14364"
      unitRef="Unit_pure">0.45</eprx:PropertyPlantAndEqupmentRateOfDepreciation>
    <eprx:PropertyPlantAndEqupmentRateOfDepreciation
      contextRef="P01_01_2023To12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="2"
      id="ixv-14365"
      unitRef="Unit_pure">0.20</eprx:PropertyPlantAndEqupmentRateOfDepreciation>
    <eprx:PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation
      contextRef="P01_01_2023To12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-14366">straight-line over the shorter of the initial term of the lease or useful life</eprx:PropertyPlantAndEquipmentDescriptionOfRateOfDepreciation>
    <eprx:PropertyPlantAndEqupmentRateOfDepreciation
      contextRef="P01_01_2023To12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="2"
      id="ixv-14367"
      unitRef="Unit_pure">0.20</eprx:PropertyPlantAndEqupmentRateOfDepreciation>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2023To12_31_2023" id="ixv-5965"> &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Research and Development Expenditures &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Research and development costs are expensed as they are incurred. These costs consist primarily of salaries and wages related to research and development activities, including share-based payments for employees engaged in research and development, clinical trial expenses and other research costs. &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RegulatoryIncomeTaxesPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-5969"> &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Investment Tax Credits &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Investment tax credits (&#x201c;ITCs&#x201d;) arising from research and development activities are deducted from the related costs and are included in profit or loss when there is reasonable assurance that the credits will be realized. ITCs arising from the acquisition or development of equipment and capitalized development costs are deducted from the cost of those assets with amortization calculated on the net amount. &lt;/div&gt;</us-gaap:RegulatoryIncomeTaxesPolicy>
    <eprx:GovernmentGrantsPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-5973"> &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Government Grants &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Government grants related to research and development activities are recognized in profit or loss as a deduction from the related expenditure when there is reasonable assurance that the grant will be received. Grants that compensate the Company for the cost of an asset are recognized in profit or loss on a systematic basis over the useful life of the asset. &lt;/div&gt;</eprx:GovernmentGrantsPolicyTextBlock>
    <us-gaap:GovernmentAssistancePolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-5977"> &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Government Assistance &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Government contributions are recognized and deducted from the related costs when there is reasonable assurance that the contribution will be received and all attached conditions have been complied with by the Company. Government contributions arising from the acquisition or development of equipment and capitalized development costs are deducted from the cost of those assets with amortization calculated on the net amount. &lt;/div&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-5981"> &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current income tax is the expected tax payable or recoverable on the taxable profit or loss for the year using tax rates enacted at the reporting date and any adjustment to tax payable from previous years. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax is recorded using the asset and liability method, providing for temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Temporary differences are not provided for if they relate to goodwill not deductible for tax purposes, or differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates and laws enacted at the reporting date and expected to apply when these differences reverse. A deferred tax asset is recognized only to the extent that it is more likely than not that future taxable profits will be available against which the asset can be utilized. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company uses a two-step process to recognize and measure the income tax benefit of uncertain tax positions taken or expected to be taken in a tax return. The tax benefit from an uncertain tax position is recognized if it more likely than not that the position will be sustained upon examination of the tax authority based solely on the technical merits of the position. A tax benefit that meets the more likely than not recognition threshold is measured as the largest amount that is greater than 50% likely to realized upon settlement with the tax authority. To the extent a full benefit is not expected to be realized, an income tax liability is established. Any change in judgement related to the expected resolution of an uncertain tax provision is recognized in the year of such a change. Interest an penalties related to income tax are included as a component of income tax expense. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <eprx:PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-14369"
      unitRef="Unit_pure">0.50</eprx:PercentageOfTaxBenefitsToBeRealizedForRecognitionInTheIncomeStatement>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-5993"> &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share-based Payments &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company grants stock options to employees, directors and officers pursuant to stock option plans described in note 13c. Employee stock-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense, net of actual forfeitures, over the requisite service period with a corresponding increase in additional paid-in capital. Stock-based compensation expense is amortized on a straight-line basis over the requisite service period for the entire award, which is generally the vesting period of the award. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Any consideration received on exercise of stock options is credited to share capital. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-6050"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share Capital and Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records proceeds from share issuances net of issue costs and any related tax effects. Common shares issued for consideration other than cash are valued based on their market value at the date the agreement to issue shares was concluded. When units are issued during a private placement, which include both common shares and share purchase warrants, the warrants are classified as equity and as such, the proceeds should be allocated based on the relative fair values of the base instrument and the warrants on the day of the announcement of the private placement. Any value of the warrants is allocated to the warrants and credited to additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital. &lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-6059"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign Currency Translation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The functional currency for each of the Company and the Company&#x2019;s subsidiaries is the currency of the primary economic environment in which each entity operates. Determination of functional currency may involve certain judgments to determine the primary economic environment. The Company reconsiders the functional currency of its entities if there is a change in events and conditions which determine the primary economic environment. The functional currency of Eupraxia Pharmaceuticals Inc., the parent entity, and each of the Company&#x2019;s subsidiaries is the Canadian dollar. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transactions in foreign currencies are translated to the functional currency of the entity at the exchange rate at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the reporting date are retranslated at the period end date exchange rates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-monetary&lt;/div&gt; items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-monetary&lt;/div&gt; assets and liabilities denominated in foreign currencies that are measured at fair value are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-translated&lt;/div&gt; to the functional currency at the exchange rate at the date that the fair value was determined. Foreign currency differences arising on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-translation&lt;/div&gt; are recognized in profit or loss. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The reporting currency of the Company&#x2019;s consolidated financial statements is the U.S. dollar. All assets and liabilities are translated from the functional currency to the reporting currency using the spot rate at the period end date, equity components are translated at the historical rate, and income and expenses are translated using the average exchange rate for the period. All foreign currency differences arising on translation from functional to reporting currency are included in accumulated other comprehensive income. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-6125"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or group of assets. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset or asset group. As of December&#160;31, 2023 and 2022, the Company determined that there were no indicators of impairment of long-lived assets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-6134"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Cash and cash equivalents include cash on hand, bank deposits, and highly liquid investments with original maturities of three months or less from the date of purchase that are readily convertible to known amounts of cash and subject to insignificant risk of changes in value. Cash equivalents are recorded at cost plus accrued interest. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-6141"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short Term Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Short term investments include highly liquid investments with original maturity dates greater than three months and less than one year and cannot be redeemed prior to maturity without incurring a penalty. &lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-6191"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial Instruments and Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures certain financial instruments and other items at fair value into a three-level hierarchy established by US GAAP that prioritizes those inputs to valuation techniques used to measure fair value on the degree to which they are observable. This hierarchy includes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;i.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 1 &#x2013; Unadjusted quoted prices in active markets for identical instruments. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ii.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 2 &#x2013; Inputs other than quoted prices included within Level 1 that are observable for the financial instrument, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability and inputs that are derived principally from or corroborated by observable market data by correlation or other means. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;iii.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inputs are unobservable and reflect the Company&#x2019;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets and liabilities are classified on the lowest level of input that is significant to the fair value measurements. Reclassification of the level may be a result of changes in the observability of the valuation inputs for certain instruments within the fair value hierarchy. The carrying value of accounts receivable, accounts payable, and accrued expense approximate fair value due to the short-term nature of these instruments. On a recurring basis, the Company&#x2019;s cash and cash equivalents and marketable securities are measured at fair value. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-6292"> &lt;div style="text-align: justify; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases classified as operating leases are recorded as lease liabilities based on the present value of minimum lease payments over the lease term, discounted using the lessor&#x2019;s rate implicit in the lease or the Company&#x2019;s incremental borrowing rate, if the lessor&#x2019;s implicit rate is not readily determinable. The lease term includes all periods covered by renewal and termination options where the Company is reasonably certain to exercise the renewal options or not to exercise the termination options. Corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets are recognized consisting of the lease liabilities, initial direct costs and any lease incentive payments. Lease liabilities are drawn down as lease payments are made and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets are depreciated over the term of the lease. Operating lease expenses are recognized on a straight-line basis over the term of the lease, consisting of interest accrued on the lease liability and depreciation of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset, adjusted for changes in index-based variable lease payments in the period of change. Lease payments on short-term operating leases with lease terms twelve months or less are expensed on a straight-line basis over the lease term. &lt;/div&gt;&lt;/div&gt; </us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-6305"> &lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upcoming Accounting Standards and Interpretations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has not yet adopted certain new standards, amendments and interpretations to existing standards, which have been published but are only effective for accounting periods beginning on or after January&#160;1, 2024 or later periods. The new and amended standards are not expected to have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-6337">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;AMOUNTS RECEIVABLE &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Government grants (Note 14)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,892&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;GST/HST recoverable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;85,879&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,658&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Other refundable tax credits &lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104,733&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37,165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;190,612&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;89,715&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Other refundable tax credits are due to tax incentives for R&amp;amp;D costs incurred by Eupraxia Australia (Note 14 &#x2013; Research and Development Expenses). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <eprx:NontradeReceivablesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-6347"> &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Government grants (Note 14)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,892&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;GST/HST recoverable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;85,879&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,658&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Other refundable tax credits &lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104,733&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37,165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;190,612&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;89,715&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Other refundable tax credits are due to tax incentives for R&amp;amp;D costs incurred by Eupraxia Australia (Note 14 &#x2013; Research and Development Expenses). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;</eprx:NontradeReceivablesTableTextBlock>
    <us-gaap:GrantsReceivableCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14374"
      unitRef="Unit_USD">13892</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GovernmentAssistanceAmountCumulativeCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14375"
      unitRef="Unit_USD">85879</us-gaap:GovernmentAssistanceAmountCumulativeCurrent>
    <us-gaap:GovernmentAssistanceAmountCumulativeCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14376"
      unitRef="Unit_USD">38658</us-gaap:GovernmentAssistanceAmountCumulativeCurrent>
    <eprx:OtherRefundableTaxCreditsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14377"
      unitRef="Unit_USD">104733</eprx:OtherRefundableTaxCreditsCurrent>
    <eprx:OtherRefundableTaxCreditsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14378"
      unitRef="Unit_USD">37165</eprx:OtherRefundableTaxCreditsCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14379"
      unitRef="Unit_USD">190612</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14380"
      unitRef="Unit_USD">89715</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-6527">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PROPERTY AND EQUIPMENT &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Property and equipment consisted of the following: &lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 60%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Computers&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Office&lt;br/&gt;furniture&#160;and&lt;br/&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leasehold&lt;br/&gt;Improvements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Lab&lt;br/&gt;Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td colspan="20" style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: 0em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at January&#160;1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;101,754&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;73,267&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;134,333&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;289,569&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;598,923&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20,279&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,551&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;209,720&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;235,550&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposals&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(47,603&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8,158&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(55,761&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency adjustments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,852&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4,261&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8,589&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(25,736&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(42,438&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;70,578&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;66,399&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;125,744&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;473,553&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;736,274&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;18,534&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;54,843&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;73,377&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposals&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5,488&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(16,124&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(21,612&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency adjustments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,001&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,597&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,992&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,613&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;85,625&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;67,996&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;128,767&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;525,264&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;807,652&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td colspan="21" style="height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td colspan="20" style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated Depreciation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: 0em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at January&#160;1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;71,187&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;46,965&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;91,345&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;38,631&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;248,128&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;17,153&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,256&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,366&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;73,328&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;110,103&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposals&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(43,540&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5,342&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(48,882&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency adjustments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,295&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,853&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6,410&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4,981&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(16,539&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;42,505&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;44,026&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;99,301&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;106,978&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;292,810&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;17,612&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,492&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13,849&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;76,930&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;112,883&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposals&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5,162&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(11,604&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(16,766&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency adjustments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,226&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,149&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,666&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,097&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,138&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;56,181&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;49,667&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;115,816&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;176,401&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;398,065&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td colspan="21" style="height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td colspan="20" style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net Book Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: 0em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;28,073&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;22,373&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;26,443&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;366,575&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;443,464&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29,444&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18,329&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12,951&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;348,863&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;409,587&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2023&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, depreciation expense of $&lt;/div&gt;112,883&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and $&lt;/div&gt;110,103&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively, was recognized with $&lt;/div&gt;13,276&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; included in general and administrative and $&lt;/div&gt;99,606&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; included in research and development ($&lt;/div&gt;13,870&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and $&lt;/div&gt;96,233&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; for general and administrative, and research and development in &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively).&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-6536"> &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Property and equipment consisted of the following: &lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 60%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Computers&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Office&lt;br/&gt;furniture&#160;and&lt;br/&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leasehold&lt;br/&gt;Improvements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Lab&lt;br/&gt;Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td colspan="20" style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: 0em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at January&#160;1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;101,754&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;73,267&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;134,333&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;289,569&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;598,923&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20,279&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,551&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;209,720&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;235,550&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposals&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(47,603&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8,158&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(55,761&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency adjustments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,852&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4,261&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8,589&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(25,736&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(42,438&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;70,578&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;66,399&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;125,744&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;473,553&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;736,274&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;18,534&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;54,843&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;73,377&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposals&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5,488&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(16,124&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(21,612&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency adjustments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,001&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,597&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,992&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,613&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;85,625&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;67,996&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;128,767&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;525,264&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;807,652&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td colspan="21" style="height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td colspan="20" style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated Depreciation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: 0em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at January&#160;1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;71,187&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;46,965&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;91,345&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;38,631&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;248,128&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;17,153&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,256&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,366&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;73,328&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;110,103&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposals&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(43,540&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5,342&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(48,882&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency adjustments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,295&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,853&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(6,410&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4,981&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(16,539&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;42,505&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;44,026&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;99,301&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;106,978&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;292,810&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;17,612&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,492&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13,849&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;76,930&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;112,883&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disposals&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5,162&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(11,604&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(16,766&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency adjustments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,226&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,149&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,666&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,097&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,138&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;56,181&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;49,667&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;115,816&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;176,401&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;398,065&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td colspan="21" style="height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td colspan="20" style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net Book Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: 0em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;28,073&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;22,373&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;26,443&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;366,575&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;443,464&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As at December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29,444&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18,329&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12,951&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;348,863&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;409,587&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14381"
      unitRef="Unit_USD">101754</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14382"
      unitRef="Unit_USD">73267</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14383"
      unitRef="Unit_USD">134333</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14384"
      unitRef="Unit_USD">289569</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021"
      decimals="0"
      id="ixv-14385"
      unitRef="Unit_USD">598923</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14386"
      unitRef="Unit_USD">20279</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14387"
      unitRef="Unit_USD">5551</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="P01_01_2022To12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14388"
      unitRef="Unit_USD">209720</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14389"
      unitRef="Unit_USD">235550</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14390"
      unitRef="Unit_USD">47603</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14391"
      unitRef="Unit_USD">8158</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14392"
      unitRef="Unit_USD">55761</us-gaap:PropertyPlantAndEquipmentDisposals>
    <eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14393"
      unitRef="Unit_USD">-3852</eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments>
    <eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14394"
      unitRef="Unit_USD">-4261</eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments>
    <eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14395"
      unitRef="Unit_USD">-8589</eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments>
    <eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2022To12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14396"
      unitRef="Unit_USD">-25736</eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments>
    <eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14397"
      unitRef="Unit_USD">-42438</eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14398"
      unitRef="Unit_USD">70578</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14399"
      unitRef="Unit_USD">66399</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14400"
      unitRef="Unit_USD">125744</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14401"
      unitRef="Unit_USD">473553</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14402"
      unitRef="Unit_USD">736274</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="P01_01_2023To12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14403"
      unitRef="Unit_USD">18534</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="P01_01_2023To12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14404"
      unitRef="Unit_USD">54843</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14405"
      unitRef="Unit_USD">73377</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="P01_01_2023To12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14406"
      unitRef="Unit_USD">5488</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="P01_01_2023To12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14407"
      unitRef="Unit_USD">16124</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14408"
      unitRef="Unit_USD">21612</us-gaap:PropertyPlantAndEquipmentDisposals>
    <eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2023To12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14409"
      unitRef="Unit_USD">2001</eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments>
    <eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2023To12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14410"
      unitRef="Unit_USD">1597</eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments>
    <eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2023To12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14411"
      unitRef="Unit_USD">3023</eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments>
    <eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2023To12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14412"
      unitRef="Unit_USD">12992</eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments>
    <eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14413"
      unitRef="Unit_USD">19613</eprx:PropertyPlantAndEquipmentForeignCurrencyTranslationAdjustments>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14414"
      unitRef="Unit_USD">85625</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14415"
      unitRef="Unit_USD">67996</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14416"
      unitRef="Unit_USD">128767</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14417"
      unitRef="Unit_USD">525264</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14418"
      unitRef="Unit_USD">807652</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14419"
      unitRef="Unit_USD">71187</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14420"
      unitRef="Unit_USD">46965</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14421"
      unitRef="Unit_USD">91345</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14422"
      unitRef="Unit_USD">38631</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="0"
      id="ixv-14423"
      unitRef="Unit_USD">248128</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease
      contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14424"
      unitRef="Unit_USD">17153</us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease>
    <us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease
      contextRef="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14425"
      unitRef="Unit_USD">5256</us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease>
    <us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease
      contextRef="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14426"
      unitRef="Unit_USD">14366</us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease>
    <us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease
      contextRef="P01_01_2022To12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14427"
      unitRef="Unit_USD">73328</us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease>
    <us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14428"
      unitRef="Unit_USD">110103</us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
      contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14429"
      unitRef="Unit_USD">43540</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
      contextRef="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14430"
      unitRef="Unit_USD">5342</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14431"
      unitRef="Unit_USD">48882</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
    <eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14432"
      unitRef="Unit_USD">-2295</eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments>
    <eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14433"
      unitRef="Unit_USD">-2853</eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments>
    <eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14434"
      unitRef="Unit_USD">-6410</eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments>
    <eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2022To12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14435"
      unitRef="Unit_USD">-4981</eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments>
    <eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14436"
      unitRef="Unit_USD">-16539</eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14437"
      unitRef="Unit_USD">42505</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14438"
      unitRef="Unit_USD">44026</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14439"
      unitRef="Unit_USD">99301</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14440"
      unitRef="Unit_USD">106978</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14441"
      unitRef="Unit_USD">292810</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease
      contextRef="P01_01_2023To12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14442"
      unitRef="Unit_USD">17612</us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease>
    <us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease
      contextRef="P01_01_2023To12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14443"
      unitRef="Unit_USD">4492</us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease>
    <us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease
      contextRef="P01_01_2023To12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14444"
      unitRef="Unit_USD">13849</us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease>
    <us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease
      contextRef="P01_01_2023To12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14445"
      unitRef="Unit_USD">76930</us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease>
    <us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14446"
      unitRef="Unit_USD">112883</us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
      contextRef="P01_01_2023To12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14447"
      unitRef="Unit_USD">5162</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
      contextRef="P01_01_2023To12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14448"
      unitRef="Unit_USD">11604</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14449"
      unitRef="Unit_USD">16766</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
    <eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2023To12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14450"
      unitRef="Unit_USD">1226</eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments>
    <eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2023To12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14451"
      unitRef="Unit_USD">1149</eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments>
    <eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2023To12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14452"
      unitRef="Unit_USD">2666</eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments>
    <eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2023To12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14453"
      unitRef="Unit_USD">4097</eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments>
    <eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14454"
      unitRef="Unit_USD">9138</eprx:AccumulatedDepreciationDepletionAndAmortizationForeignCurrencyTranslationAdjustments>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14455"
      unitRef="Unit_USD">56181</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14456"
      unitRef="Unit_USD">49667</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14457"
      unitRef="Unit_USD">115816</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14458"
      unitRef="Unit_USD">176401</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14459"
      unitRef="Unit_USD">398065</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14460"
      unitRef="Unit_USD">28073</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14461"
      unitRef="Unit_USD">22373</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14462"
      unitRef="Unit_USD">26443</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14463"
      unitRef="Unit_USD">366575</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14464"
      unitRef="Unit_USD">443464</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14465"
      unitRef="Unit_USD">29444</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14466"
      unitRef="Unit_USD">18329</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14467"
      unitRef="Unit_USD">12951</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="0"
      id="ixv-14468"
      unitRef="Unit_USD">348863</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14469"
      unitRef="Unit_USD">409587</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14470"
      unitRef="Unit_USD">112883</us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease>
    <us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14471"
      unitRef="Unit_USD">110103</us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease>
    <us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease
      contextRef="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      id="ixv-14472"
      unitRef="Unit_USD">13276</us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease>
    <us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease
      contextRef="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      id="ixv-14473"
      unitRef="Unit_USD">99606</us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease>
    <us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease
      contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      id="ixv-14474"
      unitRef="Unit_USD">13870</us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease>
    <us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease
      contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      id="ixv-14475"
      unitRef="Unit_USD">96233</us-gaap:DepreciationExcludingLessorAssetUnderOperatingLease>
    <eprx:RightOfUseAssetTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-8379">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RIGHT-OF-USE&lt;/div&gt;&lt;/div&gt; ASSET &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The following table presents details of movement in the carrying value of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance, beginning&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;87,286&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;132,020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(42,644&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(37,791&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign Exchange&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,018&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance, ending&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;46,660&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;87,286&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;During the year ended December&#160;31, 2023 and 2022, depreciation expense of $42,644 and $37,791, respectively, was recognized with $15,740 included in general and administrative and $26,904 included in research and development ($13,877 and $23,914 for general and administrative, and research and development in 2022, respectively). &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;</eprx:RightOfUseAssetTextBlock>
    <eprx:OperatingLeaseRightOfUseAssetTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-8390"> &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The following table presents details of movement in the carrying value of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance, beginning&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;87,286&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;132,020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(42,644&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(37,791&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign Exchange&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,018&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance, ending&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;46,660&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;87,286&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</eprx:OperatingLeaseRightOfUseAssetTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14476"
      unitRef="Unit_USD">87286</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="0"
      id="ixv-14477"
      unitRef="Unit_USD">132020</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14478"
      unitRef="Unit_USD">42644</us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease>
    <us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14479"
      unitRef="Unit_USD">37791</us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease>
    <eprx:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14480"
      unitRef="Unit_USD">2018</eprx:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset>
    <eprx:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14481"
      unitRef="Unit_USD">-6943</eprx:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14482"
      unitRef="Unit_USD">46660</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14483"
      unitRef="Unit_USD">87286</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14484"
      unitRef="Unit_USD">42644</us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease>
    <us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14485"
      unitRef="Unit_USD">37791</us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease>
    <us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease
      contextRef="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      id="ixv-14486"
      unitRef="Unit_USD">15740</us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease>
    <us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease
      contextRef="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      id="ixv-14487"
      unitRef="Unit_USD">26904</us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease>
    <us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease
      contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      id="ixv-14488"
      unitRef="Unit_USD">13877</us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease>
    <us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease
      contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      id="ixv-14489"
      unitRef="Unit_USD">23914</us-gaap:OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-8540">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;ACCOUNTS PAYABLE AND ACCRUED LIABILITIES &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,968,263&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,137,336&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,040,204&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;261,933&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Wages and payroll remittances&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,357&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,996&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Employee bonus payable&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;858,628&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;513,301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Taxes payable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,423&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,921,875&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,928,566&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Bonus relates to corporate bonuses for the years ended December&#160;31, 2023 and 2022. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-8550">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,968,263&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,137,336&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,040,204&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;261,933&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Wages and payroll remittances&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,357&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,996&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Employee bonus payable&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;858,628&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;513,301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Taxes payable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,423&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,921,875&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,928,566&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Bonus relates to corporate bonuses for the years ended December&#160;31, 2023 and 2022. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <eprx:AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14490"
      unitRef="Unit_USD">1968263</eprx:AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment>
    <eprx:AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14491"
      unitRef="Unit_USD">2137336</eprx:AccountsPayableAndAccruedLiabilitiesCurrentResearchAndDevelopment>
    <eprx:AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14492"
      unitRef="Unit_USD">1040204</eprx:AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration>
    <eprx:AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14493"
      unitRef="Unit_USD">261933</eprx:AccountsPayableAndAccruedLiabilitiesCurrentGeneralAndAdministration>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14494"
      unitRef="Unit_USD">18357</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14495"
      unitRef="Unit_USD">15996</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14496"
      unitRef="Unit_USD">858628</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14497"
      unitRef="Unit_USD">513301</us-gaap:AccruedBonusesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14498"
      unitRef="Unit_USD">36423</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14499"
      unitRef="Unit_USD">3921875</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14500"
      unitRef="Unit_USD">2928566</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <eprx:DisclosureInEntiretyOfOtherLoansPayable contextRef="P01_01_2023To12_31_2023" id="ixv-8702">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;LOANS PAYABLE &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;On September&#160;10, 2021, the Company entered into a Master Loan and Security Agreement (&#x201c;Loan Agreement&#x201d;) whereby the Company borrowed $235,000 to purchase production and test equipment (see Note &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt; &#x2013; Property and Equipment). &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The Loan Agreement has a term of 36 months commencing September&#160;13, 2021. The Loan Agreement accrues interest at 5.84% per annum with monthly payments (principal and interest) being made on the 1&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;st&lt;/div&gt; of each month, beginning October&#160;1, 2021. As part of the agreement, the Company granted the lender first priority interest on the equipment it purchased. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Below is a breakdown of loan balance as at December&#160;31, 2023 and December&#160;31, 2022: &lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 73%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 73%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: bottom; width: 73%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance, beginning&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;142,127&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;216,994&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loan repayment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(79,441&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(74,845&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign exchange adjustment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 73%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: bottom; width: 73%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance, ending&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;62,709&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;142,127&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 73%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: bottom; width: 73%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;62,709&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;79,418&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: bottom; width: 73%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;62,709&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;</eprx:DisclosureInEntiretyOfOtherLoansPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn09_10_2021_LoansPayableMemberusgaapLongtermDebtTypeAxis"
      decimals="INF"
      id="ixv-14501"
      unitRef="Unit_USD">235000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtTerm
      contextRef="PAsOn09_13_2021_LoansPayableMemberusgaapLongtermDebtTypeAxis"
      id="ixv-14502">P36M</us-gaap:LongTermDebtTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn10_01_2021_LoansPayableMemberusgaapLongtermDebtTypeAxis"
      decimals="4"
      id="ixv-14503"
      unitRef="Unit_pure">0.0584</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="P10_01_2021To10_01_2021_LoansPayableMemberusgaapLongtermDebtTypeAxis"
      id="ixv-14504">monthly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-8715"> &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Below is a breakdown of loan balance as at December&#160;31, 2023 and December&#160;31, 2022: &lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 73%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 73%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: bottom; width: 73%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance, beginning&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;142,127&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;216,994&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loan repayment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(79,441&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(74,845&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign exchange adjustment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 73%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: bottom; width: 73%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance, ending&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;62,709&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;142,127&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 73%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: bottom; width: 73%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;62,709&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;79,418&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: bottom; width: 73%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;62,709&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LoansPayable
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14505"
      unitRef="Unit_USD">142127</us-gaap:LoansPayable>
    <us-gaap:LoansPayable
      contextRef="PAsOn12_31_2021"
      decimals="0"
      id="ixv-14506"
      unitRef="Unit_USD">216994</us-gaap:LoansPayable>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14507"
      unitRef="Unit_USD">79441</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14508"
      unitRef="Unit_USD">74845</us-gaap:RepaymentsOfLongTermDebt>
    <eprx:ForeignExchangeAdjustmentOnLoansPayable
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14509"
      unitRef="Unit_USD">23</eprx:ForeignExchangeAdjustmentOnLoansPayable>
    <eprx:ForeignExchangeAdjustmentOnLoansPayable
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14510"
      unitRef="Unit_USD">-22</eprx:ForeignExchangeAdjustmentOnLoansPayable>
    <us-gaap:LoansPayable
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14511"
      unitRef="Unit_USD">62709</us-gaap:LoansPayable>
    <us-gaap:LoansPayable
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14512"
      unitRef="Unit_USD">142127</us-gaap:LoansPayable>
    <us-gaap:LoansPayableCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14513"
      unitRef="Unit_USD">62709</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14514"
      unitRef="Unit_USD">79418</us-gaap:LoansPayableCurrent>
    <us-gaap:LongTermLoansPayable
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14515"
      unitRef="Unit_USD">62709</us-gaap:LongTermLoansPayable>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-8943">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;LEASE LIABILITY &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The Company entered into an operating lease agreement for its Victoria, BC facility (of approximately 4,900 square feet of office space) which expires on November 30, 2024. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The cost components of the operating lease were as follows for the years ended December&#160;31, 2023 and 2022: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:73%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Lease Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;64,996&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67,423&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Variable lease expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68,584&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;66,455&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Lease term and Discount Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average remaining lease term (years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Variable lease costs are payments that vary because of changes in facts or circumstances and include common area maintenance and property taxes related to the premises. Variable lease costs are excluded from the calculation of minimum lease payments. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The Company&#x2019;s future minimum lease payments as of December&#160;31, 2023 are as follows: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ending December 31:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60,780&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total undiscounted future minimum lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;60,780&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: balance of unused tenant allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: imputed interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,464&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Present value of lease liabilities at December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;53,316&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The lease liability balance is comprised as follows: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53,316&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50,403&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;51,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;53,316&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;101,706&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;During the year ended December&#160;31, 202&lt;div style="display:inline;"&gt;3&lt;/div&gt;, the Company subleased approximately 616 square feet office space with amounts totaling $24,387 for the year ended December&#160;31, 2023 ($24,387 &#x2013; year ended December&#160;31, 2022) being recorded as a reduction to general and administrative expenses. &lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14516"
      unitRef="Unit_sqft">4900</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LeaseExpirationDate1 contextRef="P01_01_2023To12_31_2023" id="ixv-14517">2024-11-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-8953"> &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The cost components of the operating lease were as follows for the years ended December&#160;31, 2023 and 2022: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:73%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Lease Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;64,996&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67,423&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Variable lease expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68,584&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;66,455&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Lease term and Discount Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average remaining lease term (years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14518"
      unitRef="Unit_USD">64996</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14519"
      unitRef="Unit_USD">67423</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14520"
      unitRef="Unit_USD">68584</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14521"
      unitRef="Unit_USD">66455</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2023" id="ixv-14522">P0Y11M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2022" id="ixv-14523">P1Y11M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-14524"
      unitRef="Unit_pure">0.14</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2022"
      decimals="2"
      id="ixv-14525"
      unitRef="Unit_pure">0.14</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-9060"> &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The Company&#x2019;s future minimum lease payments as of December&#160;31, 2023 are as follows: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ending December 31:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60,780&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total undiscounted future minimum lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;60,780&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: balance of unused tenant allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: imputed interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,464&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Present value of lease liabilities at December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;53,316&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14526"
      unitRef="Unit_USD">60780</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14527"
      unitRef="Unit_USD">60780</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:IncentiveFromLessor
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14528"
      unitRef="Unit_USD">0</us-gaap:IncentiveFromLessor>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14529"
      unitRef="Unit_USD">7464</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14530"
      unitRef="Unit_USD">53316</us-gaap:OperatingLeaseLiability>
    <eprx:DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-9151"> &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The lease liability balance is comprised as follows: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53,316&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50,403&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;51,303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;53,316&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;101,706&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</eprx:DisclosureInTabularFormOfOperatingLeaseLiabilityCurrentAndNonCurrentTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14531"
      unitRef="Unit_USD">53316</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14532"
      unitRef="Unit_USD">50403</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14533"
      unitRef="Unit_USD">51303</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14534"
      unitRef="Unit_USD">53316</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14535"
      unitRef="Unit_USD">101706</us-gaap:OperatingLeaseLiability>
    <eprx:AreaOfSubleasedOfficeSpace
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14536"
      unitRef="Unit_sqft">616</eprx:AreaOfSubleasedOfficeSpace>
    <us-gaap:SubleaseIncome
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14537"
      unitRef="Unit_USD">24387</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14538"
      unitRef="Unit_USD">24387</us-gaap:SubleaseIncome>
    <eprx:DisclosureInEntiretyOfLicenseAgreementTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-9277">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;AURITEC LICENSE AGREEMENT &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eupraxia USA entered into an amended and restated license agreement with Auritec Pharmaceuticals Inc. (&#x201c;Auritec&#x201d;) on October&#160;9, 2018 (as further amended, the &#x201c;Amended and Restated License Agreement&#x201d;). Under the terms of the Amended and Restated License Agreement, Auritec has granted Eupraxia USA an exclusive license (including the right to sublicense to its affiliates and third parties) under the licensed patents owned or controlled by Auritec and for all the technical information and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; relating to the technology claimed in such patents or possessed by Auritec with respect to the use of Auritec&#x2019;s &#x201c;Plexis Platform&#x201d; for the delivery of fluticasone in all medical fields (except for otolaryngology and the prevention, treatment and control of all diseases, disorders and conditions of the eye and its adnexa (collectively, the &#x201c;Excluded Fields&#x201d;)), to develop, make, have made, manufacture, use, commercialize, sell, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-license,&lt;/div&gt; offer for sale, import, and have imported products for the delivery of fluticasone drug products using the Plexis Platform in all medical fields except the Excluded Fields (&#x201c;Licensed Products&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Pursuant to the terms of the Amended and Restated License Agreement, Eupraxia USA has paid $5,000,000 to Auritec (the &#x201c;Upfront Fee&#x201d;). In addition, Eupraxia USA has agreed to pay Auritec up to $30,000,000 upon achievement of certain regulatory and commercial milestones related to products licensed under the Amended and Restated License Agreement (&#x201c;Licensed Products&#x201d;) as well as a royalty of 4% of net sales of Licensed Products by Eupraxia USA or its affiliates, subject to certain reductions. &lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the milestone payment schedule. As of December&#160;31, 2023, the only milestone that has been accrued and provided for in the financial statements is $5,000,000 related to the successful completion of the Phase 2b clinical study. It was recorded under research and development (see Note 14 &#x2013; Research and Development Expenses). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 84%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Milestone Event&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Milestone&lt;br/&gt;Payment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Successful Completion of a Phase 2b Study&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;First OA Regulatory Approval&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Second OA Regulatory Approval&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;5,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-OA&lt;/div&gt; Indication Regulatory Approval&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;10,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;First calendar year in which aggregate Net Sales by Eupraxia USA, its affiliates and sublicenses exceed $500,000,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;5,000,000&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maximum milestones payable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;30,000,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify;"&gt;Eupraxia USA also agreed to pay to Auritec 20% &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of sublicensing royalties or other consideration based on net sales of Licensed Products. Eupraxia USA further agreed to pay Auritec a percentage of Non-Royalty Monetization Revenue (as defined in the Amended and Restated License Agreement), which includes payments received for a sale of Eupraxia USA or its assets or sale or sublicense of a Licensed Product, which percentage ranges from&lt;/div&gt; 10% to 30% depending on the development stage of the most-advanced Licensed Product, up to a maximum of &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;100,000,000. The following table summarizes the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Non-Royalty&lt;/div&gt; Monetization Revenue percentage schedule: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:73%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:26%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Date of Execution&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Percentage&#160;of&#160;Non-Royalty&lt;/div&gt;&lt;br/&gt; Monetization Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prior to Successful Completion of a Phase 2b Study&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;After Successful Completion of a Phase 2b Study but prior to Successful Completion of a Phase 3 Study&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;After Successful Completion of a Phase 3 Study but prior to Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;After Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Either party may terminate the Amended and Restated License Agreement in the event of the other party&#x2019;s bankruptcy, liquidation, or dissolution. Auritec may also terminate upon a material breach of the Amended and Restated License Agreement by Eupraxia USA that is not cured within &lt;div style="display:inline;"&gt;60 days&lt;/div&gt; (&lt;div style="display:inline;"&gt;15 days&lt;/div&gt; in the case of a payment breach). Further, if Eupraxia USA directly or indirectly challenges any claim in any Auritec patent licensed under the Amended and Restated License Agreement, or assist a third party in doing so, Auritec may immediately terminate the Amended and Restated License Agreement. If Auritec directly or indirectly challenges any Eupraxia patent contemplated in the Amended and Restated License Agreement other than as reasonably required to defend Auritec patents as a basis for such challenge, or assists a third party in doing so, we may immediately terminate the Amended and Restated License Agreement. &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;</eprx:DisclosureInEntiretyOfLicenseAgreementTextBlock>
    <eprx:PaymentOfUpfrontFees
      contextRef="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis"
      decimals="0"
      id="ixv-14539"
      unitRef="Unit_USD">5000000</eprx:PaymentOfUpfrontFees>
    <eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement
      contextRef="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis"
      decimals="0"
      id="ixv-14540"
      unitRef="Unit_USD">30000000</eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement>
    <eprx:RoyaltyAsAPercentageOfNetSales
      contextRef="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis"
      decimals="2"
      id="ixv-14541"
      unitRef="Unit_pure">0.04</eprx:RoyaltyAsAPercentageOfNetSales>
    <eprx:DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-14542">The following table summarizes the milestone payment schedule.
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 84%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Milestone Event&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Milestone&lt;br/&gt;Payment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Successful Completion of a Phase 2b Study&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;First OA Regulatory Approval&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Second OA Regulatory Approval&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;5,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-OA&lt;/div&gt; Indication Regulatory Approval&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;10,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;First calendar year in which aggregate Net Sales by Eupraxia USA, its affiliates and sublicenses exceed $500,000,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;5,000,000&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maximum milestones payable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;30,000,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; </eprx:DisclosureInTabularFormOfMilestonePaymentScheduleTableTextBlock>
    <eprx:MilestonePaymentRecognizedExpense
      contextRef="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_SuccessfulCompletionOfPhaseTwoBStudyMemberEPRXMilestoneAxis"
      decimals="0"
      id="ixv-14543"
      unitRef="Unit_USD">5000000</eprx:MilestonePaymentRecognizedExpense>
    <eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement
      contextRef="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_SuccessfulCompletionOfPhaseTwoBStudyMemberEPRXMilestoneAxis"
      decimals="0"
      id="ixv-14544"
      unitRef="Unit_USD">5000000</eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement>
    <eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement
      contextRef="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_FirstOaRegulatoryApprovalMemberEPRXMilestoneAxis_MaximumMembersrtRangeAxis"
      decimals="0"
      id="ixv-14545"
      unitRef="Unit_USD">5000000</eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement>
    <eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement
      contextRef="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_SecondOaRegulatoryApprovalMemberEPRXMilestoneAxis"
      decimals="0"
      id="ixv-14546"
      unitRef="Unit_USD">5000000</eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement>
    <eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement
      contextRef="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_NonOaIndicationRegulatoryApprovalMemberEPRXMilestoneAxis"
      decimals="0"
      id="ixv-14547"
      unitRef="Unit_USD">10000000</eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement>
    <eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement
      contextRef="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis_SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMemberEPRXMilestoneAxis"
      decimals="0"
      id="ixv-14548"
      unitRef="Unit_USD">5000000</eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement>
    <eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement
      contextRef="PAsOn12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis"
      decimals="0"
      id="ixv-14549"
      unitRef="Unit_USD">30000000</eprx:PayableTowardsCommercialAndRegulatorMilestoneAchievement>
    <eprx:PercentageOfNonRoyaltyMonetizationRevenuePayable
      contextRef="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_ArithmeticAverageMembersrtRangeAxis_EupraxiaUsaMembersrtCounterpartyNameAxis"
      decimals="2"
      id="ixv-14550"
      unitRef="Unit_pure">0.20</eprx:PercentageOfNonRoyaltyMonetizationRevenuePayable>
    <eprx:PercentageOfNonRoyaltyMonetizationRevenuePayable
      contextRef="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      id="ixv-14551"
      unitRef="Unit_pure">0.10</eprx:PercentageOfNonRoyaltyMonetizationRevenuePayable>
    <eprx:PercentageOfNonRoyaltyMonetizationRevenuePayable
      contextRef="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      id="ixv-14552"
      unitRef="Unit_pure">0.30</eprx:PercentageOfNonRoyaltyMonetizationRevenuePayable>
    <eprx:MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization
      contextRef="P01_01_2023To12_31_2023_AmendedAndRestatedLicenseAgreementMemberEPRXAgreementAxis_EupraxiaUsaMembersrtCounterpartyNameAxis"
      decimals="0"
      id="ixv-14553"
      unitRef="Unit_USD">100000000</eprx:MaximumAmountIncurrableOutOfNonRoyaltyRevenueMonetization>
    <eprx:DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-9442"> The following table summarizes the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Non-Royalty&lt;/div&gt; Monetization Revenue percentage schedule: &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:73%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:26%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Date of Execution&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Percentage&#160;of&#160;Non-Royalty&lt;/div&gt;&lt;br/&gt; Monetization Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prior to Successful Completion of a Phase 2b Study&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;After Successful Completion of a Phase 2b Study but prior to Successful Completion of a Phase 3 Study&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;After Successful Completion of a Phase 3 Study but prior to Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;After Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</eprx:DisclosureInTabularFormOfCertainPercentageOfNonMonetizationRevenuePayableTableTextBlock>
    <eprx:PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty
      contextRef="P01_01_2023To12_31_2023_PriorToSuccessfulCompletionOfPhaseTwoBStudyMemberEPRXTrancheAxis"
      decimals="2"
      id="ixv-14554"
      unitRef="Unit_pure">0.30</eprx:PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty>
    <eprx:PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty
      contextRef="P01_01_2023To12_31_2023_AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMemberEPRXTrancheAxis"
      decimals="2"
      id="ixv-14555"
      unitRef="Unit_pure">0.20</eprx:PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty>
    <eprx:PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty
      contextRef="P01_01_2023To12_31_2023_AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMemberEPRXTrancheAxis"
      decimals="2"
      id="ixv-14556"
      unitRef="Unit_pure">0.15</eprx:PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty>
    <eprx:PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty
      contextRef="P01_01_2023To12_31_2023_AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMemberEPRXTrancheAxis"
      decimals="2"
      id="ixv-14557"
      unitRef="Unit_pure">0.10</eprx:PercentageOfNonMonetizationRevenueToBePaidToTheCounterparty>
    <us-gaap:LongTermDebtTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-9499">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CONVERTIBLE DEBT &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;On June&#160;21, 2021, the Company entered into a contingent convertible debt agreement (the &#x201c;Debt Agreement&#x201d;) with Silicon Valley Bank (&#x201c;SVB&#x201d;) and concurrently drew down, in full, the CDN$10,000,000 principal amount under the Debt Agreement. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The Debt Agreement has a term of 36 months (or 48 months at SVB&#x2019;s election). The Debt Agreement accrues interest at the greater of 2.45% and the Canadian prime rate, requiring monthly interest payments. An additional payment in kind will accrue at a rate of 7% per annum, which will be settled at maturity or on conversion. During the year ended December&#160;31, 2022, the Canadian prime rate ranged from 2.45% - 6.45%. During the year ended December&#160;31, 2023, the Canadian prime rate ranged from 6.45% - 7.20%. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Subject to the terms and conditions of the Debt Agreement, SVB may elect to convert the principal amount of the convertible debt and the accrued and unpaid interest thereon into common shares at a conversion price equal to CDN$5.68 per common share. The conversion price of the accrued and unpaid interest will be subject to the minimum pricing requirements of the TSX, to the extent applicable, at the time of conversion. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The Company will have the right (the &#x201c;Call Right&#x201d;) to call the convertible debt by paying to SVB an amount equal to: &lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;i.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify; line-height: normal;"&gt;125% of the principal amount of the convertible debt (less principal amounts previously repaid), if the Call Right is exercised on or before the 18 month anniversary of the date of the Debt Agreement; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;ii.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify; line-height: normal;"&gt;150% of the principal amount of the convertible debt (less principal amounts previously repaid), if the Call Right is exercised after the 18 month anniversary of the date of the Debt Agreement, &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in either case together with all accrued and unpaid interest on the principal balance of the convertible debt. If the Call Right is exercised by the Company, SVB will retain certain lookback rights in the event the Company subsequently announces its topline data from its Phase 2 clinical study or the Company enters into an agreement to be acquired in the 12 months following the exercise of the Call Right. The Company has agreed to grant SVB a security interest in all of its assets, excluding its patents and other intellectual property, and the testing and product equipment by way of the loan agreement it entered into on September&#160;10, 2021 (Note 8 &#x2013; Loans Payable) as security for its obligations under the Debt Agreement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The Company was required, on or prior to June&#160;30, 2022, to raise additional net new capital, as defined in the Debt Agreement, in the aggregate amount of CDN$10,000,000. During the year ended December&#160;31, 2022, the Company completed a CDN$14.7&#160;million financing which satisfied the net new capital requirement of the Debt Agreement (see Note &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt; &#x2013; Share C&lt;div style="display:inline;"&gt;apital)&lt;/div&gt;. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The loan balance is comprised of the following: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance &#x2013; December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,507,755&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;958,669&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Interest paid&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;(315,436&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; line-height: normal;"&gt;1,056,165&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign exchange&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;(465,157&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance &#x2013; December 31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,741,996&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;1,162,773&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Interest paid&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;(591,170&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;836,595&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign exchange&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;185,809&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance &#x2013; December 31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,336,003&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_21_2021_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"
      decimals="INF"
      id="ixv-14558"
      unitRef="Unit_CAD">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P06_21_2021To06_21_2021_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"
      decimals="0"
      id="ixv-14559"
      unitRef="Unit_CAD">10000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:LongTermDebtTerm
      contextRef="PAsOn12_31_2021_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"
      id="ixv-14560">P36M</us-gaap:LongTermDebtTerm>
    <eprx:LongTermDebtTermExtendableAtLendersDiscretion
      contextRef="P06_21_2021To06_21_2021_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"
      id="ixv-14561">P48M</eprx:LongTermDebtTermExtendableAtLendersDiscretion>
    <eprx:LongTermDebtBaseRate
      contextRef="P01_01_2022To12_31_2022_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"
      decimals="4"
      id="ixv-14562"
      unitRef="Unit_pure">0.0245</eprx:LongTermDebtBaseRate>
    <eprx:LongTermDebtPaidInKindInterestPercentage
      contextRef="P01_01_2023To12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"
      decimals="2"
      id="ixv-14563"
      unitRef="Unit_pure">0.07</eprx:LongTermDebtPaidInKindInterestPercentage>
    <eprx:LongTermDebtBaseRate
      contextRef="P01_01_2022To12_31_2022_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MinimumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis"
      decimals="4"
      id="ixv-14564"
      unitRef="Unit_pure">0.0245</eprx:LongTermDebtBaseRate>
    <eprx:LongTermDebtBaseRate
      contextRef="P01_01_2022To12_31_2022_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MaximumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis"
      decimals="4"
      id="ixv-14565"
      unitRef="Unit_pure">0.0645</eprx:LongTermDebtBaseRate>
    <eprx:LongTermDebtBaseRate
      contextRef="P01_01_2023To12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MinimumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis"
      decimals="4"
      id="ixv-14566"
      unitRef="Unit_pure">0.0645</eprx:LongTermDebtBaseRate>
    <eprx:LongTermDebtBaseRate
      contextRef="P01_01_2023To12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MaximumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis"
      decimals="4"
      id="ixv-14567"
      unitRef="Unit_pure">0.072</eprx:LongTermDebtBaseRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn12_31_2023_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"
      decimals="2"
      id="ixv-14568"
      unitRef="Unit_CAD_per_Share">5.68</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="P01_01_2023To12_31_2023_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis_WithEighteenMonthsFromTheDateOfTheDebtAgreementMemberEPRXCallRightAxis"
      decimals="2"
      id="ixv-14569"
      unitRef="Unit_pure">1.25</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="P01_01_2023To12_31_2023_AfterEighteenMonthsFromTheDateOfTheDebtAgreementMemberEPRXCallRightAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"
      decimals="2"
      id="ixv-14570"
      unitRef="Unit_pure">1.50</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <eprx:AmountToBeRaisedByWayOfEquityIssue
      contextRef="PAsOn06_30_2022_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"
      decimals="0"
      id="ixv-14572"
      unitRef="Unit_CAD">10000000</eprx:AmountToBeRaisedByWayOfEquityIssue>
    <eprx:AggegateAmountRaisedByWayOfEquityIssue
      contextRef="P01_01_2022To12_31_2022_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"
      decimals="-5"
      id="ixv-14573"
      unitRef="Unit_CAD">14700000</eprx:AggegateAmountRaisedByWayOfEquityIssue>
    <eprx:DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock
      contextRef="P01_01_2023To12_31_2023_LoanMemberdeiLegalEntityAxis"
      id="ixv-9573">&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The loan balance is comprised of the following: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance &#x2013; December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,507,755&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;958,669&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Interest paid&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;(315,436&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160; &lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; line-height: normal;"&gt;1,056,165&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign exchange&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;(465,157&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance &#x2013; December 31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,741,996&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;1,162,773&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Interest paid&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;(591,170&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;836,595&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign exchange&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;185,809&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance &#x2013; December 31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,336,003&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</eprx:DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2021_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-14574"
      unitRef="Unit_USD">7507755</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod
      contextRef="P01_01_2022To12_31_2022_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-14575"
      unitRef="Unit_USD">958669</eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod>
    <eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod
      contextRef="P01_01_2022To12_31_2022_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-14576"
      unitRef="Unit_USD">-315436</eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2022To12_31_2022_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-14577"
      unitRef="Unit_USD">1056165</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss
      contextRef="P01_01_2022To12_31_2022_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-14578"
      unitRef="Unit_USD">-465157</eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2022_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-14579"
      unitRef="Unit_USD">8741996</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod
      contextRef="P01_01_2023To12_31_2023_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-14580"
      unitRef="Unit_USD">1162773</eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod>
    <eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod
      contextRef="P01_01_2023To12_31_2023_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-14581"
      unitRef="Unit_USD">-591170</eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To12_31_2023_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-14582"
      unitRef="Unit_USD">836595</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss
      contextRef="P01_01_2023To12_31_2023_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-14583"
      unitRef="Unit_USD">185809</eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeignExchangeGainLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_ConvertibleDebtMemberusgaapFairValueByLiabilityClassAxis_LoanMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-14584"
      unitRef="Unit_USD">10336003</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-9726">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;SHARE CAPITAL AND OTHER COMPONENTS OF EQUITY &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;a)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify; line-height: normal;"&gt;Authorized &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:2%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: justify; line-height: normal;"&gt;An &lt;div style="-sec-ix-hidden:hidden108159697;display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden108159696;display:inline;"&gt;unlimited&lt;/div&gt;&lt;/div&gt; number of Common shares, with no par value, with one vote per share. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:2%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: justify; line-height: normal;"&gt;An &lt;div style="-sec-ix-hidden:hidden108159695;display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden108159693;display:inline;"&gt;unlimited&lt;/div&gt;&lt;/div&gt; number of Preferred shares, with no par value (none have been issued to date). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;b)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify; line-height: normal;"&gt;Issued &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Capital transactions which took place during the year ended December&#160;31, 2022 are as follows: &lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;i)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify; line-height: normal;"&gt;On April&#160;20, 2022, the Company announced that it had closed an overnight marketed public offering (the &#x201c;Offering&#x201d;). Pursuant to the Offering, Eupraxia issued 7,150,550 units at a price of CDN$2.05 per unit and 181,000 warrants at a price of CDN$0.30 per warrant for aggregate gross proceeds of $11,768,459 ($9,309,707 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;related to the value of the&lt;/div&gt; shares&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and&lt;/div&gt; $2,458,752 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;related to the value of the&lt;/div&gt; warrants). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at an exercise price of CDN$3.00 per common share for a period of 48 months, expiring on April 20, 2026. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;As consideration for the services rendered by the Underwriters in connection with the Offering, the Company paid the Underwriters a cash commission of $823,792 ($660,605 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;for the &lt;/div&gt; shares&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;and&lt;/div&gt; $163,187 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;for the&lt;/div&gt; warrants) which is equal to 7% of the gross proceeds raised under the Offering and granted 500,538 warrants (&#x201c;Compensation Warrant&#x201d;), which is equal to 7% of the total units and warrants issued in the Offering. Each Compensation Warrant entitles the holder thereof to acquire one common share at an exercise price of CDN$2.05 per common share for a period of 48 months, expiring on April&#160;20, 2026. An additional $68,470 in legal and agents&#x2019; expenses were also paid to the Underwriters ($54,839 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;for the&lt;/div&gt; shares&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and&lt;/div&gt; $13,631 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;for the&lt;/div&gt; warrants). The Company incurred an additional $239,620 ($192,824 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;for the&lt;/div&gt; shares&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and&lt;/div&gt; $46,796 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;for the&lt;/div&gt; warrants) in share issuance costs associated with the Offering. &lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;ii)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify; line-height: normal;"&gt;During the year ended December&#160;31, 2022, 200,000 common shares were issued on the exercise of warrants for gross proceeds of $306,770. The weighted average share price during the period in which these warrants were exercised was CDN$4.18. On exercise, $44,893 was transferred from additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital to share capital. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Capital transactions which took place during the year ended December&#160;31, 2023, are as follows: &lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;iii)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify; line-height: normal;"&gt;During the year ended December&#160;31, 2023, 2,385,484 common shares were issued on the exercise of warrants for gross proceeds of $5,241,811. The weighted average share price during the period in which these warrants were exercised was CDN$7.15. On exercise, $733,177 was transferred from additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital to share capital. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;iv)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify; line-height: normal;"&gt;During the year ended December&#160;31, 2023, 20,600 common shares were issued on the exercise of options for gross proceeds of $30,059. The weighted average share price during the period in which these options were exercised was CDN$2.00. On exercise, $18,776 was transferred from additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital to share capital. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;v)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify; line-height: normal;;text-indent: 0px;"&gt;On August&#160;18, 2023, the Company closed a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;non-brokered&lt;/div&gt; private placement (the &#x201c;Private Placement&#x201d;). Pursuant to the Private Placement, the Company issued 3,183,875 common shares at a price of CDN$7.00 per Common share for aggregate gross proceeds of $16,445,635. The Company incurred cash costs of issuing shares of $559,098. In addition, the Company issued 99,061 &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;common shares as finder&#x2019;s fees which were&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;valued at $511,681.&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="line-height:normal;background-color:white;display: inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"&gt;&lt;div style="font-size: 13.3333px; background-color: rgb(255, 255, 255); float: none; top: 0px; display: inline !important; letter-spacing: 0px;;display:inline;"&gt;Under&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the Amended Stock Option Plan (the &#x201c;Amended Plan&#x201d;), approved by the Board of Directors on October&#160;27, 2021, and ratified by Shareholders on December&#160;3, 2021, the Board of Directors may grant stock options to directors, officers, employees and consultants of the Company up to an aggregate of &lt;/div&gt;18.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the Company&#x2019;s then issued and outstanding common shares.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options granted under the Amended Plan have lives of up to &lt;/div&gt;ten years&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; from the date of grant. The vesting schedule of all granted options is determined at the discretion of the Board. Unless otherwise determined by the Board, in its sole discretion, all grants of options will vest over a &lt;/div&gt;three-year&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; period, with the first twenty-five percent (&lt;/div&gt;25&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%) of the Options vesting on the date of grant, and the remaining o&lt;div style="display:inline;"&gt;ptions&lt;/div&gt; vesting over the following &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;thirty-six-month&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; period in three equal instalments on an annual basis.&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 9%;;text-indent: 0px;"&gt;&lt;div style="font-size: 13.3333px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&#x2019;s option transactions:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:67%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;(CDN$)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding, December 31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,134,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,172,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding, December 31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,306,450&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cancelled&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(24,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;257,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding, December 31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,518,250&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.27&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:55%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Grant&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;br/&gt; Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;br/&gt; Exercisable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price&#160;(CDN$)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiry&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;br/&gt; Life&#160;(years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sep 27, 2015&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;186,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;186,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(3)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Mar 31, 2025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Nov 2, 2015&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(3)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Nov 2, 2025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Mar 5, 2018&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;452,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;452,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(3)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Mar 5, 2028&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Mar 9, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;756,950&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;567,713&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Mar 9, 2031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Mar 9, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;326,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;326,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Mar 9, 2031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;May 3, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;257,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;192,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;May 3, 2031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.35&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dec 9, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Dec 9, 2031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Mar 31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;392,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;186,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Mar 31, 2032&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dec 9, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;734,300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;407,983&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Dec 9, 2032&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;May 18, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;180,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;May 18, 2033&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.39&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;May 30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;May 30, 2033&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.42&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sep 27, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Sep 27, 2033&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,518,250&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,537,296&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.27&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7.02&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The share-based compensation expense was determined based on the &lt;div style="display:inline;"&gt;fai&lt;/div&gt;r value of options at the date of measurement using the Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:73%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options granted during the year ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected forfeiture rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average annual volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;79.60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.66&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average expected option life&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.75&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.70&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average share price (CDN$)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average exercise price (CDN$)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average fair value of options granted (CDN$)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"&gt;Share-based payments for the year ended December&#160;31, 2023, was $1,412,257 (2022 - $1,433,812) (See Note &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13&lt;/div&gt; &#x2013; General&#160;&amp;amp; Administrative Expenses and Note &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14&lt;/div&gt; &#x2013; Research&#160;&amp;amp; Development Expenses for breakdown by function). &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"&gt;As of December&#160;31, 2023, the unrecognized stock-based compensation expense related to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; stock options was $961,535, which is expected to be recognized over a weighted-average period of 2.09 years. &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;d)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Warrants &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"&gt;The following table summarizes the Company&#x2019;s warrant transactions: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise&#160;price&#160;(CDN$)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,161,898&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8.81&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Issued&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,832,088&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.94&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(289,172&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(200,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11,504,814&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.95&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,385,484&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,119,330&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.49&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;As at December&#160;31, 2023, the following warrants were out&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;standing:&lt;/div&gt; &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:63%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiry date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&#160;price&lt;br/&gt; (CDN$)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;br/&gt; contractual&#160;life&lt;br/&gt; (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Warrants&lt;br/&gt; outstanding&lt;br/&gt; and&lt;br/&gt; exercisable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;120 days after holder to be a Director/ Officer or consultant&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.7572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;243,421&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;120 days after former spouse ceases to be a Director/ Officer or consultant&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.7572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;137,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;120 days after &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;holder ceases to be a Director/ Officer or consultant&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 7.5pt; line-height: 7.5pt;;display:inline;vertical-align: super;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.4984&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;315,500&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;January 4, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;5.5993&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;0.01&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;239,080&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;January 4, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;7.1991&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;0.01&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;39,846&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;January 8, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;5.5993&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;0.02&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;31,877&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;March 9, 2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;11.20&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;2.19&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;2,826,274&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;April 20, 2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;3.00&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;2.30&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;5,196,550&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;April 20, 2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;2.05&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;2.30&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;50,054&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;April 29, 2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;11.20&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;2.33&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;39,228&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.49&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,119,330&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents unit purchase to acquire &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;315,500&lt;/div&gt; units consisting of one Common Share and one additional warrant at an exercise price of $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.75&lt;/div&gt;CDN. These underlying warrants expire two years from the date of exercise of the primary warrant. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;e)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Class&#160;B &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Voting&lt;/div&gt; shares &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;On January&#160;31, 2021, the Company entered into a contribution agreement with the Chief Scientific Officer of the Company, and certain of the Company&#x2019;s subsidiaries (the &#x201c;Contribution Agreement&#x201d;). Pursuant to the Contribution Agreement, the Company acquired AMDM Holdings Inc., a corporation wholly-owned by the Chief Scientific Officer, which held 5% of the equity interest in the Company&#x2019;s subsidiary, Eupraxia USA. In exchange, the Company issued to the Chief Scientific Officer 225 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-voting&lt;/div&gt; Class&#160;B shares (the &#x201c;Class&#160;B Shares&#x201d;) in Eupraxia Pharma Inc. representing 5% of the outstanding securities of Eupraxia Pharma. The Company holds the remaining 95% of such securities, which consists of 4,275 voting Class&#160;A shares. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Each Class&#160;B Share is exchangeable into common shares of the Company based on an exchange rate of 2,500 common shares for each Class&#160;B Share, subject to adjustments upon the occurrence of certain events, for a total of 562,500 common shares. The Class&#160;B Shares are exchangeable by the Chief Scientific Officer at her election, provided that the Company may force the exchange of the Class&#160;B Shares into common shares of the Company at any time on or after January&#160;31, 2031, or on or after January&#160;31, 2026, if the Company is listed on a stock exchange and is a reporting issuer in Canada at such time. The Company may also force the exchange of the Class&#160;B Shares into common shares if there is a change of control transaction involving the Company, a change in law which makes the exchange necessary or desirable or if there are a &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;de minimis &lt;/div&gt;&lt;/div&gt;number of Class&#160;B Shares outstanding. If the Company is listed on a stock exchange at the time of the applicable exchange, the Company may elect to pay the Chief Scientific Officer cash in lieu of issuing common shares, with such cash amount to be determined based on the then current market price of the common shares of the Company. &lt;/div&gt; </us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:PreferredStockNoParValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14585"
      unitRef="Unit_USD_per_Share">0</us-gaap:PreferredStockNoParValue>
    <us-gaap:PreferredStockNoParValue
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14586"
      unitRef="Unit_USD_per_Share">0</us-gaap:PreferredStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14587"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14588"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockNoParValue>
    <eprx:NumberOfUnitsIssued
      contextRef="PAsOn04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14589"
      unitRef="Unit_shares">7150550</eprx:NumberOfUnitsIssued>
    <eprx:SecuritiesIssuedPricePerUnit
      contextRef="PAsOn04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-14590"
      unitRef="Unit_CAD_per_Share">2.05</eprx:SecuritiesIssuedPricePerUnit>
    <eprx:NumberOfWarrantIssued
      contextRef="PAsOn04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14591"
      unitRef="Unit_shares">181000</eprx:NumberOfWarrantIssued>
    <eprx:WarrantIssuedPricePerUnit
      contextRef="PAsOn04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-14592"
      unitRef="Unit_CAD_per_Share">0.3</eprx:WarrantIssuedPricePerUnit>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14593"
      unitRef="Unit_USD">11768459</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P04_20_2022To04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14594"
      unitRef="Unit_USD">9309707</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14595"
      unitRef="Unit_USD">2458752</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:CommonStockConversionBasis
      contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      id="ixv-14596">Each unit consists of one common share and one common share purchase warrant.</us-gaap:CommonStockConversionBasis>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="PAsOn04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-14597"
      unitRef="Unit_shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-14598"
      unitRef="Unit_CAD_per_Share">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      id="ixv-14599">P48M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="PAsOn04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      id="ixv-14600">2026-04-20</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:PaymentsForUnderwritingExpense
      contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14601"
      unitRef="Unit_USD">823792</us-gaap:PaymentsForUnderwritingExpense>
    <us-gaap:PaymentsForUnderwritingExpense
      contextRef="P04_20_2022To04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14602"
      unitRef="Unit_USD">660605</us-gaap:PaymentsForUnderwritingExpense>
    <us-gaap:PaymentsForUnderwritingExpense
      contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14603"
      unitRef="Unit_USD">163187</us-gaap:PaymentsForUnderwritingExpense>
    <eprx:PercentageOfGrossProceedsRaisedUnderTheOffering
      contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-14604"
      unitRef="Unit_pure">0.07</eprx:PercentageOfGrossProceedsRaisedUnderTheOffering>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14605"
      unitRef="Unit_shares">500538</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <eprx:PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering
      contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-14606"
      unitRef="Unit_pure">0.07</eprx:PercentageOfTotalUnitsAndWarrantsIssuedInTheOffering>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_CompensationWarrantMemberEPRXWarrantAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-14607"
      unitRef="Unit_CAD_per_Share">2.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:LegalFees
      contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14608"
      unitRef="Unit_USD">68470</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="P04_20_2022To04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14609"
      unitRef="Unit_USD">54839</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14610"
      unitRef="Unit_USD">13631</us-gaap:LegalFees>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14611"
      unitRef="Unit_USD">239620</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P04_20_2022To04_20_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14612"
      unitRef="Unit_USD">192824</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P04_20_2022To04_20_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-14613"
      unitRef="Unit_USD">46796</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To12_31_2022_ExcerciseOfWarrantsMemberEPRXEventAxis"
      decimals="INF"
      id="ixv-14614"
      unitRef="Unit_shares">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To12_31_2022_ExcerciseOfWarrantsMemberEPRXEventAxis"
      decimals="0"
      id="ixv-14615"
      unitRef="Unit_USD">306770</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_ExcerciseOfWarrantsMemberEPRXEventAxis"
      decimals="INF"
      id="ixv-14616"
      unitRef="Unit_CAD_per_Share">4.18</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <eprx:TransferredFromAdditionalPaidinCapitalToShareCapital
      contextRef="P01_01_2022To12_31_2022_ExcerciseOfWarrantsMemberEPRXEventAxis"
      decimals="0"
      id="ixv-14617"
      unitRef="Unit_USD">44893</eprx:TransferredFromAdditionalPaidinCapitalToShareCapital>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_ExcerciseOfWarrantsMemberEPRXEventAxis"
      decimals="INF"
      id="ixv-14618"
      unitRef="Unit_shares">2385484</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_ExcerciseOfWarrantsMemberEPRXEventAxis"
      decimals="0"
      id="ixv-14619"
      unitRef="Unit_USD">5241811</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_ExcerciseOfWarrantsMemberEPRXEventAxis"
      decimals="INF"
      id="ixv-14620"
      unitRef="Unit_CAD_per_Share">7.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <eprx:TransferredFromAdditionalPaidinCapitalToShareCapital
      contextRef="P01_01_2023To12_31_2023_ExcerciseOfWarrantsMemberEPRXEventAxis"
      decimals="0"
      id="ixv-14621"
      unitRef="Unit_USD">733177</eprx:TransferredFromAdditionalPaidinCapitalToShareCapital>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-14622"
      unitRef="Unit_shares">20600</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14623"
      unitRef="Unit_USD">30059</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-14624"
      unitRef="Unit_CAD_per_Share">2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <eprx:TransferredFromAdditionalPaidinCapitalToShareCapital
      contextRef="P01_01_2023To12_31_2023_ExcerciseOfOptionsMemberEPRXEventAxis"
      decimals="0"
      id="ixv-14625"
      unitRef="Unit_USD">18776</eprx:TransferredFromAdditionalPaidinCapitalToShareCapital>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P08_18_2023To08_18_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-14626"
      unitRef="Unit_shares">3183875</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn08_18_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-14627"
      unitRef="Unit_CAD_per_Share">7</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P08_18_2023To08_18_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14628"
      unitRef="Unit_USD">16445635</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <eprx:CashCostsOfIssuingShares
      contextRef="P08_18_2023To08_18_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14629"
      unitRef="Unit_USD">559098</eprx:CashCostsOfIssuingShares>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P08_18_2023To08_18_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-14630"
      unitRef="Unit_shares">99061</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P08_18_2023To08_18_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-14631"
      unitRef="Unit_USD">511681</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <eprx:PercentageOfOutstandingSharesEligibleForStockOptionsIssuance
      contextRef="PAsOn12_03_2021_AmendedPlanMemberusgaapPlanNameAxis"
      decimals="3"
      id="ixv-14632"
      unitRef="Unit_pure">0.185</eprx:PercentageOfOutstandingSharesEligibleForStockOptionsIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-14633">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-14634">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_ImmediateVestingMemberusgaapVestingAxis"
      decimals="2"
      id="ixv-14635"
      unitRef="Unit_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis"
      decimals="2"
      id="ixv-14636"
      unitRef="Unit_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis"
      decimals="2"
      id="ixv-14637"
      unitRef="Unit_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P12_03_2021To12_31_2021_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis"
      decimals="2"
      id="ixv-14638"
      unitRef="Unit_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-9901"> &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 9%;;text-indent: 0px;"&gt;&lt;div style="font-size: 13.3333px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&#x2019;s option transactions:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:67%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise&#160;price&#160;(CDN$)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding, December 31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,134,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,172,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding, December 31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,306,450&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cancelled&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(24,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;257,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding, December 31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,518,250&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.27&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2021_AmendedPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-14639"
      unitRef="Unit_shares">2134250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021_AmendedPlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-14640"
      unitRef="Unit_CAD_per_Share">7.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-14641"
      unitRef="Unit_shares">1172200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-14642"
      unitRef="Unit_CAD_per_Share">3.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2022_AmendedPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-14643"
      unitRef="Unit_shares">3306450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022_AmendedPlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-14644"
      unitRef="Unit_CAD_per_Share">6.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-14645"
      unitRef="Unit_shares">20600</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-14646"
      unitRef="Unit_CAD_per_Share">2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-14647"
      unitRef="Unit_shares">24800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-14648"
      unitRef="Unit_CAD_per_Share">3.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-14649"
      unitRef="Unit_shares">257200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-14650"
      unitRef="Unit_CAD_per_Share">6.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-14651"
      unitRef="Unit_shares">3518250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-14652"
      unitRef="Unit_CAD_per_Share">6.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <eprx:DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-10081">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:55%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Grant&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;br/&gt; Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;br/&gt; Exercisable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price&#160;(CDN$)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiry&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;br/&gt; Life&#160;(years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sep 27, 2015&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;186,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;186,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(3)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Mar 31, 2025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Nov 2, 2015&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(3)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Nov 2, 2025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Mar 5, 2018&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;452,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;452,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(3)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Mar 5, 2028&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Mar 9, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;756,950&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;567,713&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Mar 9, 2031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Mar 9, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;326,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;326,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Mar 9, 2031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;May 3, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;257,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;192,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;May 3, 2031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.35&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dec 9, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Dec 9, 2031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Mar 31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;392,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;186,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Mar 31, 2032&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dec 9, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;734,300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;407,983&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Dec 9, 2032&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;May 18, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;180,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;May 18, 2033&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.39&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;May 30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;May 30, 2033&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.42&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sep 27, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Sep 27, 2033&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,518,250&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,537,296&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.27&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7.02&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </eprx:DisclosureInTabularFormOfShareBasedCompensationOptionsOutstandingAlongWithTheGrantDatesAndExpiryDateTableTextBlock>
    <eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14653">2015-09-27</eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14654"
      unitRef="Unit_shares">186250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14655"
      unitRef="Unit_shares">186250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="2"
      id="ixv-14656"
      unitRef="Unit_CAD_per_Share">8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14657">2025-03-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14658">P1Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwoNovemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14659">2015-11-02</eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwoNovemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14660"
      unitRef="Unit_shares">95000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwoNovemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14661"
      unitRef="Unit_shares">95000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwoNovemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="2"
      id="ixv-14662"
      unitRef="Unit_CAD_per_Share">8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwoNovemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14663">2025-11-02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwoNovemberTwoThousandAndFifteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14664">P1Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_FiveMarchTwoThousandAndEighteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14665">2018-03-05</eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_FiveMarchTwoThousandAndEighteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14666"
      unitRef="Unit_shares">452250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_FiveMarchTwoThousandAndEighteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14667"
      unitRef="Unit_shares">452250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_FiveMarchTwoThousandAndEighteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="2"
      id="ixv-14668"
      unitRef="Unit_CAD_per_Share">8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_FiveMarchTwoThousandAndEighteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14669">2028-03-05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_FiveMarchTwoThousandAndEighteenMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14670">P4Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14671">2021-03-09</eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14672"
      unitRef="Unit_shares">756950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14673"
      unitRef="Unit_shares">567713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="2"
      id="ixv-14674"
      unitRef="Unit_CAD_per_Share">8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14675">2031-03-09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14676">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOne1MemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14677">2021-03-09</eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOne1MemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14678"
      unitRef="Unit_shares">326800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOne1MemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14679"
      unitRef="Unit_shares">326800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOne1MemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="2"
      id="ixv-14680"
      unitRef="Unit_CAD_per_Share">8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOne1MemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14681">2031-03-09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineMarchTwoThousandAndTwentyOne1MemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14682">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThreeMayTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14683">2021-05-03</eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThreeMayTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14684"
      unitRef="Unit_shares">257000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThreeMayTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14685"
      unitRef="Unit_shares">192750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThreeMayTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="2"
      id="ixv-14686"
      unitRef="Unit_CAD_per_Share">8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThreeMayTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14687">2031-05-03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThreeMayTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14688">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14689">2021-12-09</eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14690"
      unitRef="Unit_shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14691"
      unitRef="Unit_shares">57500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="2"
      id="ixv-14692"
      unitRef="Unit_CAD_per_Share">2.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14693">2031-12-09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyOneMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14694">P7Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyFirstMarchTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14695">2022-03-31</eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyFirstMarchTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14696"
      unitRef="Unit_shares">392500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyFirstMarchTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14697"
      unitRef="Unit_shares">186750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyFirstMarchTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="2"
      id="ixv-14698"
      unitRef="Unit_CAD_per_Share">1.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyFirstMarchTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14699">2032-03-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyFirstMarchTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14700">P8Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14701">2022-12-09</eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14702"
      unitRef="Unit_shares">734300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14703"
      unitRef="Unit_shares">407983</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="2"
      id="ixv-14704"
      unitRef="Unit_CAD_per_Share">3.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14705">2032-12-09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_NineDecemberTwoThousandAndTwentyTwoMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14706">P8Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EighteenthMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14707">2023-05-18</eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EighteenthMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14708"
      unitRef="Unit_shares">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EighteenthMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14709"
      unitRef="Unit_shares">45000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EighteenthMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="2"
      id="ixv-14710"
      unitRef="Unit_CAD_per_Share">6.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EighteenthMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14711">2033-05-18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EighteenthMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14712">P9Y4M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14713">2023-05-30</eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14714"
      unitRef="Unit_shares">17200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14715"
      unitRef="Unit_shares">4300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="2"
      id="ixv-14716"
      unitRef="Unit_CAD_per_Share">6.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14717">2033-05-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_ThirtyMayTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14718">P9Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14719">2023-09-27</eprx:ShareBasedCompesnationByShareBasedOptionsGrantedDateOfGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14720"
      unitRef="Unit_shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="0"
      id="ixv-14721"
      unitRef="Unit_shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      decimals="2"
      id="ixv-14722"
      unitRef="Unit_CAD_per_Share">7.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14723">2033-09-27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_TwentySeventhSeptemberTwoThousandAndTwentyThreeMemberEPRXShareBasedCompensationOptionsExpiryDateAxis"
      id="ixv-14724">P9Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-14725"
      unitRef="Unit_shares">3518250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-14726"
      unitRef="Unit_shares">2537296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-14727"
      unitRef="Unit_CAD_per_Share">6.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis"
      id="ixv-14728">P7Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-14730"> &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The share-based compensation expense was determined based on the &lt;div style="display:inline;"&gt;fai&lt;/div&gt;r value of options at the date of measurement using the Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:73%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options granted during the year ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected forfeiture rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average annual volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;79.60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;78.66&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average expected option life&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.75&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.70&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average share price (CDN$)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average exercise price (CDN$)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average fair value of options granted (CDN$)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      id="ixv-14731"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      id="ixv-14732"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <eprx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      id="ixv-14733"
      unitRef="Unit_pure">0</eprx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <eprx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      id="ixv-14734"
      unitRef="Unit_pure">0</eprx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      id="ixv-14735"
      unitRef="Unit_pure">0.796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      id="ixv-14736"
      unitRef="Unit_pure">0.7866</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      id="ixv-14737"
      unitRef="Unit_pure">0.0354</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      id="ixv-14738"
      unitRef="Unit_pure">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-14739">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-14740">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-14741"
      unitRef="Unit_CAD_per_Share">6.91</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-14742"
      unitRef="Unit_CAD_per_Share">3.16</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-14743"
      unitRef="Unit_CAD_per_Share">6.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-14744"
      unitRef="Unit_CAD_per_Share">3.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-14745"
      unitRef="Unit_CAD_per_Share">4.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-14746"
      unitRef="Unit_CAD_per_Share">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-14747"
      unitRef="Unit_USD">1412257</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-14748"
      unitRef="Unit_USD">1433812</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-14749"
      unitRef="Unit_USD">961535</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="P01_01_2023To12_31_2023_AmendedPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-14750">P2Y1M2D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <eprx:ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-10729"> &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"&gt;The following table summarizes the Company&#x2019;s warrant transactions: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise&#160;price&#160;(CDN$)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,161,898&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8.81&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Issued&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,832,088&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.94&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(289,172&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(200,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11,504,814&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.95&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,385,484&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,119,330&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.49&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </eprx:ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2021_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-14751"
      unitRef="Unit_shares">4161898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-14752"
      unitRef="Unit_CAD_per_Share">8.81</eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2022To12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-14753"
      unitRef="Unit_shares">7832088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-14754"
      unitRef="Unit_CAD_per_Share">2.94</eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsGrantedDuringThePeriodweightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="P01_01_2022To12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-14755"
      unitRef="Unit_shares">289172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-14756"
      unitRef="Unit_CAD_per_Share">8</eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpiredDuringThePeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="P01_01_2022To12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-14757"
      unitRef="Unit_shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-14758"
      unitRef="Unit_CAD_per_Share">2.05</eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-14759"
      unitRef="Unit_shares">11504814</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-14760"
      unitRef="Unit_CAD_per_Share">4.95</eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="P01_01_2023To12_31_2023_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-14761"
      unitRef="Unit_shares">2385484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To12_31_2023_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-14762"
      unitRef="Unit_CAD_per_Share">2.9</eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExcercisedDuringThePeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2023_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-14763"
      unitRef="Unit_shares">9119330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-14764"
      unitRef="Unit_CAD_per_Share">5.49</eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice>
    <eprx:ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-10978"> &lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;As at December&#160;31, 2023, the following warrants were out&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;standing:&lt;/div&gt; &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:63%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiry date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&#160;price&lt;br/&gt; (CDN$)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;br/&gt; contractual&#160;life&lt;br/&gt; (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Warrants&lt;br/&gt; outstanding&lt;br/&gt; and&lt;br/&gt; exercisable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;120 days after holder to be a Director/ Officer or consultant&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.7572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;243,421&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;120 days after former spouse ceases to be a Director/ Officer or consultant&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.7572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;137,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;120 days after &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;holder ceases to be a Director/ Officer or consultant&lt;div style="font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 7.5pt; line-height: 7.5pt;;display:inline;vertical-align: super;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.4984&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;315,500&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;January 4, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;5.5993&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;0.01&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;239,080&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;January 4, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;7.1991&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;0.01&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;39,846&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;January 8, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;5.5993&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;0.02&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;31,877&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;March 9, 2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;11.20&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;2.19&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;2,826,274&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;April 20, 2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;3.00&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;2.30&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;5,196,550&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;April 20, 2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;2.05&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;2.30&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;50,054&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;April 29, 2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;11.20&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;2.33&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;39,228&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.49&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,119,330&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents unit purchase to acquire &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;315,500&lt;/div&gt; units consisting of one Common Share and one additional warrant at an exercise price of $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.75&lt;/div&gt;CDN. These underlying warrants expire two years from the date of exercise of the primary warrant. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </eprx:ScheduleOfShareBasedCompensationOfShareWarrantsOutstandingTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="P01_01_2023To12_31_2023_ExpiryPeriodOneMemberEPRXMaturityPeriodWarrantsAxis"
      id="ixv-14765">P120D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_ExpiryPeriodOneMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="4"
      id="ixv-14766"
      unitRef="Unit_CAD_per_Share">0.7572</eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2023_ExpiryPeriodOneMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="0"
      id="ixv-14767"
      unitRef="Unit_shares">243421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="P01_01_2023To12_31_2023_ExpiryPeriodTwoMemberEPRXMaturityPeriodWarrantsAxis"
      id="ixv-14768">P120D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_ExpiryPeriodTwoMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="4"
      id="ixv-14769"
      unitRef="Unit_CAD_per_Share">0.7572</eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2023_ExpiryPeriodTwoMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="0"
      id="ixv-14770"
      unitRef="Unit_shares">137500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="P01_01_2023To12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis"
      id="ixv-14771">P120D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="4"
      id="ixv-14772"
      unitRef="Unit_CAD_per_Share">0.4984</eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="0"
      id="ixv-14773"
      unitRef="Unit_shares">315500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_ExpiryPeriodFourMemberEPRXMaturityPeriodWarrantsAxis"
      id="ixv-14774">2024-01-04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_ExpiryPeriodFourMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="4"
      id="ixv-14775"
      unitRef="Unit_CAD_per_Share">5.5993</eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="P01_01_2023To12_31_2023_ExpiryPeriodFourMemberEPRXMaturityPeriodWarrantsAxis"
      id="ixv-14776">P0Y3D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2023_ExpiryPeriodFourMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="0"
      id="ixv-14777"
      unitRef="Unit_shares">239080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_ExpiryPeriodFiveMemberEPRXMaturityPeriodWarrantsAxis"
      id="ixv-14778">2024-01-04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_ExpiryPeriodFiveMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="4"
      id="ixv-14779"
      unitRef="Unit_CAD_per_Share">7.1991</eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="P01_01_2023To12_31_2023_ExpiryPeriodFiveMemberEPRXMaturityPeriodWarrantsAxis"
      id="ixv-14780">P0Y3D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2023_ExpiryPeriodFiveMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="0"
      id="ixv-14781"
      unitRef="Unit_shares">39846</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_ExpiryPeriodSixMemberEPRXMaturityPeriodWarrantsAxis"
      id="ixv-14782">2024-01-08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_ExpiryPeriodSixMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="4"
      id="ixv-14783"
      unitRef="Unit_CAD_per_Share">5.5993</eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="P01_01_2023To12_31_2023_ExpiryPeriodSixMemberEPRXMaturityPeriodWarrantsAxis"
      id="ixv-14784">P0Y7D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2023_ExpiryPeriodSixMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="0"
      id="ixv-14785"
      unitRef="Unit_shares">31877</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_ExpiryPeriodSevenMemberEPRXMaturityPeriodWarrantsAxis"
      id="ixv-14786">2026-03-09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_ExpiryPeriodSevenMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="2"
      id="ixv-14787"
      unitRef="Unit_CAD_per_Share">11.2</eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="P01_01_2023To12_31_2023_ExpiryPeriodSevenMemberEPRXMaturityPeriodWarrantsAxis"
      id="ixv-14788">P2Y2M8D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2023_ExpiryPeriodSevenMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="0"
      id="ixv-14789"
      unitRef="Unit_shares">2826274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_ExpiryPeriodEightMemberEPRXMaturityPeriodWarrantsAxis"
      id="ixv-14790">2026-04-20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_ExpiryPeriodEightMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="2"
      id="ixv-14791"
      unitRef="Unit_CAD_per_Share">3</eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="P01_01_2023To12_31_2023_ExpiryPeriodEightMemberEPRXMaturityPeriodWarrantsAxis"
      id="ixv-14792">P2Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2023_ExpiryPeriodEightMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="0"
      id="ixv-14793"
      unitRef="Unit_shares">5196550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_ExpiryPeriodNineMemberEPRXMaturityPeriodWarrantsAxis"
      id="ixv-14794">2026-04-20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_ExpiryPeriodNineMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="2"
      id="ixv-14795"
      unitRef="Unit_CAD_per_Share">2.05</eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="P01_01_2023To12_31_2023_ExpiryPeriodNineMemberEPRXMaturityPeriodWarrantsAxis"
      id="ixv-14796">P2Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2023_ExpiryPeriodNineMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="0"
      id="ixv-14797"
      unitRef="Unit_shares">50054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="P01_01_2023To12_31_2023_ExpiryPeriodTenMemberEPRXMaturityPeriodWarrantsAxis"
      id="ixv-14798">2026-04-29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_ExpiryPeriodTenMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="2"
      id="ixv-14799"
      unitRef="Unit_CAD_per_Share">11.2</eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="P01_01_2023To12_31_2023_ExpiryPeriodTenMemberEPRXMaturityPeriodWarrantsAxis"
      id="ixv-14800">P2Y3M29D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2023_ExpiryPeriodTenMemberEPRXMaturityPeriodWarrantsAxis"
      decimals="0"
      id="ixv-14801"
      unitRef="Unit_shares">39228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-14802"
      unitRef="Unit_CAD_per_Share">5.49</eprx:ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14803"
      unitRef="Unit_shares">9119330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-14804"
      unitRef="Unit_shares">315500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-14805"
      unitRef="Unit_CAD_per_Share">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="P01_01_2023To12_31_2023_ExpiryPeriodThreeMemberEPRXMaturityPeriodWarrantsAxis_WarrantsGrantedAsPartOfShareBasedPaymentArrangementMemberusgaapAwardTypeAxis"
      id="ixv-14806">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="PAsOn12_31_2021_AmdmHoldingsMemberEPRXAmdmHoldingsAxis_EuphraxiaUsaMembersrtOwnershipAxis"
      decimals="2"
      id="ixv-14807"
      unitRef="Unit_pure">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_31_2021To01_31_2021_AmdmHoldingsMemberEPRXAmdmHoldingsAxis_ChiefScientificOfficerMembersrtTitleOfIndividualAxis_ClassBNonVotingStockMemberusgaapStatementClassOfStockAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis"
      decimals="INF"
      id="ixv-14808"
      unitRef="Unit_shares">225</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <eprx:StockSharesIssuedAsAPercentageOfOutstandingShares
      contextRef="PAsOn12_31_2021_AmdmHoldingsMemberEPRXAmdmHoldingsAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis"
      decimals="2"
      id="ixv-14809"
      unitRef="Unit_pure">0.05</eprx:StockSharesIssuedAsAPercentageOfOutstandingShares>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis_OutstandingOfAMDMHoldingsMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="2"
      id="ixv-14810"
      unitRef="Unit_pure">0.95</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <eprx:EquityMethodInvestmentNumberOfSharedOwned
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis"
      decimals="INF"
      id="ixv-14811"
      unitRef="Unit_shares">4275</eprx:EquityMethodInvestmentNumberOfSharedOwned>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="P01_31_2021To01_31_2021_AmdmHoldingsMemberEPRXAmdmHoldingsAxis_ChiefScientificOfficerMembersrtTitleOfIndividualAxis_ClassBNonVotingStockMemberusgaapStatementClassOfStockAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis"
      decimals="INF"
      id="ixv-14812"
      unitRef="Unit_pure">2500</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <eprx:CommonStockSharesIssuableAsAResultOfStockSplit
      contextRef="PAsOn12_31_2021_AmdmHoldingsMemberEPRXAmdmHoldingsAxis_ChiefScientificOfficerMembersrtTitleOfIndividualAxis_ClassBNonVotingStockMemberusgaapStatementClassOfStockAxis_EuphraxiaPharmaIncMemberdeiLegalEntityAxis"
      decimals="INF"
      id="ixv-14813"
      unitRef="Unit_shares">562500</eprx:CommonStockSharesIssuableAsAResultOfStockSplit>
    <eprx:DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-11286">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;GENERAL AND ADMINISTRATIVE EXPENSES &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;General and administrative expenses are comprised of the following: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Office expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;389,210&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;332,951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Insurance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;367,472&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;357,763&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Travel&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;345,992&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;120,115&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Professional fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,821,798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;268,698&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public company costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;404,073&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;214,264&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Salaries and benefits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,241,079&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,641,049&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Share based payments (Note 12(c))&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;714,380&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,052,758&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total expenses during the period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,284,004&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,987,598&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </eprx:DisclosureInEntiretyOfGeneralAndAdministrationExpensesTextBlock>
    <eprx:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-11295"> &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;General and administrative expenses are comprised of the following: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Office expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;389,210&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;332,951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Insurance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;367,472&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;357,763&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Travel&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;345,992&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;120,115&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Professional fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,821,798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;268,698&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public company costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;404,073&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;214,264&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Salaries and benefits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,241,079&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,641,049&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Share based payments (Note 12(c))&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;714,380&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,052,758&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total expenses during the period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,284,004&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,987,598&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </eprx:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14814"
      unitRef="Unit_USD">389210</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14815"
      unitRef="Unit_USD">332951</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14816"
      unitRef="Unit_USD">367472</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14817"
      unitRef="Unit_USD">357763</us-gaap:GeneralInsuranceExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14818"
      unitRef="Unit_USD">345992</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14819"
      unitRef="Unit_USD">120115</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:ProfessionalFees
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14820"
      unitRef="Unit_USD">2821798</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14821"
      unitRef="Unit_USD">268698</us-gaap:ProfessionalFees>
    <us-gaap:PreOpeningCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14822"
      unitRef="Unit_USD">404073</us-gaap:PreOpeningCosts>
    <us-gaap:PreOpeningCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14823"
      unitRef="Unit_USD">214264</us-gaap:PreOpeningCosts>
    <us-gaap:LaborAndRelatedExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14824"
      unitRef="Unit_USD">2241079</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14825"
      unitRef="Unit_USD">1641049</us-gaap:LaborAndRelatedExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14826"
      unitRef="Unit_USD">714380</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14827"
      unitRef="Unit_USD">1052758</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14828"
      unitRef="Unit_USD">7284004</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14829"
      unitRef="Unit_USD">3987598</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-11463">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RESEARCH AND DEVELOPMENT EXPENSES &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Research and development expenses are comprised of the following: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:71%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Preclinical&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,616,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,073,668&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Clinical&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,595,597&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,179,535&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Manufacturing&#160;&amp;amp; analytical&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,986,502&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,177,070&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Regulatory&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;341,589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;588,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Consulting&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;660&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;"&gt;Direct research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,539,926&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,019,585&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Pipeline development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83,637&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;227,615&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;672,295&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;424,628&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Salaries and benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,794,891&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,901,257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share based payments (Note 12(c))&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;697,877&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;381,054&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;License costs (Note 10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;5,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Government grants (Note 15)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;(122,542&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;(288,515&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;SR&amp;amp;ED and other R&amp;amp;D tax incentives&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;(102,859&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;(35,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total expenses during the period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20,563,225&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,629,854&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <eprx:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-11472"> &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Research and development expenses are comprised of the following: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:71%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Preclinical&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,616,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,073,668&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Clinical&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,595,597&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,179,535&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Manufacturing&#160;&amp;amp; analytical&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,986,502&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,177,070&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Regulatory&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;341,589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;588,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Consulting&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;660&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em;"&gt;Direct research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,539,926&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,019,585&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Pipeline development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83,637&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;227,615&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;672,295&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;424,628&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Salaries and benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,794,891&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,901,257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share based payments (Note 12(c))&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;697,877&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;381,054&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;License costs (Note 10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;5,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Government grants (Note 15)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;(122,542&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;(288,515&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;SR&amp;amp;ED and other R&amp;amp;D tax incentives&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;(102,859&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;(35,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total expenses during the period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20,563,225&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,629,854&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </eprx:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock>
    <eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory
      contextRef="P01_01_2023To12_31_2023_PreclinicalMemberEPRXResearchAndDevelopmentExpensesAxis"
      decimals="0"
      id="ixv-14830"
      unitRef="Unit_USD">1616238</eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory>
    <eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory
      contextRef="P01_01_2022To12_31_2022_PreclinicalMemberEPRXResearchAndDevelopmentExpensesAxis"
      decimals="0"
      id="ixv-14831"
      unitRef="Unit_USD">1073668</eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory>
    <eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory
      contextRef="P01_01_2023To12_31_2023_ClinicalMemberEPRXResearchAndDevelopmentExpensesAxis"
      decimals="0"
      id="ixv-14832"
      unitRef="Unit_USD">4595597</eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory>
    <eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory
      contextRef="P01_01_2022To12_31_2022_ClinicalMemberEPRXResearchAndDevelopmentExpensesAxis"
      decimals="0"
      id="ixv-14833"
      unitRef="Unit_USD">7179535</eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory>
    <eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory
      contextRef="P01_01_2023To12_31_2023_ManufacturingAndAnalyticaMemberEPRXResearchAndDevelopmentExpensesAxis"
      decimals="0"
      id="ixv-14834"
      unitRef="Unit_USD">4986502</eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory>
    <eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory
      contextRef="P01_01_2022To12_31_2022_ManufacturingAndAnalyticaMemberEPRXResearchAndDevelopmentExpensesAxis"
      decimals="0"
      id="ixv-14835"
      unitRef="Unit_USD">2177070</eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory>
    <eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory
      contextRef="P01_01_2023To12_31_2023_RegulatoryMemberEPRXResearchAndDevelopmentExpensesAxis"
      decimals="0"
      id="ixv-14836"
      unitRef="Unit_USD">341589</eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory>
    <eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory
      contextRef="P01_01_2022To12_31_2022_RegulatoryMemberEPRXResearchAndDevelopmentExpensesAxis"
      decimals="0"
      id="ixv-14837"
      unitRef="Unit_USD">588652</eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory>
    <eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory
      contextRef="P01_01_2023To12_31_2023_ConsultingMemberEPRXResearchAndDevelopmentExpensesAxis"
      decimals="0"
      id="ixv-14838"
      unitRef="Unit_USD">0</eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory>
    <eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory
      contextRef="P01_01_2022To12_31_2022_ConsultingMemberEPRXResearchAndDevelopmentExpensesAxis"
      decimals="0"
      id="ixv-14839"
      unitRef="Unit_USD">660</eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory>
    <eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14840"
      unitRef="Unit_USD">11539926</eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory>
    <eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14841"
      unitRef="Unit_USD">11019585</eprx:ResearchAndDevelopmentCostsGrossExcludingOtherCategory>
    <eprx:PipelineDevelopmentOfResearchAndDevelopmentExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14842"
      unitRef="Unit_USD">83637</eprx:PipelineDevelopmentOfResearchAndDevelopmentExpense>
    <eprx:PipelineDevelopmentOfResearchAndDevelopmentExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14843"
      unitRef="Unit_USD">227615</eprx:PipelineDevelopmentOfResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14844"
      unitRef="Unit_USD">672295</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14845"
      unitRef="Unit_USD">424628</us-gaap:OtherResearchAndDevelopmentExpense>
    <eprx:SalariesAndBenefitsOfResearchAndDevelopmentExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14846"
      unitRef="Unit_USD">2794891</eprx:SalariesAndBenefitsOfResearchAndDevelopmentExpenses>
    <eprx:SalariesAndBenefitsOfResearchAndDevelopmentExpenses
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14847"
      unitRef="Unit_USD">1901257</eprx:SalariesAndBenefitsOfResearchAndDevelopmentExpenses>
    <eprx:ShareBasedPaymentsOfResearchAndDevelopmentExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14848"
      unitRef="Unit_USD">697877</eprx:ShareBasedPaymentsOfResearchAndDevelopmentExpenses>
    <eprx:ShareBasedPaymentsOfResearchAndDevelopmentExpenses
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14849"
      unitRef="Unit_USD">381054</eprx:ShareBasedPaymentsOfResearchAndDevelopmentExpenses>
    <eprx:ResearchAndDevelopmentLicenseExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14850"
      unitRef="Unit_USD">5000000</eprx:ResearchAndDevelopmentLicenseExpenses>
    <eprx:ResearchAndDevelopmentLicenseExpenses
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14851"
      unitRef="Unit_USD">0</eprx:ResearchAndDevelopmentLicenseExpenses>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14852"
      unitRef="Unit_USD">122542</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14853"
      unitRef="Unit_USD">288515</us-gaap:GovernmentAssistanceAmount>
    <eprx:SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14854"
      unitRef="Unit_USD">-102859</eprx:SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses>
    <eprx:SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14855"
      unitRef="Unit_USD">-35770</eprx:SrAndEdAndTaxIncentivesOfResearchAndDevelopmentExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14856"
      unitRef="Unit_USD">20563225</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14857"
      unitRef="Unit_USD">13629854</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GovernmentAssistanceTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-11740">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;GOVERNMENT GRANTS AND ASSISTANCE &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;National Research Council &#x2013; Industrial Research Assistance Program &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;NRC-IRAP&#x201d;)&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"&gt;On October&#160;1, 2021, the Company entered into an agreement with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NRC-IRAP&lt;/div&gt; for funding support of specified research and development activities during a project phase, commencing on September&#160;1, 2021, and ending on December&#160;15, 2023. Under the agreement, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NRC-IRAP&lt;/div&gt; would reimburse up to 80% of supported salary costs, and 50% of supported contractor fees to a maximum of $553,185. During the year ended December&#160;31, 2023, the Company claimed $122,542 pertaining to this agreement (2022 - $277,117). &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"&gt;At December&#160;31, 2023 there was $nil (2022 - $13,892) of government grants recorded in amounts receivable (Note &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt; &#x2013; Amounts Receivable) and collected subsequent to year end. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"&gt;The following table summarizes the government grants and assistance the Company received or accrued during the years ended December&#160;31, 2023 and 2022: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NRC-IRAP&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122,542&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;277,117&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;BioTalent Canada&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,398&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;122,542&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;288,515&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"&gt;Government assistance of $122,542 (2022 - $288,515) relating to research and development activities has been offset against research and development expense. &lt;/div&gt;</us-gaap:GovernmentAssistanceTextBlock>
    <eprx:PercentageOfReimburseAssistanceToSupportSalaryCost
      contextRef="P10_01_2021To10_01_2021_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis"
      decimals="2"
      id="ixv-14858"
      unitRef="Unit_pure">0.80</eprx:PercentageOfReimburseAssistanceToSupportSalaryCost>
    <eprx:PercentageOfReimburseAssistanceToSupportContractorFee
      contextRef="P10_01_2021To10_01_2021_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis"
      decimals="2"
      id="ixv-14859"
      unitRef="Unit_pure">0.50</eprx:PercentageOfReimburseAssistanceToSupportContractorFee>
    <eprx:ReimbursementAssistanceMaximumForSalaryAndContractorCosts
      contextRef="PAsOn10_01_2021_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis"
      decimals="0"
      id="ixv-14860"
      unitRef="Unit_USD">553185</eprx:ReimbursementAssistanceMaximumForSalaryAndContractorCosts>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="P01_01_2023To12_31_2023_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis"
      decimals="0"
      id="ixv-14861"
      unitRef="Unit_USD">122542</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="P01_01_2022To12_31_2022_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis"
      decimals="0"
      id="ixv-14862"
      unitRef="Unit_USD">277117</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GrantsReceivableCurrent
      contextRef="PAsOn12_31_2023_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis"
      decimals="0"
      id="ixv-14863"
      unitRef="Unit_USD">0</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="PAsOn12_31_2022_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis"
      decimals="0"
      id="ixv-14864"
      unitRef="Unit_USD">13892</us-gaap:GrantsReceivableCurrent>
    <eprx:GovernmentAssistanceTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-11757"> &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"&gt;The following table summarizes the government grants and assistance the Company received or accrued during the years ended December&#160;31, 2023 and 2022: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NRC-IRAP&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122,542&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;277,117&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;BioTalent Canada&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,398&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;122,542&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;288,515&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</eprx:GovernmentAssistanceTableTextBlock>
    <us-gaap:GovernmentAssistanceAmountCumulative
      contextRef="PAsOn12_31_2023_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis"
      decimals="0"
      id="ixv-14865"
      unitRef="Unit_USD">122542</us-gaap:GovernmentAssistanceAmountCumulative>
    <us-gaap:GovernmentAssistanceAmountCumulative
      contextRef="PAsOn12_31_2022_NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMemberusgaapGovernmentAssistanceTypeAxis"
      decimals="0"
      id="ixv-14866"
      unitRef="Unit_USD">277117</us-gaap:GovernmentAssistanceAmountCumulative>
    <us-gaap:GovernmentAssistanceAmountCumulative
      contextRef="PAsOn12_31_2023_BioTalentCanadaMemberusgaapGovernmentAssistanceTypeAxis"
      decimals="0"
      id="ixv-14867"
      unitRef="Unit_USD">0</us-gaap:GovernmentAssistanceAmountCumulative>
    <us-gaap:GovernmentAssistanceAmountCumulative
      contextRef="PAsOn12_31_2022_BioTalentCanadaMemberusgaapGovernmentAssistanceTypeAxis"
      decimals="0"
      id="ixv-14868"
      unitRef="Unit_USD">11398</us-gaap:GovernmentAssistanceAmountCumulative>
    <us-gaap:GovernmentAssistanceAmountCumulative
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14869"
      unitRef="Unit_USD">122542</us-gaap:GovernmentAssistanceAmountCumulative>
    <us-gaap:GovernmentAssistanceAmountCumulative
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14870"
      unitRef="Unit_USD">288515</us-gaap:GovernmentAssistanceAmountCumulative>
    <eprx:GovernmentAssistanceAmountForResearchAndDevelopment
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14871"
      unitRef="Unit_USD">122542</eprx:GovernmentAssistanceAmountForResearchAndDevelopment>
    <eprx:GovernmentAssistanceAmountForResearchAndDevelopment
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14872"
      unitRef="Unit_USD">288515</eprx:GovernmentAssistanceAmountForResearchAndDevelopment>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-11860">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;INCOME TAXES &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For financial reporting purposes, loss before taxes includes the following components: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:69%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold"&gt;Year ended December 31,&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Canadian&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(28,810,717&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(18,925,281&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(118,866&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(65,483&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(28,929,583&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(18,990,764&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The income tax expense consists of the following: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 83%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year ended December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Canadian&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;36,423&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;36,423&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;36,423&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36,423&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 69%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loss before taxes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(28,929,583&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(18,990,764&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Statutory Canadian corporate tax rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Expected tax recovery at statutory rates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7,810,987&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5,127,506&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Change in unrecognized deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,523,404&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,127,732&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Non-deductible share-based payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;381,285&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;414,724&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Other items not deductible for tax purposes and other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;242,460&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,570&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Adjustments related to prior years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(624,973&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(257,636&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Share issue costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(290,289&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(322,131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Foreign exchange arising on translation to reporting currency&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,384,477&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;153,247&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36,423&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax expense for the year ended December 31, 2023 arose from the operations of Eupraxia Pharma USA Inc., the Company&#x2019;s wholly-owned subsidiary in the United States. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income tax assets and liabilities result from the temporary differences between the amount of assets and liabilities recognized for financial statement and income tax purposes. The significant components of the Company&#x2019;s net deferred income tax assets are as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 69%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 8%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Convertible debt&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;733,756&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;360,307&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Depreciable assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,092,163&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,655,346&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Lease obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,925&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-capital&lt;/div&gt; losses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,348,349&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,776,875&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Share issue costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;728,046&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;694,773&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Scientific research and experimental development pool&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,093,085&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;852,776&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,546,834&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;797,401&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;121,846&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Less: valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;(26,669,004&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;)&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;(17,145,600&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;)&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net deferred income tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 10%; padding: 0pt 5pt 0pt 0pt;;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; width: 10%; padding: 0pt 5pt 0pt 0pt; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In assessing the realizability of the Company&#x2019;s deferred income tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not b realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which temporary differences become deductible and the loss carry-forwards or tax credits can be utilized. A full valuation allowance continues to be applied against deferred income tax assets as the Company has assessed that the realization of such assets does not meet the more likely than not criteria. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There are no unrecognized income tax benefits as of December 31, 2023, or 2022. Due to the net operating loss carryover position coupled with the lack of any unrecognized tax benefits, no provision has been made for any interest or penalties associated with any uncertain tax positions. It is not anticipated that there will be any significant changes to unrecognized tax benefits within the next 12 months. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In assessing the realizability of the Company&#x2019;s deferred income tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not b realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which temporary differences become deductible and the loss carry-forwards or tax credits can be utilized. A full valuation allowance continues to be applied against deferred income tax assets as the Company has assessed that the realization of such assets does not meet the more likely than not criteria. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There are no unrecognized income tax benefits as of December 31, 2023, or 2022. Due to the net operating loss carryover position coupled &lt;div style="display:inline;"&gt;wit&lt;/div&gt;h the lack of any unrecognized tax benefits, no provision has been made for any interest or penalties associated with any uncertain tax positions. It is not anticipated that there will be any significant changes to unrecognized tax benefits within the next 12 months. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company and its foreign subsidiaries have available &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-capital&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; losses for Canadian, Australian and US income tax purposes which may be carried forward to reduce taxable income in future years. If not utilized, &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-capital&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; losses in each jurisdiction will expire as follows&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;(all amounts expressed in USD):&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 24%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 17%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 17%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 17%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expiry date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-capital&#160;losses&#x2013;&lt;/div&gt;&lt;br/&gt;Canada&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-capital&#160;losses&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-capital&#160;losses&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Australia&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width:21%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:18%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:18%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:18%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2031&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;281,235&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2032&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;575,606&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;322,050&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2033&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,481,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,111,122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2034&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,935,535&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2035&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,466,288&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2036&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,797,516&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160,048&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;037&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;7,294,414&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;160,000&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2038&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;3,060,930&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2039&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;1,666,415&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2040&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;144,413&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2041&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;6,404,809&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2042&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;13,526,387&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2043&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;17,642,270&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unlimited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;1,479,139&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;69,093&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;62,277,418&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,552,359&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;69,093&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company also has approximately $&lt;/div&gt;7,752,165&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; of SR&amp;amp;ED expenditures that may be carried forward indefinitely to be deducted against future Canadian taxable income. It also has federal investment tax credits of approximately $&lt;/div&gt;1,449,886&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; available to offset future Canadian federal income taxes payable as well as provincial investment tax credits of approximately $&lt;/div&gt;511,826&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The federal tax credits are available to be carried forward &lt;/div&gt;20&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; years (expiring in 2036 to 2043) to offset future Canadian federal income taxes payable and the provincial tax credits are available to be carried forward &lt;/div&gt;10&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; years (expiring in 2026 to 2033) to offset future BC income taxes payable. The benefit of the investment tax credits has not been recognized as their realization is not reasonably assured.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company files income tax returns in Canada, United States and Australia, the jurisdictions in which the Company believes that it is subject to tax. In jurisdictions in which the Company does not believe it is subject to tax and therefore does not file income tax returns, the Company can provide no certainty that tax authorities in those jurisdictions will not subject one or more tax years (since the inception of the Company) to examination. Further, while the statute of limitations in each jurisdiction where an income tax return has been filed generally limits the examination period, as a result of loss carry-forwards, the limitation period for examination generally does not expire until several years after the loss carry-forwards are utilized. Other than routine audits by tax authorities for tax credits and tax refunds that the Company claims, the Company is not aware of any other material income tax examination currently in progress by any taxing jurisdiction. Tax years ranging from 2012 to 2023 remain subject to examinations in Canada and the United States 2022 to 2023 for Australia. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-11869">&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For financial reporting purposes, loss before taxes includes the following components: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:69%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold"&gt;Year ended December 31,&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Canadian&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(28,810,717&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(18,925,281&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(118,866&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(65,483&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(28,929,583&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(18,990,764&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14873"
      unitRef="Unit_USD">-28810717</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14874"
      unitRef="Unit_USD">-18925281</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14875"
      unitRef="Unit_USD">-118866</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14876"
      unitRef="Unit_USD">-65483</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14877"
      unitRef="Unit_USD">-28929583</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14878"
      unitRef="Unit_USD">-18990764</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-11964">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The income tax expense consists of the following: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 83%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year ended December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Canadian&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;36,423&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;36,423&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;36,423&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36,423&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14879"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14880"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14881"
      unitRef="Unit_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14882"
      unitRef="Unit_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14883"
      unitRef="Unit_USD">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14884"
      unitRef="Unit_USD">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14885"
      unitRef="Unit_USD">36423</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14886"
      unitRef="Unit_USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14887"
      unitRef="Unit_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14888"
      unitRef="Unit_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14889"
      unitRef="Unit_USD">36423</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14890"
      unitRef="Unit_USD">0</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14891"
      unitRef="Unit_USD">36423</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14892"
      unitRef="Unit_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14893"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14894"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14895"
      unitRef="Unit_USD">36423</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14896"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-12416"> &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 69%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loss before taxes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(28,929,583&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(18,990,764&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Statutory Canadian corporate tax rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Expected tax recovery at statutory rates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7,810,987&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5,127,506&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Change in unrecognized deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,523,404&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,127,732&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Non-deductible share-based payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;381,285&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;414,724&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Other items not deductible for tax purposes and other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;242,460&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,570&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Adjustments related to prior years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(624,973&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(257,636&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Share issue costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(290,289&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(322,131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Foreign exchange arising on translation to reporting currency&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,384,477&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;153,247&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36,423&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14897"
      unitRef="Unit_USD">-28929583</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14898"
      unitRef="Unit_USD">-18990764</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-14899"
      unitRef="Unit_pure">0.27</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="ixv-14900"
      unitRef="Unit_pure">0.27</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14901"
      unitRef="Unit_USD">-7810987</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14902"
      unitRef="Unit_USD">-5127506</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14903"
      unitRef="Unit_USD">9523404</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14904"
      unitRef="Unit_USD">5127732</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14905"
      unitRef="Unit_USD">381285</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14906"
      unitRef="Unit_USD">414724</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14907"
      unitRef="Unit_USD">242460</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14908"
      unitRef="Unit_USD">11570</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14909"
      unitRef="Unit_USD">-624973</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14910"
      unitRef="Unit_USD">-257636</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <eprx:EffectiveIncomeTaxReconciliationShareIssuanceCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14911"
      unitRef="Unit_USD">290289</eprx:EffectiveIncomeTaxReconciliationShareIssuanceCosts>
    <eprx:EffectiveIncomeTaxReconciliationShareIssuanceCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14912"
      unitRef="Unit_USD">322131</eprx:EffectiveIncomeTaxReconciliationShareIssuanceCosts>
    <eprx:EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14913"
      unitRef="Unit_USD">-1384477</eprx:EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency>
    <eprx:EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14914"
      unitRef="Unit_USD">153247</eprx:EffectiveIncomeTaxReconciliationForeignExchangeArisingOnTranslationToReportingCurrency>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-14915"
      unitRef="Unit_USD">36423</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-14916"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-12636">&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income tax assets and liabilities result from the temporary differences between the amount of assets and liabilities recognized for financial statement and income tax purposes. The significant components of the Company&#x2019;s net deferred income tax assets are as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 69%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 8%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Convertible debt&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;733,756&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;360,307&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Depreciable assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,092,163&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,655,346&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Lease obligation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,925&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-capital&lt;/div&gt; losses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,348,349&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,776,875&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Share issue costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;728,046&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;694,773&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Scientific research and experimental development pool&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,093,085&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;852,776&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,546,834&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;797,401&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;121,846&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Less: valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;(26,669,004&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;)&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;(17,145,600&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;)&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net deferred income tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 10%; padding: 0pt 5pt 0pt 0pt;;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; width: 10%; padding: 0pt 5pt 0pt 0pt; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <eprx:DeferredTaxAssetsConvertibleDebt
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14917"
      unitRef="Unit_USD">733756</eprx:DeferredTaxAssetsConvertibleDebt>
    <eprx:DeferredTaxAssetsConvertibleDebt
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14918"
      unitRef="Unit_USD">360307</eprx:DeferredTaxAssetsConvertibleDebt>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14919"
      unitRef="Unit_USD">3092163</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14920"
      unitRef="Unit_USD">1655346</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <eprx:DeferredTaxAssetsLeaseObligation
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14921"
      unitRef="Unit_USD">4925</eprx:DeferredTaxAssetsLeaseObligation>
    <eprx:DeferredTaxAssetsLeaseObligation
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14922"
      unitRef="Unit_USD">8122</eprx:DeferredTaxAssetsLeaseObligation>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14923"
      unitRef="Unit_USD">18348349</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14924"
      unitRef="Unit_USD">12776875</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <eprx:DeferredTaxAssetsShareIssuanceCosts
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14925"
      unitRef="Unit_USD">728046</eprx:DeferredTaxAssetsShareIssuanceCosts>
    <eprx:DeferredTaxAssetsShareIssuanceCosts
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14926"
      unitRef="Unit_USD">694773</eprx:DeferredTaxAssetsShareIssuanceCosts>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14927"
      unitRef="Unit_USD">2093085</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14928"
      unitRef="Unit_USD">852776</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14929"
      unitRef="Unit_USD">1546834</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14930"
      unitRef="Unit_USD">797401</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14931"
      unitRef="Unit_USD">121846</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14932"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14933"
      unitRef="Unit_USD">26669004</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14934"
      unitRef="Unit_USD">17145600</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14935"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14936"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14937"
      unitRef="Unit_USD">0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14938"
      unitRef="Unit_USD">0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14939"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14940"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14941"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14942"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <eprx:ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-12896">&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-capital&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; losses in each jurisdiction will expire as follows&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;(all amounts expressed in USD):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 24%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 17%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 17%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 17%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expiry date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-capital&#160;losses&#x2013;&lt;/div&gt;&lt;br/&gt;Canada&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-capital&#160;losses&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;US&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-capital&#160;losses&#x2013;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Australia&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width:21%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:18%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:18%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:18%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2031&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;281,235&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2032&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;575,606&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;322,050&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2033&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,481,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,111,122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2034&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,935,535&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2035&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,466,288&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2036&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,797,516&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160,048&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;037&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;7,294,414&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;160,000&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2038&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;3,060,930&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2039&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;1,666,415&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2040&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;144,413&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2041&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;6,404,809&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2042&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;13,526,387&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2043&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;17,642,270&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unlimited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;1,479,139&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;69,093&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;62,277,418&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,552,359&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;69,093&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </eprx:ScheduleOfNonCapitalLossesCarryForwardFutureYearsTableTextBlock>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2031MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14943"
      unitRef="Unit_USD">281235</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_TaxYear2031MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"
      decimals="0"
      id="ixv-14944"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2031MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14945"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2032MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14946"
      unitRef="Unit_USD">575606</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_TaxYear2032MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"
      decimals="0"
      id="ixv-14947"
      unitRef="Unit_USD">322050</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2032MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14948"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2033MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14949"
      unitRef="Unit_USD">2481600</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_TaxYear2033MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"
      decimals="0"
      id="ixv-14950"
      unitRef="Unit_USD">1111122</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2033MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14951"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2034MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14952"
      unitRef="Unit_USD">2935535</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_TaxYear2034MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"
      decimals="0"
      id="ixv-14953"
      unitRef="Unit_USD">160000</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2034MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14954"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2035MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14955"
      unitRef="Unit_USD">2466288</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_TaxYear2035MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"
      decimals="0"
      id="ixv-14956"
      unitRef="Unit_USD">160000</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2035MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14957"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2036MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14958"
      unitRef="Unit_USD">3797516</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_TaxYear2036MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"
      decimals="0"
      id="ixv-14959"
      unitRef="Unit_USD">160048</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2036MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14960"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2037MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14961"
      unitRef="Unit_USD">7294414</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_TaxYear2037MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"
      decimals="0"
      id="ixv-14962"
      unitRef="Unit_USD">160000</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2037MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14963"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2038MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14964"
      unitRef="Unit_USD">3060930</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_TaxYear2038MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"
      decimals="0"
      id="ixv-14965"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2038MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14966"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2039MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14967"
      unitRef="Unit_USD">1666415</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_TaxYear2039MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"
      decimals="0"
      id="ixv-14968"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2039MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14969"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2040MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14970"
      unitRef="Unit_USD">144413</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_TaxYear2040MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"
      decimals="0"
      id="ixv-14971"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2040MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14972"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2041MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14973"
      unitRef="Unit_USD">6404809</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_TaxYear2041MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"
      decimals="0"
      id="ixv-14974"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2041MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14975"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2042MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14976"
      unitRef="Unit_USD">13526387</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_TaxYear2042MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"
      decimals="0"
      id="ixv-14977"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2042MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14978"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYear2043MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14979"
      unitRef="Unit_USD">17642270</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYear2043MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14980"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis_TaxYearAfter2043MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14981"
      unitRef="Unit_USD">0</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_TaxYearAfter2043MemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis"
      decimals="0"
      id="ixv-14982"
      unitRef="Unit_USD">1479139</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis_TaxYearAfter2043MemberusgaapTaxPeriodAxis"
      decimals="0"
      id="ixv-14983"
      unitRef="Unit_USD">69093</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_CAsrtStatementGeographicalAxis"
      decimals="0"
      id="ixv-14984"
      unitRef="Unit_USD">62277418</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_USsrtStatementGeographicalAxis"
      decimals="0"
      id="ixv-14985"
      unitRef="Unit_USD">3552359</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <eprx:NonCapitalLossCarryforwardsToFutureExpire
      contextRef="PAsOn12_31_2023_AUsrtStatementGeographicalAxis"
      decimals="0"
      id="ixv-14986"
      unitRef="Unit_USD">69093</eprx:NonCapitalLossCarryforwardsToFutureExpire>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      id="ixv-14987"
      unitRef="Unit_USD">7752165</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_CanadianFederalInvestmentTaxCreditsMemberusgaapTaxCreditCarryforwardAxis"
      decimals="0"
      id="ixv-14988"
      unitRef="Unit_USD">1449886</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_ProvincialInvestmentTaxCreditsMemberusgaapTaxCreditCarryforwardAxis"
      decimals="0"
      id="ixv-14989"
      unitRef="Unit_USD">511826</us-gaap:TaxCreditCarryforwardAmount>
    <eprx:TaxCreditCarryForwardsExpirationTerm
      contextRef="P01_01_2023To12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_CanadianFederalInvestmentTaxCreditsMemberusgaapTaxCreditCarryforwardAxis"
      id="ixv-14990">P20Y</eprx:TaxCreditCarryForwardsExpirationTerm>
    <eprx:TaxCreditCarryForwardsExpirationTerm
      contextRef="P01_01_2023To12_31_2023_CanadaRevenueAgencyMemberusgaapIncomeTaxAuthorityNameAxis_ProvincialInvestmentTaxCreditsMemberusgaapTaxCreditCarryforwardAxis"
      id="ixv-14991">P10Y</eprx:TaxCreditCarryForwardsExpirationTerm>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-13299">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;COMMITMENTS &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"&gt;The Company may be required to make milestone, royalty, and other research and development funding payments under research and development collaboration and other agreements with third parties (see Note &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt; &#x2013; Auritec License Agreement). These payments are contingent upon the achievement of specific development, regulatory and/or commercial milestones. The Company has not accrued these payments as at December&#160;31, 2023 due to the uncertainty over whether these milestones will be achieved. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"&gt;Eupraxia has entered into a number of service contracts with its vendors.&#160;Some of those contracts have cancellation clauses which state Eupraxia would pay a cancellation fee of between 15% and 100% of the next service milestone if it terminates the contract.&#160;As of December&#160;31, 2023, there have been no cancellation of contracts that would trigger a cancellation fee.&lt;/div&gt; </us-gaap:CommitmentsDisclosureTextBlock>
    <eprx:CancellationFeeOnTerminationOfContract
      contextRef="P01_01_2023To12_31_2023_MinimumMembersrtRangeAxis"
      decimals="2"
      id="ixv-14992"
      unitRef="Unit_pure">0.15</eprx:CancellationFeeOnTerminationOfContract>
    <eprx:CancellationFeeOnTerminationOfContract
      contextRef="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis"
      decimals="2"
      id="ixv-14993"
      unitRef="Unit_pure">1</eprx:CancellationFeeOnTerminationOfContract>
    <eprx:CancellationFeeForCancellationOfContract contextRef="P01_01_2023To12_31_2023" id="ixv-14994">no</eprx:CancellationFeeForCancellationOfContract>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-13312">
&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; border: 0px; width: 816px;;text-indent: 0px;"&gt;
&lt;tr style="break-inside: avoid;"&gt;
&lt;td style="width: 32.625px; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;FINANCIAL INSTRUMENTS &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities, payable to Auritec, loans payable and convertible debt. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no changes to the Company&#x2019;s risk exposures or management of risks during the year ended December&#160;31, 2023. The Company&#x2019;s risk exposures and the impact on the Company&#x2019;s financial instruments are summarized below: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Credit risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"&gt;Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company believes it has no significant credit risk, as its cash and cash equivalents and short-term investments, being its primary exposure to credit risk, is with a large Canadian bank. The Company&#x2019;s maximum exposure to credit risk is the carrying value of these financial assets. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify;text-indent: 0px;"&gt;Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. The Company&#x2019;s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at December&#160;31, 2023, the Company had cash and cash equivalents of $19,341,756 (2022 - $18,263,389) in addition to current liabilities of $19,373,903 (2022 - $3,058,387). &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management is currently working on certain strategic alternatives including, but not limited to raising additional capital and strategic alternatives to its existing contingent convertible debt facility. There is no assurance, however, that any or all of these alternatives will materialize or that additional funding will be available, if and when needed.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"&gt; &lt;/div&gt; &lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Market risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: currency risk, interest rate risk and other price risk. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Interest rate risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market i&lt;div style="display:inline;"&gt;nteres&lt;/div&gt;t rates. The Company is exposed to interest rate cash flow risk; and to the extent that the prevailing market interest rates differ from the interest rate on the Company&#x2019;s monetary assets and liabilities, the Company is exposed to interest rate price risk. At December&#160;31, 2023, the Company maintains a convertible debt facility totaling CDN$10,000,000 as well as having an equipment loan of $235,000 of which a principal balance of $62,709 remains as at December&#160;31, 2023. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The convertible debt accrues interest at the greater of 2.45% and the Canadian prime rate, requiring monthly interest payments. An additional payment in kind accrues at a rate of 7% per annum, which will be settled at maturity or on conversion. The equipment loan accrues interest at a fixed rate of 5.84%. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;As at December&#160;31, 2023, management has determined the effect on the future results of operations due to a change in the current Canadian prime rate. An impact of a 1% change in the Canadian prime rate would impact the amount of interest to be paid over the remaining term of the convertible debt facility by approximately $43,807. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Currency risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company is exposed to currency risk due to its frequency of transactions in US dollars. The Company does not use derivatives to hedge against this risk, however, it has purchased US dollars to cover the majority of the costs of the Company&#x2019;s Phase 2 clinical trial.&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;At December 31, 2023, the Company held cash of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;933,816&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (2022 &#x2013; $&lt;/div&gt;1,159,926&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;, had accounts payable of $1,292,128 (2022 &#x2013; $1,814,067), &lt;div style="display:inline;"&gt;a&lt;/div&gt; payable owing to Auritec of $5,000,000 (2022 &#x2013; nil) and a loan payable of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;62,709&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (2022 &#x2013; $&lt;/div&gt;142,127&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;) denominated in US dollars which were translated to Canadian dollars at &lt;/div&gt;1.3226&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (2022 &#x2013; &lt;/div&gt;1.3544&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;). The impact of a 10% change in the exchange rates would have an impact of approximately $&lt;/div&gt;542,102&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (2022 &#x2013; $&lt;/div&gt;79,627&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;) on profit or loss. The Company also has cash in accounts payable in Australian dollars, Great British pounds and Euros. The impact of a &lt;/div&gt;10&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% change in the exchanges of these currencies would have an immaterial effect on future cash flows.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other price risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk and foreign currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer or by factors affecting all similar financial instruments traded in the market. The Company is not exposed to significant price risk with respect to commodity or equity prices. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: justify;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurement &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The Company categorizes its financial instruments measured at fair value into one of three different levels depending on the observation of inputs used in the measurement. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Level&#160;1: Fair value is based on unadjusted quoted prices for identical assets or liabilities in active markets &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Level&#160;2: Fair value is based on inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;Level&#160;3: Fair value is based on valuation techniques that require one or more significant unobservable inputs &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, short-term investments, accounts payable and accrued liabilities, loans payable and convertible debt. With the exception of convertible debt, the carrying value of the Company&#x2019;s financial instruments approximate their fair values due to their short-term maturities. &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The following table summarizes information regarding the classification and carrying values of the Company&#x2019;s financial instruments measured at amortized cost: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 72%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets/liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,341,756&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,263,389&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Amounts receivable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;190,612&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;89,715&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;3,921,875&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;2,928,566&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Payable to Auritec&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;5,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loans payable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;62,709&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;142,127&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes information regarding the changes in fair value of liabilities measured at fair value, categorized as Level&#160;3: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 82%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:82%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Convertible&#160;Debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance &#x2013; December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,507,755&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;958,669&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Interest paid&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(315,436&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,056,165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign exchange&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(465,157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance - December 31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,741,996&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,162,773&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Interest paid&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(591,170&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;836,595&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign exchange&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;185,809&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance - December 31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,336,003&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;For the convertible debt, the key inputs that affect the ongoing valuation are the discount price, the share price and the share price volatility. &lt;/div&gt; </us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14995"
      unitRef="Unit_USD">19341756</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14996"
      unitRef="Unit_USD">18263389</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-14997"
      unitRef="Unit_USD">19373903</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-14998"
      unitRef="Unit_USD">3058387</us-gaap:LiabilitiesCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2023_CADsrtCurrencyAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-15000"
      unitRef="Unit_CAD">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2023_EquipmentLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-15001"
      unitRef="Unit_USD">235000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:OtherLongTermDebt
      contextRef="PAsOn12_31_2023_EquipmentLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-15002"
      unitRef="Unit_USD">62709</us-gaap:OtherLongTermDebt>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="PAsOn12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MinimumMembersrtRangeAxis_SiliconValleyBankMemberEPRXLenderAxis"
      decimals="4"
      id="ixv-15003"
      unitRef="Unit_pure">0.0245</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <eprx:LongTermDebtPaidInKindInterestPercentage
      contextRef="P01_01_2023To12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_SiliconValleyBankMemberEPRXLenderAxis"
      decimals="2"
      id="ixv-15004"
      unitRef="Unit_pure">0.07</eprx:LongTermDebtPaidInKindInterestPercentage>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="PAsOn12_31_2023_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="4"
      id="ixv-15005"
      unitRef="Unit_pure">0.0584</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <eprx:SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate
      contextRef="PAsOn12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-15006"
      unitRef="Unit_pure">0.01</eprx:SignificantUnobservableInputsPercentageIncreaseDecreaseInInterestRate>
    <eprx:SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax
      contextRef="PAsOn12_31_2023_CanadianPrimeRateMemberusgaapVariableRateAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-15007"
      unitRef="Unit_USD">43807</eprx:SignificantUnobservableInputImpactOfInterestRateChangesOnProfitOrLossBeforeTax>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2023_CurrencyRiskMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-15010"
      unitRef="Unit_USD">933816</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2022_CurrencyRiskMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-15011"
      unitRef="Unit_USD">1159926</us-gaap:Cash>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-15012"
      unitRef="Unit_USD">1292128</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-15013"
      unitRef="Unit_USD">1814067</us-gaap:AccountsPayableCurrent>
    <eprx:PayableTowardsRoyaltyAndOthersCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-15014"
      unitRef="Unit_USD">5000000</eprx:PayableTowardsRoyaltyAndOthersCurrent>
    <eprx:PayableTowardsRoyaltyAndOthersCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-15015"
      unitRef="Unit_USD">0</eprx:PayableTowardsRoyaltyAndOthersCurrent>
    <us-gaap:OtherLongTermDebt
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-15016"
      unitRef="Unit_USD">62709</us-gaap:OtherLongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-15017"
      unitRef="Unit_USD">142127</us-gaap:OtherLongTermDebt>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="PAsOn12_31_2023_CADsrtCurrencyAxis"
      decimals="4"
      id="ixv-15018"
      unitRef="Unit_pure">1.3226</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="PAsOn12_31_2022_CADsrtCurrencyAxis"
      decimals="4"
      id="ixv-15019"
      unitRef="Unit_pure">1.3544</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <eprx:ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-15020"
      unitRef="Unit_USD">542102</eprx:ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates>
    <eprx:ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-15021"
      unitRef="Unit_USD">79627</eprx:ImpactOnProfitOrLossDueToAReasonablePossibleIncreaseDecreaseInExchangeRates>
    <eprx:PercentageIncreaseInSignificantUnobservableInputAssets
      contextRef="PAsOn12_31_2023_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-15022"
      unitRef="Unit_pure">0.10</eprx:PercentageIncreaseInSignificantUnobservableInputAssets>
    <eprx:PercentageIncreaseInSignificantUnobservableInputAssets
      contextRef="PAsOn12_31_2022_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-15023"
      unitRef="Unit_pure">0.10</eprx:PercentageIncreaseInSignificantUnobservableInputAssets>
    <eprx:PercentageIncreaseInSignificantUnobservableInputLiabilities
      contextRef="PAsOn12_31_2023_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-15024"
      unitRef="Unit_pure">0.10</eprx:PercentageIncreaseInSignificantUnobservableInputLiabilities>
    <eprx:PercentageIncreaseInSignificantUnobservableInputLiabilities
      contextRef="PAsOn12_31_2022_CADsrtCurrencyAxis"
      decimals="2"
      id="ixv-15025"
      unitRef="Unit_pure">0.10</eprx:PercentageIncreaseInSignificantUnobservableInputLiabilities>
    <eprx:ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-13503"> &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The following table summarizes information regarding the classification and carrying values of the Company&#x2019;s financial instruments measured at amortized cost: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 72%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial assets/liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,341,756&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,263,389&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Amounts receivable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;190,612&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;89,715&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;3,921,875&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;2,928,566&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Payable to Auritec&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;5,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loans payable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;62,709&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);"&gt;142,127&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </eprx:ScheduleOfCarryingValueOfFinancialInstrumentsAtAmortizedCostTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-15026"
      unitRef="Unit_USD">19341756</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-15027"
      unitRef="Unit_USD">18263389</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-15028"
      unitRef="Unit_USD">190612</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-15029"
      unitRef="Unit_USD">89715</us-gaap:NontradeReceivablesCurrent>
    <eprx:AccountsPayableAndAccruedLiability
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-15030"
      unitRef="Unit_USD">3921875</eprx:AccountsPayableAndAccruedLiability>
    <eprx:AccountsPayableAndAccruedLiability
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-15031"
      unitRef="Unit_USD">2928566</eprx:AccountsPayableAndAccruedLiability>
    <eprx:PayableTowardsRoyaltyAndOthersCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-15032"
      unitRef="Unit_USD">5000000</eprx:PayableTowardsRoyaltyAndOthersCurrent>
    <eprx:PayableTowardsRoyaltyAndOthersCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-15033"
      unitRef="Unit_USD">0</eprx:PayableTowardsRoyaltyAndOthersCurrent>
    <us-gaap:OtherLongTermDebt
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-15034"
      unitRef="Unit_USD">62709</us-gaap:OtherLongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-15035"
      unitRef="Unit_USD">142127</us-gaap:OtherLongTermDebt>
    <eprx:DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock
      contextRef="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      id="ixv-13615"> &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes information regarding the changes in fair value of liabilities measured at fair value, categorized as Level&#160;3: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 82%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:82%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Convertible&#160;Debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance &#x2013; December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,507,755&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;958,669&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Interest paid&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(315,436&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,056,165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign exchange&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(465,157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance - December 31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,741,996&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,162,773&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Interest paid&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(591,170&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;836,595&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign exchange&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;185,809&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance - December 31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,336,003&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </eprx:DisclosureInTabularFormOfMovementInConvertibleDebtAtFairValueTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-15037"
      unitRef="Unit_USD">7507755</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod
      contextRef="P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-15038"
      unitRef="Unit_USD">958669</eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod>
    <eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod
      contextRef="P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-15039"
      unitRef="Unit_USD">-315436</eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-15040"
      unitRef="Unit_USD">-1056165</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss
      contextRef="P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-15041"
      unitRef="Unit_USD">-465157</eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-15042"
      unitRef="Unit_USD">8741996</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod
      contextRef="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-15043"
      unitRef="Unit_USD">1162773</eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAccruedInterestDuringThePeriod>
    <eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod
      contextRef="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-15044"
      unitRef="Unit_USD">-591170</eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisInterestPaidDuringThePeriod>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-15045"
      unitRef="Unit_USD">-836595</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss
      contextRef="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-15046"
      unitRef="Unit_USD">185809</eprx:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisLiabilityForeginExchangeGainLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-15047"
      unitRef="Unit_USD">10336003</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-13842">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;INTEREST EXPENSE &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;Interest expense is comprised of the following: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:73%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Interest on SVB debt facility (Note 11)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,162,773&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;958,669&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other interest and accretion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,400&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24,187&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,170,173&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;982,856&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-13851"> &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;Interest expense is comprised of the following: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:73%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Interest on SVB debt facility (Note 11)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,162,773&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;958,669&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other interest and accretion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,400&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24,187&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,170,173&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;982,856&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-15048"
      unitRef="Unit_USD">1162773</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-15049"
      unitRef="Unit_USD">958669</us-gaap:InterestExpenseDebt>
    <eprx:OtherInterestAndAccretionExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-15050"
      unitRef="Unit_USD">7400</eprx:OtherInterestAndAccretionExpense>
    <eprx:OtherInterestAndAccretionExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-15051"
      unitRef="Unit_USD">24187</eprx:OtherInterestAndAccretionExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-15052"
      unitRef="Unit_USD">1170173</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-15053"
      unitRef="Unit_USD">982856</us-gaap:InterestExpense>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-13960">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The Company paid interest of $598,046 during the year ended December&#160;31, 2023 (2022 - $326,629). &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The Company received interest of $912,033 during the year ended December&#160;31, 2023 (2022 - $394,188). &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The Company had the following significant &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; transactions for the year ended December&#160;31, 2023: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:2%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: justify; line-height: normal;"&gt;99,061 common shares (valued at $511,678) were issued as part of the financing on August&#160;18, 2023, as a payment of finder&#x2019;s fees (see Note &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;(b)(v)). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;The Company had the following significant &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; transactions for the year ended December&#160;31, 2022: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:10%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:2%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: justify; line-height: normal;"&gt;500,538 warrants (valued at $160,147) were issued as part of the financing on April&#160;20, 2022, to the Underwriters (see&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Note&#160;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12&lt;/div&gt;(b)(i)). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;A detailed breakdown of cash and cash equivalents is as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,341,756&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,830,891&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,432,498&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19,341,756&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18,263,389&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-15054"
      unitRef="Unit_USD">598046</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-15055"
      unitRef="Unit_USD">326629</us-gaap:InterestPaidNet>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-15056"
      unitRef="Unit_USD">912033</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-15057"
      unitRef="Unit_USD">394188</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P08_18_2023To08_18_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-15058"
      unitRef="Unit_shares">99061</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P08_18_2023To08_18_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-15059"
      unitRef="Unit_USD">511678</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <eprx:NumberofWarrantsIssued
      contextRef="P04_20_2022To04_20_2022"
      decimals="0"
      id="ixv-15060"
      unitRef="Unit_shares">500538</eprx:NumberofWarrantsIssued>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P04_20_2022To04_20_2022"
      decimals="0"
      id="ixv-15061"
      unitRef="Unit_USD">160147</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-13994"> &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;A detailed breakdown of cash and cash equivalents is as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,341,756&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,830,891&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,432,498&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19,341,756&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18,263,389&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-15062"
      unitRef="Unit_USD">19341756</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-15063"
      unitRef="Unit_USD">10830891</us-gaap:Cash>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-15064"
      unitRef="Unit_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-15065"
      unitRef="Unit_USD">7432498</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-15066"
      unitRef="Unit_USD">19341756</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-15067"
      unitRef="Unit_USD">18263389</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-14101">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;SUBSEQUENT EVENT &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;text-align:justify"&gt;On March&#160;15, 2024, the Company announced it had closed its previously announced overnight marketed public offering (the &#x201c;Offering&#x201d;) of common shares of the Company (the &#x201c;Shares&#x201d;). Pursuant to the Offering, Eupraxia issued 8,260,435 Shares at a price of C$4.10 per Share for gross proceeds of $25,026,073 (CDN$33,867,784&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;), which includes the issuance of&lt;/div&gt; 943,435 Shares upon exercise of the over-allotment option. &lt;/div&gt; </us-gaap:SubsequentEventsTextBlock>
    <eprx:NumberOfUnitsIssued
      contextRef="PAsOn03_15_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-15068"
      unitRef="Unit_shares">8260435</eprx:NumberOfUnitsIssued>
    <eprx:SecuritiesIssuedPricePerUnit
      contextRef="PAsOn03_15_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      id="ixv-15069"
      unitRef="Unit_CAD_per_Share">4.1</eprx:SecuritiesIssuedPricePerUnit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P03_15_2024To03_15_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-15070"
      unitRef="Unit_USD">25026073</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P03_15_2024To03_15_2024_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-15071"
      unitRef="Unit_CAD">33867784</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P03_15_2024To03_15_2024_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-15072"
      unitRef="Unit_shares">943435</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
